﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kim, SW
   Oh, J
   Kwon, SS
   Yoo, J
   Huh, K
AF Kim, Seong-Woo
   Oh, Jaeryung
   Kwon, Soon-Sun
   Yoo, Junho
   Huh, Kuhl
TI COMPARISON OF CHOROIDAL THICKNESS AMONG PATIENTS WITH HEALTHY EYES,
   EARLY AGE-RELATED MACULOPATHY, NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION, CENTRAL SEROUS CHORIORETINOPATHY, AND POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal thickness; optical coherence tomography; age-related
   maculopathy; neovascular age-related macular degeneration; polypoidal
   choroidal vasculopathy; central serous chorioretinopathy
ID OPTICAL COHERENCE TOMOGRAPHY; CLINICOPATHOLOGICAL CORRELATION; MEMBRANES
AB Purpose: To compare choroidal thicknesses among eyes with early age-related maculopathy (ARM), neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy.
   Methods: Patients with age-related maculopathy (37 eyes), neovascular age-related macular degeneration (24 eyes), polypoidal choroidal vasculopathy (12 eyes), and central serous chorioretinopathy (31 eyes) underwent spectral-domain optical coherence tomography evaluations using a choroid scanning protocol. A horizontal linear section comprising 50 averaged scans was obtained of each macula. The choroidal thickness was measured from the outer border of the retinal pigment epithelium to the inner scleral border. Twenty-nine subjects with healthy eyes served as a control group. Analysis of covariance tests were performed to evaluate the effects of various diagnoses on choroidal thickness after removal of variance (covariates = gender, age, and refractive error).
   Results: Among the different covariates, age was associated with choroidal thickness (fovea: F = 12.067, P = 0.001). After controlling for age differences, the choroid was thicker in polypoidal choroidal vasculopathy (319.92 +/- 68.66 mu m) and central serous chorioretinopathy (367.81 +/- 105.56 mu m) patients than in controls (241.97 +/- 66.37 mu m) and age-related maculopathy patients (186.62 +/- 64.02 mu m). However, there were no significant differences in mean choroidal thickness between neovascular age-related macular degeneration (226.46 +/- 102.87 mu m) and any of the other diagnoses.
   Conclusion: The choroid was thicker in eyes with polypoidal choroidal vasculopathy or central serous chorioretinopathy than in control or age-related maculopathy groups. RETINA 31: 1904-1911, 2011
C1 [Kim, Seong-Woo; Oh, Jaeryung; Yoo, Junho; Huh, Kuhl] Korea Univ, Coll Med, Dept Ophthalmol, Seoul 136705, South Korea.
   [Kwon, Soon-Sun] Korea Univ, Coll Med, Dept Biostat, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong,5 Ga, Seoul 136705, South Korea.
EM ojr4991@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Kim, Seong-Woo/0000-0003-0073-5800
FU Ministry for Health, Welfare & Family Affairs, Republic of Korea
   [A102024]
FX Supported by a grant from the Korean Health Technology R&D Project,
   Ministry for Health, Welfare & Family Affairs, Republic of Korea
   (A102024).
CR BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Guyer DR, 2006, RETINA, P34, DOI DOI 10.1016/B978-0-323-02598-0.50009-4
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   LEESON TS, 1988, TEXT ATLAS HISTOLOGY, P677
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
NR 22
TC 223
Z9 231
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2011
VL 31
IS 9
BP 1904
EP 1911
DI 10.1097/IAE.0b013e31821801c5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825YR
UT WOS:000295318800023
PM 21878855
DA 2022-11-30
ER

PT J
AU Bessho, H
   Honda, S
   Kondo, N
   Negi, A
AF Bessho, Hiroaki
   Honda, Shigeru
   Kondo, Naoshi
   Negi, Akira
TI The association of age-related maculopathy susceptibility 2
   polymorphisms with phenotype in typical neovascular age-related macular
   degeneration and polypoidal choroidal vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID PHOTODYNAMIC THERAPY; LOC387715 A69S; MULTICENTER; VARIANTS; GENOTYPE;
   HYOGO; HTRA1
AB Purpose: To determine the association of age-related maculopathy susceptibility 2 (ARMS2) gene polymorphisms with the phenotype of typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV) and the effects of photodynamic therapy (PDT).
   Methods: The single nucleotide polymorphisms at rs10490924 (A69S) in ARMS2 of 68 tAMD and 119 PCV patients who underwent PDT were genotyped using the TaqMan assay. The baseline best corrected visual acuity (BCVA) and lesion size were compared among the three genotypes at rs10490924. A multivariate regression analysis was performed to evaluate the influence of the baseline BCVA, greatest linear dimension (GLD), and lesion phenotype (tAMD or PCV) on the association of rs10490924 with the BCVA 12 months after the first PDT.
   Results: The mean lesion size was significantly different among the GG, GT, and TT genotypes at rs10490924 in the PCV group, although no significant differences were detected in the tAMD group. PCV patients with a G allele had significantly better vision at 3 months after the initial PDT. tAMD patients with a TT genotype had significantly poorer vision at 12 months after the first PDT. In the multivariate regression analysis, the additive model of the G allele at rs10490924 was associated with a significantly better BCVA 12 months after the first PDT in tAMD and PCV patients.
   Conclusions: ARMS2 variants are likely associated with the phenotype and the effects of PDT in tAMD and PCV.
C1 [Honda, Shigeru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science and Culture, Tokyo, Japan [20592042]
FX This study was supported by a Grant-in Aid (C) 20592042 (S.H.) from the
   Ministry of Education, Science and Culture, Tokyo, Japan. The funding
   organization had no role in the design or conduct of this research.
CR Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chowers I, 2008, MOL VIS, V14, P2263
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lim JY., 2010, ACTA OPHTHALMOL
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
NR 24
TC 35
Z9 38
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 20
PY 2011
VL 17
IS 108
BP 977
EP 982
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 755OU
UT WOS:000289943700001
PM 21541271
DA 2022-11-30
ER

PT J
AU Stangos, AN
   Gandhi, JS
   Nair-Sahni, J
   Heimann, H
   Pournaras, CJ
   Harding, SP
AF Stangos, Alexandros N.
   Gandhi, Jagdeep Singh
   Nair-Sahni, Jayashree
   Heimann, Heinrich
   Pournaras, Constantin J.
   Harding, Simon P.
TI Polypoidal Choroidal Vasculopathy Masquerading as Neovascular
   Age-Related Macular Degeneration Refractory to Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; VERTEPORFIN
AB PURPOSE: To report a neovascular age-related macular degeneration pattern refractory to ranibizumab.
   DESIGN: Retrospective, observational case series.
   METHODS: Between March and May 2009, cases with neovascular age-related macular degeneration refractory to ranibizumab were investigated with indocyanine green angiography. We identified 12 eyes of 12 patients with polypoidal choroidal vasculopathy. Refractory to treatment were defined cases with persistent subretinal or intraretinal fluid, or both, after 3 or more consecutive monthly ranibizumab injections regardless of best-corrected visual acuity.
   RESULTS: All patients identified were white, of whom 6 were male. Mean age standard deviation at presentation was 75 +/- 5.6 years (range, 64 to 81 years); diagnosis, based on fluorescein angiography, comprised occult choroidal neovascularization (CNV) in 8 eyes, and 1 case each of classic-no-occult CNV, minimally classic CNV, predominantly classic CNV, and retinal angiomatous proliferation. Eight cases had switched from courses of other therapy (5 pegaptanib, 1 photodynamic therapy, 1 photodynamic therapy then pegaptanib, 1 bevacizumab). After a mean follow-up of 10.2 +/- 4.8 months (range, 3 to 18 months) and 7.6 +/- 3.9 ranibizumab injections (range, 3 to 14 injections), indocyanine green angiography revealed polypoidal choroidal vasculopathy lesions in all cases.
   CONCLUSIONS: Neovascular age-related macular degeneration refractory to a course of ranibizumab injections may harbor polypoidal choroidal vasculopathy. In such cases, indocyanine green angiography is a valuable tool for revealing polypoidal lesions. (Am J Ophthalmol 2010;150:666-673. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Stangos, Alexandros N.; Gandhi, Jagdeep Singh; Nair-Sahni, Jayashree; Heimann, Heinrich; Harding, Simon P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   [Pournaras, Constantin J.] Univ Hosp Geneva, Dept Clin Neurosci, Div Ophthalmol, Geneva, Switzerland.
   [Harding, Simon P.] Univ Liverpool, Sch Clin Sci, Ophthalmol Res Unit, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Geneva; University of Liverpool
RP Stangos, AN (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM astangos@hotmail.com
RI Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644; Harding,
   Simon/0000-0003-4676-1158
FU NOVARTIS AG; Quinitles and National Coordinating Centre for Health
   Technology assessment (UK NHS RD); Chameleon
FX DR HEIMANN HAS RECEIVED LECTURE FEES FROM NOVARTIS AG. DR HARDING HAS
   RECEIVED CONSULTING FEES FROM Novartis AG and Chameleon and receives
   grant support from Quinitles and National Coordinating Centre for Health
   Technology assessment (UK NHS R&D). Involved in Conception and design of
   study (A.N.S.); Analysis and interpretation of data (A.N.S., J.S.G.,
   J.N.-S., H.H., C.J.P., S.P.H.); Writing the article (A.N.S.); Critical
   revision of manuscript (J.S.G., J.N.-S., H.H., C.J.P., S.P.H.); Final
   approval of manuscript (A.N.S., J.S.G., J.N.-S., H.H., C.J.P., S.P.H.);
   Data collection (A.N.S.); and Literature research (A.N.S.). Ethics
   Committee approval was obtained from the Royal Liverpool University
   Hospital Review Board. All investigations adhered to the principles of
   the Declaration of Helsinki.
CR [Anonymous], 1998, Ophthalmology, V105, P1564
   [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1242
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hlushchuk R, 2007, MICROCIRCULATION, V14, P813, DOI 10.1080/10739680701370021
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Squirrell DM, 2009, CLIN EXP OPHTHALMOL, V37, P368, DOI 10.1111/j.1442-9071.2009.02044.x
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
NR 20
TC 82
Z9 85
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2010
VL 150
IS 5
BP 666
EP 673
DI 10.1016/j.ajo.2010.05.035
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679RA
UT WOS:000284177300013
PM 20719300
DA 2022-11-30
ER

PT J
AU Ozkok, A
   Sigford, DK
   Tezel, TH
AF Ozkok, Ahmet
   Sigford, Douglas K.
   Tezel, Tongalp H.
TI PATTERNS OF FUNDUS AUTOFLUORESCENCE DEFECTS IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION SUBTYPES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; polypoidal
   choroidal vasculopathy; retinal angiomatous proliferation
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   NATURAL-HISTORY; EXUDATIVE AMD; RPE
AB Purpose: To test define characteristic fundus autofluorescence patterns of different exudative age-related macular degeneration subtypes.
   Methods: Cross-sectional study. Fifty-two patients with choroidal neovascularization because of three different neovascular age-related macular degeneration subtypes were included in the study. Macular and peripheral fundus autofluorescence patterns of study subjects were compared in a masked fashion.
   Results: Fundus autofluorescence patterns of all three neovascular age-related macular degeneration subtypes revealed similar patterns. However, peripapillary hypo-autofluorescence was more common among patients with polypoidal choroidal vasculopathy (88.2%) compared with patients with retinal angiomatous proliferation (12.5%) and patients without retinal angiomatous proliferation and polypoidal choroidal vasculopathy (21.1%) (P < 0.0001).
   Conclusion: Presence of peripapillary fundus autofluorescence defects in neovascular age-related macular degeneration maybe suggestive of polypoidal choroidal vasculopathy as a variant of neovascular age-related macular degeneration.
C1 [Ozkok, Ahmet; Sigford, Douglas K.; Tezel, Tongalp H.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Tezel, Tongalp H.] Columbia Univ, Dept Ophthalmol, 635 West 165th St,Box 38, New York, NY 10032 USA.
C3 University of Louisville; Columbia University
RP Tezel, TH (通讯作者)，Columbia Univ, Dept Ophthalmol, 635 West 165th St,Box 38, New York, NY 10032 USA.
EM tht2115@cumc.columbia.edu
FU Turkish Scientific and Technological Research Council (TUBITAK) under
   2219-International Postdoctoral Research Scholarship Program
FX Supported by Turkish Scientific and Technological Research Council
   (TUBITAK) under the 2219-International Postdoctoral Research Scholarship
   Program (A.O.). The sponsor had no role in the design or conduct of this
   research.
CR Altman DG, 1991, PRACTICAL STAT MED R
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Chung H, 2012, OPHTHALMOLOGY, V119, P1056, DOI 10.1016/j.ophtha.2011.11.018
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Seidensticker F, 2011, CLIN OPHTHALMOL, V5, P1667, DOI 10.2147/OPTH.S26224
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Wabbels B, 2006, GRAEF ARCH CLIN EXP, V244, P36, DOI 10.1007/s00417-005-0043-2
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2191
EP 2196
DI 10.1097/IAE.0000000000001034
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800027
PM 27078800
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI LONG-TERM COURSE AND VISUAL OUTCOMES OF PRECHOROIDAL CLEFT IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE prechoroidal cleft; age-related macular degeneration; polypoidal
   choroidal vasculopathy; choroidal neovascularization
ID PIGMENT EPITHELIAL DETACHMENT; RANIBIZUMAB; PREVALENCE; EYES
AB Purpose: To evaluate the regression of prechoroidal cleft, its influence on visual outcomes, and differences in visual outcomes between neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Methods: This retrospective study included 61 patients exhibiting prechoroidal cleft who were treated with antivascular endothelial growth factors. The patients were divided into two groups according to the following categories: 1) regression of prechoroidal cleft: regression group versus nonregression group and 2) type of neovascularization: neovascular age-related macular degeneration group versus polypoidal choroidal vasculopathy group. Changes in the visual acuity during the follow-up period were also compared between the two groups. Results: During the 52.4 +/- 17.4-month follow-up period, regression of prechoroidal cleft was noted in 17 patients (27.9%) at a mean of 25.7 +/- 18.3 months after the first identification. The degree of the logarithm of the minimum angle of resolution of visual deterioration was greater in the nonregression group (0.59 +/- 0.56, n = 17) than that in the regression group (0.25 +/- 0.61, n = 44) (P = 0.007) and in the neovascular age-related macular degeneration group (0.56 +/- 0.61, n = 51) than that in the polypoidal choroidal vasculopathy group (0.18 +/- 0.33, n = 10) (P = 0.034). Conclusion: Approximately 27.9% of prechoroidal cleft cases eventually regressed, in conjunction with relatively favorable visual outcomes. Considering the poor visual prognosis in neovascular age-related macular degeneration accompanied by prechoroidal cleft, more caution is required for this condition.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
CR Au A, 2019, INVEST OPHTH VIS SCI, V60, P3310, DOI 10.1167/iovs.18-26478
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041145
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1661, DOI 10.1007/s00417-019-04373-4
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   Kim JH, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2578349
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Luo MY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01386-0
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Roberts MF, 2002, BRIT J OPHTHALMOL, V86, P658, DOI 10.1136/bjo.86.6.658
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Vazquez-Alfageme C, 2019, RETINA-J RET VIT DIS, V39, P664, DOI 10.1097/IAE.0000000000002029
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2021
VL 41
IS 12
BP 2436
EP 2445
DI 10.1097/IAE.0000000000003242
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XF9PZ
UT WOS:000724397400004
PM 34173365
DA 2022-11-30
ER

PT J
AU Cheng, Y
   Huang, LZ
   Li, XX
   Zhou, P
   Zeng, WT
   Zhang, CF
AF Cheng, Yong
   Huang, LvZhen
   Li, Xiaoxin
   Zhou, Peng
   Zeng, Wotan
   Zhang, ChunFang
TI Genetic and Functional Dissection of ARMS2 in Age-Related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MESSENGER-RNA EXPRESSION; BEAVER DAM EYE; EXTENDED
   FAMILIES; CHROMOSOME 10Q26; GENOMEWIDE-SCAN; JAPANESE POPULATION;
   SUSCEPTIBILITY LOCI; VISUAL IMPAIRMENT; LINKAGE ANALYSIS
AB Age-related maculopathy susceptibility 2(ARMS2) was suggested to be associated with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in multiple genetic studies in Caucasians and Japanese. To date, no biological properties have been attributed to the putative protein in nAMD and PCV. The complete genes of ARMS2 and HTRA1 including all exons and the promoter region were assessed using direct sequencing technology in 284 unrelated mainland northern Chinese individuals: 96 nAMD patients, 92 PCV patients and 96 controls. Significant associations with both nAMD and PCV were observed in 2 polymorphisms of ARMS2 and HTRA1 rs11200638, with different genotypic distributions between nAMD and PCV (p<0.001). After adjusting for rs11200638, ARMS2 rs10490924 remained significantly associated with nAMD and PCV (p<0.001). Then we overexpressed wild-type ARMS2 and ARMS2 A69S mutation (rs10490924) in RF/6A cells and RPE cells as in vitro study model. Cell proliferation, attachment, migration and tube formation were analyzed for the first time. Compare with wild-type ARMS2, A69S mutation resulted in a significant increase in proliferation and attachment but inhibited cell migration. Moreover, neither wild-type ARMS2 nor A69S mutation affected tube formation of RF/6A cells. There is a strong and consistent association of the ARMS2/HTRA1 locus with both nAMD and PCV, suggesting the two disorders share, at least partially, similar molecular mechanisms. Neither wild-type ARMS2 nor A69S mutation had direct association with neovascularisation in the pathogenesis of AMD.
C1 [Cheng, Yong; Huang, LvZhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Cheng, Yong; Huang, LvZhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Zhou, Peng] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
   [Zeng, Wotan] Chinese Natl Human Genome Ctr, Beijing, Peoples R China.
   [Zhang, ChunFang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100871, Peoples R China.
C3 Peking University; Fudan University; Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM drlixiaoxin@163.com
FU National Basic Research Program of China (973 Program) [2011CB510200]
FX Research supported by the National Basic Research Program of China (973
   Program; #2011CB510200). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Huang LZ, 2009, MOL VIS, V15, P1057
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Ning-pu, 2009, Zhonghua Yan Ke Za Zhi, V45, P393
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sayen Alexandra, 2011, Rev Prat, V61, P159
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shen WY, 2003, J GENE MED, V5, P576, DOI 10.1002/jgm.375
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang TH, 2009, OPHTHALMIC RES, V41, P36, DOI 10.1159/000163220
   Zhou P, 2007, CURR EYE RES, V32, P973, DOI 10.1080/02713680701658323
NR 61
TC 23
Z9 27
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2013
VL 8
IS 1
AR e53665
DI 10.1371/journal.pone.0053665
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 070YR
UT WOS:000313551500090
PM 23326481
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shen, YS
   Cheng, CK
AF Shen, Yi-Syun
   Cheng, Cheng-Kuo
TI Using optical coherence tomography angiography in assessment of the
   anti-vascular endothelial growth factor effect for pathological vascular
   tissue in age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Optical coherence tomography angiography; age-related macular
   degeneration; polypoidal choroidal vasculopathy; choroidal
   neovascularization; branch vascular network; vascular endothelial growth
   factor; arterialization
ID INTRAVITREAL AFLIBERCEPT; OCT ANGIOGRAPHY; PHOTODYNAMIC THERAPY;
   NEOVASCULARIZATION SECONDARY; TYPE-2 NEOVASCULARIZATION; RANIBIZUMAB;
   BEVACIZUMAB; VERTEPORFIN; INJECTIONS; NETWORKS
AB Purpose:
   Using optical coherence tomography angiography to assess and compare changes in pathological vascular tissue, including choroidal neovascularization in neovascular age-related macular degeneration and polypoidal complex in polypoidal choroidal vasculopathy, after treatment with anti-vascular endothelial growth factor.
   Methods:
   This is a retrospective observational case series study. Clinical data were collected, including that on the best-corrected visual acuity and images of spectrum domain optical coherence tomography and optical coherence tomography angiography of consecutive patients with macula-involved lesions, active pathological vascular tissue in neovascular age-related macular degeneration, and polypoidal complex in polypoidal choroidal vasculopathy who were treated with anti-vascular endothelial growth factor injection. The primary outcome measures were the lesion area, flow density, and flow area of the pathological vascular tissue obtained in optical coherence tomography angiography before treatment, as well as week-1 (W1) and week-5 (W5) after treatment. The secondary outcome measures were the best-corrected visual acuity and the anatomic changes in spectrum domain optical coherence tomography at the same periods.
   Results:
   A total of 86 eyes in 79 patients (mean age: 73.10 +/- 10.10 (range = 50-91) years, 45 males (57%), of which two eyes were treatment-naive) underwent one section of intravitreal treatment. Of which 44 eyes (40 patients) were diagnosed as typical neovascular age-related macular degeneration and 42 eyes (39 patients) as polypoidal choroidal vasculopathy. The sensitivity for detecting choroidal neovascularization in neovascular age-related macular degeneration and polypoidal complex in polypoidal choroidal vasculopathy was 75.00% (33/44) and 69.05% (29/42), respectively. There was no significant difference in the detection rate between neovascular age-related macular degeneration and polypoidal choroidal vasculopathy (p = 0.54). In the detectable group, there were significant decrease in lesion area and flow area in the optical coherence tomography angiography images after anti-vascular endothelial growth factor treatment in both the neovascular age-related macular degeneration group (lesion area: W1 = -26.94 +/- 19.50%, W5 = -35.52 +/- 30.85%, all ps < 0.001; flow area: W1 = -26.22 +/- 25.23%, W5 = -32.24 +/- 32.07%, all ps < 0.001) and the polypoidal choroidal vasculopathy group (lesion area: W1 = -25.19 +/- 20.27%, W5 = -31.55 +/- 27.04%, all ps < 0.001; flow area: W1 = -21.83 +/- 26.29%, W5 = -28.31 +/- 30.72%, all ps < 0.001). The central subfield retinal thickness in spectrum domain optical coherence tomography also showed similar amelioration in both groups. However, the flow density in optical coherence tomography angiography image and the visual outcome did not reveal any significant difference before or after intravitreal injections, and neither were there significant differences between the neovascular age-related macular degeneration and polypoidal choroidal vasculopathy groups. Concerning the effect on the optical coherence tomography angiography images of pathological vascular tissue, there were no statistical differences among different anti-vascular endothelial growth factor agents (i.e. aflibercept, ranibizumab, and bevacizumab).
   Conclusion:
   Our study revealed that optical coherence tomography angiography can be used noninvasively and quantitatively to assess the detailed pathologic vascular structures in both neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Our study also demonstrated that anti-vascular endothelial growth factor could effectively decrease the lesion size and flow area of both the choroidal neovascularization in neovascular age-related macular degeneration cases and the polypoidal complex in polypoidal choroidal vasculopathy cases; the effects were similar in both diseases.
C1 [Shen, Yi-Syun; Cheng, Cheng-Kuo] Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 11120, Taiwan.
   [Shen, Yi-Syun] Hsin Ho Mei Eye Clin, Songshan Branch, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University
RP Cheng, CK (通讯作者)，Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 11120, Taiwan.
EM b101093114@tmu.edu.tw
RI Shen, Yi-Syun/AAF-2199-2020
OI Shen, Yi-Syun/0000-0002-2771-5474; Cheng, Cheng-Kuo/0000-0002-4657-9113
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen P-J, 2012, TAIWAN J OPHTHALMOL, V4, P127
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Srour M, 2016, BR J OPHTHALMOL, V39, P1693
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 59
TC 3
Z9 3
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1267
EP 1280
AR 1120672120913012
DI 10.1177/1120672120913012
EA MAR 2020
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000523541700001
PM 32228025
DA 2022-11-30
ER

PT J
AU Yanagisawa, S
   Kondo, N
   Miki, A
   Matsumiya, W
   Kusuhara, S
   Tsukahara, Y
   Honda, S
   Negi, A
AF Yanagisawa, Suiho
   Kondo, Naoshi
   Miki, Akiko
   Matsumiya, Wataru
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Honda, Shigeru
   Negi, Akira
TI Difference between age-related macular degeneration and polypoidal
   choroidal vasculopathy in the hereditary contribution of the A69S
   variant of the age-related maculopathy susceptibility 2 gene (ARMS2)
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; JAPANESE POPULATION;
   CHINESE PATIENTS; COMMON VARIANTS; MESSENGER-RNA; RISK; HTRA1;
   POLYMORPHISMS; METAANALYSIS
AB Purpose: To investigate whether the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2) has a different hereditary contribution in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Methods: We initially conducted a comparative genetic analysis of neovascular AMD and PCV, genotyping the ARMS2 A69S variant in 181 subjects with neovascular AMD, 198 subjects with PCV, and 203 controls in a Japanese population. Genotyping was conducted using TaqMan technology.
   Results were then integrated into a meta-analysis of previous studies representing an assessment of the association between the ARMS2 A69S variant and neovascular AMD and/or PCV, comprising a total of 3,828 subjects of Asian descent. The Q-statistic test was used to assess between-study heterogeneity. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a fixed effects model. Results: The genetic effect of the A69S variant was stronger in neovascular AMD (allelic summary OR=3.09 [95% CI, 2.71-3.51], fixed effects p<0.001) than in PCV (allelic summary OR=2.13 [95% CI, 1.91-2.38], fixed effects p<0.001). The pooled risk allele frequency was significantly higher in neovascular AMD (64.7%) than in PCV (55.6%). The population attributable risks for the variant allele were estimated to be 43.9% (95% CI, 39.0%-48.4%) and 29.7% (95% CI, 25.4%-34.0%) for neovascular AMD and PCV, respectively. No significant between-study heterogeneity was observed in any statistical analysis in this meta-analysis.
   Conclusions: Our meta-analysis provides substantial evidence that the ARMS2 A69S variant confers a significantly higher risk of neovascular AMD than PCV. Furthermore, there is compelling evidence that the risk attributable to the A69S variant differs between geographic atrophy and neovascular AMD. Together with defining the molecular basis of susceptibility, understanding the relationships between this genomic region and disease subtypes will yield important insights, elucidating the biologic architecture of this phenotypically heterogeneous disorder.
C1 [Yanagisawa, Suiho; Kondo, Naoshi; Miki, Akiko; Matsumiya, Wataru; Kusuhara, Sentaro; Tsukahara, Yasutomo; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Kondo, N (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM nskondo@gmail.com
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science, and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation
FX This study was supported by a Grant-in Aid for (C) 23592567 from the
   Ministry of Education, Science, and Culture, Tokyo, Japan, and by a
   grant from the Takeda Science Foundation. None of the authors have any
   financial or conflicting interests to disclose.
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Franke A, 2008, NAT GENET, V40, P1319, DOI 10.1038/ng.221
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardy J, 2003, SCIENCE, V300, P739, DOI 10.1126/science.300.5620.739
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakamoto H, 2008, NAT GENET, V40, P730, DOI 10.1038/ng.152
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Thomson W, 2007, NAT GENET, V39, P1431, DOI 10.1038/ng.2007.32
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tong Y, 2010, MOL VIS, V16, P1958
   WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XJ, 2009, NAT GENET, V41, P205, DOI 10.1038/ng.310
NR 58
TC 15
Z9 15
U1 0
U2 8
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 31
PY 2011
VL 17
IS 383-85
BP 3574
EP 3582
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 871LP
UT WOS:000298739900002
PM 22219653
DA 2022-11-30
ER

PT J
AU Yu, Y
   Huang, LZ
   Wang, B
   Zhang, CF
   Bai, YJ
   Li, XX
AF Yu, Yang
   Huang, Lvzhen
   Wang, Bin
   Zhang, Chunfang
   Bai, Yujing
   Li, Xiaoxin
TI COL8A1 rs13095226 polymorphism shows no association with neovascular
   age-related macular degeneration or polypoidal choroidal vasculopathy in
   Chinese subjects
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; COL8A1; genetics
ID JAPANESE POPULATION; VARIANTS; GENE
AB Purpose: Age-related macular degeneration (AMD) is the main cause of visual impairment and legal blindness in older individuals. COL8A1 rs13095226 variants have recently been implicated associated with neovascular age-related macular degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV) in American studies. The aim of this study was to investigate the association between the COL8A1 rs13095226 Polymorphism and neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in Chinese people. Methods: 900 Chinese subjects-300 cases with nAMD, 300 cases with PCV and 300 controls, were enrolled in a cross-sectional observational study. The diagnoses of nAMD and PCV were confirmed by Fundus photography, Fluorescence Fundus Angiography (FFA) and Indocyanine Green Angiography (ICGA). Genomic DNA was extracted from venous blood leukocytes and genotypes of rs13095226 were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Differences in allele distribution between cases and controls were tested by chi-square tests, with age and gender adjusted by logistic regression analysis. Result: The COL8A1 rs13095226 polymorphism was not statistically significantly different from the nAMD or PCV to the normal controls (P>0.05) in Chinese Population. The association remained insignificant after adjustmentfor age and gender differences (P>0.05). Conclusions: This case-control study indicated that the COL8A1 rs13095226 polymorphism is not associated with nAMD or PCV, which suggesting this gene maybe not a susceptibility gene locus for nAMD or PCV in Chinese subjects.
C1 [Yu, Yang; Huang, Lvzhen; Wang, Bin; Bai, Yujing; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Zhang, Chunfang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
   [Yu, Yang; Huang, Lvzhen; Wang, Bin; Bai, Yujing; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Yu, Yang; Huang, Lvzhen; Wang, Bin; Bai, Yujing; Li, Xiaoxin] Beijing Key Lab Diag & Treatment Retinal & Choroi, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM drlixiaoxin@163.com
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX This study was supported by the National Basic Research Program of China
   (973 Program; 2011CB510200), the National Natural Science Foundation of
   China (grant 81100666) and the Research Fund for Science and Technology
   Program of Beijing (Z121100005312006).
CR Bessho H, 2009, MOL VIS, V15, P1107
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boiko E V, 2013, Vestn Oftalmol, V129, P86
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   McCarthy JB, 1996, BIOPOLYMERS, V40, P371, DOI 10.1002/(SICI)1097-0282(1996)40:4<371::AID-BIP3>3.3.CO;2-2
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 26
TC 5
Z9 5
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 9
BP 11635
EP 11640
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DA4ZX
UT WOS:000367812800219
PM 26617902
DA 2022-11-30
ER

PT J
AU Schwartz, SG
   Brantley, MA
AF Schwartz, Stephen G.
   Brantley, Milam A., Jr.
TI Pharmacogenetics and Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COMPLEMENT FACTOR-H; GLUCOCORTICOID-RECEPTOR GENE; INTRAVITREAL
   TRIAMCINOLONE ACETONIDE; HTRA1 PROMOTER POLYMORPHISM; C-REACTIVE
   PROTEIN; PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; LOC387715
   GENOTYPES; PREDICTIVE ROLE; IN-VIVO
AB Pharmacogenetics seeks to explain interpatient variability in response to medications by investigating genotype-phenotype correlations. There is a small but growing body of data regarding the pharmacogenetics of both nonexudative and exudative age-related macular degeneration. Most reported data concern polymorphisms in the complement factor H and age-related maculopathy susceptibility 2 genes. At this time, the data are not consistent and no definite conclusions may be drawn. As clinical trials data continue to accumulate, these relationships may become more apparent.
C1 [Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Naples, FL 34102 USA.
   [Brantley, Milam A., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
C3 Bascom Palmer Eye Institute; Vanderbilt University
RP Schwartz, SG (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 311 9th St N 100, Naples, FL 34102 USA.
EM sschwartz2@med.miami.edu
FU American Geriatrics Society; Carl M. and Mildred A. Reeves Foundation;
   NIH Center [P30-EY014801, P30-EY08126]; Research to Prevent Blindness,
   New York, NY, USA
FX This work was partially supported by the Jahnigen Career Development
   Award from the American Geriatrics Society and the Carl M. and Mildred
   A. Reeves Foundation (MAB), NIH Center Grants P30-EY014801 and
   P30-EY08126, and unrestricted grants to the University of Miami and
   Vanderbilt University from Research to Prevent Blindness, New York, NY,
   USA. S. G. Schwartz is a consultant for Alimera Sciences and Bausch +
   Lomb, and is coholder of a patent licensed to IC Labs entitled
   "Molecular targets for modulating intraocular pressure and
   differentiation of steroid responders versus non-responders."
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Ahmadieh H., RETINA IN PRESS
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2009, OPHTHAL SURG LAS IM, V40, P561, DOI 10.3928/15428877-20091030-05
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Gerzenstein SM, 2008, OPHTHALMIC GENET, V29, P166, DOI 10.1080/13816810802320217
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   McKibbin M., BRIT J OPHA IN PRESS
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Qu Y, 2011, CURR EYE RES, V36, P60, DOI 10.3109/02713683.2010.524343
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sakurai M, 2007, OPHTHALMOLOGY, V114, P1039, DOI 10.1016/j.ophtha.2007.03.025
   Schwartz SG, 2005, OPHTHALMOLOGY, V112, P2131, DOI 10.1016/j.ophtha.2005.08.014
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2006, MOL VIS, V12, P796
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Souied EH, 2005, MOL VIS, V11, P1135
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   van Rossum EFC, 2002, DIABETES, V51, P3128, DOI 10.2337/diabetes.51.10.3128
   van Rossum EFC, 2003, CLIN ENDOCRINOL, V59, P585, DOI 10.1046/j.1365-2265.2003.01888.x
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 72
TC 12
Z9 12
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 252549
DI 10.1155/2011/252549
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100005
PM 22046503
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fan, Q
   Cheung, CMG
   Chen, LJ
   Yamashiro, K
   Ahn, J
   Laude, A
   Mathur, R
   Mun, CC
   Yeo, IY
   Lim, TH
   Teo, YY
   Khor, CC
   Park, KH
   Yoshimura, N
   Pang, CP
   Wong, TY
   Cheng, CY
AF Fan, Qiao
   Cheung, Chui Ming Gemmy
   Chen, Li Jia
   Yamashiro, Kenji
   Ahn, Jeeyun
   Laude, Augustinus
   Mathur, Ranjana
   Mun, Chan Choi
   Yeo, Ian Y.
   Lim, Tock Han
   Teo, Yik-Ying
   Khor, Chiea Chuen
   Park, Kyu-Hyung
   Yoshimura, Nagahisa
   Pang, Chi Pui
   Wong, Tien Yin
   Cheng, Ching-Yu
TI Shared genetic variants for polypoidal choroidal vasculopathy and
   typical neovascular age-related macular degeneration in East Asians
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT-FACTOR-H; HEREDITARY CONTRIBUTION; ASSOCIATION; RISK; CFH;
   POLYMORPHISM; METAANALYSIS; CHINESE; MACULOPATHY; ARMS2
AB Polypoidal choroidal vasculopathy (PCV), a subtype of age-related macular degeneration (AMD) more frequently seen in East Asians, has both common and distinct clinical manifestations with typical neovascular AMD (tAMD). We aim to examine the extent to which common genetic variants are shared between these two subtypes. We performed the meta-analysis of association in a total of 1062 PCV patients, 1157 tAMD patients and 5275 controls of East Asian descent from the Genetics of AMD in Asians Consortium at the 34 known AMD loci. A total of eight loci were significantly associated with PCV, including age-related maculopathy susceptibility 2 (ARMS2)-HtrA serine peptidase 1 (HTRA1), complement factor H (CFH), C2-CFB-SKIV2L, CETP, VEGFA, ADAMTS9-AS2 and TGFBR1 (P<5x10(-4)) from the single-nucleotide polymorphism-based test and COL4A3 from the gene-based tests (P-gene = 2.02 x 10(-4)). PCV and tAMD are genetically highly correlated (r(g) = 0.69, P = 4.68 x 10(-3)), with AMD known loci accounting for up to 36% variation. Weaker association for PCV was observed at ARMS2-HTRA1 (P-dif = 4.39 x 10(-4)) and KMT2E-SRPK2(P-dif = 4.43 x 10(-3)), compared with tAMD. Variants at CFH, CETP and VEGFA exhibited different association signals in East Asians, in contrast to those in European individuals. Our data suggest a substantially shared genetic susceptibility for PCV and tAMD, while also highlight the unique associations for PCV, which is useful in understanding the pathogenesis of PCV.
C1 [Fan, Qiao] Duke NUS Medial Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Mun, Chan Choi; Yeo, Ian Y.; Khor, Chiea Chuen; Wong, Tien Yin; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Wong, Tien Yin; Cheng, Ching-Yu] Duke NUS Med Sch, Ophthalmol & Visuals Sci Acad Clin Program Eye AC, Singapore, Singapore.
   [Chen, Li Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Ahn, Jeeyun; Park, Kyu-Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi, South Korea.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore.
   [Teo, Yik-Ying] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Teo, Yik-Ying] Natl Univ Hlth Syst, Singapore, Singapore.
   [Teo, Yik-Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore, Singapore.
   [Teo, Yik-Ying; Khor, Chiea Chuen] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore.
   [Wong, Tien Yin; Cheng, Ching-Yu] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Chinese University of Hong Kong; Kyoto
   University; Seoul National University (SNU); Tan Tock Seng Hospital;
   National University of Singapore; National University of Singapore;
   National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   National University of Singapore
RP Cheng, CY (通讯作者)，The Academia, Singapore Natl Eye Ctr, Singapore Eye Res Inst, 20 Coll Rd, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg
RI Chen, Li Jia/I-5078-2014; Cheng, Ching-Yu/Y-2229-2019; Wong, Tien
   Yin/AAC-9724-2020
OI Chen, Li Jia/0000-0003-3500-5840; Cheng, Ching-Yu/0000-0003-0655-885X;
   Wong, Tien Yin/0000-0002-8448-1264; Ahn, Jeeyun/0000-0001-9017-1652;
   Yamashiro, Kenji/0000-0001-9354-8558; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU National Medical Research Council (NMRC) [0796/2003, IRG07nov013,
   IRG09nov014, NMRC 1176/2008, NIG/1003/2009, STaR/0003/2008,
   CG/SERI/2010, CSA/033/2012]; Biomedical Research Council in Singapore
   [BMRC 08/1/35/19/550, 09/1/35/19/616, 10/1/35/19/671]; Chinese
   University of Hong Kong (Hong Kong) [4054119, 2015.1.045]; BrightFocus
   Foundation, USA [M2011068]; Seoul National University Bundang Hospital
   Research Grant Fund [03-2009-008]; National Research Foundation of Korea
   - Ministry of Education, Science and Technology, Korea
   [NRF-2009-0072603, NRF-2012R1A1A2008943, NRF-2014R1A2A1A09005824]; Japan
   Society for the Promotion of Science, Tokyo, Japan [24249082]
FX We gratefully thank all the participants or volunteers who participated
   in the studies. This study was supported by the National Medical
   Research Council (NMRC grants 0796/2003, IRG07nov013, IRG09nov014, NMRC
   1176/2008, NIG/1003/2009, STaR/0003/2008, CG/SERI/2010 and CSA/033/2012)
   and Biomedical Research Council (BMRC 08/1/35/19/550, 09/1/35/19/616 and
   10/1/35/19/671) in Singapore; Direct Grants of the Chinese University of
   Hong Kong (4054119, CPP and 2015.1.045, LJC, Hong Kong); BrightFocus
   Foundation (M2011068), USA; the Seoul National University Bundang
   Hospital Research Grant Fund (grant number 03-2009-008) and National
   Research Foundation of Korea (NRF-2009-0072603, NRF-2012R1A1A2008943 and
   NRF-2014R1A2A1A09005824) grants funded by the Ministry of Education,
   Science and Technology, Korea; and grants-in-aid for scientific research
   (number 24249082) from the Japan Society for the Promotion of Science,
   Tokyo, Japan.
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Mittlbock M, 1996, STAT MED, V15, P1987, DOI 10.1002/(SICI)1097-0258(19961015)15:19<1987::AID-SIM318>3.0.CO;2-9
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Rivas MA, 2015, SCIENCE, V348, P666, DOI 10.1126/science.1261877
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yanagisawa S, 2011, MOL VIS, V17, P3574
NR 35
TC 21
Z9 22
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD DEC
PY 2017
VL 62
IS 12
BP 1049
EP 1055
DI 10.1038/jhg.2017.83
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FN9KI
UT WOS:000416353600007
PM 28835638
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Yamada, R
   Gotoh, N
   Nakanishi, H
   Hayashi, H
   Akagi-Kurashige, Y
   Tsujikawa, A
   Otani, A
   Saito, M
   Iida, T
   Oishi, A
   Matsuo, K
   Tajima, K
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Yamada, Ryo
   Gotoh, Norimoto
   Nakanishi, Hideo
   Hayashi, Hisako
   Akagi-Kurashige, Yumiko
   Tsujikawa, Akitaka
   Otani, Atsushi
   Saito, Masaaki
   Iida, Tomohiro
   Oishi, Akio
   Matsuo, Keitaro
   Tajima, Kazuo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI Significance of C2/CFB Variants in Age-Related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy in a Japanese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; COMPONENT 2 C2; FACTOR-B BF; RETICULAR
   PSEUDODRUSEN; GENETIC-VARIANTS; SUSCEPTIBILITY; CFH; ASSOCIATION;
   SMOKING; POLYMORPHISMS
AB PURPOSE. To determine whether genetic variants in the complement component 2 and factor B gene (C2/CFB) locus are associated with the risk for typical age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) in a Japanese population.
   METHODS. Four single nucleotide polymorphisms (SNPs) were genotyped across the C2/CFB locus of patients with typical AMD (n = 455) or PCV (n = 581) and of 865 controls. Differences in the observed genotypic distribution between the case and control groups were tested by logistic regression analysis for age and sex adjustments. Significant associations were confirmed using a second control group of 336 cataract patients. A further model adjusting for age-related maculopathy susceptibility 2 (ARMS2) A69S, complement factor H (CFH) I62V, age, sex and smoking status was performed, to confirm their independent association from other covariates.
   RESULTS. C2 rs547154 and CFB rs541862 were significantly associated with typical AMD and PCV in this Japanese sample (P < 0.05). These two SNPs were also significantly associated with typical AMD and PCV in evaluation of the second control cohort (P < 0.05). Furthermore, an independent association of C2/CFB variants was found for both typical AMD and PCV with age, sex, smoking, and genetic background of ARMS2 A69S and CFH I62V (vs. typical AMD: P = 0.0073, odds ratio [OR] = 0.47; vs. PCV: P = 0.0083, OR = 0.53).
   CONCLUSIONS. C2/CFB variants play a protective role in the risk of developing neovascular AMD and PCV in the Japanese. (Invest Ophthalmol Vis Sci. 2012; 53: 794-798) DOI: 10.1167/iovs.11-8468
C1 [Nakata, Isao; Yamashiro, Kenji; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Akagi-Kurashige, Yumiko; Tsujikawa, Akitaka; Otani, Atsushi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto, Japan.
   [Nakata, Isao; Yamada, Ryo; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Akagi-Kurashige, Yumiko; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, INSERM, Ctr Genom Med,U852, Kyoto, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Oishi, Akio] Gen Hosp, Kobe City Med Ctr, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Matsuo, Keitaro; Tajima, Kazuo] Aichi Canc Ctr Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi, Japan.
C3 Kyoto University; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Kyoto University; Fukushima Medical University; Kobe
   City Medical Center General Hospital; Aichi Cancer Center
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 54 Kawahara, Sakyo, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Oishi, Akio/AAE-9996-2020; Matsuo,
   Keitaro/H-6758-2019
OI Saito, Masaaki/0000-0003-1494-6350; Oishi, Akio/0000-0002-0977-9458;
   Matsuo, Keitaro/0000-0003-1761-6314; Yamada, Ryo/0000-0002-1587-630X;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390442,
   22791706, 22791653]; Japanese National Society for the Prevention of
   Blindness
FX Supported in part by Grants-in-Aid for Scientific Research 19390442,
   22791706, and 22791653 from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and by the Japanese National Society for the
   Prevention of Blindness.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 41
TC 31
Z9 35
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2012
VL 53
IS 2
BP 794
EP 798
DI 10.1167/iovs.11-8468
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VA
UT WOS:000302788600034
PM 22232432
DA 2022-11-30
ER

PT J
AU Peng, Q
   Chen, YT
   Hua, R
AF Peng, Qing
   Chen, Yutong
   Hua, Rui
TI The Modification of Fluorescein Angiography and Its Applications in
   Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Red-free angiography; Fluorescein angiography
AB Aim: To establish a novel retinal angiography method, red-free angiography (RFA), to investigate retinal changes in age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Methods: Following the venous phase of fundus fluorescein angiography (FFA), the detection mode was switched to red-free reflectance to acquire RFA images using the same parameters. Results: RFA showed subretinal fluid, polyps, and outer retinal tubulation, with a higher definition than the FFA and red-free reflectance results. Conclusions: The absorption coefficients in RFA provided more detailed images for AMD and PCV diagnosis. RFA is therefore a promising approach to supplement FFA.
C1 [Peng, Qing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.
   [Chen, Yutong; Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Liaoning, Peoples R China.
C3 Tongji University; China Medical University
RP Hua, R (通讯作者)，155 Nanjingbei St, Shenyang 110000, Liaoning, Peoples R China.
EM woodshua@126.com
OI Peng, Qing/0000-0002-6991-9432
FU Natural Science Foundation of Liaoning Province [20170541041]; Fund for
   Scientific Research of The First Hospital of China Medical University
   [FSFH201712]; National Natural Science Foundation of China [81470029]
FX This study was supported by the Natural Science Foundation of Liaoning
   Province (No. 20170541041), the Fund for Scientific Research of The
   First Hospital of China Medical University (No. FSFH201712), and the
   National Natural Science Foundation of China (grant No. 81470029).
CR Hua R, 2015, RETINA-J RET VIT DIS, V35, P2158, DOI 10.1097/IAE.0000000000000573
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
NR 5
TC 0
Z9 1
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2019
VL 61
IS 1
BP 60
EP 64
DI 10.1159/000488906
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HI8AZ
UT WOS:000456679000009
PM 29879706
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Yamada, R
   Gotoh, N
   Nakanishi, H
   Hayashi, H
   Tsujikawa, A
   Otani, A
   Saito, M
   Iida, T
   Oishi, A
   Matsuo, K
   Tajima, K
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Yamada, Ryo
   Gotoh, Norimoto
   Nakanishi, Hideo
   Hayashi, Hisako
   Tsujikawa, Akitaka
   Otani, Atsushi
   Saito, Masaaki
   Iida, Tomohiro
   Oishi, Akio
   Matsuo, Keitaro
   Tajima, Kazuo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI Association between the SERPING1 Gene and Age-Related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy in Japanese
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYMORPHISM; RISK; VARIANTS; CFH; MACULOPATHY;
   INCREASES
AB Purpose: Recently, a complement component 1 inhibitor (SERPING1) gene polymorphism was identified as a novel risk factor for age-related macular degeneration (AMD) in Caucasians. We aimed to investigate whether variations in SERPING1 are associated with typical AMD or with polypoidal choroidal vasculopathy (PCV) in a Japanese population.
   Methods: We performed a case-control study in a group of Japanese patients with typical AMD (n = 401) or PCV (n = 510) and in 2 independent control groups-336 cataract patients without age-related maculopathy and 1,194 healthy Japanese individuals. Differences in the observed genotypic distribution between the case and control groups were tested using chi-square test for trend. Age and gender were adjusted using logistic regression analysis.
   Results: We targeted rs2511989 as the haplotype-tagging single nucleotide polymorphism (SNP) for the SERPING1 gene, which was reported to be associated with the risk of AMD in Caucasians. Although we compared the genotypic distributions of rs2511989 in typical AMD and PCV patients against 2 independent control groups (cataract patients and healthy Japanese individuals), SERPING1 rs2511989 was not significantly associated with typical AMD (P = 0.932 and 0.513, respectively) or PCV (P = 0.505 and 0.141, respectively). After correction for age and gender differences based on a logistic regression model, the difference in genotypic distributions remained insignificant (P>0.05). Our sample size had a statistical power of more than 90% to detect an association of a risk allele with an odds ratio reported in the original studies for rs2511989 for developing AMD.
   Conclusions: In the present study, we could not replicate the reported association between SERPING1 and either neovascular AMD or PCV in a Japanese population; thus, the results suggest that SERPING1 does not play a significant role in the risk of developing AMD or PCV in Japanese.
C1 [Nakata, Isao; Yamashiro, Kenji; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Tsujikawa, Akitaka; Otani, Atsushi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Nakata, Isao; Yamada, Ryo; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, INSERM,U852, Kyoto, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Oishi, Akio] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Matsuo, Keitaro; Tajima, Kazuo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
C3 Kyoto University; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Kyoto University; Fukushima Medical University; Kobe
   City Medical Center General Hospital; Aichi Cancer Center
RP Nakata, I (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Matsuo, Keitaro/H-6758-2019; Oishi,
   Akio/AAE-9996-2020; Matsuda, Fumihiko/B-9893-2009
OI Saito, Masaaki/0000-0003-1494-6350; Matsuo, Keitaro/0000-0003-1761-6314;
   Oishi, Akio/0000-0002-0977-9458; Yamashiro, Kenji/0000-0001-9354-8558;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamada, Ryo/0000-0002-1587-630X
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390442,
   22791706, 27091294]; Japanese National Society for the Prevention of
   Blindness
FX The study was supported in part by grants-in-aid for scientific research
   (Nos. 19390442, 22791706, and 27091294) from the Japan Society for the
   Promotion of Science, Tokyo, Japan, and by the Japanese National Society
   for the Prevention of Blindness. No additional external funding received
   for this study. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chandak GR, 2007, DIABETOLOGIA, V50, P63, DOI 10.1007/s00125-006-0502-2
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Helgason A, 2007, NAT GENET, V39, P218, DOI 10.1038/ng1960
   Horikoshi M, 2007, DIABETOLOGIA, V50, P747, DOI 10.1007/s00125-006-0588-6
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lu F, 2010, MOL VIS, V16, P1
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Park KH, 2009, MOL VIS, V15, P200
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 34
TC 21
Z9 21
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 19
PY 2011
VL 6
IS 4
AR e19108
DI 10.1371/journal.pone.0019108
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 752EC
UT WOS:000289671100051
PM 21526158
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, LJ
AF Chen, Li Jia
TI Genetic Association of Age-Related Macular Degeneration and Polypoidal
   Choroidal Vasculopathy
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; genetics; genome-wide association
   study; next-generation sequencing; polypoidal choroidal vasculopathy
ID GENOME-WIDE ASSOCIATION; CONFERS INCREASED RISK; FACTOR-H GENE;
   STARGARDT-DISEASE; SUSCEPTIBILITY LOCI; COMMON VARIANTS; CODING
   VARIANTS; CANDIDATE GENE; CFI GENE; RARE
AB Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of irreversible blindness among the elderly population in developed countries. Although being considered as different subtypes of a same disease, neovascular AMD and PCV have differences in clinical, epidemiological, therapeutic, and genetic profiles. Both AMD and PCV are complex diseases involving multiple genetic and environmental risk factors. Different genetic strategies have been adopted to discover associated genes and variants for neovascular AMD and PCV, including genome-wide association study (GWAS), next-generation sequencing (NGS) based sequence analysis, and candidate gene analyses. So far, a number of susceptible genes have been identified for AMD and/or PCV, such as CFH, ARMS2-HTRA1, C2-CFB-SKIV2L, C3, CETP, and FGD6. Although many of these genes are shared by AMD and PCV, some showed difference between them, such as ARMS2-HTRA1 and FGD6. Also, some of the genes showed ethnic diversities, such as the CFH p.Tyr402His variant. Further larger-scale genomic studies should be warranted to identify more susceptibility genes for AMD and, in particular, PCV among different populations, and differentiate the genetic architectures between neovascular AMD and PCV.
C1 [Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Eye Ctr, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, 147K Argyle St, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
FU General Research Fund, Hong Kong [14120516]; Direct Grant of Chinese
   University of Hong Kong Medical Panel, Hong Kong [4054281]
FX This study was supported in part by the General Research Fund, Hong Kong
   [14120516 (L.J.C.)], and a Direct Grant of Chinese University of Hong
   Kong Medical Panel, Hong Kong (4054281 [L.J.C.]).
CR Aldahmesh MA, 2012, HUM MUTAT, V33, P960, DOI 10.1002/humu.22071
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Audo I, 2012, AM J HUM GENET, V90, P321, DOI 10.1016/j.ajhg.2011.12.007
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Collin RWJ, 2013, P NATL ACAD SCI USA, V110, P9856, DOI 10.1073/pnas.1220864110
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Fares-Taie L, 2013, AM J HUM GENET, V92, P265, DOI 10.1016/j.ajhg.2012.12.003
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoiom V, 2013, GENE CHROMOSOME CANC, V52, P378, DOI 10.1002/gcc.22035
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kawashima-Kumagai K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07526-9
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Ma L, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107748
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Ma L, 2016, INVEST OPHTH VIS SCI, V57, P5758, DOI 10.1167/iovs.16-20175
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Micheal S, 2018, MOL NEUROBIOL, V55, P1387, DOI 10.1007/s12035-017-0403-z
   Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Riazuddin SA, 2012, AM J HUM GENET, V90, P533, DOI 10.1016/j.ajhg.2012.01.013
   Roosing S, 2013, AM J HUM GENET, V93, P110, DOI 10.1016/j.ajhg.2013.05.005
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sergouniotis PI, 2011, AM J HUM GENET, V89, P183, DOI 10.1016/j.ajhg.2011.06.002
   Shi Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002084
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Teo KYC, 2019, ASIA-PAC J OPHTHALMO, V8, P165, DOI 10.22608/APO.201909
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wen XF, 2018, J GENE MED, V20, DOI 10.1002/jgm.3007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu DG, 2019, CELL, V179, P736, DOI 10.1016/j.cell.2019.09.019
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zuchner S, 2011, AM J HUM GENET, V88, P201, DOI 10.1016/j.ajhg.2011.01.001
NR 84
TC 6
Z9 7
U1 2
U2 8
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2020
VL 9
IS 2
BP 104
EP 109
DI 10.1097/01.APO.0000656976.47696.7d
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ4VB
UT WOS:000530163700008
PM 32195675
OA gold
DA 2022-11-30
ER

PT J
AU Gomi, F
   Tano, Y
AF Gomi, Fumi
   Tano, Yasuo
TI Polypoidal choroidal vasculopathy and treatments
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; indocyanine green
   angiography; photodynamic therapy; polypoidal choroidal vasculopathy
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; INDOCYANINE GREEN; LASER
   PHOTOCOAGULATION; VERTEPORFIN; FEATURES
AB Purpose of review
   This review assesses the current knowledge of the clinical characteristics of polypoidal choroidal vasculopathy and treatments.
   Recent findings
   Polypoidal choroidal vasculopathy is a disease with characteristic choroidal vascular abnormalities. Indocyanine green angiography is essential for diagnosis. The prevalence is higher in Asian people than in Caucasians. Photodynamic therapy is efficacious for treating polypoidal choroidal vasculopathy; 1-year results have shown greater benefit of photodynamic therapy than choroidal neovascularization secondary to age-related macular degeneration. Recurrence, however, seriously affects vision long term during follow-up after photodynamic therapy. The lower efficacy of bevacizumab- a full-length antibody of vascular endothelial growth factor- has been shown for polypoidal choroidal vasculopathy.
   Summary
   Although the polypoidal choroidal vasculopathy and age-related macular degeneration have been known to share common genetic factors, its clinical characteristics including the different responses to photodynamic therapy suggest that polypoidal choroidal vasculopathy is a separate clinical entity from age-related macular degeneration. The results of photodynamic therapy for polypoidal choroidal vasculopathy are encouraging; however, recurrence may affect vision over time. Therapeutic modalities to inhibit development of the exudative choroidal vasculature of polypoidal choroidal vasculopathy are desirable.
C1 [Gomi, Fumi; Tano, Yasuo] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, Room E7,2-2 Yamadaoka Suita, Osaka, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   GOMI F, IN PRESS BR J OPHTHA
   GOMI F, IN PRESS OPHTHALMOLO
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   GORNEZULLA F, 1998, RETINA, V18, P481
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Prakash M, 2006, AM J OPHTHALMOL, V142, P1079, DOI 10.1016/j.ajo.2006.06.059
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 53
TC 100
Z9 111
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2008
VL 19
IS 3
BP 208
EP 212
DI 10.1097/ICU.0b013e3282fb7c33
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296MG
UT WOS:000255548100007
PM 18408495
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Adewoyin, T
   Bailey, TA
   Dandekar, SS
   Jenkins, S
   Webster, AR
   Chong, NV
AF Sivaprasad, Sobha
   Adewoyin, Temi
   Bailey, Tracey A.
   Dandekar, Sam S.
   Jenkins, Sharon
   Webster, Andrew R.
   Chong, Ngaihang Victor
TI Estimation of systemic complement C3 activity in age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION; DIETARY-FAT;
   MACULOPATHY; DRUSEN; EYE; INFLAMMATION; ASSOCIATION; PROGRESSION;
   PREVALENCE
AB Objectives: To determine the role of systemic complement activation in the pathogenesis of age-related macular degeneration and to examine whether serum C3a des Arg reflects systemic complement activation, independent of individual complement component levels.
   Methods: Plasma complement C3a des Arg levels and a single nucleotide polymorphism at position 402 of the complement factor H gene (CFH) were determined in 3 groups of subjects: 42 subjects with early age-related maculopathy, 42 subjects with neovascular (wet) agerelated macular degeneration, and a control group of 38 subjects with no clinical evidence of age-related changes at the macula.
   Results: The median (range) of plasma complement C3a des Arg levels in the age-related maculopathy and neovascular age-related macular degeneration groups were 52.6 (2.8-198.1) ng/mL and 60.9 (3.1-173.1) ng/mL, respectively. The levels were significantly raised compared with the control group (n = 38), which had a median (range) plasma complement C3a des Arg level of 40.3 (6.1-81.7) ng/mL (analysis of variance, P = .02). The concentration of plasma C3a des Arg did not differ significantly between those with different CFH genotypes (P =.07).
   Conclusion: Systemic activation of the complement system may contribute to the pathogenesis of age-related macular degeneration independent of CFH polymorphism.
   Clinical Relevance: The results of this study may be relevant to aiming new treatment strategies toward reducing systemic low-grade inflammation.
C1 Kings Coll Hosp, Laser & Retinal Res Unit, London SE5 9RS, England.
   Moorfields Eye Hosp, London, England.
   UCL, Inst Ophthalmol, London, England.
   Cranfield Univ, Cranfield BioMed Ctr, Silsoe, Beds, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Cranfield University
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015; Chong, Ngaihang V/A-5141-2009; Chong,
   Victor/Q-6565-2018
OI Sivaprasad, S./0000-0001-8952-0659; Chong, Victor/0000-0002-7693-522X
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laufer J, 2001, MOL IMMUNOL, V38, P221, DOI 10.1016/S0161-5890(01)00044-X
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Maslowska M, 2005, VITAM HORM, V70, P309, DOI 10.1016/S0083-6729(05)70010-8
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 23
TC 71
Z9 76
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2007
VL 125
IS 4
BP 515
EP 519
DI 10.1001/archopht.125.4.515
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 155AC
UT WOS:000245548900009
PM 17420372
OA Bronze
DA 2022-11-30
ER

PT J
AU Cho, M
   Barbazetto, IA
   Freund, KB
AF Cho, Minhee
   Barbazetto, Irene A.
   Freund, K. Bailey
TI Refractory Neovascular Age-related Macular Degeneration Secondary to
   Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   VERTEPORFIN; AVASTIN
AB PURPOSE: To describe a neovascular pattern associated with treatment-refractory neovascular age-related macular degeneration (AMD).
   DESIGN: A retrospective observational case series.
   METHODS: SETTING: Clinical practice. PATIENT POPULATION: Twelve eyes of 12 patients with neovascular AMD in which a poor anatomic response to anti-vascular endothelial growth factor (VEGF) therapy was related to polypoidal choroidal vasculopathy (PCV). OBSERVATION PROCEDURE: Slit-lamp biomicroscopy, optical coherence tomography, fluorescein and indocyanine green angiography. MAIN OUTCOME MEASURES: Snellen visual acuity (VA), anatomic response to therapy including presence or absence of retinal edema, hemorrhage, and lipid exudates.
   RESULTS: New or persistent PCV was identified in a cohort of patients demonstrating increasing macular exudation despite regular intravitreal ranibizumab (Lucentis; Genentech Inc, South San Francisco, California, USA) or bevacizumab (Avastin; Genentech Inc) injections for a minimum of 6 months. Treatment with verteporfin photodynamic therapy (PDT), PDT/anti VEGF combination therapy, or continued anti-VEGF monotherapy resulted in complete resolution of exudation in 9 of 12 patients and partial resolution of exudation in the remaining 3 patients.
   CONCLUSION: Treatment-refractory neovascular AMD may harbor vascular abnormalities such as PCV. Modifications in therapeutic protocols may be indicated in order to improve visual and anatomic outcomes in this population. (Am J Ophthalmol 2009; 148:70 -78. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Cho, Minhee] NYU, Sch Med, Manhattan Eye Ear & Throat Hosp, Dept Ophthalmol, New York, NY 10003 USA.
   [Barbazetto, Irene A.] Columbia Univ, Sch Med, Edward S Harkness Eye Inst, New York, NY 10027 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retina Res Ctr, New York, NY 10021 USA.
C3 Manhattan Eye Ear & Throat Hospital; New York University; Columbia
   University; Vitreous Retina Macula Consultants of New York; Manhattan
   Eye Ear & Throat Hospital
RP Freund, KB (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU MACULA FOUNDATION INC, NEW YORK, NEW YORK; Genentech Inc, South San
   Francisco, California
FX THIS STUDY WAS SUPPORTED BY THE MACULA FOUNDATION INC, NEW YORK, NEW
   YORK (DR FREUND). DR FREUND HAS A financial involvement with Genentech
   Inc, South San Francisco, California. Involved in design and conduct of
   study (M.C., I.B., K.B.F.); collection, management, analysis, and
   interpretation of data (M.C, I.B., K.B.F.); and preparation, review, or
   approval Of the manuscript (M.C., I.B, K.B.F.). Lenox Hill
   Hospital/Manhattan Eye, Ear So Throat Hospital Institutional Review
   Board (IRB) approved this Study. The Study adhered to HIPAA regulations.
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hlushchuk R, 2007, MICROCIRCULATION, V14, P813, DOI 10.1080/10739680701370021
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 124
Z9 130
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 70
EP 78
DI 10.1016/j.ajo.2009.02.012
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700012
PM 19403115
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Yoneyama, S
   Imasawa, M
   Iijima, H
AF Sakurada, Yoichi
   Yoneyama, Seigo
   Imasawa, Mitsuhiro
   Iijima, Hiroyuki
TI SYSTEMIC RISK FACTORS ASSOCIATED WITH POLYPOIDAL CHOROIDAL VASCULOPATHY
   AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE end-stage renal disease; diabetes mellitus; polypoidal choroidal
   vasculopathy; neovascular age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; CHRONIC-RENAL-FAILURE;
   CARDIOVASCULAR-DISEASE; DIABETIC-RETINOPATHY; OXIDATIVE STRESS;
   POPULATION; JAPANESE; POLYMORPHISMS; PREVALENCE; HISAYAMA
AB Purpose: To compare the association of systemic risk factors between neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
   Methods: Seven hundred and three patients (235 with nAMD and 468 with PCV) were included. Associated systemic conditions, including hypertension, cardiovascular disease, stroke, diabetes mellitus, and end-stage renal disease, were investigated through an interview and questionnaire.
   Results: The prevalence of diabetes mellitus and end-stage renal disease in nAMD was significantly higher than that in PCV (P < 0.001 and P = 0.021, respectively, multivariate logistic regression analysis). Moreover, in diabetic patients with nAMD or PCV, the more severe form of diabetic retinopathy was more prevalent in nAMD cases than in PCV cases (P = 0.006, multivariate logistic regression analysis).
   Conclusion: Diabetes mellitus and end-stage renal disease are more prevalent in patients with nAMD than in those with PCV. Specific systemic conditions might be associated with the development of nAMD. RETINA 33:841-845, 2013
C1 [Sakurada, Yoichi; Yoneyama, Seigo; Imasawa, Mitsuhiro; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU Ministry of Education, Science, Sports, and Culture, Japan [23791972,
   22591937]
FX This study was supported in part by Grant-in-Aid (No. 23791972 to Y.S.
   and No. 22591937 to H. I.) from the Ministry of Education, Science,
   Sports, and Culture, Japan.
CR Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Fujishima M, 1996, DIABETES, V45, pS14, DOI 10.2337/diab.45.3.S14
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Mahdy RA, 2011, OPHTHALMIC RES, V45, P87, DOI 10.1159/000317062
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   OHMURA T, 1993, DIABETOLOGIA, V36, P1198, DOI 10.1007/BF00401066
   Pawlak K, 2008, CYTOKINE, V43, P98, DOI 10.1016/j.cyto.2008.03.011
   Pawlak K, 2007, CLIN BIOCHEM, V40, P81, DOI 10.1016/j.clinbiochem.2006.09.001
   Sakurada Y, 2011, AM J OPHTHALMOL, V152, P499, DOI 10.1016/j.ajo.2011.04.022
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Vrabec R, 2005, COLLEGIUM ANTROPOL, V29, P95
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 31
TC 30
Z9 32
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 841
EP 845
DI 10.1097/IAE.0b013e31826ffe9d
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900023
PM 23400077
DA 2022-11-30
ER

PT J
AU Chen, YFN
   Devenyi, RG
   Brent, MH
   Kertes, PJ
   Eng, KT
   Schwartz, CE
   Kohly, RP
   Chow, DR
   Wong, DT
   Berger, AR
   Altomare, F
   Giavedoni, LR
   Muni, RH
   Soon, A
   Yoo, P
   Lam, WC
AF Chen, Yufeng N.
   Devenyi, Robert G.
   Brent, Michael H.
   Kertes, Peter J.
   Eng, Kenneth T.
   Schwartz, Carol E.
   Kohly, Radha P.
   Chow, David R.
   Wong, David T.
   Berger, Alan R.
   Altomare, Fil
   Giavedoni, Louis R.
   Muni, Rajeev H.
   Soon, Alexander
   Yoo, Patrick
   Lam, Wai-Ching
TI Age-related macular degeneration: is polypoidal choroidal vasculopathy
   recognized and treated?
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHINESE PATIENTS; RANIBIZUMAB;
   COMBINATION; POPULATION; EFFICACY; ANCHOR; EYE
AB Objective: To assess how polypoidal choroidal vasculopathy (PCV) is recognized and treated, and to assess whether treatment outcomes are different between Chinese and Caucasian Canadian patients with age-related macular degeneration (AMD).
   Design: Retrospective chart review.
   Participants: 154 eyes from 135 Chinese patients and 2291 eyes from 1792 Caucasian patients who were newly diagnosed with either AMD or PCV and had more than 1 year of follow-up were included.
   Methods: All newly diagnosed AMD patients presenting to the Retina Service of 3 Toronto University Hospitals, between March 25, 2008, to September 30, 2014, were reviewed.
   Results: 10/154 eyes (6.5%) in Chinese Canadians and 16/2291 eyes (0.7%) in Caucasian Canadians were diagnosed as having PCV. Indocyanine green angiography (ICGA) was used to diagnose PCV in 20% of Chinese Canadians and 8.8% of Caucasian Canadians. Clinical practices with a larger percentage of Chinese patients were more likely to diagnose PCV in both Chinese (p = 0.004) and Caucasian patients (p = 0.03), were more likely to use photodynamic therapy (PDT) (p < 0.01), and had significantly greater central retinal thickness decrease (p < 0.001).
   Conclusion: Our study has shown that PCV is under-recognized in a Canadian population, and ICGA is underutilized. In clinical practices with a greater portion of Chinese patients, PCV is more often recognized and PDT is used more liberally.
C1 [Chen, Yufeng N.] Univ Ottawa, Ottawa, ON, Canada.
   [Devenyi, Robert G.; Brent, Michael H.; Kertes, Peter J.; Eng, Kenneth T.; Schwartz, Carol E.; Kohly, Radha P.; Chow, David R.; Wong, David T.; Berger, Alan R.; Altomare, Fil; Giavedoni, Louis R.; Muni, Rajeev H.; Lam, Wai-Ching] Univ Toronto, Dept Ophthalmol, Toronto, ON, Canada.
   [Soon, Alexander] Univ Western Ontario, London, ON, Canada.
   [Yoo, Patrick] Univ Melbourne, Melbourne, Vic, Australia.
C3 University of Ottawa; University of Toronto; Western University
   (University of Western Ontario); University of Melbourne
RP Lam, WC (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, 340 Coll St,Suite 400, Toronto, ON M5T 3A9, Canada.
EM waiching.lam@utoronto.ca
OI Wong, David/0000-0003-1376-845X
FU Novartis; Bayer; Alcon; Allergan
FX Dr. Lam-consultant to Novartis and Bayer; research grants from Novartis
   and Bayer, advisory board of Novartis and Bayer. Dr. Muni-consulting
   honoraria from Novartis and Bayer. Dr. Wong-consultant to Alcon, Bausch
   & Lomb, Bayer, and Novartis; research grants from Alcon and Bayer. Dr.
   Berger-consultant to Bayer and Novartis; honoraria from Allergan, Bayer,
   and Novartis; research funds and grants from Novartis, Alcon, and Bayer;
   equity in Arctic Dx. Dr. Brent-research support from Novartis, Allergan,
   and Bayer; advisory board of Novartis, Bayer, and Alcon.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lee GKY, 2009, HONG KONG J OPHTHALM, V13, P5
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Shah BR, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-42
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 23
TC 4
Z9 5
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2017
VL 52
IS 5
BP 475
EP 479
DI 10.1016/j.jcjo.2017.02.014
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP3PX
UT WOS:000417531200028
PM 28985807
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Kano, M
AF Saito, Masaaki
   Iida, Tomohiro
   Kano, Mariko
TI INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
   WITH GOOD BASELINE VISUAL ACUITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ranibizumab; vascular endothelial growth factor; age-related macular
   degeneration; polypoidal choroidal vasculopathy; good baseline visual
   acuity; photodynamic therapy; retinal pigment epithelial detachment;
   optical coherence tomography; retinal pigment epithelium; indocyanine
   green angiography
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED
   CLINICAL-TRIAL; PHOTODYNAMIC THERAPY; VERTEPORFIN; NEOVASCULARIZATION;
   MACULOPATHY; MEMBRANES
AB Purpose: To clarify the efficacy of ranibizumab for treating age-related macular degeneration in patients with baseline visual acuity exceeding 20/40.
   Methods: We retrospectively reviewed 40 eyes of Japanese patients with age-related macular degeneration (32 men, 8 women) treated with intravitreal injections of ranibizumab (0.5 mg/0.05 mL) (ranibizumab group). We compared the results with observation of 52 eyes (control group). All patients were followed-up for at least 12 months.
   Results: In the ranibizumab group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity (Snellen equivalent) with typical age-related macular degeneration (22 eyes) and polypoidal choroidal vasculopathy (18 eyes) statistically significantly (P < 0.0001, P = 0.015, respectively) improved from 0.17 (20/29) and 0.14 (20/28) at baseline to 0.07 (20/24) and 0.07 (20/24) at Month 12, respectively (mean numbers of treatments, 4.6 and 4.9). The central retinal thickness decreased from 262 +/- 105 mu m at baseline to 187 +/- 62 mu m at Month 12 in the ranibizumab group. In the control group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity in eyes with typical age-related macular degeneration (19 eyes) and polypoidal choroidal vasculopathy (33 eyes) statistically significant (P = 0.017, P = 0.023, respectively) declined from 0.08 (20/24) and 0.10 (20/25) at baseline to 0.18 (20/30) and 0.23 (20/34) at Month 12, respectively.
   Conclusion: Intravitreal ranibizumab maintained or improved visual acuity and anatomic changes in patients with age-related macular degeneration with better than 20/40 visual acuity. RETINA 32:1250-1259, 2012
C1 [Saito, Masaaki; Iida, Tomohiro; Kano, Mariko] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Sch Med, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 19
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1250
EP 1259
DI 10.1097/IAE.0b013e318236e503
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100004
PM 22446886
DA 2022-11-30
ER

PT J
AU Gale, CR
   Hall, NF
   Phillips, DIW
   Martyn, CN
AF Gale, CR
   Hall, NF
   Phillips, DIW
   Martyn, CN
TI Lutein and zeaxanthin status and risk of age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; PIGMENT DENSITY; HUMAN RETINA; MACULOPATHY; ASSOCIATION;
   CAROTENOIDS; ANTIOXIDANT; POPULATION; MEMBRANES; SYSTEM
AB Purpose. To investigate the relation between plasma concentrations of lutein and zeaxanthin and age-related macular degeneration in a group of elderly men and women.
   Methods. The Wisconsin Age-Related Maculopathy Grading System was used to grade features of early and late macular degeneration in 380 men and women, aged 66 to 75 years, from Sheffield, United Kingdom. Fasting blood samples were taken to assess plasma concentrations of lutein and zeaxanthin.
   Results. Risk of age-related macular degeneration (early or late) was significantly higher in people with lower plasma concentrations of zeaxanthin. Compared with those whose plasma concentrations of zeaxanthin were in the highest third of the distribution, people whose plasma concentration was in the lowest third had an odds ratio for risk of age-related macular degeneration of 2.0 (95% confidence interval [CI] 1.0-4.1), after adjustment for age and other risk factors. Risk of age-related macular degeneration was increased in people with the lowest plasma concentrations of lutein plus zeaxanthin (odds ratio [OR] 1.9, 95% CI 0.9-3.5) and in those with the lowest concentrations of lutein (OR 1.7, 95% CI 0.9 -3-3), but neither of these relations was statistically significant.
   Conclusions. These findings provide support for the view that zeaxanthin may protect against age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2003;44:2461-2465) DOI: 10.1167/iovs.02-0929.
C1 Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton
RP Gale, CR (通讯作者)，Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.
RI Gale, Catharine R/B-1653-2012
OI Gale, Catharine/0000-0002-3361-8638
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone R, 1988, INVEST OPHTH VIS SCI, V29, P850
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Hall NF, 2002, INVEST OPHTH VIS SCI, V43, P3641
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HART DJ, 1995, FOOD CHEM, V54, P101, DOI 10.1016/0308-8146(95)92669-B
   KARBASSI M, 1993, OPTOMETRY VISION SCI, V70, P923, DOI 10.1097/00006324-199311000-00009
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
NR 25
TC 187
Z9 200
U1 0
U2 20
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2003
VL 44
IS 6
BP 2461
EP 2465
DI 10.1167/iovs.02-0929
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 682FU
UT WOS:000183081700014
PM 12766044
DA 2022-11-30
ER

PT J
AU Hwang, JU
   Yang, SJ
   Yoon, YH
   Lee, JY
   Kim, JG
AF Hwang, Jong-Uk
   Yang, Sung Jae
   Yoon, Young Hee
   Lee, Joo Yong
   Kim, June-Gone
TI RECURRENT SUBMACULAR HEMORRHAGE IN PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF agent; polypoidal choroidal
   vasculopathy; submacular hemorrhage; subretinal hemorrhage
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; TISSUE-PLASMINOGEN ACTIVATOR;
   PHOTODYNAMIC THERAPY; MANAGEMENT; INJECTION; DISPLACEMENT; OUTCOMES
AB Purpose: To describe the incidence, risk factors for, and long-term visual outcomes of recurrent submacular hemorrhage in the context of age-related macular degeneration.
   Methods: Medical records of patients with neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy showing submacular hemorrhage at their first visit to our institution were reviewed. The required minimum follow-up period was 24 months, and any newly developed submacular hemorrhage larger than 1 disk area after near-complete resolution of initial hemorrhage was defined as recurrence.
   Results: A total of 47 eyes of 47 patients were eligible for inclusion. Twenty-four patients showed recurrent submacular hemorrhage during the follow-up period (Group I). Patients without recurrent submacular hemorrhage were included in Group II. The time to recurrent submacular hemorrhage in Group I patients was 21.4 +/- 9.2 months. Polypoidal choroidal vasculopathy was present in 50% of Group I patients (n = 12) and 13% of Group II patients (n = 3) (P = 0.025). Intravitreal anti-vascular endothelial growth factor injection was performed during the follow-up period in 70.8% of Group I patients (n = 17) and 95.7% of Group II patients (n = 22) (P = 0.048). Visual acuity change during the follow-up period did not significantly differ between the two groups.
   Conclusion: In patients with neovascular age-related macular degeneration presenting with submacular hemorrhage at their first visit, the incidence of recurrent submacular hemorrhage was 51.1% in our retrospective long-term follow-up study. The presence of polypoidal choroidal vasculopathy was associated with an increased risk of recurrent submacular hemorrhage. Use of anti-vascular endothelial growth factor agents was correlated with a reduced risk of such hemorrhage. Visual acuity was stably maintained over 2 years regardless of hemorrhage recurrence. RETINA 32: 652-657, 2012
C1 [Hwang, Jong-Uk; Yoon, Young Hee; Lee, Joo Yong; Kim, June-Gone] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Coll Med, Seoul 138736, South Korea.
   [Yang, Sung Jae] Univ Ulsan, Dept Ophthalmol, Gangneung Asan Hosp, Coll Med, Gangneung City, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan
RP Kim, JG (通讯作者)，Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Coll Med, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM junekim@amc.seoul.kr
OI LEE, JOO YONG/0000-0002-2187-196X
CR Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Avery RL, 1996, RETINA, V16, P186
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Conti SM, 2005, CAN J OPHTHALMOL, V40, P341, DOI 10.1016/S0008-4182(05)80077-8
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wolf A, 2008, BRIT J OPHTHALMOL, V92, P1298, DOI 10.1136/bjo.2008.138396
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 26
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2012
VL 32
IS 4
BP 652
EP 657
DI 10.1097/IAE.0b013e318233abb4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 918ET
UT WOS:000302232800002
PM 22366903
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
TI Development of subretinal hemorrhage after treatment discontinuation for
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidal vasculopathy; Type 3 macular neovascularization;
   Subretinal hemorrhage
ID DISEASE BURDEN; RISK-FACTORS; OUTCOMES
AB Purpose To investigate the incidence, risk factors, and their influence on visual outcomes of subretinal hemorrhage (SRH) in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy(PCV) who discontinue treatment.
   Methods This retrospective study included 148 patients with nAMD and PCV who discontinued treatment. The development of a 3-disc area or greater extent of SRH after treatment discontinuation was identified. Visual acuity at the final visit was compared between patients with and those without SRH. Factors associated with SRH were then analyzed.
   Results During the mean 56.8 +/- 18.2 months of follow-up, treatment was discontinued at a mean 24.1 +/- 16.3 months after diagnosis. SRH developed in 24 (16.2%) patients at a mean 21.5 +/- 17.6 months after treatment discontinuation. The visual acuity at the final follow-up was significantly worse in patients with SRH than in those without SRH (P < 0.001). There was a significant difference in the incidence of SRH among the different types of macular neovascularization (MNV) (P = 0.024). In particular, the incidence of type 3 MNV was relatively high (36.0%).
   Conclusions The development of SRH may lead to very poor visual prognosis in patients who discontinue treatment. The high risk of SRH in type 3 MNV suggests the need for caution when choosing treatment discontinuation in cases of type 3 MNV.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital (Seoul, South Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided funding for English
   editing support.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chaudhary V, 2022, RETINA-J RET VIT DIS, V42, P589, DOI 10.1097/IAE.0000000000003283
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Doguizi S, 2018, EUR J OPHTHALMOL, V28, P63, DOI 10.5301/ejo.5001001
   Elshout M, 2016, OPHTHALMOLOGY, V123, P2408, DOI 10.1016/j.ophtha.2016.07.015
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Gaffney AJ, 2014, OPHTHAL PHYSL OPT, V34, P427, DOI 10.1111/opo.12132
   Gong D, 2019, OPHTHALMOLOGY, V126, P1358, DOI 10.1016/j.ophtha.2019.04.018
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72030-6
   Kim JH, 2020, SEMIN OPHTHALMOL, V35, P33, DOI 10.1080/08820538.2019.1701045
   Kim JH, 2019, RETINA-J RET VIT DIS, V39, P1672, DOI 10.1097/IAE.0000000000002239
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2016, RETINA-J RET VIT DIS, V36, P1506, DOI 10.1097/IAE.0000000000000932
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Petersen J, 1998, GRAEF ARCH CLIN EXP, V236, P241, DOI 10.1007/s004170050071
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Westborg I, 2018, OPHTHAL EPIDEMIOL, V25, P176, DOI 10.1080/09286586.2017.1397701
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2022
VL 260
IS 10
BP 3231
EP 3239
DI 10.1007/s00417-022-05702-w
EA MAY 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4O6EP
UT WOS:000802157900001
PM 35612614
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Dimitrov, PN
   Varsamidis, M
   Lim, LL
   Baird, PN
   Vingrys, AJ
   Robman, L
AF Guymer, Robyn H.
   Dimitrov, Peter N.
   Varsamidis, Mary
   Lim, Lyndell L.
   Baird, Paul N.
   Vingrys, Algis J.
   Robman, Luba
TI Can HMG Co-A reductase inhibitors ("statins") slow the progression of
   age-related macular degeneration? The Age-Related Maculopathy Statin
   Study (ARMSS)
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; progression; randomized controlled
   trial; HMG Co-A reductase inhibitor; statin; visual function
ID VISUAL IMPAIRMENT PROJECT; FACTOR-H POLYMORPHISM; BLUE MOUNTAINS EYE;
   DARK-ADAPTATION; BRUCHS MEMBRANE; CARDIOVASCULAR HEALTH;
   ENDOTHELIAL-CELLS; RISK-FACTORS; VISION IMPAIRMENT; 5-YEAR INCIDENCE
AB Age-related macular degeneration (AMD) is responsible for the majority of visual impairment in the Western world. The role of cholesterol-lowering medications, HMG Co-A reductase inhibitors or statins, in reducing the risk of AMD or of delaying its progression has not been fully investigated. A 3-year prospective randomized controlled trial of 40 mg simvastatin per day compared to placebo in subjects at high risk of AMD progression is described. This paper outlines the primary aims of the Age-Related Maculopathy Statin Study (ARMSS), and the methodology involved. Standardized clinical grading of macular photographs and comparison of serial macular digital photographs, using the International grading scheme, form the basis for assessment of primary study outcomes. In addition, macular function is assessed at each visit with detailed psychophysical measurements of rod and cone function. Information collected in this study will assist in the assessment of the potential value of HMG Co-A reductase inhibitors (statins) in reducing the risk of AMD progression.
C1 [Guymer, Robyn H.; Dimitrov, Peter N.; Varsamidis, Mary; Lim, Lyndell L.; Baird, Paul N.; Robman, Luba] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Visual Sci, Melbourne, Vic, Australia.
   [Guymer, Robyn H.; Lim, Lyndell L.; Robman, Luba] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne; Royal Victorian Eye & Ear Hospital
RP Robman, L (通讯作者)，Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM liubov@unimelb.edu.au
OI Vingrys, Algis/0000-0001-5920-4604; Lim, Lyndell/0000-0003-2491-685X;
   Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
FU Ian Potter Foundation; John Reid Charitable Trust; Royal Victorian Eye
   and Ear Hospital; NHMRC [350224]
FX The ARMSS project is a recipient of funds from The Ian Potter
   Foundation, John Reid Charitable Trust, and Royal Victorian Eye and Ear
   Hospital and NHMRC grant 350224 (RHG/AJV). RHG is supported by an NHMRC
   career development fellowship. Merck, Sharp and Dohme (Sydney,
   Australia) supplied the active simvastatin and placebo medication for
   the trial.
CR Alcocer Luis, 2003, Am J Ther, V10, P423, DOI 10.1097/00045391-200311000-00008
   Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baker Steven K, 2005, Timely Top Med Cardiovasc Dis, V9, pE26
   Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Sotomayor MA, 2001, BIOCHEM BIOPH RES CO, V280, P486
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Demirel S, 1994, J Glaucoma, V3, P28
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 2005, IOVS, V46, P199
   GUNKEL RD, 1963, ARCH OPHTHALMOL-CHIC, V69, P4
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HANLEY JM, 1983, J BIOL CHEM, V258, P7858
   Hassell JB, 2000, CLIN EXP OPHTHALMOL, V28, P156, DOI 10.1046/j.1442-9071.2000.00312.x
   Hess D C, 2001, Expert Opin Pharmacother, V2, P153, DOI 10.1517/14656566.2.1.153
   HUNNINGHAKE DB, 1990, ATHEROSCLEROSIS, V85, P81, DOI 10.1016/0021-9150(90)90185-L
   Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9
   Jialal I, 2001, CIRCULATION, V103, P1933
   Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keeffe JE, 1999, AUST NZ J OPHTHALMOL, V27, P184, DOI 10.1046/j.1440-1606.1999.00179.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Kuvin JT, 2003, CURR OPIN CARDIOL, V18, P295, DOI 10.1097/00001573-200307000-00009
   Kwak B, 2001, SWISS MED WKLY, V131, P41
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709
   Ludvigh E, 1938, ARCH OPHTHALMOL-CHIC, V20, P37
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MJA, V175, P17
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   [NHFA] National Heart Foundation of Australia Cardiac Society of Australia and New Zealand, 2001, MED J AUST S, V175, pS57
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   SAID FS, 1959, GERONTOLOGY, V3, P213, DOI 10.1159/000210900
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Taylor H, 1988, LENS RES, V5, P175
   Taylor HR, 2002, CLIN EXP OPHTHALMOL, V30, P151, DOI 10.1046/j.1442-9071.2002.00525.x
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Watts GF, 2001, CURR CONTR TRIALS C, V2, P118, DOI 10.1186/CVM-2-3-118
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zele AJ, 2005, J NEUROSCI METH, V141, P1, DOI 10.1016/j.jneumeth.2004.05.005
NR 81
TC 18
Z9 18
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2008
VL 3
IS 3
BP 581
EP 593
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WX
UT WOS:000208238800019
PM 18982929
DA 2022-11-30
ER

PT J
AU Huang, LZ
   Li, YJ
   Guo, SC
   Sun, YY
   Zhang, CF
   Bai, YJ
   Li, SS
   Yang, F
   Zhao, M
   Wang, B
   Yu, WZ
   Zhao, MW
   Khor, CC
   Li, XX
AF Huang, Lvzhen
   Li, Yingjie
   Guo, Shicheng
   Sun, Yaoyao
   Zhang, Chunfang
   Bai, Yujing
   Li, Shanshan
   Yang, Fei
   Zhao, Min
   Wang, Bin
   Yu, Wenzhen
   Zhao, Mingwei
   Khor, Chiea Chuen
   Li, Xiaoxin
TI Different Hereditary Contribution of the CFH Gene Between Polypoidal
   Choroidal Vasculopathy and Age-Related Macular Degeneration in Chinese
   Han People
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; complement factor H; single-nucleotide polymorphism
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY; MACULOPATHY; VARIANTS
AB PURPOSE. To investigate whether 11 variants in complement factor H gene contributed differently in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) of Chinese descent.
   METHODS. We performed a case-control study in a group of Chinese patients with nAMD (n = 344) or PCV (n = 368) and contrasted the results against an independent control group comprising 511 mild cataract patients without any evidence of age-related maculopathy. Association analysis of allele and genotype frequencies was performed for 11 haplotypetagging single-nucleotide polymorphisms (SNPs) at the CFH locus (rs1061170, rs1329428, rs1410996, rs2284664, rs375396, rs529825, rs551397, rs7540032, rs800292, rs2274700, and rs1065489). Multinomial logistic regression analyses were performed to estimate and compare the effect of these 11 CFH polymorphisms on AMD and PCV, using the wild-type genotype as reference. Differences in the observed genotypic distributions between cases and controls were tested by using chi(2) tests, with age and sex adjusted for using logistic regression.
   RESULTS. CFH rs1065489 was not significantly associated with the nAMD phenotype in Chinese collections either on univariate or multivariate analysis (P > 0.05 for all comparisons). The other 10 SNPs of CFH were significantly associated with the nAMD phenotype. As for PCV, all 11 SNP markers were significantly associated with risk of PCV before or after correction for age and sex differences. Eight of the 11 SNP markers showed significant evidence of heterogeneity between AMD and PCV (P < 0.05 for all comparisons).
   CONCLUSIONS. Our data suggest that the genetic architecture at the CFH locus is complex with some markers showing significant skewing of the genotypes toward nAMD or PCV in Asians. This further supports the clinical observation that nAMD and PCV could have distinct pathogenesis mechanisms, which will require larger studies to accurately dissect.
C1 [Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Li, Shanshan; Yang, Fei; Zhao, Min; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Li, Shanshan; Yang, Fei; Zhao, Min; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Li, Shanshan; Yang, Fei; Zhao, Min; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Li, Yingjie] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, Dept Abdominal Surg Oncol, Beijing 100730, Peoples R China.
   [Guo, Shicheng] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Guo, Shicheng] Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.
   [Guo, Shicheng] Univ Texas Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX USA.
   [Zhang, Chunfang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
   [Khor, Chiea Chuen] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute & Hospital - CAMS; Peking Union
   Medical College; Fudan University; Fudan University; University of Texas
   System; University of Texas Health Science Center Houston; University of
   Texas School Public Health; Peking University; National University of
   Singapore; Singapore National Eye Center
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM zhaomingwei@medmail.com.cn; khorcc@gis.a-star.edu.sg;
   drlixiaoxin@163.com
RI Guo, Shicheng/A-1204-2016
OI Guo, Shicheng/0000-0002-7047-9972; Zhao, Min/0000-0003-0521-9186; Khor,
   Chiea Chuen/0000-0002-1128-4729
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China (NSFC) [81100666,
   81170854]; Research Fund for Science and Technology Program of Beijing
   [Z121100005312006]
FX Supported by the National Basic Research Program of China (973 Program,
   No. 2011CB510200), the National Natural Science Foundation of China
   (NSFC, No. 81100666 and No. 81170854), and the Research Fund for Science
   and Technology Program of Beijing (No. Z121100005312006).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Sayen Alexandra, 2011, Rev Prat, V61, P159
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
NR 15
TC 19
Z9 19
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2014
VL 55
IS 4
BP 2534
EP 2538
DI 10.1167/iovs.13-13437
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH1WS
UT WOS:000335913100071
PM 24692129
DA 2022-11-30
ER

PT J
AU Lorentzen, TD
   Subhi, Y
   Sorensen, TL
AF Lorentzen, Thomas Dam
   Subhi, Yousif
   Sorensen, Torben Lykke
TI Presenting characteristics and prevalence of polypoidal choroidal
   vasculopathy in Scandinavian patients with treatment-naive exudative
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Caucasians; clinical presentation; polypoidal choroidal vasculopathy;
   Scandinavians
ID 2 ANGIOGRAPHIC SUBTYPES; FACTOR-H CFH; PHOTODYNAMIC THERAPY;
   INTRAVITREAL RANIBIZUMAB; OUTCOMES; CLASSIFICATION; VERTEPORFIN;
   EFFICACY; ARMS2
AB PurposeTo study presenting characteristics and prevalence of polypoidal choroidal vasculopathy (PCV) in Scandinavian Caucasians with treatment-naive exudative age-related macular degeneration (AMD).
   MethodsWe reviewed all patients referred in year 2014 and diagnosed using fundus examination, optical coherence tomography, and fluorescein and indocyanine green angiography (ICGA). Details of found PCVs and its subtypes (clinical and angiographical) were correlated to the baseline best-corrected visual acuity (BCVA).
   ResultsOf 299 Caucasian patients with a tentative diagnosis of exudative AMD, 18 eyes of 17 patients (5.7%, CI 95%: 3.5-9.1%) had PCV. Patients with PCV were 75.8 (SD: 7.5) years old and 11 (65%) were females. Lesions were predominantly extramacular. Most eyes (56%) had subretinal haemorrhage, 39% had the exudative type and one (6%) eye had the quiescent type. Larger lesion area and disruption of the foveal inner-segment/outer-segment layer correlated with worse baseline BCVA. Polypoidal choroidal vasculopathy (PCV) type 1 was present in 50% and PCV type 2 in the other 50%. Polypoidal choroidal vasculopathy (PCV) type 1 was associated with a worse baseline BCVA and greater lesion size.
   ConclusionPolypoidal choroidal vasculopathy (PCV) is not a rare condition in Danes with exudative AMD and presents often extramacular and with haemorrhage. This study underscores the importance of ICGA as a part of the diagnostic repertoire in AMD and suggests its routine use in Scandinavian populations.
C1 [Lorentzen, Thomas Dam; Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Lorentzen, Thomas Dam; Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
CR [Anonymous], 2017, POPULATION PROJECTIO
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tan CS, 2017, ACTA OPHTHALMOL, V1346, P7, DOI [10. 1111/aos, DOI 10.1111/AOS]
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yannuzzi L., 1982, MAC SOC M MIAM FL FE
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung L, 2017, RETINA
NR 33
TC 12
Z9 12
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2018
VL 96
IS 5
BP 475
EP 480
DI 10.1111/aos.13646
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GS6JY
UT WOS:000443801700006
PM 29193780
DA 2022-11-30
ER

PT J
AU Laude, A
   Cackett, PD
   Vithana, EN
   Yeo, IY
   Wong, D
   Koh, AH
   Wong, TY
   Aung, T
AF Laude, Augustinus
   Cackett, Peter D.
   Vithana, Eranga N.
   Yeo, Ian Y.
   Wong, Doric
   Koh, Adrian H.
   Wong, Tien Y.
   Aung, Tin
TI Polypoidal choroidal vasculopathy and neovascular age-related macular
   degeneration: Same or different disease?
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Neovascular age-related macular
   degeneration; Choroidal neovascularization; Indocyanine green
   angiography; Optical coherence tomography; Vascular endothelial growth
   factor; Complement factor H; Smoking
ID COMPLEMENT FACTOR-H; INDOCYANINE GREEN VIDEOANGIOGRAPHY; ENDOTHELIAL
   GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC THERAPY; LASER
   PHOTOCOAGULATION; RISK-FACTORS; RETINAL NEOVASCULARIZATION;
   CARDIOVASCULAR-DISEASE; PATHOLOGICAL FEATURES
AB Neovascular age-related macular degeneration (nAMD) is the commonest cause of severe visual impairment in older adults in Caucasian white populations. Polypoidal choroidal vasculopathy (PCV) has been described as a separate clinical entity differing from nAMD and other macular diseases associated with subretinal neovascularization. It remains controversial as to whether or not PCV represents a subtype of nAMD. This article summarizes the current literature on the clinical, pathophysiological and epidemiological features and treatment responses of PCV and compares this condition to nAMD. Patients with PCV are younger and more likely Asians, and eyes with PCV lack drusen, often present with serosanguinous maculopathy or hemorrhagic pigment epithelial detachment, and have differing responses to photodynamic therapy and anti-vascular endothelial growth factor (VEGF) agents. There are also significant differences in angiographic and optical coherence tomography features between PCV and nAMD. Histopathological studies suggest differences in the anatomical details of the associated vascular abnormalities in the retina and choroids and the relative role of VEGF. There is emerging evidence of common molecular genetic determinants involving complement pathway and common environmental risk factors (e.g. smoking). Such information could further assist clinicians involved in the care of elderly patients with these conditions. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Cackett, Peter D.; Yeo, Ian Y.; Wong, Doric; Koh, Adrian H.; Wong, Tien Y.; Aung, Tin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp, Inst Eye, Singapore, Singapore.
   [Cackett, Peter D.; Vithana, Eranga N.; Yeo, Ian Y.; Wong, Doric; Wong, Tien Y.; Aung, Tin] Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Wong, Tien Y.; Aung, Tin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore.
C3 Singapore National Eye Center; Tan Tock Seng Hospital; National
   University of Singapore; Singapore National Eye Center; Centre for Eye
   Research Australia; University of Melbourne; National University of
   Singapore
RP Aung, T (通讯作者)，Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM tin11@pacific.net.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Wong, Damon/0000-0003-4601-9121
FU Singhealth [SHF/FG381P/2007]; Tan Tock Seng Scholarship
FX This paper was supported by Singhealth Grant SHF/FG381P/2007 and Tan
   Tock Seng Scholarship.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akagawa H, 2006, HUM MOL GENET, V15, P1722, DOI 10.1093/hmg/ddl096
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   CACKETT P, 2009, EYE
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   LEE WR, 1987, EYE, V1, P296, DOI 10.1038/eye.1987.48
   LEISHMAN R, 1957, Br J Ophthalmol, V41, P641, DOI 10.1136/bjo.41.11.641
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MANSCHOT WA, 1984, GRAEF ARCH CLIN EXP, V222, P63, DOI 10.1007/BF02150633
   MANSCHOT WA, 1985, T OPHTHAL SOC UK, V104, P880
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Onda H, 2001, AM J HUM GENET, V69, P804, DOI 10.1086/323614
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ruigrok YM, 2008, STROKE, V39, P1049, DOI 10.1161/STROKEAHA.107.497305
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vilaplana D, 2005, Arch Soc Esp Oftalmol, V80, P597
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 125
TC 268
Z9 285
U1 0
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2010
VL 29
IS 1
BP 19
EP 29
DI 10.1016/j.preteyeres.2009.10.001
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 561EU
UT WOS:000274959500002
PM 19854291
DA 2022-11-30
ER

PT J
AU Andersen, MVN
   Rosenberg, T
   la Cour, M
   Kulgaard, JF
   Prause, JU
   Alsbirk, PH
   Borch-Johnsen, K
   Peto, T
   Carstensen, B
   Bird, AC
AF Andersen, Mads Varis Nis
   Rosenberg, Thomas
   la Cour, Morten
   Kulgaard, Jens F.
   Prause, Jan U.
   Alsbirk, Poul Helge
   Borch-Johnsen, Knut
   Peto, Tunde
   Carstensen, Bendix
   Bird, Alan C.
TI Prevalence of age-related maculopathy and age-related macular
   degeneration among the inuit in Greenland: The Greenland Inuit Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID COPENHAGEN CITY EYE; GRADING SYSTEM; POPULATION; BLINDNESS; OLDER
AB Purpose: To examine the age- and gender-specific prevalence and describe the common phenotype of early age-related maculopathy (ARM) and late-stage age-related macular degeneration (AMD) among the Inuit in Greenland.
   Design: Population-based cross-sectional study.
   Participants: All >= 60-year-olds born in Greenland and living in the communities of Nuuk and Sisimiut, Greenland.
   Methods: The presence and form of early (ARM) and late age-related macular disease (AMD) were determined by grading color fundus photographs using the international classification and grading system for ARM and AMD.
   Main Outcome Measures: Prevalences of ARM and AMD were assessed by masked grading of fundus photographs.
   Results: Overall, 695 persons were included in the study (response rate, 74.8%). Prevalence of any ARM was 52.3%. Age-related maculopathy was present in the worse eye in 50.0%, 58.8%, and 44.7% of age groups 60 to 69, 70 to 79, and :80, respectively. Prevalence of any AMD was 9.5%. Any AMD was present in the worse eye in 3.9%, 14.6%, and 43.2% of age groups 60 to 69, 70 to 79, and >= 80. Prevalences of pure geographic atrophy (GA) in one or both eyes, exudative degeneration in one or both eyes, and GA in one eye and exudative degeneration in the other eye were 2.3%, 6.1 %, and 1.1 %, respectively.
   Conclusions: The prevalence of ARM is higher than in most other populations studied, and the prevalence of AMD in the oldest age group is higher than in most other populations studied. The prevalence of exudative degeneration is higher than the prevalence of GA, in contrast to findings in some of the Nordic countries-particularly Iceland-and earlier observations in Greenland.
C1 [Andersen, Mads Varis Nis; Kulgaard, Jens F.; Alsbirk, Poul Helge] Univ Copenhagen Hosp, Dept Ophthalmol, Rigshosp, DK-2100 Copenhagen, Denmark.
   [Andersen, Mads Varis Nis; la Cour, Morten; Kulgaard, Jens F.; Alsbirk, Poul Helge] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
   [Andersen, Mads Varis Nis; Rosenberg, Thomas] Natl Eye Clin Visually Impaired, Hellerup, Denmark.
   [la Cour, Morten; Kulgaard, Jens F.; Prause, Jan U.] Univ Copenhagen, Eye Pathol Sect, Inst Neurosci & Pharmacol, Copenhagen, Denmark.
   [la Cour, Morten] Glostrup Univ Hosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Borch-Johnsen, Knut; Carstensen, Bendix] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
   [Peto, Tunde; Bird, Alan C.] Moorfields Eye Hosp, London, England.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Copenhagen; University of Copenhagen; Steno Diabetes
   Center; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust
RP Andersen, MVN (通讯作者)，Univ Copenhagen, Med Retina Clin, Dept Ophthalmol E 2061, Rigshosp, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
RI Peto, Tunde/G-8812-2018; Kiilgaard, Jens Folke/H-3943-2019; la Cour,
   Morten/L-1600-2013
OI Peto, Tunde/0000-0001-6265-0381; Kiilgaard, Jens
   Folke/0000-0003-1054-1460; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
FU Medical Research Council [G0501184] Funding Source: Medline; MRC
   [G0501184] Funding Source: UKRI
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Foster PJ, 2000, BRIT J OPHTHALMOL, V84, P186, DOI 10.1136/bjo.84.2.186
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   JOHNSON GJ, 1984, CAN J OPHTHALMOL, V19, P224
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ostenfeld-Akerblom A, 1999, ACTA OPHTHALMOL SCAN, V77, P76, DOI 10.1034/j.1600-0420.1999.770117.x
   Rosenberg T, 1982, Ugeskr Laeger, V144, P571
   Rosenberg T, 1987, Arctic Med Res, V46, P13
   Rosenberg T, 1987, Arctic Med Res, V46, P64
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Van Rens G., 1988, OPHTHALMOLOGIC FINDI
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WYATT HT, 1973, CAN J OPHTHALMOL, V8, P291
   GREENLAND 2001 2002
NR 34
TC 15
Z9 16
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2008
VL 115
IS 4
BP 700
EP 707
DI 10.1016/j.ophtha.2007.12.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 281CU
UT WOS:000254475100017
PM 18267341
DA 2022-11-30
ER

PT J
AU Obata, R
   Yanagi, Y
   Kami, J
   Takahashi, H
   Inoue, Y
   Tamaki, Y
AF Obata, Ryo
   Yanagi, Yasuo
   Kami, Junko
   Takahashi, Hidenori
   Inoue, Yuji
   Tamaki, Yasuhiro
TI Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in
   Japanese patients eligible for photodynamic therapy for exudative
   age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; indocyanine-green angiography;
   photodynamic therapy; polypoidal choroidal vasculopathy; retinochoroidal
   anastomosis
ID PIGMENT EPITHELIAL DETACHMENTS; VERTEPORFIN THERAPY; VISUAL-ACUITY;
   NEOVASCULARIZATION; FEATURES; EYES; TAP
AB Purpose: To determine the percentage of Japanese patients with age-related macular degeneration (AMD) who are eligible for photodynamic therapy (PDT) with verteporfin who have either polypoidal choroidal vasculopathy (PCV) or choroidal neovascularization (CNV) with retinochoroidal anastomosis (RCA).
   Methods: The medical charts of 82 consecutive patients (83 eyes) with subfoveal CNV due to AMD were reviewed. Initially, we determined which of these eyes were eligible for PDT by using the criteria reported by two large randomized control studies, that is, the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) study and the Verteporfin in Photodynamic Therapy (VIP) study. Among the PDT-eligible patients, the percentage of eyes with PCV or CNV with RCA was determined by indocyanine green angiography (ICGA).
   Results: In total, 36 eyes (43%) of the 83 eyes were PDT-eligible; 17 (20%) based on the TAP study criteria, and 19 (23%) based on the VIP study criteria. Among these PDT-eligible eyes, ICGA revealed that 12 (33%) had PCV and 2 (6%) had CNV with RCA.
   Conclusions: With ICGA, PCV or CNV with RCA were recognized in a substantial proportion of cases eligible for PDT based on the two clinical studies. Considering that the treatment efficacy of PDT for PCV or RCA has not been established, detection of PCV or RCA prior to PDT with ICGA is highly recommended.
C1 Saitama Red Cross Hosp, Dept Ophthalmol, Urawa, Saitama 3388553, Japan.
   Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 113, Japan.
C3 University of Tokyo
RP Obata, R (通讯作者)，Saitama Red Cross Hosp, Dept Ophthalmol, 8-3-33 Kamiochiai, Urawa, Saitama 3388553, Japan.
EM robata-tky@umin.ac.jp
RI Takahashi, Hidenori/H-2945-2019; Yanagi, Yasuo/AAF-2670-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Takahashi, Hidenori/0000-0001-5331-4730; Obata, Ryo/0000-0002-1762-0797;
   Yanagi, Yasuo/0000-0002-0362-7285
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kusserow C, 2003, OPHTHALMOLOGE, V100, P197, DOI 10.1007/s00347-002-0673-2
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Talks SJ, 2004, EYE, V18, P588, DOI 10.1038/sj.eye.6700709
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   *TAP STUD GROUP, 1999, PHOTODYNAMIC THERAPY, V117, P1329
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   VOGEL A, 2001, AM J OPHTHALMOL, V131, P541
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 46
TC 25
Z9 26
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL-AUG
PY 2006
VL 50
IS 4
BP 354
EP 360
DI 10.1007/s10384-005-0337-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 091GU
UT WOS:000241015900009
PM 16897221
DA 2022-11-30
ER

PT J
AU Cheng, Y
   Li, MW
   Li, HP
   Zeng, WT
   Zhou, P
   Huang, LZ
   Li, XX
   Sun, YY
AF Cheng, Y.
   Li, M. W.
   Li, H. P.
   Zeng, W. T.
   Zhou, P.
   Huang, L. Z.
   Li, X. X.
   Sun, Y. Y.
TI Toll-like receptor 3 polymorphism is not associated with neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
   in the Chinese
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Neovascular age-related macular degeneration; TLR3; Polypoidal choroidal
   vasculopathy; Single nucleotide polymorphism
ID COMPLEMENT FACTOR-H; DOUBLE-STRANDED-RNA; GEOGRAPHIC ATROPHY; GENE;
   MACULOPATHY; POPULATION; ACTIVATION; SUSCEPTIBILITY; GROWTH; RISK
AB Toll-like receptor 3 (TLR3) variants in mainland northern Chinese patients with polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) were investigated. The complete genes of TLR3, including all exons and the promoter region, were assessed using direct sequencing technology of 284 unrelated mainland northern Chinese individuals: 96 nAMD patients, 92 PCV patients, and 96 controls. Six single nucleotide polymorphisms were identified: rs5743303, rs5743305, rs5743312, rs3775291, rs3775290, and rs6830345. The distribution of TLR3 genotypes for nAMD and PCV was not significantly different compared with normal controls. This study indicates that the TLR3 gene polymorphism is not associated with nAMD and PCV in northern Chinese patients.
C1 [Cheng, Y.; Li, M. W.; Huang, L. Z.; Li, X. X.; Sun, Y. Y.] Peking Univ, Peoples Hosp, Dept Ophthalmol, Key Lab Vis Loss & Restorat,Minist Educ, Beijing 100871, Peoples R China.
   [Li, H. P.] Peking Univ, Hosp 3, Ctr Eye,Minist Educ, Dept Ophthalmol,Key Lab Vis Loss & Restorat, Beijing 100871, Peoples R China.
   [Zeng, W. T.] Chinese Natl Human Genome Ctr, Beijing, Peoples R China.
   [Zhou, P.] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
C3 Peking University; Peking University; Fudan University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Key Lab Vis Loss & Restorat,Minist Educ, Beijing 100871, Peoples R China.
EM huanglvzhen@sina.com; drlixiaoxin@163.com
FU National Basic Research Program of China ("973" Program) [2011CB510200];
   National Natural Science Foundation of China (NSFC) [81100666]; Research
   Fund for Science and Technology Program of Beijing [Z121100005312006]
FX Research supported by the National Basic Research Program of China
   ("973" Program, #2011CB510200), the National Natural Science Foundation
   of China (NSFC, #81100666) and the Research Fund for Science and
   Technology Program of Beijing (#Z121100005312006).
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kaiser J, 2008, SCIENCE, V321, P1146, DOI 10.1126/science.321.5893.1146b
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Park DW, 2007, BIOCHEM BIOPH RES CO, V362, P1090, DOI 10.1016/j.bbrc.2007.08.119
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 39
TC 4
Z9 4
U1 0
U2 6
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2014
VL 13
IS 1
BP 302
EP 309
DI 10.4238/2014.January.17.15
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AB5RO
UT WOS:000331846400033
PM 24535857
OA Bronze
DA 2022-11-30
ER

PT J
AU Maruko, I
   Iida, T
   Saito, M
   Nagayama, D
AF Maruko, Ichiro
   Iida, Tomohiro
   Saito, Masaaki
   Nagayama, Dai
TI Combined cases of polypoidal choroidal vasculopathy and typical
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Age-related macular degeneration
ID HTRA1 PROMOTER POLYMORPHISM; 5-YEAR INCIDENCE; JAPANESE POPULATION;
   MACULOPATHY; PROGRESSION; PREVALENCE; VARIANT; LESIONS
AB When we classified neovascular exudative age-related macular degeneration (AMD) into three types of polypoidal choroidal vasculopathy (PCV), typical AMD, and retinal angiomatous proliferation (RAP) in our previous study, we reported 5.5% had the combined cases, such as one eye had PCV and the other eye had typical AMD. We examined the clinical characteristics of these combined cases in the current study.
   All cases underwent fluorescein and indocyanine green angiography (FA and ICGA) at the initial examination. All PCV cases were diagnosed definitively based on characteristic aneurysmal lesions seen on ICGA. Follow-up examinations also were conducted to determine whether polypoidal lesions had developed in the eyes with typical AMD.
   Among 349 patients with neovascular AMD, 20 (5.7%) had one eye with PCV and the other eye with typical AMD. The average age was 73 years. The mean best-corrected visual acuity levels at the initial examination in eyes with PCV and typical AMD were 0.20 and 0.43, respectively (p = 0.09). All subgroups of classic and occult CNV were observed in the eyes with typical AMD on FA. During the follow-up period (average, 21.7 months), PCV developed in ten eyes with typical AMD at the initial examination.
   Although some cases might include different stages of progression or probable cases of PCV, the combined cases in which one eye has PCV and the other eye has typical AMD suggest that those clinical entities are not independent and possibly overlap.
C1 [Maruko, Ichiro; Iida, Tomohiro; Saito, Masaaki; Nagayama, Dai] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601247, Japan.
C3 Fukushima Medical University
RP Maruko, I (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601247, Japan.
EM imaruko@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Maruko, Ichiro/AFP-1311-2022
OI Saito, Masaaki/0000-0003-1494-6350; Maruko, Ichiro/0000-0001-5647-6372
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P264, DOI 10.1177/112067210401400313
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 2002, OPHTHALMOLOGY, V109, P1588
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 23
TC 14
Z9 14
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2010
VL 248
IS 3
BP 361
EP 368
DI 10.1007/s00417-009-1276-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555GP
UT WOS:000274497200010
PM 20072785
DA 2022-11-30
ER

PT J
AU El-Amir, AN
   Sagoo, MS
   da Cruz, L
AF El-Amir, AN
   Sagoo, MS
   da Cruz, L
TI Age-related macular degeneration
SO BRITISH JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID MACULOPATHY
AB Age-related macular degeneration is the leading cause of irreversible loss of vision in the west, accounting for up to 50% of all blind registrations. With an ageing population age-related macular degeneration will have a discernible impact on society and the NHS. This article outlines our current level of understanding of age-related macular degeneration and treatment strategies.
C1 Moorfields Eye Hosp, Med Retina & Vitreo Retinal Serv, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP El-Amir, AN (通讯作者)，Moorfields Eye Hosp, Med Retina & Vitreo Retinal Serv, London EC1V 2PD, England.
OI Sagoo, Mandeep/0000-0003-1530-3824
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAWKINS BS, 1992, ARCH OPHTHALMOL-CHIC, V110, P761
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LANGLEYHAWTHORN.C, 2003, COSTS BLINDNESS ANAL
   *MAC PHOT STUD GRP, 1992, ARCH OPHTHALMOL-CHIC, V109, P1109
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   *NAT I CLIN EXC, 2003, GUID US PHOT THER AG
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Scheufele TA, 2005, INVEST OPHTH VIS SCI, V46
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 21
TC 1
Z9 1
U1 1
U2 7
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 1750-8460
EI 1759-7390
J9 BRIT J HOSP MED
JI Br. J. Hosp. Med.
PD DEC
PY 2005
VL 66
IS 12
BP 677
EP 681
DI 10.12968/hmed.2005.66.12.20206
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 019BM
UT WOS:000235810600005
PM 16417106
DA 2022-11-30
ER

PT J
AU Ng, TK
   Liang, XY
   Lai, TYY
   Ma, L
   Tam, POS
   Wang, JX
   Chen, LJ
   Chen, HY
   Pang, CP
AF Ng, Tsz Kin
   Liang, Xiao Ying
   Lai, Timothy Y. Y.
   Ma, Li
   Tam, Pancy O. S.
   Wang, Jian Xiong
   Chen, Li Jia
   Chen, Haoyu
   Pang, Chi Pui
TI HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy
   from exudative age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; JAPANESE POPULATION;
   CHROMOSOME 10Q26; CLASSIFICATION; MACULOPATHY; EXPRESSION; RETINA;
   SYSTEM; LOCUS
AB Exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) share similar abnormal choroidal vasculature, but responses to treatments are different. In this study, we sequenced the whole HTRA1 gene and its promoter by direct sequencing in a Hong Kong Chinese PCV cohort. We identified rs11200638, c.34delCinsTCCT, c.59C>T, rs1049331 and rs2293870 significantly associated with PCV. Notably, rs2672598 was significantly associated with exudative AMD (p = 1.31 x 10(-4)) than PCV (p = 0.11). Logistic regression indicated that rs2672598 (p = 2.27 x 10(-3)) remained significant after adjusting for rs11200638 in exudative AMD. Moreover, the rs11200638-rs2672598 joint genotype AA-CC conferred higher risk to exudative AMD (43.11 folds) than PCV (3.68 folds). Promoter analysis showed that rs2672598 C-allele showed higher luciferase expression than wildtype T-allele (p = 0.026), independent of rs11200638 genotype (p = 0.621). Coherently, vitreous humor HTRA1 expression with rs2672598 CC genotype was significantly higher than that with TT genotype by 2.56 folds (p = 0.02). Furthermore, rs2672598 C-allele was predicted to alter the transcription factor binding sites, but not rs11200638 A-allele. Our results revealed that HTRA1 rs2672598 is more significantly associated with exudative AMD than PCV in ARMS2/HTRA1 region, and it is responsible for elevated HTRA1 transcriptional activity and HTRA1 protein expression.
C1 [Ng, Tsz Kin; Liang, Xiao Ying; Lai, Timothy Y. Y.; Ma, Li; Tam, Pancy O. S.; Wang, Jian Xiong; Chen, Li Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Haoyu] Joint Shantou Int Eye Ctr Shantou Univ & Chinese, Shantou, Peoples R China.
C3 Chinese University of Hong Kong
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Ng, Tsz Kin/I-8061-2014; Lai, Timothy Y
   Y/AAC-2120-2020; Chen, Haoyu/A-7432-2013
OI Chen, Li Jia/0000-0003-3500-5840; Ng, Tsz Kin/0000-0001-7863-7229; Lai,
   Timothy Y Y/0000-0002-7832-6428; Chen, Haoyu/0000-0003-0676-4610
FU Health and Medical Research Fund [12130791]; General Research Fund from
   the Research Grants Council, Hong Kong [473410]; Direct Grants from the
   Medical Panel [2041771, 4054029]; Chinese University of Hong Kong
FX We express our greatest appreciation to all the participants in the
   study. This study was supported by the Health and Medical Research Fund
   (project number: 12130791 to T.K.N.), the General Research Fund from the
   Research Grants Council (grant number: 473410 to C.P.P.), Hong Kong, and
   Direct Grants from the Medical Panel (grant number: 2041771 and 4054029
   to C.P.P.), The Chinese University of Hong Kong.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2010, MOL VIS, V16, P1317
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ng TK, 2012, ASIA-PAC J OPHTHALMO, V1, P51, DOI 10.1097/APO.0b013e31823e57fe
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Ng TK, 2009, MOL VIS, V15, P2239
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 34
TC 19
Z9 20
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 24
PY 2016
VL 6
AR 28639
DI 10.1038/srep28639
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DP7CA
UT WOS:000378655400001
PM 27338780
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yadav, S
   Parry, DG
   Beare, NAV
   Pearce, IA
AF Yadav, Sohraab
   Parry, David G.
   Beare, Nick A. V.
   Pearce, Ian A.
TI Polypoidal choroidal vasculopathy: a common type of neovascular
   age-related macular degeneration in Caucasians
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RANIBIZUMAB;
   COMBINATION; AFLIBERCEPT; EVEREST
AB Aims To describe the prevalence of polypoidal choroidal vasculopathy (PCV) in a Caucasian population with neovascular age-related macular degeneration (NAMD).
   Methods All patients referred to a city AMD service over a 2-year period underwent imaging including Indocyanine Green Angiography at baseline. A panel of experts confirmed the patients with NAMD and diagnosed the lesion type including PCV. The proportion of Caucasian patients with PCV was identified. Two authors independently reviewed clinical imaging and recorded data of patients with PCV on lesion characteristics. Further information including treatments received and visual acuity at different time points was analysed.
   Results A total of 492 patients were diagnosed with NAMD during the 2-year study period. Of these patients, 204 had occult lesions (41.5%). PCV was identified in 45 patients (22.1% of occult NAMD and 9.1% of all NAMD). 23 patients received anti-vascular endothelial growth factor (VEGF) monotherapy, 8 received verteporfin photodynamic therapy (PDT) monotherapy and the remaining 14 patients were managed with combined PDT and anti-VEGF treatment.
   Conclusions The prevalence of PCV in Caucasians is higher than previously reported. Indocyanine Green Angiography should be a standard investigation for all new patients with NAMD, particularly those with occult NAMD, to avoid missing this important subset.
C1 [Yadav, Sohraab; Parry, David G.; Beare, Nick A. V.; Pearce, Ian A.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool
RP Yadav, S (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM sohraab@doctors.org.uk
RI Beare, Nicholas/AAG-4946-2019
OI Beare, Nicholas/0000-0001-8086-990X
FU Bayer; Novartis
FX Departmental grants from Bayer and Novartis. NAVB has participated in
   advisory boards for Santen Pharmaceuticals and Abbvie on uveitis,
   Novartis on retinal vein occlusion and Alimera Sciences on DMO. IAP and
   NAVB have received travel expenses from Bayer to attend ophthalmology
   conferences. NAVB is a member of the NICE AMD Clinical Guidelines
   Development Committee.
CR Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 19
TC 34
Z9 34
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2017
VL 101
IS 10
BP 1377
EP 1380
DI 10.1136/bjophthalmol-2016-310074
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GT
UT WOS:000411681700015
PM 28270486
DA 2022-11-30
ER

PT J
AU Nielsen, MK
   Subhi, Y
   Molbech, CR
   Gronskov, K
   Sorensen, TL
AF Nielsen, Marie Krogh
   Subhi, Yousif
   Molbech, Christopher Rue
   Gronskov, Karen
   Sorensen, Torben Lykke
TI Distribution of risk alleles in patients with age-related macular
   degeneration
SO DANISH MEDICAL JOURNAL
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENE POLYMORPHISMS; ASSOCIATION; EYE
AB INTRODUCTION: Age related macular degeneration (AMD) is a leading cause of vision loss in elderly people. Several single-nucleotide polymorphisms (SNP) have been shown to either increase or reduce the risk of developing AMD. In this study, we investigated the frequency of ten known risk alleles in a Danish cohort across subtypes of late AMD and explored any relationship to accelerated development of bilateral neovascular AMD.
   METHODS: A total of 206 participants were included, 73 hereof had neovascular AMD, 57 geographic atrophy (GA), 28 polypoidal choroidal vasculopathy (PCV) and 48 were healthy aged controls. Genotyping was performed using the Kompetitive allele specific polymerase chain reaction genotyping assay. Participants with neovascular AMD were followed in the clinic for four years and registered as having developed bilateral disease or having persistent unilateral disease.
   RESULTS: We found that patients with neovascular AMD and GA, but not PCV, had a higher frequency of the risk allele for rs10490g24 in age-related maculopathy susceptibility 2 (ARMS2) as well as several SNPs related to the complement pathway. Patients who developed bilateral disease within the four-year follow-up had an increased frequency of the risk-allele for rs1061170 in complement factor H (CFH).
   CONCLUSIONS: Our results support the notion that ARMS2 and CHI are central in neovascular AMD and GA, and that the risk allele for rs1061170 in CFH is associated with accelerated onset of bilateral neovascular AMD.
C1 [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher Rue; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Molbech, Christopher Rue; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Glostrup, Denmark.
   [Gronskov, Karen] Rigshosp, Dept Clin Genet, Kennedy Ctr, Appl Human Mol Genet, Glostrup, Denmark.
C3 University of Copenhagen; Rigshospitalet
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
EM mariekroghnielsen@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU Velux Foundation; Danish Eye Research Foundation; Fight for Sight
   Denmark; University of Copenhagen; Region Zealand
FX The Velux Foundation, the Danish Eye Research Foundation, Fight for
   Sight Denmark, the University of Copenhagen, and Region Zealand funded
   this study. None of the funding bodies had any role in the design,
   execution or interpretation of the research performed.
CR Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Sedeh FB, 2017, DAN MED J, V64
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
NR 20
TC 1
Z9 1
U1 0
U2 0
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 2245-1919
J9 DAN MED J
JI Dan. Med. J.
PD MAR
PY 2020
VL 67
IS 3
AR A05190295
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KZ4PA
UT WOS:000523244900002
PM 32138827
DA 2022-11-30
ER

PT J
AU Bessho, H
   Honda, S
   Kondo, N
   Kusuhara, S
   Tsukahara, Y
   Negi, A
AF Bessho, Hiroaki
   Honda, Shigeru
   Kondo, Naoshi
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Negi, Akira
TI The association of CD36 variants with polypoidal choroidal vasculopathy
   compared to typical neovascular age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID PHOTODYNAMIC THERAPY; PATHOGENESIS; LIPOPROTEIN; PHENOTYPE; GENOTYPE;
   SUSCEPTIBILITY; POLYMORPHISMS; MULTICENTER; POPULATION; HYOGO
AB Purpose: To clarify the association of cluster of differentiation 36 (CD36) variants with polypoidal choroidal vasculopathy (PCV) and compare them with those in typical neovascular age-related macular degeneration (tAMD).
   Methods: We included 349 Japanese AMD patients (210 PCV, 139 tAMD) and 198 age-matched controls. Four tag single-nucleotide polymorphisms (SNPs)-rs10499862, rs3173798, rs3211883, and rs3173800-in the CD36 region were genotyped using the TaqMan assay. Allelic and genotypic frequencies of the SNPs were tested.
   Results: Although none of the SNPs tested were associated with PCV, the allelic frequencies of rs3173798 and rs3173800 were significantly different between PCV and tAMD patients. Genotype association analysis demonstrated different associations of these two SNPs between PCV and tAMD in the genotype model. Haplotype analysis revealed that the association of the major haplotype (T-T-T-T) at four selected SNPs in CD36 differed significantly between PCV and tAMD patients.
   Conclusions: The CD36 region may be associated with the difference in genetic susceptibility for PCV and tAMD.
C1 [Bessho, Hiroaki; Honda, Shigeru; Kondo, Naoshi; Kusuhara, Sentaro; Tsukahara, Yasutomo; Negi, Akira] Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019; Voznyy, Igor/D-8497-2016
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organization had no role in the design or conduct of this
   research. The authors have no proprietary or commercial interest in any
   of the materials discussed in this article.
CR Anderson CR, 2008, AM J PATHOL, V173, P1220, DOI 10.2353/ajpath.2008.071194
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bessho H, 2011, J CLIN EXP OPHTHALMO, V2, P122
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chowers I, 2008, MOL VIS, V14, P2263
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Falush D, 2003, GENETICS, V164, P1567
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Kuniyasu A, 2003, FEBS LETT, V537, P85, DOI 10.1016/S0014-5793(03)00096-6
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim JY., 2010, ACTA OPHTHALMOL
   Love-Gregory L, 2008, HUM MOL GENET, V17, P1695, DOI 10.1093/hmg/ddn060
   Love-Gregory L, 2011, HUM MOL GENET, V20, P193, DOI 10.1093/hmg/ddq449
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006
   Silverstein RL, 2009, CLIN LIPIDOL, V4, P767, DOI 10.2217/CLP.09.57
   Stahl A, 2011, BRIT J OPHTHALMOL, V95, P1496, DOI 10.1136/bjo.2010.194241
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 47
TC 6
Z9 6
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 18
PY 2012
VL 18
IS 15-18
BP 121
EP 127
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 904ZH
UT WOS:000301239000001
PM 22275803
DA 2022-11-30
ER

PT J
AU Wakazono, T
   Yamashiro, K
   Oishi, A
   Ooto, S
   Tamura, H
   Akagi-Kurashige, Y
   Hata, M
   Takahashi, A
   Tsujikawa, A
   Yoshimura, N
AF Wakazono, Tomotaka
   Yamashiro, Kenji
   Oishi, Akio
   Ooto, Sotaro
   Tamura, Hiroshi
   Akagi-Kurashige, Yumiko
   Hata, Masayuki
   Takahashi, Ayako
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER
   AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; fixed-regimen treatment;
   intravitreal injection; polypoidal choroidal vasculopathy; recurrence
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; RANIBIZUMAB;
   BEVACIZUMAB; ENDOPHTHALMITIS; ANGIOGRAPHY; POPULATION; PREVALENCE;
   THERAPY; CATT
AB Purpose: To examine the recurrence rate of choroidal neovascularization (CNV) lesion activity in age-related macular degeneration (AMD) and associated factors after 1-year aflibercept treatment.
   Methods: Age-related macular degeneration eyes with 1-year aflibercept fixed-regimen treatment and a follow-up period of at least 18 months from the initial aflibercept injection for treatment-naive exudative AMD were retrospectively evaluated. The recurrence rate was examined. Age, gender, visual acuity, AMD subtype, greatest linear dimension, and retinal and choroidal thicknesses at the 12th month examination were compared between eyes with and without recurrence. Presence of remnant polyps and pigment epithelial detachment (PED) morphology were also compared in polypoidal choroidal vasculopathy (PCV) eyes.
   Results: Of the 98 eyes studied, 69 displayed a dry macula at the 12th month examination; 43.7% exhibited recurrence during the subsequent 12-month period in Kaplan-Meier analysis. Although no factors associated with recurrence were detected in AMD, remnant polyps and pigment epithelial detachment morphology at the 12th month examination were significantly associated with recurrence in polypoidal choroidal vasculopathy (P = 0.018 and 0.048, respectively).
   Conclusion: Continuous, proactive treatment would be considered overtreatment for more than half of the AMD eyes that achieved a dry macula. Angiography and optical coherence tomography analyses may be useful for predicting recurrence in polypoidal choroidal vasculopathy eyes.
C1 [Wakazono, Tomotaka; Yamashiro, Kenji; Oishi, Akio; Ooto, Sotaro; Tamura, Hiroshi; Akagi-Kurashige, Yumiko; Hata, Masayuki; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems, from the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), Japan
FX Supported in part by the Innovative Techno-Hub for Integrated Medical
   Bio-Imaging of the Project for Developing Innovation Systems, from the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan.
CR Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   OBANA A, 1994, AM J OPHTHALMOL, V118, P749, DOI 10.1016/S0002-9394(14)72554-1
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 25
TC 9
Z9 13
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2017
VL 37
IS 11
BP 2062
EP 2068
DI 10.1097/IAE.0000000000001451
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3LV
UT WOS:000425208800025
PM 28590316
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Guo, J
   Li, HP
   Zhang, CF
   Sun, YY
   Deng, X
   Bai, YJ
   Li, SS
   Zhao, M
   Miao, H
   Yu, WZ
   Wang, B
   Huang, LZ
   Li, XX
AF Guo, Jing
   Li, Haiping
   Zhang, Chunfang
   Sun, Yaoyao
   Deng, Xun
   Bai, YuJing
   Li, Shanshan
   Zhao, Min
   Miao, Heng
   Yu, Wenzhen
   Wang, Bin
   Huang, Lvzhen
   Li, Xiaoxin
TI TOMM40 rs2075650 polymorphism shows no association with neovascular
   age-related macular degeneration or polypoidal choroidal vasculopathy in
   a Chinese population
SO MOLECULAR VISION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E;
   SUSCEPTIBILITY GENES; JAPANESE POPULATION; QUANTITATIVE TRAIT; VARIANTS;
   GENOTYPE; MACULOPATHY; DRUSEN
AB Purpose: Age-related macular degeneration (AMD) and Alzheimer disease (AD) are age-related neurodegenerative diseases that share similar environmental risk factors, cellular pathologies, and genetic backgrounds. Recently, the rs2075650 single nucleotide polymorphism in the translocase of outer mitochondrial membrane 40 homolog (TOMM40) gene was identified as a risk factor for AMD and Alzheimer disease. We aimed to examine the associations between the TOMM40 rs2075650 polymorphism and neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in a Chinese population.
   Methods: The study consisted of 900 subjects, including 300 controls, 300 cases with nAMD, and 300 cases with PCV. Genomic DNA was extracted from venous blood leukocytes. The allelic variant of rs2075650 was determined with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Differences in the observed genotypic distributions between the case and control groups were tested using chi-square tests, with age and gender adjusted using logistic regression analysis.
   Results: The TOMM40 rs2075650 polymorphism was not statistically significantly associated with the nAMD or PCV phenotype (p>0.05). The difference remained insignificant after correction for age and gender differences based on the logistic regression models (p>0.05).
   Conclusions: Our data provide no evidence to support an association of rs2075650 in TOMM40 with nAMD or PCV, suggesting that this gene is unlikely to be a major AMD and PCV susceptibility gene locus in the Chinese population.
C1 [Guo, Jing; Sun, Yaoyao; Deng, Xun; Bai, YuJing; Li, Shanshan; Zhao, Min; Miao, Heng; Yu, Wenzhen; Wang, Bin; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Guo, Jing; Li, Haiping; Sun, Yaoyao; Deng, Xun; Bai, YuJing; Li, Shanshan; Zhao, Min; Miao, Heng; Yu, Wenzhen; Wang, Bin; Huang, Lvzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Li, Haiping] Peking Univ, Hosp 3, Ctr Eye, Beijing 100044, Peoples R China.
   [Zhang, Chunfang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM drlixiaoxin@163.com
OI Zhao, Min/0000-0003-0521-9186
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX The first three authors contributed equally to this article and are
   co-first authors. Dr. Lvzhen Huang (huanglvzhen@126.com) and Dr. Xiaoxin
   Li contributed equally to the conduct of this research and are
   considered to be co-corresponding authors. This study was supported by
   the National Basic Research Program of China (973 Program;
   #2011CB510200), National Natural Science Foundation of China Grant
   (81100666) and the Research Fund for Science and Technology Program of
   Beijing (No. Z121100005312006). The funders had no role in study design,
   data collection and analysis, the decision to publish, or preparation of
   the manuscript. The authors have no financial or conflicting interests.
CR Bessho H, 2009, MOL VIS, V15, P1107
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Cheng Y, 2013, PLOS ONE, V8
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Deelen J, 2011, AGING CELL, V10, P686, DOI 10.1111/j.1474-9726.2011.00705.x
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Holliday EG, 2013, PLOS ONE, V8
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Humphries AD, 2005, J BIOL CHEM, V280, P11535, DOI 10.1074/jbc.M413816200
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kim S, 2011, NEUROLOGY, V76, P69, DOI 10.1212/WNL.0b013e318204a397
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Ma XY, 2013, NEUROMOL MED, V15, P279, DOI 10.1007/s12017-012-8217-7
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Naj AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001130
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Potkin SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006501
   Proitsi P, 2012, NEUROBIOL AGING, V33, P1843, DOI DOI 10.1016/J.NEUR0BI0LAGING.2011.12.036
   Sayen Alexandra, 2011, Rev Prat, V61, P159
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shen L, 2010, NEUROIMAGE, V53, P1051, DOI 10.1016/j.neuroimage.2010.01.042
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Teo YY, 2008, CURR OPIN LIPIDOL, V19, P133, DOI 10.1097/MOL.0b013e3282f5dd77
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 42
TC 3
Z9 3
U1 0
U2 8
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 27
PY 2013
VL 19
BP 2050
EP 2057
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 228IY
UT WOS:000325180600001
PM 24146538
DA 2022-11-30
ER

PT J
AU Ladas, ID
   Rouvas, AA
   Moschos, MM
   Synodinos, EE
   Karagiannis, DA
   Koutsandrea, CN
AF Ladas, ID
   Rouvas, AA
   Moschos, MM
   Synodinos, EE
   Karagiannis, DA
   Koutsandrea, CN
TI Polypoidal choroidal vasculopathy and exudative age-related macular
   degeneration in Greek population
SO EYE
LA English
DT Article
DE polypoidal choroidal vasculopathy; exudative age-related macular
   degeneration
ID CLINICAL SPECTRUM
AB Purpose To study the prevalence, the clinical features, and the visual prognosis without treatment of polypoidal choroidal vasculopathy (PCV) in a large series of Greek patients presenting with exudative maculopathy.
   Methods The medical records, photographs, as well as fluorescein and indocyanine green (ICG) angiograms of a series of 268 consecutive elderly white Greek patients, who were originally diagnosed as having exudative age - related macular degeneration (AMD) were reviewed retrospectively.
   Results In all, 22 of the 268 (8.2%) patients initially suspected of having AMD were ultimately diagnosed with PCV. In 15 of the 22 (68.2%) patients with PCV, the polypoidal lesions were located in the peripapillary area. Large soft drusen were present in only two fellow eyes of the 10 (20%) patients with unilateral PCV compared with 120 fellow eyes of the 148 (81.1%) patients with unilateral AMD. At the last examination, 11 of the 22 (50%) patients with PCV and 120 of the 246 (48.8%) patients with AMD presented a visual acuity of less than 6/60 in at least one eye due to scar formation in the macula.
   Conclusions PCV is not an infrequent disease in Greece. A measurable number of Greek patients with findings suggestive of exudative AMD will instead have PCV. ICG angiography is important in differentiating between these two clinical entities. In Greeks, polypoidal lesions are predominately peripapillary and are not usually associated with macular drusen in the fellow eye. PCV and exudative AMD do not differ significantly in terms of their natural course and visual prognosis in Greek patients.
C1 Univ Athens, Med Sch Athens, Dept Ophthalmol, GR-10679 Athens, Greece.
   Univ Lausanne, Jules Gonin Eye Hosp, CH-1015 Lausanne, Switzerland.
C3 National & Kapodistrian University of Athens; University of Lausanne
RP Ladas, ID (通讯作者)，8 Meg Alexandrou Str, GR-15236 Athens, Greece.
EM ladas@ath.forthnet.gr
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 17
TC 70
Z9 76
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAY
PY 2004
VL 18
IS 5
BP 455
EP 459
DI 10.1038/sj.eye.6700706
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 818NU
UT WOS:000221252600002
PM 15131673
OA Bronze
DA 2022-11-30
ER

PT J
AU Coleman, HR
   Chan, CC
   Ferris, FL
   Chew, EY
AF Coleman, Hanna R.
   Chan, Chi-Chao
   Ferris, Frederick L., III
   Chew, Emily Y.
TI Age-related macular degeneration
SO LANCET
LA English
DT Review
ID COMPLEMENT FACTOR-H; VITAMIN-E SUPPLEMENTATION; 3RD NATIONAL-HEALTH;
   BODY-MASS INDEX; VISUAL IMPAIRMENT; RISK-FACTORS; GEOGRAPHIC ATROPHY;
   DIETARY-FAT; CIGARETTE-SMOKING; 5-YEAR INCIDENCE
AB Age-related macular degeneration is the leading cause of blindness in elderly populations of European descent. The most consistent risk factors associated with this ocular condition are increasing age and cigarette smoking. Genetic investigations have shown that complement factor H, a regulator of the alternative complement pathway, and LOC387715/HtrA1 are the most consistent genetic risk factors for age-related macular degeneration. Although the pathogenesis of this disease is unknown, oxidative stress might have an important role. Treatment with antioxidant vitamins and zinc can reduce the risk of developing advanced age-related macular degeneration by about a quarter in those at least at moderate risk. Intravitreal injections of ranibizumab, a monoclonal antibody that inhibits all forms of vascular endothelial growth factor, have been shown to stabilise loss of vision and, in some cases, improve vision in individuals with neovascular age-related macular degeneration. These findings, combined with assessments of possible environmental and genetic interactions and new approaches to modulate inflammatory pathways, will hopefully further expand our ability to understand and treat age-related macular degeneration.
C1 [Coleman, Hanna R.; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Res, NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC-1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Ferris, Frederick/0000-0002-4933-0639
FU NATIONAL EYE INSTITUTE [ZIAEY000418, ZIAEY000222, ZICEY000461] Funding
   Source: NIH RePORTER; Intramural NIH HHS [Z01 EY000222-22, Z99 EY999999,
   Z01 EY000418-04] Funding Source: Medline
CR Albanes D, 2007, JAMA-J AM MED ASSOC, V298, P400, DOI 10.1001/jama.298.4.400-a
   Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GASS JD, 1973, T AM ACAD OPHTHALMOL, V77
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Huang HY, 2007, JAMA-J AM MED ASSOC, V298, P400, DOI 10.1001/jama.298.4.400-b
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Gluud LL, 2007, JAMA-J AM MED ASSOC, V298, P402, DOI 10.1001/jama.298.4.402
   Lutty G, 1999, MOL VIS, V5
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Souied EH, 2005, MOL VIS, V11, P1135
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vu HTV, 2006, BRIT J OPHTHALMOL, V90, P389, DOI 10.1136/bjo.2005.078055
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates YR, 2007, NEW ENGL J MED, V357, P19
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 163
TC 405
Z9 421
U1 1
U2 61
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 22
PY 2008
VL 372
IS 9652
BP 1835
EP 1845
DI 10.1016/S0140-6736(08)61759-6
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 375KG
UT WOS:000261112000026
PM 19027484
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lim, LS
   Mitchell, P
   Seddon, JM
   Holz, FG
   Wong, TY
AF Lim, Laurence S.
   Mitchell, Paul
   Seddon, Johanna M.
   Holz, Frank G.
   Wong, Tien Y.
TI Age-related macular degeneration
SO LANCET
LA English
DT Article
ID BLUE MOUNTAINS EYE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INDOCYANINE
   GREEN ANGIOGRAPHY; RANDOMIZED CLINICAL-TRIALS; ENDOTHELIAL
   GROWTH-FACTOR; GEOGRAPHIC ATROPHY; RISK-FACTORS; CIGARETTE-SMOKING;
   10-YEAR INCIDENCE; CATARACT-SURGERY
AB Age-related macular degeneration is a major cause of blindness worldwide. With ageing populations in many countries, more than 20% might have the disorder. Advanced age-related macular degeneration, including neovascular age-related macular degeneration (wet) and geographic atrophy (late dry), is associated with substantial, progressive visual impairment. Major risk factors include cigarette smoking, nutritional factors, cardiovascular diseases, and genetic markers, including genes regulating complement, lipid, angiogenic, and extracellular matrix pathways. Some studies have suggested a declining prevalence of age-related macular degeneration, perhaps due to reduced exposure to modifiable risk factors. Accurate diagnosis combines clinical examination and investigations, including retinal photography, angiography, and optical coherence tomography. Dietary anti-oxidant supplementation slows progression of the disease. Treatment for neovascular age-related macular degeneration incorporates intra ocular injections of anti-VEGF agents, occasionally combined with other modalities. Evidence suggests that two commonly used anti-VEGF therapies, ranibizumab and bevacizumab, have similar efficacy, but possible differences in systemic safety are difficult to assess. Future treatments include inhibition of other angiogenic factors, and regenerative and topical therapies.
C1 [Lim, Laurence S.; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Seddon, Johanna M.] Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   University of Sydney; Westmead Institute for Medical Research; Tufts
   Medical Center; Tufts University; University of Bonn; National
   University of Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU Allergan; Bayer; Novartis; Pfizer; Solvay; Genentech; Acucela; Alcon;
   GlaxoSmithKline; Heidelberg Engineering; Optos; NATIONAL EYE INSTITUTE
   [R01EY011309] Funding Source: NIH RePORTER
FX LSL has received travel support from Novartis. PM is on advisory boards
   for Allergan, Bayer, Novartis, Pfizer, and Solvay, and has received
   travel, honorarium and research support from these companies. JMS has
   received grant support from Genentech; Tufts Medical Center has filed
   patent applications regarding some of her research. FGH is on advisory
   boards for Acucela, Alcon, Allergan, Bayer, GlaxoSmithKline, Genentech,
   Heidelberg Engineering, Optos, Novartis, and Pfizer and has received
   travel, honorarium, and research support from these companies. TYW is on
   advisory boards for Allergan, Bayer, Novartis, Pfizer, and Solvay, and
   has received travel, honorarium, and research support from these
   companies. None of the authors have stocks, equity, contract of
   employment or named position on company boards.
CR Truong A, 2011, J MOL MED, V89, P343, DOI 10.1007/s00109-010-0709-z
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Avila MP, 2011, RETINA, V32, P10
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dowling J, 2009, EYE, V23, P1999, DOI 10.1038/eye.2008.385
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P9195, DOI 10.1167/iovs.10-6793
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wormald R, 2007, COCHRANE DB SYST REV, V3
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 80
TC 1143
Z9 1212
U1 21
U2 303
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 5
PY 2012
VL 379
IS 9827
BP 1728
EP 1738
DI 10.1016/S0140-6736(12)60282-7
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 937KX
UT WOS:000303658500033
PM 22559899
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Yamagishi, T
   Yamazaki, T
   Kawasaki, R
   Kinoshita, S
AF Koizumi, Hideki
   Yamagishi, Tetsuya
   Yamazaki, Taizo
   Kawasaki, Ryo
   Kinoshita, Shigeru
TI Subfoveal choroidal thickness in typical age-related macular
   degeneration and polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Choroid; Enhanced depth imaging optical coherence tomography (EDI OCT)
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; JAPANESE
   PATIENTS; CLINICOPATHOLOGICAL CORRELATION; CLINICAL CHARACTERISTICS;
   CHINESE PATIENTS; FEATURES
AB To investigate the subfoveal choroidal thickness in eyes with typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), using enhanced depth imaging optical coherence tomography.
   Retrospective observational case series of 44 eyes of 44 patients (12 females and 32 males) with typical AMD or PCV located in the subfoveal region. Cross-sectional images of the choroid of each of the involved eyes were obtained by a spectral-domain OCT. The choroidal thickness under the fovea was retrospectively studied.
   Of the 44 eyes involved in this study, 21 eyes were diagnosed as typical AMD and the other 23 eyes were diagnosed as PCV. The difference in subfoveal choroidal thickness between the eyes with typical AMD (245 mu m) and those with PCV (293 mu m) was statistically significant, even after adjusting for age, spherical equivalent, and gender distribution (P = 0.045). When compared to eyes with subfoveal choroidal thickness less than 300 mu m, those with subfoveal choroidal thickness of 300 mu m or more were 5.6 times more likely to have PCV (adjusted odds ratio 5.60, 95% confidence interval 1.30-24.0, P = 0.021).
   The choroid under the fovea was thicker in eyes with PCV than those with typical AMD. This result suggests that the choroidal vascular lesion seen in PCV may not be just the choroidal neovascularization accompanied by saccular capillary dilations at the border, but may have a significant structural difference in the choroid compared to typical AMD.
C1 [Koizumi, Hideki; Yamagishi, Tetsuya; Yamazaki, Taizo; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.
   [Kawasaki, Ryo] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Kyoto Prefectural University of Medicine; Centre for Eye Research
   Australia; University of Melbourne
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
RI Kawasaki, Ryo/H-9716-2019; Kawasaki, Ryo/B-7266-2009
OI Kawasaki, Ryo/0000-0002-7492-6303
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 28
TC 248
Z9 263
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2011
VL 249
IS 8
BP 1123
EP 1128
DI 10.1007/s00417-011-1620-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804GM
UT WOS:000293642300002
PM 21274555
DA 2022-11-30
ER

PT J
AU Sun, S
   Li, ZQ
   Glencer, P
   Cai, BC
   Zhang, XM
   Yang, J
   Li, XR
AF Sun, Shuo
   Li, ZhiQing
   Glencer, Patrick
   Cai, BinCui
   Zhang, XiaoMin
   Yang, Jin
   Li, XiaoRong
TI Bringing the age-related macular degeneration high-risk allele
   age-related maculopathy susceptibility 2 into focus with stem cell
   technology
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE AMD; ARMS2; RPE cells; Stem cells; Genetic model
ID GROWTH-FACTOR TREATMENT; 5-YEAR INCIDENCE; ASSOCIATION; PREVALENCE;
   THERAPY; MODEL; CFH; TRANSPLANTATION; POLYMORPHISMS; ANTIOXIDANTS
AB Age-related macular degeneration (AMD) is a major cause of blindness in older adults in developed countries. It is a multifactorial disease triggered by both environmental and genetic factors. High-temperature requirement A serine peptidase 1 (HTRA1) and age-related maculopathy susceptibility 2 (ARMS2) are two genes that are strongly associated with AMD. Because ARMS2 is an evolutionarily recent primate-specific gene and because the ARMS2/HTRA1 genes are positioned at a locus on chromosome 10q26 in a region with strong linkage disequilibrium, it is difficult to distinguish the functions of the individual genes. Therefore, it is necessary to bring these genes into focus. Patient-specific induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) provides direct access to a patient's genetics and allows for the possibility of identifying the initiating events of RPE-associated degenerative diseases. In this paper, a review of recent epidemiological studies of AMD is offered. An argument for a definite correlation between the ARMS2 gene and AMD is presented. A summary of the use of ARMS2 genotyping for medical treatment is provided. Several ARMS2-related genetic models based on such stem cells as iPSCs are introduced. The possibility of applying gene-editing techniques and stem-cell techniques to better explore the mechanisms of the ARMS2 high-risk allele, which will lead to important guidance for treatment, is also discussed.
C1 [Sun, Shuo; Li, ZhiQing; Cai, BinCui; Zhang, XiaoMin; Yang, Jin; Li, XiaoRong] Tianjin Med Univ, Eye Hosp, Tianjin 300384, Peoples R China.
   [Glencer, Patrick] Nova Southeastern Coll Optometry, Ft Lauderdale, FL 33314 USA.
C3 Tianjin Medical University
RP Yang, J; Li, XR (通讯作者)，Tianjin Med Univ, Eye Hosp, Tianjin 300384, Peoples R China.
EM yangjinchina324@gmail.com; lixiaorong@tmu.edu.cn
OI Zhang, Xiaomin/0000-0003-4898-4152
FU National Natural Science Funds, China [81400412, 81670875]; Tianjin
   Natural Science Foundation, Tianjin, China [15JCZDJC34500]; LangMu young
   scientist scholarship [BJ-LM2015008L]
FX National Natural Science Funds (81400412), China; National Natural
   Science Funds (81670875), China; The Key Program of Tianjin Natural
   Science Foundation (15JCZDJC34500), Tianjin, China; a Grant of Dr. Henry
   Norman Bethune: LangMu young scientist scholarship (BJ-LM2015008L).
CR Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE59, DOI 10.1016/j.ophtha.2015.02.039
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Cramer-Morales K, 2015, FREE RADICAL BIO MED, V89, P379, DOI 10.1016/j.freeradbiomed.2015.07.017
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Fields M, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5040044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kortvely E, 2016, ADV EXP MED BIOL, V854, P23, DOI 10.1007/978-3-319-17121-0_4
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Li Y, 2016, ADV EXP MED BIOL, V854, P549, DOI 10.1007/978-3-319-17121-0_73
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Megaw R, 2015, LANCET, V385, P69, DOI 10.1016/S0140-6736(15)60384-1
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nguyen HV, 2015, J CLIN MED, V4, P567, DOI 10.3390/jcm4040567
   Nori S, 2015, STEM CELL REP, V4, P360, DOI 10.1016/j.stemcr.2015.01.006
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park UC, 2014, MOL VIS, V20, P1680
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Qu ZP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0207-x
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seminatore C, 2010, STROKE, V41, P153, DOI 10.1161/STROKEAHA.109.563015
   Silva M, 2015, CELL STEM CELL, V16, P13, DOI 10.1016/j.stem.2014.12.013
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang Guizhou, 2013, ScientificWorldJournal, V2013, P192982, DOI 10.1155/2013/192982
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yvon C, 2015, COMPUT STRUCT BIOTEC, V13, P382, DOI 10.1016/j.csbj.2015.05.001
NR 50
TC 5
Z9 5
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JUN 6
PY 2017
VL 8
AR 135
DI 10.1186/s13287-017-0584-4
PG 7
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA EW6UM
UT WOS:000402645900001
PM 28583181
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ye, ZM
   Shuai, P
   Zhai, YR
   Li, F
   Jiang, LX
   Lu, F
   Wen, F
   Huang, LL
   Zhang, DD
   Liu, XQ
   Lin, Y
   Luo, HC
   Zhang, HB
   Zhu, XJ
   Wu, ZZ
   Yang, ZL
   Gong, B
   Shi, Y
AF Ye, Zimeng
   Shuai, Ping
   Zhai, Yaru
   Li, Fang
   Jiang, Lingxi
   Lu, Fang
   Wen, Feng
   Huang, Lulin
   Zhang, Dingding
   Liu, Xiaoqi
   Lin, Ying
   Luo, Huaichao
   Zhang, Houbin
   Zhu, Xianjun
   Wu, Zhengzheng
   Yang, Zhenglin
   Gong, Bo
   Shi, Yi
TI Associations of 6p21.3 Region with Age-related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HAN CHINESE POPULATION; FACTOR-B; PREVALENCE;
   C2; POLYMORPHISMS; GENES; CFB; EYE; C3
AB Neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of blindness in aging populations. This study was conducted to investigate the associations of chromosome 6p21.3 region, including CFB-SKIV2L-TNXB-FKBPL-NOTCH4 genes, with both neovascular AMD and PCV. Six single nucleotide polymorphisms (SNPs) in this region and two known AMD-associated SNPs in CFH (rs800292) and HTRA1 (rs11200638) were genotyped in a Han Chinese cohort composed of 490 neovascular AMD patients, 419 PCV patients and 1316 controls. Among the SNPs, TNXB rs12153855 and FKBPL rs9391734 conferred an increased susceptibility to neovascular AMD (P = 2.8 x 10(-4) and 0.001, OR = 1.80 and 1.76, respectively), while SKIV2L exerted a protective effect on neovascular AMD (P = 2.2 x 10(-4), OR = 0.49). Rs12153855C and rs9391734A alleles could further increase the susceptibility to AMD in subjects with rs800292, rs11200638 and rs429608 risk alleles. However, only the association of SKIV2L rs429608 remained significant after adjusting for rs800292, rs11200638 and the other 5 SNPs. The protective haplotype AATGAG exhibited significant association with neovascular AMD (permutation P = 0.015, OR = 0.34). None of the SNPs in this region was associated with PCV. Association profiles of 6p21.3 region showed discrepancy between neovascular AMD and PCV, indicating possible molecular and pathological differences between these two retinal disorders.
C1 [Ye, Zimeng; Shuai, Ping; Zhai, Yaru; Li, Fang; Jiang, Lingxi; Lu, Fang; Huang, Lulin; Zhang, Dingding; Liu, Xiaoqi; Lin, Ying; Luo, Huaichao; Zhang, Houbin; Zhu, Xianjun; Wu, Zhengzheng; Yang, Zhenglin; Gong, Bo; Shi, Yi] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sch Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China.
   [Ye, Zimeng; Shuai, Ping; Zhai, Yaru; Li, Fang; Jiang, Lingxi; Lu, Fang; Huang, Lulin; Zhang, Dingding; Liu, Xiaoqi; Lin, Ying; Luo, Huaichao; Zhang, Houbin; Zhu, Xianjun; Wu, Zhengzheng; Yang, Zhenglin; Gong, Bo; Shi, Yi] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610054, Peoples R China.
   [Ye, Zimeng; Lu, Fang; Zhu, Xianjun; Yang, Zhenglin; Shi, Yi] Southwest Jiaotong Univ, Coll Life Sci & Engn, Chengdu, Peoples R China.
   [Shuai, Ping; Zhang, Dingding] Sichuan Prov Peoples Hosp, Hlth Management Ctr, Chengdu, Peoples R China.
   [Li, Fang; Wu, Zhengzheng] Sichuan Prov Peoples Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Wen, Feng] Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
   [Luo, Huaichao] Luzhou Med Coll, Dept Clin Med, Luzhou, Peoples R China.
   [Yang, Zhenglin; Gong, Bo; Shi, Yi] Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Southwest Jiaotong University;
   Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Southwest Medical University; Chinese Academy of Sciences
RP Gong, B; Shi, Y (通讯作者)，Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sch Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China.; Gong, B; Shi, Y (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610054, Peoples R China.; Shi, Y (通讯作者)，Southwest Jiaotong Univ, Coll Life Sci & Engn, Chengdu, Peoples R China.
EM gongbo2007@hotmail.com; yshi@uestc.edu.cn
RI Zhang, Houbin/A-8887-2012
OI Zhu, Xianjun/0000-0002-2531-7552
FU Natural Science Foundation of China [81170882, 81570888, 81371048,
   81430008, 81271007, 81470668]; Science and Technology Innovation AMP;
   Talent Project of Sichuan Province [2014-58]; Youth Innovation Medical
   Science Project of Sichuan Medical Association [Q14048]; Department of
   Science and Technology of Sichuan Province [2014JZ0004, 2011JTD0020,
   2012SZ0219, 2015SZ0052, 2014JQ0023, 2014FZ0122, 16CXTD0066]
FX We gratefully acknowledge all the subjects who kindly participated in
   this research. The sponsor or funding organization had no role in the
   design or conduct of this research. This study was supported by grants
   from the Natural Science Foundation of China (81170882 and 81570888 to
   Y. Shi, 81371048 to B. Gong, 81430008 to Z. Yang, 81271007 and 81470668
   to X. Zhu); the Science and Technology Innovation & Talent Project of
   Sichuan Province (2014-58 to P. Shuai); the Youth Innovation Medical
   Science Project of Sichuan Medical Association (Q14048 to P. Shuai); and
   the Department of Science and Technology of Sichuan Province (2014JZ0004
   to Y. Shi and 2011JTD0020 to Z. Yang, 2012SZ0219 and 2015SZ0052 to Z.
   Yang; 2014JQ0023, 2014FZ0122 and 16CXTD0066 to X. Zhu).
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bristow J, 2005, AM J MED GENET C, V139C, P24, DOI 10.1002/ajmg.c.30071
   Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chiquet-Ehrismann R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004960
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Contreras AV, 2014, MOL VIS, V20, P105
   Gbadegesin RA, 2013, J AM SOC NEPHROL, V24, P1313, DOI 10.1681/ASN.2012121148
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Havvas O, 2014, EUR J OPHTHALMOL, V24, P751, DOI 10.5301/ejo.5000427
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia LH, 2011, BIOMED ENVIRON SCI, V24, P506, DOI 10.3967/0895-3988.2011.05.008
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yakkundi A, 2015, ARTERIOSCL THROM VAS, V35, P845, DOI 10.1161/ATVBAHA.114.304539
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZY, 2001, FRONT BIOSCI-LANDMRK, V6, pD927, DOI 10.2741/Yang
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
NR 39
TC 4
Z9 4
U1 1
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 10
PY 2016
VL 6
AR 20914
DI 10.1038/srep20914
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DD3NH
UT WOS:000369828500001
PM 26861912
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lorentzen, TD
   Subhi, Y
   Sorensen, TL
AF Lorentzen, Thomas D.
   Subhi, Yousif
   Sorensen, Torben L.
TI PREVALENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS WITH
   EXUDATIVE AGE-RELATED MACULAR DEGENERATION Systematic Review and
   Meta-Analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE polypoidal choroidal vasculopathy; whites; epidemiology; clinical
   manifestation; systematic review
ID JAPANESE
AB Purpose: Polypoidal choroidal vasculopathy (PCV) is a disease with significant inter-ethnical differences. In this study, we systematically review the literature on the prevalence of PCV in whites referred with a diagnosis of exudative age-related macular degeneration (AMD).
   Methods: We searched PubMed, Embase, the Cochrane Library, and the Web of Science on 24 March, 2017 for studies evaluating the prevalence of PCV in white patients with exudative AMD. Data extraction and risk of bias assessments were performed in duplicate. Studies were included for a qualitative review and a meta-analysis, including subgroup analysis for differences in age and sex.
   Results: We included data from 11 studies (>2,200 participants). For diagnosis, indocyanine green angiography was used together with a set of supporting criteria on fundus examination and optical coherence tomography. Extramacular location was more prevalent in eyes with PCV. Drusen was present in the fellow eye in 17% to 27%. Pooled prevalence of PCV in white patients with exudative AMD was 8.7% (confidence interval 95%: 7.2%-10.3%). Patients with PCV were 3.7 years (confidence interval 95%: 2.1 years-5.3 years) younger than those with other exudative AMD. Sex did not differ significantly.
   Conclusion: Polypoidal choroidal vasculopathy is not a rare subtype of exudative AMD in whites-it is present in approximately one in 11 patients.
C1 [Lorentzen, Thomas D.; Subhi, Yousif; Sorensen, Torben L.] Zealand Univ Hosp, Clin Eye Res Div, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Lorentzen, Thomas D.; Subhi, Yousif; Sorensen, Torben L.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Clin Eye Res Div, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
CR Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Boudry C, 2016, PEERJ, V4, DOI 10.7717/peerj.1557
   Chen HY, 2012, BRIT J OPHTHALMOL, V96, P896, DOI 10.1136/bjophthalmol-2012-301589
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Guymer R, 2016, CLIN EXP OPHTHALMOL, V44, P29
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Rostom A, 2004, Evid Rep Technol Assess (Summ), P1
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 MIA
   Zeng RP, 2013, MOL VIS, V19, P729
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
NR 45
TC 40
Z9 41
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2018
VL 38
IS 12
BP 2363
EP 2371
DI 10.1097/IAE.0000000000001872
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1WG
UT WOS:000454008700017
PM 29059101
DA 2022-11-30
ER

PT J
AU Schwartz, SG
   Brantley, MA
   Kovach, JL
   Grzybowski, A
AF Schwartz, Stephen G.
   Brantley, Milam A., Jr.
   Kovach, Jaclyn L.
   Grzybowski, Andrzej
TI Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Age-related macular degeneration (AMD); age-related maculopathy
   susceptibility 2 (ARMS2); age-related eye disease study (AREDS);
   complement factor H (CFH); pharmacogenetics; vascular endothelial growth
   factor (VEGF)
ID POLYMORPHISMS PREDICT RESPONSE; VEGFR2 GENE POLYMORPHISMS; GROWTH-FACTOR
   THERAPY; FACTOR-H POLYMORPHISM; INTRAVITREAL INJECTION; PHOTODYNAMIC
   THERAPY; AREDS SUPPLEMENTS; CFH; ANTIOXIDANTS; ZINC
AB Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.
C1 [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami Miller, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
   [Brantley, Milam A., Jr.] Vanderbilt Univ Sch Med, Vanderbilt Eye Inst, Dept Ophthalmol, Nashville, TN USA.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Schwartz, Stephen G.] Bascom Palmer Eye Inst Naples, 3880 Tamiami Trail North, Naples, FL 34103 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Vanderbilt University;
   University of Warmia & Mazury; Bascom Palmer Eye Institute
RP Schwartz, SG (通讯作者)，Bascom Palmer Eye Inst Naples, 3880 Tamiami Trail North, Naples, FL 34103 USA.
EM sschwartz2@med.miami.edu
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391
FU NIH Center Core Grant [P30EY014801]; Research to Prevent Blindness, New
   York, NY; NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH
   RePORTER
FX Partially supported by NIH Center Core Grant P30EY014801 and by an
   unrestricted grant from Research to Prevent Blindness, New York, NY.
CR Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gerzenstein SM, 2008, OPHTHALMIC GENET, V29, P166, DOI 10.1080/13816810802320217
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121, P1663, DOI 10.1016/j.ophtha.2014.02.025
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hampton BM, 2015, CLIN OPHTHALMOL, V9, P873, DOI 10.2147/OPTH.S84155
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jeong SW, 2015, INVEST OPHTH VIS SCI, V56, P2737, DOI 10.1167/iovs.14-14803
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Parmeggiani F, 2015, INT J MOL SCI, V16, P19796, DOI 10.3390/ijms160819796
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Sakurai M, 2014, BRIT J OPHTHALMOL, V98, P469, DOI 10.1136/bjophthalmol-2013-304267
   Schwartz SG, 2005, OPHTHALMOLOGY, V112, P2131, DOI 10.1016/j.ophtha.2005.08.014
   Schwartz SG, 2011, J OPHTHALMOL, V2011, P25249
   Schwartz SG, 2014, OPHTHALMOLOGY, V121, pE38, DOI 10.1016/j.ophtha.2013.12.046
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Shastry BS, 2011, DISCOV MED, V12, P159
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 38
TC 3
Z9 3
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2017
VL 23
IS 4
BP 547
EP 550
DI 10.2174/1381612822666161208114847
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EN0FI
UT WOS:000395685300004
PM 27928964
DA 2022-11-30
ER

PT J
AU Kondo, N
   Honda, S
   Ishibashi, K
   Tsukahara, Y
   Negi, A
AF Kondo, Naoshi
   Honda, Shigeru
   Ishibashi, Kazuki
   Tsukahara, Yasutomo
   Negi, Akira
TI Elastin gene polymorphisms in neovascular age-related macular
   degeneration and polypoidal choroidal vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUPRAVALVULAR AORTIC-STENOSIS; PHOTODYNAMIC THERAPY; HUMAN GENOME;
   ASSOCIATION; DISEASE; LESIONS; HISTOPATHOLOGY; SUSCEPTIBILITY;
   CALCIFICATION; TRANSLOCATION
AB PURPOSE. To study and reveal genetic variation in the elastin gene (ELN) that may be associated with neovascular age-related macular degeneration (AMD) and/or polypoidal choroidal vasculopathy (PCV). Eyes with neovascular AMD and PCV exhibit substantially different structural alterations of the elastic layer in the Bruch's membrane. The hypothesis for the present study was that ELN polymorphisms may play a role in the development of neovascular AMD and PCV and that genetic differences in ELN between these two phenotypes may be a reason for the histopathologic differences. To test these hypotheses, ELN was screened for genetic variation in a Japanese case-control dataset.
   METHODS. Two hundred eighty-five subjects were enrolled: 78 with neovascular AMD, 103 with PCV, and 104 control. We genotyped five tagged single nucleotide polymorphisms (SNPs) in ELN, and allele, genotype, and haplotype frequency distributions among neovascular AMD, PCV, and control subjects were compared by chi(2) tests.
   RESULTS. A common ELN variant was significantly associated with susceptibility to PCV. The age- and sex-adjusted odds ratio was 7.56 for individuals homozygous for the risk allele compared with those carrying no more than one copy of the risk allele. Significantly different distributions were found in allele and haplotype frequencies between neovascular AMD and PCV in this region, but no particular ELN SNPs or haplotypes were significantly associated with neovascular AMD.
   CONCLUSIONS. The findings implicate ELN as a susceptibility gene for PCV, and suggest that a different pathogenic process may be involved in the phenotypic expression of neovascular AMD and PCV.
C1 [Kondo, Naoshi; Honda, Shigeru; Ishibashi, Kazuki; Tsukahara, Yasutomo; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Organ Therapeut,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Organ Therapeut,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
CR Akagawa H, 2006, HUM MOL GENET, V15, P1722, DOI 10.1093/hmg/ddl096
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973
   Bobryshev YV, 2005, ATHEROSCLEROSIS, V180, P293, DOI 10.1016/j.atherosclerosis.2005.01.024
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   de Bakker PIW, 2006, NAT GENET, V38, P1298, DOI 10.1038/ng1899
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gauderman WJ, 2003, GENET EPIDEMIOL, V25, P327, DOI 10.1002/gepi.10262
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lee JS, 2006, AM J PATHOL, V168, P490, DOI 10.2353/ajpath.2006.050338
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McIntyre LM, 2000, GENET EPIDEMIOL, V19, P18, DOI 10.1002/1098-2272(200007)19:1<18::AID-GEPI2>3.0.CO;2-Y
   Miskolczi L, 1998, NEUROSURGERY, V43, P595, DOI 10.1097/00006123-199809000-00110
   Miyashita A, 2007, HUM MOL GENET, V16, P2854, DOI 10.1093/hmg/ddm244
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Onda H, 2001, AM J HUM GENET, V69, P804, DOI 10.1086/323614
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2002, AM J HUM GENET, V71, P1386, DOI 10.1086/344780
NR 46
TC 54
Z9 61
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 1101
EP 1105
DI 10.1167/iovs.07-1145
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271TZ
UT WOS:000253812900039
PM 18326737
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Gillies, M
   Fraser-Bell, S
AF Teo, Kelvin Yi Chong
   Gillies, Mark
   Fraser-Bell, Samantha
TI The Use of Vascular Endothelial Growth Factor Inhibitors and
   Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A
   Subtype of Neovascular Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE anti-VEGF; AMD; photodynamic therapy; polypoidal choroidal vasculopathy;
   PCV
ID VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL AFLIBERCEPT INJECTION; CENTRAL SEROUS CHORIORETINOPATHY;
   ONE-YEAR OUTCOMES; RANIBIZUMAB INJECTIONS; JAPANESE PATIENTS;
   CLINICAL-TRIAL; EFFICACY; BEVACIZUMAB
AB Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations as compared to Caucasians. PCV and nAMD share pathological mechanisms, including pathological expression of vascular endothelial growth factor (VEGF). The advent of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be considered. This review aims to summarize the current evidence for the treatment of PCV, especially whether VEGF inhibitors should be used alone or in combination with PDT.
C1 [Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Teo, Kelvin Yi Chong] Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Teo, Kelvin Yi Chong] Sydney Eye Hosp, Sydney Eye Hosp Fdn, Sydney, NSW 2000, Australia.
   [Gillies, Mark; Fraser-Bell, Samantha] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2000, Australia.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; University of Sydney
RP Teo, KYC (通讯作者)，Singapore Natl Eye Ctr, Singapore 168751, Singapore.; Teo, KYC (通讯作者)，Singapore Eye Res Inst, Singapore 169856, Singapore.; Teo, KYC (通讯作者)，Sydney Eye Hosp, Sydney Eye Hosp Fdn, Sydney, NSW 2000, Australia.
EM kelvinteo@mac.com; mark.gillies@sydney.edu.au; sfraserbell@gmail.com
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Teo,
   Kelvin/0000-0002-7458-7081
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   LEE WK, 2017, INVESTIG OPHTHALMOL, V58
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Li X., 2016, P AM AC OPHTH ANN M
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lorentzen T. D., 2017, ACTA OPHTHALMOL
   Lorentzen T. D., 2017, RETINA
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong C. W., 2016, PROG RETIN EYE RES
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 97
TC 16
Z9 17
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2018
VL 19
IS 9
AR 2611
DI 10.3390/ijms19092611
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HA1OU
UT WOS:000449988100147
PM 30177632
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
TI NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED
   MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; natural course; polypoidal choroidal
   vasculopathy; antivascular endothelial growth factor; intraretinal
   fluid; subretinal fluid
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL-COHERENCE-TOMOGRAPHY; TYPE-3
   NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT; TREATMENTS TRIALS;
   SUBRETINAL FLUID; RANIBIZUMAB; ACUITY; HISTORY; BEVACIZUMAB
AB Purpose: To evaluate the 24-month natural course of visual changes in patients discontinuing treatment despite persistent or recurrent fluid and factors predictive of visual prognosis.
   Methods: This retrospective, observational study included 35 patients (35 eyes) who initially received anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD), but discontinued treatment despite persistent or recurrent fluid. The best-corrected visual acuity (BCVA) at treatment discontinuation was determined and compared with the 24-month BCVA, which was then compared between polypoidal choroidal vasculopathy and other neovascular age-related macular degeneration subtypes. Baseline characteristics predictive of visual outcome and the degree of visual change were also analyzed.
   Results: The mean number of anti-vascular endothelial growth factor injections before treatment discontinuation was 4.0 +/- 1.6. The mean logarithm of minimal angle of resolution of BCVA at treatment discontinuation and that at 24 months were 1.02 +/- 0.20 (Snellen equivalents = 20/209) and 1.60 +/- 0.56 (20/796), respectively (P < 0.001). The 24-month BCVA was not different between polypoidal choroidal vasculopathy and other neovascular age-related macular degeneration subtypes (P = 0.803). The type of fluid (intraretinal fluid vs. no intraretinal fluid) was predictive of 24-month BCVA (P = 0.004) and the degree of changes in BCVA (P = 0.043).
   Conclusion: Marked deterioration in visual acuity was noted in patients discontinuing treatment, regardless of neovascular age-related macular degeneration subtypes. The presence of intraretinal fluid was associated with worse visual prognosis, suggesting that patients with intraretinal fluid should be strongly warned about their poor prognosis before they decide to discontinue treatment.
C1 [Kim, Jae Hui; Kim, Jong Woo] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX Supported by Kim's Eye Hospital Research Center.
CR Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Wang BZ, 2012, OPTOMETRY VISION SCI, V89, P1399, DOI 10.1097/OPX.0b013e3182678d82
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 31
TC 23
Z9 23
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2017
VL 37
IS 12
BP 2254
EP 2261
DI 10.1097/IAE.0000000000001494
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3NL
UT WOS:000425214400006
PM 28092343
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Nakayama, T
   Mori, R
   Sato, N
   Kawamura, A
   Mizutani, Y
   Yuzawa, M
AF Tanaka, Koji
   Nakayama, Tomohiro
   Mori, Ryusaburo
   Sato, Naoyuki
   Kawamura, Akiyuki
   Mizutani, Yoshihiro
   Yuzawa, Mitsuko
TI Associations of Complement Factor H (CFH) and Age-Related Maculopathy
   Susceptibility 2 (ARMS2) Genotypes with Subtypes of Polypoidal Choroidal
   Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; GENE
AB PURPOSE. To clarify whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes are associated with subtypes of polypoidal choroidal vasculopathy (PCV), such as polypoidal choroidal neovascularization (CNV) and typical PCV.
   METHODS. Two hundred eighty-seven patients were categorized as having polypoidal CNV (85 patients) or typical PCV (202 patients) on the basis of indocyanine green angiographic findings. In total, 277 subjects without age-related macular degeneration (i.e., free of PCV and CNV), served as controls. I62V (rs800292) in the CFH gene and A69S (rs10490924) in the ARMS2 gene were genotyped, and case-control studies were performed in subjects with these PCV subtypes.
   RESULTS. The polypoidal CNV group included no subjects homozygous for the A/A genotype of rs800292, whereas 7% of the typical PCV group had this genotype. Case-control studies of polypoidal CNV and typical PCV showed significant differences in all distributions of rs10490924 between these two groups. In contrast, the distributions of rs10490924 did not differ between the typical PCV and control groups. Logistic regression analysis with adjustment for confounding factors showed the distributions of rs10490924 to differ significantly between the controls and polypoidal CNV cases (P = 2.1 x 10(-10); OR, 10.87). The T/T genotype was significantly more common in the polypoidal CNV than in the typical PCV group (P = 3.6 x 10(-14); OR, 19.61).
   CONCLUSIONS. PCV may be genetically divisible into polypoidal CNV and typical PCV. The rs800292 variant of the CFH gene is a potential marker for typical CNV. The rs10490924 variant of the ARMS2 gene was shown to be associated with polypoidal CNV. Typical PCV was not associated with this variant. (Invest Ophthalmol Vis Sci. 2011;52:7441-7444) DOI:10.1167/iovs.11-7546
C1 [Nakayama, Tomohiro] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Lab Med,Itabashi Ku, Tokyo 1738610, Japan.
   [Tanaka, Koji; Mori, Ryusaburo; Kawamura, Akiyuki; Mizutani, Yoshihiro; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1738610, Japan.
C3 Nihon University; Nihon University
RP Nakayama, T (通讯作者)，Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Lab Med,Itabashi Ku, Ooyaguchi Kamimachi, Tokyo 1738610, Japan.
EM nakayama.tomohiro@nihon-u.ac.jp
RI Nakayama, Tomohiro/GYU-0303-2022; Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy; The
   Ministry of Health and Welfare of Japan
FX Supported by the Research Committee on Chorioretinal Degenerations and
   Optic Atrophy and by The Ministry of Health and Welfare of Japan (MY).
CR Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mizutani Y, 2006, INT J BIOMED SCI, V2, P9
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sato N, 2009, BIOCHEM BIOPH RES CO, V380, P548, DOI 10.1016/j.bbrc.2009.01.117
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 18
TC 43
Z9 49
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2011
VL 52
IS 10
BP 7441
EP 7444
DI 10.1167/iovs.11-7546
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827YU
UT WOS:000295467200053
PM 21896867
DA 2022-11-30
ER

PT J
AU Ueta, T
   Iriyama, A
   Francis, J
   Takahashi, H
   Adachi, T
   Obata, R
   Inoue, Y
   Tamaki, Y
   Yanagi, Y
AF Ueta, Takashi
   Iriyama, Aya
   Francis, Jasmine
   Takahashi, Hidenori
   Adachi, Tomoko
   Obata, Ryo
   Inoue, Yuji
   Tamaki, Yasuhiro
   Yanagi, Yasuo
TI Development of typical age-related macular degeneration and polypoidal
   choroidal vasculopathy in fellow eyes of Japanese patients with
   exudative age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 2ND EYE; CLINICAL CHARACTERISTICS; VISUAL-ACUITY; NEOVASCULARIZATION
AB PURPOSE: To investigate the development of typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in fellow eyes of Japanese patients with exudative AMD.
   DESIGN: Retrospective observational consecutive case series.
   METHODS: Two hundred and sixteen Japanese patients were enrolled in this study from the outpatient clinic of the University of Tokyo Hospital. Ninety-one patients had typical AMD and one hundred and twenty-five patients had PCV. The average follow-up period was 33.6 and 25.1 months for typical AMD and PCV patients.
   RESULTS: The cumulative incidence of involvement in fellow eyes with overall exudative AMD, including both typical AMD and PCV, was 3.4% in one year, 9.3% in three years, and 11.3% in five years. It was 3.6%, 7.3%, and 11.2% in typical AMD, and 3.2%, 11.1%, and 11.1% in PCV in one, three, and five years, respectively. Before the development of exudative AMD, patients with typical AMD had a variety of funduscopic findings including retinal pigment epithelium (RPE) atrophy, drusen, drusenoid pigment epithelial detachments (PED), and normal macula. PCV patients, on the other hand, had funduscopic findings of RPE atrophy. Inner choroidal vascular abnormality of vascular network and polypoidal. formation was observed in several eyes before the clinical manifestation of exudative changes.
   CONCLUSIONS: Typical AMD and PCV had similar probabilities of involving the fellow eye in unilaterally affected Japanese patients. RPE atrophy was a prevailing finding in fellow eyes of patients who developed PCV. In PCV, choroidal vascular network and polypoidal formation gradually grow before exudative changes.
C1 [Ueta, Takashi; Iriyama, Aya; Takahashi, Hidenori; Adachi, Tomoko; Obata, Ryo; Inoue, Yuji; Tamaki, Yasuhiro; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Francis, Jasmine] New York Eye & Ear Infirm, New York, NY 10003 USA.
C3 University of Tokyo; New York Eye & Ear Infirmary of Mount Sinai
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Takahashi, Hidenori/H-2945-2019; Yanagi, Yasuo/AAF-2670-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Takahashi, Hidenori/0000-0001-5331-4730; Obata, Ryo/0000-0002-1762-0797;
   Yanagi, Yasuo/0000-0002-0362-7285; Francis, Jasmine/0000-0002-7637-3108
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 24
TC 35
Z9 37
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2008
VL 146
IS 1
BP 96
EP 101
DI 10.1016/j.ajo.2008.03.002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 321IW
UT WOS:000257299100016
PM 18439567
DA 2022-11-30
ER

PT J
AU Chung, SE
   Kang, SW
   Lee, JH
   Kim, YT
AF Chung, Song Ee
   Kang, Se Woong
   Lee, Jung Hye
   Kim, Yun Taek
TI Choroidal Thickness in Polypoidal Choroidal Vasculopathy and Exudative
   Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION
AB Purpose: To compare choroidal thickness between eyes with polypoidal choroidal vasculopathy (PCV) and eyes with age-related macular degeneration (AMD).
   Design: Observational, comparative case series.
   Participants: Twenty-five eyes with PCV, 14 uninvolved fellow eyes with PCV, 30 eyes with exudative AMD, 17 eyes with early AMD, and 20 eyes of age-matched normal subjects.
   Methods: Choroidal thickness was measured using enhanced-depth imaging optical coherence tomography. Subfoveal choroidal thickness in each eye was analyzed by measurement of the vertical distance from the Bruch's membrane to the innermost scleral layer. Nasal, superior, temporal, and inferior choroidal thicknesses, 1500 mu m apart from the foveal center, were also evaluated in all eyes.
   Main Outcome Measures: Choroidal thickness in each group.
   Results: Mean (+/- standard deviation) subfoveal choroidal thickness in eyes with PCV and in their uninvolved fellow eyes was 438.3 +/- 87.8 mu m and 372.9 +/- 112.0 mu m, respectively, which was significantly greater than in eyes of age-matched normal subjects (224.8 +/- 52.9 mu m) (P < 0.001 and P = 0.003, respectively). Subfoveal choroidal thickness of eyes with exudative AMD (171.2 +/- 38.5 mu m) and eyes with early AMD (177.4 +/- 49.7 mu m) was thinner than that of age-matched normal subjects (P = 0.004 and P = 0.078, respectively). Choroidal thickness at each of the other 4 points showed a similar tendency.
   Conclusions: This study demonstrates thickening of choroid in the eyes with PCV, in contrast with choroidal thinning observed in eyes with AMD. These findings suggest involvement of different pathogenic mechanisms in PCV from those in exudative AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 840-845 (C) 2011 by the American Academy of Ophthalmology.
C1 [Chung, Song Ee; Kang, Se Woong; Lee, Jung Hye; Kim, Yun Taek] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
OI Kim, Yun Taek/0000-0001-9104-4241
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 36
TC 437
Z9 469
U1 1
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2011
VL 118
IS 5
BP 840
EP 845
DI 10.1016/j.ophtha.2010.09.012
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757MM
UT WOS:000290090300008
PM 21211846
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Oishi, A
   Singh, A
   Nissen, MH
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Oishi, Akio
   Singh, Amardeep
   Nissen, Mogens Holst
   Sorensen, Torben Lykke
TI T-cell differentiation and CD56+levels in polypoidal choroidal
   vasculopathy and neovascular age-related macular degeneration
SO AGING-US
LA English
DT Article
DE polypoidal choroidal vasculopathy; age-related macular degeneration;
   T-cells; immunosenescence
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; CLINICOPATHOLOGICAL
   CORRELATION; CYTOMEGALOVIRUS-INFECTION; PERIPHERAL-BLOOD; EXPRESSION;
   NAIVE; HUMANS; MAINTENANCE; ASSOCIATION
AB Polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (AMD) are prevalent age-related diseases characterized by exudative changes in the macula. Although they share anatomical and clinical similarities, they are also distinctly characterized by their own features, e.g. vascular abnormalities in PCV and drusen-mediated progression in neovascular AMD. PCV remains etiologically uncharacterized, and ongoing discussion is whether PCV and neovascular AMD share the same etiology or constitute two substantially different diseases. In this study, we investigated T-cell differentiation and aging profile in human patients with PCV, patients with neovascular AMD, and age-matched healthy control individuals. Fresh venous blood was prepared for flow cytometry to investigate CD4(+) and CD8(+) T-cell differentiation (naive, central memory, effector memory, effector memory CD45ra(+)), loss of differentiation markers CD27 and CD28, and expression of aging marker CD56. Patients with PCV were similar to the healthy controls in all aspects. In patients with neovascular AMD we found significantly accelerated T-cell differentiation (more CD28-CD27-cells) and aging (more CD56(+) cells) in the CD8(+) T-cell compartment. These findings suggest that PCV and neovascular AMD are etiologically different in terms of T cell immunity, and that neovascular AMD is associated with T-cell immunosenescence.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Singh, Amardeep; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Nissen, Mogens Holst; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Oishi, Akio] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Singh, Amardeep] Skane Univ Hosp Malmo Lund, Dept Ophthalmol, Lund, Sweden.
   [Nissen, Mogens Holst] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Kyoto University; Lund University; Skane
   University Hospital; University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.; Subhi, Y (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020; Oishi, Akio/AAE-9996-2020; Singh,
   Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Oishi, Akio/0000-0002-0977-9458;
   Krogh Nielsen, Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation; Fight for Sight Denmark; Velux
   Foundation; University of Copenhagen
FX This study was funded by the Danish Eye Research Foundation, Fight for
   Sight Denmark, and the Velux Foundation. Author Y.S. is recipient of a
   faculty stipend from the University of Copenhagen that covers salary.
   The funding bodies had no role in the design or conduct of this
   research.
CR Almehmadi M, 2014, IMMUNOLOGY, V142, P258, DOI 10.1111/imm.12250
   Moro-Garcia MA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00107
   Booiman T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183357
   Cantisan S, 2017, EXP GERONTOL, V95, P98, DOI 10.1016/j.exger.2017.04.011
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Czesnikiewicz-Guzik M, 2008, CLIN IMMUNOL, V127, P107, DOI 10.1016/j.clim.2007.12.002
   den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kos FJ, 2002, IMMUNOL CELL BIOL, V80, P364, DOI 10.1046/j.1440-1711.2002.01098.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Michel JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00530
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Nikolich-Zugich J, 2014, J IMMUNOL, V193, P2622, DOI 10.4049/jimmunol.1401174
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Ozaki S, 2000, INVEST OPHTH VIS SCI, V41, P568
   Rifai N, 2001, CLIN CHEM, V47, P28
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SINGH A, 2017, SCI REP UK, V7
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Vallejo AN, 2011, AGEING RES REV, V10, P354, DOI 10.1016/j.arr.2010.09.006
   Van Acker HH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00892
   Vossen MTM, 2008, J IMMUNOL, V180, P3739, DOI 10.4049/jimmunol.180.6.3739
   Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013
   Wertheimer AM, 2014, J IMMUNOL, V192, P2143, DOI 10.4049/jimmunol.1301721
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
   Zeng RP, 2013, MOL VIS, V19, P729
NR 61
TC 20
Z9 20
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV
PY 2017
VL 9
IS 11
BP 2436
EP 2452
DI 10.18632/aging.101329
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA FO5IP
UT WOS:000416887700016
PM 29165313
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Nishikawa, K
   Oishi, A
   Hata, M
   Miyake, M
   Ooto, S
   Yamashiro, K
   Miyata, M
   Tamura, H
   Ueda-Arakawa, N
   Takahashi, A
   Kawashima, Y
   Tsujikawa, A
AF Nishikawa, Keiichi
   Oishi, Akio
   Hata, Masayuki
   Miyake, Masahiro
   Ooto, Sotaro
   Yamashiro, Kenji
   Miyata, Manabu
   Tamura, Hiroshi
   Ueda-Arakawa, Naoko
   Takahashi, Ayako
   Kawashima, Yu
   Tsujikawa, Akitaka
TI Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular
   Degeneration and polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB TREATMENT; VISUAL-ACUITY; RECURRENCE
AB Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD). However, data about long-term outcome in real-world clinical practice is scarce. We recruited 98 AMD patients and investigated four-year visual outcome. During the four years, 25 patients dropped out. The survivors received 7.0 +/- 0.1 injections during the first year and 8.0 +/- 7.4 injections in the following three years. The logarithm of minimum angle of resolution (logMAR) at baseline, year one, and year four was 0.28, 0.14 (P = 0.033), and 0.22 (P = 0.697), respectively. The gain of vision was not different among AMD subtypes (typical AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation; P = 0.513) Among the investigated factors, the presence of external limiting membrane (ELM), the absence of vitreoretinal adhesion, and thicker choroid at baseline were associated with better logMAR values at year four (coefficient beta = -0.388, 0.201, and -0.001; P = 7.34 x 10(-6); 0.01, and 0.028, respectively). In the present study, vision was retained at baseline level after the four-year treatment with aflibercept. The status of ELM, vitreoretinal adhesion, and choroidal thickness were predictive factors for final vision.
C1 [Nishikawa, Keiichi; Oishi, Akio; Hata, Masayuki; Miyake, Masahiro; Ooto, Sotaro; Yamashiro, Kenji; Miyata, Manabu; Tamura, Hiroshi; Ueda-Arakawa, Naoko; Takahashi, Ayako; Kawashima, Yu; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kyoto University
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011; Miyata,
   Manabu/U-9008-2018; Miyake, Masahiro/V-1261-2019
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Miyake, Masahiro/0000-0001-7410-3764; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558;
   Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [17H06820];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems from the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
FX This work was supported in part by a grant-in-aid for scientific
   research (No. 17H06820) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and the Innovative Techno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems
   from the Ministry of Education, Culture, Sports, Science and Technology
   (MEXT), Tokyo, Japan. None of these organizations had any role in the
   design or conduct of this research.
CR Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 26
TC 18
Z9 18
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 6
PY 2019
VL 9
AR 3620
DI 10.1038/s41598-019-39995-5
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN7SH
UT WOS:000460391500003
PM 30842468
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ueda-Arakawa, N
   Ooto, S
   Nakata, I
   Yamashiro, K
   Tsujikawa, A
   Oishi, A
   Yoshimura, N
AF Ueda-Arakawa, Naoko
   Ooto, Sotaro
   Nakata, Isao
   Yamashiro, Kenji
   Tsujikawa, Akitaka
   Oishi, Akio
   Yoshimura, Nagahisa
TI Prevalence and Genomic Association of Reticular Pseudodrusen in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; CLINICAL
   CHARACTERISTICS; FUNDUS AUTOFLUORESCENCE; JAPANESE POPULATION; GENE
   POLYMORPHISMS; HIGH-RISK; MACULOPATHY; LOC387715; VARIANT
AB PURPOSE: To survey the prevalence of reticular pseudodrusen in late age-related macular degeneration (AMD) using multiple imaging methods, and to investigate the association between reticular pseudodrusen and polymorphisms in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.
   DESIGN: Retrospective case series.
   METHODS: This study included 216 consecutive patients with late AMD (typical AMD, polypoidal choroidal vasculopathy [PCV], retinal angiomatous proliferation [RAP], or geographic atrophy). Eyes were assessed for reticular pseudodrusen using the blue channel of color fundus photography, infrared reflectance, fundus autofluorescence, and spectral-domain optical coherence tomography. The major AMD-associated single nucleotide polymorphisms (CFH Y402 rs1061170, CFH 162 V rs800292, and ARMS2 A69S rs10490924) were genotyped.
   RESULTS: Forty-nine eyes of 30 patients had a reticular pattern in >= 2 imaging modalities and were diagnosed with reticular pseudodrusen. Of these, 16 had bilateral late AMD, whereas 32 of 186 patients without reticular pseudodrusen had bilateral late AMD (P < .001). The prevalence of reticular pseudodrusen was 83% in RAP, 50% in geographic atrophy, 9% in typical AMD, and 2% in PCV. The frequency of the T allele in ARMS2 A69S in patients with and without reticular pseudodrusen was 78.6% and 59.9%, respectively (P = .007).
   CONCLUSIONS: The prevalence of reticular pseudodrusen was low in PCV cases. About 50% of patients with reticular pseudodrusen had bilateral late AMD. The connection of ARMS2 risk allele and reticular pseudodrusen was confirmed in a Japanese population. (Am J Ophthalmol 2013;155:260-269. (c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Ooto, Sotaro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Tsujikawa, Akitaka/0000-0003-0779-7799;
   Yamashiro, Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21791679]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Publication
   of this article was supported in part by the Grant-in-Aid for Scientific
   Research (21791679) from the Japan Society for the Promotion of Science
   (JSPS), Tokyo, Japan. Contributions of authors: conception and design
   (S.O.); analysis and interpretation (N.U.A., S.O., I.N.); writing the
   manuscript (N.U.A., S.O.); critical revision of the manuscript (S.O.,
   K.Y., A.T., A.O., N.Y.); final approval of the article (N.U.A., S.O.,
   I.N., K.Y., A.T., A.O., N.Y.); data collection (N.U.A., I.N., K.Y.);
   statistical expertise (N.U.A., S.O., I.N.); obtaining funding (S.O.,
   K.Y., N.Y.); literature search (N.U.A., S.O.); and technical support
   (I.N., K.Y.).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 47
TC 90
Z9 93
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2013
VL 155
IS 2
BP 260
EP 269
DI 10.1016/j.ajo.2012.08.011
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078YQ
UT WOS:000314137400009
PM 23111182
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher R.
   Sorensen, Torben L.
TI Altered proportion of CCR2(+) and CX3CR1(+) circulating monocytes in
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; monocytes; chemokine receptors; wet
   macular degeneration
ID 2 ANGIOGRAPHIC SUBTYPES; CHEMOATTRACTANT PROTEIN-1; ACCUMULATION;
   MACROPHAGES; EXPRESSION; BLOOD
AB BackgroundWe investigated the expression of chemokine receptors CCR2 (C-C chemokine receptor) 2 and CX3CR1 (C-X3-C receptor 1) on circulating monocyte subsets in patients with neovascular age-related macular degeneration (AMD) and patients with polypoidal choroidal vasculopathy (PCV).
   MethodsWe recruited patients with neovascular AMD, patients with PCV and age-matched healthy controls for this prospective case-control study. All participants underwent comprehensive clinical examination and imaging. Freshly sampled venous blood was prepared for flow cytometry, where we determined the proportion of CCR2(+)- and CX3CR1(+)-positive cells in monocyte subsets identified using monocyte identification and subgrouping surface markers CD14, CD16 and HLA-DR.
   ResultsPatients with neovascular AMD had significantly increased proportion of CCR2(+) and CX3CR1(+) non-classical monocytes. PCV type 1 was associated with significantly increased CCR2(+) and CX3CR1(+) in all monocyte subsets when compared to PCV type 2.
   ConclusionsNeovascular AMD is associated with increased expression of angiogenesis-associated chemokine receptors in the pro-inflammatory non-classical monocytes. PCV differs from neovascular AMD immunologically and show immunological heterogeneity across angiographic subtypes.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher R.; Sorensen, Torben L.] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher R.; Sorensen, Torben L.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation (Taastrup, Denmark); Fight for Sight
   Denmark (Copenhagen, Denmark); Velux Foundation (Soborg, Denmark);
   University of Copenhagen (Copenhagen, Denmark)
FX This study was funded by the Danish Eye Research Foundation (Taastrup,
   Denmark), Fight for Sight Denmark (Copenhagen, Denmark), the Velux
   Foundation (Soborg, Denmark) and the University of Copenhagen
   (Copenhagen, Denmark). The funding bodies had no role in the design or
   conduct of this research.
CR Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104
   Clover AJP, 2011, BURNS, V37, P1386, DOI 10.1016/j.burns.2011.08.001
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lorentzen TD, 2017, RETINA, DOI [10. 1097/IAE. 0000000000001872, DOI 10.1097/IAE.0000000000001872.[EPUBAHEAD0]
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Shantsila E, 2011, J THROMB HAEMOST, V9, P1056, DOI 10.1111/j.1538-7836.2011.04244.x
   Stansfield BK, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-014-0040-3
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
NR 26
TC 16
Z9 16
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2018
VL 46
IS 6
BP 661
EP 669
DI 10.1111/ceo.13152
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP5JZ
UT WOS:000440911000011
PM 29360187
DA 2022-11-30
ER

PT J
AU Yoneyama, S
   Sakurada, Y
   Mabuchi, F
   Sugiyama, A
   Kubota, T
   Iijima, H
AF Yoneyama, Seigo
   Sakurada, Yoichi
   Mabuchi, Fumihiko
   Sugiyama, Atsushi
   Kubota, Takeo
   Iijima, Hiroyuki
TI Genetic Variants in the SKIV2L Gene in Exudative Age-related Macular
   Degeneration in the Japanese Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; polypoidal choroidal vasculopathy;
   retinal angiomatous proliferation; superkiller viralicidic activity
   2-like gene
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT COMPONENT 2; RETINAL
   ANGIOMATOUS PROLIFERATION; HAN CHINESE POPULATION; FACTOR-B; FACTOR-H;
   ASSOCIATION; POLYMORPHISMS; C2; CFH
AB Background: To investigate whether genetic variant in superkiller viralicidic activity 2-like (SKIV2L) gene is associated with exudative age-related macular degeneration (AMD) including neovascular AMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP).
   Materials and Methods: A total of 517 patients with exudative AMD comprised of 157patients with neovascular AMD, 333 patients with PCV, and 27patients with RAP, and 205 controls were enrolled in this study. Rs429608 inSKIV2L, rs800292 in complement factor H (CFH), rs10490924 in age-related maculopathy susceptibility2 (ARMS2) gene was genotyped using TaqMan technology. Logistic regression analysis was performed to correlate the risk for exudative AMD with demographic and genetic factors.
   Results: The A allele frequency of rs429608 in the SKIV2L gene was significantly higher in controls (13.9%) than in those with neovascular AMD (5.7%, p = 0.002), PCV (7.2%, p = 0.003) and RAP (3.7%, p = 0.0345). After adjusting for age, gender, ARMS2 A69S, and CFHI62V, the A allele of rs429608 was significantly protective against neovascular AMD (odds ratio [OR] 0.24, 95% confidence interval [CI] 0.122-0.484, p<0.001), PCV (OR 0.43, 95% CI 0.262-0.704, p = 0.001), RAP (OR 0.09, 95% CI 0.014-0.581, p = 0.011).
   Conclusions: A SKIV2L variant was associated with protection against exudative AMD regardless of subtypes in the Japanese population.
C1 [Yoneyama, Seigo; Sakurada, Yoichi; Mabuchi, Fumihiko; Sugiyama, Atsushi; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi 4093898, Japan.
   [Kubota, Takeo] Univ Yamanashi, Fac Med, Dept Epigenet, Kofu, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Kofu, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU JSPS (Japan Society for the Promotion of Science) KAKENHI [23791972]
FX This study was supported in part by JSPS (Japan Society for the
   Promotion of Science) KAKENHI Grant Number 23791972.
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Schmid M, 2008, TRENDS BIOCHEM SCI, V33, P501, DOI 10.1016/j.tibs.2008.07.003
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Xu YL, 2008, MOL VIS, V14, P1373
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 27
TC 12
Z9 12
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2014
VL 35
IS 3
BP 151
EP 155
DI 10.3109/13816810.2014.921313
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA AN3GJ
UT WOS:000340473500005
PM 24865191
DA 2022-11-30
ER

PT J
AU Chou, YB
   Hsu, CH
   Chen, WS
   Chen, SJ
   Hwang, DK
   Huang, YM
   Li, AF
   Lu, HHS
AF Chou, Yu-Bai
   Hsu, Chung-Hsuan
   Chen, Wei-Shiang
   Chen, Shih-Jen
   Hwang, De-Kuang
   Huang, Yi-Ming
   Li, An-Fei
   Lu, Henry Horng-Shing
TI Deep learning and ensemble stacking technique for differentiating
   polypoidal choroidal vasculopathy from neovascular age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIAGNOSIS
AB Polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) share some similarity in clinical imaging manifestations. However, their disease entity and treatment strategy as well as visual outcomes are very different. To distinguish these two vision-threatening diseases is somewhat challenging but necessary. In this study, we propose a new artificial intelligence model using an ensemble stacking technique, which combines a color fundus photograph-based deep learning (DL) model and optical coherence tomography-based biomarkers, for differentiation of PCV from nAMD. Furthermore, we introduced multiple correspondence analysis, a method of transforming categorical data into principal components, to handle the dichotomous data for combining with another image DL system. This model achieved a robust performance with an accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve of 83.67%, 80.76%, 84.72%, and 88.57%, respectively, by training nearly 700 active cases with suitable imaging quality and transfer learning architecture. This work could offer an alternative method of developing a multimodal DL model, improve its efficiency for distinguishing different diseases, and facilitate the broad application of medical engineering in a DL model design.
C1 [Chou, Yu-Bai; Chen, Shih-Jen; Hwang, De-Kuang; Huang, Yi-Ming] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chou, Yu-Bai; Chen, Shih-Jen; Hwang, De-Kuang; Huang, Yi-Ming; Li, An-Fei] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan.
   [Hsu, Chung-Hsuan; Chen, Wei-Shiang; Lu, Henry Horng-Shing] Natl Yang Ming Chiao Tung Univ, Inst Stat, Hsinchu, Taiwan.
   [Li, An-Fei] Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Cheng Hsin General
   Hospital
RP Lu, HHS (通讯作者)，Natl Yang Ming Chiao Tung Univ, Inst Stat, Hsinchu, Taiwan.
EM hslu@stat.nctu.edu.tw
RI Hwang, DK De-Kuang/J-3931-2016
OI Hwang, DK De-Kuang/0000-0001-6346-8485
FU Ministry of Science and Technology, Taiwan [MOST 108-3011-F-075-001]
FX All the authors in this study were supported and funded by a scientific
   project from Ministry of Science and Technology, Taiwan. (Project
   Number: MOST 108-3011-F-075-001).
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Costa Patricio Soares, 2013, J Aging Res, V2013, P302163, DOI 10.1155/2013/302163
   Greenacre Michael J, 1994, CORRES ANAL SOCIAL S
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Le Q.V., 2019, PMLR97
   LeCun Y., 2015, NATURE, V521, P436, DOI DOI 10.1038/NATURE14539
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Sourial N, 2010, J CLIN EPIDEMIOL, V63, P638, DOI 10.1016/j.jclinepi.2009.08.008
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P621, DOI 10.1111/ceo.13462
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1244-5
   Yang JY, 2020, GRAEF ARCH CLIN EXP, V258, P17, DOI 10.1007/s00417-019-04493-x
   Yue S., 2017, IMBALANCED MALWARE I
NR 23
TC 5
Z9 5
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 30
PY 2021
VL 11
IS 1
AR 7130
DI 10.1038/s41598-021-86526-2
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RH5OU
UT WOS:000636268600001
PM 33785808
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ciardella, AP
   Donsoff, IM
   Huang, SJ
   Costa, DL
   Yannuzzi, LA
AF Ciardella, AP
   Donsoff, IM
   Huang, SJ
   Costa, DL
   Yannuzzi, LA
TI Polypoidal choroidal vasculopathy
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; photodynamic treatment; polypoidal
   choroidal vasculopathy; subretinal hemorrhage
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY;
   PIGMENT EPITHELIAL DETACHMENTS; SENILE MACULAR DEGENERATION;
   CLINICOPATHOLOGICAL CORRELATION; LASER PHOTOCOAGULATION; BLACK-WOMEN;
   NEOVASCULARIZATION; PATIENT; IPCV
AB Polypoidal choroidal vasculopathy was first described as a peculiar hemorrhagic disorder of the macula, characterized by recurrent sub-retinal and sub-retinal pigment epithelium bleeding in middle aged black women. The use of indocyanine green angiography and subsequently of optical coherent tomography has widened our ability to study and understand the pathophysiology of this disorder. The primary abnormality involves the choroidal circulation, and the characteristic lesion is an inner choroidal vascular network of vessels ending in an aneurysmal bulge or outward projection, visible clinically as a reddish orange, spheroid, polyp-like structure. We have also recognized that individuals of African-American and Asian descents are more at risk for developing polypoidal choroidal vasculopathy as the disorder seems to preferentially affect pigmented individuals. However, it has been shown that while that still holds true, patients of other racial backgrounds may be afflicted. Particularly, polypoidal choroidal vasculopathy has been found to be present in about 8-13% of white patients with clinical appearance of exudative age-related macular degeneration. Polypoidal choroidal vasculopathy has also been reported in Irish, French, German, and Italian patients. The natural course of the disease often follows a remitting-relapsing course, and clinically, it is associated with chronic, multiple, recurrent serosanguineous detachments of the retinal pigment epithelium and neurosensory retina with long-term preservation of good vision. Photodynamic treatment appears to be a promising alternative to conventional laser therapy, for the treatment of polypoidal choroidal vasculopathy. In conclusion, polypoidal choroidal vasculopathy seems to be a distinct clinical entity that should be differentiated from other types of choroidal neovascularization associated with age-related macular degeneration and other known choroidal degenerative, inflammatory, and ischemic disorders. (Surv Ophthalmol 49:25-37, 2004. (C) 2004 Elsevier Inc. All rights reserved.).
C1 Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Manhattan Eye Ear & Throat Hospital
RP Ciardella, AP (通讯作者)，Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, 210 E 64th St, New York, NY 10021 USA.
CR AUHJA RM, 2000, BR J OPHTHALMOL, V84, P479
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   CAPONE A, 1994, ARCH OPHTHALMOL-CHIC, V112, P1091, DOI 10.1001/archopht.1994.01090200097029
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Iijima Hiroyuki, 2000, Nippon Ganka Gakkai Zasshi, V104, P943
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   KLEINER RC, 1984, OPHTHALMOLOGY, V91, P941
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Lois N, 2001, BRIT J OPHTHALMOL, V85, P1011
   MACCUMBER MW, 1995, RETINA, V15, P11
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Mohand-Said M, 2002, J FR OPHTALMOL, V25, P517
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schneider U, 2001, OPHTHALMOLOGE, V98, P1186, DOI 10.1007/s003470170012
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi L A, 1992, Eur J Ophthalmol, V2, P103
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, FEBR 1982 MAC SOC M
   Yuzawa M, 2001, JPN J OPHTHALMOL, V45, P192, DOI 10.1016/S0021-5155(00)00378-6
NR 60
TC 266
Z9 284
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2004
VL 49
IS 1
BP 25
EP 37
DI 10.1016/j.survophthal.2003.10.007
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 765UN
UT WOS:000188302300002
PM 14711438
DA 2022-11-30
ER

PT J
AU Apte, RS
AF Apte, Rajendra S.
TI Age-Related Macular Degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; EYE DISEASE; GEOGRAPHIC ATROPHY;
   CHOLESTEROL EFFLUX; CIGARETTE-SMOKING; SEVERITY SCALE; BETA-CAROTENE;
   RISK-FACTORS; VISION LOSS; PROGRESSION
AB Age-Related Macular Degeneration Age-related macular degeneration is the leading cause of vision loss in older persons in industrialized nations. Micronutrient supplementation can reduce the risk of progression to advanced AMD. Treatment of neovascular AMD with anti-vascular endothelial growth factor pharmacotherapy reduces vision loss.
   Key Clinical Points Age-Related Macular Degeneration Age-related macular degeneration (AMD), the leading cause of vision loss in persons older than 60 years of age in industrialized nations, may be asymptomatic in early stages. A baseline examination by an eye care provider establishes the diagnosis of AMD and helps to determine the disease stage. Ancillary testing that includes optical coherence tomography is used in staging disease, guiding treatment, and assessing the response to therapy. Neovascular AMD is treated with anti-vascular endothelial growth factor pharmacotherapy. Treatment should be initiated soon after the diagnosis to prevent severe vision loss. Micronutrient supplementation, as tested in the Age-Related Eye Disease Studies, is recommended to reduce the risk of progression of intermediate-stage AMD to advanced AMD. Patients should be counseled regarding smoking cessation, blood-pressure control (if they have hypertension), and monitoring of their vision with an Amsler grid.
C1 [Apte, Rajendra S.] Washington Univ Sch Med, Dev Biol & Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ Sch Med, Dev Biol & Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@wustl.edu
OI Apte, Rajendra/0000-0003-2281-2336
FU NEI NIH HHS [R01 EY019287] Funding Source: Medline
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Csaky KG, 2019, SURV OPHTHALMOL, V64, P353, DOI 10.1016/j.survophthal.2019.01.014
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hwang CK, 2021, OPHTHALMOL RETINA, V5, P108, DOI 10.1016/j.oret.2020.10.008
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Ou WC, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.10
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Strunz T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102267
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub4
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 55
TC 13
Z9 13
U1 8
U2 33
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 5
PY 2021
VL 385
IS 6
BP 539
EP 547
DI 10.1056/NEJMcp2102061
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TZ7DN
UT WOS:000684629900012
PM 34347954
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shin, JY
   Choi, M
   Chung, B
   Byeon, SH
AF Shin, Joo Youn
   Choi, Moonjung
   Chung, Byunghoon
   Byeon, Suk Ho
TI Pigment epithelial tears after ranibizumab injection in polypoidal
   choroidal vasculopathy and typical age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Polypoidal choroidal vasculopathy; Ranibizumab; Retinal pigment
   epithelial tear
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR;
   CLINICOPATHOLOGICAL CORRELATION; INTRAVITREAL BEVACIZUMAB; NEOVASCULAR
   MEMBRANES; DETACHMENT; THERAPY; VERTEPORFIN; MICRORIPS; RISK
AB The purpose of the study was to compare the rates and characteristics of retinal pigment epithelial (RPE) tears between typical exudative age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV) after injection of intravitreal ranibizumab (IVR).
   In total, 836 eyes from 784 patients with exudative AMD treated with IVR were analyzed. The presence, type, size, and height of pigment epithelial detachment (PED) in OCT before injection were evaluated, and the occurrence rate of RPE tears within three months of injection between tAMD and PCV was compared.
   In total, 515 eyes (61.6 %) had tAMD and 321 eyes (38.4 %) were diagnosed as PCV. RPE tears developed in 18 eyes (3.5 %) in the tAMD group, while only two eyes (0.62 %) were associated with PCV (p = 0.009, Chi-square test). Eleven of the eighteen eyes with RPE tears in tAMD had fibrovascular PED with contractile neovascular tissue under the surface of the RPE and a cleft at baseline. Two eyes with RPE tears in PCV showed large hemorrhagic PED before presenting with an RPE tear.
   RPE tears after IVR were significantly less common in PCV than in tAMD. The different characteristics of RPE tears between the two disease entities suggest differences in the pathogenesis underlying the event.
C1 [Shin, Joo Youn; Choi, Moonjung; Chung, Byunghoon; Byeon, Suk Ho] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res,Severance Hosp, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res,Severance Hosp, 134 Shinchon Dong, Seoul 120752, South Korea.
EM shbyeon@yuhs.ac
OI Shin, Joo Youn/0000-0003-4543-477X; Byeon, suk ho/0000-0001-8101-0830
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2013R1A1A2007865]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (2013R1A1A2007865)
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   IE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443, DOI 10.1001/archopht.1992.01080220105030
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
NR 40
TC 12
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2015
VL 253
IS 12
BP 2151
EP 2160
DI 10.1007/s00417-015-2977-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CX0ZV
UT WOS:000365426900012
PM 25744335
DA 2022-11-30
ER

PT J
AU Liu, K
   Lai, TYY
   Ma, L
   Lai, FHP
   Young, AL
   Brelen, ME
   Tam, POS
   Pang, CP
   Chen, LJ
AF Liu, Ke
   Lai, Timothy Y. Y.
   Ma, Li
   Lai, Frank H. P.
   Young, Alvin L.
   Brelen, Marten E.
   Tam, Pancy O. S.
   Pang, Chi Pui
   Chen, Li Jia
TI Ethnic differences in the association of SERPING1 with age-related
   macular degeneration and polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FACTOR-H GENE; CLINICAL CHARACTERISTICS;
   CHINESE POPULATION; POLYMORPHISM; VARIANTS; SUSCEPTIBILITY; JAPANESE;
   LOCI
AB Neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of irreversible blindness in developed countries. In this study, we investigated the association of single nucleotide polymorphisms (SNPs) in the serpin peptidase inhibitor, clade G, member 1 (SERPING1) gene with neovascular AMD and PCV. Two haplotype-tagging SNPs, rs1005510 and rs11603020, of SERPING1 were genotyped in 708 unrelated Chinese individuals: 200 neovascular AMD, 233 PCV and 275 controls. A meta-analysis was also performed for all reported associations ofSERPING1 SNPs with AMD and PCV. None of the tagging SNPs had a significant association with neovascular AMD or PCV (P > 0.05) in our study cohort. The meta-analyses showed that the most-studied SNP rs2511989 was not significantly associated with all forms of AMD, neovascular AMD, or PCV in East Asians (P = 0.98, 0.93 and 0.30, respectively) but was associated with AMD in Caucasians (P = 0.04 for all AMD and 0.004 for neovascular AMD). Therefore, the results of our study and meta-analysis suggest that SERPING1 is not a major genetic component of AMD or PCV in East Asians but is a genetic risk factor for AMD in Caucasians, providing evidence for an ethnic diversity in the genetic etiology of AMD.
C1 [Liu, Ke; Lai, Timothy Y. Y.; Ma, Li; Young, Alvin L.; Brelen, Marten E.; Tam, Pancy O. S.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Ke] Shenzhen Eye Hosp, Shenzhen, Peoples R China.
   [Lai, Frank H. P.; Young, Alvin L.; Brelen, Marten E.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Liu, Ke] Shenzhen Key Lab Ophthalmol, Shenzhen, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Lai, Timothy Y Y/AAC-2120-2020; Brelen, Marten
   E./D-1133-2016
OI Chen, Li Jia/0000-0003-3500-5840; Lai, Timothy Y Y/0000-0002-7832-6428;
   Lai, Hiu Ping/0000-0002-4446-3790
FU Endowment Fund for Lim Por-Yen Eye Genetics Research Centre; Research
   Grants Council, Hond Kong [473410]
FX The authors express their gratitude to all participants in this study.
   This study was supported in part by an Endowment Fund for Lim Por-Yen
   Eye Genetics Research Centre and a General Research Fund from the
   Research Grants Council (grant number: 473410), Hong Kong.
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Carter JG, 2011, ACTA OPHTHALMOL, V89, pE212, DOI 10.1111/j.1755-3768.2009.01788.x
   Chen HY, 2012, MOL VIS, V18, P816
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lu F, 2010, MOL VIS, V16, P1
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park KH, 2009, MOL VIS, V15, P200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 41
TC 18
Z9 19
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 24
PY 2015
VL 5
AR 9424
DI 10.1038/srep09424
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE3CL
UT WOS:000351701900001
PM 25800435
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liang, XY
   Lai, TYY
   Liu, DTL
   Fan, AH
   Chen, LJ
   Tam, POS
   Chiang, SWY
   Ng, TK
   Lam, DSC
   Pang, CP
AF Liang, Xiao Ying
   Lai, Timothy Y. Y.
   Liu, David T. L.
   Fan, Alex H.
   Chen, Li Jia
   Tam, Pancy O. S.
   Chiang, Sylvia W. Y.
   Ng, Tsz Kin
   Lam, Dennis S. C.
   Pang, Chi Pui
TI Differentiation of Exudative Age-Related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy in the ARMS2/HTRA1 Locus
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; GENE POLYMORPHISMS; LOC387715 A69S; CFH;
   MACULOPATHY; POPULATION; VARIANTS; RISK; SUSCEPTIBILITY; CLASSIFICATION
AB PURPOSE. To differentiate the associations of exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) with the ARMS2/HTRA1 locus.
   METHODS. The entire ARMS2 sequence was sequenced and HTRA1 rs11200638 genotyped in 568 unrelated Chinese individuals: 156 exudative AMD patients, 164 PCV patients, and 248 controls. A meta-analysis was performed to examine the effects of rs10490924 and rs11200638 at the ARMS2/HTRA1 locus in PCV.
   RESULTS. In total, 31 polymorphisms in ARMS2 were identified. Significant associations with both exudative AMD and PCV were observed in 11 of them and HTRA1 rs11200638, with different genotypic distributions between exudative AMD and PCV (P < 0.001). After adjusting for rs11200638, ARMS2 rs10490924 remained significantly associated with exudative AMD (P = 0.011), but not with PCV (P = 0.077). Meta-analysis showed consistent allelic associations of rs10490924 and rs11200638 with PCV in different study populations.
   CONCLUSIONS. There is a strong and consistent association of the ARMS2/HTRA1 locus with both exudative AMD and PCV, suggesting the two disorders share, at least partially, similar molecular mechanisms. Different effect sizes indicate the existence of additional genetic and environmental factors affecting them to different extents. (Invest Ophthalmol Vis Sci. 2012;53:3175-3182) DOI:10.1167/iovs.11-8135
C1 [Liang, Xiao Ying; Lai, Timothy Y. Y.; Liu, David T. L.; Fan, Alex H.; Chen, Li Jia; Tam, Pancy O. S.; Chiang, Sylvia W. Y.; Ng, Tsz Kin; Lam, Dennis S. C.; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Pang, Chi P/I-5388-2014; Ng, Tsz
   Kin/I-8061-2014; Lam, Dennis/AAL-1211-2020; Lai, Timothy Y
   Y/AAC-2120-2020
OI Chen, Li Jia/0000-0003-3500-5840; Ng, Tsz Kin/0000-0001-7863-7229; Lai,
   Timothy Y Y/0000-0002-7832-6428
FU University Grants Committee; Endowment Fund for Lim Por-Yen Eye Genetics
   Research Centre; Research Grants Council, Hong Kong [473410]
FX Supported in part by a block grant from the University Grants Committee,
   the Endowment Fund for Lim Por-Yen Eye Genetics Research Centre, and the
   General Research Fund from the Research Grants Council (473410), Hong
   Kong.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 42
TC 34
Z9 35
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 3175
EP 3182
DI 10.1167/iovs.11-8135
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953JY
UT WOS:000304864600076
PM 22491416
DA 2022-11-30
ER

PT J
AU Coleman, H
   Chew, E
AF Coleman, Hanna
   Chew, Emily
TI Nutritional supplementation in age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; antioxidant vitamins; long-chain
   polyunsaturated fatty acids; lutein/zeaxanthin; macular edema; zinc
ID MODIFIABLE RISK-FACTORS; EYE DISEASE; ZEAXANTHIN; LUTEIN; CAROTENOIDS;
   ASSOCIATIONS; ANCILLARY; EFFICACY
AB Purpose of review
   This review assesses the current status of the knowledge of the role of nutrition in age-related macular degeneration - a leading cause of vision loss in the persons with European ancestry.
   Recent findings
   We will evaluate the different nutritional factors and both observational and interventional studies used to assess the association of nutrition with age-related macular degeneration. Persons with intermediate risk of age-related macular degeneration or advanced age-related macular degeneration in one eye are recommended to take the formulation proven in the Age-Related Eye Disease Study (AREDS) to be successful in preventing the development of advanced age-related macular degeneration by 25%. The formulation consists of vitamins C, E, beta-carotene and zinc. In addition, observational data suggest that high dietary intake of macular xanthophylls lutein and zeaxanthin are associated with a lower risk of advanced age-related macular degeneration. Similarly, long-chain polyunsaturated fatty acids derived from fish consumption are also associated with a decreased risk of advanced age-related macular degeneration.
   Summary
   Persons with intermediate age-related macular degeneration or advanced age-related macular degeneration (neovascular or central geographic atrophy) in one eye should consider taking the AREDS-type supplements. Further evaluation of nutritional factors, specifically, lutein/zeaxanthin and omega-3 fatty acids will be tested in a multicenter controlled, randomized trial - the Age-Related Eye Disease Study 2 (AREDS2).
C1 NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, E (通讯作者)，NEI, Div Epidemiol & Clin Res, NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
FU Intramural NIH HHS [Z99 EY999999, ZIA EY000489-01] Funding Source:
   Medline
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Trumbo PR, 2006, AM J CLIN NUTR, V84, P971, DOI 10.1093/ajcn/84.5.971
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
NR 16
TC 61
Z9 70
U1 4
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2007
VL 18
IS 3
BP 220
EP 223
DI 10.1097/ICU.0b013e32814a586b
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162BL
UT WOS:000246061200007
PM 17435429
DA 2022-11-30
ER

PT J
AU Li, FT
   Li, YJ
   Li, MW
   Sun, YY
   Bai, YJ
   Yang, F
   Guo, J
   Chen, Y
   Huang, LZ
   Li, XX
AF Li, Fangting
   Li, Yingjie
   Li, Mingwu
   Sun, Yaoyao
   Bai, Yujing
   Yang, Fei
   Guo, Jing
   Chen, Yi
   Huang, Lvzhen
   Li, Xiaoxin
TI ABCA1 rs1883025 Polymorphism Shows No Association with Neovascular
   Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy in
   a Northern Chinese Population
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration, neovascular; Polypoidal choroidal
   vasculopathy; ABCA1; High-density lipoprotein cholesterol; Northern
   Chinese population
ID ATP-BINDING CASSETTE; GENETIC-VARIANTS; COMMON VARIANTS; LOCI;
   SUSCEPTIBILITY; THERAPY; CLONING; TIMP3; RISK
AB Purpose: To analyze the association between ABCA1 rs1883025 variants with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in a northern Chinese population. Methods: The study enrolled 900 subjects, including 300 controls, 300 cases with nAMD and 300 cases with PCV. Genomic DNA was extracted from venous blood leukocytes. Single-nucleotide polymorphisms in the ABCA1 (rs1883025) gene were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: The ABCA1 rs1883025 polymorphism was not significantly associated with nAMD (22.5%; p>0.05) or PCV (20.8%; p>0.05) in a northern Chinese population. The association remained insignificant after adjustment for age and gender differences (p>0.05). Conclusions: This study suggests that ABCA1 rs1883025 variants are not associated with nAMD or PCV in a Chinese population, which is likely due to an ethnic difference. (C) 2014 S. Karger AG, Basel
C1 [Li, Fangting; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Yang, Fei; Guo, Jing; Chen, Yi; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Li, Fangting; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Yang, Fei; Guo, Jing; Chen, Yi; Huang, Lvzhen; Li, Xiaoxin] Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Vis Loss & Restorat, Minist Educ, Beijing 100730, Peoples R China.
   [Li, Fangting; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Yang, Fei; Guo, Jing; Chen, Yi; Huang, Lvzhen; Li, Xiaoxin] Chinese Acad Med Sci, Peking Union Med Coll, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100730, Peoples R China.
   [Li, Yingjie] Chinese Acad Med Sci, Peking Union Med Coll, Dept Abdominal Surg Oncol, Canc Inst & Hosp, Beijing 100730, Peoples R China.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Cancer Institute & Hospital - CAMS; Peking Union Medical
   College
RP Huang, LZ (通讯作者)，Peking Univ, Peoples Hosp, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM huanglvzhen@126.com
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX This study was supported by the National Basic Research Program of China
   (973 Program; No. 2011CB510200), the National Natural Science Foundation
   of China (grant No. 81100666) and the Research Fund for Science and
   Technology Program of Beijing (No. Z121100005312006).
CR Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406
   LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Qin Xue-ying, 2012, Beijing Da Xue Xue Bao Yi Xue Ban, V44, P407
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987
   Sayen Alexandra, 2011, Rev Prat, V61, P159
   Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shen WY, 2003, J GENE MED, V5, P576, DOI 10.1002/jgm.375
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yokoyama S, 2006, J ATHEROSCLER THROMB, V13, P1, DOI 10.5551/jat.13.1
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 36
TC 7
Z9 7
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 51
IS 4
BP 210
EP 215
DI 10.1159/000357978
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH2GG
UT WOS:000335938900006
PM 24685762
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI IMPROVING THE AGE-RELATED MACULAR DEGENERATION CONSTRUCT A New
   Classification System
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; drusen; atrophy; geographic atrophy;
   macular neovascularization; optical coherence tomography; pachydrusen;
   pseudodrusen; soft drusen; subretinal drusenoid deposit
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SUBRETINAL DRUSENOID DEPOSITS;
   OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   RETINITIS PUNCTATA ALBESCENS; LARGE COLLOID DRUSEN; RETICULAR
   PSEUDODRUSEN; CLINICAL CHARACTERISTICS; GEOGRAPHIC ATROPHY; TYPE-3
   NEOVASCULARIZATION
AB Previous models of disease in age-related macular degeneration (AMD) were incomplete in that they did not encompass subretinal drusenoid deposits (pseudodrusen), subtypes of neovascularization, and polypoidal choroidal vasculopathy. In addition, Type 3 neovascularization starts in the retina and may not necessarily involve the choroid. As such, the term choroidal neovascularization is not appropriate for these eyes. The new aspects in the AMD construct are to include specific lipoprotein extracellular accumulations, namely drusen and subretinal drusenoid deposits, as early AMD. The deposition of specific types of deposit seems to be highly correlated with choroidal thickness and topographical location in the macula. Late AMD includes macular neovascularization or atrophy. The particular type of extracellular deposit is predictive of the future course of the patient. For example, eyes with subretinal drusenoid deposits have a propensity to develop outer retinal atrophy, complete outer retinal and retinal pigment epithelial atrophy, or Type 3 neovascularization as specific forms of late AMD. Given Type 3 neovascularization may never involve the choroid, the term macular neovascularization is suggested for the entire spectrum of neovascular disease in AMD. In contrast to older classification systems, the proposed system encompasses the relevant presentations of disease and more precisely predicts the future course of the patient. In doing so, the concept was developed that there may be genetic risk alleles, which are not necessarily the same alleles that influence disease expression.
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
   [Spaide, Richard F.] LuEsther T Mertz Retina Res Lab, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU Macula Foundation, New York, NY; Topcon Medical Systems; Heidelberg
   Engineering
FX Supported in part by the Macula Foundation, New York, NY.; The author
   receives royalties and consulting fees from Topcon Medical Systems,
   royalties from DORC, and has received consulting fees from Heidelberg
   Engineering.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   De Bats F, 2013, ISRN OPHTHALMOL, V16
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Guigui B, 2013, RETINA-J RET VIT DIS, V33, P1346, DOI 10.1097/IAE.0b013e318283127d
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Invernizzi A, 2017, AM J OPHTHALMOL, V175, P68, DOI 10.1016/j.ajo.2016.11.014
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kamami-Levy C, 2014, J FR OPHTALMOL, V37, P780, DOI 10.1016/j.jfo.2014.06.003
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Littink KW, 2012, OPHTHALMOLOGY, V119, P1899, DOI 10.1016/j.ophtha.2012.02.037
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Marques JP, 2015, RETINA-J RET VIT DIS, V35, P1985, DOI 10.1097/IAE.0000000000000619
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mathis T, 2016, OSLI RETINA, V47, P1154, DOI 10.3928/23258160-20161130-12
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2009, ARCH OPHTHALMOL-CHIC, V127, P703, DOI 10.1001/archophthalmol.2009.87
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Small KW, 2016, OPHTHALMOLOGY, V123, P9, DOI 10.1016/j.ophtha.2015.10.006
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, DIS EXPRESSION NONEX
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vincent A, 2012, RETINA-J RET VIT DIS, V32, P1643, DOI 10.1097/IAE.0b013e318240a574
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2012, KLIN MONATSBL AUGENH, V229, P399, DOI 10.1055/s-0031-1299404
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 94
TC 76
Z9 76
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2018
VL 38
IS 5
BP 891
EP 899
DI 10.1097/IAE.0000000000001732
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2BU
UT WOS:000440625700013
PM 28557901
DA 2022-11-30
ER

PT J
AU Feng, J
   Chen, L
   Yuan, MK
   Pan, CT
   Jiang, YR
AF Feng, Jing
   Chen, Li
   Yuan, Mengke
   Pan, Chungting
   Jiang, Yanrong
TI Aqueous humor levels of cytokines in polypoidal choroidal vasculopathy
   and age-related macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Polypoidal choroidal vasculopathy; age-related macular degeneration;
   aqueous humor; cytokines
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   INTRAVITREAL TRIAMCINOLONE; INFLAMMATORY CYTOKINES; PHOTODYNAMIC
   THERAPY; VITREOUS LEVELS; TNF-ALPHA; BEVACIZUMAB; NEOVASCULARIZATION;
   ANGIOGENESIS
AB Objective: To investigate the differential aqueous concentrations of interleukin 6 (IL-6), interferon alpha (IFN alpha), monocyte chemoattractant protein 1 (MCP1), tumor necrosis factor alpha (TNF alpha), transforming growth factor beta (TGF beta), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) in eyes with polypoidal choroidal vasculopathy (PCV) or age-related macular degeneration (AMD). Methods: The clinical interventional study included a control group of 8 patients who underwent cataract surgery and a study group of 25 patients with either PCV or AMD. Aqueous humor samples were obtained. Cytokine expression in the aqueous humor samples was measured by Luminex X-MAP technology. Results: Significantly higher concentrations of MCP1 and TNF alpha were found in the aqueous humor of PCV and AMD patients than those in the aqueous humor of control patients. TGF beta was significantly higher in the aqueous humor of AMD patients than that of the control group (P=0.004). The level of VEGF was not significantly different among groups. In the neovascular AMD group, aqueous levels of IL6 and MCP1 were significantly associated with retinal thickness at 3 mm and 6 mm (P=0.017, P=0.027, respectively). In the PCV group, aqueous level of VEGF was significantly associated with retinal thickness at 1 mm and 6 mm (P=0.024, P=0.042, respectively). Conclusion: Besides VEGF, other inflammatory cytokines and angiogenesic factors, like MCP1, TGF beta and TNF alpha may be associated with PCV and AMD, especially with AMD. This finding may have implications for the medical treatment of PCV and AMD.
C1 [Feng, Jing; Jiang, Yanrong] Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Feng, Jing] PLA Rocket Force Gen Hosp, Beijing, Peoples R China.
   [Chen, Li] Beijing Jian Gong Hosp, Beijing, Peoples R China.
   [Yuan, Mengke] Gen Hosp, Beijing Jingmei Grp, Beijing, Peoples R China.
   [Pan, Chungting; Jiang, Yanrong] Peking Univ, Int Hosp, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Jiang, YR (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM bluefu-ture2008@163.com
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Forte R, 2010, ACTA OPHTHALMOL, V88, pe305, DOI 10.1111/j.1755-3768.2010.02021.x
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Petrovic MG, 2007, AM J OPHTHALMOL, V143, P175, DOI 10.1016/j.ajo.2006.07.032
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kobayashi S, 2005, BIOL PHARM BULL, V28, P242, DOI 10.1248/bpb.28.242
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee WJ, 2012, BRIT J OPHTHALMOL, V96, P1426, DOI 10.1136/bjophthalmol-2012-301913
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Ma Y, 2011, AM J OPHTHALMOL, V152, P678, DOI 10.1016/j.ajo.2011.03.007
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Serrati S, 2009, BIOCHEM PHARMACOL, V77, P813, DOI 10.1016/j.bcp.2008.10.036
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Silva R, 2012, OPHTHALMOLOGICA, V228, P197, DOI 10.1159/000339893
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
NR 46
TC 2
Z9 2
U1 3
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 7
BP 7270
EP 7278
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GO8WE
UT WOS:000440379700101
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Mori, K
   Nakata, I
   Tsuchihashi, T
   Horie-Inoue, K
   Nakanishi, H
   Tsujikawa, A
   Saito, M
   Iida, T
   Yamada, R
   Matsuda, F
   Inoue, S
   Awata, T
   Yoneya, S
   Yoshimura, N
AF Yamashiro, Kenji
   Mori, Keisuke
   Nakata, Isao
   Tsuchihashi, Takashi
   Horie-Inoue, Kuniko
   Nakanishi, Hideo
   Tsujikawa, Akitaka
   Saito, Masaaki
   Iida, Tomohiro
   Yamada, Ryo
   Matsuda, Fumihiko
   Inoue, Satoshi
   Awata, Takuya
   Yoneya, Shin
   Yoshimura, Nagahisa
TI Association of Elastin Gene Polymorphism to Age-Related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; PHOTODYNAMIC THERAPY; NO ASSOCIATION;
   SUSCEPTIBILITY; MULTICENTER; INCREASES; MEMBRANES; VARIANT; HYOGO; RISK
AB PURPOSE. To see if there is an association in Japanese between elastin gene (ELN) polymorphisms and neovascular age-related macular degeneration (AMD) or its subtypes, typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV).
   METHODS. The authors genotyped five single nucleotide polymorphisms (SNPs), rs2301995, rs2856728, rs868005, rs884843, and rs13239907, at Kyoto University and Saitama Medical University. A case-control study was performed on 1296 patients with AMD and 478 controls.
   RESULTS. A statistically significant association was detected between the rs2301995 SNP and AMD (P = 0.018). Furthermore, subtype analysis revealed a significant association of rs2301995 with tAMD (P = 0.0018), but not with PCV. The genotype distribution of rs2301995 also differed significantly between tAMD and PCV (P = 0.00030). The trend in genotype distribution of rs2301995 was similar between the Kyoto and the Saitama studies. The A allele frequency was higher in tAMD, whereas it was similar in PCV and in controls, which is opposite to that reported in a previous study that the A allele frequency is higher in PCV, whereas it is similar in tAMD and in controls. Haplotype analysis also showed that the ELN polymorphism is significantly associated with tAMD (P = 0.0055), but not with PCV.
   CONCLUSIONS. ELN is associated with AMD in Japanese. Furthermore, the findings suggest that ELN is a susceptibility gene for tAMD but not for PCV, which is opposite to that reported in a previous study that ELN is the susceptibility gene for PCV but not for tAMD. (Invest Ophthalmol Vis Sci. 2011;52:8780-8784) DOI:10.1167/iovs.11-8205
C1 [Yamashiro, Kenji; Nakata, Isao; Nakanishi, Hideo; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 6068507, Japan.
   [Nakata, Isao; Nakanishi, Hideo; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto 6068507, Japan.
   [Mori, Keisuke; Tsuchihashi, Takashi; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama, Japan.
   [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, Iruma, Saitama, Japan.
   [Awata, Takuya] Saitama Med Univ, Div Endocrinol & Diabet, Dept Med, Iruma, Saitama, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
C3 Kyoto University; Kyoto University; Saitama Medical University; Saitama
   Medical University; Saitama Medical University; Fukushima Medical
   University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Awata, Takuya/0000-0003-2622-8129;
   Yamada, Ryo/0000-0002-1587-630X; Yamashiro, Kenji/0000-0001-9354-8558;
   Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (Tokyo, Japan) [21249084,
   200791294]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX Supported in part by the Japan Society for the Promotion of Science
   (Tokyo, Japan) Grants-in-Aid for Scientific Research 21249084 and
   200791294, and the Japan National Society for the Prevention of
   Blindness, Tokyo, Japan.
CR Chen LJ, 2006, MOL VIS, V12, P1536
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
NR 39
TC 19
Z9 20
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 8780
EP 8784
DI 10.1167/iovs.11-8205
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400005
PM 22003121
DA 2022-11-30
ER

PT J
AU Gotoh, N
   Kuroiwa, S
   Kikuchi, T
   Arai, J
   Arai, S
   Yoshida, N
   Yoshimura, N
AF Gotoh, N
   Kuroiwa, S
   Kikuchi, T
   Arai, J
   Arai, S
   Yoshida, N
   Yoshimura, N
TI Apolipoprotein E polymorphisms in Japanese patients with polypoidal
   choroidal vasculopathy and exudative age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; E GENE; EPSILON-4 ALLELE; TYPE-4 ALLELE;
   E PHENOTYPE; ASSOCIATION; RISK; FREQUENCY; FEATURES; DISEASE
AB PURPOSE: To study the genotypes, allelic frequencies, and polymorphisms of apolipoprotein E (Apo E) in unrelated Japanese patients with polypoidal choroidal vasculopathy (PCV) or exudative age-related macular degeneration (AMD) and control subjects without macular degeneration.
   DESIGN: Cross-sectional study.
   METHODS: Blood samples from 225 subjects older than 50 years were used. The 225 subjects included 58 patients with PCV, 85 with AMD, and 82 without macular degeneration. Coding exons of the Apo E gene were amplified by polymerase chain reaction, and the DNA sequences were determined by direct sequencing with an automated sequencer.
   RESULTS: Apo E epsilon3epsilon3 was the most frequent genotype with a prevalence of 79.3% in PCV patients, 76.5% in AMD patients, and 67.1% in the control subjects. However, the differences in the percentages were not statistically significant among the three groups. The most frequently found allele in the three groups was epsilon3. Patients with PCV and AMD were less likely to have epsilon2 and epsilon4 than the control subjects, but the differences were not statistically significant. Five minor Apo E single nucleotide polymorphisms, including epsilon5 and epsilon7, were found.
   CONCLUSION: Japanese patients with PCV and AMD were less likely to have epsilon2 and epsilon4 polymorphisms, but the differences from the normals were not statistically significant for the Apo E genotypes and allelic frequencies. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
   Shinshu Univ, Res Ctr Human & Environm Sci, Matsumoto, Nagano 3908621, Japan.
C3 Shinshu University; Shinshu University
RP Yoshimura, N (通讯作者)，Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
EM nagaeye@hsp.md.shinshu-u.ac.jp
CR Copin B, 2002, AM J HUM GENET, V70, P1575, DOI 10.1086/340733
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   DEKNIJFF P, 1994, LANCET, V343, P1234, DOI 10.1016/S0140-6736(94)92451-1
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GHISELLI G, 1982, LANCET, V2, P405
   Katsuya T, 2002, J HYPERTENS, V20, P2017, DOI 10.1097/00004872-200210000-00021
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   MAEDA H, 1989, J BIOCHEM-TOKYO, V105, P51, DOI 10.1093/oxfordjournals.jbchem.a122618
   MATSUNAGA A, 1995, CLIN GENET, V48, P93
   MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310
   Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Ressiniotis T, 2004, ARCH OPHTHALMOL-CHIC, V122, P258, DOI 10.1001/archopht.122.2.258
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Schmidt S, 2000, MOL VIS, V6, P287
   SCHMIDT S, 2003, OPTHALMIC GENET, V23, P209
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Shastry BS, 2002, J HUM GENET, V47, P561, DOI 10.1007/s100380200086
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977
   TAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P48, DOI 10.1093/oxfordjournals.jbchem.a122420
   UUSITUPA M, 1994, LANCET, V343, P57, DOI 10.1016/S0140-6736(94)90912-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vickers JC, 2002, MOL VIS, V8, P389
   Yamamura T, 1999, J LIPID RES, V40, P253
   YAMANOUCHI Y, 1994, JPN J HUM GENET, V39, P315, DOI 10.1007/BF01874050
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 34
Z9 39
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2004
VL 138
IS 4
BP 567
EP 573
DI 10.1016/j.ajo.2004.05.025
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 864UO
UT WOS:000224658600008
PM 15488782
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Bhargava, M
   Xiang, L
   Mathur, R
   Mun, CC
   Wong, D
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Bhargava, Mayuri
   Xiang, Li
   Mathur, Ranjana
   Mun, Chan Choi
   Wong, Doric
   Wong, Tien Yin
TI Six-month visual prognosis in eyes with submacular hemorrhage secondary
   to age-related macular degeneration or polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Submacular hemorrhage; Optical coherence tomography; Prognosis;
   Age-related macular degeneration
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; PHOTODYNAMIC THERAPY; NATURAL-HISTORY; RANIBIZUMAB;
   MANAGEMENT; GAS; INJECTION; LESIONS
AB To determine clinical or imaging prognostic features for visual outcome in eyes with submacular hemorrhage secondary to age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
   A prospective case series of 11 eyes from 11 patients with submacular hemorrhage secondary to AMD or PCV. All participants had measurement of clinical characteristics, fundus angiogram, and indocyanine green angiography, spectral domain optical coherence tomography (OCT, Cirrus, Zeiss) at baseline and 6 months.
   Median visual acuity improved from 20/132 to 20/63 at month 6. The median improvement in vision was 0.20 LogMAR units. Proportion of eyes with best-corrected visual acuity (BCVA) a parts per thousand yen1.0 increased from 6/11 (54.5 %) at baseline to 8/11 (72.7 %) at month 6. Eyes with BCVA > 1.0 were more likely to have larger area of hemorrhage and thinner subfoveal neurosensory retinal thickness at baseline and at month 6.
   Thinner neurosensory retina demonstrated on OCT at baseline may be a useful prognostic sign for limited visual recovery.
C1 [Cheung, Chui Ming Gemmy; Bhargava, Mayuri; Mathur, Ranjana; Mun, Chan Choi; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Bhargava, Mayuri; Xiang, Li; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Bhargava, Mayuri; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Cheung, CMG (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
FU National Medical Research Council [NMRC/NIG/1003/2009]
FX This study was supported by National Medical Research Council grant
   NMRC/NIG/1003/2009.
CR Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Todorich B, 2011, RETINA-J RET VIT DIS, V31, P1749, DOI 10.1097/IAE.0b013e31821504df
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 21
Z9 22
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2013
VL 251
IS 1
BP 19
EP 25
DI 10.1007/s00417-012-2029-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064KP
UT WOS:000313074100004
PM 22638617
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Bordato, A
   Amato, A
   Borghesan, F
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Bordato, Alessandro
   Amato, Alessia
   Borghesan, Federico
   Bandello, Francesco
   Parodi, Maurizio B.
TI QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PARAMETER
   VARIATIONS AFTER TREATMENT OF MACULAR NEOVASCULARIZATION SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; OCT; OCTA; MNV; vessel density; vessel
   tortuosity; evolution
ID CHOROIDAL NEOVASCULARIZATION; TYPE-1
AB Purpose: Macular neovascularization (MNV) secondary to age-related macular degeneration can be characterized by quantitative optical coherence tomography angiography. The aim of the study was to assess the evolution of quantitative optical coherence tomography angiography parameters after 1 year of antivascular endothelial growth factor injections. Methods: Naive age-related macular degeneration-related MNV eyes were prospectively recruited to analyze optical coherence tomography and optical coherence tomography angiography parameters, including MNV vessel tortuosity (VT) and reflectivity, at baseline and at the end of the follow-up. Macular neovascularization eyes were categorized by a MNV VT cutoff, and quantitative parameter variations were documented after 1 year of treatment. We divided MNV eyes into Group 1 (MNV VT < 8.40) and Group 2 (MNV VT > 8.40). Results: Thrity naive age-related macular degeneration-related MNV eyes (30 patients) were included. Our cohort included 18 Type 1 MNV and 12 Type 2 MNV lesions. Baseline central macular thickness (411 +/- 85 mu m) improved to 323 +/- 54 mu m at 1 year (P < 0.01). Only Group 1 MNV displayed significant visual improvement. Macular neovascularization VT values remained stable over the follow-up in both subgroups. Group 2 MNV eyes showed increased MNV reflectivity and increased MNV area at the end of the follow-up. Quantitative retinal capillary plexa parameters were found to be worse in Group 2 MNV. Outer retinal atrophy occurred in 2 of the 18 eyes in MNV Group 1 (11%) and in 6 of the 12 eyes in MNV Group 2 (50%) after 1 year. Vessel density proved to be always worse in Group 2 than in Group 1. Conclusion: Macular neovascularization VT provides information on the blood flow and identifies two subgroups with different final anatomical and visual outcomes, regardless of the treatment effect.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Bordato, Alessandro; Amato, Alessia; Borghesan, Federico; Bandello, Francesco; Parodi, Maurizio B.] Univ Vita Salute San Raffaele, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Adler P., 2013, POROUS MEDIA GEOMETR
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Goldman D, 2000, J THEOR BIOL, V206, P181, DOI 10.1006/jtbi.2000.2113
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Nelis P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26475-5
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Tomita Y, 2005, J CEREBR BLOOD F MET, V25, P858, DOI 10.1038/sj.jcbfm.9600077
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 19
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2021
VL 41
IS 7
BP 1463
EP 1469
DI 10.1097/IAE.0000000000003065
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5LP
UT WOS:000711809200015
PM 33315820
DA 2022-11-30
ER

PT J
AU Roh, HC
   Kim, SJ
   Kang, SW
   Eun, JS
   Choi, KJ
AF Roh, Hyeon Cheol
   Kim, Sang Jin
   Kang, Se Woong
   Eun, Jun Soo
   Choi, Kyung Jun
TI Long-term outcomes of polypoidal choroidal vasculopathy in comparison
   with typical exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Long-term outcomes of treatment;
   Polypoidal choroidal vasculopathy
ID INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; VERTEPORFIN; SUBTYPES;
   ATROPHY
AB Purpose To compare long-term outcomes between typical exudative age-related macular degeneration (TexAMD) and polypoidal choroidal vasculopathy (PCV), and to investigate factors related to the outcomes.
   Methods This retrospective study included 319 eyes (164 with TexAMD and 155 with PCV) treated with anti-vascular endothelial growth factor and followed more than 5 years. The primary outcome was visual acuity (VA) change from baseline to final visit. Linear regression analyses were used to determine factors associated with final VA.
   Results Baseline logMAR VA was 0.7 +/- 0.5 in the TexAMD group and 0.5 +/- 0.4 in the PCV group (p < 0.001). After a mean follow-up of 9 years, final VA was also significantly worse in the TexAMD group than in the PCV group (0.9 +/- 0.6 vs. 0.6 +/- 0.5; p < 0.001). The PCV group showed longer maintenance of improved vision and later onset of significant visual decline than the TexAMD group. In multivariate analysis, loss to follow-up, worse baseline VA, macular atrophy, and subretinal fibrosis were significantly associated with poor final VA in both groups.
   Conclusion PCV eyes showed relatively favorable long-term visual outcome than TexAMD eyes. The results of this study emphasized the importance of compliance with treatment, along with other well-known prognostic factors.
C1 [Roh, Hyeon Cheol; Kim, Sang Jin; Kang, Se Woong; Eun, Jun Soo; Choi, Kyung Jun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Roh, Hyeon Cheol] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Ophthalmol, Chang Won, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM swkang@skku.edu
OI Roh, Hyeon Cheol/0000-0003-2157-6087
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Horner F, 2019, CLIN OPHTHALMOL, V13, P2461, DOI 10.2147/OPTH.S218378
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
NR 35
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2022
VL 260
IS 1
BP 83
EP 92
DI 10.1007/s00417-021-05190-4
EA AUG 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YI0WK
UT WOS:000681163000003
PM 34350467
DA 2022-11-30
ER

PT J
AU Ahmadi, MA
   Lim, JI
AF Ahmadi, M. Amir
   Lim, Jennifer I.
TI Pharmacotherapy of age-related macular degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE age-related macular degeneration; anti-VEGF; combination therapy;
   geographic atrophy; pharmacotherapy; photodynamic therapy
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   EPITHELIUM-DERIVED FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; METASTATIC
   COLORECTAL-CANCER; RANDOMIZED CLINICAL-TRIAL; FACTOR-H POLYMORPHISM;
   OCULAR NEOVASCULARIZATION; FACTOR VEGF; IN-VIVO
AB Background: Age-related macular degeneration is the leading cause of blindness in the developed world. The number of persons with vision loss from age-related macular degeneration is projected to increase dramatically over the next few decades. Therefore, effective therapeutic and prophylactic agents are greatly needed. Objective: This article will discuss some of the newer treatment strategies that may help to reduce the incidence of visual loss from age-related macular degeneration. Some of these therapies and strategies can be implemented today, while many are hypothetical based on current laboratory data and ongoing clinical trials. Methods: A review of the literature and ongoing clinical trials was undertaken. Conclusion: Current therapies using antioxidants for prevention of the progression of age-related macular degeneration and anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration have given us tools for tackling this disease better and reducing the number of patients with vision loss. Combinations of some of the existing treatments and new forms of therapy may yet further decrease the treatment burden in the future.
C1 [Lim, Jennifer I.] Univ Illinois, Dept Ophthalmol, Illinois Eye & Ear Infirm, Retina Serv, Chicago, IL 60612 USA.
   [Ahmadi, M. Amir] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Lim, JI (通讯作者)，Univ Illinois, Dept Ophthalmol, Illinois Eye & Ear Infirm, Retina Serv, Suite 2-50,MC 648,1855 W Taylor St, Chicago, IL 60612 USA.
EM jennylim@uic.edu
FU Genentech and honoraria from Pfizer
FX This manuscript was funded by a Core grant and the Cless Retina fund.
   Jennifer I Lim has received grants from Genentech and honoraria from
   Pfizer, Allergan, Optovue and Genentech.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Debefve E, 2008, ANGIOGENESIS, V11, P235, DOI 10.1007/s10456-008-9106-4
   Dejneka NS, 2004, MOL VIS, V10, P964
   Easton JB, 2004, EXPERT OPIN THER TAR, V8, P551, DOI 10.1517/14728222.8.6.551
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KAISER PK, 2007, AAO ANN M
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   NGUYEN Q, 2007, RET SOC ANN SCI M BO
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nilsson B, 1998, BLOOD, V92, P1661, DOI 10.1182/blood.V92.5.1661
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Silva RLE, 2006, EXP EYE RES, V83, P1260, DOI 10.1016/j.exer.2006.07.003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Speicher Matthew A, 2003, Expert Opin Emerg Drugs, V8, P239, DOI 10.1517/14728214.8.1.239
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   THOMPSON JT, 2006, AAO ANN M
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEN R, 2005, INVEST OPHTHALMOL VI, V46
NR 51
TC 6
Z9 7
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD DEC
PY 2008
VL 9
IS 17
BP 3045
EP 3052
DI 10.1517/14656560802473480
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 377AR
UT WOS:000261224600009
PM 19006477
OA Green Published
DA 2022-11-30
ER

PT J
AU Kondo, N
   Bessho, H
   Honda, S
   Negi, A
AF Kondo, Naoshi
   Bessho, Hiroaki
   Honda, Shigeru
   Negi, Akira
TI SOD2 gene polymorphisms in neovascular age-related macular degeneration
   and polypoidal choroidal vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT COMPONENT 2; MANGANESE SUPEROXIDE-DISMUTASE; MULTILOCUS
   GENOTYPE DATA; FACTOR-H POLYMORPHISM; FACTOR-B BF; POPULATION-STRUCTURE;
   CODING VARIANT; CANCER RISK; ASSOCIATION; SUSCEPTIBILITY
AB Purpose: A nonsynonymous coding variant in the manganese superoxide dismutase (SOD2) gene (V16A, rs4880) has been implicated in neovascular age-related macular degeneration (AMD). However, the findings have been inconsistent. Two studies in Japanese populations reported an opposite direction of association of the same allele at the V16A variant, whereas one study in a Northern Irish population found no effect of the variant on the risk of developing neovascular AMD. To address these apparently contradictory reports, we validated the association in a Japanese population.
   Methods: In a Japanese population, we genotyped the V16A variant in 116 neovascular AMD patients, 140 polypoidal choroidal vasculopathy (PCV) patients, and 189 control participants. This association was also tested in a population of PCV participants to avoid variable findings across studies due to underlying sample heterogeneity and because disease phenotype was not well described in previous studies. We analyzed a tagging single nucleotide polymorphism (SNP) in addition to the V16A variant to capture all common SOD2 variations verified by the HapMap project. Genotyping was conducted using TaqMan technology. Associations were tested using single-SNP and haplotype analyses as well as a meta-analysis of the published literature. Population stratification was also evaluated in our study population.
   Results: We found no detectable association of the V16A variant or any other common SOD2 variation with either neovascular AMD or PCV, as demonstrated by both single-SNP and haplotype analyses. Population structure analyses precluded stratification artifacts in our study cohort. A meta-analysis of the association between the V16A variant and neovascular AMD also failed to detect a significant association.
   Conclusions: We found no evidence to support the role of any common SOD2 variations including the V16A variant in the susceptibility to neovascular AMD or PCV. Our study highlights the importance and difficulty in replicating genetic association studies of complex human diseases.
C1 [Kondo, Naoshi; Bessho, Hiroaki; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Kondo, N (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM nskondo@gmail.com
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science, and Culture, Tokyo, Japan [17591836]
FX This study was supported by a Grant-in-Aid (C) 17591836 from the
   Ministry of Education, Science, and Culture, Tokyo, Japan. The authors
   have no financial or conflicting interests to disclose.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bessho H, 2009, MOL VIS, V15, P1107
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cox A, 2007, NAT GENET, V39, P352, DOI 10.1038/ng1981
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Falush D, 2003, GENETICS, V164, P1567
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kubo M, 2007, NAT GENET, V39, P212, DOI 10.1038/ng1945
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen AR, 2005, J NEUROIMMUNOL, V166, P197, DOI 10.1016/j.jneuroim.2005.06.002
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pearce CL, 2008, HUM MOL GENET, V17, P2456, DOI 10.1093/hmg/ddn145
   Pritchard JK, 2000, GENETICS, V155, P945
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yamada K, 2007, P NATL ACAD SCI USA, V104, P2815, DOI 10.1073/pnas.0610765104
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 61
TC 23
Z9 24
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 9
PY 2009
VL 15
IS 193
BP 1819
EP 1826
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 501OT
UT WOS:000270391900001
PM 19753309
DA 2022-11-30
ER

PT J
AU Cho, SC
   Cho, J
   Park, KH
   Woo, SJ
AF Cho, Soo Chang
   Cho, JoonHee
   Park, Kyu Hyung
   Woo, Se Joon
TI Massive submacular haemorrhage in polypoidal choroidal vasculopathy
   versus typical neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE incidence rate; massive submacular haemorrhage; polypoidal choroidal
   vasculopathy; typical neovascular age&#8208; related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL HEMORRHAGE; NATURAL-HISTORY
AB Purpose To investigate the incidence rate of massive submacular haemorrhage (SMH) and risk factors in polypoidal choroidal vasculopathy (PCV) and typical neovascular age-related macular degeneration (tnAMD).
   Methods A total of 465 patients who were diagnosed with either PCV (n = 245) or tnAMD (n = 220) from 2003 to 2014 were enrolled. Cumulative incidence of massive SMH in PCV and that in tnAMD were compared. Risk factors of massive SMH were also analysed.
   Results Massive SMH occurred in 32 patients (13.1%) with PCV and 9 patients (4.1%) with tnAMD. Incidence rates of massive SMH 5 and 10 years after the first visit were 11.1% and 29.9% in PCV and 4.3% and 9.9% in tnAMD, respectively. Incidence rates of massive SMH in PCV were significantly higher than those in tnAMD (hazard ratio [HR], 2.66; p = 0.007). Cox regression analysis revealed that mean number of photodynamic therapies (PDTs) per year (HR, 4.24; p < 0.001), cluster type of polypoidal lesion (HR, 3.42; p = 0.003) in PCV, and mean number of anti-VEGF injections per year (HR, 1.58; p < 0.001) in tnAMD were significantly associated with risk of massive SMH. For patients with severe vision loss, proportion of incident massive SMH was significantly higher in PCV (29.5%) than in tnAMD (6.9%, p < 0.001).
   Conclusion The incidence rate of massive SMH in eyes with PCV was about three times higher than that in eyes with tnAMD. Treatment methods that can reduce the incidence of massive SMH should be considered, especially for eyes with PCV.
C1 [Cho, Soo Chang; Cho, JoonHee; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnam, South Korea.
   [Cho, Soo Chang] Ewha Womans Univ, Mokdong Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Cho, JoonHee] Hyemin Eye Hosp, Seoul, South Korea.
C3 Seoul National University (SNU); Ewha Womans University
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI ; Woo, Se Joon/I-7357-2013
OI Park, Kyu Hyung/0000-0002-5516-8121; Woo, Se Joon/0000-0003-3692-7169
FU National Research Foundation (NRF) Bio & Medical Technology Development
   Program [2018M3A9B5021319, 2020R1F1A1072795]; Korean government (MSIT)
FX This study was supported by the National Research Foundation (NRF) Bio &
   Medical Technology Development Program (Grant No. 2018M3A9B5021319,
   2020R1F1A1072795) funded by the Korean government (MSIT). The funding
   organization had no role in the design or conduct of this study.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chang Young Suk, 2018, Korean J Ophthalmol, V32, P361, DOI 10.3341/kjo.2017.0095
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 29
TC 2
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2021
VL 99
IS 5
BP E706
EP E714
DI 10.1111/aos.14676
EA DEC 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD5RN
UT WOS:000595306800001
PM 33289345
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Yanagi, Y
   Agrawal, R
   Teo, HY
   Seen, S
   Yeo, IYS
   Mathur, R
   Chan, CM
   Lee, SY
   Wong, EYM
   Wong, D
   Wong, TY
   Cheung, GCM
AF Ting, Daniel Shu Wei
   Yanagi, Yasuo
   Agrawal, Rupesh
   Teo, Hwei Yee
   Seen, Sophia
   Yeo, Ian Yew San
   Mathur, Ranjana
   Chan, Choi Mun
   Lee, Shu Yen
   Wong, Edmund Yick Mun
   Wong, Doric
   Wong, Tien Yin
   Cheung, Gemmy Chui Ming
TI Choroidal Remodeling in Age-related Macular Degeneration and Polypoidal
   Choroidal Vasculopathy: A 12-month Prospective Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EYES; THICKNESS; THERAPY; DISEASE
AB Choroid thinning occurs in age-related macular degeneration (AMD). However, it remains unclear whether the reduction is due to reduction in choroidal vessels or shrinkage of choroidal stroma, or both. The purpose of this study was to evaluate the changes of the choroidal vascular and stromal area in 118 patients with typical AMD (t-AMD) and polypoidal choroidal vasculopathy (PCV) over a 12-month period. We used spectral-domain optical coherence tomography (SD-OCT) with enhanced depth imaging (EDI) mode to measure the subfoveal choroidal thickness (CT), central retinal thickness (CRT) and choroidal vascularity index (CVI - ratio of luminal area to total choroidal area). At baseline, PCV eyes had higher CRT (471.6 mu m vs 439.1 mu m, p = 0.02), but comparable subfoveal CT and CVI, compared to t-AMD. Eyes with high CVI at baseline showed marked reduction in stromal area compared with eyes with average or low CVI. Over 12 months, CRT and subfoveal CT significantly decreased (p < 0.001) in both subtypes. Eyes with high baseline CVI showed significant CVI reduction from baseline to month 12 (p < 0.001), whereas eyes with average to low baseline CVI showed increase in CVI. These differences in choroidal vascularity may reflect different predominant pathogenic processes and remodeling in AMD eyes with varying spectrum.
C1 [Ting, Daniel Shu Wei; Yanagi, Yasuo; Agrawal, Rupesh; Yeo, Ian Yew San; Mathur, Ranjana; Chan, Choi Mun; Lee, Shu Yen; Wong, Edmund Yick Mun; Wong, Doric; Wong, Tien Yin; Cheung, Gemmy Chui Ming] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Ting, Daniel Shu Wei; Yanagi, Yasuo; Yeo, Ian Yew San; Mathur, Ranjana; Lee, Shu Yen; Wong, Edmund Yick Mun; Wong, Doric; Wong, Tien Yin; Cheung, Gemmy Chui Ming] Duke NUS Med Sch, Singapore 168751, Singapore.
   [Agrawal, Rupesh; Teo, Hwei Yee] Tan Tock Seng Hosp, Dept Ophthalmol, Eye Inst, Natl Healthcare Grp, Singapore, Singapore.
   [Agrawal, Rupesh] Nanyang Technol Univ, Singapore, Singapore.
   [Seen, Sophia] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Tan Tock Seng Hospital; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; National University of
   Singapore
RP Cheung, GCM (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.; Cheung, GCM (通讯作者)，Duke NUS Med Sch, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Yanagi, Yasuo/AAF-2670-2020; Wong, Tien Yin/AAC-9724-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Agrawal, Rupesh/0000-0002-6662-5850;
   Yanagi, Yasuo/0000-0002-0362-7285; Wong, Damon/0000-0003-4601-9121;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Bidwai, Pooja
   Vishal/0000-0002-3077-4395
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, ACTA OPHTHALMOL, V91, pE580, DOI 10.1111/aos.12117
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Gupta P., 2017, RETINA IN PRESS
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   National Advisory Eye Council Vision Research - A National Plan, 1999, NIH PUBLICATION, V1, P98
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 23
TC 56
Z9 59
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 11
PY 2017
VL 7
AR 7868
DI 10.1038/s41598-017-08276-4
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD3OO
UT WOS:000407442500008
PM 28801615
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, K
   Ma, L
   Lai, TYY
   Brelen, ME
   Tam, POS
   Tham, CC
   Pang, CP
   Chen, LJ
AF Liu, Ke
   Ma, Li
   Lai, Timothy Y. Y.
   Brelen, Marten E.
   Tam, Pancy O. S.
   Tham, Clement C.
   Pang, Chi Pui
   Chen, Li Jia
TI Evaluation of the association of C5 with neovascular age-related macular
   degeneration and polypoidal choroidal vasculopathy
SO EYE AND VISION
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Complete component 5; C5; Genetic association; Single-nucleotide
   polymorphism
ID COMPLEMENT-FACTOR-H; LOC387715/HTRA1 POLYMORPHISMS; CHINESE; RISK; GENE;
   SMOKING; DRUSEN; IDENTIFICATION; PATHOGENESIS; EPIGENETICS
AB Background Neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are sight-threatening maculopathies with both environmental and genetic risk factors. We have previously shown relative risks posed by genes of the complement pathways to neovascular AMD and PCV. Methods In this study, we investigated the haplotype-tagging single nucleotide polymorphisms (SNPs) in the complement component 5 (C5) gene in 708 unrelated Chinese individuals: 200 neovascular AMD patients, 233 PCV patients and 275 controls. Six tagging SNPs in C5 were genotyped. Univariate single SNP association analysis, haplotype-based association analysis and gene-gene interaction analysis between C5 and other AMD-associated genes were performed. Results The results revealed none of the six tagging SNPs of the C5 gene had a significant association with neovascular AMD or PCV (P > 0.05). We also found insignificant haplotype-based association, and no significant SNP-SNP interaction between C5 and other genes (including C2-CFB-RDBP-SKIV2L, SERPING1, CETP, ABCG1, PGF, ANGPT2, CFH and HTRA1) for neovascular AMD and PCV. Conclusions This study showed no statistical significance in the genetic association of C5 with neovascular AMD or PCV in a Hong Kong Chinese population. Further studies in large samples from different populations are warranted to elucidate the role of C5 in the genetic susceptibility of AMD and PCV.
C1 [Liu, Ke; Ma, Li; Lai, Timothy Y. Y.; Brelen, Marten E.; Tam, Pancy O. S.; Tham, Clement C.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Brelen, Marten E.; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.; Chen, LJ (通讯作者)，Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Tham, Chee Yung Clement/AAD-6528-2020; Lai,
   Timothy Y Y/AAC-2120-2020; Brelen, Marten E./D-1133-2016
OI Chen, Li Jia/0000-0003-3500-5840; Tham, Chee Yung
   Clement/0000-0003-4407-6907; Lai, Timothy Y Y/0000-0002-7832-6428; 
FU General Research Fund, Hong Kong [14120516]; Chinese University of Hong
   Kong Medical Panel, Hong Kong [4054281]; Endowment Fund for Lim Por-Yen
   Eye Genetics Research Centre, Hong Kong
FX This study was supported in part by the General Research Fund, Hong Kong
   (14120516 [LJC]), the Direct Grant of Chinese University of Hong Kong
   Medical Panel, Hong Kong (4054281 [LJC]), and the Endowment Fund for Lim
   Por-Yen Eye Genetics Research Centre, Hong Kong.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Ma L, 2016, INVEST OPHTH VIS SCI, V57, P5758, DOI 10.1167/iovs.16-20175
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 49
TC 6
Z9 6
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD NOV 7
PY 2019
VL 6
IS 1
AR 34
DI 10.1186/s40662-019-0161-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JL6GS
UT WOS:000495629000001
PM 31720301
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kawashima, Y
   Oishi, A
   Tsujikawa, A
   Yamashiro, K
   Miyake, M
   Ueda-Arakawa, N
   Yoshikawa, M
   Takahashi, A
   Yoshimura, N
AF Kawashima, Yu
   Oishi, Akio
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Miyake, Masahiro
   Ueda-Arakawa, Naoko
   Yoshikawa, Munemitsu
   Takahashi, Ayako
   Yoshimura, Nagahisa
TI Effects of aflibercept for ranibizumab-resistant neovascular age-related
   macular degeneration and polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Aflibercept; Optical coherence tomography; Genotype
ID COMPLEMENT FACTOR-H; INTRAVITREAL AFLIBERCEPT; VEGF TRAP; BEVACIZUMAB;
   TACHYPHYLAXIS; VERTEPORFIN; LOC387715; THERAPY; LAPTOP; FLUID
AB To evaluate visual and anatomic outcomes in response to the conversion of treatment in patients with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to previous treatment. We also investigated the effect of genetic factors.
   We recruited patients with AMD or PCV refractory to ranibizumab and initiated aflibercept treatment. Changes in the logarithm of minimum angle of resolution (logMAR) and central retinal thickness (CRT) measured using optical coherence tomography (OCT) 6 months after the conversion were compared between the AMD and PCV groups. We also genotyped each patient for the ARMS2 A69S, CFH Y402H, and I62V alleles, and investigated the association between genotype and treatment response.
   Mean age of the participants was 75.6 +/- 8.0 years. There were 15 patients with AMD and 26 patients with PCV. While PCV patients gained about 1 line of vision (0.40 +/- 0.37 to 0.31 +/- 0.40, P = 0.003), AMD patients did not show significant improvement (0.41 +/- 0.37 to 0.42 +/- 0.39, P = 0.699) despite the decrease in CRT (202.1 +/- 113.7 to 131.2 +/- 55.7 mu m, P = 0.003). The prevalence of dry retina after treatment was higher among PCV patients (80.8 vs 46.7 %, P = 0.024). There was no significant difference between patients with risk and non-risk alleles for ARMS2 A69S, CFH Y402H, and I62V.
   In AMD or PCV patients refractory to ranibizumab, switching to aflibercept is generally effective regardless of patient genotype. PCV patients may benefit more significantly than AMD patients.
C1 [Kawashima, Yu; Oishi, Akio; Tsujikawa, Akitaka; Yamashiro, Kenji; Miyake, Masahiro; Ueda-Arakawa, Naoko; Yoshikawa, Munemitsu; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shougoin Kawahara Cho, Kyoto 6068507, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science [21592256]; Ministry of
   Education, Culture, Sports, Science and Technology (MEXT), Japan
FX This research was supported in part by grants-in-aid for scientific
   research from the Japan Society for the Promotion of Science (No.
   21592256) and the Innovative Techno-Hub for Integrated Medical
   Bio-Imaging of the Project for Developing Innovation Systems, from the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P668
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 34
TC 41
Z9 46
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2015
VL 253
IS 9
BP 1471
EP 1477
DI 10.1007/s00417-014-2838-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ0MQ
UT WOS:000360290700007
PM 25391986
DA 2022-11-30
ER

PT J
AU Tan, CS
   Ting, DS
   Lim, LW
AF Tan, Colin S.
   Ting, Dominic S.
   Lim, Louis W.
TI Multicolour imaging for the detection of polypoidal choroidal
   vasculopathy and age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; fluorescein angiography; multicolour
   imaging; ophthalmic imaging; polypoidal choroidal vasculopathy
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT;
   THICKNESSES; EVEREST; ANGIOGRAPHY; MULTICENTER; MANAGEMENT; OUTCOMES
AB Importance Multicolour is a new imaging technology and its sensitivity for detecting polypoidal choroidal vasculopathy (PCV) and age-related macular degeneration (AMD) has not been well described. Background To evaluate the accuracy of multicolour imaging compared to colour fundus photography (CFP) in differentiating AMD and PCV from normal eyes, and in detecting PCV. Design Prospective cohort study at a tertiary referral centre. Participants Fifty consecutive patients with PCV or AMD. Methods Standardized multimodal imaging, including CFP, multicolour imaging, and fluorescein and indocyanine green angiography, were graded by a Central Reading Center using standardized grading protocols. Main Outcomes and Measures Sensitivity, specificity, positive and negative predictive values (PPV and NPV). Results Of 100 eyes, 44 had PCV, 33 had AMD, and 23 were normal. Multicolour imaging had higher specificity (73.9% vs 52.2%) and NPV (94% vs 85.7%) compared to CFP for detecting all types of AMD. For the detection of PCV, multicolour had higher sensitivity (86.4% vs 59.1%) and NPV (89.3% vs 74.3%). Polypoidal lesions were detected in 39 of 44 eyes (88.6%) using multicolour imaging, while the branching vascular network (BVN) was detected in 16 of 44 eyes (36.4%). Using BVN as a parameter, infrared imaging specificity and PPV for detecting PCV were 96.6% and 88.9%, respectively. Conclusions and Relevance Multicolour imaging is superior to standard CFP in differentiating AMD and PCV from normal eyes, and in detecting features of PCV. Specific features seen on multicolour imaging can alert ophthalmologists to the likely presence of these diseases so that additional definitive investigations can be performed.
C1 [Tan, Colin S.] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Tan, Colin S.; Ting, Dominic S.; Lim, Louis W.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Tan, Colin S.] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Tan, Colin S.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Ting, Dominic S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
C3 Tan Tock Seng Hospital; National University of Singapore; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; National University of
   Singapore
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU National Medical Research Council [NMRC/TA/0039/2015]; Tan Tock Seng
   Hospital Center Grant [NMRC/CG/M012/2017]
FX National Medical Research Council, Grant/Award Number:
   NMRC/TA/0039/2015; Tan Tock Seng Hospital Center Grant, Grant/Award
   Number: (NMRC/CG/M012/2017)
CR Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brady CJ, 2014, OSLI RETINA, V45, P556, DOI 10.3928/23258160-20141118-11
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Graham KW, 2017, RETINA, V38, P1
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CS, 2018, OSLI RETINA, V49, P4, DOI 10.3928/23258160-20171215-01
   Tan CS, 2016, OSLI RETINA, V47, P1081, DOI 10.3928/23258160-20161130-01
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tan CSH, 2014, INVEST OPHTH VIS SCI, V55, P6452, DOI 10.1167/iovs.13-13771
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P339, DOI 10.1136/bjophthalmol-2013-304000
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   WOON WH, 1992, BRIT J OPHTHALMOL, V76, P470, DOI 10.1136/bjo.76.8.470
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
NR 28
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2019
VL 47
IS 5
BP 621
EP 630
DI 10.1111/ceo.13462
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA II9GP
UT WOS:000475504600008
PM 30578655
OA Bronze
DA 2022-11-30
ER

PT J
AU Ma, D
   Kumar, M
   Khetan, V
   Sen, P
   Bhende, M
   Chen, S
   Yu, TTL
   Lee, S
   Navajas, EV
   Matsubara, JA
   Ju, MJ
   Sarunic, MV
   Raman, R
   Beg, MF
AF Ma, Da
   Kumar, Meenakshi
   Khetan, Vikas
   Sen, Parveen
   Bhende, Muna
   Chen, Shuo
   Yu, Timothy T. L.
   Lee, Sieun
   Navajas, Eduardo V.
   Matsubara, Joanne A.
   Ju, Myeong Jin
   Sarunic, Marinko V.
   Raman, Rajiv
   Beg, Mirza Faisal
TI Clinical explainable differential diagnosis of polypoidal choroidal
   vasculopathy and age-related macular degeneration using deep learning
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Differential diagnosis; Explainable AI model; Optical coherence
   tomography; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Deep learning; Convolutional Neural Network
ID OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; DISEASES
AB Background: This study aims to achieve an automatic differential diagnosis between two types of retinal pa-thologies with similar pathological features -Polypoidal choroidal vasculopathy (PCV) and wet age-related macular degeneration (AMD) from volumetric optical coherence tomography (OCT) images, and identify clinically-relevant pathological features, using an explainable deep-learning-based framework.Methods: This is a retrospective study with data from a cross-sectional cohort. The OCT volume of 73 eyes from 59 patients was included in this study. Disease differentiation was achieved through single-B-scan-based clas-sification followed by a volumetric probability prediction aggregation step. We compared different labeling strategies with and without identifying pathological B-scans within each OCT volume. Clinical interpretability was achieved through normalized aggregation of B-scan-based saliency maps followed by maximum-intensity-projection onto the en face plane. We derived the PCV score from the proposed differential diagnosis frame -work with different labeling strategies. The en face projection of saliency map was validated with the pathologies identified in Indocyanine green angiography (ICGA).Results: Model trained with both labeling strategies achieved similar level differentiation power (>90%), with good correspondence between pathological features detected from the projected en face saliency map and ICGA.Conclusions: This study demonstrated the potential clinical application of non-invasive differential diagnosis using AI-driven OCT-based analysis, with minimal requirement of labeling efforts, along with clinical explain-ability achieved through automatically detected disease-related pathologies.
C1 [Ma, Da] Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
   [Ma, Da; Chen, Shuo; Yu, Timothy T. L.; Lee, Sieun; Sarunic, Marinko V.; Beg, Mirza Faisal] Simon Fraser Univ, Sch Engn Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
   [Kumar, Meenakshi; Khetan, Vikas; Sen, Parveen; Bhende, Muna; Raman, Rajiv] Sankara Nethralaya, Med Res Fdn, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Lee, Sieun] Univ Nottingham, Sch Med, Mental Hlth & Clin Neurosci, Nottingham, England.
   [Navajas, Eduardo V.; Matsubara, Joanne A.; Ju, Myeong Jin] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Navajas, Eduardo V.; Matsubara, Joanne A.; Ju, Myeong Jin] Univ British Columbia, Vancouver Gen Hosp, Eye Care Ctr, Vancouver, BC, Canada.
   [Ju, Myeong Jin] Univ British Columbia, Sch Biomed Engn, Vancouver, BC, Canada.
   [Sarunic, Marinko V.] UCL, Inst Ophthalmol, London, England.
   [Sarunic, Marinko V.] UCL, Dept Med Phys & Biomed Engn, London, England.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Simon Fraser
   University; University of Nottingham; University of British Columbia;
   University of British Columbia; University of British Columbia;
   University of London; University College London; University of London;
   University College London
RP Ma, D (通讯作者)，Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Beg, MF (通讯作者)，Simon Fraser Univ, Sch Engn Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.; Raman, R (通讯作者)，Sankara Nethralaya, Sankara Nethralaya Eye Hosp, Chennai, Tamil Nadu, India.
EM dma@wakehealth.edu; rajivpgraman@gmail.com; faisal-lab@sfu.ca
RI Ma, Da/H-3215-2019
OI Ma, Da/0000-0002-3542-7798; Yu1, Timothy/0000-0001-8758-0578; Kumar,
   Meenakshi/0000-0002-2681-6521; Bhende, Muna/0000-0002-9251-170X
FU National Sciences and Engineering Research Council of Canada; Canadian
   Institutes of Health Research; Michael Smith Foundation for Health
   Research; Alzheimer Society Research Program, Compute Canada; Wake
   Forest University School of Medicine Startup Funding, and Precision
   Imaging Beacon, University of Nottingham
FX Acknowledgment This study was funded by the National Sciences and
   Engineering Research Council of Canada; Canadian Institutes of Health
   Research; Michael Smith Foundation for Health Research; Alzheimer
   Society Research Program, Compute Canada, Wake Forest University School
   of Medicine Startup Funding, and Precision Imaging Beacon, University of
   Nottingham. The sponsor or funding organization had no role in the
   design or conduct of this research.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Caruana R, 2001, ADV NEUR IN, V13, P402
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Fenner BJ, 2022, OPHTHALMOL RETINA, V6, P179, DOI 10.1016/j.oret.2021.09.009
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   Heisler M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.20
   Heo TY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050261
   Howard J, 2018, PROCEEDINGS OF THE 56TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS (ACL), VOL 1, P328
   Hwang DDJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88543-7
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Irie R, 2020, MAGN RESON MED SCI, V19, P351, DOI 10.2463/mrms.mp.2019-0106
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kingma J., 2014, ARXIV
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kouw W. M., 2018, INTRO DOMAIN ADAPTAT
   Kumar M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231901
   Lau T, 2015, INDIAN J OPHTHALMOL, V63, P378, DOI 10.4103/0301-4738.159860
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lin AC, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.6.32
   Ma D, 2021, COMPUT MED IMAG GRAP, V94, DOI 10.1016/j.compmedimag.2021.101988
   Ma D, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00853
   Ma D, 2020, INVEST OPHTH VIS SCI, V61
   Prechelt L, 1998, LECT NOTES COMPUT SC, V1524, P55
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Qiu SR, 2020, BRAIN, V143, P1920, DOI 10.1093/brain/awaa137
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Singh B, 2015, 2015 IEEE 14TH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA), P364, DOI 10.1109/ICMLA.2015.113
   Singh RK, 2021, NEURAL COMPUT APPL, V33, P8871, DOI 10.1007/s00521-020-05636-6
   Singh Vineeta, 2013, J Ayurveda Integr Med, V4, P77, DOI 10.4103/0975-9476.113872
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Tomita N, 2018, COMPUT BIOL MED, V98, P8, DOI 10.1016/j.compbiomed.2018.05.011
   Tomographic P.O.C., 2018, CLASSIFICATION CHORO
   Tsai YY, 2022, TRANSL VIS SCI TECHN, V11, DOI 10.1167/tvst.11.2.6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Xia W, 2021, J MAGN RESON IMAGING, V54, P880, DOI 10.1002/jmri.27592
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yoo TK, 2021, MED BIOL ENG COMPUT, V59, P401, DOI 10.1007/s11517-021-02321-1
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zang PX, 2021, IEEE T BIO-MED ENG, V68, P1859, DOI 10.1109/TBME.2020.3027231
NR 55
TC 1
Z9 1
U1 4
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD APR
PY 2022
VL 143
AR 105319
DI 10.1016/j.compbiomed.2022.105319
PG 13
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 0O1HC
UT WOS:000783279200003
PM 35220077
DA 2022-11-30
ER

PT J
AU Hatz, K
   Prunte, C
AF Hatz, Katja
   Pruente, Christian
TI Polypoidal choroidal vasculopathy in Caucasian patients with presumed
   neovascular age-related macular degeneration and poor ranibizumab
   response
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   DOSING REGIMEN; DIAGNOSIS; EFFICACY; SAFETY
AB Aims To determine the prevalence of polypoidal choroidal vasculopathy (PCV) in patients with presumed neovascular age-related macular degeneration (AMD) who were considered poor responders to ranibizumab.
   Methods Caucasian patients with suspected neovascular AMD, presumed to be choroidal neovascularisation, previously treated with >= 8 intravitreal injections of ranibizumab 0.5 mg (Lucentis; Novartis AG, Basel, Switzerland) administered as required during optical coherence tomography-guided dosing were retrospectively included. Eyes were categorised according to the time from injection 1 to injection 6 (group 1: <12 months; group 2: >= 12 months). Indocyanine green angiography (ICGA) was used to re-evaluate eyes for PCV. Suitable candidates received reduced-fluence photodynamic therapy/ranibizumab combination therapy supplemented by ranibizumab monotherapy, as required.
   Results 202 eyes were included (group 1: 73.8%; group 2: 26.2%). The prevalence of PCV in group 1 (21.5%) was significantly higher than in group 2 (3.8%; p=0.003). After initiation of combination therapy, 16 eyes with PCV received 3.1 +/- 2.5 ranibizumab injections/year vs 8.4 +/- 2.4 injections/year before initiation of combination therapy (p<0.001).
   Conclusions In Caucasian patients with presumed neovascular AMD, PCV prevalence is increased in eyes that respond poorly to ranibizumab monotherapy. ICGA improved PCV diagnosis in poor responders; combination therapy may be beneficial for eyes with PCV.
C1 [Hatz, Katja; Pruente, Christian] Vista Klin, CH-4102 Binningen, Switzerland.
   [Hatz, Katja; Pruente, Christian] Kantonsspital Liestal, Dept Ophthalmol, CH-4410 Liestal, Switzerland.
C3 Kantonsspital Baselland
RP Hatz, K (通讯作者)，Vista Klin, Hauptstr 55, CH-4102 Binningen, Switzerland.
EM khatz@vistaklinik.ch
FU Heidelberg Engineering (Heidelberg, Germany)
FX Funding for medical writing support was provided by Heidelberg
   Engineering (Tiergartenstrasse 15, 69121 Heidelberg, Germany). The
   sponsor had no role in the design or conduct of this research.
CR [Anonymous], VIS EPAR PROD INF
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   de Crecchio G, 2011, CURR DRUG TARGETS, V12, P206, DOI 10.2174/138945011794182782
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Kuerzinger GRK, 2006, KLIN MONATSBL AUGENH, V223, P691, DOI 10.1055/s-2006-926977
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Massacesi AL, 2008, GRAEF ARCH CLIN EXP, V246, P89, DOI 10.1007/s00417-007-0638-x
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Parravano M, 2012, EUR J OPHTHALMOL, V22, P598, DOI 10.5301/ejo.5000087
   Reche-Frutos J, 2011, EUR J OPHTHALMOL, V21, P783, DOI 10.5301/EJO.2011.6526
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 31
TC 63
Z9 68
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2014
VL 98
IS 2
BP 188
EP 194
DI 10.1136/bjophthalmol-2013-303444
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 294TF
UT WOS:000330069300011
PM 24246375
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Bunting, R
   Guymer, R
AF Bunting, Roland
   Guymer, Robyn
TI Treatment of age-related macular degeneration
SO AUSTRALIAN PRESCRIBER
LA English
DT Article
DE anti-vascular endothelial growth factor; bevacizumab; choroidal
   neovascularisation; ranibizumab
ID RANIBIZUMAB; METAANALYSIS
AB Age-related macular degeneration is a common cause of visual loss. There may be choroidal neovascularisation or geographic atrophy.
   Evidence is accumulating for the importance of avoidable risk factors in age-related macular degeneration, such as smoking and obesity.
   Research confirms that there is an important hereditary component to the disease.
   Anti-vascular endothelial growth factors have improved the outlook for patients suffering from neovascular age-related macular degeneration. Recent work has concentrated on refining the frequency and pattern of delivery of these drugs to the vitreous cavity.
   There are few treatment options for geographic atrophy.
C1 [Bunting, Roland] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Royal Victorian Eye & Ear Hospital
RP Bunting, R (通讯作者)，Univ Melbourne, Melbourne, Vic 3010, Australia.
OI Guymer, Robyn/0000-0002-9441-4356
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   National Eye Institute, AG REL EYE DIS STUD
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 9
TC 3
Z9 3
U1 0
U2 0
PU NATL PRESCRIBING SERVICE LTD
PI DEAKIN
PA STE 3, 2 PHIPPS CLOSE, DEAKIN, ACT 2600, AUSTRALIA
SN 0312-8008
J9 AUST PRESCR
JI Aust. Prescr.
PD JUN
PY 2012
VL 35
IS 3
BP 90
EP 93
DI 10.18773/austprescr.2012.038
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 963DY
UT WOS:000305601500012
OA gold
DA 2022-11-30
ER

PT J
AU Hall, NF
   Gale, CR
   Syddall, H
   Martyn, CN
   Phillips, DIW
AF Hall, NF
   Gale, CR
   Syddall, H
   Martyn, CN
   Phillips, DIW
TI Relation between size at birth and risk of age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; IN-UTERO;
   CIGARETTE-SMOKING; ADULT LIFE; MACULOPATHY; GROWTH; ROTTERDAM; DEATH
AB PURPOSE. To determine whether poor fetal growth, as determined by size at birth, is associated with increased risk of age-related macular degeneration.
   METHODS. A total of 660 men and women born in Sheffield United Kingdom, between 1922 and 1930 and whose size at birth was available were traced and invited to take part in the study. Of these, 392 attended for ophthalmic examination. Age-related macular degeneration in these volunteers was determined by the Wisconsin Age-Related Maculopathy Grading System.
   RESULTS. The mean birth weight of subjects with macular degeneration (early or late) was heavier than that of those without (7.6 lb vs. 7.3 lb, respectively; P = 0.03). After adjustment for age, gender, and risk factors for macular degeneration, a significantly increased risk of macular degeneration was found in subjects with higher birth weight (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.1-2.0 for each SD [1 lb, 5 oz] increase in birth weight). Other parameters describing size at birth showed a weaker relation or no relation with macular degeneration, but one of the measures of fetal proportion (head circumference-to-birth weight ratio) was significantly associated with risk of macular degeneration. Subjects with macular degeneration had a significantly lower head circumference-to-birth weight ratio than did those without (11.2 vs. 12.0 respectively, P = 0.01).
   CONCLUSIONS. The finding that age-related macular degeneration was associated with increased rather than decreased birth weight was unexpected. Failure of the developing fetus's normal brain-sparing mechanism is a possible explanation for our finding of a lower head circumference-to-birth weight ratio among subjects with macular degeneration.
C1 Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.
C3 University of Southampton
RP Hall, NF (通讯作者)，Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Tremona Rd, Southampton SO16 6YD, Hants, England.
RI Gale, Catharine R/B-1653-2012
OI Gale, Catharine/0000-0002-3361-8638
CR BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Evans JR, 1998, INVEST OPHTH VIS SCI, V39, P1740
   Foss AJE, 1998, BRIT J OPHTHALMOL, V82, P1125, DOI 10.1136/bjo.82.10.1125
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019
   HALL N, 1998, OPHTHALMIC EPIDEMIOL, V5, P1
   Hall NF, 2001, INVEST OPHTH VIS SCI, V42, P614
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Law CM, 1996, J HYPERTENS, V14, P935
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2
   Martyn CN, 1996, BRIT MED J, V312, P1393
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Sayer AA, 1998, AGE AGEING, V27, P579, DOI 10.1093/ageing/27.5.579
   Scheidegger R, 1998, NITRIC OXIDE-BIOL CH, V2, P8, DOI 10.1006/niox.1997.0156
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 33
TC 12
Z9 12
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2002
VL 43
IS 12
BP 3641
EP 3645
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 620LE
UT WOS:000179534200008
PM 12454030
DA 2022-11-30
ER

PT J
AU Wu, KF
   Wen, F
   Zuo, CG
   Li, M
   Zhang, XZ
   Chen, H
   Zeng, RP
AF Wu, Kunfang
   Wen, Feng
   Zuo, Chengguo
   Li, Meng
   Zhang, Xiongze
   Chen, Hui
   Zeng, Renpan
TI Lack of Association with PEDF Met72Thr Variant in Neovascular
   Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
   in a Han Chinese Population
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Neovascular age-related macular
   degeneration; Pigment epithelium-derived factor; Han Chinese population;
   polymorphisms
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR GENE
   POLYMORPHISMS; PIGMENT EPITHELIUM; BOVINE EYES; RISK; IDENTIFICATION;
   ANGIOGENESIS; EXPRESSION; MEMBRANES
AB Purpose: To investigate whether Met72Thr (rs1136287), a common single nucleotide polymorphism (SNP) variant of the pigment epithelium-derived factor (PEDF) gene, is associated with neovascular age-related macular degeneration (nAMD) or polypoidal choroidal vasculopathy (PCV) in a Han Chinese cohort.
   Methods: We genotyped Met72Thr (rs1136287) in persons of Han Chinese descent: 177 PCV patients, 131 nAMD patients, and 182 control persons. Genotyping was accomplished using the Multiplex SNaPshot system and by direct DNA sequencing. Genotypes and allele frequencies of patients and controls were evaluated for the SNP using PLINK software.
   Results: The minor allele frequency of the PEDF Met72Thr variant did not differ significantly between either PCV or nAMD and the control group: p = 0.3822 and p = 0.9822, respectively. The p-values for the additive, dominant, and recessive models were not statistically significant for PCV or nAMD.
   Conclusions: No evidence was found to support a role for the Met72Thr variant in susceptibility to either PCV or nAMD in a Han Chinese cohort.
C1 [Wu, Kunfang; Wen, Feng; Zuo, Chengguo; Li, Meng; Zhang, Xiongze; Chen, Hui; Zeng, Renpan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81070745]
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81070745).
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bessho H, 2009, MOL VIS, V15, P1107
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Iida Tomohiro, 2005, Nippon Ganka Gakkai Zasshi, V109, P383
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Li M, 2010, MOL VIS, V16, P231
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mattes D, 2009, MOL VIS, V15, P343
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ogata N, 2004, AM J OPHTHALMOL, V137, P935, DOI 10.1016/j.ajo.2003.08.058
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Qu Y, 2011, CURR EYE RES, V36, P60, DOI 10.3109/02713683.2010.524343
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984
   WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhou XY, 2009, CHINESE MED J-PEKING, V122, P2711, DOI 10.3760/cma.j.issn.0366-6999.2009.22.007
NR 42
TC 8
Z9 8
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JAN
PY 2012
VL 37
IS 1
BP 68
EP 72
DI 10.3109/02713683.2011.618289
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 861YJ
UT WOS:000298056700011
PM 22029535
DA 2022-11-30
ER

PT J
AU Ogasawara, M
   Koizumi, H
   Yamamoto, A
   Itagaki, K
   Saito, M
   Maruko, I
   Okada, AA
   Iida, T
   Sekiryu, T
AF Ogasawara, Masashi
   Koizumi, Hideki
   Yamamoto, Akiko
   Itagaki, Kanako
   Saito, Masaaki
   Maruko, Ichiro
   Okada, Annabelle A.
   Iida, Tomohiro
   Sekiryu, Tetsuju
TI Prognostic factors after aflibercept therapy for typical age-related
   macular degeneration and polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Choroidal vascular
   hyperpermeability; Polypoidal choroidal vasculopathy
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; VASCULAR HYPERPERMEABILITY;
   CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; THICKNESS; OUTCOMES; VEGF
AB Purpose To determine factors predictive of visual outcomes in eyes treated with intravitreal aflibercept injections (IAIs) for typical neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
   Study design Retrospective, multicenter, institutional, consecutive, interventional case series.
   Methods One hundred nine eyes (107 patients) with treatment-naive neovascular AMD at 3 university hospitals were studied. After a loading phase of 3 monthly 2.0-mg IAIs, injections were administered every 2 months. The baseline clinical characteristics were investigated in relation to the 12-month visual outcomes. Changes in the mean best-corrected visual acuity (BCVA) were measured at 12 months after initiation of aflibercept therapy.
   Results Forty-five eyes (41.3%) had typical neovascular AMD, and 64 eyes (58.7%) had PCV. The changes in the mean BCVA at 12 months compared with baseline did not differ significantly (P = .737) between the 2 groups. Stepwise analysis showed that larger gains in the BCVA at 12 months were associated with poor BCVA (P < .001), no pigment epithelial detachment (P = .004), and subretinal fluid (P = .039) at baseline in eyes with typical neovascular AMD; larger gains in the BCVA were associated with poorer BCVA (P < .001), presence of choroidal vascular hyperpermeability (CVH) (P = .013), and subretinal fluid (P = .044) at baseline in eyes with PCV.
   Conclusions Although poorer BCVA and the presence of subretinal fluid predicted larger gains in BCVA in both subtypes treated with aflibercept, eyes with typical neovascular AMD had greater improvement if no pigment epithelial detachment was present, while eyes with PCV had greater improvement if CVH was present.
C1 [Ogasawara, Masashi; Itagaki, Kanako; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
   [Koizumi, Hideki; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University; Kyorin
   University
RP Sekiryu, T (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
EM sekiryu@fmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Saito, Masaaki/ABI-2783-2020
OI Maruko, Ichiro/0000-0001-5647-6372; Saito, Masaaki/0000-0003-1494-6350;
   Sekiryu, Tetsuju/0000-0001-8042-2729
FU Novartis Pharma; Alcon; Bausch Lomb; Bayer; Canon; HOYA; Kowa; NIDEK;
   Santen Pharmaceutical; Senju Pharmaceutical; Topcon; Wakamoto
   Pharmaceutical; Pfizer; AMO; Mitsubishi Tanabe Pharma; XOMA
FX M. Ogasawara, None; Hideki Koizumi, Grant (Novartis Pharma), Moderator
   fees (Alcon, Bausch & Lomb, Bayer, Canon, HOYA, Kowa, NIDEK, Novartis
   Pharma, Santen Pharmaceutical, Senju Pharmaceutical, Topcon, Wakamoto
   Pharmaceutical); A. Yamamoto, Lecture fees (Bayer, Novartis Pharma,
   Pfizer, Santen Pharmaceutical); K. Itagaki, None; M. Saito, Grant
   (Bayer, Novartis Pharma, Santen Pharmaceutical), Moderator fees (Alcon,
   AMO, Bayer, HOYA, Novartis Pharma, Santen Pharmaceutical, Senju
   Pharmaceutical); I. Maruko, Moderator fees (Alcon, Bayer, NIDEK,
   Novartis Pharma, Santen Pharmaceutical, Topcon); A. A. Okada, Grant
   (Bayer, Mitsubishi Tanabe Pharma), Advisory board fee (Bayer),
   Consultant fee (XOMA), Lecture fees (Bayer, Novartis Pharma, Santen
   Pharmaceutical), Research funds (Bayer, Mitsubishi Tanabe Pharma); T.
   Iida, Grant (Bayer, Nidek, Novartis Pharma, Santen Pharmaceutical),
   Lecture fees (Bayer, Novartis Pharma, Santen Pharmaceutical); T.
   Sekiryu, None.
CR Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Saito M, 2013, EYE, V27, P931, DOI 10.1038/eye.2013.114
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Takahashi S, 2011, BIOL PHARM BULL, V34, P1785, DOI 10.1248/bpb.34.1785
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 26
TC 13
Z9 13
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2018
VL 62
IS 5
BP 584
EP 591
DI 10.1007/s10384-018-0605-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR6CR
UT WOS:000442733200008
PM 29974277
DA 2022-11-30
ER

PT J
AU Jung, JH
   Lee, JK
   Lee, JE
   Oum, BS
AF Jung, Jae Ho
   Lee, Ja Kyun
   Lee, Ji Eun
   Oum, Boo Sup
TI RESULTS OF VITRECTOMY FOR BREAKTHROUGH VITREOUS HEMORRHAGE ASSOCIATED
   WITH AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE breakthrough vitreous hemorrhage; vitrectomy; age-related macular
   degeneration; polypoidal choroidal vasculopathy; subretinal hemorrhage;
   antivascular endothelial growth factor; photo-dynamic therapy
ID INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; SECONDARY;
   NEOVASCULARIZATION; MANAGEMENT; SURGERY
AB Purpose: The purpose of this study was to evaluate the results of vitrectomy in patients with vitreous hemorrhage associated with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Methods: A retrospective review was conducted of consecutive cases of patients undergoing pars plana vitrectomy for nonclearing vitreous hemorrhage associated with neovascular AMD or PCV.
   Results: Twenty-four eyes of 23 patients were included. The mean length of time from the onset of vitreous hemorrhage to operation was 4.3 months. Twelve eyes had AMD, and 12 eyes of 11 patients had PCV. Additional treatments for active choroidal neovascularization or PCV were required in 12 eyes during follow-up. The mean visual acuity improved significantly from a logarithm of the minimum angle of resolution of 2.79 +/- 0.85 before operation to 1.61 +/- 0.98 at 2 months after operation (P < 0.001). Visual acuity was >= 20/200 in 9 eyes (37.5%) at 2 months after operation; 1 eye was in the AMD group, and the other eyes were in the PCV group. Improvement was more frequently observed in the PCV group (P = 0.005).
   Conclusion: In this series, the functional outcomes of vitrectomy for vitreous hemorrhage associated with AMD were inferior to outcomes of the PCV group. Vitrectomy is beneficial for improving visual function in select cases of breakthrough vitreous hemorrhage. RETINA 30: 865-873, 2010
C1 [Jung, Jae Ho; Lee, Ja Kyun; Lee, Ji Eun; Oum, Boo Sup] Pusan Natl Univ, Coll Med, Dept Ophthalmol, Pusan 609735, South Korea.
   [Lee, Ji Eun; Oum, Boo Sup] Pusan Natl Univ, Med Res Inst, Pusan 609735, South Korea.
C3 Pusan National University; Pusan National University
RP Lee, JE (通讯作者)，Pusan Natl Univ, Coll Med, Dept Ophthalmol, 1-10 Ami Dong, Pusan 609735, South Korea.
EM jlee@pusan.ac.kr
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Azzolini C, 1991, Eur J Ophthalmol, V1, P142
   DIEDLER JL, 1989, J FR OPHTALMOL, V12, P343
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi Fumi, 1998, Nippon Ganka Gakkai Zasshi, V102, P436
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   KREIGER AE, 1983, RETINA-J RET VIT DIS, V3, P318, DOI 10.1097/00006982-198300340-00017
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   ORTH DH, 1982, RETINA-J RET VIT DIS, V2, P89, DOI 10.1097/00006982-198200220-00006
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roufail E, 2008, CLIN EXP OPHTHALMOL, V36, P36, DOI 10.1111/j.1442-9071.2007.01651.x
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SMIDDY WE, 1988, RETINA-J RET VIT DIS, V8, P88, DOI 10.1097/00006982-198808020-00002
   TANI PM, 1980, AM J OPHTHALMOL, V90, P525, DOI 10.1016/S0002-9394(14)75023-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 27
TC 26
Z9 34
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2010
VL 30
IS 6
BP 865
EP 873
DI 10.1097/IAE.0b013e3181c969e9
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AG
UT WOS:000278549100004
PM 20182402
DA 2022-11-30
ER

PT J
AU Zhang, XZ
   Wen, F
   Zuo, CG
   Li, M
   Chen, H
   Wu, KF
AF Zhang, Xiongze
   Wen, Feng
   Zuo, Chengguo
   Li, Meng
   Chen, Hui
   Wu, Kunfang
TI Association of Genetic Variation on Chromosome 9p21 with Polypoidal
   Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   CORONARY-ARTERY-DISEASE; CHINESE PATIENTS; CLINICOPATHOLOGICAL
   CORRELATION; INTRACRANIAL ANEURYSMS; RISK LOCI; POLYMORPHISMS; FEATURES
AB PURPOSE. Polypoidal choroidal vasculopathy (PCV) contains aneurismal morphologic and histopathologic feature and it is considered to be a possible distinct entity from neovascular age-related macular degeneration (AMD). In this study, the association of identified risk variants for intracranial aneurysm on chromosome 9p21 with PCV and neovascular AMD in a Chinese Han population was investigated.
   METHODS. The authors genotyped rs1333040 and rs10757278 on 9p21 in 177 PCV patients, 131 neovascular AMD patients, and 182 controls using a genotyping method and direct DNA sequencing. Allele and genotypes frequencies in the PCV and neovascular AMD groups were compared with controls using a free open-source software and binary logistic regression analysis.
   RESULTS. Rs1333040 was not associated with PCV or neovascular AMD. Rs10757278 was significantly associated with PCV [risk allele: A, P (allelic) = 0.014; odds ratio = 1.44; 95% confidence interval, 1.08-1.94], but not associated with neovascular AMD. After adjusting for sex, age, smoking status, history of hypertension, type 2 diabetes, and coronary artery disease, the odds ratio for homozygous carriers of rs10757278-A was 2.10 (95% confidence interval, 1.14 3.85) for PCV.
   CONCLUSIONS. The rs10757278 on chromosome 9p21 is significantly associated with the risk of PCV but not with neovascular AMD in the Chinese Han population. (Invest Ophthalmol Vis Sci. 2011;52:8063-8067) DOI:10.1167/iovs.11-7820
C1 [Zhang, Xiongze; Wen, Feng; Zuo, Chengguo; Li, Meng; Chen, Hui; Wu, Kunfang] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022; wu, kaili/A-1227-2011
FU National Natural Science Foundation of China [81070745]
FX Supported by the National Natural Science Foundation of China Grant
   81070745.
CR Anderson CD, 2010, STROKE, V41, P1123, DOI 10.1161/STROKEAHA.110.580589
   ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973
   Burns D, 1997, BASIC PATHOLOGY, P325
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deka R, 2010, STROKE, V41, P1132, DOI 10.1161/STROKEAHA.109.574640
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657
   Haas P, 2011, ACTA OPHTHALMOL, V89, P335, DOI 10.1111/j.1755-3768.2009.01697.x
   Hashikata H, 2010, STROKE, V41, P1138, DOI 10.1161/STROKEAHA.109.576694
   Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72
   Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447
   Menashe I, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-36
   Miskolczi L, 1998, NEUROSURGERY, V43, P595, DOI 10.1097/00006123-199809000-00110
   Miskolczi L, 1998, NEUROSURGERY, V43, P600
   Musunuru K, 2010, CIRC-CARDIOVASC GENE, V3, P445, DOI 10.1161/CIRCGENETICS.109.923508
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Olsson S, 2011, J NEUROL NEUROSUR PS, V82, P384, DOI 10.1136/jnnp.2009.187427
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Ruigrok YM, 2008, STROKE, V39, P1049, DOI 10.1161/STROKEAHA.107.497305
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106
   Schneider U, 1997, OPHTHALMOLOGICA, V211, P115, DOI 10.1159/000310775
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Visel A, 2010, NATURE, V464, P409, DOI 10.1038/nature08801
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
NR 51
TC 20
Z9 20
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2011
VL 52
IS 11
BP 8063
EP 8067
DI 10.1167/iovs.11-7820
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 834MY
UT WOS:000295966600037
PM 21896860
DA 2022-11-30
ER

PT J
AU Eperjesi, F
   Maiz-Fernandez, C
   Bartlett, HE
AF Eperjesi, F.
   Maiz-Fernandez, C.
   Bartlett, H. E.
TI Reading performance with various lamps in age-related macular
   degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; lighting; reading; spectral radiance
ID VISUAL FUNCTION; LOW-VISION; ACUITY; CLASSIFICATION; PSYCHOPHYSICS;
   MACULOPATHY; LUMINANCE; SYSTEM
AB The purpose of this study was to determine if there was an objective difference in reading between four commonly available lamps, of varying spectral radiance, for 13 subjects with age-related maculopathy (ARM) or non-exudative age-related macular degeneration (AMD) - logMAR visual acuity between 0.04 and 0.68. At a constant illuminance of 2000 lux, there was no interaction between ARM and AMD subgroups and no statistically significant difference between the lamps: standard (clear envelope) incandescent, daylight simulation (blue tint envelope) incandescent, compact fluorescent and halogen incandescent, for any reading outcome measure (threshold print size p = 0.67, critical print size p = 0.74, acuity reserve p = 0.84 and mean reading rate p = 0.78). For lamps typically used in low-vision rehabilitation, a clinically significant effect of spectral radiance on reading for people with ARM or non-exudative AMD is unlikely.
C1 Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Eperjesi, F (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
EM f.eperjesi@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Eperjesi, Frank/0000-0003-4358-0095; Bartlett Eperjesi, Hannah
   E/0000-0002-7531-6902
CR ABRAMOV I, 1977, J OPT SOC AM, V67, P195, DOI 10.1364/JOSA.67.000195
   AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Cheong Allen C Y, 2002, Clin Exp Optom, V85, P229
   CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330
   Cohen JM, 1988, J VISION REHABIL, V2, P15
   COLLINS J, 1987, OPTICIAN, V15, P32
   COLLINS J, 1987, EVALUATION 3 TYPES L
   CULLINAN TR, 1979, LANCET, V8117, P642
   De l'Aune WR, 2000, J VISUAL IMPAIR BLIN, V94, P281, DOI 10.1177/0145482X0009400505
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Evans J., 1995, STUDIES MED POPULATI, V57
   FONDA GE, 1981, MANAGEMENT LOW VISIO
   Fosset C, 2004, BIOL TRACE ELEM RES, V98, P1, DOI 10.1385/BTER:98:1:01
   GILL JM, 1982, OPHTHALMIC OPT, V24, P282
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Julian WG, 1984, LIGHTING RES TECHNOL, V16, P34
   KITCHIN JE, 1981, AUST J OPTOM, V64, P176
   LAGROW SJ, 1986, J VISUAL IMPAIR BLIN, V83, P888
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   Lindner H., 1989, Lighting Research and Technology, V21, P1
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mehr EB, 1975, LOW VISION CARE
   SILVER JH, 1978, T OPHTHAL SOC UK, V98, P262
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   SOLDATOVA AM, 1990, OFTALMOL ZH, V7, P403
   WHITAKER D, 1993, OPTOMETRY VISION SCI, V70, P963, DOI 10.1097/00006324-199311000-00014
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 35
TC 16
Z9 17
U1 0
U2 8
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0275-5408
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2007
VL 27
IS 1
BP 93
EP 99
DI 10.1111/j.1475-1313.2006.00431.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131ZD
UT WOS:000243910600011
PM 17239195
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Nakayama, T
   Yuzawa, M
   Wang, ZX
   Kawamura, A
   Mori, R
   Nakashizuka, H
   Sato, N
   Mizutani, Y
AF Tanaka, Koji
   Nakayama, Tomohiro
   Yuzawa, Mitsuko
   Wang, Zhaoxia
   Kawamura, Akiyuki
   Mori, Ryusaburou
   Nakashizuka, Hiroyuki
   Sato, Naoyuki
   Mizutani, Yoshihiro
TI Analysis of candidate genes for age-related macular degeneration
   subtypes in the Japanese population
SO MOLECULAR VISION
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT FACTOR-H; HTRA1 PROMOTER
   POLYMORPHISM; CARDIOVASCULAR-DISEASE; NO ASSOCIATION; RISK; MACULOPATHY;
   SMOKING; HOMOCYSTEINE; LOC387715
AB Purpose: Age-related macular degeneration (AMD) is thought to be a polygenetic disease. It is divided into three subtypes; neovascular AMD (nAMD), polypoidal choroidal vasculopathy, and retinal angiomatous proliferation (RAP). These subtypes are thought to have different pathophysiological and genetic backgrounds. We aimed to investigate the relationships between single nucleotide polymorphisms (SNPs) in candidate genes and subtypes of AMD in the Japanese population.
   Methods: We genotyped 685 AMD patients and 277 controls for four SNPs of the selected candidate genes: rs800292 in complement factor H, rs10490924 in age-related maculopathy susceptibility 2 (ARMS2), rs2301995 in elastin (ELN), and rs1801133 in methylenetetrahydrofolate reductase (MTHFR). Case-control studies were performed using these AMD subtypes. Logistic regression analysis was performed using a history of hypertension, diabetes mellitus, and smoking as cardiovascular risks.
   Results: The genotype-dominant or recessive distribution of all four SNPs differed significantly between the controls and the AMD patients. In the subtype analysis, there were significant differences between the controls and the AMD patients in genotype distributions. This was true for all AMD subtype analyses of both rs800292 (complement factor H) and rs10490924 (ARMS2). Logistic regression analysis indicated the TT genotype of the ARMS2 gene to be significantly more common in RAP patients (p=1.54x10(-13), odds ratio: 22.18). In contrast, there were significant differences in the genotype distribution between the controls and nAMD patients only for rs2301995 (ELN, p=0.022) and rs1801133 (MTHFR, p=2.50x10(-3)).
   Conclusions: Our results indicate that SNPs of the ARMS2 gene may serve as strong genetic markers of RAP, and that SNPs of the ELN and MTHFR genes are potential genetic markers for nAMD.
C1 [Nakayama, Tomohiro] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Lab Med,Itabashi Ku, Tokyo 1738610, Japan.
   [Tanaka, Koji; Yuzawa, Mitsuko; Kawamura, Akiyuki; Mori, Ryusaburou; Nakashizuka, Hiroyuki; Mizutani, Yoshihiro] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1738610, Japan.
C3 Nihon University; Nihon University
RP Nakayama, T (通讯作者)，Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Lab Med,Itabashi Ku, Ooyaguchi Kamimachi, Tokyo 1738610, Japan.
EM nakayama.tomohiro@nihon-u.ac.jp
RI Tanaka, Koji/H-3119-2019; Nakayama, Tomohiro/GYU-0303-2022
OI Tanaka, Koji/0000-0003-3323-4148; 
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy;
   Ministry of Health and Welfare of Japan
FX We thank all patients who participated in this study. This work was
   funded in part by the Research Committee on Chorioretinal Degenerations
   and Optic Atrophy, and by The Ministry of Health and Welfare of Japan
   (Mitsuko Yuzawa).
CR ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Bobryshev YV, 2005, ATHEROSCLEROSIS, V180, P293, DOI 10.1016/j.atherosclerosis.2005.01.024
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   FERNANDEZBLANCO CT, 2004, ARCH SOC ESP OFTALMO, V79, P229
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haas P, 2009, ACTA OPHTHALMOL
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee I, 2007, BIOSCI BIOTECH BIOCH, V71, P1203, DOI 10.1271/bbb.60657
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mizutani Y, 2006, INT J BIOMED SCI, V2, P9
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sato N, 2009, BIOCHEM BIOPH RES CO, V380, P548, DOI 10.1016/j.bbrc.2009.01.117
   Sawabe M, 2009, J ATHEROSCLER THROMB, V16, P91, DOI 10.5551/jat.E612
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yoshida T, 2007, MOL VIS, V13, P545
NR 39
TC 32
Z9 35
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 22
PY 2011
VL 17
IS 297-99
BP 2751
EP 2758
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 837XL
UT WOS:000296244100001
PM 22065928
DA 2022-11-30
ER

PT J
AU Jain, S
   Hamada, S
   Membrey, WL
   Chong, V
AF Jain, S
   Hamada, S
   Membrey, WL
   Chong, V
TI Screening for age-related macular degeneration using nonstereo digital
   fundus photographs
SO EYE
LA English
DT Article
DE AMD; CNV; screening; digital; PDT
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   DIABETIC-RETINOPATHY; DIODE-LASER; MACULOPATHY; PHOTOCOAGULATION;
   VERTEPORFIN
AB Age-related macular degeneration (AMD) is a disease with significant visual morbidity and accounts for the majority of blind registrations in the developed world including the UK. Certain forms of neovascular AMD are amenable to treatment but require expeditious referral to a retinal specialist.
   Aim To evaluate the possibility of using nonstereo fundus photographs as a low-cost screening tool for neovascular AMD.
   Design Retrospective review of patients referred to the macular clinic of a teaching hospital in London. Methods A total of 198 randomised digital fundus photographs, without any other clinical information, were presented to two independent ophthalmic interns who graded them into one of the three categories: normal, age-related maculopathy (ARM), or neovascular age-related macular degeneration (AMD) to determine the urgency of referral to clinic. The results were compared with the known diagnosis for each patient and sensitivities and specificities for each diagnostic category calculated.
   Results The intraobserver Kappa statistic was 0.75 and 0.91 for grader 1 and 2, respectively. The interobserver Kappa was 0.54. The mean sensitivity and specificity for the identification of ARM was 60.5 and 76.3%, respectively The mean sensitivity and specificity for the identification of AMD was 85.7 and 78.8%, respectively.
   Conclusion Nonstereo digital fundus photograph is a reasonable screening tool for CNV and may aid in decreasing the visual morbidity it causes by enabling timely referrals and treatment.
C1 Kings Coll Hosp London, Retinal Res Unit, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Jain, S (通讯作者)，Leicester Royal Infirm, Dept Ophthalmol, Leicester LE1 5WW, Leics, England.
EM drsaurabhjain@hotmail.com
RI Chong, Victor/Q-6565-2018; Chong, Ngaihang V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; 
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Haddad WM, 2002, GRAEF ARCH CLIN EXP, V240, P31, DOI 10.1007/s00417-001-0404-4
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   MABERLEY DAL, EYE
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   Ryder REJ, 1998, DIABETIC MED, V15, P721, DOI 10.1002/(SICI)1096-9136(199809)15:9<721::AID-DIA694>3.0.CO;2-B
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Sternberg P, 2004, AM J OPHTHALMOL, V137, P483, DOI 10.1016/j.ajo.2003.11.023
   ULBIG MW, 1993, BRIT J OPHTHALMOL, V77, P218, DOI 10.1136/bjo.77.4.218
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Williamson TH, 1998, BRIT J OPHTHALMOL, V82, P5, DOI 10.1136/bjo.82.1.5
   2005, RETINA, V25, P119
NR 19
TC 22
Z9 22
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD APR
PY 2006
VL 20
IS 4
BP 471
EP 475
DI 10.1038/sj.eye.6701916
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 029KL
UT WOS:000236561100012
PM 15895024
OA Bronze
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Tsujikawa, A
   Nishida, A
   Kurimoto, Y
AF Yamashiro, Kenji
   Tsujikawa, Akitaka
   Nishida, Akihiro
   Kurimoto, Yasuo
TI Determinants of patient satisfaction with photodynamic therapy for
   neovascular age-related macular degeneration or polypoidal choroidal
   vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; patient satisfaction; photodynamic
   therapy; polypoidal choroidal vasculopathy; scotoma; visual distortion
ID QUALITY-OF-LIFE; CENTRAL VISUAL-FIELD; VERTEPORFIN THERAPY; LESIONS
AB Purpose: To evaluate the determinants of patient satisfaction with photodynamic therapy (PDT) for neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
   Methods: Questionnaires were mailed to 69 patients who had undergone PDT for AMD or PCV at the Kobe City General Hospital. The questionnaire considered the following parameters: subjective change in visual acuity, subjective change in the relative scotoma in central vision, subjective change in visual distortion, and patient satisfaction with PDT scored on a 100-point scale.
   Results: Nine patients (14%) reported their subjective visual acuity change as "significantly improved" and 21 (32%) as "slightly improved"; 18 (27%) reported "no change"; 12 (18%) reported their visual acuity as "slightly worsened"; and 6 (9%) as "significantly worsened." Subjective change in the central scotoma was reported improved in 43 patients (64%) and visual distortion had improved subjectively in 31 patients (47%). The satisfaction score was 59 +/- 25 in patients who had undergone PDT for AMD and 75 +/- 24 in those with PCV. Not only the visual acuity change but also the subjective change in central scotoma and visual distortion correlated significantly with the satisfaction score.
   Conclusions: More patients who have undergone PDT for AMD or PCV perceive improvement in central scotoma and visual distortion than in visual acuity. Since these subjective changes correlated significantly with the satisfaction score, subjective change in central scotoma and visual distortion, in addition to visual acuity, should be taken into account in evaluating the benefits of PDT.
C1 Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo 6500046, Japan.
   Inst Biomed Res & Innovat, Dept Regenerat Med, Kobe, Hyogo, Japan.
   Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kobe City Medical Center General Hospital; Institute for Biomedical
   Research & Innovation (IBRI); Kyoto University
RP Yamashiro, K (通讯作者)，Kobe City Gen Hosp, Dept Ophthalmol, 4-6 Minatojima Nakamachi, Kobe, Hyogo 6500046, Japan.
EM yamashro@kcgh.gr.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   Meyer CH, 2005, AM J OPHTHALMOL, V139, P214, DOI 10.1016/j.ajo.2004.07.034
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   2001, AM J OPHTHALMOL, V131, P541
NR 18
TC 6
Z9 7
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP-OCT
PY 2007
VL 51
IS 5
BP 368
EP 374
DI 10.1007/s10384-007-0465-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 218YG
UT WOS:000250051300009
PM 17926114
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Liew, G
   Gopinath, B
   Wong, TY
AF Mitchell, Paul
   Liew, Gerald
   Gopinath, Bamini
   Wong, Tien Y.
TI Age-related macular degeneration
SO LANCET
LA English
DT Review
ID BLUE-MOUNTAINS-EYE; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL
   ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED
   CLINICAL-TRIAL; GEOGRAPHIC ATROPHY SECONDARY; RANIBIZUMAB-TREATED
   PATIENTS; SIMPLIFIED SEVERITY SCALE; GENOME-WIDE ASSOCIATION;
   POPULATION-BASED-COHORT
AB Age-related macular degeneration is a leading cause of visual impairment and severe vision loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary changes) to late-stage (neovascular and atrophic). Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids). Progression from early-stage to late-stage disease can be slowed with high-dose zinc and antioxidant vitamin supplements. Intravitreal anti-vascular endothelial growth factor therapy (eg, ranibizumab, aflibercept, or bevacizumab) is highly effective at treating neovascular age-related macular degeneration, and has markedly decreased the prevalence of visual impairment in populations worldwide. Currently, no proven therapies for atrophic disease are available, but several agents are being investigated in clinical trials. Future progress is likely to be from improved efforts in prevention and risk-factor modification, personalised medicine targeting specific pathways, newer anti-vascular endothelial growth factor agents or other agents, and regenerative therapies.
C1 [Mitchell, Paul; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Wong, Tien Y.] Duke Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
C3 University of Sydney; Westmead Institute for Medical Research; National
   University of Singapore; Singapore National Eye Center
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Westmead Inst Med Res, Ctr Vis Res,Dept Ophthalmol, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU Australian National Health & Medical Research Council (Canberra,
   Australia)
FX This work was supported by the Australian National Health & Medical
   Research Council (Canberra, Australia).
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Casparis H, 2017, COCHRANE DB SYST REV, V2
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gass, 1998, STEREOSCOPIC ATLAS M
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Grzybowski A, 2017, GRAEF ARCH CLIN EXP, V255, P1687, DOI 10.1007/s00417-017-3740-8
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lawrenson JG, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1186/1471-2415-7-3
   LEE WK, 2017, INVEST OPHTH VIS SCI, V58
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   MacLaren RE, 2016, OPHTHALMOLOGY, V123, pS98, DOI 10.1016/j.ophtha.2016.06.041
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   SanGiovanni JP, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017228
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 133
TC 514
Z9 539
U1 28
U2 145
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 29
PY 2018
VL 392
IS 10153
BP 1147
EP 1159
DI 10.1016/S0140-6736(18)31550-2
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GV3BV
UT WOS:000445968800029
PM 30303083
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Liu, R
   Li, JQ
   Li, ZJ
   Yu, SS
   Yang, Y
   Yan, H
   Zeng, J
   Tang, SB
   Ding, XY
AF Liu, Ran
   Li, Jiaqing
   Li, Zijing
   Yu, Shanshan
   Yang, Yu
   Yan, Hong
   Zeng, Jing
   Tang, Shibo
   Ding, Xiaoyan
TI DISTINGUISHING POLYPOIDAL CHOROIDAL VASCULOPATHY FROM TYPICAL
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION BASED ON SPECTRAL DOMAIN
   OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; neovascular age-related macular
   degeneration; optical coherence tomography; sensitivity; specificity;
   Youden index; receiver operating characteristic curve
ID INDOCYANINE GREEN ANGIOGRAPHY; DIGITAL FUNDUS PHOTOGRAPHY; FEATURES;
   LESIONS; OPHTHALMOSCOPY; SPECIFICITY; SENSITIVITY
AB Purpose:To investigate the sensitivity and specificity of spectral domain optical coherence tomography in distinguishing polypoidal choroidal vasculopathy (PCV) from typical neovascular age-related macular degeneration (nAMD).Methods:One hundred and eighty-eight eyes in 156 patients with active PCV or typical nAMD were enrolled prospectively. Three spectral domain optical coherence tomography manifestations, pigment epithelium detachment, double-layer sign, and thumb-like polyps were estimated in all the eyes. A diagnostic test to differentiate PCV from nAMD based on spectral domain optical coherence tomography was performed. Furthermore, the sensitivity and specificity was validated in a retrospective series of patients.Results:Pigment epithelium detachment, double-layer sign, and thumb-like polyps were more common in PCV eyes than in nAMD eyes. When the cutoff point was set as at least 2 positive signs out of 3 in the diagnostic test, the sensitivity was 89.4% and specificity was 85.3%. The results of the validation test further confirmed the strategy, with satisfying sensitivity (87.5%) and specificity (86.2%).Conclusion:Spectral domain optical coherence tomography is sensitive and specific in distinguishing PCV from nAMD. From these results, the presence of at least two out three signs (pigment epithelium detachment, double-layer sign, and thumb-like polyps) indicates a positive test and is therefore suggested to be the screening strategy for PCV.
C1 [Liu, Ran; Li, Jiaqing; Li, Zijing; Yu, Shanshan; Yang, Yu; Yan, Hong; Zeng, Jing; Tang, Shibo; Ding, Xiaoyan] Zhongshan Ophthalm Ctr, Vitreoretinal Dept, State Key Lab Ophthalmol, 54 Xianlie S Rd, Guangzhou, Guangdong, Peoples R China.
RP Ding, XY (通讯作者)，Zhongshan Ophthalm Ctr, Vitreoretinal Dept, State Key Lab Ophthalmol, 54 Xianlie S Rd, Guangzhou, Guangdong, Peoples R China.
EM dingxy75@gmail.com
RI Li, Zijing/ABE-5039-2021; yu, shanshan/AIC-2220-2022; TANG,
   Shi/GXH-5719-2022
OI yu, shanshan/0000-0001-6182-8328; 
FU Fundamental Research Funds of State Key Laboratory of Ophthalmology;
   National Natural Science Foundation of China [81470645]
FX Supported by the Fundamental Research Funds of State Key Laboratory of
   Ophthalmology and National Natural Science Foundation of China 81470645.
CR Abe Sachi, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-76
   [Anonymous], 2005, NIHON GANKA GAKKAI Z, V109, P417
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 25
TC 50
Z9 53
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2016
VL 36
IS 4
BP 778
EP 786
DI 10.1097/IAE.0000000000000794
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ0IC
UT WOS:000373884700017
PM 26428604
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, CG
   Lee, DW
   Yoo, SJ
   Lew, YJ
   Cho, HJ
   Kim, JY
   Lee, SH
   Kim, JW
AF Kim, Jae Hui
   Kim, Chul Gu
   Lee, Dong Won
   Yoo, Su Jin
   Lew, Young Ju
   Cho, Han Joo
   Kim, Joo Yeon
   Lee, Seok Hyun
   Kim, Jong Woo
TI Intravitreal aflibercept for submacular hemorrhage secondary to
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidal vasculopathy; Hemorrhage; Aflibercept
ID ENDOTHELIAL GROWTH-FACTOR; VISUAL IMPAIRMENT; VEGF TRAP; RANIBIZUMAB;
   PREVALENCE; VITRECTOMY; EFFICACY; LESIONS; ADULTS
AB Purpose To evaluate the efficacy of intravitreal aflibercept monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Methods This prospective, phase 4 clinical trial included 29 patients diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD (7 patients) or PCV (22 patients). Patients were initially administered 3 monthly aflibercept injections, followed by 1 injection every 2 months. The primary outcome measure was changes in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during the 56-week study period. Other key outcome measures were the proportion of patients who exhibited changes in BCVA of >= 15 ETDRS letters from baseline and changes in central retinal thickness (CRT). Results The mean size of hemorrhage was 6.2 +/- 4.8-disc-diameter area. The mean BCVA significantly improved from 52.9 +/- 17.8 ETDRS letters at week 0 (baseline) to 71.8 +/- 16.1 letters at week 56 (P < 0.001). At week 56, improvement in BCVA of >= 15 letters was noted in 16 patients (55.2%), whereas none of the patients experienced a loss of >= 15 letters. The mean CRT significantly decreased from 498.9 +/- 194.2 mu m at week 0 to 248.3 +/- 45.0 mu m at week 56 (P < 0.001). During the study period, retinal break developed in one patient. Conclusions Intravitreal aflibercept administered every 2 months after the 3 initial monthly doses was found to be an effective and safe treatment method for submacular hemorrhage secondary to neovascular AMD.
C1 [Kim, Jae Hui; Kim, Chul Gu; Lee, Dong Won; Yoo, Su Jin; Lew, Young Ju; Cho, Han Joo; Kim, Joo Yeon; Lee, Seok Hyun; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JW (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kjwood@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
FU Bayer Korea [17860] Funding Source: Medline
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bardak H, 2018, EUR J OPHTHALMOL, V28, P306, DOI 10.5301/ejo.5001074
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Fleissig E, 2017, GRAEF ARCH CLIN EXP, V255, P1341, DOI 10.1007/s00417-017-3648-3
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kherani S, 2018, AM J OPHTHALMOL, V189, P86, DOI 10.1016/j.ajo.2018.02.015
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2018, GRAEF ARCH CLIN EXP, V256, P469, DOI 10.1007/s00417-017-3877-5
   Kim JH, 2018, JPN J OPHTHALMOL, V62, P54, DOI 10.1007/s10384-017-0549-2
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2018, OPHTHALMOL RETINA, V2, P180, DOI 10.1016/j.oret.2017.07.012
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 37
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2020
VL 258
IS 1
BP 107
EP 116
DI 10.1007/s00417-019-04474-0
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KI9XF
UT WOS:000511711500015
PM 31741044
DA 2022-11-30
ER

PT J
AU Cohn, AC
   Busija, L
   Robman, LD
   Dimitrov, PN
   Varsamidis, M
   Lim, LL
   Baird, PN
   Guymer, RH
AF Cohn, Amy C.
   Busija, Lucy
   Robman, Liubov D.
   Dimitrov, Peter N.
   Varsamidis, Mary
   Lim, Lyndell L.
   Baird, Paul N.
   Guymer, Robyn H.
TI Younger Siblings, C-Reactive Protein, and Risk of Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; C-reactive protein; inflammation;
   sibling exposure
ID FACTOR-H POLYMORPHISM; CHLAMYDIA-PNEUMONIAE INFECTION;
   EPSTEIN-BARR-VIRUS; COMPLEMENT-SYSTEM; CARDIOVASCULAR-DISEASE;
   MULTIPLE-SCLEROSIS; CELL RESPONSE; BIRTH-ORDER; MACULOPATHY;
   INFLAMMATION
AB In this study, we examined the relationship between exposure to siblings and 1) the risk of age-related macular degeneration (AMD) and 2) C-reactive protein levels. We retrospectively analyzed pooled cross-sectional data from 2 studies: the Cardiovascular Health and Age-Related Maculopathy Study (2001-2002) and the Age-Related Maculopathy Statin Study (2004-2006). Associations between number of siblings and AMD were assessed by using multinomial logistic regression. Associations between number of siblings and C-reactive protein levels were examined by using a generalized linear model for. distribution. A higher number of younger siblings was associated with significantly lower odds of early AMD in those with a family history of AMD (odds ratio = 0.2, 95% confidence interval: 0.1, 0.8) (P = 0.022) but was unrelated to AMD for those who had no family history of the disease (odds ratio = 1.0, 95% confidence interval: 0.9, 1.2) (P = 0.874). A higher number of younger siblings correlated with lower C-reactive protein levels (beta = -0.19, 95% confidence interval: -0.38, -0.01) (P = 0.036). This supports the theory that immune modulation contributes to AMD pathogenesis and suggests that exposure to younger siblings might be protective when there is a family history of AMD.
C1 [Cohn, Amy C.; Busija, Lucy; Robman, Liubov D.; Dimitrov, Peter N.; Varsamidis, Mary; Lim, Lyndell L.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Cohn, Amy C.; Busija, Lucy; Robman, Liubov D.; Dimitrov, Peter N.; Varsamidis, Mary; Lim, Lyndell L.; Baird, Paul N.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
   [Busija, Lucy] Univ Melbourne, Dept Med, Melbourne EpiCtr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rh.guymer@unimelb.edu.au
RI Busija, Lucy/Y-6064-2019
OI Busija, Lucy/0000-0001-7464-9089; Guymer, Robyn/0000-0002-9441-4356;
   Lim, Lyndell/0000-0003-2491-685X; Baird, Paul/0000-0002-1305-3502
FU Australian National Health and Medical Research Council [128201, 350224,
   529923]; Ramaciotti Foundation; Hugh D. Williamson Foundation; Lions
   Clubs of Victoria; Ian Potter Foundation; John Reid Charitable Trust;
   NHMRC Practitioner Fellowship [529905]; NHMRC Senior Research Fellowship
   [1028444]; Eye Foundation/Novartis Medical Retina Fellowship; Melbourne
   Centre for Epidemiology, Biostatistics, and Health Services Research;
   Centre for Research Excellence in Translational Neuroscience; NHMRC
   Centre for Research Excellence [1001216]
FX Data on siblings and covariates were collected in the course of 2
   studies supported by the Australian National Health and Medical Research
   Council (grants 128201 and 350224). Additional support for these studies
   was provided by the Ramaciotti Foundation, the Hugh D. Williamson
   Foundation, the Lions Clubs of Victoria, the Ian Potter Foundation, and
   the John Reid Charitable Trust. Personnel support was provided through a
   NHMRC Practitioner Fellowship 529905 (R.H.G.), a NHMRC Senior Research
   Fellowship 1028444 (P.N.B.), an Eye Foundation/Novartis Medical Retina
   Fellowship (A.C.C.), and a postdoctoral fellowship jointly funded by the
   Melbourne Centre for Epidemiology, Biostatistics, and Health Services
   Research and the Centre for Research Excellence in Translational
   Neuroscience (L.B.). The Centre for Eye Research Australia is a
   recipient of a NHMRC Centre for Research Excellence grant (1001216) and
   the Australian National Health and Medical Research Council grant
   (529923) for the Centre for Clinical Research Excellence and Operational
   Infrastructure Support from the Victorian Government.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Adams CL, 2003, IMMUNOLOGY, V108, P274, DOI 10.1046/j.1365-2567.2003.01583.x
   Altieri A, 2006, NEUROLOGY, V67, P1979, DOI 10.1212/01.wnl.0000247036.98444.38
   Amyes E, 2003, J EXP MED, V198, P903, DOI 10.1084/jem.20022058
   ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200
   Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100
   Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Cardwell CR, 2011, INT J EPIDEMIOL, V40, P363, DOI 10.1093/ije/dyq207
   Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AM, 2008, AM J EPIDEMIOL, V167, P1182, DOI 10.1093/aje/kwn042
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Levin LI, 2003, JAMA-J AM MED ASSOC, V289, P1533, DOI 10.1001/jama.289.12.1533
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Ponsonby AL, 2006, CLIN EXP IMMUNOL, V146, P463, DOI 10.1111/j.1365-2249.2006.03235.x
   Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shen Y, 2003, PROG NEUROBIOL, V70, P463, DOI 10.1016/j.pneurobio.2003.08.001
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369
   Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2
   STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yeh ETH, 2004, CIRCULATION, V109, P11, DOI 10.1161/01.CIR.0000129507.12719.80
NR 55
TC 2
Z9 2
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 1
PY 2013
VL 177
IS 9
BP 933
EP 943
DI 10.1093/aje/kws332
PG 11
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 139IR
UT WOS:000318576300011
PM 23548752
OA Bronze
DA 2022-11-30
ER

PT J
AU Feigl, B
AF Feigl, Beatrix
TI Age-related maculopathy in the light of ischaemia
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related maculopathy; hypoxia; ischaemia; mfERG; multifocal
   electroretinogram
ID ENDOTHELIAL GROWTH-FACTOR; CARDIOVASCULAR RISK-FACTORS; FACTOR-H
   POLYMORPHISM; CHOROIDAL BLOOD-FLOW; MACULAR DEGENERATION; RETINAL
   FUNCTION; INTRAVITREAL BEVACIZUMAB; BRUCHS MEMBRANE; MULTIFOCAL
   ELECTRORETINOGRAM; PHOTODYNAMIC THERAPY
AB This manuscript focuses on the pathogenesis of age-related maculopathy (ARM) and the documentation of new treatments in ARM. Ischaemia will be given special consideration, as it is believed to play a central role in both early ARM and late ARM or age-related macular degeneration (AMD). Reduced choroidal and retinal blood flow causes ischaemia of Bruch's membrane, retinal pigment epithelium and neuroretina in the early course of ARM. This is thought to be the primary trigger of the condition. Chronic ischaemia upregulates vascular endothelial growth factor (VEGF), which induces abnormal vessel growth in neovascular AMD. The role of ischaemia in neovascular AMD is supported by the evidence of effective new treatments targeting VEGF.
C1 Queensdland Univ Technol, Sch Optometry, Brisbane, Qld, Australia.
   Queensdland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR ABRAHAMMARIN ML, 2006, GRAEFES ARCH CL 0928
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arboix A, 2006, CLIN NEUROL NEUROSUR, V108, P638, DOI 10.1016/j.clineuro.2005.10.010
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P296, DOI 10.1167/iovs.03-0424
   BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Bui BV, 2003, EXP EYE RES, V77, P125, DOI 10.1016/S0014-4835(03)00132-5
   *CERA, CENTR FOC IMP AG REL
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Cukras Catherine, 2007, International Ophthalmology Clinics, V47, P51, DOI 10.1097/IIO.0b013e31802bd785
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Dhalla M, 2006, RETINA, V29, P988
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ezzati M, 2005, CIRCULATION, V112, P489, DOI 10.1161/CIRCULATIONAHA.104.521708
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2006, VISUAL NEUROSCI, V23, P863, DOI 10.1017/S0952523806230190
   Feigl B, 2005, DOC OPHTHALMOL, V111, P135, DOI 10.1007/s10633-005-5319-7
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Feigl B, 2007, CLIN NEUROPHYSIOL, V118, P887, DOI 10.1016/j.clinph.2006.12.012
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Galvan V, 2006, MINI-REV MED CHEM, V6, P667, DOI 10.2174/138955706777435742
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   JOHNSON L, 1999, EXP EYE RES, V73, P887
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P774, DOI 10.1177/112067210601600522
   Kergoat H, 2006, INVEST OPHTH VIS SCI, V47, P5423, DOI 10.1167/iovs.06-0602
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krukier II, 2006, B EXP BIOL MED+, V141, P216, DOI 10.1007/s10517-006-0131-2
   Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715
   MARMOR MF, 1985, DOC OPHTHALMOL, V60, P347, DOI 10.1007/BF00158923
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Maulik N, 2006, ANTIOXID REDOX SIGN, V8, P2161, DOI 10.1089/ars.2006.8.2161
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 2001, RETINA, P1064
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shimada Y, 2005, GRAEF ARCH CLIN EXP, V243, P132, DOI 10.1007/s00417-004-1072-y
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tinjust D, 2002, AVIAT SPACE ENVIR MD, V73, P1189
   *TREATM AG REL MAC, 2006, GRAEFES ARCH CLIN EX, V44, P1132
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zele AJ, 2006, GRAEF ARCH CLIN EXP, V244, P425, DOI 10.1007/s00417-005-0121-5
   Zele AJ, 2005, J NEUROSCI METH, V141, P1, DOI 10.1016/j.jneumeth.2004.05.005
NR 106
TC 15
Z9 18
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JUL
PY 2007
VL 90
IS 4
BP 263
EP 271
DI 10.1111/j.1444-0938.2007.00152.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 171TP
UT WOS:000246758600007
PM 17535365
DA 2022-11-30
ER

PT J
AU Takahashi, Y
   Koizumi, H
   Hasegawa, T
   Izumi, T
   Maruko, I
   Sonoda, S
   Sakamoto, T
   Iida, T
AF Takahashi, Yohei
   Koizumi, Hideki
   Hasegawa, Taiji
   Izumi, Takahiko
   Maruko, Ichiro
   Sonoda, Shozo
   Sakamoto, Taiji
   Iida, Tomohiro
TI Comparison of subfoveal choroidal structures in typical neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal structure; Choroidal
   vasculopathy; Optical coherence tomography; Polypoidal choroidal
   thickness
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY; VASCULAR
   HYPERPERMEABILITY; THICKNESS; EYES; BINARIZATION; IMAGES
AB Purpose To evaluate and compare the intrachoroidal structures of eyes with typical neovascular age-related macular degeneration (AMD) with those of eyes with polypoidal choroidal vasculopathy (PCV).
   Study design Retrospective and comparative case series.
   Methods Eighty-four treatment-naive eyes of 84 patients (22 women and 62 men) with typical neovascular AMD or PCV located in the subfoveal region were studied. Cross-sectional images of the retina and choroid were obtained by swept-source optical coherence tomography (SS-OCT). The horizontal SS-OCT images were analyzed by a manual delineation technique and by a binarization method.
   Results Thirty-nine eyes with typical neovascular AMD and 45 eyes with PCV were studied. Although the subfoveal choroidal thickness (SCT) did not differ significantly between the 2 subtypes (255.1 +/- 86.7 mu m in typical neovascular AMD and 289.2 +/- 116.5 mu m in PCV, P = 0.29), the ratio of the large choroidal vessel layer (LCVL) thickness to the SCT was significantly larger in the eyes with PCV than in the eyes with typical neovascular AMD (0.863 +/- 0.084 vs 0.803 +/- 0.125, P = 0.023). The binarization method did not find significant differences in the choroidal structure between the 2 subtypes. Multivariate logistic regression analyses found the ratio of the LCVL thickness to the SCT to be the only significantly different factor between typical neovascular AMD and PCV (P = 0.035).
   Conclusion The intrachoroidal structures of typical neovascular AMD and PCV eyes differ significantly. In eyes with PCV, there seemed to be a greater dilation of the large choroidal vessels.
C1 [Takahashi, Yohei; Koizumi, Hideki; Hasegawa, Taiji; Izumi, Takahiko; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara, Nishihara, Okinawa 9030125, Japan.
   [Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Dept Ophthalmol, Kagoshima, Japan.
C3 Tokyo Women's Medical University; University of Ryukyus; Kagoshima
   University
RP Koizumi, H (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.; Koizumi, H (通讯作者)，Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara, Nishihara, Okinawa 9030125, Japan.
EM hkoizumi@med.u-ryukyu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Hasegawa, Taiji/ABG-8260-2021
OI Maruko, Ichiro/0000-0001-5647-6372; 
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [25670739]
FX The authors thank Yuji Yamamoto, Department of Ophthalmology, Kyoto
   Prefectural University of Medicine, for statistical expertise. This
   study was supported in part by grant no. 25670739 from the Ministry of
   Education, Culture, Sports, Science and Technology-Japan (Dr. Koizumi).
CR Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   Izumi T, 2017, BRIT J OPHTHALMOL, V101, P433, DOI 10.1136/bjophthalmol-2016-308921
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953
NR 25
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2018
VL 62
IS 5
BP 576
EP 583
DI 10.1007/s10384-018-0615-4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR6CR
UT WOS:000442733200007
PM 30069649
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Nakannura, Y
   Yoneyama, S
   Mabuchi, F
   Gotoh, T
   Tateno, Y
   Sugiyama, A
   Kubota, T
   Iijima, H
AF Sakurada, Yoichi
   Nakannura, Yuki
   Yoneyama, Seigo
   Mabuchi, Fumihiko
   Gotoh, Teruhiko
   Tateno, Yasushi
   Sugiyama, Atsushi
   Kubota, Takeo
   Iijima, Hiroyuki
TI Aqueous Humor Cytokine Levels in Patients with Polypoidal Choroidal
   Vasculopathy and Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Aqueous humor; Cytokines; Age-related macular degeneration; Polypoidal
   choroidal vasculopathy
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; MONOCYTE CHEMOATTRACTANT
   PROTEIN-1; EPITHELIUM-DERIVED FACTOR; PIGMENT-EPITHELIUM;
   DIABETIC-RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB; MACROPHAGES; VEGF
AB Purpose:To investigate the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous humor levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular AMD. Methods: Forty eyes from 40 patients with treatment-naive exudative AMD consisting of 18 eyes with neovascular AMD and 22 eyes with PCV were studied. Twenty eyes from 20 patients with no retinal pathology who underwent cataract surgery served as controls. Aqueous humor samples were collected just before intravitreal ranibizumab injection in 40 eyes with exudative AMD and before cataract surgery in 20 control eyes. Concentrations of 14 cytokines were determined by chemilunninescence-based ELISA: interleukin (IL)-1 alpha, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, vascular endothelial growth factor (VEGF), monocytechemoattractant protein 1, interferon-gamma-inducible protein (IP)-10 and C-reactive protein (CRP). Results: After adjusting for gender, age and axial length, concentrations of CRP and IP-10 were significantly higher in eyes with neovascular AMD or PCV compared with control eyes (p < 0.05), and IP-10 levels were strongly associated with lesion size (p = 0.002). None of the 14 cytokines, including VEGF, were significantly different between eyes with neovascular AMD and those with PCV. Conclusion: Aqueous humor concentrations of CRP and IP-10 were elevated in eyes with PCV or neovascular AMD. IP-10 could be associated with the pathogenesis of neovascular AMD and PCV. (C) 2014 S. Karger AG, Basel
C1 [Sakurada, Yoichi; Yoneyama, Seigo; Mabuchi, Fumihiko; Gotoh, Teruhiko; Tateno, Yasushi; Sugiyama, Atsushi; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo, Yamanashi 4093898, Japan.
   [Nakannura, Yuki] Univ Yamanashi, Fac Med, Dept Immunol, Chuo, Yamanashi 4093898, Japan.
   [Kubota, Takeo] Univ Yamanashi, Fac Med, Dept Epigenet, Chuo, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi; University of
   Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU Ministry of Education, Science, Sports and Culture, Japan [23791972]
FX This study was supported in part by a grant-in-aid (No. 23791972) from
   the Ministry of Education, Science, Sports and Culture, Japan.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kakehashi A, 2008, DIABETES RES CLIN PR, V79, P438, DOI 10.1016/j.diabres.2007.10.018
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sawada O, 2011, JPN J OPHTHALMOL, V55, P401, DOI 10.1007/s10384-011-0027-1
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
NR 32
TC 44
Z9 48
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 53
IS 1
BP 2
EP 7
DI 10.1159/000365487
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA5UA
UT WOS:000348972100002
PM 25472810
DA 2022-11-30
ER

PT J
AU Kondo, N
   Honda, S
   Ishibashi, K
   Tsukahara, Y
   Negi, A
AF Kondo, Naoshi
   Honda, Shigerij
   Ishibashi, Kazuki
   Tsukahara, Yasutomo
   Negi, Akira
TI LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and
   age-related macular degeneration in a Japanese population
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; PHOTODYNAMIC THERAPY;
   PREVALENCE; MACULOPATHY; GENE; EYE; VERTEPORFIN; INCREASES; RISK
AB PURPOSE: To investigate whether variants in the LOC387715 locus and the HtrA serine peptidase I (HTRA1) gene within the 10q26 locus are associated with polypoidal choroidal vasculopathy (PCV) and wet age-related macular degeneration (AMD) in a Japanese population, and whether genetic diversity exists between PCV and wet AMD in this locus.
   DESIGN: Cross-sectional study.
   METHODS: We genotyped 243 Japanese individuals, including 76 PCV cases, 73 wet AMD cases, and 94 controls using, two single nucleotide polymorphisms (SNPs) that are located in the LOC387715 locus (rs10490924) or the HTRA1 gene (rs11200638). Genotyping was performed using TaqMan assays (Applied Biosystems, Foster City, California, USA).
   RESULTS: Two SNPs generated highly significant allelic associations with PCV (rs10490924, P = 5.7 x 10(-6); rs11200638, P = 5.2 X 10(-6)) and AMD (rs10490924, P = 1.4 x 10(-6); rs11200638, P = 3.4 x 10(-7)). The odds ratios and population attributable risks were higher for the AMD cases than for the PCV cases. Homo-ygotes for the risk allele at rs11200638 had a 6.33-fold increased risk of PCV and a 13.77-fold increased risk of wet AMD when compared with homozygotes for the wild-type allele. There were no significant differences in either allelic or genotypic frequencies between PCV and AMD cases.
   CONCLUSIONS: The LOC387715/HTRA1 variants are associated with PCV and wet AMD in the Japanese population. The associations are stronger in AMD than in PCV. PCV and AMD share common genetic factors, which suggests that PCV and wet AMD are similar in some pathophysiologic aspects.
C1 Kobe Univ, Grad Sch Med, Dept Organ Therapeut, Div Ophthalmol, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Organ Therapeut, Div Ophthalmol, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
OI Kondo, Naoshi/0000-0001-6025-3876
CR BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x
   Scholl HPN, 2007, MOL VIS, V13, P196
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 31
TC 119
Z9 132
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2007
VL 144
IS 4
BP 608
EP 612
DI 10.1016/j.ajo.2007.06.003
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 217GW
UT WOS:000249937400020
PM 17692272
DA 2022-11-30
ER

PT J
AU Muether, PS
   Neuhann, I
   Buhl, C
   Hermann, MM
   Kirchhof, B
   Fauser, S
AF Muether, Philipp S.
   Neuhann, Irmingard
   Buhl, Christoph
   Hermann, Manuel M.
   Kirchhof, Bernd
   Fauser, Sascha
TI INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; drusen;
   endostatin; intraocular growth factors; platelet-derived growth factor;
   vascular endothelial growth factor; VEGF
ID AQUEOUS-HUMOR LEVELS; EPITHELIUM-DERIVED FACTOR; CHOROIDAL
   NEOVASCULARIZATION; MACULOPATHY; EXPRESSION; MEMBRANES; BEVACIZUMAB;
   PREVALENCE; ENDOSTATIN; SYSTEM
AB Purpose: To analyze intraocular growth factor and cytokine concentrations in eyes with different stages of age-related macular degeneration (AMD) compared with controls.
   Methods: The Clinical Age-Related Maculopathy Staging (CARMS) system was used for assignment of patients into the respective categories. Aqueous humor specimens were taken before cataract surgery in 21 controls (CARMS 1) and in 17 early (CARMS 2) and 16 intermediate (CARMS 3) AMD patients. In 18 neovascular (CARMS 5) AMD patients, specimens were taken immediately before anti-vascular endothelial growth factor intravitreal therapy. Luminex multiplex bead assays were conducted for endostatin, angiogenin, vascular endothelial growth factor, platelet-derived growth factor AA, placental growth factor, thrombospondin 2, and fibroblast growth factor a.
   Results: Vascular endothelial growth factor concentrations were elevated in CARMS 3 (P = 0.037) and tended to be elevated in CARMS 5 (P = 0.093), whereas levels in CARMS 2 (P = 0.425) were similar to CARMS 1. Platelet-derived growth factor levels were diminished in CARMS 2 (P = 0.020), with a trend to lower levels for CARMS 3 (P = 0.099) and CARMS 5 (P = 0.082) compared with CARMS 1. For CARMS 5, antiangiogenic endostatin was elevated (P < 0.002), while antiangiogenic thrombospondin 2 was reduced (P = 0.029).
   Conclusion: Clinical Age-Related Maculopathy Staging 3 dry AMD was associated with higher vascular endothelial growth factor levels than CARMS 5 neovascular AMD. Therefore, intraocular vascular endothelial growth factor concentrations do not seem to reflect choroidal neovascularization activity in neovascular AMD directly. Platelet-derived growth factor was decreased in most forms of AMD. The antiangiogenic endostatin was exclusively elevated in neovascular AMD, while thrombospondin 2 was reduced. Age-related macular degeneration disease seems to be associated with a generally altered cytokine system.
C1 [Muether, Philipp S.; Buhl, Christoph; Hermann, Manuel M.; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
   [Neuhann, Irmingard] Red Cross Hosp, Eye Dept, Munich, Germany.
C3 University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
EM philmuether@mac.com
FU Koeln Fortune Program/Faculty of Medicine, University of Cologne; Gilen;
   Nolting; Imhoff Foundation
FX Supported by the Koeln Fortune Program/Faculty of Medicine, University
   of Cologne. Additional support was provided by Gilen, Nolting, and
   Imhoff Foundation.
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Skeie JM, 2011, MOL VIS, V17, P576
   Tatar O, 2006, EXP EYE RES, V83, P329, DOI 10.1016/j.exer.2005.12.017
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
NR 25
TC 27
Z9 30
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1809
EP 1814
DI 10.1097/IAE.0b013e318285cd9e
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500008
PM 23492946
DA 2022-11-30
ER

PT J
AU Ulvik, SO
   Seland, JH
   Wentzel-Larsen, T
AF Ulvik, SO
   Seland, JH
   Wentzel-Larsen, T
TI Refraction, axial length and age-related maculopathy
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; axial length
   refraction
ID VISUAL-ACUITY; POPULATION; RISK
AB Purpose: To study the relationship between age-related maculopathy (ARM)/ age-related macular degeneration (AMD) and phakic refraction and between ARM/AMD and axial length.
   Methods: The study was a point prevalence study that included 663 randomly selected persons aged over 65 years. We measured axial length and refraction. Fundus images were graded for ARM according to a modified Wisconsin Age-related Maculopathy Grading System standard. Data from both eyes were available from most participants. We analysed the results for both individual eyes and pairs.
   Results: The mean axial length was 23.22 mm for right eyes and 23.21 mm for left eyes. Women had a 0.57-mm shorter mean axial length than men. The mean refraction was + 1.0 dioptres (D) for right eyes and + 0.9 D for left eyes. At 70 years of age women were more hypermetropic than men by 0.66 D. There was no significant difference in refraction or axial length among the groups with different ARM stages.
   Conclusion: We found no statistically significant relationship between axial length/refraction and AMD/ARM. There was a statistically significant sex difference in axial length and refraction, where women had shorter axial lengths and were more hypermetropic than men.
C1 Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway.
   Univ Bergen, Dept Ophthalmol, Bergen, Norway.
   Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen; University of Bergen; Haukeland University Hospital
RP Seland, JH (通讯作者)，Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway.
EM johan.seland@helse-bergen.no
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Eysteinsson T, 2002, ACTA OPHTHALMOL SCAN, V80, P11, DOI 10.1034/j.1600-0420.2002.800103.x
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gudmundsdottir E, 2000, ACTA OPHTHALMOL SCAN, V78, P642, DOI 10.1034/j.1600-0420.2000.078006642.x
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEIGHTON DA, 1972, ACTA OPHTHALMOL, V50, P815
   MIDELFART A, 1994, ACTA OPHTHALMOL, V72, P61
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P73
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 23
TC 9
Z9 10
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2005
VL 83
IS 4
BP 419
EP 423
DI 10.1111/J.1600-0420.2005.00520.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953FY
UT WOS:000231063200003
OA Bronze
DA 2022-11-30
ER

PT J
AU Gotoh, N
   Nakanishi, H
   Hayashi, H
   Yamada, R
   Otani, A
   Tsujikawa, A
   Yamashiro, K
   Tamura, H
   Saito, M
   Saito, K
   Iida, T
   Matsuda, F
   Yoshimura, N
AF Gotoh, Norimoto
   Nakanishi, Hideo
   Hayashi, Hisako
   Yamada, Ryo
   Otani, Atsushi
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Tamura, Hiroshi
   Saito, Masaaki
   Saito, Kuniharu
   Iida, Tomohiro
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI ARMS2 (LOC387715) Variants in Japanese Patients with Exudative
   Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; GENE POLYMORPHISMS;
   PHOTODYNAMIC THERAPY; ASSOCIATION; POPULATION; SUSCEPTIBILITY;
   MACULOPATHY; RISK; CFH
AB PURPOSE: To determine the characteristics of the poly, morphisms in the ARMS2 gene in Japanese patients with age, related macular degeneration (AMD) and those with polypoidal choroidal vasculopathy (PCV) and in healthy controls, and also to show possible associations of the polymorphisms with the disease.
   DESIGN: Case-control association study.
   METHODS: Fifty,six unrelated Japanese individuals with AMD, 55 with PCV, and 77 controls were studied. The most common polymorphism in the ARMS2 gene on chromosome 10 was resequenced. Association tests were performed for inferred haplotypes.
   RESULTS: A total of 22 polymorphisms were identified, and 13 were shared with those in White persons with AMD. The sequence of the deletion,and,insertion polymorphism, de1443ins54, a functional polymorphism causing an instability of the messenger ribonucleic acid of ARMS2 in the Japanese, did not differ from that in White persons. Among the polymorphisms seen in the White population, rs10490923 (R3H) as well as 7 other polymorphisms were not observed in the Japanese. One haplotype, which contained the T allele of the rs10490924 (A69S) and the variant of de1443ins54 polymorphism, had an odds ratio of 3.14 (P=7.8 x 10(-6)) for AMD and 2.00 (P=.0058) for PCV. Among the 9 polymorphisms that were unique to the Japanese population, 2 had a minor allelic frequency of more than 0.05, and these 2 polymorphism were included as nonrisk haplotypes.
   CONCLUSIONS: The de1443ins54 polymorphism is a common variant between White and Japanese populations. It is strongly associated not only with AMD but also with PCV. (Am J Ophthalmol 2009;147:1037-1041. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
   [Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
   [Yamada, Ryo] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan.
   [Saito, Masaaki; Saito, Kuniharu; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Matsuda, Fumihiko] Ctr Natl Genotypage, Evry, France.
C3 Kyoto University; Kyoto University; University of Tokyo; Fukushima
   Medical University; CEA; UDICE-French Research Universities; Universite
   Paris Saclay
RP Yoshimura, N (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.
EM nagaeye@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Matsuda, Fumihiko/B-9893-2009; Saito,
   Masaaki/ABI-2783-2020
OI TAMURA, Hiroshi/0000-0002-7740-2732; Saito, Masaaki/0000-0003-1494-6350;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamada, Ryo/0000-0002-1587-630X
FU MINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY;
   Prevention of Blindness, Shinjuku, Tokyo, Japan
FX THIS STUDY WAS SUPPORTED IN PART BY THE MINISTRY OF EDUCATION, CULTURE,
   SPORTS, SCIENCE AND TECHNOLOGY of Japan, Chiyoda, Tokyo, Japan and by
   Japan National Society for the Prevention of Blindness, Shinjuku, Tokyo,
   Japan. The authors indicate no financial conflict of interest. Involved
   in design of study (N.G., R.Y., N.Y.); conduct of laboratory study
   (N.G., N.H., H.H.); collection of samples (N.G., H.N., H.H., A.O., A.T.,
   K.Y., H.T., M.S., K.S., T.I.); management (F.M., N.Y.), analysis (N.G.),
   and interpretation,of data (N.G., N.H., H.H., N.Y.); preparation of the
   manuscript (N.G., N.Y.); and approval of the manuscript (N.Y.). This
   study was performed in accordance the Declaration of Helsinki and was
   approved by the Institutional Review Board (IRB) of Kyoto University
   Graduate School of Medicine and the IRB of the Fukushima Medical
   University. All personal information associated with the blood samples
   was encrypted. The authors thank Drs Yoshiki Ueda, Nagahama City
   Hospital, Nagahama, Japan and Shoji Kuriyama, Otsu Red Cross Hospital,
   Otsu, Japan, for their assistance in recruiting participants.
CR BAER CA, RETINA IN PRESS
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2008, AM J OPHTHALMOL, V145, P582, DOI 10.1016/j.ajo.2007.10.023
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Ozaki M, 2008, INVEST OPHTH VIS SCI, V49, P3976, DOI 10.1167/iovs.08-1805
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takahashi Masazumi, 2003, J Bioinform Comput Biol, V1, P253, DOI 10.1142/S021972000300006X
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoshida T, 2007, MOL VIS, V13, P545
NR 35
TC 74
Z9 80
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2009
VL 147
IS 6
BP 1037
EP 1041
DI 10.1016/j.ajo.2008.12.036
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 451ZE
UT WOS:000266508600017
PM 19268887
DA 2022-11-30
ER

PT J
AU Englander, M
   Kaiser, PK
AF Englander, Miriam
   Kaiser, Peter K.
TI Combination therapy for the treatment of neovascular age-related macular
   degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE antiplatelet-derived growth factor; combination treatment; neovascular
   AMD; radiation therapy; triple therapy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; X-RAY-IRRADIATION; PHOTODYNAMIC
   THERAPY; TRIAMCINOLONE ACETONIDE; RANIBIZUMAB THERAPY; VERTEPORFIN;
   SAFETY; BEVACIZUMAB
AB Purpose of review
   To discuss the current combination treatments that involve existing as well as novel drugs that show promise for the treatment of neovascular age-related macular degeneration.
   Recent findings
   Photodynamic therapy in combination with antivascular endothelial growth factor (VEGF) and steroids is currently used as a second-line therapy in patients not responding to monotherapy with anti-VEGF agents or in whom the treatment burden of monthly injections is too great. It is used as a primary therapy for idiopathic polypoidal choroidal vasculopathy. Radiation and antiplatelet-derived growth factor therapy show promising results and are currently under investigation.
   Summary
   Using combination treatments that target other pathways involved in angiogenesis will hopefully improve on the results of current anti-VEGF agents and may result in greater visual improvement and more convenient dosing regimens.
C1 [Englander, Miriam; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave,Desk i3, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Consultant; Alcon; Novartis; Genentech; Bayer; Regeneron; Oraya;
   Ophthotech; Research to Prevent Blindness
FX Financial disclosure: P.K.K. - Consultant, Alcon, Novartis, Genentech,
   Bayer, Regeneron, Oraya, Ophthotech and an unrestricted grant from
   Research to Prevent Blindness.
CR Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Wagsater D, 2009, ATHEROSCLEROSIS, V202, P415, DOI 10.1016/j.atherosclerosis.2008.04.050
NR 21
TC 13
Z9 13
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2013
VL 24
IS 3
BP 233
EP 238
DI 10.1097/ICU.0b013e32835f8eaa
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ML
UT WOS:000317394000008
PM 23429601
DA 2022-11-30
ER

PT J
AU Hara, R
   Kawaji, T
   Inomata, Y
   Tahara, J
   Sagara, N
   Fukushima, M
   Tanihara, H
AF Hara, Ryuhei
   Kawaji, Takahiro
   Inomata, Yasuya
   Tahara, Jin
   Sagara, Nina
   Fukushima, Mikiko
   Tanihara, Hidenobu
TI Photodynamic therapy alone versus combined with intravitreal bevacizumab
   for neovascular age-related macular degeneration without polypoidal
   choroidal vasculopathy in Japanese patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Combined therapy;
   Japanese patients; Photodynamic therapy; Polypoidal choroidal
   vasculopathy
ID VERTEPORFIN THERAPY; RANIBIZUMAB; AVASTIN; TRIAL; TRIAMCINOLONE;
   INJECTION; SECONDARY; OUTCOMES; FOCUS
AB To compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone (PDT group), and this therapy combined with intravitreal bevacizumab (IVB) (COMB group)-for neovascular age-related macular degeneration (AMD), not including patients with polypoidal choroidal vasculopathy (PCV) who were presumed to have AMD.
   This retrospective study evaluated 23 eyes in the PDT group and 22 eyes in the COMB group. IVB (1.25 mg) was administered within 2 weeks after PDT. Main outcome measures were best-corrected visual acuity (VA), central foveal thickness by optical coherence tomography, and number of treatments.
   At month 12, the PDT group had gained 0.7 letter mean VA and the COMB group, 8.8 letters (P = 0.04). Ten eyes (43%) in the PDT group and 19 eyes (86%) in the COMB group received only one treatment, and significant difference was found (P = 0.005). No severe ocular or systemic safety concerns were discovered.
   Our 12-month results of PDT combined with IVB for Japanese patients with AMD without PCV appeared to be more effective than those of PDT alone with fewer treatments.
C1 [Hara, Ryuhei; Kawaji, Takahiro; Inomata, Yasuya; Tahara, Jin; Sagara, Nina; Fukushima, Mikiko; Tanihara, Hidenobu] Kumamoto Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Kumamoto 8608556, Japan.
C3 Kumamoto University
RP Kawaji, T (通讯作者)，Kumamoto Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM kawag@white.plala.or.jp
RI Kawaji, Takahiro/AAH-2481-2020
FU Ministry of Education, Science, Sports and Culture, Japan; Ministry of
   Health and Welfare, Japan
FX The authors' work was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Science, Sports and Culture,
   Japan, and from the Ministry of Health and Welfare, Japan.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   WOLF S, 2007, INVEST OPHTHALMOL VI, V48
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 11
Z9 11
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2010
VL 248
IS 7
BP 931
EP 936
DI 10.1007/s00417-010-1343-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 602JB
UT WOS:000278134300002
PM 20221623
DA 2022-11-30
ER

PT J
AU Hayashi, H
   Yamashiro, K
   Gotoh, N
   Nakanishi, H
   Nakata, I
   Tsujikawa, A
   Otani, A
   Saito, M
   Iida, T
   Matsuo, K
   Tajima, K
   Yamada, R
   Yoshimura, N
AF Hayashi, Hisako
   Yamashiro, Kenji
   Gotoh, Norimoto
   Nakanishi, Hideo
   Nakata, Isao
   Tsujikawa, Akitaka
   Otani, Atsushi
   Saito, Masaaki
   Iida, Tomohiro
   Matsuo, Keitaro
   Tajima, Kazuo
   Yamada, Ryo
   Yoshimura, Nagahisa
TI CFH and ARMS2 Variations in Age-Related Macular Degeneration, Polypoidal
   Choroidal Vasculopathy, and Retinal Angiomatous Proliferation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; PHOTODYNAMIC THERAPY;
   INTRAVITREAL BEVACIZUMAB; GENE POLYMORPHISMS; JAPANESE POPULATION; NO
   ASSOCIATION; RISK; LOC387715; VARIANT
AB PURPOSE. To seek an association in Japanese individuals between the CFH polymorphisms Y402H and I62V and the ARMS2 polymorphism A69S and age-related macular degeneration (AMD) or its three subtypes: typical (t)AMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP).
   METHODS. The three polymorphisms were genotyped in a case-control study of 1351 control subjects and 962 patients with AMD.
   RESULTS. The three polymorphisms correlated with AMD (Y402H, P = 1.54 x 10(-6); I62V, P = 1.94 x 10(-29); and A69S, P = 9.56 x 10(-43)). The I62V and A69S polymorphisms were associated with all three subtypes: tAMD (P = 3.74 x 10(-18) and 1.37 x 10(-35), respectively), PCV (P = 3.18 x 10(-19) and 3.96 x 10(-18), respectively), and RAP (P = 0.034 and 2.49 x 10(-18), respectively). Y402H was associated with tAMD (P = 3.00 x 10(-5)) and with PCV (P = 9.73 x 10(-5)), but no association was found with RAP, possibly because of the small sample size and the rare minor allele. The risk allele contribution of A69S was stronger for RAP than for tAMD or PCV and was stronger for tAMD than for PCV.
   CONCLUSIONS. CFH Y402H is associated with AMD, tAMD, and PCV, whereas I62V is associated with all three subtypes. ARMS2 A69S has a strong association with all three subtypes, with the association being strongest for RAP and weakest for PCV. PCV and RAP may thus be subtypes of AMD that are genetically distinct from tAMD. (Invest Ophthalmol Vis Sci. 2010;51:5914-5919) DOI:10.1167/iovs.10-5554
C1 [Yamashiro, Kenji] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
   [Hayashi, Hisako; Gotoh, Norimoto; Nakanishi, Hideo; Nakata, Isao; Yamada, Ryo] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto 6068507, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Matsuo, Keitaro] Aichi Canc Ctr, Res Inst, Div Epidemiol, Nagoya, Aichi 464, Japan.
   [Tajima, Kazuo] Aichi Canc Ctr, Res Inst, Div Prevent, Nagoya, Aichi 464, Japan.
C3 Kyoto University; Kyoto University; Fukushima Medical University; Aichi
   Cancer Center; Aichi Cancer Center
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Matsuo, Keitaro/H-6758-2019
OI Saito, Masaaki/0000-0003-1494-6350; Matsuo, Keitaro/0000-0003-1761-6314;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamada, Ryo/0000-0002-1587-630X
FU Japanese Society for the Promotion of Science, Tokyo [21249084,
   200791294]; Japanese National Society for the Prevention of Blindness,
   Tokyo, Japan
FX Supported in part by Grants-in-aid for Scientific Research 21249084 and
   200791294 from the Japanese Society for the Promotion of Science, Tokyo,
   and the Japanese National Society for the Prevention of Blindness,
   Tokyo, Japan.
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakanishi H, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000660
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nielsen DM, 1998, AM J HUM GENET, V63, P1531, DOI 10.1086/302114
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Okamoto H, 2006, MOL VIS, V12, P156
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shimada H, 2005, GRAEF ARCH CLIN EXP, V243, P519, DOI 10.1007/s00417-004-1073-x
   Souied EH, 2005, MOL VIS, V11, P1135
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
NR 61
TC 97
Z9 107
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5914
EP 5919
DI 10.1167/iovs.10-5554
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400066
PM 20574013
DA 2022-11-30
ER

PT J
AU Chopdar, A
   Chakravarthy, U
   Verma, D
AF Chopdar, A
   Chakravarthy, U
   Verma, D
TI Age related macular degeneration
SO BRITISH MEDICAL JOURNAL
LA English
DT Review
ID RANDOMIZED CONTROLLED TRIAL
AB An epidemic of "ageing" is impending in the Western world. According to the latest predictions released by the United Nations, the number of people aged over 60 will triple from 606 million worldwide in 2000 to nearly 2 billion by 2050. The increase in the population aged over 80 is expected to be more than fivefold, from 69 million in 2000 to 379 million by 2050. People aged over 60 constitute about 20% of the population in more developed regions of the world; by 2050 they will probably account for 33%.(1) The United Kingdom is predicted to have about 16 million people over the age of 60 by 2040.(2) One major implication of this demographic change is the emergence of conditions that are directly related to ageing. Age related macular degeneration is already the leading cause of blindness in the Western world. Between 20 and 25 million people are affected worldwide, a figure that will triple with the increase in the ageing population in the next 30-40 years.(2) According to the World Health Organization, 8 million people have severe blindness due to age related macular degeneration, excluding the countries where data are scare.(3) in a recent systematic review Fletcher et al estimate that somewhere between 182 000 and 300 000 people in the United Kingdom are blind or partially sighted as a result of age related macular degeneration(4).
C1 E Surrey Hosp, Surrey RH1 5RH, England.
   Queens Univ Belfast, Belfast, Antrim, North Ireland.
   Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
   Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA USA.
C3 East Surrey Hospital; Queens University Belfast; University of Southern
   California
RP Chopdar, A (通讯作者)，E Surrey Hosp, Surrey RH1 5RH, England.
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   CHOPDAR A, 1996, FUNDUS FLUORESCEIN A, P4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   EVANS JR, 2000, COCHRANE DB SYST REV
   Fletcher A, 2001, LOW VISION SERVICES
   FLINN ED, 2002, AEROSPACE AM, V4, P18
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   National Statistics Office, NAT POP PROJ
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   United Nations, WORLD POP PROSP 2000
   World Health Organization, 144 WHO
NR 22
TC 125
Z9 139
U1 0
U2 9
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD MAR 1
PY 2003
VL 326
IS 7387
BP 485
EP 488
DI 10.1136/bmj.326.7387.485
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 653EC
UT WOS:000181421400021
PM 12609947
OA Green Published
DA 2022-11-30
ER

PT J
AU Nano, ME
   Lansingh, V
   Pighin, MS
   Zarate, N
   Nano, H
   Carter, MJ
   Furtado, JM
   Nano, CC
   Vernengo, LF
   Luna, JD
   Eckert, KA
AF Eugenia Nano, Maria
   Lansingh, Van Charles
   Soledad Pighin, Maria
   Zarate, Natalia
   Nano, Hugo
   Carter, Marissa Janine
   Furtado, Joao Marcello
   Crespo Nano, Clelia
   Fiocca Vernengo, Luciana
   Domingo Luna, Jose
   Allison Eckert, Kristen
TI Risk factors of age-related macular degeneration in Argentina
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Age-related macular degeneration; Risk factors; Sunlight exposure;
   Family history; Argentina; Case-control study
ID VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE; BLINDNESS; POPULATION;
   ASSOCIATION; CONSUMPTION; PROGRESSION; HEALTH; TRENDS
AB Purposes: To assess the risk factors of age-related macular degeneration in Argentina using a case-control study.
   Methods: Surveys were used for subjects' antioxidant intake, age/gender, race, body mass index, hypertension, diabetes (and type of treatment), smoking, sunlight exposure, red meat consumption, fish consumption, presence of age-related macular degeneration and family history of age-related macular degeneration. Main effects models for logistic regression and ordinal logistic regression were used to analyze the results.
   Results: There were 175 cases and 175 controls with a mean age of 75.4 years and 75.5 years, respectively, of whom 236 (67.4%) were female. Of the cases with age-related macular degeneration, 159 (45.4%) had age-related macular degeneration in their left eyes, 154 (44.0%) in their right eyes, and 138 (39.4%) in both eyes. Of the cases with age-related macular degeneration in their left eyes, 47.8% had the dry type, 40.3% had the wet type, and the type was unknown for 11.9%. The comparable figures for right eyes were: 51.9%, 34.4%, and 13.7%, respectively. The main effects model was dominated by higher sunlight exposure (OR [odds ratio]: 3.3) and a family history of age-related macular degeneration (OR: 4.3). Other factors included hypertension (OR: 2.1), smoking (OR: 2.2), and being of the Mestizo race, which lowered the risk of age-related macular degeneration (OR: 0.40). Red meat/fish consumption, body mass index, and iris color did not have an effect. Higher age was associated with progression to more severe age-related macular degeneration.
   Conclusion: Sunlight exposure, family history of age-related macular degeneration, and an older age were the significant risk factors. There may be other variables, as the risk was not explained very well by the existing factors. A larger sample may produce different and better results.
C1 [Eugenia Nano, Maria; Lansingh, Van Charles; Soledad Pighin, Maria; Zarate, Natalia; Nano, Hugo; Carter, Marissa Janine; Furtado, Joao Marcello; Crespo Nano, Clelia; Fiocca Vernengo, Luciana; Domingo Luna, Jose; Allison Eckert, Kristen] Fdn Hugo Nano, Buenos Aires, DF, Argentina.
RP Lansingh, V (通讯作者)，Lansingh Int Agcy Prevent Blindness VIS 2020 Lati, 3720 San Simeon Cr, Weston, FL 33331 USA.
EM vlansingh@v2020la.org
RI Pighin, María S/D-4907-2019; Furtado, Joao M./AAB-5356-2022; Furtado,
   Joao/D-4436-2012; Lansingh, Van/C-8672-2018
OI Pighin, María S/0000-0003-2369-7579; Furtado, Joao
   M./0000-0003-2490-5747; NANO, Mario/0000-0002-0657-596X; Lansingh,
   Van/0000-0002-0090-4195
FU ORBIS
FX Preparation of the manuscript was funded by ORBIS, which had no role in
   any aspect of the study.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Central Intelligence Agency, 2012, WORLD FACTB 2012
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Furtado JM, 2012, SURV OPHTHALMOL, V57, P149, DOI 10.1016/j.survophthal.2011.07.002
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   United Nations Department of Economic and Socia Affairs, POP EST PROJ SECT WO
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   World Health Organization, GLOB STRAT DIET PHYS
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 30
TC 6
Z9 8
U1 0
U2 16
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2013
VL 76
IS 2
BP 80
EP 84
DI 10.1590/S0004-27492013000200005
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177TM
UT WOS:000321398300005
PM 23828466
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hata, M
   Tsujikawa, A
   Miyake, M
   Yamashiro, K
   Ooto, S
   Oishi, A
   Nakanishi, H
   Takahashi, A
   Yoshimura, N
AF Hata, Masayuki
   Tsujikawa, Akitaka
   Miyake, Masahiro
   Yamashiro, Kenji
   Ooto, Sotaro
   Oishi, Akio
   Nakanishi, Hideo
   Takahashi, Ayako
   Yoshimura, Nagahisa
TI Two-year visual outcome of ranibizumab in typical neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Typical neovascular age-related macular degeneration; Polypoidal
   choroidal vasculopathy; Ranibizumab; ARMS2 A69S; CFH I62V
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; SUBGROUP
   ANALYSIS; LOC387715 A69S; ASSOCIATION; MACULOPATHY; PROGNOSIS; VARIANTS;
   SUSCEPTIBILITY; POLYMORPHISMS
AB Purpose To investigate the 2-year outcomes of intravitreal injections of ranibizumab in typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV). Factors associated with visual outcomes are examined.
   Methods We retrospectively reviewed medical records of 128 consecutive eyes with treatment-naive subfoveal AMD treated with ranibizumab and followed for >= 24 months. The association between visual outcomes and single nucleotide polymorphisms (SNPs) in ARMS2 A69S and CFH I62V genes were examined.
   Results Fifty-eight eyes were diagnosed with tAMD and 70 eyes with PCV. In tAMD eyes, visual acuity (VA) improved at 3 months (P=0.020) but returned to the baseline level at 6 months. Thereafter, VA was maintained until 24 months. In PCV eyes, VA significantly improved at 3 months (P=0.015) and persisted at 12 months (P=0.025), but the VA improvement dissipated by 24 months. With regard to genetic associations with VA and VA change, neither VA nor VA change showed significant associations with these SNPs at all time points in tAMD. In the PCV eyes, there were significant associations between ARMS2 A69S and VA at baseline and 1 year (P=0.017 and P=0.025, respectively). However, VA change showed no significant difference among these genotypes in PCV.
   Conclusions Intravitreal ranibizumab significantly improved the VA initially, but this improvement did not persist at 2 years post-treatment. In PCV, ARMS2 A69S polymorphism is associated with the baseline and 12-month VA, but is not associated with the visual prognosis at 24 months.
C1 [Hata, Masayuki; Tsujikawa, Akitaka; Miyake, Masahiro; Yamashiro, Kenji; Ooto, Sotaro; Oishi, Akio; Nakanishi, Hideo; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS, Tokyo, Japan)
   [21592256]; Japan National Society for the Prevention of Blindness
   (Tokyo, Japan)
FX This study was supported, in part, by the Japan Society for the
   Promotion of Science (JSPS, Tokyo, Japan, Grant-in-Aid for Scientific
   Research, no. 21592256) and the Japan National Society for the
   Prevention of Blindness (Tokyo, Japan).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Bessho H, 2011, MOL VIS, V17, P977
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen HY, 2012, MOL VIS, V18, P816
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 45
TC 19
Z9 21
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2015
VL 253
IS 2
BP 221
EP 227
DI 10.1007/s00417-014-2688-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA6FI
UT WOS:000349004600009
PM 24961698
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Oishi, A
   Singh, A
   Nissen, MH
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Oishi, Akio
   Singh, Amardeep
   Nissen, Mogens Hoist
   Sorensen, Torben Lykke
TI Plasma markers of chronic low-grade inflammation in polypoidal choroidal
   vasculopathy and neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE biomarker; degeneration; inflammaging; neovascular age-related macular;
   plasma; polypoidal choroidal vasculopathy
ID C-REACTIVE PROTEIN; ENDOTHELIAL DYSFUNCTION; CIRCULATING MONOCYTES;
   OXIDATIVE STRESS; UP-REGULATION; SERUM-LEVELS; FACTOR-B; ACTIVATION;
   INTERLEUKIN-6; EXPRESSION
AB Purpose Ageing is the strongest predictor of neovascular age-related macular degeneration (AMD), where neuroinflammation is known to play a major role. Less is known about polypoidal choroidal vasculopathy (PCV), which is an important differential diagnosis to neovascular AMD. Here, we report plasma markers of inflammation with age (inflammaging) in patients with PCV, patients with neovascular AMD and a healthy age-matched control group. Methods We isolated plasma from fresh venous blood obtained from participants (n = 90) with either PCV, neovascular AMD, or healthy maculae. Interleukin(IL)-1 beta, IL-6, IL-8, IL-10 and tumour necrosis factor receptor 2 (TNF-R2) were measured using U-PLEX Human Assays. Routine plasma C-reactive protein (CRP) was measured using Dimension Vista 1500. Results Patients with PCV had plasma levels of IL-1 beta, IL-6, IL-8, IL-10 and TNF-R2 similar to that in healthy controls. Patients with neovascular AMD had significantly higher plasma IL-1 beta, IL-6 and IL-10 than healthy controls, whereas no significant differences were observed for plasma IL-8 and TNF-R2. Differences between plasma IL-1 beta, IL-6 and IL-10 possessed a positive but weak ability in discriminating neovascular AMD from PCV. Both patients with PCV and patients with neovascular AMD had significantly higher levels of routine plasma CRP. Conclusion Patients with PCV differ from patients with neovascular AMD in terms of plasma inflammaging profile. Apart from increased CRP, no signs of inflammaging were observed in patients with PCV. In patients with neovascular AMD, we find a specific angiogenesis-twisted inflammaging profile.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Singh, Amardeep; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Nissen, Mogens Hoist; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Oishi, Akio] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Singh, Amardeep] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
   [Nissen, Mogens Hoist] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Kyoto University; Lund University; Skane
   University Hospital; University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Oishi, Akio/AAE-9996-2020; Subhi, Yousif/ABG-6330-2020; Singh,
   Amardeep/ABI-4544-2020
OI Oishi, Akio/0000-0002-0977-9458; Subhi, Yousif/0000-0001-6620-5365;
   Krogh Nielsen, Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation (Taastrup, Denmark); Fight for Sight
   Denmark (Copenhagen, Denmark); Velux Foundation (Soborg, Denmark);
   University of Copenhagen (Copenhagen, Denmark)
FX This work was supported by the Danish Eye Research Foundation (Taastrup,
   Denmark), Fight for Sight Denmark (Copenhagen, Denmark), the Velux
   Foundation (Soborg, Denmark) and a faculty stipend from the University
   of Copenhagen (Copenhagen, Denmark). The funding bodies had no role in
   the design or conduct of this research. Author YS has previously
   received travel grant for conferences from Novartis and Bayer (not in
   relation to this work). Author MKN has previously received travel grant
   for conference from Novartis (not in relation to this work). Author CRM
   has previously received a travel grant from Bayer (not in relation to
   this work). Author AO has received grants from Novartis and Alcon, and
   speaker honoraria from Novartis and Bayer (not in relation to this
   work). Authors AS, MHS and TLS declare that no potential conflict of
   interests exists in relation to this work.
CR Ambreen F, 2015, MOL VIS, V21, P985
   Bruunsgaard H, 2006, DAN MED BULL, V53, P285
   Chan IH, 2015, J INTERF CYTOK RES, V35, P948, DOI 10.1089/jir.2014.0221
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fischer WH, 1999, J IMMUNOL, V162, P453
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51
   Graf J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006242
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kutty RK, 2016, MOL VIS, V22, P1156
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Lorentzen TD, 2017, ACTA OPHTHALMOL, DOI [10.1111/aos.13646, DOI 10.1111/A0S.13646]
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   O'Neal WK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Putin E, 2016, AGING-US, V8, P1021, DOI 10.18632/aging.100968
   Ridker PM, 2004, CIRCULATION, V109, P1955, DOI 10.1161/01.CIR.0000125690.80303.A8
   Rifai N, 2001, CLIN CHEM, V47, P403
   Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Speidl WS, 2005, J AM COLL CARDIOL, V45, P30, DOI 10.1016/j.jacc.2004.09.052
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
   Zeng RP, 2013, MOL VIS, V19, P729
NR 70
TC 30
Z9 32
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP 99
EP 106
DI 10.1111/aos.13886
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000027
PM 30288946
OA Bronze
DA 2022-11-30
ER

PT J
AU Ma, L
   Tang, SM
   Rong, SS
   Chen, HY
   Young, AL
   Kumaramanickavel, G
   Pang, CP
   Chen, LJ
AF Ma, Li
   Tang, Shu Min
   Rong, Shi Song
   Chen, Haoyu
   Young, Alvin L.
   Kumaramanickavel, Govindasamy
   Pang, Chi Pui
   Chen, Li Jia
TI Association of PEDF polymorphisms with age-related macular degeneration
   and polypoidal choroidal vasculopathy: a systematic review and
   meta-analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE
   ASSOCIATION; CULTURED RETINAL PERICYTES; FACTOR GENE POLYMORPHISMS;
   PIGMENT-EPITHELIUM; MET72THR POLYMORPHISM; ANTIOXIDATIVE PROPERTIES;
   DIABETIC-RETINOPATHY; CELL-DEATH
AB This study assesses the association of the pigment epithelium-derived factor (PEDF) gene with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Publications in MEDLINE and EMBASE up to 21/08/2014 were searched for case-control association studies of PEDF with AMD and/or PCV. Reported studies giving adequate genotype and/or allele information were included. Pooled odds ratios (OR) and 95% confidence intervals (CI) of each polymorphism were estimated. Our literature search yielded 297 records. After excluding duplicates and reports with incomplete information, 8 studies were eligible for meta-analysis, involving 2284 AMD patients versus 3416 controls, and 317 PCV patients versus 371 controls. Four PEDF polymorphisms were meta-analyzed: rs1136287, rs12150053, rs12948385 and rs9913583, but none was significantly associated with AMD or PCV. The most-investigated polymorphism, rs1136287, had a pooled-OR of 1.02 (95% CI: 0.94-1.11, P = 0.64) for AMD. In subgroup analysis by ethnicity, no significant association was identified. Polymorphisms present in single report showed no association. Therefore, existing data in literature does not support the role of PEDF in the genetic susceptibility of AMD and PCV, although replication in specific populations is warranted. Since the pooled-sample size for PCV was small, there is a need of PEDF genotyping in larger samples of PCV.
C1 [Ma, Li; Tang, Shu Min; Rong, Shi Song; Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Haoyu; Pang, Chi Pui] Chinese Univ Hong Kong, Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Guangdong, Peoples R China.
   [Kumaramanickavel, Govindasamy] Narayana Nethralaya Hlth City, Bangalore, Karnataka, India.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Shantou University
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chu, Kai On/E-2325-2016; Rong, Shi Song/L-9735-2019; KUMARAMANICKAVEL,
   GOVINDASAMY/AAN-9203-2021; Chen, Haoyu/A-7432-2013; Chen, Li
   Jia/I-5078-2014
OI Rong, Shi Song/0000-0001-8352-6363; KUMARAMANICKAVEL,
   GOVINDASAMY/0000-0001-8516-8301; Chen, Haoyu/0000-0003-0676-4610; Chen,
   Li Jia/0000-0003-3500-5840
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Balasubbu S, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-158
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Bessho H, 2009, MOL VIS, V15, P1107
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Huang C, 2013, MOL VIS, V19, P1211
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Kim HS, 2013, GENES GENOM, V35, P335, DOI 10.1007/s13258-013-0090-8
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenekoop R, 1999, MOL VIS, V5
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mattes D, 2009, MOL VIS, V15, P343
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Park DH, 2012, JPN J OPHTHALMOL, V56, P145, DOI 10.1007/s10384-012-0119-6
   Qu Y, 2011, CURR EYE RES, V36, P60, DOI 10.3109/02713683.2010.524343
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subramanian P, 2013, J BIOL CHEM, V288, P23928, DOI 10.1074/jbc.M113.487884
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   [文峰 WEN Feng], 2011, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V29, P289
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamagishi S, 2002, INT J TISSUE REACT, V24, P137
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 72
TC 13
Z9 14
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 30
PY 2015
VL 5
AR 9497
DI 10.1038/srep09497
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE6JE
UT WOS:000351941900001
PM 25820866
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Honda, S
   Kurimoto, Y
   Kagotani, Y
   Yamamoto, H
   Takagi, H
   Uenishi, M
AF Honda, Shigeru
   Kurimoto, Yasuo
   Kagotani, Yasuaki
   Yamamoto, Hiroyuki
   Takagi, Hitoshi
   Uenishi, Mamoru
CA Hyogo Macular Dis Study Grp
TI Photodynamic therapy for typical age-related macular degeneration and
   polypoidal choroidal vasculopathy: A 30-month multicenter study in
   Hyogo, Japan
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; multicenter study; photodynamic
   therapy; polypoidal choroidal vasculopathy
ID RETINAL ANGIOMATOUS PROLIFERATION; RANDOMIZED CLINICAL-TRIAL;
   PROSPECTIVE CASE SERIES; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN THERAPY;
   PATHOLOGICAL MYOPIA; NEOVASCULARIZATION; LESIONS; GENE
AB To evaluate the long-term effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degeneration (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV).
   A multicenter prospective study of 207 eyes of 201 patients (tAMD, 123 eyes; PCV, 84 eyes) treated with PDT. Sex, age, best-corrected visual acuity (BCVA), greatest linear dimension, and lesion type were evaluated for pretreatment factors. PDT frequency, BCVA at 30 months post-PDT, frequency of recurrence, and mean recurrence period were compared as posttreatment outcomes.
   The 30 months post-PDT mean BCVA was significantly lower than the pre-PDT value in the tAMD group, but it remained unchanged in the PCV group. There was no difference in PDT frequency between the two groups. Multivariate analysis revealed that lesion type was the only predicting factor significantly associated with BCVA at 30 months post-PDT. The incidence of recurrence before 30 months post-PDT was not significantly different between the tAMD and PCV groups, whereas the mean duration of the PDT effect was significantly longer in the PCV group than in the tAMD group.
   PDT may have some advantages for PCV patients, but not for tAMD patients. However, as PCV often recurred 12 months post-PDT, long-term observation after the treatment is crucial.
C1 [Honda, Shigeru] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kurimoto, Yasuo] Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Kagotani, Yasuaki] Ono Municipal Hosp, Dept Ophthalmol, Ono, Hokkaido, Japan.
   [Yamamoto, Hiroyuki] Nippon Steel Hirohata Hosp, Dept Ophthalmol, Himeji, Hyogo, Japan.
   [Takagi, Hitoshi] Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Amagasaki, Hyogo, Japan.
   [Uenishi, Mamoru] Mitsubishi Kobe Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
C3 Kobe University; Kobe City Medical Center General Hospital
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Honda, Shigeru/W-4761-2019
OI Oishi, Akio/0000-0002-0977-9458; Imai, Hisanori/0000-0001-8879-3604
CR Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P237, DOI 10.1007/s00417-007-0651-0
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 33
Z9 39
U1 0
U2 4
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2009
VL 53
IS 6
BP 593
EP 597
DI 10.1007/s10384-009-0741-0
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 534NK
UT WOS:000272904200005
PM 20020237
DA 2022-11-30
ER

PT J
AU Rishi, P
   Rishi, E
   Mathur, G
   Raval, V
AF Rishi, P.
   Rishi, E.
   Mathur, G.
   Raval, V.
TI Ocular perfusion pressure and choroidal thickness in eyes with
   polypoidal choroidal vasculopathy, wet-age-related macular degeneration,
   and normals
SO EYE
LA English
DT Article
DE ocular perfusion; choroid; optical coherence tomography; polypoidal
   choroidal vasculopathy; age-related macular degeneration; enhanced depth
   imaging
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL IMPAIRMENT; CLINICAL SPECTRUM;
   RETINOPATHY; POPULATION; PREVALENCE; MACULOPATHY; SEVERITY
AB Purpose To measure the choroidal thickness and ocular perfusion pressure in eyes with polypoidal choroidal vasculopathy (PCV), wet-age-related macular degeneration (AMD), and age-matched normal subjects, and look for a possible association between the two.
   Methods This was a prospective study including 22 eyes with PCV, 33 eyes with wet-AMD, and 35 age-matched normal eyes. Choroidal thickness was measured using enhanced depth imaging (EDI) with spectral-domain optical coherence tomography (SD OCT). Mean ocular perfusion pressure (MOPP) was calculated using the mathematical formula 2/3[DBP +1/3{SBP x DBP}] - IOP (DBP-diastolic blood pressure, SBP-systolic blood pressure, IOP-intraocular pressure). Analyses were carried out using SPSS 14 software and comparisons of mean made using't' tests.
   Results Eyes with PCV showed increased (285.9 mu m; subfoveal) choroidal thickness, whereas eyes with wet-AMD (119.4 mu m; subfoveal) showed reduced choroidal thickness in comparison with normal eyes (186.77 mu m; subfoveal). MOPP in the PCV group was 57.85 mm Hg (P value 0.00), in the wet-AMD group was 52.1 mm Hg (P-value 0.12), and in the normal group was 49.79 mm Hg.
   Conclusion It is postulated that higher MOPP in eyes with PCV could have an etiologic implication in disease manifestation and progression. Larger studies with longer follow-up may help validate these findings.
C1 [Rishi, P.; Rishi, E.; Mathur, G.; Raval, V.] Sankara Nethralya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras 600006, Tamil Nadu, India.
RP Rishi, P (通讯作者)，Sankara Nethralya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM docrishi@yahoo.co.in
RI Rishi, Pukhraj/AAZ-5296-2020
OI raval, vishal/0000-0002-8446-2696
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Guyton AC, 1986, TXB MED PHYSL, P393
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   LEE WR, 1987, EYE, V1, P296, DOI 10.1038/eye.1987.48
   LEISHMAN R, 1957, Br J Ophthalmol, V41, P641, DOI 10.1136/bjo.41.11.641
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   MANSCHOT WA, 1984, GRAEF ARCH CLIN EXP, V222, P63, DOI 10.1007/BF02150633
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Spaide RF, 1995, RETINA, V15
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong TT, 2009, INVEST OPHTH VIS SCI, V50, P4097, DOI 10.1167/iovs.08-2822
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 46
Z9 50
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD SEP
PY 2013
VL 27
IS 9
BP 1038
EP 1043
DI 10.1038/eye.2013.106
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 216TK
UT WOS:000324307100007
PM 23764988
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Foo, VHX
   Yoshida, A
AF Yanagi, Yasuo
   Foo, Valencia Hui Xian
   Yoshida, Akitoshi
TI Asian age-related macular degeneration: from basic science research
   perspective
SO EYE
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT FACTOR-H; PACHYCHOROID
   SPECTRUM DISORDERS; BRUCHS MEMBRANE; JAPANESE PATIENTS; SERINE-PROTEASE;
   FELLOW EYES; HTRA1; NEOVASCULARIZATION; DRUSEN
AB In Asian populations, polypoidal choroidal vasculopathy (PCV), a distinct phenotype of neovascular age-related macular degeneration (AMD), is more prevalent than Caucasians. Recently, there has been significant focus on how PCV differs from typical AMD. Although typical AMD and PCV share a variety of mechanisms by which abnormal angiogenic process occurs at the retinochoroidal interface, PCV has different clinical characteristics such as aneurysm-like dilation at the terminal of choroidal neovascular membranes, less frequent drusen and inner choroidal degeneration due to the thickened choroid. Recent studies support an important role for inflammation, angiogenesis molecules and lipid metabolism in the pathogenesis of neovascular AMD. Furthermore, although less attention has been paid to the role of the choroid in AMD, accumulating evidence suggests that the choriocapillaris and choroid also play a pivotal role in drusenogenesis, typical AMD and PCV. This review discusses the basic pathogenic mechanisms of AMD and explores the difference between typical AMD and PCV.
C1 [Yanagi, Yasuo; Foo, Valencia Hui Xian] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Yanagi, Yasuo; Foo, Valencia Hui Xian] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Duke NUS Med Sch, Singapore, Singapore.
   [Yoshida, Akitoshi] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   Asahikawa Medical College
RP Yanagi, Y (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.; Yanagi, Y (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.; Yanagi, Y (通讯作者)，Duke NUS Med Sch, Singapore, Singapore.
EM yasuo.yanagi@snec.com.sg
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022
OI Yanagi, Yasuo/0000-0002-0362-7285
CR Aboelnour A, 2016, EXP EYE RES, V147, P138, DOI 10.1016/j.exer.2016.05.015
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chen CY, 2018, MATRIX BIOL, V70, P84, DOI 10.1016/j.matbio.2018.03.013
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chu Q, 2016, J AM CHEM SOC, V138, P9473, DOI 10.1021/jacs.6b03463
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujimura S, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-013-2363-y
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Globus O, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18203-2
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim GY, 2012, MOL CELL BIOL, V32, P4482, DOI 10.1128/MCB.00872-12
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   KORTE GE, 1989, ARCH OPHTHALMOL-CHIC, V107, P1654, DOI 10.1001/archopht.1989.01070020732037
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lee JH, 2016, OPHTHALMOLOGY, V123, P2066, DOI 10.1016/j.ophtha.2016.06.033
   Liao SM, 2017, MOL VIS, V23, P318
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARSHALL GE, 1993, BRIT J OPHTHALMOL, V77, P515, DOI 10.1136/bjo.77.8.515
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Melo E, 2018, EBIOMEDICINE, V27, P258, DOI 10.1016/j.ebiom.2017.12.011
   Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Munoz SS, 2018, J BIOL CHEM, V293, P4071, DOI 10.1074/jbc.RA117.001278
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Svenningsen AF, 2017, CELL MOL LIFE SCI, V74, P4561, DOI 10.1007/s00018-017-2592-z
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Talbot CPJ, 2018, PROG LIPID RES, V69, P21, DOI 10.1016/j.plipres.2017.12.001
   Tan X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160985
   Tan X, 2015, SCI REP-UK, V5, DOI 10.1038/srep15702
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yuda K, 2012, AM J PATHOL, V181, P1464, DOI 10.1016/j.ajpath.2012.06.028
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 99
TC 15
Z9 17
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2019
VL 33
IS 1
BP 34
EP 49
DI 10.1038/s41433-018-0225-x
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HG9YX
UT WOS:000455369700004
PM 30315261
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Pereira, FB
   Veloso, CE
   Kokame, GT
   Nehemy, MB
AF Pereira, Frederico Braga
   Veloso, Carlos Eduardo
   Kokame, Gregg T.
   Nehemy, Marcio B.
TI Characteristics of Neovascular Age-Related Macular Degeneration in
   Brazilian Patients
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Brazil; Choroidal neovascularization;
   Fluorescein angiography; Indocyanine green angiography; Optical
   coherence tomography; Polypoidal choroidal vasculopathy; Retinal
   angiomatous proliferation
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY; CHINESE
   PATIENTS; CLINICAL CHARACTERISTICS; RISK-FACTORS; SUBTYPES; RANIBIZUMAB;
   GUIDELINES
AB Purpose: To report features of neovascular age-related macular degeneration (AMD) in Brazilian patients. Procedures: Data were prospectively collected from patients diagnosed with neovascular AMD. Eyes were classified as having typical neovascular AMD, polypoidal choroidal vasculopathy (PCV), or retinal angiomatous proliferation (RAP). Results: In total, 265 eyes of 207 patients of predominantly Caucasian ancestry were included; 166 (62.6%) eyes had typical neovascular AMD, 65 (24.5%) eyes had PCV, and 34 (12.8%) eyes had RAP. RAP demonstrated a higher percentage of bilateral cases (p = 0.015). The mean foveal subfield thickness was significantly lower in eyes with PCV (p < 0.001). Cases with typical neovascular AMD had a higher percentage of predominantly classic and minimally classic lesions on fluorescein angiography (FA; p = 0.005). Conclusions: In Brazilian patients, PCV and RAP represented 24.5 and 12.8% of neovascular AMD cases. Neovascular AMD subtypes differ in relation to clinical features, mean foveal subfield thickness and FA presentation. (C) 2015 S. Karger AG, Basel
C1 [Pereira, Frederico Braga; Veloso, Carlos Eduardo; Nehemy, Marcio B.] Univ Fed Minas Gerais, Dept Ophthalmol, BR-30220110 Belo Horizonte, MG, Brazil.
   [Kokame, Gregg T.] Univ Hawaii, Sch Med, Honolulu, HI 96822 USA.
C3 Universidade Federal de Minas Gerais; University of Hawaii System
RP Pereira, FB (通讯作者)，Univ Fed Minas Gerais, Dept Ophthalmol, Rua Palmira 343,Apt 202, BR-30220110 Belo Horizonte, MG, Brazil.
EM fbragap@hotmail.com
RI Veloso, Carlos Eduardo dos Reis/E-1815-2016; Nehemy,
   Marcio/ABD-5089-2021
OI Veloso, Carlos Eduardo dos Reis/0000-0002-8817-7200; Nehemy,
   Marcio/0000-0002-4104-0346
CR Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arai K, 2003, FOLIA OPHTHALMOL JPN, V54, P513
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Moreira JPD, 2013, CAD SAUDE PUBLICA, V29, P62, DOI 10.1590/S0102-311X2013000100008
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Owens SL, 1996, BRIT J OPHTHALMOL, V80, P263, DOI 10.1136/bjo.80.3.263
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singerman Lawrence J, 2005, Retina, V25, pS1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 50
TC 26
Z9 26
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 4
BP 233
EP 242
DI 10.1159/000439359
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU3NW
UT WOS:000363433100007
PM 26394133
DA 2022-11-30
ER

PT J
AU Cerman, E
   Eraslan, M
   Cekic, O
AF Cerman, Eren
   Eraslan, Muhsin
   Cekic, Osman
TI Age-related macular degeneration and Alzheimer disease
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; Alzheimer disease; amyloid-beta;
   drusen; senile plaques
ID SOLUBLE AMYLOID OLIGOMERS; COMPLEMENT ACTIVATION; OXIDATIVE STRESS;
   APOLIPOPROTEIN-E; POTENTIAL ROLE; BETA PEPTIDES; RISK-FACTORS;
   BLOOD-FLOW; DRUSEN; PATHOGENESIS
AB This review highlight the similarities in the pathogenesis between Alzheimer disease and age-related macular degeneration. All studies published between 1990 and 2014 were reviewed to identify the common pathological pathways. Alzheimer disease and age-related macular degeneration share common features such as vitronectin and amyloid-beta accumulation, increased oxidative stress, and apolipoprotein and complement activation pathways, which are reviewed as histologic and immunologic common features.
C1 [Cerman, Eren; Eraslan, Muhsin; Cekic, Osman] Marmara Univ, Dept Ophthalmol, Fac Med, Istanbul, Turkey.
C3 Marmara University
RP Cekic, O (通讯作者)，Marmara Univ, Dept Ophthalmol, Fac Med, Istanbul, Turkey.
EM ocekic@hotmail.com
RI eraslan, muhsin/E-7686-2016; Cekic, Osman/H-3027-2019
OI eraslan, muhsin/0000-0002-1829-3329; Cekic, Osman/0000-0003-0911-8649
CR AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H
   Aliev G, 2014, CURR MED CHEM, V21, P2208, DOI 10.2174/0929867321666131227161303
   Aliev G, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/962984
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   DAHLBACK K, 1993, J INVEST DERMATOL, V100, P166, DOI 10.1111/1523-1747.ep12462792
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dolan H, 2010, ANN NEUROL, V68, P231, DOI 10.1002/ana.22055
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Eisenberg DTA, 2010, AM J PHYS ANTHROPOL, V143, P100, DOI 10.1002/ajpa.21298
   Esbjorner EK, 2014, CHEM BIOL, V21, P732, DOI 10.1016/j.chembiol.2014.03.014
   Gotz J, 2004, INT J DEV NEUROSCI, V22, P453, DOI 10.1016/j.ijdevneu.2004.07.013
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390
   JANSEN JH, 1993, AM J PATHOL, V143, P1356
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kiddle SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044260
   Kosenko EA, 2014, CNS NEUROL DISORD-DR, V13, P112, DOI 10.2174/18715273113126660130
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Loffler T, 2013, NEUROBIOL AGING, V34, P2379, DOI 10.1016/j.neurobiolaging.2013.04.008
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McGeer Patrick L, 2002, Sci Aging Knowledge Environ, V2002, pre3, DOI 10.1126/sageke.2002.29.re3
   McKinnon SJ, 2003, FRONT BIOSCI-LANDMRK, V8, pS1140, DOI 10.2741/1172
   Moreira PI, 2013, CURR OPIN CLIN NUTR, V16, P440, DOI 10.1097/MCO.0b013e328361c7d1
   Murakami K, 2011, J BIOL CHEM, V286, P44557, DOI 10.1074/jbc.M111.279208
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2013, INT REV IMMUNOL, V32, P97, DOI 10.3109/08830185.2012.740536
   Olofsson SO, 2005, J INTERN MED, V258, P395, DOI 10.1111/j.1365-2796.2005.01556.x
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D., 1992, Ophthalmologe, V89, P363
   Percy M, 2014, J ALZHEIMERS DIS, V38, P907, DOI 10.3233/JAD-131409
   Perez-Garmendia R, 2013, CURR NEUROPHARMACOL, V11, P491, DOI 10.2174/1570159X11311050004
   Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010
   Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Roher AE, 2012, VASC HEALTH RISK MAN, V8, P599, DOI 10.2147/VHRM.S34874
   Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6
   Shin TM, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-16
   Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348
   Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wostyn P, 2010, MED HYPOTHESES, V74, P973, DOI 10.1016/j.mehy.2009.12.019
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zanjani H, 2005, ALZ DIS ASSOC DIS, V19, P55, DOI 10.1097/01.wad.0000165506.60370.94
   Zhao Y, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/316523
NR 70
TC 13
Z9 14
U1 0
U2 2
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2015
VL 45
IS 5
SI SI
BP 1004
EP 1009
DI 10.3906/sag-1406-146
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT0ZI
UT WOS:000362526300004
PM 26738339
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Mehta, S
AF Mehta, Sonia
TI Age-Related Macular Degeneration
SO PRIMARY CARE
LA English
DT Review
DE Age-related macular degeneration; Nonexudative age-related macular
   degeneration; Dry AMD; Exudative age-related macular degeneration; Wet
   AMD; Neovascular age-related macular degeneration
ID RANIBIZUMAB; MACULOPATHY; RISK; EYE
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. AMD is diagnosed based on characteristic retinal findings in individuals older than 50. Early detection and treatment are critical in increasing the likelihood of retaining good and functional vision.
C1 Thomas Jefferson Univ Hosp, Dept Ophthalmol, Wills Eye Hosp, Vitreoretinal Dis & Surg Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Mehta, S (通讯作者)，Thomas Jefferson Univ Hosp, Dept Ophthalmol, Wills Eye Hosp, Vitreoretinal Dis & Surg Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM soniamehtamd@gmail.com
CR AAO Retina/Vitreous PPP Panel Hoskins Center for Quality Eye Care, AM AC OPHTH PREF PRA
   *AM AC FAM PHYS, 1999, AAFP REF MAN SEL POL, P213
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   [Anonymous], 2010, US AGE SPECIFIC PREV
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomi Anca, 2011, Oftalmologia, V55, P54
   US Preventative Services Task Force, 1996, SCREEN VIS IMP GUID, P373
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 34
TC 64
Z9 70
U1 19
U2 126
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-4543
EI 1558-299X
J9 PRIMARY CARE
JI Primary Care
PD SEP
PY 2015
VL 42
IS 3
BP 377
EP +
DI 10.1016/j.pop.2015.05.009
PG 16
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CP7PI
UT WOS:000360079800008
PM 26319344
DA 2022-11-30
ER

PT J
AU Jirarattanasopa, P
   Ooto, S
   Nakata, I
   Tsujikawa, A
   Yamashiro, K
   Oishi, A
   Yoshimura, N
AF Jirarattanasopa, Pichai
   Ooto, Sotaro
   Nakata, Isao
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Oishi, Akio
   Yoshimura, Nagahisa
TI Choroidal Thickness, Vascular Hyperpermeability, and Complement Factor H
   in Age-Related Macular Degeneration and Polypoidal Choroidal
   Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; CLINICOPATHOLOGICAL CORRELATION; EYES;
   POLYMORPHISM; RANIBIZUMAB
AB PURPOSE. To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   METHODS. Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
   RESULTS. Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
   CONCLUSIONS. Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV. (Invest Ophthalmol Vis Sci. 2012; 53:3663-3672) DOI:10.1167/iovs.12-9619
C1 [Ooto, Sotaro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
   [Jirarattanasopa, Pichai] Prince Songkla Univ, Fac Med, Dept Ophthalmol, Hat Yai, Thailand.
C3 Kyoto University; Prince of Songkla University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Yamashiro, Kenji/0000-0001-9354-8558;
   Jirarattanasopa, Pichai/0000-0003-0584-5101; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P112, DOI 10.1016/j.ajo.2010.07.004
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 138
Z9 150
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2012
VL 53
IS 7
BP 3663
EP 3672
DI 10.1167/iovs.12-9619
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 971CM
UT WOS:000306181200048
PM 22570352
DA 2022-11-30
ER

PT J
AU Lima, LH
   Schubert, C
   Ferrara, DC
   Merriam, JE
   Imamura, Y
   Freund, KB
   Spaide, RF
   Yannuzzi, LA
   Allikmets, R
AF Lima, Luiz H.
   Schubert, Carl
   Ferrara, Daniela C.
   Merriam, Joanna E.
   Imamura, Yutaka
   Freund, K. Bailey
   Spaide, Richard F.
   Yannuzzi, Lawrence A.
   Allikmets, Rando
TI Three Major Loci Involved in Age-Related Macular Degeneration Are Also
   Associated with Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS;
   JAPANESE PATIENTS; GENE; SUSCEPTIBILITY; POLYMORPHISM; TRANSLOCATION;
   VERTEPORFIN; MACULOPATHY
AB Purpose: To investigate the frequency of variants in 3 major age-related macular degeneration (AMD)-associated loci in patients of European-American descent with polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional, case-control association study.
   Participants: Fifty-five patients with PCV, 368 patients with advanced AMD, and 368 age-matched and ethnically matched unaffected controls of European-American descent.
   Methods: Association analysis of allele and genotype frequencies, determined by TaqMan assays, was performed for the following haplotype-tagging single nucleotide polymorphisms (htSNPs): risk alleles in the complement factor H (CFH) gene (Y402H and IVS14) in the ARMS2/HTRA1 locus on 10q26 (A69S) and protective alleles in CFH (IVS1 and IVS6) and in the complement factor B/complement component C2 (CFB/C2) locus (IVS10 and H9L).
   Main Outcome Measures: Allele and genotype frequencies of the htSNPs in the CFH, CFB/C2, and ARMS2/HTRA1 loci.
   Results: Four AMD-associated haplotype-tagging alleles (rs547154, rs1061170, rs1410996, rs10490924) in the 3 major loci, CFH, CFB/C2, and ARMS2/HTRA1, also were statistically significantly associated with the PCV phenotype (P<0.05). Three other alleles from the same loci (rs4151667, rs529825, rs3766404) showed a trend toward association (P<0.2) but did not reach statistical significance, possibly because of the combined effects of a relatively small sample size and low minor allele frequency in the screened populations.
   Conclusions: The PCV phenotype in Caucasian patients is associated with the major alleles/genotypes in the AMD-associated loci, suggesting that PCV and AMD are genetically similar in the tested loci.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2010; 117: 1567-1570 (C) 2010 by the American Academy of Ophthalmology.
C1 [Allikmets, Rando] Columbia Univ, Eye Inst Res Addit, Dept Ophthalmol, New York, NY 10032 USA.
   [Lima, Luiz H.; Ferrara, Daniela C.; Imamura, Yutaka; Freund, K. Bailey; Spaide, Richard F.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Lima, Luiz H.; Ferrara, Daniela C.; Imamura, Yutaka; Freund, K. Bailey; Spaide, Richard F.; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retina Res Ctr, New York, NY 10021 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Columbia University
RP Allikmets, R (通讯作者)，Columbia Univ, Eye Inst Res Addit, Dept Ophthalmol, 160 Ft Washington Ave,7th Floor,Room 715, New York, NY 10032 USA.
EM rla22@columbia.edu
RI Lima, Luiz H/V-4940-2017; Allikmets, Rando/ABD-4533-2021; Spaide,
   Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Lima, Luiz H/0000-0001-7304-909X; Freund, K. Bailey/0000-0002-7888-9773
FU National Institutes of Health [EY13435, EY017404]; The Macula
   Foundation, Inc.; Research to Prevent Blindness, Inc.; Koureisha
   Ganshikkan Kenkyu Zaidan; Mishima Saiichi-kinen Gankakenkyu
   Kokusaikouryu Kikin; Takeda Kagaku Shinkou Zaidan; NATIONAL EYE
   INSTITUTE [R24EY017404, R01EY013435] Funding Source: NIH RePORTER
FX Supported by grants National Institutes of Health EY13435, EY017404, The
   Macula Foundation, Inc., and an unrestricted grant to the Department of
   Ophthalmology, Columbia University, from Research to Prevent Blindness,
   Inc. Dr. Imamura was funded by grants from Koureisha Ganshikkan Kenkyu
   Zaidan, Mishima Saiichi-kinen Gankakenkyu Kokusaikouryu Kikin, and
   Takeda Kagaku Shinkou Zaidan.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 32
TC 82
Z9 87
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2010
VL 117
IS 8
BP 1567
EP 1570
DI 10.1016/j.ophtha.2009.12.018
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634QU
UT WOS:000280598900017
PM 20378180
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, ZJ
   Ma, L
   Brelen, ME
   Chen, HY
   Tsujikawa, M
   Lai, TY
   Ho, M
   Sayanagi, K
   Hara, C
   Hashida, N
   Tam, POS
   Young, AL
   Nishida, K
   Tham, CC
   Pang, CP
   Chen, LJ
AF Chen, Zhen Ji
   Ma, Li
   Brelen, Marten E.
   Chen, Haoyu
   Tsujikawa, Motokazu
   Lai, Timothy Y.
   Ho, Mary
   Sayanagi, Kaori
   Hara, Chikako
   Hashida, Noriyasu
   Tam, Pancy O. S.
   Young, Alvin L.
   Nishida, Kohji
   Tham, Clement C.
   Pang, Chi Pui
   Chen, Li Jia
TI Identification of TIE2 as a susceptibility gene for neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE genetics; macula; experimental-laboratory; neovascularisation
ID ENDOTHELIAL GROWTH-FACTOR; ASSOCIATION; POLYMORPHISMS; VARIANTS;
   CHINESE; ANGIOPOIETIN-2; MUTATIONS; PATHWAY
AB Purpose The endothelial and cell-specific angiopoietin-Tie pathway plays an important regulatory role in angiogenesis. In this study, we investigated the associations of the TIE2 (tyrosine kinase, endothelial, TEK) gene with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), using haplotype-tagging single-nucleotide polymorphisms (SNPs) analysis. Methods This study involved totally 2343 subjects, including a Hong Kong Chinese cohort (214 nAMD patients, 236 PCV patients and 433 control subjects), a Shantou Chinese cohort (189 nAMD patients, 187 PCV patients and 531 control subjects) and an Osaka Japanese cohort (192 nAMD patients, 204 PCV patients and 157 control subjects). Thirty haplotype-tagging SNPs in TIE2 were genotyped in the Hong Kong cohort using TaqMan technology. Two SNPs (rs625767 and rs2273717) showing association in the Hong Kong cohort were genotyped in the Shantou and Osaka cohorts. The SNP-disease association of individual and pooled cohorts were analysed. Results Two SNPs (rs625767 and rs2273717) showed suggestive association with both nAMD and PCV in the Hong Kong cohort. In the meta-analysis involving all the three cohorts, rs625767 showed significant associations with nAMD (p=0.01; OR=0.82, 95% CI 0.70 to 0.96; I-2=0%), PCV (p=0.02; OR=0.83, 95% CI 0.71 to 0.97; I-2=27%) and pooled nAMD and PCV (p=0.002; OR=0.82, 95% CI 0.72 to 0.93; I-2=0%), with low inter-cohort heterogeneities. Conclusion This study revealed TIE2 as a novel susceptibility gene for nAMD and PCV in Japanese and Chinese. Further studies in other populations are warranted to confirm its role.
C1 [Chen, Zhen Ji; Ma, Li; Brelen, Marten E.; Lai, Timothy Y.; Tam, Pancy O. S.; Young, Alvin L.; Tham, Clement C.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ma, Li] Dalian Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China.
   [Brelen, Marten E.; Ho, Mary; Young, Alvin L.; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   [Chen, Haoyu] Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Tsujikawa, Motokazu; Sayanagi, Kaori; Hara, Chikako; Hashida, Noriyasu; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka, Japan.
   [Tham, Clement C.] Hong Kong Eye Hosp, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Dalian Medical University; Chinese
   University of Hong Kong; Prince of Wales Hospital; Osaka University
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Tham, Chee Yung Clement/AAD-6528-2020; Chen, Haoyu/A-7432-2013
OI Tham, Chee Yung Clement/0000-0003-4407-6907; Chen,
   Haoyu/0000-0003-0676-4610; Ho, Mary/0000-0001-8864-2988; Lai,
   Timothy/0000-0002-7832-6428; Hara, Chikako/0000-0001-9320-5408; Chen,
   Zhen Ji/0000-0002-9782-2494
FU General Research Fund, Hong Kong [14120516]; Direct Grant of Chinese
   University of Hong Kong Medical Panel, Hong Kong [4054281]; National
   Natural Science Foundation of China (NSFC) [81500764]; Endowment Fund
   for Lim Por-Yen Eye Genetics Research Centre, Hong Kong
FX This study was supported in part by the General Research Fund, Hong Kong
   (14120516 (LJC)), Direct Grant of Chinese University of Hong Kong
   Medical Panel, Hong Kong (4054281 (LJC)), National Natural Science
   Foundation of China (NSFC, 81500764 (LJC)), and the Endowment Fund for
   Lim Por-Yen Eye Genetics Research Centre, Hong Kong.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Daly C, 2013, CANCER RES, V73, P108, DOI 10.1158/0008-5472.CAN-12-2064
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Fodor LE, 2018, INT J IMMUNOGENET, V45, P102, DOI 10.1111/iji.12365
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Limaye N, 2009, NAT GENET, V41, P118, DOI 10.1038/ng.272
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Ma L, 2016, INVEST OPHTH VIS SCI, V57, P5758, DOI 10.1167/iovs.16-20175
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Parikh SM, 2017, CURR OPIN HEMATOL, V24, P432, DOI 10.1097/MOH.0000000000000361
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rubio RG, 2016, DEV OPHTHALMOL, V55, P28, DOI 10.1159/000431129
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Souma T, 2016, J CLIN INVEST, V126, P2575, DOI 10.1172/JCI85830
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zheng QP, 2013, GENE, V523, P195, DOI 10.1016/j.gene.2013.02.053
NR 35
TC 3
Z9 3
U1 2
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2021
VL 105
IS 7
BP 1035
EP 1040
DI 10.1136/bjophthalmol-2019-315746
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB1QQ
UT WOS:000667719500026
PM 32152144
DA 2022-11-30
ER

PT J
AU Kawasaki, R
   Yasuda, M
   Song, SJ
   Chen, SJ
   Jonas, JB
   Wang, JJ
   Mitchell, P
   Wong, TY
AF Kawasaki, Ryo
   Yasuda, Miho
   Song, Su Jeong
   Chen, Shih-Jen
   Jonas, Jost B.
   Wang, Jie Jin
   Mitchell, Paul
   Wong, Tien Y.
TI The Prevalence of Age-Related Macular Degeneration in Asians A
   Systematic Review and Meta-Analysis
SO OPHTHALMOLOGY
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PRADESH EYE DISEASE; RISK-FACTORS;
   PHOTODYNAMIC THERAPY; JAPANESE POPULATION; ADULT-POPULATION; CLINICAL
   CHARACTERISTICS; GENE POLYMORPHISMS; RACIAL-DIFFERENCES; CHINESE
   PATIENTS
AB Objective: To determine the prevalence of age-related macular degeneration (AMD) in Asian populations and to compare this with prevalence in white populations.
   Design: A clear understanding of AMD prevalence in Asians is essential to meet future demands for eye health care.
   Methods: We searched published literature reporting AMD prevalence in Asian populations. We limited studies examined to those using standardized grading systems ( either the Wisconsin Age-Related Maculopathy Grading System or the international classification proposed by the International ARM Epidemiological Study Group). We used metaanalytical methods to calculate age-specific pooled prevalence of AMD using inverse-variance weighting in a random effect model. We also calculated pooled estimates of age-standardized prevalence. A metaregression model was used to examine gender differences and differences between Asian and white populations.
   Results: We identified 9 studies reporting AMD prevalence from 4 Asian populations. Pooled prevalence estimates of early and late AMD in Asian populations aged 40 to 79 years were 6.8% (95% confidence interval [CI], 4.6%-8.9%) and 0.56% ( 95% CI, 0.30%-0.81%), respectively; corresponding prevalence estimates in white populations were 8.8% ( 95% CI, 3.8%-13.8%) and 0.59% ( 95% CI, 0.35%-0.84%), respectively. Reliable prevalence estimates of AMD in Asian persons aged >= 80 years were not available owing to small subject numbers in this age category.
   Conclusions: Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. Further studies in Asian populations are warranted to investigate whether certain specific AMD phenotypes or subtypes, such as polypoidal choroidal vasculopathy, are more common.
C1 [Wong, Tien Y.] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Yong Loo Lin Sch Med, Singapore 168751, Singapore.
   [Kawasaki, Ryo; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Kawasaki, Ryo] Yamagata Univ, Fac Med, Dept Ophthalmol & Visual Sci, Yamagata 990, Japan.
   [Yasuda, Miho] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 812, Japan.
   [Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Jonas, Jost B.] Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vision Res, Sydney, NSW 2006, Australia.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Yamagata University; Kyushu University;
   Sungkyunkwan University (SKKU); Samsung Medical Center; Taipei Veterans
   General Hospital; Ruprecht Karls University Heidelberg; University of
   Sydney; Westmead Institute for Medical Research
RP Wong, TY (通讯作者)，Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Yong Loo Lin Sch Med, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014; Kawasaki, Ryo/H-9716-2019; Wong, Tien
   Yin/AAC-9724-2020; Kawasaki, Ryo/B-7266-2009
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Kawasaki, Ryo/0000-0002-7492-6303
FU National Health and Medical Research Council, Australia [52993]
FX Funded by the National Health and Medical Research Council, Australia,
   52993".
CR Ahmad O. B., 2000, GPE DISCUSSION PAPER, V31
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Weerd M, 2009, STROKE, V40, P1105, DOI 10.1161/STROKEAHA.108.532218
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   United Nations Population Division, WORLD POP PROSP 2008
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 40
TC 303
Z9 312
U1 0
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2010
VL 117
IS 5
BP 921
EP 927
DI 10.1016/j.ophtha.2009.10.007
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 590XM
UT WOS:000277261800012
PM 20110127
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
AF Kim, Jae-Hui
   Kim, Jong-Woo
   Kim, Chul-Gu
TI Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth
   Factor Agents for the Initial Treatment of Neovascular Age-Related
   Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   type 3 macular neovascularization; ranibizumab; aflibercept
ID RETINAL ANGIOMATOUS PROLIFERATION; INTRAVITREAL AFLIBERCEPT; TYPE-3
   NEOVASCULARIZATION; RANIBIZUMAB; DIAGNOSIS; STROKE; RISK; EYES
AB BACKGROUND: This study aimed to investigate the trend of selecting ranibizumab and aflibercept for the initial treatment of neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). METHODS: This was a retrospective study that included 460 patients who were diagnosed with treatment-naive neovascular AMD and PCV and were initially treated with either ranibizumab or aflibercept. The patients were divided into two groups: the ranibizumab group (n = 96) and the aflibercept group (n = 324). The patients' characteristics and the proportion of the subtypes of macular neovascularization (MNV) were compared between the two groups. RESULTS: Patients in the ranibizumab group were significantly older (mean 74.3 +/- 8.4 years) than those in the aflibercept group (mean 70.4 +/- 8.8 years; p < 0.001). In the ranibizumab group, the proportions of type 1 or 2 MNV, type 3 MNV, and PCV were 50.0%, 27.1%, and 22.9%, respectively. In the aflibercept group, the proportions were 35.2%, 6.8%, and 58.0%, respectively. There was a significant difference in the proportion of MNV subtypes between the ranibizumab and aflibercept groups (p < 0.001). Ranibizumab was used in 54.2% of patients with type 3 MNVs. However, in patients with PCV, aflibercept was used in 89.5% of patients. CONCLUSIONS: Ranibizumab was preferred as an initial treatment agent in older patients and those with type 3 MNV, whereas aflibercept was highly preferred in patients with PCV. The different characteristics and efficacy of the two agents may have partially contributed to this trend.
C1 [Kim, Jae-Hui; Kim, Jong-Woo; Kim, Chul-Gu] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul 07301, South Korea.
C3 Konyang University
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul 07301, South Korea.
EM kimoph@gmail.com; kjwood@kimeye.com; chulgukim@kimeye.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chhablani J, 2019, ASIA-PAC J OPHTHALMO, V8, P43, DOI 10.22608/APO.2018136
   Cho HJ, 2018, RETINA-J RET VIT DIS, V38, P2150, DOI 10.1097/IAE.0000000000001862
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gong D, 2019, OPHTHALMOLOGY, V126, P1358, DOI 10.1016/j.ophtha.2019.04.018
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kim JH, 2021, RETINA-J RET VIT DIS, V41, P1251, DOI 10.1097/IAE.0000000000003010
   Kim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041145
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Parikh R, 2019, OPHTHALMOL RETINA, V3, P16, DOI 10.1016/j.oret.2018.08.002
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
NR 35
TC 3
Z9 3
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2021
VL 10
IS 16
AR 3580
DI 10.3390/jcm10163580
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UG3EA
UT WOS:000689139000001
PM 34441876
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ji, YY
   Zhang, XZ
   Wu, KF
   Su, Y
   Li, M
   Zuo, CG
   Wen, F
AF Ji, Yuying
   Zhang, Xiongze
   Wu, Kunfang
   Su, Yu
   Li, Meng
   Zuo, Chengguo
   Wen, Feng
TI Association of rs6982567 near GDF6 with neovascular age-related macular
   degeneration and polypoidal choroidal vasculopathy in a Han Chinese
   cohort
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Han Chinese population; Neovascular age-related macular degeneration;
   Polypoidal choroidal vasculopathy; Polymorphisms; Growth differentiation
   factor 6
ID DEVELOPMENTAL ANOMALIES; DIFFERENTIATION; GENE; GROWTH; TENDON; LOCUS;
   EYE; POPULATION; SPECTRUM; LIGAMENT
AB Background: Growth differentiation factor 6 (GDF6) has been reported to be a novel disease gene for age-related macular degeneration (AMD) in Caucasians. This study aimed to investigate whether rs6982567 was associated with neovascular AMD (nAMD) or polypoidal choroidal vasculopathy (PCV) in a Han Chinese cohort.
   Methods: A total of 612 participants ( 251 PCV patients, 157 nAMD patients and 204 controls) were included in this study. The SNaPshot system was used to genotype the rs6982567. PLINK software was used to evaluate the genotypes and allele frequencies of patients and controls.
   Results: The allele frequencies of rs6982567 were not significantly associated with nAMD, PCV or PCV and nAMD combined. Subjects with the TT genotype had a 2.42 fold greater risk of PCV (95% confidence interval, 1.07-5.43, p = 0.0290) than subjects with CC genotype. A recessive model of rs6982567 was statistically significantly associated with PCV ( odds ratio, 2.29; 95% confidence interval, 1.04-5.05; p = 0.0351). However, the association did not withstand stringent Bonferroni correction. There were no significant differences in genotype distributions or models in nAMD.
   Conclusions: There was a possible weak association between the rs6982567 near GDF6 and PCV in this replication study with an independent Han Chinese cohort. A complete survey of the GDF6 locus with a larger sample size is needed in future studies.
C1 [Ji, Yuying; Zhang, Xiongze; Wu, Kunfang; Su, Yu; Li, Meng; Zuo, Chengguo; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81271011, 81200705];
   Fundamental Research Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81271011 and 81200705) and the Fundamental Research
   Funds of State Key Laboratory of Ophthalmology. The authors indicated no
   financial disclosures.
CR Asai-Coakwell M, 2007, AM J HUM GENET, V80, P306, DOI 10.1086/511280
   Asai-Coakwell M, 2009, HUM MOL GENET, V18, P1110, DOI 10.1093/hmg/ddp008
   Chang CB, 1999, DEVELOPMENT, V126, P3347
   Chassaing N, 2014, CLIN GENET, V86, P326, DOI 10.1111/cge.12275
   Chen HY, 2012, MOL VIS, V18, P816
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   den Hollander AI, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-102
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gonzalez-Rodriguez J, 2010, BRIT J OPHTHALMOL, V94, P1100, DOI 10.1136/bjo.2009.173500
   Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   Haddad-Weber M, 2010, CYTOTHERAPY, V12, P505, DOI 10.3109/14653241003709652
   Hanel ML, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-43
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li M, 2010, MOL VIS, V16, P231
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Mikic B, 2009, J ORTHOP RES, V27, P1603, DOI 10.1002/jor.20916
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Williams LA, 2008, INT J BIOL SCI, V4, P318
   Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537
   Wong YP, 2005, ACTA ORTHOP, V76, P421, DOI 10.1080/17453670510041330
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 37
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 22
PY 2014
VL 14
AR 140
DI 10.1186/1471-2415-14-140
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ4AA
UT WOS:000348163600001
PM 25416513
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, GF
   Zou, XL
AF Wang, Guan-Feng
   Zou, Xiu-Lan
TI Tissue factor with age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE wet age-related macular degeneration; choroidal neovascularzation;
   tissue factor; photodynamic therapy; immunotherapy
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION; FACTOR EXPRESSION;
   MODEL; EYE; ANGIOGENESIS; INFLAMMATION; PERSPECTIVE; CELLS; EGR-1
AB Wet age-related macular degeneration which incidence increases year by year is a blinding eye disease, but current clinical methods of treatment on this disease are limited and the outcome is not ideal. Recent studies have found abnormally high expression of tissue factors which are targets for the treatment of wet age-related macular degeneration to achieve a certain effect in the choroidal neovascularization. Related literatures are reviewed as following.
C1 [Wang, Guan-Feng; Zou, Xiu-Lan] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Ophthalmol, Guangzhou 510010, Guangdong, Peoples R China.
   [Wang, Guan-Feng] Jinan Univ, Guangzhou 510630, Guangdong, Peoples R China.
C3 Southern Theater Command General Hospital; Jinan University
RP Zou, XL (通讯作者)，Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Ophthalmol, Guangzhou 510010, Guangdong, Peoples R China.
EM xlzou2003@yahoo.com.cn
FU National Youth Science Foundation of China [81000368]
FX Foundation item: National Youth Science Foundation of China (No.
   81000368)
CR Al-latayfeh M, 2012, CSH PERSPECT BIOL, V2
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bavendiek U, 2002, J BIOL CHEM, V277, P25032, DOI 10.1074/jbc.M204003200
   Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Croce K, 2007, CURR OPIN HEMATOL, V14, P55, DOI 10.1097/00062752-200701000-00011
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5963, DOI 10.1167/iovs.10-6440
   Li D, 2010, YANKE XINJINZHAN, V30, P797
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Lu F, 2009, INVEST OPHTH VIS SCI, V50, P3890, DOI 10.1167/iovs.08-2833
   Mallat Z, 2001, CIRC RES, V88, P998, DOI 10.1161/hh1001.090571
   Medearis S, 2011, INVEST OPHTH VIS SCI, V52, P6545, DOI 10.1167/iovs.10-6772
   Norris LA, 2006, THROMB RES, V117, P475, DOI 10.1016/j.thromres.2005.03.009
   Panes O, 2007, BLOOD, V109, P5242, DOI 10.1182/blood-2006-06-030619
   Redecha P, 2007, BLOOD, V110, P2423, DOI 10.1182/blood-2007-01-070631
   Stephens AC, 2008, THROMB RES, V122, P99, DOI 10.1016/j.thromres.2007.08.021
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Versteeg HH, 2001, THROMB HAEMOSTASIS, V86, P1353
NR 29
TC 8
Z9 9
U1 0
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2012
VL 5
IS 5
BP 609
EP 613
DI 10.3980/j.issn.2222-3959.2012.05.13
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 028CH
UT WOS:000310399900013
PM 23166874
DA 2022-11-30
ER

PT J
AU Cheong, KX
   Grewal, DS
   Teo, KYC
   Gan, ATL
   Jaffe, GJ
   Cheung, GCM
AF Cheong, Kai Xiong
   Grewal, Dilraj Singh
   Teo, Kelvin Yi Chong
   Gan, Alfred Tau Liang
   Jaffe, Glenn Jay
   Cheung, Gemmy Chui Ming
TI The relationship between pigment epithelial detachment and visual
   outcome in neovascular age-related macular degeneration and polypoidal
   choroidal vasculopathy
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB TREATMENT; THERAPY; ACUITY;
   EYES; BEVACIZUMAB; BIOMARKERS; MORPHOLOGY; SECONDARY; RELEVANT
AB Background/objectives To compare the detailed optical coherence tomography (OCT)-based morphological parameters of pigment epithelial detachment (PED) in eyes presenting with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to assess whether these PED-associated parameters influence 1-year visual outcomes. Subject/methods We analysed images from a prospective observational study of treatment-naive Asian participants with nAMD or PCV. An independent reading centre graded baseline morphological features of PED on spectral-domain OCT, including greatest height, greatest width, greatest volume, morphology (predominantly dome shaped versus peaked), presence of retinal pigment epithelium (RPE) tear and cholesterol bands. The influence of these baseline features on 12 months best corrected visual acuity (BCVA) was evaluated. Results Seventy-eight eyes of 78 participants with PED were studied. In total, 40 (51.3%) participants had nAMD and 38 (48.7%) had PCV. Eyes with PCV, compared with nAMD, had PED of greater height (455.9 mu m versus 389.9 mu m; P = 0.035) and had higher prevalence of RPE tear (22.9 versus 5.3%; P = 0.041). In the multivariate analysis, only baseline BCVA was significantly associated with month 12 BCVA, but none of the PED-associated OCT parameters at baseline influenced month 12 BCVA. Conclusions Despite the differences in PED height and prevalence of RPE tear between nAMD and PCV, none of these PED morphological factors on OCT at baseline significantly influenced visual outcome at 12 months.
C1 [Cheong, Kai Xiong; Teo, Kelvin Yi Chong; Gan, Alfred Tau Liang; Cheung, Gemmy Chui Ming] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Grewal, Dilraj Singh; Jaffe, Glenn Jay] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Teo, Kelvin Yi Chong; Cheung, Gemmy Chui Ming] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Duke
   University; National University of Singapore
RP Cheung, GCM (通讯作者)，Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.; Cheung, GCM (通讯作者)，Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Cheong, Kai Xiong/AAI-7243-2020
OI Grewal, Dilraj/0000-0002-2229-5343; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Teo, Kelvin/0000-0002-7458-7081
FU Duke/Duke-NUS Research Collaborations Grant
   [Duke/Duke-NUS/RECA(Pilot)2016/0020]; Biomedical Research Council
   Singapore Grant [SPF2014/002]; National Medical Research Council Open
   Fund Large Collaborative Grant [NMRC/LCG/004/2018]
FX This study is supported by the Duke/Duke-NUS Research Collaborations
   Grant: Duke/Duke-NUS/RECA(Pilot)2016/0020, the Biomedical Research
   Council Singapore Grant: SPF2014/002 and the National Medical Research
   Council Open Fund Large Collaborative Grant: NMRC/LCG/004/2018.
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CM, 2018, ANN EYE SCI, V3, P56, DOI [10.21037/aes.2018.11.02, DOI 10.21037/AES.2018.11.02]
   Cheung CMG, 2020, OPHTHALMOL RETINA, V3, P1045
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Ristau T, 2013, J CLIN EXP OPHTHALMO, V4, p264J, DOI DOI 10.4172/2155-9570.1000264
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Tyagi P, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0824-0
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 43
TC 5
Z9 6
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2020
VL 34
IS 12
BP 2257
EP 2263
DI 10.1038/s41433-020-0803-6
EA FEB 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6KF
UT WOS:000512842400001
PM 32047280
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ma, L
   Liu, K
   Tsujikawa, M
   Chen, HY
   Brelen, ME
   Chan, VCK
   Lai, TYY
   Sayanagi, K
   Hara, C
   Hashida, N
   Tam, POS
   Young, AL
   Chen, WQ
   Nishida, K
   Pang, CP
   Chen, LJ
AF Ma, Li
   Liu, Ke
   Tsujikawa, Motokazu
   Chen, Haoyu
   Brelen, Marten E.
   Chan, Vesta C. K.
   Lai, Timothy Y. Y.
   Sayanagi, Kaori
   Hara, Chicako
   Hashida, Noriyasu
   Tam, Pancy O. S.
   Young, Alvin L.
   Chen, Weiqi
   Nishida, Kohji
   Pang, Chi Pui
   Chen, Li Jia
TI Association of ABCG1 With Neovascular Age-Related Macular Degeneration
   and Polypoidal Choroidal Vasculopathy in Chinese and Japanese
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE ABCG1; gene; association; age-related macular degeneration; polypoidal
   choroidal vasculopathy
ID CELLULAR CHOLESTEROL EFFLUX; HARDY-WEINBERG EQUILIBRIUM;
   HIGH-DENSITY-LIPOPROTEIN; POLYMORPHISM; DISEASE; GENES; INFLAMMATION;
   POPULATION; EXPRESSION; VARIANTS
AB PURPOSE. We investigated the association of the ATP-binding cassette, subfamily G, member 1 (ABCG1) gene with polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) in independent Chinese and Japanese cohorts.
   METHODS. A total of 12 haplotype-tagging single-nucleotide polymorphisms (SNPs) and the SNP rs57137919 in the ABCG1 gene were first analyzed in a Hong Kong Chinese cohort of 235 nAMD, 236 PCV, and 365 controls, using TaqMan genotyping assays. Two SNPs (rs57137919 and rs225396) that showed a disease-association were genotyped in a Shantou Chinese cohort of 189 nAMD, 187 PCV, and 670 controls, and an Osaka Japanese cohort of 192 nAMD, 204 PCV, and 157 controls, totaling 2435 subjects. Association analysis was performed in individual cohorts, followed by a pooled analysis of the data from all three cohorts.
   RESULTS. In the Hong Kong cohort, SNP rs57137919 was associated with PCV (odds ratio [OR] = 1.35). A tagging SNP rs225396 was associated with nAMD (OR = 1.28) and PCV (OR = 1.32). In the Osaka cohort, SNP rs225396 was associated with nAMD (OR = 1.42) and PCV (OR = 1.74). In the pooled analysis involving the 3 study cohorts, rs225396 showed an enhanced association with nAMD (P = 0.01, OR = 1.21, I-2 = 14%) and PCV (P = 0.0001, OR = 1.35, I-2 = 46%).
   CONCLUSIONS. In this study, we have newly identified a haplotype-tagging SNP, rs225396, in ABCG1 to be associated with PCV and nAMD in Chinese and Japanese cohorts. This provides new evidence to support ABCG1 as a susceptibility gene for PCV and nAMD. Further replication in other populations should be warranted.
C1 [Ma, Li; Liu, Ke; Brelen, Marten E.; Lai, Timothy Y. Y.; Tam, Pancy O. S.; Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Ke] Shenzhen Eye Hosp, Shenzhen, Peoples R China.
   [Tsujikawa, Motokazu; Sayanagi, Kaori; Hara, Chicako; Hashida, Noriyasu; Nishida, Kohji] Shenzhen Key Lab Ophthalmol, Shenzhen, Peoples R China.
   [Chen, Haoyu; Chen, Weiqi; Pang, Chi Pui; Chen, Li Jia] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka, Japan.
   [Chan, Vesta C. K.; Young, Alvin L.; Chen, Li Jia] Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Osaka University; Chinese University of
   Hong Kong; Prince of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Hashida, Noriyasu/AAF-1187-2020; Chen, Haoyu/A-7432-2013; Brelen, Marten
   E./D-1133-2016; Chen, Li Jia/I-5078-2014; Lai, Timothy Y Y/AAC-2120-2020
OI Hashida, Noriyasu/0000-0002-8241-5378; Chen, Haoyu/0000-0003-0676-4610;
   Chen, Li Jia/0000-0003-3500-5840; Lai, Timothy Y Y/0000-0002-7832-6428;
   Nishida, Kohji/0000-0001-9069-3610
FU National Natural Science Foundation of China [81500764]; Direct Grants
   of the Chinese University of Hong Kong [4054281, 4054119]
FX Supported in part by the National Natural Science Foundation of China
   (81500764, LJC) and the Direct Grants of the Chinese University of Hong
   Kong (4054281, LJC and 4054119, CPP).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Beecham GW, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004606
   Bojanic DD, 2010, J LIPID RES, V51, P169, DOI [10.1194/jlr.M900250-JLR200, 10.1194/M900250-JLR200]
   Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujiyoshi M, 2007, J NEUROCHEM, V100, P968, DOI 10.1111/j.1471-4159.2006.04240.x
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097044
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Ma Long, 2010, Zhonghua Yixue Yichuanxue Zazhi, V27, P506, DOI 10.3760/cma.j.issn.1003-9406.2010.05.007
   Mayo O, 2008, TWIN RES HUM GENET, V11, P249, DOI 10.1375/twin.11.3.249
   Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Wollmer MA, 2007, NEUROGENETICS, V8, P179, DOI 10.1007/s10048-007-0087-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Y, 2011, ATHEROSCLEROSIS, V219, P648, DOI 10.1016/j.atherosclerosis.2011.05.043
NR 34
TC 8
Z9 9
U1 1
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5758
EP 5763
DI 10.1167/iovs.16-20175
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600091
PM 27787563
OA gold
DA 2022-11-30
ER

PT J
AU Proitsi, P
   Lupton, MK
   Dudbridge, F
   Tsolaki, M
   Hamilton, G
   Daniilidou, M
   Pritchard, M
   Lord, K
   Martin, BM
   Craig, D
   Todd, S
   McGuinness, B
   Hollingworth, P
   Harold, D
   Kloszewska, I
   Soininen, H
   Mecocci, P
   Velas, B
   Gill, M
   Lawlor, B
   Rubinsztein, DC
   Brayne, C
   Passmore, PA
   Williams, J
   Lovestone, S
   Powell, JF
AF Proitsi, Petroula
   Lupton, Michelle K.
   Dudbridge, Frank
   Tsolaki, Magda
   Hamilton, Gillian
   Daniilidou, Makrina
   Pritchard, Megan
   Lord, Kathryn
   Martin, Belinda M.
   Craig, David
   Todd, Stephen
   McGuinness, Bernadette
   Hollingworth, Paul
   Harold, Denise
   Kloszewska, Iwona
   Soininen, Hilkka
   Mecocci, Patrizia
   Velas, Bruno
   Gill, Michael
   Lawlor, Brian
   Rubinsztein, David C.
   Brayne, Carol
   Passmore, Peter A.
   Williams, Julie
   Lovestone, Simon
   Powell, John F.
TI Alzheimer's disease and age-related macular degeneration have different
   genetic models for complement gene variation
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer's disease (AD); Age-related macular degeneration (AMD);
   Complement pathway; Single nucleotide polymorphisms (SNPs); Genetic
   models
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; MOUSE MODELS;
   ALTERNATIVE PATHWAY; IDENTIFIES VARIANTS; ACTIVATION; RISK; DRUSEN;
   PROGRESSION; BIOMARKERS
AB Alzheimer's disease (AD) and age-related macular degeneration (AMD) are both neurodegenerative disorders which share common pathological and biochemical features of the complement pathway. The aim of this study was to investigate whether there is an association between well replicated AMD genetic risk factors and AD. A large cohort of AD (n = 3898) patients and controls were genotyped for single nucleotide polymorphisms (SNPs) in the complement factor H (CFH), the Age-related maculopathy susceptibility protein 2 (ARMS2) the complement component 2 (C2), the complement factor B (CFB), and the complement component 3 (C3) genes. While significant but modest associations were identified between the complement factor H, the age-related maculopathy susceptibility protein 2, and the complement component 3 single nucleotide polymorphisms and AD, these were different in direction or genetic model to that observed in AMD. In addition the multilocus genetic model that predicts around a half of the sibling risk for AMD does not predict risk for AD. Our study provides further support to the hypothesis that while activation of the alternative complement pathway is central to AMD pathogenesis, it is less involved in AD. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Proitsi, Petroula] KCL, Inst Psychiat, Dept Neurosci, MRC,Ctr Neurodegenerat Res, London SE5 8AF, England.
   [Dudbridge, Frank] London Sch Hyg & Trop Med, Bloomsbury Ctr Genet Epidemiol & Stat, Dept Noncommunicable Dis Epidemiol, London WC1, England.
   [Tsolaki, Magda; Daniilidou, Makrina] Aristotle Univ Thessaloniki, Memory & Dementia Ctr, GR-54006 Thessaloniki, Greece.
   [Hamilton, Gillian] Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh, Midlothian, Scotland.
   [Craig, David; Todd, Stephen; McGuinness, Bernadette; Passmore, Peter A.] Queens Univ Belfast, Sch Med & Dent, Ageing Grp, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Hollingworth, Paul; Harold, Denise; Williams, Julie] Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, MRC Ctr Neuropsychiat Genet & Genom, Cardiff, S Glam, Wales.
   [Kloszewska, Iwona] Med Univ Lodz, Dept Old Age Psychiat & Psychot Disorders, Lodz, Poland.
   [Soininen, Hilkka] Univ Kuopio, Dept Neurol, Kuopio, Finland.
   [Soininen, Hilkka] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
   [Mecocci, Patrizia] Univ Perugia, Dept Clin & Expt Med, Sect Gerontol & Geriatr, I-06100 Perugia, Italy.
   [Velas, Bruno] Hop Toulouse, Dept Internal & Geriatr Med, Toulouse, France.
   [Gill, Michael] Trinity Coll Dublin, Inst Mol Med, Dublin, Ireland.
   [Lawlor, Brian] St James Hosp, Mercers Inst Res Aging, Dublin, Ireland.
   [Rubinsztein, David C.] Univ Cambridge, Dept Med Genet, Cambridge Inst Med Res, Cambridge, England.
   [Brayne, Carol] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.
C3 University of London; King's College London; University of London;
   London School of Hygiene & Tropical Medicine; Aristotle University of
   Thessaloniki; University of Edinburgh; Queens University Belfast;
   Cardiff University; Medical University Lodz; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland;
   University of Perugia; CHU de Toulouse; Trinity College Dublin; Trinity
   College Dublin; University of Cambridge; University of Cambridge
RP Proitsi, P (通讯作者)，KCL, Inst Psychiat, Dept Neurosci, MRC,Ctr Neurodegenerat Res, De Crespigny Pk,PO55, London SE5 8AF, England.
EM petroula.proitsi@kcl.ac.uk
RI Mecocci, Patrizia/W-2116-2019; Brayne, Carol/AAA-4285-2020; Todd,
   Stephen/AAF-6729-2020; Hunter, Gillian/A-1952-2015; McGuinness,
   Bernadette/AAH-2755-2021; Rubinsztein, David C/C-3472-2011; Powell,
   John/G-4412-2011
OI Mecocci, Patrizia/0000-0003-0729-5246; Brayne,
   Carol/0000-0001-5307-663X; McGuinness, Bernadette/0000-0002-7028-5633;
   Tsolaki, Magda/0000-0002-2072-8010; Pritchard, Megan
   Ruth/0000-0001-8872-3614; Williams, Julie/0000-0002-4069-0259; Proitsi,
   Petroula/0000-0002-2553-6974; Harold, Denise/0000-0001-5195-0143; Gill,
   Michael/0000-0003-0206-5337; Lupton, Michelle/0000-0002-7274-7299; Todd,
   Stephen/0000-0002-2312-9195; Lovestone, Simon/0000-0003-0473-4565;
   Powell, John/0000-0001-6124-439X
FU Alzheimer's Research UK; MRC Centre for Neurodegeneration Research; NIHR
   BRC Centre for Mental Health at the South London; Maudsley NHS
   Foundation Trust; Alzheimer's Society; European Union
   [HEALTH-F4-2009-242257]; Ulster Garden Villages, Research and
   Development Office, Health and Personal Social Services, Northern
   Ireland; Alzheimers Research UK [ART-RF2007-3] Funding Source:
   researchfish; Medical Research Council [G0902227, G0801418B, G1000718]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0611-10084] Funding Source: researchfish; MRC [G0902227,
   G1000718] Funding Source: UKRI
FX This work was supported by the Alzheimer's Research UK; the MRC Centre
   for Neurodegeneration Research; the NIHR BRC Centre for Mental Health at
   the South London and Maudsley NHS Foundation Trust; the Alzheimer's
   Society; the 7th Framework Programme of the European Union (ADAMS
   project, HEALTH-F4-2009-242257); and the Ulster Garden Villages,
   Research and Development Office, Health and Personal Social Services,
   Northern Ireland. Petroula Proitsi is an Alzheimer's Research UK
   Post-Doctoral Fellow. David C. Rubinsztein is a Wellcome Trust Senior
   Research Fellow in Clinical Science.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EIKELENBOOM P, 1989, VIRCHOWS ARCH B, V56, P259
   EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397
   Fonseca MI, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-4
   Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gatta LB, 2008, DEMENT GERIATR COGN, V26, P169, DOI 10.1159/000151050
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Hye A, 2006, BRAIN, V129, P3042, DOI 10.1093/brain/awl279
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lovestone S, 2007, J NUTR HEALTH AGING, V11, P359
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGeer PL, 2002, TRENDS MOL MED, V8, P519, DOI 10.1016/S1471-4914(02)02422-X
   MCGEER PL, 1989, NEUROSCI LETT, V107, P341, DOI 10.1016/0304-3940(89)90843-4
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Turunen M, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2009.08.010
   Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhou J, 2008, J NEUROCHEM, V106, P2080, DOI 10.1111/j.1471-4159.2008.05558.x
NR 46
TC 16
Z9 16
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD AUG
PY 2012
VL 33
IS 8
AR 1843.e9
DI 10.1016/j.neurobiolaging.2011.12.036
PG 9
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 969QN
UT WOS:000306070800039
PM 22300950
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Long-term switching between ranibizumab and aflibercept in neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidal vasculopathy; Switching; Ranibizumab; Aflibercept
ID INTRAVITREAL AFLIBERCEPT; VERTEPORFIN; RESISTANT; OUTCOMES; THERAPY
AB Purpose To investigate the rate and timing of switching between ranibizumab and aflibercept and to evaluate the difference in the switching rates among the different subtypes of neovascularization. Methods This retrospective study included 386 patients (386 eyes) who had been diagnosed with neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) and treated with ranibizumab (ranibizumab group, n = 260) or aflibercept (aflibercept group, n = 126). The rate and timing of switching from ranibizumab to aflibercept or vice versa were evaluated. Within the ranibizumab and the aflibercept groups, the switching rates were compared among the 3 subtypes of neovascularization: PCV, type 1 or 2 neovascularization, and type 3 neovascularization. Results During the mean 44.9 +/- 15.9 months of follow-up period, switching rate was significantly higher in the ranibizumab group (28.8%, 75 patients) than in the aflibercept group (9.5%, 12 patients) (P < 0.001). No difference was observed in the mean duration between the diagnosis and switching among the ranibizumab (18.7 +/- 14.6 months) and the aflibercept groups (14.8 +/- 14.5 months) (P = 0.379). In the ranibizumab group, the switching rate was markedly higher in PCV (39.6%) than in type 1 or 2 neovascularization (17.6%) or in type 3 neovascularization (13.3%) (P < 0.001). In the aflibercept group, there was no significant difference in the switching rates among the subtypes of neovascularization (P = 0.811). Conclusions Although the timings of switching were similar, switching rate was higher in patients undergoing ranibizumab therapy than in those undergoing aflibercept therapy. The switching rate was especially higher in PCV patients undergoing ranibizumab therapy.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital (Seoul, South Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided funding for English
   editing support. The sponsor had no role in the design or conduct of
   this research.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P8, DOI 10.1016/j.oret.2018.09.001
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Empeslidis T, 2019, ADV THER, V36, P1532, DOI 10.1007/s12325-019-00971-0
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 42
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2020
VL 258
IS 8
BP 1677
EP 1685
DI 10.1007/s00417-020-04710-y
EA MAY 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MN9RI
UT WOS:000530207200002
PM 32361804
DA 2022-11-30
ER

PT J
AU Su, Y
   Zhang, XZ
   Zuo, CG
   Li, M
   Wu, KF
   Ji, YY
   Wen, F
AF Su, Yu
   Zhang, Xiongze
   Zuo, Chengguo
   Li, Meng
   Wu, Kunfang
   Ji, Yuying
   Wen, Feng
TI Three Variants of or near VEGF-A Gene are Not Associated with
   Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal
   Vasculopathy in a Han Chinese Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Han Chinese population; neovascular age-related macular degeneration;
   polymorphisms; polypoidal choroidal vasculopathy; vascular endothelial
   growth factor A
ID ENDOTHELIAL GROWTH-FACTOR; POLYMORPHISMS; RISK
AB Purpose: To investigate whether three previously identified variants for age-related macular degeneration (AMD), the single nucleotide polymorphism (SNP) variants of or near the vascular endothelial growth factor A gene (VEGFA), were associated with neovascular AMD or polypoidal choroidal vasculopathy (PCV) in a Han Chinese cohort.
   Methods: This was a case-control study comprising 251 PCV patients, 157 neovascular AMD patients, and 204 control participants in a Han Chinese population. The rs833069, rs943080 and rs4711751 SNP were genotyped using the Multiplex SNaPshot system. Genotypes and allele frequencies of patients and controls were evaluated for the SNPs using PLINK software.
   Results: None of the allelic or genotypic effects of these three variants was significantly associated with PCV, neovascular AMD or combined both patient categories.
   Conclusions: No association was found to support the role for the rs833069, rs943080 and rs4711751 variants of or near VEGFA gene in susceptibility to either PCV or neovascular AMD in Han Chinese population. Further replication is necessary to validate these results.
C1 [Su, Yu; Zhang, Xiongze; Zuo, Chengguo; Li, Meng; Wu, Kunfang; Ji, Yuying; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
RI meng, li/GVT-2063-2022
OI Su, Yu/0000-0002-4159-1033
FU National Natural Science Foundation of China [81271011, 81200705];
   Fundamental Research Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China [grant numbers: 81271011 and 81200705] and the Fundamental
   Research Funds of State Key Laboratory of Ophthalmology.
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fang AM, 2009, MOL VIS, V15, P2710
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang YM, 2013, J INT MED RES, V41, P317, DOI 10.1177/0300060513475570
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Li M, 2010, MOL VIS, V16, P231
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Park DH, 2012, JPN J OPHTHALMOL, V56, P145, DOI 10.1007/s10384-012-0119-6
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 30
TC 1
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2015
VL 36
IS 3
BP 218
EP 223
DI 10.3109/13816810.2013.858753
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA CR4UJ
UT WOS:000361334700003
PM 24303777
DA 2022-11-30
ER

PT J
AU Jin, KW
   Kim, JH
   Park, JY
   Park, SJ
   Park, KH
   Lee, JY
   Woo, SJ
AF Jin, Ki Won
   Kim, Jae Hui
   Park, Jun Young
   Park, Sang Jun
   Park, Kyu Hyung
   Lee, Joo Yong
   Woo, Se Joon
TI Long-term outcomes of ranibizumab vs. aflibercept for neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; GROWTH-FACTOR THERAPY; REAL-WORLD
   OUTCOMES; TREAT-AND-EXTEND; INTRAVITREAL RANIBIZUMAB; VEGF-TRAP; TRIAL;
   AMD
AB To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-naive eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort analysis was conducted on data up to 4 years of follow-ups. The primary outcome was the visual acuity (VA) change from baseline. The secondary outcomes included the number of injections, proportion of eyes without a yearly injection, and the number of eyes with treatment switching. Subgroup analyses were performed for typical nAMD and PCV. Typical nAMD was defined as nAMD other than PCV. We included VA-matched 215 eyes of 209 patients (131 and 84 eyes with RBZ and AFL, respectively). The crude mean VA changes from baseline were+6.7 vs.+2.6,+2.1 vs.-0.4,-1.3 vs.-1.8, and-2.2 vs. - 5.0 letters in the RBZ and AFL groups, at 1, 2, 3, and 4 years, respectively (p>0.05). The adjusted predicted VA by linear mixed model, proportion of eyes stratified by VA, and the survival curve for significant vision loss were comparable during the 4-year follow-up (p>0.05). The mean number of injections were similar between the RBZ and AFL groups (2.9 vs. 3.0, respectively, p=0.692). The subgroup analysis for typical nAMD and PCV showed similar results between the groups. The visual outcomes did not differ between RBZ and AFL during 4 years with comparable numbers of injections. Our study reflects the long-term, real-world clinical practice and treatment pattern of two treatments for typical nAMD and PCV.
C1 [Jin, Ki Won; Park, Jun Young; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 173-82 Gumi Ro, Seongnam 13620, Gyeonggi Do, South Korea.
   [Kim, Jae Hui] Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Joo Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); University of Ulsan; Asan Medical
   Center
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 173-82 Gumi Ro, Seongnam 13620, Gyeonggi Do, South Korea.; Lee, JY (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM ophthalmo@amc.seoul.kr; sejoon1@snu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1F1A1072795]; Asan Institute for Life Sciences [2019IP0832-1];
   Asan Medical Center, Republic of Korea
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No. 2020R1F1A1072795)
   and a Grant from Asan Institute for Life Sciences (2019IP0832-1), Asan
   Medical Center, Republic of Korea. The funding organization had no role
   in the design or conduct of this study.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P8, DOI 10.1016/j.oret.2018.09.001
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gayadine-Harricham Y, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7465270
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horner F, 2019, CLIN OPHTHALMOL, V13, P2461, DOI 10.2147/OPTH.S218378
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lukic M, 2021, EUR J OPHTHALMOL, V31, P1940, DOI 10.1177/1120672120938565
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yang BCL, 2019, TAIWAN J OPHTHALMOL, V9, P249, DOI 10.4103/tjo.tjo_34_19
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 44
TC 1
Z9 1
U1 2
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 16
PY 2021
VL 11
IS 1
AR 14623
DI 10.1038/s41598-021-93899-x
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TM1BH
UT WOS:000675288400010
PM 34272419
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ueta, T
   Obata, R
   Inoue, Y
   Iriyama, A
   Takahashi, H
   Yamaguchi, T
   Tamaki, Y
   Yanagi, Y
AF Ueta, Takashi
   Obata, Ryo
   Inoue, Yuji
   Iriyama, Aya
   Takahashi, Hidenori
   Yamaguchi, Takuhiro
   Tamaki, Yasuhiro
   Yanagi, Yasuo
TI Background Comparison of Typical Age-related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy in Japanese Patients
SO OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; BLUE MOUNTAINS EYE; BEAVER-DAM EYE;
   ENDOTHELIAL GROWTH-FACTOR; LONG-TERM INCIDENCE; BODY-MASS INDEX;
   RISK-FACTORS; CATARACT-SURGERY; CLINICAL CHARACTERISTICS; PHOTODYNAMIC
   THERAPY
AB Objective: To compare background factors of the 2 most dominant subtypes of exudative age-related macular degeneration (AMD) in the Japanese population: typical AMD and polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional comparison.
   Participants: Consecutive patients with typical AMD (n = 89) and PCV (n = 138) for the primary survey. For the secondary survey, the number of participants was extended to include 148 typical AMD and 170 PCV patients. All the patients included in the present study had been followed up at The University of Tokyo Hospital outpatient macular clinic.
   Methods: Background data on gender; age; body mass index; smoking; alcohol consumption; and histories of hypertension, diabetes mellitus (DM), hyperlipidemia, ischemic heart disease, stroke, intensive light exposure, central serous chorioretinopathy (CSC), cataract surgery, glaucoma, and steroid use were obtained mainly through interview. The interviewers were masked to the subtype diagnosis of AMD. Univariate and multivariate logistic regression analyses were performed to identify differences in the background factors between typical AMD and PCV. In the secondary survey, the association of a history of CSC and PCV was confirmed further, and funduscopic findings of an atrophic retinal pigment epithelial (RIDE) tract and focal photocoagulation scars that could indicate a history of CSC were investigated.
   Main Outcome Measures: Frequency and mean of background factors inpatients with typical AMD or PCV.
   Results: The 2 groups showed similar backgrounds with the exception of their histories of DM and CSC. A history of DM was more frequent in typical AMD (24.7% vs. 13.0% in the primary survey; P = 0.027), whereas a history of CSC was more prevalent in PCV (3.4% vs. 14.7% in the secondary survey; P = 0.0005). Funduscopic findings of an atrophic RPE tract or focal photocoagulation scars were found more frequently in PCV (0.7% vs. 7.6%; P = 0.002).
   Conclusions: Background factors of typical AMD and PCV are similar but not identical. A history of DM and CSC are more frequent in typical AMD and PCV, respectively.
C1 [Ueta, Takashi] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Yamaguchi, Takuhiro] Univ Tokyo, Grad Sch Med, Dept Clin Trial Data Management, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo
RP Ueta, T (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM ueta-tky@umin.ac.jp
RI Takahashi, Hidenori/H-2945-2019; Yanagi, Yasuo/AAA-5441-2022; Yanagi,
   Yasuo/AAF-2670-2020
OI Takahashi, Hidenori/0000-0001-5331-4730; Obata, Ryo/0000-0002-1762-0797;
   Yanagi, Yasuo/0000-0002-0362-7285
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Chiyoda-ku, Tokyo, Japan
FX Supported in part by a Grant-in-Aid from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan. Chiyoda-ku, Tokyo,
   Japan.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haimovici R, 1997, OPHTHALMOLOGY, V104, P1653, DOI 10.1016/S0161-6420(97)30082-7
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klais CM, 2006, RETINA, V2, P1135, DOI DOI 10.1016/B978-0-323-02598-0.50069-02-S2.0-84917282576
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   OHMURA T, 1993, DIABETOLOGIA, V36, P1198, DOI 10.1007/BF00401066
   Pizzimenti JJ, 2005, PHARMACOTHERAPY, V25, P1141, DOI 10.1592/phco.2005.25.8.1141
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   SPAIDE RF, 1996, OPHTHALMOLOGY, V103, P2079
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yap EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P689, DOI 10.1001/archopht.1996.01100130681007
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 46
TC 66
Z9 71
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2009
VL 116
IS 12
BP 2400
EP 2406
DI 10.1016/j.ophtha.2009.06.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530HE
UT WOS:000272579200021
PM 19815291
DA 2022-11-30
ER

PT J
AU Park, DH
   Shin, JP
   Kim, IT
AF Park, Dong Ho
   Shin, Jae Pil
   Kim, In Taek
TI ASSOCIATION OF PLASMA MALONDIALDEHYDE WITH ARMS2 GENETIC VARIANTS AND
   PHENOTYPES IN POLYPOIDAL CHOROIDAL VASCULOPATHY AND AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; ARMS2; PCV; plasma MDA
ID LIPID-PEROXIDATION; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION;
   NITRIC-OXIDE; JAPANESE; HTRA1; SUSCEPTIBILITY; ANTIOXIDANTS;
   INFLAMMATION; POLYMORPHISM
AB Purpose: To evaluate the relationships between plasma malondialdehyde (MDA) level and ARMS2 variants and phenotypes in patients with polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD).
   Methods: This study is a retrospective case-control study. Plasma MDA was measured in 84 controls, 62 patients with PCV, and 42 patients with nAMD. Participants were genotyped for ARMS2 polymorphism. Phenotypes including bilaterality and greatest linear dimension based on fluorescein angiography (FA-GLD) and indocyanine green angiography (ICGA-GLD), were evaluated.
   Results: Plasma MDA in the PCV and nAMD groups was higher than in the control group (P < 0.001, respectively). For ARMS2 variants, plasma MDA of homozygous high-risk genotype (TT) was higher than that of homozygous low-risk genotype (GG) in all groups (P < 0.001, respectively). Plasma MDA was higher in homozygous high-risk genotype than in heterozygous genotype in the control, PCV, and nAMD groups (P = 0.021, 0.002, and 0.004, respectively). In the nAMD group, there was a correlation between plasma MDA and both FA-GLD (r = 0.418, P = 0.006) and ICGA-GLD (r = 0.329, P = 0.033). There was a difference in plasma MDA between patients with unilateral and bilateral lesions in both PCV and nAMD (P = 0.017 and 0.019, respectively).
   Conclusion: This study revealed significant relationships between the plasma MDA level and ARMS2 variants and phenotypes in PCV and nAMD.
C1 [Park, Dong Ho; Shin, Jae Pil; Kim, In Taek] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Taegu 700721, South Korea.
C3 Kyungpook National University
RP Park, DH (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, 50 Samduk Dong 2 Ga, Taegu 700721, South Korea.
EM sarasate2222@gmail.com
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology [2012004585]; Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea [A111345]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education,
   Science and Technology (2012004585) and by the Korea Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345).
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Harman D, 1998, ANN NY ACAD SCI, V854, P1, DOI 10.1111/j.1749-6632.1998.tb09886.x
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   Suzuki M, 2007, MOL VIS, V13, P772
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Winkler BS, 1999, MOL VIS, V5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 45
TC 5
Z9 5
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1167
EP 1176
DI 10.1097/IAE.0000000000000047
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GP
UT WOS:000337149000019
PM 24240564
DA 2022-11-30
ER

PT J
AU Chen, XL
   Hu, QR
   Bai, YJ
   Deng, Y
   Wang, HW
   Liu, S
   Wang, YL
   Yue, YK
AF Chen, Xiao-Li
   Hu, Qin-Rui
   Bai, Yu-Jing
   Deng, Yu
   Wang, Hai-Wei
   Liu, Shan
   Wang, Yin-Lin
   Yue, Yan-Kun
TI A comparison of risk factors for age-related macular degeneration and
   polypoidal choroidal vasculopathy in Chinese patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Risk factor; Asthma; Hyperlipidemia
ID MACULOPATHY; PREVALENCE; POPULATION; DISEASE; EVEREST
AB Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are important vision-threatening diseases worldwide. For effective treatment, the risk factors for the diseases merit investigation. This study aimed to compare the risk factors for nAMD vs. PCV in Chinese patients.
   A total of 946 participants were recruited in this case-control study, including 281 patients with nAMD, 306 patients with PCV, and 359 controls. All participants underwent comprehensive ophthalmic examinations. Information on risk factors were collected by questionnaire. Multivariate logistic regression analyses were performed to investigate the difference in risk factors between nAMD and PCV. In a subgroup of subjects, serum lipid data were obtained and analyzed.
   Risk factors for nAMD included older age (OR 1.03, P = 0.001), male gender (OR 1.55, P = 0.020), asthma (OR 2.50, P = 0.028), smoking (OR 1.92, P = 0.001), and family history (OR 6.82, P = 0.001), while smoking (OR 1.67, P = 0.013) was the only risk factor for PCV. Compared to patients with PCV, patients with nAMD were more likely to be older and suffer from hyperlipidemia, coronary artery disease, rheumatism, and tumor. Interestingly, higher levels of high-density lipoprotein were positively associated with PCV in the subgroup analysis (OR 7.74, P = 0.011). Besides, results were quite different between the combination of patients with nAMD and PCV and patients with nAMD or PCV alone.
   The risk factors for nAMD and PCV is varying with the exception of smoking. Our findings suggest that different strategies might be applied in the clinical management and scientific research on nAMD and PCV.
C1 [Chen, Xiao-Li; Deng, Yu; Wang, Hai-Wei; Liu, Shan; Wang, Yin-Lin; Yue, Yan-Kun] Capital Med Univ, Fuxing Hosp, Dept Ophthalmol, 20 St FuXingMenWai, Beijing 100038, Peoples R China.
   [Hu, Qin-Rui] Xiamen Univ, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiamen Eye Ctr, Eye Inst,Med Coll, Xiamen, Fujian, Peoples R China.
   [Bai, Yu-Jing] ShenZhen Sibion Co Ltd, Shenzhen, Peoples R China.
C3 Capital Medical University; Xiamen University
RP Yue, YK (通讯作者)，Capital Med Univ, Fuxing Hosp, Dept Ophthalmol, 20 St FuXingMenWai, Beijing 100038, Peoples R China.
EM fuxingyk@sina.com
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Srinivasan S, 2017, EYE, V31, P846, DOI 10.1038/eye.2017.72
   Sun YB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037178
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 41
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2018
VL 256
IS 8
BP 1449
EP 1457
DI 10.1007/s00417-018-4020-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM8AY
UT WOS:000438426900010
PM 29858677
DA 2022-11-30
ER

PT J
AU Ozawa, S
   Ishikawa, K
   Ito, Y
   Nishihara, H
   Yamakoshi, T
   Hatta, Y
   Terasaki, H
AF Ozawa, Shinsuke
   Ishikawa, Kohei
   Ito, Yasuki
   Nishihara, Hiroaki
   Yamakoshi, Tomomi
   Hatta, Yoshiyuki
   Terasaki, Hiroko
TI DIFFERENCES IN MACULAR MORPHOLOGY BETWEEN POLYPOIDAL CHOROIDAL
   VASCULOPATHY AND EXUDATIVE AGE-RELATED MACULAR DEGENERATION DETECTED BY
   OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; macular morphology; optical coherence
   tomography; polypoidal choroidal vasculopathy; serous retinal detachment
ID RETINAL THICKNESS; LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY;
   VISUAL-ACUITY; NEOVASCULARIZATION; BEVACIZUMAB; FEATURES
AB Purpose: To evaluate the differences in the optical coherence tomographically determined macular morphology in eyes with polypoidal choroidal vasculopathy (PCV) from eyes with exudative age-related macular degeneration (AMD) quantitatively.
   Methods: The medical records of 208 eyes of 203 Japanese patients with PCV or exudative AMD who were newly treated for choroidal neovascularization were reviewed. The six linear, low-resolution, high-speed scans of 6 mm were analyzed using a manually assisted computer algorithm, which allowed us to manually draw spline lines arbitrarily on the images so that the subretinal fluid and neurosensory retina could be segmented. The thickness of the neurosensory retina and height of the serous retinal detachment (SRD) within the central 3-mm and 6-mm areas were calculated.
   Results: SRDs were observed in 53% (63/119) of the eyes with exudative AMD and in 78% (69/89) of the eyes with PCV (P < 0.001). The height of the SRD was 21.9 +/- 3.7 mu m (+/- SEMs) in eyes with exudative AMD and 56.3 +/- 7.4 mu m in eyes with PCV (P < 0.001). The thickness of the neurosensory retina was 300.0 +/- 5.2 mu m in eyes with exudative AMD and 275.8 +/- 4.7 mu m in eyes with PCV (P < 0.001).
   Conclusion: Eyes with PCV are characterized by a higher incidence of SRDs, greater SRD height, and less intraretinal edema than eyes with exudative AMD. RETINA 29:793-802, 2009
C1 [Ishikawa, Kohei] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Ishikawa, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM kohei@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Terasaki, Hiroko/M-5054-2014
OI Ito, Yasuki/0000-0001-9219-9261; 
FU Ministry of Education, Science, Sports and Culture, Japan [18791272,
   19500416, 16390497, 18390466]
FX Supported by Grants-in-Aid for Scientific Research (18791272, 19500416,
   16390497, and 18390466) from the Ministry of Education, Science, Sports
   and Culture, Japan.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ishikawa K, 2008, JPN J OPHTHALMOL, V52, P182, DOI 10.1007/s10384-008-0528-8
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singerman Lawrence J, 2005, Retina, V25, pS1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 34
Z9 37
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP 793
EP 802
DI 10.1097/IAE.0b013e3181a3b7d9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HS
UT WOS:000267496600009
PM 19516119
DA 2022-11-30
ER

PT J
AU Liang, XY
   Chen, LJ
   Ng, TK
   Tuo, J
   Gao, JL
   Tam, POS
   Lai, TYY
   Chan, CC
   Pang, CP
AF Liang, X. Y.
   Chen, L. J.
   Ng, T. K.
   Tuo, J.
   Gao, J-L
   Tam, P. O. S.
   Lai, T. Y. Y.
   Chan, C-C
   Pang, C. P.
TI FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related
   macular degeneration and polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
ID FORMYL PEPTIDE RECEPTOR; PIGMENT EPITHELIAL-CELLS; FORMYLPEPTIDE
   RECEPTOR; BRUCHS MEMBRANE; FUNCTIONAL DOMAINS; ALZHEIMERS-DISEASE;
   ASSOCIATION; POLYMORPHISMS; INFLAMMATION; CHEMOTAXIS
AB Purpose To determine the genetic association of an inflammation-related gene, formyl peptide receptor 1 (FPR1), in exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Methods The coding region of FPR1 gene was sequenced in 554 unrelated Chinese individuals: 155 exudative AMD patients, 179 PCV patients, and 220 controls. Interactions and combined effects of FPR1 with complement factor H (CFH), high temperature requirement factor A1 (HTRA1), and smoking were also investigated. Results A total of 28 polymorphisms in FPR1 were identified. Single nucleotide polymorphisms (SNP) rs78488639 increased the risk to exudative AMD (P = 0.043) and PCV (P = 0.016), whereas SNP rs867229 decreased the risk to exudative AMD (P = 0.0026), but not PCV. Homozygous G allele of rs1042229 was associated with exudative AMD (P = 0.0394, odds ratio (OR) = 2.27, 95% confident interval: 1.08-4.74), but not with PCV. Exudative AMD, but not PCV, was associated with the heterozygous genotypes of rs2070746 (P = 0.019, OR = 0.57) and rs867229 (P = 0.0082, OR = 0.54).
   Significantly, interactions were identified among FPR1 rs78488639, CFH rs800292, and HTRA1 rs11200638 in both exudative AMD and PCV. Combined heterozygous risk alleles of CFH rs800292 GA and FPR1 rs78488639 CA were posed to PCV (P = 2.22 x 10(-4), OR = 10.47), but not exudative AMD. Furthermore, FPR1 rs78488639 CA combining with HTRA1 rs11200638 and smoking was also predisposed risks to exudative AMD and PCV.
   Conclusion FPR1 is associated with exudative AMD and PCV in a Hong Kong Chinese cohort. FPR1 rs78488639 interacted with CFH rs800292, HTRA1 rs11200638, and smoking, enhancing risk to exudative AMD and PCV.
C1 [Liang, X. Y.; Chen, L. J.; Ng, T. K.; Tam, P. O. S.; Lai, T. Y. Y.; Pang, C. P.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
   [Tuo, J.; Chan, C-C] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Gao, J-L] NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
C3 Chinese University of Hong Kong; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); National Institutes of Health
   (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases
   (NIAID)
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 4-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Ng, Tsz Kin/I-8061-2014; Lai, Timothy Y Y/AAC-2120-2020; Gao,
   Ji-Liang/Y-4397-2019; Chen, Li Jia/I-5078-2014
OI Ng, Tsz Kin/0000-0001-7863-7229; Lai, Timothy Y Y/0000-0002-7832-6428;
   Chen, Li Jia/0000-0003-3500-5840
FU Endowment Fund for Lim Por-Yen Eye Genetics Research Centre; Chinese
   University of Hong Kong; General Research Fund from the Research Grants
   Council, Hong Kong [473410]; NATIONAL EYE INSTITUTE [ZIAEY000418]
   Funding Source: NIH RePORTER
FX We express our greatest appreciation to all the study participants. This
   study was supported in part by the Endowment Fund for Lim Por-Yen Eye
   Genetics Research Centre, the Chinese University of Hong Kong and the
   General Research Fund from the Research Grants Council (grant number
   473410), Hong Kong.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042
   Benachour H, 2009, PHARMACOGENOMICS, V10, P951, DOI [10.2217/pgs.09.29, 10.2217/PGS.09.29]
   Bhattacharya M, 2007, PHARMACOGENOMICS J, V7, P190, DOI 10.1038/sj.tpj.6500416
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boxer LA, 1979, J LAB CLIN MED
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen LJ, 2006, MOL VIS, V12, P1536
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GAO JL, 1993, J BIOL CHEM, V268, P25395
   Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657
   Gwinn MR, 1999, J PERIODONTOL, V70, P1194, DOI 10.1902/jop.1999.70.10.1194
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAVILAND DL, 1993, BIOCHEMISTRY-US, V32, P4168, DOI 10.1021/bi00067a003
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janetopoulos C, 2008, FEBS LETT, V582, P2075, DOI 10.1016/j.febslet.2008.04.035
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5
   Le YY, 2005, FEBS J, V272, P769, DOI 10.1111/j.1742-4658.2004.04514.x
   LEHMEYER JE, 1979, BLOOD, V54, P35
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maney P, 2009, J PERIODONTOL, V80, P1498, DOI 10.1902/jop.2009.090103
   Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Ng TK, 2012, ASIA-PAC J OPHTHALMO, V1, P51, DOI 10.1097/APO.0b013e31823e57fe
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PEREZ HD, 1993, J BIOL CHEM, V268, P2292
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
NR 51
TC 19
Z9 20
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2014
VL 28
IS 12
BP 1502
EP 1510
DI 10.1038/eye.2014.226
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6FQ
UT WOS:000346365600015
PM 25277308
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Iejima, D
   Itabashi, T
   Kawamura, Y
   Noda, T
   Yuasa, S
   Fukuda, K
   Oka, C
   Iwata, T
AF Iejima, Daisuke
   Itabashi, Takeshi
   Kawamura, Yuich
   Noda, Toru
   Yuasa, Shinsuke
   Fukuda, Keiichi
   Oka, Chio
   Iwata, Takeshi
TI HTRA1 (High Temperature Requirement A Serine Peptidase 1) Gene Is
   Transcriptionally Regulated by Insertion/Deletion Nucleotides Located at
   the 3 ' End of the ARMS2 (Age-related Maculopathy Susceptibility 2) Gene
   in Patients with Age-related Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE DNA-binding Protein; Photoreceptor; Retina; Retinal Degeneration;
   Transcription Regulation; ARMS2; EMSA; HTRA1; Age-related Macular
   Degeneration
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PROTEASE; EXPRESSION;
   DIFFERENTIATION; OVEREXPRESSION; POLYMORPHISM; VARIANT
AB Background: The biological function of insertion/deletion sequences associated with AMD has not been fully characterized. Results: The HTRA1 regulatory region contains an insertion/deletion sequence that is significantly up-regulated in retinal neuronal cell lines. Conclusion:HTRA1 expression is enhanced by a mutation in the insertion/deletion in the HTRA1 regulatory region. Significance: This is the characterization of the HTRA1 regulatory elements and the effect of insertion/deletion sequences associated with AMD.
   Dry age-related macular degeneration (AMD) accounts for over 85% of AMD cases in the United States, whereas Japanese AMD patients predominantly progress to wet AMD or polypoidal choroidal vasculopathy. Recent genome-wide association studies have revealed a strong association between AMD and an insertion/deletion sequence between the ARMS2 (age-related maculopathy susceptibility 2) and HTRA1 (high temperature requirement A serine peptidase 1) genes. Transcription regulator activity was localized in mouse retinas using heterozygous HtrA1 knock-out mice in which HtrA1 exon 1 was replaced with -galactosidase cDNA, thereby resulting in dominant expression of the photoreceptors. The insertion/deletion sequence significantly induced HTRA1 transcription regulator activity in photoreceptor cell lines but not in retinal pigmented epithelium or other cell types. A deletion construct of the HTRA1 regulatory region indicated that potential transcriptional suppressors and activators surround the insertion/deletion sequence. Ten double-stranded DNA probes for this region were designed, three of which interacted with nuclear extracts from 661W cells in EMSA. Liquid chromatography-mass spectrometry (LC-MS/MS) of these EMSA bands subsequently identified a protein that bound the insertion/deletion sequence, LYRIC (lysine-rich CEACAM1 co-isolated) protein. In addition, induced pluripotent stem cells from wet AMD patients carrying the insertion/deletion sequence showed significant up-regulation of the HTRA1 transcript compared with controls. These data suggest that the insertion/deletion sequence alters the suppressor and activator cis-elements of HTRA1 and triggers sustained up-regulation of HTRA1. These results are consistent with a transgenic mouse model that ubiquitously overexpresses HtrA1 and exhibits characteristics similar to those of wet AMD patients.
C1 [Iejima, Daisuke; Itabashi, Takeshi; Kawamura, Yuich; Iwata, Takeshi] Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Tokyo 1528902, Japan.
   [Noda, Toru] Natl Hosp Org Tokyo Med Ctr, Div Ophthalmol, Tokyo 1528902, Japan.
   [Yuasa, Shinsuke; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo 1608582, Japan.
   [Oka, Chio] Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan.
C3 Keio University; Nara Institute of Science & Technology
RP Iwata, T (通讯作者)，Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Tokyo 1528902, Japan.
EM takeshi_iwata@kankakuki.go.jp
RI Fukuda, Keiichi/L-3777-2013
OI Yuasa, Shinsuke/0000-0001-5593-7552; Itabashi,
   Takeshi/0000-0002-2222-3446
FU Japanese Ministry of Health, Labor, and Welfare [10103254]; National
   Hospital Organization of Japan [09005752]; Japan Society for the
   Promotion of Science [23890258]
FX This work was supported by Japanese Ministry of Health, Labor, and
   Welfare Grant 10103254 and National Hospital Organization of Japan Grant
   09005752 (to T. I.). This work was also supported by Japan Society for
   the Promotion of Science Grant 23890258 (to D. I.).
CR Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Domigan CK, 2014, CELL, V159, P473, DOI 10.1016/j.cell.2014.10.008
   Ferrer-Vaquer A, 2008, DEV DYNAM, V237, P1893, DOI 10.1002/dvdy.21597
   Foucaud-Scheunemann C, 2003, FEMS MICROBIOL LETT, V224, P53, DOI 10.1016/S0378-1097(03)00419-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hansen G, 2013, CELL MOL LIFE SCI, V70, P761, DOI 10.1007/s00018-012-1076-4
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Huang Y, 2014, ONCOL LETT, V8, P493, DOI 10.3892/ol.2014.2231
   Jiang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046058
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Minegishi Y, 2013, HUM MOL GENET, V22, P3559, DOI 10.1093/hmg/ddt210
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Noch E, 2011, CANCER BIOL THER, V11, P32, DOI 10.4161/cbt.11.1.13835
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Robertson CL, 2014, CANCER RES, V74, P6184, DOI 10.1158/0008-5472.CAN-14-1357
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seki T, 2010, CELL STEM CELL, V7, P11, DOI 10.1016/j.stem.2010.06.003
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Tu ZD, 2011, J NEUROIMMUNOL, V230, P183, DOI 10.1016/j.jneuroim.2010.07.022
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wu XH, 2014, FEBS LETT, V588, P143, DOI 10.1016/j.febslet.2013.11.022
   Xu YQ, 2014, J CELL BIOCHEM, V115, P1112, DOI 10.1002/jcb.24751
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhu F, 2010, HEPATOB PANCREAT DIS, V9, P508
NR 40
TC 16
Z9 18
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 30
PY 2015
VL 290
IS 5
BP 2784
EP 2797
DI 10.1074/jbc.M114.593384
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CB0JA
UT WOS:000349310700020
PM 25519903
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Baek, J
   Lee, JH
   Jung, BJ
   Kook, L
   Lee, WK
AF Baek, Jiwon
   Lee, Jae Hyung
   Jung, Byung Joo
   Kook, Lee
   Lee, Won Ki
TI Morphologic features of large choroidal vessel layer: age-related
   macular degeneration, polypoidal choroidal vasculopathy, and central
   serous chorioretinopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Large choroidal vessel (Haller vessel); Pachyvessel; Age-related macular
   degeneration; Polypoidal choroidal vasculopathy; Central serous
   chorioretinopathy; Pachychoroid
ID OPTICAL COHERENCE TOMOGRAPHY; PACHYCHOROID NEOVASCULOPATHY; VORTEX VEIN;
   THICKNESS; EYES; SEX
AB PurposeTo compare choroidal vascular characteristics of age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy (CSC) by qualitative and quantitative analyses using swept-source en face optical coherence tomographic (OCT) images.MethodsEyes with non-neovascular AMD (n=32), neovascular AMD (n=30), thick and thin choroid PCV (n=33 and 27), and CSC (n=34) were enrolled. Subfoveal choroidal thickness (SFCT) and the presence and patterns of pachyvessels were assessed. En face images of the large choroidal vessel layer were converted to binary images for the analysis of vascular density.ResultsPachyvessels were identified in 8 (25%), 14 (46%), 28 (85%), 26 (96%), and 34 (100%) non-neovascular AMD, neovascular AMD, thin choroid PCV, thick choroid PCV, and CSC eyes, respectively (P<0.001). The pattern of pachyvessels was focal in non-neovascular AMD (100%), neovascular AMD (79%), and thin choroid PCV (89%) while the pattern was mostly diffuse in CSC (88%) and thick choroid PCV (81%). The mean choroidal vascular density in a 6x6mm(2) macular area of each group was 45.3%, 46.9%, 47.0%, 52.5%, and 54.8%, respectively (P<0.001). Post hoc analysis revealed significantly higher vascular density in CSC compared with other types (all P<0.001) except PCV with thick choroid (P=0.066).ConclusionsSimilarities in vascular density of the large choroidal vessel layer and pachyvessel pattern were between CSC and thick choroid PCV and between AMD and thin choroid PCV, suggesting common pathophysiology involving choroidal changes in these eyes.
C1 [Baek, Jiwon] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Ophthalmol, Bucheon, South Korea.
   [Lee, Jae Hyung; Jung, Byung Joo; Kook, Lee; Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, 222 Banpodae Ro, Seoul 06591, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, 222 Banpodae Ro, Seoul 06591, South Korea.
EM wklee@catholic.ac.kr
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   Fujiwara A, 2016, AM J OPHTHALMOL, V170, P1, DOI 10.1016/j.ajo.2016.07.006
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Gupta MP, 2016, CLIN OPHTHALMOL, V10, P1275, DOI 10.2147/OPTH.S105080
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P4811, DOI 10.1167/iovs.14-14447a
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   Yu PK, 2013, EXP EYE RES, V115, P144, DOI 10.1016/j.exer.2013.07.006
NR 27
TC 49
Z9 50
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2018
VL 256
IS 12
BP 2309
EP 2317
DI 10.1007/s00417-018-4143-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ4RZ
UT WOS:000449389300005
PM 30259090
DA 2022-11-30
ER

PT J
AU Baradaran-Rafii, A
   Sarvari, M
   Alavi-Moghadam, S
   Payab, M
   Goodarzi, P
   Aghayan, HR
   Larijani, B
   Rezaei-Tavirani, M
   Biglar, M
   Arjmand, B
AF Baradaran-Rafii, Alireza
   Sarvari, Masoumeh
   Alavi-Moghadam, Sepideh
   Payab, Moloud
   Goodarzi, Parisa
   Aghayan, Hamid Reza
   Larijani, Bagher
   Rezaei-Tavirani, Mostafa
   Biglar, Mahmood
   Arjmand, Babak
TI Cell-based approaches towards treating age-related macular degeneration
SO CELL AND TISSUE BANKING
LA English
DT Review
DE Age-related macular degeneration; Animal models; Cell therapy; Clinical
   trials
ID RETINAL-PIGMENT EPITHELIUM; MESENCHYMAL STEM-CELLS; ANIMAL-MODELS;
   STARGARDT DISEASE; THERAPY; TRANSPLANTATION; SUSCEPTIBILITY; MECHANISMS;
   SMOKING; VISION
AB Age-related macular degeneration as one of the most common causes of worldwide vision loss needs a proper approach for treatment. Therein, cell therapy and regenerative medicine can hold a great promise to be an effective approach. Accordingly, some preclinical and clinical studies were conducted to search around the therapeutic influence of stem cells in Age-related macular degeneration models and subjects. Hereupon, the purpose of the current review is to discuss the mechanisms of age-related macular degeneration, appropriate animal models along with suitable dosage and route of stem cell administration for its treatment.
C1 [Baradaran-Rafii, Alireza] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Baradaran-Rafii, Alireza] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Sarvari, Masoumeh; Alavi-Moghadam, Sepideh; Aghayan, Hamid Reza; Arjmand, Babak] Univ Tehran Med Sci, Cell Therapy & Regenerat Med Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran.
   [Payab, Moloud] Univ Tehran Med Sci, Obes & Eating Habits Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran.
   [Goodarzi, Parisa] Univ Tehran Med Sci, Brain & Spinal Cord Injury Res Ctr, Neurosci Inst, Tehran, Iran.
   [Larijani, Bagher; Biglar, Mahmood] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran.
   [Rezaei-Tavirani, Mostafa] Shahid Beheshti Univ Med Sci, Prote Res Ctr, Tehran, Iran.
   [Arjmand, Babak] Univ Tehran Med Sci, Metabol & Genom Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Tehran University of Medical Sciences; Tehran
   University of Medical Sciences; Tehran University of Medical Sciences;
   Tehran University of Medical Sciences; Shahid Beheshti University
   Medical Sciences; Tehran University of Medical Sciences
RP Arjmand, B (通讯作者)，Univ Tehran Med Sci, Cell Therapy & Regenerat Med Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran.
EM alirbr@gmail.com; maasoomehsarvari@yahoo.com; sepidalavi@gmail.com;
   Moloudpayab@gmail.com; pr_goodarzi@yahoo.com; hr.aghayan@gmail.com;
   emrc@tums.ac.ir; Tavirany@yahoo.com; m.bigl@gmail.com;
   arjmand_itb@yahoo.com
RI larijani, Bagher/ABE-3315-2020; Arjmand, babak/AAS-3830-2020; Aghayan,
   Hamid Reza/I-5413-2017
OI larijani, Bagher/0000-0001-5386-7597; Arjmand,
   babak/0000-0001-5001-5006; Aghayan, Hamid Reza/0000-0002-8348-1449
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00115
   Aziz K., 2019, CELL BASED THERAPY D, P245
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Council NR, 2006, OVERCOMING CHALLENGE
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Darbre PD, 1988, INTRO PRACTICAL MOL
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Denayer T, 2014, NEW HORIZ TRANSL MED, V2, P5, DOI 10.1016/j.nhtm.2014.08.001
   Djulbegovic B, 2007, J MED PHILOS, V32, P79, DOI 10.1080/03605310701255719
   Ebersberger I, 2002, AM J HUM GENET, V70, P1490, DOI 10.1086/340787
   Fox IJ, 2014, SCIENCE, V345, P889, DOI 10.1126/science.1247391
   Goodarzi P, 2019, CELL TISSUE BANK, V20, P141, DOI 10.1007/s10561-019-09773-8
   Goodarzi P, 2018, ADV EXP MED BIOL, V1119, P119, DOI 10.1007/5584_2018_251
   Goodarzi Parisa, 2015, Med J Islam Repub Iran, V29, P168
   Goodarzi Parisa, 2014, Acta Med Iran, V52, P651
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Guan Y, 2013, CURR MOL MED, V13, P1419
   He YX, 2014, INT J MOL SCI, V15, P14456, DOI 10.3390/ijms150814456
   HELD JR, 1983, ANN NY ACAD SCI, V406, P13, DOI 10.1111/j.1749-6632.1983.tb53481.x
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Hubrecht RC, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9100754
   Humphray SJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r139
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Immonen IJ, 2009, INVEST OPHTH VIS SCI, V50, P714
   Isasi R, 2016, APPL TRANSL GENOM, V11, P27, DOI 10.1016/j.atg.2016.11.001
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jian Q, 2015, EXP EYE RES, V132, P34, DOI 10.1016/j.exer.2015.01.008
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Krause M, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00656
   Larijani BP, 2019, CELL BIOL TRANSLATIO
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Liu YF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4598167
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   MacPherson A, 2019, NAT MED, V25, P1037, DOI 10.1038/s41591-019-0511-6
   Middleton S, 2010, VET CLIN N AM-FOOD A, V26, P557, DOI 10.1016/j.cvfa.2010.09.002
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Mustari MJ, 2017, ILAR J, V58, P216, DOI 10.1093/ilar/ilx009
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oner A, 2018, TURK OFTALMOL DERG, V48, P33, DOI 10.4274/tjo.89972
   Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev-bioeng-070909-105309
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rabadan-Diehl C, 2013, J DEV ORIG HLTH DIS, V4, P3, DOI 10.1017/S2040174412000487
   Riva L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02154-5
   Rowe-Rendleman C, 2004, BRAIN RES BULL, V62, P549, DOI 10.1016/S0361-9230(03)00072-8
   Schleidgen S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2688-z
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2010, MOL VIS, V16, P2412
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sharma A, 2020, EYE, V34, P1310, DOI 10.1038/s41433-020-0831-2
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Singh MS, 2018, INVEST OPHTH VIS SCI, V59, pAMD78, DOI 10.1167/iovs.18-24426
   Siqueira RC, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt91
   Soleimani M, 2016, ARCH NEUROSCI, V3, DOI 10.5812/archneurosci.21564
   Stein G, 2018, NEXT GENERATION THER
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sugitani S, 2013, EXP EYE RES, V116, P254, DOI 10.1016/j.exer.2013.09.013
   Sun YD, 2012, ANN NUTR METAB, V60, P293, DOI 10.1159/000338444
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tsuruma K, 2014, STEM CELL TRANSL MED, V3, P42, DOI 10.5966/sctm.2013-0020
   Twigger Simon N, 2004, Genome Biol, V5, P314, DOI 10.1186/gb-2004-5-3-314
   Vazquez-Chona FR, 2005, MOL VIS, V11, P958
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zernii EY, 2016, CNS NEUROL DISORD-DR, V15, P267, DOI 10.2174/1871527315666151110124957
NR 84
TC 11
Z9 11
U1 3
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1389-9333
EI 1573-6814
J9 CELL TISSUE BANK
JI Cell Tissue Banking
PD SEP
PY 2020
VL 21
IS 3
BP 339
EP 347
DI 10.1007/s10561-020-09826-3
EA MAR 2020
PG 9
WC Cell Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA NF2PP
UT WOS:000562572600001
PM 32157501
DA 2022-11-30
ER

PT J
AU Mucciolo, DP
   Marcucci, R
   Sodi, A
   Cesari, F
   Murro, V
   Rogolino, A
   Rizzo, S
   Giusti, B
   Virgili, G
   Prisco, D
   Gori, AM
AF Mucciolo, Dario Pasquale
   Marcucci, Rossella
   Sodi, Andrea
   Cesari, Francesca
   Murro, Vittoria
   Rogolino, Angela
   Rizzo, Stanislao
   Giusti, Betti
   Virgili, Gianni
   Prisco, Domenico
   Gori, Anna Maria
TI Circulating endothelial and progenitor cells in age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; endothelial progenitor cells;
   circulating endothelial cells; ranibizumab
ID HEMATOPOIETIC STEM-CELLS; GROWTH-FACTOR; ANTI-VEGF; CHOROIDAL
   NEOVASCULARIZATION; CARDIOVASCULAR EVENTS; PLASMA-LEVELS; RANIBIZUMAB;
   BEVACIZUMAB; VASCULOGENESIS; RECRUITMENT
AB Purpose: To evaluate circulating endothelial and circulating progenitor cells as biomarkers in age-related macular degeneration patients (both exudative and atrophic forms) in order to establish the possible clinical implication of their assessment. Methods: We have enrolled 44 age-related macular degeneration patients: 22 patients with a recently diagnosed exudative (neovascular) form (Group A) and 22 patients with an atrophic (dry) form (Group B). The control group consisted of 22 age and sex-matched healthy subjects (Group C). The number of circulating endothelial progenitor cells (CD34+/KDR+, CD133+/KDR+, and CD34+/KDR+/CD133+), circulating progenitor cells (CD34+, CD133+, and CD34+/CD133+), and circulating endothelial cells were determined in the peripheral venous blood samples by flow cytometry. Neovascular age-related macular degeneration patients were evaluated at baseline and 4 weeks after a loading phase of three consequent intravitreal injections of ranibizumab. Results: Comparing age-related macular degeneration patients with the control group, endothelial progenitor cell and circulating progenitor cell levels were not significantly different, while age-related macular degeneration patients showed significantly higher levels of circulating endothelial cells (p = 0.001). Anti-vascular endothelial growth factor treatment with intravitreal ranibizumab was associated with a significant reduction of endothelial progenitor cell levels, with no significant influence on circulating progenitor cells and circulating endothelial cells. Conclusion: We reported higher levels of circulating endothelial cells in age-related macular degeneration patients in comparison with the control group, thereby supporting the hypothesis of an involvement of endothelial dysregulation in the age-related macular degeneration and a reduction of the endothelial progenitor cell level in neovascular age-related macular degeneration patients after three intravitreal injections of ranibizumab.
C1 [Mucciolo, Dario Pasquale; Sodi, Andrea; Murro, Vittoria; Rizzo, Stanislao; Virgili, Gianni] Univ Florence, Careggi Teaching Hosp, Dept Neurosci Psychol Drug Res & Child Hlth, Largo Brambilla 3, I-50134 Florence, Italy.
   [Marcucci, Rossella; Cesari, Francesca; Rogolino, Angela; Giusti, Betti; Prisco, Domenico; Gori, Anna Maria] Univ Florence, Dept Expt & Clin Med, Florence, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi;
   University of Florence
RP Mucciolo, DP (通讯作者)，Univ Florence, Careggi Teaching Hosp, Dept Neurosci Psychol Drug Res & Child Hlth, Largo Brambilla 3, I-50134 Florence, Italy.
EM dario.mucciolo@gmail.com
RI Mucciolo, Dario Pasquale/K-1307-2018; murro, vittoria/K-1309-2018;
   Marcucci, Rossella/K-8471-2016; Virgili, Gianni/P-6607-2014
OI Mucciolo, Dario Pasquale/0000-0002-1661-5312; murro,
   vittoria/0000-0002-9249-4460; Virgili, Gianni/0000-0002-9960-2989;
   Marcucci, Rossella/0000-0001-9549-7176
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc11-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc10-S062]
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Cesari F, 2012, EUR J CLIN INVEST, V42, P927, DOI 10.1111/j.1365-2362.2012.02670.x
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Cuadrado-Godia E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132415
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Erdbruegger U, 2006, CLIN CHIM ACTA, V373, P17, DOI 10.1016/j.cca.2006.05.016
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Fadini GP, 2008, ATHEROSCLEROSIS, V197, P496, DOI 10.1016/j.atherosclerosis.2007.12.039
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Haefliger IO, 2001, PROG RETIN EYE RES, V20, P209, DOI 10.1016/S1350-9462(00)00020-3
   Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223
   Hristov M, 2008, PHARMACOL RES, V58, P148, DOI 10.1016/j.phrs.2008.07.008
   King Thomas F J, 2014, J Stem Cells, V9, P93, DOI jsc.2014.9.2.93
   Lee HJ, 2015, NEPHRON, V130, P151, DOI 10.1159/000430471
   Liao YL, 2004, DIABETES CARE, V27, P978, DOI 10.2337/diacare.27.4.978
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Mancia Giuseppe, 2008, Ther Adv Cardiovasc Dis, V2, P5, DOI 10.1177/1753944707087409
   Manresa N, 2015, J NUTR HEALTH AGING, V19, P228, DOI 10.1007/s12603-014-0531-3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Sasahara M, 2009, INVEST OPHTH VIS SCI, V50, P1575, DOI 10.1167/iovs.08-1900
   Say EAT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055079
   Scotti F, 2014, RETINA-J RET VIT DIS, V34, P1802, DOI 10.1097/IAE.0000000000000147
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stoll BR, 2003, BLOOD, V102, P2555, DOI 10.1182/blood-2003-02-0365
   Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 50
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2020
VL 30
IS 5
BP 956
EP 965
DI 10.1177/1120672119863306
EA JUL 2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OB6JS
UT WOS:000477325900001
PM 31328962
DA 2022-11-30
ER

PT J
AU Cackett, P
   Yeo, I
   Cheung, CMG
   Vithana, EN
   Wong, D
   Tay, WT
   Tai, ES
   Aung, T
   Wong, TY
AF Cackett, Peter
   Yeo, Ian
   Cheung, Chui Ming Gemmy
   Vithana, Eranga N.
   Wong, Doric
   Tay, Wan Ting
   Tai, E. Shyong
   Aung, Tin
   Wong, Tien Y.
TI Relationship of Smoking and Cardiovascular Risk Factors with Polypoidal
   Choroidal Vasculopathy and Age-related Macular Degeneration in Chinese
   Persons
SO OPHTHALMOLOGY
LA English
DT Article
ID GENE POLYMORPHISMS; CIGARETTE-SMOKING; 5-YEAR INCIDENCE;
   NATIONAL-HEALTH; MACULOPATHY; DISEASE; SINGAPORE; ASSOCIATION; EYE;
   HYPERTENSION
AB Purpose: Polypoidal choroidal vasculopathy (PCV) has been described as a distinct clinical entity from choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The present study aimed to determine risk factors for PCV and to compare associations with those for CNV secondary to AMD.
   Design: Case-control study.
   Participants: Patients of Chinese ethnicity with clinically and angiographically diagnosed PCV (n = 123) or CNV secondary to AMD (n = 128) were recruited from a tertiary eye hospital in Singapore. Controls without signs of PCV, CNV secondary to AMD, or other retinal pathologic features (n = 1489) were selected from a population-based study.
   Methods: Patients underwent an ophthalmologic examination including digital color fundus photography, stereoscopic fluorescein angiography (FA), and indocyanine green angiography (ICGA). Classification into PCV or CNV secondary to AMD was based on FA and ICGA findings. Risk factors were determined from a standardized interview, with blood pressure recorded using a digital automatic blood pressure monitor.
   Main Outcome Measures: Polypoidal choroidal vasculopathy or CNV secondary to AMD.
   Results: Persons who smoked were more likely to have PCV (39.9% vs. 13.4%) or CNV secondary to AMD (45.0% vs. 12.3%) than those who did not smoke. After controlling for age, gender, diabetes, hypercholesterolemia, and hypertension, persons who smoked were 4 times more likely to have PCV (odds ratio [OR], 4.4; 95% confidence interval [CI], 2.5-7.7; P < 0.001) and CNV secondary to AMD (OR, 4.9; 95% CI, 2.7-8.8; P < 0.001). A significant, negative association also was found between diastolic blood pressure and CNV secondary to AMD (OR, 0.7; 95% CI, 0.5-0.9; P = 0.017, adjusted for age, gender, smoking, diabetes, and hypercholesterolemia), but diastolic blood pressure was not associated with PCV.
   Conclusions: Smoking but not other vascular risk factors is significantly associated with both PCV and CNV secondary to AMD in Chinese persons. The similarity of associations suggests that there may be common risk factors and pathological mechanisms.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 846-852 (C) 2011 by the American Academy of Ophthalmology.
C1 [Cackett, Peter; Yeo, Ian; Cheung, Chui Ming Gemmy; Wong, Doric; Aung, Tin; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Cackett, Peter; Yeo, Ian; Cheung, Chui Ming Gemmy; Vithana, Eranga N.; Tay, Wan Ting; Aung, Tin; Wong, Tien Y.] Singapore Eye Res Inst, Singapore, Singapore.
   [Tai, E. Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
   [Aung, Tin; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Centre for Eye Research Australia;
   University of Melbourne
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020; Tai, E Shyong/J-9831-2013
OI Wong, Tien Yin/0000-0002-8448-1264; Wong, Damon/0000-0003-4601-9121;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Tai, E
   Shyong/0000-0003-2929-8966
FU Singhealth, Singapore [SHF/FG381P/2007]; Biomedical Research Council,
   Singapore [03/1/27/18/216, 08/1/35/19/550]; National Medical Research
   Council, Singapore [0838/2004]
FX Supported by Singhealth, Singapore (grant no.: SHF/FG381P/2007); the
   Biomedical Research Council, Singapore (grant nos.: 03/1/27/18/216 and
   08/1/35/19/550); and the National Medical Research Council, Singapore
   (grant no.: 0838/2004).
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Cutter J, 2001, B WORLD HEALTH ORGAN, V79, P908
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hughes K, 1997, J EPIDEMIOL COMMUN H, V51, P394, DOI 10.1136/jech.51.4.394
   HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeganathan VSE, 2009, MICROCIRCULATION, V16, P534, DOI 10.1080/10739680902975222
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kramer H, 2004, AM J HYPERTENS, V17, P963, DOI 10.1016/j.amjhyper.2004.06.001
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lutty G, 1999, MOL VIS, V5
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sabanayagam C, 2009, J HYPERTENS, V27, P2209, DOI 10.1097/HJH.0b013e328330141d
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 57
TC 51
Z9 55
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2011
VL 118
IS 5
BP 846
EP 852
DI 10.1016/j.ophtha.2010.09.026
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757MM
UT WOS:000290090300009
PM 21146223
DA 2022-11-30
ER

PT J
AU Bacci, T
   Essilfie, JO
   Leong, BCS
   Freund, KB
AF Bacci, Tommaso
   Essilfie, Juliet O.
   Leong, Belinda C. S.
   Freund, K. Bailey
TI Exudative non-neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Exudative non-neovascular AMD;
   Intraretinal fluid; Retinal pseudocyst; Type 3 macular
   neovascularization; Perifoveal exudative vascular anomalous complex
   (PEVAC)
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; TYPE-3 NEOVASCULARIZATION; EDEMA;
   RETINA; CELLS
AB Purpose To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD) eyes presenting with intraretinal exudation and no evidence of neovascularization or structural alterations of native retinal vessels. Methods This was a retrospective review of the MMI and electronic health records for 3 consecutive patients presenting with unilateral exudative non-neovascular age-related macular degeneration. MMI included confocal color fundus photography (CFP), fundus autofluorescence (FAF), fluorescein angiography (FA), spectral domain optical coherence tomography (SD-OCT), swept-source optical coherence tomography angiography (SS-OCTA), and spectral domain optical coherence tomography angiography (SD-OCTA). Dense B-scan OCTA (DB-OCTA) patterns and implemented image post-processing were used to improve spatial resolution in the OCTA analysis and remove projection artifacts. Results Three eyes of 3 patients (1 male and 2 females, ages 72-87) developed intraretinal fluid (IRF) producing retinal edema during regular follow-up for non-neovascular AMD. FA, SS-OCTA, and DB-OCTA demonstrated no evidence of macular neovascularization or discrete retinal vascular abnormalities that could explain the IRF accumulation. Two eyes received intravitreal anti-VEGF therapy and demonstrated prompt resolution of IRF with periodic recurrences over time. Conclusion Exudative non-neovascular AMD is a novel clinical phenotype characterized by the presence of non-neovascular intraretinal exudation producing macular edema. Differentiating this condition from other manifestations of AMD requires appropriate use of MMI. Further study is needed to assess the clinical impact and optimal management of exudative non-neovascular AMD.
C1 [Bacci, Tommaso; Essilfie, Juliet O.; Leong, Belinda C. S.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.
   [Bacci, Tommaso] Univ Siena, Siena Univ Hosp, Dept Med, Ophthalmol Unit, Siena, Italy.
   [Essilfie, Juliet O.; Freund, K. Bailey] NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
   [Essilfie, Juliet O.; Freund, K. Bailey] Lenox Hill Hosp, Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
   [Leong, Belinda C. S.] Retina Associates, Sydney, NSW, Australia.
C3 Vitreous Retina Macula Consultants of New York; University of Siena;
   University Hospital of Siena; New York University; Manhattan Eye Ear &
   Throat Hospital; Northwell Health
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.; Freund, KB (通讯作者)，NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.; Freund, KB (通讯作者)，Lenox Hill Hosp, Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
EM kbfnyf@aol.com
RI Bacci, Tommaso/GQA-8840-2022; Freund, K. Bailey/V-7488-2018
OI Bacci, Tommaso/0000-0001-7477-2263; Freund, K.
   Bailey/0000-0002-7888-9773
FU TheMacula Foundation Inc., New York, NY
FX This work was supported by TheMacula Foundation Inc., New York, NY.
CR Abegg M, 2014, OPHTHALMOLOGY, V121, P142, DOI 10.1016/j.ophtha.2013.08.045
   Bacci T, 2020, OPHTHALMOLOGY, V127, P887, DOI 10.1016/j.ophtha.2020.03.036
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Breazzano MP, 2020, RETINA-J RET VIT DIS, V40, pE55, DOI 10.1097/IAE.0000000000002892
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   FINE BS, 1962, INVEST OPHTH VISUAL, V1, P304
   Freund KB, 2018, AM J OPHTHALMOL, V190, P78, DOI 10.1016/j.ajo.2018.03.029
   Gelfand JM, 2012, BRAIN, V135, P1786, DOI 10.1093/brain/aws098
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ou Kepeng, 2019, Cell Physiol Biochem, V52, P668, DOI 10.33594/000000047
   Querques G, 2011, J FR OPHTALMOL, V34, DOI 10.1016/j.jfo.2011.03.002
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Sacconi R, 2020, AM J OPHTHALMOL, V218, P59, DOI 10.1016/j.ajo.2020.04.025
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2017, AM J OPHTHALMOL, V184, P137, DOI 10.1016/j.ajo.2017.10.009
   Scharf J, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100884
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Yafai Y, 2007, GLIA, V55, P642, DOI 10.1002/glia.20495
NR 37
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2021
VL 259
IS 5
BP 1123
EP 1134
DI 10.1007/s00417-020-05021-y
EA NOV 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY3DR
UT WOS:000593044000001
PM 33242167
DA 2022-11-30
ER

PT J
AU Myers, CE
   Klein, BEK
   Gangnon, R
   Sivakumaran, TA
   Iyengar, SK
   Klein, R
AF Myers, Chelsea E.
   Klein, Barbara E. K.
   Gangnon, Ronald
   Sivakumaran, Theru A.
   Iyengar, Sudha K.
   Klein, Ronald
TI Cigarette Smoking and the Natural History of Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; COMPLEMENT FACTOR-H; VISUAL-ACUITY; CHOROIDAL
   NEOVASCULARIZATION; INFLAMMATORY MARKERS; UNITED-STATES; RISK-FACTORS;
   CFH GENE; ASSOCIATION; MACULOPATHY
AB Purpose: To examine the association of current cigarette smoking and pack-years smoked with the incidence and progression of age-related macular degeneration (AMD) and to examine the interactions of current smoking and pack-years smoked with complement factor H (CFH, rs1061170) and age-related maculopathy susceptibility 2 (ARMS2, rs10490924) genotype.
   Design: A longitudinal population-based study of AMD in a representative American community. Examinations were performed every 5 years over a 20-year period.
   Participants: A total of 4439 participants in the population-based Beaver Dam Eye Study (BDES).
   Methods: Age-related macular degeneration status was determined from grading retinal photographs. Multi-state models were used to model the relationship of current smoking and pack-years smoked and interactions with CFH and ARMS2 with the incidence and progression of AMD over the entire age range.
   Main Outcome Measures: Incidence and progression of AMD over a 20-year period and interactions between current smoking and pack-years smoked with CFH and ARMS2 genotype.
   Results: The incidence of early AMD over the 20-year period was 24.4%, and the incidence of late AMD was 4.5%. Current smoking was associated with an increased risk of transitioning from minimal to moderate early AMD. A greater number of pack-years smoked was associated with an increased risk of transitioning from no AMD to minimal early AMD and from severe early AMD to late AMD. Current smoking and a greater number of pack-years smoked were associated with an increased risk of death. There were no statistically significant multiplicative interactions between current smoking or pack-years smoked and CFH or ARMS2 genotype.
   Conclusions: Current smoking and a greater number of pack-years smoked increase the risk of the progression of AMD. This has important health care implications because smoking is a modifiable behavior. (C) 2014 by the American Academy of Ophthalmology.
C1 [Myers, Chelsea E.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat Genet & Ophthalmol, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center
RP Myers, CE (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM myers@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714
FU National Institutes of Health [EY06594]; National Eye Institute;
   Research to Prevent Blindness
FX This research is supported by National Institutes of Health Grant
   EY06594 (Drs. B. E. K. Klein and R. Klein). The National Eye Institute
   provided funding for the entire study, including collection and analyses
   of data. Additional support was provided by Senior Scientific
   Investigator Awards from Research to Prevent Blindness (Drs. B. E. K.
   Klein and R. Klein). The funding organizations had no role in the design
   and conduct of the study; collection, management, analysis, and
   interpretation of the data; or preparation, review, or approval of the
   manuscript.
CR [Anonymous], [No title captured]
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P451, DOI 10.1001/archopht.122.4.451
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, BEAVER DAM EYE STUDY, P61
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   Ryu E, 2010, MOL VIS, V16, P2811
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
NR 41
TC 48
Z9 51
U1 1
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2014
VL 121
IS 10
BP 1949
EP 1955
DI 10.1016/j.ophtha.2014.04.040
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ3ME
UT WOS:000342697300024
PM 24953792
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Liu, K
   Chen, LJ
   Lai, TYY
   Tam, POS
   Ho, M
   Chiang, SWY
   Liu, DTL
   Young, AL
   Yang, ZL
   Pang, CP
AF Liu, Ke
   Chen, Li Jia
   Lai, Timothy Y. Y.
   Tam, Pancy O. S.
   Ho, Mary
   Chiang, Sylvia W. Y.
   Liu, David T. L.
   Young, Alvin L.
   Yang, Zhenglin
   Pang, Chi Pui
TI Genes in the High-Density Lipoprotein Metabolic Pathway in Age-related
   Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID CHINESE HAN POPULATION; ESTER TRANSFER PROTEIN; CIGARETTE-SMOKING;
   VARIANTS; ASSOCIATION; POLYMORPHISMS; CFH; SUSCEPTIBILITY; DISEASE;
   INFLAMMATION
AB Purpose: To investigate the associations of genetic variants in the high-density lipoprotein (HDL) metabolism pathway with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional, case-control association study.
   Participants: A Chinese case-control group of 200 neovascular AMD patients, 233 PCV patients, and 275 control subjects.
   Methods: Eight single nucleotide polymorphisms (SNPs) from 6 genes of the HDL metabolism pathway and 2 known AMD-associated SNPs, rs800292 (from complement factor H [CFH]) and rs11200638 (from HtrA serine peptidase 1 [HTRA1]), were genotyped in all study subjects using the TaqMan genotyping technology (Applied Biosystems, Foster City, CA).
   Main Outcome Measures: Allele and genotypic frequencies of selected SNPs.
   Results: The SNP rs3764261 in the cholesteryl ester transfer protein (CETP) gene was associated significantly with neovascular AMD (P = 1.82 x 10(-4); odds ratio [OR], 1.89) and PCV (P = 4.04 x 10(-4); OR, 1.80). The associations remained significant after adjusting for the CFH SNP rs800292 and the HTRA1 SNP rs11200638. A significant interaction between the CETP SNP rs3764261 and the CFH SNP rs800292 existed in both neovascular AMD and PCV, the rs800292 G allele conferring a significantly increased risk of the diseases only in individuals carrying the risk allele T of rs3764261. A borderline association was detected between the ATP-binding cassette, subfamily G, member 1 (ABCG1) gene SNP rs57137919 and PCV (P = 0.03).
   Conclusions: Our results showed that CETP is a susceptibility gene for neovascular AMD and PCV and that ABCG1 a putative gene for PCV. CETP exerts a modifying effect on CFH in the genetic risk. Our data suggest a link of the HDL metabolism pathway with neovascular AMD and PCV. Ophthalmology 2014;121:911-916 (C) 2014 by the American Academy of Ophthalmology.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Ke; Chen, Li Jia; Lai, Timothy Y. Y.; Tam, Pancy O. S.; Chiang, Sylvia W. Y.; Liu, David T. L.; Young, Alvin L.; Pang, Chi Pui] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Li Jia; Ho, Mary; Liu, David T. L.; Young, Alvin L.] Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Sichuan Provincial People's Hospital; Sichuan
   Provincial People's Hospital
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Lai, Timothy Y Y/AAC-2120-2020; Pang, Chi
   P/I-5388-2014
OI Chen, Li Jia/0000-0003-3500-5840; Lai, Timothy Y Y/0000-0002-7832-6428; 
CR Barter PJ, 2012, J LIPID RES, V53, P1755, DOI 10.1194/jlr.R024075
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jarvik GP, 2010, J LIPID RES, V51, P983, DOI 10.1194/jlr.M000125
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lettre G, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001300
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oliveira HCF, 2011, IUBMB LIFE, V63, P248, DOI 10.1002/iub.448
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Vergeer M, 2010, CIRCULATION, V122, P470, DOI 10.1161/CIRCULATIONAHA.109.912519
   Xu Y, 2011, ATHEROSCLEROSIS, V219, P648, DOI 10.1016/j.atherosclerosis.2011.05.043
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 38
TC 45
Z9 47
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2014
VL 121
IS 4
BP 911
EP 916
DI 10.1016/j.ophtha.2013.10.042
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE2MV
UT WOS:000333808100023
PM 24393350
DA 2022-11-30
ER

PT J
AU Coscas, G
   Lupidi, M
   Coscas, F
   Benjelloun, F
   Zerbib, J
   Dirani, A
   Semoun, O
   Souied, EH
AF Coscas, Gabriel
   Lupidi, Marco
   Coscas, Florence
   Benjelloun, Faycal
   Zerbib, Jennifer
   Dirani, Ali
   Semoun, Oudy
   Souied, Eric H.
TI Toward a Specific Classification of Polypoidal Choroidal Vasculopathy:
   Idiopathic Disease or Subtype of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal abnormal network;
   choroidal thickness; enhanced depth imaging (EDI); en face optical
   coherence tomography (OCT); polypoidal choroidal vasculopathy; choroidal
   abnormal network; type 1 choroidal neovascularization (CNV)
ID ASSOCIATIONS; DIAGNOSIS; FEATURES; JAPANESE; A69S
AB PURPOSE. To suggest a clinical distinction between idiopathic polypoidal choroidal vasculopathy (PCV) and secondary polyps associated with neovascular age-related macular degeneration (NV-AMD).
   METHODS. The study was a retrospective case series of 52 eyes of 52 consecutive patients (31 females and 21 males) diagnosed with PCV. Initial diagnosis was based on scanning laser ophthalmoscope-indocyanine green angiography (SLO-ICGA) in association with fluorescein angiography (FA) and optical coherence tomography (OCT). All the data and images were analyzed in a masked fashion by four experienced examiners in two different sessions: the first, to classify patients into the two hypothesized groups (idiopathic polyps or NV-AMD-related polyps); the second, following a predetermined scheme, to describe objective features. The results obtained in each session underwent a cross multivariate analysis to identify statistically significant differences (P <= 0.05) between the two groups.
   RESULTS. The two groups were clinically different on the basis of FA (leakage origin [P = 0.001] and presence of drusen [P = 0.001]), ICGA (evidence of choroidal neovascularization [CNV; P = 0.001] and/or branching vascular network [BVN; P = 0.001]), OCT imaging (type of pigmented epithelium detachment [P = 0.001], presence of BVN [P = 0.001], and subfoveal choroidal thickness [P = 0.001]). Further significant differences were observed according to the location of lesion (uni- or multifocal) (P = 0.001), type of CNV (P = 0.001), and best-corrected visual acuity (P = 0.001).
   CONCLUSIONS. Our study demonstrated clinical and statistically significant differences between idiopathic PCV and NV-AMD-related polyps that could be considered as distinct entities. Although they share some similarities, mainly the sub-RPE location, the ability to identify a specific clinical pattern suggests a more specific therapeutic approach for these two entities.
C1 [Coscas, Gabriel; Coscas, Florence; Benjelloun, Faycal; Zerbib, Jennifer; Semoun, Oudy; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Coscas, Gabriel; Lupidi, Marco; Coscas, Florence] Ctr Odeon, Paris, France.
   [Lupidi, Marco] Univ Perugia, S Maria Misericordia Hosp, Eye Clin, I-06100 Perugia, Italy.
   [Dirani, Ali] St Joseph Univ, Fac Med, Beirut, Lebanon.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Perugia
RP Coscas, G (通讯作者)，Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM gabriel.coscas@gmail.com
OI Lupidi, Marco/0000-0002-6817-2488
CR Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kleiner RC, 1984, OPHTHALMOLOGY S9, V94, P110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 38
TC 64
Z9 67
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2015
VL 56
IS 5
BP 3187
EP 3195
DI 10.1167/iovs.14-16236
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK7UJ
UT WOS:000356439200052
PM 26024102
DA 2022-11-30
ER

PT J
AU Casaroli-Marano, R
   Pinero, A
   Adan, A
   Castro, J
   Armada, F
   Cervera, E
   Llopis, MD
   Abreu, P
   Esteban, E
   Arias, L
   Fernandez-Arias, I
   Kim, HK
   Acebes, X
   Acosta, B
   Bahaya, Y
   Barrios, M
   Blazquez, A
   Bueno, R
   Bures, A
   Carnota, P
   Castanos, A
   Cubillas, M
   Degollada, N
   Fernandez, C
   Fuste, C
   Garcia, P
   Gil, MA
   Graell, X
   Granados, M
   Guerra, P
   Hernandez, A
   Kalitovics, N
   Llorente, S
   Mesa, JC
   Molina, JJ
   Mones, A
   Montero, J
   Nadal, E
   Navarro, M
   Ortiz, JV
   Ortiz, S
   Otxoa, I
   Pereira, E
   Perez, JR
   Planas, N
   Prades, S
   Rodriguez, E
   Rosal, F
   Ruiz, A
   Sanchez, A
   Udaondo, P
   Vargas, JC
   Villota, E
   Zarallo, J
AF Casaroli-Marano, Ricardo
   Pinero, Antonio
   Adan, Alfredo
   Castro, Joaquin
   Armada, Felix
   Cervera, Enrique
   Diaz Llopis, Manuel
   Abreu, Pedro
   Esteban, Eduardo
   Arias, Luis
   Fernandez-Arias, Isabel
   Kim, Hae Kyung
   Acebes, Xenia
   Acosta, Barbara
   Bahaya, Yasmin
   Barrios, Maria
   Blazquez, Ana
   Bueno, Rocio
   Bures, Anniken
   Carnota, Pablo
   Castanos, Amanda
   Cubillas, Marta
   Degollada, Nuria
   Fernandez, Carlos
   Fuste, Celia
   Garcia, Pere
   Antonia Gil, Maria
   Graell, Xavier
   Granados, Maria
   Guerra, Pablo
   Hernandez, Adrian
   Kalitovics, Nicolas
   Llorente, Sara
   Carlos Mesa, Juan
   Jose Molina, Juan
   Mones, Anna
   Montero, Javier
   Nadal, Elisa
   Navarro, Marta
   Vicente Ortiz, Jesus
   Ortiz, Santiago
   Otxoa, Iker
   Pereira, Ernesto
   Ramon Perez, Jose
   Planas, Nuria
   Prades, Sergi
   Rodriguez, Elena
   Rosal, Felicita
   Ruiz, Antonio
   Sanchez, Angel
   Udaondo, Patricia
   Carlos Vargas, Juan
   Villota, Eva
   Zarallo, Jesus
CA SEE Study Grp
TI Prevalence of age-related macular degeneration in Spain
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; NATURAL COURSE; RISK-FACTORS;
   MACULOPATHY; ROTTERDAM; CLASSIFICATION; PATHOGENESIS; PROGRESSION;
   AUSTRALIA
AB Aim To estimate the prevalence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) in the Spanish population aged >= 65 years.
   Methods Individuals were selected by random stratified sampling of census data from eight Spanish health districts encompassing a wide geographic area. Participants underwent an ophthalmologic evaluation including fundus imaging, and ARM and AMD were defined according to the International ARM Epidemiological Study Group classification. The age-and gender-adjusted prevalences and CIs for ARM and neovascular and atrophic forms of AMD were calculated.
   Results Of the 3028 individuals invited to participate, 2132 attended the ophthalmologic evaluation (840 men (70.9% response) and 1292 women (69.7% response); 978 aged 65-74 years (77.6% response), 1154 aged >= 75 years (65.3% response)). The overall prevalence of ARM and AMD was 10.3% (95% CI 8.7% to 11.8%) and 3.4% (95% CI 2.5% to 4.3%), respectively. AMD increased from 1.3% in individuals aged 65-74 years to 8.5% in those aged >= 80 years. Neovascular and atrophic AMD accounted for 1.9% and 1.5% of individuals, respectively.
   Conclusions The prevalence of AMD in this large, population-based Spanish sample was similar to that observed in other large-scale population-based studies. However, the prevalence of ARM was lower than found in similar studies.
C1 [Casaroli-Marano, Ricardo; Adan, Alfredo; Bures, Anniken; Degollada, Nuria; Jose Molina, Juan; Ortiz, Santiago] Hosp Clin Barcelona, Barcelona, Spain.
   [Pinero, Antonio; Barrios, Maria; Bueno, Rocio; Guerra, Pablo; Hernandez, Adrian; Nadal, Elisa; Navarro, Marta; Pereira, Ernesto] Valme Univ Hosp, Seville, Spain.
   [Castro, Joaquin; Cubillas, Marta; Fernandez, Carlos; Rosal, Felicita; Villota, Eva] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
   [Armada, Felix; Granados, Maria; Llorente, Sara; Vicente Ortiz, Jesus; Zarallo, Jesus] La Paz Univ Hosp, Madrid, Spain.
   [Cervera, Enrique; Diaz Llopis, Manuel; Montero, Javier; Udaondo, Patricia] Valencia Gen Hosp, Valencia, Spain.
   [Abreu, Pedro; Acosta, Barbara; Bahaya, Yasmin; Antonia Gil, Maria; Kalitovics, Nicolas; Ramon Perez, Jose; Carlos Vargas, Juan] Virgen de La Candelaria Hosp, Santa Cruz De Tenerife, Spain.
   [Esteban, Eduardo; Castanos, Amanda; Rodriguez, Elena; Ruiz, Antonio] Virgen Macarena Hosp, Seville, Spain.
   [Arias, Luis; Acebes, Xenia; Blazquez, Ana; Carnota, Pablo; Fuste, Celia; Garcia, Pere; Graell, Xavier; Carlos Mesa, Juan; Mones, Anna; Otxoa, Iker; Planas, Nuria; Prades, Sergi; Sanchez, Angel] Bellvitge Univ Hosp, Barcelona, Spain.
   [Fernandez-Arias, Isabel; Kim, Hae Kyung] Pfizer SA, Alcobendas, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; Hospital Valme;
   Central University Hospital Asturias; University of Oviedo; Hospital
   Universitario La Paz; Hospital Universitario Virgen Macarena; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital; University of Barcelona; Pfizer
RP Fernandez-Arias, I (通讯作者)，Pfizer Espana, Med Unit, Avda Europa 20-B,Parque Empresarial La Moraleja, Madrid 28108, Spain.
EM isabel.fernandez-arias@pfizer.com
RI Casaroli-Marano, Ricardo Pedro/D-4535-2014; Vargas, Julio Celso
   Borello/AAR-4671-2021
OI Casaroli-Marano, Ricardo Pedro/0000-0003-1812-9323; Vargas, Julio Celso
   Borello/0000-0001-8321-5362; LLORENTE GONZALEZ,
   SARA/0000-0001-8815-4757; ARIAS, LUIS/0000-0001-7041-5576; Udaondo,
   Patricia/0000-0002-5241-0066; Zarallo-Gallardo,
   Jesus/0000-0003-3218-7554; Adan, Alfredo/0000-0002-0849-8814
FU Pfizer S.A.
FX This study was supported by Pfizer S.A.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hamada S, 2006, EYE, V20, P199, DOI 10.1038/sj.eye.6701852
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Ram?rez-Sebasti?n, 1991, REV ESP GERIATR GERO, V26, P21
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 28
TC 20
Z9 20
U1 0
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2011
VL 95
IS 7
BP 931
EP 936
DI 10.1136/bjo.2010.187773
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778PX
UT WOS:000291717700008
PM 21216795
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Stasiukonyte, N
   Liutkeviciene, R
   Vilkeviciute, A
   Banevicius, M
   Kriauciuniene, L
AF Stasiukonyte, Neringa
   Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Banevicius, Mantas
   Kriauciuniene, Loresa
TI Associations between Rs4244285 and Rs762551 gene polymorphisms and
   age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; cytochrome P450; gene polymorphism
ID CARDIOVASCULAR RISK-FACTORS; APOLIPOPROTEIN-E; BLADDER-CANCER; VISUAL
   IMPAIRMENT; 5-YEAR INCIDENCE; MACULOPATHY; DISEASE; CHOLESTEROL;
   PREVALENCE; DRUSEN
AB Background: Age-related macular degeneration is the leading cause of blindness in elderly individuals in developed countries. The etiology and pathophysiology of age-related macular degeneration have not been elucidated yet. Knowing that the main pathological change of age-related macular degeneration is formation of drusen containing about 40% of lipids, there have been attempts to find associations between age-related macular degeneration and genes controlling lipid metabolism.
   Purpose: To determine the frequency of CYP2C19 (G681A) Rs4244285 and CYP1A2 (-163C>A) Rs762551 genotypes in patients with age-related macular degeneration.
   Methods: The study enrolled 150 patients with early age-related macular degeneration and 296 age- and gender-matched healthy controls. The genotyping of Rs4244285 and Rs762551 was carried out by using the real-time polymerase chain reaction method.
   Results: The CYP1A2 (-163C>A) Rs762551 C/C genotype was more frequently detected in patients with age-related macular degeneration than in the control group (32.7% vs. 21.6%, p = 0.011) and was associated with an increased risk of developing early age-related macular degeneration (OR = 1.759, 95% CI: 1.133-2.729; p = 0.012). The CYP1A2 (-163C>A) Rs762551 C/A genotype was more frequently documented in the control group compared with patients with age-related macular degeneration (46.3% vs. 30.7%, p = 0.002) and was associated with a decreased risk of having age-related macular degeneration (OR = 0.580. 95% CI: 0.362-0.929, p = 0.023) in the co-dominant model.
   Conclusion: The study showed that the CYP1A2 (-163C>A) Rs762551 C/C genotype was associated with an increased risk of age-related macular degeneration.
C1 [Stasiukonyte, Neringa] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Banevicius, Mantas; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
CR Altayli E, 2009, INT UROL NEPHROL, V41, P259, DOI 10.1007/s11255-008-9444-6
   BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cornelis MC, 2004, J MED GENET, V41, P758, DOI 10.1136/jmg.2004.022012
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cui XY, 2013, ENVIRON HEALTH PREV, V18, P136, DOI 10.1007/s12199-012-0302-x
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Figueroa JD, 2008, CARCINOGENESIS, V29, P1955, DOI 10.1093/carcin/bgn163
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Janha RE, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471-2148-14-71
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korytina G, 2012, BALK MED J, V29, P252, DOI 10.5152/balkanmedj.2012.039
   Kupstyte N, 2015, PHARMACOGENOMICS, V16, P181, DOI 10.2217/pgs.14.165
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Luoma PV, 2008, EUR J CLIN PHARMACOL, V64, P841, DOI 10.1007/s00228-008-0515-5
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Mirzaev KB, 2014, J PHARM PHARMACOL, V2, P322
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Pavanello S, 2010, EUR J EPIDEMIOL, V25, P491, DOI 10.1007/s10654-010-9479-8
   Piehler Armin P, 2007, Tidsskr Nor Laegeforen, V127, P2930
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Seddon J, 1994, INVEST OPHTH VIS SCI
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shin DJ, 2012, YONSEI MED J, V53, P1113, DOI 10.3349/ymj.2012.53.6.1113
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Soyama Akiko, 2005, Drug Metab Pharmacokinet, V20, P24, DOI 10.2133/dmpk.20.24
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Sychev DA, 2015, PHARMACOGN PERS MED, V8, P111, DOI 10.2147/PGPM.S78986
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   The Age-Related Eye Disease Study Research Group, 2001, AM J OPHTHALMOL, V132, P688
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Tsukino H, 2004, J CANCER RES CLIN, V130, P99, DOI 10.1007/s00432-003-0512-0
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Villanueva CM, 2009, CANCER CAUSE CONTROL, V20, P121, DOI 10.1007/s10552-008-9226-6
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zabalza M, 2012, HEART, V98, P100, DOI 10.1136/hrt.2011.227652
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 70
TC 2
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD AUG
PY 2017
VL 38
IS 4
BP 357
EP 364
DI 10.1080/13816810.2016.1242018
PG 8
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FE1OM
UT WOS:000407987500011
DA 2022-11-30
ER

PT J
AU Lee, K
   Park, YG
   Park, YH
AF Lee, Kook
   Park, Young Gun
   Park, Young-Hoon
TI VISUAL PROGNOSIS AFTER PNEUMATIC DISPLACEMENT OF SUBMACULAR HEMORRHAGE
   ACCORDING TO AGE-RELATED MACULAR DEGENERATION SUBTYPES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; pneumatic displacement; polypoidal
   choroidal vasculopathy; retinal angiomatous proliferation; submacular
   hemorrhage
AB Purpose: This study compared the visual outcome after pneumatic displacement of submacular hemorrhage among patients with different subtypes of age-related macular degeneration (AMD).
   Methods: We retrospectively reviewed the medical records of 67 patients (67 eyes) who underwent treatment for submacular hemorrhage associated with AMD. All the patients underwent pneumatic displacement. Demographic parameters, visual acuity, and anatomical features were analyzed among AMD subtypes: typical AMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP).
   Results: Among the eyes with submacular hemorrhage, 24, 30, and 13 eyes had typical AMD, PCV, and RAP, respectively. Post-treatment best-corrected visual acuity was best in the PCV group and worst in the RAP group (P < 0.001). The proportion of eyes with improved visual acuity was highest in the PCV subtype and lowest in the RAP subtype (P = 0.044). Logistic regression analysis showed that AMD subtype (P = 0.016) and time to treatment (<7 days) (P = 0.037) are associated with the final visual outcome.
   Conclusion: The final post-treatment visual outcome after the incidence of submacular hemorrhage was best in the PCV group and worst in the RAP group. Age-related macular degeneration subtype is a significant factor associated with the visual prognosis of submacular hemorrhage.
C1 [Lee, Kook; Park, Young Gun; Park, Young-Hoon] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, 222 Banpo Daero, Seoul 06591, South Korea.
   [Park, Young-Hoon] Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea
RP Park, YH (通讯作者)，Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, 222 Banpo Daero, Seoul 06591, South Korea.
EM parkyh@catholic.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2016R1A6A1A03010528]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF), funded by the Ministry of Education
   [2016R1A6A1A03010528].
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bae K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168474
   Baek J, 2018, RETINA-J RET VIT DIS, V38, P1993, DOI 10.1097/IAE.0000000000001817
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim JH, 2018, SEMIN OPHTHALMOL, V33, P820, DOI 10.1080/08820538.2018.1511814
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
NR 30
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2304
EP 2311
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100007
PM 31985556
DA 2022-11-30
ER

PT J
AU Agawa, T
   Usui, Y
   Wakabayashi, Y
   Okunuki, Y
   Juan, M
   Umazume, K
   Kezuka, T
   Takeuchi, M
   Yamauchi, Y
   Goto, H
AF Agawa, Tsuyoshi
   Usui, Yoshihiko
   Wakabayashi, Yoshihiro
   Okunuki, Yoko
   Juan, Ma
   Umazume, Kazuhiko
   Kezuka, Takeshi
   Takeuchi, Masaru
   Yamauchi, Yasuyuki
   Goto, Hiroshi
TI PROFILE OF INTRAOCULAR IMMUNE MEDIATORS IN PATIENTS WITH AGE-RELATED
   MACULAR DEGENERATION AND THE EFFECT OF INTRAVITREAL BEVACIZUMAB
   INJECTION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; cytokine; chemokine; bevacizumab;
   inflammation
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; INDUCIBLE
   PROTEIN-10 IP-10; AQUEOUS-HUMOR LEVELS; SOLUBLE FAS LIGAND; CHOROIDAL
   NEOVASCULARIZATION; STERILE ENDOPHTHALMITIS; IN-VITRO; EXPRESSION;
   ANGIOGENIN
AB Purpose: To measure intraocular cytokine levels in patients with exudative age-related macular degeneration and analyze changes in the cytokine profile 2 days after intravitreal bevacizumab injection.
   Methods: This prospective case-control study enrolled 37 patients (37 eyes) with age-related macular degeneration including polypoidal choroidal vasculopathy. Twenty-eight age-matched patients (28 eyes) who underwent cataract surgery were used as controls. Undiluted aqueous humor samples were collected after intravitreal bevacizumab injection. Two days after intravitreal bevacizumab injection, cataract surgery was performed and undiluted aqueous humor samples were collected at the beginning of surgery (10 eyes). Twenty-three cytokines were measured using flow cytometry. P values were corrected in multiple comparisons using the conservative Bonferroni-Holm method. The level of significance was set at 0.0022 (0.05/23).
   Results: At baseline, aqueous humor levels of vascular endothelial growth factor, angiogenin, interferon gamma-inducible protein (IP)-10, macrophage inflammatory protein (MIP)-1 beta, monokine induced by interferon gamma (Mig), and monocyte chemotactic protein (MCP)-1 were significantly higher in the age-related macular degeneration group than in the control group (P < 0.0022). The result of exploratory multivariate analysis showed that elevated angiogenin level was an important factor that discriminates the two groups (P = 0.0004). Two days after intravitreal bevacizumab injection, vascular endothelial growth factor levels tended to be reduced (P = 0.049), whereas interleukin (IL)-6 and IL-8 levels increased significantly (P < 0.0022).
   Conclusion: Vascular endothelial growth factor and also angiogenin, IP-10, MCP-1, MIP-1 beta, and Mig may be related to the pathogenesis of age-related macular degeneration. Intravitreal bevacizumab injection increases inflammatory cytokine levels, suggesting the induction of an inflammatory process.
C1 [Agawa, Tsuyoshi; Usui, Yoshihiko; Wakabayashi, Yoshihiro; Okunuki, Yoko; Juan, Ma; Umazume, Kazuhiko; Kezuka, Takeshi; Yamauchi, Yasuyuki; Goto, Hiroshi] Tokyo Med Univ Hosp, Dept Ophthalmol, Tokyo 1600023, Japan.
   [Takeuchi, Masaru] Natl Def Med Coll, Dept Ophthalmol, Saitama, Japan.
C3 Tokyo Medical University; National Defense Medical College - Japan
RP Wakabayashi, Y (通讯作者)，Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.
EM wbaki@tokyo-med.ac.jp
RI /AAD-1824-2020; Okunuki, Yoko/ABE-8090-2020
OI Okunuki, Yoko/0000-0002-1612-7925
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21791715]
FX Supported by a Grant-in-Aid for Young Scientists (B) 21791715 from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan.
CR Abu El-Asrar AM, 2006, EUR CYTOKINE NETW, V17, P155, DOI 10.1684/ecn.2006.0033
   Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2009, AM J OPHTHALMOL, V148, P66, DOI 10.1016/j.ajo.2009.02.013
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boulday G, 2006, J IMMUNOL, V176, P3098, DOI 10.4049/jimmunol.176.5.3098
   Boyd SR, 2002, BRIT J OPHTHALMOL, V86, P448, DOI 10.1136/bjo.86.4.448
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Elner SG, 1998, ARCH OPHTHALMOL-CHIC, V116, P1597, DOI 10.1001/archopht.116.12.1597
   ELNER SG, 1991, LAB INVEST, V64, P819
   Fan W, 2002, IN VITRO CELL DEV-AN, V38, P228
   FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   Gao XW, 2008, ACTA BIOCH BIOPH SIN, V40, P619, DOI 10.1111/j.1745-7270.2008.00442.x
   Hasegawa M, 2011, CLIN RHEUMATOL, V30, P231, DOI 10.1007/s10067-010-1610-4
   Huang L, 2009, J NEUROL SCI, V285, P220, DOI 10.1016/j.jns.2009.07.005
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131
   Meleth AD, 2005, INVEST OPHTH VIS SCI, V46, P4295, DOI 10.1167/iovs.04-1057
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ness T, 2010, RETINA-J RET VIT DIS, V30, P332, DOI 10.1097/IAE.0b013e3181baf691
   Park SP, 2009, CLIN EXP OPHTHALMOL, V37, P490, DOI 10.1111/j.1442-9071.2009.02061.x
   Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Skeie JM, 2011, MOL VIS, V17, P576
   STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626
   Sugita S, 2000, BRIT J OPHTHALMOL, V84, P1130, DOI 10.1136/bjo.84.10.1130
   Taban M, 2007, AM J OPHTHALMOL, V144, P50, DOI 10.1016/j.ajo.2007.03.051
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wakabayashi Y, 2008, DIABETIC MED, V25, P875, DOI 10.1111/j.1464-5491.2008.02466.x
   Wakabayashi Y, 2010, RETINA-J RET VIT DIS, V30, P339, DOI 10.1097/IAE.0b013e3181bd2f44
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
NR 53
TC 39
Z9 40
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1811
EP 1818
DI 10.1097/IAE.0000000000000157
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400017
PM 24801651
DA 2022-11-30
ER

PT J
AU Yuda, K
   Inoue, Y
   Tomidokoro, A
   Tamaki, Y
   Yanagi, Y
AF Yuda, Kentaro
   Inoue, Yuji
   Tomidokoro, Atsuo
   Tamaki, Yasuhiro
   Yanagi, Yasuo
TI Nerve fiber layer thickness in exudative age-related macular
   degeneration in Japanese patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Nerve fiber layer thickness;
   Polypoidal choroidopathy; Fourier-domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; H GENE
   POLYMORPHISM; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS; NO
   ASSOCIATION; POPULATION; REPRODUCIBILITY; EYE; RISK
AB To examine the peripapillary retinal nerve fiber (RNFL) thickness in Japanese patients with two major forms of exudative age-related macular degeneration (AMD), i.e., typical AMD and polypoidal choroidal vasculopathy (PCV).
   This is a prospective observational consecutive study. One hundred patients diagnosed with unilateral exudative AMD, with the fellow eyes free of exudative change, were included. Peripapillary RNFL thickness was measured using three-dimensional Fourier-domain optical coherence tomography (3D-OCT). Peripapillary RNFL thickness was compared between the affected eyes and fellow eyes in 100 patients.
   RNFL thickness in the eyes with exudative AMD did not differ significantly from the fellow eyes. There was also no association between the lesion size and the peripapillary RNFL thickness.
   There is no relationship between exudative AMD and peripapillary RNFL thickness in Japanese patients.
C1 [Yuda, Kentaro; Inoue, Yuji; Tomidokoro, Atsuo; Tamaki, Yasuhiro; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenthal EZ, 2000, OPHTHALMOLOGY, V107, P2278, DOI 10.1016/S0161-6420(00)00341-9
   Carpineto P, 2003, OPHTHALMOLOGY, V110, P190, DOI 10.1016/S0161-6420(02)01296-4
   Cheung CYL, 2008, OPHTHALMOLOGY, V115, P1347, DOI 10.1016/j.ophtha.2007.11.027
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gabriele ML, 2007, INVEST OPHTH VIS SCI, V48, P3154, DOI 10.1167/iovs.06-1416
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gupta N, 2007, EXP EYE RES, V84, P176, DOI 10.1016/j.exer.2006.09.013
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Oishi A, 2009, EYE, V23, P299, DOI 10.1038/sj.eye.6703077
   Okamoto H, 2006, MOL VIS, V12, P156
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
NR 28
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2010
VL 248
IS 3
BP 353
EP 359
DI 10.1007/s00417-009-1222-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555GP
UT WOS:000274497200009
PM 19882162
DA 2022-11-30
ER

PT J
AU Yoshida, Y
   Kohno, T
   Yamamoto, M
   Yoneda, T
   Iwami, H
   Shiraki, K
AF Yoshida, Yusaku
   Kohno, Takeya
   Yamamoto, Manabu
   Yoneda, Tasuku
   Iwami, Hisashi
   Shiraki, Kunihiko
TI Two-year results of reduced-fluence photodynamic therapy combined with
   intravitreal ranibizumab for typical age-related macular degeneration
   and polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Ranibizumab; Reduced-fluence photodynamic therapy
ID VERTEPORFIN PLUS RANIBIZUMAB; ENDOTHELIAL GROWTH-FACTOR; DOSING REGIMEN;
   BEVACIZUMAB; NEOVASCULARIZATION; COMBINATION; EFFICACY; INJECTION;
   SAFETY
AB To report the 2-year results of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal ranibizumab (IVR) for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Twenty-four previously untreated eyes of 23 AMD patients with decimal best-corrected visual acuity (BCVA) of less than 0.7 received the combined therapy, followed by retreatments as needed over the subsequent 2 years. When the BCVA was better than or equal to 0.7, only 3 monthly IVR injections were performed during the retreatment.
   The BCVAs were maintained in 7 of 10 typical AMD eyes and in 13 of 14 PCV eyes at month 24. The mean BCVA improved in the PCV group (P < 0.05) but not in the typical AMD group. The central foveal thickness decreased in both groups (P < 0.01, P < 0.001). The mean numbers of the total PDT and IVR injections were 1.8 and 7.2 in the typical AMD group and 1.8 and 6.4 in the PCV group.
   After RF-PDT combined therapy with administration of retreatments as needed that consisted of either 3 IVR injections alone or combined therapy, the BCVA was maintained in typical AMD and improved in PCV during a 2-year follow-up period.
C1 [Yoshida, Yusaku; Kohno, Takeya; Yamamoto, Manabu; Yoneda, Tasuku; Iwami, Hisashi; Shiraki, Kunihiko] Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan.
C3 Osaka Metropolitan University
RP Yoshida, Y (通讯作者)，Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
EM m1158667@med.osaka-cu.ac.jp
RI Yamamoto, Manabu/AAS-1130-2020
OI Yamamoto, Manabu/0000-0001-6666-8706
CR Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sawa M, 2012, JPN J OPHTHALMOL, V56, P470, DOI 10.1007/s10384-012-0154-3
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
NR 38
TC 31
Z9 33
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2013
VL 57
IS 3
BP 283
EP 293
DI 10.1007/s10384-013-0234-z
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 143BP
UT WOS:000318841600007
PM 23413039
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Ng, WY
   Ng, SR
   Tan, SP
   Yeo, IYS
   Mathur, R
   Chan, CM
   Tan, ACS
   Tan, GSW
   Wong, TY
   Cheung, CMG
AF Ting, Daniel Shu Wei
   Ng, Wei Yan
   Ng, Si Rui
   Tan, Shu Pei
   Yeo, Ian Yew San
   Mathur, Ranjana
   Chan, Choi Mun
   Tan, Anna Cheng Sim
   Tan, Gavin Siew Wei
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Choroidal Thickness Changes in Age-Related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC
   THERAPY; GEOGRAPHIC ATROPHY; TREATMENTS TRIALS; SMOKING; ASSOCIATION;
   VEGF; VERTEPORFIN; INJECTION
AB PURPOSE: To describe 12-month changes in choroidal thickness after anti-vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   DESIGN: Prospective, consecutive, noninterventional, longitudinal case series.
   METHODS: This study included patients with typical AMD and PCV who received anti-VEGF therapy Over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure choroidal thickness.
   RESULTS: Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and received fewer anti-VEGF injections (3.9 vs 5.6, P = .02) than patients with typical AMD. Baseline subfoveal choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 m, P < .01). Subfoveal choroidal thickness decreased significantly in both typical AMD (213.7 mu m to 190.3 mu m, P < .001) and PCV (240.8 mu m to 213.4 mu m, P < .01) eyes, but no significant change was noted in fellow unaffected eyes. Reduction in choroidal thickness was associated with elevated C-reactive protein (odds ratio [OR]: 1.4, P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness.
   CONCLUSIONS: A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Ting, Daniel Shu Wei; Ng, Wei Yan; Ng, Si Rui; Yeo, Ian Yew San; Mathur, Ranjana; Chan, Choi Mun; Tan, Anna Cheng Sim; Tan, Gavin Siew Wei; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Ting, Daniel Shu Wei; Tan, Shu Pei; Yeo, Ian Yew San; Mathur, Ranjana; Tan, Gavin Siew Wei; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Ting, Daniel Shu Wei; Yeo, Ian Yew San; Mathur, Ranjana; Tan, Gavin Siew Wei; Wong, Tien Yin] Natl Univ Singapore, Grad Sch Med, Duke NUS Natl Univ Singapore, Singapore 117548, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Bidwai, Pooja Vishal/0000-0002-3077-4395
FU Bayer; Novartis; GlaxoSmithKline; Roche
FX CHUI MING GEMMY CHEUNG: BOARD MEMbership: Bayer, Novartis; Consultancy:
   Bayer, Novartis; Grants: Bayer, Novartis, GlaxoSmithKline, Roche;
   Lectures: Bayer, Novartis; Manuscript: Bayer, Novartis;
   Travel/accommodation: Allergan. Tien Yin Wong: Board membership: Abbott,
   Novartis, Pfizer, Allergan, Bayer; Consultancy: Abbott, Novartis,
   Pfizer, Allergan, Bayer. All financial activities are based in
   Singapore. The following authors have no financial disclosures: Daniel
   Shu Wei Ting, Wei Yan Ng, Si Rui Ng, Shu Pei Tan, Ian Yew San Yeo,
   Ranjana Mathur, Choi Mun Chan, Anna Cheng Sim Tan, and Gavin Siew Wei
   Tan. All authors attest that they meet the current ICMJE criteria for
   authorship.
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P7775, DOI 10.1167/iovs.14-14915
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, ACTA OPHTHALMOL, V91, pE580, DOI 10.1111/aos.12117
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Comyn O, 2012, INVEST OPHTH VIS SCI, V53, P7754, DOI 10.1167/iovs.12-10895
   Dervisogullan MS, 2015, CUTAN OCUL TOXICOL, V34, P217, DOI 10.3109/15569527.2014.950380
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   National Advisory Eye Council, 1999, NIH PUBLICATION, V98-4120
   Ogasawara Masashi, 2012, Nippon Ganka Gakkai Zasshi, V116, P643
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Wong IY, 2013, RETINA-J RET VIT DIS, V33, P423, DOI 10.1097/IAE.0b013e3182753b5a
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 42
TC 66
Z9 71
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2016
VL 164
BP 128
EP 136
DI 10.1016/j.ajo.2015.12.024
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI7CS
UT WOS:000373657300016
PM 26743619
DA 2022-11-30
ER

PT J
AU Eng, KT
   Kertes, PJ
AF Eng, Kenneth T.
   Kertes, Peter J.
TI Ranibizumab in neovascular age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   ranibizumab; bevacizumab
AB Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.
C1 [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
   [Eng, Kenneth T.] Hop Hotel Dieu, Kingston, ON, Canada.
   [Eng, Kenneth T.; Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON M5S 1A1, Canada.
   [Eng, Kenneth T.] Queens Univ, Dept Ophthalmol, Kingston, ON K7L 3N6, Canada.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; Queens University -
   Canada; University of Toronto; Queens University - Canada
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, Room M1-202A,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   [AED] Age-related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V110, P1417
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis DP, 1996, OPHTHALMOLOGY, V103, P2099
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2006, OPHTHALMOLOGY, V113, P267, DOI 10.1016/j.ophthzi.2005.10.031
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, ASS RES VIS OPHTH 20
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McColm J, 2004, MOL VIS, V10, P512
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Renno RZ, 2000, INVEST OPHTH VIS SCI, V41, P3963
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenfeld PJ, 2006, ASS RES VIS OPHTH 20
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 52
TC 13
Z9 20
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9092
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2006
VL 1
IS 4
BP 451
EP 466
DI 10.2147/ciia.2006.1.4.451
PG 16
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WR
UT WOS:000208238200015
PM 18046922
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, HY
   Zhao, XY
   Yuan, MZ
   Chen, YX
AF Zhou, Huiying
   Zhao, Xinyu
   Yuan, Mingzhen
   Chen, Youxin
TI Comparison of cytokine levels in the aqueous humor of polypoidal
   choroidal vasculopathy and neovascular age-related macular degeneration
   patients
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Aqueous humor; Cytokines; Age-related macular degeneration; Polypoidal
   choroidal vasculopathy
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; GROWTH-FACTOR; PROFILE; CELLS; GENE
AB Background The concentrations of cytokines in the aqueous humor from neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) may vary. The study was conducted to compare various cytokine levels in the aqueous humor of eyes with PCV, nAMD and control. Methods The present case control study included 49 treatment-naive eyes from 49 patients (PCV 24, nAMD 11, and cataract 14 eyes). Totally 34 angiogenic and inflammatory cytokines in the aqueous humor were measured by Luminex bead-based multiplex array. Results After adjusting for gender and age by multivariate logistic analysis, concentrations of IL-31, LIF, SDF1-alpha, VEGF-A, VEGF-D were significantly higher in eyes with nAMD or PCV compared with control eyes (all P < 0.05, times in nAMD: 59.5, 6.0, 7.0, 4.5, 5.6, respectively, times in PCV: 51.9, 5.21, 6.6, 4.0, 5.1, respectively), and concentrations of HGF, IP-10, MCP-1, IL-13 were significantly lower in eyes with nAMD or PCV than in control eyes (all P < 0.05, times in nAMD: 2.6, 2.0, 4.5, 4.7, respectively, times in PCV: 1.9, 3.0, 3.0, 2.8, respectively), but none of the 34 cytokines, including VEGF and IL-8, showed significantly different between eyes with nAMD and PCV. Conclusions Various cytokines involved in inflammation and angiogenesis including elevated IL-31, LIF, SDF1-alpha, VEGF-A, VEGF-D might be involved in the pathogenesis of nAMD or PCV. None of the 34 cytokines may help to differentiate nAMD and PCV.
C1 [Zhou, Huiying; Zhao, Xinyu; Yuan, Mingzhen; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Ophthalmol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Ophthalmol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
FU NSFC [:81670879]
FX The authors are thankful for the financial support of NSFC Grant
   No:81670879.
CR Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Balne PK, 2018, DATA BRIEF, V19, P1570, DOI 10.1016/j.dib.2018.05.085
   Byrne AM, 2016, MOL VIS, V22, P264
   Campochiaro PA, 2016, AM J OPHTHALMOL, V168, P13, DOI 10.1016/j.ajo.2016.04.017
   Davidi S, 2017, ONCOTARGET, V8, P16430, DOI 10.18632/oncotarget.14857
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Forooghian F, 2016, CAN J OPHTHALMOL, V51, P87, DOI 10.1016/j.jcjo.2015.11.001
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Hollborn M, 2016, MOL BIOL REP, V43, P803, DOI 10.1007/s11033-016-4016-9
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jin EZ, 2015, INT J CLIN EXP PATHO, V8, P13928
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Laiva AL, 2018, INT J PHARMACEUT, V544, P372, DOI 10.1016/j.ijpharm.2018.03.032
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moussa Kareem, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS128, DOI 10.1097/ICB.0000000000000464
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Yan XQ, 2017, J CELL MOL MED, V21, P2298, DOI 10.1111/jcmm.13150
   Yang XF, 2018, CHINESE MED J-PEKING, V131, P75, DOI 10.4103/0366-6999.221263
NR 33
TC 14
Z9 16
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 8
PY 2020
VL 20
IS 1
AR 15
DI 10.1186/s12886-019-1278-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KL6BA
UT WOS:000513505500002
PM 31914968
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Lau, T
   Wong, IY
   Iu, L
   Chhablani, J
   Yong, T
   Hideki, K
   Lee, J
   Wong, R
AF Lau, Tiffany
   Wong, Ian Y.
   Iu, Lawrence
   Chhablani, Jay
   Yong, Tao
   Hideki, Koizumi
   Lee, Jacky
   Wong, Raymond
TI En-face optical coherence tomography in the diagnosis and management of
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; en-face optical coherence tomography;
   polypoidal choroidal vasculopathy
ID RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY; OCT; ANGIOGRAPHY; FEATURES;
   EYE
AB Optical coherence tomography (OCT) is a noninvasive imaging modality providing high-resolution images of the central retina that has completely transformed the field of ophthalmology. While traditional OCT has produced longitudinal cross-sectional images, advancements in data processing have led to the development of en-face OCT, which produces transverse images of retinal and choroidal layers at any specified depth. This offers additional benefit on top of longitudinal cross-sections because it provides an extensive overview of pathological structures in a single image. The aim of this review was to discuss the utility of en-face OCT in the diagnosis and management of age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). En-face imaging of the inner segment/outer segment junction of retinal photoreceptors has been shown to be a useful indicator of visual acuity and a predictor of the extent of progression of geographic atrophy. En-face OCT has also enabled high-resolution analysis and quantification of pathological structures such as reticular pseudodrusen (RPD) and choroidal neovascularization, which have the potential to become useful markers for disease monitoring. En-face Doppler OCT enables subtle changes in the choroidal vasculature to be detected in eyes with RPD and AMD, which has significantly advanced our understanding of their pathogenesis. En-face Doppler OCT has also been shown to be useful for detecting the polypoid lesions and branching vascular networks diagnostic of PCV. It may therefore serve as a noninvasive alternative to fluorescein and indocyanine green angiography for the diagnosis of PCV and other forms of the exudative macular disease.
C1 [Lau, Tiffany; Wong, Raymond] Hong Kong Eye Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Ian Y.; Iu, Lawrence] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Lee, Jacky] Caritas Med Ctr, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Chhablani, Jay] LV Prasad Eye Inst, Dept Ophthalmol, Hyderabad, Telangana, India.
   [Yong, Tao] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Hideki, Koizumi] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 University of Hong Kong; L. V. Prasad Eye Institute; Peking University;
   Tokyo Women's Medical University
RP Wong, IY (通讯作者)，Room 301,Level 3,Block B,Cyberport 4, Pokfulam, Hong Kong, Peoples R China.
EM ianyhwong@gmail.com
RI Iu, Lawrence/K-7441-2019
OI Iu, Lawrence/0000-0001-6898-5043; Lee, Jacky W.Y./0000-0001-6249-3304
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kiernan DF, 2012, RETINA-J RET VIT DIS, V32, P1077, DOI 10.1097/IAE.0b013e31823c23bc
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Rosen RB, 2009, INVEST OPHTH VIS SCI, V50, P851, DOI 10.1167/iovs.08-1855
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   van Velthoven Mirjam E J, 2005, BMC Ophthalmol, V5, P12, DOI 10.1186/1471-2415-5-12
   Wanek J, 2011, AM J OPHTHALMOL, V152, P807, DOI 10.1016/j.ajo.2011.04.027
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 28
TC 14
Z9 14
U1 0
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2015
VL 63
IS 5
BP 378
EP 383
DI 10.4103/0301-4738.159860
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5OC
UT WOS:000357736600004
PM 26139796
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Siaudvytyte, L
   Mitkute, D
   Balciuniene, J
AF Siaudvytyte, Lina
   Mitkute, Dovile
   Balciuniene, Jurate
TI Quality of Life in Patients With Age-Related Macular Degeneration
SO MEDICINA-LITHUANIA
LA English
DT Article
DE age-related macular degeneration; quality of life
ID VISUAL IMPAIRMENT; DEPRESSION
AB The aim of this study was to evaluate the quality of life in persons affected by age-related macular degeneration.
   Material and Methods. The study was performed in the Clinic of Ophthalmology, Hospital of Lithuanian University of Health Sciences. A total of 140 patients completed the Visual Functioning Questionnaire and the Hospital Anxiety and Depression Scale (HADS) during this prospective study. The patients were divided into two groups: patients with age-related macular degeneration (70 patients) and control patients (70 patients).
   Results. There was a significant difference in the quality of life between groups (P<0.0001). Analyzing patients with age-related macular degeneration within the group (patients with monocular or binocular disorders), significant differences in near vision (P=0.003), far vision (P=0.04), color vision (P=0.01), and social functioning (P=0.02) were observed. Mental health (r=0.326, P=0.02), dependency (r=0.340, P=0.02), and role difficulties (r=0.355. P=0.01) were found to be significantly associated with general vision in the age-related macular degeneration group.
   Conclusions. Age-related macular degeneration appeared to have a great impact on the quality of life. General vision impairment caused by age-related macular degeneration affects patient's mental health, dependency, and role difficulties.
C1 [Siaudvytyte, Lina; Balciuniene, Jurate] Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, LT-50028 Kaunas, Lithuania.
   [Mitkute, Dovile] Lithuanian Univ Hlth Sci, Fac Med, Med Acad, LT-50028 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Balciuniene, J (通讯作者)，Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, LT-50028 Kaunas, Lithuania.
EM jurate.balciuniene@kaunoklinikos.lt
RI Balciuniene, Vilma Jurate/AAL-3006-2020
OI Balciuniene, Vilma Jurate/0000-0001-6126-9351
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Morse JH, 1983, UNDERSTANDING LOW VI, P43
   Mykletun A, 2001, BRIT J PSYCHIAT, V179, P540, DOI 10.1192/bjp.179.6.540
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
NR 14
TC 16
Z9 18
U1 4
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PY 2012
VL 48
IS 2
BP 109
EP 111
DI 10.3390/medicina48020015
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 945NS
UT WOS:000304283800007
PM 22491386
OA gold
DA 2022-11-30
ER

PT J
AU Cheng, Y
   Huang, LZ
   Li, XX
   Qi, HJ
   Zhou, P
   Yu, WZ
   Jiang, YA
   Wadsworth, S
   Scaria, A
AF Cheng, Yong
   Huang, Lvzhen
   Li, Xiaoxin
   Qi, Huijun
   Zhou, Peng
   Yu, Wenzhen
   Jiang, Yide A.
   Wadsworth, Samuel
   Scaria, Abraham
TI Prevalence of Neutralizing Factors Against Adeno-Associated Virus Types
   2 in Age-Related Macular Degeneration and Polypoidal Choroidal
   Vasculopathy
SO CURRENT GENE THERAPY
LA English
DT Article
DE Neutralizing factors; adeno-associated virus types 2; age related
   macular degeneration; polypoidal choroidal vasculopathy
ID MEDIATED GENE-TRANSFER; ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT
   EPITHELIUM; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; VISUAL
   IMPAIRMENT; JAPANESE PATIENTS; IMMUNE-RESPONSES; VIRAL VECTORS;
   ANTIBODIES
AB Adeno-associated virus type 2 (AAV2) mediated gene therapy providing a potential treatment in the eye. However, immune responses can limit virally mediated gene transfer and therapy. To assess preexisting AAV2 neutralizing factors (NF) titers in peripheral blood and the vitreous in patients with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). 130 subjects were enrolled: 50 with neovascular AMD, 30 with PCV, and 50 controls. The serum and the vitreous were obtained for AAV2 NF assay. We found AAV2 NF are present in all of AMD, PCV patients and controls we tested. There were no significant differences in prevalence of NAb in serum between AMD, PCV and controls (P=0.999). There was no correlation between NF in serum and in vitreous (P>0.05), and NF in vitreous was significantly less than in serum. Our results for the first time showed in Chinese population, NF against AAV2 was present in serum of all the patients with AMD or PCV and controls, and there were no significant differences among these groups. Therefore, it demonstrated there were no correlations between AAV2 NF titer and these diseases. We found NF in vitreous was considerably less than in serum in all groups. We also found no direct correlation between NF in vitreous and in serum suggesting serum antibody levels may not be used to predict their counterparts in the vitreous. Our results will provide crucial information for future clinical studies in the development of new therapies based on AAV2 mediated gene delivery in the eye.
C1 [Cheng, Yong; Huang, Lvzhen; Li, Xiaoxin; Qi, Huijun; Zhou, Peng; Yu, Wenzhen] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Jiang, Yide A.; Wadsworth, Samuel; Scaria, Abraham] Genzyme Corp, Sanofi Genzyme R&D Ctr, Framingham, MA 01701 USA.
C3 Peking University; Sanofi-Aventis; Genzyme Corporation
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 1 11 XiZhiMen South Ave, Beijing 100871, Peoples R China.
EM drlixiaoxin@163.com
FU Genzyme Corporation of USA; National Basic Research Program of China
   (973 Program) [2011CB510200]; National Natural Science Foundation of
   China (NSFC) [81100666]; Research Fund for Science and Technology
   Program of Beijing [Z121100005312006]
FX Funding/Support: This study was supported by Genzyme Corporation of USA,
   National Basic Research Program of China (973 Program) grant
   2011CB510200, the National Natural Science Foundation of China (NSFC,
   No. 81100666), the Research Fund for Science and Technology Program of
   Beijing (No. Z121100005312006).
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Anand V, 2000, HUM GENE THER, V11, P449, DOI 10.1089/10430340050015914
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   Berns K I, 1999, Trans Am Clin Climatol Assoc, V110, P75
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830
   Chiang A, 2011, CURR OPIN OPHTHALMOL, V22, P199, DOI 10.1097/ICU.0b013e32834597d9
   Colella P, 2010, CURR GENE THER, V10, P371, DOI 10.2174/156652310793180670
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cottard V, 2004, J CLIN IMMUNOL, V24, P162, DOI 10.1023/B:JOCI.0000019781.64421.5c
   Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;406::AID-JMV22&gt;3.0.CO;2-N
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916
   Ge Y, 2001, BLOOD, V97, P3733, DOI 10.1182/blood.V97.12.3733
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Halbert CL, 1998, J VIROL, V72, P9795, DOI 10.1128/JVI.72.12.9795-9805.1998
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Li C, 2012, GENE THER, V19, P288, DOI 10.1038/gt.2011.90
   Li QH, 2008, MOL VIS, V14, P1760
   Liu Ning-pu, 2009, Zhonghua Yan Ke Za Zhi, V45, P393
   Lorenz B, 2010, CURR GENE THER, V10, P350, DOI 10.2174/156652310793180698
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mingozzi F, 2007, CURR GENE THER, V7, P316, DOI 10.2174/156652307782151425
   Moskalenko M, 2000, J VIROL, V74, P1761, DOI 10.1128/JVI.74.4.1761-1766.2000
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Peden CS, 2004, J VIROL, V78, P6344, DOI 10.1128/JVI.78.12.6344-6359.2004
   Rolling F, 1999, HUM GENE THER, V10, P641, DOI 10.1089/10430349950018715
   Sanftner LM, 2004, MOL THER, V9, P403, DOI 10.1016/j.ymthe.2003.12.005
   Sayen Alexandra, 2011, Rev Prat, V61, P159
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shen WY, 2003, J GENE MED, V5, P576, DOI 10.1002/jgm.375
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Sun JY, 2003, GENE THER, V10, P964, DOI 10.1038/sj.gt.3302039
   TOBIASCH E, 1994, J MED VIROL, V44, P215, DOI 10.1002/jmv.1890440218
   Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997
   Wobus CE, 2000, J VIROL, V74, P9281, DOI 10.1128/JVI.74.19.9281-9293.2000
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7
NR 49
TC 8
Z9 8
U1 2
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PD JUN
PY 2013
VL 13
IS 3
BP 182
EP 188
DI 10.2174/1566523211313030003
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 139SL
UT WOS:000318604400003
PM 23590636
DA 2022-11-30
ER

PT J
AU Xu, ZY
   Wang, WS
   Yang, JY
   Zhao, JC
   Ding, DY
   He, F
   Chen, D
   Yang, ZK
   Li, XR
   Yu, WH
   Chen, YX
AF Xu, Zhiyan
   Wang, Weisen
   Yang, Jingyuan
   Zhao, Jianchun
   Ding, Dayong
   He, Feng
   Chen, Di
   Yang, Zhikun
   Li, Xirong
   Yu, Weihong
   Chen, Youxin
TI Automated diagnoses of age-related macular degeneration and polypoidal
   choroidal vasculopathy using bi-modal deep convolutional neural networks
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; degeneration; retina; choroid; neovascularisation
ID CLASSIFICATION; DISEASES; IMAGES
AB Aims
   To investigate the efficacy of a bi-modality deep convolutional neural network (DCNN) framework to categorise age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) from colour fundus images and optical coherence tomography (OCT) images.
   Methods
   A retrospective cross-sectional study was proposed of patients with AMD or PCV who came to Peking Union Medical College Hospital. Diagnoses of all patients were confirmed by two retinal experts based on diagnostic gold standard for AMD and PCV. Patients with concurrent retinal vascular diseases were excluded. Colour fundus images and spectral domain OCT images were taken from dilated eyes of patients and healthy controls, and anonymised. All images were pre-labelled into normal, dry or wet AMD or PCV. ResNet-50 models were used as the backbone and alternate machine learning models including random forest classifiers were constructed for further comparison. For human-machine comparison, the same testing data set was diagnosed by three retinal experts independently. All images from the same participant were presented only within a single partition subset.
   Results
   On a test set of 143 fundus and OCT image pairs from 80 eyes (20 eyes per-group), the bi-modal DCNN demonstrated the best performance, with accuracy 87.4%, sensitivity 88.8% and specificity 95.6%, and a perfect agreement with diagnostic gold standard (Cohen's kappa 0.828), exceeds slightly over the best expert (Human1, Cohen's kappa 0.810). For recognising PCV, the model outperformed the best expert as well.
   Conclusion
   A bi-modal DCNN for automated classification of AMD and PCV is accurate and promising in the realm of public health.
C1 [Xu, Zhiyan; Yang, Jingyuan; He, Feng; Chen, Di; Yang, Zhikun; Yu, Weihong; Chen, Youxin] Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Xu, Zhiyan; Yang, Jingyuan; He, Feng; Chen, Di; Yang, Zhikun; Yu, Weihong; Chen, Youxin] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Wang, Weisen] Renmin Univ China, Sch Informat, AI & Media Comp Lab, Beijing, Peoples R China.
   [Zhao, Jianchun; Ding, Dayong] Visionary Intelligence Ltd, Vistel AI Lab, Beijing, Peoples R China.
   [Li, Xirong] Renmin Univ China, Dept State Of The Art Ophthalmol AI Res & Dev, Key Lab DEKE, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College;
   Renmin University of China; Renmin University of China
RP Chen, YX (通讯作者)，Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM chenyouxinpumch@163.com
RI Li, Xirong/AAD-3347-2019
OI Li, Xirong/0000-0002-0220-8310; He, Feng/0000-0001-7152-3034; chen,
   di/0000-0002-6983-1641; Xu, Zhiyan/0000-0002-3674-8198
FU Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]; CAMS Initiative for Innovative Medicine grant
   [2018-I2M-AI-001]; Pharmaceutical collaborative innovation research
   project of Beijing Science and Technology Commission [Z191100007719002];
   National Natural Science Foundation of China [61672523]; Beijing Natural
   Science Foundation Haidian original innovation joint fund [19L2062];
   Beijing Natural Science Foundation grant [4202033]
FX This work was supported by The Non-profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences grant number 2018PT32029,
   CAMS Initiative for Innovative Medicine grant number 2018-I2M-AI-001,
   Pharmaceutical collaborative innovation research project of Beijing
   Science and Technology Commission grant number Z191100007719002,
   National Natural Science Foundation of China grant number 61672523,
   Beijing Natural Science Foundation Haidian original innovation joint
   fund grant number 19L2062 and Beijing Natural Science Foundation grant
   number 4202033.
CR Ben-David A, 2008, EXPERT SYST APPL, V34, P825, DOI 10.1016/j.eswa.2006.10.022
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   CARSKI TR, 1978, JAMA-J AM MED ASSOC, V240, P635
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   El-Baz A, 2017, COMPUT MATH METHOD M, V2017, DOI 10.1155/2017/2361061
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Green RW, 1999, MOL VIS, V5
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khalid S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7148245
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liefers B, 2017, BIOMED OPT EXPRESS, V8, P5160, DOI 10.1364/BOE.8.005160
   Owens SL, 1996, BRIT J OPHTHALMOL, V80, P263, DOI 10.1136/bjo.80.3.263
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Rashno Abdolreza, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P3426, DOI 10.1109/EMBC.2018.8512998
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   Suzuki K, 2012, INT J BIOMED IMAGING, V2012, DOI 10.1155/2012/792079
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang HL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215076
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
NR 33
TC 12
Z9 13
U1 0
U2 18
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2021
VL 105
IS 4
BP 561
EP 566
DI 10.1136/bjophthalmol-2020-315817
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF3VI
UT WOS:000634768800020
PM 32499330
OA Bronze
DA 2022-11-30
ER

PT J
AU Lee, H
   Jang, M
   Kim, HC
   Chung, H
AF Lee, Hyungwoo
   Jang, Minsu
   Kim, Hyung Chan
   Chung, Hyewon
TI Association of imaging factors derived from convolutional neural network
   with visual outcomes in age-related macular degeneration and polypoidal
   choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RANIBIZUMAB; DISEASE; ACUITY
AB We investigated the association of visual outcome in typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) with or without pachychoroid with lesion areas on optical coherence tomography (OCT) quantified by convolutional neural network (CNN) analysis. Treatment-naive 132 nAMD and 45 PCV eyes treated with ranibizumab or aflibercept for at least 12 months were retrospectively reviewed. Significant factors, including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED) and subretinal hyperreflective material (SHRM) area quantified by CNN at baseline and 12 months, were analyzed by logistic regression analyses for 3-line visual gain or maintenance of 20/30 Snellen vision. Visual gain at the final visit in nAMD was associated with a smaller SHRM at baseline (OR 0.167, P = 0.03), greater decrease in SRF and SHRM from baseline to month 12 (OR 1.564, P = 0.02; OR 12.877, P = 0.01, respectively). Visual gain in nAMD without pachychoroid was associated with a greater decrease in SRF and SHRM (OR 1.574, P = 0.03, OR 1.775, P = 0.04). No association was found in nAMD with pachychoroid and any type of PCV. Greater decrease in SRF and SHRM from baseline to month 12 was associated with favorable visual outcomes in nAMD without pachychoroid but not in nAMD with pachychoroid and PCV.
C1 [Lee, Hyungwoo; Jang, Minsu; Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Chung, H (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, Seoul, South Korea.
EM hchung@kuh.ac.kr
FU Konkuk University [2018-A019-0335]
FX This paper was supported by Konkuk University in 2018 [Grant Number
   2018-A019-0335].
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 26
TC 1
Z9 1
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 27
PY 2019
VL 9
AR 19857
DI 10.1038/s41598-019-56420-z
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KF0RK
UT WOS:000508958900012
PM 31882702
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brown, MM
   Brown, GC
   Sharma, S
   Stein, JD
   Roth, Z
   Campanella, J
   Beauchamp, GR
AF Brown, Melissa M.
   Brown, Gary C.
   Sharma, Sanjay
   Stein, Joshua D.
   Roth, Zachary
   Campanella, Joseph
   Beauchamp, George R.
TI The burden of age-related macular degeneration: a value-based analysis
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE health state comparison; quality of life; utility analysis
ID QUALITY-OF-LIFE; UTILITY ANALYSIS; PROSTATE-CANCER; HEALTH STATES;
   COST-UTILITY; SCALE
AB Purpose of review
   The quality-of-life loss and the financial consequences associated with age-related macular degeneration are assessed.
   Recent findings
   The quality-of-life loss associated with macular degeneration is markedly underestimated by the general public, nonophthalmic physicians, and ophthalmologists who treat patients with this condition. Mild age-related macular degeneration causes a 17% decrement in the quality of life of the average patient, similar to that encountered with moderate cardiac angina or symptomatic human immunodeficiency virus syndrome. Moderate age-related macular degeneration causes a 40% decrease in the average patient's quality of life, similar to that associated with severe cardiac angina or renal dialysis. Very severe age-related macular degeneration causes a large 63% decrease in the average patient's quality of life, similar to that encountered with end-stage prostatic cancer or a catastrophic stroke that leaves a person bedridden, incontinent and requiring constant nursing care. The return on investment is high for both treatment with current age-related macular degeneration therapies and the research costs invested in the development of age-related macular degeneration treatment modalities.
   Summary
   Age-related macular degeneration is a major public health problem that has a devastating effect upon patients and marked adverse financial consequences for the economy.
C1 Ctr Value Based Med, Flourtown, PA 19031 USA.
   Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Eye Res Inst, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   Queens Med Coll, Cost Effect Ocular Hlth Policy Unit, Kingston, ON, Canada.
   NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   Texas SW Sch Med, Dallas, TX USA.
C3 University of Pennsylvania; University of Pennsylvania; Jefferson
   University; Jefferson University; New York University
RP Brown, MM (通讯作者)，Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
EM mbrown@valuebasedmedicine.com
RI Brown, Martin M/B-3288-2009
OI Stein, Joshua/0000-0003-2937-6987
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bosch JL, 1996, MED DECIS MAKING, V16, P217, DOI 10.1177/0272989X9601600305
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown GC, 2000, J DIABETES COMPLICAT, V14, P18, DOI 10.1016/S1056-8727(00)00061-1
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Brown MM, 2005, EVIDENCE BASED VALUE, P1
   *BUR LAB STAT, DAT DIS UN
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   CASE KE, 1996, PRINCIPLES EC, P1
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chapman GB, 1998, MED DECIS MAKING, V18, P278, DOI 10.1177/0272989X9801800304
   *CORP RAND, RAND 36 IT HLTH SURV
   DRUMMOND MF, 2000, METHODS EC EVALUATIO, P139
   Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   HOUSER M, 2003, PITTSBURGH TRIB 0223
   Kaplan RM, 1998, INT J QUAL HEALTH C, V10, P509, DOI 10.1093/intqhc/10.6.509
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773
   Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Lunde I M, 1993, Scand J Prim Health Care, V11, P98, DOI 10.3109/02813439308994910
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MCLEOD RS, 1991, GASTROENTEROLOGY, V101, P1307, DOI 10.1016/0016-5085(91)90081-U
   Miyamoto J M, 1985, Med Decis Making, V5, P191, DOI 10.1177/0272989X8500500208
   OLEARY JF, 1995, MED DECIS MAKING, V15, P132, DOI 10.1177/0272989X9501500205
   Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580
   SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3
   Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5
   Schrader GD, 1997, PSYCHOTHER PSYCHOSOM, V66, P258, DOI 10.1159/000289144
   Sharma S, 1997, CAN J OPHTHALMOL, V32, P359
   Stein J D, 2002, J Clin Hypertens (Greenwich), V4, P181, DOI 10.1111/j.1524-6175.2002.00970.x
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300
   Tengs TO, 2001, STROKE, V32, P964, DOI 10.1161/01.STR.32.4.964
   Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P1042, DOI 10.1007/s001980170015
   [No title captured]
NR 50
TC 70
Z9 71
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JUN
PY 2006
VL 17
IS 3
BP 257
EP 266
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 055XC
UT WOS:000238483500007
PM 16794438
DA 2022-11-30
ER

PT J
AU Batioglu, F
   Demirel, S
   Ozmert, E
AF Batioglu, Figen
   Demirel, Sibel
   Ozmert, Emin
TI Fundus Autofluorescence Imaging in Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; choroidal neovascularization; fundus
   autofluorescence; geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; MEASURING GEOGRAPHIC ATROPHY; BEAVER DAM
   EYE; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; JUNCTIONAL ZONE;
   VISUAL-LOSS; HUMAN RPE; HIGH-RISK; LIPOFUSCIN
AB Fundus autofluorescence (FAF) is a noninvasive imaging technology that provides information on the distribution of lipofuscin within the retinal pigment epithelial cells. Progressive accumulation of lipofuscin within retinal pigment epithelial cells is involved in the pathogenesis of age-related macular degeneration (AMD). Fundus autofluorescence imaging using a confocal scanning laser ophthalmoscope is a useful technique to identify high-risk characteristics in patients with nonexudative AMD. It gives also some valuable knowledge and clues in differantial diagnosis of exudative age-related macular degeneration. This review comprises an introduction to fundus autofluorescence, a review of FAF imaging in AMD, and the recent classification of geographic atrophy (GA) and early AMD phenotypes by the Fundus Autofluorescence in Age-related Macular Degeneration Study. The association of phenotype and atrophy progression and choroidal neovascularization development are also summarized.
C1 [Batioglu, Figen; Demirel, Sibel; Ozmert, Emin] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Koza Sokak,Mesa Ikizler Sitesi 70-40, Gop, Cankaya Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI DEMIREL, SIBEL/GQH-3232-2022; Batıoğlu, Figen/AAQ-3727-2020; Demirel,
   Sibel/AAQ-4282-2020
OI DEMIREL, SIBEL/0000-0002-2477-9974; Batıoğlu, Figen/0000-0002-5834-7512;
   Demirel, Sibel/0000-0002-6430-6565
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Chung JE, 2004, ARCH OPHTHALMOL-CHIC, V122, P1078, DOI 10.1001/archopht.122.7.1078
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Framme C, 2006, OPHTHAL SURG LAS IM, V37, P406, DOI 10.3928/15428877-20060901-08
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hashimoto T, 1999, JPN J OPHTHALMOL, V43, P375, DOI 10.1016/S0021-5155(99)00094-5
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   International ARM Epidemiology Study Group, 1995, SURV OPHTHALML, V39, P365
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P81, DOI 10.1055/s-2008-1034951
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 50
TC 6
Z9 6
U1 2
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JAN
PY 2015
VL 30
IS 1
BP 65
EP 73
DI 10.3109/08820538.2013.810285
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW7YT
UT WOS:000346478400014
PM 23952079
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Zucchiatti, I
   Cicinelli, MV
   Cascavilla, ML
   Bandello, F
AF Parodi, Maurizio Battaglia
   Zucchiatti, Ilaria
   Cicinelli, Maria Vittoria
   Cascavilla, Maria Lucia
   Bandello, Francesco
TI NUTRITIONAL SUPPLEMENTATION IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; age-related eye disease study;
   compliance; nutritional supplementation; vitamins
ID EYE DISEASE; CLINICAL-TRIAL; AREDS; RECOMMENDATIONS; ADHERENCE; IMPACT;
   RISK
AB Purpose: To evaluate the rate of adherence to prescribed nutritional supplementation in patients affected by age-related macular degeneration, in an Italian tertiary referral tertiary center.
   Methods: Patients with age-related macular degeneration, age-related eye disease study Categories 3 and 4, were recruited and underwent an 11-item questionnaire.
   Results: The study included a total of 193 patients meeting the age-related eye disease study nutritional supplementation criteria (174 patients with age-related eye disease study Category 4 and 19 with Category 3). Seventy-seven (40%) were taking oral supplementation, 70 of whom (90%) 1 tablet/day. Oral supplementation was recommended by the personal ophthalmologist in 85 patients (44%), including all those currently receiving it. Eight patients of 85 (9.4%) rejected supplementation despite it being recommended, mostly because they were already taking other medicines. Ninety-four patients (48%) claimed they had not received any information from their ophthalmologist.
   Conclusion: Our data reveal that Italian patients with age-related eye disease study Categories 3 and 4 have a low adherence to nutritional supplementation. In 65% of cases, patients were not adequately informed by their ophthalmologist of the potential benefits of oral supplementation for age-related macular degeneration; indeed, 108 patients (56%) were not even aware such nutritional treatments are available. Ophthalmologists should be aware of the importance of giving advice to persons with age-related macular degeneration regarding the benefits of oral supplements.
C1 [Parodi, Maurizio Battaglia; Zucchiatti, Ilaria; Cicinelli, Maria Vittoria; Cascavilla, Maria Lucia; Bandello, Francesco] Univ Vita Salute, Hosp San Raffaele, Dept Ophthalmol, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Zucchiatti, I (通讯作者)，Univ Vita Salute, Dept Ophthalmol, San Raffaele Sci Inst, I-20132 Milan, Italy.
EM ilaria.zucchiatti@gmail.com
RI Zucchiatti, Ilaria/ABA-7083-2020; bandello, francesco/AAH-2405-2019;
   Parodi, Maurizio Battaglia/K-7876-2016; cicinelli, maria
   vittoria/M-1611-2019
OI bandello, francesco/0000-0003-3238-9682; cicinelli, maria
   vittoria/0000-0003-2938-0409; Cascavilla, Maria
   Lucia/0000-0002-6344-5512; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Fahed DC, 2011, EUR J OPHTHALMOL, V21, P67, DOI 10.5301/EJO.2010.4138
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Kandula S, 2010, CLIN OPHTHALMOL, V4, P375
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
NR 16
TC 3
Z9 3
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2016
VL 36
IS 6
BP 1119
EP 1125
DI 10.1097/IAE.0000000000000852
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN5VJ
UT WOS:000377139100025
PM 26579787
DA 2022-11-30
ER

PT J
AU Nomura, Y
   Ueta, T
   Iriyama, A
   Inoue, Y
   Obata, R
   Tamaki, Y
   Yamaguchi, T
   Yanagi, Y
AF Nomura, Yoko
   Ueta, Takashi
   Iriyama, Aya
   Inoue, Yuji
   Obata, Ryo
   Tamaki, Yasuhiro
   Yamaguchi, Takuhiro
   Yanagi, Yasuo
TI Vitreomacular Interface in Typical Exudative Age-related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; JAPANESE PATIENTS;
   PATHOGENESIS; ADHESION
AB Purpose: To investigate the association in Japanese between posterior vitreous attachment and the pathologies of typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), 2 major forms of exudative AMD.
   Design: Retrospective observational case series.
   Participants: A total of 378 eyes from 302 subjects (132 with typical AMD, 126 with PCV, 120 controls) from the University of Tokyo Hospital.
   Methods: Posterior vitreous detachment (PVD) and vitreomacular adhesion (VMA) were investigated by B-mode ultrasonography and spectral-domain optical coherence tomography (SD-OCT), respectively. The greatest linear dimension (GLD) of initial photodynamic therapy (PDT) in a subset of the patients (n = 92) receiving PDT was also investigated.
   Main Outcome Measures: Number of eyes with complete PVD and with VMA. The GLD of initial PDT.
   Results: In typical AMD eyes, the frequency of complete PVD was significantly lower (63 [56.8%] of 111 eyes) than in the controls (52 [70.3%] of 74 eyes, risk ratio [RR] 0.76, P = 0.021) and the frequency of VMA tended to be higher (14/115 [12.2%] in typical AMD eyes and 6/86 [7.0%] in the controls, RR 2.15, P = 0.099). The frequency of complete PVD [77 [63.1%] of the 122 eyes] and VMA (9/108 [8.3%]) in PCV eyes was the same as the controls (RR 0.91, P = 0.415 and RR 1.29, P = 0.615). In patients with unilateral exudative AMD, the frequency of complete PVD was lower in typical AMD eyes than in fellow eyes (odds ratio [OR] 0.111, P = 0.026) and VMA was observed in 7 (17.5%) and 3 (7.5%) typical AMD and fellow eyes, respectively (OR 2.33, P = 0.34), whereas in PCV eyes, the frequency of complete PVD was higher (OR 8.00, P = 0.045) and the frequency of VMA was the same as in the fellow eyes (OR 0.80, P = 1.00). The GLD of the eyes without complete PVD or with VMA was significantly larger than that in the eyes with complete PVD in typical AMD eyes (P = 0.042) and the same as that in the eyes with complete PVD in PCV eyes (P = 0.67).
   Conclusions: There is an association between posterior vitreous attachment and typical AMD. However, this association is not evident in PCV.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 853-859 (C) 2011 by the American Academy of Ophthalmology.
C1 [Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Yamaguchi, Takuhiro] Univ Tokyo, Grad Sch Med, Dept Clin Trial Data Management, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
FX Supported in part by a Grant in Aid from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan.
CR Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P32, DOI 10.1016/j.ajo.2009.07.036
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nigam N, 2010, RETINA-J RET VIT DIS, V30, P246, DOI 10.1097/IAE.0b013e3181baf6dc
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 28
Z9 32
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2011
VL 118
IS 5
BP 853
EP 859
DI 10.1016/j.ophtha.2010.09.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757MM
UT WOS:000290090300010
PM 21095010
DA 2022-11-30
ER

PT J
AU Itty, S
   Day, S
   Lyles, KW
   Stinnett, SS
   Vajzovic, LM
   Mruthyunjaya, P
AF Itty, Sujit
   Day, Shelley
   Lyles, Kenneth W.
   Stinnett, Sandra S.
   Vajzovic, Lejla M.
   Mruthyunjaya, Prithvi
TI VITAMIN D DEFICIENCY IN NEOVASCULAR VERSUS NONNEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitamin D; 25-hydroxyvitamin D; vitamin D deficiency; age-related
   macular degeneration; neovascular AMD; nonneovascular AMD
ID CLINICAL-TRIAL; IMMUNE-SYSTEM; ASSOCIATION; RETINOPATHY; RISK;
   MACULOPATHY; CALCITRIOL; MORTALITY; HEALTH; CELLS
AB Purpose: To compare 25-hydroxyvitamin D (25OHD) levels in patients with neovascular age-related macular degeneration (NVAMD) with patients with nonneovascular age-related macular degeneration and control patients.
   Methods: Medical records of all patients diagnosed with age-related macular degeneration and tested for serum 25OHD level at a single medical center were reviewed. Control patients were selected from patients diagnosed with pseudophakia but without age-related macular degeneration. The lowest 25OHD level available for each patient was recorded.
   Results: Two hundred sixteen patients with nonneovascular age-related macular degeneration, 146 with NVAMD, and 100 non-age-related macular degeneration control patients were included. The levels of 25OHD (mean +/- SD) were significantly lower in NVAMD patients (26.1 +/- 14.4 ng/mL) versus nonneovascular age-related macular degeneration (31.5 +/- 18.2 ng/mL, P = 0.003) and control (29.4 +/- 10.1 ng/mL, P = 0.049) patients. The prevalence of vitamin D insufficiency (<30 ng/mL 25OHD), deficiency (<20 ng/mL), and severe deficiency (<10 ng/mL) were highest in the NVAMD group. The highest quintile of 25OHD was associated with a 0.35 (95% confidence interval, 0.18-0.68) odds ratio for NVAMD.
   Conclusion: This is the largest study to compare 25OHD levels in patients with the different clinical forms of age-related macular degeneration. Mean 25OHD levels were lower and vitamin D deficiency was more prevalent in NVAMD patients. These associations suggest that further research is necessary regarding vitamin D deficiency as a potentially modifiable risk factor for the development of NVAMD.
C1 [Itty, Sujit; Vajzovic, Lejla M.; Mruthyunjaya, Prithvi] Duke Univ, Dept Ophthalmol, Med Ctr, Durham, NC 27706 USA.
   [Day, Shelley] Stanford Med Ctr, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Lyles, Kenneth W.] Duke Univ, Dept Med, Med Ctr, Durham, NC 27706 USA.
   [Lyles, Kenneth W.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
   [Lyles, Kenneth W.] Carolinas Ctr Med Excellence, Cary, NC USA.
   [Stinnett, Sandra S.] Duke Univ, Med Ctr, Div Biostat, Durham, NC 27706 USA.
C3 Duke University; Stanford University; Duke University; Geriatric
   Research Education & Clinical Center; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Duke University
RP Mruthyunjaya, P (通讯作者)，Duke Eye Ctr, DUMC 3802, Durham, NC 27710 USA.
EM prithvi.m@duke.edu
OI Stinnett, Sandra/0000-0001-7192-0195; mruthyunjaya,
   prithvi/0000-0003-1087-9736; Day Ghafoori, Shelley/0000-0001-6674-7877
FU NIH Grant [2P308716-06]; NATIONAL INSTITUTE ON AGING [P30AG028716,
   P60AG011268] Funding Source: NIH RePORTER
FX Supported in part by NIH Grant 2P308716-06 (K.W.L).
CR Adams JS, 2010, J CLIN ENDOCR METAB, V95, P471, DOI 10.1210/jc.2009-1773
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   [Anonymous], 2013, JAMA, V309, P2005
   Bao BY, 2008, INT J CANCER, V122, P2699, DOI 10.1002/ijc.23460
   Ben-Shoshan M, 2007, MOL CANCER THER, V6, P1433, DOI 10.1158/1535-7163.MCT-06-0677
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Freedman DM, 2007, JNCI-J NATL CANCER I, V99, P1594, DOI 10.1093/jnci/djm204
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Kaur H, 2011, DIABETES CARE, V34, P1400, DOI 10.2337/dc11-0103
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krishnan AV, 2011, ANNU REV PHARMACOL, V51, P311, DOI 10.1146/annurev-pharmtox-010510-100611
   Lai JKC, 2012, INTERN MED J, V42, P43, DOI 10.1111/j.1445-5994.2011.02471.x
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Patrick PA, 2012, ARCH OPHTHALMOL-CHIC, V130, P756, DOI 10.1001/archophthalmol.2011.2749
   Payne JF, 2012, ENDOCR PRACT, V18, P185, DOI 10.4158/EP11147.OR
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Perkins AJ, 2004, J CLIN EPIDEMIOL, V57, P1040, DOI 10.1016/j.jclinepi.2004.03.002
   SAS Institute Inc, 1999, SAS STAT 9 2 US GUID
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Yin ZH, 2011, INVEST OPHTH VIS SCI, V52, P7359, DOI 10.1167/iovs.11-7605
   2001, ARCH OPHTHALMOL, V119, P1417
NR 35
TC 27
Z9 28
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1779
EP 1786
DI 10.1097/IAE.0000000000000178
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400013
PM 24946100
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ly, A
   Nivison-Smith, L
   Zangerl, B
   Assaad, N
   Kalloniatis, M
AF Ly, Angelica
   Nivison-Smith, Lisa
   Zangerl, Barbara
   Assaad, Nagi
   Kalloniatis, Michael
TI Self-reported optometric practise patterns in age-related macular
   degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; diagnosis; optometrist; patterns of
   practice
ID DARK-ADAPTATION; PERIMETRY; OPHTHALMOLOGISTS; NUTRITION; ATTITUDES;
   BARRIERS; CARE
AB BackgroundThe use of advanced imaging in clinical practice is emerging and the use of this technology by optometrists in assessing patients with age-related macular degeneration is of interest. Therefore, this study explored contemporary, self-reported patterns of practice regarding age-related macular degeneration diagnosis and management using a cross-sectional survey of optometrists in Australia and New Zealand.
   MethodsPractising optometrists were surveyed on four key areas, namely, demographics, clinical skills and experience, assessment and management of age-related macular degeneration. Questions pertaining to self-rated competency, knowledge and attitudes used a five-point Likert scale.
   ResultsCompleted responses were received from 127 and 87 practising optometrists in Australia and New Zealand, respectively. Advanced imaging showed greater variation in service delivery than traditional techniques (such as slitlamp funduscopy) and trended toward optical coherence tomography, which was routinely performed in age-related macular degeneration by 49 per cent of respondents. Optical coherence tomography was also associated with higher self-rated competency, knowledge and perceived relevance to practice than other modalities. Most respondents (93 per cent) indicated that they regularly applied patient symptoms, case history, visual function results and signs from traditional testing, when queried about their management of patients with age-related macular degeneration. Over half (63 per cent) also considered advanced imaging, while 31 per cent additionally considered all of these as well as the disease stage and clinical guidelines. Contrary to the evidence base, 68 and 34 per cent rated nutritional supplements as highly relevant or relevant in early age-related macular degeneration and normal aging changes, respectively.
   ConclusionsThese results highlight the emergence of multimodal and advanced imaging (especially optical coherence tomography) in the assessment of age-related macular degeneration by optometrists. Clinically significant variations in self-rated test competency and the understanding regarding nutritional supplements for different stages of age-related macular degeneration suggest that further work to up-skill optometrists may be required.
C1 [Ly, Angelica; Nivison-Smith, Lisa; Zangerl, Barbara; Assaad, Nagi; Kalloniatis, Michael] Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Nivison-Smith, Lisa; Zangerl, Barbara; Kalloniatis, Michael] Univ New South Wales, Sch Optometry & Vis Sci, Kensington, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW, Australia.
C3 University of New South Wales Sydney
RP Kalloniatis, M (通讯作者)，Ctr Eye Hlth, Sydney, NSW, Australia.; Kalloniatis, M (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Kensington, NSW, Australia.
EM m.kalloniatis@unsw.edu.au
RI Ly, Angelica/J-2070-2019
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Nivison-Smith, Lisa/0000-0001-6677-1949
FU University of New South Wales [P535430]; National Health and Medical
   Research Council (NHMRC) [1033224]; NHMRC
FX This work was supported, in part, by grants and awards from the
   University of New South Wales (Early Career Research Grant 2016
   #P535430, an Australian Postgraduate Award) and a National Health and
   Medical Research Council (NHMRC) grant (#1033224). Guide Dogs NSW/ACT is
   a partner in the NHMRC grant and also provided a supplementary PhD
   scholarship for Angelica Ly and support for Lisa Nivison-Smith.
CR Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Alnahedh T, 2015, CLIN EXP OPTOM, V98, P263, DOI 10.1111/cxo.12238
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, AG REL MAC DEG
   American Optometric Association Consensus Panel on Care of the Patient with Age-Related Macular Degeneration, 2004, CAR PAT AG REL MAC D
   Anderton PJ, 2007, CLIN EXP OPTOM, V90, P238, DOI 10.1111/j.1444-0938.2007.00153.x
   Batioglu F, 2015, SEMIN OPHTHALMOL, V30, P65, DOI 10.3109/08820538.2013.810285
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Carnett W G, 1999, Qual Manag Health Care, V8, P13
   Choi AYJ, ARVO ABSTRACTS 2016
   Dabasia PL, 2014, OPHTHAL PHYSL OPT, V34, P592, DOI 10.1111/opo.12150
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Downie LE, 2015, NUTRITION, V31, P669, DOI 10.1016/j.nut.2014.10.020
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P932, DOI 10.1097/OPX.0000000000000246
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frederikson LG, 2008, CLIN EXP OPTOM, V91, P353, DOI 10.1111/j.1444-0938.2007.00225.x
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Graham AM, 2007, CLIN EXP OPTOM, V90, P244, DOI 10.1111/j.1444-0938.2007.00148.x
   Grover Lori L, 2008, Optometry, V79, P355, DOI 10.1016/j.optm.2008.04.098
   Heidarian A, 2013, CLIN EXP OPTOM, V96, P557, DOI 10.1111/cxo.12059
   Jamous KF, 2014, OPHTHAL PHYSL OPT, V34, P580, DOI 10.1111/opo.12146
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   KALLONIATIS M, 1993, OPHTHAL PHYSL OPT, V13, P155, DOI 10.1111/j.1475-1313.1993.tb00445.x
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, P145
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Ly A, 2016, OPTOM VIS SCI
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   MacDonald KA, 2014, J MED LIBR ASSOC, V102, P210, DOI 10.3163/1536-5050.102.3.013
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Optometry Board of Australia, 2015, OPT REG DAT
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Shah R, 2007, OPHTHAL PHYSL OPT, V27, P113, DOI 10.1111/j.1475-1313.2006.00481.x
   Suttle CM, 2015, OPTOMETRY VISION SCI, V92, P514, DOI 10.1097/OPX.0000000000000550
   Suttle CM, 2012, CLIN EXP OPTOM, V95, P28, DOI 10.1111/j.1444-0938.2011.00663.x
   The Angiogenesis Foundation, 2012, REP BAS AUSTR WET AG
   The Macular Degeneration Foundation, 2008, PROJ VIS MACUL DEG F
   The Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID
   Ting DSW, 2011, CLIN EXP OPHTHALMOL, V39, P230, DOI 10.1111/j.1442-9071.2010.02446.x
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Veloski J, 2005, AM J MED QUAL, V20, P151, DOI 10.1177/1062860605274520
   White A, 2014, CLIN EXP OPHTHALMOL, V42, P107, DOI 10.1111/ceo.12270
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 52
TC 8
Z9 8
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2017
VL 100
IS 6
BP 718
EP 728
DI 10.1111/cxo.12528
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM4FI
UT WOS:000414968100025
PM 28266060
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Chong, NV
   Bailey, TA
AF Sivaprasad, S
   Chong, NV
   Bailey, TA
TI Serum elastin-derived peptides in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION; EXTRACELLULAR-MATRIX;
   GENE-TRANSCRIPTION; RISK-FACTORS; MACULOPATHY; DRUSEN; ANTIBODIES;
   EMPHYSEMA; METALLOPROTEINASES
AB PURPOSE. Dysregulation of the extracellular matrix (ECM) plays an important role in the pathogenesis of age-related macular degeneration (AMD). Elastin is a fibrous protein constituent of the ECM, degradation of which may be detected by the presence of serum elastin-derived peptides (S-EDPs) in circulation. This study was undertaken to estimate levels of S-EDPs in patients with AMD compared with age-matched control subjects.
   METHODS. Fifty-six patients with AMD were classified into two groups: early age-related maculopathy (ARM) and neovascular AMD. The control group consisted of 15 age-matched subjects with no AMD. S-EDP levels in the serum of these subjects was estimated by competitive ELISA, using solubilized alpha-elastin from human aorta and polyclonal antibodies to this antigen.
   RESULTS. S-EDPs were significantly higher in patients with AMD than in control subjects. In addition, subjects with neovascular AMD had higher levels of S-EDPs than did those with early disease.
   CONCLUSIONS. The cause of this association between S-EDPs and AMD is unknown, but it suggests that systemic elastin degradation may increase the risk of conversion from early ARM to neovascular AMD. Further studies are needed to confirm whether the serum level of S-EDPs is a useful predictor of conversion from early ARM to neovascular AMD.
C1 Kings Coll Hosp London, Laser & Retinal Res Unit, London SE5 9RS, England.
   Cranfield Univ, Cranfield BioMed Ctr, Silsoe, Beds, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   Cranfield University
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Chong, Ngaihang V/A-5141-2009; Chong, Victor/Q-6565-2018; Sivaprasad,
   S./D-6876-2015
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson CR, 2004, J HISTOCHEM CYTOCHEM, V52, P1063, DOI 10.1369/jhc.4A6250.2004
   BAYDANOFF S, 1987, ATHEROSCLEROSIS, V66, P163, DOI 10.1016/0021-9150(87)90192-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bizbiz L, 1997, ATHEROSCLEROSIS, V131, P73, DOI 10.1016/S0021-9150(97)06076-0
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bouissou H, 1985, DEGENERATIVE DIS CON, P203
   Carreras I, 2002, J CELL BIOCHEM, V85, P592, DOI 10.1002/jcb.10163
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Colburn KK, 2003, J INVEST MED, V51, P104, DOI 10.1136/jim-51-02-12
   DIGHIERO G, 1986, ANN NY ACAD SCI, V475, P135, DOI 10.1111/j.1749-6632.1986.tb20863.x
   Fulop T, 1998, PATHOL BIOL, V46, P497
   FULOP T, 1990, CLIN PHYSIOL BIOCH, V8, P273
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HORNEBECK W, 1986, STRUCTURAL GLYCOPROT, P58
   HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kuang PP, 2003, AM J PHYSIOL-CELL PH, V285, pC1349, DOI 10.1152/ajpcell.00173.2003
   KUCICH U, 1983, AM REV RESPIR DIS, V127, pS28
   Labat-Robert J, 2004, AGEING RES REV, V3, P233, DOI 10.1016/j.arr.2003.10.002
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lindholt JS, 1997, EUR J VASC ENDOVASC, V14, P12, DOI 10.1016/S1078-5884(97)80219-5
   MECHAM RP, 1982, METHOD ENZYMOL, V82, P744
   Nackman GB, 1996, ANN NY ACAD SCI, V800, P260, DOI 10.1111/j.1749-6632.1996.tb33325.x
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Pardo A, 1999, HISTOL HISTOPATHOL, V14, P227, DOI 10.14670/HH-14.227
   PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petersen E, 2002, EUR J VASC ENDOVASC, V24, P440, DOI 10.1053/ejvs.2002.1750
   Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3
   SAULNIER JM, 1991, CLIN CHIM ACTA, V200, P129, DOI 10.1016/0009-8981(91)90084-P
   SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VINE N, 1991, CLIN SCI, V81, P233, DOI 10.1042/cs0810233
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WEI SM, 1993, J IMMUNOL METHODS, V164, P175
NR 46
TC 27
Z9 28
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2005
VL 46
IS 9
BP 3046
EP 3051
DI 10.1167/iovs.04-1277
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 959AH
UT WOS:000231488800006
PM 16123400
DA 2022-11-30
ER

PT J
AU Liew, G
   Mitchell, P
   Wong, TY
   Iyengar, SK
   Wang, JJ
AF Liew, Gerald
   Mitchell, Paul
   Wong, Tien Yin
   Iyengar, Sudha K.
   Wang, Jie Jin
TI CKD increases the risk of age-related macular degeneration
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; BLUE-MOUNTAINS EYE; DENSE DEPOSIT DISEASE;
   BLOOD-CELL COUNT; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   CARDIOVASCULAR-DISEASE; RENAL-DISEASE; ASSOCIATION; COMPLEMENT;
   MACULOPATHY
AB Age-related macular degeneration is the leading cause of irreversible blindness in the United States and often coexists with chronic kidney disease. Both conditions share common genetic and environmental risk factors. A total of 1183 participants aged 54+ were examined in the population-based, prospective cohort Blue Mountains Eye Study (Australia) to determine if chronic kidney disease increases the risk of age-related macular degeneration. Moderate chronic kidney disease (estimated glomerular filtration rate < 60 ml/min per 1.73 m(2) based on the Cockcroft-Gault equation) was present in 24% of the population (286 of 1183). The 5-yr incidence of early age-related macular degeneration was 3.9% in participants with no/mild chronic kidney disease (35 of 897) and 17.5% in those with moderate chronic kidney disease (50 of 286). After adjusting for age, sex, cigarette smoking, hypertension, complement factor H polymorphism, and other risk factors, persons with moderate chronic kidney disease were 3 times more likely to develop early age-related macular degeneration than persons with no/mild chronic kidney disease (odds ratio = 3.2; 95% confidence interval, 1.8 to 5.7, P < 0.0001). Each SD (14.8 ml/min per 1.73 m(2)) decrease in Cockcroft-Gault estimated glomerular filtration rate was associated with a doubling of the adjusted risk for early age-related macular degeneration (odds ratio = 2.0; 95% confidence interval, 1.5 to 2.8, P < 0.0001). In conclusion, persons with chronic kidney disease have a higher risk of early age-related macular degeneration, suggesting the possibility of shared pathophysiologic mechanisms between the two conditions.
C1 [Liew, Gerald; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Wong, Tien Yin; Wang, Jie Jin] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
C3 University of Sydney; Westmead Institute for Medical Research; Centre
   for Eye Research Australia; University of Melbourne; National University
   of Singapore; Singapore National Eye Center; Case Western Reserve
   University
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Liew,
   Gerald/AAB-6870-2022; Wong, Tien Yin/AAC-9724-2020; wang,
   jie/GRS-0942-2022; /S-1190-2019
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   /0000-0001-7488-250X
FU NATIONAL EYE INSTITUTE [R01EY015810] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY015810, EY015810] Funding Source: Medline
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Bostom AG, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022011.35035.F3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007
   Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Ejerblad E, 2004, J AM SOC NEPHROL, V15, P2178, DOI 10.1097/01.ASN.0000135048.35659.10
   Elsayed EF, 2007, ARCH INTERN MED, V167, P1130, DOI 10.1001/archinte.167.11.1130
   Freedman BI, 2007, ARCH INTERN MED, V167, P1113, DOI 10.1001/archinte.167.11.1113
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hsu CC, 2005, JAMA-J AM MED ASSOC, V293, P2892, DOI 10.1001/jama.293.23.2892
   Jones GRD, 2003, CLIN BIOCHEM REV, V24, P95
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Matejas V, 2006, NEPHROL DIAL TRANSPL, V21, P3283, DOI 10.1093/ndt/gfl463
   RAMBAUSEK M, 1987, SEMIN NEPHROL, V7, P370
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2006, ARCH INTERN MED, V166, P188, DOI 10.1001/archinte.166.2.188
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Vidt DG, 2006, AM J CARDIOL, V97, p20A, DOI 10.1016/j.amjcard.2005.11.012
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 32
TC 47
Z9 47
U1 1
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD APR
PY 2008
VL 19
IS 4
BP 806
EP 811
DI 10.1681/ASN.2007080844
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 283TJ
UT WOS:000254659100024
PM 18216312
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Lee, TG
   Kim, CG
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Lee, Tae Gon
   Kim, Chul Gu
TI PREVALENCE OF SUBTYPES OF RETICULAR PSEUDODRUSEN IN NEWLY DIAGNOSED
   EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL
   VASCULOPATHY IN KOREAN PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE reticular pseudodrusen; subtype; age-related macular degeneration;
   choroidal neovascularization; drusen; retinal angiomatous proliferation
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY;
   SUBRETINAL DRUSENOID DEPOSITS; VISUAL IMPAIRMENT; HEALTHY-SUBJECTS;
   ADAPTIVE OPTICS; BLOOD-FLOW; FELLOW EYE; NEOVASCULARIZATION; ASSOCIATION
AB Purpose: To evaluate the prevalence and characteristics of subtypes of pseudodrusen in newly diagnosed exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Methods: This retrospective cross-sectional study included 321 eyes of 321 patients who were newly diagnosed with exudative AMD or PCV. Reticular pseudodrusen was classified into dot pseudodrusen and ribbon pseudodrusen; the prevalence of each subtype was estimated and compared between exudative AMD excluding retinal angiomatous proliferation (RAP), PCV, and RAP. Patient age and choroidal thickness were compared between patients with dot pseudodrusen only and those with ribbon pseudodrusen.
   Results: The prevalence of reticular pseudodrusen was 13.9% (15 of 108 eyes) in exudative AMD excluding RAP, 3.4% (6 of 175 eyes) in PCV, and 68.4% (27 of 38 eyes) in RAP. Among the eyes with pseudodrusen, dot pseudodrusen and ribbon pseudodrusen were noted in 100% and 40.0%, respectively, in exudative AMD excluding RAP, 100% and 16.7%, respectively, in PCV, and 96.2% and 69.2%, respectively, in RAP. Ribbon pseudodrusen was more frequently observed in RAP (P = 0.032). Patients with ribbon pseudodrusen were significantly older (77.3 +/- 6.6 years vs. 72.9 +/- 8.1 years, P = 0.042) than those with dot pseudodrusen only.
   Conclusion: The markedly higher incidence of ribbon pseudodrusen in RAP may suggest possible influence of ribbon pseudodrusen on the development of RAP.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Kim, Chul Gu] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Yeongdeungpo Dong 4 Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX Supported by Kim's Eye Hospital Research Center.
CR Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim JH, 2013, GRAEF ARCH CLIN EXP, V251, P1091, DOI 10.1007/s00417-012-2147-9
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim M, 2012, INVEST OPHTH VIS SCI, V53, P7710, DOI 10.1167/iovs.12-10464
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nateras OS, 2014, CURR EYE RES, V39, P1059, DOI 10.3109/02713683.2014.892997
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Straubhaar M, 2000, ARCH OPHTHALMOL-CHIC, V118, P211
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 39
TC 29
Z9 29
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2015
VL 35
IS 12
BP 2604
EP 2612
DI 10.1097/IAE.0000000000000633
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF4OV
UT WOS:000371329800026
PM 26049615
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Loenhardt, T
   Janssen, A
   Fisher, SA
   Rivera, A
   Keilhauer, CN
   Weber, BHF
AF Fritsche, Lars G.
   Loenhardt, Thomas
   Janssen, Andreas
   Fisher, Sheila A.
   Rivera, Andrea
   Keilhauer, Claudia N.
   Weber, Bernhard H. F.
TI Age-related macular degeneration is associated with an unstable ARMS2
   (LOC387715) mRNA
SO NATURE GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; X-LINKED RETINOSCHISIS; MACULOPATHY; HTRA1;
   SUSCEPTIBILITY; POLYMORPHISM; HAPLOTYPE; DISEASE; VARIANT; GENE
AB Age-related macular degeneration (AMD) is a prevalent multifactorial disorder of the central retina(1-3). Genetic variants at two chromosomal loci, 1q31 and 10q26, confer major disease risks, together accounting for more than 50% of AMD pathology(4-9). Signals at 10q26 center over two nearby genes, ARMS2 (age-related maculopathy susceptibility 2, also known as LOC387715)(8,9) and HTRA1 (high-temperature requirement factor A1)(10,11), suggesting two equally probable candidates. Here we show that a deletion-insertion polymorphism in ARMS2 (NM_001099667.1: c.*372_815del443ins54) is strongly associated with AMD, directly affecting the transcript by removing the polyadenylation signal and inserting a 54-bp element known to mediate rapid mRNA turnover. As a consequence, expression of ARMS2 in homozygous carriers of the indel variant is not detectable. Confirming previous findings(12), we demonstrate a mitochondrial association of the normal protein and further define its retinal localization to the ellipsoid region of the photoreceptors. Our data suggest that ARMS2 has a key role in AMD, possibly through mitochondria-related pathways.
C1 [Fritsche, Lars G.; Loenhardt, Thomas; Janssen, Andreas; Rivera, Andrea; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Fisher, Sheila A.] St Thomas Hosp, London WC2R 2LS, England.
   [Fisher, Sheila A.] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England.
   [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
C3 University of Regensburg; Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London; University of Wurzburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Weber, Bernhard
   H.F./0000-0002-8808-7723
CR Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   DUDBRIDGE F, 2006, 5 MRC BIOST UN
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khabar KSA, 2005, J INTERF CYTOK RES, V25, P1, DOI 10.1089/jir.2005.25.1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wu WWH, 2003, J BIOL CHEM, V278, P28139, DOI 10.1074/jbc.M302464200
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd
NR 28
TC 305
Z9 318
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUL
PY 2008
VL 40
IS 7
BP 892
EP 896
DI 10.1038/ng.170
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 319MA
UT WOS:000257166500025
PM 18511946
DA 2022-11-30
ER

PT J
AU Chen, M
   Xu, HP
AF Chen, Mei
   Xu, Heping
TI Parainflammation, chronic inflammation, and age-related macular
   degeneration
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Review
DE retina; blood-retina barrier; immune privilege; microglia; complement
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN;
   AMYLOID-BETA STIMULATION; INNATE IMMUNE-RESPONSES; NLRP3 INFLAMMASOME;
   OXIDATIVE STRESS; BRUCHS MEMBRANE; RAT RETINA; CELL-DEATH
AB Inflammation is an adaptive response of the immune system to noxious insults to maintain homeostasis and restore functionality. The retina is considered an immune-privileged tissue as a result of its unique anatomic and physiologic properties. During aging, the retina suffers from a low-grade chronic oxidative insult, which sustains for decades and increases in level with advancing age. As a result, the retinal innate-immune system, particularly microglia and the complement system, undergoes low levels of activation (parainflammation). In many cases, this parainflammatory response can maintain homeostasis in the healthy aging eye. However, in patients with age-related macular degeneration, this parainflammatory response becomes dysregulated and contributes to macular damage. Factors contributing to the dysregulation of age-related retinal parainflammation include genetic predisposition, environmental risk factors, and old age. Dysregulated parainflammation (chronic inflammation) in age-related macular degeneration damages the blood retina barrier, resulting in the breach of retinal-immune privilege, leading to the development of retinal lesions. This review discusses the basic principles of retinal innate-immune responses to endogenous chronic insults in normal aging and in age-related macular degeneration and explores the difference between beneficial parainflammation and the detrimental chronic inflammation in the context of age-related macular degeneration.
C1 [Chen, Mei; Xu, Heping] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X
FU Fight for Sight [1361/1362, 1425/1426]; Dunhill Medical Trust
   [R188/0211]; Research into Ageing [322]; National Eye Research Center
   [SCIAD 061]; The Dunhill Medical Trust [R188/0211] Funding Source:
   researchfish; Fight for Sight [1361/62, 1425/26] Funding Source:
   researchfish
FX Funding support is provided by Fight for Sight (1361/1362; 1425/1426),
   Dunhill Medical Trust (R188/0211), Research into Ageing (322), and
   National Eye Research Center (SCIAD 061). The authors acknowledge the
   researchers who have greatly contributed to this field but whose work
   was not cited as a result of space limitations. The authors thank Drs.
   Derek Brazil and Adrien Kissenpfennig for critically reading the
   manuscript and for helping with English expression.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Aspengren S, 2006, PIGM CELL RES, V19, P136, DOI 10.1111/j.1600-0749.2005.00290.x
   Avichezer D, 2003, J EXP MED, V198, P1665, DOI 10.1084/jem.20030413
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307
   Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881
   Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan-Ling T, 2007, MICROCIRCULATION, V14, P63, DOI 10.1080/10739680601073451
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen M, 2010, EUR J IMMUNOL, V40, P2870, DOI 10.1002/eji.201040323
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen XT, 2013, J NEUROPATH EXP NEUR, V72, P782, DOI 10.1097/NEN.0b013e31829e8375
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9
   Desai A, 2010, J LEUKOCYTE BIOL, V87, P1001, DOI 10.1189/jlb.0809542
   DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x
   Ferguson Thomas A, 2007, Chem Immunol Allergy, V92, P140, DOI 10.1159/000099265
   Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fumagalli M, 2009, NAT CELL BIOL, V11, P921, DOI 10.1038/ncb0809-921
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Ghaemi-Oskouie F, 2011, CURR RHEUMATOL REP, V13, P160, DOI 10.1007/s11926-011-0162-1
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Goto M, 2008, BIOSCI TRENDS, V2, P218
   Gregerson DS, 1998, OCUL IMMUNOL INFLAMM, V6, P257, DOI 10.1076/ocii.6.4.257.4029
   Gregerson DS, 2003, INVEST OPHTH VIS SCI, V44, P3083, DOI 10.1167/iovs.02-1014
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hjelmeland LM, 1999, MOL VIS, V5
   Hoffman M, 2004, ATHEROSCLEROSIS, V172, P1, DOI 10.1016/S0021-9150(03)00164-3
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Ida H, 2003, PHYSIOL GENOMICS, V15, P258, DOI 10.1152/physiolgenomics.00126.2003
   Ilhan N, 2014, OCULAR IMMUNOLOGY IN, P1, DOI 10.3109/09273948.2014.970283
   Inoue Y, 2009, BRAIN RES, V1256, P55, DOI 10.1016/j.brainres.2008.12.023
   Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Johnson JD, 2006, J LEUKOCYTE BIOL, V79, P425, DOI 10.1189/jlb.0905523
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lathe R, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-36
   Lehmann U, 2010, NEUROBIOL DIS, V40, P177, DOI 10.1016/j.nbd.2010.05.022
   Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2011, MOL VIS, V17, P1588
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mangge H, 2010, CURR MED CHEM, V17, P4511, DOI 10.2174/092986710794183006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Mian MF, 2008, J LEUKOCYTE BIOL, V83, P774, DOI 10.1189/jlb.0707481
   Min JK, 2015, OCUL IMMUNOL INFLAMM, V23, P205, DOI 10.3109/09273948.2014.891755
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Ozgonul C, 2014, OCUL IMMUNOL INFLAMM, P1
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Sasaki M, 2010, J HEPATOL, V53, P318, DOI 10.1016/j.jhep.2010.03.008
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Severino V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.445
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Soulas C, 2009, AM J PATHOL, V174, P1808, DOI 10.2353/ajpath.2009.081010
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Starr C., 1989, BIOL UNITY DIVERSITY, P398
   Steinle JJ, 2009, J GERONTOL A-BIOL, V64, P325, DOI 10.1093/gerona/gln052
   Stoll G, 2006, STROKE, V37, P1923, DOI 10.1161/01.STR.0000226901.34927.10
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tavazzi E, 2014, CURR HIV RES, V12, P97, DOI 10.2174/1570162X12666140526114956
   Taylor AW, 2010, ADV EXP MED BIOL, V681, P143, DOI 10.1007/978-1-4419-6354-3_12
   Taylor AW, 1996, NEUROIMMUNOMODULAT, V3, P195, DOI 10.1159/000097271
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Tegla CA, 2009, J NEUROIMMUNOL, V213, P3, DOI 10.1016/j.jneuroim.2009.06.006
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   van Kampen E, 2014, J LEUKOCYTE BIOL, V96, P833, DOI 10.1189/jlb.1A0114-017R
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VERGANI S, 1986, BRIT J OPHTHALMOL, V70, P60, DOI 10.1136/bjo.70.1.60
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wallace FA, 2001, J LEUKOCYTE BIOL, V69, P449
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang Y, 2006, INT J OBESITY, V30, P439, DOI 10.1038/sj.ijo.0803173
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhang J, 1997, INVEST OPHTH VIS SCI, V38, P1848
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 180
TC 175
Z9 181
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD NOV
PY 2015
VL 98
IS 5
BP 713
EP 725
DI 10.1189/jlb.3RI0615-239R
PG 13
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Immunology
GA CW3SI
UT WOS:000364911700005
PM 26292978
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Meuer, SM
   Huang, GH
AF Klein, R
   Klein, BEK
   Tomany, SC
   Meuer, SM
   Huang, GH
TI Ten-year incidence and progression of age-related maculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; RETINAL-PIGMENT EPITHELIUM; BILATERAL MACULAR DRUSEN;
   VISUAL-ACUITY; 5-YEAR INCIDENCE; FOLLOW-UP; 2ND EYE; DEGENERATION;
   PREVALENCE; POPULATION
AB Purpose: The aim of the study was to describe the 10-year incidence and progression of retinal drusen, retinal pigmentary abnormalities, and signs of late age-related maculopathy.
   Design: Population-based cohort study.
   Participants: The study included 4926 persons, 43 to 86 years of age at the time of a baseline examination from 1988 through 1990, living in Beaver Dam, Wisconsin, of whom 3684 participated in a 5-year follow-up examination and 2764 participated in a 10-year follow-up.
   Methods: Characteristics of drusen and other lesions typical of age-related maculopathy were determined by grading stereoscopic color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcomes Measures: Incidence of drusen type and size, pigmentary abnormalities, geographic atrophy, and exudative degeneration.
   Results: The 10-year incidence of early age-related maculopathy was 12.1% and of late age-related maculopathy it was 2.1 %. There was a statistically significant increased incidence of age-related maculopathy lesions with age (P < 0.05). Individuals 75 years of age or older at baseline had significantly (P < 0.01) higher 10-year incidences of the following characteristics than people 43 to 54 years of age: larger sized drusen (125 mum-249 mum, 26.3% vs. 3.3%; greater than or equal to250 mum, 16.2% vs. 1.0%), soft indistinct drusen (22.2% vs. 2.2%), retinal pigment abnormalities (19.5% vs. 0.8%), exudative macular degeneration (4.1 % vs. 0%), and pure geographic atrophy (3.1 % vs. 0%). Compared with those with small numbers of only small, hard drusen (1-2), those with large numbers of only hard drusen (8 or more) had an increased 10-year incidence of both soft drusen (12.3% vs. 6.7%) and pigmentary abnormalities (4.9% vs. 1.7%). Eyes with soft indistinct drusen or retinal pigmentary abnormalities at baseline, were more likely to develop late age-related macular degeneration at follow-up than eyes without these lesions (15.1 % vs. 0.4% and 20.0% vs. 0.8%, respectively).
   Conclusions: These population-based estimates document the high incidence of signs of age-related maculopathy in people 75 years of age or older. Our findings demonstrate that large numbers of hard drusen predict the incidence of soft drusen and pigmentary abnormalities and that the presence of the latter lesions significantly increases the risk for the development of geographic atrophy and exudative macular degeneration. (C) 2002 by the American Academy of Ophthalmology.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR [Anonymous], 1991, Ophthalmology, V98, P823
   [Anonymous], [No title captured]
   [Anonymous], 1999, SAS STAT US GUID VER
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   GANLEY JP, 1983, VITAL HLTH STAT SERI, V11
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P207
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   ROY M, 1990, Eye (London), V4, P813
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   TIELSCH JA, 1995, PREVENT BLINDNESS AM, P1
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   2000, POPULATION PROJECTIO
NR 54
TC 379
Z9 391
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2002
VL 109
IS 10
BP 1767
EP 1779
AR PII S0161-6420(02)01146-6
DI 10.1016/S0161-6420(02)01146-6
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 601AW
UT WOS:000178424800010
PM 12359593
DA 2022-11-30
ER

PT J
AU Miki, A
   Honda, S
   Kojima, H
   Nishizaki, M
   Nagai, T
   Fujihara, M
   Uenishi, M
   Kita, M
   Kurimoto, Y
   Negi, A
AF Miki, Akiko
   Honda, Shigeru
   Kojima, Hiroshi
   Nishizaki, Masaya
   Nagai, Tomoko
   Fujihara, Masashi
   Uenishi, Mamoru
   Kita, Mihori
   Kurimoto, Yasuo
   Negi, Akira
CA Hyogo Macular Dis Study Grp
TI Visual outcome of photodynamic therapy for typical neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
   over 5 years of follow-up
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Long-term outcome; Photodynamic therapy; Age-related macular
   degeneration; Polypoidal choroidal vasculopathy; Multicenter study
ID RETINAL ANGIOMATOUS PROLIFERATION; RANDOMIZED CLINICAL-TRIALS; JAPANESE
   PATIENTS; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN THERAPY; RANIBIZUMAB;
   MULTICENTER; EFFICACY; HYOGO; FOCUS
AB To evaluate the long-term effects of photodynamic therapy (PDT) on typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV).
   This was a multicenter prospective study of 139 eyes from 136 patients (tAMD: 74 eyes; PCV: 65 eyes) who underwent PDT as the initial treatment. The change in best-corrected visual acuity (BCVA), predictive factors for the BCVA at 60 months, frequency of recurrence, and mean recurrence period were analyzed.
   The pre-PDT BCVA and greatest linear dimension (GLD) did not differ between the two groups. The mean BCVA (logMAR) was significantly improved at 6 months post-initial PDT (post-PDT) in the PCV group (-0.11, P = 0.0091). However, at 60 months post-PDT, the mean BCVA was significantly worse than baseline in the tAMD (+0.21, P = 0.0035) and PCV (+0.21, P = 0.0076) groups. Pre-PDT BCVA, age, and GLD were the factors significantly associated with the BCVA at 60 months post-PDT. Although the frequency of recurrence did not significantly differ between the two phenotype groups, the mean recurrence period was significantly longer in the PCV group than in the tAMD group (15.7 vs. 8.6 months, P = 0.0020).
   PDT may not have benefits for visual acuity in cases of tAMD and PCV over 5 years of follow-up.
C1 [Miki, Akiko; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kojima, Hiroshi; Kurimoto, Yasuo] Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Nishizaki, Masaya] Ono Municipal Hosp, Dept Ophthalmol, Ono, Hokkaido, Japan.
   [Nagai, Tomoko] Steel Mem Hirohata Hosp, Dept Ophthalmol, Himeji, Hyogo, Japan.
   [Fujihara, Masashi; Uenishi, Mamoru] Mitsubishi Kobe Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Kita, Mihori] Hyogo Kenritsu Amagasaki Hosp, Dept Ophthalmol, Amagasaki, Hyogo, Japan.
C3 Kobe University; Kobe City Medical Center General Hospital
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P237, DOI 10.1007/s00417-007-0651-0
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 34
TC 7
Z9 10
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2013
VL 57
IS 3
BP 301
EP 307
DI 10.1007/s10384-013-0237-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 143BP
UT WOS:000318841600009
PM 23508554
DA 2022-11-30
ER

PT J
AU Wong, WL
   Su, XY
   Li, X
   Cheung, CMG
   Klein, R
   Cheng, CY
   Wong, TY
AF Wong, Wan Ling
   Su, Xinyi
   Li, Xiang
   Cheung, Chui Ming G.
   Klein, Ronald
   Cheng, Ching-Yu
   Wong, Tien Yin
TI Global prevalence of age-related macular degeneration and disease burden
   projection for 2020 and 2040: a systematic review and meta-analysis
SO LANCET GLOBAL HEALTH
LA English
DT Article
ID RISK-FACTORS; GRADING SYSTEM; EYE DISEASE; MACULOPATHY; POPULATION;
   RANIBIZUMAB; ROTTERDAM; SINGAPORE
AB Background Numerous population-based studies of age-related macular degeneration have been reported around the world, with the results of some studies suggesting racial or ethnic differences in disease prevalence. Integrating these resources to provide summarised data to establish worldwide prevalence and to project the number of people with age-related macular degeneration from 2020 to 2040 would be a useful guide for global strategies.
   Methods We did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013. Only studies using retinal photographs and standardised grading classifications (the Wisconsin age-related maculopathy grading system, the international classification for age-related macular degeneration, or the Rotterdam staging system) were included. Hierarchical Bayesian approaches were used to estimate the pooled prevalence, the 95% credible intervals (CrI), and to examine the difference in prevalence by ethnicity (European, African, Hispanic, Asian) and region (Africa, Asia, Europe, Latin America and the Caribbean, North America, and Oceania). UN World Population Prospects were used to project the number of people affected in 2014 and 2040. Bayes factor was calculated as a measure of statistical evidence, with a score above three indicating substantial evidence.
   Findings Analysis of 129 664 individuals (aged 30-97 years), with 12 727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively. We found a higher prevalence of early and any age-related macular degeneration in Europeans than in Asians (early: 11.2% vs 6.8%, Bayes factor 3.9; any: 12.3% vs 7.4%, Bayes factor 4.3), and early, late, and any age-related macular degeneration to be more prevalent in Europeans than in Africans (early: 11.2% vs 7.1%, Bayes factor 12.2; late: 0.5% vs 0.3%, 3.7; any: 12.3% vs 7.5%, 31.3). There was no difference in prevalence between Asians and Africans (all Bayes factors <1). Europeans had a higher prevalence of geographic atrophy subtype (1.11%, 95% CrI 0.53-2.08) than Africans (0.14%, 0.04-0.45), Asians (0.21%, 0.04-0.87), and Hispanics (0.16%, 0.05-0.46). Between geographical regions, cases of early and any age-related macular degeneration were less prevalent in Asia than in Europe and North America (early: 6.3% vs 14.3% and 12.8% [Bayes factor 2.3 and 7.6]; any: 6.9% vs 18.3% and 14.3% [3.0 and 3.8]). No significant gender effect was noted in prevalence (Bayes factor <1.0). The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).
   Interpretation These estimates indicate the substantial global burden of age-related macular degeneration. Summarised data provide information for understanding the effect of the condition and provide data towards designing eye-care strategies and health services around the world.
C1 [Wong, Wan Ling; Su, Xinyi; Li, Xiang; Cheung, Chui Ming G.; Cheng, Ching-Yu; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Wan Ling; Su, Xinyi; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wong, Wan Ling; Su, Xinyi; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore 119228, Singapore.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Cheng, Ching-Yu] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching-Yu] Duke NUS Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; University of Wisconsin System;
   University of Wisconsin Madison; National University of Singapore;
   National University of Singapore
RP Cheng, CY (通讯作者)，Natl Univ Hlth Syst, Dept Ophthalmol, 1E Kent Ridge Rd,NUHS Tower Block Level 7, Singapore 119228, Singapore.
EM ching-yu_cheng@nuhs.edu.sg
RI Mitchell, Paul/P-1498-2014; Su, Xinyi/GNW-6209-2022; Wong, Tien
   Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019
OI Su, Xinyi/0000-0002-1480-6713; Wong, Tien Yin/0000-0002-8448-1264;
   Cheng, Ching-Yu/0000-0003-0655-885X; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU National Medical Research Council, Singapore
FX National Medical Research Council, Singapore.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   DAS BN, 1994, J ROY SOC MED, V87, P219
   de Weerd M, 2009, STROKE, V40, P1105, DOI 10.1161/STROKEAHA.108.532218
   Dellaportas P, 2002, STAT COMPUT, V12, P27, DOI 10.1023/A:1013164120801
   Denwood M, RUNJAGS INTERFACE UT
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Jeffreys H., 1961, THEORY PROBABILITY
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, OPHTHALMIC IN PRESS
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee GKY, 2009, HONG KONG J OPHTHALM, V13, P5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lunn D, 2009, STAT MED, V28, P3049, DOI 10.1002/sim.3680
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROUHIAINEN H, 1990, ACTA OPHTHALMOL, V68, P554
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   United Nations Population Division, WORLD POP PROSP 2010
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 51
TC 2164
Z9 2234
U1 19
U2 203
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD FEB
PY 2014
VL 2
IS 2
BP E106
EP E116
DI 10.1016/S2214-109X(13)70145-1
PG 11
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA AH8YO
UT WOS:000336424300017
PM 25104651
OA gold, Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Coco-Martin, RM
   Pichel-Mouzo, M
   Fernandez, I
   Plata-Cordero, M
   Lopez-Miguel, A
AF Coco-Martin, Rosa M.
   Pichel-Mouzo, Maria
   Fernandez, Itziar
   Plata-Cordero, Maria
   Lopez-Miguel, Alberto
TI Reliability of colour perimetry to assess macular pigment optical
   density in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; macular pigment optical density;
   colour perimetry technique; intra-session repeatability; inter-examiner
   reproducibility
ID HETEROCHROMATIC FLICKER PHOTOMETRY; MINIMUM-MOTION; VITAMIN-C; IN-VIVO;
   AUTOFLUORESCENCE; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION; REPEATABILITY;
   CAROTENOIDS; ZEAXANTHIN
AB Background: The aim of this study was to determine the intra-session repeatability and inter-examiner reproducibility of the colour perimetry technique when assessing in vivo macular pigment optical density in age-related macular degeneration patients. Methods: Age-related macular degeneration patients were classified into four groups: early age-related macular degeneration, intermediate age-related macular degeneration, atrophic age-related macular degeneration and neovascular age-related macular degeneration after undergoing fundus photography (TRC 50DX type IA) and spectral-domain optical coherence tomography analysis (Topcon 3D-2000). Central fixation was confirmed in all patients using the MP-1 microperimeter (Nidek, Padua, Italy). To analyse repeatability, one examiner obtained three consecutive macular pigment optical density measures with MonCV3 device (Metrovision, Perenchies, France). To study agreement between two observers, a second examiner performed another macular pigment optical density measurement in random order. Within-subject standard deviation, coefficient of variation, and intraclass correlation coefficient data were obtained. Results: Fifty two (32 females and 20 males) consecutive age-related macular degeneration patients having a mean age of 71.5 +/- 8.2 years were recruited. Six had early age-related macular degeneration, 25 had intermediate age-related macular degeneration, 10 had atrophic age-related macular degeneration and 11 had neovascular age-related macular degeneration. For repeatability, coefficient of variation values ranged from 22.3% (neovascular age-related macular degeneration) to 41.0% (atrophic age-related macular degeneration) and intraclass correlation coefficient values from 0.52 (intermediate age-related macular degeneration) to 0.79 (neovascular age-related macular degeneration). For agreement between two examiners, coefficient of variation values ranged from 20.1% (intermediate age-related macular degeneration) to 37.8% (neovascular age-related macular degeneration) and intraclass correlation coefficient values from 0.61 (neovascular age-related macular degeneration) to 0.80 (atrophic age-related macular degeneration). Conclusion: The reliability (intra-session repeatability and inter-examiner reproducibility) of colour perimetry technique to assess macular pigment optical density in age-related macular degeneration patients is only moderate. Thus, it cannot be recommended to be performed when evaluating and monitoring age-related macular degeneration patients in the daily clinic.
C1 [Coco-Martin, Rosa M.; Pichel-Mouzo, Maria; Fernandez, Itziar; Plata-Cordero, Maria; Lopez-Miguel, Alberto] Univ Valladolid, Inst Univ Oftalmobiol Aplicada IOBA, Campus Miguel Delibes,P Belen 17, E-47011 Valladolid, Spain.
   [Coco-Martin, Rosa M.; Lopez-Miguel, Alberto] Inst Salud Carlos III, Red Temat Invest Cooperat Salud Oftalmol Oftared, Madrid, Spain.
   [Fernandez, Itziar] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Valladolid, Spain.
C3 Universidad de Valladolid; Instituto de Salud Carlos III; CIBER - Centro
   de Investigacion Biomedica en Red; CIBERBBN
RP Coco-Martin, RM (通讯作者)，Univ Valladolid, Inst Univ Oftalmobiol Aplicada IOBA, Campus Miguel Delibes,P Belen 17, E-47011 Valladolid, Spain.
EM rosa@ioba.med.uva.es
RI Fernández, Itziar/AAF-9590-2020; López-Miguel, Alberto/K-6117-2014;
   Martin, Rosa Maria Coco/H-4511-2015
OI Fernández, Itziar/0000-0002-5077-4448; López-Miguel,
   Alberto/0000-0001-9429-1571; Martin, Rosa Maria Coco/0000-0002-1811-1417
FU Fundacion Eugenio Rodriguez Pascual (Spain); Spanish Ministry of Economy
   and Competitiveness [RETICS D12/0034/0001]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported in part by the Fundacion Eugenio Rodriguez Pascual
   (Spain), and by the Spanish Ministry of Economy and Competitiveness
   through Research Project RETICS D12/0034/0001 (Oftared).
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Bartlett H, 2010, BRIT J OPHTHALMOL, V94, P753, DOI 10.1136/bjo.2009.175901
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41
   Bland M., 2000, INTRO MED STAT, P269
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Broendsted AE, 2011, OPHTHALMIC RES, V46, P118, DOI 10.1159/000323576
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Crochet M, 2009, INVEST OPHTH VIS SCI, V50, P2743
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   Demirel S, 2016, OPTOMETRY VISION SCI, V93, P632, DOI 10.1097/OPX.0000000000000834
   Dragostinoff N, 2012, GRAEF ARCH CLIN EXP, V250, P1261, DOI 10.1007/s00417-012-1946-3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Howells O, 2013, GRAEF ARCH CLIN EXP, V251, P871, DOI 10.1007/s00417-012-2127-0
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kutzko KE, 2000, INVEST OPHTH VIS SCI, V41, P2006
   Loughman J, 2012, ACTA OPHTHALMOL, V90, pe90, DOI 10.1111/j.1755-3768.2011.02294.x
   Obana A, 2018, EXP EYE RES, V168, P100, DOI 10.1016/j.exer.2017.12.015
   Obana A, 2014, GRAEF ARCH CLIN EXP, V252, P1221, DOI 10.1007/s00417-014-2574-x
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Robson AG, 2006, VISUAL NEUROSCI, V23, P275, DOI 10.1017/S0952523806232115
   Robson AG, 2005, PERCEPTION, V34, P1029, DOI 10.1068/p5196
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, P3094, DOI 10.1167/iovs.18-23886
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 34
TC 2
Z9 2
U1 1
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1480
EP 1486
AR 1120672119870362
DI 10.1177/1120672119870362
EA AUG 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000483860500001
PM 31422700
DA 2022-11-30
ER

PT J
AU Yoneyama, S
   Sakurada, Y
   Kikushima, W
   Sugiyama, A
   Matsubara, M
   Fukuda, Y
   Tanabe, N
   Parikh, R
   Mabuchi, F
   Kashiwagi, K
   Iijima, H
AF Yoneyama, Seigo
   Sakurada, Yoichi
   Kikushima, Wataru
   Sugiyama, Atsushi
   Matsubara, Mio
   Fukuda, Yoshiko
   Tanabe, Naohiko
   Parikh, Ravi
   Mabuchi, Fumihiko
   Kashiwagi, Kenji
   Iijima, Hiroyuki
TI Genetic factors associated with response to as-needed aflibercept
   therapy for typical neovascular age-related macular degeneration and
   polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RANIBIZUMAB; VARIANTS; A69S
AB In the present study, we investigated the association between susceptible genetic variants to age-related macular degeneration (AMD) and response to as-needed intravitreal aflibercept injection (IAI) therapy for exudative AMD including both typical neovascular AMD and polypoidal choroidal vasculopathy (PCV) over 12-months. A total of 234 patients with exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI over 12 months. Seven variants of 6 genes including ARMS2 A69S (rs10490924), CFH (I62V:rs800292 and rs1329428), C2-CFB-SKIV2L(rs429608), C3 (rs2241394), CETP (rs3764261) and ADAMTS-9 (rs6795735) were genotyped for all participants using TaqMan technology. After adjusting for age, gender, baseline BCVA and AMD subtype, A (protective) allele of C2-CFB-SKIV2L rs429608 was associated with visual improvement at 12-month (P=0.003). Retreatment was associated with T(risk) allele of ARMS2 A69S (P=2.0x10(-4); hazard ratio: 2.18:95%CI: 1.47-3.24) and C(risk) allele of CFH rs1329428 (P=2.0x10(-3); hazard ratio: 1.74:95%CI: 1.16-2.59) after adjusting for the baseline confounders. The need for additional injections was also associated with T allele of ARMS2 A69S (P=1.0x10(-5)) and C allele of CFH rs1329428 (P=3.0x10(-3)) after adjusting for the baseline confounders. The variants of ARMS2 and CFH are informative for both physicians and patients to predict recurrence and to quantify the need for additional injections.
C1 [Yoneyama, Seigo; Sakurada, Yoichi; Kikushima, Wataru; Sugiyama, Atsushi; Matsubara, Mio; Fukuda, Yoshiko; Tanabe, Naohiko; Mabuchi, Fumihiko; Kashiwagi, Kenji; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Chuo Ku, Yamanashi, Japan.
   [Parikh, Ravi] NYU, Sch Med, New York, NY USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
C3 University of Yamanashi; New York University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Chuo Ku, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
OI Parikh, Ravi/0000-0003-3369-4224
FU MEXT | Japan Society for the Promotion of Science (JSPS) [19K18841]
   Funding Source: Medline
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Cheng CY., 2015, NAT COMMUN, V6
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   YAMASHIRO K, 2017, SCI REP UK, V0007
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
NR 24
TC 9
Z9 9
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 28
PY 2020
VL 10
IS 1
AR 7188
DI 10.1038/s41598-020-64301-z
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NB7SI
UT WOS:000560714100014
PM 32346038
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cugati, S
   de Loryn, T
   Pham, T
   Arnold, J
   Mitchell, P
   Wang, JJ
AF Cugati, Sudha
   de Loryn, Tania
   Pham, Thuan
   Arnold, Jennifer
   Mitchell, Paul
   Wang, Jie Jin
TI Australian prospective study of cataract surgery and age-related macular
   degeneration: Rationale and methodology
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE cataract surgery; AMD; blindness
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; QUALITY-OF-LIFE; VISUAL-ACUITY;
   5-YEAR INCIDENCE; FUNCTIONAL IMPAIRMENT; DIABETIC-RETINOPATHY;
   INTRAOCULAR-LENS; OLDER COMMUNITY; GRADING SYSTEM
AB Background. Cataract surgery is the most frequently performed ophthalmic procedure worldwide. While benefits gained from cataract surgery outweigh surgical risks, there have been concerns that older persons may have an increased risk of developing age-related macular degeneration (AMD) after cataract surgery. Objective: The Australian Prospective Study of Cataract Surgery and Age-Related Macular Degeneration Study aims to assess the risk of AMD in a large cohort of older patients following cataract surgery. The current report describes the study rationale, design and methodology. Design: Longitudinal study Participants: Approximately 2000 cataract surgical patients aged 65 years or older are being recruited from both public and private sources in western Sydney, Australia. Methods: At study visits, participants are interviewed using standardized questionnaires to obtain information on demographic, medical, and ocular conditions and AMD risk factors, together with data on general health and vision-related quality of life. Eye examinations include visual acuity, intraocular pressure, keratometry and A-scan measurements, plus lens and retinal photography, following pupil dilatation. Retinal photographs taken before cataract surgery, and at 1, 6, 12, and 24 months after surgery are graded for early and late AMD lesions, using the Wisconsin age-related maculopathy grading system. The 1-month post-operative retinal photographs supplement the baseline macular assessment for cases in which cataract occludes a clear view of the macula pre-operatively. It is intended that study participants will be followed for up to five years post-operatively to clarify the question of whether aphakic or pseudophakic, compared to phakic eyes, have a greater risk of developing AMD.
C1 [Cugati, Sudha; de Loryn, Tania; Pham, Thuan; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Cugati, Sudha; de Loryn, Tania; Pham, Thuan; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmesd Millennium Inst, Westmead, NSW 2145, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin-wang@wmi.usyd.edu.au
RI wang, jie/GRS-0942-2022; Cugati, Sudha/ABB-1331-2021; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *AUSTR HLTH INS CO, MED BEN SCH STAT
   Bachani D, 1999, INT OPHTHALMOL, V23, P49, DOI 10.1023/A:1006435312612
   BERNTHPETERSEN P, 1982, ACTA OPHTHALMOL, V60, P461
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040
   Busbee BG, 2002, OPHTHALMOLOGY, V109, P606, DOI 10.1016/S0161-6420(01)00971-X
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Castells X, 1999, OPHTHALMOLOGY, V106, P676, DOI 10.1016/S0161-6420(99)90150-1
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chan FA, 2003, J CATARACT REFR SURG, V29, P537, DOI 10.1016/S0886-3350(02)01622-X
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   *ETDRS COORD CTR, 1980, MAN OP
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Hawkins WR, 1997, OPHTHALMOLOGY, V104, P900, DOI 10.1016/S0161-6420(97)30212-7
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P313, DOI 10.1111/j.1442-9071.1996.tb01601.x
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KRILL AE, 1973, AM J OPHTHALMOL, V76, P875, DOI 10.1016/0002-9394(73)90076-7
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P408, DOI 10.1016/S0886-3350(99)00418-6
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   McDowell I, 1996, J NUTR EDUC, V2nd, DOI DOI 10.1016/S0022-3182(88)80070-0
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P406, DOI 10.1016/S0161-6420(98)93019-6
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOSS SE, 1989, INVEST OPHTH VIS SCI, V30, P823
   OLIVER M, 1966, AM J OPHTHALMOL, V62, P1145, DOI 10.1016/0002-9394(66)92567-0
   Panchapakesan J, 2004, EYE, V18, P278, DOI 10.1038/sj.eye.6700641
   Panchapakesan J, 2003, BRIT J OPHTHALMOL, V87, P168, DOI 10.1136/bjo.87.2.168
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rakoczy P, 1998, AUST NZ J OPHTHALMOL, V26, P67
   Rochtchina E, 2003, CLIN EXP OPHTHALMOL, V31, P233, DOI 10.1046/j.1442-9071.2003.00635.x
   Saw SM, 2002, J CATARACT REFR SURG, V28, P445, DOI 10.1016/S0886-3350(01)01016-1
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Tan AG, 2004, CLIN EXP OPHTHALMOL, V32, P284, DOI 10.1111/j.1442-9071.2004.00817.x
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, DOI UNSP 107875-879
NR 55
TC 13
Z9 13
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD NOV-DEC
PY 2007
VL 14
IS 6
BP 408
EP 414
DI 10.1080/09286580701316124
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 245JX
UT WOS:000251932000011
PM 18161615
DA 2022-11-30
ER

PT J
AU de Crecchio, G
   Chan, RVP
   Manzi, G
   Romano, MR
AF de Crecchio, G.
   Chan, R. V. P.
   Manzi, G.
   Romano, M. R.
TI Polypoidal Choroidal Vasculopathy: Recent Advances in Therapy
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Polypoidal choroidal vasculopathy; choroidal neovascularization;
   age-related macular degeneration; photodynamic therapy; antiVEGF;
   triamcinolone; combination therapy
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   TRIAMCINOLONE ACETONIDE; LASER PHOTOCOAGULATION; SUBMACULAR HEMORRHAGE;
   CLINICAL SPECTRUM; VERTEPORFIN
AB Polypoidal Choroidal Vasculopathy (PCV) is a condition characterized by chronic, multiple, recurrent serous and/or hemorrhagic detachments of the retinal pigment epithelium (RPE) and neurosensory retina. Although it has been described to more often affect Asians and individuals of pigmented races, PCV may also be present in white patients who present with the clinical appearance of age related macular degeneration (AMD). PCV and its treatment are discussed, including the use of combination therapy.
C1 [Romano, M. R.] Univ Molise, Dipartimento Sci Salute, I-86100 Campobasso, Italy.
   [de Crecchio, G.] Univ Naples Federico II, Dipartimento Oftalmol, Naples, Italy.
   [Chan, R. V. P.] Unita Operat Oculist, Naples, Italy.
   [Manzi, G.] New York Presbyterian Hosp, Dept Ophthalmol, Weill Cornell Med Coll, New York, NY USA.
C3 University of Molise; University of Naples Federico II; Cornell
   University; NewYork-Presbyterian Hospital
RP Romano, MR (通讯作者)，Univ Molise, Dipartimento Sci Salute, Via de Santis, I-86100 Campobasso, Italy.
EM romanomario@email.it
RI Romano, Mario R/I-8320-2012
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P264, DOI 10.1177/112067210401400313
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori F, 2007, BRIT J OPHTHALMOL, V91, P1104, DOI 10.1136/bjo.2007.116178
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zuo CG, 2010, GRAEF ARCH CLIN EXP, V248, P191, DOI 10.1007/s00417-009-1210-7
NR 74
TC 4
Z9 4
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 206
EP 211
DI 10.2174/138945011794182782
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000008
PM 20887241
DA 2022-11-30
ER

PT J
AU Sayanagi, K
   Gomi, F
   Ikuno, Y
   Akiba, M
   Nishida, K
AF Sayanagi, Kaori
   Gomi, Fumi
   Ikuno, Yasushi
   Akiba, Masahiro
   Nishida, Kohji
TI Comparison of spectral-domain and high-penetration OCT for observing
   morphologic changes in age-related macular degeneration and polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE High-penetration optical coherence tomography; Optical coherence
   tomography; Age-related macular degeneration; Choroid
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   SWEPT-SOURCE; THICKNESS; SPEED; VISUALIZATION; THERAPIES
AB We compared the visibility of retinal and choroidal pathologies using high-penetration optical coherence tomography (HP-OCT) with a long-wavelength light source (1,050 nm) and conventional spectral-domain OCT (SD-OCT) in age-related macular degeneration (AMD).
   One hundred and forty-six eyes were included: 63 eyes with AMD, 79 eyes with polypoidal choroidal vasculopathy (PCV), and four eyes with retinal angiomatous proliferation. The SD-OCT and HP-OCT images were compared using the grading criteria to grade the visibility of the retinal changes, the line corresponding to the retinal pigment epithelium (RPE), and the chorioscleral interface (CSI). In 132 eyes with a pigment epithelial detachment (PED), we graded the structures inside the PED, Bruch's line, and the CSI. We compared the visibility of those changes in eyes with subretinal hyperreflective changes due to a subretinal hemorrhage (SRH) (n = 17) or a hemorrhage inside the PED (HPED) (n = 12).
   HP-OCT provided superior visibility of the following structures compared to SD-OCT (P < 0.01): the CSI, structures inside the PED, Bruch's line inside the PED, the CSI inside the PED, SRH, type 1 CNV, polyps, and HPED. There were no significant differences between the two OCT devices in the scores for the RPE line, retinal morphology, or type 2 CNV and/or fibrin.
   HP-OCT visualizes morphologies beneath the RPE better than SD-OCT, and is equivalent to SD-OCT for visualizing morphologies above the RPE.
C1 [Sayanagi, Kaori; Gomi, Fumi; Ikuno, Yasushi; Nishida, Kohji] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
   [Akiba, Masahiro] Topcon Corp, Tokyo, Japan.
   [Gomi, Fumi] Osaka Univ, Sch Med, Dept Ophthalmol E7, Suita, Osaka 5650871, Japan.
C3 Osaka University; Topcon Corporation; Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol E7, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Gomi, Fumi/0000-0003-0807-8817
CR Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Usui S, 2012, AM J OPHTHALMOL, V153, P10, DOI 10.1016/j.ajo.2011.05.037
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
NR 25
TC 8
Z9 11
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2014
VL 252
IS 1
BP 3
EP 9
DI 10.1007/s00417-013-2474-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 283JY
UT WOS:000329243500002
PM 24136628
DA 2022-11-30
ER

PT J
AU Ristau, T
   Ersoy, L
   Hahn, M
   den Hollander, AI
   Kirchhof, B
   Liakopoulos, S
   Fauser, S
AF Ristau, Tina
   Ersoy, Lebriz
   Hahn, Moritz
   den Hollander, Anneke I.
   Kirchhof, Bernd
   Liakopoulos, Sandra
   Fauser, Sascha
TI Nongenetic Risk Factors for Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; nongenetic risk factor
ID 15-YEAR CUMULATIVE INCIDENCE; BEAVER-DAM EYE; ALCOHOL-CONSUMPTION;
   PHYSICAL-ACTIVITY; DIETARY-FAT; MACULOPATHY; PROGRESSION; COMPLEMENT;
   ASSOCIATION; DISEASE
AB PURPOSE. To create a risk model for neovascular age-related macular degeneration (nAMD) based on nongenetic factors.
   METHODS. In this case-control study, 1459 individuals were included, 445 patients showed nAMD and 1014 were healthy controls. Participants were randomly assigned into a training set (containing two-thirds of individuals) and a validation set. Stepwise logistic regression analysis was performed for 25 environmental risk factors in the training set. The risk model with the remaining factors was then validated in the validation set using receiver operating characteristics (ROC) curve and Hosmer-Lemeshow-Test. Additionally, a genetic risk model including variants in the complement factor H gene (CFH, rs1061170) and the age-related maculopathy susceptibility 2 gene (ARMS2, rs10490924) was generated.
   RESULTS. The environmental risk model with the factors age, alcohol use, allergy, education, sunlight exposure, fish consumption, and physical exercise showed an AUC of 0.80 (95% confidence interval [CI] 0.76-0.84) in the training set. Validation of the model showed adequate calibration (Hosmer-Lemeshow P = 0.81). The AUC for the genetic model was 0.77 (95% CI 0.730-0.808), for the combined environmental and genetic model 0.92 (95% CI 0.887-0.947).
   CONCLUSIONS. Seven nongenetic factors are able to provide equivalent discrimination between nAMD patients and controls to genetic risk models. Most of them are modifiable and give the opportunity for counseling patients.
C1 [Ristau, Tina; Ersoy, Lebriz; Kirchhof, Bernd; Liakopoulos, Sandra; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; Radboud University
   Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Hollander, Anneke den/N-4911-2014
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gill JMR, 2008, SPORTS MED, V38, P807, DOI 10.2165/00007256-200838100-00002
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Mckay GJ, 2010, MOL VIS, V16, P194
   MORRIS JN, 1994, MED SCI SPORT EXER, V26, P807
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
NR 35
TC 15
Z9 15
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 5228
EP 5232
DI 10.1167/iovs.14-14299
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500071
PM 25074767
OA Green Published
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Membrey, WL
   Sivagnanavel, V
   Gonzalez, JG
   Liu, DTL
   Chan, WM
   Lam, DSC
   Jackson, H
   Chong, NV
AF Sivaprasad, S.
   Membrey, W. L.
   Sivagnanavel, V.
   Gonzalez, J. G.
   Liu, D. T. L.
   Chan, W. M.
   Lam, D. S. C.
   Jackson, H.
   Chong, N. V.
TI Second eye of patients with unilateral neovascular age-related macular
   degeneration: Caucasians vs Chinese
SO EYE
LA English
DT Article
DE drusen; racial differences; macular degeneration
ID RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; JAPANESE POPULATION; FELLOW
   EYES; FOLLOW-UP; MACULOPATHY; DRUSEN; PROGRESSION; ROTTERDAM; HISAYAMA
AB Purpose To investigate the correlation between morphological features of choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) in the first eye and the severity of age-related maculopathy (ARM) in the fellow eyes in two racial groups: Caucasians and Chinese.
   Participants A total of 135, fluorescein angiograms of patients with unilateral neovascular AMD and ARM in the fellow eyes were included in the study: 38 Caucasians from King's College Hospital, UK; 45 Caucasians from West Kent Eye Centre, UK; 52 Chinese from Hong Kong Eye Hospital, Hong Kong.
   Main outcome measures CNV subtype in the affected eye and ARM severity in the second eyes.
   Results Although the proportion of CNV subtypes in the three groups were similar, the Chinese cohort showed significantly less ARM severity compared to the Caucasian cohorts (P < 0.05).
   Conclusion Although drusen and retinal pigmentary changes may be prognostic indicators of CNV, this study suggest that other factors contribute significantly to the pathogenesis of CNV in AMD.
C1 Kings Coll Hosp, Retinal Res Unit, London SE5 9RS, England.
   Princess Royal Univ Hosp, W Kent Eye Ctr, Orpington, Kent, England.
   Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   Chinese University of Hong Kong
RP Chong, NV (通讯作者)，Kings Coll Hosp, Retinal Res Unit, Normandy Bldg,Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Sivaprasad, S./D-6876-2015; Chong, Ngaihang
   V/A-5141-2009; Lam, Dennis/AAL-1211-2020
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659; 
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Jain I S, 1984, Indian J Ophthalmol, V32, P343
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   ROY M, 1990, Eye (London), V4, P813
   SANBERG MA, 1998, OPHTHALMOLOGY, V105, P441
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WU L, 1987, EYE SCI, V3, P175
   WU L, 1987, EYE SCI, V3, P179
   WU ZQ, 1992, CHINESE J OPHTHALMOL, V28, P246
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 28
TC 9
Z9 10
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2006
VL 20
IS 8
BP 923
EP 926
DI 10.1038/sj.eye.6702056
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 071TO
UT WOS:000239625700010
PM 16123783
OA Bronze
DA 2022-11-30
ER

PT J
AU Yuk, JS
   Hwang, JH
AF Yuk, Jin-Sung
   Hwang, Je Hyung
TI Menopause and the Risk of Developing Age-Related Macular Degeneration in
   Korean Women
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; cohort study; diabetes mellitus;
   menopause; risk factors
ID REPRODUCTIVE FACTORS; VISUAL IMPAIRMENT; HORMONE REPLACEMENT; EYE
   DISEASE; ESTROGEN; GENDER; ASSOCIATION; POPULATION; PREVALENCE;
   BLINDNESS
AB Previous studies have shown that menopausal hormone therapy in postmenopausal women results in a higher prevalence of age-related macular degeneration. This study aimed to evaluate the effects of menopause and patient factors on the development of age-related macular degeneration in Korean women. Data between 2011 and 2014 were collected from the Korean National Health Insurance database. In this retrospective cohort study, 97,651 participants were premenopausal and 33,598 were menopausal. Participants were divided into menopausal and premenopausal groups to analyze the risk factors associated with the development of age-related macular degeneration. The prevalence of age-related macular degeneration was compared between the two groups. Other patient factors were also analyzed. Using a 1:1 propensity score matching method and adjusting for variables, the incidence of age-related macular degeneration was not significantly different between the two groups. Age and diabetes mellitus were associated with an increased risk of developing age-related macular degeneration, regardless of menopause. Menopause was not a risk factor for age-related macular degeneration. These findings may help physicians identify women with diabetes who are at a greater risk of developing age-related macular degeneration.
C1 [Yuk, Jin-Sung] Inje Univ, Sanggye Paik Hosp, Dept Obstet & Gynecol, 1342 Dongil Ro, Seoul 139707, South Korea.
   [Hwang, Je Hyung] Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, 1342 Dongil Ro, Seoul 139707, South Korea.
C3 Inje University; Inje University
RP Hwang, JH (通讯作者)，Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, 1342 Dongil Ro, Seoul 139707, South Korea.
EM cnnsbs@naver.com; violentviolet15@daum.net
OI Yuk, Jin-Sung/0000-0002-5478-634X; Hwang, Jehyung/0000-0001-8081-7771
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Freedman RR, 2001, AM J HUM BIOL, V13, P453, DOI 10.1002/ajhb.1077
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Park JY, 2021, RETINA-J RET VIT DIS, V41, P409, DOI 10.1097/IAE.0000000000002845
   Patnaik JL, 2020, OPHTHAL EPIDEMIOL, V27, P148, DOI 10.1080/09286586.2019.1701041
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spinelli MG, 2004, CLIN OBSTET GYNECOL, V47, P428, DOI 10.1097/00003081-200406000-00019
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 30
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 7
AR 1899
DI 10.3390/jcm11071899
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0L6VA
UT WOS:000781609000001
PM 35407510
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ambati, J
   Ambati, BK
   Yoo, SH
   Ianchulev, S
   Adamis, AP
AF Ambati, J
   Ambati, BK
   Yoo, SH
   Ianchulev, S
   Adamis, AP
TI Age-related macular degeneration: Etiology, pathogenesis, and
   therapeutic strategies
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; drusen;
   macular dystrophies
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; VASCULAR-PERMEABILITY FACTOR; GLYCATION
   END-PRODUCTS; NITRIC-OXIDE SYNTHASE; EXTERNAL-BEAM RADIATION;
   STARGARDT-DISEASE GENE; ADHESION MOLECULE-1 ICAM-1; BASAL LINEAR DEPOSIT
AB Age-related macular degeneration is the principal cause of registered legal blindness among those aged over 65 in the United States, western Europe, Australia, and Japan. Despite intensive research, the precise etiology of molecular events that underlie age-related macular degeneration is poorly understood. However, investigations on parallel fronts are addressing this prevalent public health problem. Sophisticated biochemical and biophysical techniques have refined our understanding of the pathobiology of drusen, geographic atrophy, and retinal pigment epithelial detachments. Epidemiological identification of risk factors has facilitated an intelligent search for underlying mechanisms and fueled clinical investigation of behavior modification. Gene searches have not only brought us to the cusp of identifying the culpable gene loci in age-related macular degeneration, but also localized genes responsible for other macular dystrophies. Recent and ongoing investigations, often cued by tumor biology, have revealed an important role for various growth factors, particularly in the neovascular form of the condition. Transgenic and knockout studies have provided important mechanistic insights into the development of choroidal neovascularization, the principal cause of vision loss in age-related macular degeneration. This in turn has culminated in preclinical and clinical trials of directed molecular interventions.
C1 Eyetech Res Ctr, Woburn, MA 01801 USA.
   Univ Kentucky, Dept Ophthalmol, Ocular Angiogenesis Lab, Lexington, KY USA.
   Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
   Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
   Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA.
C3 University of Kentucky; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; University System of Georgia; Augusta
   University; Bascom Palmer Eye Institute; University of Miami; Harvard
   University; Boston Children's Hospital; Harvard Medical School
RP Adamis, AP (通讯作者)，Eyetech Res Ctr, 42 Cummings Pk, Woburn, MA 01801 USA.
CR Abramson DH, 2002, ARCH OPHTHALMOL-CHIC, V120, P1602
   Adachi Y, 1998, INT J ONCOL, V13, P1031
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Alvarez A, 2001, J LEUKOCYTE BIOL, V70, P199
   Alvarez A, 2001, BRIT J PHARMACOL, V133, P485, DOI 10.1038/sj.bjp.0704096
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Ambati J, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Applegate CA, 2001, INVEST OPHTH VIS SCI, V42, pS230
   APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Baffi J, 2001, INVEST OPHTH VIS SCI, V42, pS227
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becerra SP, 2001, INVEST OPHTH VIS SCI, V42, pS772
   BECERRA SP, 1993, J BIOL CHEM, V268, P23148
   Becker MD, 1999, INVEST OPHTH VIS SCI, V40, P612
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blodi BA, 2001, INVEST OPHTH VIS SCI, V42, pS311
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293
   BUSH RA, 1991, EXP EYE RES, V53, P741, DOI 10.1016/0014-4835(91)90109-R
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carron JA, 2000, INT J BIOCHEM CELL B, V32, P1137, DOI 10.1016/S1357-2725(00)00065-0
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   COTE J, 2002, ASS RES VIS OPHTH AN
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   CUNNINGHAM JJ, 1994, METABOLISM, V43, P1558, DOI 10.1016/0026-0495(94)90016-7
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V28, P357, DOI 10.1111/j.1751-1097.1978.tb07718.x
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DEMETRIADES AMM, 2002, ASS RES VIS OPHTH AN
   DETURCO EBR, 1991, J NEUROSCI, V11, P3667
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dulak J, 2000, ARTERIOSCL THROM VAS, V20, P659, DOI 10.1161/01.ATV.20.3.659
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   EVANS J, 1995, CAUSES BLINDNESS PAR
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FERGUSON TA, 2002, ASS RES VIS OPHTH AN
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   FOLK JC, 1985, OPHTHALMOLOGY, V92, P594
   FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690
   FRANCOIS J, 1975, AM J OPHTHALMOL, V79, P206, DOI 10.1016/0002-9394(75)90073-2
   Frank HA, 1996, EUR J CLIN NUTR, V50, pS13
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   FRIBERG TR, 2002, ASS RES VIS OPHTH AN
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Fukuzawa K, 1998, LIPIDS, V33, P751, DOI 10.1007/s11745-998-0266-y
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GEHLBACH PL, 2002, ASS RES VIS OPHTH AN
   Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546
   Gilbert RE, 2000, DIABETOLOGIA, V43, P1360, DOI 10.1007/s001250051539
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Gutsmann-Conrad A, 1998, EXP CELL RES, V241, P404, DOI 10.1006/excr.1998.4069
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haas A, 2000, OPHTHALMOLOGY, V107, P1358, DOI 10.1016/S0161-6420(00)00154-8
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAGEMAN GS, 2002, ASS RES VIS OPHTH AN
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968
   HANSSEN R, 1930, Z AUGENHEILKD, V72, P360
   Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Hegner C., 1916, KLIN MONATSBL AUGENH, V57, P27
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heidenkummer H.-P., 1995, Ophthalmologe, V92, P631
   HEIER JS, 2002, ASS RES VIS OPHTH AN
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   HIRATA A, 1992, INVEST OPHTH VIS SCI, V33, P2079
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Hussain AA, 2001, INVEST OPHTH VIS SCI, V42, pS223
   Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   JAFFE EA, 1982, NATURE, V295, P246, DOI 10.1038/295246a0
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaven C, 2001, OPHTHALMOLOGICA, V215, P284, DOI 10.1159/000050875
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Kruse FE, 1998, GRAEF ARCH CLIN EXP, V236, P461, DOI 10.1007/s004170050106
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Lee PC, 2000, MICROVASC RES, V60, P269, DOI 10.1006/mvre.2000.2265
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   Li WY, 1999, MECH AGEING DEV, V110, P137, DOI 10.1016/S0047-6374(99)00047-0
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lonchampt M, 2001, INVEST OPHTH VIS SCI, V42, P429
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luna J, 1996, LAB INVEST, V75, P563
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Maguire MG, 2001, INVEST OPHTH VIS SCI, V42, pS233
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P1477
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mandai M, 2000, JPN J OPHTHALMOL, V44, P530, DOI 10.1016/S0021-5155(00)00217-3
   MARCUS DM, 2002, ASS RES VIS OPHTH AN
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Matsunaga H, 1999, MOL VIS, V5, pU6
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCFARLANE S, 2001, INVEST OPHTH VIS SCI, V42, pS414
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   MILLER H, 1985, AM J OPHTHALMOL, V99, P263, DOI 10.1016/0002-9394(85)90354-X
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P204
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moromizato Y, 2000, AM J PATHOL, V157, P1277, DOI 10.1016/S0002-9440(10)64643-3
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   NISHIMURA T, 1990, OPHTHALMOLOGICA, V200, P39, DOI 10.1159/000310075
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nozaki M, 2001, INVEST OPHTH VIS SCI, V42, pS228
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867
   Pagenstecher H. a. G., 1875, ATLAS PATHOLOGISCHEN
   PALM R, 1986, ACTA NEUROL SCAND, V74, P308
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Paul LA, 1927, Z AUGENHEILKD, V63, P205
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   POLAK BCP, 1995, BRIT J OPHTHALMOL, V79, P922, DOI 10.1136/bjo.79.10.922
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1377, DOI 10.1001/archopht.1986.01050210131040
   POTTER JW, 1981, J AM OPTOM ASSOC, V52, P503
   Pournaras CJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1553, DOI 10.1001/archopht.1997.01100160723009
   Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rawes V, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1291
   RAZ I, 1989, DIABETES RES CLIN EX, V11, P73
   Razavi S, 2001, INVEST OPHTH VIS SCI, V42, pS773
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson MR, 2002, EXP EYE RES, V74, P309, DOI 10.1006/exer.2001.1132
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Rodriguez-Coleman H, 2002, RETINA-J RET VIT DIS, V22, P228, DOI 10.1097/00006982-200204000-00019
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rulon LL, 2000, BIOL TRACE ELEM RES, V75, P79, DOI 10.1385/BTER:75:1-3:79
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   SAKURAI E, IN PRESS INVEST OPHT
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schalch W, 1992, EXS, V62, P280
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schneider S, 1998, RETINA-J RET VIT DIS, V18, P242, DOI 10.1097/00006982-199803000-00009
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SCHWARTZ BS, 1989, J BIOL CHEM, V264, P7512
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seaber JH, 1997, GRAEF ARCH CLIN EXP, V235, P76, DOI 10.1007/BF00941733
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sennlaub F, 1999, INVEST OPHTH VIS SCI, V40, P2773
   Sennlaub F, 2001, J CLIN INVEST, V107, P717, DOI 10.1172/JCI10874
   Shafiee A, 2000, INVEST OPHTH VIS SCI, V41, P2378
   Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SINGERMAN LJ, 2002, ASS RES VIS OPHTH AN
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SLAKTER JS, 2002, ASS RES VIS OPHTH AN
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spandau U, 2000, INVEST OPHTH VIS SCI, V41, pS836
   Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   SUNER IJ, 2002, ASS RES VIS OPHTH AN
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Suzuma I, 1999, INVEST OPHTH VIS SCI, V40, P2122
   Suzuma K, 1999, AM J PATHOL, V154, P343, DOI 10.1016/S0002-9440(10)65281-9
   Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tanemura M, 2001, INVEST OPHTH VIS SCI, V42, pS96
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Thach AB, 1997, INT OPHTHALMOL, V20, P205
   THOMAS EL, 2002, ASS RES VIS OPHTH AN
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
   UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317
   Valmaggia Christophe, 2001, Documenta Ophthalmologica, V103, P201, DOI 10.1023/A:1013047722865
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Watkins ML, 2000, AM J EPIDEMIOL, V152, P149, DOI 10.1093/aje/152.2.149
   WATZKE RC, 1993, CURR EYE RES, V12, P133, DOI 10.3109/02713689308999481
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   WILCOX DK, 1988, INVEST OPHTH VIS SCI, V29, P1205
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514
   Wood JPM, 2001, ARCH OPHTHALMOL-CHIC, V119, P81
   Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984
   WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060
   WYSZYNSKI RE, 1989, INVEST OPHTH VIS SCI, V30, P2341
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yamada H, 1999, J CELL PHYSIOL, V179, P149, DOI 10.1002/(SICI)1097-4652(199905)179:2<149::AID-JCP5>3.3.CO;2-U
   YAN SD, 1994, J BIOL CHEM, V269, P9889
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yasukawa T, 2000, CURR EYE RES, V21, P952, DOI 10.1076/ceyr.21.6.952.6992
   Yellayi S, 2002, P NATL ACAD SCI USA, V99, P7616, DOI 10.1073/pnas.102650199
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
   ZHANG NL, 1993, INVEST OPHTH VIS SCI, V34, P2412
   Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 522
TC 719
Z9 841
U1 2
U2 122
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2003
VL 48
IS 3
BP 257
EP 293
DI 10.1016/S0039-6257(03)00030-4
PG 37
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 680YC
UT WOS:000183006800002
PM 12745003
DA 2022-11-30
ER

PT J
AU Telander, DG
AF Telander, David G.
TI Inflammation and Age-Related Macular Degeneration (AMD)
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); inflammation; immune system;
   retinal degeneration; pathogenesis; drusen; Factor H gene; complement
ID RETINAL-PIGMENT EPITHELIUM; GLOMERULONEPHRITIS TYPE-II;
   COMPLEMENT-SYSTEM; FACTOR-H; CHOROIDAL NEOVASCULARIZATION;
   CHLAMYDIA-PNEUMONIAE; GENETIC-FACTORS; HOST-DEFENSE; DRUSEN; ANTIBODIES
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. The cause of AMD is complex and many risk factors have been implicated including age, family history (genetics), diet, smoking, and other environmental risk factors. Over the past decade, studies has found that inflammation play a large role in the pathogenesis of age-related macular degeneration (AMD). In fact, the main genetic changes (polymorphism) associated with AMD were found to be genes that regulate inflammation, most notably complement Factor H. This review ties together many studies done over the past decade to give us new insight into the role inflammation plays in the development of AMD.
C1 [Telander, David G.] Univ Calif Davis, Med Ctr, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Telander, DG (通讯作者)，Univ Calif Davis, Ctr Eye, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM dgtelander@ucdavis.edu
FU Research to Prevent Blindness, New York; Genetech.
FX Supported in part by The Research to Prevent Blindness, New York,
   unrestricted departmental grant and a research investigator-sponsored
   trial through Genetech.
CR AIZUSS DH, 1985, INVEST OPHTH VIS SCI, V26, P1262
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Smet MD, 2001, PROG RETIN EYE RES, V20, P761, DOI 10.1016/S1350-9462(01)00011-8
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Framme C, 1998, KLIN MONATSBL AUGENH, V213, P252, DOI 10.1055/s-2008-1034983
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   GIESE MJ, 1994, INVEST OPHTH VIS SCI, V35, P1026
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Karagianni N, 2010, ADV EXP MED BIOL, V703, P1, DOI 10.1007/978-1-4419-5635-4_1
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   KORNZWEIG A L, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P668
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 57
TC 60
Z9 70
U1 1
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 192
EP 197
DI 10.3109/08820538.2011.570849
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200015
PM 21609232
DA 2022-11-30
ER

PT J
AU Tsuchiya, D
   Yamamoto, T
   Kawasaki, R
   Yamashita, H
AF Tsuchiya, Daijiro
   Yamamoto, Teiko
   Kawasaki, Ryo
   Yamashita, Hidetoshi
TI TWO-YEAR VISUAL OUTCOMES AFTER PHOTODYNAMIC THERAPY IN AGE-RELATED
   MACULAR DEGENERATION PATIENTS WITH OR WITHOUT POLYPOIDAL CHOROIDAL
   VASCULOPATHY LESIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photodynamic therapy; choroidal vasculopathy; age-related macular
   degeneration
ID VERTEPORFIN THERAPY
AB Purpose: To describe the visual outcomes 2 years after photodynamic therapy in Japanese patients with age-related macular degeneration (AMD) with or without polypoidal choroidal vasculopathy (PCV) lesions.
   Methods: Sixty-three eyes of 63 consecutive patients with AMD or AMD + PCV who underwent photodynamic therapy were included in this study. Fluorescein and indocyanine green angiography were performed to diagnose AMD and AMD + PCV. Change in mean visual acuity and recurrence of active lesion during the follow-up period up to 2 years were assessed.
   Results: Patients with typical AMD maintained visual acuity for 2 years after photodynamic therapy. For patients with AMD + PCV, the visual acuity was maintained during the first year but started decreasing by 0.09 logarithm of the minimum angle of resolution units per 3 months (95% confidence intervals [Cl], 0.06-0.14) after 1 year. Moreover, patients with AMD + PCV had 82% higher risk of a recurrence of active lesions for each increase in 3 months of follow-up time after 1 year; this suggested that the risk of recurrence had increased later in follow-up after 1 year. Recurrence of active PCV lesions and massive subretinal hemorrhages were the main reasons for the late worsening of visual acuity.
   Conclusion: The visual acuity after photodynamic therapy in AMD patients was maintained for 2 years after the initial treatment. Patients with AMD + PCV had stable visual outcome within 1 year but not after 1 year; there are risks of late recurrences and massive hemorrhages after 1 year in patients with AMD + PCV.
C1 [Tsuchiya, Daijiro; Yamamoto, Teiko; Kawasaki, Ryo; Yamashita, Hidetoshi] Yamagata Univ, Fac Med, Dept Ophthalmol & Visual Sci, Yamagata 990, Japan.
   [Kawasaki, Ryo] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Yamagata University; Centre for Eye Research Australia; University of
   Melbourne
RP Yamashita, H (通讯作者)，Yamagata Univ, Fac Med, Dept Ophthalmol & Visual Sci, Yamagata 990, Japan.
EM hyama-tky@umin.ac.jp
RI Kawasaki, Ryo/B-7266-2009; Kawasaki, Ryo/H-9716-2019
OI Kawasaki, Ryo/0000-0002-7492-6303; 
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 20
TC 39
Z9 45
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2009
VL 29
IS 7
BP 960
EP 965
DI 10.1097/IAE.0b013e3181a3b7c5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470DT
UT WOS:000267955400009
PM 19491727
DA 2022-11-30
ER

PT J
AU Imai, H
   Honda, S
   Nakanishi, Y
   Yamamoto, H
   Tsukahara, Y
   Negi, A
AF Imai, H.
   Honda, S.
   Nakanishi, Y.
   Yamamoto, H.
   Tsukahara, Y.
   Negi, A.
TI Different transitions of multifocal electroretinogram recordings between
   patients with age-related macular degeneration and polypoidal choroidal
   vasculopathy after photodynamic therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CLINICAL-TRIAL; PROSPECTIVE
   CASE SERIES; RETINAL FUNCTION; PATHOLOGICAL MYOPIA; VERTEPORFIN THERAPY;
   NEOVASCULARIZATION; LESIONS; ERG
AB Aim: To compare and evaluate the transitions in retinal function after photodynamic therapy (PDT) between age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) using multifocal electroretinograms (mfERGs).
   Methods: 10 eyes with choroidal neovascularisation (CNV) secondary to AMD and 11 eyes with CNV secondary to PCV were included in the study. mfERGs were recorded before PDT, and 1 week and 3 months after PDT. mfERG recordings were acquired by a Veris system (V.3.1.3) using a 103 hexagon stimulus. The first-order kernel was used to calculate amplitudes and latencies. Mean amplitudes and latencies from two central rings rated 0-4 degrees of visual angle were analysed and compared with each disease.
   Results: In AMD, the mean first negative peak (N1) amplitudes tended to decrease, and the mean first positive peak (N1P1) amplitudes reduced to significant levels (p = 0.047) 1 week after PDT. 3 months after PDT, there were no significant differences in the mean N1 and N1P1 amplitudes compared with pre-PDT values. In PCV, there were no significant changes in the mean N1 and N1P1 amplitudes 1 week after treatment. However, 3 months after PDT, mean amplitudes showed significant increases in N1 (p = 0.008) and N1P1 (p = 0.006) amplitudes compared with pre-PDT values.
   Conclusions: mfERG recording transitions are different between patients with AMD and those with PCV. In patients with AMD, these results may show transient impairments in retinal function 1 week after PDT, but in those with PCV, the efficacy of PDT is superior to the impairment after PDT.
C1 Kobe Univ, Grad Sch Med, Dept Organ Therapeut, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Imai, H (通讯作者)，Kobe Univ, Grad Sch Med, Dept Organ Therapeut, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM h-i@excite.co.jp
RI Honda, Shigeru/W-4761-2019
OI Imai, Hisanori/0000-0001-8879-3604
CR Apostolopoulos MN, 2002, AM J OPHTHALMOL, V134, P667, DOI 10.1016/S0002-9394(02)01700-2
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LIANG L, 2003, DOC OPHTHALMOL, V107, P165
   Marmor MF, 1999, ARCH OPHTHALMOL-CHIC, V117, P184
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moschos MN, 2003, EUR J OPHTHALMOL, V13, P461, DOI 10.1177/112067210301300507
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   SEGATO T, 1993, AGING-CLIN EXP RES, V5, P165, DOI 10.1007/BF03324151
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 36
TC 15
Z9 16
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2006
VL 90
IS 12
BP 1524
EP 1530
DI 10.1136/bjo.2006.092783
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 106WX
UT WOS:000242133800021
PM 16825279
OA Green Published
DA 2022-11-30
ER

PT J
AU Gupta, P
   Ting, DSW
   Thakku, G
   Wong, TY
   Cheng, CY
   Wong, E
   Mathur, R
   Wong, D
   Yeo, I
   Cheung, CMG
AF Gupta, Preeti
   Ting, Daniel Shu Wei
   Thakku, Gowtham
   Wong, Tien-Yin
   Cheng, Ching-Yu
   Wong, Edmund
   Mathur, Ranjana
   Wong, Doric
   Yeo, Ian
   Cheung, Chui Ming Gemmy
TI DETAILED CHARACTERIZATION OF CHOROIDAL MORPHOLOGIC AND VASCULAR FEATURES
   IN AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal morphologic and vascular characteristics; choroidal thickness;
   age-related macular degeneration; polypoidal choroidal vasculopathy;
   enhanced depth imaging; optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; VORTEX VEIN;
   THICKNESS; EYES; DISEASE; HYPERPERMEABILITY; CLASSIFICATION;
   MACULOPATHY; PRESSURE
AB Purpose: To characterize and compare morphologic and vascular features of the choroid in patients with typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) and to determine if PCV subtypes can be identified based on these choroidal features.
   Methods: Choroidal features of patients with AMD and PCV recruited from the prospectively planned Asian AMD Phenotyping Study were analyzed. Patients underwent choroidal imaging using spectral-domain optical coherence tomography with enhanced depth imaging. Raw optical coherence tomographic images were loaded on a custom-written application on MATLAB that enabled delineation for detailed morphologic and vascular analyses, including the curvature of the choroid-sclera interface, number of inflection points, choroidal thickness and choroidal vascular area within the macular (6 mm centered on fovea) and foveal (1.5 mm centered on fovea) regions. An inflection point represents the contour of the choroid-sclera interface, with > 1 point signaling irregular shape.
   Results: A total of 156 eyes of 156 patients (78 affected eyes of 78 patients with typical AMD and 78 affected eyes of 78 patients with PCV) were analyzed. Eyes with PCV had thicker baseline choroidal thickness and greater choroidal vascular area compared with those with typical AMD (P < 0.05); these differences were no longer significant after adjusting for age and hypertension (P > 0.05). Typical PCV subtype with choroidal thickness of >= 257 mu m had significantly greater choroidal vascular area at macular (mean difference = 0.054 mm(2); P < 0.001) and foveal (mean difference = 0.199 mm(2); P < 0.001) regions compared with eyes with typical AMD. However, eyes with PCV without thick choroid had similar choroidal vascular area as eyes with typical AMD.
   Conclusion: Based on the choroidal vascular features, two subtypes of PCV can be classified: typical PCV with increased choroid vascularity and polypoidal choroidal neovascularization with low choroidal vascularity. These data provide further understanding of different AMD and PCV subtypes.
C1 [Gupta, Preeti; Ting, Daniel Shu Wei; Thakku, Gowtham; Wong, Tien-Yin; Cheng, Ching-Yu; Wong, Edmund; Mathur, Ranjana; Wong, Doric; Yeo, Ian; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Gupta, Preeti; Ting, Daniel Shu Wei; Thakku, Gowtham; Wong, Tien-Yin; Cheng, Ching-Yu; Wong, Edmund; Mathur, Ranjana; Wong, Doric; Yeo, Ian; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Vitreoretinal Dept, Singapore, Singapore.
   [Gupta, Preeti; Thakku, Gowtham; Wong, Tien-Yin; Cheng, Ching-Yu; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Gupta, Preeti; Thakku, Gowtham; Wong, Tien-Yin; Cheng, Ching-Yu; Cheung, Chui Ming Gemmy] Natl Univ Hlth Syst, Singapore, Singapore.
   [Ting, Daniel Shu Wei; Wong, Tien-Yin; Cheng, Ching-Yu; Mathur, Ranjana; Yeo, Ian; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Bidwai, Pooja Vishal/0000-0002-3077-4395; Wong,
   Damon/0000-0003-4601-9121; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/1003/2009]; Biomedical
   Research Council (BMRC) [101/35/19/671]
FX Supported by the National Medical Research Council grant
   NMRC/NIG/1003/2009 and Biomedical Research Council (BMRC) Grant No.
   101/35/19/671. The funding organization had no role in the design or
   conduct of this research.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee WK, 2016, RETINA IN PRESS
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Niblack W, 1986, ADV COMPUTER GRAPHIC
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wei X, 2016, RNA BIOL, P1
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu PK, 2013, EXP EYE RES, V115, P144, DOI 10.1016/j.exer.2013.07.006
NR 36
TC 31
Z9 33
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2017
VL 37
IS 12
BP 2269
EP 2280
DI 10.1097/IAE.0000000000001481
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3NL
UT WOS:000425214400008
PM 28145972
DA 2022-11-30
ER

PT J
AU Matsumiya, W
   Honda, S
   Otsuka, K
   Miki, A
   Nagai, T
   Imai, H
   Kusuhara, S
   Nakamura, M
AF Matsumiya, Wataru
   Honda, Shigeru
   Otsuka, Keiko
   Miki, Akiko
   Nagai, Takayuki
   Imai, Hisanori
   Kusuhara, Sentaro
   Nakamura, Makoto
TI Comparison of the Effectiveness and Prognostic Factors of Intravitreal
   Ranibizumab between Typical Neovascular Age-Related Macular Degeneration
   and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up
SO OPHTHALMOLOGICA
LA English
DT Article
DE Ranibizumab; Polypoidal choroidal vasculopathy; Typical neovascular
   age-related macular degeneration; Two-year outcome (24 months);
   Predictive factor
ID PHOTODYNAMIC THERAPY; JAPANESE PATIENTS; EFFICACY; VERTEPORFIN;
   BEVACIZUMAB; SAFETY; EYES; AMD
AB Purpose: To compare the response to ranibizumab between patients with typical neovascular age-related macular degeneration (tAMD) and those with polypoidal choroidal vasculopathy (PCV), and to determine the predictors for the outcomes. Methods: Fifty-nine eyes from 59 consecutive patients (tAMD: 27 eyes, PCV: 32 eyes) were treated with three monthly ranibizumab injections followed by as-needed retreatment. Best-corrected visual acuity (BCVA) and morphological parameters were evaluated over 24 months of follow-up. Results: The mean BCVA in tAMD and PCV patients was significantly improved at 3 months (-0.22 and -0.09 logMAR units, respectively). The improvement in BCVA was sustained up to 24 months in tAMD (p = 0.01) but not in PCV patients. The significant predictor for good response to ranibizumab in tAMD patients was the improvement of BCVA at 3 months, whereas that in PCV patients was the anatomical resolution at 3 months. Conclusions: Ranibizumab is an effective therapy for tAMD and PCV over 24 months. The predictors for good outcome might be different between tAMD and PCV. (C) 2015 S. Karger AG, Basel
C1 [Matsumiya, Wataru; Honda, Shigeru; Otsuka, Keiko; Miki, Akiko; Nagai, Takayuki; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Matsumiya, W (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol,Dept Surg, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM ytkmatsu@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Nakamura, Makoto/0000-0002-6464-4302; Imai,
   Hisanori/0000-0001-8879-3604; Kusuhara, Sentaro/0000-0002-6458-539X
FU Ministry of Education, Science and Culture, Tokyo, Japan [26861449];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in-Aid (B) 26861449 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (W.M.) and by a
   grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organizations had no role in the design or conduct of this
   research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Evans J.S.B.T., 1996, RATIONALITY REASONIN
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 13
Z9 13
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 1
BP 33
EP 39
DI 10.1159/000431000
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ9KP
UT WOS:000360933700004
PM 26112059
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Long-term Clinical Course after Vitrectomy for Breakthrough Vitreous
   Hemorrhage Secondary to Neovascular Age-related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMBINED CATARACT-SURGERY; SUBMACULAR
   HEMORRHAGE; NATURAL-HISTORY; OUTCOMES
AB To investigate the long-term clinical course after vitrectomy for breakthrough vitreous hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). This retrospective study included 45 eyes that underwent vitrectomy due to breakthrough vitreous hemorrhage secondary to neovascular AMD. The patients were divided into 2 groups: neovascular AMD group and PCV group. Within each group, the status of the eye within 6 months after the surgery and that at the final follow-up was identified. The visual acuity at the final visit was additionally compared between the 2 groups. The patients were followed up for a mean period of 39.9 +/- 19.4 months after the surgery. In the neovascular AMD group (n = 17), re-bleeding requiring vitrectomy was noted in 4 eyes and extensive scar formation was noted in 6 eyes within 6 months after the surgery. At the final visit, treatment was discontinued due to poor visual outcome in 10 eyes. In the PCV group (n = 28), re-bleeding requiring vitrectomy was noted in 1 eye, and extensive scar formation was noted in 4 eyes within 6 months after the surgery. At the final visit, treatment was discontinued in 8 eyes. The visual acuity at the final visit was significantly better in the PCV group (P = 0.003). The long-term clinical course after vitrectomy for breakthrough vitreous hemorrhage was markedly different between neovascular AMD and PCV, showing significantly better long-term visual outcomes in PCV.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Baek J, 2018, RETINA-J RET VIT DIS, V38, P1993, DOI 10.1097/IAE.0000000000001817
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Chaudhry NA, 2002, OPHTHALMIC SURG LAS, V33, P16
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim J. H., 2017, EYE LONDON ENGLAND
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2168, DOI 10.1097/IAE.0000000000001845
   Kim JH, 2018, GRAEF ARCH CLIN EXP, V256, P469, DOI 10.1007/s00417-017-3877-5
   Kim JH, 2018, JPN J OPHTHALMOL, V62, P54, DOI 10.1007/s10384-017-0549-2
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   Narayanan Raja, 2015, Int J Retina Vitreous, V1, P25, DOI 10.1186/s40942-015-0025-4
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Rahmani S, 2018, SEMIN OPHTHALMOL, V33, P95, DOI 10.1080/08820538.2017.1353826
   Rizzo S, 2010, RETINA-J RET VIT DIS, V30, P1065, DOI 10.1097/IAE.0b013e3181cd48b0
   Roberts MF, 2002, BRIT J OPHTHALMOL, V86, P658, DOI 10.1136/bjo.86.6.658
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roufail E, 2008, CLIN EXP OPHTHALMOL, V36, P36, DOI 10.1111/j.1442-9071.2007.01651.x
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 32
TC 5
Z9 5
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 15
PY 2020
VL 10
IS 1
AR 359
DI 10.1038/s41598-019-57297-8
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MO3QD
UT WOS:000551443900010
PM 31941971
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Cheung, CMG
   Koizumi, H
   Govindahar, V
   Chhablani, J
   Lai, TYY
AF Chaikitmongkol, Voraporn
   Cheung, Chui Ming Gemmy
   Koizumi, Hideki
   Govindahar, Vishal
   Chhablani, Jay
   Lai, Timothy Y. Y.
TI Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology,
   Etiology, Diagnosis, and Treatment
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; diagnosis; genetics; polypoidal
   choroidal vasculopathy; treatment
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   C-REACTIVE PROTEIN; MACULAR DEGENERATION; INDOCYANINE GREEN;
   INTRAVITREAL BEVACIZUMAB; ANGIOGRAPHIC LESION; RISK-FACTORS; CHINESE;
   EFFICACY
AB Polypoidal choroidal vasculopathy (PCV) is a condition characterized by multiple, recurrent, serosanguineous pigment epithelial detachments, and neurosensory retinal detachments due to abnormal aneurysmal neovascular lesions. It is generally considered as a variant of neovascular age-related macular degeneration, but there are some differences between the clinical presentation, natural history, and treatment response between patients with PCV and typical neovascular age-related macular degeneration patients. Over the past decade, new research and technological advancements have greatly improved our understanding of the PCV disease process and the management of PCV. This review aims to summarize the recent research findings to highlight the epidemiology, pathogenesis, genetics, the application of various diagnostic tools for PCV, and the available treatment options for PCV.
C1 [Chaikitmongkol, Voraporn] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Chiang Mai, Thailand.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Koizumi, Hideki] Univ Ryukyus, Dept Ophthalmol, Nishihara, Okinawa, Japan.
   [Chhablani, Jay] LV Prasad Eye Inst, Bhubaneswar, India.
   [Govindahar, Vishal] Univ Pittsburgh, Dept Ophthalmol, Med Ctr, Pittsburgh, PA 15260 USA.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
C3 Chiang Mai University; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; University of
   Ryukyus; L. V. Prasad Eye Institute; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Chinese University
   of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, 147K Argyle St, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; Chhablani,
   Jay/0000-0003-1772-3558; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Fukuyama H, 2018, OPHTHALMOL RETINA, V2, P803, DOI 10.1016/j.oret.2017.11.016
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Meng QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143924
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singh SR, 2021, EUR J OPHTHALMOL, V31, P218, DOI 10.1177/1120672119883593
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CS, 2019, OPHTHALMOL RETINA, V3, P400, DOI 10.1016/j.oret.2019.01.009
   Tan CS, 2017, JAMA OPHTHALMOL, V135, P1316, DOI 10.1001/jamaophthalmol.2017.4453
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   THOMAS JW, 1993, RETINA-J RET VIT DIS, V13, P93, DOI 10.1097/00006982-199313020-00001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1244-5
   Yang JY, 2020, GRAEF ARCH CLIN EXP, V258, P17, DOI 10.1007/s00417-019-04493-x
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhan ZY, 2019, GRAEF ARCH CLIN EXP, V257, P2349, DOI 10.1007/s00417-019-04445-5
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   [张雅琳 Zhang Yalin], 2016, [兵工学报, Acta Armamentarii], V37, P165
NR 97
TC 11
Z9 11
U1 2
U2 5
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAY-JUN
PY 2020
VL 9
IS 3
BP 260
EP 268
DI 10.1097/01.APO.0000656992.00746.48
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LY2AH
UT WOS:000540322300012
PM 32332215
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, K
   Chen, LJ
   Tam, POS
   Shi, Y
   Lai, TYY
   Liu, DTL
   Chiang, SWY
   Yang, MM
   Yang, ZL
   Pang, CP
AF Liu, Ke
   Chen, Li Jia
   Tam, Pancy O. S.
   Shi, Yi
   Lai, Timothy Y. Y.
   Liu, David T. L.
   Chiang, Sylvia W. Y.
   Yang, Mingming
   Yang, Zhenglin
   Pang, Chi Pui
TI Associations of the C2-CFB-RDBP-SKIV2L Locus with Age-related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; COMPONENT 2 C2; FACTOR-B BF; GENE POLYMORPHISMS;
   VARIANT; C3; SUSCEPTIBILITY; CFB; RISK; INCREASES
AB Purpose: To investigate the associations of the C2-CFB-RDBP-SKIV2L region with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional, case-control association study.
   Participants: A Chinese case-control group of 200 neovascular AMD patients, 233 PCV patients, and 275 control subjects.
   Methods: An association analysis was performed of the C2-CFB-RDBP-SKIV2L locus with both neovascular AMD and PCV in a Chinese population using 19 haplotype-tagging single nucleotide polymorphisms (SNPs) and 6 previously reported SNPs across the C2-CFB-RDBP-SKIV2L region. All SNPs were genotyped using the TaqMan genotyping technology (TaqMan; Applied Biosystems [ABI], Foster City, CA).
   Main Outcome Measures: Allele and haplotype frequencies of the SNPs in the C2-CFB-RDBP-SKIV2L region.
   Results: The SKIV2L SNPs rs429608 and rs453821 were significantly associated with neovascular AMD (P = 7.39 x 10(-5); odds ratio [OR], 0.22; 95% confidence interval [CI], 0.10-0.50; and P = 0.001; OR, 0.38; 95% CI, 0.21-0.70, respectively), whereas borderline associations were detected for C2 rs547154 (P = 0.002) and RDBP rs760070 (P = 0.003). Conditional haplotype analysis revealed that SKIV2L rs429608 could account fully for the global haplotype association identified in this region. The association of SKIV2L rs429608 with neovascular AMD remained significant after adjusting for CFH rs800292 and HTRA1 rs11200638. No individual SNP or haplotype was associated significantly with PCV.
   Conclusions: In this concurrent investigation of the associations of the entire C2-CFB-RDBP-SKIV2L region with neovascular AMD and PCV, the results suggested that SKIV2L is a likely causal gene for neovascular AMD, conferring a significant protective effect independent of CFH and HTRA1. These data do not support a significant role of this region in PCV, suggesting different molecular mechanisms between neovascular AMD and PCV.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:837-843 (C) 2013 by the American Academy of Ophthalmology.
C1 [Liu, Ke; Chen, Li Jia; Tam, Pancy O. S.; Lai, Timothy Y. Y.; Liu, David T. L.; Chiang, Sylvia W. Y.; Yang, Mingming; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Chen, Li Jia; Liu, David T. L.] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Shi, Yi; Yang, Zhenglin] Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.
   [Shi, Yi; Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Sichuan Provincial People's Hospital; Sichuan
   Provincial People's Hospital
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020; Chen, Li Jia/I-5078-2014; Pang, Chi
   P/I-5388-2014
OI Lai, Timothy Y Y/0000-0002-7832-6428; Chen, Li Jia/0000-0003-3500-5840; 
FU Endowment Fund for Lim Por-Yen Eye Genetics Research Centre; General
   Research Fund from the Research Grants Council, Hong Kong, China
   [473410]; National Natural Science Foundation of China [81025006]
FX Supported in part by an Endowment Fund for Lim Por-Yen Eye Genetics
   Research Centre; the General Research Fund from the Research Grants
   Council (grant no.: 473410), Hong Kong, China; and the National Natural
   Science Foundation of China (grant no.: 81025006).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Purcell S, 2007, BIOINFORMATICS, V23, P255, DOI 10.1093/bioinformatics/btl580
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZY, 1998, GENOMICS, V53, P338, DOI 10.1006/geno.1998.5499
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 55
TC 32
Z9 34
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2013
VL 120
IS 4
BP 837
EP 843
DI 10.1016/j.ophtha.2012.10.003
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 122UL
UT WOS:000317343500029
PM 23260260
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Augood, C
   Bentham, GC
   de Jong, PTVM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vingerling, JR
   Vioque, J
   Young, IS
   Fletcher, AE
AF Chakravarthy, U.
   Augood, C.
   Bentham, G. C.
   de Jong, P. T. V. M.
   Rahu, M.
   Seland, J.
   Soubrane, G.
   Tomazzoli, L.
   Topouzis, F.
   Vingerling, J. R.
   Vioque, J.
   Young, I. S.
   Fletcher, A. E.
TI Cigarette smoking and age-related macular degeneration in the EUREYE
   study
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; VISUAL IMPAIRMENT; POOLED FINDINGS;
   UNITED-KINGDOM; GRADING SYSTEM; 3 CONTINENTS; EYE DISEASE; FOLLOW-UP;
   MACULOPATHY
AB Objective: To examine the association between cigarette smoking and age-related maculopathy (ARM) including age-related macular degeneration (AMD) in the European population.
   Design: Cross-sectional study.
   Participants: Four thousand seven hundred fifty randomly sampled >= 65-year-olds from 7 study centers across Europe (Norway, Estonia, United Kingdom, France, Italy, Greece, and Spain).
   Methods: Participants underwent an eye examination and digital retinal photography. The images were graded at a single center. Smoking history was ascertained by a structured questionnaire administered by trained fieldworkers. Multinomial and binary logistic regressions were used to examine the association between smoking history and ARM grade and type of AMD, taking account of potential confounders and the multicenter study design.
   Main Outcome Measures: Photographic images were graded according to the International Classification System for ARM and stratified using the Rotterdam staging system into 5 exclusive stages (ARM 0-3 and ARM 4, also known as AMD). Age-related macular degeneration also was classified as neovascular AMD or geographic atrophy (GA).
   Results: One hundred fifty-eight cases were categorized as AMD (109 neovascular AMD and 49 GA); 2260 had no signs of ARM (ARM 0). Current smokers had increased odds of neovascular AMD (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.4-4.8) or GA (OR, 4.8; 95% CI, 2.1-11.1), whereas for ex-smokers the odds were around 1.7. Compared with people with unilateral AMD, those with bilateral AMD were more likely to have a history of heavy smoking in the previous 25 years (OR, 5.1; 95% CI, 1.3-20.0). The attributable fraction for AMD due to smoking was 27% (95% CI, 19%-33%). There was no consistent association with ARM grades 1 to 3 and smoking.
   Conclusions: These findings highlight the need for increasing public awareness of the risks associated with smoking and the benefit of quitting smoking. Patients with unilateral disease who are current smokers should be advised of the risk of second-eye disease.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   Univ E Anglia, Ctr Environm Risk, Norwich NR4 7TJ, Norfolk, England.
   Acad Med Ctr, Netherlands Ophthalm Res Inst, Royal Netherlands Acad Arts & Sci, Amsterdam, Netherlands.
   Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   Haykeland Sykehus Univ Bergen, Bergen, Norway.
   Univ Paris 12, Clin Ophthalmol, Paris, France.
   Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   Aristotle Univ Thessaloniki, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
   Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Univ Miguel Hernandez, Dipartimento Salud Publ, Alicante, Spain.
   Queens Univ Belfast, Ctr Clin & Populat Sci, Belfast, Antrim, North Ireland.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Queens University Belfast; University of East Anglia; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; National
   Institute for Health Development - Estonia; University of Bergen;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Verona;
   Aristotle University of Thessaloniki; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Universidad Miguel
   Hernandez de Elche; Queens University Belfast
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Rahu, Mati/A-9981-2008; Vioque, Jesus/A-1066-2008
OI Vioque, Jesus/0000-0002-2284-148X; Chakravarthy,
   Usha/0000-0002-2606-3734; Topouzis, Fotis/0000-0002-8966-537X; Young,
   Ian/0000-0003-3890-3152
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cavelaars AEJM, 2000, BRIT MED J, V320, P1102, DOI 10.1136/bmj.320.7242.1102
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Clarke R, 1998, J EPIDEMIOL COMMUN H, V52, P364, DOI 10.1136/jech.52.6.364
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maresh JG, 2005, PHYSIOL GENOMICS, V21, P308, DOI 10.1152/physiolgenomics.00310.2004
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 33
TC 148
Z9 151
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1157
EP 1163
DI 10.1016/j.ophtha.2006.09.022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600020
PM 17337063
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Nagayama, D
AF Saito, M.
   Iida, T.
   Nagayama, D.
TI Photodynamic therapy with verteporfin for age-related macular
   degeneration or polypoidal choroidal vasculopathy: comparison of the
   presence of serous retinal pigment epithelial detachment
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; JAPANESE PATIENTS; NEOVASCULARIZATION;
   POPULATION; OCCULT; VARIANT
AB Aim: To evaluate outcomes after photodynamic therapy (PDT) with verteporfin in Japanese patients with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) and compare results with the presence/absence of a retinal pigment epithelial detachment (PED).
   Methods: We retrospectively reviewed 183 eyes with subfoveal choroidal neovascularisation secondary to AMD with more than 3 months' follow-up (range 3 to 36; mean 15.6). A serous PED developed in 44 of 183 eyes.
   Results: A total of 124 eyes (67.8%) completed 12 months' follow-up. In 49 eyes with typical AMD, the best-corrected visual acuity (BCVA) improved a mean of 0.48 line. A significant (p<0.05 to p<0.0005) decline in VA occurred in eyes with a serous PED during any 3-month period. In 75 eyes with PCV, the BCVA at 12 months improved a mean of 1.79 lines. There was no significant difference between the BCVA in 22 eyes with a PED and 53 eyes without a PED during any 3 months.
   Conclusions: In eyes with typical AMD, a serous PED was associated with a significant decline in BCVA compared with eyes without a serous PED. In eyes with PCV, the visual outcomes were unaffected by a serous PED. When PDT is administered, differentiating PCV from typical AMD using indocyanine green angiography is important.
C1 [Saito, M.; Iida, T.; Nagayama, D.] Fukushima Med Univ Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Ladas ID, 2007, OPHTHALMOLOGICA, V221, P313, DOI 10.1159/000104761
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 43
Z9 44
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2008
VL 92
IS 12
BP 1642
EP 1647
DI 10.1136/bjo.2007.137075
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 376ZW
UT WOS:000261222500016
PM 18782798
DA 2022-11-30
ER

PT J
AU Thee, EF
   Colijn, JM
   Cougnard-Gregoire, A
   Meester-Smoor, MA
   Verzijden, T
   Hoyng, CB
   Fauser, S
   Hense, HW
   Silva, R
   Creuzot-Garcher, C
   Ueffing, M
   Delcourt, C
   den Hollander, AI
   Klaver, CCW
AF Thee, Eric F.
   Colijn, Johanna M.
   Cougnard-Gregoire, Audrey
   Meester-Smoor, Magda A.
   Verzijden, Timo
   Hoyng, Carel B.
   Fauser, Sascha
   Hense, Hans-Werner
   Silva, Rufino
   Creuzot-Garcher, Catherine
   Ueffing, Marius
   Delcourt, Cecile
   den Hollander, Anneke, I
   Klaver, Caroline C. W.
CA European Eye Epidemiology Consorti
   EYE-RISK Project
TI The Phenotypic Course of Age-Related Macular Degeneration for
   ARMS2/HTRA1
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; ARMS2; Europe; Genetics; HTRA1
ID GEOGRAPHIC ATROPHY SECONDARY; 10Q26 LOCUS; HTRA1; ASSOCIATION; RISK;
   PROGRESSION; DISEASE; ARMS2; SUSCEPTIBILITY; POLYMORPHISM
AB Purpose: Age-related maculopathy susceptibility 2 (ARMS2) is considered the most enigmatic of the genes for age-related macular degeneration (AMD). We investigated the phenotypic course and spectrum of AMD for the risk haplotype at the ARMS2 and high-temperature requirement A serine peptidase 1 (HTRA1) locus in a large European consortium.
   Design: Pooled analysis of 4 case-control and 6 cohort studies.
   Participants: Individuals (N = 17 204) aged 55 years or older participating in the European Eye Epidemiology consortium.
   Methods: Age-related macular degeneration features and macular thickness were determined on multimodal images; data on genetics and phenotype were harmonized. Risks of AMD features for rs3750486 genotypes at the ARMS2/HTRA1 locus were determined by logistic regression and were compared with a genetic risk score (GRS) of 19 variants at the complement pathway. Lifetime risks were estimated with Kaplan-Meier analyses in population-based cohorts.
   Main Outcome Measures: Age-related macular degeneration features and stage.
   Results: Of 2068 individuals with late AMD, 64.7% carried the ARMS2/HTRA1 risk allele. For homozygous carriers, the odds ratio (OR) of geographic atrophy was 8.6 (95% confidence interval [CI], 6.5-11.4), of choroidal neovascularization (CNV) was 11.2 (95% CI, 9.4-13.3), and of mixed late AMD was 12.2 (95% CI, 7.3-20.6). Cumulative lifetime risk of late AMD ranged from 4.4% for carriers of the nonrisk genotype to 9.4% and 26.8% for heterozygous and homozygous carriers. The latter received the diagnosis of late AMD 9.6 years (95% CI, 8.0-11.2) earlier than carriers of the nonrisk genotype. The risk haplotype was not associated with hard or soft drusen < 125 mu m (OR, 1.2; 95% CI, 0.9-1.7), but risks increased significantly for soft drusen >= 125 mu m (OR, 2.1; 95% CI, 1.5-3.0), up to an OR of 7.2 (95% CI, 3.8-13.8) for reticular pseudodrusen. Compared with persons with a high GRS for complement, homozygous carriers of ARMS2/HTRA1 showed a higher risk of CNV (OR, 4.1; 95% CI, 3.2-5.4); risks of other characteristics were not different.
   Conclusions: Carriers of the risk haplotype at ARMS2/HTRA1 have a particularly high risk of late AMD at a relatively early age. Data suggest that risk variants at ARMS2/HTRA1 act as a strong catalyst of progression once early signs are present. The phenotypic spectrum resembles that of complement genes, only with higher risks of CNV. (C) 2022 by the American Academy of Ophthalmology.
C1 [Thee, Eric F.; Colijn, Johanna M.; Meester-Smoor, Magda A.; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Thee, Eric F.; Colijn, Johanna M.; Meester-Smoor, Magda A.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Cougnard-Gregoire, Audrey; Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219,Team LEHA, Bordeaux, France.
   [Hoyng, Carel B.; den Hollander, Anneke, I; Klaver, Caroline C. W.] Radboud Univ Nijmegen, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Med Ctr, Nijmegen, Netherlands.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] Hoffmann La Roche Ag, Basel, Switzerland.
   [Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res Light & Image AIBI, Coimbra, Portugal.
   [Silva, Rufino] Coimbra Hosp & Univ Ctr, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Creuzot-Garcher, Catherine] Univ Hosp Dijon, Dept Ophthalmol, Eye & Nutr Res Grp, INRAe, Dijon, France.
   [Ueffing, Marius] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Klaver, Caroline C. W.] Univ Basel, Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   Radboud University Nijmegen; University of Cologne; Roche Holding;
   University of Munster; Universidade de Coimbra; Universidade de Coimbra;
   Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de
   Coimbra; CHU Dijon Bourgogne; INRAE; Institut Agro; AgroSup Dijon;
   Universite de Bourgogne; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Basel
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481
FU Netherlands Organization of Scientific Research (Nederlandse organisatie
   voor wetenschappelijk onderzoek [NWO]) Investments [175.010.2005.011,
   911-03-012]; Genetic Laboratory of the Department of Internal Medicine,
   ErasmusMedical Center; Research Institute for Diseases in the Elderly
   [014-93-015]; Netherlands Genomics Initiative/Netherlands Organisation
   for Scientific Research 810)
FX The generation and management of GWAS genotype data for the Rotterdam
   Study (I, II, and III) was executed by the Human Genotyping Facility of
   the Genetic Laboratory of the Department of Internal Medicine, Erasmus
   Medical Center, Rotterdam, TheNetherlands. The GWAS datasets are
   supported by the Netherlands Organization of Scientific Research
   (Nederlandse organisatie voor wetenschappelijk onderzoek [NWO])
   Investments (nos.: 175.010.2005.011 and 911-03-012); the Genetic
   Laboratory of the Department of Internal Medicine, ErasmusMedical
   Center; the Research Institute forDiseases in the Elderly (grant no.:
   014-93-015 [RIDE2]); and theNetherlands Genomics Initiative/Netherlands
   Organisation for Scientific Research 810).
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Janssen F, 2021, ELIFE, V10, DOI 10.7554/eLife.66590
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Khanani AM, 2021, AM J OPHTHALMOL, V232, P49, DOI 10.1016/j.ajo.2021.06.017
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Kortvely E, 2016, ADV EXP MED BIOL, V854, P23, DOI 10.1007/978-3-319-17121-0_4
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   May A, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108605
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617
   Mutlu U, 2018, JAMA NEUROL, V75, P1256, DOI 10.1001/jamaneurol.2018.1563
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017228
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.32
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zouache MA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90883-3
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 50
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2022
VL 129
IS 7
BP 752
EP 764
DI 10.1016/j.ophtha.2022.02.026
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3I5IT
UT WOS:000832751000009
PM 35240203
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Seshasai, S
   Liao, J
   Toh, QC
   Cheng, CY
   Cheung, GCM
   Sethi, S
   Wong, TY
   Sabanayagam, C
AF Seshasai, Sudarshan
   Liao, Jiemin
   Toh, Qi Chun
   Cheng, Ching-Yu
   Cheung, Gemmy Chui Ming
   Sethi, Sunil
   Wong, Tien Yin
   Sabanayagam, Charumathi
TI Serum Leptin and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE leptin; AMD; population
ID SINGAPORE MALAY EYE; ALZHEIMERS A-BETA; PLASMA LEPTIN; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; GENDER-DIFFERENCES; OXIDATIVE STRESS; DRUSEN
   DEPOSITS; WEIGHT-LOSS; PREVALENCE
AB PURPOSE. Leptin, a 167-amino acid protein secreted by adipocytes, has been shown to reduce beta-amyloid deposition and intracellular lipid concentration in animal models, two key pathogenic mechanisms underlying aging. We examined the association between serum leptin levels and AMD.
   METHODS. We conducted a population-based case-control study including Chinese and Indian adults aged 40 to 80 years who participated in the Singapore Epidemiology of Eye Diseases Study (2007-2011). Age-related macular degeneration was assessed from retinal photographs graded using a modified Wisconsin Age-Related Maculopathy Grading System (n = 426; early = 389, late = 37). Controls (n = 927) without AMD were frequency matched for age, sex, and ethnicity. Serum leptin levels were measured using direct sandwich ELISA.
   RESULTS. Participants with AMD had lower levels of leptin compared with those without (mean [SD] = 10.0 [11.5] ng/mL versus 12.9 [16.4] ng/mL; P = 0.001). Mean levels of leptin among those with late, early, and without AMD were 8.8, 10.1, and 12.9 ng/mL (P trend = 0.005). In multivariable models adjusting for potential confounders, including smoking, body mass index, blood pressure, and high-density lipoprotein cholesterol, increasing quartiles of leptin were associated with lower odds of AMD, odds ratio (95% confidence interval) of AMD was 0.56 (0.34-0.92) comparing highest to lowest quartile of serum leptin. In subgroup analyses, the inverse association between leptin and AMD was significant in women, Indian ethnicity, and ex-smokers.
   CONCLUSIONS. Higher serum leptin levels were inversely associated with AMD. These findings, if confirmed in prospective studies, may provide insights into new pathogenic pathways and possibly therapeutic targets in AMD.
C1 [Seshasai, Sudarshan; Cheung, Gemmy Chui Ming; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Liao, Jiemin; Cheng, Ching-Yu; Wong, Tien Yin; Sabanayagam, Charumathi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Toh, Qi Chun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin; Sabanayagam, Charumathi] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin; Sabanayagam, Charumathi] Natl Univ Singapore, Duke NUS Grad Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore 117548, Singapore.
   [Sethi, Sunil] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Sabanayagam, C (通讯作者)，The Acad, Singapore Eye Res Inst, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
EM charumathi.sabanayagam@seri.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019; Sabanayagam,
   Charumathi/C-1294-2011
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Sabanayagam, Charumathi/0000-0002-4042-4719; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Singapore Ministry of Health's National Medical Research Council (NMRC)
   under Talent Development Scheme [NMRC/TA/0008/2012,
   NMRC/STaR/0003/2008]; Biomedical Research Council (BMRC), Singapore
   [08/1/35/19/550]
FX Supported by the Singapore Ministry of Health's National Medical
   Research Council (NMRC) under its Talent Development Scheme
   NMRC/TA/0008/2012 (CS), NMRC/STaR/0003/2008, and Biomedical Research
   Council (BMRC), Singapore 08/1/35/19/550.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Baumgartner RN, 1999, METABOLISM, V48, P378, DOI 10.1016/S0026-0495(99)90089-6
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen MD, 1999, CHINESE MED J-PEKING, V112, P801
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527
   Cojocaru Manole, 2013, Maedica (Bucur), V8, P68
   Coppari R, 2012, NAT REV DRUG DISCOV, V11, P692, DOI 10.1038/nrd3757
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dentchev T, 2003, MOL VIS, V9, P184
   Diano S, 2008, J CLIN INVEST, V118, P26, DOI 10.1172/JCI34511
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   Fernandez-Riejos P, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/568343
   Fewlass DC, 2004, FASEB J, V18, P1870, DOI 10.1096/fj.04-2572com
   Folch J, 2012, J MOL ENDOCRINOL, V49, pR149, DOI 10.1530/JME-12-0151
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Greco SJ, 2009, BIOCHEM BIOPH RES CO, V380, P98, DOI 10.1016/j.bbrc.2009.01.041
   Gupta A, 2013, MED HYPOTHESES, V81, P797, DOI 10.1016/j.mehy.2013.08.023
   Hellstrom L, 2000, J INTERN MED, V247, P457, DOI 10.1046/j.1365-2796.2000.00678.x
   Holden KF, 2009, NEUROBIOL AGING, V30, P1483, DOI 10.1016/j.neurobiolaging.2007.11.024
   Irving AJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0155
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Koh KK, 2008, CIRCULATION, V117, P3238, DOI 10.1161/CIRCULATIONAHA.107.741645
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee EB, 2011, ANN NY ACAD SCI, V1243, P15, DOI 10.1111/j.1749-6632.2011.06274.x
   Lieb W, 2009, JAMA-J AM MED ASSOC, V302, P2565, DOI 10.1001/jama.2009.1836
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Marwarha G, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-41
   Matarese G, 2005, P NATL ACAD SCI USA, V102, P5150, DOI 10.1073/pnas.0408995102
   Meister B, 2000, Vitam Horm, V59, P265, DOI 10.1016/S0083-6729(00)59010-4
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morton GJ, 2007, J PHYSIOL-LONDON, V583, P437, DOI 10.1113/jphysiol.2007.135590
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olstad R, 2011, OPEN BEHAV SCI J, V5, P8
   Paz G, 2010, INT J CLIN PRACT, V64, P1808, DOI 10.1111/j.1742-1241.2010.02536.x
   Power DA, 2001, DEMENT GERIATR COGN, V12, P167, DOI 10.1159/000051252
   Rajagopalan P, 2013, NEUROREPORT, V24, P58, DOI 10.1097/WNR.0b013e32835c5254
   Roemmich JN, 1998, AM J PHYSIOL-ENDOC M, V275, pE543, DOI 10.1152/ajpendo.1998.275.3.E543
   Sainz N, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/784343
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sweeney G, 2010, NAT REV CARDIOL, V7, P22, DOI 10.1038/nrcardio.2009.224
   Swierczynski J, 2006, J PHYSIOL PHARMACOL, V57, P85
   Tome MA, 1997, EUR J ENDOCRINOL, V137, P655, DOI 10.1530/eje.0.1370655
   Wallace AM, 2001, CIRCULATION, V104, P3052, DOI 10.1161/hc5001.101061
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarkesh-Esfahani SH, 2011, J IMMUNOL, V186
   Zhang F, 2008, J NEUROCHEM, V107, P578, DOI 10.1111/j.1471-4159.2008.05645.x
   Zhang JY, 2012, J TRAUMA ACUTE CARE, V72, P982, DOI 10.1097/TA.0b013e3182405459
NR 65
TC 11
Z9 11
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1880
EP 1886
DI 10.1167/iovs.14-15933
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600060
PM 25711634
DA 2022-11-30
ER

PT J
AU Bergeron-Sawitzke, J
   Gold, B
   Olsh, A
   Schlotterbeck, S
   Lemon, K
   Visvanathan, K
   Allikmets, R
   Dean, M
AF Bergeron-Sawitzke, Julie
   Gold, Bert
   Olsh, Adam
   Schlotterbeck, Sarah
   Lemon, Kendal
   Visvanathan, Kala
   Allikmets, Rando
   Dean, Michael
TI Multilocus analysis of age-related macular degeneration
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE age-related macular degeneration; complement; ARMS2; HTRA1
ID COMPLEMENT FACTOR-H; EYE DISEASE; RISK; SMOKING; GENES; CFH;
   POLYMORPHISMS; METAANALYSIS; ASSOCIATION; MACULOPATHY
AB Age-related macular degeneration (AMD) is a late onset vision disorder. Recent studies demonstrate that alterations in complement cascade genes are associated with AMD. Of the three identified complement loci, variants in complement factor H (CFH) have the highest impact as does an independent locus at 10q26. Our matched case-control study using the Age-Related Eye Disease Study (AREDS) cohort confirms and extends the associations in these loci. Subjects were genotyped for single nucleotide polymorphisms (SNPs) from CFH, complement component 2 (C2), complement component 3 (C3), complement factor B (CFB), age-related maculopathy susceptibility (ARMS2), HtrA serine peptidase 1 (HTRA1), and apolipoprotein E (APOE). Individual SNPs, and haplotypes showed risk trends consistent with those seen in other population studies for CFH, C3, C2, and CFB. SNP rs10490924 on chromosome 10 in exon 1 of the ARMS2 gene showed a highly significant association with an odds ratio (OR) of 3.2 (95% CI 2.4-4.2) for the risk allele and rs11200638 located in the proximal promoter region of HTRA1 showed a higher significant association with an OR of 3.4 (95% CI 2.5-4.6) with our AMD cases. We found that APOE haplotypes were not significantly associated with disease status. Adjustments for other risk factors did not significantly alter the observed associations. This study validates the complement pathway's involvement in AMD and suggests that allelic variants in complement genes have a direct role in disease. These results also support previous findings that variants in the region of 10q26 exert an independent risk for AMD. European Journal of Human Genetics (2009) 17, 1190-1199; doi:10.1038/ejhg.2009.23; published online 4 March 2009
C1 [Gold, Bert; Olsh, Adam; Schlotterbeck, Sarah; Lemon, Kendal; Dean, Michael] NCI, Expt Immunol Lab, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.
   [Bergeron-Sawitzke, Julie] SAIC Frederick, Basic Sci Program, Human Genet Sect, Frederick, MD USA.
   [Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10027 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Science Applications International Corporation (SAIC);
   SAIC-Frederick; Johns Hopkins University; Johns Hopkins Bloomberg School
   of Public Health; Columbia University; Columbia University
RP Dean, M (通讯作者)，NCI, Expt Immunol Lab, Canc & Inflammat Program, Ctr Canc Res, Bldg 560,Room 21-18, Frederick, MD 21702 USA.
EM dean@ncifcrf.gov
RI Allikmets, Rando/ABD-4533-2021; Dean, Michael C/G-8172-2012;
   Visvanathan, Kumar/AAC-4349-2020; Dean, Michael/R-7501-2019
OI Dean, Michael C/0000-0003-2234-0631; Visvanathan,
   Kumar/0000-0002-1176-5442; Sawitzke, Julie/0000-0002-1715-4626
FU Intramural Research Program of the National Institutes of Health;
   National Cancer Institute; Center for Cancer Research; SAIC-Frederick
   [NO1-CO-12400]; National Eye Institute [EY13435, EY017404]; Macula
   Vision Research Foundation; Wallach Foundation; Elyachar Foundation;
   Kaplen Foundation; Wigdeon Point Charitable Foundation; Research to
   Prevent Blindness; NATIONAL CANCER INSTITUTE [ZIABC005652, ZIABC005725,
   ZIABC011301] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY013435, R24EY017404] Funding Source: NIH RePORTER
FX This study was supported in part by the Intramural Research Program of
   the National Institutes of Health, National Cancer Institute, Center for
   Cancer Research, and SAIC-Frederick under contract no. NO1-CO-12400 and
   with grants from the National Eye Institute EY13435 and EY017404 (RA);
   the Macula Vision Research Foundation; Wallach Foundation (RA); Elyachar
   Foundation (RA); Kaplen Foundation (RA); Wigdeon Point Charitable
   Foundation (RA); and an unrestricted grant to the Department of
   Ophthalmology, Columbia University, from Research to Prevent Blindness.
   The costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be marked as an
   advertisement in accordance with 18 USC Section 1734 solely to indicate
   this fact.
CR ALLIKMETS A, 2009, NEJM IN PRESS
   Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jacques PF, 1999, INT J VITAM NUTR RES, V69, P198, DOI 10.1024/0300-9831.69.3.198
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
NR 30
TC 74
Z9 74
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP
PY 2009
VL 17
IS 9
BP 1190
EP 1199
DI 10.1038/ejhg.2009.23
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 489VA
UT WOS:000269449900015
PM 19259132
OA Green Accepted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Lee, TG
   Lew, YJ
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Lee, Tae Gon
   Lew, Young Ju
TI Imaging Suprachoroidal Layer in Exudative Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; choroidal thickness; enhanced-depth
   imaging; optical coherence tomography; suprachoroidal layer;
   suprachoroidal space
ID OPTICAL COHERENCE TOMOGRAPHY; SWEPT-SOURCE OCT; CHOROIDAL THICKNESS;
   ELASTIC PROPERTIES; SPECTRAL-DOMAIN; SURGERY; SCLERA; EYES
AB Purpose: To evaluate the prevalence of a visible suprachoroidal layer (SCL) on optical coherence tomography (OCT) in exudative age-related macular degeneration (AMD).
   Materials and methods: This retrospective study included 252 eyes of 252 patients with treatment-naive typical exudative AMD (n = 80), polypoidal choroidal vasculopathy (PCV) (n = 138) and retinal angiomatous proliferation (RAP) (n = 34). The presence of SCL was identified based on enhanced-depth imaging OCT images, and the prevalence was compared among the three disease groups. In addition, subfoveal choroidal thickness was compared between patients with and without SCL.
   Results: The SCL was noted in 56 eyes (22.2%). The prevalence was 22.5% in typical exudative AMD (18 of 80 eyes), 18.8% in PCV (26 of 138 eyes) and 35.3% in RAP (12 of 34 eyes) (p = 0.118). Patients with SCL showed significantly thinner choroid (207.5 +/- 83.9 mu m versus 279.7 +/- 116.5 mu m, p < 0.001) and were relatively older (72.1 +/- 8.1 versus 70.1 +/- 8.7 years, p = 0.124) than those without SCL.
   Conclusion: The prevalence of visible SCL was 22.2% in patients with exudative AMD. Age-related changes, including choroidal thinning, may contribute to the development of a visible SCL.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Lew, Young Ju] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX The authors report no conflicts of interest. This study is supported by
   Kim's Eye Hospital Research Center.
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Anderson OA, 2008, INVEST OPHTH VIS SCI, V49, P4041, DOI 10.1167/iovs.07-1660
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Ehlers JP, 2014, BRIT J OPHTHALMOL, V98, P1329, DOI 10.1136/bjophthalmol-2014-305294
   Ehlers JP, 2014, CURR OPIN OPHTHALMOL, V25, P221, DOI 10.1097/ICU.0000000000000044
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Jackson TL, 2006, INVEST OPHTH VIS SCI, V47, P4942, DOI 10.1167/iovs.06-0362
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Michalewska Z, 2013, M AM SOC RET SPEC
   Michalewska Z, 2015, GRAEF ARCH CLIN EXP, V253, P2087, DOI 10.1007/s00417-015-2937-y
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P487, DOI 10.1097/IAE.0000000000000350
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P244, DOI 10.1097/IAE.0000000000000281
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Schaal KB, 2014, OPHTHALMOLOGY, V121, P1020, DOI 10.1016/j.ophtha.2013.11.030
   Spaide RF, 2014, AM J OPHTHALMOL, V158, P1267, DOI 10.1016/j.ajo.2014.08.035
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Tyagi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048188
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Uyama M, 2000, OPHTHALMOLOGY, V107, P441, DOI 10.1016/S0161-6420(99)00141-4
   Watson PG, 2004, EXP EYE RES, V78, P609, DOI 10.1016/S0014-4835(03)00212-4
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
NR 27
TC 2
Z9 2
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2016
VL 41
IS 5
BP 715
EP 720
DI 10.3109/02713683.2015.1056374
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO6ZK
UT WOS:000377931800018
PM 26269259
DA 2022-11-30
ER

PT J
AU Ma, L
   Brelen, ME
   Tsujikawa, M
   Chen, H
   Chu, WK
   Lai, TYY
   Ng, DSC
   Sayanagi, K
   Hara, C
   Hashida, N
   Chan, VCK
   Tam, POS
   Young, AL
   Chen, W
   Nishida, K
   Pang, CP
   Chen, LJ
AF Ma, Li
   Brelen, Marten E.
   Tsujikawa, Motokazu
   Chen, Haoyu
   Chu, Wai Kit
   Lai, Timothy Y. Y.
   Ng, Danny S. C.
   Sayanagi, Kaori
   Hara, Chicako
   Hashida, Noriyasu
   Chan, Vesta C. K.
   Tam, Pancy O. S.
   Young, Alvin L.
   Chen, Weiqi
   Nishida, Kohji
   Pang, Chi Pui
   Chen, Li Jia
TI Identification of ANGPT2 as a New Gene for Neovascular Age-Related
   Macular Degeneration and Polypoidal Choroidal Vasculopathy in the
   Chinese and Japanese Populations
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE ANGPT2; gene association; age-related macular degeneration; polypoidal
   choroidal vasculopathy; gene-gene interaction
ID ANGIOPOIETIN-2; ASSOCIATION; RISK; POLYMORPHISMS; ANGIOGENESIS;
   ACTIVATION; EXPRESSION; VARIANTS; ANTIBODY; TARGET
AB PURPOSE. We determine the angiopoietin 2 (ANGPT2) gene as a new susceptibility gene for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
   METHODS. A total of 34 haplotype-tagging single-nucleotide polymorphisms (SNPs) were first genotyped in an exploratory Hong Kong Chinese cohort. Suggestive SNPs were replicated in a Shantou Chinese cohort and an Osaka Japanese cohort, with a total of 2343 subjects. The SNP rs800292 in the complement factor H (CFH) gene was genotyped in all the subjects. Genetic association and gene-gene interaction were analyzed.
   RESULTS. In the Hong Kong cohort, four SNPs in ANGPT2 (rs13255574, rs4455855, rs13269021, and rs11775442) were nominally associated with nAMD and PCV. The four ANGPT2 SNPs showed the same trends of association in the Shantou and Osaka cohorts. Combining the data from the 3 study cohorts revealed that SNPs rs4455855 and rs13269021 achieved study-wise significance (P < 0.0016), conferring an approximately 1.3-fold of increased risk for nAMD and PCV. Interaction analysis revealed the CFH SNP rs800292 has a highly significant interaction with the ANGPT2 SNP rs13269021 in nAMD and PCV in the combined analysis. Subsequent stratification analysis confirmed the interaction.
   CONCLUSIONS. This study reveals ANGPT2 as a new susceptibility gene for nAMD and PCV, and it may affect disease susceptibility in association with CFH. Thus, this report provides new insights into the genetic architecture of nAMD and PCV.
C1 [Ma, Li; Brelen, Marten E.; Chu, Wai Kit; Lai, Timothy Y. Y.; Ng, Danny S. C.; Tam, Pancy O. S.; Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Tsujikawa, Motokazu; Sayanagi, Kaori; Hara, Chicako; Hashida, Noriyasu; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka, Japan.
   [Chen, Haoyu; Chen, Weiqi; Pang, Chi Pui; Chen, Li Jia] Shantou Univ Chinese Univ Hong Kong Joint Shantou, Shantou, Peoples R China.
   [Chan, Vesta C. K.; Young, Alvin L.; Chen, Li Jia] Prince Wales Hosp, Ctr Eye, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Osaka University; Chinese University of
   Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Brelen, Marten E./D-1133-2016; Chu, Wai
   Kit/F-9405-2016; Ng, Danny Siu Chun/AAG-3081-2020; Lai, Timothy Y
   Y/AAC-2120-2020; Hashida, Noriyasu/AAF-1187-2020; Chen,
   Haoyu/A-7432-2013
OI Chen, Li Jia/0000-0003-3500-5840; Chu, Wai Kit/0000-0003-2903-3247; Ng,
   Danny Siu Chun/0000-0001-6566-1019; Lai, Timothy Y
   Y/0000-0002-7832-6428; Hashida, Noriyasu/0000-0002-8241-5378; Chen,
   Haoyu/0000-0003-0676-4610; Nishida, Kohji/0000-0001-9069-3610
FU National Natural Science Foundation of China [81500764]; General
   Research Fund, Hong Kong [14120516]; Direct Grants of the Chinese
   University of Hong Kong, Hong Kong [4054281, 4054119]
FX Supported in part by the National Natural Science Foundation of China
   (81500764 [LJC]), a research grant from the General Research Fund, Hong
   Kong (14120516 [LJC]), and the Direct Grants of the Chinese University
   of Hong Kong, Hong Kong (4054281 [LJC] and 4054119 [CPP]).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058156
   Chen JZ, 2010, BIOCHEM BIOPH RES CO, V398, P212, DOI 10.1016/j.bbrc.2010.06.062
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Conroy AL, 2013, CELL HOST MICROBE, V13, P215, DOI 10.1016/j.chom.2013.01.010
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hu JH, 2014, SCIENCE, V343, P416, DOI 10.1126/science.1244880
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Kanakaraj P, 2012, MABS-AUSTIN, V4, P600, DOI 10.4161/mabs.21227
   Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199
   Koenig P, 2015, J BIOL CHEM, V290, P21773, DOI 10.1074/jbc.M115.662783
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer NJ, 2011, AM J RESP CRIT CARE, V183, P1344, DOI 10.1164/rccm.201005-0701OC
   Moss A, 2013, CYTOKINE GROWTH F R, V24, P579, DOI 10.1016/j.cytogfr.2013.05.009
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Oliner JD, 2012, INVEST OPHTH VIS SCI, V53, P2170, DOI 10.1167/iovs.11-7381
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Scholz A, 2011, BLOOD, V118, P5050, DOI 10.1182/blood-2011-03-343293
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 43
TC 19
Z9 22
U1 1
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20575
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8LC
UT WOS:000396939600045
PM 28192798
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU May, A
   Su, F
   Dinh, B
   Ehlen, R
   Tran, C
   Adivikolanu, H
   Shaw, PX
AF May, Adam
   Su, Fei
   Dinh, Brian
   Ehlen, Rachael
   Tran, Christina
   Adivikolanu, Harini
   Shaw, Peter X.
TI Ongoing controversies and recent insights of the ARMS2-HTRA1 locus in
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; ARMS2-HTRA1 gene locus; Extracellular
   matrix; TGF-Beta signaling; Complement system; Linkage disequilibrium
ID SERINE-PROTEASE HTRA1; COMPLEMENT FACTOR-H; HIGH-TEMPERATURE
   REQUIREMENT; GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS;
   EXTRACELLULAR-MATRIX; CHROMOSOME 10Q26; RISK-FACTORS; SUSCEPTIBILITY
   GENES; RHESUS-MONKEYS
AB Age-related macular degeneration (AMD) is the most common cause of central vision loss among elderly populations in industrialized countries. Genome-wide association studies have consistently associated two genomic loci with progression to late-stage AMD: the complement factor H (CFH) locus on chromosome 1q31 and the age related maculopathy susceptibility 2-HtrA serine peptidase 1 (ARMS2-HTRA1) locus on chromosome 10q26. While the CFH risk variant has been shown to alter complement activity, the ARMS2-HTRA1 risk haplotype remains enigmatic due to high linkage disequilibrium and inconsistent functional findings spanning two genes that are plausibly causative for AMD risk. In this review, we detail the genetic and functional evidence used to support either ARMS2 or HTRA1 as the causal gene for AMD risk, emphasizing both the historical development and the current understanding of the ARMS2-HTRA1 locus in AMD pathogenesis. We conclude by summarizing the evidence in favor of HTRA1 and present our hypothesis whereby HTRA1-derived ECM fragments mediate AMD pathogenesis.
C1 [May, Adam; Su, Fei; Dinh, Brian; Ehlen, Rachael; Tran, Christina; Adivikolanu, Harini; Shaw, Peter X.] Univ Calif San Diego, Viterbi Family Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
   [May, Adam; Su, Fei; Dinh, Brian; Ehlen, Rachael; Tran, Christina; Adivikolanu, Harini; Shaw, Peter X.] Univ Calif San Diego, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
   [May, Adam; Su, Fei; Dinh, Brian; Ehlen, Rachael; Tran, Christina; Adivikolanu, Harini; Shaw, Peter X.] Univ Calif San Diego, Altman Clin & Translat Res Inst, 9452 Med Ctr Dr, La Jolla, CA 92093 USA.
   [Su, Fei; Dinh, Brian] Univ Calif San Diego, Div Cardiovasc Med, Dept Med, 9452 Med Ctr Dr, La Jolla, CA 92093 USA.
   [Ehlen, Rachael] BlueNalu Inc, 6197 Cornerstone Court East, San Diego, CA 92121 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Shaw, PX (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Dept Ophthalmol, 9415 Campus Point Dr, San Diego, CA 92093 USA.
EM a5may@ucsd.edu; sophiasucn@gmail.com; btdinh@ucsd.edu;
   rachael.ehlen@gmail.com; cdtran@ucsd.edu; hadiviko@ucsd.edu;
   pshaw@ucsd.edu
OI May, Adam/0000-0003-0713-8371; Su, Fei/0000-0002-2891-0925; Ehlen,
   Rachael/0000-0002-4222-6193; Tran, Christina/0000-0002-3226-7522
FU National Eye Institute at the National Institutes of Health [R01
   EY023693, P30 EY022589]
FX This work was supported by the National Eye Institute at the National
   Institutes of Health [Grant N.: R01 EY023693, P30 EY022589].
CR Adair-Kirk TL, 2008, INT J BIOCHEM CELL B, V40, P1101, DOI 10.1016/j.biocel.2007.12.005
   Ajayi F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.046
   Akhtar-Schaefer I., 2019, SIGNALING MICROGLIA, P3
   Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Altobelli E, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4041-2
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Campioni M, 2010, MOL CANCER RES, V8, P1248, DOI 10.1158/1541-7786.MCR-09-0473
   Cannarrozzi G, 2010, CELL, V141, P355, DOI 10.1016/j.cell.2010.02.036
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chamberland A, 2009, J BIOL CHEM, V284, P27352, DOI 10.1074/jbc.M109.037051
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chang CB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021923
   Chekuri A, 2019, AGING CELL, V18, DOI 10.1111/acel.13011
   Chen CY, 2018, MATRIX BIOL, V70, P84, DOI 10.1016/j.matbio.2018.03.013
   Chen JC, 2020, NICOTINE TOB RES, V22, P900, DOI 10.1093/ntr/ntz099
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chu Q, 2016, J AM CHEM SOC, V138, P9473, DOI 10.1021/jacs.6b03463
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dentchev T., 2003, DRUSEN NORMAL RETINA
   Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerhardt MJ, 2017, J MOL CELL BIOL, V9, P516, DOI 10.1093/jmcb/mjx024
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hou J, 2005, J CELL BIOCHEM, V94, P470, DOI 10.1002/jcb.20328
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jin Y., 2014, VEGF NOTCH TGFSS BMP
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kim GY, 2012, MOL CELL BIOL, V32, P4482, DOI 10.1128/MCB.00872-12
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klose R, 2018, ONCOGENE, V37, P4260, DOI 10.1038/s41388-018-0258-4
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Liao SM, 2017, MOL VIS, V23, P318
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   MacFarlane EG, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022269
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nie GY, 2005, DEV DYNAM, V233, P1102, DOI 10.1002/dvdy.20399
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Pahl L, 2013, EXP EYE RES, V116, P234, DOI 10.1016/j.exer.2013.09.012
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]
   Ricard-Blum S, 2019, MATRIX BIOL, V75-76, P170, DOI 10.1016/j.matbio.2017.11.005
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Svenningsen AF, 2017, CELL MOL LIFE SCI, V74, P4561, DOI 10.1007/s00018-017-2592-z
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tennstaedt A, 2012, J BIOL CHEM, V287, P20931, DOI 10.1074/jbc.M111.316232
   Tiaden AN, 2012, STEM CELLS, V30, P2271, DOI 10.1002/stem.1190
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Ye L, 2016, CANCER LETT, V380, P586, DOI 10.1016/j.canlet.2015.10.036
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 127
TC 4
Z9 4
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2021
VL 210
AR 108605
DI 10.1016/j.exer.2021.108605
EA SEP 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO5AU
UT WOS:000694707700006
PM 33930395
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
TI BACILLARY LAYER DETACHMENT IN A KOREAN COHORT WITH NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bacillary layer detachment; choroidal
   neovascularization; polypoidal choroidal vasculopathy; subretinal
   hemorrhage
ID PREVALENCE; THERAPY; DISEASE
AB Purpose: To evaluate the incidence and characteristics of bacillary layer detachment (BALAD) in neovascular age-related macular degeneration. Methods: This retrospective study was performed at Kim's Eye Hospital in South Korea. Patients who were diagnosed with neovascular age-related macular degeneration between January 2017 and December 2017 were included. The incidence of BALAD was compared among different types of macular neovascularization (MNV). The best-corrected visual acuity and central retinal thickness at diagnosis were compared between patients showing BALAD at diagnosis and those who did not. Results: Among the 442 patients included, BALAD was observed in 20 patients (4.5%). There was a significant difference in the incidence of BALAD between Type 1 MNV (2.7%), Type 2 MNV (12.5%), and Type 3 MNV (0%) (P < 0.001). The best-corrected visual acuity was significantly worse (mean 1.26 +/- 0.79 vs. 0.62 +/- 0.50, P = 0.001), and the central retinal thickness was significantly greater (mean 648.2 +/- 211.1 mu m vs. 464.0 +/- 175.5 mu m, P < 0.001) in patients with BALAD than in those without it. After antivascular endothelial growth factor therapy, all BALADs resolved. Conclusion: This study first reported the incidence of the BALAD in neovascular age-related macular degeneration in a Korean population. The incidence of BALAD was the highest in Type 2 MNVs. Bacillary layer detachment generally develops in eyes with great macular thickness and poor visual acuity.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
CR Agarwal A, 2021, RETINA-J RET VIT DIS, V41, P774, DOI 10.1097/IAE.0000000000002914
   Atas Ferdane, 2021, Rom J Ophthalmol, V65, P183, DOI 10.22336/rjo.2021.36
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Jung JJ, 2021, RETINA-J RET VIT DIS, V41, P2106, DOI 10.1097/IAE.0000000000003153
   Kim JH, 2016, JPN J OPHTHALMOL, V60, P466, DOI 10.1007/s10384-016-0466-9
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Kohli GM, 2022, OCUL IMMUNOL INFLAMM, V30, P703, DOI 10.1080/09273948.2020.1823423
   Liakopoulos S, 2013, OSLI RETINA, V44, pS11, DOI 10.3928/23258160-20131101-03
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Ramtohul P, 2022, OPHTHALMOL RETINA, V6, P185, DOI 10.1016/j.oret.2021.09.010
   Ramtohul P, 2021, RETINA-J RET VIT DIS, V41, pE42, DOI 10.1097/IAE.0000000000003155
   Ramtohul P, 2021, RETINA-J RET VIT DIS, V41, pE12, DOI 10.1097/IAE.0000000000003014
   Ramtohul P, 2020, OPHTHALMOL RETINA, V4, P587, DOI 10.1016/j.oret.2020.01.017
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Sharma A, 2022, RETINA-J RET VIT DIS, V42, P107, DOI 10.1097/IAE.0000000000003261
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Venkatesh R, 2021, EUR J OPHTHALMOL, DOI 10.1177/11206721211064017
   Venkatesh R, 2022, CAN J OPHTHALMOL, V57, P328, DOI 10.1016/j.jcjo.2021.05.017
   Venkatesh R, 2021, OCUL IMMUNOL INFLAMM, DOI 10.1080/09273948.2021.1903934
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zatreanu Luca, 2021, Retin Cases Brief Rep, DOI 10.1097/ICB.0000000000001141
NR 25
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2022
VL 42
IS 6
BP 1028
EP 1037
DI 10.1097/IAE.0000000000003437
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1K9HA
UT WOS:000798904200007
PM 35152248
DA 2022-11-30
ER

PT J
AU Augood, CA
   Vingerling, JR
   de Jong, PTVM
   Chakravarthy, U
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Bentham, G
   Rahu, M
   Vioque, J
   Young, IS
   Fletcher, AE
AF Augood, CA
   Vingerling, JR
   de Jong, PTVM
   Chakravarthy, U
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Bentham, G
   Rahu, M
   Vioque, J
   Young, IS
   Fletcher, AE
TI Prevalence of age-related maculopathy in older Europeans - The European
   Eye Study (EUREYE)
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULAR DEGENERATION; VISUAL IMPAIRMENT; RISK-FACTORS;
   UNITED-KINGDOM; POPULATION; MORTALITY; ROTTERDAM; DISEASE; PEOPLE
AB Objective: To estimate the prevalence of age-related maculopathy in an older population from 7 European countries.
   Methods: Randomly sampled people 65 years and older were invited to an eye examination in centers across 7 European countries (Norway, Estonia, United Kingdom, France, Italy, Greece, and Spain). Fundus images of each eye were graded at a single reading center. Prevalence rates were calculated for stage of age-related maculopathy with 95% confidence intervals (CIs) estimated for clustered data.
   Results: Of 5040 participants (45% response rate), 4753 (2128 men and 2625 women) had gradable fundus images. The prevalences were grade 0, 47.59% (95% CI, 43.53%-51.65%); grade 1,36.48%( 95% CI, 32.66%-40.30%); grade 2,10.14% (95% CI, 8.92% to 11.37%); grade 3,2.46% (95% CI, 1.79%-3.13%); and grade 4 (age-related macular degeneration [AMD]), 3.32% (95% CI, 2.52%-4.13%) and large drusen only (>= 125 mu m), 15.41% (95% CI, 13.61%-17.21%). The prevalence of geographic atrophic AMD was 1.2% (95% CI, 0.8%-1.7%) and of neovascular AMD, 2.3% (95% CI, 1.7%-2.9%). The prevalence of bilateral AMD was 1.4% (95% CI, 1.0%-1.8%).
   Conclusion: Age-specific prevalences of age-related maculopathy in the European Eye Study (EUREYE) are similar to other population-based studies in Western populations.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Netherlands Ophthalm Res Inst,KNAW, NL-1105 AZ Amsterdam, Netherlands.
   Queens Univ Belfast, Dept Ophthalmol, Belfast BT7 1NN, Antrim, North Ireland.
   Queens Univ Belfast, Ctr Clin & Populat Sci, Belfast BT7 1NN, Antrim, North Ireland.
   Univ Bergen, Haukeland Sykehus, Oyeavdelingen, N-5020 Bergen, Norway.
   Univ De Creteil, Clin Ophtalmol, Paris, France.
   Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol B, GR-54006 Thessaloniki, Greece.
   Univ E Anglia, Ctr Environm Risk, Norwich NR4 7TJ, Norfolk, England.
   Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Queens University Belfast; Queens University
   Belfast; University of Bergen; Haukeland University Hospital; University
   of Verona; Aristotle University of Thessaloniki; University of East
   Anglia; National Institute for Health Development - Estonia; Universidad
   Miguel Hernandez de Elche
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Rahu, Mati/A-9981-2008; Vioque, Jesus/A-1066-2008
OI Vioque, Jesus/0000-0002-2284-148X; Topouzis, Fotis/0000-0002-8966-537X;
   Young, Ian/0000-0003-3890-3152; Chakravarthy, Usha/0000-0002-2606-3734
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   *STAT, 2003, STAT STAT SOFTW REL
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 31
TC 308
Z9 315
U1 0
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2006
VL 124
IS 4
BP 529
EP 535
DI 10.1001/archopht.124.4.529
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 031CB
UT WOS:000236680600011
PM 16606879
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Gotoh, N
   Yamashiro, K
   Nakanishi, H
   Saito, M
   Iida, T
   Yoshimura, N
AF Gotoh, Norimoto
   Yamashiro, Kenji
   Nakanishi, Hideo
   Saito, Masaaki
   Iida, Tomohiro
   Yoshimura, Nagahisa
TI Haplotype Analysis of the ARMS2/HTRA1 Region in Japanese Patients with
   Typical Neovascular Age-Related Macular Degeneration or Polypoidal
   Choroidal Vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; ARMS2; association study; HTRA1;
   polypoidal choroidal vasculopathy
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; GENETIC
   SUSCEPTIBILITY; ASSOCIATION; VARIANT; LOC387715; RISK; CFH; DISEASE;
   INCREASES
AB Purpose: To compare the genomic contribution of the ARMS2/HTRA1 region of chromosome 10q26 to typical neovascular age-related macular degeneration (nAMD) (also known as typical exudative AMD) and to polypoidal choroidal vasculopathy (PCV).
   Methods: DNA samples were prepared from 84 patients with typical nAMD, 181 patients with PCV, and 276 control participants. All of the 18 haplotype-tagging single-nucleotide polymorphisms (SNPs) derived from the HapMap data and the potential functional variant, rs11200638, which extended the ARMS2/HTRA1 region by 85.2 kb, were genotyped. Associations were tested using single-SNP and haplotype analyses.
   Results: Statistically significant associations were found for six of the 19 SNPs with both typical nAMD and PCV (P < 1 x 10(-3)), peaking at a segment containing three of the SNPs: rs3793917, rs10490924, and rs11200638 (P < 10(-7)). Six common haplotypes were inferred from the nine SNPs spanning 33 kb, which included the six SNPs associated with both phenotypes. Among the six common haplotypes, one showed a positive association with typical nAMD, and two, including the one mentioned above, were associated with PCV. In addition, they corresponded to the risk alleles rs10490924 and rs11200638.
   Conclusions: The association pattern and haplotype estimation in the ARMS2/HTRA1 region of Japanese patients with PCV were very similar to those of Japanese patients with typical nAMD. The polymorphisms responsible for nAMD and PCV may be located in this region or in the strong linkage disequilibrium of rs10490924 and rs11200638. Jpn J Ophthalmol 2010;54:609-614 (C) Japanese Ophthalmological Society 2010
C1 [Gotoh, Norimoto; Yamashiro, Kenji; Nakanishi, Hideo; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
C3 Kyoto University; Fukushima Medical University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Yamashiro, Kenji/0000-0001-9354-8558
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan National Society for The Prevention of Blindness
FX This study was supported in part by the Ministry of Education, Culture,
   Sports, Science and Technology of Japan and by the Japan National
   Society for The Prevention of Blindness.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2008, AM J OPHTHALMOL, V145, P582, DOI 10.1016/j.ajo.2007.10.023
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kamatani N, 2004, AM J HUM GENET, V75, P190, DOI 10.1086/422853
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Machida S, 2010, CLIN OPHTHALMOL, V4, P793
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Ozaki M, 2008, INVEST OPHTH VIS SCI, V49, P3976, DOI 10.1167/iovs.08-1805
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1982, MAC SOC M 5 FEBR MIA
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
NR 39
TC 18
Z9 21
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2010
VL 54
IS 6
BP 609
EP 614
DI 10.1007/s10384-010-0865-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709VK
UT WOS:000286469300014
PM 21191724
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Moshfeghi, AA
   Puliafito, CA
AF Rosenfeld, PJ
   Moshfeghi, AA
   Puliafito, CA
TI Optical coherence tomography findings after an intravitreal injection of
   bevacizumab (Avastin (R)) for neovascular age-related macular
   degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PHARMACOKINETICS; ANTIBODY; SAFETY; FAB
AB To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.
C1 Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MICHELS S, 2004, RETIN PHYS, V1, P16
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
NR 10
TC 719
Z9 775
U1 0
U2 20
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2005
VL 36
IS 4
BP 331
EP 335
DI 10.3928/1542-8877-20050701-14
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 968DA
UT WOS:000232140900012
PM 16156152
DA 2022-11-30
ER

PT J
AU Buentello-Volante, B
   Rodriguez-Ruiz, G
   Miranda-Duarte, A
   Pompa-Mera, EN
   Graue-Wiechers, F
   Bekker-Mendez, C
   Ayala-Ramirez, R
   Quezada, C
   Rodriguez-Loaiza, JL
   Zenteno, JC
AF Buentello-Volante, Beatriz
   Rodriguez-Ruiz, Gabriela
   Miranda-Duarte, Antonio
   Pompa-Mera, Ericka N.
   Graue-Wiechers, Federico
   Bekker-Mendez, Carolina
   Ayala-Ramirez, Raul
   Quezada, Carlos
   Rodriguez-Loaiza, Jose L.
   Zenteno, Juan C.
TI Susceptibility to advanced age-related macular degeneration and alleles
   of complement factor H, complement factor B, complement component 2,
   complement component 3, and age-related maculopathy susceptibility 2
   genes in a Mexican population
SO MOLECULAR VISION
LA English
DT Article
ID RISK-FACTORS; R102G POLYMORPHISM; EYE DISEASE; PREVALENCE; CFH; VARIANT;
   INDIVIDUALS; MUTATIONS; INCREASES; HAPLOTYPE
AB Purpose: To investigate the association of age-related macular degeneration (AMD)-high risk alleles of the complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), complement component 3 (C3), and age-related maculopathy susceptibility 2 (ARMS2) genes in a Mexican population for the first time.
   Methods: Genotyping was performed for the Y402H variant of CFH, for the L9H, R32Q, and K565E variants of CFB, the E318D variant of C2, the A69S variant of ARMS2, and the R102G variant of C3 in 159 Mexican mestizo patients at advanced stages of AMD, i.e., CARMS (Clinical Age-Related Maculopathy Staging System) grade 4 or 5. The frequency of these variants was also investigated in a group of 152 control subjects without AMD. Genomic DNA was extracted from blood leukocytes, and genotyping was performed using PCR followed by direct sequencing. Allele-specific restriction enzyme digestion was used to detect the R102G polymorphism in C3.
   Results: There were significant differences in the allelic distribution between the two groups for CFH Y402H (p=1x10(-5)), ARMS A69S (p=4x10(-7)), and CFB R32Q (p=0.01). The odds ratios (95% confidence interval) obtained for the risk alleles of these three variants were 3.8 (2.4-5.9), 3.04 (2.2-4.3), and 2.5 (1.1-5.7), respectively. Haplotype analysis including the two most significantly associated alleles (CFH Y402H and ARMS A69S) indicated that the C-T combination conferred an odds ratio (95% confidence interval) of 6.9 (3.2-14.8). The exposed attributable risk for this particular haplotype was 85.5%.
   Conclusions: This is the first case-control investigation of AMD-high risk alleles in a Latino population. Our results support that CFH, ARMS2, and CFB AMD-risk alleles are consistently associated with the disease, even in ethnic groups with a complex admixture of ancestral populations such as Mexican mestizos.
C1 [Buentello-Volante, Beatriz; Rodriguez-Ruiz, Gabriela; Zenteno, Juan C.] Inst Ophthalmol Conde de Valenciana Mexico City, Dept Genet, Mexico City, DF, Mexico.
   [Buentello-Volante, Beatriz; Rodriguez-Ruiz, Gabriela; Zenteno, Juan C.] Inst Ophthalmol Conde de Valenciana Mexico City, Res Unit, Mexico City, DF, Mexico.
   [Miranda-Duarte, Antonio] Natl Rehabil Inst, Dept Genet, Mexico City, DF, Mexico.
   [Pompa-Mera, Ericka N.; Bekker-Mendez, Carolina] Hosp Infectol, Ctr Med Nacl La Raza, IMSS, Unidad Invest Med Inmunol & Infectol, Mexico City, DF, Mexico.
   [Graue-Wiechers, Federico; Ayala-Ramirez, Raul; Quezada, Carlos; Rodriguez-Loaiza, Jose L.] Inst Ophthalmol Conde de Valenciana Mexico City, Retina Dept, Mexico City, DF, Mexico.
   [Zenteno, Juan C.] Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City 04510, DF, Mexico.
C3 Instituto Mexicano del Seguro Social; Universidad Nacional Autonoma de
   Mexico
RP Zenteno, JC (通讯作者)，Inst Ophthalmol Conde de Valenciana Chimalpopoca, Dept Genet, 14 Col Obrera, Mexico City 06800, DF, Mexico.
EM jczenteno@institutodeoftalmologia.org
RI Volante, Beatriz Buentello/AAF-3142-2019
OI Volante, Beatriz Buentello/0000-0003-4529-990X; Quezada Ruiz,
   Carlos/0000-0002-9909-6553; Miranda-Duarte, Antonio/0000-0001-6530-4636;
   Bekker Mendez, Vilma Carolina/0000-0002-6161-1425
FU CONACYT [71,110]
FX This work was supported by CONACYT grant 71,110.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   BIRD AC, 1995, INT ARM EPIDEMIOLOGI, V5, P367
   Burchard EG, 2005, AM J PUBLIC HEALTH, V95, P2161, DOI 10.2105/AJPH.2005.068668
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorodezky C, 2001, HUM IMMUNOL, V62, P979, DOI 10.1016/S0198-8859(01)00296-8
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2010, MOL VIS, V16, P1324
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 43
TC 18
Z9 18
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 11
PY 2012
VL 18
IS 262-63
BP 2518
EP 2525
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 022JB
UT WOS:000309953200002
PM 23112567
DA 2022-11-30
ER

PT J
AU Carpentier, S
   Knaus, M
   Suh, MY
AF Carpentier, Shannon
   Knaus, Maria
   Suh, Miyoung
TI Associations between Lutein, Zeaxanthin, and Age-Related Macular
   Degeneration: An Overview
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE lutein; zeaxanthin; carotenoids; age-related macular degeneration; eye
   health; elderly
ID PIGMENT OPTICAL-DENSITY; MODIFIABLE RISK-FACTORS; CIGARETTE-SMOKING;
   BETA-CAROTENE; NUTRITIONAL MANIPULATION; SERUM CONCENTRATIONS;
   SPATIAL-DISTRIBUTION; LIPID-PEROXIDATION; PRIMATE RETINAS;
   ADIPOSE-TISSUE
AB Age-related macular degeneration, the leading cause of blindness in the elderly, is a degenerative condition of the macula characterized by death or dysfunction of the photoreceptors. With the aging population growing, the incidence of age-related macular degeneration is expected to increase. This raises concern about the future of visual dysfunction related falls and the resulting injuries in the elderly population. Lutein and zeaxanthin are macular pigments that may play a role in reducing the development and progression of age-related macular degeneration. Evidence is accumulating on the consumption of lutein and zeaxanthin (in whole food or supplemental form), the resulting concentrations in the serum, and tissue distribution throughout the body, particularly in the retina. Lutein and zeaxanthin intake increases serum concentrations which in turn increases macular pigment density. Existing literature focuses on factors affecting macular pigment density, functions of lutein and zeaxanthin as blue-light filters and antioxidants, and risk factors associated with age-related macular degeneration. Few studies have focused on the impact of dietary lutein and zeaxanthin on retinal function and the potential to preserve vision and prevent further degeneration. This presents an opportunity for further research to determine an effective dose that delays the progression of age-related macular degeneration.
C1 [Carpentier, Shannon; Knaus, Maria; Suh, Miyoung] Univ Manitoba, Dept Human Nutr Sci, Winnipeg, MB R3T 2N2, Canada.
   [Knaus, Maria] Misericordia Hlth Ctr, Winnipeg, MB R3C 1A2, Canada.
C3 University of Manitoba
RP Suh, MY (通讯作者)，Univ Manitoba, Dept Human Nutr Sci, H514 Duff Roblin Bldg, Winnipeg, MB R3T 2N2, Canada.
EM suh@ms.umanitoba.ca
OI Suh, Miyoung/0000-0002-8263-4626
CR Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   ANDERSON SM, 1973, PHOTOCHEM PHOTOBIOL, V18, P403, DOI 10.1111/j.1751-1097.1973.tb06440.x
   [Anonymous], 2005, Altern Med Rev, V10, P128
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Cardinault N, 2003, EXP GERONTOL, V38, P573, DOI 10.1016/S0531-5565(03)00039-1
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Chang Y, 2002, MED PHYS, V29, P2621, DOI 10.1118/1.1515761
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Coyne T, 2005, AM J CLIN NUTR, V82, P685, DOI 10.1093/ajcn/82.3.685
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Dagnelie G, 2000, Optometry, V71, P147
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dietrich M, 2003, AM J CLIN NUTR, V77, P160, DOI 10.1093/ajcn/77.1.160
   Facchini FS, 2000, AM J CLIN NUTR, V72, P776
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1986, ADV FREE RADICAL BIO, V2, P1, DOI 10.1016/S8755-9668(86)80024-2
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Harper AlfredE., 1999, MODERN NUTR HLTH DIS, P3
   Hasler CM, 2002, J NUTR, V132, P3772, DOI 10.1093/jn/132.12.3772
   HYMAN L, 1992, EPIDEMIOLOGY AMD AGE, P1
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Connell E, 2006, ANN ACAD MED SINGAP, V35, P821
   OLSON JA, 1984, J NATL CANCER I, V73, P1439
   Paolisso G, 1996, DIABETOLOGIA, V39, P357, DOI 10.1007/BF00418354
   Polidori MC, 2003, BRIT J NUTR, V90, P147, DOI 10.1079/BJN2003890
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STAHL W, 1993, ANN NY ACAD SCI, V691, P10, DOI 10.1111/j.1749-6632.1993.tb26153.x
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Trevisan M, 2001, AM J EPIDEMIOL, V154, P348, DOI 10.1093/aje/154.4.348
   van den Berg H, 1998, INT J VITAM NUTR RES, V68, P360
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416
   WIEGAND RD, 1986, INVEST OPHTH VIS SCI, V27, P727
   Wingerath T, 1998, ARCH BIOCHEM BIOPHYS, V355, P271, DOI 10.1006/abbi.1998.0734
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zhang SM, 1997, AM J CLIN NUTR, V66, P626, DOI 10.1093/ajcn/66.3.626
NR 115
TC 117
Z9 131
U1 8
U2 64
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2009
VL 49
IS 4
BP 313
EP 326
AR PII 908799934
DI 10.1080/10408390802066979
PG 14
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 410IB
UT WOS:000263569600002
PM 19234943
DA 2022-11-30
ER

PT J
AU Hsu, J
   Maguire, MG
   Fine, SL
AF Hsu, J
   Maguire, MG
   Fine, SL
TI Laser prophylaxis for age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; choroidal neovascularization; drusen; laser
   photocoagulation; macular degeneration
ID PIGMENT EPITHELIAL-CELLS; CHOROIDAL NEOVASCULARIZATION; GRID
   PHOTOCOAGULATION; DRUSEN REDUCTION; 5-YEAR INCIDENCE; BRUCHS MEMBRANE;
   FOLLOW-UP; MACULOPATHY; RISK; ABNORMALITIES
AB Background: Age-related macular degeneration (AMD) is the most common cause of severe and irreversible vision loss among people 50 years of age or older in many Western countries. Most of the available treatments for AMD are intended for the late stage, specifically for choroidal neovascularization (CNV). Effective preventive treatments could have an even greater impact on the vision of the millions of people at risk for vision loss from AMD. Drusen are typically the earliest lesions seen in patients with AMD and precede the development of CNV. In 1973, Gass noted the disappearance of drusen in eyes that received laser photocoagulation, which led to the hypothesis that laser-induced drusen reduction could alter the natural course of AMD.
   Methods: We reviewed relevant articles found through a search of MEDLINE through February 2005 by means of the following key words, alone or in combination: drusen, laser, photocoagulation, age-related macular degeneration, macula and choroidal neovascularization.
   Results: Reports ranging from individual cases and case series to randomized controlled pilot studies have described various laser treatment protocols and their effects on eyes with high-risk drusen but no neovascular changes. These reports provide evidence that laser photocoagulation can induce drusen reduction. Although some investigators have reported a corresponding improvement in visual function, others have found no change or even worsening. The results in several of the larger randomized controlled studies suggest that CNV may occur at an increased rate in laser-treated eyes with high-risk drusen in patients who have neovascular AMD in the other eye. The long-term effects of laser treatment in patients with high-risk drusen in both eyes and no neovascular changes have yet to be determined.
   Interpretation: The outcome of clinical trials such as the Prophylactic Treatment of Age-Related Macular Degeneration and the Complications of Age-Related Macular Degeneration Prevention Trial will help to determine the role of laser prophylaxis in patients with AMD.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Fine, SL (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM stuart.fine@uphs.upenn.edu
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1998, Ophthalmology, V105, P11
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FIGUEROA MS, 1997, RETINA, V17, P385
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON C, 1997, INVEST OPHTHALMOL  S, V38, P18
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   FRIBERG TR, 2002, INVEST OPHTHALMOL VI, V43
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GLASER BM, 1985, ARCH OPHTHALMOL-CHIC, V103, P1870
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Ho A. C., 1997, Investigative Ophthalmology and Visual Science, V38, pS17
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hyver SW, 1997, ARCH OPHTHALMOL-CHIC, V115, P554, DOI 10.1001/archopht.1997.01100150556022
   JAVORNIK NB, 1992, INVEST OPHTH VIS SCI, V33, P1230
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   MATSUMOTO M, 1994, INVEST OPHTH VIS SCI, V35, P4245
   *NAT EYE I, 1997, AG REL MAC DEG STAT
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   PATZ A, 1988, T AM OPHTHAL SOC, V86, P276
   PATZ A, 1988, T AM OPHTHAL SOC, V92, P289
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Ruiz-Moreno JM, 2003, RETINA-J RET VIT DIS, V23, P315, DOI 10.1097/00006982-200306000-00005
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SORSBY A, 1966, 114 PUBL HLTH MED SU
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
   YOSHIMURA N, 1995, INVEST OPHTH VIS SCI, V36, P1686
NR 68
TC 8
Z9 14
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 320
EP 331
DI 10.1016/S0008-4182(05)80075-4
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400008
PM 15947802
DA 2022-11-30
ER

PT J
AU Nangia, V
   Jonas, JB
   Kulkarni, M
   Matin, A
AF Nangia, Vinay
   Jonas, Jost B.
   Kulkarni, Maithili
   Matin, Arshia
TI PREVALENCE OF AGE-RELATED MACULAR DEGENERATION IN RURAL CENTRAL INDIA
   The Central India Eye and Medical Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; visual impairment; low vision;
   blindness; refractive error; Central India Eye and Medical Study
ID ELDERLY CHINESE POPULATION; ARAVIND COMPREHENSIVE EYE; BLUE MOUNTAINS
   EYE; VISUAL IMPAIRMENT; ADULT-POPULATION; UNITED-STATES; LOW-VISION;
   SOUTHERN INDIA; BEIJING EYE; MACULOPATHY
AB Purpose: To evaluate the prevalence of age-related macular degeneration (AMD) in the adult population of rural central India.
   Methods: The population-based Central India Eye and Medical Study was conducted in rural central India and included 4,711 subjects (aged >= 30 years). Age-related macular degeneration was defined by the international classification of the Wisconsin age-related maculopathy grading system.
   Results: Fundus photographs were available for 4,542 subjects (96.4%). In subjects aged >= 40, >= 50, and >= 60 years, prevalence of early AMD was 6.1 +/- 0.4% (95% confidence interval [CI]: 5.3-6.9%), 8.2 +/- 0.6% (95% CI: 7.0-9.4%), and 8.3 +/- 0.8% (95% CI: 6.8-9.9%), respectively, and that of late AMD was 0.2 +/- 0.8% (95% CI: 0.1-0.4%), 0.2 +/- 0.1% (95% CI: 0.1-0.4%), and 0.6 +/- 0.2% (95% CI: 0.2-1.0%), respectively. The prevalence of early AMD increased from 1.3 +/- 0.3% per subject in the 30-year-old to 40-year-old group, to 3.6 +/- 0.5% in the 41-year-old to 50-year-old group, to 7.9 +/- 0.9% in the 51-year-old to 60-year-old group, to 10.0 +/- 1.1% in the 61-year-old to 70-year-old group, to 8.3 +/- 0.2% in the 71-year-old to 80-year-old group, and to 8.0 +/- 5.5% in the >= 81-year-old group. Age-related macular degeneration was causative for visual impairment (best-corrected visual acuity in the better eye:,20/60 and >= 20/400) in 3 of 342 subjects (0.9%) and for blindness (visual acuity,20/400) in 0 of 17 subjects.
   Conclusion: After age adjustment, AMD was found less frequently in the adult population of rural central India than in European populations. Accordingly, visual impairment because of AMD was relatively uncommon in rural central India. RETINA 31:1179-1185, 2011
C1 [Jonas, Jost B.] Univ Heidelberg, Dept Ophthalmol, Med Fac Mannheim, D-6800 Mannheim, Germany.
   [Nangia, Vinay; Jonas, Jost B.; Kulkarni, Maithili; Matin, Arshia] Suraj Eye Inst, Nagpur, Maharashtra, India.
C3 Ruprecht Karls University Heidelberg; Suraj Eye Institute
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@umm.de
FU Om Drishti Trust, Nagpur; Heidelberg Engineering Co, Heidelberg,
   Germany; Rotary Sight Saver, the Netherlands; Orbis, India; Carl Zeiss
   Meditec Co, Jena, Germany
FX Supported by an unrestricted grant from the Om Drishti Trust, Nagpur,
   the Heidelberg Engineering Co, Heidelberg, Germany, the Rotary Sight
   Saver, the Netherlands, the Orbis, India, and the Carl Zeiss Meditec Co,
   Jena, Germany.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goold LA, 2010, BRIT J OPHTHALMOL, V94, P150, DOI 10.1136/bjo.2009.163808
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nangia V, 2010, OPHTHALMOLOGY, V117, P1360, DOI 10.1016/j.ophtha.2009.11.040
   Nangia V, 2010, OPHTHALMOLOGY, V117, P705, DOI 10.1016/j.ophtha.2009.09.003
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2006, OPHTHALMOLOGY, V113, pe1
NR 40
TC 18
Z9 19
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2011
VL 31
IS 6
BP 1179
EP 1185
DI 10.1097/IAE.0b013e3181f57ff2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769JT
UT WOS:000291009400024
PM 21293316
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Leiby, BE
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Leiby, Benjamin E.
   Tasman, William S.
TI Preventing depression in age-related macular degeneration
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE SCORE; LATE-LIFE
   DEPRESSION; OLDER-ADULTS; DRUG-THERAPY; DISABILITY; DIAGNOSIS;
   QUESTIONNAIRE; FEASIBILITY; POPULATION
AB Context: Age-related macular degeneration is a prevalent disease of aging that may cause irreversible vision loss, disability, and depression. The latter is rarely recognized or treated in oplithalmologic settings.
   Objective: To deter-mine whether problem-solving treatment can prevent depressive disorders in patients with recent vision loss.
   Design: Randomized, controlled trial.
   Setting: Outpatient ophthalmology offices in Philadelphia, Pennsylvania.
   Patients: Two hundred six patients aged 65 years or older with recent diagnoses of neovascular age-related macular degeneration in one eye and pre-existing age-related macular degeneration in the fellow eye.
   Intervention: Patients were randomly assigned to problem-solving treatment (n = 105) or usual care (n = 10 1). Problem-solving treatment therapists delivered 6 sessions during 8 weeks in subjects' homes.
   Main Outcome Measures: Outcomes were assessed at 2 months for short-term effects and 6 months for maintenance effects. These included DSM-IV-defined diagnoses of depressive disorders, National Eye Institute Vision Function Questionnaire-17 scores, and rates of relinquishing valued activities.
   Results: The 2-month incidence rate of depressive disorders in problem-solving-treated subjects was significantly lower than controls (11.6% vs 23.2%, respectively; odds ratio, 0.39; 95% confidence interval, 0.17-0.92; P=.03). Problem-solving treatment also reduced the odds of relinquishing a valued activity (odds ratio, 0.48; 95% confidence interval, 0.25-0.96; P=.04). This effect mediated the relationship between treatment group and depression. By 6 months, most earlier observed benefits had diminished, though problem-solving treatment subjects were less likely to suffer persistent depression chi(2)(1,3)=846; P=.04).
   Conclusions: Problem-solving treatment prevented depressive disorders and loss of valued activities in patients with age-related macular degeneration as a short-term treatment, but these benefits were not maintained over time. Booster or rescue treatments may be necessary to sustain problem-solving treatment's preventative effect. This study adds important new information to the emerging field of enhanced-care models to prevent or treat depression in older persons.
C1 Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NATIONAL EYE INSTITUTE [U01EY015839] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [T32DK060455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTH [R01MH061331] Funding Source: NIH RePORTER; NEI NIH HHS [U01 EY
   015839, U01 EY015839] Funding Source: Medline; NIDDK NIH HHS [T32
   DK060455] Funding Source: Medline; NIMH NIH HHS [R01 MH061331, R01
   MH61331] Funding Source: Medline
CR Arean PA, 2003, J AM GERIATR SOC, V51, P1808, DOI 10.1046/j.1532-5415.2003.51569.x
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Bruce ML, 2001, AM J GERIAT PSYCHIAT, V9, P102, DOI 10.1176/appi.ajgp.9.2.102
   Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081
   Charney DS, 2003, ARCH GEN PSYCHIAT, V60, P664, DOI 10.1001/archpsyc.60.7.664
   Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569
   CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Cole MG, 2004, INT J GERIATR PSYCH, V19, P1019, DOI 10.1002/gps.1200
   Crystal S, 2003, J AM GERIATR SOC, V51, P1718, DOI 10.1046/j.1532-5415.2003.51555.x
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hegel MT, 2004, FAM MED, V36, P204
   Hegel MT, 2003, PROBLEM SOLVING TREA
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   Institute of Medicine, 1994, RED RISKS MENT DIS
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Norton MC, 2006, AM J GERIAT PSYCHIAT, V14, P237, DOI 10.1097/01.JGP.0000196626.34881.42
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Reynolds CF, 2006, NEW ENGL J MED, V354, P1130, DOI 10.1056/NEJMoa052619
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Smit F, 2006, ARCH GEN PSYCHIAT, V63, P290, DOI 10.1001/archpsyc.63.3.290
   Solberg LI, 2003, AM J MANAG CARE, V9, P131
   Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618
   Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Whyte EM, 2006, INT J GERIATR PSYCH, V21, P746, DOI 10.1002/gps.1555
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
NR 33
TC 116
Z9 117
U1 0
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD AUG
PY 2007
VL 64
IS 8
BP 886
EP 892
DI 10.1001/archpsyc.64.8.886
PG 7
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 197GM
UT WOS:000248542600003
PM 17679633
OA Bronze
DA 2022-11-30
ER

PT J
AU Damico, FM
   Gasparin, F
   Scolari, MR
   Pedral, LS
   Takahashi, BS
AF Damico, Francisco Max
   Gasparin, Fabio
   Scolari, Mariana Ramos
   Pedral, Lycia Sampaio
   Takahashi, Beatriz Sayuri
TI New approaches and potential treatments for dry age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Review
DE Macular degeneration/drug therapy; Retina; Retinal pigment epithelium;
   Inflammation; Complement activation
ID PHOTORECEPTOR DEGENERATION; COMPLEMENT ACTIVATION; RETINAL DEGENERATION;
   GEOGRAPHIC ATROPHY; GLATIRAMER ACETATE; BRUCHS MEMBRANE; DRUSEN;
   PATHOGENESIS; DELIVERY; THERAPY
AB Emerging treatments for dry age-related macular degeneration (AMD) and geographic atrophy focus on two strategies that target components involved in physiopathological pathways: prevention of photoreceptors and retinal pigment epithelium loss (neuro-protection induction, oxidative damage prevention, and visual cycle modification) and suppression of inflammation. Neuroprotective drugs, such as ciliary neurotrophic factor, brimonidine tartrate, tandospirone, and anti-amyloid beta antibodies, aim to prevent apoptosis of retinal cells. Oxidative stress and depletion of essential micronutrients are targeted by the Age-Related Eye Disease Study (AREDS) formulation. Visual cycle modulators reduce the activity of the photoreceptors and retinal accumulation of toxic fluorophores and lipofuscin. Eyes with dry age-related macular degeneration present chronic inflammation and potential treatments include corticosteroid and complement inhibition. We review the current concepts and rationale of dry age-related macular degeneration treatment that will most likely include a combination of drugs targeting different pathways involved in the development and progression of age-related macular degeneration.
C1 [Damico, Francisco Max; Gasparin, Fabio; Scolari, Mariana Ramos; Pedral, Lycia Sampaio; Takahashi, Beatriz Sayuri] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Damico, FM (通讯作者)，Rua Barata Ribeiro 414,Conj 11, BR-01308000 Sao Paulo, Brazil.
EM fmdamico@usp.br
RI Damico, Francisco Max/G-1175-2015
OI Damico, Francisco Max/0000-0002-2594-0336
FU CNPq [150614/2009-8]; FAPESP [2010/08331-8]
FX Francisco Max Damico (CNPq - 150614/2009-8) and Mariana Ramos Scolari
   (FAPESP - 2010/08331-8).
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Burke J, 1996, SURV OPHTHALMOL, V41, pS9, DOI 10.1016/S0039-6257(96)82027-3
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Donello JE, 2001, J PHARMACOL EXP THER, V296, P216
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Glybina IV, 2010, INVEST OPHTH VIS SCI, V51, P4243, DOI 10.1167/iovs.09-4492
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KUBOTA R, 2009, INVEST OPHTHALMOL VI, V50
   Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Mata NL, 2011, INVEST OPHTHALMOL VI, P52
   MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tatton W, 2003, SURV OPHTHALMOL, V48, pS25, DOI 10.1016/S0039-6257(03)00005-5
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vogel R, 2009, INVEST OPHTHALMOL VI, P50
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Woldemussie E, 2007, VISUAL NEUROSCI, V24, P745, DOI 10.1017/S0952523807070605
   Yong VW, 2002, NEUROLOGY, V59, P802, DOI 10.1212/WNL.59.6.802
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 53
TC 36
Z9 53
U1 2
U2 22
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2012
VL 75
IS 1
BP 71
EP 75
DI 10.1590/S0004-27492012000100016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 934LE
UT WOS:000303444800016
PM 22552424
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ng, WY
   Cheung, CMG
   Mathur, R
   Chan, CM
   Yeo, IYS
   Wong, E
   Lee, SY
   Loh, BK
   Wong, D
   Wong, TY
AF Ng, Wei Yan
   Cheung, Chui Ming Gemmy
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian Yew San
   Wong, Edmund
   Lee, Shu Yen
   Loh, Boon Kwang
   Wong, Doric
   Wong, Tien Yin
TI Trends in Age-Related Macular Degeneration Management in Singapore
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   anti-vascular endothelial growth factor; photodynamic therapy; trends
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   RANIBIZUMAB TREATMENT; TREATMENT PATTERNS; CLINICAL-PRACTICE;
   BEVACIZUMAB; SAFETY; SECONDARY; OUTCOMES; HORIZON
AB Purpose. To describe the trends and patterns of anti-vascular endothelial growth factor (anti-VEGF) therapy and photodynamic therapy (PDT) use for age-related macular degeneration (AMD) in the National Eye Centre in Singapore over a 4-year period.
   Methods. Data on the total number of intravitreal anti-VEGF injections and PDT treatment over a 4-year period at the Singapore National Eye Centre were obtained from centralized electronic records. Patients aged 40 years and older treated for AMD were included. Data retrieved included the annual treatment load in terms of number of new patients and total treatment episodes, and treatment burden for patients was studied in terms of number of injections per year and cumulative injection numbers over 3 years. Potential influence on retreatment by choice of drug, use of adjunct PDT, and diagnosis of polypoidal choroidal vasculopathy were further analyzed.
   Results. From 2009 to 2012, a total of 6157 injections were performed on 1380 unique individual patients. The total number of injections performed per calendar year increased from 962 in 2009 to 2278 in 2012. The number of unique incident cases increased from 287 in 2009 to 446 in 2012. The mean number of injections over the first year increased from 2.62 in 2009 to 3.19 in 2012 (p < 0.001). Choice of anti-VEGF therapy did not significantly alter the cumulative injections required. Patients diagnosed as having polypoidal choroidal vasculopathy had similar injection episodes (p = 0.178), whereas choice of anti-VEGF and adjunct PDT had no effect on the overall treatment.
   Conclusions. Anti-VEGF treatment of AMD continues to increase substantially year on year in the past few years, in alignment with experience from other countries. However, the cumulative number of injections per patient remains low, and many patients discontinue treatment within the first year. These data demonstrate that undertreatment remains a significant concern in clinical settings.
C1 [Ng, Wei Yan; Cheung, Chui Ming Gemmy; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian Yew San; Wong, Edmund; Lee, Shu Yen; Loh, Boon Kwang; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Finger RP, 2013, MED J AUSTRALIA, V198, P260, DOI 10.5694/mja12.11295
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Huang OS, 2013, OPHTHAL EPIDEMIOL, V20, P52, DOI 10.3109/09286586.2012.751429
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Teo KYC, 2014, ANN ACAD MED SINGAP, V43, P192
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Waisbourd M, 2011, ISR MED ASSOC J, V13, P141
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
NR 37
TC 11
Z9 12
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 872
EP 877
DI 10.1097/OPX.0000000000000283
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500010
PM 24879088
DA 2022-11-30
ER

PT J
AU Karampelas, M
   Malamos, P
   Petrou, P
   Georgalas, I
   Papaconstantinou, D
   Brouzas, D
AF Karampelas, Michael
   Malamos, Panagiotis
   Petrou, Petros
   Georgalas, Ilias
   Papaconstantinou, Dimitrios
   Brouzas, Dimitrios
TI Retinal Pigment Epithelial Detachment in Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Age-related macular degeneration; Drusenoid; Fibrovascular;
   Haemorrhagic; Pigment epithelial detachment; Serous
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   ANTI-VEGF THERAPY; BRUCHS MEMBRANE; NATURAL-HISTORY; INTRAVITREAL
   BEVACIZUMAB; MORPHOMETRIC-ANALYSIS; PHOTODYNAMIC THERAPY; SEROUS
   DETACHMENTS; VISUAL-ACUITY
AB Retinal pigment epithelial detachment is defined as a separation of the retinal pigment epithelium from the inner collagenous layer of Bruch's membrane. It is a common manifestation in both dry and wet types of age-related macular degeneration. This review aims to provide a comprehensive guide to the pathophysiology, clinical and imaging characteristics, natural course and treatment of the various types of pigment epithelial detachments in order to assist in diagnosis and management of this important feature of age-related macular degeneration.
C1 [Karampelas, Michael] Hippokrateion Hosp, Dept Ophthalmol, Athens, Greece.
   [Malamos, Panagiotis] Imaging Fundus & Macula, Athens, Greece.
   [Petrou, Petros; Georgalas, Ilias; Papaconstantinou, Dimitrios; Brouzas, Dimitrios] Natl & Kapodistrian Univ Athens, Div Ophthalmol 1, Sch Med, G Gennimatas Gen Hosp, Athens, Greece.
C3 Hippokration General Hospital; Athens Medical School; National &
   Kapodistrian University of Athens
RP Karampelas, M (通讯作者)，Hippokrateion Hosp, Dept Ophthalmol, Athens, Greece.
EM mikekarampelas@hotmail.com
OI Karampelas, Michael/0000-0002-1344-241X
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Camacho N, 2015, BRIT J OPHTHALMOL, V99, P1277, DOI 10.1136/bjophthalmol-2014-306226
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Laatikainen L, 1991, Eur J Ophthalmol, V1, P79
   Larsen PP, 2019, RETINA-J RET VIT DIS, V39, P2369, DOI 10.1097/IAE.0000000000002311
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Roth F, 2007, ATLAS FUNDUS AUTOFLU, P165
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Tvenning AO, 2019, CLIN OPHTHALMOL, V13, P233, DOI 10.2147/OPTH.S188315
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Veronese C, 2016, RETINA-J RET VIT DIS, V36, P645, DOI 10.1097/IAE.0000000000000914
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1997, INDOCYANINE GREEN AN
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 85
TC 7
Z9 10
U1 0
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2020
VL 9
IS 4
BP 739
EP 756
DI 10.1007/s40123-020-00291-5
EA AUG 2020
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA9GG
UT WOS:000560657900001
PM 32809132
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gil-Martinez, M
   Santos-Ramos, P
   Fernandez-Rodriguez, M
   Abraldes, MJ
   Rodriguez-Cid, MJ
   Santiago-Varela, M
   Fernandez-Ferreiro, A
   Gomez-Ulla, F
AF Gil-Martinez, Maria
   Santos-Ramos, Paz
   Fernandez-Rodriguez, Maribel
   Abraldes, Maximino J.
   Jose Rodriguez-Cid, Maria
   Santiago-Varela, Maria
   Fernandez-Ferreiro, Anxo
   Gomez-Ulla, Francisco
TI Pharmacological Advances in the Treatment of Age-related Macular
   Degeneration
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Age-related macular degeneration; choroidal neovascularization;
   pharmacology; vascular endothelial growth factor; molecules; treatment
ID VISION-RELATED FUNCTION; RANIBIZUMAB TREATMENT; EYE DISEASE; SEVERITY
   SCALE; CLINICAL-TRIAL; MANAGEMENT; EFFICACY; AFLIBERCEPT; ASSOCIATION;
   OUTCOMES
AB Age-related macular degeneration is an acquired degenerative disease that is responsible for severe loss of vision in elderly people. There are two types: dry age-related macular degeneration and wet age-related macular degeneration. Its treatment has been improved and tries to be tailored in the future. The aim of this review is to summarize the pharmacological advances in the treatment of age-related macular degeneration. Regarding dry AMD, there is no effective treatment to reduce its progression. However, some molecules such as lampalizumab and eculizumab were under investigation, although they have shown low efficacy. Herein, in an attempt to prevent dry AMD progression, the most important studies suggested increasing the antioxidants intake and quitting the smoke habit. On the other hand, wet AMD has more developed treatment. Nowadays, the gold standard treatment is anti-VEGF injections. However, more effective molecules are currently under investigation. There are different molecules under research for dry AMD and wet AMD. This fact could help us treat our patients with more effective and lasting drugs but more clinical trials and safety studies are required in order to achieve an optimal treatment.
C1 [Gil-Martinez, Maria; Santos-Ramos, Paz; Fernandez-Rodriguez, Maribel; Abraldes, Maximino J.; Jose Rodriguez-Cid, Maria; Santiago-Varela, Maria] Hosp Univ Santiago de Compostela, Dept Ophthalmol, Santiago De Compostela, Spain.
   [Gil-Martinez, Maria; Fernandez-Rodriguez, Maribel; Abraldes, Maximino J.; Gomez-Ulla, Francisco] Inst Oftalmol Gomez Ulla, Santiago De Compostela, Spain.
   [Fernandez-Rodriguez, Maribel; Abraldes, Maximino J.; Jose Rodriguez-Cid, Maria; Gomez-Ulla, Francisco] Univ Santiago de Compostela, Dept Surg, Santiago De Compostela, Spain.
   [Fernandez-Ferreiro, Anxo] Univ Hosp Santiago de Compostela SERGAS, Pharm Dept, Santiago De Compostela, Spain.
   [Fernandez-Ferreiro, Anxo] Univ Hosp Santiago de Compostela SERGAS, Pharmacol Grp, Santiago De Compostela, Spain.
   [Fernandez-Ferreiro, Anxo] Hlth Res Intitute IDIS, Santiago De Compostela, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela;
   Universidade de Santiago de Compostela
RP Gomez-Ulla, F (通讯作者)，Inst Oftalmol Gomez Ulla, Santiago De Compostela, Spain.; Gomez-Ulla, F (通讯作者)，Univ Santiago de Compostela, Dept Surg, Santiago De Compostela, Spain.; Fernandez-Ferreiro, A (通讯作者)，Univ Hosp Santiago de Compostela SERGAS, Pharm Dept, Santiago De Compostela, Spain.; Fernandez-Ferreiro, A (通讯作者)，Univ Hosp Santiago de Compostela SERGAS, Pharmacol Grp, Santiago De Compostela, Spain.; Fernandez-Ferreiro, A (通讯作者)，Hlth Res Intitute IDIS, Santiago De Compostela, Spain.
EM anxordes@gmail.com; mez-ulla@institutogomez-ulla.es
RI Santiago-Varela, Maria/AAU-7058-2020
OI Santiago-Varela, Maria/0000-0002-0892-4094
FU Instituto de Salud Carlos III-ISCIII [PI17/00940]; RETICS Oftared
   [RD16/0008/0003]; FEDER; ISCIII (Juan Rodes research grant) [JR18/0014]
FX This work was partially funded and supported by Instituto de Salud
   Carlos III-ISCIII (PI17/00940) and (RETICS Oftared, RD16/0008/0003) and
   co-funded by FEDER. Anxo Fernandez-Ferreiro acknowledges the support of
   ISCIII (Juan Rodes research grant JR18/0014).
CR Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Arias Luis, 2016, Clin Ophthalmol, V10, P861, DOI 10.2147/OPTH.S106092
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Arslan J, 2018, PHARMACOGENOMICS, V19, P435, DOI 10.2217/pgs-2017-0183
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Fernandez-Ferreiro A, 2017, INVEST OPHTH VIS SCI, V58, P2843, DOI 10.1167/iovs.17-21812
   Fernandez-Ferreiro A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20766
   Fernández-Ferreiro Anxo, 2016, Farm Hosp., V40, P1, DOI 10.7399/fh.2016.40.1.10417
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FINE SL, 1980, ARCH OPHTHALMOL-CHIC, V98, P832
   Freiberg FJ, 2019, BRIT J OPHTHALMOL, V103, P469, DOI 10.1136/bjophthalmol-2018-311865
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   GUERRERONARANJO JL, 2013, INVEST OPHTHALMOL VI, V54
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Luaces-Rodriguez A, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020066
   Luttrull JK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202097
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malamos P, 2018, OPHTHALMOLOGICA, V240, P213, DOI 10.1159/000487610
   Mansour AM, 2018, BRIT J OPHTHALMOL, V102, P1387, DOI 10.1136/bjophthalmol-2017-311591
   Maronas O, 2020, CURR MED CHEM, V27, P549, DOI 10.2174/0929867326666190711105325
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKenzie JAG, 2012, AM J PATHOL, V180, P399, DOI 10.1016/j.ajpath.2011.09.035
   Miller N.D.L.J.S, PHARM TREATMENTS AMD
   Mirshahi Ahmad, 2017, Med Hypothesis Discov Innov Ophthalmol, V6, P23
   Najafabadi HS, 2017, ARCH IRAN MED, V20, P525
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Radhika M, 2014, J OPHTHALMIC INFLAMM, V4, DOI 10.1186/s12348-014-0022-z
   Ramulu PY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1335, DOI 10.1001/archophthalmol.2010.224
   Rempel V, 2013, ACS MED CHEM LETT, V4, P41, DOI 10.1021/ml300235q
   Ross AE, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119285
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Ueda-Consolvo T, 2017, JPN J OPHTHALMOL, V61, P347, DOI 10.1007/s10384-017-0515-z
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wong P, 2017, MOL VIS, V23, P718
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zimmermann T, 2018, BRIT J CLIN PHARMACO, V84, P865, DOI 10.1111/bcp.13502
NR 92
TC 14
Z9 14
U1 8
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2020
VL 27
IS 4
BP 583
EP 598
DI 10.2174/0929867326666190726121711
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA KU3AG
UT WOS:000519578800005
PM 31362645
DA 2022-11-30
ER

PT J
AU Rastogi, N
   Smith, RT
AF Rastogi, Neelesh
   Smith, R. Theodore
TI Association of age-related macular degeneration and reticular macular
   disease with cardiovascular disease
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; age-related maculopathy;
   cardiovascular disease; coronary artery disease; reticular macular
   disease; reticular drusen; reticular pseudodrusen; subretinal drusenoid
   deposits
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION;
   APOLIPOPROTEIN-E GENE; CHOROIDAL BLOOD-FLOW; RISK-FACTORS; LARGE DRUSEN;
   PSEUDODRUSEN; PREVALENCE; PATHOGENESIS
AB Age-related macular degeneration is the leading cause of adult blindness in the developed world. Thus, major endeavors to understand the risk factors and pathogenesis of this disease have been undertaken. Reticular macular disease is a proposed subtype of age related macular degeneration correlating histologically with subretinal drusenoid deposits located between the retinal pigment epithelium and the inner segment ellipsoid zone. Reticular lesions are more prevalent in females and in older age groups and are associated with a higher mortality rate. Risk factors for developing age-related macular degeneration include hypertension, smoking, and angina. Several genes related to increased risk for age-related macular degeneration and reticular macular disease are also associated with cardiovascular disease. Better understanding of the clinical and genetic risk factors for age-related macular degeneration and reticular macular disease has led to the hypothesis that these eye diseases are systemic. A systemic origin may help to explain why reticular disease is diagnosed more frequently in females as males suffer cardiovascular mortality at an earlier age, before the age of diagnosis of reticular macular disease and age-related macular degeneration. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Rastogi, Neelesh; Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
C3 New York University
RP Smith, RT (通讯作者)，NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
OI smith, theodore/0000-0002-1693-943X
FU Research to Prevent Blindness; Foundation Fighting Blindness
FX This work was funded by unrestricted funds from Research to Prevent
   Blindness (RTS) and an individual investigator research award from the
   Foundation Fighting Blindness (RTS).
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   BROEKHUYSE RM, 1975, OPHTHALMOLOGICA, V171, P82, DOI 10.1159/000307448
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Ghatrehsamani K, 2009, GENET TEST MOL BIOMA, V13, P809, DOI 10.1089/gtmb.2009.0080
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grallert H, 2012, EUR HEART J, V33, P238, DOI 10.1093/eurheartj/ehr372
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Haab O., 1888, SIEBIENTER PERIODISC, P429
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Huang C, 2013, MOL VIS, V19, P1211
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9
   Leveziel N, 2007, MOL VIS, V13, P2153
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marik PE, 2009, CLIN CARDIOL, V32, P365, DOI 10.1002/clc.20604
   McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Morris DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037878
   Muller H., 1856, ARCH OPHTHALMOL-CHIC, V2, P1
   Nair J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094328
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Petrovic D., 2010, Cardiovascular & Hematological Agents in Medicinal Chemistry, V8, P47
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Polfus LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074642
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Qian Q, 2009, MOL BIOL REP, V36, P1257, DOI 10.1007/s11033-008-9306-4
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saito Y, 1998, RETINA-J RET VIT DIS, V18, P103, DOI 10.1097/00006982-199818020-00002
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sharma Barnali, 2013, J Indian Med Assoc, V111, P388
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Takeuchi F, 2012, PLOS ONE, V7
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zhang HF, 2011, THROMB RES, V127, P400, DOI 10.1016/j.thromres.2010.12.018
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 112
TC 30
Z9 31
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2016
VL 61
IS 4
BP 422
EP 433
DI 10.1016/j.survophthal.2015.10.003
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP4DB
UT WOS:000378444500003
PM 26518628
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Hoshino, J
   Mukai, R
   Nakamura, K
   Kishi, S
   Akiyama, H
AF Matsumoto, Hidetaka
   Hoshino, Junki
   Mukai, Ryo
   Nakamura, Kosuke
   Kishi, Shoji
   Akiyama, Hideo
TI Clinical characteristics and pachychoroid incidence in Japanese patients
   with neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; MACULOPATHY; PREVALENCE
AB The phenotypes of neovascular age-related macular degeneration (nAMD) are recognized as differing between Caucasian and Asian patients. Pachychoroid is thought to be more prevalent in Asians than in Caucasians, and may be involved in the development of nAMD in Asian patients. Therefore, we investigated the clinical characteristics and pachychoroid incidence in Japanese patients with nAMD. We retrospectively analyzed 385 eyes of 370 consecutive Japanese patients with treatment naive nAMD. According to the nAMD nomenclature, type 1 macular neovascularization (MNV) was observed in 132 eyes (34.3%), polypoidal choroidal vasculopathy (PCV) in 137 (35.6%), mixed type 1 and type 2 MNV in 32 (8.3%), type 2 MNV in 43 (11.2%), and type 3 MNV in 41 (10.6%). Pachychoroid was seen in 58.3% of type 1 MNV, 75.2% of PCV, 34.4% of mixed type 1 and type 2 MNV, 14.0% of type 2 MNV, and 0% of type 3 MNV. Compared to nAMD patients without pachychoroid (188 eyes), those who had nAMD with pachychoroid (197 eyes) were significantly younger, had a higher proportion of males, greater central choroidal thickness, and a higher frequency of macular vortex vein anastomoses (all P < 0.001). Furthermore, drusen subtypes differed significantly between the two groups (P < 0.001). These results suggest that most Japanese nAMD patients might have type 1 MNV or PCV. Moreover, in approximately half of patients, nAMD might be associated with pachychoroid, and choroidal congestion may be involved in the development of MNV in these cases.
C1 [Matsumoto, Hidetaka; Hoshino, Junki; Mukai, Ryo; Nakamura, Kosuke; Kishi, Shoji; Akiyama, Hideo] Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hoshino J, 2021, GRAEF ARCH CLIN EXP, V259, P2175, DOI 10.1007/s00417-021-05130-2
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95904-9
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94412-0
   Matsumoto H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75789-w
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sawada T, 2021, GRAEF ARCH CLIN EXP, V259, P1191, DOI 10.1007/s00417-020-05005-y
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P231, DOI 10.1097/IAE.0000000000003057
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi K, 2000, AM J OPHTHALMOL, V129, P191, DOI 10.1016/S0002-9394(99)00425-0
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yanai H., 2015, STATCEL USEFUL ADD I
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 31
TC 0
Z9 0
U1 1
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 16
PY 2022
VL 12
IS 1
AR 4492
DI 10.1038/s41598-022-08666-3
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZU6UH
UT WOS:000769975800017
PM 35296769
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU McGowan, A
   Silvestri, G
   Moore, E
   Silvestri, V
   Patterson, CC
   Maxwell, AP
   McKay, GJ
AF McGowan, Amy
   Silvestri, Giuliana
   Moore, Evelyn
   Silvestri, Vittorio
   Patterson, Christopher C.
   Maxwell, Alexander P.
   McKay, Gareth J.
TI Retinal Vascular Caliber, Iris Color, and Age-Related Macular
   Degeneration in the Irish Nun Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retinal vascular caliber; age-related macular degeneration; iris color
ID DIABETIC-RETINOPATHY; BLOOD-PRESSURE; RISK-FACTORS; MACULOPATHY;
   DISEASE; ATHEROSCLEROSIS; PROGRESSION
AB PURPOSE. To evaluate the relationship between retinal vascular caliber (RVC), iris color, and age-related macular degeneration (AMD) in elderly Irish nuns.
   METHODS. Data from 1233 participants in the cross-sectional observational Irish Nun Eye Study were assessed from digital photographs with a standardized protocol using computer-assisted software. Macular images were graded according to the modified Wisconsin Age-related Maculopathy Grading System. Regression models were used to assess associations, adjusting for age, mean arterial blood pressure, body mass index, refraction, and fellow RVC.
   RESULTS. In total, 1122 (91%) participants had gradable retinal images of sufficient quality for vessel assessment (mean age: 76.3 years [range, 56-100 years]). In an unadjusted analysis, we found some support for a previous finding that individuals with blue iris color had narrower retinal venules compared to those with brown iris color (P < 0.05), but this was no longer significant after adjustment. Age-related macular degeneration status was categorized as no AMD, any AMD, and late AMD only. Individuals with any AMD (early or late AMD) had significantly narrower arterioles and venules compared to those with no AMD in an unadjusted analysis, but this was no longer significant after adjustment. A nonsignificant reduced risk of any AMD or late AMD only was observed in association with brown compared to blue iris color, in both unadjusted and adjusted analyses.
   CONCLUSIONS. Retinal vascular caliber was not significantly associated with iris color or early/late AMD after adjustment for confounders. A lower but nonsignificant AMD risk was observed in those with brown compared to blue iris color.
C1 [McGowan, Amy; Patterson, Christopher C.; Maxwell, Alexander P.; McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Silvestri, Giuliana] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland.
   [Moore, Evelyn; Silvestri, Vittorio] Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP McKay, GJ (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Maxwell, Alexander
   P./0000-0002-6110-7253; Silvestri, Giuliana/0000-0001-5662-5374
FU Medical Research Council United Kingdom [MR/K003364/1]; Diabetes United
   Kingdom [11/0004400]; Northern Ireland Health & Personal Social Services
   Research and Development Office, Belfast, Grant Recognised Research
   Group Project [4.41]; MRC [MR/K003364/1] Funding Source: UKRI; Medical
   Research Council [MR/K003364/1] Funding Source: researchfish; Public
   Health Agency [STL/3714/07] Funding Source: researchfish
FX Supported by the Medical Research Council United Kingdom Grant
   MR/K003364/1; Diabetes United Kingdom Grant 11/0004400; and the Northern
   Ireland Health & Personal Social Services Research and Development
   Office, Belfast, Grant Recognised Research Group Project 4.41. The
   funding organizations had no role in the design or conduct of this
   research.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Cheung CYL, 2014, ALZHEIMERS DEMENT, V10, P135, DOI 10.1016/j.jalz.2013.06.009
   Cheung CYL, 2013, STROKE, V44, P2402, DOI 10.1161/STROKEAHA.113.001738
   Cheung CYL, 2012, HYPERTENSION, V60, P1094, DOI 10.1161/HYPERTENSIONAHA.111.189142
   Cheung N, 2007, INVEST OPHTH VIS SCI, V48, P1018, DOI 10.1167/iovs.06-0978
   Cheung N, 2012, ARCH OPHTHALMOL-CHIC, V130, P783, DOI 10.1001/archophthalmol.2012.727
   Chin YC, OPHTHALMIC EPIDEMIOL
   Ding J, 2012, CLIN EXP OPTOM, V95, P290, DOI 10.1111/j.1444-0938.2012.00725.x
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Li X, 2013, INVEST OPHTH VIS SCI, V54, P3650, DOI 10.1167/iovs.12-11126
   Liew G, 2007, INVEST OPHTH VIS SCI, V48, P52, DOI 10.1167/iovs.06-0672
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Mitchell P, 2007, HYPERTENSION, V49, P1156, DOI 10.1161/HYPERTENSIONAHA.106.085910
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   Rochtchina E, 2008, INVEST OPHTH VIS SCI, V49, P1362, DOI 10.1167/iovs.07-0150
   Saaddine J., 2004, Morbidity and Mortality Weekly Report, V53, P1069
   Sasongko MB, 2012, AM J OPHTHALMOL, V153, P176, DOI 10.1016/j.ajo.2011.06.005
   Sherry LM, 2002, CLIN EXP OPHTHALMOL, V30, P179, DOI 10.1046/j.1442-9071.2002.00520.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Wong TY, 2011, ARCH OPHTHALMOL-CHIC, V129, P95, DOI 10.1001/archophthalmol.2010.347
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yau JWY, 2012, DIABETES RES CLIN PR, V95, P265, DOI 10.1016/j.diabres.2011.10.027
NR 33
TC 8
Z9 9
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 382
EP 387
DI 10.1167/iovs.14-15523
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800041
PM 25525170
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Luo, MY
   Zhao, XY
   Zhao, N
   Yuan, MZ
   Yang, JY
   Dai, RP
   Chen, YX
AF Luo Mingyue
   Zhao Xinyu
   Zhao Nan
   Yuan Mingzhen
   Yang Jingyuan
   Dai Rongping
   Chen Youxin
TI Comparison of choriocapillary flow density between fellow eyes of
   polypoidal choroidal vasculopathy and neovascular age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID CLASSIFICATION; PREVALENCE; RPE
AB Background To compare the choriocapillary flow density (CFD) among the fellow eyes of polypoidal choroidal vasculopathy (PCV), neovascular age-related macular degeneration (nAMD), and healthy controls using spectral-domain optical coherence angiography tomography (SD-OCTA). Methods This is a cross-sectional study that includes the fellow eyes of 38 patients with unilateral PCV, 36 patients with unilateral nAMD, and 36 eyes from 36 healthy volunteers. The PCV group was further classified into polypoidal CNV (P-CNV) and typical PCV (T-PCV) for subgroup analysis. The age, subfoveal choroidal thickness (SFCT), Age-Related Eye Disease Study (AREDS) classification, and fellow eye diagnosis were acquired. All subjects underwent SD-OCTA with a 6.0-mm scan pattern. Circles with radius of 1.00, 1.50, and 3.00 mm were manually selected in the choriocapillaris (CC) slab, and the CFD was calculated as the percentage of the flow area to the whole selected area as CFD-1.00, 1.50, and 3.00, respectively. Univariate and multivariate analysis were performed to study the correlation between the aforementioned factors with CFD. Results The mean CFD-1.00, 1.50, and 3.00 of the nAMD group were 61.51, 63.18, and 66.20, respectively; these were significantly lower than those of the PCV group (65.90, 66.89, and 67.94; P < 0.001, P < 0.001, and P = 0.010; respectively) and control group (66.28, 66.96, and 68.42; P < 0.001, P < 0.001, and P = 0.001, respectively), and no difference was detected between the PCV and control group or between PCV subtypes. The AREDS classification and fellow eye diagnosis were correlated with CFD in univariate analysis; however, only the fellow eye diagnosis showed a significant correlation after multiple linear regression. Conclusions The CFD of nAMD fellow eyes was significantly lower than that of PCV and control eyes, and no difference was detected between PCV and control group, indicating that CC loss plays a different role in the early pathogenesis of nAMD and PCV.
C1 [Luo Mingyue; Zhao Xinyu; Yuan Mingzhen; Yang Jingyuan; Dai Rongping; Chen Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Luo Mingyue; Zhao Xinyu; Yuan Mingzhen; Yang Jingyuan; Dai Rongping; Chen Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
   [Zhao Nan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Cent Labs, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
   Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
RI Zhao, Nan/GQH-3848-2022
OI Zhao, Nan/0000-0001-5358-866X; Luo, Mingyue/0000-0002-8121-7361
FU Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]
FX This work was supported by The Non-profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences (2018PT32029).
CR Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Chen LL, 2018, INT J OPHTHALMOL-CHI, V11, P1588, DOI 10.18240/ijo.2018.10.03
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pettenkofer Moritz, 2019, Ophthalmic Surg Lasers Imaging Retina, V50, P302, DOI 10.3928/23258160-20190503-07
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Wang Q, 2018, GRAEF ARCH CLIN EXP, V256, P1615, DOI 10.1007/s00417-018-4038-1
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yang JY, 2019, GRAEF ARCH CLIN EXP, V257, P1393, DOI 10.1007/s00417-019-04326-x
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 5
Z9 5
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 22
PY 2020
VL 20
IS 1
AR 162
DI 10.1186/s12886-020-01386-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ6NY
UT WOS:000530280900001
PM 32321472
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Keenan, TDL
   Guymer, RH
   Chakravarthy, U
   Schmitz-Valckenberg, S
   Klaver, CC
   Wong, WT
   Chew, EY
AF Fleckenstein, Monika
   Keenan, Tiarnan D. L.
   Guymer, Robyn H.
   Chakravarthy, Usha
   Schmitz-Valckenberg, Steffen
   Klaver, Caroline C.
   Wong, Wai T.
   Chew, Emily Y.
TI Age-related macular degeneration
SO NATURE REVIEWS DISEASE PRIMERS
LA English
DT Article
ID COMPLEMENT FACTOR-H; OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT
   EPITHELIUM; QUALITY-OF-LIFE; GEOGRAPHIC ATROPHY SECONDARY; BRUCHS
   MEMBRANE; GENETIC RISK; MEDITERRANEAN DIET; CHOROIDAL
   NEOVASCULARIZATION; CIGARETTE-SMOKING
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in the industrialized world. AMD is characterized by accumulation of extracellular deposits, namely drusen, along with progressive degeneration of photoreceptors and adjacent tissues. AMD is a multifactorial disease encompassing a complex interplay between ageing, environmental risk factors and genetic susceptibility. Chronic inflammation, lipid deposition, oxidative stress and impaired extracellular matrix maintenance are strongly implicated in AMD pathogenesis. However, the exact interactions of pathophysiological events that culminate in drusen formation and the associated degeneration processes remain to be elucidated. Despite tremendous advances in clinical care and in unravelling pathophysiological mechanisms, the unmet medical need related to AMD remains substantial. Although there have been major breakthroughs in the treatment of exudative AMD, no efficacious treatment is yet available to prevent progressive irreversible photoreceptor degeneration, which leads to central vision loss. Compelling progress in high-resolution retinal imaging has enabled refined phenotyping of AMD in vivo. These insights, in combination with clinicopathological and genetic correlations, have underscored the heterogeneity of AMD. Hence, our current understanding promotes the view that AMD represents a disease spectrum comprising distinct phenotypes with different mechanisms of pathogenesis. Hence, tailoring therapeutics to specific phenotypes and stages may, in the future, be the key to preventing irreversible vision loss.
   Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. This Primer describes the different stages of AMD, its epidemiology, the current understanding of its pathophysiology and diagnostic modalities. Additionally, it outlines existing treatment options and highlights the outstanding issues, suggesting future research avenues.
C1 [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
   [Keenan, Tiarnan D. L.; Chew, Emily Y.] NIH, NEI, Div Epidemiol & Clin Applicat, Bldg 10, Bethesda, MD 20892 USA.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Klaver, Caroline C.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Klaver, Caroline C.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C.] Radboud Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
   [Wong, Wai T.] NIH, NEI, Sect Neuron Glia Interact Retinal Dis, Bldg 10, Bethesda, MD 20892 USA.
C3 Utah System of Higher Education; University of Utah; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI); Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne; Queens University Belfast; University of Bonn; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Radboud University Nijmegen; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI)
RP Fleckenstein, M (通讯作者)，Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.; Chew, EY (通讯作者)，NIH, NEI, Div Epidemiol & Clin Applicat, Bldg 10, Bethesda, MD 20892 USA.
EM monika.fleckenstein@hsc.utah.edu; echew@nei.nih.gov
OI Chew, Emily/0000-0003-0999-9802; Guymer, Robyn/0000-0002-9441-4356;
   Chakravarthy, Usha/0000-0002-2606-3734; Keenan,
   Tiarnan/0000-0002-2253-1772
FU National Institutes of Health Core Grant [EY014800]; Research to Prevent
   Blindness, New York, NY; German Research Foundation (DFG) [FL 658/4-1,
   FL 658/4-2]
FX M.F. and S.S.-V. were in part supported by National Institutes of Health
   Core Grant (EY014800), and an Unrestricted Grant from Research to
   Prevent Blindness, New York, NY, to the Department of Ophthalmology &
   Visual Sciences, University of Utah and the German Research Foundation
   (DFG) grant FL 658/4-1 and FL 658/4-2.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   American Academy of Ophthalmology, 2019, AGE RELATED MACULAR
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arens-Arad T, 2020, CURR BIOL, V30, P176, DOI 10.1016/j.cub.2019.11.028
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Askou AL, 2019, MOL THER-NUCL ACIDS, V16, P38, DOI 10.1016/j.omtn.2019.01.012
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Balyen L, 2019, ASIA-PAC J OPHTHALMO, V8, P264, DOI 10.22608/APO.2018479
   Bartfeld S, 2017, J MOL MED, V95, P729, DOI 10.1007/s00109-017-1531-7
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Borrelli E, 2019, OPHTHALMOL RETINA, V3, P979, DOI 10.1016/j.oret.2019.05.026
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Calvert M, 2018, JAMA-J AM MED ASSOC, V319, P483, DOI 10.1001/jama.2017.21903
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P920, DOI 10.1016/j.oret.2019.06.012
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   den Hollander AI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017202
   Ding K, 2017, MABS-AUSTIN, V9, P269, DOI 10.1080/19420862.2016.1268305
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   ENGEL FL, 1971, VISION RES, V11, P563, DOI 10.1016/0042-6989(71)90077-0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fingler J, 2008, INVEST OPHTH VIS SCI, V49, P5055, DOI 10.1167/iovs.07-1627
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Langhe R, 2020, CURR EYE RES, V45, P349, DOI 10.1080/02713683.2019.1669665
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Mazerik JN, 2018, CELL MED, V10, DOI 10.1177/2155179018773758
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   McGrail Kimberlyn, 2011, Healthc Pap, V11, P8
   McGrail Kimberlyn, 2009, Healthc Pap, V9, P8
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MEGAW ED, 1979, APPL ERGON, V10, P27, DOI 10.1016/0003-6870(79)90006-1
   Meira J, 2020, CLIN OPHTHALMOL, V14, P171, DOI 10.2147/OPTH.S234858
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Muller PL., 2020, OPHTHALMOLOGICA, V244, P42
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   National Institute for Health and Care Excellence, 2018, NICE GUID NG82
   Nattagh Khashayar, 2020, Transl Vis Sci Technol, V9, P6, DOI 10.1167/tvst.9.7.6
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Obana A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66962-2
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Oswald J, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418774433
   Parfitt A, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000276
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Pfau M., 2020, JAMA OPHTHALMOL, V125, P369
   Pfau M, 2019, OPHTHALMOL RETINA, V4, P238
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Ra H., 2018, PLOS ONE, V13
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Rim TH, 2020, OPHTHALMOLOGY, V127, P1371, DOI 10.1016/j.ophtha.2020.04.019
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh Miin, 2020, J Vitreoretin Dis, V4, P377, DOI 10.1177/2474126420916607
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2020, AM J OPHTHALMOL, V216, pA7, DOI 10.1016/j.ajo.2020.05.012
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SanGiovanni JP., 2013, PLOS ONE, V8
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Silverman SM, 2019, J EXP MED, V216, P1925, DOI 10.1084/jem.20190009
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Skevington SM, 2012, HEALTH EXPECT, V15, P49, DOI 10.1111/j.1369-7625.2010.00650.x
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suri R, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105489
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tisdale AK, 2019, JAMA OPHTHALMOL, V137, P543, DOI 10.1001/jamaophthalmol.2019.0292
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   VIRGILI G, 2018, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003303.PUB4
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Winkler TW., 2018, PLOS ONE, V13
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2020, OPHTHALMOLOGICA, V243, P399, DOI 10.1159/000510887
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zhang Q, 2019, INVEST OPHTH VIS SCI, V60, P3468, DOI 10.1167/iovs.19-26690
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 280
TC 101
Z9 102
U1 31
U2 61
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2056-676X
J9 NAT REV DIS PRIMERS
JI Nat. Rev. Dis. Primers
PD MAY 6
PY 2021
VL 7
IS 1
AR 31
DI 10.1038/s41572-021-00265-2
PG 25
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SK8MC
UT WOS:000656470300001
PM 33958600
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Huang, LZ
   Li, MW
   Ma, XY
   Li, YJ
   Zhang, CF
   Sun, YY
   Bai, YJ
   Wang, B
   Yu, WZ
   Zhao, MW
   Khor, CC
   Li, XX
AF Huang, Lvzhen
   Li, Mingwu
   Ma, Xiaoyun
   Li, Yingjie
   Zhang, Chunfang
   Sun, Yaoyao
   Bai, Yujing
   Wang, Bin
   Yu, Wenzhen
   Zhao, Mingwei
   Khor, Chiea Chuen
   Li, Xiaoxin
TI rs4711751 and rs1999930 Are Not Associated with Neovascular Age-Related
   Macular Degeneration or Polypoidal Choroidal Vasculopathy in the Chinese
   Population
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Gene polymorphism; rs1999930; rs4711751
ID VARIANTS; POLYMORPHISMS
AB Purpose: rs1999930 and rs4711751 have recently been identified as novel variants associated with advanced age-related macular degeneration (AMD) in populations of European ancestry. We aimed to investigate whether these two single nucleotide polymorphisms (SNPs) were associated with neovascular AMD (nAMD) or with polypoidal choroidal vasculopathy (PCV), a variant of AMD in Asians, using a Chinese case-control study. Methods: A total of 900 subjects, including 300 controls, 300 cases with nAMD and 300 cases with PCV, were included in the present study. Genomic DNA was extracted from venous blood leukocytes. The allelic variants of rs1999930 and rs4711751 were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The differences in allele distribution between cases and controls were tested by a. 2 test, with additional adjustments for age and gender using logistic regression. The statistical power was also calculated. Values of p < 0.05 were considered statistically significant. Results: No statistically significant association was observed between the two polymorphisms of nAMD or PCV phenotype (p > 0.05 for all comparisons). The difference remained insignificant after correction for age and gender (p > 0.05 for all comparisons). The statistical powers to detect the association between these two SNPs and nAMD or PCV range from 0.05 to 0.36, assuming conventional levels of statistical significance. Conclusions: In the present study, we could not replicate the reported association of these two SNPs and either nAMD or PCV in a Chinese population, suggesting that they are unlikely to be a major AMD and PCV susceptibility gene locus in the Chinese population. Considering the low power value, a large sample size is required to draw more reliable conclusions. (C) 2014 S. Karger AG, Basel
C1 [Huang, Lvzhen; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Huang, Lvzhen; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Union Med Coll, Chinese Acad Med Sci, Canc Inst & Hosp, Key Lab Vis Loss & Restorat,Minist Educ, Beijing 100021, Peoples R China.
   [Huang, Lvzhen; Li, Mingwu; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Union Med Coll, Chinese Acad Med Sci, Canc Inst & Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100021, Peoples R China.
   [Li, Yingjie] Peking Union Med Coll, Chinese Acad Med Sci, Canc Inst & Hosp, Dept Abdominal Surg Oncol, Beijing 100021, Peoples R China.
   [Zhang, Chunfang] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
   [Ma, Xiaoyun] Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai, Peoples R China.
   [Ma, Xiaoyun] Guanghua Integrat Med Hosp, Shanghai, Peoples R China.
   [Khor, Chiea Chuen] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute & Hospital - CAMS; Peking Union
   Medical College; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute & Hospital - CAMS; Peking Union
   Medical College; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute & Hospital - CAMS; Peking Union
   Medical College; Peking University; National University of Singapore;
   Singapore National Eye Center
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM zhaomingwei@medmail.com.cn
OI Khor, Chiea Chuen/0000-0002-1128-4729
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX This study was supported by the National Basic Research Program of China
   (973 Program; 2011CB510200), the National Natural Science Foundation of
   China (grant 81100666) and the Research Fund for Science and Technology
   Program of Beijing (Z121100005312006). The funders had no role in study
   design, data collection and analysis, the decision to publish, or
   preparation of the manuscript.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lutty G, 1999, MOL VIS, V5
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   Yannuzzi LA, 1982, MAC SOC M MIAM FEBR
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 19
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 52
IS 2
BP 102
EP 106
DI 10.1159/000362763
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AP6SC
UT WOS:000342206900008
PM 25228097
DA 2022-11-30
ER

PT J
AU Lantry, LE
AF Lantry, Laura E.
TI Drug evaluation: Ranibizumab, a mAb against VEGF-A for the potential
   treatment of age-related macular degeneration and other ocular
   complications
SO CURRENT OPINION IN MOLECULAR THERAPEUTICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; TECHNOLOGY
   EVALUATION; CRYSTAL-STRUCTURE; ANTIBODY; COMBINATION; FRAGMENT; SAFETY
AB Genentech Inc and Novartis Ophthalmics AG have developed and launched the humanized anti-VEGF antibody fragment ranibizumab, a 48-kDa humanized antibody fragment that inhibits all forms of biologically active VEGF-A, for the treatment of age-related macular degeneration by intravitreal administration. Phase I to III clinical trials to confirm the role of ranibizumab in the treatment of choroidal neovascularization (phase II and III), diabetic macular edema (phase II and III), retinal venous occlusion (phase II and III), telangiectasia (phase I and II), central serous chorioretinopathy (phase I), polypoidal choroidal vasculopathy (phase I/II), conjunctival neoplasms (phase I) and von Hippel-Lindau syndrome (phase I) are ongoing.
C1 Bracco Res USA, Princeton, NJ 08540 USA.
C3 Bracco
RP Lantry, LE (通讯作者)，Bracco Res USA, 305 Coll Rd E Princeton, Princeton, NJ 08540 USA.
EM laura.lantry@bru.bracco.com
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Baca M, 1997, J BIOL CHEM, V272, P10678
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHANG TS, 2006, INVEST OPHTHALMOL VI, V47
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   *CRVO, 2006, LUC CENTR RET VEIN O
   DAMICO GA, 2004, INVEST OPHTHALMOL S2, V45, pU341
   Davis JL, 2004, CURR OPIN MOL THER, V6, P195
   ENDE E, 2007, J MERRILL LYNCH 0111
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GAMER A, 1994, PATHOBIOLOGY OCULAR, P1625
   Gaudreault J, 2004, INVEST OPHTH VIS SCI, V45, pU730
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GAUDREAULT J, 2003, ANN MEET ASS RES VIS, V44
   GAUDREULT J, 2002, ANN MEET ASS RES VIS, V43
   *GEN INC, 2006, CO PUBL GEN INC
   *GEN INC, COMP WORLD WID WEB S
   *GEN INC, 2006, CLIN TRIALS GOV
   *GEN INC, 2007, CO NEWSLETTER
   HAUGHNEY PC, 2005, INVEST OPHTHALMOL  S, V46, pS1383
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HEIER JS, 2005, INVEST OPHTHALMOL  S, V46, pS1393
   Hunt DWC, 2003, IDRUGS, V6, P464
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   KOROTKIN A, 2006, INVEST OPHTHALMOL, V47
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LALWANI G, 2006, ANN MEET ASS RES VIS, pB726
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LOWE J, 2003, ANN MEET ASS RES VIS, V44
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   OPTHALMICS AGN, 2007, MIMS LONDON     0410
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   ROSENFELD PJ, 2006, INVEST OPHTHALMOL VI, V47
   Salgaller ML, 2003, CURR OPIN MOL THER, V5, P657
   SMELSER G, 1965, EYE STRUCTURE, P109
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 63
TC 17
Z9 20
U1 0
U2 4
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1464-8431
EI 2040-3445
J9 CURR OPIN MOL THER
JI Curr. Opin. Mol. Ther.
PD DEC
PY 2007
VL 9
IS 6
BP 592
EP 602
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 235MT
UT WOS:000251239100009
PM 18041670
DA 2022-11-30
ER

PT J
AU Lana, TP
   Costa, SMD
   Ananina, G
   Hirata, FE
   Rim, PHH
   Medina, FM
   de Vasconcellos, JPC
   de Melo, MB
AF Lana, Tamires Prates
   da Silva Costa, Sueli Matilde
   Ananina, Galina
   Hirata, Fabio Endo
   Hyun Rim, Priscila Hae
   Medina, Flavio MacCord
   Cabral de Vasconcellos, Jose Paulo
   de Melo, Monica Barbosa
TI Association of HTRA1 rs11200638 with age-related macular degeneration
   (AMD) in Brazilian patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE 10q26; AMD; complex disease; genetic polymorphism; SNP
ID COMPLEMENT FACTOR-H; PROMOTER POLYMORPHISM; Y402H POLYMORPHISM; GENE
   POLYMORPHISMS; SUSCEPTIBILITY; RISK; LOC387715/ARMS2; MACULOPATHY;
   EXPRESSION; VARIANTS
AB Age-related macular degeneration is a multifactorial disease that can lead to vision impairment in older individuals. Although the etiology of age-related macular degeneration remains unknown, risk factors include age, ethnicity, smoking, hypertension, obesity, and genetic factors. Two main loci have been identified through genome-wide association studies, on chromosomes 1 and 10. Among the variants located at the 10q26 region, rs11200638, located at the HTRA1 gene promoter, has been associated with age-related macular degeneration in several populations and is considered the main polymorphism. We conducted a replication case-control study to analyze the frequency and participation of rs11200638 in the etiology of age-related macular degeneration in a sample of patients and controls from the State of Sao Paulo, Brazil, through polymerase chain reaction and enzymatic digestion. The frequency of the A allele was 57.60% in patients with age-related macular degeneration and 36.45% in controls (p value < 1e-07), representing a 2.369-fold higher risk factor for the disease. Both the AA and AG genotypes were observed more frequently in the age-related macular degeneration group compared to the control group (p = 1.21(e-07) and 0.0357, respectively). No statistically significant results were observed after stratification in dry versus wet types or advanced versus non-advanced forms. To our knowledge, this is the first time the association between rs11200638 and overall age-related macular degeneration has been reported in South America.
C1 [Lana, Tamires Prates; da Silva Costa, Sueli Matilde; Ananina, Galina; de Melo, Monica Barbosa] Univ Estadual Campinas, UNICAMP, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, POB 6010, BR-13083875 Campinas, SP, Brazil.
   [Hirata, Fabio Endo; Hyun Rim, Priscila Hae; Medina, Flavio MacCord; Cabral de Vasconcellos, Jose Paulo] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Ophthalmol, Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas
RP de Melo, MB (通讯作者)，Univ Estadual Campinas, UNICAMP, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, POB 6010, BR-13083875 Campinas, SP, Brazil.
EM melomb@uol.com.br
RI Medina, Flavio/AFM-1303-2022
FU National Council of Technological and Scientific Development (CNPq)
   [472645/2008]; Coordination for the Improvement of Higher Education
   Personnel (CAPES) [33003017065-2014]
FX We thank the National Council of Technological and Scientific
   Development (CNPq; grant 472645/2008), Coordination for the Improvement
   of Higher Education Personnel (CAPES; grant 33003017065-2014) for
   financial support.
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   [Anonymous], 2007, BRAZ 500 AN POV
   Askari M, 2015, REP BIOCHEM MOL BIOL, V4, P43
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Sacconi DPD, 2016, OPHTHALMIC GENET, V37, P459, DOI 10.3109/13816810.2015.1120315
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Hirata FE, 2015, OPHTHALMIC GENET, V36, P224, DOI 10.3109/13816810.2013.867449
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Instituto Brasileiro de geografia e Estatistica (IBGE), 2010, SIN RES CENS 2010
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Salzano FM, 2014, GENET MOL BIOL, V37, P151, DOI 10.1590/S1415-47572014000200003
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Silva AS, 2012, MOL VIS, V18, P2288
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tong Y, 2010, MOL VIS, V16, P1958
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 36
TC 7
Z9 7
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 1
BP 46
EP 50
DI 10.1080/13816810.2017.1354382
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA GA7MM
UT WOS:000428520500009
PM 28846052
DA 2022-11-30
ER

PT J
AU Khurana, RN
   Porco, TC
   Claman, DM
   Boldrey, EE
   Palmer, JD
   Wieland, MR
AF Khurana, Rahul N.
   Porco, Travis C.
   Claman, David M.
   Boldrey, Edwin E.
   Palmer, James D.
   Wieland, Mark R.
TI INCREASING SLEEP DURATION IS ASSOCIATED WITH GEOGRAPHIC ATROPHY AND
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE geographic atrophy; age-related macular degeneration; sleep history;
   sleep patterns; sleep duration; neovascular AMD; early AMD
ID METAANALYSIS; IMPAIRMENT
AB Purpose:Sleeping too much or too little has been associated with adverse health outcomes including total mortality, cardiovascular disease, Type 2 diabetes, and hypertension. This study explored the relationship between sleep patterns and age-related macular degeneration (AMD).Methods:One thousand and three consecutive patients in a retina practice were prospectively surveyed regarding sleep histories. Each patient then had a masked ophthalmic examination and was graded on the modified Wisconsin Age-Related Maculopathy System. The relationship between AMD grade and sleep hours was analyzed in a logistic regression model. Multivariable analysis was performed after adjustment for age, gender, and smoking history.Results:In multivariable analysis, controlling for age, gender, and smoking history, sleep hours are not associated with neovascular AMD (P = 0.97) but are associated with geographic atrophy (P = 0.02). Sleeping >8 hours is associated with geographic atrophy (age-adjusted odds ratio, 7.09; 95% confidence interval, 1.59-31.6) compared with patients without AMD.Conclusion:Longer sleep duration is associated with geographic atrophy secondary to AMD. These altered sleep patterns may be another morbidity of AMD, but further study is necessary.
C1 [Khurana, Rahul N.; Boldrey, Edwin E.; Palmer, James D.; Wieland, Mark R.] Northern Calif Retina Vitreous Associates, 2485 Hosp Dr,Suite 200, Mountain View, CA 94040 USA.
   [Khurana, Rahul N.; Porco, Travis C.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Claman, David M.] Univ Calif San Francisco, Sleep Disorders Ctr, Dept Internal Med, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Khurana, RN (通讯作者)，Northern Calif Retina Vitreous Associates, 2485 Hosp Dr,Suite 200, Mountain View, CA 94040 USA.
EM rnkhurana@gmail.com
OI Khurana, Rahul/0000-0001-5198-1353
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cappuccio FP, 2010, SLEEP, V33, P585, DOI 10.1093/sleep/33.5.585
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   HANSCOM TA, 1980, ANN OPHTHALMOL, V12, P1058
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Knutson KL, 2006, SLEEP, V29, P878, DOI 10.1093/sleep/29.7.878
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 16
TC 12
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 255
EP 258
DI 10.1097/IAE.0000000000000706
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500003
PM 26815930
DA 2022-11-30
ER

PT J
AU Donaldson, MJ
   Pulido, JS
AF Donaldson, Mark J.
   Pulido, Jose S.
TI Treatment of nonexudative (dry) age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anecortave; ciliary neurotrophic
   factor; drusen; geographic atrophy; lutein; macular translocation
   surgery; rheopheresis; zeaxanthin
ID RETINAL-PIGMENT EPITHELIUM; MEMBRANE DIFFERENTIAL FILTRATION;
   CHLAMYDIA-PNEUMONIAE INFECTION; GEOGRAPHIC ATROPHY; LASER TREATMENT;
   CHOROIDAL NEOVASCULARIZATION; RISK-FACTORS; 5-YEAR INCIDENCE; VITAMIN-A;
   MACULOPATHY
AB Purpose of review
   The purpose of this report is to review the recent literature and summarize currently available and potential new treatment options for nonexudative age-related macular degeneration.
   Recent findings
   High-dose vitamin supplementation may have some associated systemic toxicity. It is important to check that the patient is taking beta-carotene and not vitamin A as retinal acetate or palmitate, which have been associated with osteoporosis and hepatotoxicity. High-dose vitamins E and C may be associated with cardiovascular disease. Decreasing inflammation by lowering systemic cardiac C-reactive protein, fibrinogen and cholesterol may be important, especially in light of recent epidemiologic and genetic data. The results of randomized trials of laser treatment for drusen and rheopheresis should be available during 2006. Treatment with these modalities before the results of the trials are evaluated should be avoided.
   Summary
   The holy grail of therapy for age-related macular degeneration is to avoid the development of choroidal neovascularization. High-dose vitamin supplementation should be used only in those in whom it is indicated and inflammatory parameters including highly sensitive C-reactive protein, fibrogen and cholesterol should be stabilized because there are data associating these parameters with age-related macular degeneration and also with cardiovascular disease.
C1 Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Pulido, JS (通讯作者)，Mayo Clin & Mayo Fdn, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM pulido.jose@mayo.edu
RI Donaldson, Mark/B-4504-2011
OI Donaldson, Mark/0000-0002-7269-8028
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bok Dean, 2005, Retina, V25, pS27, DOI 10.1097/00006982-200512001-00010
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cannon CP, 2005, NEW ENGL J MED, V352, P1646, DOI 10.1056/NEJMoa043528
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   FALLON MB, 1990, J GASTROEN HEPATOL, V5, P334, DOI 10.1111/j.1440-1746.1990.tb01635.x
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P662, DOI 10.1001/archopht.122.4.662-b
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kaplan M, 2006, INT J INFECT DIS, V10, P116, DOI 10.1016/j.ijid.2004.10.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaul D, 2001, MOL CELL BIOCHEM, V219, P65, DOI 10.1023/A:1011006707414
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lim L, 2004, CLIN EXP OPHTHALMOL, V32, P341, DOI 10.1111/j.1442-9071.2004.00832.x
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Melhus H, 1998, ANN INTERN MED, V129, P770, DOI 10.7326/0003-4819-129-10-199811150-00003
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Pulido JS, 2004, ARCH OPHTHALMOL-CHIC, V122, P662, DOI 10.1001/archopht.122.4.662-a
   Pulido JS, 2002, T AM OPHTHAL SOC, V100, P106
   REGILLO C, 2004, ANN M AM AC OPHTH S, P10
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Shor A, 1999, JAMA-J AM MED ASSOC, V282, P2071, DOI 10.1001/jama.282.21.2071
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vivekananthan DP, 2004, LANCET, V363, P662
   Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   West Emily S., 2005, International Ophthalmology Clinics, V45, P41
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 74
TC 13
Z9 15
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JUN
PY 2006
VL 17
IS 3
BP 267
EP 274
DI 10.1097/01.icu.0000193101.13551.e5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 055XC
UT WOS:000238483500008
PM 16794439
DA 2022-11-30
ER

PT J
AU Evans, JR
   Henshaw, K
AF Evans, J. R.
   Henshaw, K.
TI Antioxidant vitamin and mineral supplements for preventing age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID BETA-CAROTENE SUPPLEMENTATION; RANDOMIZED CONTROLLED-TRIAL; BASE-LINE
   CHARACTERISTICS; LONG-TERM SUPPLEMENTATION; KILLER-CELL ACTIVITY;
   LOW-DOSE ASPIRIN; ALPHA-TOCOPHEROL; HIGH-RISK; CANCER PREVENTION;
   CLINICAL-TRIAL
AB Background
   Some observational studies have suggested that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
   Objectives
   The aim of this review was to examine the evidence as to whether or not taking vitamin or mineral supplements prevents the development of AMD.
   Search strategy
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) in The Cochrane Library (2007, Issue 3), MEDLINE (1966 to August 2007), SIGLE (1980 to 2005/ 03), EMBASE (1980 to August 2007), National Research Register (2007, Issue 3), AMED (1985 to January 2006) and PubMed (on 24 January 2006 covering last 60 days), reference lists of identified reports and the Science Citation Index. We contacted investigators and experts in the field for details of unpublished studies.
   Selection criteria
   We included all randomised trials comparing an antioxidant vitamin and/or mineral supplement ( alone or in combination) to control. We included only studies where supplementation had been given for at least one year.
   Data collection and analysis
   Both review authors independently extracted data and assessed trial quality. Data were pooled using a fixed-effect model.
   Main results
   Three randomised controlled trials were included in this review ( 23,099 people randomised). These trials investigated alpha-tocopherol and beta-carotene supplements. There was no evidence that antioxidant vitamin supplementation prevented or delayed the onset of AMD. The pooled risk ratio for any age-related maculopathy (ARM) was 1.04 (95% CI 0.92 to 1.18), for AMD (late ARM) was 1.03 (95% CI 0.74 to 1.43). Similar results were seen when the analyses were restricted to beta- carotene and alpha-tocopherol.
   Authors' conclusions
   There is no evidence to date that the general population should take antioxidant vitamin and mineral supplements to prevent or delay the onset of AMD. There are several large ongoing trials. People with AMD should see the related Cochrane review "Antioxidant vitamin and mineral supplements for slowing the progression of age- related macular degeneration" written by the same author.
C1 [Evans, J. R.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WCIE 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Evans, JR (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WCIE 7HT, England.
EM jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Albanes D, 1986, J NUTR GROWTH CANCER, V3, P207
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambler J S, 1995, Ophthalmic Epidemiol, V2, P137, DOI 10.3109/09286589509057095
   ANDREWS J, 1969, BRIT MED J, V2, P416, DOI 10.1136/bmj.2.5654.416
   *ATBC CANC PREV ST, 1994, ANN EPIDEMIOL, V4, P1
   BENNER SE, 1994, SEMIN HEMATOL, V31, P26
   BENTON D, 1995, PSYCHOPHARMACOLOGY, V117, P298, DOI 10.1007/BF02246104
   Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blok WL, 1997, EUR J CLIN INVEST, V27, P1003, DOI 10.1046/j.1365-2362.1997.2240775.x
   BLUMBERG J, 1994, NUTR REV, V52, P242, DOI 10.1111/j.1753-4887.1994.tb01430.x
   BOGDEN JD, 1990, J AM COLL NUTR, V9, P214
   Brewer GJ, 1997, J LAB CLIN MED, V129, P649, DOI 10.1016/S0022-2143(97)90200-6
   Brown BG, 1998, CAN J CARDIOL, V14, p6A
   Buring J E, 1994, Ann Epidemiol, V4, P75
   BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012
   BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109
   Buring Julie E., 1994, Annals of Epidemiology, V4, P111
   BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F
   Cairns J, 1991, Ann Epidemiol, V1, P395
   Caligiuri MP, 1997, PSYCHOPHARMACOLOGY, V132, P61, DOI 10.1007/s002130050320
   Camargo CA, 1997, CIRCULATION, V95, P577, DOI 10.1161/01.CIR.95.3.577
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen W G, 1998, Ophthalmic Epidemiol, V5, P133, DOI 10.1076/opep.5.3.133.8368
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Chylack L T Jr, 1995, Ophthalmic Epidemiol, V2, P59, DOI 10.3109/09286589509057085
   Cianfriglia F, 1994, Minerva Stomatol, V43, P255
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   CLAUSEN J, 1989, BIOL TRACE ELEM RES, V20, P135, DOI 10.1007/BF02919106
   Constans J, 1996, CLIN INFECT DIS, V23, P654, DOI 10.1093/clinids/23.3.654
   COSTANTINO JP, 1988, AM J CLIN NUTR, V48, P1277, DOI 10.1093/ajcn/48.5.1277
   Cucinotta D, 1994, J NEUROL, V241, pS129
   de Klerk NH, 1998, INT J CANCER, V75, P362, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;362::AID-IJC6&gt;3.0.CO;2-0
   DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290
   DOBSON HM, 1984, SCOT MED J, V29, P176, DOI 10.1177/003693308402900308
   Evans J., 1996, HEALTH TRENDS, V28, P5
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 1994, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253
   Fairley CK, 1996, INT J GYNECOL CANCER, V6, P225, DOI 10.1046/j.1525-1438.1996.06030225.x
   FONTHAM ETH, 1995, CANCER EPIDEM BIOMAR, V4, P801
   Fotouhi N, 1996, AM J CLIN NUTR, V63, P553, DOI 10.1093/ajcn/63.4.553
   Gail MH, 1998, CONTROL CLIN TRIALS, V19, P352, DOI 10.1016/S0197-2456(98)00016-6
   Galan P, 1997, INT J VITAM NUTR RES, V67, P450
   GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220
   GAREWAL H, 1995, P ANN M AM SOC CLIN, V14
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Gerstein HC, 1996, DIABETES CARE, V19, P1225, DOI 10.2337/diacare.19.11.1225
   Girodon F, 1997, J AM COLL NUTR, V16, P357, DOI 10.1080/07315724.1997.10718698
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297
   GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204
   GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153
   GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301
   GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6
   GYGER M, 1989, NEW ENGL J MED, V321, P120
   Hartman TJ, 1998, CANCER EPIDEM BIOMAR, V7, P335
   HEBERT PR, 1993, CIRCULATION, V88, P1437, DOI 10.1161/01.CIR.88.4.1437
   Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440
   HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hercberg S, 1998, INT J VITAM NUTR RES, V68, P3
   Johnson MA, 1997, NUTR REV, V55, P400, DOI 10.1111/j.1753-4887.1997.tb01582.x
   Jyothirmayi R, 1996, ORAL ONCOL, V32B, P373, DOI 10.1016/S0964-1955(96)00010-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RM, 2003, TRENDS COGN SCI, V7, P190, DOI 10.1016/S1364-6613(03)00093-7
   KUKLINSKI B, 1994, MOL ASPECTS MED, V15, P143, DOI 10.1016/0098-2997(94)90023-X
   LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010
   Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1&lt;31::AID-IJC6&gt;3.0.CO;2-1
   Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1
   Leng G C, 1997, Vasc Med, V2, P279
   Levine N, 1997, CANCER EPIDEM BIOMAR, V6, P957
   LI JY, 1993, CHUNG HUA CHUNG LIU, V15, P165
   Li Wen-Guang, 1992, Chinese Journal of Preventive Medicine, V26, P268
   Liede K, 1998, Oral Dis, V4, P78
   Liede KE, 1998, ANN MED, V30, P542, DOI 10.3109/07853899709002602
   Liede KE, 1998, EUR J CLIN NUTR, V52, P872, DOI 10.1038/sj.ejcn.1600646
   Lonn EM, 1996, AM J CARDIOL, V78, P914, DOI 10.1016/S0002-9149(96)00467-5
   Ma J, 1997, CANCER RES, V57, P1098
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0
   MANSON JE, 1994, AM J PREV MED, V10, P156, DOI 10.1016/S0749-3797(18)30612-3
   Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7
   Marchioli R, 1993, G Ital Cardiol, V23, P933
   Mayne ST, 1998, AM J CLIN NUTR, V68, P642, DOI 10.1093/ajcn/68.3.642
   MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701
   MEYSKENS FL, 1994, J CLIN ONCOL, V12, P2060, DOI 10.1200/JCO.1994.12.10.2060
   MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615
   MUNOZ N, 1985, LANCET, V2, P111
   Munoz N, 1996, IARC SCI PUBL, P125
   NORTON EWD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1460, DOI 10.1001/archopht.1993.01090110018003
   ODonnell CJ, 1997, CIRCULATION, V95, P1132
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   PASTORINO U, 1988, ACTA ONCOL, V27, P773, DOI 10.3109/02841868809094356
   PENG YM, 1993, CANCER EPIDEM BIOMAR, V2, P145
   Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720
   PRASAD MPR, 1995, ORAL ONCOL, V31B, P155, DOI 10.1016/0964-1955(95)00013-8
   Primary prevention project (PPP) in the Mario Negri Institute in Milan, 1996, RICERCA E, V12, P175
   Rapola JM, 1998, HEART, V79, P454, DOI 10.1136/hrt.79.5.454
   Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8
   Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693
   RECCHIA F, 1995, J INTERF CYTOK RES, V15, P605, DOI 10.1089/jir.1995.15.605
   Reed P. I., 1995, Acta Endoscopica, V25, P45, DOI 10.1007/BF02965773
   RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835
   Ridker PM, 1998, CIRCULATION, V97, P425
   Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6
   ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502
   SALVINI S, 1992, J CLIN ENDOCR METAB, V74, P139, DOI 10.1210/jc.74.1.139
   Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704
   Santos MS, 1997, AM J CLIN NUTR, V66, P917, DOI 10.1093/ajcn/66.4.917
   Santos MS, 1998, AM J CLIN NUTR, V68, P164, DOI 10.1093/ajcn/68.1.164
   Santos MS, 1996, AM J CLIN NUTR, V64, P772, DOI 10.1093/ajcn/64.5.772
   SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8
   Schaumberg D. A., 1996, American Journal of Epidemiology, V143, pS9
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   Sharma Y R, 1989, Indian J Ophthalmol, V37, P134
   SHOULSON I, 1989, ARCH NEUROL-CHICAGO, V46, P1052, DOI 10.1001/archneur.1989.00520460028009
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202
   STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S
   Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1
   TAKAMATSU S, 1995, J INT MED RES, V23, P342, DOI 10.1177/030006059502300504
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   Teikari JM, 1998, J EPIDEMIOL COMMUN H, V52, P468, DOI 10.1136/jech.52.7.468
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P68, DOI 10.1034/j.1600-0420.1998.760112.x
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621
   Tornwall ME, 1997, ARTERIOSCL THROM VAS, V17, P3475, DOI 10.1161/01.ATV.17.12.3475
   Tsubono Y, 1997, JPN J CANCER RES, V88, P344, DOI 10.1111/j.1349-7006.1997.tb00387.x
   Varis K, 1998, SCAND J GASTROENTERO, V33, P294, DOI 10.1080/00365529850170892
   VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924
   Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668
   WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936
   WRIGHT JP, 1985, GASTROENTEROLOGY, V88, P512, DOI 10.1016/0016-5085(85)90514-1
   YU SY, 1991, BIOL TRACE ELEM RES, V29, P289, DOI 10.1007/BF03032685
   YU SY, 1990, BIOL TRACE ELEM RES, V24, P105, DOI 10.1007/BF02917199
   Zaridze D, 1993, Ann Epidemiol, V3, P225
   Zee RYL, 1999, CIRCULATION, V99, P340, DOI 10.1161/01.CIR.99.3.340
NR 154
TC 43
Z9 44
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2008
IS 1
AR CD000253
DI 10.1002/14651858.CD000253.pub2
PG 29
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 259GC
UT WOS:000252926800099
PM 18253971
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, JH
   Yang, YL
   Zheng, YQ
   Qiu, MH
   Xie, ML
   Lin, WJ
   Zhang, MZ
   Pang, CP
   Chen, HY
AF Chen, Jian-Huan
   Yang, Yunli
   Zheng, Yuqian
   Qiu, Minghui
   Xie, Mingliang
   Lin, Wenjie
   Zhang, Mingzhi
   Pang, Chi Pui
   Chen, Haoyu
TI No association of age-related maculopathy susceptibility protein 2/HtrA
   serine peptidase 1 or complement factor H polymorphisms with early
   age-related maculopathy in a Chinese cohort
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; VARIANT INCREASES; CFH GENE; RISK; POPULATION;
   SMOKING; DRUSEN; AMD; PREVALENCE
AB Purpose: Single nucleotide polymorphisms (SNPs) of age-related maculopathy susceptibility protein 2/HtrA serine peptidase 1 (ARMS2/HTRA1) and complement factor H (CFH) have been reported to be associated with age-related macular degeneration (AMD). The purpose of this study was to investigate the association of ARMS2/HTRA1 and CFH SNPs with early age-related maculopathy (ARM) in a Han Chinese cohort.
   Methods: The cohort consisted of 315 unrelated subjects, including 158 patients with early ARM and 157 recruited controls. Early ARM was diagnosed and graded according to the Age-Related Eye Disease Study criteria. Four SNPs in ARMS2/HTRA1 and six SNPs in CFH previously reported to be associated with AMD were genotyped using TaqMan genotyping assays. Logistic regression implemented with the R statistical language was used for association analysis.
   Results: None of the ARMS2/HTRA1 and CFH SNPs showed any significant association with early ARM (all p>0.453), with the odds ratios ranging from 0.88 to 1.17. None of the SNPs were associated with unilateral or bilateral early ARM or any grade of early ARM (all p>0.249).
   Conclusions: The association of ARMS2/HTRA1 and CFH SNPs in early ARM was not detected in our cohort. The findings in the current study indicated that the effects of ARMS2/HTRA1 and CFH in early ARM could be much lower compared to those in AMD.
C1 [Chen, Jian-Huan; Yang, Yunli; Zheng, Yuqian; Qiu, Minghui; Zhang, Mingzhi; Pang, Chi Pui; Chen, Haoyu] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou 515041, Guangdong, Peoples R China.
   [Chen, Jian-Huan; Yang, Yunli; Zheng, Yuqian; Qiu, Minghui; Zhang, Mingzhi; Pang, Chi Pui; Chen, Haoyu] Chinese Univ Hong Kong, Shantou 515041, Guangdong, Peoples R China.
   [Chen, Jian-Huan; Pang, Chi Pui; Chen, Haoyu] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Xie, Mingliang; Lin, Wenjie] NanAo Peoples Hosp, Shantou, Peoples R China.
C3 Shantou University; Chinese University of Hong Kong
RP Chen, HY (通讯作者)，Shantou Univ, Joint Shantou Int Eye Ctr, North Dongxia Rd, Shantou 515041, Guangdong, Peoples R China.
EM drchenhaoyu@gmail.com
RI Pang, Chi P/I-5388-2014; Chen, Jian-Huan/ABB-9660-2021; Chu, Kai
   On/E-2325-2016; Chen, Haoyu/A-7432-2013; Chen, Jian-Huan/L-7188-2017
OI Chen, Jian-Huan/0000-0001-8714-2543; Chen, Haoyu/0000-0003-0676-4610;
   Chen, Jian-Huan/0000-0001-8714-2543
FU National Natural Science Foundation of China [30,901,646, 81,170,853,
   81,000,397]; Natural Science Foundation of Guangdong Province, China
   [8151503102000019]; Science and Technology Planning Project of Guangdong
   Province, China [2010B031600130, 2011B031300013]; Joint Shantou
   International Eye Center, Shantou University/The Chinese University of
   Hong Kong [10-020, 10-021, 10-022]
FX This study was supported in part by the research grant from National
   Natural Science Foundation of China (30,901,646, 81,170,853 and
   81,000,397), Natural Science Foundation of Guangdong Province, China
   (No. 8151503102000019), Science and Technology Planning Project of
   Guangdong Province, China (2010B031600130 and 2011B031300013) and Joint
   Shantou International Eye Center, Shantou University/The Chinese
   University of Hong Kong (10-020, 10-021 and 10-022).
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   [Anonymous], 2001, AM J OPHTHAL, V132
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen JH, 2012, MOL VIS, V18, P765
   Chen JH, 2012, INVEST OPHTH VIS SCI, V53, P779, DOI 10.1167/iovs.11-8277
   Chen JH, 2009, BIOCHEM SOC T, V37, P1415, DOI 10.1042/BST0371415
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Cukras Catherine, 2007, International Ophthalmology Clinics, V47, P51, DOI 10.1097/IIO.0b013e31802bd785
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rao KN, 2011, INDIAN J OPHTHALMOL, V59, pS31, DOI 10.4103/0301-4738.73685
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 45
TC 5
Z9 5
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 1
PY 2013
VL 19
BP 944
EP 954
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 142RZ
UT WOS:000318816100001
PM 23687431
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Hong, T
   Chang, AA
AF Broadhead, Geoffrey K.
   Hong, Thomas
   Chang, Andrew A.
TI Treating the untreatable patient: current options for the management of
   treatment-resistant neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE anti-vascular endothelial growth factor; neovascular age-related macular
   degeneration; refractory; treatment-resistant
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL
   ANGIOMATOUS PROLIFERATION; PIGMENT EPITHELIAL DETACHMENT;
   OPTICAL-COHERENCE-TOMOGRAPHY; 2.0 MG RANIBIZUMAB; 3-YEAR FOLLOW-UP;
   INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; TRIAMCINOLONE ACETONIDE
AB Anti-vascular endothelial growth factor (anti-VEGF) agents represent the current standard of care for neovascular age-related macular degeneration (nAMD). Although effective in a majority of cases, a significant proportion of patients have persisting retinal exudation despite regular anti-VEGF therapy. This exudation is considered to produce poorer visual outcomes in these patients. Some of these patients may have misdiagnosed nAMD variants such as polypoidal choroidal vasculopathy; however, the majority of these eyes have what has been termed treatment-resistant nAMD. Currently, the best way to care for these patients is uncertain. Here, we review the evidence for different approaches to the management of treatment-resistant nAMD, including high-dose anti-VEGF therapy, combination regimes and switching of anti-VEGF agents, and discuss possible therapeutic approaches for patients with treatment-resistant nAMD.
C1 [Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13 Pk House 187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
FU Bayer; Alcon; Novartis
FX Dr Andrew Chang has acted as a consultant for and has received grant
   from Bayer, Alcon and Novartis. This work has not been presented at any
   meeting.
CR Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cho M, 2010, BRIT J OPHTHALMOL, V94, P597, DOI 10.1136/bjo.2008.149724
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Kiddee W, 2013, SURV OPHTHALMOL, V58, P291, DOI 10.1016/j.survophthal.2012.08.003
   Kim YM, 2011, RETINA-J RET VIT DIS, V31, P2123, DOI 10.1097/IAE.0B013E31822F5720
   Kloos P, 2011, KLIN MONATSBL AUGENH, V228, P340, DOI 10.1055/s-0031-1273230
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Konstantinidis L, 2010, EUR J OPHTHALMOL, V20, P955, DOI 10.1177/112067211002000524
   Krebs I, 2010, ACTA OPHTHALMOL, V91, P178
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kurup SK, 2010, ACTA OPHTHALMOL, V88, pe145, DOI 10.1111/j.1755-3768.2009.01560.x
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   Parke DW, 2012, CLIN OPHTHALMOL, V6, P1347, DOI 10.2147/OPTH.S34653
   Peyman G, 2011, EUR J OPHTHALMOL, V21, P162, DOI 10.5301/EJO.2010.3272
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Semeraro F, 2013, INT J IMMUNOPATH PH, V26, P765, DOI 10.1177/039463201302600321
   Shah Sanket U, 2012, Acta Ophthalmol, V90, pe569, DOI 10.1111/j.1755-3768.2011.02372.x
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Soheilian M, 2013, RETINA
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Veritti D, 2013, OPHTHALMOLOGICA, V230, P131, DOI 10.1159/000351651
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Wu L, 2013, J OCUL PHARMACOL TH, V29, P366, DOI 10.1089/jop.2012.0203
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P416
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 92
TC 31
Z9 34
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2014
VL 92
IS 8
BP 713
EP 723
DI 10.1111/aos.12463
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0WJ
UT WOS:000345342600027
PM 24925048
DA 2022-11-30
ER

PT J
AU Ertekin, S
   Yildirim, O
   Dinc, E
   Ayaz, L
   Fidanci, SB
   Tamer, L
AF Ertekin, Sevda
   Yildirim, Ozlem
   Dinc, Erdem
   Ayaz, Lokman
   Fidanci, Senay Balci
   Tamer, Lulufer
TI Evaluation of circulating miRNAs in wet age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; CHOROIDAL NEOVASCULARIZATION; DIFFERENTIAL
   EXPRESSION; MICRORNA EXPRESSION; BREAST-CANCER; GROWTH-FACTOR;
   ANGIOGENESIS; INVASION; TARGETS; PLASMA
AB Purpose: In the present study, we aimed to investigate the changes in plasma miRNA in patients with wet age-related macular degeneration.
   Methods: The expression profiles of 384 miRNAs in plasma from 33 patients (22 male, 11 female) who were diagnosed with wet age-related macular degeneration with fundus examination, fundus fluorescein angiography, and optical coherence tomography and 31 controls (17 male, 14 female) were evaluated using high-throughput quantitative real-time PCR.
   Results: Our results demonstrated that the expression level of five miRNAs (miR-17-5p, miR-20a-5p, miR-24-3p, miR-106a-5p, and miR-223-3p) was significantly upregulated in patients with age-related macular degeneration when compared to the control group (p<0.05). The expression level of 11 miRNAs (miR-21-5p, miR-25-3p, miR-140-3p, miR-146b-5p, miR-192-5p, miR-335-5p, miR-342-3p, miR-374a-5p, miR-410, miR-574-3p, and miR-660-5p) was significantly downregulated in patients (p<0.05). In addition, ten miRNAs (miR-26b-5p, miR-27b-3p, miR-29a-3p, miR-139-3p, miR-212-3p, miR-324-3p, miR-324-5p, miR-532-3p, miR-744-5p, and miR-Let-7c) were expressed only in the patient group.
   Conclusions: Our results suggest that plasma miRNA levels may change in wet age-related macular degeneration. These molecules may have an important therapeutic target in patients who are unresponsive to antivascular endothelial growth factor therapy. However, further studies must be conducted for possible effects of miRNAs in vascular disorders of eye such as age-related macular degeneration.
C1 [Ertekin, Sevda] Osmaniye State Hosp, Ophthalmol Clin, TR-80000 Osmaniye, Turkey.
   [Yildirim, Ozlem; Dinc, Erdem] Mersin Univ, Dept Ophthalmol, Mersin, Turkey.
   [Fidanci, Senay Balci] Trakya Univ, Fac Pharm, Dept Biochem, Edirne, Turkey.
   [Fidanci, Senay Balci; Tamer, Lulufer] Mersin Univ, Dept Biochem, Edirne, Turkey.
C3 Osmaniye State Hospital; Mersin University; Trakya University; Mersin
   University
RP Ertekin, S (通讯作者)，Osmaniye State Hosp, Ophthalmol Clin, TR-80000 Osmaniye, Turkey.
EM sevdaertekin@gmail.com
RI Ayaz, Lokman/K-6716-2013; Tamer, Lulufer/AAG-5796-2021; BALCI,
   Senay/W-4931-2019
OI Ayaz, Lokman/0000-0002-2876-055X; BALCI, Senay/0000-0002-7498-604X
FU Mersin University Scientific Research Fund [BAP-TF CTB (SE) 201- TU]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. This study was
   supported by Mersin University Scientific Research Fund (Grant No:
   BAP-TF CTB (SE) 201- TU). The authors thank Aysegul Gorur for helping
   miRNA analysis.
CR Ayaz L, 2013, J CANCER RES CLIN, V139, P1499, DOI 10.1007/s00432-013-1469-2
   Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367
   Biyashev D, 2012, BLOOD, V119, P2679, DOI 10.1182/blood-2011-07-370635
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chen L, 2014, BMB REP, V47, P39, DOI 10.5483/BMBRep.2014.47.1.079
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Geng L, 2013, ONCOGENE
   He YJ, 2013, EXP THER MED, V5, P813, DOI 10.3892/etm.2013.915
   Hu ZB, 2012, CARCINOGENESIS, V33, P828, DOI 10.1093/carcin/bgs030
   Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116
   Kanaan Z, 2013, ANN SURG, V258, P400, DOI 10.1097/SLA.0b013e3182a15bcc
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu SG, 2013, ONCOL LETT, V5, P1639, DOI 10.3892/ol.2013.1251
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ragusa M, 2013, MOL VIS, V19, P430
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shi L, 2013, CIRC RES, V113, P1320, DOI 10.1161/CIRCRESAHA.113.301824
   Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105
   Urbich C, 2012, BLOOD, V119, P1607, DOI 10.1182/blood-2011-08-373886
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Villarreal G, 2011, INVEST OPHTH VIS SCI, V52, P3391, DOI 10.1167/iovs.10-6165
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200
   Zhao BT, 2014, CANCER LETT, V342, P43, DOI 10.1016/j.canlet.2013.08.030
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhu Longping, 2013, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V29, P524
NR 38
TC 70
Z9 73
U1 0
U2 20
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 29
PY 2014
VL 20
BP 1057
EP 1066
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AP3JR
UT WOS:000341972500001
PM 25221421
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
AF Owsley, Cynthia
   McGwin, Gerald, Jr.
TI Driving and Age-Related Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; MEDIATED
   DARK-ADAPTATION; OLDER DRIVERS; DEPRESSIVE SYMPTOMS; MEDICAL CONDITIONS;
   VEHICLE CRASHES; FATAL CRASHES; HIGH-RISK; CESSATION
AB This article reviews the research literature on driving and age-related macular degeneration, which is motivated by the link between driving and the quality of life of older adults and their increased collision rate. It addresses the risk of crashes, driving performance, driving difficulty, self-regulation, and interventions to enhance, safety, and considers directions for future research.
C1 [Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu; mcgwin@uab.edu
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [P30AG022838, R01AG004212] Funding Source:
   NIH RePORTER; NEI NIH HHS [R21 EY014071-05, R21 EY014071] Funding
   Source: Medline; NIA NIH HHS [P30 AG022838-019002, R01 AG004212-14, R01
   AG004212-19, P30 AG022838, R01 AG004212, P30 AG022838-059002, R01
   AG004212-20A1, R01 AG004212-21, P30 AG022838-049002] Funding Source:
   Medline
CR *AAA, 2008, ROADW REV
   *AAA, 2008, WELC SEN ORG
   *AARP, 2008, AARP DRIV SAF PROGR
   Anstey KJ, 2006, J AM GERIATR SOC, V54, P121, DOI 10.1111/j.1532-5415.2005.00471.x
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bandura A., 1986, SOCIAL FDN THOUGHT A
   Bedard M, 2008, TRAFFIC INJ PREV, V9, P70, DOI 10.1080/15389580701670705
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bowers AR, 2005, INVEST OPHTH VIS SCI, V46, P66, DOI 10.1167/iovs.04-0271
   Brooks JO, 2005, OPTOMETRY VISION SCI, V82, P689, DOI 10.1097/01.opx.0000174722.96171.86
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Dellinger AM, 2002, AM J EPIDEMIOL, V155, P234, DOI 10.1093/aje/155.3.234
   Dingus T. A., 2006, 100 CAR NATURALISTIC
   Eby DW, 2003, J SAFETY RES, V34, P371, DOI 10.1016/j.jsr.2003.09.006
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343
   Forrest KYZ, 1997, J AM GERIATR SOC, V45, P1214, DOI 10.1111/j.1532-5415.1997.tb03772.x
   Freeman EE, 2006, INVEST OPHTH VIS SCI, V47, P514, DOI 10.1167/iovs.05-0934
   Freeman EE, 2006, AM J PUBLIC HEALTH, V96, P1254, DOI 10.2105/AJPH.2005.069146
   FREUND K, 2004, P TRANSPORTATION AGI, P114
   Higgins KE, 2005, OPTOMETRY VISION SCI, V82, P647, DOI 10.1097/01.opx.0000174725.32907.86
   HU PS, 1999, SUMMARY TRENDS 1995
   Huss C, 2004, J VISUAL IMPAIR BLIN, V98, P641, DOI 10.1177/0145482X0409801008
   Huss C., 1988, J VIS REHABIL, V2, P31
   JANKE MK, AGE RELATED DISABILI, P1994
   Janke MK, 1994, TRANSPORT RES REC, V1438, P77
   JETTE AM, 1992, HUM FACTORS, V34, P25, DOI 10.1177/001872089203400104
   JOSE RT, 1975, NEW OUTLOOK BLIND, V69, P305
   KELLEHER DK, 1974, DRIVING AID BIOPTIC
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KORB DR, 1970, AMER J OPT ARCH AM A, V47, P619
   Li GH, 2003, ACCIDENT ANAL PREV, V35, P227, DOI 10.1016/S0001-4575(01)00107-5
   LIPPMAN O, 1979, P AM ASS AUTOMOTIVE, V23, P204
   LIPPMANN O, 1988, J VISUAL IMPAIR BLIN, V82, P182
   Lyman S, 2002, INJ PREV, V8, P116, DOI 10.1136/ip.8.2.116
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334
   Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x
   MAROTTOLI RA, 1993, J GERONTOL, V48, pS255, DOI 10.1093/geronj/48.5.S255
   Marottoli RA, 2007, J GERONTOL A-BIOL, V62, P1113, DOI 10.1093/gerona/62.10.1113
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267
   McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524
   McKnight A, 1982, ELDERLY DRIVER RETRA
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Murakami E, 1997, COMP COMPUTER ASSIST
   *NAT SAF COUNC, 2008, COACH MAT DRIV
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   Owsley C, 2004, AM J PREV MED, V26, P222, DOI 10.1016/j.amepre.2003.12.005
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 2004, P TRANSP AG SOC DEC, P44
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Park W L, 1995, J Am Optom Assoc, V66, P274
   PARK WL, 1992, J AM OPTOM ASSOC, V64, P54
   Peli E., 2002, DRIVING CONFIDENCE P
   Planek T.W., 1968, INVESTIGATION PROBLE
   Politzer M R, 1995, J Am Optom Assoc, V66, P18
   Prochaska J O, 1992, Prog Behav Modif, V28, P183
   Ragland DR, 2005, J GERONTOL A-BIOL, V60, P399, DOI 10.1093/gerona/60.3.399
   Rosenstock I, 1990, HLTH BEHAV HLTH ED T, P39
   Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sims RV, 2000, J GERONTOL A-BIOL, V55, pM22
   Slade SV, 2002, OPHTHAL PHYSL OPT, V22, P1, DOI 10.1046/j.1475-1313.2002.00007.x
   Stalvey Beth T, 2003, Health Promot Pract, V4, P109, DOI 10.1177/1524839902250757
   Staplin L.K., 2003, MODEL DRIVER SCREENI, DOI [10.21949/1525526, DOI 10.21949/1525526]
   Staplin L, 2006, TOP GERIATR REHABIL, V22, P129
   Stutts JC, 1998, J AM GERIATR SOC, V46, P854, DOI 10.1111/j.1532-5415.1998.tb02719.x
   Suen S. L., 2004, TRANSPORTATION AGING, V27, P97
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   SZLYK JP, 2000, J REHABILITATION RES, V37, P1
   Vogel GL, 1991, J AM OPTOM ASSOC, V62, P288
   Windsor TD, 2006, CLIN INTERV AGING, V1, P205, DOI 10.2147/ciia.2006.1.3.205
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
   Wouters PIJ, 2000, ACCIDENT ANAL PREV, V32, P643, DOI 10.1016/S0001-4575(99)00095-0
NR 90
TC 21
Z9 22
U1 0
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2008
VL 102
IS 10
SI SI
BP 621
EP 635
DI 10.1177/0145482X0810201007
PG 15
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 365YI
UT WOS:000260445400007
PM 20046818
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhao, M
   Bai, YJ
   Xie, WK
   Shi, X
   Li, FT
   Yang, F
   Sun, YY
   Huang, LZ
   Li, XX
AF Zhao, Min
   Bai, Yujing
   Xie, Wankun
   Shi, Xuan
   Li, Fangting
   Yang, Fei
   Sun, Yaoyao
   Huang, Lvzhen
   Li, Xiaoxin
TI Interleukin-1 beta Level Is Increased in Vitreous of Patients with
   Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal
   Choroidal Vasculopathy (PCV)
SO PLOS ONE
LA English
DT Article
ID DIABETIC-RETINOPATHY; CELL-DEATH; INFLAMMATION; ACTIVATION; DRUSEN;
   CYTOKINES; SYSTEM; EYE; CLASSIFICATION; INFLAMMASOMES
AB Purpose
   To examine the expression of pro-interleukin-1 beta (pro-IL-1 beta) and interleukin-1 beta (IL-1 beta) in the vitreous body of patients with neovascular age-related macular degeneration(nAMD), polypoidal choroidal vasculopathy (PCV), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO) or Eales' disease to further elucidate the role of IL-1 beta and inflammation in the pathogenesis of neovascular retinal disease.
   Design
   Prospective clinical laboratory investigation study.
   Methods
   All patients enrolled had vitreous hemorrhage due to nAMD, PCV, PDR, RVO or Eales' disease that required vitrectomy. Patients were excluded for any history of active intraocular inflammation, or other ophthalmic surgery besides vitrectomy. Control samples were obtained from patients with idiopathic macular epiretinal membrane. A total of fifty vitreous samples were collected from patient during vitrectomy. Pro-IL-1 beta and IL-1 beta expression were measured by enzyme-linked immunosorbent assay (ELISA). Results were analyzed statistically using nonparametric tests.
   Results
   Expression of pro-IL-1 beta protein was increased by 2.83-fold and 9.19-fold in PCV and nAMD vitreous samples relative to control, respectively. Expression of IL-beta protein was increased by 10-fold and 4.83-fold in PCV and nAMD vitreous samples relative to control, respectively.
   Conclusions
   Our results demonstrate that expression of pro-IL-1 beta and IL-1 beta proteins is higher in PCV and nAMD. The roles of pro-IL-1 beta and IL-1 beta as inflammatory mediators in the development of PCV and nAMD may be associated with photoreceptor degeneration and neovascularization which necessitates further study.
C1 [Zhao, Min; Bai, Yujing; Xie, Wankun; Shi, Xuan; Li, Fangting; Yang, Fei; Sun, Yaoyao; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Zhao, Min; Bai, Yujing; Xie, Wankun; Shi, Xuan; Li, Fangting; Yang, Fei; Sun, Yaoyao; Huang, Lvzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Zhao, Min; Bai, Yujing; Xie, Wankun; Shi, Xuan; Li, Fangting; Yang, Fei; Sun, Yaoyao; Huang, Lvzhen; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM drlixiaoxin@163.com
RI Xie, Wankun/K-8623-2017
OI Xie, Wankun/0000-0003-0178-3361; Zhao, Min/0000-0003-0521-9186
FU National Basic Research Program of China (973 Program) [2011CB510200];
   Peking University People's Hospital Research and Development Funds
   [RDB2013-21, 2118000540]; Beijing Nova Program [Z131102000413004]
FX Xiaoxin Li was supported by National Basic Research Program of China
   (973 Program, 2011CB510200). Min Zhao was supported by Peking University
   People's Hospital Research and Development Funds (RDB2013-21,
   2118000540). Yujing Bai was supported by Beijing Nova Program
   (Z131102000413004). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dong N, 2013, MOL VIS, V19, P1734
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Asrar Ahmed M Abu, 2011, Mol Vis, V17, P1829
   Feng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068149
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227
   Kowluru RA, 2004, INVEST OPHTH VIS SCI, V45, P4161, DOI 10.1167/iovs.04-0633
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Leal SM, 2012, CYTOKINE, V58, P107, DOI 10.1016/j.cyto.2011.12.022
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murugeswari P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107551
   Okumura Chikara, 2013, Nihon Rinsho, V71, P1497
   Rock KL, 2011, IMMUNOL REV, V243, P191, DOI 10.1111/j.1600-065X.2011.01040.x
   Rosenbaum JT, 2012, NEW ENGL J MED, V367, P768, DOI 10.1056/NEJMcibr1204973
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Xie WK, 2011, MOL VIS, V17, P3512
   Xu J, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556-276X-8-54
NR 41
TC 42
Z9 43
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2015
VL 10
IS 5
AR e0125150
DI 10.1371/journal.pone.0125150
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CI7AU
UT WOS:000354916100023
PM 25978536
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Pradella, FM
   Nisihara, R
   Sato, MT
   Grandinetti, AA
   Novello, SB
   Pires, M
   Schebelski, D
   Messias-Reason, I
AF Pradella, Fernando M.
   Nisihara, Renato
   Sato, Mario T.
   Grandinetti, Alexandre A.
   Novello, Sergio B.
   Pires, Marcelo
   Schebelski, Diego
   Messias-Reason, Iara
TI Circulating levels of mannose-binding lectin (MBL) in age-related
   macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Age-related macular degeneration; Drusen; Immuno-regulation;
   Mannose-binding lectin; Inflammation; Retina
ID H VARIANT INCREASES; COMPLEMENT; SYSTEM; POLYMORPHISM; POPULATION;
   PREVALENCE; PATHWAY; DISEASE; RISK; EYE
AB Purpose: To assess whether the serum levels of mannose-binding lectin of the lectin complement pathway are associated with age-related macular degeneration. Methods: Patients with age-related macular degeneration and age-matched controls underwent full ophthalmologic examination and optical coherence tomography. Using a time-resolved immuno-fluorometric assay, blood samples were evaluated to determine the serum mannose-binding lectin levels. Results: A total of 136 individuals were evaluated, including 68 patients with age-related macular degeneration (34 exudative and 34 nonexudative) and 68 age-matched controls. The median mannose-binding lectin level was 608 ng/mL (range, 30-3,415 ng/mL) in patients with age-related macular degeneration and 739 ng/mL (range, 30-6,039 ng/mL) in controls, with no difference between the groups. Additionally, the median mannose-binding lectin level was 476 ng/mL (range, 30-3,415 ng/mL) in exudative cases and 692 ng/mL (range, 30-2,587 ng/mL) in nonexudative cases. Con-clusions: Serum mannose-binding lectin levels were not associated with age-related macular degeneration or with the exudative and nonexudative forms of the disease.
C1 [Pradella, Fernando M.; Sato, Mario T.; Grandinetti, Alexandre A.; Novello, Sergio B.; Pires, Marcelo; Schebelski, Diego; Messias-Reason, Iara] Univ Fed Parana, Dept Ophthalmol, Curitiba, PR, Brazil.
   [Nisihara, Renato] Univ Fed Parana, Immunopathol Mol Lab, Curitiba, PR, Brazil.
   [Nisihara, Renato] Univ Positivo, Dept Med, Curitiba, PR, Brazil.
C3 Universidade Federal do Parana; Universidade Federal do Parana;
   Universidade Positivo
RP Pradella, FM (通讯作者)，Av Silva Jardim,2014, BR-80250200 Curitiba, PR, Brazil.
EM fmpradella@gmail.com
RI Nisihara, Renato RN/I-9654-2016
OI Nisihara, Renato RN/0000-0002-1234-8093; Jose de Messias Reason,
   Iara/0000-0002-5573-260X
CR Abbas AK., 2018, CELL MOL IMMUNOL
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2014, CLIN EXP OPHTHALMOL, V42, P53, DOI 10.1111/ceo.12235
   Chow SP, 2011, CLIN EXP OPHTHALMOL, V39, P871, DOI 10.1111/j.1442-9071.2011.02572.x
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Frederiksen PD, 2006, J IMMUNOL METHODS, V315, P49, DOI 10.1016/j.jim.2006.07.001
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Geng PL, 2015, DIABETES CARE, V38, P868, DOI 10.2337/dc14-1873
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Luo C, 2011, MOL VIS, V17, P1588
   Osthoff M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134107
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rohrer B, 2012, MOL IMMUNOL, V48, pe1
   Scholl HP, 2008, PLOS ONE, V3, P1
   Scorza M, 2015, CLIN CHIM ACTA, V451, P78, DOI 10.1016/j.cca.2015.03.007
   Smith JR, 2008, CLIN EXPT OPHTHALMOL, V36, P188
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Ulrich JN, 2008, CLIN EXP OPHTHALMOL, V36, P431, DOI 10.1111/j.1442-9071.2008.01793.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 29
TC 0
Z9 1
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2018
VL 81
IS 2
BP 120
EP 124
DI 10.5935/0004-2749.20180027
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH4GI
UT WOS:000433360900008
PM 29846424
OA gold
DA 2022-11-30
ER

PT J
AU Skalicky, SE
   Fenwick, E
   Martin, KR
   Crowston, J
   Goldberg, I
   McCluskey, P
AF Skalicky, Simon E.
   Fenwick, Eva
   Martin, Keith R.
   Crowston, Jonathan
   Goldberg, Ivan
   McCluskey, Peter
TI Impact of age-related macular degeneration in patients with glaucoma:
   understanding the patients' perspective
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE activity limitation; age-related macular degeneration; glaucoma; Rasch
   analysis; utility value
ID QUALITY-OF-LIFE; VISUAL-FIELD LOSS; OCULAR SURFACE DISEASE; OPEN-ANGLE
   GLAUCOMA; OLDER-ADULTS; LOSS INCREASES; AMBIENT LIGHT; RISK-FACTORS;
   VISION; EYE
AB BackgroundThe aim of the study is to measure the impact of age-related macular degeneration on vision-related activity limitation and preference-based status for glaucoma patients.
   DesignThis was a cross-sectional study.
   ParticipantsTwo-hundred glaucoma patients of whom 73 had age-related macular degeneration were included in the research.
   MethodsSociodemographic information, visual field parameters and visual acuity were collected. Age-related macular degeneration was scored using the Age-Related Eye Disease Study system.
   Main Outcome MeasuresThe Rasch-analysed Glaucoma Activity Limitation-9 and the Visual Function Questionnaire Utility Index measured vision-related activity limitation and preference-based status, respectively. Regression models determined factors predictive of vision-related activity limitation and preference-based status. Differential item functioning compared Glaucoma Activity Limitation-9 item difficulty for those with and without age-related macular degeneration.
   ResultsMean age was 73.7 (10.1)years. Lower better eye mean deviation (: 1.42, 95% confidence interval: 1.24-1.63, P<0.001) and age-related macular degeneration (: 1.26 95% confidence interval: 1.10-1.44, P=0.001) were independently associated with worse vision-related activity limitation. Worse eye visual acuity (: 0.978, 95% confidence interval: 0.961-0.996, P=0.018), high risk age-related macular degeneration (: 0.981, 95% confidence interval: 0.965-0.998, P=0.028) and severe glaucoma (: 0.982, 95% confidence interval: 0.966-0.998, P=0.032) were independently associated with worse preference-based status. Glaucoma patients with age-related macular degeneration found using stairs, walking on uneven ground and judging distances of foot to step/curb significantly more difficult than those without age-related macular degeneration.
   ConclusionsVision-related activity limitation and preference-based status are negatively impacted by severe glaucoma and age-related macular degeneration. Patients with both conditions perceive increased difficulty walking safely compared with patients with glaucoma alone.
C1 [Skalicky, Simon E.; Goldberg, Ivan; McCluskey, Peter] Univ Sydney, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Goldberg, Ivan] Eye Associates, Sydney, NSW, Australia.
   [Goldberg, Ivan; McCluskey, Peter] Sydney Eye Hosp, Sydney, NSW, Australia.
   [Skalicky, Simon E.] Royal Melbourne Hosp, Dept Ophthalmol, Parkville, Vic, Australia.
   [Skalicky, Simon E.] Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia.
   [Skalicky, Simon E.; Fenwick, Eva; Crowston, Jonathan] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Skalicky, Simon E.; Martin, Keith R.] Addenbrookes Hosp, Ophthalmol Dept, Cambridge, England.
   [Martin, Keith R.] Univ Cambridge, Cambridge NIHR Biomed Res Ctr, Cambridge, England.
C3 University of Sydney; Royal Melbourne Hospital; Royal Melbourne
   Hospital; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; University of Cambridge
RP Skalicky, SE (通讯作者)，32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM seskalicky@gmail.com
RI McCluskey, Peter J/H-7607-2013
OI McCluskey, Peter J/0000-0002-8177-1637
FU National Health and Medical Research Council (NHMRC) [1072987]
FX The second author, Dr Eva Fenwick, is funded by the National Health and
   Medical Research Council (NHMRC) Early Career Fellowship grant no.
   1072987. The Centre for Eye Research Australia receives operational
   infrastructure support from the Victorian Government.
CR Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Alexander MS, 2014, OPTOMETRY VISION SCI, V91, P990, DOI 10.1097/OPX.0000000000000316
   Alexander MS, 2014, OPTOMETRY VISION SCI, V91, P975, DOI 10.1097/OPX.0000000000000286
   Anderson DR, 1992, AUTOMATED STATIC PER, V123
   Arora KS, 2013, OPHTHALMOLOGY, V120, P2476, DOI 10.1016/j.ophtha.2013.07.020
   Asaoka R, 2011, INVEST OPHTH VIS SCI, V52, P7007, DOI 10.1167/iovs.11-7643
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   Burton R, 2012, OPTOMETRY VISION SCI, V89, P1282, DOI 10.1097/OPX.0b013e3182686165
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Crabb DP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009710
   Crabb DP, 2005, GRAEF ARCH CLIN EXP, V243, P210, DOI 10.1007/s00417-004-0984-x
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Dev MK, 2014, CURR EYE RES, V39, P232, DOI 10.3109/02713683.2013.838973
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans K, 2009, CLIN OPHTHALMOL, V3, P433
   Fenwick EK, 2011, BRIT J OPHTHALMOL, V95, P774, DOI 10.1136/bjo.2010.191312
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Glen FC, 2012, INVEST OPHTH VIS SCI, V53, P3629, DOI 10.1167/iovs.11-8538
   Goldberg I, 2009, J GLAUCOMA, V18, P6, DOI 10.1097/IJG.0b013e3181752c83
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gothwal VK, 2014, INVEST OPHTH VIS SCI, V55, P1361, DOI 10.1167/iovs.13-13729
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jiang XJ, 2012, OPHTHALMOLOGY, V119, P2245, DOI 10.1016/j.ophtha.2012.05.030
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keltner JL, 2007, J GLAUCOMA, V16, P665, DOI 10.1097/IJG.0b013e318057526d
   Khadka J, 2011, INVEST OPHTH VIS SCI, V52, P6971, DOI 10.1167/iovs.11-7423
   Kowalski JW, 2012, QUAL LIFE RES, V21, P323, DOI 10.1007/s11136-011-9938-z
   Lahav K, 2011, ARCH OPHTHALMOL-CHIC, V129, P16, DOI 10.1001/archophthalmol.2010.332
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Linacre J., 2012, USERS GUIDE WINSTEPS
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   McKean-Cowdin R, 2008, OPHTHALMOLOGY, V115, P941, DOI 10.1016/j.ophtha.2007.08.037
   Medeiros FA, 2015, OPHTHALMOLOGY, V122, P293, DOI 10.1016/j.ophtha.2014.08.014
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Musch DC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1694, DOI 10.1001/archopht.124.12.1694
   Nassiri N, 2013, OPTOMETRY VISION SCI, V90, P745, DOI 10.1097/OPX.0000000000000003
   Nelson P, 2003, J GLAUCOMA, V12, P139, DOI 10.1097/00061198-200304000-00009
   Pearson Isobel, 2013, J Med Econ, V16, P1307, DOI 10.3111/13696998.2013.839946
   PERASALO R, 1994, ACTA OPHTHALMOL, V72, P175
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Ramulu PY, 2013, INVEST OPHTH VIS SCI, V54, P666, DOI 10.1167/iovs.12-10618
   Ramulu PY, 2009, ARCH OPHTHALMOL-CHIC, V127, P82, DOI 10.1001/archophthalmol.2008.523
   Rentz AM, 2014, JAMA OPHTHALMOL, V132, P310, DOI 10.1001/jamaophthalmol.2013.7639
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   Rossi GCM, 2013, J OCUL PHARMACOL TH, V29, P390, DOI 10.1089/jop.2011.0159
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sawada H, 2014, J GLAUCOMA, V23, P81, DOI 10.1097/IJG.0b013e318265bbdc
   Skalicky S, 2008, J GLAUCOMA, V17, P546, DOI 10.1097/IJG.0b013e318163bdd1
   Skalicky SE, 2015, CLIN EXP OPHTHALMOL, V43, P335, DOI 10.1111/ceo.12454
   Skalicky SE, 2012, AM J OPHTHALMOL, V153, P1, DOI 10.1016/j.ajo.2011.05.033
   Svensson E, 2001, J REHABIL MED, V33, P47, DOI 10.1080/165019701300006542
   Tarkkanen A, 2008, ACTA OPHTHALMOL, V86, P697, DOI 10.1111/j.1600-0420.2007.01109.x
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Warrian KJ, 2009, BRIT J OPHTHALMOL, V93, P310, DOI 10.1136/bjo.2008.139592
   Wolfram C, 2013, OPHTHALMOLOGICA, V229, P227, DOI 10.1159/000350553
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wu SY, 2008, INVEST OPHTH VIS SCI, V49, P1333, DOI 10.1167/iovs.07-1252
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zhou CD, 2014, QUAL LIFE RES, V23, P999, DOI 10.1007/s11136-013-0518-2
NR 68
TC 6
Z9 6
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2016
VL 44
IS 5
BP 377
EP 387
DI 10.1111/ceo.12672
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA DR5JG
UT WOS:000379938700004
PM 26482212
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Meng, LH
   Luo, MY
   Yu, WH
   Min, HY
   Dai, RP
   Koh, A
   Chen, YX
AF Zhao, Xinyu
   Meng, Lihui
   Luo, Mingyue
   Yu, Weihong
   Min, Hanyi
   Dai, Rongping
   Koh, Adrian
   Chen, Youxin
TI The influence of delayed treatment due to COVID-19 on patients with
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO THERAPEUTIC ADVANCES IN CHRONIC DISEASE
LA English
DT Article
DE COVID-19; neovascular age-related macular degeneration; polypoidal
   choroidal vasculopathy; prognosis
ID VISUAL-ACUITY; RANIBIZUMAB; DIAGNOSIS
AB Purpose: To explore the impact of coronavirus disease 2019 (COVID-19) on the prognosis of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and share the experience in managing them during pandemics.
   Method: This is a retrospective study of nAMD and PCV patients treated at Peking Union Medical College Hospital from 31 December 2019 to 1 August 2020. Baseline demographic and clinical characteristics, best corrected visual acuity (BCVA), optical coherence tomography (OCT) features, duration of delayed treatment and number of anti-vascular endothelial growth factor (VEGF) injections were analyzed.
   Results: A total of 130 nAMD patients (155 eyes) and 76 PCV patients (89 eyes) were identified. Compared to the conditions before COVID-19, the BCVA of delayed cases decreased significantly, and the proportion of patients presenting with sub-macular scar was significantly greater in the delayed treatment group (p < 0.05). The BCVA of non-delayed cases remained stable, with the percentage of patients with disease activity sub-retinal fluid and hemorrhage at the fovea decreasing significantly (p < 0.05). The stable cases who did not require anti-VEGF treatment had significantly worse baseline and final BCVA, these patients were likely to be chronic and 'burnt out' cases with significantly worse anatomical structures (p < 0.05).
   Conclusions: The delayed cases due to the pandemic suffered compromised visual function and a higher rate of sub-macular scar formation, while the visual function of non-delayed cases remained stable with favorable anatomical outcomes, suggesting the importance of regular follow-up for nAMD and PCV patients. Besides, effective measures of hospitals during pandemics are crucial to provide timely treatment for chronic disease.
C1 [Zhao, Xinyu; Meng, Lihui; Luo, Mingyue; Yu, Weihong; Min, Hanyi; Dai, Rongping; Chen, Youxin] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Shuaifuyuan 1, Beijing 100730, Peoples R China.
   [Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Zhao, Xinyu; Meng, Lihui; Luo, Mingyue; Yu, Weihong; Min, Hanyi; Dai, Rongping] Chinese Acad Med Sci, China Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Koh, Adrian] Camden Med Ctr, Singapore, Singapore.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Chinese Academy of Medical
   Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Shuaifuyuan 1, Beijing 100730, Peoples R China.
EM 478252553@qq.com
RI meng, li/GVT-2063-2022
OI Chen, Youxin/0000-0002-7231-5058
FU Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by The Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences (2018PT32029).
CR Agarwal D, 2020, INDIAN J OPHTHALMOL, V68, P1216, DOI 10.4103/ijo.IJO_1391_20
   Antaki F, 2020, GRAEF ARCH CLIN EXP, V258, P1567, DOI 10.1007/s00417-020-04693-w
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Goldstein DA, 2020, JAMA ONCOL, V6, P1694, DOI 10.1001/jamaoncol.2020.2493
   Koh A., 2020, OPHTHALMOLOGY, V127, pE49X
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1335, DOI 10.1007/s00417-020-04697-6
   Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8
   Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moskowitz CS, 2020, JAMA ONCOL, V6, P1326, DOI 10.1001/jamaoncol.2020.2370
   Onoyama T, 2021, DIGEST ENDOSC, V33, P549, DOI 10.1111/den.13804
   Peng FJ, 2020, CAN J CARDIOL, V36, P915, DOI 10.1016/j.cjca.2020.04.010
   Pramesh CS, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2011595
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   Smith JR, 2020, OPHTHALMOLOGY, V127, pE65, DOI 10.1016/j.ophtha.2020.05.037
   Tiew S, 2020, EYE, V34, P2148, DOI 10.1038/s41433-020-0783-6
   Wang WP, 2020, IN VIVO, V34, P1675, DOI 10.21873/invivo.11960
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Zhao XY, 2020, RETINA-J RET VIT DIS, V40, P477, DOI 10.1097/IAE.0000000000002389
   Zou HC, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00714-2
NR 29
TC 4
Z9 4
U1 1
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2040-6223
EI 2040-6231
J9 THER ADV CHRONIC DIS
JI Ther. Adv. Chronic Dis.
PD JUN
PY 2021
VL 12
AR 20406223211026389
DI 10.1177/20406223211026389
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UF2QV
UT WOS:000688424400001
PM 34221305
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sabanayagam, C
   Lye, WK
   Januszewski, A
   Abdul, RBBM
   Cheung, GCM
   Kumari, N
   Wong, TY
   Cheng, CY
   Lamoureux, E
AF Sabanayagam, Charumathi
   Lye, Weng Kit
   Januszewski, Andrzej
   Abdul, Riswana Banu Binte Mohammed
   Cheung, Gemmy Chui Ming
   Kumari, Neelam
   Wong, Tien Y.
   Cheng, Ching-Yu
   Lamoureux, Ecosse
TI Urinary Isoprostane Levels and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; Asians; isoprostane; oxidative stress
ID C-REACTIVE PROTEIN; STRESS IN-VIVO; OXIDATIVE STRESS;
   LIPID-PEROXIDATION; OXIDANT STRESS; NITRIC-OXIDE; RISK-FACTORS;
   F-2-ISOPROSTANES; MARKERS; PLASMA
AB PURPOSE. Oxidative stress, characterized by an excessive production of reactive oxygen intermediates has been suggested to play a role in the pathogenesis of age-related macular degeneration (AMD). We examined the association of urinary F2-isoprostanes (F2-IsoPs), a marker of lipid peroxidation and the most reliable marker of oxidative damage with AMD.
   METHODS. We included 238 adults with AMD and 390 age-and sex-matched controls without AMD who participated in a population-based cross-sectional study in Singapore (Singapore Chinese Eye Study, 2009-2011). AMD was graded from retinal photographs using the Wisconsin Age-Related Maculopathy Grading System. Urinary-free F2-IsoPs (pmol/mmol of creatinine) were measured by gas chromatography mass spectrometry (GC-MS). The association between F2-IsoPs and AMD was examined using unconditional logistic regression models adjusted for potential confounders including smoking, body mass index (BMI), blood pressure, total and high-density lipoprotein cholesterol, and history of cardiovascular disease.
   RESULTS. Higher levels of F2-IsoPs were associated with AMD independent of potential confounders. Compared to quartile 1 (Q1) of F2-IsoPs, the multivariable odds ratio (95% confidence interval) of AMD in quartiles 2, 3, and 4 were 2.05 (1.26-3.32), 1.80 (1.10-2.94), and 1.76 (1.06-2.94), respectively. In subgroup analyses comparing Q4 to Q1, this association was stronger in women, those with BMI less than 25 kg/m(2) and those with hypertension, but no significant interaction was found (P interaction > 0.1 for each strata).
   CONCLUSIONS. Higher levels of urinary F2-IsoPs levels were associated with AMD independent of potential confounders in Chinese adults.
C1 [Sabanayagam, Charumathi; Abdul, Riswana Banu Binte Mohammed; Cheung, Gemmy Chui Ming; Wong, Tien Y.; Cheng, Ching-Yu; Lamoureux, Ecosse] Singapore Eye Res Inst, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
   [Sabanayagam, Charumathi; Abdul, Riswana Banu Binte Mohammed; Cheung, Gemmy Chui Ming; Wong, Tien Y.; Cheng, Ching-Yu; Lamoureux, Ecosse] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Sabanayagam, Charumathi; Cheung, Gemmy Chui Ming; Wong, Tien Y.; Cheng, Ching-Yu; Lamoureux, Ecosse] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Sabanayagam, Charumathi; Lye, Weng Kit; Cheng, Ching-Yu] Natl Univ Singapore, Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Januszewski, Andrzej] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia.
   [Kumari, Neelam] Khoo Teck Puat Hosp, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; University of Sydney
RP Sabanayagam, C (通讯作者)，Singapore Eye Res Inst, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
EM charumathi.sabanayagam@seri.com.sg
RI Januszewski, Andrzej/R-4299-2019; Cheng, Ching-Yu/Y-2229-2019;
   Lamoureux, Ecosse/Z-5482-2019; Wong, Tien Yin/AAC-9724-2020;
   Sabanayagam, Charumathi/C-1294-2011
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Sabanayagam, Charumathi/0000-0002-4042-4719; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Singapore Ministry of Health's National Medical Research Council (NMRC)
   under its Talent Development Scheme [NMRC/TA/0008/2012,
   NMRC/STaR/0003/2008]; Biomedical Research Council (BMRC)
   [08/1/35/19/550]
FX Supported by grants from the Singapore Ministry of Health's National
   Medical Research Council (NMRC) under its Talent Development Scheme
   NMRC/TA/0008/2012, NMRC/STaR/0003/2008, and Biomedical Research Council
   (BMRC), 08/1/35/19/550.
CR Barocas DA, 2011, J UROLOGY, V185, P2102, DOI 10.1016/j.juro.2011.02.020
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Danulescu R, 2012, MED-SURG J, V116, P1136
   Devaraj S, 2001, CLIN CHEM, V47, P1974
   Dohi Y, 2007, INT J CARDIOL, V115, P63, DOI 10.1016/j.ijcard.2006.04.006
   Fessel JP, 2005, ANTIOXID REDOX SIGN, V7, P202, DOI 10.1089/ars.2005.7.202
   Freigang S, 2016, EUR J IMMUNOL, V46, P1818, DOI 10.1002/eji.201545676
   Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236
   Harrison D, 2003, AM J CARDIOL, V91, p7A
   Il'yasova D, 2005, OBES RES, V13, P1638, DOI 10.1038/oby.2005.201
   IL'Yasova D, 2008, BIOMARKERS, V13, P41, DOI 10.1080/13547500701617708
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee R, 2012, CURR MED CHEM, V19, P2504, DOI 10.2174/092986712800493057
   LeLeiko RM, 2009, AM J CARDIOL, V104, P638, DOI 10.1016/j.amjcard.2009.04.047
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu W, 2009, FREE RADICAL BIO MED, V47, P1101, DOI 10.1016/j.freeradbiomed.2009.07.028
   LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1
   Milne GL, 2007, NAT PROTOC, V2, P221, DOI 10.1038/nprot.2006.375
   Milne GL, 2005, BIOMARKERS, V10, pS10, DOI 10.1080/13547500500216546
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montuschi P, 2007, CURR MED CHEM, V14, P703, DOI 10.2174/092986707780059607
   Mori TA, 1999, ANAL BIOCHEM, V268, P117, DOI 10.1006/abio.1998.3037
   Morrow JD, 2005, ARTERIOSCL THROM VAS, V25, P279, DOI 10.1161/01.ATV.0000152605.64964.c0
   Morrow JD, 2002, AM J RESP CRIT CARE, V166, pS25, DOI 10.1164/rccm.2206011
   Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1
   Musiek ES, 2005, LIPIDS, V40, P987, DOI 10.1007/s11745-005-1460-7
   Ohashi N, 2000, J CHROMATOGR B, V746, P17, DOI 10.1016/S0378-4347(00)00201-2
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449
   Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735
   Proudfoot J, 1999, ANAL BIOCHEM, V272, P209, DOI 10.1006/abio.1999.4187
   Richelle M, 1999, FEBS LETT, V459, P259, DOI 10.1016/S0014-5793(99)01259-4
   Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6
   Scholz H, 2003, CARDIOVASC RES, V59, P945, DOI 10.1016/S0008-6363(03)00538-8
   Schwedhelm E, 2004, CIRCULATION, V109, P843, DOI 10.1161/01.CIR.0000116761.93647.30
   Sciascia S, 2012, INFLAMM RES, V61, P809, DOI 10.1007/s00011-012-0468-0
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Shao B, 2009, J LIPID RES, V50, P599, DOI 10.1194/jlr.E900001-JLR200
   Shishehbor MH, 2006, FREE RADICAL BIO MED, V41, P1678, DOI 10.1016/j.freeradbiomed.2006.09.001
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Swindle EJ, 2007, IMMUNOL REV, V217, P186, DOI 10.1111/j.1600-065X.2007.00513.x
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsai IJ, 2009, FREE RADICAL BIO MED, V46, P263, DOI 10.1016/j.freeradbiomed.2008.10.028
   Vassalle C, 2003, CORONARY ARTERY DIS, V14, P213, DOI 10.1097/01.mca.0000063504.13456.c3
   WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94
   Winkler BS, 1999, MOL VIS, V5
   Wiswedel I, 2009, METHODS MOL BIOL, V580, P3, DOI 10.1007/978-1-60761-325-1_1
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 58
TC 7
Z9 7
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 5
BP 2538
EP 2543
DI 10.1167/iovs.16-21263
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3DV
UT WOS:000404591500013
PM 28492872
OA gold
DA 2022-11-30
ER

PT J
AU Jonasson, F
   Arnarsson, A
   Eiriksdottir, G
   Harris, TB
   Launer, LJ
   Meuer, SM
   Klein, BE
   Klein, R
   Gudnason, V
   Cotch, MF
AF Jonasson, Fridbert
   Arnarsson, Arsaell
   Eiriksdottir, Gudny
   Harris, Tamara B.
   Launer, Lenore J.
   Meuer, Stacy M.
   Klein, Barbara E.
   Klein, Ronald
   Gudnason, Vilmundur
   Cotch, Mary Frances
TI Prevalence of Age-related Macular Degeneration in Old Persons: Age,
   Gene/Environment Susceptibility Reykjavik Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; RACIAL-DIFFERENCES; VISUAL IMPAIRMENT; MACULOPATHY;
   BLINDNESS; POPULATION; BALTIMORE; ROTTERDAM; AUSTRALIA; RISK
AB Purpose: To describe the prevalence and signs of early and late age-related macular degeneration (AMD) in an old cohort.
   Design: Population-based cohort study.
   Participants: We included 5272 persons aged >= 66 years, randomly sampled from the Reykjavik area.
   Methods: Fundus images were taken through dilated pupils using a 45-degree digital camera and graded for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy (GA) using the modified Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Age-related macular degeneration in an elderly cohort.
   Results: The mean age of participants was 76 years. The prevalence of early AMD was 12.4% (95% confidence interval [CI], 11.0-13.9) for those aged 66 to 74 years and 36% (95% CI, 30.9-41.1) for those aged >= 85 years. The prevalence of exudative AMD was 3.3% (95% CI, 2.8-3.8). The prevalence of pure GA was 2.4% (95% CI, 2.0-2.8). The highest prevalence of late AMD was among those aged >= 85 years: 11.4% (95% CI, 8.2-14.5) for exudative AMD and 7.6% (95% CI, 4.8-10.4) for pure GA.
   Conclusions: Persons aged >= 85 years have a 10-fold higher prevalence of late AMD than those aged 70 to 74 years. The high prevalence of late AMD in the oldest age group and expected increase of elderly people in the western world in coming years call for improved preventive measures and novel treatments.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 825-830 (C) 2011 by the American Academy of Ophthalmology.
C1 [Jonasson, Fridbert; Gudnason, Vilmundur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
   [Jonasson, Fridbert] Landspitali Univ Hosp, Reykjavik, Iceland.
   [Arnarsson, Arsaell] Univ Akureyri, Akureyri, Iceland.
   [Eiriksdottir, Gudny] Iceland Heart Assoc, Kopavogur, Iceland.
   [Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
   [Meuer, Stacy M.; Klein, Barbara E.; Klein, Ronald] Univ Wisconsin, Madison, WI USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
C3 University of Iceland; Landspitali National University Hospital;
   University of Akureyri; Icelandic Heart Association; National Institutes
   of Health (NIH) - USA; NIH National Institute on Aging (NIA); University
   of Wisconsin System; University of Wisconsin Madison; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Jonasson, F (通讯作者)，Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
EM fridbert@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021; Gudnason, Vilmundur/AAE-7126-2019;
   Gudnason, Vilmundur/K-6885-2015
OI Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason,
   Vilmundur/0000-0001-5696-0084; Klein, Ronald/0000-0002-4428-6237; Cotch,
   Mary Frances/0000-0002-2046-4350
FU National Institutes of Health, National Institute on Ageing and the
   National Eye Institute [Z01-EY00401, N01-AG-1-2100]; IHA; Icelandic
   Parliament; University of Iceland; NATIONAL EYE INSTITUTE [ZIAEY000401,
   Z01EY000401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [N01AG012100, ZIAAG007380, ZIAAG007480] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (Intramural Research
   Program of the National Institute on Ageing and the National Eye
   Institute, Z01-EY00401 National Institutes of Health contract number
   N01-AG-1-2100), the IHA, the Icelandic Parliament, and the University of
   Iceland Research Fund.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Qiu CX, 2008, DIABETES, V57, P1645, DOI 10.2337/db07-1455
   Qiu CX, 2009, ANN NEUROL, V65, P569, DOI 10.1002/ana.21614
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 28
TC 71
Z9 71
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2011
VL 118
IS 5
BP 825
EP 830
DI 10.1016/j.ophtha.2010.08.044
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757MM
UT WOS:000290090300006
PM 21126770
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Harder, B
   Spandau, UH
   Kamppeter, BA
   Libondi, T
   Sauder, G
AF Jonas, J. B.
   Harder, B.
   Spandau, U. H.
   Kamppeter, B. A.
   Libondi, T.
   Sauder, G.
TI Bevacizumab for occult subfoveal neovascularization in age-related
   macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE intravitreal bevacizumab; Avastin; exudative age-related macular
   degeneration; intraocular antiangiogenesis
ID THERAPY
AB PURPOSE. To report on the treatment of exudative age-related macular degeneration by intravitreal bevacizumab (Avastin).
   METHODS. A 78-year-old patient experienced a progressive loss of visual acuity in her right eye due to an occult subfoveal neovascular membrane in age-related macular degeneration. She received an intravitreal injection of 1.5 mg bevacizumab.
   RESULTS. Within 4 weeks after the injection, visual acuity improved from 0.40 to 0.60 with complete resolution of subretinal and intraretinal leakage and edema as shown on optical coherence tomography. Pre-existing metamorphopsias disappeared. Intraocular pressure remained in the normal range. During the follow-up, there were no sings of intraocular inflammation or any other intraocular pathology induced by the intravitreal injection.
   CONCLUSIONS. Intravitreal bevacizumab may potentially be helpful in the treatment of exudative age-related macular degeneration and may deserve further evaluation.
C1 Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 5
TC 8
Z9 11
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2006
VL 16
IS 5
BP 774
EP 775
DI 10.1177/112067210601600522
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117TJ
UT WOS:000242895900024
PM 17061237
DA 2022-11-30
ER

PT J
AU Papavasileiou, E
   Steel, DHW
   Liazos, E
   McHugh, D
   Jackson, TL
AF Papavasileiou, Evangelia
   Steel, David H. W.
   Liazos, Efstathios
   McHugh, Dominic
   Jackson, Timothy L.
TI INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR, PERFLUOROPROPANE (C3F8), AND
   RANIBIZUMAB OR PHOTODYNAMIC THERAPY FOR SUBMACULAR HEMORRHAGE SECONDARY
   TO WET AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE gas tamponade; idiopathic polypoidal choroidal vasculopathy; neovascular
   age-related macular degeneration; submacular hemorrhage; tissue
   plasminogen activator
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PNEUMATIC DISPLACEMENT; SUBRETINAL
   HEMORRHAGE; SURGICAL-MANAGEMENT; ASSISTED REMOVAL; RETINAL TOXICITY; GAS
   INJECTION; TPA; FIBRINOLYSIS; BEVACIZUMAB
AB Purpose: To report a combined intravitreal treatment for submacular hemorrhage.
   Methods: This retrospective, noncomparative, interventional case series included 7 patients with neovascular age-related macular degeneration and 2 with idiopathic polypoidal choroidal vasculopathy, presenting with fovea-involving submacular hemorrhage >= 4 disk areas in size, of <10 days of duration. All patients received a single 0.05-mL intravitreal injection of 50 mu g alteplase, 0.3 mL of 100% C3F8, and facedown positioning for 1 week. Patients with newly diagnosed age-related macular degeneration received 3 consecutive monthly intravitreal injections of 0.5 mg ranibizumab, followed by monthly retreatment as needed. Those with idiopathic polypoidal choroidal vasculopathy were treated with photodynamic therapy.
   Results: Mean (+/-SD) logarithm of the minimum angle of resolution visual acuity improved from 0.75 +/- 0.35 at presentation to 0.35 +/- 0.30 at a mean final follow-up of 15.1 months (P = 0.0078). Median Snellen acuity improved from 20/200 to 20/32. Visual acuity was stable in one case and improved in eight. The average size of submacular hemorrhage was 6.8 disk areas at presentation, reducing to 2.6 within 1 month (P = 0.0039). Subfoveal hemorrhage was displaced in all cases within 9 weeks. The mean pretreatment central retinal thickness of 669 mu m reduced to 528 mu m (P = 0.0039). One case developed transiently elevated intraocular pressure. Two developed breakthrough vitreous hemorrhage. No adverse events were attributed to tissue plasminogen activator.
   Conclusion: Tissue plasminogen activator and C3F8, combined with intravitreal ranibizumab or photodynamic therapy, may result in anatomical clearance of submacular hemorrhage and improved visual acuity, in a condition with an otherwise poor visual prognosis. RETINA 33:846-853, 2013
C1 [Papavasileiou, Evangelia; Liazos, Efstathios; McHugh, Dominic] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
   [Steel, David H. W.] Sunderland Eye Infirm, Sunderland, England.
   [Jackson, Timothy L.] Kings Coll London, Sch Med, London WC2R 2LS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
RI Steel, David H W/I-8053-2015
OI Steel, David H W/0000-0001-8734-3089; Jackson,
   Timothy/0000-0001-7618-1555
CR Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chaudhry NA, 1999, OPHTHALMIC SURG LAS, V30, P176
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Chen SN, 2001, RETINA-J RET VIT DIS, V21, P460, DOI 10.1097/00006982-200110000-00007
   Chung J, 2008, OPHTHAL SURG LAS IM, V39, P114, DOI 10.3928/15428877-20080301-06
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   CRITTENDEN JJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P831, DOI 10.1001/archopht.1985.01050060091032
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hattenbach LO, 1999, RETINA-J RET VIT DIS, V19, P383, DOI 10.1097/00006982-199909000-00003
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Holland D, 2004, OPHTHALMOLOGICA, V218, P64, DOI 10.1159/000074569
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   JOHNSON RN, 1989, ARCH OPHTHALMOL-CHIC, V107, P891, DOI 10.1001/archopht.1989.01070010913040
   JOHNSON RN, 1988, OPHTHALMOLOGY, V95, P592
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   KIMURA AE, 1994, RETINA-J RET VIT DIS, V14, P83, DOI 10.1097/00006982-199401000-00018
   LAMBROU FH, 1987, AM J OPHTHALMOL, V104, P619, DOI 10.1016/0002-9394(87)90175-9
   LAMBROU FH, 1987, ARCH OPHTHALMOL-CHIC, V105, P995
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   LINCOFF H, 1980, ARCH OPHTHALMOL-CHIC, V98, P1610
   Lincoff H, 2001, RETINA-J RET VIT DIS, V21, P191, DOI 10.1097/00006982-200104000-00021
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Mahesh Gopalakrishnan, 2003, Indian Journal of Ophthalmology, V51, P349
   MANNING LM, 1994, AUST NZ J OPHTHALMOL, V22, P59, DOI 10.1111/j.1442-9071.1994.tb01697.x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matt G, 2010, KLIN MONATSBL AUGENH, V227, P221, DOI 10.1055/s-0028-1109750
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Min W K, 1990, Korean J Ophthalmol, V4, P58
   Min W K, 1990, Korean J Ophthalmol, V4, P12
   Min W K, 1994, Korean J Ophthalmol, V8, P45
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   SALONEN EM, 1985, J BIOL CHEM, V260, P2302
   Sawada Kosaku, 2008, Nippon Ganka Gakkai Zasshi, V112, P382
   Serracarbassa PD, 2009, ARQ BRAS OFTALMOL, V72, P403, DOI 10.1590/S0004-27492009000300026
   SNYDER RW, 1987, ARCH OPHTHALMOL-CHIC, V105, P1277, DOI 10.1001/archopht.1987.01060090135044
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   TOTH CA, 1992, AM J OPHTHALMOL, V113, P175, DOI 10.1016/S0002-9394(14)71530-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
   Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 58
TC 19
Z9 19
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 846
EP 853
DI 10.1097/IAE.0b013e318271f278
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900024
PM 23400079
DA 2022-11-30
ER

PT J
AU Smith, BT
   Joseph, DP
   Grand, MG
AF Smith, Bradley T.
   Joseph, Daniel P.
   Grand, M. Gilbert
TI Treatment of neovascular age-related macular degeneration: past, present
   and future directions
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE avastin; choroidal neovascularization; lucentis; macular degeneration;
   optical coherence tomography; vascular endothelial growth factor
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; INTRAVITREAL
   INJECTION; VERTEPORFIN; BEVACIZUMAB; RANIBIZUMAB
AB Purpose of review
   The treatment options of choroidal neovascularization due to age-related macular degeneration have expanded. Prior to ocular photodynamic therapy the only available treatment was laser photocoagulation. Clinicians and patients were not particularly enthusiastic despite its ability to stabilize vision. The purpose of the review is to review the past and current concepts of neovascular age-related macular degeneration therapy and to provide a short overview of upcoming treatments.
   Recent findings
   Photodynamic therapy provided us with the first realistic means to address subfoveal choroidal neovascularization lesions from age-related macular degeneration. Antivascular endothelial growth factors now allow better visual outcomes than mere stabilization of vision and other promising treatments are undergoing study at this time.
   Summary
   Age-related macular degeneration therapy has undergone a significant revolution in recent years. Understanding the historical perspective of treatment provides a better appreciation of current therapies. Still there is no cure for this disease and more promising treatments are currently under investigation.
C1 Washington Univ, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, St Louis, MO 63130 USA.
C3 Washington University (WUSTL)
RP Smith, BT (通讯作者)，Washington Univ, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, 4921 Parkview Pl,Suite 12B, St Louis, MO 63130 USA.
EM smithbradleythomas@Msn.com
RI Smith, Bradley/ABB-2596-2021
OI Smith, Bradley/0000-0002-9456-5429
CR *AM SOC RET SPEC, 2006, PREF TRENDS SURV
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BROWN D, 2006, PIER STUDY PRESENTAT
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LALWANI G, 2006, ARVO ANN M 1 MAY 200
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
NR 26
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2007
VL 18
IS 3
BP 240
EP 244
DI 10.1097/ICU.0b013e32810c8e05
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162BL
UT WOS:000246061200011
PM 17435433
DA 2022-11-30
ER

PT J
AU Zhu, ZT
   Liao, H
   Wang, W
   Scheetz, J
   Zhang, J
   He, MG
AF Zhu, Zhuoting
   Liao, Huan
   Wang, Wei
   Scheetz, Jane
   Zhang, Jian
   He, Mingguang
TI Association between age-related macular degeneration and subjective
   cognitive complaints
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MEMORY COMPLAINTS; ALZHEIMERS-DISEASE; NATIONAL-HEALTH; UNITED-STATES;
   OLDER-PEOPLE; EYE DISEASE; IMPAIRMENT; DEMENTIA; RISK; POPULATION
AB Purpose To investigate the association between age-related macular degeneration (AMD) and subjective cognitive complaints (SCCs) in the USA.
   Methods A total of 5604 participants aged 40 years and older from the 2005-2008 National Health and Nutrition Examination Survey were included. Retinal photography was graded into no AMD, early and late AMD based on the modification of the Wisconsin Age-Related Maculopathy Grading System. SCCs were based on the self-reported difficulty in remembering or confusion. Sample weights were used to generate nationally representative data. Multivariate regression analyses were used to assess the association between AMD severity and SCCs, controlling for potential confounders.
   Results Participants with any AMD had higher prevalence of SCCs relative to participants without AMD (6.8% vs 13.6%, p<0.001). After adjusting for potential confounding factors, presence of any AMD was significantly associated with 1.62-fold higher odds of having SCCs (95% CI 1.16 to 2.27, p=0.007). Similarly, participants with early (OR 1.58; 95% CI 1.14 to 2.17, p=0.007) and late AMD (OR 2.02; 95% CI 1.08 to 3.79, p=0.030) were also associated with elevated odds of reporting SCCs after controlling for confounders.
   Conclusions We found significant associations between AMD severity and SCCs in this US population. More attention should be paid on the subjective memory function and potential risk of cognitive decline among patients with AMD.
C1 [Zhu, Zhuoting; Wang, Wei; Zhang, Jian; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
   [Liao, Huan] Univ Bonn, Inst Reconstruct Neurobiol, Neural Regenerat Grp, Bonn, Germany.
   [Scheetz, Jane] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
C3 Sun Yat Sen University; University of Bonn; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne
RP He, MG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
EM mingguanghe@gmail.com
RI Wang, Wei/J-4000-2016
OI Wang, Wei/0000-0002-5273-3332; He, Mingguang/0000-0002-6912-2810
FU Fundamental Research Funds of the State Key Laboratory in Ophthalmology;
   University of Melbourne at Research Accelerator Program; Centre for Eye
   Research Australia
FX The present work was supported by Fundamental Research Funds of the
   State Key Laboratory in Ophthalmology. MH receives support from the
   University of Melbourne at Research Accelerator Program and the Centre
   for Eye Research Australia receives Operational Infrastructure Support
   from the Victorian state government.
CR Atkinson RC., 1968, PSYCHOL LEARNING MOT, V2, P89, DOI DOI 10.1016/S0079-7421(08)60422-3
   Benito-Leon J, 2010, J ALZHEIMERS DIS, V22, P159, DOI 10.3233/JAD-2010-100972
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Crous-Bou M, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0297-z
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   DuGoff EH, 2014, HEALTH SERV RES, V49, P284, DOI 10.1111/1475-6773.12090
   Geerlings MI, 1999, AM J PSYCHIAT, V156, P531
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Halahakoon DC, 2019, JAMA PSYCHIAT, V76, P239, DOI 10.1001/jamapsychiatry.2018.3631
   Harrabi H, 2015, INVEST OPHTH VIS SCI, V56, P1217, DOI 10.1167/iovs.14-15370
   Jackson GR, 2003, NEUROL CLIN, V21, P709, DOI 10.1016/S0733-8619(02)00107-X
   Jean-Pierre P, 2015, SLEEP MED, V16, P845, DOI 10.1016/j.sleep.2015.02.531
   Jessen F, 2007, PSYCHOL MED, V37, P1753, DOI 10.1017/S0033291707001122
   Jessen F, 2014, ALZHEIMERS DEMENT, V10, P844, DOI 10.1016/j.jalz.2014.01.001
   Jessen F, 2014, ALZHEIMERS DEMENT, V10, P76, DOI 10.1016/j.jalz.2012.09.017
   Jessen F, 2010, ARCH GEN PSYCHIAT, V67, P414, DOI 10.1001/archgenpsychiatry.2010.30
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5
   Jorm AF, 2004, NEUROLOGY, V63, P1960, DOI 10.1212/01.WNL.0000144348.70643.F2
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kelley BJ, 2007, NEUROL CLIN, V25, P577, DOI 10.1016/j.ncl.2007.03.008
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kryscio RJ, 2014, NEUROLOGY, V83, P1359, DOI 10.1212/WNL.0000000000000856
   Lee PL, 2014, SCAND J PSYCHOL, V55, P136, DOI 10.1111/sjop.12107
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mitchell AJ, 2014, ACTA PSYCHIAT SCAND, V130, P439, DOI 10.1111/acps.12336
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Peter J, 2014, ALZHEIMERS DEMENT, V10, P99, DOI 10.1016/j.jalz.2013.05.1764
   Reid LM, 2006, DEMENT GERIATR COGN, V22, P471, DOI 10.1159/000096295
   Reisberg B, 2008, INT PSYCHOGERIATR, V20, P1, DOI 10.1017/S1041610207006412
   Reisberg B, 2008, ALZHEIMERS DEMENT, V4, pS98, DOI 10.1016/j.jalz.2007.11.017
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Sajjad A, 2015, STROKE, V46, P170, DOI 10.1161/STROKEAHA.114.006616
   Schultz Stephanie A, 2015, Alzheimers Dement (Amst), V1, P33
   Shim RS, 2011, J AM BOARD FAM MED, V24, P33, DOI 10.3122/jabfm.2011.01.100121
   Tepest R, 2008, DEMENT GERIATR COGN, V26, P323, DOI 10.1159/000161057
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   UN Department of Economic and Social Affairs Population Division, 2017, WORLD POP AG 2017
   van der Flier WM, 2004, J NEUROL, V251, P671, DOI 10.1007/s00415-004-0390-7
   Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252
   Wang WY, 2016, INT J HYG ENVIR HEAL, V219, P850, DOI 10.1016/j.ijheh.2016.07.012
   Wennberg AMV, 2017, SEMIN NEUROL, V37, P395, DOI 10.1055/s-0037-1604351
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Willis JR, 2017, JAMA OPHTHALMOL, V135, P926, DOI 10.1001/jamaophthalmol.2017.2553
   Wilson RS, 2009, NEUROLOGY, V72, P460, DOI 10.1212/01.wnl.0000341782.71418.6c
   Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wooldridge JM, 2007, J ECONOMETRICS, V141, P1281, DOI 10.1016/j.jeconom.2007.02.002
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zheng DD, 2018, JAMA OPHTHALMOL, V136, P989, DOI 10.1001/jamaophthalmol.2018.2493
NR 62
TC 2
Z9 2
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2020
VL 104
IS 9
BP 1228
EP 1233
DI 10.1136/bjophthalmol-2019-314853
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA PI3IA
UT WOS:000600986900009
PM 31801734
DA 2022-11-30
ER

PT J
AU Xu, LA
   Wang, SA
   Li, YB
   Jonas, JB
AF Xu, Liang
   Wang, Shuang
   Li, Yibin
   Jonas, Jost B.
TI Retinal vascular abnormalities and prevalence of age-related macular
   degeneration in adult Chinese: The Beijing eye study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; RISK
AB PURPOSE: To evaluate whether retinal vessel abnormalities are associated with early or late age-related macular degeneration (AMD) in adult Chinese.
   DESIGN: Population-based prevalence study.
   METHODS: The Beijing Eye Study included 4439 (83.4%) subjects of 5324 living in a rural area or urban region of Greater Beijing, age older than 40+ years, and invited to participate. The participants underwent a detailed ophthalmic examination, including fundus photography. The photographs were graded using the Wisconsin Age-Related Maculopathy Grading system for evaluation of AMD, and using the Atherosclerosis Risk in Communities protocol for assessment of retinal vascular abnormalities. We examined focal and generalized arteriolar narrowing, arteriolar sheathing, and arteriovenous crossing abnormalities.
   RESULTS: Fundus photographs were available for 8655 eyes of 4376 (98.6%) subjects. Neither early nor late AMD was significantly (P > .15) associated with any of the retinal vascular abnormalities.
   CONCLUSIONS: Retinal vascular abnormalities are not markedly associated with the prevalence of early or late AMD.
C1 Univ Heidelberg, Augenklin, Fac Clin Med, Dept Ophthalmol, D-68167 Mannheim, Germany.
   Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   Capital Univ Med Sci, Beijing, Peoples R China.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Capital Medical University
RP Jonas, JB (通讯作者)，Univ Heidelberg, Augenklin, Fac Clin Med, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   IKRAM MK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
NR 7
TC 20
Z9 27
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2006
VL 142
IS 4
BP 688
EP 689
DI 10.1016/j.ajo.2006.05.028
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092LS
UT WOS:000241098900029
PM 17011870
DA 2022-11-30
ER

PT J
AU Wang, GF
AF Wang, Gaofeng
TI Chromosome 10q26 locus and age-related macular degeneration: A progress
   update
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE age-related macular degeneration; PLEKHA1; ARMS2; HTRA1; single
   nucleotide polymorphism; indel; gene annotation; promoter; transcript
   splice variants
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; HTRA1 PROMOTER
   POLYMORPHISM; SERINE-PROTEASE; MESSENGER-RNA; RISK-FACTORS;
   SUSCEPTIBILITY GENES; COMMON VARIANTS; RHESUS-MONKEYS; ARMS2
AB Age-related macular degeneration (AMD) is the leading cause of late-onset central vision loss in developed countries. Both genetic and environmental factors contribute to the onset of AMD. Variation at a locus on chromosome 10q26 has been consistently associated with this disease and represents one of the two strongest genetic effects being identified in AMD. At least three genes are located within the bounds of the locus: pleckstrin homology domain containing family A member 1 (PLEKHA1) age-related maculopathy susceptibility 2 (ARMS2) and high-temperature requirement A serine peptidase 1 (HTRA1) all of which are associated with AMD. Due to the strong linkage disequilibrium (LD) across this region statistical genetic analysis alone is incapable of distinguishing the effect of an individual gene in the locus. Uncertainty remains however in regards to which gene is responsible for the linkage and association of the locus with AMD. Investigating functional consequences of the associated variants and related genes tends to be essential to identifying the biologically responsible gene(s) underlying AMD. This review examines the recent progress and current uncertainty on the genetic and functional analyses of the 10q26 locus in AMD with a focus on ARMS2 and HTRAl. A discussion which entails the possible multi-faceted approaches for pinpointing the gene(s) in the locus underlying the pathogenesis of AMD is also included. (c) 2013 Elsevier Ltd. All rights reserved.
C1 Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Dr John T Macdonald Fdn,Dept Human Genet, Miami, FL 33136 USA.
C3 University of Miami
RP Wang, GF (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Dr John T Macdonald Fdn,Dept Human Genet, 1501 NW 10th Ave,BRB 525,M860, Miami, FL 33136 USA.
EM gwang@med.miami.edu
FU Bright Focus Foundation grant [M-2012048]; James & Esther King
   Biomedical Research award [3KN08]
FX I thank Jonathan Haines, William Scott and Margaret Pericak Vance for
   feedback on early versions of this review. I also thank Kevin Dickson,
   Emily Minor and Lili Tewes for assistance. This study was supported by a
   Bright Focus Foundation grant (M-2012048) and a James & Esther King
   Biomedical Research award (3KN08).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Ashurst JL, 2003, ANNU REV GENOM HUM G, V4, P69, DOI 10.1146/annurev.genom.4.070802.110300
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bolognani F, 2008, J NEUROSCI RES, V86, P481, DOI 10.1002/jnr.21473
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Chowers I, 2008, MOL VIS, V14, P2263
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Harrington JJ, 2001, NAT BIOTECHNOL, V19, P440, DOI 10.1038/88107
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Lavner Y, 2005, GENE, V345, P127, DOI 10.1016/j.gene.2004.11.035
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Minor EA, 2013, INVEST OPHTH VIS SCI, V54, P5913, DOI 10.1167/iovs.13-12273
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Szafranski K, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r154
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2013, JAMA OPHTHALMOL, V131, P804, DOI 10.1001/jamaophthalmol.2013.589
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weger M, 2007, MOL VIS, V13, P1274
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 78
TC 18
Z9 18
U1 0
U2 27
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2014
VL 119
BP 1
EP 7
DI 10.1016/j.exer.2013.11.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 304LH
UT WOS:000330747900001
PM 24291204
DA 2022-11-30
ER

PT J
AU Reynders, S
   Lafaut, BA
   Aisenbrey, S
   Vanden Broecke, C
   Lucke, K
   Walter, P
   Kirchhof, B
   Bartz-Schmidt, KU
AF Reynders, S
   Lafaut, BA
   Aisenbrey, S
   Vanden Broecke, C
   Lucke, K
   Walter, P
   Kirchhof, B
   Bartz-Schmidt, KU
TI Clinicopathologic correlation in hemorrhagic age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; TISSUE-PLASMINOGEN ACTIVATOR;
   INDOCYANINE GREEN ANGIOGRAPHY; EXPERIMENTAL SUBRETINAL HEMORRHAGE;
   RETINAL-PIGMENT EPITHELIUM; PARS-PLANA VITRECTOMY; SUBMACULAR
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; SURGICAL DRAINAGE; NATURAL-HISTORY
AB Purpose: To analyze and compare the histopathology of surgically extracted membranes in hemorrhagic age-related macular degeneration (AMD) versus extracted classic, mixed and occult choroidal neovascularization (CNV) in AMD. Methods: Thirty consecutive membranes, surgically removed in hemorrhagic AMD, were analyzed and compared with consecutive series of 50 classic, 20 mixed and 20 occult membrane specimens in exudative AMD. The specimens were serially sectioned and stained in a stepped fashion with hematoxylin-eosin, Masson trichrome and periodic acid-Schiff stain. Results: Diffuse drusen were observed in all hemorrhagic AMD specimens, fibrovascular tissue was found in 29 of 30 specimens which was located subretinally in 11 specimens and/or in Bruch's membrane in 28 specimens. A hemorrhage was located subretinally in 21 specimens, in the stroma of the fibrovascular tissue in 17 specimens, at the choroidal side of the diffuse drusen adjacent to fibrovascular tissue in 13 specimens and at the choroidal side of the fibrovascular tissue in Bruch's membrane in 8 specimens. Grossly dilated thin-walled vessels were identified in one hemorrhagic AMD case, suggestive of polypoidal choroidal vasculopathy. Scarred tears of the retinal pigment epithelium were identified in two specimens. Conclusion: A large spectrum of histo-architectural lesions is recognized in hemorrhagic maculopathy. Hemorrhages do not only characteristically appear in the subretinal space or in the stroma of the neovascular tissue but also at the choroidal side of the diffuse drusen adjacent to the neovascular complex and at the choroidal side of the intra-Bruch's fibrovascular tissue.
C1 State Univ Ghent Hosp, Dept Pathol, B-9000 Ghent, Belgium.
   Dept Ophthalmol, B-8000 Brugge, Belgium.
   Univ Eye Hosp, Cologne, Germany.
   Hosp Eye, Bremen, Germany.
   Univ Tubingen Hosp, Dept Ophthalmol, Tubingen, Germany.
C3 Ghent University; Ghent University Hospital; University of Cologne;
   Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Lafaut, BA (通讯作者)，State Univ Ghent Hosp, Dept Pathol, B-9000 Ghent, Belgium.
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2001, GRAEF ARCH CLIN EXP, V239, P5, DOI 10.1007/s004170000224
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lauer AK, 2000, RETINA-J RET VIT DIS, V20, P492, DOI 10.1097/00006982-200009000-00010
   Lee BL, 1996, RETINA-J RET VIT DIS, V16, P64, DOI 10.1097/00006982-199616010-00011
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 44
TC 13
Z9 13
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2002
VL 240
IS 4
BP 279
EP 285
DI 10.1007/s00417-002-0448-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552GV
UT WOS:000175612300005
PM 11981641
DA 2022-11-30
ER

PT J
AU Davis, SJ
   Lauer, AK
   Flaxel, CJ
AF Davis, Stephen J.
   Lauer, Andreas K.
   Flaxel, Christina J.
TI POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INTRAVITREAL BEVACIZUMAB; JAPANESE PATIENTS; RANIBIZUMAB;
   EFFICACY; VERTEPORFIN
AB Purpose: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV).
   Methods: This is a retrospective chart review of 27 patients at a single center with PCV.
   Results: The mean age was 74.3 with 48% being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59%, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86%. The vision improved in 41% with 36% maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy.
   Conclusion: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67% and vision was found to be improved or maintained in 77% of patients.
C1 [Davis, Stephen J.; Lauer, Andreas K.; Flaxel, Christina J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Flaxel, CJ (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM flaxelc@ohsu.edu
FU Research to Prevent Blindness
FX Supported in part by an unrestricted grant from the Research to Prevent
   Blindness.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   LOZANORECHY D, 1993, AM J OPHTHALMOL, V116, P140, DOI 10.1016/S0002-9394(14)71277-2
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 31
TC 23
Z9 23
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2014
VL 34
IS 11
BP 2185
EP 2191
DI 10.1097/IAE.0000000000000206
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0DK
UT WOS:000344607100011
PM 24978430
DA 2022-11-30
ER

PT J
AU Jonasson, F
   Arnarsson, A
   Peto, T
   Sasaki, H
   Sasaki, K
   Bird, AC
AF Jonasson, F
   Arnarsson, A
   Peto, T
   Sasaki, H
   Sasaki, K
   Bird, AC
TI 5-year incidence of age-related maculopathy in the reykjavik eye study
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BLUE MOUNTAINS EYE; MACULAR DEGENERATION;
   FOLLOW-UP; GRADING SYSTEM; PREVALENCE; DRUSEN; PROGRESSION; ICELAND;
   RISK
AB Purpose: To examine the age- and gender-specific 5-year incidence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) in citizens of Reykjavik.
   Design: Population-based, prospective cohort study.
   Participants: The cohort was a population-based random sample of citizens 50 years and older. Of 1379 eligible subjects, 1045 had a baseline examination in 1996; 846 of the 958 survivors (88.2%) had a 5-year follow-up examination in 2001.
   Methods: The incidence of various characteristics of drusen and pigmentary changes that are typical of ARM were determined using the international classification and grading system for ARM and AMD.
   Main Outcome Measures: Early ARM and AMD were assessed by masked grading of stereo fundus photographs.
   Results: Hypopigmentation developed at 5 years in 10.7% of people 50 to 59 years of age (95% confidence interval [CI], 6.9-14.4) and in 25.7% those 70 to 79 years of age (95% Cl, 18.4-33.0) at baseline. Age-related macular degeneration developed in no one who was 50 to 59 years of age at baseline. Geographic atrophy (GA) developed in 4.6% (95% Cl, 1.2-7.9) and exudative AMD in none of those who were 70 years and older at baseline.
   Conclusions: Geographic atrophy is the predominant type of AMD in Iceland, and the ratio of GA to neovascular AMD is higher than in racially similar populations. (C) 2005 by the American Academy of Ophthalmology.
C1 Univ Iceland, Dept Ophthalmol, Univ Eye Dept, Reykjavik, Iceland.
   Moorfields Eye Hosp, London, England.
   Kanazawa Med Univ, Uchinada, Ishikawa 92002, Japan.
C3 Landspitali National University Hospital; University of Iceland;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Kanazawa Medical University
RP Jonasson, F (通讯作者)，Univ Iceland, Dept Ophthalmol, Univ Eye Dept, Landspitalinn 101, Reykjavik, Iceland.
EM fridbert@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021; Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   DANIELSEN R, 1982, ACTA MED SCAND, V212, P277
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2003, EYE, V17, P747, DOI 10.1038/sj.eye.6700374
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   KATZ ML, 1992, EXP EYE RES, V54, P239, DOI 10.1016/S0014-4835(05)80213-1
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kristinsson JK, 1997, ACTA OPHTHALMOL SCAN, V75, P249
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   *SPSS INC, 2000, SPSS COMP PROGR VERS
   *STATA CORP, 2000, STATA COMP PROGR VER
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 29
TC 41
Z9 42
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2005
VL 112
IS 1
BP 132
EP 138
DI 10.1016/j.ophtha.2004.07.020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886QG
UT WOS:000226242800023
PM 15629833
DA 2022-11-30
ER

PT J
AU Matsumiya, W
   Honda, S
   Yanagisawa, S
   Miki, A
   Nagai, T
   Tsukahara, Y
AF Matsumiya, Wataru
   Honda, Shigeru
   Yanagisawa, Suiho
   Miki, Akiko
   Nagai, Takayuki
   Tsukahara, Yasutomo
TI Evaluation of clinical and genetic indicators for the early response to
   intravitreal ranibizumab in exudative age-related macular degeneration
SO PHARMACOGENOMICS
LA English
DT Article
DE 3 months results; age-related macular degeneration; age-related
   maculopathy susceptibility 2; anatomical outcome; complement factor H;
   ranibizumab; single nucleotide polymorphism
ID COMPLEMENT FACTOR-H; ASSOCIATION; RISK; DISEASE; VEGF; PHARMACOGENETICS;
   POLYMORPHISMS; GENOTYPES; OUTCOMES; THERAPY
AB Aim: This study was conducted to evaluate the possible clinical and genetic indicators for an early response to intravitreal ranibizumab (IVR) in exudative age-related macular degeneration (AMD). Patients & methods: The records of 120 eyes from 120 Japanese patients with treatment-naive exudative AMD were retrospectively reviewed. Three consecutive IVR treatments were performed every month. Achievement of anatomical resolution was evaluated by ophthalmoscopy and optical coherence tomography. Multivariable logistic regression ana-lysis was conducted by analyzing SNPs in the ARMS2 locus (A69S) and in the CFH gene (I62V and Y402H), in addition to clinical factors. Results: The mean central retinal thickness of overall patients was significantly decreased (-120.1 +/- 122.8 mu m, p = 2.7 x 10(-19)) at 3 months after the initial treatment. In the logistic regression ana-lysis, the poor anatomical resolution of the lesion at 3 months was associated with the combination of CFH I62V + CFH Y402H variants (p = 0.0021), and the polypoidal choroidal vasculopathy lesions (p = 0.044). Conclusion: The CFH variants and the polypoidal choroidal vasculopathy lesion may influence the early anatomical resolution with IVR in exudative AMD.
C1 [Matsumiya, Wataru; Honda, Shigeru; Yanagisawa, Suiho; Miki, Akiko; Nagai, Takayuki; Tsukahara, Yasutomo] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S Honda), and
   by a grant from the Takeda Science Foundation, Osaka, Japan (S Honda).
   The funding organization had no role in the design or conduct of this
   research. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang W, 2013, MOL VIS, V19, P702
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 34
TC 13
Z9 13
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD APR
PY 2014
VL 15
IS 6
BP 833
EP 843
DI 10.2217/PGS.14.51
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AI9BC
UT WOS:000337220200019
PM 24897289
DA 2022-11-30
ER

PT J
AU Kravitz, D
   Gariano, RF
AF Kravitz, Daniel
   Gariano, Ray F.
TI Current Trends in Age-Related Macular Degeneration
SO POSTGRADUATE MEDICINE
LA English
DT Article
DE age-related macular degeneration; retina; prevention; treatment
ID INTRAVITREAL BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY;
   NEOVASCULARIZATION; VERTEPORFIN; SMOKING; TRIAL
AB Age-related macular degeneration is the leading cause of irreversible blindness in older persons of the developed world. Addressing treatable risk factors reduces the incidence and progression of this condition. Recent advances in understanding and treating macular degeneration have dramatically improved the visual prognosis.
C1 [Kravitz, Daniel; Gariano, Ray F.] Stanford Univ, Sch Med, Dept Ophthalmol, Palo Alto, CA 94305 USA.
C3 Stanford University
RP Gariano, RF (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Rm A157,300 Pasteur Dr, Palo Alto, CA 94305 USA.
EM rgariano@stanford.edu
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scholl HPN, 2007, MOL VIS, V13, P196
   SEDDON J, 2006, RETINA, V2, P1017
   Singh Rishi, 2007, International Ophthalmology Clinics, V47, P65, DOI 10.1097/IIO.0b013e31802bd6b3
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
NR 26
TC 0
Z9 0
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD JAN
PY 2009
VL 121
IS 1
BP 136
EP 140
DI 10.3810/pgm.2009.01.1963
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 399ML
UT WOS:000262803900014
PM 19179822
DA 2022-11-30
ER

PT J
AU Kniggendorf, V
   Dreyfuss, JL
   Regatieri, CV
AF Kniggendorf, Vinicius
   Dreyfuss, Juliana L.
   Regatieri, Caio, V
TI Age-related macular degeneration: a review of current therapies and new
   treatments
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Review
DE Macular degeneration; Angiogenesis inhibitors; Drug therapy; Choroidal
   neovascularization; Vascular endothelial growth factor A
ID ENDOTHELIAL GROWTH-FACTOR; ANKYRIN REPEAT PROTEIN; VEGF-TRAP; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL INJECTION; VISUAL IMPAIRMENT; EYE
   DISEASE; STEM-CELLS; RANIBIZUMAB; AFLIBERCEPT
AB Age-related macular degeneration is the leading cause of vision loss in elderly individuals, as well as a medical and socio-economic challenge. The treatment of dry age-related macular degeneration is based on vitamin supplementation. New treatment studies are focused on preventing the progression of degeneration and repopulating the atrophic macula. Recently, research on the treatment of neovascular age-related macular degeneration experienced a breakthrough with the advent of anti-vascular endothelial growth factor inhibitors. Nevertheless, despite the fact that ranibizumab, aflibercept, and bevacizumab are effective in reducing severe visual impairment, patients usually lose some vision over time. Therefore, the search for new therapies and diagnostic methods is fundamentally important. Current studies are focused on new anti-vascular endothelial growth factor drugs, nucleoside reverse transcriptase inhibitors, antibody against sphingosine-1-phosphate, anti-platelet-derived growth factor, gene therapy, and RNA interference. The results of ongoing clinical studies may improve the therapy of age-related macular degeneration.
C1 [Kniggendorf, Vinicius; Regatieri, Caio, V] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Dreyfuss, Juliana L.; Regatieri, Caio, V] Univ Fed Sao Paulo, Dept Biochem, Mol Biol Div, Escola Paulista Med, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP Kniggendorf, V (通讯作者)，Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Escola Paulista Med, Sao Paulo, SP, Brazil.
EM vinicius_kdorf@yahoo.com.br
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   de Oliveira AL, 2016, REV PORT INVESTIG CO, V2, P3
   Dias JRD, 2019, RETINA-J RET VIT DIS, V39, P648, DOI 10.1097/IAE.0000000000002001
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Garcia JM, 2015, WORLD J STEM CELLS, V7, P160, DOI 10.4252/wjsc.v7.i1.160
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain RK, 2003, CANCER CELL, V3, P515, DOI 10.1016/S1535-6108(03)00138-7
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Le KN, 2015, J PHARMACOL EXP THER, V355, P288, DOI 10.1124/jpet.115.227223
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Brien N, 2009, J LIPID RES, V50, P2245, DOI 10.1194/jlr.M900048-JLR200
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Philippidis A, 2014, HUM GENE THER, V25, P482, DOI 10.1089/hum.2014.2526
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Rodrigues GA, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2554-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Saoji K, 2018, INDIAN J OPHTHALMOL, V66, P252, DOI 10.4103/ijo.IJO_969_16
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P805, DOI 10.1136/bjophthalmol-2018-312453
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Tamaskovic R, 2012, METHOD ENZYMOL, V503, P101, DOI 10.1016/B978-0-12-396962-0.00005-7
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Vadlapudi Aswani Dutt, 2012, Recent Pat Biomed Eng, V5, P83
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
NR 98
TC 6
Z9 6
U1 0
U2 3
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2020
VL 83
IS 6
BP 552
EP 561
DI 10.5935/0004-2749.20200082
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PU0DG
UT WOS:000608977600016
PM 32785436
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Lee, TG
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Lee, Tae Gon
   Kim, Chul Gu
   Lee, Dong Won
TI Radiating hemorrhage in exudative age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Hemorrhage; Radiating hemorrhage; Choroidal neovascularization;
   Age-related macular degeneration; Polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; TISSUE-PLASMINOGEN ACTIVATOR;
   SUBRETINAL DRUSENOID DEPOSITS; THICK SUBMACULAR HEMORRHAGE; ENDOTHELIAL
   GROWTH-FACTOR; PNEUMATIC DISPLACEMENT; PHOTODYNAMIC THERAPY; VISUAL
   PROGNOSIS; RANIBIZUMAB; VERTEPORFIN
AB To investigate the characteristics of radiating hemorrhage secondary to exudative age-related macular degeneration (AMD) and its clinical significance.
   This retrospective, observational case series included 288 eyes of 288 patients who initially presented with submacular hemorrhage secondary to exudative AMD. First, we estimated the incidence of radiating hemorrhage; we then compared the incidence of polypoidal choroidal vasculopathy (PCV) compared with that of the other subtypes of AMD. Optical coherence tomography (OCT) images were analyzed to identify the level of hemorrhage. The extent of submacular hemorrhage was compared between eyes with and without radiating hemorrhage.
   Radiating hemorrhage was identified in 41 eyes (14.2 %). In 36 of these eyes, the OCT scanning line included the area of radiating hemorrhage. In 31 of these, OCT showed avulsion of the outer retinal layers, including the outer nuclear layer and photoreceptor layer. The outer plexiform layer and inner retinal layer were relatively well preserved. The extent of submacular hemorrhage was significantly smaller in eyes with radiating hemorrhage (mean 4.2 +/- 2.9 disc areas) than in eyes without it (mean 8.3 +/- 6.2 disc areas) (P < 0.001). In addition, the incidence of radiating hemorrhage was significantly higher in eyes with submacular hemorrhage secondary to PCV (19.4 %) than in those with the other subtypes of AMD (7.5 %; P = 0.025).
   Radiating hemorrhage in exudative AMD was found to be a deep retinal hemorrhage generally accompanied with relatively small-sized submacular hemorrhage. The incidence of this type of hemorrhage was higher in PCV than in the other subtypes of AMD.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This work reported here was supported by Grants to J.H. Kim, Y.S. Chang,
   J.W. Kim, T.G. Lee, C.G. Kim, and D.W. Lee provided by Kim's Eye
   Hospital Research Center.
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Nayak S, 2015, SEMIN OPHTHALMOL, V30, P53, DOI 10.3109/08820538.2013.807849
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
NR 25
TC 7
Z9 8
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2016
VL 60
IS 6
BP 466
EP 475
DI 10.1007/s10384-016-0466-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA6CC
UT WOS:000386711800007
PM 27456843
DA 2022-11-30
ER

PT J
AU Skaf, AR
   Mahmoud, TH
AF Skaf, Ayham R.
   Mahmoud, Tamer H.
TI Surgical Treatment of Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; geographic atrophy; macular translocation;
   RPE transplantation; submacular hemorrhage; submacular surgery
ID TISSUE-PLASMINOGEN ACTIVATOR; RETINAL-PIGMENT EPITHELIUM; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; RANDOMIZED PILOT TRIAL; THICK SUBMACULAR
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; PHOTODYNAMIC THERAPY; PERIPHERAL
   RETINECTOMY; INTRAVITREAL INJECTION; SUBRETINAL HEMORRHAGE
AB Choroidal neovascularization (CNV) and geographic atrophy (GA) are serious and potentially devastating complications of age-related macular degeneration (AMD), a leading cause of blindness in the developed world. While anti-vascular endothelial growth factor (VEGF) therapies have emerged as the current standard treatment of choice for choroidal neovascularization, the requirement for indefinite injections places a tremendous burden on physicians and patients, and may have disappointing outcomes in hemorrhagic neovascular AMD. No superior agents exist to treat large subretinal hemorrhage and geographic atrophy. Over the years, several vitreoretinal surgical approaches have been developed to treat macular degeneration, and these surgical options may still play a role in the management of specific complications of AMD. This review summarizes the principles, techniques, and results of surgical treatments for neovascular and non-neovascular age-related macular degeneration, with emphasis on submacular surgery for removal of CNV, full and limited macular translocation, retinal pigment epithelium, and choroid transplants as well as treatment of thick subretinal hemorrhage.
C1 [Skaf, Ayham R.; Mahmoud, Tamer H.] Wayne State Univ, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA.
C3 Wayne State University
RP Mahmoud, TH (通讯作者)，Wayne State Univ, Kresge Eye Inst, Dept Ophthalmol, 4717 St Antoine, Detroit, MI 48201 USA.
EM tmahmoud@med.wayne.edu
OI Mahmoud, Tamer/0000-0002-9792-4159
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   FINE HF, RETINA, V30, P1588
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Haverbeke GM, 2010, RETINA-J RET VIT DIS, V30, P1739, DOI 10.1097/IAE.0b013e3181f57d3d
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HERIOT WJ, 1996, AAO ANN VITR UPD CHI
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kamei M, 2009, DEV OPHTHALMOL, V44, P82, DOI 10.1159/000223948
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krasnov M M, 1992, Eur J Ophthalmol, V2, P122
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Luke M, 2009, GRAEF ARCH CLIN EXP, V247, P745, DOI 10.1007/s00417-009-1050-5
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SABATES FN, 1992, AM J OPHTHALMOL, V114, P241, DOI 10.1016/S0002-9394(14)74008-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 66
TC 13
Z9 14
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 181
EP 191
DI 10.3109/08820538.2011.577133
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200014
PM 21609231
DA 2022-11-30
ER

PT J
AU Singh, SR
   Lupidi, M
   Mishra, SB
   Paez-Escamilla, M
   Querques, G
   Chhablani, J
AF Singh, Sumit Randhir
   Lupidi, Marco
   Mishra, Sai Bhakti
   Paez-Escamilla, Manuel
   Querques, Giuseppe
   Chhablani, Jay
TI Unique optical coherence tomographic features in age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE outer retinal tubulations; onion sign; prechoroidal cleft; intraretinal
   pseudocyst; subretinal pseudocyst; cystoid degeneration; choroidal
   caverns; activated RPE; hyperreflective crystalline deposits
ID OUTER RETINAL TUBULATION; PIGMENT EPITHELIAL DETACHMENT;
   CLINICOPATHOLOGICAL CORRELATION; ANGIOGRAPHY; DRUSEN; TEAR; OCT
AB Age-related macular degeneration is a major cause of blindness worldwide characterized by the presence of drusen and leading to retinal pigment epithelium and outer retinal changes in advanced stages. Approximately 10% of eyes with age-related macular degeneration develop neovascular complications and present with retinal or sub-retinal pigment epithelium exudation, hemorrhage, or both. Recent advances in imaging techniques, especially optical coherence tomography (OCT), help in early identification of disease and guide various treatment decisions; however, not all signs are suggestive of ongoing exudation or neovascular activity. Although uncommon, multiple OCT-based signs are reported that may be difficult to appreciate clinically. Prompt identification of these signs such as outer retinal tubulation, cystoid degeneration, or pseudocysts may avoid unnecessary interventions. Moreover, certain OCT-based features involving the choroid, such as prechoridal cleft and choroidal cavern, have also been found in eyes with age-related macular degeneration. We discuss these unique OCT-based signs, their pathogenesis, clinical relevance, and management. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Singh, Sumit Randhir; Mishra, Sai Bhakti; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, India.
   [Singh, Sumit Randhir; Mishra, Sai Bhakti] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
   [Lupidi, Marco] Univ Perugia, S Maria della Misericordia Hosp, Dept Surg & Biomed Sci, Sect Ophthalmol, Perugia, Italy.
   [Paez-Escamilla, Manuel] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; Hospital Santa
   Maria della Misericordia; University of Perugia; University of Texas
   System; University of Texas Southwestern Medical Center Dallas;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558; Paez-Escamilla,
   Manuel/0000-0003-3488-9680; Lupidi, Marco/0000-0002-6817-2488
CR [Anonymous], EUR J OPHTHALMOL
   [Anonymous], J OPHTHALMOL
   Burggraaff MC, 2014, INVEST OPHTH VIS SCI, V55, P952, DOI 10.1167/iovs.13-12912
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Christakopoulos C, 2013, ACTA OPHTHALMOL, V91, pE248, DOI 10.1111/aos.12000
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Corbelli E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166968
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Ellabban AA, 2012, EYE, V26, P1086, DOI 10.1038/eye.2012.101
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1966, ARCH OPHTHALMOL-CHIC, V75, P334
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Holz FG, 2010, ESSENT OPHTHALMOL, P1, DOI 10.1007/978-3-540-85540-8
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   King BJ, 2017, OPTOMETRY VISION SCI, V94, P411, DOI 10.1097/OPX.0000000000001031
   Krombach F, 1997, ENVIRON HEALTH PERSP, V105, P1261, DOI 10.2307/3433544
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sergouniotis PI, 2012, OPHTHALMOLOGY, V119, P596, DOI 10.1016/j.ophtha.2011.09.017
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 54
TC 7
Z9 8
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2020
VL 65
IS 4
BP 451
EP 457
DI 10.1016/j.survophthal.2020.01.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LD0GF
UT WOS:000525710900005
PM 31978382
DA 2022-11-30
ER

PT J
AU Covert, D
   Berdeaux, G
   Mitchell, J
   Bradley, C
   Barnes, R
AF Covert, David
   Berdeaux, Gilles
   Mitchell, Jan
   Bradley, Clare
   Barnes, Rod
TI Quality of life and health economic assessments of age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cost of blindness and
   cost-effectiveness; low vision; quality of life measures; visual
   function measures; visual impairment
ID VISUAL FUNCTION QUESTIONNAIRE; WELL-BEING QUESTIONNAIRE; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; COST-EFFECTIVENESS; GLOBAL BLINDNESS;
   LOW-VISION; IMPAIRMENT; DISEASE; IMPACT; DISABILITY
AB In this article, we review measures of patient-reported outcomes that can show whether a treatment for age-related macular degeneration also provides patient-perceived benefits. In addition, we look at health economic measurements currently being used to develop cost-effectiveness models for age-related macular degeneration.
C1 Alcon Res Ltd, Ft Worth, TX USA.
   Royal Holloway Univ London, Surrey, England.
C3 Novartis; Alcon; University of London; Royal Holloway University London
RP Covert, D (通讯作者)，Alcon Labs Inc, 6201 S Freeway,TC-41, Ft Worth, TX 76134 USA.
OI Bradley, Clare/0000-0002-4079-0364
CR Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100
   Bradley C., 1994, HDB PSYCHOL DIABETES, DOI 10.4324/9781315077369
   Bradshaw JS, 2000, SUPRAMOL CHEM, V12, P23, DOI 10.1080/10610270008029802
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brezin AP, 2005, ARCH OPHTHALMOL-CHIC, V123, P1117, DOI 10.1001/archopht.123.8.1117
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388
   MCMILLAN CV, 2001, P BRIT PSYCHOL SOC, V9, P71
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell J, 2001, QUAL LIFE RES, V10, P465, DOI 10.1023/A:1012540100613
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   *NAT I CLIN EXC, 2003, GUID US PHOT THER AG
   Park W, 1999, INT OPHTHALMOL CLIN, V39, P143, DOI 10.1097/00004397-199903940-00010
   Phillips KA, 2003, TODAYS THERAPEUTIC T, V21, P71
   Plowright R, 1999, QUAL LIFE RES, V8, P650
   Pouwer F, 2000, PSYCHOL MED, V30, P455, DOI 10.1017/S0033291700001719
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith AF, 1996, BRIT J OPHTHALMOL, V80, P276, DOI 10.1136/bjo.80.4.276
   SPEIGHT J, 1999, QUAL LIFE RES, V8, P576
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Ware JE., 1993, SCORING SF 36 SF 36
   Witthaus E, 2001, DIABETIC MED, V18, P619, DOI 10.1046/j.1464-5491.2001.00529.x
NR 40
TC 10
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN
PY 2007
VL 52
SU 1
BP S20
EP S25
DI 10.1016/j.survophthal.2006.10.014
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 135KZ
UT WOS:000244153800003
PM 17240252
DA 2022-11-30
ER

PT J
AU Yuan, DQ
   Yuan, DL
   Yuan, ST
   Liu, QH
AF Yuan, Dongqing
   Yuan, Donglan
   Yuan, Songtao
   Liu, Qinghuai
TI The Age-related Maculopathy Susceptibility 2 Polymorphism and Polypoidal
   Choroidal Vasculopathy in Asian Populations A Meta-Analysis
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CIGARETTE-SMOKING; ASSOCIATION; ARMS2; CFH;
   PHENOTYPE; VARIANTS; GENE; GENOTYPE; A69S
AB Objective: To assess the role of the age-related maculopathy susceptibility 2 (ARMS2) A69S polymorphism as a risk factor for polypoidal choroidal vasculopathy (PCV) in Asian populations.
   Methods: We performed a meta-analysis of the association of the A69S variant with PCV in Asian populations using data available from 14 case-control studies involving 6552 subjects. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed-and random-effects models. Sensitivity analysis also was performed.
   Main Outcome Measures: Understanding the relationship between the A69S variant and PCV is essential to provide new insights into pathophysiology and potential targets for intervention of PCV.
   Results: The pooled OR in random-effects models for genotype TG+TT versus wild homozygous genotype GG is 2.39 (95% CI, 1.98-2.89), the OR of heterozygous genotype TG versus GG is 1.66 (95% CI, 1.37-2.00), the OR of homozygous genotype TT versus GG is 4.74 (95% CI, 3.94-5.70), and the OR of allele T versus G is 2.14 (95% CI, 1.79-2.56). A sensitivity analysis indicated the robustness of our findings.
   Conclusions: Our analysis provides evidence that the A69S variant is associated with an increased risk of PCV in Asian populations. The variant of A69S could be a promising genetic biomarker of PCV.
C1 [Yuan, Dongqing; Yuan, Songtao; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Yuan, Donglan] Nanjing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964
FU National Basic Research Program of China (973 Program) [2011CB510200];
   General Project of the National Natural Science Funds [30973257]
FX Supported by National Basic Research Program of China (973 Program, No.
   2011CB510200) and General Project of the National Natural Science Funds
   (No. 30973257). The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Bessho H, 2011, MOL VIS, V17, P977
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chantaren P, 2012, CLIN OPHTHALMOL, V6, P465, DOI 10.2147/OPTH.S30529
   Chen HY, 2012, MOL VIS, V18, P816
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Garhofer G, 2011, MICROVASC RES, V82, P351, DOI 10.1016/j.mvr.2011.07.001
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kanda A, 2010, MOL VIS, V16, P1317
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Tanaka K, 2011, MOL VIS, V17, P2751
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 41
TC 10
Z9 12
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2051
EP 2057
DI 10.1016/j.ophtha.2013.03.026
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400022
PM 23697955
DA 2022-11-30
ER

PT J
AU Yates, JRW
   Sepp, T
   Matharu, BK
   Khan, JC
   Thurlby, DA
   Shahid, H
   Clayton, DG
   Hayward, C
   Morgan, J
   Wright, AF
   Armbrecht, AM
   Dhillon, B
   Deary, IJ
   Redmond, E
   Bird, AC
   Moore, AT
AF Yates, John R. W.
   Sepp, Tiina
   Matharu, Baljinder K.
   Khan, Jane C.
   Thurlby, Deborah A.
   Shahid, Humma
   Clayton, David G.
   Hayward, Caroline
   Morgan, Joanne
   Wright, Alan F.
   Armbrecht, Ana Maria
   Dhillon, Baljean
   Deary, Ian J.
   Redmond, Elizabeth
   Bird, Alan C.
   Moore, Anthony T.
CA Genetic Factors AMD Study G
TI Complement C3 variant and the risk of age-related macular degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GLOMERULONEPHRITIS TYPE-II; DENSE DEPOSIT DISEASE; FACTOR-H
   POLYMORPHISM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CHOROIDAL
   NEOVASCULARIZATION; GENETIC-POLYMORPHISM; MOLECULAR ANALYSIS; COMMON;
   CFH; SUSCEPTIBILITY
AB Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors. Complement activation is implicated in the pathogenesis.
   Methods: We tested for an association between age-related macular degeneration and 13 single-nucleotide polymorphisms (SNPs) spanning the complement genes C3 and C5 in case subjects and control subjects from the southeastern region of England. All subjects were examined by an ophthalmologist and had independent grading of fundus photographs to confirm their disease status. To test for replication of the most significant findings, we genotyped a set of Scottish cases and controls.
   Results: The common functional polymorphism rs2230199 (Arg80Gly) in the C3 gene, corresponding to the electrophoretic variants C3S (slow) and C3F (fast), was strongly associated with age-related macular degeneration in both the English group (603 cases and 350 controls, P=5.9 x 10(sup -5)) and the Scottish group (244 cases and 351 controls, P=5.0 x 10(sup -5)). The odds ratio for age-related macular degeneration in C3 S/F heterozygotes as compared with S/S homozygotes was 1.7 (95% confidence interval [CI], 1.3 to 2.1); for F/F homozygotes, the odds ratio was 2.6 (95% CI, 1.6 to 4.1). The estimated population attributable risk for C3F was 22%.
   Conclusions: Complement C3 is important in the pathogenesis of age-related macular degeneration. This finding further underscores the influence of the complement pathway in the pathogenesis of this disease.
C1 Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Med Genet,Addenbrookes Hosp, Cambridge CB2 0XY, England.
   Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland.
   Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   UCL, London, England.
   Moorfields Eye Hosp, London, England.
C3 Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's
   Hospital; University of Cambridge; Wellcome Trust Sanger Institute;
   University of Edinburgh; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust
RP Yates, JRW (通讯作者)，Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Med Genet,Addenbrookes Hosp, MRC Bldg,Box 139,, Cambridge CB2 0XY, England.
EM jrwy1@cam.ac.uk
RI Hayward, Caroline/M-8818-2016; Deary, Ian J/C-6297-2009
OI Hayward, Caroline/0000-0002-9405-9550; Deary, Ian J/0000-0002-1733-263X
FU MRC [G0000067, MC_U127584475] Funding Source: UKRI; Medical Research
   Council [MC_U127584475, G0000067] Funding Source: Medline; Wellcome
   Trust Funding Source: Medline
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   AZEN EA, 1968, SCIENCE, V162, P905, DOI 10.1126/science.162.3856.905
   BARTOK I, 1995, J IMMUNOL, V154, P5367
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOCH C, 1986, IMMUNOGENETICS, V23, P322, DOI 10.1007/BF00398796
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MCLEAN RH, 1984, J PEDIATR-US, V105, P179, DOI 10.1016/S0022-3476(84)80110-9
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Patel D, 2006, POSTGRAD MED J, V82, P774, DOI 10.1136/pgmj.2006.047001
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WELCH TR, 1990, J PEDIATR-US, V116, pS92, DOI 10.1016/S0022-3476(05)82709-X
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 41
TC 641
Z9 685
U1 2
U2 46
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 9
PY 2007
VL 357
IS 6
BP 553
EP 561
DI 10.1056/NEJMoa072618
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 197VP
UT WOS:000248584900006
PM 17634448
OA Green Published
DA 2022-11-30
ER

PT J
AU Lima, LH
   Freund, KB
   Klancnik, JM
   Spaide, RF
AF Lima, Luiz H.
   Freund, K. Bailey
   Klancnik, James M., Jr.
   Spaide, Richard F.
TI INTRARETINAL CRYSTALLINE DEPOSITS IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; intraretinal crystalline deposits;
   neovascular age-related macular degeneration; retinal crystals; spectral
   domain-optical coherence tomography
ID DYSTROPHY; TELANGIECTASIS; MUTATIONS; CYP4V2
AB Purpose: The purpose of this study was to describe intraretinal crystalline deposits detected in eyes with neovascular age-related macular degeneration.
   Methods: A retrospective review of patients seen during a 6-month period with the diagnosis of neovascular age-related macular degeneration was performed to identify patients with intraretinal crystalline deposits, defined as pinpoint refractile bodies within the neurosensory retina. The characteristics of the deposits, including their shape, size, distribution, and location within the retina, were determined by analyzing color and red-free fundus photographs and spectral domain-optical coherence tomography images.
   Results: Fourteen eyes of 13 patients with neovascular age-related macular degeneration manifesting intraretinal crystalline deposits were identified. The patients had no history of ocular or systemic disease or prior medication use known to be associated with intraretinal crystals. Intravitreal antivascular endothelial growth factor injection was used in 10 eyes, laser photocoagulation in 3 eyes, and intravitreal triamcinolone in 1 eye. The retinal crystals were detected in the macula overlying or adjacent to the areas of choroidal neovascularization. The crystalline deposits could be localized with spectral domain-optical coherence tomography to both the outer nuclear and the outer plexiform layers.
   Conclusion: Intraretinal crystalline deposits localized to the outer nuclear and outer plexiform layers can be detected in eyes with a history of neovascular age-related macular degeneration, often after treatment with a variety of different modalities. Potential etiologies of these deposits include residual lipid material from choroidal neovascularization leakage, degenerated Muller cell elements, and because these deposits were found in eyes with assorted forms of treatment, an external factor such as diet may play a role. RETINA 30: 542-547, 2010
C1 [Lima, Luiz H.; Freund, K. Bailey; Klancnik, James M., Jr.; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Lima, Luiz H.; Freund, K. Bailey; Klancnik, James M., Jr.; Spaide, Richard F.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retina Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020; Lima, Luiz H/V-4940-2017; Freund, K.
   Bailey/V-7488-2018
OI Lima, Luiz H/0000-0001-7304-909X; Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and Throat
   Hospital
FX Supported by the LuEsther T. Mertz Retina Research Center, Manhattan
   Eye, Ear, and Throat Hospital.
CR Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cohen SM, 2007, RETINA-J RET VIT DIS, V27, P59, DOI 10.1097/01.iae.0000256663.94734.e1
   Drenser K, 2006, SURV OPHTHALMOL, V51, P535, DOI 10.1016/j.survophthal.2006.08.006
   Goralczyk R, 2000, INVEST OPHTH VIS SCI, V41, P1513
   GORDON HT, 1982, CRC CR REV FOOD SCI, V18, P59, DOI 10.1080/10408398209527357
   KAISERKUPFER MI, 1994, AM J OPHTHALMOL, V118, P569, DOI 10.1016/S0002-9394(14)76572-9
   Lee KYC, 2005, INVEST OPHTH VIS SCI, V46, P3812, DOI 10.1167/iovs.05-0378
   Li AR, 2004, AM J HUM GENET, V74, P817, DOI 10.1086/383228
   MOISSEIEV J, 1990, AM J OPHTHALMOL, V109, P604, DOI 10.1016/S0002-9394(14)70699-3
   Nadim Farah, 2001, International Ophthalmology, V24, P113, DOI 10.1023/A:1021189215498
   ROS AM, 1985, PHOTODERMATOLOGY, V2, P183
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
NR 14
TC 9
Z9 9
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2010
VL 30
IS 4
BP 542
EP 547
DI 10.1097/IAE.0b013e3181c713e4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AE
UT WOS:000278548900002
PM 20084051
DA 2022-11-30
ER

PT J
AU Olson, JH
   Erie, JC
   Bakri, SJ
AF Olson, Joshua H.
   Erie, Jay C.
   Bakri, Sophie J.
TI Nutritional Supplementation and Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related; Macular Degeneration; Eye; Retina; Macula; Drusen; AREDS;
   Nutrition; Zinc; Carotenoids; Vitamin; Omega-3; Docosahexaenoic acid;
   Eicosapentaenoic acid
ID DIETARY ANTIOXIDANTS; VITAMIN-C; PRIMARY PREVENTION; ALPHA-TOCOPHEROL;
   GAMMA-TOCOPHEROL; 5-YEAR INCIDENCE; FATTY-ACIDS; FOLIC-ACID; ORAL ZINC;
   MACULOPATHY
AB The prevalence of Age-related macular degeneration (AMD) is increasing as the population of elderly in the United States grows. Currently the pathogenesis is not fully understood, however oxidative injury is felt to play a significant role. The Age-Related Eye Disease Study (AREDS) established that a supplemental combination of dietary antioxidants of zinc, beta-carotene, vitamin C and vitamin E slowed progression of AMD. Recently lutein, zeaxanthin, B vitamins, and omega-3 fatty acids have also been reported to decrease AMD progression, while vitamin E and beta-carotene where found to increase the risk of late AMD. AREDS2 is currently underway, further examining the effects of omega-3 fatty acids, carotenoids, and the original AREDS formulation. While awaiting the results of AREDS2, it is important to understand the evidence currently available, so that physicians can safely advise patients today. This review examines the most current literature available exploring nutritional supplementation in age-related macular degeneration.
C1 [Olson, Joshua H.; Erie, Jay C.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
OI Olson, Joshua/0000-0002-3065-4596
FU Research to Prevent Blindness, New York, NY; Research to Prevent
   Blindness (RPB), Inc., New York, NY
FX This manuscript was supported by Research to Prevent Blindness, New
   York, NY.; This study was made possible in part by an unrestricted grant
   from Research to Prevent Blindness (RPB), Inc., New York, NY.
CR ALVAREZ RA, 1987, AM J CLIN NUTR, V46, P481, DOI 10.1093/ajcn/46.3.481
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   CLANDININ MT, 1994, J PEDIATR-US, V125, pS25, DOI 10.1016/S0022-3476(06)80733-X
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Diplock AT, 1998, BRIT J NUTR, V80, pS77, DOI 10.1079/BJN19980106
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MASSACESI KR, 2004, ASS RES VIS OPHTHALM, V42, pS234
   McGregor GP, 2006, CURR OPIN CLIN NUTR, V9, P697, DOI 10.1097/01.mco.0000247478.79779.8f
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM., 1999, VITAMIN NUTR INFORMA, V2, P1
   SIGEL H, 1983, ZINC ITS ROLE BIOL N
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   SOLOMONS NW, 1980, AM J CLIN NUTR, V33, P2031, DOI 10.1093/ajcn/33.9.2031
   STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   WAGNER PA, 1985, GERIATRICS, V40, P111
   WINKLER BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Woo KS, 1999, J AM COLL CARDIOL, V34, P2002, DOI 10.1016/S0735-1097(99)00469-6
   2009, AGE RELATED EYE DIS, V2
NR 54
TC 17
Z9 17
U1 0
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 131
EP 136
DI 10.3109/08820538.2011.577131
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200008
PM 21609225
DA 2022-11-30
ER

PT J
AU Yazama, F
   Kadonosono, K
   Itoh, N
   Ohno, S
AF Yazama, F
   Kadonosono, K
   Itoh, N
   Ohno, S
TI Role of matrix metalloproteinase-7 in angiogenesis associated with
   age-related macular degeneration
SO JOURNAL OF ELECTRON MICROSCOPY
LA English
DT Article
DE ultrathin frozen sections; immunoelectron microscopy; matrix
   metalloproteinase-7; age-related macular degeneration; choroidal
   neovascularization; retinal pigment epithelial cells
ID CHOROIDAL NEOVASCULAR MEMBRANES; ENDOTHELIAL GROWTH-FACTOR;
   RETINAL-PIGMENT EPITHELIUM; INTEGRIN ALPHA(V)BETA(3); FAS LIGAND;
   EXPRESSION; LOCALIZATION; MECHANISMS; IMMUNOCYTOCHEMISTRY; CELLS
AB To investigate the possible role of matrix metalloproteinase-7 in choroidal neovascularization associated with age-related macular degeneration, immunoelectron microscopy using ultrathin frozen sections and conventional transmission electron microscopy were performed in subfoveal fibrovascular membranes from patients with age-related macular degeneration. Immunoelectron microscopy revealed that matrix metalloproteinase-7 was expressed within basal laminar deposits and amorphous materials around the retinal pigment epithelial cells. The results support a role for matrix metalloproteinase-7 in the development of choroidal neovascularization in age-related macular degeneration.
C1 Yokohama City Univ, Sch Med, Dept Anat, Kanagawa 2360004, Japan.
   Yokohama City Univ, Sch Med, Dept Ophthalmol, Kanagawa 2360004, Japan.
C3 Yokohama City University; Yokohama City University
RP Yazama, F (通讯作者)，Hiroshima Prefectural Univ, Sch Bioresources, Lab Cell Biol & Morphol, Shobara, Hiroshima 7270023, Japan.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Luna J, 1996, LAB INVEST, V75, P563
   Nagase H, 1997, BIOL CHEM, V378, P151
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P380, DOI 10.1001/archopht.1964.00970020380016
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STERNFELD MD, 1989, CURR EYE RES, V8, P1029, DOI 10.3109/02713688908997395
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Yazama F, 1997, ANAT REC, V248, P51, DOI 10.1002/(SICI)1097-0185(199705)248:1<51::AID-AR6>3.0.CO;2-I
NR 25
TC 6
Z9 7
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-0744
J9 J ELECTRON MICROSC
JI J. Electron Microsc.
PY 2002
VL 51
IS 2
BP 127
EP 131
DI 10.1093/jmicro/51.2.127
PG 5
WC Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy
GA 545FH
UT WOS:000175205900006
PM 12005165
DA 2022-11-30
ER

PT J
AU Lee, J
   Kim, M
   Lee, CS
   Kim, SS
   Koh, HJ
   Lee, SC
   Byeon, SH
AF Lee, Junwon
   Kim, Min
   Lee, Christopher Seungkyu
   Kim, Sung Soo
   Koh, Hyoung Jun
   Lee, Sung Chul
   Byeon, Suk Ho
TI DRUSEN SUBTYPES AND CHOROIDAL CHARACTERISTICS IN ASIAN EYES WITH TYPICAL
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pachydrusen; neovascular age-related macular degeneration; choroidal
   thickness; drusen type
ID CLINICAL CHARACTERISTICS; VASCULOPATHY
AB Purpose: To investigate the prevalence of pachydrusen, soft drusen, and subretinal drusenoid deposits in eyes with different neovascular age-related macular degeneration (nAMD) subtypes, determine the relationship between each drusen type and the choroidal thickness, and analyze the distinct features of each nAMD subtype according to the drusen type. Methods: Medical records involving 454 eyes from 454 patients with nAMD were retrospectively reviewed. The prevalence of each drusen type and the choroidal thickness and choroidal characteristics were evaluated according to the nAMD subtype. Results: Pachydrusen were prevalent in the typical nAMD (40.4%) and polypoidal choroidal vasculopathy (47.8%) groups and were not detected in the retinal angiomatous proliferation group. No significant drusen were detected in 24.3% of typical nAMD, 43.3% of polypoidal choroidal vasculopathy, and 0% of retinal angiomatous proliferation groups. Regardless of the nAMD subtype, pachydrusen, soft drusen, and subretinal drusenoid deposits were associated with a thick, moderately thick, and thin choroid, respectively. For eyes with typical nAMD, the prevalence of choroidal vascular hyperpermeability and extrafoveal neovascularization was significantly higher in the pachydrusen group than in the other groups. By contrast, the prevalence of Type 2 neovascularization was significantly lower in the pachydrusen group than in the subretinal drusenoid deposit group (P < 0.001 for all). Conclusion: The prevalence of various drusen differed according to the nAMD subtypes, and each drusen type was strongly associated with the choroidal thickness. Typical nAMD showed distinct features according to the accompanying drusen type.
C1 [Lee, Junwon; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul; Byeon, Suk Ho] Yonsei Univ, Eye & ENT Hosp, Severance Hosp, Inst Vis Res,Coll Med,Dept Ophthalmol, Seoul, South Korea.
   [Kim, Min; Lee, Christopher Seungkyu] Yonsei Univ, Gangnam Severance Hosp, Inst Human Barrier Res, Dept Ophthalmol,Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, 134 Shinchon Dong, Seoul 03722, South Korea.
EM shbyeon@yuhs.ac.kr
OI Lee, Junwon/0000-0003-0543-7132; Kim, Sung Soo/0000-0002-0574-7993; ,
   Sung Chul/0000-0001-9438-2385; Lee, Christopher/0000-0001-5054-9470;
   Kim, Min/0000-0003-1873-6959; Koh, Hyoung Jun/0000-0002-5932-8516;
   Byeon, suk ho/0000-0001-8101-0830
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Ersoy L, 2016, BRIT J OPHTHALMOL, V100, P1047, DOI 10.1136/bjophthalmol-2015-306806
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2018, RETINA
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 20
TC 22
Z9 22
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 490
EP 498
DI 10.1097/IAE.0000000000002419
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700012
PM 30550531
DA 2022-11-30
ER

PT J
AU Zeng, RP
   Zhang, XZ
   Wu, KF
   Su, Y
   Wen, F
AF Zeng, Renpan
   Zhang, Xiongze
   Wu, Kunfang
   Su, Yu
   Wen, Feng
TI MMP9 Gene Polymorphism is not Associated with Polypoidal Choroidal
   Vasculopathy and Neovascular Age-related Macular Degeneration in a
   Chinese Han Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Chinese Han population; matrix metalloproteinase 9; neovascular
   age-related macular degeneration; polypoidal choroidal vasculopathy;
   single nucleotide polymorphism
ID BRUCHS MEMBRANE; MATRIX METALLOPROTEINASES; MORPHOMETRIC-ANALYSIS;
   PHOTODYNAMIC THERAPY; FEATURES; LESIONS; PREVALENCE; MECHANISMS;
   PROGRAM; DISEASE
AB Background: Recently, one of our studies has revealed that the serum matrix metalloproteinase 9 (MMP9) level is elevated in polypoidal choroidal vasculopathy (PCV) but not in age-related macular degeneration (AMD). Previous studies have demonstrated that abnormal extracellular matrix (ECM) metabolism plays an important role in the pathogenesis of AMD and PCV. MMP9 is an important regulating enzyme in ECM metabolism, and the MMP9 gene may be a candidate gene for the susceptibility of PCV and AMD. In this study, we aimed to investigate whether the MMP9 gene polymorphism is associated with PCV and neovascular AMD (nAMD) in a Chinese Han population.
   Methods: We performed a case-control study in a Chinese Han population. Three tag single nucleotide polymorphisms (SNPs) (rs17576, rs3787268 and rs2274755) of the MMP9 gene were genotyped in 251 patients with PCV, 157 patients with nAMD, and 204 control individuals using the Multiplex SNaPshot system and the direct DNA sequencing technique. The three SNPs genotypes and allele frequencies in the PCV, nAMD and control groups were evaluated using PLINK software and binary logistic regression analysis.
   Results: In the PCV, nAMD, and control groups, the minor allele frequencies were 0.2099, 0.2070 and 0.2108 for the rs17576 variant; 0.4442, 0.4522 and 0.4461 for the rs3787268 variant; and 0.1036, 0.1338 and 0.1225 for the rs2274755 variant, respectively. The three tag SNPs were not significantly associated with susceptibility to PCV (p = 0.9524, 0.9553, and 0.3672, respectively) or nAMD (p = 0.9015, 0.8692, and 0.6543, respectively). None of the p values for the additive, dominant, or recessive models were statistically significant in the PCV or nAMD group.
   Conclusions: No evidence was found to support an association between the MMP9 gene variants and susceptibility to either nAMD or PCV in a Chinese Han population.
C1 [Zeng, Renpan; Zhang, Xiongze; Wu, Kunfang; Su, Yu; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zeng, Renpan] Chinese Peoples Armed Police Forces, Sichuan Prov Corps Hosp, Dept Ophthalmol, Leshan, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
FU National Natural Science Foundation of China [81271011, 81200705]
FX This study was supported by the National Natural Science Foundation of
   China [grant numbers: 81271011 and 81200705].
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Byeon Suk Ho, 2011, Ophthalmology, V118, P600, DOI 10.1016/j.ophtha.2010.11.010
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Chew DKW, 2004, J VASC SURG, V40, P1001, DOI 10.1016/j.jvs.2004.08.035
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hadler-Olsen E, 2011, FEBS J, V278, P28, DOI 10.1111/j.1742-4658.2010.07920.x
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jo HS, 2000, P I MECH ENG D-J AUT, V214, P545, DOI 10.1243/0954407001527835
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim CS, 2010, CURR VASC PHARMACOL, V8, P75, DOI 10.2174/157016110790226697
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Zeng RP, 2013, MOL VIS, V19, P729
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 45
TC 5
Z9 5
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2014
VL 35
IS 4
BP 235
EP 240
DI 10.3109/13816810.2014.952832
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA AT8YC
UT WOS:000345213900005
PM 25162123
DA 2022-11-30
ER

PT J
AU Piatti, A
   Croce, A
   Mazzacane, D
   Traina, G
   Ambrosino, L
   Boni, L
   Lisi, L
   Cascella, MC
   Grunberger, A
AF Piatti, Alberto
   Croce, Antonella
   Mazzacane, Danilo
   Traina, Giovanni
   Ambrosino, Lina
   Boni, Luigi
   Lisi, Luca
   Cascella, Maria Caterina
   Grunberger, Alberto
TI Effect of 2-year nutritional supplementation on progression of
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Carotenoids; omega-3 fatty acids; macular degeneration
AB Purpose:
   To examine the effect of a long-term nutritional supplementation on age-related macular degeneration progression.
   Methods:
   In this prospective, double-blind, placebo-controlled study, 80 patients with intermediate age-related macular degeneration were randomized (2:1) to receive 1 tablet/day of a nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids or placebo. Age-related macular degeneration progression assessed by digital fundus photography (primary outcome) and best-corrected visual acuity were evaluated. Differences between arms were tested using chi-square test or Fisher's exact test.
   Results:
   Seventy-four patients completed the follow-up at 24 months (48 in the treated arm and 26 in the placebo arm). An age-related macular degeneration progression was observed in the 2.1% of patients of the treated arm and in the 15.4% of patients in the placebo arm (p = 0.05, Fisher's exact test). Best-corrected visual acuity data alone were not statistically significant among groups.
   Conclusion:
   A clinically meaningful stabilization of intermediate age-related macular degeneration over a period of 2 years may be obtained by treating patients with a mixture of carotenoids, vitamins and omega-3 fatty acids.
C1 [Piatti, Alberto] ASL TO5, Moncalieri, Italy.
   [Croce, Antonella] ASL Citta Torino, Turin, Italy.
   [Mazzacane, Danilo] ASST Pavia & Melegnano, Pavia, Italy.
   [Traina, Giovanni] ASL Toscana Nord Ovest, Pisa, Italy.
   [Ambrosino, Lina] ASL Napoli I Ctr, Naples, Italy.
   [Boni, Luigi] ASL Toscana Sud Est, Arezzo, Italy.
   [Lisi, Luca] ASL Roma 2, Rome, Italy.
   [Cascella, Maria Caterina] ASL Bari, Bari, Italy.
   [Grunberger, Alberto] SASSL Nuoro, ATS Sardegna, Nuoro, Italy.
C3 Ospedale Sandro Pertini
RP Piatti, A (通讯作者)，ASL TO5 Moncalieri, Via Vittime Bologna 20, I-10024 Moncalieri, TO, Italy.
EM piatti.alberto@aslto5.piemonte.it
RI BONI, LUIGI/AAC-6005-2022; Piatti, Alberto/CAG-6422-2022
OI BONI, LUIGI/0000-0002-5906-3810; 
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Evans J. R., 2017, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000254.PUB4
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
NR 11
TC 5
Z9 5
U1 1
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2020
VL 30
IS 2
BP 376
EP 381
DI 10.1177/1120672119836007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA7WI
UT WOS:000524153600030
PM 30880442
DA 2022-11-30
ER

PT J
AU Dedania, VS
   Grob, S
   Zhang, K
   Bakri, SJ
AF Dedania, Vaidehi S.
   Grob, Seanna
   Zhang, Kang
   Bakri, Sophie J.
TI PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; ARMS2; bevacizumab; complement factor
   H (CFH); eye; genetics; HTRA1; ranibizumab; retina; single-nucleotide
   polymorphisms; vascular endothelial growth factor
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   RANIBIZUMAB; PIGMENT EPITHELIUM; RISK; ASSOCIATION; BEVACIZUMAB; GENE;
   SUSCEPTIBILITY; VARIANT
AB Purpose: To determine whether there is an association between response to intravitreal anti-vascular endothelial growth factor agents and genotype in patients with neovascular age-related macular degeneration.
   Methods: Analysis of the current literature evaluating pharmacogenetics of treatment response in patients with neovascular age-related macular degeneration.
   Results: Studies have demonstrated associations between various genotypes and response to intravitreal anti-vascular endothelial growth factor agents. Lower-risk genotypes of the CFH, ARMS2, HTRA1, and VEGF-A genes may be associated with improved visual outcomes. Additionally, frequency of injections may be associated with certain genotypes.
   Conclusion: Genetic background may influence an individual's response to treatment of neovascular age-related macular degeneration. Further studies to investigate biologic pathways of neovascular age-related macular degeneration and gene products that are directly involved might lead to better understanding of contribution of various genes to treatment response.
C1 [Dedania, Vaidehi S.] Albany Med Ctr, Lions Eye Inst, Albany, NY USA.
   [Grob, Seanna] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
   [Grob, Seanna; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, Inst Genom Med, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 Albany Medical College; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; University of California System;
   University of California San Diego; Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Research to Prevent Blindness, New York, New York; Veterans Affairs
   [I01BX001898] Funding Source: NIH RePORTER
FX Supported by Research to Prevent Blindness, New York, New York (S.J.B.).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P1239, DOI 10.2217/pgs.13.100
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Saeed MU, 2013, CLIN OPHTHALMOL, V7, P533, DOI 10.2147/OPTH.S31016
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tong Y, 2010, MOL VIS, V16, P1958
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 42
TC 24
Z9 29
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2015
VL 35
IS 3
BP 381
EP 391
DI 10.1097/IAE.0000000000000466
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4AO
UT WOS:000350293100013
PM 25635578
DA 2022-11-30
ER

PT J
AU Stone, EM
AF Stone, Edwin M.
TI Genetic Testing for Age-Related Macular Degeneration Not Indicated Now
SO JAMA OPHTHALMOLOGY
LA English
DT Review
ID EYE DISEASE; CFH; ANTIOXIDANTS; SUPPLEMENTS; ZINC
AB Age-related macular degeneration is a very common condition that is caused by a complex interplay of genetic and environmental factors. It is likely that, in the future, genetic testing will allow physicians to achieve better clinical outcomes by administering specific treatments to patients based on their genotypes. However, improved outcomes for genotyped patients have not yet been demonstrated in a prospective clinical trial, and as a result, the costs and risks of routine genetic testing currently outweigh the benefits for patients with age-related macular degeneration.
C1 Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Stephen A Wynn Inst Vis Res,Dept Ophthalmol & Vis, Iowa City, IA 52242 USA.
C3 Howard Hughes Medical Institute; University of Iowa
RP Stone, EM (通讯作者)，Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Stephen A Wynn Inst Vis Res,Dept Ophthalmol & Vis, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM edwin-stone@uiowa.edu
OI Stone, Edwin M./0000-0003-3343-4414
CR Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
NR 7
TC 24
Z9 24
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2015
VL 133
IS 5
BP 598
EP 600
DI 10.1001/jamaophthalmol.2015.0369
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK2NF
UT WOS:000356046700015
PM 25789813
DA 2022-11-30
ER

PT J
AU Chin, YC
   Bhargava, M
   Khor, CC
   Cheung, CMG
   Wong, TY
AF Chin, Y. C.
   Bhargava, M.
   Khor, C. C.
   Cheung, C. M. G.
   Wong, T. Y.
TI Polypoidal choroidal vasculopathy and systemic lupus erythematosus
SO LUPUS
LA English
DT Article
DE antiphospholipid syndrome; Systemic lupus erythematosus; age-related
   macular degeneration; polypoidal choroidal vasculopathy
AB Systemic lupus erythematosus (SLE) associated with antiphospholipid syndrome can have ocular complications. We report a 44-year-old Chinese lady with recurrent relapses of SLE and antiphospholipid syndrome with high disease activity, presenting with visual distortion in her right eye for 2 months. There was subretinal hemorrhage in her right eye, confirmed on investigations to be choroidal neovascularization secondary to a variant of age-related macular degeneration known as polypoidal choroidal vasculopathy (PCV). Anti-vascular endothelial growth factor therapy resolved her eye condition. SLE could be associated with PCV via common mechanisms, including complement pathway activation and vasculitis involving the choroidal circulation.
C1 [Chin, Y. C.; Bhargava, M.; Khor, C. C.; Cheung, C. M. G.; Wong, T. Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Chin, Y. C.; Bhargava, M.; Khor, C. C.; Cheung, C. M. G.; Wong, T. Y.] Natl Univ Hlth Syst, Dept Ophthalmol, Singapore, Singapore.
   [Khor, C. C.] Genome Inst Singapore, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Khor, Chiea
   Chuen/0000-0002-1128-4729; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
CR Chen HY, 2012, MOL VIS, V18, P816
   KLINKHOFF AV, 1986, ARTHRITIS RHEUM-US, V29, P1152, DOI 10.1002/art.1780290914
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Palejwala NV, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/290898
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
NR 5
TC 5
Z9 5
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961-2033
EI 1477-0962
J9 LUPUS
JI Lupus
PD MAR
PY 2014
VL 23
IS 3
BP 319
EP 322
DI 10.1177/0961203313519160
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA AA8QE
UT WOS:000331359200012
PM 24407425
DA 2022-11-30
ER

PT J
AU Bessho, H
   Kondo, N
   Honda, S
   Kuno, S
   Negi, A
AF Bessho, Hiroaki
   Kondo, Naoshi
   Honda, Shigeru
   Kuno, Shin-ichi
   Negi, Akira
TI Coding variant Met72Thr in the PEDF gene and risk of neovascular
   age-related macular degeneration and polypoidal choroidal vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; MULTILOCUS GENOTYPE DATA; FACTOR-H
   POLYMORPHISM; POPULATION-STRUCTURE; JAPANESE POPULATION; GEOGRAPHIC
   ATROPHY; MACULOPATHY; PREVALENCE; SUSCEPTIBILITY; ANGIOGENESIS
AB Purpose: Using a candidate-gene approach, a recent case-control study identified a previously unknown association between neovascular age-related macular degeneration (AMD) and the coding Met72Thr variant in the pigment epithelium-derived factor (PEDF) gene in a Taiwan Chinese population. However, a subsequent replication study failed to see this association in a white European population. We noted an important difference in the sample ascertainment scheme between these two studies. The original study did not consider findings of indocyanine green (ICG) angiography for disease classification, which is the only way to obtain a clear image of polypoidal choroidal vasculopathy (PCV) lesions. This suggests that their cohort might include a considerable amount of PCV, given its high prevalence in the Chinese population. In contrast, the replication study intentionally excluded PCV from the case cohort on the basis of ICG angiograms. Therefore, the inconsistent finding might be caused by potential sample heterogeneity between these two studies. In this respect, this association needed to be examined in a case series of clearly defined individuals with neovascular AMD and PCV. The aim of this study was to validate the previously reported association of the PEDF Met72Thr variant in a well characterized Japanese population with neovascular AMD and PCV.
   Methods: We genotyped the Met72Thr variant (rs1136287) in 116 patients with neovascular AMD, 140 patients with PCV, and 189 control participants in a Japanese population. Genotyping was performed using TaqMan technology. We tested for an association of this variant with neovascular AMD and PCV separately. We also evaluated population stratification in our study cohort.
   Results: We found no statistically significant evidence for association between rs1136287 and either neovascular AMD or PCV under any genetic models (trend, genotypic, dominant, and recessive genetic models; p>0.05). Population structure analyses excluded stratification artifact in our study population.
   Conclusions: We report a lack of association between the PEDF Met72Thr variant and either neovascular AMD or PCV in a Japanese population. We conclude that the Met72Thr variant does not play a significant role in the risk of developing neovascular AMD or PCV.
C1 [Kondo, Naoshi] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kuno, Shin-ichi] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan.
   [Kuno, Shin-ichi] Kobe Univ, Grad Sch Med, Clin Genome Informat Ctr, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Institute for Biomedical Research & Innovation (IBRI);
   Kobe University
RP Kondo, N (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM nskondo@gmail.com
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science, and Culture, Tokyo, Japan [17591836]
FX This study was supported by a grant-in-aid (C) 17591836 from the
   Ministry of Education, Science, and Culture, Tokyo, Japan. None of the
   authors have any financial or conflicting interests to disclose.
CR Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falush D, 2003, GENETICS, V164, P1567
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kubo M, 2007, NAT GENET, V39, P212, DOI 10.1038/ng1945
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mattes D, 2009, MOL VIS, V15, P343
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pritchard JK, 2000, GENETICS, V155, P945
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yamada K, 2007, P NATL ACAD SCI USA, V104, P2815, DOI 10.1073/pnas.0610765104
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 61
TC 16
Z9 17
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 2
PY 2009
VL 15
IS 116-17
BP 1107
EP 1114
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 459UR
UT WOS:000267136600002
PM 19503741
DA 2022-11-30
ER

PT J
AU Park, JY
   Park, YJ
   Park, SJ
   Park, KH
   Yeo, JH
   Kim, JG
   Yoon, YH
   Lee, JY
   Woo, SJ
AF Park, Jun Young
   Park, Young Joo
   Park, Sang Jun
   Park, Kyu Hyung
   Yeo, Joon Hyung
   Kim, June-Gone
   Yoon, Young Hee
   Lee, Joo Yong
   Woo, Se Joon
TI Comparison of visual outcomes of polypoidal choroidal vasculopathy and
   typical neovascular age-related macular degeneration-up to 10 years of
   follow-up
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; real-world study; visual outcome
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR;
   RANIBIZUMAB; SAFETY; SUBGROUP; EFFICACY
AB Purpose To investigate long-term visual outcomes of patients with polypoidal choroidal vasculopathy (PCV) and typical neovascular age-related macular degeneration (nAMD) in the real-world setting. Methods Retrospective, multicenter, noninterventional consecutive cohort study. Two hundred eighty-five eyes of 261 patients with PCV and 902 eyes of 877 patients with typical nAMD, who could be followed up 1 year or longer from 2005 to 2018, were included. Mean changes in best-corrected visual acuity (BCVA) from baseline in the PCV and the typical nAMD groups were compared. Results Mean follow-up period of total patients was 4.3 +/- 2.8 (1-10) years. Baseline BCVA was better in the PCV group than that in the typical nAMD group (0.59 +/- 0.52 versus 0.79 +/- 0.63 logMAR, p < 0.001). The mean changes in BCVA from baseline in the PCV and nAMD group were +2.1 and -0.1 letters at 1 year, -0.2 and -3.7 letters at 3 years, -3.9 and -10.5 letters at 5 years and - 8.7 and - 12.1 letters at 7 years, respectively. Before 2006, the initial BCVA was sustained for approximately 1 year in eyes with PCV and for less than half year in eyes with typical nAMD. However, after 2007, when anti-VEGF agents were available, the initial BCVA was sustained for 4 years in eyes with PCV, while it was sustained for 1 year in eyes with typical nAMD. Conclusion In the real-world, long-term BCVA deteriorated in both PCV and typical nAMD groups, but the PCV group showed better visual outcomes than the typical nAMD group.
C1 [Park, Jun Young; Park, Young Joo; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
   [Park, Jun Young] Eulji Univ, Uijeongbu Eulji Med Ctr, Dept Ophthalmol, Sch Med, Uijongbu, South Korea.
   [Park, Young Joo] Kangwon Natl Univ, Grad Sch Med, Dept Ophthalmol, Kangwon Natl Univ Hosp, Chunchon, South Korea.
   [Yeo, Joon Hyung] Chung Ang Univ, Coll Med, Dept Ophthalmol, Gwangmyeong Hosp, Gwangmyeong, South Korea.
   [Kim, June-Gone; Yoon, Young Hee; Lee, Joo Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
C3 Seoul National University (SNU); Eulji University; Kangwon National
   University; Kangwon National University Hospital; Chung Ang University;
   Chung Ang University Hospital; University of Ulsan
RP Lee, JY (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Woo, SJ (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM ophthalmo@amc.seoul.kr; sejoon1@snu.ac.kr
RI Woo, Se Joon/I-7357-2013; Park, Sang Jun/C-3234-2015
OI Woo, Se Joon/0000-0003-3692-7169; LEE, JOO YONG/0000-0002-2187-196X;
   Park, Kyu Hyung/0000-0002-5516-8121; Park, Sang Jun/0000-0003-0542-2758;
   Park, Jun young/0000-0002-1664-7605
FU Seoul National University Bundang Hospital [18-2018-024]
FX .This study was supported by a research grant (18-2018-024) from Seoul
   National University Bundang Hospital. The funding organization had no
   role in the design or conduct of this study.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, EYE, V31, P166, DOI 10.1038/eye.2016.276
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Koh A, 2020, RETINA-J RET VIT DIS, V40, P1529, DOI 10.1097/IAE.0000000000002624
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagong M, 2021, CLIN OPHTHALMOL, V15, P1995, DOI 10.2147/OPTH.S303884
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP E1579
EP E1588
DI 10.1111/aos.15149
EA APR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000776742000001
PM 35363434
DA 2022-11-30
ER

PT J
AU Neelam, K
   Nolan, J
   Chakravarthy, U
   Beatty, S
AF Neelam, Kumari
   Nolan, John
   Chakravarthy, Usha
   Beatty, Stephen
TI Psychophysical Function in Age-related Maculopathy
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related maculopathy; color vision; hyperacuity; perimetry;
   psychophysical tests; Spatial vision; temporal function; visual
   adaptation
ID FREQUENCY-DOUBLING TECHNOLOGY; QUALITY-OF-LIFE; FOVEAL FLICKER
   SENSITIVITY; EGER MACULAR STRESSOMETER; PREFERRED RETINAL LOCI; CONTRAST
   LETTER CHARTS; BLUE-ON-YELLOW; WAVELENGTH AUTOMATED PERIMETRY; ABNORMAL
   DARK-ADAPTATION; VITAMIN-A-DEFICIENCY
AB Age-related macular degeneration (AMD), the late stage of age-related maculopathy (ARM), is the leading cause of blind registration in developed Countries. The Visual loss in AMD occurs due to dysfunction and death of photoreceptors (rods and cones) secondary to an atrophic or a neovascular event. The psychophysical tests of vision, which depend on the functional status of the photoreceptors, may detect subtle alterations in the macula before morphological fundus changes are apparent ophthalmoscopically, and before traditional measures of visual acuity exhibit deterioration, and may be a useful tool for assessing and monitoring patients with ARM. Furthermore, worsening of these visual functions over time may reflect disease progression, and some of these, alone or iti combination with other parameters, may act as a prognostic indicator for identifying eyes at, risk for developing neovascular AMD. Lastly, psychophysical tests often correlate with subjective and relatively undefined symptoms in patients With early ARM, and may reflect limitation of daily activities for ARM patients. However, clinical studies investigating psychophysical function have largely been cross-sectional in nature, with small sample sizes, and lack consistency in terms Of the grading and classification of ARM. This article aims to comprehensively review the literature germane to psychophysical tests in ARM, and to furnish the reader with an insight into this complex area of research. (Surv Ophdialmol 54:167-210, 2009. (C) 2009 Elsevier Inc. All rights reserved.)
C1 [Neelam, Kumari] Alexandra Hosp, Dept Ophthalmol & Visual Sci, Natl Healthcare Grp, Singapore 159964, Singapore.
   [Neelam, Kumari; Nolan, John; Beatty, Stephen] Waterford Inst Technol, Waterford, Ireland.
   [Neelam, Kumari; Beatty, Stephen] Waterford Reg Hosp, Waterford, Ireland.
   [Chakravarthy, Usha] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha] Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
C3 South East Technological University (SETU); Queens University Belfast
RP Neelam, K (通讯作者)，Alexandra Hosp, Dept Ophthalmol & Visual Sci, Natl Healthcare Grp, 378 Alexandra Rd, Singapore 159964, Singapore.
EM Kumari.neelam@Alexhosp.com.sg
RI ; Nolan, John/N-4921-2014
OI Chakravarthy, Usha/0000-0002-2606-3734; Nolan, John/0000-0002-5503-7084
CR Abadi RV, 1996, OPHTHAL PHYSL OPT, V16, P455, DOI 10.1046/j.1475-1313.1996.96000129.x
   AKUTSU H, 1991, J GERONTOL, V46, pP325, DOI 10.1093/geronj/46.6.P325
   ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P303, DOI 10.1136/bjo.68.5.303
   ALPERN M, 1981, INVEST OPHTH VIS SCI, V20, P183
   ALPERN M, 1971, VISION RES, V11, P539, DOI 10.1016/0042-6989(71)90075-7
   Anderson AJ, 2000, CLIN EXP OPHTHALMOL, V28, P223, DOI 10.1046/j.1442-9071.2000.00299.x
   Anderson AJ, 2001, VISION RES, V41, P2449, DOI 10.1016/S0042-6989(01)00139-0
   Anderson AJ, 2000, VISION RES, V40, P2579, DOI 10.1016/S0042-6989(00)00121-8
   Anderson AJ, 2005, INVEST OPHTH VIS SCI, V46, P1540, DOI 10.1167/iovs.04-0968
   ANDRACCHI S, 1991, ACTA ANAT, V141, P289
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   ARDEN G, 1988, DOC OPHTHALMOL, V69, P167, DOI 10.1007/BF00153698
   ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198
   ARDEN GB, 1988, CLIN VISION SCI, V2, P303
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Artes PH, 2002, INVEST OPHTH VIS SCI, V43, P2654
   ATCHISON DA, 1990, OPTOMETRY VISION SCI, V67, P179, DOI 10.1097/00006324-199003000-00006
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BALDASARE J, J VIS IMPAIR BLINDNE, P785
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P594, DOI 10.1111/j.1475-1313.2004.00245.x
   BARTLETT H, 2004, OPTOM PRACTISE, V5, P15
   Beirne RO, 2006, INVEST OPHTH VIS SCI, V47, P4624, DOI 10.1167/iovs.05-1227
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Blumenthal EZ, 2003, OPHTHALMOLOGY, V110, P1895, DOI 10.1016/S0161-6420(03)00541-4
   BODISWOL.I, 1972, SCIENCE, V178, P769, DOI 10.1126/science.178.4062.769
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BOUMA H, 1974, VISION RES, V14, P273, DOI 10.1016/0042-6989(74)90077-7
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bowman K J, 1978, Mod Probl Ophthalmol, V19, P71
   BOWMAN KJ, 1980, ACTA OPHTHALMOL, V58, P337
   Bowman KJ, 1984, COLOUR VISION DEFICI, VVII, P363
   BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BRETON ME, 1991, INVEST OPHTH VIS SCI, V32, P2931
   BRETON ME, 1989, GLAUCOMAS, P677
   BRINDLEY GS, 1959, J PHYSIOL-LONDON, V147, P194, DOI 10.1113/jphysiol.1959.sp006234
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   BURTON KB, 1993, VISION RES, V33, P939, DOI 10.1016/0042-6989(93)90077-A
   BUSTAMANTE JJ, 1995, AM J PHYSIOL-REG I, V269, pR1346
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   CAMPBELL CJ, 1959, ARCH OPHTHALMOL-CHIC, V62, P287
   CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574
   CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056
   CARTERDAWSON L, 1979, INVEST OPHTH VIS SCI, V18, P437
   Casson R, 2001, BRIT J OPHTHALMOL, V85, P360, DOI 10.1136/bjo.85.3.360
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHILARIS GA, 1962, AM J OPHTHALMOL, V53, P311, DOI 10.1016/0002-9394(62)91181-9
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   COLETTA NJ, 1986, VISION RES, V26, P917, DOI 10.1016/0042-6989(86)90150-1
   COLETTA NJ, 1984, VISION RES, V24, P1333, DOI 10.1016/0042-6989(84)90188-3
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   COMERFORD JP, 1979, AM OPTOM ASS, V50, P683
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CORNELISSEN FW, 1991, DOC OPHTHALMOL, V78, P195, DOI 10.1007/BF00165681
   CRASSINI B, 1988, PERCEPTION, V17, P315, DOI 10.1068/p170315
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   CUMMINGS RW, 1991, INVEST OPHTH VIS SCI, V32, P816
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   DELANGEDZN H, 1958, J OPT SOC AM, V48, P777, DOI 10.1364/JOSA.48.000777
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   DeValois RL, 1988, SPATIAL VISION
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   DOUTHWAITE WA, 1985, OPHTHAL PHYSL OPT, V5, P15, DOI 10.1016/0275-5408(85)90023-7
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Dutta S. K., 1981, Nutrition Research, V1, P443, DOI 10.1016/S0271-5317(81)80048-6
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1824
   EISNER A, 1993, DOC OPHTH P, V56, P175
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1994, J OPT SOC AM A, V11, P33, DOI 10.1364/JOSAA.11.000033
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   Elliott DB, 2000, OPTOMETRY VISION SCI, V77, P13, DOI 10.1097/00006324-200001000-00009
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   ENOCH JM, 1978, INVEST OPHTH VIS SCI, V17, P208
   ERIKSEN CW, 1977, B PSYCHONOMIC SOC, V9, P81, DOI 10.3758/BF03336936
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Fine EM, 1998, OPTOMETRY VISION SCI, V75, P191, DOI 10.1097/00006324-199803000-00024
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FORSIUS H, 1964, ACTA OPHTHALMOL, V42, P55
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRYCZKOWSKI AW, 1988, ACTA ANAT, V132, P265
   GELLER AM, 1992, J OPT SOC AM A, V9, P472, DOI 10.1364/JOSAA.9.000472
   GLASER BM, 1985, ARCH OPHTHALMOL-CHIC, V103, P1870
   GLASER JS, 1977, AM J OPHTHALMOL, V83, P255, DOI 10.1016/0002-9394(77)90624-9
   GOLDBERG SH, 1983, SCIENCE, V221, P180, DOI 10.1126/science.6857279
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   GREVE EL, 1979, DOCUM OPHTHAL P SERI, V19, P371
   GREVE EL, 1976, DOC OPHTHAL        P, V9, P327
   GRIGSBY SS, 1991, INVEST OPHTH VIS SCI, V32, P3252
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hammond BR, 2005, OPHTHAL PHYSL OPT, V25, P315, DOI 10.1111/j.1475-1313.2005.00271.x
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   Harwerth RS, 2004, INVEST OPHTH VIS SCI, V45, P3152, DOI 10.1167/iovs.04-0227
   Harwerth RS, 1999, INVEST OPHTH VIS SCI, V40, P2242
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hecht S, 1936, J GEN PHYSIOL, V19, P965, DOI 10.1085/jgp.19.6.965
   HERLONG HF, 1981, HEPATOLOGY, V1, P348, DOI 10.1002/hep.1840010412
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOOD DC, 1984, INVEST OPHTH VIS SCI, V25, P864
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   HYVARINEN L, 1983, ACTA OPHTHALMOL, V61, P161
   Jackson A., 2004, OPTOMETRY PRACTICE, V5, P53
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2006, OPHTHAL PHYSL OPT, V26, P431, DOI 10.1111/j.1475-1313.2006.00390.x
   JIN J, 1994, VISUAL NEUROSCI, V11, P389, DOI 10.1017/S0952523800001735
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P645, DOI 10.1001/archopht.1993.01090050079034
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P651, DOI 10.1001/archopht.1993.01090050085035
   JOHNSON CA, 1994, TECHNICAL DIGEST SER, V16, P290
   Johnston AW, 1991, PROBLEMS OPTOMETRY, V3, P394
   Julian WG, 1984, LIGHTING RES TECHNOL, V16, P34
   JUST MA, 1980, PSYCHOL REV, V87, P329, DOI 10.1037/0033-295X.87.4.329
   KATZ ML, 1991, INVEST OPHTH VIS SCI, V32, P1968
   KATZ ML, 1993, EXP EYE RES, V57, P393, DOI 10.1006/exer.1993.1140
   KELLY DH, 1966, J OPT SOC AM, V56, P1628, DOI 10.1364/JOSA.56.001628
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Kerrigan-Baumrind LA, 2000, INVEST OPHTH VIS SCI, V41, P741
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   KOLB H, 1991, VISION VISUAL DYSFUN, V6, P128
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KOWLER E, 1987, VISION RES, V27, P45, DOI 10.1016/0042-6989(87)90142-8
   Kuyk T, 1998, OPTOMETRY VISION SCI, V75, P174, DOI 10.1097/00006324-199803000-00022
   LACHENMAYR BJ, 1992, INVEST OPHTH VIS SCI, V33, P3539
   LACHENMAYR BJ, 1992, INVEST OPHTH VIS SCI, V33, P3010
   LAKSHMINARAYANAN V, 1995, INT OPHTHALMOL, V19, P109, DOI 10.1007/BF00133181
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LANUM J, 1978, SURV OPHTHALMOL, V22, P221, DOI 10.1016/0039-6257(78)90070-X
   LEFTON LA, 1974, J EXP PSYCHOL, V102, P975, DOI 10.1037/h0036542
   LEGEIN CP, 1982, DOC OPHTHALMOL, V53, P123, DOI 10.1007/BF00142482
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   LEGGE GE, 1990, J OPT SOC AM A, V7, P2002, DOI 10.1364/JOSAA.7.002002
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   LEGGE GE, 1987, CONTRAST POLARITY LO, P288
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LEI I, 1977, AM J OPTOM PHYSL OPT, V54, P528
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P385
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   LEIGH RJ, 1989, INVEST OPHTH VIS SCI, V30, P288
   Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933
   LIEM ATA, 1992, AM J OPHTHALMOL, V114, P149, DOI 10.1016/S0002-9394(14)73978-9
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Lovie-Kitchin JE, 1989, CLIN EXP OPTOM, V72, P79
   LYNN JR, 1980, GLAUCOMAS BASIC SCI
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   MARC RE, 1982, CELL BIOL EYE, P435
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   MAYER MJ, 1995, VISION RES, V35, P1575, DOI 10.1016/0042-6989(94)00252-H
   MAYER MJ, 1988, J OPT SOC AM A, V5, P2201, DOI 10.1364/JOSAA.5.002201
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McKendrick Allison M, 2005, Clin Exp Optom, V88, P73
   MCMAHON TT, 1993, OPTOMETRY VISION SCI, V70, P506, DOI 10.1097/00006324-199306000-00010
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   MORA BN, 1989, TRENDS NEUROSCI, V12, P282, DOI 10.1016/0166-2236(89)90004-0
   Morrison R. E., 1983, EYE MOVEMENTS READIN, P31
   MORRISON SA, 1978, AM J CLIN NUTR, V31, P276, DOI 10.1093/ajcn/31.2.276
   NAS-NRC, 1980, ADV OPHTHALMOL, V41, P103
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   OLVER J, INVEST OPHTHALMOL VI, V47
   *OPHTH TECHN ASS C, 2002, OPHTHALMOLOGY, V109, P2362
   OREGAN JK, 1980, PERCEPT PSYCHOPHYS, V28, P112, DOI 10.3758/BF03204335
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 1990, CLIN VISION SCI, V5, P325
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   Paczka JA, 2001, AM J OPHTHALMOL, V131, P188, DOI 10.1016/S0002-9394(00)00644-9
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Perfetti C.A., 1981, INTERACTIVE PROCESSE, P269, DOI DOI 10.4324/9781315108506-11
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   QUIGLEY HA, 1988, OPHTHALMOLOGY, V95, P357
   RANINEN A, 1986, VISION RES, V26, P1249, DOI 10.1016/0042-6989(86)90105-7
   RANINEN A, 1991, VISION RES, V31, P1875, DOI 10.1016/0042-6989(91)90182-5
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   REGAN D, 1983, OPHTHALMOLOGY, V90, P1192
   REGAN D, 1988, CLIN VISION SCI, V2, P235
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   ROHALY AM, 1993, J OPT SOC AM A, V10, P1591, DOI 10.1364/JOSAA.10.001591
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   ROVAMO J, 1988, VISION RES, V28, P785, DOI 10.1016/0042-6989(88)90025-9
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   RUSHTON WAH, 1964, PHOTOCHEM PHOTOBIOL, V3, P561, DOI 10.1111/j.1751-1097.1964.tb08174.x
   RUSSELL RM, 1973, LANCET, V2, P1161
   SACHS MB, 1971, J OPT SOC AM, V61, P1176, DOI 10.1364/JOSA.61.001176
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1967, BR J OPHTHALMOL, V60, P324
   Schmitt NJ, 2003, AM J OPHTHALMOL, V136, P314, DOI 10.1016/S0002-9394(03)00208-3
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Seiple W, 2001, OPTOMETRY VISION SCI, V78, P169, DOI 10.1097/00006324-200103000-00010
   SEKULER R, 1974, ANNU REV PSYCHOL, V25, P195, DOI 10.1146/annurev.ps.25.020174.001211
   SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376
   SEVERIN SL, 1963, ARCH OPHTHALMOL-CHIC, V70, P593
   SEVERIN SL, 1967, ARCH OPHTHALMOL-CHIC, V77, P2, DOI 10.1001/archopht.1967.00980020004002
   Shady S, 2004, P NATL ACAD SCI USA, V101, P5170, DOI 10.1073/pnas.0303452101
   SHEU S, 2002, CHINESE MED J, V65, P435
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   SKOTTUN BC, 1981, INVEST OPHTH VIS SCI, V21, P877
   SLOAN LL, 1973, AM J OPHTHALMOL, V76, P745, DOI 10.1016/0002-9394(73)90572-2
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Soliman MAE, 2002, OPHTHALMOLOGY, V109, P444, DOI 10.1016/S0161-6420(01)00988-5
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stahl W, 2001, BIOFACTORS, V15, P95, DOI 10.1002/biof.5520150209
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Stockman A, 2000, VISION RES, V40, P1711, DOI 10.1016/S0042-6989(00)00021-3
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   SUNNESS JS, 1989, APPL OPTICS, V28, P1158, DOI 10.1364/AO.28.001158
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Swanson William H, 2003, Ophthalmol Clin North Am, V16, P179, DOI 10.1016/S0896-1549(03)00004-X
   TAFT M, 1979, MEM COGNITION, V7, P427
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   *TAP, 1909, ARCH OPHTHALMOL-CHIC, V117, P1329
   THIBOS LN, 1993, OPTOMETRY VISION SCI, V70, P279, DOI 10.1097/00006324-199304000-00006
   Thomas R, 2002, J GLAUCOMA, V11, P46, DOI 10.1097/00061198-200202000-00009
   THORNDYKE PW, 1977, COGNITIVE PSYCHOL, V9, P77, DOI 10.1016/0010-0285(77)90005-6
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Trevino SG, 2005, J EXP BIOL, V208, P4151, DOI 10.1242/jeb.01881
   Trible JR, 2000, AM J OPHTHALMOL, V129, P740, DOI 10.1016/S0002-9394(00)00354-8
   TULVING E, 1963, J EXP PSYCHOL, V66, P319, DOI 10.1037/h0048802
   Turpin A, 2002, INVEST OPHTH VIS SCI, V43, P322
   TYLER CW, 1981, INVEST OPHTH VIS SCI, V20, P204
   TYLER CW, 1991, INVEST OPHTH VIS SCI, V32, P2552
   TYLER CW, 1984, INVEST OPHTH VIS SCI, V25, P1035
   TYLER CW, 1992, TECHNICAL DIGEST SER, V10, P82
   VANTOI V, 1995, J PHYSIOL-LONDON, V482, P189
   VERRIEST G, 1963, J OPT SOC AM, V53, P185, DOI 10.1364/JOSA.53.000185
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VIRTANEN P, 1993, CURR OPIN OPHTHALMOL, V4, P33, DOI 10.1097/00055735-199306000-00006
   von Noorden GK, 1962, AM J OPHTHALMOL, V53, P642
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WARTH JA, 1981, J LAB CLIN MED, V98, P189
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Westcott MC, 2002, BRIT J OPHTHALMOL, V86, P761, DOI 10.1136/bjo.86.7.761
   WESTHEIMER G, 1983, VISION RES, V23, P759, DOI 10.1016/0042-6989(83)90197-9
   Westheimer G, 1972, HDB SENSORY PHYSL, P170
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1994, ST HEAL T, V11, P88
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1152
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1998
   Wild JM, 1998, INVEST OPHTH VIS SCI, V39, P54
   WILLIAMS DR, 1987, J OPT SOC AM A, V4, P1514, DOI 10.1364/JOSAA.4.001514
   WILLIAMS DR, 1981, VISION RES, V21, P1357, DOI 10.1016/0042-6989(81)90242-X
   WILSON HR, 1999, CEREB CORTEX, V13, P445
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wolffsohn JS, 2006, BRIT J OPHTHALMOL, V90, P432, DOI 10.1136/bjo.2005.085787
   WOLKSTEIN M, 1980, OPHTHALMOLOGY, V87, P1140
   Woods RL, 1995, CLIN EXP OPTOM, V78, P43, DOI [10.1111/j.1444-0938.1995.tb00787.x, DOI 10.1111/J.1444-0938.1995.TB00787.X]
   WU G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1556, DOI 10.1001/archopht.1990.01070130058030
   Yamada N, 1999, ARCH OPHTHALMOL-CHIC, V117, P1479
   [No title captured]
NR 361
TC 76
Z9 77
U1 0
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2009
VL 54
IS 2
BP 167
EP 210
DI 10.1016/j.survophthal.2008.12.003
PG 44
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 427PM
UT WOS:000264791200001
PM 19298899
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yoshikawa, T
   Ogata, N
   Wada, M
   Otsuji, T
   Takahashi, K
AF Yoshikawa, Tadanobu
   Ogata, Nahoko
   Wada, Mitsumasa
   Otsuji, Tsuyoshi
   Takahashi, Kanji
TI Characteristics of age-related macular degeneration in patients with
   diabetic retinopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Diabetic retinopathy; Polypoidal
   choroidal vasculopathy (PCV); Choroidal neovascularization (CNV)
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ADULT JAPANESE POPULATION; BEAVER-DAM
   EYE; RISK-FACTORS; CLINICAL CHARACTERISTICS; PHOTODYNAMIC THERAPY;
   PIGMENT EPITHELIUM; 5-YEAR INCIDENCE; MACULOPATHY; PREVALENCE
AB The purpose of this study was to determine the clinical characteristics of age-related macular degeneration (AMD) in patients with diabetic retinopathy (DR).
   Retrospective, consecutive case series. Twenty-six eyes of 25 Japanese patients were studied. All patients were diagnosed as having exudative AMD with DR. Patients with no apparent DR, dry AMD, neovascular maculopathy associated with high myopia, and age < 50 years were excluded. The clinical characteristics of AMD in patients with DR, e.g., gender, age, stage of DR, and type of AMD were evaluated.
   In the 26 eyes, 2 eyes (7.7%) were classified as mild nonproliferative DR (NPDR), 7 (27.0%) with moderate NPDR, 16 (61.5%) with severe NPDR and 1 eye (3.8%) with PDR. Of the 26 eyes with exudative AMD, 21 eyes (80.8%) were classified as neovascular AMD, 4 (15.4%) as polypoidal choroidal vasculopathy and 1 eye (3.8%) as a retinal angiomatous proliferation. Among the eyes with neovascular AMD, 9 eyes (42.9%) were classified as predominantly classic choroidal neovascularization (CNV).
   There is a predominance of men, neovascular AMD and predominantly classic CNV in Japanese AMD patients with DR. The exudative AMD in patients with DR may have different clinical characteristics from those without DR.
C1 [Ogata, Nahoko] Nara Med Univ, Dept Ophthalmol, Nara 6348522, Japan.
   [Yoshikawa, Tadanobu; Wada, Mitsumasa; Otsuji, Tsuyoshi] Kansai Med Univ, Takii Hosp, Dept Ophthalmol, Osaka, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Hirakata Hosp, Dept Ophthalmol, Osaka, Japan.
C3 Nara Medical University; Kansai Medical University; Kansai Medical
   University
RP Ogata, N (通讯作者)，Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Nara 6348522, Japan.
EM ogata@takii.kmu.ac.jp
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2006, OPHTHALMOLOGY, V113, P1378, DOI 10.1016/j.ophtha.2006.02.052
   KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MIYAJIMA H, 2001, FOLIA OPHTHALMOL JPN, V52, P498
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PROCTOR B, 2007, ARVO S, V2149
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tahara Yoshihisa, 2000, Rinsho Ganka, V54, P573
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Varma R, 2007, OPHTHALMOLOGY, V114, P1332, DOI 10.1016/j.ophtha.2006.10.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Xie XW, 2008, GRAEF ARCH CLIN EXP, V246, P1519, DOI 10.1007/s00417-008-0884-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YOSHIMURA N, 2004, FOLIA OPHTHALMOL JPN, V55, P155
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 44
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2011
VL 55
IS 3
BP 235
EP 240
DI 10.1007/s10384-011-0010-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778XI
UT WOS:000291742300009
PM 21538005
DA 2022-11-30
ER

PT J
AU Yang, F
   Sun, YY
   Jin, ZT
   Cheng, Y
   Li, SS
   Bai, YJ
   Huang, LZ
   Li, XX
AF Yang, Fei
   Sun, Yaoyao
   Jin, Zhongtian
   Cheng, Yong
   Li, Shanshan
   Bai, Yujing
   Huang, Lvzhen
   Li, Xiaxin
TI Complement Factor I Polymorphism Is Not Associated with Neovascular
   Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
   in a Chinese Population
SO OPHTHALMOLOGICA
LA English
DT Article
DE Complement factor I; Polymorphism; Neovascular age-related macular
   degeneration; Polypoidal choroidal vasculopathy; Chinese population
ID SUSCEPTIBILITY GENES; ALTERNATIVE PATHWAY; ACTIVATION; VARIANTS; RISK;
   MACULOPATHY; PROGRESSION; SYSTEM
AB Purpose: To identify the associations of the two complement factor I (CFI) polymorphisms rs10033900 and rs2285714 with risk of neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in a Chinese case-control study. Methods: A total of 900 subjects-300 controls, 300 cases with nAMD and 300 cases with PCV were included in the present study. Genomic DNA was extracted from venous blood leukocytes. The allelic variants of rs10033900 and rs2285714 were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The differences in allele distribution between the cases and controls were tested by a X-2 test with age and gender adjusted for by logistic regression analysis. We also performed a meta-analysis of the case-control studies of rs10033900 and rs2285714 based on the currently available evidence from the literature. The meta-analysis was conducted via an inverse-variance, fixed-effects model, as previously described. Results: No statistically significant association was observed between the two polymorphisms of CFI and AMD risk, including nAMD, PCV and combined AMD (p > 0.05 for all comparisons). By meta-analysis, we detected significant associations between both of the SNPs and late AMD, which is consistent with previous results (odds ratio, OR, rs10033900 = 0.814, p rs10033900 < 0.001; OR rs2285714 = 1.221, p rs2285714 < 0.001). For rs2285714, the results of the meta-analysis were less reliable due to its heterogeneity. Conclusions: In our case-control study, neither of the two SNPs most studied (rs10033900 or rs2285714) in the CFI gene was a risk factor for developing nAMD or PCV in a Chinese population. Additional large, comprehensive and well-designed association studies are needed to better understand the role of ethnicity and other gene interactions in the association between the CFI gene and AMD. (C) 2014 S. Karger AG, Basel
C1 [Yang, Fei; Sun, Yaoyao; Cheng, Yong; Li, Shanshan; Bai, Yujing; Huang, Lvzhen; Li, Xiaxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Jin, Zhongtian] Peking Univ, Peoples Hosp, Ctr Hepatobiliary Surg, Beijing 100044, Peoples R China.
   [Yang, Fei; Sun, Yaoyao; Cheng, Yong; Li, Shanshan; Bai, Yujing; Huang, Lvzhen; Li, Xiaxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Yang, Fei; Sun, Yaoyao; Cheng, Yong; Li, Shanshan; Bai, Yujing; Huang, Lvzhen; Li, Xiaxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Huang, LZ (通讯作者)，Peking Univ, Peoples Hosp, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM huanglvzhen@126.com; drlixiaoxin@163.com
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX This study was supported by the National Basic Research Program of China
   (973 Program; No. 2011CB510200), the National Natural Science Foundation
   of China (grant No. 81100666) and the Research Fund for Science and
   Technology Program of Beijing (No. Z121100005312006).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng Y, 2013, CURR GENE THER, V13, P182, DOI 10.2174/1566523211313030003
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fraczek LA, 2010, MOL IMMUNOL, V48, P9, DOI 10.1016/j.molimm.2010.08.016
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2010, MOL VIS, V16, P2412
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Wu Pei-bei, 2013, Zhonghua Yan Ke Za Zhi, V49, P350
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang Z, 2010, ARCH DERMATOL RES, V302, P619, DOI 10.1007/s00403-010-1029-4
NR 31
TC 6
Z9 7
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 232
IS 1
BP 37
EP 45
DI 10.1159/000358241
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ9AW
UT WOS:000338000200004
PM 24732209
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Koizumi, H
   Tamashiro, T
   Itagaki, K
   Nakayama, M
   Maruko, I
   Wakugawa, S
   Terao, N
   Onoe, H
   Wakatsuki, Y
   Kasai, A
   Ogasawara, M
   Shintake, H
   Sugano, Y
   Yamamoto, A
   Kataoka, K
   Hasegawa, T
   Izumi, T
   Kawai, M
   Maruko, R
   Sekiryu, T
   Okada, AA
   Iida, T
   Mori, R
AF Tanaka, Koji
   Koizumi, Hideki
   Tamashiro, Tamaki
   Itagaki, Kanako
   Nakayama, Makiko
   Maruko, Ichiro
   Wakugawa, Sorako
   Terao, Nobuhiro
   Onoe, Hajime
   Wakatsuki, Yu
   Kasai, Akihito
   Ogasawara, Masashi
   Shintake, Hiroaki
   Sugano, Yukinori
   Yamamoto, Akiko
   Kataoka, Keiko
   Hasegawa, Taiji
   Izumi, Takahiko
   Kawai, Moeko
   Maruko, Ruka
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
   Mori, Ryusaburo
TI Short-term results for brolucizumab in treatment-naive neovascular
   age-related macular degeneration: a Japanese multicenter study
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Brolucizumab; Multicenter study; Treatment
ID AFLIBERCEPT
AB Purpose To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naive neovascular age-related macular degeneration (AMD) in a Japanese multicenter study. Study design Retrospective case control study Methods The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months. Best-corrected visual acuity (BCVA) changes, anatomical outcomes, and complications were investigated. Results Of the 43 eyes that completed loading doses, the AMD subtype was type 1 and type 2 macular neovascularization (MNV) in 51%, polypoidal choroidal vasculopathy (PCV) in 42%, and type 3 MNV in 7%. At 3 months after initiating treatment, BCVA significantly improved (P = 0.002) and central retinal thickness significantly decreased (P < 0.0001). At 3 months, complete retinal and subretinal fluid resolution was achieved in 91% of all eyes and complete regression of polypoidal lesions was achieved in 82% of PCV eyes. Iritis occurred in 8 eyes of 8 patients (14%), but resolved using topical or subtenon corticosteroid injection without visual loss in all cases. Conclusions IVBr for treatment-naive neovascular AMD was effective in the short-term, achieving significantly improved BCVA, good retinal fluid resolution, and a high rate of polypoidal lesion regression. However, iritis was noted in 14% of patients which may limit use of this drug.
C1 [Tanaka, Koji; Onoe, Hajime; Wakatsuki, Yu; Mori, Ryusaburo] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Koizumi, Hideki; Tamashiro, Tamaki; Wakugawa, Sorako] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, Nishihara, Okinawa, Japan.
   [Itagaki, Kanako; Kasai, Akihito; Ogasawara, Masashi; Shintake, Hiroaki; Sugano, Yukinori; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Yamamoto, Akiko; Kataoka, Keiko; Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Hasegawa, Taiji; Izumi, Takahiko; Kawai, Moeko; Maruko, Ruka; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 Nihon University; University of Ryukyus; Fukushima Medical University;
   Kyorin University; Tokyo Women's Medical University
RP Tanaka, K (通讯作者)，Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
EM tanaka.koji@nihon-u.ac.jp
CR Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Hikichi T, 2021, JPN J OPHTHALMOL, V65, P208, DOI 10.1007/s10384-021-00819-7
   Honda S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92567-4
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sharma A, 2022, OCUL IMMUNOL INFLAMM, V30, P1508, DOI 10.1080/09273948.2021.1897628
   Singer M, 2022, OPHTHALMOL RETINA, V6, P97, DOI 10.1016/j.oret.2021.05.003
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Veritti D, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14020265
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2022
VL 66
IS 4
BP 379
EP 385
DI 10.1007/s10384-022-00922-3
EA MAY 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2E9BV
UT WOS:000799533800001
PM 35595951
DA 2022-11-30
ER

PT J
AU Gess, AJ
   Fung, AE
   Rodriguez, JG
AF Gess, Adam J.
   Fung, Anne E.
   Rodriguez, Jorge G.
TI Imaging in Neovascular Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; fluorescein angiography; fundus
   autofluorescence; imaging; indocyanine green angiography; optical
   coherence tomography
ID OPTICAL-COHERENCE-TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PIGMENT
   EPITHELIAL DETACHMENT; INDOCYANINE GREEN ANGIOGRAPHY; FUNDUS
   AUTOFLUORESCENCE; FLUORESCEIN ANGIOGRAPHY; PHOTODYNAMIC THERAPY;
   CLINICAL-TRIAL; LIPOFUSCIN; DISEASES
AB Imaging plays an essential role in the diagnosis and treatment of age-related macular degeneration (AMD). This review describes the imaging modalities most commonly employed by ophthalmologists caring for patients with neovascular AMD. Imaging modalities discussed include fluorescein angiography, optical coherence tomography, indocyanine green angiography, and fundus autofluorescence.
C1 [Fung, Anne E.] Pacific Eye Associates, San Francisco, CA 94115 USA.
   [Gess, Adam J.; Fung, Anne E.] Calif Pacific Med Ctr, San Francisco, CA USA.
   [Rodriguez, Jorge G.] CPMC, Ophthalm Diagnost Ctr, San Francisco, CA USA.
C3 California Pacific Medical Center; California Pacific Medical Center
RP Fung, AE (通讯作者)，Pacific Eye Associates, 2100 Webster St 214, San Francisco, CA 94115 USA.
EM annefungmd@yahoo.com
CR Berkow JW, 1997, FLUORESCEIN INDOCYAN
   Bonte CA, 1998, RETINA-J RET VIT DIS, V18, P476, DOI 10.1097/00006982-199805000-00018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2001, RETINA, V2001, P1100
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Domalpally A, 2009, RETINA-J RET VIT DIS, V29, P775, DOI 10.1097/IAE.0b013e3181a0848b
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gass J, 1997, STEREOSCOPIC ATLAS M, P24
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P167
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Olsen TW, 1996, ARCH OPHTHALMOL-CHIC, V114, P97, DOI 10.1001/archopht.1996.01100130093018
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   SANDHU SS, 2005, BR J OPHTHALMOL, V89, P1184
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   *VIP STUD GROUP, 2001, AM J OPHTHALMOL, V31, P540
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 35
TC 29
Z9 31
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 225
EP 233
DI 10.3109/08820538.2011.582533
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200019
PM 21609236
DA 2022-11-30
ER

PT J
AU Lynch, AM
   Mandava, N
   Patnaik, JL
   Frazer-Abel, AA
   Wagner, BD
   Palestine, AG
   Mathias, MT
   Siringo, FS
   Cathcart, JN
   Holers, VM
AF Lynch, Anne M.
   Mandava, Naresh
   Patnaik, Jennifer L.
   Frazer-Abel, Ashley A.
   Wagner, Brandie D.
   Palestine, Alan G.
   Mathias, Marc T.
   Siringo, Frank S.
   Cathcart, Jennifer N.
   Holers, V. Michael
TI Systemic activation of the complement system in patients with advanced
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Advanced age-related macular degeneration; neovascular age-related
   macular degeneration; geographic atrophy; complement
ID MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM; DRUSEN; RISK;
   ATHEROSCLEROSIS; INFLAMMATION; ASSOCIATION; COMPONENTS; FRAGMENTS;
   COMMON
AB Purpose: To examine the role of systemic activation of the complement system (assessed by levels of circulating C3a, Ba, and sC5b-9) in patients (n = 122) with advanced age-related macular degeneration, geographic atrophy, and neovascular age-related macular degeneration, compared with cataract controls (n = 27). Methods: Plasma complement factors were measured using enzyme-linked immunosorbent assays. Statistical analysis included univariate and multivariate logistic regression (p < 0.05). Results: Adjusted for age, the odds ratios of C3a and sC5b-9 for any advanced age-related macular degeneration were 1.78 (95% confidence interval = 1.16-2.73, p < 0.01) and 1.20 (95% confidence interval = 1.04-1.39, p = 0.01), respectively. We found a significantly elevated adjusted odds ratio of C3a (adjusted odds ratio = 1.71, 95% confidence interval = 1.12-2.60, p = 0.01) and sC5b-9 (adjusted odds ratio = 1.22, 95% confidence interval = 1.04-1.43, p = 0.01) for neovascular age-related macular degeneration. Adjusted for age, neither C3a, sC5b-9, nor Ba were associated with geographic atrophy. Conclusion: We suggest a role for elevated plasma levels of C3a and sC5b-9 in patients with neovascular age-related macular degeneration. The study's results reinforce the need for more investigation to assess the impact of therapeutic interventions targeted at the complement signaling pathways in age-related macular degeneration.
C1 [Lynch, Anne M.; Mandava, Naresh; Patnaik, Jennifer L.; Palestine, Alan G.; Mathias, Marc T.; Siringo, Frank S.; Cathcart, Jennifer N.] Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO 80045 USA.
   [Frazer-Abel, Ashley A.] Univ Colorado, Exsera BioLabs, Sch Med, Aurora, CO 80045 USA.
   [Wagner, Brandie D.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
   [Holers, V. Michael] Univ Colorado, Dept Med, Sch Med, Aurora, CO 80045 USA.
   [Holers, V. Michael] Univ Colorado, Dept Immunol, Sch Med, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; Colorado School of Public Health; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Lynch, AM (通讯作者)，Univ Colorado, Sch Med, Dept Ophthalmol, Div Ophthalm Epidemiol, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM anne.lynch@ucdenver.edu
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BrightFocus Foundation, 2017, SOURC MAC DEG FATS F
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   FALK RJ, 1987, AM J PATHOL, V127, P182
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hadders MA, 2012, CELL REP, V1, P200, DOI 10.1016/j.celrep.2012.02.003
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hertle E, 2014, INT J CARDIOL, V174, P400, DOI 10.1016/j.ijcard.2014.04.057
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lynch AM, 2010, BJOG-INT J OBSTET GY, V117, P456, DOI 10.1111/j.1471-0528.2009.02473.x
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Lynch AM, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.035
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484
   Morgan BP, 2016, IMMUNOBIOLOGY, V221, P747, DOI 10.1016/j.imbio.2015.04.006
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Rus V, 1990, Med Interne, V28, P305
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   The Robert Wood Johnson Foundation, 2017, STAT OB COL
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 50
TC 19
Z9 19
U1 1
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2020
VL 30
IS 5
BP 1061
EP 1068
DI 10.1177/1120672119857896
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OB6JS
UT WOS:000578575700054
PM 31203676
DA 2022-11-30
ER

PT J
AU Yildirim, Z
   Ucgun, NI
   Yildirim, F
AF Yildirim, Zuhal
   Ucgun, Nil Irem
   Yildirim, Filiz
TI The role of oxidative stress and antioxidants in the pathogenesis of
   age-related macular degeneration
SO CLINICS
LA English
DT Article
DE Oxidative stress; Antioxidants; Protein oxidation; AMD
ID LIPID-PEROXIDATION; DIETARY-FAT; POSSIBLE MECHANISM; PROTEIN PRODUCTS;
   NITRIC-OXIDE; DRUSEN; GLUTATHIONE; DAMAGE; RISK; ASSOCIATION
AB OBJECTIVE: To investigate the role of oxidant/antioxidant status and protein oxidation in the development of age-related macular degeneration.
   METHOD: The activities of serum superoxide dismutase and glutathione peroxidase and the levels of serum malondialdehyde, advanced oxidation protein products, glutathione and vitamin C were measured in 25 patients with age-related macular degeneration and 25 control subjects without age-related macular degeneration.
   RESULT: The malondialdehyde and advanced oxidation protein product levels in the serum were significantly higher in the age-related macular degeneration patient group than in the control group (p < 0.05). The superoxide dismutase activity in the serum was significantly lower in the age-related macular degeneration patient group than in the control group (p < 0.05). The levels of vitamin C and glutathione and the activity of glutathione peroxidase in the serum were unchanged between groups (p > 0.05).
   CONCLUSION: The results of the present study suggest that decreased effectiveness of the antioxidant defense system and increased oxidative stress may play a role in the pathogenesis of age-related macular degeneration.
C1 [Yildirim, Zuhal] Etimesgut Publ Hlth Lab, Ankara, Turkey.
   [Ucgun, Nil Irem] Ankara Numune Training & Res Hosp, Ophthalmol Clin 2, Ankara, Turkey.
   [Yildirim, Filiz] Duatepe Govt Hosp, Clin Internal Med, Ankara, Turkey.
C3 Ankara Numune Training & Research Hospital
RP Yildirim, Z (通讯作者)，Etimesgut Publ Hlth Lab, Ankara, Turkey.
EM zyildirim2004@yahoo.com
CR Alderman CJJ, 2002, FREE RADICAL BIO MED, V32, P377, DOI 10.1016/S0891-5849(01)00735-3
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halliwell B., 1989, FREE RADICAL BIO MED, P1
   Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Irmak MK, 2003, CELL BIOCHEM FUNCT, V21, P283, DOI 10.1002/cbf.1024
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KURTEL H, 1992, AM J PHYSIOL, V263, pG573, DOI 10.1152/ajpgi.1992.263.4.G573
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MAPSON LW, 1961, ANN NY ACAD SCI, V92, P284, DOI 10.1111/j.1749-6632.1961.tb46127.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Olivares-Corichi IM, 2005, FRONT BIOSCI-LANDMRK, V10, P838, DOI 10.2741/1577
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Penninckx M, 2000, ENZYME MICROB TECH, V26, P737, DOI 10.1016/S0141-0229(00)00165-4
   PRYOR WA, 1991, FREE RADICAL BIO MED, V10, P177, DOI 10.1016/0891-5849(91)90073-C
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1228
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   SUN Y, 1988, CLIN CHEM, V34, P497
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Touyz RM, 2004, BRAZ J MED BIOL RES, V37, P1263, DOI 10.1590/S0100-879X2004000800018
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   WitkoSarsat V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/ki.1996.186
   YOSHIOKA T, 1979, AM J OBSTET GYNECOL, V135, P372, DOI 10.1016/0002-9378(79)90708-7
   1993, CH OPHTHALMOL, V111, P104
NR 46
TC 77
Z9 81
U1 0
U2 29
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 5
BP 743
EP 746
DI 10.1590/S1807-59322011000500006
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 797JZ
UT WOS:000293122900006
PM 21789374
DA 2022-11-30
ER

PT J
AU Cicinelli, MV
   Rabiolo, A
   Sacconi, R
   Carnevali, A
   Querques, L
   Bandello, F
   Querques, G
AF Cicinelli, Maria Vittoria
   Rabiolo, Alessandro
   Sacconi, Riccardo
   Carnevali, Adriano
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Optical coherence tomography angiography in dry age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE reticular pseudodrusen; drusen; age-related macular degeneration;
   geographic atrophy; optical coherence tomography; angiography
ID RETICULAR PSEUDODRUSEN; SWEPT-SOURCE; CHOROIDAL THICKNESS; GEOGRAPHIC
   ATROPHY; ULTRAHIGH-SPEED; CHORIOCAPILLARIS; DRUSEN; EYES;
   NEOVASCULARIZATION; ASSOCIATION
AB Optical coherence tomography angiography is a new imaging modality that provides noninvasive characterization and quantification of the microvasculature in different retinal conditions. The purpose of this study was to give an updated review of the features of dry age-related macular degeneration investigated by means of new-generation optical coherence tomography angiography. We searched PubMed and Medline using the terms "optical coherence tomography angiography" associated with "age-related macular degeneration," "drusen," "reticular pseudodrusen," and "geographic atrophy" and reviewed publications up to January 2017. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Cicinelli, Maria Vittoria; Rabiolo, Alessandro; Sacconi, Riccardo; Carnevali, Adriano; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Sacconi, Riccardo] Univ Verona, Univ Hosp Verona, Dept Ophthalmol, Verona, Italy.
   [Carnevali, Adriano] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Verona; Azienda Ospedaliera Universitaria Integrata
   Verona; Magna Graecia University of Catanzaro
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, Raffaele IRCCS Osped San, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Rabiolo, Alessandro/J-2831-2019; bandello, francesco/AAH-2405-2019;
   cicinelli, maria vittoria/M-1611-2019
OI bandello, francesco/0000-0003-3238-9682; cicinelli, maria
   vittoria/0000-0003-2938-0409; Rabiolo, Alessandro/0000-0002-7772-5929;
   Sacconi, Riccardo/0000-0003-2891-2012; Querques,
   Giuseppe/0000-0002-3292-9581
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corbelli E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166968
   Corvi F, 2016, BR J OPHTHALMOL
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gous G, 2016, COMMUNICATION
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P428, DOI 10.1136/bjophthalmol-2016-308925
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zheng F, 2016, OSLI RETINA, V47, P517, DOI 10.3928/23258160-20160601-02
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 44
TC 22
Z9 23
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2018
VL 63
IS 2
BP 236
EP 244
DI 10.1016/j.survophthal.2017.06.005
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX4EN
UT WOS:000426025600007
PM 28648383
DA 2022-11-30
ER

PT J
AU Rezar-Dreindl, S
   Eibenberger, K
   Buehl, W
   Maccora, K
   Waldstein, S
   Baratsits, M
   Schmidt-Erfurth, U
   Sacu, S
AF Rezar-Dreindl, Sandra
   Eibenberger, Katharina
   Buehl, Wolf
   Maccora, Katia
   Waldstein, Sebastian
   Baratsits, Magdalena
   Schmidt-Erfurth, Ursula
   Sacu, Stefan
TI CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; intravitreal aflibercept;
   functional outcome
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PIGMENT EPITHELIAL DETACHMENT;
   RETINAL ANGIOMATOUS PROLIFERATION; GROWTH-FACTOR TREATMENT; INTRAVITREAL
   AFLIBERCEPT; SUBMACULAR HEMORRHAGE; RANIBIZUMAB; RESOLUTION; TEARS
AB Purpose: To prospectively evaluate the outcomes of different subtypes of neovascular age-related macular degeneration during intravitreal aflibercept monotherapy. Methods: Forty-four eyes of 44 patients with treatment-naive polypoidal choroidal vasculopathy (PCV, n = 12), hemorrhagic choroidal neovascularization (hCNV, n = 12), pigment epithelium detachment (PED, n = 11), or retinal angiomatous proliferation (RAP, n = 9) were included and followed for 12 months. All patients received intravitreal aflibercept monotherapy. Results: Mean visual acuity at baseline in PCV was 67 +/- 16 Early Treatment Diabetic Retinopathy Study letters (20/50 Snellen equivalent), in hCNV 55 +/- 21 (20/80), in RAP lesions 64 +/- 11 (20/50), and in PED 74 +/- 7 (20/32). At Month 12, visual acuity in PCV was 66 +/- 16 (20/50), in hCNV 69 +/- 17 (20/40), in RAP 68 +/- 12 (20/50), and in PED 69 +/- 18 (20/40). At the 12-month follow-up, visual acuity improved or was stable (+/- 5 letters from baseline) in 84% of eyes (37/44 patients), with hCNV showing the greatest mean visual acuity gain. Mean central retinal thickness in patients with PCV was 523 +/- 251 mu m, in hCNV 497 +/- 171, in RAP lesions 573 +/- 132, and in PED 541 +/- 158 and decreased to 310 +/- 91 mu m in PCV, 323 +/- 75 mu m in hCNV, 357 +/- 173 mu m in RAP lesions, and 422 +/- 150 mu m in PED. The mean area of atrophy increased from 2.0 +/- 3.6 mm(2) at baseline to 4.6 +/- 8.6 mm(2) at Month 12 (mean difference [95% confidence interval] -0.8 [-8.5 to 7.0], P = 0.8), with the greatest atrophy in patients with PED at Month 12. Conclusion: All subtypes of neovascular age-related macular degeneration showed anatomical improvement and stabilization of visual function during intravitreal treatment.
C1 [Rezar-Dreindl, Sandra; Eibenberger, Katharina; Buehl, Wolf; Maccora, Katia; Waldstein, Sebastian; Baratsits, Magdalena; Schmidt-Erfurth, Ursula; Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
FU Bayer Healthcare
FX This study received a research grant from Bayer Healthcare.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Chou HD, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0497-0
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dimopoulos S, 2015, CLIN OPHTHALMOL, V9, P1537, DOI 10.2147/OPTH.S87919
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Hwang JU, 2012, RETINA-J RET VIT DIS, V32, P652, DOI 10.1097/IAE.0b013e318233abb4
   Kim JH, 2018, JPN J OPHTHALMOL, V62, P54, DOI 10.1007/s10384-017-0549-2
   Kim K, 2019, RETINA-J RET VIT DIS, V39, P303, DOI 10.1097/IAE.0000000000001947
   Lazzeri S, 2015, OPHTHALMOLOGICA, V233, P74, DOI 10.1159/000371393
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tran THC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/8984313
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 26
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 103
EP 110
DI 10.1097/IAE.0000000000002786
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100015
PM 32091488
DA 2022-11-30
ER

PT J
AU Tamer, C
   Oksuz, H
   Sogut, S
AF Tamer, Cengaver
   Oksuz, Huseyin
   Sogut, Sadik
TI Serum dehydroepiandrosterone sulphate level in age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID HIGH-DOSE SUPPLEMENTATION; PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS;
   CLINICAL-TRIAL; BETA-CAROTENE; SEX-HORMONES; VISION LOSS; VITAMIN-C;
   DAMAGE; PATHOGENESIS
AB PURPOSE: To evaluate plasma dehydroepiandrosterone sulphate (DHEAS) levels in patients diagnosed with age-related macular degeneration (AMD) and controls.
   DESIGN: Case-controlled, prospective, comparative noninterventional study.
   METHODS: This study involved 32 men and 35 women with exudative AMD, 37 men and 38 women with nonexudative AMD, and 32 men and 32 women of an age,matched control group. The Wisconsin Age,Related Maculopathy Grading System was used to asses the severity of AMD lesions. DHEAS levels were measured and compared according to a gender based subdivision Analysis of variance was used to assess the association between DHEAS and AMD. Linear regression model was used to examine the relation among DHEAS level and AMD severity scale.
   RESULTS: Mean +/- SD of DHEAS levels in exudative AMD, nonexudative AMD, and controls in men was 2.67 +/- 0.68 mu mol/l, 2.89 +/- 0.95 mu mol/l, and 4.43 +/- 1.44 mu mol/l, respectively (P =.001), and in women was 1.64 +/- 0.72 mu mol/l, 1.85 +/- 0.73 mu mol/l, and 2.78 +/- 0.91 mu mol/l, respectively (P = .001). Post hoc Tukey analyses revealed a significant reduction in serum DHEAS level in both AMD groups, compared with controls for men and women (P =.001), while no difference was found between AMD groups in both men and women (P = .668 and 0.49, respectively). Regres, sion analyses revealed an inverse correlation among serum DHEAS level and AMD severity scale both in men and women (P = .006 and .007, respectively).
   CONCLUSIONS: This study suggests an inverse correlation between serum DHEAS level and AMD severity scale with a considerably reduced DHEAS level in AMD.
C1 Mustafa Kemal Univ, Dept Ophthalmol, TR-03110 Antakya, Turkey.
   Mustafa Kemal Univ, Dept Biochem, Antakya, Turkey.
C3 Mustafa Kemal University; Mustafa Kemal University
RP Tamer, C (通讯作者)，Mustafa Kemal Univ, Dept Ophthalmol, TR-03110 Antakya, Turkey.
EM cengavertamer@yahoo.ca
CR ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bednarek-Tupikowska G, 2000, Med Sci Monit, V6, P40
   Berr C, 1996, P NATL ACAD SCI USA, V93, P13410, DOI 10.1073/pnas.93.23.13410
   BIRKENHAGERGILLESSE EG, 1994, ANN NY ACAD SCI, V719, P543, DOI 10.1111/j.1749-6632.1994.tb56858.x
   Bucolo C, 2005, NEUROREPORT, V16, P1203, DOI 10.1097/00001756-200508010-00014
   Bucolo C, 2004, EUR J PHARMACOL, V498, P111, DOI 10.1016/j.ejphar.2004.06.067
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Demirbag R, 2005, SCAND CARDIOVASC J, V39, P172, DOI 10.1080/14017430510035862
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551
   Orshal JM, 2004, AM J PHYSIOL-REG I, V286, pR233, DOI 10.1152/ajpregu.00338.2003
   Parker L N, 1980, Endocr Rev, V1, P392
   Reddy VN, 2001, INVEST OPHTH VIS SCI, V42, P3247
   Rocha EM, 2000, BRIT J OPHTHALMOL, V84, P76, DOI 10.1136/bjo.84.1.76
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schunkert H, 1999, AM J HYPERTENS, V12, P1140, DOI 10.1016/S0895-7061(99)00128-4
   Sullivan DA, 1998, ADV EXP MED BIOL, V438, P11
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 33
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2007
VL 143
IS 2
BP 212
EP 216
DI 10.1016/j.ajo.2006.09.054
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 137CV
UT WOS:000244271400003
PM 17157799
DA 2022-11-30
ER

PT J
AU Brantley, MA
   Osborn, MP
   Sanders, BJ
   Rezaei, KA
   Lu, P
   Li, C
   Milne, GL
   Cai, J
   Sternberg, P
AF Brantley, Milam A., Jr.
   Osborn, Melissa P.
   Sanders, Barton J.
   Rezaei, Kasra A.
   Lu, Pengcheng
   Li, Chun
   Milne, Ginger L.
   Cai, Jiyang
   Sternberg, Paul, Jr.
TI Plasma Biomarkers of Oxidative Stress and Genetic Variants in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; PIGMENT EPITHELIAL-CELLS; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; REDOX STATUS;
   VITAMIN-C; RISK; GLUTATHIONE; SUSCEPTIBILITY
AB PURPOSE: To compare plasma levels of oxidative stress biomarkers in patients with age-related macular degeneration (AMD) and controls and to evaluate a potential relationship between biochemical markers of oxidative stress and AMD susceptibility genotypes.
   DESIGN: Prospective case-control study.
   METHODS: Plasma levels of oxidative stress biomarkers were determined in 77 AMD patients and 75 controls recruited from a clinical practice. Cysteine, cystine (CySS), glutathione, isoprostane, and isofuran were measured, and participants were genotyped for polymorphisms in the complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.
   RESULTS: CySS was elevated in cases compared with controls (P = .013). After adjustment for age, sex, and smoking, this association was not significant. In all participants, CySS levels were associated with the CFH polymorphism rs3753394 (P = .028) as well as an 8-allele CFH haplotype (P = .029) after correction for age, gender, and smoking. None of the other plasma markers was related to AMD status in our cohort.
   CONCLUSIONS: Our investigation of the gene-environment interaction involved in AMD revealed a relationship between a plasma biomarker of oxidative stress, CySS, and CFH genotype. These data suggest a potential association between inflammatory regulators and redox status in AMD pathogenesis. (Am J Ophthalmol 2012; 153:460-467. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Brantley, Milam A., Jr.; Osborn, Melissa P.; Sanders, Barton J.; Rezaei, Kasra A.; Cai, Jiyang; Sternberg, Paul, Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Lu, Pengcheng; Li, Chun] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA.
   [Li, Chun] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Milne, Ginger L.] Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University
RP Sternberg, P (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM paul.sternberg@vanderbilt.edu
RI Li, Chun/R-1095-2019; Milne, Ginger/D-7648-2014; Li, Chun/B-8388-2012
OI Li, Chun/0000-0002-8819-2443; Milne, Ginger/0000-0003-3890-151X; 
FU National Institutes of Health, Bethesda, Maryland [EY007892, P30
   EY08126, P30 ES000267]; American Geriatrics Society, New York, New York;
   Carl M. & Mildred A. Reeves Foundation, Columbus, Indiana; Research to
   Prevent Blindness, Inc, New York, New York; NATIONAL EYE INSTITUTE
   [R01EY007892, R29EY007892, P30EY008126] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267]
   Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest, and none were reported. Publication
   of this article was supported by Grants EY007892 (P.S.), P30 EY08126,
   and P30 ES000267 (G.L.M.) from the National Institutes of Health,
   Bethesda, Maryland; the Jahnigen Career Development Award from the
   American Geriatrics Society, New York, New York (M.A.B.); the Carl M. &
   Mildred A. Reeves Foundation, Columbus, Indiana (M.A.B.); and an
   unrestricted departmental grant from Research to Prevent Blindness, Inc,
   New York, New York. Involved in Study design and conduct (M.A.B., J.C.,
   P.S.); Data collection (B.J.S., K.A.R., G.L.M., J.C.); Data management,
   analysis, and interpretation (M.A.B., M.P.O., P.L., C.L., G.L.M., J.C.,
   P.S.); Manuscript preparation (MAD., M.P.O., J.C., P.S.); and Manuscript
   review and approval (M.A.B., M.P.O., B.J.S., K.A.R., P.L., CL., G.L.M.,
   J.C., P.S.). All procedures were approved prospectively by the local
   institutional review board, the Vanderbilt University Human Research
   Protection Program. Research adhered to the tenets of the Declaration of
   Helsinki and was conducted in accordance with Health Insurance
   Portability and Accountability Act regulations. Informed consent was
   obtained from all participants on study enrollment. The authors thank
   the staff of the Eicosanoid Core Laboratory for the measurements of
   isoprostanes and isofurans, as well as Jonathan Flames, Jeffrey Canter,
   and the DNA Resources Core of the Center for Human Genetics Research at
   Vanderbilt University for assistance with genotyping.
CR Andersson A, 2000, ATHEROSCLEROSIS, V151, P535, DOI 10.1016/S0021-9150(99)00418-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bicikova M, 2004, CLIN CHEM LAB MED, V42, P518, DOI 10.1515/CCLM.2004.088
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calabrese V, 2006, ANTIOXID REDOX SIGN, V8, P1975, DOI 10.1089/ars.2006.8.1975
   Chen LJ, 2006, MOL VIS
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Davies SS, 2011, FREE RADICAL BIO MED, V50, P559, DOI 10.1016/j.freeradbiomed.2010.11.023
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fessel JP, 2005, ANTIOXID REDOX SIGN, V7, P202, DOI 10.1089/ars.2005.7.202
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Go YM, 2011, FREE RADICAL BIO MED, V50, P495, DOI 10.1016/j.freeradbiomed.2010.11.029
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Milne GL, 2007, NAT PROTOC, V2, P221, DOI 10.1038/nprot.2006.375
   Montine TJ, 2007, J MOL NEUROSCI, V33, P114, DOI 10.1007/s12031-007-0044-1
   Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Morrow JD, 2002, AM J RESP CRIT CARE, V166, pS25, DOI 10.1164/rccm.2206011
   MORROW JD, 1991, FREE RADICAL BIO MED, V10, P195, DOI 10.1016/0891-5849(91)90076-F
   Morrow JD, 1999, METHOD ENZYMOL, P3003
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roberts LJ, 2005, BRAIN PATHOL, V15, P143
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sekhar RV, 2011, DIABETES CARE, V34, P162, DOI 10.2337/dc10-1006
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vento M, 2009, PEDIATRICS, V124, pE439, DOI 10.1542/peds.2009-0434
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   2001, ARCH OPHTHALMOL, V119, P1417
NR 60
TC 34
Z9 34
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2012
VL 153
IS 3
BP 460
EP 467
DI 10.1016/j.ajo.2011.08.033
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907CB
UT WOS:000301394300010
PM 22035603
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zanke, B
   Hawken, S
   Carter, R
   Chow, D
AF Zanke, Brent
   Hawken, Steven
   Carter, Ronald
   Chow, David
TI A genetic approach to stratification of risk for age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age-related macular degeneration; genetics; predictive model
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY; PREVALENCE; VARIANT; DISEASE;
   POLYMORPHISM; ASSOCIATION; MACULOPATHY; IMMUNOLOGY; LOC387715
AB The genetic determinants of age-related macular degeneration (AMD) are reviewed and a novel approach to risk determination based upon inherited genetic polymorphisms and smoking history is presented. Although AMD was long thought to have primarily an environmental etiology, genetic variation is now known to account for the majority of the disease risk, with variations in the genes of the complement pathways playing a prominent role. Independent and validated clinical studies have implicated the C3 gene and its regulator, complement factor H (1q31.1), complement component 2 (6q21.33), and complement factor B (6q21.33). Subtle variations in complement activity increase the risk of symptomatic macular inflammation with age. A second group of AMD-associated genetic markers may aggravate complement-mediated inflammation by permitting retinal oxidative damage. Variation within the chromosomal site (10q26) coding a mitochondrial-associated protein (age-related maculopathy susceptibility 2) and an independent variation within the mitochondrial genome itself (A4917G) suggest a contributing pathophysiological role of retinal oxidative stress. A genetic panel of disease-susceptibility markers and smoking history can identify a group of individuals with greater than 65% lifetime risk of AMD. The introduction of genetic marker testing into clinical practice may identify patients with early disease who may be aided by presymptomatic monitoring or inclusion into trials of newer prophylactic agents.
C1 [Zanke, Brent] Ottawa Hlth Res Inst, Div Epidemiol, Ottawa, ON, Canada.
   [Hawken, Steven] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
   [Carter, Ronald] Hamilton Reg Lab Med Program, Genet Lab, Hamilton, ON, Canada.
   [Chow, David] St Michaels Hosp, Dept Ophthalmol, Toronto, ON M5B 1W8, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Toronto; University Toronto Affiliates; Saint
   Michaels Hospital Toronto
RP Zanke, B (通讯作者)，Univ Ottawa Med, 501 Smythe Rd, Ottawa, ON K1H 8L6, Canada.
EM brent.zanke@ohri.ca
OI Hawken, Steven/0000-0002-3341-9022
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   D'Errico M, 2008, MUTAT RES-REV MUTAT, V659, P4, DOI 10.1016/j.mrrev.2007.10.003
   David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978
   Demchuk E, 2007, ENVIRON HEALTH PERSP, V115, P231, DOI 10.1289/ehp.8870
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Johnson AD, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-6
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McRae AF, 2008, GENOME RES, V18, P911, DOI 10.1101/gr.074872.107
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moreira PI, 2008, CNS NEUROL DISORD-DR, V7, P3
   Park KH, 2009, MOL VIS, V15, P200
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Truedsson L, 2007, AUTOIMMUNITY, V40, P560, DOI 10.1080/08916930701510673
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuste J, 2008, INFECT IMMUN, V76, P3761, DOI 10.1128/IAI.00291-08
   Zogopoulos G, 2007, HUM GENET, V122, P345, DOI 10.1007/s00439-007-0404-5
NR 44
TC 19
Z9 20
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2010
VL 45
IS 1
BP 22
EP 27
DI 10.3129/i09-209
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558YD
UT WOS:000274783900004
PM 20130705
DA 2022-11-30
ER

PT J
AU Klein, R
   Lee, KE
   Tsai, MY
   Cruickshanks, KJ
   Gangnon, RE
   Klein, BEK
AF Klein, Ronald
   Lee, Kristine E.
   Tsai, Michael Y.
   Cruickshanks, Karen J.
   Gangnon, Ronald E.
   Klein, Barbara E. K.
TI Oxidized Low-density Lipoprotein and the Incidence of Age-related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; OXIDATIVE STRESS; VISUAL IMPAIRMENT; LIPID-PEROXIDATION;
   PIGMENT EPITHELIUM; MULTISTATE-MODELS; PROGRESSION; POPULATION; DISEASE;
   ACUITY
AB Purpose: To examine the relationship between serum oxidized low-density lipoprotein (ox-LDL) cholesterol and the incidence of age-related macular degeneration (AMD) over a 25-year period in a sample of persons from the population-based Beaver Dam Eye Study (BDES).
   Design: Observational prospective cohort study.
   Participants: A total of 4972 people from the BDES (aged 43-84 years and living in Beaver Dam, Wisconsin in 1988) seen during at least 1 of 6 examination phases at approximately 5-year intervals between 1988 and 2016.
   Methods: A 50% random sample of participants (N = 2468) was selected for ox-LDL measurements. Stored frozen specimens from every examination phase were processed using an enzyme-linked immunosorbent assay from a single batch. All available intervals were included for a person, resulting in 6586 person-visits.
   Main Outcome Measures: Age-related macular degeneration was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was defined using a 5-step severity scale. The severity of the worse eye at each examination was used for analyses. A multi-state Markov (MSM) model was fit to simultaneously assess the ox-LDL relationship to all AMD transitions, including incidence of any AMD, incidence of late AMD, and worsening and improvement of AMD over the 25 years of the study.
   Results: The mean (standard deviation) level of ox-LDL was 75.3 (23.1) U/L at the baseline examination. When adjusting for age, sex, ARMS2 and CFH risk alleles, and examination phase, the ox-LDL at the beginning of a period was not statistically significantly associated with the incidence of any AMD (hazard ratio per 10 U/L oxLDL was 1.03, 95% confidence interval 0.98,1.09). Furthermore, ox-LDL was not associated with worsening anywhere along the AMD severity scale, nor with incidence of late AMD. The lack of relationships of ox-LDL to the incidence of any AMD or worsening of AMD remained after adjustment for history of statin use, smoking status, body mass index, and history of cardiovascular disease (data not shown).
   Conclusions: Our findings do not provide evidence for statistically significant relationships between ox-LDL and AMD disease development or worsening of AMD. (C) 2018 by the American Academy of Ophthalmology
C1 [Klein, Ronald; Lee, Kristine E.; Cruickshanks, Karen J.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 Walnut St,417 WARF, Madison, WI 53726 USA.
   [Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [Cruickshanks, Karen J.; Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237; Gangnon, Ronald/0000-0003-2587-6714
FU National Institutes of Health, Bethesda, MD [EY06594]; Research to
   Prevent Blindness, New York, NY; NATIONAL EYE INSTITUTE [U10EY006594]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG011099]
   Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): B.E.K.K. and R.K.:
   Supported by grant EY06594 from the National Institutes of Health,
   Bethesda, MD and an unrestricted grant from Research to Prevent
   Blindness, New York, NY. The sponsor or funding organization had no role
   in the design or conduct of this research.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 1976, Prev Med, V5, P207
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 2003, ARCH OTOLARYNGOL, V129, P1041, DOI 10.1001/archotol.129.10.1041
   Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P451, DOI 10.1001/archopht.122.4.451
   Fessel JP, 2005, ANTIOXID REDOX SIGN, V7, P202, DOI 10.1089/ars.2005.7.202
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Handelman GJ, 2000, BLOOD PURIFICAT, V18, P343, DOI 10.1159/000014460
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kuno Noriyuki, 2011, Curr Mol Pharmacol, V4, P196
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Locatelli F, 2003, NEPHROL DIAL TRANSPL, V18, P1272, DOI 10.1093/ndt/gfg074
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Mulder DJ, 2006, DIABETES TECHNOL THE, V8, P523, DOI 10.1089/dia.2006.8.523
   Myers GL, 2006, CLIN CHEM, V52, P5, DOI 10.1373/clinchem.2005.0525144
   Penfold PL, 2005, MACULAR DEGENERATION, P25, DOI 10.1007/3-540-26977-0_2
   Pow DV, 2005, MACULAR DEGENERATION, P123, DOI 10.1007/3-540-26977-0_8
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Team RDC, 2009, R LANG ENV STAT COMP
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
NR 42
TC 8
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2019
VL 126
IS 5
BP 752
EP 758
DI 10.1016/j.ophtha.2018.12.026
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HU0XG
UT WOS:000464995000026
PM 30572074
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Sakamoto, T
   Sheu, SJ
   Arimura, N
   Sameshima, S
   Shimura, M
   Uemura, A
   Kawano, H
   Wu, TT
   Kubota, T
   Sohma, R
   Noda, Y
AF Sakamoto, Taiji
   Sheu, Shwu-Jiuan
   Arimura, Noboru
   Sameshima, Seiji
   Shimura, Masahiko
   Uemura, Akinori
   Kawano, Hiroki
   Wu, Tsung-Tien
   Kubota, Toshiaki
   Sohma, Rika
   Noda, Yoshihiro
TI VITRECTOMY FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH VITREOUS
   HEMORRHAGE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; pars
   plana vitrectomy; polypoidal choroidal vasculopathy; posterior vitreous
   detachment
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; POSTERIOR VITREOMACULAR
   ADHESION; OPTICAL COHERENCE TOMOGRAPHY; TRACTION; RISK; VASCULOPATHY;
   MACULOPATHY
AB Purpose: The purpose of this study was to study the effect of pars plana vitrectomy (PPV) for age-related macular degeneration with vitreous hemorrhage on choroidal neo-vascularization (CNV).
   Methods: A retrospective interventional case series in which 92 eyes with age-related macular degeneration with vitreous hemorrhage that received PPV were studied. Among them, 60 eyes without pre- or posttreatment other than PPV were selected. Choroidal neo-vascularization was expressed as the incidence of bleeding 6 months before and after PPV. The status of CNV after PPV was compared and classified as worsened, remained, regressed, disappeared, or unclassified. The influence of posterior vitreous detachment was examined.
   Results: The incidence of bleeding was reduced dramatically after PPV (1.11 +/- 0.44 in preoperative 6 months vs. 0.03 +/- 0.18 in postoperative 6 months, P < 0.0001). The status of CNV improved in most cases; 40 of 54 classifiable eyes (74.1%) were categorized as "regressed" or "disappeared." Postoperative visual acuity was significantly better than preoperative visual acuity (P < 0.0001). The status of CNV subsided more in those eyes without posterior vitreous detachment than in those with posterior vitreous detachment (odds ratio, 1.02; 95% confidence interval, -0.01-2.08; P = 0.054).
   Conclusion: The activity of CNV was reduced after PPV in eyes with age-related macular degeneration with vitreous hemorrhage. Visual acuity significantly improved, with only rare severe complications. The involvement of vitreomacular traction in the patho-physiology of CNV in age-related macular degeneration is possible. RETINA 30: 856-864, 2010
C1 [Sakamoto, Taiji; Arimura, Noboru; Sameshima, Seiji; Kawano, Hiroki] Kagoshima Univ, Sch Dent & Med Sci, Dept Ophthalmol, Kagoshima 8908520, Japan.
   [Sheu, Shwu-Jiuan; Wu, Tsung-Tien] Natl Yang Ming Univ, Sch Med, Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan.
   [Shimura, Masahiko] NTT Tohoku Hosp, Sendai, Miyagi, Japan.
   [Uemura, Akinori] Kagoshima City Hosp, Kagoshima, Japan.
   [Kubota, Toshiaki; Sohma, Rika] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan.
   [Noda, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 812, Japan.
C3 Kagoshima University; Kaohsiung Veterans General Hospital; National Yang
   Ming Chiao Tung University; Kagoshima City Hospital; University of
   Occupational & Environmental Health - Japan; Kyushu University
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
RI Kubota, Toshiaki/AAN-4334-2021
FU Research Committee on Chorioretinal Degeneration and Optic Atrophy,
   Ministry of Health, Labor, and Welfare; Ministry of Education, Science,
   and Culture of Japan; Kaohsiung Veterans General Hospital, Kaohsiung,
   Taiwan [VGHKS 98-063]
FX Supported in part by a grant from the Research Committee on
   Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor,
   and Welfare; by a Grant-in-Aid for Scientific Research from the Ministry
   of Education, Science, and Culture of Japan; and by Grant VGHKS 98-063
   from Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
CR Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   De la Paz MA, 1998, INVEST OPHTH VIS SCI, V39, P1256
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Karatas M, 2005, EYE, V19, P676, DOI 10.1038/sj.eye.6701622
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Meyer CH, 2006, EYE, V20, P1090, DOI 10.1038/sj.eye.6702121
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
NR 30
TC 17
Z9 20
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2010
VL 30
IS 6
BP 856
EP 864
DI 10.1097/IAE.0b013e3181c969cb
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AG
UT WOS:000278549100003
PM 20182401
DA 2022-11-30
ER

PT J
AU Bosch-Morell, F
   Villagrasa, V
   Ortega, T
   Acero, N
   Munoz-Mingarro, D
   Gonzalez-Rosende, ME
   Castillo, E
   Sanahuja, MA
   Soriano, P
   Martinez-Solis, I
AF Bosch-Morell, Francisco
   Villagrasa, Victoria
   Ortega, Teresa
   Acero, Nuria
   Munoz-Mingarro, Dolores
   Eugenia Gonzalez-Rosende, M.
   Castillo, Encarna
   Amparo Sanahuja, M.
   Soriano, Pilar
   Martinez-Solis, Isabel
TI Medicinal plants and natural products as neuroprotective agents in
   age-related macular degeneration
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE age-related macular degeneration; bilberry; blueberry; curcuma;
   carotenoids; ginkgo; polyphenols; saffron; vitamins
ID GINKGO-BILOBA EXTRACTS; SAFFRON SUPPLEMENTATION; OXIDATIVE STRESS;
   CROCUS-SATIVUS; ANTHOCYANINS; CROCETIN; EYE; CURCUMIN; DISEASE; LUTEIN
AB The retina may suffer neurodegenerative damages, as other tissues of the central nervous system do, and serious eye diseases may develop. One of them is age-related macular degeneration, which causes progressive loss of vision due to retina degeneration. Treatment of age-related macular degeneration focuses on antioxidant agents and anti-vascular endothelial growth factor compounds, among others, that prevent/ diminish oxidative stress and reduce neovascularisation respectively. The phytochemicals, medicinal plants and/or plant-diet supplements might be a useful adjunct in prevention or treatment of age-related macular degeneration owing to their antioxidant and anti-vascular endothelial growth factor properties. This review article presents the most investigated plants and natural products in relation to age-related macular degeneration, such as saffron, ginkgo, bilberry and blueberry, curcuma or turmeric, carotenoids, polyphenols, and vitamins C and E. This study provides up-to-date information on the effects, treatments, safety and efficiency of these phytotherapy products.
C1 [Bosch-Morell, Francisco; Martinez-Solis, Isabel] Univ Cardenal Herrera CEU, CEU Univ, Biomed Sci Inst, Valencia, Spain.
   [Bosch-Morell, Francisco] Univ Cardenal Herrera CEU, CEU Univ, Dept Biomed Sci, Fac Hlth Sci, Valencia, Spain.
   [Villagrasa, Victoria; Eugenia Gonzalez-Rosende, M.; Castillo, Encarna; Amparo Sanahuja, M.; Martinez-Solis, Isabel] Univ Cardenal Herrera CEU, CEU Univ, Dept Pharm, Fac Hlth Sci, Valencia, Spain.
   [Ortega, Teresa] Univ Complutense Madrid, Dept Pharmacol Pharmacognosy & Bot, Madrid, Spain.
   [Acero, Nuria] Univ San Pablo CEU, CEU Univ, Dept Pharmaceut & Hlth Sci, Fac Pharm, Madrid, Spain.
   [Munoz-Mingarro, Dolores] Univ San Pablo CEU, CEU Univ, Dept Chem & Biochem, Fac Pharm, Madrid, Spain.
   [Soriano, Pilar; Martinez-Solis, Isabel] Univ Valencia, ICBiBE Bot Garden, Valencia, Spain.
C3 Universidad CEU Cardenal Herrera; Universidad CEU Cardenal Herrera;
   Universidad CEU Cardenal Herrera; Complutense University of Madrid; San
   Pablo CEU University; San Pablo CEU University; University of Valencia
RP Martinez-Solis, I (通讯作者)，Univ Cardenal Herrera CEU, CEU Univ, Biomed Sci Inst, Valencia, Spain.; Martinez-Solis, I (通讯作者)，Univ Cardenal Herrera CEU, CEU Univ, Dept Pharm, Fac Hlth Sci, Valencia, Spain.; Martinez-Solis, I (通讯作者)，Univ Valencia, ICBiBE Bot Garden, Valencia, Spain.
EM isolis@uchceu.es
RI Mingarro, Dolores Muñoz -/K-5910-2016; Solis, Isabel
   Martínez/K-4045-2017; Acero, N./H-3627-2017
OI Acero, N./0000-0001-9307-3839; soriano guarinos,
   pilar/0000-0001-6736-1482; Reis, AlessanRSS/0000-0001-8486-7469
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   Basnet P, 2011, MOLECULES, V16, P4567, DOI 10.3390/molecules16064567
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Broadhead GK, 2016, CRIT REV FOOD SCI, V56, P2767, DOI 10.1080/10408398.2013.879467
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Bukhari SI, 2018, BIOMED PHARMACOTHER, V98, P733, DOI 10.1016/j.biopha.2017.12.090
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chassagne F, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00775
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christodoulou E, 2015, J PHARM PHARMACOL, V67, P1634, DOI 10.1111/jphp.12456
   Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Di Marco F, 2013, AM J NEURODEGENER DI, V2, P208
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Evans J. R., 2017, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000254.PUB4
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fernandez-Araque A, 2017, NUTR HOSP, V34, P469, DOI 10.20960/nh.420
   Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Fursova A Zh, 2005, Adv Gerontol, V16, P76
   Gerding H, 2009, KLIN MONATSBL AUGENH, V226, P216, DOI 10.1055/s-0028-1109326
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hatziagapiou K, 2019, CURR NEUROPHARMACOL, V17, P377, DOI 10.2174/1570159X16666180321095705
   Heitmar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030649
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Huang WY, 2018, J AGR FOOD CHEM, V66, P1638, DOI 10.1021/acs.jafc.7b06135
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jia YP, 2017, MOLECULES, V22, DOI 10.3390/molecules22040610
   Jitsanong T, 2011, TOXICOL IN VITRO, V25, P167, DOI 10.1016/j.tiv.2010.10.014
   Bagur MJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23010030
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kanakis CD, 2009, J PHOTOCH PHOTOBIO B, V95, P204, DOI 10.1016/j.jphotobiol.2009.03.006
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Khoo HE, 2017, FOOD NUTR RES, V61, P1, DOI 10.1080/16546628.2017.1361779
   Kim EK, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0301-2
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Leone Sheila, 2018, Phytother Res, V32, P2364, DOI 10.1002/ptr.6181
   Levy Y, 1998, EYE, V12, P967, DOI 10.1038/eye.1998.250
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li S, 2019, INT J BIOL SCI, V15, P2016, DOI 10.7150/ijbs.30536
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Manisha Singh, 2012, Journal of Pharmacy Research, V5, P5028
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Martinez-Solis I, 2019, PLANTA MED, V85, P1292, DOI 10.1055/a-0947-5712
   Melnyk JP, 2010, FOOD RES INT, V43, P1981, DOI 10.1016/j.foodres.2010.07.033
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39
   Mohanta TK, 2014, NAT PROD RES, V28, P746, DOI 10.1080/14786419.2013.879303
   Mojaverrostami S, 2018, ADV PHARM BULL, V8, P575, DOI 10.15171/apb.2018.066
   Montes P, 2015, CNS NEUROL DISORD-DR, V14, P132, DOI 10.2174/1871527314666150202151440
   Moratalla-Lopez N, 2019, MOLECULES, V24, DOI 10.3390/molecules24152827
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Mykhailenko O, 2019, PHYTOCHEMISTRY, V162, P56, DOI 10.1016/j.phytochem.2019.02.004
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Nassiri-Asl M, 2015, BIOACTIVE NUTRACEUTICALS AND DIETARY SUPPLEMENTS IN NEUROLOGICAL AND BRAIN DISEASE: PREVENTION AND THERAPY, P29, DOI 10.1016/B978-0-12-411462-3.00003-5
   Natoli R, 2010, MOL VIS, V16, P1801
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Peddada KV, 2019, INT OPHTHALMOL, V39, P725, DOI 10.1007/s10792-018-0845-y
   Pescosolido N, 2014, PLANTA MED, V80, P249, DOI 10.1055/s-0033-1351074
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Poma Anna, 2012, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V11, P37
   Radomska-Lesniewska DM, 2019, CENT EUR J IMMUNOL, V44, P181, DOI 10.5114/ceji.2019.87070
   Rahaiee S, 2015, J FOOD SCI TECH MYS, V52, P1881, DOI 10.1007/s13197-013-1238-x
   Ravikrishnan R, 2011, FOOD CHEM TOXICOL, V49, P2841, DOI 10.1016/j.fct.2011.08.011
   Reinisalo M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/340520
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Saberi-Karimian M, 2019, CRIT REV FOOD SCI, V59, P299, DOI 10.1080/10408398.2017.1366892
   Sandmann G, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070219
   Shu ZM, 2019, INT J PHARMACOL, V15, P1, DOI 10.3923/ijp.2019.1.9
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Spadiene A, 2013, CENT EUR J MED, V8, P736, DOI 10.2478/s11536-012-0146-1
   Srinivasan K, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P413, DOI 10.1016/B978-0-12-401717-7.00042-3
   Tamaddonfard E, 2013, PHARMACOL REP, V65, P1272, DOI 10.1016/S1734-1140(13)71485-3
   Trease GE, 2009, PHARMACOGNOSY
   Ude C, 2013, CLIN PHARMACOKINET, V52, P727, DOI 10.1007/s40262-013-0074-5
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   WHO (World Health Organization), 2007, MON SEL MED PLANTS, V3
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu ZH, 2017, J FUNCT FOODS, V39, P186, DOI 10.1016/j.jff.2017.10.031
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
NR 100
TC 15
Z9 16
U1 2
U2 54
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD DEC
PY 2020
VL 15
IS 12
BP 2207
EP 2216
DI 10.4103/1673-5374.284978
PG 10
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA MG0WP
UT WOS:000545755700005
PM 32594032
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jin, GM
   Zou, MJ
   Chen, AM
   Zhang, YC
   Young, CA
   Wang, SB
   Zheng, DY
AF Jin, Guangming
   Zou, Minjie
   Chen, Aiming
   Zhang, Yichi
   Young, Charlotte A.
   Wang, Shi-Bin
   Zheng, Danying
TI Prevalence of age-related macular degeneration in Chinese populations
   worldwide: A systematic review and meta-analysis
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; Chinese population; meta-analysis;
   prevalence
ID RACIAL-DIFFERENCES; VISUAL IMPAIRMENT; RISK-FACTORS; MACULOPATHY
AB Importance Age-related macular degeneration (AMD) is a leading cause of irreversible blindness, but the magnitude of AMD among Chinese populations worldwide is still unknown. Background To investigate the prevalence of AMD in Chinese populations worldwide. Design Meta-analysis. Participants Nine studies with 29 344 subjects in total. Methods All population-based studies on AMD prevalence in Chinese populations worldwide were identified and only studies using standardized AMD grading systems (Wisconsin Age-Related Maculopathy Grading System, Age-Related Eye Disease Study System of Classifying AMD, the International Classification and Grading System for AMD or the Clinical Classification of Age-Related Macular Degeneration) were included. We used meta-analysis to estimate the pooled prevalence and its 95% confidence interval (95% CI) of AMD, and to explore the racial differences and regional differences. Main Outcome Measures Age-specific prevalence, gender-specific prevalence and pooled prevalence of early and late AMD among Chinese population worldwide. Results Altogether, 9 studies with 29 344 individuals were included and analysed. The crude pooled prevalence of early and late AMD among Chinese populations worldwide aged 50 years and above is 4.9% (95% CI: 3.1%-7.7%) and 0.7% (95% CI: 0.5%-1.1%), respectively. Corresponding crude prevalence among Caucasian populations are 10.1% (95% CI: 5.7%-17.2%) and 1.6% (95% CI: 1.0%-2.4%). There are statistically significant differences within age and gender subgroups. Conclusions and Relevance Among persons aged 50+ years, both early AMD and late AMD in Chinese populations worldwide were less common compared with that reported from Caucasian populations. Considering the significant racial or ethnic differences in AMD prevalence between Chinese and Caucasian people, further studies are needed to explore the possible mechanism behind this discrepancy.
C1 [Jin, Guangming; Zheng, Danying] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Zou, Minjie] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.
   [Chen, Aiming] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China.
   [Zhang, Yichi] Sun Yat Sen Univ, Dept Ophthalmol, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China.
   [Young, Charlotte A.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Wang, Shi-Bin] Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Mental Hlth Ctr, 123 Huifu West Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; University of California System; University of
   California San Francisco; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital
RP Zheng, DY (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.; Wang, SB (通讯作者)，Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Mental Hlth Ctr, 123 Huifu West Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM spiriorwang@126.com; zhengdyy@163.com
RI Young, Charlotte A/F-4405-2018
OI Young, Charlotte A/0000-0002-9402-7663; Zou, Minjie/0000-0001-7706-6663;
   Jin, Guangming/0000-0001-9994-6338
FU National Natural Science Foundation of China [81873673]
FX National Natural Science Foundation of China, Grant/Award Number:
   81873673
CR Boyle MH., 1998, EVID-BASED MENT HEAL, V1, P37, DOI DOI 10.1136/EBMH.1.2.37
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li Y, 2006, WOODHEAD TEXT SER, P1, DOI 10.1533/9781845691462.1
   Loney PL, 2000, CHRONIC DIS CAN, V1, P37
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   United Nations DoEaSA Population Division, 2015, ESAPWP241 UN DOEASA
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang CS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004354
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yeung L, 2010, ACTA OPHTHALMOL, V88, P753, DOI 10.1111/j.1755-3768.2009.01711.x
   Zhang KY, 2018, INT OPHTHALMOL, V38, P1659, DOI 10.1007/s10792-017-0639-7
NR 28
TC 15
Z9 16
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2019
VL 47
IS 8
BP 1019
EP 1027
DI 10.1111/ceo.13580
EA JUL 2019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JO4BS
UT WOS:000477403400001
PM 31268226
DA 2022-11-30
ER

PT J
AU Kabatas, N
   Dogan, AS
   Yilmaz, M
   Kabatas, EU
   Bicer, T
   Caliskan, S
   Celikay, O
   Ucar, F
   Gurdal, C
AF Kabatas, Naciye
   Dogan, Aysun Sanal
   Yilmaz, Mevlut
   Kabatas, Emrah Utku
   Bicer, Tolga
   Caliskan, Sinan
   Celikay, Osman
   Ucar, Fatma
   Gurdal, Canan
TI Association between age-related macular degeneration and 25(OH) vitamin
   D levels in the Turkish population
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Choroid neovascular membrane; Macular degeneration; Optical coherence
   Tomography; Fibrosis; Retina; Vitamin D; Vitamin D deficiency
ID D DEFICIENCY; PATHWAYS; EUROPE; HEALTH; CELLS
AB Purpose: Age-related macular degeneration is the most common cause of blindness in developed countries, and several factors have been attributed for its etiology. This study was conducted to explore the relationship between serum vitamin D levels and age-related macular degeneration. Methods: We retrospectively analyzed the data of 114 patients with age-related macular degeneration. A total of 102 patients who did not have any other diseases than refractive error were allocated to the control group. The best-corrected visual acuity, fundus findings, and spectral domain optical coherence tomography findings were analyzed. Patients were allocated to groups based on the Age-related Eye Disease Study classification. Serum 25(OH) vitamin D levels were measured. The central foveal thickness and the subfoveal choroidal thickness were measured by optical coherence tomography. Results: The 25(OH) vitamin D levels in age- and gender-matched patients with age-related macular degeneration and in healthy subjects were 14.6 +/- 9.8 and 29.14 +/- 15.1 ng/ml, respectively. The age-related macular degeneration group had significantly lower vitamin D levels than the control group (p > 0.001). The subfoveal choroidal thickness was lower in patients with age-related macular degeneration (p>0.001). The 25(OH) vitamin D level showed a weak positive correlation with choroidal thickness (r=0.357, p=0.01). When the level of 25(OH) vitamin D was evaluated according to the stages of age-related macular degeneration, it was found to be lower in the advanced-stage disease (p=0.01). The risk for the development of choroid neovascular membrane and subretinal fibrosis was found to increase with decreased vitamin D levels. Conclusions: Significantly decreased levels of 25(OH) vitamin D in advanced-stage age-related macular degeneration suggest a significant correlation existing between vitamin D deficiency and age-related macular degeneration development. Further studies are required to examine whether vitamin D supplementation has an effect on the development and progression of age-related macular degeneration.
C1 [Kabatas, Naciye; Dogan, Aysun Sanal; Yilmaz, Mevlut; Kabatas, Emrah Utku; Bicer, Tolga; Caliskan, Sinan; Celikay, Osman; Gurdal, Canan] Diskapi Yildirim Beyazit Res & Educ Hosp, Dept Ophtalmol, Ankara, Turkey.
   [Ucar, Fatma] Diskapi Yildirim Beyazit Res & Educ Hosp, Dept Med Chem, Ankara, Turkey.
C3 Diskapi Yildirim Beyazit Training & Research Hospital; Diskapi Yildirim
   Beyazit Training & Research Hospital
RP Kabatas, N (通讯作者)，Diskapi Yildirim Beyazit Res & Educ Hosp, Dept Ophtalmol, Ankara, Turkey.
EM aktasnaciye@yahoo.com
RI Yılmaz, Mevlüt/ACV-9049-2022
OI Yilmaz, Mevlut/0000-0001-7896-7279
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Andersen R, 2005, EUR J CLIN NUTR, V59, P533, DOI 10.1038/sj.ejcn.1602108
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Cidem M, 2017, TURK J MED SCI, V47, P728, DOI 10.3906/sag-1508-30
   Cutillas-Marco E, 2012, PHOTODERMATOL PHOTO, V28, P159, DOI 10.1111/j.1600-0781.2012.00649.x
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Gezen-Ak D, 2014, NOROPSIKIYATRI ARS, V51, P157, DOI 10.4274/npa.y7076
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Holick MF, 2005, J NUTR, V135, p2726S, DOI 10.1093/jn/135.11.2726S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim KL, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011908, 10.1097/md.0000000000011908]
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Roth DE, 2018, ANN NY ACAD SCI, V1430, P44, DOI 10.1111/nyas.13968
   Saeidlou SN, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0096-y
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Smith M, 2010, BIOSCI HORIZ, V3, P124
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Wu W, 2016, INVEST OPHTH VIS SCI, V57, P2168, DOI 10.1167/iovs.15-18218
NR 30
TC 1
Z9 1
U1 3
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PY 2022
VL 85
IS 1
BP 7
EP 12
DI 10.5935/0004-2749.20220002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XE1IR
UT WOS:000723149600003
PM 34586223
OA gold
DA 2022-11-30
ER

PT J
AU Lai, YH
   Grattan, J
   Shi, YY
   Young, G
   Muldrew, A
   Chakravarthy, U
AF Lai, Yuhua
   Grattan, Joanne
   Shi, Yanyun
   Young, Graham
   Muldrew, Alyson
   Chakravarthy, Usha
TI FUNCTIONAL AND MORPHOLOGIC BENEFITS IN EARLY DETECTION OF NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION USING THE PREFERENTIAL HYPERACUITY
   PERIMETER
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID RANIBIZUMAB
AB Purpose: To estimate the usefulness of preferential hyperacuity perimetry (PHP) in detecting conversion of early to late age-related macular degeneration in the Carotenoids and co-antioxidants in patients with Age-Related Maculopathy, a multicenter randomized controlled clinical trial.
   Methods: This was a nested case control study within the Carotenoids and co-antioxidants in patients with Age-Related Maculopathy (CARMA) clinical trial and included all participants enrolled in a single center (n = 200). Data are from participants who progressed to neovascular age-related macular degeneration (nvAMD) during time on study, Group 1 (n = 10) before the use of PHP and Group 2 (n = 10) during use of PHP. We also randomly selected 21 other participants (Group 3) who did not progress to nvAMD during time on study as a control group. Change in best-corrected visual acuity and contrast sensitivity and size of neovascular lesion at detection of conversion to nvAMD in Groups 1 and 2.
   Results: At detection of nvAMD, mean best-corrected visual acuity in Group 1 was 57.5 letters versus 67.4 in Group 2. In Group 1, the change in best-corrected visual acuity from baseline to detection of nvAMD was twice that of Group 2 (21.6 +/- 9.0 versus 11.9 +/- 10.7) with a mean difference of 9.7 letters (95% confidence interval, 0.41 to 19.0, P = 0.04, independent-samples t-test). The size of the neovascular lesion at detection was 3.06 mm(2) in Group 1 versus 0.89 mm(2) in Group 2 (P = 0.02). Two thirds of the participants in Group 2 were asymptomatic at detection of nvAMD compared with one fifth in Group 1. Preferential hyperacuity perimetry distortion maps were abnormal in 9 of 10 eyes in Group 2, which were confirmed by optical coherence tomography. Of the 21 eyes in Group 3, PHP maps were normal in 18 and abnormal in 3.
   Conclusion: Preferential hyperacuity perimetry detected abnormalities in central visual function with high reliability. Eyes with nvAMD lesions detected by PHP had smaller lesions and better function when compared with the group before the introduction of PHP. The false-negative rate was <10% on PHP. The PHP distortion map was helpful in alerting clinicians to the presence of subclinical nvAMD. RETINA 31: 1620-1626, 2011
C1 [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vasc & Vis Sci, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Lai, Yuhua; Young, Graham; Muldrew, Alyson; Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Belfast, Antrim, North Ireland.
   [Shi, Yanyun] Shanxi Eye Hosp, Weinan, Peoples R China.
C3 Queens University Belfast; Shanxi Medical University
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Vasc & Vis Sci, Inst Clin Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Klatt C, 2006, OPHTHALMOLOGE, V103, P945, DOI 10.1007/s00347-006-1381-0
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lowenstein A, 2007, RETINA, V27, P873
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Trevino Richard, 2008, Optometry, V79, P397, DOI 10.1016/j.optm.2007.09.017
NR 12
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1620
EP 1626
DI 10.1097/IAE.0b013e31820d3ed1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100022
PM 21610564
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Li, X
   Mathur, R
   Lee, SY
   Chan, CM
   Yeo, I
   Loh, BK
   Williams, R
   Wong, EYM
   Wong, D
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Li, Xiang
   Mathur, Ranjana
   Lee, Shu Yen
   Chan, Choi Mun
   Yeo, Ian
   Loh, Boon Kwang
   Williams, Rachel
   Wong, Edmund Yick-Mun
   Wong, Doric
   Wong, Tien Yin
TI A Prospective Study of Treatment Patterns and 1-Year Outcome of Asian
   Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; PHOTODYNAMIC THERAPY; RANIBIZUMAB TREATMENT;
   INTRAVITREAL BEVACIZUMAB; VERTEPORFIN; SAFETY; PREVALENCE; EFFICACY
AB Objective: To study the treatment patterns and visual outcome over one year in Asian patients with choroidal neovascular membrane secondary to age-related macular degeneration (AMD-CNV) and polypoidal choroidal vasculopathy (PCV).
   Design: Prospective cohort, non-interventional study.
   Methods: 132 treatment-naive patients who received treatment for AMD-CNV and PCV were included. All patients underwent standardized examination procedures including retinal imaging at baseline and follow-up. AMD-CNV and PCV were defined on fundus fluorescein angiography and indocyanine green angiography at baseline. Patients were treated according to standard of care. We report the visual acuity (VA) and optical coherence tomography (OCT) measurements at baseline, month 3 and month 12 The factors influencing month 12 outcomes were analyzed.
   Main Outcome Measure: Type of treatment, number of Anti-vascular endothelial growth factor (VEGF) treatments, visual outcome over one year.
   Results: Anti-VEGF monotherapy was the initial treatment in 89.1% of AMD-CNV, but only 15.1% of PCV. The mean number of anti-VEGF injections up to month 12 was 3.97 (4.51 AMD-CNV, 3.43 PCV, p = 0.021). Baseline OCT, month 3 OCT and month 3 VA were significant in determining continuation of treatment after month 3. At month12, mean VA improved from 0.82 (similar to 20/132) at baseline to 0.68 (similar to 20/96) at month 12 (mean gain 6.5 ETDRS letters, p = 0.002). 34.2% of eyes (38/113 eyes) gained >= 15 ETDRS letters and 14.4% (16/113 eyes) lost >= 15 ETDRS letters. There were no significant differences in visual outcome between AMD-CNV and PCV (p = 0.51). Factors predictive of month 12 visual outcome were baseline VA, baseline OCT central macular thickness, month 3 VA and age.
   Conclusions: There is significant variation in treatment patterns in Asian eyes with exudative maculopathy. There is significant visual improvement in all treatment groups at one year. These data highlight the need for high quality clinical trial data to provide evidence-based management of Asian AMD.
C1 [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Lee, Shu Yen; Chan, Choi Mun; Yeo, Ian; Loh, Boon Kwang; Wong, Edmund Yick-Mun; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Vitreoretinal Serv, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Li, Xiang; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
   [Williams, Rachel] GlaxoSmithKline, R&D Projects, Clin Platforms & Sci, Worldwide Epidemiol, Philadelphia, PA USA.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore;
   GlaxoSmithKline
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Vitreoretinal Serv, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
FU National Medical Research Council [NMRC/NIG/1003/2009]; GlaxoSimthKline
   [WEUSKOP5855]
FX This study was supported by National Medical Research Council grant:
   NMRC/NIG/1003/2009; GlaxoSimthKline Research and Development Protocol
   WEUSKOP5855. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang S, 2011, JPN J OPHTHALMOL, V55, P123, DOI 10.1007/s10384-010-0910-1
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 33
TC 42
Z9 43
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2014
VL 9
IS 6
AR e101057
DI 10.1371/journal.pone.0101057
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK5ZO
UT WOS:000338506400069
PM 24978485
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU von der Emde, L
   Guymer, RH
   Pfau, M
   Caruso, E
   Sivarajah, P
   Hodgson, LAB
   McGuinness, MB
   Sloan, KR
   Wu, ZC
AF von der Emde, Leon
   Guymer, Robyn H.
   Pfau, Maximilian
   Caruso, Emily
   Sivarajah, Pyrawy
   Hodgson, Lauren A. B.
   McGuinness, Myra B.
   Sloan, Kenneth R.
   Wu, Zhichao
TI NATURAL HISTORY OF QUANTITATIVE AUTOFLUORESCENCE IN INTERMEDIATE
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; quantitative autofluorescence; retinal
   pigment epithelium; drusen
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; LIPOFUSCIN;
   FLUORESCENCE; RPE; A2E
AB Purpose: To investigate differences in quantitative autofluorescence (qAF) imaging measurements between eyes with and without large drusen, and whether qAF measurements change over time in the eyes with large drusen. Methods: Eighty-five eyes from participants with bilateral large drusen and 51 eyes from healthy participants underwent qAF imaging at least once, and the age-related macular degeneration participants were reviewed 6-monthly. Normalized grey values at 9 degrees to 11 degrees eccentricity from the fovea were averaged to provide a summary measure of qAF values (termed qAF(8)). Results: In a multivariable model, qAF(8) measurements were not significantly different between age-related macular degeneration eyes with large drusen and healthy eyes (P = 0.130), and qAF(8) measurements showed a decline over time in the age-related macular degeneration eyes (P = 0.013). Conclusion: These findings add to the body of evidence that qAF levels are not increased in eyes with large drusen compared with healthy eyes, and qAF levels show a significant decline over time in the age-related macular degeneration eyes. These findings highlight how the relationship between qAF levels and retinal pigment epithelium health does not seem to be straightforward. Further investigation is required to better understand this relationship, especially if qAF levels are to be used as an outcome measure in intervention trials.
C1 [von der Emde, Leon; Guymer, Robyn H.; Caruso, Emily; Sivarajah, Pyrawy; Hodgson, Lauren A. B.; McGuinness, Myra B.; Wu, Zhichao] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [von der Emde, Leon; Pfau, Maximilian] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Guymer, Robyn H.; Wu, Zhichao] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham Sch Med, Birmingham, AL USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Bonn; University of Melbourne; University of Alabama
   System; University of Alabama Birmingham
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
OI McGuinness, Myra/0000-0002-5422-040X
FU National Health & Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985]; BUPA Health Foundation (Australia); Centre for
   Eye Research Australia (CERA)
FX Supported by National Health & Medical Research Council of Australia
   (project grant no.: APP1027624 [R. H. Guymer], and fellowship grant no.:
   GNT1103013 (R. H. Guymer), APP1104985 [Z. Wu]), and BUPA Health
   Foundation (Australia) (R. H. Guymer). CERA receives operational
   infrastructure support from the Victorian Government. The web-based
   Research Electronic Data Capture (REDCap) application and open-source
   platform OpenClinica allowed secure electronic data capture. The study
   is sponsored by the Centre for Eye Research Australia (CERA), an
   independent medical research institute and a not-for-profit company.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Charng J, 2017, INVEST OPHTH VIS SCI, V58, P4940, DOI 10.1167/iovs.17-22540
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Smith T, 2016, JAMA OPHTHALMOL, V134, P824, DOI 10.1001/jamaophthalmol.2016.1466
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Wang Y, 2019, EXP EYE RES, V184, P48, DOI 10.1016/j.exer.2019.04.004
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
NR 24
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2021
VL 41
IS 4
BP 694
EP 700
DI 10.1097/IAE.0000000000002923
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5KP
UT WOS:000711806600005
PM 32740494
DA 2022-11-30
ER

PT J
AU Calcagni, A
   Howells, O
   Eperjesi, F
   Bartlett, H
   Denniston, AKO
   Gibson, JM
   Hogg, CR
   Matthews, TD
AF Calcagni, Antonio
   Howells, Olivia
   Eperjesi, Frank
   Bartlett, Hannah
   Denniston, Alastair K. O.
   Gibson, Jonathan M.
   Hogg, Christopher R.
   Matthews, Timothy D.
TI Colour contrast sensitivity in eyes at high risk of neovascular
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; colour vision; contrast sensitivity;
   psychophysics; ChromaTest
ID BRUCHS MEMBRANE; INFLAMMATION; PREVALENCE; BLIND
AB Purpose: To generate the first published reference database of colour contrast sensitivity in eyes at high risk of neovascular age-related macular degeneration and to explore this important feature in quality of vision. Background: Quality of vision depends on many factors. Changes in chromatic contrast sensitivity remain largely unexplored in eyes at high risk of neovascular age-related macular degeneration; they may however not only be relevant for quality of life but also an early indicator of the onset of the disease, so it is important to have a means to evaluate any variation in colour contrast sensitivity, especially in view of the likely increase in neovascular age-related macular degeneration as the population ages. Methods: This prospective longitudinal study evaluated colour contrast sensitivity along the protan and tritan colour axes in 145 eyes at high risk of neovascular age-related macular degeneration. Results: Colour contrast sensitivity showed statistically significant correlations with age and visual acuity, but not gender nor laterality (i.e. whether the right or left eye was being tested). There was significant variability among individuals, especially for the tritan axis, with some subjects well within normal limits for age and others with very poor colour contrast sensitivity. Conclusion: This study has generated the first published colour contrast sensitivity reference database for eyes at high risk of neovascular age-related macular degeneration. It has also shown a high inter-individual variability of colour contrast sensitivity in eyes at high risk of neovascular age-related macular degeneration, but the significance of this is unclear. Further work is required to establish if eyes with high colour contrast sensitivity thresholds (i.e. poor colour vision) have a higher risk of developing neovascular age-related macular degeneration over time, and this is the subject of ongoing work.
C1 [Calcagni, Antonio; Howells, Olivia; Eperjesi, Frank; Bartlett, Hannah; Gibson, Jonathan M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
   [Calcagni, Antonio; Howells, Olivia; Denniston, Alastair K. O.; Matthews, Timothy D.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
   [Calcagni, Antonio; Hogg, Christopher R.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Calcagni, Antonio; Howells, Olivia; Gibson, Jonathan M.] Heart England NHS Fdn Trust, MIDRU, Birmingham, W Midlands, England.
   [Denniston, Alastair K. O.] Univ Birmingham, Acad Unit Ophthalmol, Birmingham, W Midlands, England.
C3 Aston University; University of Birmingham; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Heart of England NHS Foundation Trust; University of Birmingham
RP Calcagni, A (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM a.calcagni@aston.ac.uk
RI Denniston, Alastair/ABD-1238-2020
OI Denniston, Alastair/0000-0001-7849-0087; Calcagni, Antonio Salvatore
   Pio/0000-0002-1446-3546; Bartlett Eperjesi, Hannah E/0000-0002-7531-6902
FU Dunhill Medical Trust [R304/0713]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by the Dunhill Medical Trust (Grant number R304/0713).
CR Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Balaskas K, 2013, BRIT J OPHTHALMOL, V97, P558, DOI 10.1136/bjophthalmol-2012-302305
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   Falsini B, 2007, INVEST OPHTH VIS SCI, V48, P4811, DOI 10.1167/iovs.07-0306
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Heitmar R, 2013, INVEST OPHTH VIS SCI, V54, P2807, DOI 10.1167/iovs.12-10493
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   Luthert PJ., 2011, DIAGN HISTOPATHOL, V17, P10, DOI [10.1016/j.mpdhp.2010.10.004, DOI 10.1016/J.MPDHP.2010.10.004]
   Macular Society, 2016, AG REL MAC DEG COLL
   Madill SA., 2010, EMPIRICAL PSYCHOPHYS
   Mitrut I, 2010, OPHTHALMOLOGY, V117, P1280, DOI 10.1016/j.ophtha.2010.01.047
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   SIVAGNANAVEL V, 2005, INVEST OPHTH VIS S S, V46
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 27
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1487
EP 1494
AR 1120672119866386
DI 10.1177/1120672119866386
EA AUG 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000483253800001
PM 31411062
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Xu, L
   You, QS
   Cui, TT
   Jonas, JB
AF Xu, Liang
   You, Qi Sheng
   Cui, Tongtong
   Jonas, Jost B.
TI Association between asymmetry in cataract and asymmetry in age-related
   macular degeneration. The Beijing Eye Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Cataract; Age-related macular degeneration; Beijing Eye Study
ID RISK-FACTORS; VISUAL IMPAIRMENT; LENS OPACITIES; 10-YEAR INCIDENCE;
   ADULT-POPULATION; REFRACTIVE ERROR; POOLED FINDINGS; BEAVER DAM;
   MACULOPATHY; PREVALENCE
AB To examine in an intra-individual comparison whether cataract is associated with age-related macular degeneration (AMD).
   The population-based Beijing Eye Study included 4,439 subjects (age: 40+ years) out of 5,324 subjects invited to be examined. Using lens and fundus photographs, the amount of AMD was graded according to the Wisconsin Age-Related Maculopathy Grading system and the degree of cataract was graded using the system of the Age-Related Eye Disease Study.
   Photographs with sufficient quality for bilateral examination of the lens and macula were available for 3,826 (86.2%) participants with a mean age of 55.3 +/- 10.0 years (range: 40-90 years) and a mean refractive error of -0.38 +/- 2.18 diopters (range: -20.13 diopters to +7.50 diopters). The side difference in presence of early AMD and late AMD respectively was not significantly associated with the inter-eye difference in the amount of nuclear cataract [P = 0.27 and P = 0.28 (r = 0.02) respectively), amount of cortical cataract (P = 0.12 and P = 0.05 respectively), and amount of subcapsular posterior cataract (P = 0.91 and P = 0.85 respectively). In a similar manner, the side difference in the presence of early AMD and late AMD was not significantly associated with the inter-eye difference in the presence of nuclear cataract (P = 0.99 and P = 0.99 respectively), cortical cataract (P = 0.25 and P = 1.00 respectively), and subcapsular posterior cataract (P = 0.59 and P = 0.05 respectively). The side difference in the number of macular drusen was not significantly associated with the inter-eye difference in the amount of nuclear cataract (P = 0.74), amount of cortical cataract (P = 0.19) and amount of subcapsular posterior cataract (P = 0.88). As a corollary, unilateral pseudophakia or aphakia was not significantly associated with inter-eye differences in the count (P = 0.59) of drusen, and overall presence of early AMD (P = 0.99) or late AMD (P = 0.99).
   In an intra-individual, inter-eye comparison, avoiding interdependencies of systemic parameters, inter-eye difference was not significantly associated with any characteristics of age-related macular degeneration in either any type of cataract or in pseudophakia. This suggests that the development of cataract or cataract surgery did not markedly influence the development of age-related macular degeneration.
C1 [Xu, Liang; You, Qi Sheng; Cui, Tongtong; Jonas, Jost B.] Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Lane, Beijing 100005, Peoples R China.
EM xlbio@yahoo.cn; Jost.Jonas@umm.de
RI You, Qisheng/A-3619-2014; You, Qisheng/AAG-7153-2020
OI You, Qisheng/0000-0003-0743-7320; You, Qisheng/0000-0003-0743-7320
FU Beijing Municipal Natural Science Foundation; Bureau of International
   Cooperation, Beijing Municipal Science & Technology Commission
FX Supported by Beijing Municipal Natural Science Foundation and Bureau of
   International Cooperation, Beijing Municipal Science & Technology
   Commission
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   *GROUP AG REL EYE, 2001, AM J OPHTHALMOL, V131, P167
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2006, OPHTHALMOLOGY, V113, P747, DOI 10.1016/j.ophtha.2006.01.026
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 45
TC 14
Z9 14
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2011
VL 249
IS 7
BP 981
EP 985
DI 10.1007/s00417-010-1571-y
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784NG
UT WOS:000292163400005
PM 21174115
DA 2022-11-30
ER

PT J
AU Tan, JSL
   Mitchell, P
   Rochtchina, E
   Wang, JJ
AF Tan, Jennifer S. L.
   Mitchell, Paul
   Rochtchina, Elena
   Wang, Jie Jin
TI Statins and the long-term risk of incident age-related macular
   degeneration: The Blue Mountains Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY
AB center dot PURPOSE: To assess the relationship between statin use and the long-term incidence of age-related macular degeneration (AMD). DESIGN: Population-based cohort study.
   center dot METHODS: Of 3,654 baseline (1992 to 1994) participants in the Blue Mountains Eye Study initially aged 49+ years, 2,335 were reexamined after five years (1997 to 1999) and 1,952 after 10 years (2002 to 2004). Stereo, scopic macular photographs were graded using the Wisconsin Age-related Maculopathy Grading System. History, physical examination, and fasting blood samples provided data on possible risk factors. Discrete linear logistic models were used to assess risk of incident AMD.
   center dot RESULTS: After controlling for age, gender, and other confounding factors, compared with nonusers, statin users had a reduced risk of developing indistinct soft drusen, the principal late AMD precursor lesion (hazard ratio, 0.33; 95% confidence interval, 0.13 to 0.84).
   center dot CONCLUSIONS: Statin use was not significantly associated with overall early AMD incidence, but was protective for indistinct soft drusen, a key late AMD precursor lesion.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
NR 7
TC 55
Z9 57
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2007
VL 143
IS 4
BP 685
EP 687
DI 10.1016/j.ajo.2006.11.021
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 154WE
UT WOS:000245537800022
PM 17386278
DA 2022-11-30
ER

PT J
AU Freund, KB
   Staurenghi, G
   Jung, JJ
   Zweifel, SA
   Cozzi, M
   Hill, L
   Blotner, S
   Tsuboi, M
   Gune, S
AF Freund, K. Bailey
   Staurenghi, Giovanni
   Jung, Jesse J.
   Zweifel, Sandrine A.
   Cozzi, Mariano
   Hill, Lauren
   Blotner, Steven
   Tsuboi, Min
   Gune, Shamika
TI Macular neovascularization lesion type and vision outcomes in
   neovascular age-related macular degeneration: post hoc analysis of
   HARBOR
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Consensus on Neovascular Age-Related Macular Degeneration Nomenclature
   (CONAN); Macular neovascularization; Neovascular age-related macular
   degeneration; Ranibizumab; Visual acuity
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL
   COHERENCE TOMOGRAPHY; BASE-LINE PREDICTORS; 2.0 MG RANIBIZUMAB;
   CHOROIDAL NEOVASCULARIZATION; VISUAL OUTCOMES; PHOTODYNAMIC THERAPY;
   GEOGRAPHIC ATROPHY; VERTEPORFIN
AB Purpose To characterize relationships between Consensus on Neovascular Age-Related Macular Degeneration Nomenclature (CONAN) Study Group classifications of macular neovascularization (MNV) and visual responses to ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Methods This was a post hoc analysis of the phase 3 HARBOR trial of ranibizumab in nAMD. Analyses included ranibizumab-treated eyes with baseline multimodal imaging data; baseline MNV; subretinal and/or intraretinal fluid at screening, baseline, or week 1; and spectral-domain optical coherence tomography images through month 24 (n = 700). Mean best-corrected visual acuity (BCVA) over time and mean BCVA change at months 12 and 24 were compared between eyes with type 1, type 2/mixed type 1 and 2 (type 2/M), and any type 3 MNV at baseline. Results At baseline, 263 (37.6%), 287 (41.0%), and 150 (21.4%) eyes had type 1, type 2/M, and any type 3 lesions, respectively. Type 1 eyes had the best mean BCVA at baseline (59.0 [95% CI: 57.7-60.3] letters) and month 24 (67.7 [65.8-69.6] letters), whereas type 2/M eyes had the worst (50.0 [48.6-51.4] letters and 60.8 [58.7-62.9] letters, respectively). Mean BCVA gains at month 24 were most pronounced for type 2/M eyes (10.8 [8.9-12.7] letters) and similar for type 1 (8.7 [6.9-10.5] letters) and any type 3 eyes (8.3 [6.3-10.3] letters). Conclusion Differences in BCVA outcomes between CONAN lesion type subgroups support the use of an anatomic classification system to characterize MNV and prognosticate visual responses to anti-vascular endothelial growth factor therapy for nAMD.
C1 [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Staurenghi, Giovanni; Cozzi, Mariano] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Jung, Jesse J.] East Bay Retina Consultants Inc, Oakland, CA USA.
   [Jung, Jesse J.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Zweifel, Sandrine A.] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Zweifel, Sandrine A.] Univ Zurich, Zurich, Switzerland.
   [Hill, Lauren; Blotner, Steven; Tsuboi, Min; Gune, Shamika] Genentech Inc, San Francisco, CA 94080 USA.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   University of Milan; Luigi Sacco Hospital; University of California
   System; University of California San Francisco; University of Zurich;
   University Zurich Hospital; University of Zurich; Roche Holding;
   Genentech
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.; Freund, KB (通讯作者)，NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
EM kbfreund@gmail.com
RI ; Freund, K. Bailey/V-7488-2018
OI Cozzi, Mariano/0000-0001-7777-2461; Freund, K.
   Bailey/0000-0002-7888-9773
FU Genentech, Inc.,Roche Group (South San Francisco, CA)
FX Financial support was provided by Genentech, Inc., a member of the Roche
   Group (South San Francisco, CA), for the study and thirdparty writing
   assistance, which was provided by Karina D. HamiltonPeel, PhD, CMPP, of
   Envision Pharma Group. The sponsor participated in the design of the
   study; collection, management, analysis, and interpretation of the data;
   and preparation, review, and approval of the manuscript.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Breazzano MP, 2021, JAMA OPHTHALMOL, V139, P456, DOI 10.1001/jamaophthalmol.2021.0036
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   Lavinsky Fabio, 2016, Int J Retina Vitreous, V2, P25
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Lin TZ, 2020, BRIT J OPHTHALMOL, V104, P58, DOI 10.1136/bjophthalmol-2018-313447
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 54
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2437
EP 2447
DI 10.1007/s00417-022-05586-w
EA MAR 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000763860600001
PM 35239009
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Friedman, D
   Parker, JS
   Kimble, JA
   Delori, FC
   McGwin, G
   Curcio, CA
AF Friedman, Duncan
   Parker, John S.
   Kimble, James A.
   Delori, Francois C.
   McGwin, Gerald, Jr.
   Curcio, Christine A.
TI QUANTIFICATION OF FLUORESCEIN-STAINED DRUSEN ASSOCIATED WITH AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; drusen; fluorescein angiography;
   fundus photography
ID BRUCHS MEMBRANE; HUMAN RETINA; OCULAR DRUSEN; DEPOSITS; MACULOPATHY;
   CHOLESTEROL; PREVALENCE; COLOR; EYES; PHOTOGRAPHS
AB Background: Previous studies of age-related macular degeneration have not quantified the number of drusen that accumulate fluorescein. Histopathologic studies have demonstrated druse subregions with different degrees of hydrophobicity, and these subregions might potentially exhibit different degrees of fluorescein uptake.
   Methods: We evaluated macular drusen from 35 age-related macular degeneration patients by measuring druse area in color digital images and fluorescein angiograms, using 2 morphometric methods.
   Results: Of 828 drusen evaluated, 405 had a corresponding fluorescein angiogram signal. About half of all drusen per eye (49.57%) stained in each participant. Among fluorescein-stained drusen, druse size measured in color images did not differ significantly from the sizes measured in corresponding fluorescein images (P = 0.8105), across the range of druse sizes.
   Conclusion: These findings indicate that our understanding of drusen subregion staining may not directly correlate to in vivo observations of macular drusen in age-related macular degeneration. RETINA 32:19-24, 2012
C1 [Friedman, Duncan; Parker, John S.; Kimble, James A.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Harvard
   University; Harvard Medical School; Schepens Eye Research Institute
RP Friedman, D (通讯作者)，1720 Univ Blvd,Suite 601, Birmingham, AL 35233 USA.
EM dafried@uab.edu
FU NATIONAL EYE INSTITUTE [R01EY006109] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY006109, R01 EY006109-24] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Heimann H, 2007, RETINAL VASCULAR DIS, P193
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Moldow B, 2001, BRIT J OPHTHALMOL, V85, P592, DOI 10.1136/bjo.85.5.592
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Neelam K, 2009, RETINA-J RET VIT DIS, V29, P192, DOI 10.1097/IAE.0b013e31818c178f
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2004, AM J OPHTHALMOL, V137, P924, DOI 10.1016/j.ajo.2003.12.043
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Vision Problems in the U.S. National Eye Institute, 2008, VIS PROBL US
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 40
TC 7
Z9 7
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2012
VL 32
IS 1
BP 19
EP 24
DI 10.1097/IAE.0b013e318219e5e9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 870IE
UT WOS:000298661800004
PM 21878853
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ramakrishnan, MS
   Yu, YX
   VanderBeek, BL
AF Ramakrishnan, Meera S.
   Yu, Yinxi
   VanderBeek, Brian L.
TI Association of Visit Adherence and Visual Acuity in Patients With
   Neovascular Age-Related Macular Degeneration Secondary Analysis of the
   Comparison of Age-Related Macular Degeneration Treatment Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GLAUCOMA MEDICATION ADHERENCE; RANIBIZUMAB; RETENTION; THERAPY;
   PATTERNS; SURVIVAL; OUTCOMES; IMPACT; CARE
AB This secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial randomized clinical trial assesses the association of patient adherence and visual acuity in individuals with neovascular age-related macular degeneration.
   Importance Visit adherence has been shown to play a significant role in patient health outcomes. The effect of missing visits on visual acuity (VA) in individuals with neovascular age-related macular degeneration has yet to be characterized. Objective To quantify the association between patients' adherence to randomized clinical trial visits and VA in individuals with neovascular age-related macular degeneration based on 4 visit adherence metrics. Design, Setting, and Participants This is a secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial randomized clinical trial. Individuals with age-related macular degeneration were recruited from 44 clinical centers in the United States between February 2008 and December 2009. The 2-year study protocol required 1 visit every 4 weeks (every 21-35 days for a total of 26 visits) for monthly vs pro re nata treatments of bevacizumab vs ranibizumab. Analysis took place from November 2018 through May 2019. Exposures Visit adherence was measured in 4 ways: total number of missed visits, average number of days (avg days) between each visit, longest duration in days (max days) between visits, and visit constancy (the tally of 3-month periods with at least 1 visit attended). Average and max days were also categorized as on time (28-35 days), late (36-60 days), and very late (>60 days). Main Outcomes and Measures Change in Early Treatment Diabetic Retinopathy Study VA between the baseline and the last visit. Linear multivariate regression models were applied to analyze the association between visit adherence and change in VA, controlling for age, sex, baseline VA, anti-vascular endothelial growth factor drug, number of injections, and dosing regimen. Results Of 1178 patients, the mean (SD) age was 79.1 (7.3) years, and 727 (61.7%) were women. The mean (SD) number of missed visits was 2.4 (3.1). Overall, 1091 patients (92.6%) had complete visit constancy during the entire study period. Average days were categorized with 1060 patients (90.0%) classified as on time, 108 (9.2%) were late, and 10 (0.8%) were very late. For max days between visits, 197 patients (16.7%) were on time, 773 (65.6%) were late, and 208 (17.7%) were very late. After controlling for covariates, the late (avg days = -6.1; max days = -2.0) and very late (avg days = -12.5; max days = -5.9) groups saw fewer letters in both the avg and max days categories than patients in the on-time group (P < .001). Conclusions and Relevance These results provide evidence to support the concept that visit adherence contributes to VA outcomes in neovascular age-related macular degeneration. The magnitude of the association of visit adherence with VA outcomes in this clinical scenario suggests that substantial effort should be expended to strive for visit adherence or therapeutic strategies that reduce the visit burden without compromising VA outcomes.
   Question What is the association between visit adherence and visual outcomes in individuals with neovascular age-related macular degeneration? Findings In a secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial randomized clinical trial of 1178 individuals, patients were expected to attend visits every 4 weeks; each missed visit was associated with an average visual acuity letter score decline of 0.7. Compared with patients who were on time, those who averaged between 36 and 60 days and more than 60 days between visits lost 6.1 and 12.5 letters, respectively. Meaning Visit adherence may contribute to visual acuity outcomes in neovascular age-related macular degeneration.
C1 [Ramakrishnan, Meera S.; VanderBeek, Brian L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Yu, Yinxi] Univ Penn, Ctr Preventat Ophthalmol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [VanderBeek, Brian L.] Univ Penn, Ctr Pharmacoepidemiol Res & Training, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [VanderBeek, Brian L.] Univ Penn, Perelman Sch Med, Leonard Davis Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine
RP VanderBeek, BL (通讯作者)，Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM vanderbeek@uphs.upenn.edu
OI Folk, James/0000-0002-6271-2906; Russell, Stephen/0000-0003-3776-1367
FU National Eye Institute/National Institutes of Health [1K23EY025729-01];
   University of Pennsylvania Core Grant for Vision Research
   [2P30EY001583]; Research to Prevent Blindness; Paul MacKall AMP; Evanina
   Bell MacKall Foundation
FX This study received funding from the National Eye Institute/National
   Institutes of Health (grant 1K23EY025729-01) and the University of
   Pennsylvania Core Grant for Vision Research (grant 2P30EY001583).
   Additional funding was provided by Research to Prevent Blindness and the
   Paul MacKall & Evanina Bell MacKall Foundation. Funding from each of the
   above sources was received in the form of block research grants to the
   Scheie Eye Institute.
CR Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778
   Glasser D, 2019, OPHTHALMOLOGY, V126, P189, DOI 10.1016/j.ophtha.2018.09.025
   Ickovics JR, 2002, ANTIVIR THER, V7, P185
   Joseph A, 2017, SEMIN OPHTHALMOL, V32, P86, DOI 10.1080/08820538.2016.1228406
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   Mugavero MJ, 2010, AIDS PATIENT CARE ST, V24, P607, DOI 10.1089/apc.2010.0086
   Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705
   Newman-Casey PA, 2016, EXPERT REV OPHTHALMO, V11, P5, DOI 10.1586/17469899.2016.1134318
   Newman-Casey PA, 2015, OPHTHALMOLOGY, V122, P2010, DOI 10.1016/j.ophtha.2015.06.039
   Newman-Casey PA, 2015, OPHTHALMOLOGY, V122, P1308, DOI 10.1016/j.ophtha.2015.03.026
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rhee MK, 2005, DIABETES EDUCATOR, V31, P240, DOI 10.1177/0145721705274927
   Russell CL, 2013, CLIN TRANSPLANT, V27, pE580, DOI 10.1111/ctr.12203
   Schwartz GR, 2008, SURV OPHTHALMOL, V53, pS57, DOI 10.1016/j.survophthal.2008.08.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Tripathi A, 2011, AIDS RES HUM RETROV, V27, P751, DOI [10.1089/aid.2010.0268, 10.1089/AID.2010.0268]
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
NR 27
TC 23
Z9 23
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2020
VL 138
IS 3
BP 237
EP 242
DI 10.1001/jamaophthalmol.2019.4577
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1MQ
UT WOS:000520936000001
PM 32027349
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Olvera, MA
   Clark, AF
   Stone, EM
AF Mullins, Robert F.
   Olvera, Marissa A.
   Clark, Abbot F.
   Stone, Edwin M.
TI Fibulin-5 distribution in human eyes: Relevance to age-related macular
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; fibulins; extracellular matrix;
   Bruch's membrane
ID BINDING-PROTEIN
AB Fibulin-5 is an extracellular matrix glycoprotein that participates in elastogenesis. Mutations in the gene for fibulin-5 have been found to be associated with age-related macular degeneration. Little is known, however, about the expression of this gene in normal eyes or eyes with age-related macular degeneration. In this study, we evaluated the expression of the fibulin-5 protein in human donor eyes and localized this protein to Bruch's membrane and the intercapillary pillars of the choriocapillaris in normal eyes. In eyes with age-related macular degeneration, fibulin-5 was localized to pathologic basal deposits beneath the retinal pigment epithelium as well as some small drusen. These results suggest that fibulin-5 may promote extracellular deposit formation in macular degeneration. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Iowa, Carver Coll Med, Carver Family Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   Alcon Res Ltd, Glaucoma Res, Ft Worth, TX USA.
C3 University of Iowa; Novartis; Alcon
RP Mullins, RF (通讯作者)，Univ Iowa, Carver Coll Med, Carver Family Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, 375 Newton Rd,4135E MERF, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Stone, Edwin M./0000-0003-3343-4414; Mullins, Robert/0000-0002-5006-0891
FU NEI NIH HHS [R01 EY017451, EY-016822, R01 EY016822, EY-014563, R03
   EY014563] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY017451,
   R03EY014563, R01EY016822] Funding Source: NIH RePORTER
CR Albig AR, 2004, DNA CELL BIOL, V23, P367, DOI 10.1089/104454904323145254
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   Mullins RF, 2006, MOL VIS, V12, P224
   Nguyen AD, 2004, CIRC RES, V95, P1067, DOI 10.1161/01.RES.0000149568.85071.FB
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Winkler BS, 1999, MOL VIS, V5
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
NR 12
TC 30
Z9 31
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2007
VL 84
IS 2
BP 378
EP 380
DI 10.1016/j.exer.2006.09.021
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 129WT
UT WOS:000243761500017
PM 17109857
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bockelbrink, A
   Roll, S
   Ruether, K
   Rasch, A
   Greiner, W
   Willich, SN
AF Bockelbrink, Angelina
   Roll, Stephanie
   Ruether, Klaus
   Rasch, Andrej
   Greiner, Wolfgang
   Willich, Stefan N.
TI Cataract surgery and the development or progression of age-related
   macular degeneration: A systematic review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cataract surgery; systematic review
ID BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; BEAVER DAM EYE; RISK-FACTORS;
   VISUAL FUNCTION; LENS OPACITIES; MACULOPATHY; ASSOCIATION; EXPOSURE;
   SUNLIGHT
AB Age-related macular degeneration and cataract are the most frequent eye disorders of elderly people worldwide. The aim of this systematic review was to evaluate the effect of cataract surgery on the development and progression of age-related macular degeneration. Data were collected by means of a systematic literature search in 28 databases and an additional update in Pubmed. Search results were evaluated using pre-defined inclusion and exclusion criteria. All relevant publications were rated in terms of scientific quality and analyzed regarding their results. The literature search generated a total of 2,827 hits. Seven publications on five observational studies and two non-randomized clinical trials were eligible for analysis. The observational studies provided some evidence for an increased incidence of late age-related macular degeneration, respectively, for a promoting influence of cataract surgery on the progression of early types of age-related macular degeneration. The clinical trials did yield inconsistent results. In conclusion, only a small number of published studies investigated the development or progression of age-related macular degeneration following cataract surgery. The scientific level of evidence of these articles was not high and results were inconsistent, nevertheless a promoting influence of cataract surgery on the progression of early age-related macular degeneration can be assumed.
C1 [Bockelbrink, Angelina; Roll, Stephanie; Willich, Stefan N.] Charite Univ Med Berlin, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany.
   [Ruether, Klaus] Univ Med Ctr, Charite Campus Virchow Clin, Dept Ophthalmol, Berlin, Germany.
   [Rasch, Andrej; Greiner, Wolfgang] Univ Bielefeld, Fac Publ Hlth, D-4800 Bielefeld, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Bielefeld
RP Bockelbrink, A (通讯作者)，Charite Univ Med Berlin, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany.
EM angelina.bockelbrink@charite.de
OI Rasch, Andrej/0000-0003-4098-4502; Roll, Stephanie/0000-0003-1191-3289
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Arnarsson A, 2002, DEV OPHTHALMOL, V35, P12
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Dholakia Sheena A., 2004, Indian Journal of Ophthalmology, V52, P311
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   HOLZ FC, 2006, DTSCH ARZTEBLATT, V103, P482
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   MANGIONE CM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1305, DOI 10.1001/archopht.1995.01100100093037
   PAULEIKHOFF D, 2005, DTSCH ARZTEBLATT, V102, P3186
   Phillips KA, 2003, TODAYS THERAPEUTIC T, V21, P71
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   THYLEFORS B, 1992, CURR OPIN OPHTHALMOL, V3, P824, DOI 10.1097/00055735-199212000-00016
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 30
TC 55
Z9 56
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2008
VL 53
IS 4
BP 359
EP 367
DI 10.1016/j.survophthal.2008.04.001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 321ZH
UT WOS:000257344500004
PM 18572053
DA 2022-11-30
ER

PT J
AU Sawada, T
   Kakinoki, M
   Wang, XY
   Kawamura, H
   Saishin, Y
   Ohji, M
AF Sawada, Tomoko
   Kakinoki, Masashi
   Wang, Xiying
   Kawamura, Hajime
   Saishin, Yoshitsugu
   Ohji, Masahito
TI Bimonthly injections of ranibizumab for age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Bimonthly injection;
   Visual acuity; Central retinal subfield thickness
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   RANIBIZUMAB; VEGF-TRAP; EFFICACY; SAFETY; PHARMACOKINETICS; VERTEPORFIN;
   PREVALENCE; EXPRESSION
AB Purpose To evaluate the efficacy of bimonthly intravitreal injections of ranibizumab for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in a pilot study.
   Methods This study was a prospective, interventional case series. Thirty eyes of 30 patients received prospectively at least three bimonthly intravitreal injections of ranibizumab (0.5 mg/0.05 ml) without loading doses. The best-corrected visual acuity (BCVA) and the central retinal subfield thickness (CRST) were measured before and monthly after the injections.
   Results Twenty-eight patients received the three planned injections; one patient refused the third injection, one patient did not receive the third injection because blood pressure was raised, and one patient received a rescue injection at month 5 because of increased retinal thickness. The mean logarithm of the minimum angle of resolution (logMAR) BCVA was 0.44 +/- 0.37 before treatment and significantly improved to 0.25 +/- 0.34 at month 6 (p < 0.001). The mean CRST was 335 +/- 85.9 mu m before treatment and decreased significantly to 261 +/- 78.1 mu m at month 6 (p < 0.001). Nine of 30 patients received six planned injections for 12 months. The mean logMAR BCVA was 0.38 +/- 0.39 before treatment and significantly improved to 0.18 +/- 0.33 atmonth 12 (p = 0.005). The mean CRST was 360 +/- 110.8 mu m before treatment and decreased significantly to 249 +/- 57.0 mu m at month 12 (p = 0.025).
   Conclusions Bimonthly injections of ranibizumab may be effective for treating AMD and PCV.
C1 [Sawada, Tomoko; Kakinoki, Masashi; Wang, Xiying; Kawamura, Hajime; Saishin, Yoshitsugu; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
   [Wang, Xiying] Harbin Med Univ, Key Lab, Harbin, Peoples R China.
C3 Shiga University of Medical Science; Harbin Medical University
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24592668]; Ministry of Health, Labour and Welfare
FX This work was supported in part by a grant from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (#24592668)
   and a grant from the Ministry of Health, Labour and Welfare. The authors
   have no proprietary interests in any aspect of this study. The funding
   organizations had no role in the design or conduct of this study. The
   Institutional Review Board of Shiga University of Medical Science
   Hospital approved this study, which is registered at
   http://www.umin.ac.jp (No. UMIN000005691). All patients provided written
   informed consent before participation.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   US Food and Drug Administration, 2011, FDA LAB INF EYL
   Wang X, 2013, GRAEFES ARCH CLIN EX
NR 31
TC 10
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2014
VL 252
IS 10
BP 1545
EP 1551
DI 10.1007/s00417-014-2612-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0NB
UT WOS:000344631600004
PM 24705851
DA 2022-11-30
ER

PT J
AU Viturino, MG
   Neto, JM
   Bajano, FF
   Costa, SM
   Roque, AB
   Borges, GF
   Ananina, G
   Rim, PH
   Medina, FM
   Costa, FF
   de Vasconcellos, JP
   de Melo, MB
AF Viturino, Marina G. M.
   Neto, Jamil M.
   Bajano, Flavia F.
   Costa, Sueli M. S.
   Roque, Alicia B.
   Borges, Gessica F. S.
   Ananina, Galina
   Rim, Priscila H. H.
   Medina, Flavio M.
   Costa, Fernando F.
   de Vasconcellos, Jose P. C.
   de Melo, Monica B.
TI Evaluation of APOE polymorphisms and the risk for age-related macular
   degeneration in a Southeastern Brazilian population
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Apolipoprotein E; polymorphism; age-related macular degeneration;
   pathogenesis; lipid transport pathway; genetic risk
ID APOLIPOPROTEIN-E GENE; EPSILON-4 ALLELE; ASSOCIATION; SUSCEPTIBILITY;
   SMOKING
AB This study aimed to evaluate the role of APOE polymorphisms (rs429358 and rs7412) in the risk of age-related macular degeneration in a sample of the Southeastern Brazilian population. Seven hundred and five unrelated individuals were analyzed, 334 with age-related macular degeneration (case group), and 371 without the disease (control group). In the case group, patients were further stratified according to disease phenotypes, divided into dry and wet age-related macular degeneration, and non-advanced and advanced age-related macular degeneration. APOE polymorphisms (rs429358 and rs7412) were evaluated through polymerase chain reaction and direct sequencing. In the comparison of cases vs. controls, none of the associations reached statistical significance, considering the Bonferroni-adjusted P-value, although there was a suggestive protection for the E3/E4 genotype (OR = 0.626; P-value = 0.037) and E4 carriers (OR = 0.6515; P-value = 0.047). Statistically significant protection for both the E3/E4 genotype and E4 carriers was observed in the comparisons: advanced age-related macular degeneration vs. controls (OR = 0.3665, P-value = 0.491 x 10(-3) and OR = 0.4031, P-value = 0.814 x 10(-3), respectively), advanced age-related macular degeneration vs. non-advanced age-related macular degeneration (OR = 0.2529, P-value = 0.659 x 10(-4) and OR = 0.2692, P-value = 0.631 x 10(-4), respectively). In the comparison of wet age-related macular degeneration vs. control, protection was statistically significant only for E3/E4 (OR = 0.4052, P-value = 0.001). None of the comparisons demonstrated any significant association for E2 genotypes or E2 carriers in age-related macular degeneration risk in this study. Findings suggest a protective role of the E4 haplotype in the APOE gene in the risk for advanced and wet forms of age-related macular degeneration, in a sample of the Brazilian population. To our knowledge, this is the first Brazilian study to show the association between APOE polymorphisms and age-related macular degeneration.
C1 [Viturino, Marina G. M.; Neto, Jamil M.; Roque, Alicia B.; Borges, Gessica F. S.; Rim, Priscila H. H.; de Vasconcellos, Jose P. C.] Univ Estadual Campinas, Dept Ophthalmol, Fac Med Sci, BR-13083887 Campinas, SP, Brazil.
   [Bajano, Flavia F.; Costa, Sueli M. S.; Ananina, Galina; de Melo, Monica B.] Univ Estadual Campinas, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, BR-13083875 Campinas, SP, Brazil.
   [Medina, Flavio M.] Univ Estado Rio De Janeiro, Dept Ophthalmol, Fac Med Sci, BR-20551030 Rio De Janeiro, RJ, Brazil.
   [Costa, Fernando F.] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, BR-13083878 Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas;
   Universidade do Estado do Rio de Janeiro; Universidade Estadual de
   Campinas
RP de Melo, MB (通讯作者)，Univ Estadual Campinas, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, BR-13083875 Campinas, SP, Brazil.
EM melomb@uol.com.br
RI Miguel-Neto, Jamil/GLT-9254-2022; Costa, Fernando F/D-1566-2012; Medina,
   Flavio/AFM-1303-2022
OI Miguel-Neto, Jamil/0000-0002-7024-1294; Costa, Fernando
   F/0000-0002-4632-572X; 
FU Fund for Support to Teaching, Research and Outreach Activities (FAEPEX)
   [1525/15, 251/18]; Sao Paulo Research Foundation (FAPESP) [2010/18353-9]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported by the Fund for Support to Teaching, Research and Outreach
   Activities (FAEPEX) grants 1525/15 and 251/18 and by Sao Paulo Research
   Foundation (FAPESP) grant 2010/18353-9.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Fernandez-Vega B, 2020, ACTA OPHTHALMOL, V98, pE282, DOI 10.1111/aos.14280
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Guillaume D, 1996, J NEUROCHEM, V66, P2410
   Huebbe P, 2017, AGEING RES REV, V37, P146, DOI 10.1016/j.arr.2017.06.002
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liutkeviciene R, 2018, OPHTHALMIC GENET, V39, P457, DOI 10.1080/13816810.2018.1479429
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Mao XY, 2017, ARCH MED RES, V48, P370, DOI 10.1016/j.arcmed.2017.08.002
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sun E, 2011, MOL VIS, V17, P997
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhong L, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0069-4
NR 34
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD MAY
PY 2021
VL 246
IS 10
BP 1148
EP 1155
DI 10.1177/1535370220985466
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA SF5ZS
UT WOS:000652834000003
PM 33467888
OA Green Published
DA 2022-11-30
ER

PT J
AU Brucker, AJ
AF Brucker, Alexander J.
TI AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; angiogenesis
ID MACULOPATHY; PREVALENCE; RISK
AB Age-related macular degeneration (AMD) is a significant source of morbidity in aging adults. The damage to the macula and vision loss in advanced forms of wet AMD stems from choroidal neovascularization that originates in the choroid and proliferates through breaks in the Bruch membrane. Although inhibitors of angiogenesis have been a recent advance in the treatment of AMD associated with neovascularization, these agents do not appear to cure the condition. Rather, antiangiogensis agents halt or slow progression of AMD in most cases. The development of additional treatments to provide more effective disease control may depend on addressing several pathophysiologic processes simultaneously. The search for more effective treatments will require a better understanding of the different physiologic processes involved with this disease process. RETINA 29:S54-S56, 2009
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Brucker, AJ (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
EM brucker@retinajournal.com
CR de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   National Advisory Eye Council (U.S.), 1993, NIH PUBL
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
NR 11
TC 0
Z9 0
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S54
EP S56
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700020
DA 2022-11-30
ER

PT J
AU Dieguez, HH
   Romeo, HE
   Fleitas, MFG
   Aranda, ML
   Milne, GA
   Rosenstein, RE
   Dorfman, D
AF Dieguez, Hernan H.
   Romeo, Horacio E.
   Gonzalez Fleitas, Maria F.
   Aranda, Marcos L.
   Milne, Georgia A.
   Rosenstein, Ruth E.
   Dorfman, Damian
TI Superior cervical gangliectomy induces non-exudative age-related macular
   degeneration in mice
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Age-related macular degeneration; Superior cervical ganglion; Choroid;
   Retinal pigment epithelium; Photoreceptors; Experimental model
ID RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL OXIDATIVE STRESS;
   BRUCHS-MEMBRANE; BLOOD-FLOW; DRUSEN FORMATION; MOUSE MODEL; MACULOPATHY;
   CHORIOCAPILLARIS; RPE; PATHOGENESIS
AB Non-exudative age-related macular degeneration, a prevalent cause of blindness, is a progressive and degenerative disease characterized by alterations in Bruch's membrane, retinal pigment epithelium, and photoreceptors exclusively localized in the macula. Although experimental murine models exist, the vast majority take a long time to develop retinal alterations and, in general, these alterations are ubiquitous, with many resulting from non-eye-specific genetic manipulations; additionally, most do not always reproduce the hallmarks of human age-related macular degeneration. Choroid vessels receive sympathetic innervation from the superior cervical ganglion, which, together with the parasympathetic system, regulates blood flow into the choroid. Choroid blood flow changes have been involved in age-related macular degeneration development and progression. At present, no experimental models take this factor into account. The aim of this work was to analyze the effect of superior cervical gangliectomy (also known as ganglionectomy) on the choroid, Bruch's membrane, retinal pigment epithelium and retina. Adult male C57BL/6J mice underwent unilateral superior cervical gangliectomy and a contralateral sham procedure. Although superior cervical gangliectomy induced ubiquitous choroid and choriocapillaris changes, it induced Bruch's membrane thickening, loss of retinal pigment epithelium melanin content and retinoid isomerohydrolase, the appearance of drusen-like deposits, and retinal pigment epithelium and photoreceptor atrophy, exclusively localized in the temporal side. Moreover, superior cervical gangliectomy provoked a localized increase in retinal pigment epithelium and photoreceptor apoptosis, and a decline in photoreceptor electroretinographic function. Therefore, superior cervical gangliectomy recapitulated the main features of human non-exudative age-related macular degeneration, and could become a new experimental model of dry age-related macular degeneration, and a useful platform for developing new therapies.
C1 [Dieguez, Hernan H.; Gonzalez Fleitas, Maria F.; Aranda, Marcos L.; Milne, Georgia A.; Rosenstein, Ruth E.; Dorfman, Damian] Univ Buenos Aires, CONICET, Lab Retinal Neurochem & Expt Ophthal, Dept Human Biochem,Sch Med CEFyBO, C1121ABG, Buenos Aires, DF, Argentina.
   [Romeo, Horacio E.] Pontifical Catholic Univ Argentina, CONICET, UCA, Fac Med Sci,BIOMED, C1107AFB, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Pontifical Catholic University of
   Argentina
RP Dorfman, D (通讯作者)，Univ Buenos Aires, CONICET, Lab Retinal Neurochem & Expt Ophthal, Dept Human Biochem,Sch Med CEFyBO, C1121ABG, Buenos Aires, DF, Argentina.
EM ddorfman@fmed.uba.ar
OI Dieguez, Hernan/0000-0001-6036-5755; Ruth,
   Rosenstein/0000-0002-8804-4395; Aranda, Marcos/0000-0003-1891-3476;
   Dorfman, Damian/0000-0002-7967-9866; Gonzalez Fleitas, Maria
   Florencia/0000-0001-5795-8365
FU National Scientific and Technical Research Council (CONICET) [PIP 0707];
   National Agency for Science and Technology, Argentina (ANPCYT) [BID 2014
   PICT 1563, BID 2015 PICT 0356]; University of Buenos Aires (UBA)
   [20020130100564]
FX This work was funded by the National Scientific and Technical Research
   Council (CONICET; PIP 0707), the National Agency for Science and
   Technology, Argentina (ANPCYT; BID 2014 PICT 1563 and BID 2015 PICT
   0356) and the University of Buenos Aires (UBA; 20020130100564).
CR Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BILL A, 1985, INVEST OPHTH VIS SCI, V26, P410
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bordone MP, 2012, J NEUROCHEM, V122, P392, DOI 10.1111/j.1471-4159.2012.07767.x
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Duke-Elder S., 1966, DIS UVEAL TRACT SYST, P740
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fernandez DC, 2009, INVEST OPHTH VIS SCI, V50, P3922, DOI 10.1167/iovs.08-3344
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gonzalez-Garcia E, 2016, DOC OPHTHALMOL, V133, P31, DOI 10.1007/s10633-016-9545-y
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KOSS MC, 1994, EXP EYE RES, V59, P715, DOI 10.1006/exer.1994.1157
   Leonard DS, 2003, EXP EYE RES, V76, P473, DOI 10.1016/S0014-4835(02)00331-7
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MISHIMA H, 1981, A GRAEF ARCH KLIN EX, V216, P209, DOI 10.1007/BF00408162
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   ROMEO HE, 1991, J AUTONOM NERV SYST, V32, P159, DOI 10.1016/0165-1838(91)90066-C
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182
   Trivino A, 2005, HISTOL HISTOPATHOL, V20, P393, DOI 10.14670/HH-20.393
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 59
TC 9
Z9 9
U1 0
U2 1
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD FEB
PY 2018
VL 11
IS 2
AR dmm031641
DI 10.1242/dmm.031641
PG 11
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA FX5GL
UT WOS:000426106000007
PM 29361515
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ambati, J
   Atkinson, JP
   Gelfand, BD
AF Ambati, Jayakrishna
   Atkinson, John P.
   Gelfand, Bradley D.
TI Immunology of age-related macular degeneration
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Review
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE; GENOME-WIDE
   ASSOCIATION; C-REACTIVE PROTEIN; CHOROIDAL NEOVASCULARIZATION;
   GEOGRAPHIC ATROPHY; BRUCHS MEMBRANE; OXIDATIVE STRESS
AB Age-related macular degeneration (AMD) is a leading cause of blindness in aged individuals. Recent advances have highlighted the essential role of immune processes in the development, progression and treatment of AMD. In this Review we discuss recent discoveries related to the immunological aspects of AMD pathogenesis. We outline the diverse immune cell types, inflammatory activators and pathways that are involved. Finally, we discuss the future of inflammation-directed therapeutics to treat AMD in the growing aged population.
C1 [Ambati, Jayakrishna; Gelfand, Bradley D.] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   [Atkinson, John P.] Washington Univ, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40506 USA.
C3 University of Kentucky; University of Kentucky; Washington University
   (WUSTL); University of Kentucky; University of Kentucky
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
RI Gelfand, Brad/L-3926-2019
FU US National Institutes of Health (NIH) [R01EY018836, R01EY020672,
   R01EY022238]; Doris Duke Charitable Foundation, USA; Ellison Medical
   Foundation, USA; Burroughs Wellcome Fund, USA; Reeves Foundation, USA;
   Dr. E. Vernon Smith and Eloise C. Smith Endowment, USA; Research to
   Prevent Blindness Unrestricted Grant, USA; NIH [I041592, AR007279,
   AR0483335, GM099111, HL112303]; Edward N. and Della L. Thome Memorial
   Foundation, USA; Alexion Pharmaceuticals, USA; National Center for
   Advancing Translational Sciences, USA [UL1TR000117]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY018836, R01EY022238, R01EY020672]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [U54HL112303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASES [T32AR007279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF GENERAL MEDICAL SCIENCES [R01GM099111] Funding Source: NIH RePORTER
FX J.A. is supported by US National Institutes of Health (NIH) grants
   (R01EY018836, R01EY020672 and R01EY022238), the Doris Duke Charitable
   Foundation, USA, the Ellison Medical Foundation, USA, the Burroughs
   Wellcome Fund, USA, the Reeves Foundation, USA, a Dr. E. Vernon Smith
   and Eloise C. Smith Endowment and a Research to Prevent Blindness
   Unrestricted Grant, USA. J.P.A. is supported by NIH grants (AI041592,
   AR007279, AR0483335, GM099111 and HL112303), the Edward N. and Della L.
   Thome Memorial Foundation, USA, and Alexion Pharmaceuticals, USA. B.D.G.
   is suported by the National Center for Advancing Translational Sciences,
   USA, grants UL1TR000117 and UL1TR000117. The content of this article is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMD Alliance International, 2010, GLOB EC COST VIS IMP
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hoppe G, 2004, BBA-MOL BASIS DIS, V1689, P33, DOI 10.1016/j.bbadis.2004.01.004
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Mevorach D, 2010, APOPTOSIS, V15, P1114, DOI 10.1007/s10495-010-0530-8
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   STREILEIN JW, 1995, EYE, V9, P236, DOI 10.1038/eye.1995.46
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Szeplaki G, 2009, MOL IMMUNOL, V46, P2784, DOI 10.1016/j.molimm.2009.04.028
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wu GX, 2009, CIRC RES, V104, P550, DOI 10.1161/CIRCRESAHA.108.191361
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 160
TC 386
Z9 400
U1 9
U2 141
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
PD JUN
PY 2013
VL 13
IS 6
BP 438
EP 451
DI 10.1038/nri3459
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 151FE
UT WOS:000319445300011
PM 23702979
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Zhang, XZ
   Li, M
   Wen, F
   Zuo, CG
   Chen, H
   Wu, KF
   Zeng, RP
AF Zhang, Xiongze
   Li, Meng
   Wen, Feng
   Zuo, Chengguo
   Chen, Hui
   Wu, Kunfang
   Zeng, Renpan
TI Different impact of high-density lipoprotein-related genetic variants on
   polypoidal choroidal vasculopathy and neovascular age-related macular
   degeneration in a Chinese Han population
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE high-density lipoprotein; age-related macular degeneration; polypoidal
   choroidal vasculopathy; genetic polymorphism
ID GENOME-WIDE ASSOCIATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   SERINE-PROTEASE; CHOLESTEROL; HTRA1; POLYMORPHISMS; LIPC; CFH
AB Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are both major serosanguinous maculopathies among the Asian elderly. They are similar in phenotype. Genetic variants in high-density lipoprotein (HDL) pathway were discovered to be associated with AMD in two genome-wide association studies. In this study with a Chinese Han cohort, we investigated the impacts of these genetic variants on nAMD and PCV separately. The missense coding variants and previously identified variants at LIPC, ABCA1,CETP, LPL and FADS1 loci were genotyped in 157 nAMD patients, 250 PCV patients and 204 controls without any macular abnormality. The known variants in CFH, ARMS2 and near HTRA1 were also genotyped. Fasting serum cholesterol levels were determined. The variants in CFH, ARMS2 and near HTRA1 were strongly associated with both PCV (P < 10(-6), 10(-7) and 10(-7) respectively) and nAMD (P < 10(-6), 10(-16) and 10(-17) respectively). None of the studied HDL-related variants were significantly associated with nAMD. A missense variant in CETP, rs5882, was significantly associated with PCV (P = 2.73 x 10(-4)). The rs5882 GG genotype had a 3.53-fold (95% CI: 1.93-6.45) increased risk for PCV, and conferred a significantly lower serum HDL-cholesterol level for PCV patients than the AA genotype (P = 0.048). These results suggest the need to separate PCV from nAMD in association studies especially with Asian cohorts, and that the HDL pathway may involve in the pathogenesis of PCV and nAMD differently. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xiongze; Li, Meng; Wen, Feng; Zuo, Chengguo; Chen, Hui; Wu, Kunfang; Zeng, Renpan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81200705, 81070745];
   Fundamental Research Funds of State Key Laboratory of Ophthalmology
FX This study was funded by the National Natural Science Foundation of
   China (grant number: 81200705 & 81070745) and the Fundamental Research
   Funds of State Key Laboratory of Ophthalmology.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Atmon G, 2005, MECH AGEING DEV, V126, P341, DOI 10.1016/j.mad.2004.08.026
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Barzilai N, 2003, JAMA-J AM MED ASSOC, V290, P2030, DOI 10.1001/jama.290.15.2030
   Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Darabi M, 2009, HORM METAB RES, V41, P554, DOI 10.1055/s-0029-1192034
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107
   GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Menashe I, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-36
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nielsen DM, 1998, AM J HUM GENET, V63, P1531, DOI 10.1086/302114
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ortiz-Munoz G, 2009, FASEB J, V23, P3129, DOI 10.1096/fj.08-127928
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sanders AE, 2010, JAMA-J AM MED ASSOC, V303, P150, DOI 10.1001/jama.2009.1988
   Tall AR, 2007, ARTERIOSCL THROM VAS, V27, P257, DOI 10.1161/01.ATV.0000256728.60226.77
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thompson A, 2008, JAMA-J AM MED ASSOC, V299, P2777, DOI 10.1001/jama.299.23.2777
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 42
TC 52
Z9 55
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2013
VL 108
BP 16
EP 22
DI 10.1016/j.exer.2012.12.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 099JS
UT WOS:000315617900003
PM 23274582
DA 2022-11-30
ER

PT J
AU Levinger, N
   Beykin, G
   Grunin, M
   Almeida, D
   Levy, J
   Levine, H
   Averbukh, E
   Chowers, I
AF Levinger, Nadav
   Beykin, Gala
   Grunin, Michelle
   Almeida, Diego
   Levy, Jaime
   Levine, Hagai
   Averbukh, Edward
   Chowers, Itay
TI Socioeconomic status and visual outcome in patients with neovascular
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; preventive medicine;
   screening; socioeconomics and education in medicine; ophthalmology;
   medical therapies; retinal pathology; research; practice management
ID POPULATION; IMPAIRMENT; BLINDNESS; ACUITY
AB Purpose
   Visual outcome in patients with neovascular age-related macular degeneration is variable. We aimed to evaluate for association between socioeconomic status visual acuity in neovascular age-related macular degeneration.
   Methods
   A retrospective single-center study of a consecutive group of neovascular age-related macular degeneration patients was performed. Socioeconomic status was determined for each patient based on the 2008 Israeli census. Medical information was extracted from medical records and included visual acuity and optical coherence tomography parameters. Associations between socioeconomic status and clinical outcomes were analyzed.
   Results
   A total of 233 patients were included in the analysis. A correlation was found between low baseline visual acuity of the first eye diagnosed with neovascular age-related macular degeneration and low socioeconomic status (r = -0.13, p = 0.049; n = 233). The difference between the visual acuity of the lowest and the highest socioeconomic status categories at baseline was approximately 3 ETDRS lines (p = 0.048). Socioeconomic status and baseline visual acuity of the second eye of the same individual with neovascular age-related macular degeneration were not correlated (r = -0.05, p = 0.95). Socioeconomic status was not associated with the number of anti-vascular endothelial growth factor injections of the first or second eye, or the visual acuity outcome of the first or second eye after 1 year of therapy (p = 0.421, p = 0.9, respectively). Central subfield thickness of the first eye at presentation as measured by spectral-domain optical coherence tomography was associated with socioeconomic status (r = -0.31 p = 0.001).
   Conclusion
   Individuals of lower socioeconomic status presented at more advanced stage of the disease when developing neovascular age-related macular degeneration in the first eye but not in the second eye. The research underscores the importance of improving referral patterns and awareness for the lowest socioeconomic status classes.
C1 [Levinger, Nadav; Beykin, Gala; Grunin, Michelle; Almeida, Diego; Levy, Jaime; Averbukh, Edward; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Levine, Hagai] Hadassah Hebrew Univ Med Ctr, Braun Sch Publ Hlth & Community Med, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Hadassah Univ Hosp, Kiryat Hadassah, POB 12000, IL-9112001 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858; Levy, Jaime/0000-0003-0043-4354;
   Levinger, Nadav/0000-0002-3682-0225
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   [Anonymous], 2019, 2008 CENSUS POPULATI
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   More P, 2019, EYE, V33, P1224, DOI 10.1038/s41433-019-0393-3
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   Riva I, 2018, J GLAUCOMA, V27, P776, DOI 10.1097/IJG.0000000000000989
   Rottenberg Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6353-1
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   Nguyen V, 2018, CLIN EXP OPHTHALMOL, V46, P266, DOI 10.1111/ceo.13038
   Zhang XZ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1121, DOI 10.1001/archopht.126.8.1121
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P1198, DOI 10.1001/jamaophthalmol.2013.4694
NR 13
TC 1
Z9 1
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1094
EP 1100
AR 1120672120920783
DI 10.1177/1120672120920783
EA MAY 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000534531800001
PM 32363931
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Su, Y
   Hu, ZZ
   Pan, T
   Chen, L
   Xie, P
   Liu, QH
AF Su, Yun
   Hu, Zizhong
   Pan, Ting
   Chen, Lu
   Xie, Ping
   Liu, Qinghuai
TI Complement factor B gene polymorphisms and risk of age-related macular
   degeneration: A meta-analysis
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Complement factor B; age-related macular degeneration; polymorphism
ID ANTI-VEGF TREATMENT; COMPONENT 2 C2; COMMON VARIATION; HTRA1 GENE;
   FACTOR-H; ASSOCIATION; SUSCEPTIBILITY; C3; VARIANTS; CFB
AB Objective: To investigate the potential correlation between complement factor B polymorphisms and age-related macular degeneration. Methods: We retrieved relevant articles systematically by searching PubMed and Web of Science databases. The pooled odds ratios and 95% confidence intervals were calculated for five complement factor B polymorphism rs641153, rs4151667, rs1048709, rs2072633, and rs12614 using data from included articles in both random effects and fixed effect models. Subgroup meta-analysis based on age-related macular degeneration type, choroidal neovascular disease (rs641153 and rs4151667), geographic atrophy (rs641153 and rs4151667), and races was also performed. Results: In the overall comparison, we observed that the distribution of rs641153 and the risk of age-related macular degeneration were significantly correlated (p < 0.00001). Similar results were obtained in subgroup analysis based on race (Caucasians, p < 0.00001; Asians, p = 0.003) and age-related macular degeneration type (choroidal neovascular disease, p < 0.00001; geographic atrophy, p = 0.04). As for complement factor B rs4151667, the genotypic effects were also demonstrated statistically significant in overall analysis (p < 0.00001) and only in Caucasians diagnosed with choroidal neovascular disease (p = 0.004), but not in Asians. Moreover, no statistically significant correlations between the complement factor B polymorphisms rs1048709 (p = 0.63), rs2072633 (p = 0.72), rs12614 (p = 0.98) and susceptibility to age-related macular degeneration were detected in either overall or subgroup analysis. Conclusion: Collectively, we demonstrated that the complement factor B genes rs641153 and rs4151667, but not rs1048709, rs2072633, rs12614, were associated with the susceptibility of age-related macular degeneration and might play predictive roles in future age-related macular degeneration diagnosis. More studies are needed to verify these findings.
C1 [Su, Yun; Hu, Zizhong; Pan, Ting; Chen, Lu; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Pan, Ting] Nanjing Med Univ, Affiliated Changzhou 2 Peoples Hosp, Dept Ophthalmol, Changzhou, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI hu, zizhong/0000-0001-6289-1804; Liu, Qinghuai/0000-0003-1605-1964
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bonyadi MHJ, 2017, INT OPHTHALMOL, V37, P1397, DOI 10.1007/s10792-016-0413-2
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Park KH, 2009, MOL VIS, V15, P200
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
   Zhuang WJ, 2014, OPHTHALMIC GENET, V35, P156, DOI 10.3109/13816810.2014.921314
NR 46
TC 3
Z9 3
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2020
VL 30
IS 4
BP 743
EP 755
DI 10.1177/1120672119840245
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MF1JK
UT WOS:000545106200018
PM 30974970
DA 2022-11-30
ER

PT J
AU Dosunmu, EO
   Bakri, SJ
AF Dosunmu, Eniolami O.
   Bakri, Sophie J.
TI Mimickers of Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE drusen; macular degeneration; geographic atrophy; Stargardt's; pattern
   dystrophy; Best disease; central serous chorioretinopathy
ID JUXTAFOVEOLAR RETINAL TELANGIECTASIS; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT EPITHELIUM; FUNDUS DYSTROPHY;
   PATTERN; DRUSEN
AB In the Western World, the leading cause of irreversible blindness is Age-Related Macular Degeneration (ARMD). It can have significant visual impairment, and it is important that the practicing ophthalmologist is knowledgeable in the diagnosis and treatment of ARMD. Equally important is knowledge in the diagnosis of other disease entities that may mimic ARMD, as this may change the prognosis, treatment and visual outcome of patients. This article discusses those diseases that mimic ARMD and their distinguishing features.
C1 [Dosunmu, Eniolami O.; Bakri, Sophie J.] Mayo Clin, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.
EM Bakri.sophie@mayo.edu
FU Research to Prevent Blindness, New York, NY
FX This manuscript was supported by Research to Prevent Blindness, New
   York, NY.
CR AISH S F S, 1980, British Journal of Ophthalmology, V64, P652
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   CIBIS GW, 1980, ARCH OPHTHALMOL-CHIC, V98, P1785
   COOPER LZ, 1967, ARCH OPHTHALMOL-CHIC, V77, P434
   DEUTMAN AF, 1970, BRIT J OPHTHALMOL, V54, P373, DOI 10.1136/bjo.54.6.373
   DEUTMAN AF, 1970, ARCH OPHTHALMOL-CHIC, V83, P558
   FISHMAN GA, 1977, ARCH OPHTHALMOL-CHIC, V95, P73
   FISHMAN GA, 1990, AUST NZ J OPHTHALMOL, V18, P123
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   HSIEH RC, 1977, ARCH OPHTHALMOL-CHIC, V95, P429
   Hussain N, 2006, CLIN EXP OPHTHALMOL, V34, P137, DOI 10.1111/j.1442-9071.2006.01171.x
   KINGHAM JD, 1978, ARCH OPHTHALMOL-CHIC, V96, P1177, DOI 10.1001/archopht.1978.03910060011003
   KINGHAM JD, 1977, AM J OPHTHALMOL, V84, P526
   KOBRIN J L, 1981, International Ophthalmology Clinics, V21, P167, DOI 10.1097/00004397-198102130-00014
   KRILL AE, 1966, AM J OPHTHALMOL, V61, P1405, DOI 10.1016/0002-9394(66)90478-8
   Mansour AM, 2007, EUR J OPHTHALMOL, V17, P680, DOI 10.1177/112067210701700434
   Marmor F., 1990, OPHTHALMOLOGY, V97, P380
   MARMOR MF, 1977, AM J OPHTHALMOL, V84, P32, DOI 10.1016/0002-9394(77)90320-8
   Miller DG, 2001, CURR OPIN OPHTHALMOL, V12, P222, DOI 10.1097/00055735-200106000-00014
   Noemi L, 2001, ARCH OPHTHALMOL-CHIC, V119, P359
   Savige J, 2009, NAT REV NEPHROL, V5, P356, DOI 10.1038/nrneph.2009.65
   SMALL KW, 1992, ARCH OPHTHALMOL-CHIC, V110, P515, DOI 10.1001/archopht.1992.01080160093040
   SMALL KW, 1989, OPHTHALMOLOGY, V96, P1747
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Welch R B, 1977, Trans Am Ophthalmol Soc, V75, P164
   Westerfeld Corey, 2008, Semin Ophthalmol, V23, P59, DOI 10.1080/08820530701745249
   YAMADA K, 1992, OPHTHALMOLOGICA, V205, P69, DOI 10.1159/000310315
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   ZHANG K, 1995, SURV OPHTHALMOL, V40, P51, DOI 10.1016/S0039-6257(95)80047-6
NR 41
TC 2
Z9 2
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 209
EP 215
DI 10.3109/08820538.2011.577134
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200017
PM 21609234
DA 2022-11-30
ER

PT J
AU Semba, RD
   Moaddel, R
   Cotch, MF
   Jonasson, F
   Eiriksdottir, G
   Harris, TB
   Launer, LJ
   Sun, K
   Klein, R
   Schaumberg, DA
   Jonsson, P
   Gudnason, V
   Ferrucci, L
AF Semba, Richard D.
   Moaddel, Ruin
   Cotch, Mary Frances
   Jonasson, Fridbert
   Eiriksdottir, Gudny
   Harris, Tamara B.
   Launer, Lenore J.
   Sun, Kai
   Klein, Ronald
   Schaumberg, Debra A.
   Jonsson, Palmi
   Gudnason, Vilmundur
   Ferrucci, Luigi
TI Serum lipids in adults with late age-related macular degeneration: a
   case-control study
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE Age-related macular degeneration; Aging; Geographic atrophy; Lipids;
   Mass spectrometry; Neovascular AMD
ID PLASMA; STABILITY; DISEASE
AB BackgroundLipids are implicated in the pathogenesis of age-related macular degeneration (AMD). The relationship between systemic lipids and AMD has not been well characterized. The objective was to investigate the relationship between serum lipids and AMD in older adults using a lipidomic approach.MethodsIn a case-control study, 240 adults, aged 66years, a third each having geographic atrophy, neovascular AMD, or no signs of AMD, were selected from a population-based sample of participants in the Age Gene/Environment Susceptibility-Reykjavik Study. The exposure was serum lipids and risk factors for AMD. The outcome was late AMD, assessed through fundus images taken through dilated pupils using a 45-degree digital camera and grading for neovascular AMD and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.ResultsOf 177 serum lipid species measured, there were no significant differences in serum lipids between controls and those with geographic atrophy or neovascular AMD, respectively. Adults with neovascular AMD had higher total serum lysophosphatidylcholine (LPC) (P=0.004) and serum LPC 18:0 (P=0.0002) compared to those with geographic atrophy.ConclusionLate AMD was not characterized by alterations in systemic lipids compared with normal controls. These findings suggest that there may be differences in the LPC pathway between adults with neovascular AMD and geographic atrophy.
C1 [Semba, Richard D.; Sun, Kai] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Smith Bldg,M015,400 N Broadway, Baltimore, MD 21287 USA.
   [Moaddel, Ruin; Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Baltimore, MD 21224 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   [Jonasson, Fridbert; Jonsson, Palmi; Gudnason, Vilmundur] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
   [Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Epidemiol & Populat Sci, Intramural Res Program, Bethesda, MD 20892 USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth Madison, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med, Salt Lake City, UT USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Iceland; Landspitali National University Hospital;
   Icelandic Heart Association; National Institutes of Health (NIH) - USA;
   NIH National Institute on Aging (NIA); University of Wisconsin System;
   University of Wisconsin Madison; Utah System of Higher Education;
   University of Utah
RP Semba, RD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Smith Bldg,M015,400 N Broadway, Baltimore, MD 21287 USA.
EM rdsemba@jhmi.edu
RI Gudnason, Vilmundur/AAE-7126-2019; Jonasson, Fridbert/ABA-9889-2021;
   Moaddel, Ruin/AAE-3378-2020
OI Gudnason, Vilmundur/0000-0001-5696-0084; Cotch, Mary
   Frances/0000-0002-2046-4350; Moaddel, Ruin/0000-0002-6812-0127
FU National Institutes of Health [R01 AG027012, R01 EY017362,
   N01-AG-1-2100, HHSN271201200022C]; National Institute on Aging; National
   Eye Institute [ZIAEY00401]; Iceland Heart Association; Icelandic
   Parliament; University of Iceland Research Fund; NATIONAL EYE INSTITUTE
   [ZIAEY000401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [ZIAAG000971, ZIAAG007380] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants R01
   AG027012 and R01 EY017362, the Intramural Research Programs of the
   National Institute on Aging and the National Eye Institute (ZIAEY00401
   and National Institutes of Health contract numbers N01-AG-1-2100 and
   HHSN271201200022C), the Iceland Heart Association, the Icelandic
   Parliament, and the University of Iceland Research Fund. The National
   Eye Institute was involved in the design and conduct of the study in
   regard to collection of fundus photographs. The funders had no role in
   data collection, management, analysis, and interpretation of the data;
   and preparation, review, or approval of the manuscript; and decision to
   submit the manuscript for publication.
CR Baker PRS, 2014, J LIPID RES, V55, P2432, DOI 10.1194/jlr.D051581
   Benesch MGK, 2016, J BIOMED RES, V30, P272, DOI 10.7555/JBR.30.20150058
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Grzelczyk A, 2013, BIOCHIMIE, V95, P667, DOI 10.1016/j.biochi.2012.10.009
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Heiskanen LA, 2013, ANAL CHEM, V85, P8757, DOI 10.1021/ac401857a
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Matthan NR, 2010, J LIPID RES, V51, P2826, DOI 10.1194/jlr.D007534
   Quehenberger O, 2011, NEW ENGL J MED, V365, P1812, DOI 10.1056/NEJMra1104901
   Schlame M, 2017, BBA-MOL CELL BIOL L, V1862, P3, DOI 10.1016/j.bbalip.2016.08.010
   Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x
   Surma MA, 2015, EUR J LIPID SCI TECH, V117, P1540, DOI 10.1002/ejlt.201500145
   van Leeuwen E.M., 2018, PROG RETIN EYE RES
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 15
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD JAN 8
PY 2019
VL 18
AR 7
DI 10.1186/s12944-018-0954-7
PG 4
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA HG8TB
UT WOS:000455275700002
PM 30621701
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kikuchi, M
   Nakamura, M
   Ishikawa, K
   Suzuki, T
   Nishihara, H
   Yamakoshi, T
   Nishio, K
   Taki, K
   Niwa, T
   Hamajima, N
   Terasaki, H
AF Kikuchi, Masato
   Nakamura, Makoto
   Ishikawa, Kohei
   Suzuki, Toshimitsu
   Nishihara, Hiroaki
   Yamakoshi, Tomomi
   Nishio, Kazuko
   Taki, Kentaro
   Niwa, Toshimitsu
   Hamajima, Nobuyuki
   Terasaki, Hiroko
TI Elevated C-reactive protein levels in patients with polypoidal choroidal
   vasculopathy and patients with neovascular age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; CARDIOVASCULAR-DISEASE; JAPANESE
   POPULATION; CLINICOPATHOLOGICAL CORRELATION; MACULOPATHY; INFLAMMATION;
   PREVALENCE; HOMOCYSTEINE; INDIVIDUALS
AB Purpose: To determine the relationship between systemic C-reactive protein (CRP) levels and polypoidal choroidal vasculopathy (PCV) and advanced neovascular age-related macular degeneration (AMD) in Japanese patients. Design: Case-control study.
   Participants: Ninety-seven patients with PCV, 176 with advanced neovascular AMD, and 262 control subjects without any macular abnormality were studied.
   Methods: Color fundus photographs of the macular area were taken from both eyes in all subjects. Indocyanine green angiography and fluorescein angiography were performed for diagnosis. The CRIP level was measured by a high-sensitivity assay using a latex aggregation immunoassay, and the levels in patients with PCV and neovascular AMD were compared with that in the control group using the Kruskal-Wallis test. Associations between CRP and PCV or neovascular AMD were compared using logistic regression analysis by computing the odds ratios (ORs) and 95% confidence intervals (Cls) after the study populations were divided into quartiles.
   Main Outcome Measures: The CRP levels inpatients with PCV, patients with neovascular AMD, and control subjects. Standard univariate and multivariate analyses between groups.
   Results: Median CRIP levels were significantly higher in cases with PCV (0.94 mg/1) or with advanced neovascular AMD (0.95 mg/l) than in control subjects (0.43 mg/l) (P < 0.001 for Kruskal-Wallis test). After adjusting for baseline characteristics such as age, gender, smoking status, alcohol use, body mass index, history, and use of antiinflammatory drugs, the increase in risk was significant for the highest quartile of CRP for both PCV (OR, 3.53; 95% Cl, 1.49-8.40) and neovascular AMD (OR, 4.08; 95% Cl, 1.94-8.56), and for the third quartile of CRP for neovascular AMD (OR, 2.29; 95% Cl, 1.07-4.91). The trends for an increase in risk of disease with increase in CRP were statistically significant for both PCV (P = 0.001) and neovascular AMD (P < 0.001).
   Conclusions: The significant associations between elevated serum CRP levels and PCV or neovascular AMD in the Japanese strongly suggest that inflammatory processes are involved in the pathogenesis of PCV and neovascular AMD. Ophthalmology 2007,-114:1722-1727 (c) 2007 by the American Academy of Ophthalmology.
C1 Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   Nagoya Univ, Grad Sch Med, Dept Prevent Med Biostat & Med Decis Making, Nagoya, Aichi, Japan.
   Nagoya Univ, Grad Sch Med, Dept Clin Prevent Med, Nagoya, Aichi, Japan.
C3 Nagoya University; Nagoya University; Nagoya University
RP Nakamura, M (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM makonaka@med.nagoya-u.ac.jp
RI Hamajima, Nobuyuki/I-7237-2014; Terasaki, Hiroko/M-5054-2014
OI Nakamura, Makoto/0000-0002-6464-4302
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   MOLD C, 1984, J IMMUNOL, V133, P882
   Nishio Kazuko, 2004, Nagoya J Med Sci, V67, P45
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yamada S, 2001, AM J EPIDEMIOL, V153, P1183, DOI 10.1093/aje/153.12.1183
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 44
TC 96
Z9 104
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2007
VL 114
IS 9
BP 1722
EP 1727
DI 10.1016/j.ophtha.2006.12.021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206LA
UT WOS:000249183700019
PM 17400294
DA 2022-11-30
ER

PT J
AU Mauschitz, MM
   Finger, RP
AF Mauschitz, Matthias M.
   Finger, Robert P.
TI Age-Related Macular Degeneration and Cardiovascular Diseases: Revisiting
   the Common Soil Theory
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cardiovascular disease; epidemiology
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CORONARY-HEART-DISEASE; RISK-FACTORS;
   MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS RISK; GEOGRAPHIC ATROPHY;
   PHYSICAL-ACTIVITY; OXIDATIVE STRESS; FOLIC-ACID; ASSOCIATION
AB Age-related macular degeneration (AMD), a complex disease associated with aging, remains one of the leading causes of visual loss in high-income countries and its prevalence is expected to increase over the next decades. Polypoidal choroidal vasculopathy has been considered a variant of neovascular AMD and is highly prevalent in Asian populations. Similarly, cardiovascular disease (CVD)-another complex disease associated with aging-is a leading cause of morbidity and mortality in high-income countries and its prevalence is also expected to increase due to population aging. Previous studies reported an increased risk for CVD in AMD patients, indicating an underlying "common soil." Reviewing the current literature, consistent evidence for common risk factors and mutual comorbidity was identified for both diseases. Cardiovascular risk factors include smoking, diet, and low levels of physical activity, which also play a role in AMD pathogenesis. Several studies demonstrated AMD patients to be at higher risk for CVD compared to the general older population. The complexity of both diseases, however, complicates research on their relation, and thus studies ought to be interpreted with caution. Herein we present an overview of selected studies and their main "take-home messages" on this topic, and hypothesize on the patho-etiologic "common ground" of these 2 diseases.
C1 [Mauschitz, Matthias M.; Finger, Robert P.] Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Finger, RP (通讯作者)，Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Robert.Finger@ukbonn.de
CR Ahmad M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175691
   Ahotupa M, 2017, FREE RADICAL RES, V51, P439, DOI 10.1080/10715762.2017.1319944
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aragam KG, 2020, CIRC RES, V126, P1159, DOI 10.1161/CIRCRESAHA.120.315928
   Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720
   Berger S, 2015, AM J CLIN NUTR, V102, P276, DOI 10.3945/ajcn.114.100305
   Bindu GH, 2011, CHOLESTEROL, DOI 10.1155/2011/274629
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Burke A, 2003, PROG CARDIOVASC DIS, V46, P79, DOI 10.1016/S0033-0620(03)00076-8
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Colijn JM., 2019, OPHTHALMOLOGY, V126
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Cymerman RM, 2016, CURR EYE RES, V41, P1482, DOI 10.3109/02713683.2015.1128552
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Duncan MS, 2019, JAMA-J AM MED ASSOC, V322, P642, DOI 10.1001/jama.2019.10298
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Francula-Zaninovic S, 2018, CURR CARDIOL REV, V14, P153, DOI 10.2174/1573403X14666180222102312
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   JARRETT RJ, 1984, DIABETOLOGIA, V26, P99
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Kondo T, 2019, CIRC J, V83, P1980, DOI 10.1253/circj.CJ-19-0323
   Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mano F, 2021, OPHTHALMOL RETINA, V5, P743, DOI 10.1016/j.oret.2020.11.011
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mauschitz MM., 2021, AM J OPHTHALMOL, V236, P99
   McDermott J H, 2000, J Am Pharm Assoc (Wash), V40, P785
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P229, DOI 10.1080/09286586.2016.1276934
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   North BJ, 2012, CIRC RES, V110, P1097, DOI 10.1161/CIRCRESAHA.111.246876
   Perk Joep, 2012, Int J Behav Med, V19, P403, DOI [10.1016/j.atherosclerosis.2012.05.007, 10.1093/eurheartj/ehs092, 10.1007/s12529-012-9242-5]
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rezaee F, 2006, PROTEOMICS, V6, P721, DOI 10.1002/pmic.200500191
   Sahu Y, 2021, INT OPHTHALMOL, V41, P753, DOI 10.1007/s10792-020-01620-0
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Senoner T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092090
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Siri-Tarino PW, 2016, CURR OPIN LIPIDOL, V27, P323, DOI 10.1097/MOL.0000000000000310
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tahmasebpour HR, 2005, RADIOGRAPHICS, V25, P1561, DOI 10.1148/rg.256045013
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang J, 2019, BIOMED OPT EXPRESS, V10, P1532, DOI 10.1364/BOE.10.001532
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zhang LL, 2022, JAMA CARDIOL, V7, P259, DOI 10.1001/jamacardio.2021.5340
NR 97
TC 1
Z9 1
U1 1
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2022
VL 11
IS 2
BP 94
EP 99
DI 10.1097/APO.0000000000000496
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1A1JH
UT WOS:000791521300004
PM 35213420
OA gold
DA 2022-11-30
ER

PT J
AU Lim, FPM
   Wong, CW
   Loh, BK
   Chan, CM
   Yeo, I
   Lee, SY
   Mathur, R
   Wong, D
   Wong, TY
   Cheung, CMG
AF Lim, Fiona Pin Miao
   Wong, Chee Wai
   Loh, Boon Kwang
   Chan, Choi Mun
   Yeo, Ian
   Lee, Shu Yen
   Mathur, Ranjana
   Wong, Doric
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Prevalence and clinical correlates of focal choroidal excavation in eyes
   with age-related macular degeneration, polypoidal choroidal vasculopathy
   and central serous chorioretinopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY
AB Purpose To describe the prevalence and clinical characteristics of focal choroidal excavation (FCE) in patients with exudative maculopathy due to age-related macular degeneration with choroidal neovascularisation (AMD-CNV), polypoidal choroidal vasculopathy (PCV) and central serous chorioretinopathy (CSC).
   Methods Three hundred and forty-three patients (343 presenting eyes and 255 fellow unaffected eyes) from consecutive patients presenting with untreated AMD-CNV, PCV or CSC are prospectively recruited. Two independent retinal specialists masked to the clinical diagnosis graded the presence of FCE by examining the findings from spectral-domain optical coherence tomography (SD-OCT). The frequency and clinical characteristics of FCE in each of the three clinical diagnosis groups were compared.
   Results The diagnosis in the presenting eye was AMD-CNV in 92 patients, PCV in 149 patients, retinal angiomatous proliferation (RAP) in 3 patients and CSC in 99 patients; 255 fellow eyes free of clinical diseases were also graded. The prevalence of FCE was 2.3% (total 14 eyes; 10 presenting eyes, 4 fellow eyes) out of 598 eyes examined. In presenting eyes, FCE was most prevalent in PCV (6.0%), followed by AMD-CNV (1.0%) and CSC (0%), p=0.02. In fellow eyes, the prevalence of FCE was 2.9%, 0% and 1.2% in patients with PCV, AMD-CNV and CSC, respectively. Eyes with FCE had a significantly longer axial length (24.93+/-1.65 mm vs 23.49+/-1.10 mm, p<0.001), but otherwise, all other characteristics were similar.
   Conclusions FCE is more common in PCV than AMD-CNV and CSC. Disturbance in the choroid/retinal pigment epithelium/Bruch membrane interface affected by FCE may be linked to the pathogenesis of PCV and AMD-CNV.
C1 [Lim, Fiona Pin Miao; Wong, Chee Wai; Loh, Boon Kwang; Chan, Choi Mun; Yeo, Ian; Lee, Shu Yen; Mathur, Ranjana; Wong, Doric; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Chan, Choi Mun; Yeo, Ian; Lee, Shu Yen; Mathur, Ranjana; Wong, Doric; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
   [Yeo, Ian; Lee, Shu Yen; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Yeo, Ian; Lee, Shu Yen; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Vitreoretinal Serv, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
FU National Medical Research Council [NMRC/NIG/1003/2009]
FX This study was supported by National Medical Research Council grant
   NMRC/NIG/1003/2009.
CR Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   FINE SL, 1980, ARCH OPHTHALMOL-CHIC, V98, P832
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Katome T, 2012, CASE REP OPHTHALM, V3, P96, DOI 10.1159/000337880
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Kuroda Y, 2014, INVEST OPHTH VIS SCI, V55, P6046, DOI 10.1167/iovs.14-14723
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Lee JH, 2014, AM J OPHTHALMOL, V157, P710, DOI 10.1016/j.ajo.2013.12.011
   Lim FPM, 2014, EYE, V28, P1088, DOI 10.1038/eye.2014.78
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
NR 19
TC 24
Z9 25
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2016
VL 100
IS 7
BP 918
EP 923
DI 10.1136/bjophthalmol-2015-307055
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4JI
UT WOS:000380747000009
PM 26504178
DA 2022-11-30
ER

PT J
AU Tikellis, G
   D Robman, L
   Dimitrov, P
   Nicolas, C
   McCarty, CA
   Guymer, RH
AF Tikellis, G.
   D Robman, L.
   Dimitrov, P.
   Nicolas, C.
   McCarty, C. A.
   Guymer, R. H.
TI Characteristics of progression of early age-related macular
   degeneration: the Cardiovascular Health and Age-Related Maculopathy
   Study
SO EYE
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; progression;
   drusen
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; VITAMIN-E; 5-YEAR INCIDENCE;
   FOLLOW-UP; SMOKING; ROTTERDAM; DRUSEN; SUPPLEMENTATION; ABNORMALITIES
AB Aims: To determine the risk of age-related macular degeneration (AMD) progression posed by the presence of each early AMD characteristic.
   Methods: A prospective cohort study of 254 participants aged 50 years and older, all with early AMD features at their baseline visit followed for an average of 7 years. Stereoscopic colour fundus photographs were graded for early AMD features using the International Classification System. AMD status was stratified into six exclusive levels along a continuum of disease severity according to drusen type, pigmentary abnormalities, or late AMD. Progression was assessed according to three definitions: a change between or within a severity level, or by side by side grading.
   Results: The progression rate of early AMD ranged between 3.4 and 4.67% per annum depending upon the definition used. In total, 15 (6%) cases progressed from early AMD to the late complication of AMD. After controlling for age and smoking, cases with soft indistinct drusen at baseline were at a greater risk of progressing from early to late AMD than were cases without this characteristic (OR = 3.72, 95% CI 1.20-11.54; P = 0.02).
   Conclusion: Our proposed definitions of AMD progression give rates that are consistent with current knowledge of progression and its determinants. Each early AMD characteristic conveys its own risk of progression to an eye, with soft indistinct drusen carrying the greater risk. An international consensus on what defines AMD progression would greatly help the research community when trying to assess the importance of new risk factors and the effectiveness of novel interventions.
C1 Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic 8002, Australia.
   Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Monash
   University
RP Tikellis, G (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM gtike@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; McCarty,
   Catherine/0000-0003-1089-0142
CR Azad R, 1983, Indian J Ophthalmol, V31 Suppl, P878
   BIRD AC, 1995, SURV OPHTHALMOL, V39, P333
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chan D, 1998, OPTOMETRY VISION SCI, V75, P476, DOI 10.1097/00006324-199807000-00015
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   TAYLOR HR, 2002, BRIT MED J, V325, P7354
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 25
TC 26
Z9 26
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2007
VL 21
IS 2
BP 169
EP 176
DI 10.1038/sj.eye.6702151
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131WN
UT WOS:000243902300005
PM 16732219
OA Bronze
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Lacroux, A
   Carriere, I
AF Delcourt, C
   Lacroux, A
   Carriere, I
CA POLA Study Grp
TI The three-year incidence of age-related macular degeneration: The
   "Pathologies Oculaires Liees L'age" (POLA) prospective study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; MACULOPATHY; RISK; EYE
AB PURPOSE: To assess the 3-year incidence of age-related macular degeneration (AMD) in a French population.
   DESIGN: The "Pathologies Oculaires Liees l'Age" (POLA) Study, a population-based prospective cohort study.
   METHODS: Retinal photographs were graded according to the international classification. Early age-related maculopathy (ARM) was defined by the presence of (1) soft indistinct drusen (> 125 mu m) and/or (2) soft distinct drusen (> 125 mu m) associated with pigmentary abnormalities.
   RESULTS: The 3-year incidence of AMD was 0.49% (95% confidence interval [CI]: 0.13 to 0.85) and increased significantly with age, reaching 3.41% (95% CI: 0 to 7.2) in participants aged 80 years or more. After adjustment for age, eyes with early ARM at baseline were 78 times more at risk of developing AMD than eyes without early ARM (OR = 78.4, 95% CI: 14.6 to 420.1).
   CONCLUSIONS: This study confirms that AMD develops mainly in subjects aged 80 years or older, and in Subjects with early ARM.
C1 Univ Victor Segalen Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France.
   Inst Rech Dev, Res Unit, Montpellier, France.
   INSERM, Res Unit, E0361, Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Institut de
   Recherche pour le Developpement (IRD); Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite de Montpellier
RP Delcourt, C (通讯作者)，Univ Victor Segalen Bordeaux 2, INSERM, U593, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM delcourt@montp.inserm.fr
RI Carrière, Isabelle/W-8728-2019; Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481; Carriere,
   Isabelle/0000-0002-3617-0752
CR Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2003, OPHTHALMOLOGY, V110, P2318, DOI 10.1016/S0161-6420(03)00713-9
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
NR 6
TC 24
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2005
VL 140
IS 5
BP 924
EP 926
DI 10.1016/j.ajo.2005.05.002
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 990PL
UT WOS:000233755600026
PM 16310477
DA 2022-11-30
ER

PT J
AU Shen, YC
   Wang, HY
   Xu, XY
   Chen, C
   Zhu, SP
   Cheng, L
   Fang, JW
   Liu, K
   Xu, X
AF Shen, Yinchen
   Wang, Hanying
   Xu, Xiaoyin
   Chen, Chong
   Zhu, Shaopin
   Cheng, Lu
   Fang, Junwei
   Liu, Kun
   Xu, Xun
TI Metabolomics study of treatment response to conbercept of patients with
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE anti-vegf; neovascular age-related macular degeneration; polypoidal
   choroidal vasculopathy; metabolomics; treatment response
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; LIPIDOMIC PROFILE;
   AQUEOUS-HUMOR; RANIBIZUMAB; AFLIBERCEPT; MANAGEMENT; CELLS
AB Background: Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are major causes of blindness in aged people. 30% of the patients show unsatisfactory response to anti-vascular endothelial growth factor (anti-VEGF) drugs. This study aims to investigate the relationship between serum metabolome and treatment response to anti-VEGF therapy. Methods: A prospective longitudinal study was conducted between March 2017 and April 2019 in 13 clinical sites in China. The discovery group were enrolled from Shanghai General Hospital. The validation group consisted of patients from the other 12 sites. Participants received at least one intravitreal injection of 0.5 mg anti-VEGF drug, conbercept, and were divided into two groups - responders and non-responders. Serum samples of both groups were processed for UHPLC-MS/MS analysis. We constructed principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) models to investigate the metabolic differences between two groups using SIMCA-P. Area under curve (AUC) was calculated to screen the biomarkers to predict treatment response. Metabolites sub-classes and enriched pathways were obtained using MetaboAnalyst5.0. Results: 219 eyes from 219 patients (nAMD = 126; PCV = 93) were enrolled. A total of 248 metabolites were detected. PCA and PLS-DA models of the discovery group demonstrated that the metabolic profiles of responders and non-responders clearly differed. Eighty-five differential metabolites were identified, including sub-classes of diacylglycerophosphocholines, lysophosphatidylcholine (LPC), fatty acids, phosphocholine, etc. Responders and non-responders differed most significantly in metabolism of LPC (p = 7.16 x 10<^>-19) and diacylglycerophosphocholine (p = 6.96 x 10<^>-17). LPC 18:0 exhibited the highest AUC, which is 0.896 with 95% confidence internal between 0.833 and 0.949, to discriminate responders. The predictive accuracy of LPC 18:0 was 72.4% in the validation group. Conclusions: This study suggests that differential metabolites may be useful for guiding treatment options for nAMD and PCV. Metabolism of LPC and diacylglycerophosphocholine were found to affect response to conbercept treatment. LPC 18:0 was a potential biomarker to discriminate responders from non-responders.
C1 [Shen, Yinchen; Wang, Hanying; Xu, Xiaoyin; Chen, Chong; Zhu, Shaopin; Cheng, Lu; Fang, Junwei; Liu, Kun; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Shen, Yinchen; Wang, Hanying; Xu, Xiaoyin; Chen, Chong; Zhu, Shaopin; Cheng, Lu; Fang, Junwei; Liu, Kun; Xu, Xun] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Shen, Yinchen; Wang, Hanying; Xu, Xiaoyin; Chen, Chong; Zhu, Shaopin; Cheng, Lu; Fang, Junwei; Liu, Kun; Xu, Xun] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Shen, Yinchen; Wang, Hanying; Xu, Xiaoyin; Chen, Chong; Zhu, Shaopin; Cheng, Lu; Fang, Junwei; Liu, Kun; Xu, Xun] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Shen, Yinchen; Wang, Hanying; Xu, Xiaoyin; Chen, Chong; Zhu, Shaopin; Cheng, Lu; Fang, Junwei; Liu, Kun; Xu, Xun] Shanghai Engn Ctr Precise Diag & Treatment Eye Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Fang, JW; Liu, K (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.; Fang, JW; Liu, K (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Fang, JW; Liu, K (通讯作者)，Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.; Fang, JW; Liu, K (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Fang, JW; Liu, K (通讯作者)，Shanghai Engn Ctr Precise Diag & Treatment Eye Dis, Shanghai, Peoples R China.
EM fagnjunwei@163.com; drliukun@sjtu.edu.cn
FU National Natural Science Foundation of China [8217040425, 81870667,
   81800831, 82101141]; National Key Ramp;D Program of China
   [2016YFC0904800, 2019YFC0840607]; Program of Shanghai Academic Research
   Leader [21XD1402700]; Bethune.Lumitin Young and Middle-aged Ophthalmic
   Research Fund [BJ-LM2021010J]; Science and Technology Research Project
   of Songjiang District [2020SJ307]
FX This work was funded by the National Natural Science Foundation of China
   (No. 8217040425, 81870667, 81800831, 82101141), National Key R & D
   Program of China (No. 2016YFC0904800, 2019YFC0840607), Program of
   Shanghai Academic Research Leader (21XD1402700), Bethune.Lumitin Young
   and Middle-aged Ophthalmic Research Fund (No. BJ-LM2021010J), and
   Science and Technology Research Project of Songjiang District (No.
   2020SJ307). The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Almannai M, 2019, MOLECULES, V24, DOI 10.3390/molecules24183251
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Cabrerizo J, 2017, ACTA OPHTHALMOL, V95, P727, DOI 10.1111/aos.13374
   Cabrerizo J, 2017, J GLAUCOMA, V26, P349, DOI 10.1097/IJG.0000000000000603
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gao Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58346-3
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Jin J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0812-4
   Kananen F, 2021, ACTA OPHTHALMOL, V99, pE1063, DOI 10.1111/aos.14774
   Karki P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040981
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Knottnerus SJG, 2018, REV ENDOCR METAB DIS, V19, P93, DOI 10.1007/s11154-018-9448-1
   Lagarkova MA, 2008, CELL CYCLE, V7, P2929, DOI 10.4161/cc.7.18.6700
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Mitchell SL, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10113141
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Samson FP, 2021, ACS OMEGA, V6, P5953, DOI 10.1021/acsomega.1c00196
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Semba RD, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-018-0954-7
   Storey PP, 2020, CAN J OPHTHALMOL, V55, P286, DOI 10.1016/j.jcjo.2020.01.015
   The Clinical Guideline and Clinical Pathway Development Committee of Age-Related Macular Degeneration, 2013, CHIN J OCUL FUNDUS D, V29, P343, DOI [10.3760/cma.j.issn.1005-1015.2013.04.002, DOI 10.3760/CMA.J.ISSN.1005-1015.2013.04.002]
   Toto L, 2021, CURR DRUG TARGETS, V22, P1054, DOI 10.2174/1389450122999210128180725
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Wakusawa R, 2008, AM J OPHTHALMOL, V146, P235, DOI 10.1016/j.ajo.2008.03.019
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Yamashita M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19473-0
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhao HJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.682367
NR 36
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 19
PY 2022
VL 13
AR 991879
DI 10.3389/fphar.2022.991879
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5D0ZN
UT WOS:000864679800001
PM 36199690
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Akkoyun, I
   Budde, WM
   Kreissig, I
   Degenring, RF
AF Jonas, JB
   Akkoyun, I
   Budde, WM
   Kreissig, I
   Degenring, RF
TI Intravitreal reinjection of triamcinolone for exudative age-related
   macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; ACETONIDE; INHIBITION; RECURRENCE
AB Objective: To evaluate the outcome of repeated intravitreal injections of triamcinolone acetonide for the treatment of exudative age-related macular degeneration.
   Methods: This prospective, comparative nonrandomized clinical interventional. study included 13 patients with progressive exudative age-related macular degeneration with occult, or predominantly occult, subfoveal neovascularization. All patients had shown an increase or stabilization of visual acuity after a first intravitreal injection of 25 mg of triamcinolone acetonide. They received a second intravitreal injection of 25 mg of triamcinolone acetonide 3.1 to 18 months after the first injection. Mean +/- SD follow-up time after the second injection was 5.2 +/- 3.6 months (median, 5.3 months). A control group included 24 patients with exudative age-related macular degeneration who did not receive treatment for their maculopathy. The main outcome measures were visual acuity and intraocular pressure.
   Results: In the study group, mean +/- SD visual acuity increased significantly (P = .005 and P = .003, respectively) from 0.17 +/- 0.11 to 0.32 +/- 0.26 and from 0.15 +/- 0.14 to 0.23 +/- 0.19, respectively, after the first and second injections. An increase in visual acuity was found for 10 patients (77%) after the first and second injections. In the control group, visual acuity did not vary significantly during follow-up (P = .81). The difference in change in visual acuity between the study group and control group was significant (P = .01 [Snellen lines] and P = .05 [logMAR units]). The peak in visual acuity and, in a chronologically parallel manner, the peak in intraocular pressure elevation occurred 2 to 5 months after each injection.
   Conclusions: Repeated intravitreal injection of 25 mg of triamcinolone acetonide may lead to an increase in visual acuity in patients with exudative age-related macular degeneration, with the peak in visual acuity and intraocular pressure elevation occurring about 2 to 5 months after each injection.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@ma.augen.uni-heidelberg.de
RI AKKOYUN, IMREN VARDARLI/AAK-7713-2021
OI AKKOYUN, IMREN VARDARLI/0000-0002-2860-7424
CR Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 17
TC 98
Z9 119
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2004
VL 122
IS 2
BP 218
EP 222
DI 10.1001/archopht.122.2.218
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771GH
UT WOS:000188776900010
PM 14769599
OA Bronze
DA 2022-11-30
ER

PT J
AU Oguido, APMT
   Casella, AMB
   Matsuo, T
   Ramos, EHD
   Berbel, R
   Silva, RMA
AF Miyagusko Taba Oguido, Ana Paula
   Barbante Casella, Antonio Marcelo
   Matsuo, Tiemi
   de Freitas Ramos Filho, Eduardo Henrique
   Berbel, Rodrigo
   Alcantara Silva, Ricardo Montanheiro
TI Prevalence of age-related macular degeneration in Japanese immigrants
   and their descendants living in Londrina (PR) - Brazil
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/epidemiology; Risk factors; Prevalence, Macula
   lutea.; Ethnic groups; Sex factors; Middle aged; Aged; Aged, 80 and
   over; Brazil/epidemiology
ID VISUAL IMPAIRMENT; EYE DISEASE; MACULOPATHY; POPULATION
AB Purpose: To determine the prevalence of early and late-stage age-related macular degeneration (ARMD) and its association with risk factors such as age, gender, smoking, body mass index, hypertension and diabetes history, cataracts and pseudophakia. Design: Population-based cross-sectional study in an elderly Japanese-Brazilian population from Londrina (Parana, Brazil). Methods: The study included 483 (80.5%) of the 600 registered members of a local association for Japanese immigrants and their descendants, aged 60 years and up. The presence of early and late-stage age-related macular degeneration was determined using the standard protocol and the international classification system. Results: The mean age of the study subjects was 71 years. The overall prevalence of age-related macular degeneration was 15.1% (CI 95%; 12-18.7). The prevalence of early-stage age-related macular degeneration was 13.8% (CI 95%; 10.9-17.3), geographic atrophy was present in 0.4% and neovascular age-related macular degeneration in 0.8%. Age-related macular degeneration was significantly (p=0.004) and linearly (p=0.001) associated with age. Conclusion: Our study population displays a prevalence of early and late-stage age-related macular degeneration and component lesions similar to those of other Western countries, and data suggest a higher prevalence than that reported for populations in Japan. Since the age-related macular degeneration prevalence tends to rise as the population ages, studies identifying risk factors and exploring prevention methods are becoming increasingly important.
C1 [Miyagusko Taba Oguido, Ana Paula; Barbante Casella, Antonio Marcelo; Matsuo, Tiemi; de Freitas Ramos Filho, Eduardo Henrique; Berbel, Rodrigo; Alcantara Silva, Ricardo Montanheiro] Univ Estadual Londrina, Londrina, PR, Brazil.
C3 Universidade Estadual de Londrina
RP Oguido, APMT (通讯作者)，Rua Mato Grosso 1412,Apto 23, BR-86010180 Londrina, PR, Brazil.
EM aoguido@sercomtel.com.br
RI Casella, Marcelo/AAD-7747-2021; Barbante, Carlo/B-3195-2011
OI Oguido, Ana Paula Miyagusko Taba/0000-0003-0634-1714
CR Bird A C, 1999, Community Eye Health, V12, P8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P621, DOI 10.1016/j.survophthal.2004.08.016
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim JI, 2002, AGE-RELATED MACULAR DEGENERATION, P101
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MEDINA NH, 1997, THESIS U FEDERAL SAO
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Sasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4210, DOI 10.1167/iovs.01-1221
   *U WI DEP OPHTH VI, FUND PHOTH READ CTR
   YOUNG RW, 1992, J NATL MED ASSOC, V84, P353
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 23
TC 13
Z9 13
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2008
VL 71
IS 3
BP 375
EP 380
DI 10.1590/S0004-27492008000300013
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530JT
UT WOS:000272586900013
PM 18641824
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ehmann, DS
   Ho, AC
AF Ehmann, David S.
   Ho, Allen C.
TI Cataract surgery and age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cataract; phacoemulsification
ID 10-YEAR INCIDENCE; VISUAL-ACUITY; RANIBIZUMAB; MACULOPATHY; RISK;
   PHACOEMULSIFICATION; OUTCOMES; ANCHOR; MARINA; IMPACT
AB Purpose of reviewThe following review describes the recent evidence regarding the effect of cataract surgery on age-related macular degeneration (AMD).Recent findingsFor patients with both visually significant cataracts and AMD, recent evidence supports the role of cataract surgery with reports demonstrating improved visual acuity, absence of significant disease progression, and improved quality of life.SummaryRecent evidence does not find cataract surgery to cause or worsen AMD.
C1 [Ehmann, David S.; Ho, Allen C.] Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Ehmann, DS (通讯作者)，Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM dehmann@midatlanticretina.com
OI Ho, Allen/0000-0003-3921-608X
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cao H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071731
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kobelt G, 2002, J CATARACT REFR SURG, V28, P1742, DOI 10.1016/S0886-3350(02)01220-8
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Ma YY, 2016, OPTOMETRY VISION SCI, V93, P165, DOI 10.1097/OPX.0000000000000772
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Olson RJ, 1998, AM J OPHTHALMOL, V125, P612, DOI 10.1016/S0002-9394(98)00017-8
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Yang H, 2014, CURR OPIN OPHTHALMOL, V25, P40, DOI 10.1097/ICU.0000000000000020
NR 31
TC 15
Z9 16
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JAN
PY 2017
VL 28
IS 1
BP 58
EP 62
DI 10.1097/ICU.0000000000000331
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EF3SI
UT WOS:000390244300010
PM 27684293
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Brown, DM
   Heier, JS
   Boyer, DS
   Kaiser, PK
   Chung, CY
   Kim, RY
AF Rosenfeld, Philip J.
   Brown, David M.
   Heier, Jeffrey S.
   Boyer, David S.
   Kaiser, Peter K.
   Chung, Carol Y.
   Kim, Robert Y.
CA MARINA Study Grp
TI Ranibizumab for neovascular age-related macular degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; EXPRESSION; FAMILY
AB Background: Ranibizumab - a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A - has been evaluated for the treatment of neovascular age-related macular degeneration.
   Methods: In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.
   Results: We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P < 0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P < 0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P < 0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab.
   Conclusions: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836.)
C1 Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   Methodist Hosp, Vitreoretinal Consultants, Houston, TX 77030 USA.
   Ophthalm Consultants Boston, Boston, MA USA.
   Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
C3 Bascom Palmer Eye Institute; University of Miami; The Methodist Hospital
   System; The Methodist Hospital - Houston; Ophthalmic Consultants of
   Boston; Retina Vitreous Associates Medical Group; Cleveland Clinic
   Foundation; Roche Holding; Genentech
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Liew, Gerald/AAB-6870-2022; Zhang, Kang/Y-2740-2019; Eben-Chaime,
   Moshe/F-1871-2012; ORTEGA, ANA/D-2408-2017
OI Zhang, Kang/0000-0002-4549-1697; Eben-Chaime, Moshe/0000-0001-8759-0549;
   ORTEGA, ANA/0000-0003-1456-2437; Kaiser, Peter/0000-0001-5126-045X
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   NUSSENBLATT RB, 1996, UVEITIS FUNDAMENTALS, P64
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
NR 27
TC 4229
Z9 4459
U1 4
U2 282
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 5
PY 2006
VL 355
IS 14
BP 1419
EP 1431
DI 10.1056/NEJMoa054481
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 090UA
UT WOS:000240976200004
PM 17021318
DA 2022-11-30
ER

PT J
AU Fajnkuchen, F
   Cohen, SY
   Thay, N
   Ayrault, S
   Delahaye-Mazza, C
   Grenet, T
   Nghiem-Buffet, S
   Quentel, G
   Giocanti-Auregan, A
AF Fajnkuchen, Franck
   Cohen, Salomon Y.
   Thay, Nathalie
   Ayrault, Sandrine
   Delahaye-Mazza, Corinne
   Grenet, Typhaine
   Nghiem-Buffet, Sylvia
   Quentel, Gabriel
   Giocanti-Auregan, Audrey
TI BRIDGE ARCH-SHAPED SEROUS RETINAL DETACHMENT IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fibrosis; ranibizumab; serous retinal
   detachment
ID OPTICAL-COHERENCE-TOMOGRAPHY; RANIBIZUMAB
AB Purpose:To describe bridge arch-shaped serous retinal detachment (SRD) in exudative age-related macular degeneration and evaluate its functional outcomes.Methods:In this monocentric, retrospective, noncomparative case series, patients were included. Patients with exudative age-related macular degeneration and bridge arch-shaped SRD treated with ranibizumab were included. Anatomical patterns of SRD and functional outcomes were assessed.Results:Twenty-two eyes with bridge arch-shaped SRD of 22 patients with age-related macular degeneration were included. Serous retinal detachments were characterized by a steep angle at the junction between the retinal pigment epithelium and the sensory retina (mean, 53.45 12.5 degrees), and characterized by the presence of adhesion areas between the sensory retina and a fibrous complex developed from the choroidal neovascularization. In 15 eyes, the choroidal neovascularization was classic choroidal neovascularization and a fibrotic evolution was observed. Serous retinal detachments were compartmentalized in 14 eyes, leading to a multipocket structure. Visual acuity decreased from 49.9 +/- 19.2 letters (20/100) to 40.3 +/- 18.6 letters (20/160), corresponding to a mean change of -9.6 +/- 19.4 letters.Conclusion:This was the first study to describe the specific morphologic features of bridge arch-shaped SRD, a previously undescribed type of SRD complicating exudative age-related macular degeneration. Patients with bridge arch-shaped SRD responded to intravitreal injections of ranibizumab, but their visual prognosis was unfavorable, compared with the literature. The presence of bridge arch-shaped SRD seemed to be a marker for the fibrotic evolution of the choroidal neovascularization.
C1 [Fajnkuchen, Franck; Cohen, Salomon Y.; Thay, Nathalie; Ayrault, Sandrine; Delahaye-Mazza, Corinne; Grenet, Typhaine; Nghiem-Buffet, Sylvia; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
   [Fajnkuchen, Franck; Grenet, Typhaine; Nghiem-Buffet, Sylvia; Giocanti-Auregan, Audrey] Hop Avicenne, Hop Paris, Dept Ophthalmol, Assistance Publ, F-93009 Bobigny, France.
   [Fajnkuchen, Franck; Grenet, Typhaine; Nghiem-Buffet, Sylvia; Giocanti-Auregan, Audrey] Univ Paris 13, Bobigny, France.
   [Cohen, Salomon Y.] Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Cohen, Salomon Y.] Paris Est Creteil Univ, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris 13; Universite Paris 13; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Fajnkuchen, F (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM franck.fajnkuchen@avc.aphp.fr
FU CIL-Assoc, association for research and education, Paris, France
FX Supported in part by CIL-Assoc, association for research and education,
   Paris, France.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Kim Hyung Chan, 2012, Korean J Ophthalmol, V26, P347, DOI 10.3341/kjo.2012.26.5.347
   Martin DF, 2012, OPHTHALMOLOGY, V119, P1388
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Yamaguchi Y, 2007, AM J OPHTHALMOL, V144, P260, DOI 10.1016/j.ajo.2007.04.007
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 19
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP 476
EP 482
DI 10.1097/IAE.0000000000000746
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG1MW
UT WOS:000371833200006
PM 26355948
DA 2022-11-30
ER

PT J
AU Moshfeghi, DM
   Lewis, H
AF Moshfeghi, DM
   Lewis, H
TI Age-related macular degeneration: Evaluation and treatment
SO CLEVELAND CLINIC JOURNAL OF MEDICINE
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BEAVER DAM EYE; VERTEPORFIN
   PHOTODYNAMIC THERAPY; PRESUMED OCULAR HISTOPLASMOSIS; ENDOTHELIAL
   GROWTH-FACTOR; FOVEAL TRANSLOCATION; SUBMACULAR SURGERY; SURGICAL
   REMOVAL; VISUAL FUNCTION; 5-YEAR INCIDENCE
AB Any patient age 50 or older with distorted vision or vision loss may have age-related macular degeneration and should be immediately referred to an ophthalmologist. Early diagnosis and treatment are essential to preserve the current level of vision. We outline risk factors, clinical signs, what happens to the retina, and what treatments are currently available, as well as recommendations about vitamin and mineral supplementation.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Div Ophthalmol, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Moshfeghi, DM (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 130,9500 Euclid Ave, Cleveland, OH 44195 USA.
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647
   Aiello LP, 1996, ARCH OPHTHALMOL-CHIC, V114, P1252, DOI 10.1001/archopht.1996.01100140452016
   Berger AS, 1997, ARCH OPHTHALMOL-CHIC, V115, P991, DOI 10.1001/archopht.1997.01100160161004
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujii GY, 2001, AM J OPHTHALMOL, V131, P90, DOI 10.1016/S0002-9394(00)00769-8
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Fujikado T, 1998, AM J OPHTHALMOL, V125, P647, DOI 10.1016/S0002-9394(98)00021-X
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KORNZWEIG AL, 1957, AM J OPHTHALMOL, V44, P29, DOI 10.1016/0002-9394(57)91952-9
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lewis H, 1998, AM J OPHTHALMOL, V126, P127
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   Lin SB, 2000, AM J OPHTHALMOL, V130, P76, DOI 10.1016/S0002-9394(00)00394-9
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sternberg P, 2000, ARCH OPHTHALMOL-CHIC, V118, P1428
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 49
TC 3
Z9 4
U1 0
U2 0
PU CLEVELAND CLINIC
PI CLEVELAND
PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA
SN 0891-1150
J9 CLEV CLIN J MED
JI Clevel. Clin. J. Med.
PD DEC
PY 2003
VL 70
IS 12
BP 1017
EP +
DI 10.3949/ccjm.70.12.1017
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 753QK
UT WOS:000187241900003
PM 14686682
DA 2022-11-30
ER

PT J
AU Ooto, S
   Suzuki, M
   Vongkulsiri, S
   Sato, T
   Spaide, RF
AF Ooto, Sotaro
   Suzuki, Mihoko
   Vongkulsiri, Sritatath
   Sato, Taku
   Spaide, Richard F.
TI MULTIMODAL VISUAL FUNCTION TESTING IN EYES WITH NONEXUDATIVE AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN; GEOGRAPHIC
   ATROPHY; RETINAL SENSITIVITY; SOFT DRUSEN; FUNDUS AUTOFLUORESCENCE;
   FELLOW EYE; MACULOPATHY; PREVALENCE; DISEASE
AB Purpose:
   To investigate the interactions among drusen type and multimodal vision testing in eyes with nonexudative age-related macular degeneration.
   Methods:
   Fifty-one eyes of 39 patients with nonexudative age-related macular degeneration underwent fundus imaging including spectral domain optical coherence tomography, color fundus photograph, and autofluorescence imaging, each of which was graded by 2 masked readers. Multimodal vision testing included visual acuity using the Early Treatment Diabetic Retinopathy Study protocol refraction, contrast sensitivity, and microperimetry.
   Results:
   Generalized estimating equation modeling showed that the significant predictors of contrast sensitivity was the presence of pseudodrusen (P = 0.012) and refractive error (P = 0.028). The presence of pseudodrusen inversely correlated with contrast sensitivity. The significant predictors of parafoveal microperimetry score were area of confluent hypoautofluorescence (P = 0.026) and the presence of pseudodrusen (P = 0.027). Both of them showed an inverse correlation with microperimetry score. The only significant predictor of macular microperimetry score was the presence of pseudodrusen (P = 0.004), which showed an inverse correlation with microperimetry score.
   Conclusion:
   The analysis of predictors of the visual function highlights the importance of pseudodrusen. Pseudodrusen are not only the risk factor of late age-related macular degeneration but also affect visual function. Recognition of this problem is important for low-vision rehabilitation and therapeutic strategies for late age-related macular degeneration.
C1 [Ooto, Sotaro; Suzuki, Mihoko; Vongkulsiri, Sritatath; Sato, Taku; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Ooto, Sotaro; Suzuki, Mihoko; Vongkulsiri, Sritatath; Sato, Taku; Spaide, Richard F.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU LuEsther T. Mertz Retinal Research Foundation; Alcon, Japan
FX Supported by the LuEsther T. Mertz Retinal Research Foundation.; S.
   Ooto, M. Suzuki, and T. Sato received grant from Alcon, Japan. R. F.
   Spaide is a consultant and received royalties from Topcon. S.
   Vongkulsiri has no conflicting interests to disclose.
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 45
TC 26
Z9 27
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1726
EP 1734
DI 10.1097/IAE.0000000000000608
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600003
PM 25932557
DA 2022-11-30
ER

PT J
AU Green-Simms, AE
   Bakri, SJ
AF Green-Simms, Amy E.
   Bakri, Sophie J.
TI Vitreomacular Traction and Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; macula; retina; vitreomacular
   traction; vitreous
ID VITREORETINAL JUNCTURE; ADHESION; RISK
AB The interaction between the vitreous and the internal limiting membrane of the retina is important in the pathoetiology of numerous ocular disease processes. Recent studies have focused on the vitreo-retinal interface in the context of age-related macular degeneration (AMD), linking vitreo-retinal adhesion to exudative AMD in particular. This review summarizes our knowledge of vitreous anatomy and recent investigations regarding vitreomacular adhesion and AMD.
C1 [Green-Simms, Amy E.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
FU Research to Prevent Blindness, New York, NY
FX This manuscript was supported by Research to Prevent Blindness, New
   York, NY.
CR FOOS RY, 1972, INVEST OPHTH VISUAL, V11, P801
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nishikawa S, 1996, CURR EYE RES, V15, P37, DOI 10.3109/02713689609017609
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Sebag J, 1989, VITREOUS STRUCTURE F, P17
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
NR 10
TC 14
Z9 16
U1 0
U2 0
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 137
EP 138
DI 10.3109/08820538.2011.559512
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200009
PM 21609226
DA 2022-11-30
ER

PT J
AU Zeng, RP
   Wen, F
   Zhang, XZ
   Zuo, CG
   Li, M
   Chen, H
   Wu, KF
AF Zeng, Renpan
   Wen, Feng
   Zhang, Xiongze
   Zuo, Chengguo
   Li, Meng
   Chen, Hui
   Wu, Kunfang
TI An rs9621532 Variant Near the TIMP3 Gene is not Associated with
   Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal
   Vasculopathy in a Chinese Han Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; tissue inhibitor of metalloproteinase 3; single nucleotide
   polymorphism; Chinese Han population
ID SORSBYS FUNDUS DYSTROPHY; POWER ANALYSIS PROGRAM; TISSUE INHIBITOR;
   JAPANESE PATIENTS; PHOTODYNAMIC THERAPY; SUSCEPTIBILITY; POLYMORPHISMS;
   ANGIOGENESIS; PREVALENCE; DISEASE
AB Background: Recently, two genome-wide association studies with large cohorts both identified rs9621532, a new single nucleotide polymorphism (SNP) that is associated with advanced age-related macular degeneration (AMD) and located near the TIMP3 gene. Previous studies have demonstrated that AMD and polypoidal choroidal vasculopathy (PCV) share some common genetic background and that the incidence of PCV is higher in Asian populations than Caucasian populations. In this study, we aimed to investigate whether the rs9621532 SNP is associated with neovascular AMD (nAMD) and PCV in a Chinese Han population.
   Methods: We performed a case-control study in a Chinese Han population. The rs9621532 SNP was genotyped in 136 patients with nAMD, 195 patients with PCV, and 181 control individuals using the Multiplex SNaPshot system and the direct DNA sequencing technique. Rs9621532 genotypes and allele frequencies in the nAMD, PCV and control groups were evaluated using PLINK software.
   Results: In the nAMD, PCV, and control groups, the minor allele frequencies of the rs9621532 variant were 0.05147, 0.02564, and 0.03039, respectively. The rs9621532 SNP was not significantly associated with susceptibility to nAMD (p = 0.1773) or PCV (p = 0.6933). None of the p-values for the additive or dominant models were found to be statistically significant in the nAMD or PCV groups. No recessive homozygotes were genotyped in any of the three groups.
   Conclusions: No evidence was found to support an association between the rs9621532 variant and susceptibility to either nAMD or PCV in a Chinese Han population.
C1 [Zeng, Renpan; Wen, Feng; Zhang, Xiongze; Zuo, Chengguo; Li, Meng; Chen, Hui; Wu, Kunfang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81070745]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81070745). The authors report no conflicts of interest.
   The authors alone are responsible for the content and writing of this
   paper.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Byeon Suk Ho, 2011, Ophthalmology, V118, P600, DOI 10.1016/j.ophtha.2010.11.010
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 38
TC 7
Z9 7
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2012
VL 33
IS 3
BP 139
EP 143
DI 10.3109/13816810.2011.643440
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 977TN
UT WOS:000306687800004
PM 22171703
DA 2022-11-30
ER

PT J
AU Chau, KY
   Sivaprasad, S
   Patel, N
   Donaldson, TA
   Luthert, PJ
   Chong, NV
AF Chau, K. Y.
   Sivaprasad, S.
   Patel, N.
   Donaldson, T. A.
   Luthert, P. J.
   Chong, N. V.
TI Plasma levels of matrix metalloproteinase-2 and-9 (MMP-2 and MMP-9) in
   age-related macular degeneration
SO EYE
LA English
DT Article
DE MMP-2; MMP-9; age-related macular degeneration
ID BRUCHS MEMBRANE; MACULOPATHY; MATRIX-METALLOPROTEINASE-9; PREVALENCE;
   ACTIVATION; PROTEIN; SERUM
AB Background Several studies indicate that age-related macular degeneration (AMD) and atherosclerosis may share common pathogenetic pathways. The aim of this study was to determine the role of systemic matrix metalloproteinases (MMPs) in AMD, given that MMPs are implicated in the pathogenesis of atherosclerosis.
   Methods This study determined the plasma matrix metalloproteinases (MMP-2 and MMP-9) levels in three groups of subjects: group 1 included subjects with age-related maculopathy ( ARM), group 2 included subjects with choroidal neovascularization (CNV) owing to AMD and group 3 consisted of age-matched controls.
   Results The mean plasma levels of MMP-2 were not significantly different in the three groups. In contrast, the mean plasma MMP-9 levels were significantly higher in ARM and CNV groups compared to that of the control group. However, there was no significant difference in MMP-9 levels between ARM and CNV groups.
   Conclusion This is the first study that reveals a link between raised plasma MMP-9 levels with AMD. Further studies are required to identify the factors that contribute to this association.
C1 [Sivaprasad, S.; Patel, N.; Chong, N. V.] Kings Coll Hosp London, Laser & Retinal Res Unit, London SE5 9RS, England.
   [Chau, K. Y.; Donaldson, T. A.; Luthert, P. J.; Chong, N. V.] UCL, Inst Ophthalmol, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; University College London
RP Chong, NV (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Chau, Kai-Yin (David)/C-2845-2011; Chong,
   Ngaihang V/A-5141-2009; Sivaprasad, S./D-6876-2015; Chau,
   David/P-8335-2019
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659;
   Chau, David/0000-0002-5797-2922; Luthert, Philip/0000-0001-7276-6898
CR Auge N, 2004, CIRCULATION, V110, P571, DOI 10.1161/01.CIR.0000136995.83451.1D
   Beuche W, 2000, NEUROREPORT, V11, P3419, DOI 10.1097/00001756-200011090-00003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung TW, 2004, J GASTROEN HEPATOL, V19, P565, DOI 10.1111/j.1440-1746.2004.03344.x
   Farias E, 2000, INT J CANCER, V89, P389, DOI 10.1002/1097-0215(20000720)89:4<389::AID-IJC12>3.0.CO;2-J
   Girolamo F, 2004, HISTOCHEM CELL BIOL, V122, P261, DOI 10.1007/s00418-004-0705-x
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Kai HK, 1998, J AM COLL CARDIOL, V32, P368, DOI 10.1016/S0735-1097(98)00250-2
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549
   Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tayebjee MH, 2005, THROMB RES, V115, P205, DOI 10.1016/j.thromres.2004.08.023
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 28
TC 73
Z9 80
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 855
EP 859
DI 10.1038/sj.eye.6702722x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800020
PM 17304258
OA Bronze
DA 2022-11-30
ER

PT J
AU Gotoh, N
   Yamada, R
   Nakanishi, H
   Saito, M
   Iida, T
   Matsuda, F
   Yoshimura, N
AF Gotoh, Norimoto
   Yamada, Ryo
   Nakanishi, Hideo
   Saito, Masaaki
   Iida, Tomohiro
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical
   exudative age-related macular degeneration and polypoidal choroidal
   vasculopathy phenotype in the Japanese population
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal vasculopathy; genetic
   analysis
ID COMPLEMENT FACTOR-H; CLINICOPATHOLOGICAL CORRELATION; PROMOTER
   POLYMORPHISM; GENE POLYMORPHISM; VARIANT INCREASES; NO ASSOCIATION;
   RISK; SUSCEPTIBILITY; INDIVIDUALS; MACULOPATHY
AB Background: Typical exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are two of the major macular diseases found in Asians. Although genomic studies have shown a contribution by CFH and LOC387715/HTRA1 polymorphisms to the development of these two diseases, the correlation of the clinical phenotypes to these genotypes has not been determined in Asian patients.
   Methods: The prevalence of the CFH Y402H and HTRA1 rs11200638 genotypes was determined in 116 patients with typical exudative AMD and in 204 patients with PCV. Potential correlations of these polymorphisms were tested retrospectively and cross-sectionally for bilaterality of the disease, final visual acuity and the greatest linear dimension of the choroidal neovascular (CNV) lesion.
   Results: There was no significant difference in the incidence of CFH Y402H (P = 0.598) and HTRA1 rs11200638 (P = 0.290) between eyes with typical exudative AMD and with PCV. There was a significant association between the lesion size and HTRA1 rs11200638. For eyes with typical AMD, the size of the lesion (6363 +/- 2837 mu m) was significantly larger in the high-risk homozygous group (AA), than in the low-risk homozygous group (GG) (3866 +/- 1947 mu m; P = 0.0003). The same tendency was observed for the size of the lesion in PCV cases (homozygous group: 6347 +/- 2673 mu m, non-risk homozygous group: 4405 +/- 2066 mu m, P = 1.3 x 10(-5)).
   Conclusions: A common genetic background may exist between typical exudative AMD and PCV patients. Among the patients with these two clinical entities, those with a homozygous HTRA1 rs11200638 risk allele had larger CNV lesions.
C1 [Gotoh, Norimoto; Nakanishi, Hideo; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 6068507, Japan.
   [Gotoh, Norimoto; Yamada, Ryo; Nakanishi, Hideo; Matsuda, Fumihiko] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto 6068507, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.
   [Matsuda, Fumihiko] Ctr Natl Genotypage, Evry, France.
C3 Kyoto University; Kyoto University; Fukushima Medical University; CEA;
   UDICE-French Research Universities; Universite Paris Saclay
RP Yoshimura, N (通讯作者)，Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Shogoinkawaharacho 54, Kyoto 6068507, Japan.
EM nagaeye@kuhp.kyoto-u.ac.jp
RI Matsuda, Fumihiko/B-9893-2009; Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Yamada, Ryo/0000-0002-1587-630X
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan National Society for the Prevention of Blindness
FX This study was supported in part by the Ministry of Education, Culture,
   Sports, Science and Technology of Japan and the Japan National Society
   for the Prevention of Blindness.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chen CS, 2006, BIOL BLOOD MARROW TR, V12, P42, DOI 10.1016/j.bbmt.2005.11.132
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Okamoto H, 2006, MOL VIS, V12, P156
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Takahashi Masazumi, 2003, J Bioinform Comput Biol, V1, P253, DOI 10.1142/S021972000300006X
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 MIA
   Yoshida T, 2007, MOL VIS, V13, P545
NR 43
TC 66
Z9 69
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2008
VL 36
IS 5
BP 437
EP 442
DI 10.1111/j.1442-9071.2008.01791.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 341PT
UT WOS:000258727600009
PM 18939352
DA 2022-11-30
ER

PT J
AU Qureshi, IZ
   Ambreen, F
AF Qureshi, Irfan Zia
   Ambreen, Fareeha
TI Serum APOE, leptin, CFH and HTRA1 levels in Pakistani age related
   macular degeneration patients
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE AMD; APOE; Leptin; CFH; HTRA1
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; SERINE-PROTEASE; INFLAMMATION;
   POLYMORPHISM; GROWTH
AB Objective: To determine the association between serum levels of apolipoprotein E, leptin, complimentary factor H and high temperature requirement A-1 in patients with age-related macular degeneration.
   Methods: This case-control study was conducted at the Quaid-i-Azam University, Islamabad, Pakistan, from May to October 2013, and comprised patients with age-related macular degeneration and matching controls. The confirmation of age-related macular degeneration was carried out through slit lamp examination, fundoscopy and ocular coherence tomography. The selected subjects were not suffering with any other systemic or ophthalmic complication(s). Serum apolipoprotein E, leptin, complimentary factor H and high temperature requirement A-1 were estimated in serum samples of all subjects. SPSS 18 was used for data analysis.
   Results: Of the 190 participants, 90(47.4%) were patients with age-related macular degeneration and 100(52.6%) were controls. Significantly elevated serum apolipoprotein E (p<0.0024) and high temperature requirement A-1 (p<0.0001) levels were observed in the patients, while serum leptin (p<0.008) and complimentary factor H (p<0.0001) levels were significantly reduced. Logistic regression showed that lower leptin (p<0.026) and elevated high temperature requirement A-1 (p<0.0001) were the relevant risk factors.
   Conclusion: Serum apolipoprotein E, leptin, complimentary factor H and high temperature requirement A-1 levels were altered in age-related macular degeneration patients.
C1 [Qureshi, Irfan Zia; Ambreen, Fareeha] Quaid I Azam Univ, Dept Anim Sci, Lab Anim & Human Physiol, Islamabad, Pakistan.
C3 Quaid I Azam University
RP Qureshi, IZ (通讯作者)，Quaid I Azam Univ, Dept Anim Sci, Lab Anim & Human Physiol, Islamabad, Pakistan.
EM irfanziaqureshi@gmail.com
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cui JZ, 2001, AM J OPHTHALMOL, V132, P792, DOI 10.1016/S0002-9394(01)01105-9
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   Freedman David A., 2009, STAT MODELS THEORY P, P128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pavan PR, 1996, OPHTHALMOLOGY, V103, P586, DOI 10.1016/S0161-6420(96)30649-0
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Silva AS, 2012, MOL VIS, V18, P2288
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Szmitko PE, 2003, CIRCULATION, V108, P1917, DOI 10.1161/01.CIR.0000089190.95415.9F
   Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 26
TC 3
Z9 3
U1 0
U2 1
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD JUN
PY 2017
VL 67
IS 6
BP 852
EP 857
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA EW9VA
UT WOS:000402866300007
PM 28585581
DA 2022-11-30
ER

PT J
AU Chau, KY
   Sivaprasad, S
   Patel, N
   Donaldson, TA
   Luthert, PJ
   Chong, NV
AF Chau, K. Y.
   Sivaprasad, S.
   Patel, N.
   Donaldson, T. A.
   Luthert, P. J.
   Chong, N. V.
TI Plasma levels of matrix metalloproteinase-2 and-9 (MMP-2 and MMP-9) in
   age-related macular degeneration
SO EYE
LA English
DT Article
DE MMP-2; MMP-9; age-related macular degeneration
ID BEAVER DAM EYE; BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   MACULOPATHY; MATRIX-METALLOPROTEINASE-9; PREVALENCE; DISEASE;
   ACTIVATION; PROTEIN; SERUM
AB Background Several studies indicate that age-related macular degeneration (AMD) and atherosclerosis may share common pathogenetic pathways. The aim of this study was to determine the role of systemic matrix metalloproteinases (MMPs) in AMD, given that MMPs are implicated in the pathogenesis of atherosclerosis.
   Methods This study determined the plasma matrix metalloproteinases (MMP-2 and MMP-9) levels in three groups of subjects: group 1 included subjects with age-related maculopathy (ARM), group 2 included subjects with choroidal neovascularization (CNV) owing to AMD and group 3 consisted of age-matched controls.
   Results The mean plasma levels of MMP-2 were not significantly different in the three groups. In contrast, the mean plasma MMP-9 levels were significantly higher in ARM and CNV groups compared to that of the control group. However, there was no significant difference in MMP-9 levels between ARM and CNV groups.
   Conclusion This is the first study that reveals a link between raised plasma MMP-9 levels with AMD. Further studies are required to identify the factors that contribute to this association.
C1 [Sivaprasad, S.; Patel, N.; Chong, N. V.] Kings Coll Hosp, Laser & Retinal Res Unit, London SE5 9RS, England.
   [Chau, K. Y.; Donaldson, T. A.; Luthert, P. J.; Chong, N. V.] UCL, Inst Ophthalmol, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; University College London
RP Chong, NV (通讯作者)，Kings Coll Hosp, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Chau, Kai-Yin (David)/C-2845-2011; Chong,
   Ngaihang V/A-5141-2009; Sivaprasad, S./D-6876-2015; Chau,
   David/P-8335-2019
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659;
   Chau, David/0000-0002-5797-2922; Luthert, Philip/0000-0001-7276-6898
CR Auge N, 2004, CIRCULATION, V110, P571, DOI 10.1161/01.CIR.0000136995.83451.1D
   Beuche W, 2000, NEUROREPORT, V11, P3419, DOI 10.1097/00001756-200011090-00003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung TW, 2004, J GASTROEN HEPATOL, V19, P565, DOI 10.1111/j.1440-1746.2004.03344.x
   Farias E, 2000, INT J CANCER, V89, P389, DOI 10.1002/1097-0215(20000720)89:4<389::AID-IJC12>3.0.CO;2-J
   Girolamo F, 2004, HISTOCHEM CELL BIOL, V122, P261, DOI 10.1007/s00418-004-0705-x
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Kai HK, 1998, J AM COLL CARDIOL, V32, P368, DOI 10.1016/S0735-1097(98)00250-2
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549
   Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tayebjee MH, 2005, THROMB RES, V115, P205, DOI 10.1016/j.thromres.2004.08.023
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 28
TC 73
Z9 80
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2007
VL 21
IS 12
BP 1511
EP 1515
DI 10.1038/sj.eye.6702722
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 240ZL
UT WOS:000251626600011
PM 17304258
OA Bronze
DA 2022-11-30
ER

PT J
AU Traband, A
   Shaffer, JA
   VanderBeek, BL
AF Traband, Anastasia
   Shaffer, James A.
   VanderBeek, Brian L.
TI SYSTEMIC BETA-BLOCKERS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; beta-blocker; choroidal
   neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION
AB Purpose: To evaluate whether oral beta-blockers (BBs) are associated with a decreased number of intravitreal injections in patients with incident neovascular age-related macular degeneration.
   Methods: A retrospective cohort study of subjects with a new diagnosis of neovascular age-related macular degeneration was conducted using a medical claims database from a large national US insurer. Two cohorts were created for comparison consisting of patients with regular use of BBs or calcium channel blockers. The main outcome measured was the difference in the mean number of intravitreal injections administered between the two cohorts.
   Results: After inclusion and exclusion criteria, 239 BB and 155 calcium channel blocker subjects remained for analysis. Univariate analysis revealed that the mean number of injections in the BB cohort was 6.43 (95% confidence interval [CI] 5.90-6.95) versus 6.55 (95% CI 5.85-7.25) in the calcium channel blocker cohort (P = 0.78). After multivariate adjustment, the mean number of injections in the BB group was 6.32 (95% CI 5.77-6.87) versus 6.71 (95% CI 6.02-7.40) in the calcium channel blocker group. The overall difference between the 2 groups was -0.39 (95% CI difference -1.29 to 0.51; P = 0.40).
   Conclusion: The use of oral BBs is not associated with a decreased number of intravitreal injections in incident neovascular age-related macular degeneration patients.
C1 [Traband, Anastasia; VanderBeek, Brian L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Shaffer, James A.; VanderBeek, Brian L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [VanderBeek, Brian L.] Univ Penn, Perelman Sch Med, Leonard Davis Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine
RP VanderBeek, BL (通讯作者)，Univ Penn, Scheie Eye Inst, 51 N,39th St,5th Floor, Philadelphia, PA 19104 USA.
EM Brian.VanderBeek@uphs.upenn.edu
OI VanderBeek, Brian L./0000-0003-4953-118X; Traband,
   Anastasia/0000-0002-4655-1495
FU National Institutes of Health K23 Award [1K23EY025729-01]; University of
   Pennsylvania Core Grant for Vision Research [2P30EY001583-41]; NATIONAL
   EYE INSTITUTE [K23EY025729, P30EY001583, K12EY015398] Funding Source:
   NIH RePORTER
FX National Institutes of Health K23 Award (1K23EY025729-01) and University
   of Pennsylvania Core Grant for Vision Research (2P30EY001583-41).
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Virgili G, 2007, COCHRANE DB SYST REV, V3
   Wormald R, 2007, COCHRANE DB SYST REV, V3
NR 15
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2017
VL 37
IS 1
BP 41
EP 46
DI 10.1097/IAE.0000000000001226
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH7JF
UT WOS:000391948300006
PM 27467380
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shoshany, N
   Weiner, C
   Safir, M
   Einan-Lifshitz, A
   Pokroy, R
   Kol, A
   Modai, S
   Shomron, N
   Pras, E
AF Shoshany, Nadav
   Weiner, Chen
   Safir, Margarita
   Einan-Lifshitz, Adi
   Pokroy, Russell
   Kol, Ayala
   Modai, Shira
   Shomron, Noam
   Pras, Eran
TI Rare Genetic Variants in Jewish Patients Suffering from Age-Related
   Macular Degeneration
SO GENES
LA English
DT Article
DE degeneration; genetics; macula; WES (whole-exome sequencing)
ID HIGH-RISK; CFH; C3; COMMON
AB Purpose: To identify rare genetic variants in early age-related macular degeneration (AMD) utilizing whole-exome sequencing (WES). Methods: Eight non-related early-AMD families of different Jewish ethnicities were ascertained. Initial mutation screening (phase-1) included common complement factor-H (CFH) p.Y402H; and age related maculopathy susceptibility 2 (ARMS2) p.A69S; and rare variants complement factor-I (CFI) p.V412M; and hemicentin1 (HMCN1) c.4163delC identified previously in our population. Four families, whose initial screening for the aforementioned variants was negative, underwent WES (phase-2). Bioinformatics filtering was based on functionality (from a panel of 234 genes with proven or presumed association to AMD); predicted severity; and frequency (rare variants with minor allele frequency <1%). When applicable, further screening for specific rare variants was carried out on additional cases of similar ethnicities and phenotypes (phase-3). Results: Phase-1 identified three families carrying CFI p.V412M mutation. WES analysis detected probable disease-related variants in three out of the remaining families. These included: a family with a variant in PLEKHA1 gene p.S177N; a family with previously reported variant p.R1210C in CFH gene; and two families with the C3 p.R735W variant. Conclusions: Rare, high-penetrance variants have a profound contribution to early-AMD pathogenesis. Utilization of WES in genetic research of multifactorial diseases as AMD, allows a thorough comprehensive analysis with the identification of previously unreported rare variants.
C1 [Shoshany, Nadav; Weiner, Chen; Safir, Margarita; Einan-Lifshitz, Adi; Pokroy, Russell; Kol, Ayala; Pras, Eran] Shamir Formerly Assaf Harofeh Med Ctr, Matlows Ophthalmogenet Lab, Dept Ophthalmol, IL-70300 Zerifin, Israel.
   [Weiner, Chen; Safir, Margarita; Einan-Lifshitz, Adi; Shomron, Noam; Pras, Eran] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Modai, Shira; Shomron, Noam] Variantyx Inc, Framingham, MA 01701 USA.
C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler
   Faculty of Medicine
RP Safir, M (通讯作者)，Shamir Formerly Assaf Harofeh Med Ctr, Matlows Ophthalmogenet Lab, Dept Ophthalmol, IL-70300 Zerifin, Israel.; Safir, M (通讯作者)，Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
EM drshoshany@gmail.com; c.cweiner@gmail.com; sapir.margarita@gmail.com;
   adi.einan@gmail.com; pokroy@gmail.com; ayalak1977@gmail.com;
   shira.modai@variantyx.com; nshomron@tauex.tau.ac.il; eranpras@gmail.com
RI Pokroy, Russell/AAM-9861-2020
OI Pokroy, Russell/0000-0002-6489-8353; Safir,
   Margarita/0000-0002-1814-8316
FU Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorders; The Medical Research Fund; Ernest And Nusia Gothelf
   research funds, Sackler Faculty of Medicine, Tel-Aviv University,
   Tel-Aviv, Israel; Chief Scientist Office of the Ministry of Health,
   Israel [7205]; 'Lirot' Association; Consortium for Mapping Retinal
   Degeneration Disorders in Israel
FX This study was supported by the Claire and Amedee Maratier Institute for
   the Study of Blindness and Visual Disorders; The Hirsh and
   GeniaWasserman, The Medical Research Fund and Ernest And Nusia Gothelf
   research funds, Sackler Faculty of Medicine, Tel-Aviv University,
   Tel-Aviv, Israel. This work was also supported in part by grant no. 7205
   from the Chief Scientist Office of the Ministry of Health, Israel;
   'Lirot' Association and the Consortium for Mapping Retinal Degeneration
   Disorders in Israel.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Bonyadi MHJ, 2019, INT OPHTHALMOL, V39, P949, DOI 10.1007/s10792-018-0853-y
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Cayci FS, 2012, PEDIATR NEPHROL, V27, P2327, DOI 10.1007/s00467-012-2283-9
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Database of Single Nucleotide Polymorphisms (dbSNP), 2000, DATABASE SINGLE NUCL
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhang R, 2015, GENE, V567, P51, DOI 10.1016/j.gene.2015.04.068
NR 37
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD OCT
PY 2019
VL 10
IS 10
AR 825
DI 10.3390/genes10100825
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA JP6UA
UT WOS:000498397100096
PM 31635417
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wen, LY
   Wan, L
   Lai, JN
   Chen, CS
   Chen, JJY
   Wu, MY
   Hu, KC
   Chiu, LT
   Tien, PT
   Lin, HJ
AF Wen, Li-Yen
   Wan, Lei
   Lai, Jung-Nien
   Chen, Chih Sheng
   Chen, Jamie Jiin-Yi
   Wu, Ming-Yen
   Hu, Kai-Chieh
   Chiu, Lu-Ting
   Tien, Peng-Tai
   Lin, Hui-Ju
TI Increased risk of Alzheimer's disease among patients with age-related
   macular degeneration: A nationwide population-based study
SO PLOS ONE
LA English
DT Article
ID ACUTE ISCHEMIC-STROKE; OXIDATIVE STRESS; AMYLOID-BETA; PATHOGENESIS;
   DEMENTIA
AB Objective This study aimed to investigate the risk of Alzheimer's disease among patients with age-related macular degeneration and its association with confounding comorbidities.
   Method This was a population-based, retrospective cohort study. By accessing data from the National Health Insurance Research Database of Taiwan, we identified 10,578 patients aged 50-100 years who were newly diagnosed with age-related macular degeneration between 2000 and 2012 and 10,578 non- age-related macular degeneration individuals. The comorbidities assessed were osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, and chronic obstructive pulmonary disease.
   Results Patients with age-related macular degeneration had a 1.23-fold increased risk of their condition advancing to Alzheimer's disease (aHR = 1.23, 95% CI = 1.04-1.46). The younger patients were diagnosed with age-related macular degeneration, the more likely patients got Alzheimer's disease (50-64 age group: aHR = 1.97, 95% CI = 1.04-3.73; 65-79 age group: aHR = 1.27, 95% CI = 1.02-1.58; 80-100 age group: aHR = 1.06, 95% CI = 0.78-1.45). In addition, there were significantly higher risks of Alzheimer's disease for patients with cirrhosis (aHR = 1.50, 95% CI = 1.09-2.06) in the age-related macular degeneration cohort than in the non-age-related macular degeneration cohort.
   Conclusion Patients with age-related macular degeneration may exhibit a higher risk of Alzheimer's disease than people without age-related macular degeneration.
C1 [Wen, Li-Yen; Wan, Lei; Lai, Jung-Nien; Chen, Jamie Jiin-Yi; Wu, Ming-Yen; Lin, Hui-Ju] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Wan, Lei] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
   [Wan, Lei] China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan.
   [Chen, Chih Sheng] Asia Univ Hosp, Div Chinese Med, Taichung, Taiwan.
   [Chen, Jamie Jiin-Yi; Wu, Ming-Yen; Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Chen, Jamie Jiin-Yi; Wu, Ming-Yen; Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Dept Mol Genet, Taichung, Taiwan.
   [Hu, Kai-Chieh; Chiu, Lu-Ting] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Tien, Peng-Tai] China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan.
C3 China Medical University Taiwan; Asia University Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan
RP Lin, HJ (通讯作者)，China Med Univ, Sch Chinese Med, Taichung, Taiwan.; Tien, PT; Lin, HJ (通讯作者)，China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.; Tien, PT; Lin, HJ (通讯作者)，China Med Univ Hosp, Dept Mol Genet, Taichung, Taiwan.; Tien, PT (通讯作者)，China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan.
EM miketien913@gmail.com; irisluu2396@gmail.com
RI Wan, Lei/AAU-5286-2021
OI Wan, Lei/0000-0002-9525-3232
FU Taiwan Ministry of Health and Welfare Clinical Trial Center
   [MOHW109-TDU-B-212-114004]; MOST Clinical Trial Consortium for Stroke
   [MOST 109-2321-B-039-002]; China Medical University Hospital
   [DMR-104-063, DMR-105-087, DMR-106-084]; China Medical University,
   Taichung, Taiwan [CMU108-MF-40, CMU109-MF-62]; Tseng-Lien Lin
   Foundation, Taichung, Taiwan
FX This study is supported in part by Taiwan Ministry of Health and Welfare
   Clinical Trial Center (MOHW109-TDU-B-212-114004), MOST Clinical Trial
   Consortium for Stroke (MOST 109-2321-B-039-002), China Medical
   University Hospital (DMR-104-063, DMR-105-087, DMR-106-084), China
   Medical University, Taichung, Taiwan (CMU108-MF-40; CMU109-MF-62)
   Tseng-Lien Lin Foundation, Taichung, Taiwan.
CR Agostinho P, 2010, CURR PHARM DESIGN, V16, P2766, DOI 10.2174/138161210793176572
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Barage SH, 2015, NEUROPEPTIDES, V52, P1, DOI 10.1016/j.npep.2015.06.008
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   Cerman E, 2015, TURK J MED SCI, V45, P1004, DOI 10.3906/sag-1406-146
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chen ZC, 2014, NEUROSCI BULL, V30, P271, DOI 10.1007/s12264-013-1423-y
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z
   De-Paula Vanessa J, 2012, Subcell Biochem, V65, P329, DOI 10.1007/978-94-007-5416-4_14
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   Dentchev T, 2003, MOL VIS, V9, P184
   Dentchev T., 2003, AM J OPHTHALMOL, V136, P787
   Durazzo TC, 2014, ALZHEIMERS DEMENT, V10, pS122, DOI 10.1016/j.jalz.2014.04.009
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hong T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147646
   Hsieh CY, 2015, J FORMOS MED ASSOC, V114, P254, DOI 10.1016/j.jfma.2013.09.009
   Huang WJ, 2016, BIOMED REP, V4, P519, DOI 10.3892/br.2016.630
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kao WH, 2018, PHARMACOEPIDEM DR S, V27, P1060, DOI 10.1002/pds.4267
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Korczyn AD, 2008, ALZHEIMERS DEMENT, V4, P176, DOI 10.1016/j.jalz.2007.11.008
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623
   Mendiola-Precoma J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2589276
   Mouton-Liger F, 2012, BBA-MOL BASIS DIS, V1822, P885, DOI 10.1016/j.bbadis.2012.01.009
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613
   Octave J N, 2005, Bull Mem Acad R Med Belg, V160, P445
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8416763
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48
   Sung SF, 2016, INT J CARDIOL, V215, P277, DOI 10.1016/j.ijcard.2016.04.069
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang JY, 2017, DIABETES RES CLIN PR, V124, P41, DOI 10.1016/j.diabres.2016.10.024
NR 44
TC 7
Z9 7
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2021
VL 16
IS 5
AR e0250440
DI 10.1371/journal.pone.0250440
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SX8UE
UT WOS:000665471900015
PM 33961642
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kramer, M
   Hasanreisoglu, M
   Feldman, A
   Axer-Siegel, R
   Sonis, P
   Maharshak, I
   Monselise, Y
   Gurevich, M
   Weinberger, D
AF Kramer, Michal
   Hasanreisoglu, Murat
   Feldman, Anna
   Axer-Siegel, Ruth
   Sonis, Paulina
   Maharshak, Idit
   Monselise, Yehudit
   Gurevich, Michael
   Weinberger, Dov
TI Monocyte chemoattractant protein-1 in the aqueous humour of patients
   with age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related-macular-degeneration; cytokines;
   monocyte-chemoattractant-protein-1; IL-6; TNF-alpha
ID NECROSIS-FACTOR-ALPHA; CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTORS;
   DUAL ROLE; EXPRESSION; CYTOKINES; SUPPRESSES; MACROPHAGE; MEMBRANES;
   LESIONS
AB Background: To investigate the role of inflammation in age-related macular degeneration by measuring the levels of cytokines in the aqueous humour.
   Methods: Samples of aqueous humour were collected from 34 patients with age-related macular degeneration and 16 age-matched control subjects undergoing cataract surgery. Age-related macular degeneration stage was determined clinically, before surgery. Levels of cytokines were measured using Luminex X-MAP technology, and positive results were verified by Western blot.
   Results: Age-related macular degeneration was moderate in 18 patients and advanced in 16. The advanced age-related macular degeneration group was further divided into patients with active choroidal neovascularization (n = 7), disciform scar (n = 7) or central geographic atrophy (n = 2). Higher-than-normal levels of monocyte chemoattractant protein-1 in the aqueous humour were associated with advanced age-related macular degeneration (200 +/- 140 pg/mL vs. 100 +/- 61 pg/mL; P = 0.03), especially active choroidal neovascularization (255 +/- 155 pg/mL; P = 0.02), Western blot analysis verified the monocyte chemoattractant protein-1 findings. Patients with disciform scar showed a trend of abnormally high levels of interleukin-12 (p70) (1.7 +/- 2.4 pg/mL vs. 0.2 +/- 1 pg/mL; P = 0.07), tumour necrosis factor-alpha (1.8 +/- 2.4 pg/mL vs. 0.3 +/- 1 pg/mL; P = 0.06) and interleukin-12 (4.7 +/- 6.4 pg/mL vs. 1.2 +/- 2.1 pg/mL; P = 0.08).
   Conclusion: Elevated levels of inflammation-related cytokines in the aqueous humour in various stages of age-related macular degeneration may suggest a pathogenic role of inflammation. Monocyte chemoattractant protein-1 may be indicative of the angiogenic phase. Further corroborative studies are required.
C1 [Kramer, Michal; Hasanreisoglu, Murat; Axer-Siegel, Ruth; Maharshak, Idit; Weinberger, Dov] Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   [Monselise, Yehudit] Rabin Med Ctr, Clin Immunol Lab, IL-49100 Petah Tiqwa, Israel.
   [Feldman, Anna; Sonis, Paulina; Gurevich, Michael] Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, Neurogen Lab, IL-52621 Tel Hashomer, Israel.
   [Kramer, Michal; Feldman, Anna; Axer-Siegel, Ruth; Gurevich, Michael; Weinberger, Dov] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
C3 Rabin Medical Center; Rabin Medical Center; Chaim Sheba Medical Center;
   Tel Aviv University; Sackler Faculty of Medicine
RP Kramer, M (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
EM mkramer@netvision.net.il
RI Gurevich, Michael/H-1157-2014; Maharshak, Idit/W-5886-2019;
   Hasanreisoglu, Murat/K-3887-2012
OI Hasanreisoglu, Murat/0000-0001-9885-5653; Gurevich,
   Michael/0000-0003-1529-4876
CR Abe T, 2003, GRAEF ARCH CLIN EXP, V241, P982, DOI 10.1007/s00417-003-0725-6
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   FAJARDO LF, 1992, AM J PATHOL, V140, P539
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kent D, 2003, MOL VIS, V9, P747
   Kocher AA, 2006, J MOL CELL CARDIOL, V40, P455, DOI 10.1016/j.yjmcc.2005.11.013
   Kramer M, 2005, OCUL IMMUNOL INFLAMM, V13, P1
   Lee S, 2002, J LEUKOCYTE BIOL, V71, P469
   Lim CP, 2009, J INVEST DERMATOL, V129, P851, DOI 10.1038/jid.2008.337
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Smith IL, 1999, J INFECT DIS, V179, P1249, DOI 10.1086/314710
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 34
TC 30
Z9 31
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2012
VL 40
IS 6
BP 617
EP 625
DI 10.1111/j.1442-9071.2011.02747.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017QF
UT WOS:000309604700014
PM 22172228
DA 2022-11-30
ER

PT J
AU Sutter, FKP
   Menghini, M
   Barthelmes, D
   Fleischhauer, JC
   Kurz-Levin, MM
   Bosch, MM
   Helbig, H
AF Sutter, Florian K. P.
   Menghini, Moreno
   Barthelmes, Daniel
   Fleischhauer, Jobannes C.
   Kurz-Levin, Malaika M.
   Bosch, Martina M.
   Helbig, Horst
TI Is pseudophakia a risk factor for neovascular age-related macular
   degeneration?
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE MOUNTAINS EYE; CATARACT-EXTRACTION; INTRAOCULAR-LENS; BEAVER DAM;
   MACULOPATHY; PREVALENCE; SURGERY; ASSOCIATION; IMPLANTATION; POPULATION
AB PURPOSE. To examine the possible association between pseudophakia and neovascular age-related macular degeneration (AMD).
   METHODS. Reports of all patients undergoing fluorescein angiography in the authors' department over a 6-year period were retrospectively reviewed. Four hundred ninety-nine patients with recent onset of neovascular AMD in one eye and early age-related maculopathy (ARM) in the fellow eye were included in the study. Lens status (phakic or pseudophakic) in both eyes at the time of onset of neovascular AMD and the time between cataract surgeries (if performed) and onset of neovascular AMD were determined.
   RESULTS. There was no significant difference in lens status between eyes with neovascular AMD and fellow eyes with early ARM (115/499 [23.0%] vs. 112/499 (22.4%] pseudophakic; P = 0.88, odds ratio 1.035, 95% Cl 0.770-1.391). Subgroup analysis revealed no difference between the groups with large drusen, small drusen, or pigmentary changes only (respectively, 20.3% vs. 19.6% pseudophakic, P = 0.92; 20.5% vs. 23.3% pseudophakic, P = 0.84; 33.3% vs. 31.7% pseudophakic, P = 1.0). Pseudophakic eyes with neovascular AMD had not been pseudophakic for a significantly longer period at the time of onset of neovascular AMD than their pseudophakic fellow eyes at the same time point (225.9 +/- 170.4 vs. 209.9 +/- 158.2 weeks, P = 0.27).
   CONCLUSIONS. The results do not support the hypothesis that pseudophakia is a major risk factor for the development of neovascular AMD.
C1 Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital
RP Sutter, FKP (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
EM florian.sutter@usz.ch
OI Menghini, Moreno/0000-0002-1432-2524
CR ABITBOL O, 2004, J FR OPHTALMOL, V27
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chua BE, 2004, EYE, V18, P765, DOI 10.1038/sj.eye.6701366
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Libre PE, 2003, AM J OPHTHALMOL, V136, P961, DOI 10.1016/S0002-9394(03)00906-1
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pinto RVB, 2004, OPHTHAL SURG LAS IM, V35, P63, DOI 10.3928/1542-8877-20040101-14
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Ruiz-Moreno JM, 2003, J REFRACT SURG, V19, P534, DOI 10.3928/1081-597X-20030901-08
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   VANDERHOEVE J, 1918, GRAEFES ARCH CLIN EX, V98, P1
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 24
TC 41
Z9 42
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2007
VL 48
IS 4
BP 1472
EP 1475
DI 10.1167/iovs.06-0766
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153CB
UT WOS:000245408200006
PM 17389473
DA 2022-11-30
ER

PT J
AU Yildirim, O
   Ates, NA
   Tamer, L
   Muslu, N
   Ercan, B
   Atik, U
   Kanik, A
AF Yildirim, O
   Ates, NA
   Tamer, L
   Muslu, N
   Ercan, B
   Atik, U
   Kanik, A
TI Changes in antioxidant enzyme activity and malondialdehyde level in
   patients with age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; catalase; malondialdehyde; aging and
   oxidative stress
ID FREE-RADICALS; DAMAGE; RETINA
AB Age-related macular degeneration is the leading cause of legal blindness in the developed world, and yet its pathogenesis remains poorly understood. Oxidative stress may play a major role in the etiology and pathogenesis of age-related disorders such as age-related macular degeneration. Catalase is an antioxidant enzyme which plays an important role in the detoxification of free oxygen radicals. Malondialdehyde is a marker that shows free radical damage. We have measured the erythrocyte activity of catalase and the serum level of malondialdehyde in 30 patients with age-related macular degeneration and 60 healthy subjects. Patients with age-related macular degeneration showed significantly lower catalase activity compared to healthy subjects ( p = 0.002). Plasma malondialdehyde level of the patient group was significantly higher than that of the controls ( p = 0.038). Copyright (C) 2004 S. Karger AG, Basel.
C1 Mersin Univ, Fac Med, Dept Ophthalmol, TR-33070 Mersin, Turkey.
   Mersin Univ, Fac Med, Dept Med Biol & Genet, TR-33070 Mersin, Turkey.
   Mersin Univ, Fac Med, Dept Biochem, TR-33070 Mersin, Turkey.
   Mersin Univ, Fac Med, Dept Biostat, TR-33070 Mersin, Turkey.
C3 Mersin University; Mersin University; Mersin University; Mersin
   University
RP Yildirim, O (通讯作者)，Mersin Univ, Tip Fak, Hastanesi Zeytinlibahce Cad, TR-33070 Mersin, Turkey.
EM dryildirimoz@hotmail.com
RI Tamer, Lulufer/AAG-5796-2021; ARAS, Nurcan/Q-2039-2015; Ates,
   Nurbay/F-6629-2018; KANIK, Emine Arzu/G-7929-2015
OI ARAS, Nurcan/0000-0002-3227-1150; Muslu, Necati/0000-0002-4189-2282
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEUTLER E, 1975, RED CELL METABOLISM, P105
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V28, P357, DOI 10.1111/j.1751-1097.1978.tb07718.x
   FEENEY L, 1976, INVEST OPHTH VISUAL, V15, P789
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   HARMAN D, 1988, MOL CELL BIOCHEM, V84, P155, DOI 10.1007/BF00421050
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   IRENE CP, 1992, CLIN CHEM, V38, P66
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   LAILA G, 1991, CLIN CHEM, V37, P1932
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   ROSENFELD PJ, 1999, AGE RELATED MACULAR, P69
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SICKEL W, 1972, HDB SENSORY PHYSL, P667
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Vanella A, 1982, GERONTOLOGY, V18, P185
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   YAGI K, 1994, ADV EXP MED BIOL, V366, P1
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 35
TC 35
Z9 39
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2004
VL 218
IS 3
BP 202
EP 206
DI 10.1159/000076845
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814KT
UT WOS:000220974300007
PM 15103217
DA 2022-11-30
ER

PT J
AU Casten, R
   Rovner, B
AF Casten, Robin
   Rovner, Barry
TI Depression in Age-Related Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SUBTHRESHOLD DEPRESSION; VISION
   REHABILITATION; PREDICTS DEPRESSION; SELF-MANAGEMENT; OLDER-ADULTS;
   HEALTH; NEUROTICISM; IMPAIRMENT; PREVALENCE
AB Age-related macular degeneration (AMD) is a major cause of disability in the elderly, substantially degrades the quality of their lives, and is a risk factor for depression. Rates of depression in AMD are substantially greater than those found in the general population of older people, and are on par with those of other chronic and disabling diseases. This article discusses the effect of depression on vision-related disability in patients with AMD, suggests methods for screening for depression, and summarizes interventions for preventing depression in this high-risk group.
C1 [Casten, Robin] Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Rovner, Barry] Jefferson Hosp Neurosci, Dept Psychiat, Philadelphia, PA 19107 USA.
   [Rovner, Barry] Jefferson Hosp Neurosci, Dept Neurol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University
RP Casten, R (通讯作者)，Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM robin.casten@jefferson.edu; barry.rovner@jefferson.edu
FU NATIONAL EYE INSTITUTE [U01EY015839] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH
   RePORTER; NEI NIH HHS [U01 EY015839] Funding Source: Medline; NIMH NIH
   HHS [R01 MH061331-01A1, R01 MH061331-02, R01 MH061331-04, R01
   MH061331-03, R01 MH061331] Funding Source: Medline
CR Alliance for Aging Research, 1999, IND OLD AM INV OUR N
   *AM OPT ASS, 1994, CAR PAT AGE REL MAC
   American Academy of Ophthalmology Vision Rehabilitation Committee, 2007, PREF PRACT PATT GUID
   APA, 1994, DIAGNOSTIC STAT MANU
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   *CIGNA BEH, 2007, DEPR MED ILLN
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa P.T., 1992, REVISED NEO PERSONAL
   COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Cuijpers P, 2007, ACTA PSYCHIAT SCAND, V115, P434, DOI 10.1111/j.1600-0447.2007.00998.x
   Cuijpers P, 2004, ACTA PSYCHIAT SCAND, V109, P325, DOI 10.1111/j.1600-0447.2004.00301.x
   Dreer LE, 2005, REHABIL PSYCHOL, V50, P232, DOI 10.1037/0090-5550.50.3.232
   DZurilla T. J, 1990, PSYCHOL ASSESSMENT J, V2, P156, DOI 10.1037/1040-3590.2.2.156
   Horowitz A, 2005, AGING MENT HEALTH, V9, P563, DOI 10.1080/13607860500193500
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Mrazek P.G., 1994, REDUCING RISKS MENTA
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   *SUBST AB MENT HLT, 1999, DHHS PUBL, V497
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   Waern M, 2002, BMJ-BRIT MED J, V324, P1355, DOI 10.1136/bmj.324.7350.1355
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 37
TC 38
Z9 40
U1 1
U2 9
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2008
VL 102
IS 10
SI SI
BP 591
EP 599
DI 10.1177/0145482X0810201003
PG 9
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 365YI
UT WOS:000260445400003
PM 20011131
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sabeti, F
   Maddess, T
   Essex, RW
   Saikal, A
   James, AC
   Carle, CF
AF Sabeti, Faran
   Maddess, Ted
   Essex, Rohan W.
   Saikal, Aiasha
   James, Andrew C.
   Carle, Corinne F.
TI Multifocal Pupillography in Early Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE multifocal; objective perimetry; pupils; age-related macular
   degeneration
ID ON-YELLOW PERIMETRY; FLICKER PERIMETRY; PUPIL PERIMETRY; VISUAL
   FUNCTION; EYE DISEASE; SENSITIVITY; TESTS; CONE
AB Purpose. To investigate the potential of multifocal pupillographic objective perimetry to assess changes in retinal function with clinical severity of age-related macular degeneration (AMD).
   Methods. Pupil responses were recorded from 40 subjects with AMD and 23 normal control subjects (mean +/- SD age, 71.3 +/- 5.1 years). Age-related macular degeneration subjects were classified according to the Age-Related Eye Disease Study (AREDS) classification system and allocated into one of four AMD severity groups. Three multifocal pupillographic objective perimetry stimulus variants that were identical in luminance but varied in spatiotemporal sequence were used. In one of the three protocols, stimuli were presented with a pedestal flicker for 266 milliseconds at 15 Hz.
   Results. On average, response amplitudes demonstrated a significant change in sensitivity with progression from early-stage (0.32 +/- 0.08 dB, t = 3.88) to late-stage (-1.60 +/- 0.12 dB, t = -12.7) age-related macular degeneration. Response delays followed a similar trend with the longest delays in AREDS4 (57.2 +/- 1.9 milliseconds, t = 29.5). Ring analysis identified the largest mean effect on responses within the central 6 degrees of fixation. The NewStimuli protocol achieved the best diagnostic accuracy across all severity groups with area under the curve values of 0.85 +/- 0.066 (AREDS1), 0.908 +/- 0.085 (AREDS2), 0.929 +/- 0.040 (AREDS3), and 1.0 +/- 0.0 (AREDS4).
   Conclusions. The mean effect of AMD on contraction amplitudes and response delays reflected the severity of disease, and the NewStimuli protocol achieved good diagnostic accuracy across all AMD severity groups. Multifocal pupillographic objective perimetry may potentially be a useful method in monitoring progression of AMD and assessing change in retinal function with novel interventions in early AMD. Longitudinal studies are required to identify biomarkers that predict eyes at risk of progression.
C1 [Sabeti, Faran; Maddess, Ted; Essex, Rohan W.; Saikal, Aiasha; James, Andrew C.; Carle, Corinne F.] Australian Natl Univ, ARC Ctr Excellence Vis Sci, John Curtin Sch Med Res, Canberra, ACT 0200, Australia.
   [Sabeti, Faran; Maddess, Ted; Essex, Rohan W.; Saikal, Aiasha; James, Andrew C.; Carle, Corinne F.] Australian Natl Univ, Ctr Visual Sci, John Curtin Sch Med Res, Canberra, ACT 0200, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Canberra Hosp, Dept Ophthalmol, Canberra, ACT 0200, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; John Curtin School of Medical Research;
   Australian National University; Canberra Hospital
RP Sabeti, F (通讯作者)，Australian Natl Univ, Eccles Inst Neurosci, John Curtin Sch Med Res, GPO Box 4, Canberra, ACT 0200, Australia.
EM faran.sabeti@anu.edu.au
RI James, Andrew C/C-9307-2009; Sabeti, Faran/AAR-1767-2021; Carle,
   Corinne/A-1729-2011; Maddess, Teddy L/A-3200-2008
OI James, Andrew C/0000-0002-2447-8549; Carle, Corinne/0000-0002-3309-9073;
   Maddess, Teddy L/0000-0003-4591-3658; SABETI, Faran/0000-0001-9187-7569;
   Essex, Rohan/0000-0001-5323-0334
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]; AusIndustry; Seeing Machines, Canberra
FX Funding for this research was received from the Australian Research
   Council (ARC) through the ARC Centre of Excellence in Vision Science
   (CE0561903), AusIndustry, and Seeing Machines, Canberra. The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   Carle CF, 2013, INVEST OPHTH VIS SCI, V54, P467, DOI 10.1167/iovs.12-10829
   Carle CF, 2012, CLIN EXP OPHTHALMOL, V40, P136
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P604, DOI 10.1167/iovs.10-5737
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P604, DOI 10.1111/j.1442-9071.2012.02756.x
   Chen YJ, 2008, OPTOMETRY VISION SCI, V85, P471, DOI 10.1097/OPX.0b013e318177ec02
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   James AC, 2012, J GLAUCOMA, V21, P571, DOI 10.1097/IJG.0b013e31821e8413
   Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033
   KARDON RH, 1991, OPHTHALMOLOGY, V98, P485, DOI 10.1016/s0161-6420(91)32267-x
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nitta K, 2006, RETINA-J RET VIT DIS, V26, P797, DOI 10.1097/01.iae.0000244263.98642.61
   Park JC, 2011, INVEST OPHTH VIS SCI, V52, P6624, DOI 10.1167/iovs.11-7586
   Pelosini L, 2013, RETINA-J RET VIT DIS, V33, P548, DOI 10.1097/IAE.0b013e3182670fea
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Sabeti F, 2013, GRAEF ARCH CLIN EXP, V251, P1707, DOI 10.1007/s00417-013-2273-z
   Sabeti F, 2013, DOC OPHTHALMOL, V126, P125, DOI 10.1007/s10633-012-9366-6
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Sabeti F, 2011, VISION RES, V51, P303, DOI 10.1016/j.visres.2010.10.015
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Tan L, 2001, VISION RES, V41, P1073, DOI 10.1016/S0042-6989(01)00030-X
   Wilhelm H, 2000, INVEST OPHTH VIS SCI, V41, P1229
NR 36
TC 20
Z9 20
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 904
EP 915
DI 10.1097/OPX.0000000000000319
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500014
PM 24987814
DA 2022-11-30
ER

PT J
AU Mukhtar, S
   Ambati, BK
AF Mukhtar, Sabrina
   Ambati, Balamurali K.
TI The value of nutritional supplements in treating Age-Related Macular
   Degeneration: a review of the literature
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Macular degeneration; Nutrition; Public health; Retina
ID PLASMA HOMOCYSTEINE; FOLIC-ACID; ENDOTHELIAL DYSFUNCTION;
   CARDIOVASCULAR-DISEASE; DIETARY ANTIOXIDANTS; ISCHEMIC-STROKE; GENETIC
   RISK; NITRIC-OXIDE; FATTY-ACIDS; VITAMIN-E
AB PurposeTo describe and evaluate the value of nutritional supplements in the management of age-related macular degeneration (AMD) through a review of the current literature.MethodsAn extensive literature search was performed, and key research articles exploring AREDS and AREDS-2 formulations, genetics, omega fatty acids, calcium and folic acid in high-risk women were reviewed. PubMed and Web of Science databases were used for generating articles to review.ResultsThe AREDS and AREDS-2 trials, while difficult to validate, show support for antioxidant supplementation in reducing AMD progression in Caucasian populations. While genetic guided personalized medicine has been studied mainly with complement factor H and age-related maculopathy susceptibility 2 risk alleles, the data have not been reproducible. Women at a higher risk of cardiovascular disease may benefit from antioxidant therapies in preventing AMD. Omega 3 fatty acid supplementation has been widely supported through observational studies; however, randomized controlled trials have not shown benefit in disease progression. Calcium exposure has been linked to increased mechanisms in cell death and may be detrimental to older individuals with AMD.ConclusionThe data regarding nutritional supplements in preventing AMD progression are inconclusive, and therefore recommendations should be based on risk factors and demographic data.
C1 [Mukhtar, Sabrina] Univ Pittsburgh, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
   [Ambati, Balamurali K.] Pacific Clear Vis Inst, 112 Darlene Lane, Eugene, OR 97401 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Mukhtar, S (通讯作者)，Univ Pittsburgh, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM mukhtars@upmc.edu; bambati@pcvi.com
CR Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720
   BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044
   Calder PC, 2009, BRIT J NUTR, V101, pS1, DOI 10.1017/S0007114509377867
   Carneiro A, 2015, ANTIAGEING NUTR EVID
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Casas JP, 2004, ARCH NEUROL-CHICAGO, V61, P1652, DOI 10.1001/archneur.61.11.1652
   Chakravarthy U, 2007, OPHTHALMOLOGY, V358, P2606
   Chambers JC, 1999, ARTERIOSCL THROM VAS, V19, P2922, DOI 10.1161/01.ATV.19.12.2922
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Connor W E, 1988, Prog Clin Biol Res, V282, P275
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Domagala TB, 2000, J CARDIOVASC RISK, V5, P239
   Dudman NPB, 1999, CIRC RES, V84, P409, DOI 10.1161/01.RES.84.4.409
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Harvey H, 2014, EXP BRAIN RES, V232, P3363, DOI 10.1007/s00221-014-4078-7
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Homocysteine Studies Collaboration, 2001, JAMA-J AM MED ASSOC, V288, P2015
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lawrenson JG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub2
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   McDowell IFW, 2000, J NUTR, V130, p369S, DOI 10.1093/jn/130.2.369S
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Nappo F, 1999, JAMA-J AM MED ASSOC, V281, P2113, DOI 10.1001/jama.281.22.2113
   National Risk Management Research Laboratory Office of Research & Development US EPA, 2006, EXPL PALL CAR PEOPL, P1
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rodrigo R, 2003, J CLIN PHARMACOL, V43, P1299, DOI 10.1177/0091270003258190
   Rojas-Fernandez CH, 2016, ANN PHARM, V51, P1
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Silverman MD, 2002, ARTERIOSCL THROM VAS, V22, P587, DOI 10.1161/01.ATV.0000014221.30108.08
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stankovic S, 2010, CRIT REV CL LAB SCI, V47, P72, DOI 10.3109/10408361003791520
   Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514
   TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 78
TC 13
Z9 13
U1 1
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2019
VL 39
IS 12
BP 2975
EP 2983
DI 10.1007/s10792-019-01140-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JY0IH
UT WOS:000504108000030
PM 31313070
DA 2022-11-30
ER

PT J
AU Lee, J
   Kim, YN
   Kim, JG
AF Lee, Junyeop
   Kim, You Na
   Kim, June-Gone
TI Monthly Alternating Injections of Aflibercept and Bevacizumab for
   Neovascular Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE aflibercept; age-related macular degeneration; alternating injection;
   bevacizumab
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL AFLIBERCEPT; VEGF-TRAP;
   RANIBIZUMAB; THERAPY; BINDING; EYES
AB We investigated the efficacy of monthly alternating injections of aflibercept and bevacizumab (MAAB) for maintenance treatment in patients with neovascular age-related macular degeneration (AMD) who showed improvement with the initial monthly injections but presented with rapid worsening after conversion to bimonthly injections. We included 72 patients with neovascular AMD who showed improvement with loading injections of aflibercept. For maintenance treatment, bevacizumab was administered every alternate month between the bimonthly aflibercept injections in 24 (33.3%) eyes showing worsening (MAAB group). The other eyes were treated with aflibercept (BiA group) bimonthly. Baseline low retinal thickness, thick choroid, and presence of intraretinal fluid were associated with worsening after extending the injection intervals. Visual improvement was lower in the MAAB group than in the BiA group, but the final visual outcomes were comparable. Additional bevacizumab stabilized the early fluctuation of retinal thickness, thus maintaining long-term visual stability without increasing the risk of geographic atrophy or disciform scar until the second year. Previously treated eyes or those with polypoidal choroidal vasculopathy responded less to the initial loading doses and showed worsening under the bimonthly regimen. MAAB was effective in preventing anatomical and functional deterioration when bimonthly aflibercept proved insufficient for the maintenance treatment of neovascular AMD.
C1 [Lee, Junyeop; Kim, You Na; Kim, June-Gone] Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul 05505, South Korea.
C3 University of Ulsan
RP Kim, JG (通讯作者)，Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul 05505, South Korea.
EM j.lee@amc.seoul.kr; youna.kim.oph@gmail.com; junekim@amc.seoul.kr
OI Lee, Junyeop/0000-0001-5887-8033
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2018R1A5A1025511]
FX This research was funded by National Research Foundation of Korea (NRF)
   grant funded by the Korea government (MSIT) (2018R1A5A1025511).
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Cardoso PN, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6835782
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cheng S, 2016, OSLI RETINA, V47, P458, DOI 10.3928/23258160-20160419-09
   Dans KC, 2019, GRAEF ARCH CLIN EXP, V257, P741, DOI 10.1007/s00417-018-04232-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jorstad OK, 2015, ACTA OPHTHALMOL, V93, pE510, DOI 10.1111/aos.12681
   Kang EC, 2017, GRAEF ARCH CLIN EXP, V255, P2157, DOI 10.1007/s00417-017-3776-9
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mimouni M, 2018, JPN J OPHTHALMOL, V62, P652, DOI 10.1007/s10384-018-0619-0
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Slean Geraldine R, 2016, Int J Retina Vitreous, V2, P2, DOI 10.1186/s40942-016-0028-9
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
NR 27
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1543
DI 10.3390/jcm11061543
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0C0ST
UT WOS:000775033900001
PM 35329868
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rakoczy, PE
   Zhang, D
   Robertson, T
   Barnett, NL
   Papadimitriou, J
   Constable, IJ
   Lai, CM
AF Rakoczy, PE
   Zhang, D
   Robertson, T
   Barnett, NL
   Papadimitriou, J
   Constable, IJ
   Lai, CM
TI Progressive age-related changes similar to age-related macular
   degeneration in a transgenic mouse model
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CATHEPSIN-D; STARGARDT-DISEASE; BRUCHS
   MEMBRANE; ACCUMULATION; LIPOFUSCIN; ROD; MACULOPATHY; DRUSEN; ABCR
AB Age-related macular degeneration (AMD) is the major cause of blindness in the developed world. its pathomechanism is unknown and its late onset, complex genetics and strong environmental components have all hampered investigations. Here we demonstrate the development of an animal model for AMD that reproduces features associated with geographic atrophy, a transgenic mouse line (mcd/mcd) expressing a mutated form of cathepsin D that is enzymatically inactive thus impairing processing of phagocytosed photoreceptor outer segments in the retinal pigment epithelial (RPE) cells. Pigmentary changes indicating RPE cell atrophy and a decreased response to flash electroretinograms were observed in 11- to 12-month-old mcd/mcd mice. Histological studies showed RPE cell proliferation, photoreceptor degeneration, shortening of photoreceptor outer segments, and accumulation of immunoreactive photoreceptor breakdown products in the RPE cells. An accelerated photoreceptor cell death was detected in 12-month-old mcd/mcd mice. Transmission electron microscopy demonstrated presence of basal laminar and linear deposits that are considered to be the hallmarks of AMD. Small hard drusen associated with human age-related maculopathy were absent in the mcd/mcd mouse model at the ages analyzed. in summary, this model presents several features of AMD, thus providing a valuable tool for investigating the underlying biological processes and pathomechanism of AMD.
C1 Lions Eye Inst, Nedlands, WA 6009, Australia.
   Univ Western Australia, Dept Ophthalmol & Visual Sci, Crawley, WA, Australia.
   Univ Western Australia, Dept Pathol, Crawley, WA, Australia.
   Univ Queensland, Vis Touch & Hearing Res Ctr, Brisbane, Qld, Australia.
C3 Lions Eye Institute; University of Western Australia; University of
   Western Australia; University of Western Australia; University of
   Queensland
RP Rakoczy, PE (通讯作者)，Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM rakoczy@cyllene.uwa.edu.au
RI Lai, Chooi-May/H-5224-2014; Barnett, Nigel L/F-1226-2010
OI Barnett, Nigel L/0000-0002-0704-2233; constable, ian/0000-0002-2140-6478
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bazzett LB, 1999, GYNECOL ONCOL, V74, P181, DOI 10.1006/gyno.1999.5426
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cheng T, 1997, J NEUROSCI, V17, P8118, DOI 10.1523/jneurosci.17-21-08118.1997
   Couissi D, 1997, CLIN EXP METASTAS, V15, P349, DOI 10.1023/A:1018489819092
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dryja T. P., 1998, SCIENCE, V279
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Goto Y, 1996, J OPT SOC AM A, V13, P577, DOI 10.1364/JOSAA.13.000577
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAYASAKA S, 1983, SURV OPHTHALMOL, V27, P245, DOI 10.1016/0039-6257(83)90125-X
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   IVY GO, 1989, ADV EXP MED BIOL, V266, P31
   Katz ML, 1995, MECH AGEING DEV, V84, P29, DOI 10.1016/0047-6374(95)01633-B
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Lutty G, 1999, MOL VIS, V5
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Okubo A, 2000, INVEST OPHTH VIS SCI, V41, P4305
   Pardue MT, 1998, INVEST OPHTH VIS SCI, V39, P2443
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Rakoczy PE, 1998, INVEST OPHTH VIS SCI, V39, P2095
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Ren JC, 2000, EXP EYE RES, V70, P467, DOI 10.1006/exer.1999.0804
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shen WY, 2001, ARCH OPHTHALMOL-CHIC, V119, P1033, DOI 10.1001/archopht.119.7.1033
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   WIEDERANDERS B, 1984, MECH AGEING DEV, V24, P265, DOI 10.1016/0047-6374(84)90112-X
   WILCOX DK, 1988, INVEST OPHTH VIS SCI, V29, P1205
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
   ZIMMERMAN WF, 1983, EXP EYE RES, V36, P151, DOI 10.1016/0014-4835(83)90098-2
NR 52
TC 136
Z9 143
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2002
VL 161
IS 4
BP 1515
EP 1524
DI 10.1016/S0002-9440(10)64427-6
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 601NQ
UT WOS:000178453000043
PM 12368224
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Kim, Chul Gu
TI Characteristics of Submacular Hemorrhages in Age-Related Macular
   Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   hemorrhage; neovascular age-related macular degeneration; polypoidal
   choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; NATURAL-HISTORY; CLINICAL
   CHARACTERISTICS; SUBRETINAL HEMORRHAGE; KOREAN PATIENTS; RANIBIZUMAB;
   NEOVASCULARIZATION; VERTEPORFIN
AB Purpose. The aims of this research are to report the incidence and characteristics of submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and to compare the detailed morphologic features of hemorrhages between typical neovascular AMD and polypoidal choroidal vasculopathy (PCV).
   Methods. This retrospective observational study included 791 eyes of 791 patients who had newly diagnosed neovascular AMD at a single institution. The incidence and extent of submacular hemorrhage of one disc area or greater were estimated and compared between typical neovascular AMD and PCV. In addition, submacular hemorrhages were classified into groups according to location (location of fovea at the center of the hemorrhage versus at the periphery of the hemorrhage) and morphology (circular versus irregular margin). The proportion of each subtype of neovascular AMD was evaluated according to the aforementioned classification.
   Results. Among those included, 129 (16.3%) eyes exhibited submacular hemorrhage at initial presentation. Among the 627 eyes with available indocyanine green angiography findings, the incidence of submacular hemorrhage was greater in PCV (23.6%, 78 of 330 eyes) than in typical neovascular AMD (9.4%, 28 of 297 eyes; chi(2) test, P<.001). When divided into four groups according to hemorrhage shape and location (central and circular, central and irregular, peripheral and circular, and peripheral irregular), the proportion of eyes in these groups was significantly different between the two disease groups (chi(2) test, P=.018).
   Conclusions. The incidence of submacular hemorrhage was greater in PCV than in typical neovascular AMD. The morphology and location of submacular hemorrhage may provide useful clues to differentiate PCV from typical neovascular AMD.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hwang JU, 2012, RETINA-J RET VIT DIS, V32, P652, DOI 10.1097/IAE.0b013e318233abb4
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 34
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2017
VL 94
IS 5
BP 556
EP 563
DI 10.1097/OPX.0000000000001066
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET7ID
UT WOS:000400468100003
PM 28403037
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Tilleul, J
   Puche, N
   Zerbib, J
   Laloum, F
   Querques, G
   Souied, EH
AF Leveziel, Nicolas
   Tilleul, Julien
   Puche, Nathalie
   Zerbib, Jennyfer
   Laloum, Franck
   Querques, Giuseppe
   Souied, Eric H.
TI Genetic Factors Associated with Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Age-related maculopathy; Genetic
   factors; Personalized medicine; Missing heritability; Genome-wide
   association studies; Atrophic age-related macular degeneration;
   Exudative age-related macular degeneration; Complement factor H gene
   (CFH); LOC387715; Age-related maculopathy susceptibility 2 gene (ARMS2);
   HtrA serine peptidase 1 gene (HTRA1); Complement component 2, 3, 9 (C2,
   C3, C9); Genetic profiling; Asian
ID COMPLEMENT-FACTOR-H; APOLIPOPROTEIN-E GENE; BODY-MASS INDEX; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; C-REACTIVE PROTEIN; MITOCHONDRIAL-DNA
   HAPLOGROUPS; GENOME-WIDE ASSOCIATION; COPY NUMBER VARIATION;
   CIGARETTE-SMOKING; E POLYMORPHISMS
AB Age-related macular degeneration (AMD) is a complex, multifactorial disease associated with environmental and genetic factors. This review emphasizes the clinical impact of the major genetic factors mainly located in the complement factor H gene and on the 10q26 locus, and their current and future implications for the management of AMD. Copyright (C) 2011 S. Karger AG, Basel
C1 [Leveziel, Nicolas; Tilleul, Julien; Puche, Nathalie; Zerbib, Jennyfer; Laloum, Franck; Querques, Giuseppe; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Hop Intercommunal Creteil, Creteil, France.
   [Leveziel, Nicolas; Souied, Eric H.] UPEC, Dept Ophthalmol, Fac Med Henri Mondor, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP
RP Leveziel, N (通讯作者)，Hop Henri Mondor, Serv Ophtalmol, 51 Ave Marechal de Lattre de Tassigny, FR-94010 Creteil, France.
EM nicolas.leveziel@chicreteil.fr
OI Nicolas, Leveziel/0000-0001-8533-9457; Querques,
   Giuseppe/0000-0002-3292-9581
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BRADLEY AE, 1966, AM J OPHTHALMOL, V61, P1
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ellsworth RE, 2010, CURR GENOMICS, V11, P146, DOI 10.2174/138920210791110951
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janssens ACJW, 2007, GENET MED, V9, P528, DOI 10.1097/GIM.0b013e31812eece0
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jorgensen TJ, 2009, AM J EPIDEMIOL, V170, P986, DOI 10.1093/aje/kwp242
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein C, 2011, LANCET, V377, P613, DOI 10.1016/S0140-6736(11)60062-7
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   KLOCCKENERGRUIS.B, 2011, INVEST OPHTHALMOL VI
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Lee SY, 2011, J PATHOL, V223, P15, DOI 10.1002/path.2766
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liu MM, 2011, INVEST OPHTHALMOL VI
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McDermott U, 2011, NEW ENGL J MED, V364, P340, DOI 10.1056/NEJMra0907178
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NG TK, 2011, INVEST OPHTHALMOL VI
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Payami H, 1996, AM J HUM GENET, V58, P803
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   PITAS RE, 1987, J BIOL CHEM, V262, P14352
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Utheim OA, 2008, ACTA OPHTHALMOL, V86, P401, DOI 10.1111/j.1600-0420.2007.01070.x
   Vergeer M, 2011, NEW ENGL J MED, V364, P136, DOI 10.1056/NEJMoa0907687
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   WICKREMASINGHE SS, 2011, INVEST OPHTHALMOL VI
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y., 2011, HUM MOL GENET
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 191
TC 22
Z9 23
U1 2
U2 16
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 3
DI 10.1159/000328981
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 821DP
UT WOS:000294955400001
PM 21757876
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Obana, A
   Hiramitsu, T
   Gohto, Y
   Ohira, A
   Mizuno, S
   Hirano, T
   Bernstein, PS
   Fujii, H
   Iseki, K
   Tanito, M
   Hotta, Y
AF Obana, Akira
   Hiramitsu, Tadahisa
   Gohto, Yuko
   Ohira, Akihiro
   Mizuno, Satoshi
   Hirano, Toru
   Bernstein, Paul S.
   Fujii, Hisako
   Iseki, Ken
   Tanito, Masaki
   Hotta, Yoshihiro
TI Macular carotenoid levels of normal subjects and age-related maculopathy
   patients in a Japanese population
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT DENSITY; RAMAN MEASUREMENT; DEGENERATION; LUTEIN; ZEAXANTHIN
AB Purpose: Macular carotenoid pigments composed of lutein and zeaxanthin are thought to affect the development of age-related maculopathy (ARM). Macular carotenoid levels were measured in normal Japanese subjects and Japanese patients with ARM.
   Design: Observational case-control series.
   Participants: One hundred normal eyes of 100 normal subjects and 187 eyes of 97 patients with ARM; all were Japanese. The definitions of early ARM and late ARM (exudative age-related macular degeneration [AMD] and dry AMD) were used according to an accepted international classification system.
   Methods: Macular carotenoid levels were measured using resonance Raman spectroscopy.
   Main Outcome Measure: Raman signal intensity generated from carbon-carbon double bond vibrations of lutein and zeaxanthin.
   Results: The mean (+/- standard deviation [SD]) macular carotenoid level in normal subjects was 1471 +/- 540 Raman counts. The macular carotenoid levels in normal subjects declined with age. The mean macular carotenoid level was 620 +/- 204 (+/- SD) in eyes with early ARM and 427 +/- 283 (+/- SD) in eyes with late ARM (equal to AMD). The macular carotenoid levels of early ARM and AMD were significantly lower than those in normal subjects older than 60 years (1100 +/- 340 [+/- SD]). No difference was revealed in carotenoid levels by the severity for ARM, type of AMD (exudative, atrophic, and disciform scar), or types of choroidal neovascularization (classic, minimally classic, occult, polypoidal choroidal vasculopathy), although small numbers in some groups weakened statistical power. Macular carotenoid levels were affected by the severity of macular disease in the opposing eye. The average for normal eyes where AMD was found in the opposite eye was significantly lower than that of normal eyes in the absence of AMD in the opposite eye (i.e., healthy volunteers older than 60 years).
   Conclusions: Macular carotenoids decreased even in older healthy individuals. The ARM patients showed lower macular carotenoid levels than healthy people. Low macular carotenoid levels may be one of the risk factors of progression in ARM. Ophthalmology 2008; 115:147-157 (c) 2008 by the American Academy of Ophthalmology.
C1 [Obana, Akira; Gohto, Yuko] Seirei Hamamatsu Gen Hosp, Dept Ophthalmol, Hamamatsu, Shizuoka, Japan.
   [Obana, Akira; Hiramitsu, Tadahisa; Hirano, Toru] Hamamatsu Univ Sch Med, Photon Med Res Ctr, Hamamatsu, Shizuoka 43131, Japan.
   [Ohira, Akihiro; Tanito, Masaki] Shimane Univ, Sch Med, Dept Ophthalmol, Shimane, Japan.
   [Mizuno, Satoshi] JARD Inc, Tokyo, Japan.
   [Bernstein, Paul S.] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA.
   [Fujii, Hisako] Osaka City Univ, Grad Sch Med, Ctr Drug & Food Clin Evaluat, Osaka 558, Japan.
   [Iseki, Ken] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Clin Pharmaceut & Therapeut, Sapporo, Hokkaido, Japan.
   [Hotta, Yoshihiro] Hamamatsu Univ Sch Med, Dept Ophthalmol, Hamamatsu, Shizuoka 43131, Japan.
C3 Hamamatsu University School of Medicine; Shimane University; Utah System
   of Higher Education; University of Utah; Osaka Metropolitan University;
   Hokkaido University; Hamamatsu University School of Medicine
RP Obana, A (通讯作者)，2-12-12 Sumiyoshi,Naka Ku, Hamamatsu, Shizuoka 4308558, Japan.
RI ohira, akihiro/G-8352-2017; Hotta, Yoshihiro/O-5115-2019
OI ohira, akihiro/0000-0002-1307-5592; Hotta, Yoshihiro/0000-0003-4052-5066
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 28
TC 78
Z9 83
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2008
VL 115
IS 1
BP 147
EP 157
DI 10.1016/j.ophtha.2007.02.028
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FK
UT WOS:000252137300022
PM 18166409
DA 2022-11-30
ER

PT J
AU Tamaki, Y
AF Tamaki, Yasuhiro
TI Prospects for nanomedicine in treating age-related macular degeneration
SO NANOMEDICINE
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   dendritic photosensitizer; drug-delivery system; gene therapy;
   nanotechnology; PCI; photochemical internalization; photodynamic
   therapy; polyion complex micelle
ID POLYION COMPLEX MICELLES; BLOCK-COPOLYMER MICELLES; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; DRUG-DELIVERY; GENE DELIVERY;
   POLYMER; ACCUMULATION; CORE; DNA
AB Polyion complex (PIC) micelles have a size range of tens of nanometers formed through electrostatic interaction. In experimental choroidal neovascularization (CNV) in rats, the PIC micelle accumulates to the CNV lesions and is retained. PIC micelles can be used for effective drug delivery to CNV. A novel dendritic photosensitizer encapsulated by a polymeric-micelle formulation was employed for an effective photodynamic therapy for age-related macular degeneration. With its highly selective accumulation on experimental CNV lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity. Gene therapy is a promising approach to treat age-related macular degeneration. A ternary complex, composed of a core containing DNA packaged with cationic peptides and enveloped in the anionic dendrimer phthalocyanine, has been developed, which provides the photosensitizing action. Subconjunctival injection of the ternary complex followed by laser irradiation resulted in transgene expression only in the laser-irradiated site in rats.
C1 Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Tamaki, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM tamaki-tky@umin.ac.jp
CR Behr JP, 1997, CHIMIA, V51, P34
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Conwell CC, 2005, NON-VIRAL GENE THERAPY: GENE DESIGN AND DELIVERY, P3
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Harada A, 2001, EUR J PHARM SCI, V13, P35, DOI 10.1016/S0928-0987(00)00205-0
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   Harada A, 2001, J CONTROL RELEASE, V72, P85, DOI 10.1016/S0168-3659(01)00264-4
   Harada-Shiba M, 2002, GENE THER, V9, P407, DOI 10.1038/sj.gt.3301665
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOGEST A, 2004, ADV DRUG DELIV REV, V56, P95
   HOGEST A, 2000, HUM GENE THER, V11, P869
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   Lee M, 2003, GENE THER, V10, P1535, DOI 10.1038/sj.gt.3302034
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   Miyata K, 2004, J AM CHEM SOC, V126, P2355, DOI 10.1021/ja0379666
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8
   Nishiyama N, 2001, PHARMACEUT RES, V18, P1035, DOI 10.1023/A:1010908916184
   Nishiyama N, 2005, NAT MATER, V4, P934, DOI 10.1038/nmat1524
   Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/jbc.M211891200
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Stackhouse MA, 2000, GENE THER, V7, P1085, DOI 10.1038/sj.gt.3301233
   Yanagi Y, 2003, INVEST OPHTH VIS SCI, V44, P751, DOI 10.1167/iovs.02-0222
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Yasukawa T, 1999, INVEST OPHTH VIS SCI, V40, P2690
NR 36
TC 19
Z9 19
U1 1
U2 15
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD APR
PY 2009
VL 4
IS 3
BP 341
EP 352
DI 10.2217/NNM.09.10
PG 12
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 432VK
UT WOS:000265162200014
PM 19331541
DA 2022-11-30
ER

PT J
AU Chang, YS
   Lee, WJ
   Lim, CC
   Wang, SH
   Hsu, SM
   Chen, YC
   Cheng, CY
   Teng, YT
   Huang, YH
   Lai, CC
   Tseng, SH
AF Chang, Yi-Sheng
   Lee, Wan-Ju
   Lim, Chen-Chee
   Wang, Shih-Hao
   Hsu, Sheng-Min
   Chen, Yi-Chian
   Cheng, Chia-Yi
   Teng, Yu-Ti
   Huang, Yi-Hsun
   Lai, Chun-Chieh
   Tseng, Sung-Huei
TI Real-world use of ranibizumab for neovascular age-related macular
   degeneration in Taiwan
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ELDERLY CHINESE POPULATION; INTRAVITREAL RANIBIZUMAB; RISK-FACTORS;
   OUTCOMES; THERAPY; VERTEPORFIN; BEVACIZUMAB; PREVALENCE; PATTERNS;
   TRIALS
AB This study investigated the "real-world" use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012-2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean +/- standard deviation age 69.4 +/- 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining >= 1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.
C1 [Chang, Yi-Sheng; Hsu, Sheng-Min; Huang, Yi-Hsun; Tseng, Sung-Huei] Natl Cheng Kung Univ, Coll Med, Dept Ophthalmol, Tainan, Taiwan.
   [Chang, Yi-Sheng; Lee, Wan-Ju; Lim, Chen-Chee; Wang, Shih-Hao; Hsu, Sheng-Min; Chen, Yi-Chian; Cheng, Chia-Yi; Teng, Yu-Ti; Huang, Yi-Hsun; Lai, Chun-Chieh; Tseng, Sung-Huei] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan, Taiwan.
   [Lee, Wan-Ju] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan.
   [Cheng, Chia-Yi] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Teng, Yu-Ti; Huang, Yi-Hsun; Lai, Chun-Chieh] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University Hospital; National Cheng Kung University; National
   Taiwan University; National Taiwan University Hospital; National Cheng
   Kung University
RP Chang, YS; Tseng, SH (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Ophthalmol, Tainan, Taiwan.; Chang, YS; Tseng, SH (通讯作者)，Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan, Taiwan.
EM willis@mail.ncku.edu.tw; shtseng1@gmail.com
RI Lee, Wan-Ju/AAC-7025-2020
OI Lee, Wan-Ju/0000-0002-9972-8899
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], REIMB OPHTH PREP TAI
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Devenyi R, 2016, CAN J OPHTHALMOL, V51, P55, DOI 10.1016/j.jcjo.2015.11.008
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Hsu WC, 2016, J FORMOS MED ASSOC, V115, P325, DOI 10.1016/j.jfma.2015.12.001
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karampelas M, 2015, OPHTHALMOL THER, V4, P43, DOI 10.1007/s40123-015-0031-5
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Nallamothu BK, 2008, CIRCULATION, V118, P1294, DOI 10.1161/CIRCULATIONAHA.107.703579
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Silverman SL, 2009, AM J MED, V122, P114, DOI 10.1016/j.amjmed.2008.09.030
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang WY, 2010, DIABETES RES CLIN PR, V88, pS3, DOI 10.1016/S0168-8227(10)70002-4
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 42
TC 5
Z9 5
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 10
PY 2018
VL 8
AR 7486
DI 10.1038/s41598-018-25864-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF2JF
UT WOS:000431763700019
PM 29748599
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Thomas, MJ
   Aziz, AA
   Weng, CY
   Danzig, CJ
   Yiu, G
   Kiss, S
   Waheed, NK
   Kaiser, PK
AF Khanani, Arshad M.
   Thomas, Mathew J.
   Aziz, Aamir A.
   Weng, Christina Y.
   Danzig, Carl J.
   Yiu, Glenn
   Kiss, Szilard
   Waheed, Nadia K.
   Kaiser, Peter K.
TI Review of gene therapies for age-related macular degeneration
SO EYE
LA English
DT Review
ID LEBER CONGENITAL AMAUROSIS; IMMUNE-RESPONSES; RPE65 MUTATIONS;
   VORETIGENE NEPARVOVEC; SUBRETINAL INJECTION; NEOVASCULAR AMD; GENOMIC
   DNA; OPEN-LABEL; DELIVERY; SAFETY
AB Gene therapies aim to deliver a therapeutic payload to specified tissues with underlying protein deficiency. Since the 1990s, gene therapies have been explored as potential treatments for chronic conditions requiring lifetime care and medical management. Ocular gene therapies target a range of ocular disorders, but retinal diseases are of particular importance due to the prevalence of retinal disease and the current treatment burden of such diseases on affected patients, as well as the challenge of properly delivering these therapies to the target tissue. The purpose of this review is to provide an update on the most current data available for five different retinal gene therapies currently undergoing clinical trials for use against age-related macular degeneration (AMD) and the development of novel delivery routes for the administration of such therapies. Research has been performed and compiled from PubMed and the select authors of this manuscript on the treatment and effectiveness of five current retinal gene therapies: Luxturna, ADVM-022, RGX-314, GT-005, and HMR59. We present the available data of current clinical trials for the treatment of neovascular and dry age-related macular degeneration with different AAV-based gene therapies. We also present current research on the progress of developing novel routes of administration for ocular gene therapies. Retinal gene therapies offer the potential for life-changing treatment for chronic conditions like age-related macular degeneration with a single administration. In doing so, gene therapies change the landscape of treatment options for these chronic conditions for both patient and provider.
C1 [Khanani, Arshad M.; Aziz, Aamir A.] Sierra Eye Associates, Reno, NV 89502 USA.
   [Khanani, Arshad M.; Thomas, Mathew J.; Aziz, Aamir A.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Weng, Christina Y.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
   [Danzig, Carl J.] Tand Eye Inst, Deerfield Beach, FL USA.
   [Danzig, Carl J.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
   [Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Kiss, Szilard] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Waheed, Nadia K.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Baylor College of Medicine; State University System of Florida; Florida
   Atlantic University; University of California System; University of
   California Davis; Cornell University; NewYork-Presbyterian Hospital;
   Tufts University; Cleveland Clinic Foundation
RP Khanani, AM (通讯作者)，Sierra Eye Associates, Reno, NV 89502 USA.; Khanani, AM (通讯作者)，Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
EM arshad.khanani@gmail.com
OI Thomas, Mathew/0000-0003-2820-151X; Kiss, Szilard/0000-0003-3433-8432
CR ADVERUM, 2021, ADV PROV UPD ADVM 02
   [Anonymous], AAVCAGSCD59 TREATM W
   [Anonymous], TREATM ADV DRY AG RE
   Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4
   Athanasopoulos T, 2017, HEMATOL ONCOL CLIN N, V31, P753, DOI 10.1016/j.hoc.2017.06.007
   Bahadorani Sepehr, 2017, F1000Res, V6, P519, DOI 10.12688/f1000research.10998.1
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475
   Busbee B, 2021, INVEST OPHTH VIS SCI, V62
   Chung DC, 2018, CLIN EXP OPHTHALMOL, V46, P247, DOI 10.1111/ceo.13022
   Chung SH, 2021, HUM GENE THER, V32, P682, DOI 10.1089/hum.2020.281
   de Smet MD, 2018, INVEST OPHTH VIS SCI, V59, P311, DOI 10.1167/iovs.17-22233
   den Hollander AI, 2006, AM J HUM GENET, V79, P556, DOI 10.1086/507318
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Dreismann AK, 2021, GENE THER, V28, P265, DOI 10.1038/s41434-021-00239-9
   Duker, 2019, ANG EX DEG 2019 MIAM
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   Emami-Naeini Parisa, 2019, Int Ophthalmol Clin, V59, P195, DOI 10.1097/IIO.0000000000000251
   Chacon-Camacho OF, 2015, WORLD J CLIN CASES, V3, P112, DOI 10.12998/wjcc.v3.i2.112
   FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949
   Gao J, 2020, CLIN OPHTHALMOL, V14, P3855, DOI 10.2147/OPTH.S231804
   Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644
   Gelfman CM, 2021, J OCUL PHARMACOL TH, V37, P181, DOI 10.1089/jop.2021.0001
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Keeler AM, 2019, ANNU REV VIROL, V6, P601, DOI 10.1146/annurev-virology-092818-015530
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Khabou H, 2018, HUM GENE THER, V29, P1235, DOI 10.1089/hum.2018.144
   Khanani AM, 2020, RETINAL PHYS
   Khanani AM, 2020, INVEST OPHTH VIS SCI, V61
   Kiss S, 2021, MOL THER, V29, P102
   Kiss S, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.1.34
   Kiss S, 2020, MOL THER-METH CLIN D, V18, P345, DOI 10.1016/j.omtm.2020.06.007
   Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946
   KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Mehta Neesurg, 2021, Int Ophthalmol Clin, V61, P151, DOI 10.1097/IIO.0000000000000366
   Mendell JR, 2010, NEW ENGL J MED, V363, P1429, DOI 10.1056/NEJMoa1000228
   Moisseiev E, 2016, CLIN OPHTHALMOL, V10, P173, DOI 10.2147/OPTH.S89784
   Naso MF, 2017, BIODRUGS, V31, P317, DOI 10.1007/s40259-017-0234-5
   Nienhuis AW, 2006, MOL THER, V13, P1031, DOI 10.1016/j.ymthe.2006.03.001
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Peluso R, 2003, GENE THERAPY THERAPE, P71
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Pennesi ME, 2011, INVEST OPHTH VIS SCI, V52, P8166, DOI 10.1167/iovs.11-8298
   Pillay S, 2017, J VIROL, V91, DOI 10.1128/JVI.0391-17
   Rodrigues GA, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2554-7
   Ruan GX, 2017, MOL THER, V25, P331, DOI 10.1016/j.ymthe.2016.12.006
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Scheller EL, 2009, J DENT RES, V88, P585, DOI 10.1177/0022034509337480
   Seitz IP, 2017, INVEST OPHTH VIS SCI, V58, P5784, DOI 10.1167/iovs.17-22473
   Shen JK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1606
   Tamura R, 2020, NEUROL MED-CHIR, V60, P483, DOI 10.2176/nmc.ra.2020-0049
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tsai YT, 2018, OPHTHALMOLOGY, V125, P1421, DOI 10.1016/j.ophtha.2018.04.001
   Vandamme C, 2017, HUM GENE THER, V28, P1061, DOI 10.1089/hum.2017.150
   Waheed NK, 2021, ANG EX DEG 2021
   Weleber RG, 2016, OPHTHALMOLOGY, V123, P1606, DOI 10.1016/j.ophtha.2016.03.003
   Willoughby AS, 2018, AM J OPHTHALMOL, V186, P144, DOI 10.1016/j.ajo.2017.11.020
   Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996
   Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
   Yiu G, 2018, OPHTHALMOL RETINA, V2, P1, DOI 10.1016/j.oret.2017.09.015
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Zaiss AK, 2002, J VIROL, V76, P4580, DOI 10.1128/JVI.76.9.4580-4590.2002
NR 76
TC 6
Z9 6
U1 6
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 303
EP 311
DI 10.1038/s41433-021-01842-1
EA JAN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000741317500004
PM 35017696
DA 2022-11-30
ER

PT J
AU Beutel, J
   Rudolf, M
   Grisanti, S
AF Beutel, Julia
   Rudolf, Martin
   Grisanti, Salvatore
TI Current and future therapies for age-related macular degeneration
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Review
DE age-related macular degeneration; angiogenesis; apoptosis; inflammation;
   therapy; VEGF
ID EPITHELIUM-DERIVED FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RANDOMIZED
   CLINICAL-TRIALS; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   OCULAR NEOVASCULARIZATION; VERTEPORFIN THERAPY; CRYSTAL-STRUCTURE;
   10-YEAR INCIDENCE; VEGF EXPRESSION
AB Background: Age-related macular degeneration is the leading cause of blindness, with an increasing incidence as the elderly population expands. Objective: In this article we review current therapeutic strategies and discuss possible future targets. Methods: A review of the literature and ongoing clinical trials was undertaken. Results: Currently, established therapies for neovascular AMD-like photodynamic therapy and anti-VEGF therapies allow stabilization or even improvement of vision. Potential future drugs under development for advanced AMD or its prevention target the signal transduction cascade of different angiogenic molecules. These drugs intervene at different levels of the involved processes including the RNA production and specific protein expression as well as inflammatory, apoptotic, or metabolic processes. Conclusion: Combining different strategies targeting angiogenesis, inflammation and apoptosis, or interfering early in - or even prior to - the formation of choroidal neovascularization, may improve the future management of age-related macular degeneration.
C1 [Beutel, Julia; Rudolf, Martin; Grisanti, Salvatore] Univ Lubeck, Univ Eye Hosp, Lubeck, Germany.
C3 University of Lubeck
RP Grisanti, S (通讯作者)，Hosp Eye, Univ Clin Schleswig Holstein, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM salvatore.grisanti@uk-sh.de
CR Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cheng LY, 2001, J OCUL PHARMACOL TH, V17, P295, DOI 10.1089/108076801750295326
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Danis DP, 2003, CURR EYE RES, V26, P45, DOI 10.1076/ceyr.26.1.45.14252
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Donsante A, 2001, GENE THER, V8, P1343, DOI 10.1038/sj.gt.3301541
   Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Griffioen A W, 2000, IDrugs, V3, P336
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   KOGYO KKK, 2003, Patent No. 6617160
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Leonard P, 2008, J MOL BIOL, V384, P1203, DOI 10.1016/j.jmb.2008.09.076
   LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0
   Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mikecz K, 2000, Curr Opin Investig Drugs, V1, P199
   Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   MOUSA E, 2008, INVEST OPHTHALMOL VI, V49
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Sima J, 2004, FEBS LETT, V564, P19, DOI 10.1016/S0014-5793(04)00297-2
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang B, 2005, METHOD FIND EXP CLIN, V27, P179, DOI 10.1358/mf.2005.27.3.890875
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 92
TC 8
Z9 9
U1 1
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PD JUN
PY 2009
VL 14
IS 2
BP 341
EP 362
DI 10.1517/14728210902824141
PG 22
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 461NO
UT WOS:000267274400009
PM 19392638
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Kawasaki, R
   Uchida, A
   Koto, T
   Shinoda, H
   Tsubota, K
   Wong, TY
   Ozawa, Y
AF Sasaki, Mariko
   Kawasaki, Ryo
   Uchida, Atsuro
   Koto, Takashi
   Shinoda, Hajime
   Tsubota, Kazuo
   Wong, Tien Yin
   Ozawa, Yoko
TI Early Signs of Exudative Age-Related Macular Degeneration in Asians
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; early age-related macular
   degeneration; drusen; pigmentary abnormalities; polypoidal choroidal
   vasculopathy; Asian
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULOPATHY; PREVALENCE; EYES
AB Purpose. To investigate the relationship between the early signs of age-related macular degeneration (AMD) and the risk of developing exudative AMD (typical AMD or polypoidal choroidal vasculopathy [PCV]) in the fellow eye of Japanese patients with unilateral exudative AMD, focusing particularly on eyes with only pigmentary abnormality.
   Methods. This study is a retrospective observational consecutive case series. We retrospectively reviewed the medical charts of patients who revisited the AMD clinic from 2010 to 2011 and confirmed 129 cases with unilateral exudative AMD at their first visit (baseline). The non-affected eyes at baseline (the second eye) were categorized by the presence of early signs of AMD. The incidence of exudative AMD (typical AMD or PCV) in the fellow eye was confirmed by fluorescein and indocyanine green angiography.
   Results. Of the 129 patients, 14 (10.9%) developed exudative AMD in the fellow eye (median follow-up, 3.2 years; n = 7 typical AMD and n = 7 PCV). Eyes with both pigmentary abnormalities and large drusen were more likely to develop typical AMD (age-and sex-adjusted odds ratio = 9.46, 95% confidence interval = 1.05 to 85.0), whereas pigmentary abnormalities without large drusen were associated with PCV (age-and sex-adjusted odds ratio = 15.9, 95% confidence interval = 1.8 to 140.5).
   Conclusions. There was a difference in the association between early signs of AMD and incident development of either typical AMD or PCV. Further research is warranted to determine whether pigmentary abnormalities alone may be an important risk factor for PCV in Asians.
C1 [Sasaki, Mariko; Uchida, Atsuro; Koto, Takashi; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
   [Sasaki, Mariko; Kawasaki, Ryo; Wong, Tien Yin] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [Kawasaki, Ryo] Yamagata Univ, Fac Med, Dept Publ Hlth, Yamagata 990, Japan.
   [Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Keio University; Centre for Eye Research Australia; Royal Victorian Eye
   & Ear Hospital; University of Melbourne; Yamagata University; National
   University of Singapore; Singapore National Eye Center
RP Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Ozawa, Yoko/AAH-9888-2020; Kawasaki, Ryo/B-7266-2009; Kawasaki,
   Ryo/H-9716-2019; Uchida, Atsuro/GVT-8593-2022; Wong, Tien
   Yin/AAC-9724-2020
OI Kawasaki, Ryo/0000-0002-7492-6303; Wong, Tien Yin/0000-0002-8448-1264;
   Uchida, Atsuro/0000-0002-1378-7151
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 24
TC 19
Z9 19
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 849
EP 853
DI 10.1097/OPX.0000000000000317
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500006
PM 24978864
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Stanescu-Segall, D
   Balta, F
   Jackson, TL
AF Stanescu-Segall, Dinu
   Balta, Florian
   Jackson, Timothy L.
TI Submacular hemorrhage in neovascular age-related macular degeneration: A
   synthesis of the literature
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE subretinal hemorrhage; neovascular age-related; macular degeneration;
   anti-vascular endothelial; growth factor; bevacizumab; ranibizumab;
   tissue plasminogen activator; pneumatic displacement; vitrectomy; gas;
   macular translocation
ID TISSUE-PLASMINOGEN-ACTIVATOR; RETINAL-PIGMENT EPITHELIUM; INDOCYANINE
   GREEN ANGIOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; PARS-PLANA VITRECTOMY;
   MASSIVE INTRAOCULAR HEMORRHAGE; SINGLE INTRAVITREAL INJECTION; ANTI-VEGF
   INJECTIONS; PNEUMATIC DISPLACEMENT; SUBRETINAL HEMORRHAGE
AB Large submacular hemorrhage, an uncommon manifestation of neovascular age-related macular degeneration, may also occur with idiopathic polypoidal choroidal vasculopathy. Submacular hemorrhage damages photoreceptors owing to iron toxicity, fibrin meshwork contraction, and reduced nutrient flux, with subsequent macular scarring. Clinical and experimental studies support prompt treatment, as tissue damage can occur within 24 hours. Without treatment the natural history is poor, with a mean final visual acuity (VA) of 20/1600. Reported treatments include retinal pigment epithelial patch, macular translocation, pneumatic displacement, intravitreal or subretinal tissue plasminogen activator, intravitreal anti-vascular endothelial growth factor (VEGF) drugs, and combinations thereof. In the absence of comparative studies, we combined eligible studies to assess the VA change before and after each treatment option. The greatest improvement occurred after combined pars plana vitrectomy, subretinal tissue plasminogen activator, intravitreal gas, and anti-vascular endothelial growth factor treatment, with VA improving from 20/1000 to 20/400. The best final VA occurred using combined intravitreal tissue plasminogen activator, gas, and anti-vascular endothelial growth factor therapy, with VA improving from 20/200 to 20/100. Both treatments had an acceptable safety profile, but most studies were small, and larger randomized controlled trials are needed to determine both safety and efficacy. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
C1 [Stanescu-Segall, Dinu] Ctr Nord Explorat Ophtalmol, Lille, France.
   [Balta, Florian] Bucharest Eye Hosp & Clin, Bucharest, Romania.
   [Jackson, Timothy L.] Kings Coll London, Sch Med, Dept Ophthalmol, London, England.
C3 University of London; King's College London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RJ, England.
EM tjackson1@nhs.net
RI Balta, Florian/A-3858-2017
OI Jackson, Timothy/0000-0001-7618-1555
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Acheampong P, 2012, EXPERT OPIN DRUG MET, V8, P271, DOI 10.1517/17425255.2012.652615
   Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   BENNER JD, 1991, ARCH OPHTHALMOL-CHIC, V109, P1731, DOI 10.1001/archopht.1991.01080120115039
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2001, OPHTHALMOLOGY, V108, P435, DOI 10.1016/S0161-6420(00)00666-7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN GC, 1982, CAN J OPHTHALMOL, V17, P227
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Chen SN, 2001, RETINA-J RET VIT DIS, V21, P460, DOI 10.1097/00006982-200110000-00007
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Chuang LH, 2011, OPHTHALMIC RES, V45, P31, DOI 10.1159/000315617
   Cohen A, 1999, BIODRUGS, V11, P115, DOI 10.2165/00063030-199911020-00005
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Faure C, 2011, BRIT J OPHTHALMOL, V95, P743, DOI 10.1136/bjo.2010.190462
   FELDMAN EL, 1986, INT OPHTHALMOL CLIN, V26, P159, DOI 10.1097/00004397-198602620-00009
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   HAMPTON GR, 1986, GRAEF ARCH CLIN EXP, V224, P234, DOI 10.1007/BF02143061
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hesgaard HB, 2012, ACTA OPHTHALMOL, V90, pe498, DOI 10.1111/j.1755-3768.2011.02352.x
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   JAFFE GJ, 1990, OPHTHALMOLOGY, V97, P184
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   Johnson MW, 2000, OPHTHALMOLOGY, V107, P2120, DOI 10.1016/S0161-6420(00)00568-6
   JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kamei M, 2009, DEV OPHTHALMOL, V44, P82, DOI 10.1159/000223948
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim S H, 1995, Korean J Ophthalmol, V9, P59
   KIMURA AE, 1994, RETINA-J RET VIT DIS, V14, P83, DOI 10.1097/00006982-199401000-00018
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Nourinia Ramin, 2010, J Ophthalmic Vis Res, V5, P168
   Ogawa T, 2000, RETINA-J RET VIT DIS, V20, P684, DOI 10.1097/00006982-200006000-00024
   Oh IK, 2009, OPHTHALMOLOGICA, V223, P78, DOI 10.1159/000173715
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   RIJKEN DC, 1995, BAILLIERE CLIN HAEM, V8, P291, DOI 10.1016/S0950-3536(05)80269-0
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Sawa M, 2006, OPHTHALMOLOGY, V113, P814, DOI 10.1016/j.ophtha.2006.01.037
   Schmidt JC, 2004, OPHTHALMOLOGE, V101, P584, DOI 10.1007/s00347-003-0912-1
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Schutt F, 2002, CLIN EXP OPHTHALMOL, V30, P110, DOI 10.1046/j.1442-6404.2002.00494.x
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Simpson ARH, 2013, INVEST OPHTH VIS SCI, V54, P2028, DOI 10.1167/iovs.12-11258
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Sparrow JM, 2012, EYE, V26, P821, DOI 10.1038/eye.2012.51
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   STERNBERG P, 1990, ARCH OPHTHALMOL-CHIC, V108, P720, DOI 10.1001/archopht.1990.01070070106045
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   THOMPSON JT, 2005, T AM OPHTHAL SOC, V103, P107
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Tognetto D, 2011, CLIN OPHTHALMOL, V5, P459, DOI 10.2147/OPTH.S15864
   TOTH CA, 1992, AM J OPHTHALMOL, V113, P175, DOI 10.1016/S0002-9394(14)71530-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   Tsai TH, 2007, EYE, V21, P721, DOI 10.1038/sj.eye.6702312
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 158
TC 63
Z9 67
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2016
VL 61
IS 1
BP 18
EP 32
DI 10.1016/j.survophthal.2015.04.004
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ6LV
UT WOS:000367213700002
PM 26212151
DA 2022-11-30
ER

PT J
AU Thier, A
   Holmberg, C
AF Thier, Anne
   Holmberg, Christine
TI The patients' view: age-related macular degeneration and its effects - a
   meta-synthesis
SO DISABILITY AND REHABILITATION
LA English
DT Review
DE Age-related macular degeneration; visual impairment; vascular
   endothelial growth factor inhibitor therapy; patients' experiences;
   meta-synthesis; qualitative research
ID OLDER-ADULTS; VISUAL IMPAIRMENT; LIVED EXPERIENCE; DISEASE BURDEN;
   VISION; CARE; REHABILITATION; SENSE; LIFE
AB Aim:The aim of this meta-synthesis is to find out what it means for patients with age-related macular degeneration to live with visual impairment, how they cope with the illness and how they experience their medical care, including vascular endothelial growth factor inhibitor therapy. Method:Inclusion criteria: qualitative studies exploring patients' experiences with age-related macular degeneration in their daily lives and with medical care, published in journals in English or German. The included studies were analysed following the rules and principles of grounded theory. Results:For the analysis, twenty-four articles matching the inclusion criteria were identified. Three main analytic themes emerged from the included studies: (i) a life shaped by losses; (ii) the burden of medical treatment; and (iii) coping with vision loss. For patients, visual impairment/vision loss means living with multiple losses in various domains of life. With the introduction of vascular endothelial growth factor inhibitor therapy, patients with neovascular age-related macular degeneration have a good chance of slowing down the disease progression; therapy does, however, also represent a major burden. Conclusion:New strategies need to be conceived to reduce the burden of medical treatment and to improve the dissemination of information about age-related macular degeneration.
C1 [Thier, Anne; Holmberg, Christine] Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Brandenburg, Germany.
   [Holmberg, Christine] Brandenburg Univ Technol Cottbus Senftenberg, Joint Fac, Fac Hlth Sci, Brandenburg Med Sch Theodor Fontane, Potsdam, Germany.
   [Holmberg, Christine] Univ Potsdam, Potsdam, Germany.
C3 University of Potsdam
RP Thier, A (通讯作者)，Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Hochstr 15, D-14770 Brandenburg, Germany.
EM anne.thier@mhb-fontane.de
OI Thier, Anne/0000-0003-1724-6018; Holmberg, Christine/0000-0002-8852-4620
FU Friebe foundation (Germany) [T0498/30395/17]
FX This study was funded by the Friebe foundation (Germany). The project
   number is T0498/30395/17.
CR Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Burton AE, 2015, J HEALTH PSYCHOL, V20, P1285, DOI 10.1177/1359105313511134
   CASP, 2018, CRIT APPR PROGR CASP
   Charmaz Kathy, 2014, CONSTRUCTING GROUNDE
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Cimarolli VR, 2005, J VISUAL IMPAIR BLIN, V99, P521, DOI 10.1177/0145482X0509900904
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Emsfors A, 2017, J CLIN NURS, V26, P2680, DOI 10.1111/jocn.13749
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Finfgeld DL, 2003, QUAL HEALTH RES, V13, P893, DOI 10.1177/1049732303253462
   Finger RP, 2007, OPHTHALMOLOGE, V104, P839, DOI 10.1007/s00347-007-1600-3
   Harrer M, 1995, LEHRBUCH PSYCHOSOZIA, P409
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Husler S, 2013, KLIN MONATSBL AUGENH, V230, P1251, DOI 10.1055/s-0033-1351029
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lam N, 2013, CAN J OPHTHALMOL, V48, P458, DOI 10.1016/j.jcjo.2013.02.014
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Mayer H, 2015, J QUALITATIVE FORSCH, V2, P146
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mogk M, 2008, J VISUAL IMPAIR BLIN, V102, P581, DOI 10.1177/0145482X0810201002
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Moore LW, 2003, J ADV NURS, V43, P10
   Noyes J., 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184.CH20
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Porter Eileen J, 2008, Home Health Care Serv Q, V27, P167, DOI 10.1080/01621420802317260
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schilling OK, 2006, PSYCHOL AGING, V21, P703, DOI 10.1037/0882-7974.21.4.703
   Sivaprasad S, 2019, OPHTHALMOL THER, V8, P115, DOI 10.1007/s40123-019-0160-3
   Smith TM, 2008, J VISUAL IMPAIR BLIN, V102, P725
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   van der Aa HPA, 2015, QUAL LIFE RES, V24, P969, DOI 10.1007/s11136-014-0835-0
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wahl HW, 2008, OPHTHALMOLOGE, V105, P735, DOI 10.1007/s00347-008-1724-0
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 45
TC 6
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-8288
EI 1464-5165
J9 DISABIL REHABIL
JI Disabil. Rehabil.
PD FEB 27
PY 2022
VL 44
IS 5
BP 661
EP 671
DI 10.1080/09638288.2020.1775901
EA JUN 2020
PG 11
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA ZK6RO
UT WOS:000547314500001
PM 32574120
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Kreissig, I
   Hugger, P
   Sauder, G
   Panda-Jonas, S
   Degenring, R
AF Jonas, JB
   Kreissig, I
   Hugger, P
   Sauder, G
   Panda-Jonas, S
   Degenring, R
TI Intravitreal triamcinolone acetonide for exudative age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CRYSTALLINE CORTISONE; CHOROIDAL NEOVASCULARIZATION; ADJUNCTIVE
   TREATMENT; RETINAL TOXICITY; INJECTION; EDEMA; PHARMACOKINETICS;
   MACULOPATHY; INHIBITION; PREVALENCE
AB Aim: To evaluate the effect of intravitreal triamcinolone acetonide on the visual acuity of patients with exudative age related macular degeneration, to assess the duration of a possible effect, and to evaluate clinical side effects of the treatment.
   Methods: The study included 67 patients (71 eyes) who presented with exudative age related macular degeneration of predominantly or total occult type (n = 68) or classic type (n = 3), and who received once, or repeatedly, an intravitreal injection of 25 mg of crystalline triamcinolone acetonide. Mean follow up time was 7.46 (SD 3.54) months (range 3.1-19.57 months).
   Results: Visual acuity increased significantly (p <0.001) from 0.16 (0.11) to a mean maximum of 0.23 (0.17). Postoperative visual acuity was highest 1-3 months after the injection. 47 (66.2%) eyes gained in maximal visual acuity and 11 (15.5%) eyes lost in visual acuity. Intraocular pressure increased significantly (p <0.001) from 15.1 (3.1) mm H9 at baseline to a maximal value of 23.0 (8.25) mm Hg. At the end of follow up, intraocular pressure again decreased significantly (p<0.001) to 16.8 (4.9) mm Hg. No cases of postoperative infectious endophthalmitis, rhegmatogenous retinal detachment, or proliferative vitreoretinopathy occurred. Owing to a decrease in visual acuity after an initial increase, six patients received a second intravitreal triamcinolone acetonide injection after which visual acuity increased again in three eyes.
   Conclusions: Intravitreal injection of 25 mg of crystalline triamcinolone acetonide merits further study for the treatment of exudative age related macular degeneration.
C1 Heidelberg Univ, Augenklin, Dept Ophthalmol, Fac Clin Med Mannheim, D-68167 Mannheim, Germany.
   Heidelberg Univ, Hosp Eye, Fac Clin Med Mannheim, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Heidelberg Univ, Augenklin, Dept Ophthalmol, Fac Clin Med Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@ougen.ma.uni-heidelberg.de
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Berger AS, 1996, INVEST OPHTH VIS SCI, V37, P2318
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DEGENRING RF, 2003, IN PRESS BR J OPHTHA
   Giles C L, 1974, Am J Ophthalmol, V77, P438
   Gillies MC, 2001, INVEST OPHTH VIS SCI, V42, pS522
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, GRAEF ARCH CLIN EXP, V239, P464, DOI 10.1007/s004170100293
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Kivilcim M, 2000, OPHTHALMIC SURG LAS, V31, P474
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   McCullough DG, 1998, J ECON ENTOMOL, V91, P785, DOI 10.1093/jee/91.4.785
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 51
TC 173
Z9 198
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2003
VL 87
IS 4
BP 462
EP 468
DI 10.1136/bjo.87.4.462
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 660XM
UT WOS:000181860300022
PM 12642311
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Ahmed, D
   Stattin, M
   Haas, AM
   Graf, A
   Krepler, K
   Ansari-Shahrezaei, S
AF Ahmed, Daniel
   Stattin, Martin
   Haas, Anna-Maria
   Graf, Alexandra
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI Drusen characteristics of type 2 macular neovascularization in
   age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Type 2 macular neovascularization;
   Drusen; Subretinal drusenoid deposits
ID RETICULAR PSEUDODRUSEN; CHOROIDAL NEOVASCULARIZATION; NATURAL-HISTORY;
   FELLOW EYES; VISION LOSS; LESION TYPE; SUBTYPES; CLASSIFICATION;
   PREVALENCE; DEPOSITS
AB Background Type 2 macular neovascularization (MNV) is supposed to be a rare condition in age-related macular degeneration (AMD). The main purpose of this study was to assess accompanying factors of type 2 MNV in AMD. Methods Retrospective data analysis of eyes previously diagnosed with neovascular AMD in a tertiary eye care center (Medical Retina Unit, Rudolf Foundation Hospital, Vienna, Austria) between June 2008 and December 2017. Drusen subtypes, fibrosis, atrophy and subfoveal choroidal thickness (SFCT) of both eyes in patients with type 2 MNV lesions were categorized based on multimodal imaging. Results Type 2 MNV was diagnosed in 27 (3.2%) of 835 eyes (749 patients). Drusen characteristics in type 2 MNV were observed as followed: drusen < 63 mu m in 2 eyes (7.4%), drusen >= 63 mu m in 10 eyes (37%), subretinal drusenoid deposits (SDD) in 8 eyes (29.6%), cuticular drusen in 2 eye (7.4%) and no drusen were evident in 10 eyes (37%). Drusen distribution in 23 fellow eyes was detected as followed: drusen < 63 mu m in 2 eyes (8.7%), drusen >= 63 mu m in 9 eyes (39.1%), SDD in 5 eyes (21.7%), cuticular drusen in 1 eye (4.3%) and no drusen were evident in 9 eyes (39.1%). Mean SFCT was 140 +/- 49 mu m in affected eyes and 152 +/- 41 mu m in the fellow eyes. Patients with drusen or SDD were significantly younger (mean 70.88 +/- 6.85,p = 0.04) than patients without deposits (mean 77.40 +/- 5.74). Conclusions Type 2 MNV remains a rare entity in AMD. It was frequently seen in the absence of drusen, a hallmark of AMD. These findings contribute to the heterogeneity of phenotypes related to pure type 2 lesions.
C1 [Ahmed, Daniel; Stattin, Martin; Haas, Anna-Maria; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Ahmed, Daniel; Stattin, Martin; Haas, Anna-Maria; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Spitalgasse 23, A-1090 Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
EM siamak.ansari-shahrezaei@wienkav.at
OI Ansari Shahrezaei, Siamak/0000-0001-8032-4686; Graf,
   Alexandra/0000-0003-0035-2658
FU Topcon
FX Ilse Krebs, MD, a senior clinical advisor without affiliation to the
   study concept, was consulted in case of grading disagreement. The
   computing and post-processing of the figures were supported by Senior
   Clinical Advisor Carl Glittenberg, a Topcon employee.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2017, RETINA PHILADELPHIA
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 36
TC 3
Z9 3
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 25
PY 2020
VL 20
IS 1
AR 381
DI 10.1186/s12886-020-01651-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY3WR
UT WOS:000576324600001
PM 32977799
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Blinder, KJ
   Shah, GK
   Thomas, MA
   Holekamp, NM
   Joseph, DP
   Grand, G
   Sharma, S
AF Blinder, KJ
   Shah, GK
   Thomas, MA
   Holekamp, NM
   Joseph, DP
   Grand, G
   Sharma, S
TI Surgical removal of peripapillary choroidal neovascularization
   associated with age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OCULAR HISTOPLASMOSIS SYNDROME; RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC
   THERAPY; LASER PHOTOCOAGULATION; VERTEPORFIN; MEMBRANES; EXCISION
AB BACKGROUND AND OBJECTIVE: To describe the results of surgical treatment of peripapillary choroidal neovascularization in age-related macular degeneration as an option to both laser photocoagulation and photodynamic therapy.
   PATIENTS AND METHODS: Retrospective review of patients with peripapillary choroidal neovascularization secondary to age-related macular degeneration who were not eligible for or refused laser photocoagulation. Patients without the diagnosis of age-related macular degeneration and those who had extension of their neovascularization subfoveally were excluded from the review.
   RESULTS: Eleven patients total were identified who met the specified inclusion criteria. The male to female ratio was 4:7, with an age range of 63 to 94 years (mean = 7 8 years). The mean area of involved retina temporal to the optic disc was 5 clock hours, with the distance of the temporal edge of the lesion from the fovea ranging from 100 to 2,000 pm. The mean duration of follow-up was 23 months, with 27% (3 of 11) experiencing recurrent choroidal neovascularization. The preoperative and postoperative visual acuity ranges were both 20/25 to counting fingers. Sixty-four percent (7 of 11) of patients had stable or improved visual acuity postoperatively, with a mean visual acuity change of I line visual improvement.
   CONCLUSION: In cases where photodynamic therapy and laser photocoagulation are not indicated, the surgical treatment of peripapillary choroldal neovascularization secondary to age-related macular degeneration may prove beneficial.
C1 Washington Univ, Sch Med, Barnes Retina Inst, St Louis, MO 63144 USA.
   Queens Univ, Kingston, ON, Canada.
C3 Washington University (WUSTL); Queens University - Canada
RP Blinder, KJ (通讯作者)，Washington Univ, Sch Med, Barnes Retina Inst, 1600 S Brentwood Blvd,Suite 800, St Louis, MO 63144 USA.
RI Thomas, Megan/GWQ-4391-2022
CR Atebara NH, 1998, OPHTHALMOLOGY, V105, P1598, DOI 10.1016/S0161-6420(98)99024-8
   BLINDER KJ, 1991, INT OPHTHALMOL, V15, P215
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
NR 12
TC 8
Z9 8
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2005
VL 36
IS 5
BP 358
EP 364
DI 10.3928/1542-8877-20050901-03
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 965QU
UT WOS:000231966200001
PM 16238033
DA 2022-11-30
ER

PT J
AU Chong, EW
   Wang, YY
   Robman, LD
   Aung, KZ
   Makeyeva, GA
   Giles, GG
   Graves, S
   Cicuttini, FM
   Guymer, RH
AF Chong, Elaine W.
   Wang, Yuanyuan
   Robman, Liubov D.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Giles, Graham G.
   Graves, Stephen
   Cicuttini, Flavia M.
   Guymer, Robyn H.
TI Age Related Macular Degeneration and Total Hip Replacement Due to
   Osteoarthritis or Fracture: Melbourne Collaborative Cohort Study
SO PLOS ONE
LA English
DT Article
ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT; SYMPTOMATIC HIP; SYNOVIAL-FLUID;
   INFLAMMATION; OLDER; EPIDEMIOLOGY; AUSTRALIA; PEOPLE; DRUSEN
AB Osteoarthritis is the leading cause of total hip replacement, accounting for more than 80% of all total hip replacements. Emerging evidence suggests that osteoarthritis has a chronic inflammatory component to its pathogenesis similar to age-related macular degeneration. We evaluated the association between age-related macular degeneration and total hip replacement as proxy for severe osteoarthritis or fractured neck of femur in the Melbourne Collaborative Cohort Study. 20,744 participants had complete data on both age-related macular degeneration assessed from colour fundus photographs taken during 2003-2007 and total hip replacement. Total hip replacements due to hip osteoarthritis and fractured neck of femur during 2001-2011 were identified by linking the cohort records to the Australian Orthopedic Association National Joint Replacement Registry. Logistic regression was used to examine the association between age-related macular degeneration and risk of total hip replacement due to osteoarthritis and fracture separately, adjusted for confounders. There were 791 cases of total hip replacement for osteoarthritis and 102 cases of total hip replacement due to fractured neck of femur. After adjustment for age, sex, body mass index, smoking, and grouped country of birth, intermediate age-related macular degeneration was directly associated with total hip replacement for osteoarthritis (odds ratio 1.22, 95% CI 1.00-1.49). Late age-related macular degeneration was directly associated with total hip replacement due to fractured neck of femur (odds ratio 5.21, 95% CI2.25-12.02). The association between intermediate age-related macular degeneration and an increased 10-year incidence of total hip replacement due to osteoarthritis suggests the possibility of similar inflammatory processes underlying both chronic diseases. The association of late age-related macular degeneration with an increased 10-year incidence of total hip replacement due to fractured neck of femur may be due to an increased prevalence of fractures in those with poor central vision associated with the late complications of age-related macular degeneration.
C1 [Chong, Elaine W.; Robman, Liubov D.; Aung, Khin Zaw; Makeyeva, Galina A.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia CERA, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Chong, Elaine W.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wang, Yuanyuan; Robman, Liubov D.; Cicuttini, Flavia M.] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia.
   [Giles, Graham G.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
   [Graves, Stephen] Repatriat Gen Hosp, Dept Orthopaed, Adelaide, SA, Australia.
   [Graves, Stephen] Univ Adelaide, Australian Orthopaed Assoc Natl Joint Replacement, Discipline Publ Hlth, Sch Populat Hlth & Clin Practice, Adelaide, SA, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; Singapore
   National Eye Center; Florey Institute of Neuroscience & Mental Health;
   Monash University; University of Melbourne; Cancer Council Victoria;
   Flinders University South Australia; University of Adelaide
RP Chong, EW (通讯作者)，Univ Melbourne, Ctr Eye Res Australia CERA, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
EM elainechongwt@alumni.unimelb.edu.au
RI Graves, Stephen E/A-9463-2016; Wang, Yuanyuan/AAC-1109-2019; Cicuttini,
   Flavia/H-4978-2014
OI Graves, Stephen E/0000-0002-1629-319X; Wang,
   Yuanyuan/0000-0002-7629-4178; Giles, Graham/0000-0003-4946-9099;
   Cicuttini, Flavia/0000-0002-8200-1618; Guymer, Robyn/0000-0002-9441-4356
FU Victoria Health, The Cancer Council Victoria; National Health & Medical
   Research Council of Australia (NHMRC) [209057, 251533, 396414];
   Ophthalmic Research Institute of Australia; American Health Assistance
   Foundation [M2008-082]; NHMRC Centre for Clinical Research Excellence
   Grant [529923]; Commonwealth Department of Health
FX Victoria Health, The Cancer Council Victoria and National Health &
   Medical Research Council of Australia (NHMRC) [Program Grant 209057,
   Capacity Building Grant 251533 and Enabling Grant 396414] funded the
   MCCS study. Ophthalmic component was funded by the Ophthalmic Research
   Institute of Australia and American Health Assistance Foundation #
   M2008-082. CERA is a recipient of the NHMRC Centre for Clinical Research
   Excellence Grant [529923] and Operational Infrastructure Support from
   the Victorian Government. The AOA NJRR is funded by the Commonwealth
   Department of Health. People support was provided through the NHMRC
   public health medical scholarship (EC), Novartis Medical Retinal
   Fellowship (EC), NHMRC Career Development Fellowship (YW, # 1065464),
   Wagstaff Fellowship (LR), NHMRC Career Development (RG, # 300052) and
   Practitioner (RG, # 529905) Fellowships. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Bondeson J, 2010, ARTHRITIS RHEUM-US, V62, P647, DOI 10.1002/art.27290
   DEAN G, 1993, BRIT J RHEUMATOL, V32, P671
   Deloitte Access Economics, 2011, EYES FUT CLEAR OUTL
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1
   Graves SE, 2004, MED J AUSTRALIA, V180, pS31
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hong T, 2014, INVEST OPHTH VIS SCI, V55, P7589, DOI 10.1167/iovs.14-14262
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   MAROTTOLI RA, 1992, J AM GERIATR SOC, V40, P861, DOI 10.1111/j.1532-5415.1992.tb01980.x
   Masud T, 2001, AGE AGEING, V30, P3, DOI 10.1093/ageing/30.suppl_4.3
   Murphy LB, 2010, OSTEOARTHR CARTILAGE, V18, P1372, DOI 10.1016/j.joca.2010.08.005
   Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-105
   Rahman N, 2007, IMP DIS ASS ARTHR OS
   Registry AOANJR, 2013, ANN REPORT
   Salaffi F, 2005, AGING CLIN EXP RES, V17, P255
   Sanders KM, 1999, MED J AUSTRALIA, V170, P467, DOI 10.5694/j.1326-5377.1999.tb127845.x
   Scanzello CR, 2008, CURR OPIN RHEUMATOL, V20, P565, DOI 10.1097/BOR.0b013e32830aba34
   Skrzeczynska-Moncznik J, 2009, ACTA BIOCHIM POL, V56, P355
   Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419
   Stevens Judy A., 2000, Morbidity and Mortality Weekly Report, V49, P3
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Valdes AM, 2010, CURR OPIN RHEUMATOL, V22, P139, DOI 10.1097/BOR.0b013e3283367a6e
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
NR 35
TC 11
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2015
VL 10
IS 9
AR e0137322
DI 10.1371/journal.pone.0137322
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CQ9WL
UT WOS:000360965800043
PM 26355683
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kokame, GT
   Lai, JC
   Wee, R
   Yanagihara, R
   Shantha, JG
   Ayabe, J
   Hirai, K
AF Kokame, Gregg T.
   Lai, James C.
   Wee, Raymond
   Yanagihara, Ryan
   Shantha, Jessica G.
   Ayabe, Julia
   Hirai, Kelsi
TI Prospective clinical trial of Intravitreal aflibercept treatment for
   PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC
   study): 6 month results
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; Polypoidal choroidal vasculopathy;
   Aflibercept; Exudative macular degeneration; Retinal pigment epithelial
   detachment
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN;
   DIAGNOSIS
AB Background: Polypoidal choroidal vasculopathy is a variant of choroidal neovascularization and neovascular age related macular degeneration presenting with hemorrhagic and exudative changes within the macula and/or peripapillary region leading to vision loss. In contrast to neovascular age related macular degeneration, polypoidal choroidal vasculopathy has differing clinical manifestations and treatment strategies. Historically, polypoidal choroidal vasculopathy complexes are less responsive to anti-vascular endothelial growth factor therapy with no prospective clinical trials evaluating aflibercept in management of polypoidal choroidal vasculopathy. Herein we prospectively evaluate the efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy.
   Methods: A prospective, open-label, investigator-sponsored trial of intravitreal aflibercept for polypoidal choroidal vasculopathy in 21 eyes was conducted. Injections were administered monthly for 3 initial treatments, then every other month with monthly evaluations. The primary outcome measures were the mean change in best corrected visual acuity and adverse events. Secondary outcome measures included stabilization of vision, presence of subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment, and regression of polypoidal complexes on indocyanine green angiography.
   Results: At 6 months, the median visual acuity was 20/40 (range 20/25-20/200) with a mean Early Treatment Diabetic Retinopathy Study vision of 68.4 letters. There was a gain of 2.76 Early Treatment Diabetic Retinopathy Study letters at 6 months (p = 0.15). No patient developed severe vision loss (= 15 letters) and vision was stable or improved in 19/21 eyes (91 %). Subretinal fluid resolved in 13/18 eyes (72 %), and subretinal hemorrhage resolved in 6/8 eyes (75 %) respectively. The polyps regressed in 14/21 eyes (67 %) and the branching vascular network decreased in 1 eye and was stable in all other eyes. The retinal pigment epithelial detachment improved in 13/15 eyes (87 %). Bimonthly treatment occurred in 15/21 patients (71 %). There were no adverse events.
   Conclusions: Intravitreal aflibercept results in stabilization of vision, resolution of exudative and hemorrhagic complications with regression of polyps in polypoidal choroidal vasculopathy. Eyes with polypoidal choroidal vasculopathy previously treated with ranibizumab and bevacizumab can show marked improvement in the retinal pigment epithelial detachments and persistent polyps with aflibercept therapy.
C1 [Kokame, Gregg T.; Lai, James C.] Univ Hawaii, Dept Surg, Sch Med, Div Ophthalmol, 651 Ilalo St, Honolulu, HI 96813 USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond; Yanagihara, Ryan; Shantha, Jessica G.] Retina Ctr Pali Momi, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond; Yanagihara, Ryan; Shantha, Jessica G.] Retina Consultants Hawaii, 1380 Lusitana St 506, Honolulu, HI 96813 USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond; Yanagihara, Ryan; Shantha, Jessica G.] Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
   [Yanagihara, Ryan; Ayabe, Julia; Hirai, Kelsi] Univ Hawaii, Sch Med, John A Burns Sch Med, 651 Ilalo St, Honolulu, HI 96813 USA.
C3 University of Hawaii System; University of Hawaii System
RP Kokame, GT (通讯作者)，Univ Hawaii, Dept Surg, Sch Med, Div Ophthalmol, 651 Ilalo St, Honolulu, HI 96813 USA.; Kokame, GT (通讯作者)，Retina Ctr Pali Momi, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.; Kokame, GT (通讯作者)，Retina Consultants Hawaii, 1380 Lusitana St 506, Honolulu, HI 96813 USA.; Kokame, GT (通讯作者)，Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
OI Yanagihara, Ryan/0000-0001-6898-9335
FU Regeneron Pharmaceuticals (Tarrytown, New York); Regeneron
FX This work was supported as an investigator-sponsored trial by Regeneron
   Pharmaceuticals (Tarrytown, New York). Regeneron participated in study
   design and funding of this study.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, KOREAN J OPHTHALMOL, V26, P157
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hosokawa M, 2015, BR J OPHTHALMOL
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 23
Z9 24
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 27
PY 2016
VL 16
AR 127
DI 10.1186/s12886-016-0305-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS9KL
UT WOS:000381101500002
PM 27465105
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Marangoni, D
   Falsini, B
   Piccardi, M
   Ambrosio, L
   Minnella, AM
   Savastano, MC
   Bisti, S
   Maccarone, R
   Fadda, A
   Mello, E
   Concolino, P
   Capoluongo, E
AF Marangoni, Dario
   Falsini, Benedetto
   Piccardi, Marco
   Ambrosio, Lucia
   Minnella, Angelo Maria
   Savastano, Maria Cristina
   Bisti, Silvia
   Maccarone, Rita
   Fadda, Antonello
   Mello, Enrica
   Concolino, Paola
   Capoluongo, Ettore
TI Functional effect of Saffron supplementation and risk genotypes in early
   age-related macular degeneration: a preliminary report
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Saffron; Gene polymorphism;
   Electroretinography
ID COMPLEMENT FACTOR-H; ALTERNATIVE PATHWAY; FLICKER SENSITIVITY; OXIDATIVE
   STRESS; CELL-DEATH; MACULOPATHY; SUSCEPTIBILITY; CAROTENOIDS; CROCIN;
   SYSTEM
AB Background: To determine whether the functional effects of oral supplementation with Saffron, a natural compound that proved to be neuroprotective in early age-related macular degeneration, are influenced by complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) risk genotypes.
   Methods: Thirty-three early AMD patients, screened for CFH (rs1061170) and ARMS2 (rs10490924) polymorphisms and receiving Saffron oral supplementation (20 mg/day) over an average period of treatment of 11 months (range, 6-12), were longitudinally evaluated by clinical examination and focal electroretinogram (fERG)-derived macular (18 degrees) flicker sensitivity estimate. fERG amplitude and macular sensitivity, the reciprocal value of the estimated fERG amplitude threshold, were the main outcome measures.
   Results: After three months of supplementation, mean fERG amplitude and fERG sensitivity improved significantly when compared to baseline values (p < 0.01). These changes were stable throughout the follow-up period. No significant differences in clinical and fERG improvements were observed across different CFH or ARMS2 genotypes.
   Conclusions: The present results indicate that the functional effect of Saffron supplementation in individual AMD patients is not related to the major risk genotypes of disease.
C1 [Marangoni, Dario; Falsini, Benedetto; Piccardi, Marco; Minnella, Angelo Maria; Savastano, Maria Cristina] Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, I-00168 Rome, Italy.
   [Ambrosio, Lucia] Univ Naples Federico II, Dipartimento Sci Oftalmol, I-580131 Naples, Italy.
   [Marangoni, Dario; Bisti, Silvia; Maccarone, Rita] Univ Aquila, DISCAB, Dipartimento Sci Clin & Applicate Biotecnol, I-67100 Laquila, Italy.
   [Fadda, Antonello] Ist Super Sanita, Lab Ingn Biomed, I-00161 Rome, Italy.
   [Mello, Enrica; Concolino, Paola; Capoluongo, Ettore] Univ Cattolica Sacro Cuore, Ist Biochim Clin, I-00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Naples Federico II; University of L'Aquila; Istituto
   Superiore di Sanita (ISS); Catholic University of the Sacred Heart;
   IRCCS Policlinico Gemelli
RP Marangoni, D (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, Lgo F Vito 1, I-00168 Rome, Italy.
EM dariomarangoni80@yahoo.it
RI Ambrosio, Lucia/F-2345-2018; minnella, angelo maria/AAQ-6250-2020;
   Falsini, Benedetto/V-1070-2019; Piccardi, Marco/AAA-7849-2019; Falsini,
   Benedetto/AAC-5907-2022; Savastano, Maria Cristina/I-5355-2015;
   concolino, paola/AAB-7427-2022; Fadda, Antonello/J-1560-2012; concolino,
   paola/K-5264-2016
OI Ambrosio, Lucia/0000-0001-5488-8429; minnella, angelo
   maria/0000-0001-5896-5313; Falsini, Benedetto/0000-0002-1694-1062;
   Savastano, Maria Cristina/0000-0003-1397-4333; Fadda,
   Antonello/0000-0001-7004-5245; MACCARONE, Rita/0000-0003-0648-3771;
   Falsini, Benedetto/0000-0002-3569-4968; CAPOLUONGO, Ettore
   Domenico/0000-0003-4402-8403; Concolino, Paola/0000-0002-3472-8898;
   concolino, paola/0000-0002-0523-5744; PICCARDI,
   Marco/0000-0002-9836-7534
FU MIUR-PRIN
FX The publication was supported by a MIUR-PRIN (2010-2011) research grant
   to SB.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Capoluongo E, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.03.008
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hosseinzadeh H., 2002, BMC PHARMACOL, V15, P2
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   Mello E, 2012, CLIN CHEM LAB MED, V50, P1031, DOI 10.1515/cclm-2011-0859
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Natoli R, 2010, MOL VIS, V16, P1801
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   OHIA SE, 1994, RES COMMUN MOL PATH, V85, P21
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 56
TC 35
Z9 36
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD SEP 25
PY 2013
VL 11
AR 228
DI 10.1186/1479-5876-11-228
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 228YL
UT WOS:000325228000003
PM 24067115
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Knudtson, MD
   Wong, TY
   Cotch, MF
   Liu, K
   Burke, G
   Saad, MF
   Jacobs, DR
AF Klein, R
   Klein, BEK
   Knudtson, MD
   Wong, TY
   Cotch, MF
   Liu, K
   Burke, G
   Saad, MF
   Jacobs, DR
TI Prevalence of age-related macular degeneration in 4 racial/ethnic groups
   in the multi-ethnic study of atherosclerosis
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; NUTRITION EXAMINATION SURVEY; BEAVER
   DAM EYE; GEOGRAPHIC REGION; NATIONAL-HEALTH; UNITED-STATES; MACULOPATHY;
   POPULATION; WISCONSIN; ETHNICITY
AB Objective: To describe the prevalence of age-related macular degeneration (AMD) in 4 racial/ethnic groups (white, black, Hispanic, and Chinese) that participated in the second examination of the Multi-ethnic Study of Atherosclerosis (MESA).
   Design: Prospective cohort study.
   Participants: Six thousand one hundred seventy-six 45- to 85-year-old subjects selected from 6 United States communities.
   Methods: Fundus images were taken using a 450 digital camera through dark-adapted pupils and were graded for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measure: Age-related macular degeneration.
   Results: Prevalences of AMD were 2.4% (black), 4.2% (Hispanic), 4.6% (Chinese), to 5.4% (white) (P < 0.001 for any differences among groups). The highest prevalence of any AMD occurred in those 75 to 84 years old, varying from 7.4% in blacks to 15.8% in whites and Chinese (P = 0.03). Estimated prevalences of late AMD were 0.3% (black), 0.2% (Hispanic), 0.6% (white), and 1.0% (Chinese). These differences were marginally significant (age and gender adjusted, P = 0.08). The frequency of exudative AMD was highest in Chinese (age- and gender-adjusted odds ratio, 4.30; 95% confidence interval, 1.30-14.27) compared with whites. Differences in age, gender, pupil size, body mass index, smoking, alcohol drinking history, diabetes, and hypertension status did not explain the variability among the 4 racial/ethnic groups.
   Conclusions: Low prevalences of AMD were found in the MESA cohort in all groups. A lower prevalence of AMD was found in blacks compared with whites. The higher prevalence of exudative AMD in Chinese needs further study.
C1 UW Madison, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Melbourne, Ctr Eye Res, Melbourne, Vic, Australia.
   NEI, NIH, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   Wake Forest Univ, Dept Publ Hlth Sci, Wake Forest, NC USA.
   Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
   Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Melbourne; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Northwestern University; Wake Forest
   University; University of California System; University of California
   Los Angeles; Northwestern University
RP Klein, R (通讯作者)，UW Madison, Dept Ophthalmol & Visual Sci, 4th Floor WARF,610 N Walnut St, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Jacobs, David/0000-0002-7232-0543;
   Cotch, Mary Frances/0000-0002-2046-4350
FU NATIONAL EYE INSTITUTE [Z01EY000403] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069979] Funding Source:
   NIH RePORTER; Intramural NIH HHS [ZIA EY000403-15, ZIA EY000403-11, ZIA
   EY000403-13, Z01 EY000403-06, Z99 EY999999, ZIA EY000403-14, ZIA
   EY000403-08, ZIA EY000403-12, ZIA EY000403-09, Z01 EY000403-07, ZIA
   EY000403-10] Funding Source: Medline; NHLBI NIH HHS [HL69979-03, R01
   HL069979] Funding Source: Medline
CR AHTZ H, 1975, INT OPHTHALMOL CLIN, V15, P169
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   BRESSLER SB, IN PRESS OPHTHALMOLO
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P179
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P175
   Wu Z Q, 1992, Zhonghua Yan Ke Za Zhi, V28, P246
NR 27
TC 278
Z9 282
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2006
VL 113
IS 3
BP 373
EP 380
DI 10.1016/j.ophtha.2005.12.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017LD
UT WOS:000235694200003
PM 16513455
DA 2022-11-30
ER

PT J
AU Maller, JB
   Fagerness, JA
   Reynolds, RC
   Neale, BM
   Daly, MJ
   Seddon, JM
AF Maller, Julian B.
   Fagerness, Jesen A.
   Reynolds, Robyn C.
   Neale, Benjamin M.
   Daly, Mark J.
   Seddon, Johanna M.
TI Variation in complement factor 3 is associated with risk of age-related
   macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; VARIANT; CFH; GENES; Y402H
AB The association of variants in complement factors H and B with age-related macular degeneration has led to more intense genetic and functional analysis of the complement pathway. We identify a nonsynonymous coding change in complement factor 3 that is strongly associated with risk of age-related macular degeneration in a large case-control sample.
C1 Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   MIT, Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   Tufts Univ New England Med Ctr, New England Eye Ctr, Ophthal Epidemiol & Genet Serv, Boston, MA 02111 USA.
   Kings Coll London, Inst Psychiat, Social Genet & Dev Psychiat Ctr, London SE5 8AP, England.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Tufts
   Medical Center; University of London; King's College London; Harvard
   University; Harvard Medical School
RP Seddon, JM (通讯作者)，Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM mjdaly@chgr.mgh.harvard.edu; jseddon@tufts-nemc.org
RI Daly, Mark J/B-2453-2017; maller, julian B/A-9323-2009
OI Daly, Mark J/0000-0002-0949-8752; Maller, Julian/0000-0002-1565-9559
FU NCRR NIH HHS [U54 RR020278] Funding Source: Medline; NEI NIH HHS [R01
   EY011309, N01-EY-0-2127, EY11309] Funding Source: Medline; NATIONAL
   CENTER FOR RESEARCH RESOURCES [U54RR020278] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [N01EY002127, R01EY011309] Funding
   Source: NIH RePORTER
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   WYATT RJ, 1987, RECENT DEV MUCOSAL I
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 14
TC 335
Z9 364
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2007
VL 39
IS 10
BP 1200
EP 1201
DI 10.1038/ng2131
PG 2
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 214KW
UT WOS:000249737400014
PM 17767156
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Iacono, P
   Papayannis, A
   Alto, G
   Buzzotta, A
   Arrigo, A
   Cicinelli, MV
   Bandello, F
AF Parodi, Maurizio Battaglia
   Iacono, Pierluigi
   Papayannis, Alexandros
   Alto, Giorgio
   Buzzotta, Alessio
   Arrigo, Alessandro
   Cicinelli, Maria Vittoria
   Bandello, Francesco
TI Near-infrared fundus autofluorescence in early age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Near-infrared autofluorescence; age-related macular degeneration; drusen
ID CLASSIFICATION; PATTERNS
AB Purpose: To describe the patterns on near-infrared fundus autofluorescence in eyes affected by early age-related macular degeneration. Design: Cross-sectional observational case series. Participants: A total of 84 eyes of 84 patients suffering from early age-related macular degeneration (>63 mu m but <125 mu m drusen and no-to-mild retinal pigment epithelium abnormalities) were enrolled. Methods: Patients underwent best-corrected visual acuity, biomicroscopy, infrared reflectance, short-wavelength fundus autofluorescence, and near-infrared fundus autofluorescence. Eyes were classified according to different patterns of near-infrared fundus autofluorescence. Main outcome was definition of relative prevalence and features of each near-infrared fundus autofluorescence pattern; secondary outcomes were correlation between near-infrared fundus autofluorescence and short-wavelength fundus autofluorescence and between near-infrared fundus autofluorescence patterns and best-corrected visual acuity. Results: Four different patterns of near-infrared fundus autofluorescence identified: normal foveal signal (Pattern A, 7%); normal foveal signal with hyperautofluorescent/hypoautofluorescent spots not involving the fovea (Pattern B, 65.5%); hyperautofluorescent/hypoautofluorescent spots involving the fovea (Pattern C, 15.5%); patchy pattern (Pattern D, 12%). best-corrected visual acuity was lower in eyes with foveal signal alteration (Patterns C and D). Conclusion: Near-infrared fundus autofluorescence pattern in early age-related macular degeneration might be suggestive of visual function deterioration when the fovea is involved. Longitudinal studies are warranted to confirm our preliminary results.
C1 [Parodi, Maurizio Battaglia; Alto, Giorgio; Buzzotta, Alessio; Arrigo, Alessandro; Cicinelli, Maria Vittoria; Bandello, Francesco] San Raffaele Vita Salute Univ, Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
   [Iacono, Pierluigi] IRCCS Fdn Bietti, Rome, Italy.
   [Papayannis, Alexandros] Osped Conegliano, Dept Ophthalmol, Conegliano, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS
   - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia;
   ULSS 2 Marca TV; Ospedale Conegliano
RP Parodi, MB (通讯作者)，San Raffaele Vita Salute Univ, Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM maubp@yahoo.it
RI Iacono, Pierluigi/AAD-3158-2020; PAPAYANNIS, Alex D/A-7951-2010;
   bandello, francesco/AAH-2405-2019; cicinelli, maria
   vittoria/M-1611-2019; Papayannis, Alex/ABC-7701-2020
OI bandello, francesco/0000-0003-3238-9682; cicinelli, maria
   vittoria/0000-0003-2938-0409; Papayannis, Alex/0000-0002-5189-9381;
   Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bressler Neil M, 2005, Retina, V25, P130, DOI 10.1097/00006982-200507001-00016
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Parodi MB, 2009, BRIT J OPHTHALMOL, V93, P771, DOI 10.1136/bjo.2008.139576
   Parodi MB, 2008, RETINA-J RET VIT DIS, V28, P801, DOI 10.1097/IAE.0b013e31816f859d
   Parodi MB, 2017, GRAEF ARCH CLIN EXP, V255, P271, DOI 10.1007/s00417-016-3450-7
   Parodi MB, 2015, BRIT J OPHTHALMOL, V99, P1354, DOI 10.1136/bjophthalmol-2014-306237
   Parodi MB, 2014, AM J OPHTHALMOL, V158, P1247, DOI 10.1016/j.ajo.2014.08.028
   Parodi MB, 2014, AM J OPHTHALMOL, V158, P1086, DOI 10.1016/j.ajo.2014.07.026
   Peters S, 2006, Z NATURFORSCH C, V61, P427
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P202, DOI 10.3109/08820538.2012.708806
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 27
TC 3
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1448
EP 1453
AR 1120672119885047
DI 10.1177/1120672119885047
EA OCT 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000493433900001
PM 31661979
DA 2022-11-30
ER

PT J
AU Shah, AR
   Del Priore, LV
AF Shah, Ankoor R.
   Del Priore, Lucian V.
TI Subfoveal exudative age-related macular degeneration: evidence for
   preoccult disease
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; clinical trials; macular degeneration;
   meta-analysis; subfoveal neovascularization
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VERTEPORFIN PHOTODYNAMIC
   THERAPY; NATURAL-HISTORY; CLINICOPATHOLOGICAL CORRELATION; PERIPHERAL
   RETINECTOMY; BEVACIZUMAB AVASTIN; ANECORTAVE ACETATE; SUBGROUP ANALYSIS;
   RANIBIZUMAB; TRANSLOCATION
AB Purpose of review A careful analysis of randomized clinical trials on exudative age-related macular degeneration reveals apparent differences in behavior of untreated control eyes among these trials. A priori there are two possible explanations: each study contains a unique subpopulation of patients; or apparent differences arise from differences in time of entry of these eyes into clinical trials.
   Recent findings To correctly account for differences in time of entry into clinical trials, we introduced a horizontal translation factor, expressed in months, to shift each data subset horizontally to maximize r(2) for the cumulative trend line; this increases the overall r(2) to 0.95, demonstrating that most of the variation in visual acuity over time is explained by the initial visual acuity. This analysis also suggests that occult disease is an earlier stage than minimally classic and predominantly classic disease and that there is a subclinical stage of subfoveal exudation ('preoccult') for patients with age-related macular degeneration.
   Summary The pattern of vision loss experienced in age-related macular degeneration eyes with subfoveal choroidal neovascularization is uniform across a wide range of clinical trials, with apparent differences in initial and final visual acuity in untreated eyes arising from differences in the time of entry into clinical trials. Our data suggest that visual loss may occur during a preoccult phase of choroidal neovascularization, prior to the development of occult disease.
C1 [Shah, Ankoor R.; Del Priore, Lucian V.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University
RP Del Priore, LV (通讯作者)，635 W 165th St, New York, NY 10032 USA.
EM ldelpriore@yahoo.com
FU Eye Surgery Fund; Robert L. Burch III Fund; Foundation Fighting
   Blindness; Hickey Foundation; Macula Foundation; Doris Duke Foundation;
   Research to Prevent Blindness
FX The present study is supported by the Eye Surgery Fund, the Robert L.
   Burch III Fund, the Foundation Fighting Blindness, the Hickey
   Foundation, the Macula Foundation, the Doris Duke Foundation, and
   unrestricted funds from Research to Prevent Blindness.
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2008, CURR OPIN OPHTHALMOL, V19, P202, DOI 10.1097/ICU.0b013e3282fc9c35
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, RETINA-J RET VIT DIS, V22, P818, DOI 10.1097/00006982-200212000-00027
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 42
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 182
EP 187
DI 10.1097/ICU.0b013e328329b669
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200006
PM 19367162
DA 2022-11-30
ER

PT J
AU Pecen, PE
   Kaiser, PK
AF Pecen, Paula E.
   Kaiser, Peter K.
TI Current phase 1/2 research for neovascular age-related macular
   degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE antiangiogenesis; neovascular age-related macular degeneration; phase
   1/2 clinical trial
AB Purpose of review
   The purpose of this review is to provide an update of phase 1 and 2 clinical trials in neovascular age-related macular degeneration that are either currently underway or recently completed by the end of 2014.
   Recent findings
   Three gene therapy options are currently in early clinical trials, administered via intravitreal (AAV2-sFLT01) or subretinal (AVA-101 and RetinoStat) injection to express angiogenesis inhibitors. Several eye drops are being developed for topical administration for various angiogenic inhibitors, including regorafenib, squalamine lactate, and PAN-90806. Early development of systemic administration options may be intravenous (iSONEP) or oral (X-82). Initial study of local radiation therapy may be via proton beam irradiation or stereotactic radiotherapy. Several intravitreal injections are being studied including human immuno-conjugate molecule (hl-con1), abicipar pegol, PF582, DE-120, ESBA 1008, and REGN2176-3.
   Summary
   Numerous treatment options of neovascular age-related macular degeneration are in phase 1/2 clinical trials including gene therapy, eye drops, systemic dosing, localized irradiation, and various intravitreal injections. Future phase 3 trial results will be observed closely to determine which of these therapies will be the next novel treatment of neovascular age-related macular degeneration.
C1 [Pecen, Paula E.; Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk i3, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Brown DM, 2014, ANG EX DEG 2014 FEBR
   Clarke JM, 2014, CANCER TREAT REV, V40, P1065, DOI 10.1016/j.ctrv.2014.07.001
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dugel PU, 2014, AM SOC RET SPEC ANN
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Heier JS, 2014, AM SOC RET SPEC 2014
   Heier JS, 2014, RET SOC 2014 ANN M S
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Levinson DR, 2012, OEI031000360 DEP HLT
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
NR 17
TC 32
Z9 34
U1 0
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2015
VL 26
IS 3
BP 188
EP 193
DI 10.1097/ICU.0000000000000147
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF1RV
UT WOS:000352326200008
PM 25822255
DA 2022-11-30
ER

PT J
AU Shultz, RW
   Bakri, SJ
AF Shultz, Ryan W.
   Bakri, Sophie J.
TI Treatment for Submacular Hemorrhage Associated with Neovascular
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE subretinal; tPA; pneumatic; vitrectomy; anticoagulation;
   neovascularization
ID TISSUE-PLASMINOGEN-ACTIVATOR; MASSIVE INTRAOCULAR HEMORRHAGE; PARS-PLANA
   VITRECTOMY; SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT; INTRAVITREAL
   BEVACIZUMAB; PHOTODYNAMIC THERAPY; ASSISTED REMOVAL; SURGICAL REMOVAL;
   NATURAL-HISTORY
AB Submacular hemorrhage associated with neovascular age-related macular degeneration is a complication known to have potentially devastating effects on visual acuity. Multiple treatment modalities have been suggested including intravitreal anti-vascular endothelial growth factor injections, photodynamic therapy, pneumatic displacement with or without adjuvant intravitreal tissue plasminogen activator, and pars plana vitrectomy with or without adjuvant subretinal tissue plasminogen activator. However, there remains no consensus on optimal treatment, as clinical trials for neovascular age-related macular degeneration have excluded patients with submacular hemorrhage. This manuscript offers guidelines to the management of subretinal hemorrhage based on its size and characteristics, and highlights the need for clinical trials in this area.
C1 [Shultz, Ryan W.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
FU Research to Prevent Blindness, Inc., New York, New York
FX Supported by Research to Prevent Blindness, Inc., New York, New York.
   The authors have no financial interest in any product mentioned in the
   study.
CR Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   HERIOT WJ, AAO 1996 OR VAIL VIT
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   KWAN S, 2006, INVEST OPHTH VIS SCI, V47, P2662
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Pulido JS, 2007, RETINA-J RET VIT DIS, V27, P1071, DOI 10.1097/IAE.0b013e31804ac032
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
NR 63
TC 21
Z9 22
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD NOV
PY 2011
VL 26
IS 6
BP 361
EP 371
DI 10.3109/08820538.2011.585368
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 839UC
UT WOS:000296393900002
PM 22044334
DA 2022-11-30
ER

PT J
AU Arnett, JJ
   Brodowska, K
   Gallagher, DS
   Eller, AW
   Friberg, TR
   Anetakis, AJ
   Martel, JN
AF Arnett, Justin J.
   Brodowska, Katarzyna
   Gallagher, Denise S.
   Eller, Andrew W.
   Friberg, Thomas R.
   Anetakis, Alexander J.
   Martel, Joseph N.
TI RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER
   RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; choroidal neovascularization; endophthalmitis; exudative AMD;
   intravitreal injection
ID INTRAVITREAL INJECTION
AB Purpose: To evaluate alterations in treatment burden and course of exudative age-related macular degeneration in patients who contracted endophthalmitis from intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: Retrospective study at the University of Pittsburgh Medical Center examining frequency of anti-VEGF injections, activity of choroidal neovascularization, and visual acuity before and after endophthalmitis treatment. Results: Twenty-one patients meeting inclusion criteria were identified, of whom 7 (33%) patients did not restart anti-VEGF treatment 12 months after endophthalmitis because of quiescence of exudative age-related macular degeneration without significant visual acuity loss (P> 0.05). Patients who resumed anti-VEGF treatment exhibited 32% and 38% decreases in injection frequency by 12 and 24 months after endophthalmitis, respectively (P< 0.05). On first optical coherence tomography follow-up, 10 patients exhibited quiescence of choroidal neovascularization activity, although there were no measurable changes in macular thickness (P> 0.05). No differences in post-endophthalmitis exudative age-related macular degeneration progression or treatment burden were observed when factoring adjuvant intravitreal steroid therapy, culture results, nor choroidal neovascularization subtypes. Conclusion: Endophthalmitis resolution is associated with a decrease in choroidal neovascularization activity and a reduction of anti-VEGF treatment burden in patients with exudative age-related macular degeneration.
C1 [Arnett, Justin J.; Brodowska, Katarzyna; Gallagher, Denise S.; Eller, Andrew W.; Friberg, Thomas R.; Anetakis, Alexander J.; Martel, Joseph N.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
   [Brodowska, Katarzyna; Gallagher, Denise S.; Eller, Andrew W.; Friberg, Thomas R.; Anetakis, Alexander J.; Martel, Joseph N.] Univ Pittsburgh, Dept Ophthalmol, Retina & Vitreous Serv, Med Ctr, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Martel, JN (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst, Sch Med, 203 Lothrop St,Suite 828, Pittsburgh, PA 15213 USA.
EM marteljn@upmc.edu
FU Eye and Ear Institute of Pittsburgh; Research to Prevent Blindness
FX This study was performed at the UPMC Eye Center, Pittsburgh, PA, 15213,
   with support from the Eye and Ear Institute of Pittsburgh and the
   Research to Prevent Blindness. The funders had no role in the design and
   conduct of the study, in the collection, analysis, and interpretation of
   the data, or in the preparation, review, or approval of the manuscript.
   J. N. Martel has had full access to all the data in the study and takes
   responsibility for the integrity of the data and the accuracy of the
   data analysis.
CR Arroyo AG, 2010, CARDIOVASC RES, V86, P226, DOI 10.1093/cvr/cvq049
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Kally Peter M, 2017, Retin Cases Brief Rep, V11, P316, DOI 10.1097/ICB.0000000000000352
   Kim SJ, 2015, OSLI RETINA, V46, P996, DOI 10.3928/23258160-20151027-02
   Kokame GT, 2019, RETIN CASES BRIEF RE
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Peng XN, 2018, EXP EYE RES, V176, P88, DOI 10.1016/j.exer.2018.06.030
   Sachdeva MM, 2016, J OPHTHALMIC INFLAMM, V6, DOI 10.1186/s12348-015-0069-5
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
NR 11
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1719
EP 1723
DI 10.1097/IAE.0000000000002666
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800010
PM 31800459
DA 2022-11-30
ER

PT J
AU Wong, CW
   Yanagi, Y
   Lee, WK
   Ogura, Y
   Yeo, I
   Wong, TY
   Cheung, CMG
AF Wong, Chee Wai
   Yanagi, Yasuo
   Lee, Won-Ki
   Ogura, Yuichiro
   Yeo, Ian
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Age-related macular degeneration and polypoidal choroidal vasculopathy
   in Asians
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Asian age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Choroidal neovascularization; Photodynamic therapy; Laser
   photocoagulation; Anti-vascular endothelial growth factor
ID TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN
   PHOTODYNAMIC THERAPY; CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL
   COHERENCE TOMOGRAPHY; C-REACTIVE PROTEIN; INTRAVITREAL RANIBIZUMAB
   INJECTIONS; SUBMACULAR HEMORRHAGE SECONDARY; COMPLEMENT-FACTOR-H;
   INDOCYANINE GREEN ANGIOGRAPHY
AB Age-relatedmacular degeneration (AMD) is the leading cause of irreversible blindness in elderly people globally. It is estimated that there will be more Asians with AMD than the rest of the world combined by 2050. In Asian populations, polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative AMD, while choroidal neovascularization secondary to AMD (CNV-AMD) is the typical subtype in Western populations. The two subtypes share many common clinical features and risk factors, but also have different epidemiological and clinical characteristics, natural history and treatment outcomes that point to distinct pathophysiological processes. Recent research in the fields of genetics, proteomics and imaging has provided further clarification of differences between PCV and CNV-AMD. Importantly, these differences have manifested as disparity in response to intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) treatment between PCV and CNV-AMD, emphasizing the need for accurate diagnosis of PCV and in distinguishing PCV from CNV-AMD, particularly in Asian patients. Current clinical trials of intravitreal anti-VEGF therapy and photodynamic therapy will provide clearer perspectives of evidence-based management of PCV and may lead to paradigm shifts in therapeutic strategies away from those currently employed in the treatment of CNV-AMD. Further research is needed to clarify the relative contribution of specific pathways in inflammation, complement activation, extracellular matrix dysregulation, lipid metabolism and angiogenesis to the pathogenesis of PCV. Findings from this research, together with improved diagnostic technology and new therapeutics, will facilitate more optimal management of Asian AMD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Wong, Chee Wai; Yanagi, Yasuo; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 16851, Singapore.
   [Wong, Chee Wai; Yanagi, Yasuo; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Chee Wai; Yanagi, Yasuo; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore 117548, Singapore.
   [Lee, Won-Ki] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Seoul, South Korea.
   [Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   Catholic University of Korea; Seoul St. Mary's Hospital; Nagoya City
   University
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 16851, Singapore.
EM wong.tien.yin@snec.com.sg
RI Yanagi, Yasuo/AAA-5441-2022; Wong, Tien Yin/AAC-9724-2020; Yanagi,
   Yasuo/AAF-2670-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Yanagi, Yasuo/0000-0002-0362-7285
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 2014, VISUAL OUTCOME PATIE
   [Anonymous], 1996, PREAM AC OPHTH M CHI
   [Anonymous], ARCH OPHTHALMOL, V117, P1329
   [Anonymous], 2014, AFLIBERCEPT POLYPOID
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2008, RETINA-J RET VIT DIS, V28, P81, DOI 10.1097/IAE.0b013e31815e9351
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen HY, 2012, MOL VIS, V18, P816
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   CIALDINI AP, 1989, OPHTHALMIC SURG LAS, V20, P93
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Furuta M, 2013, RETINA-J RET VIT DIS, V33, P71, DOI 10.1097/IAE.0b013e318263ceb4
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M., 2015, RETINA PHILADELPHIA
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Introini U, 2015, OPHTHALMOLOGICA, V233, P82, DOI 10.1159/000368561
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim H., 2015, GRAEFES ARC CLIN EXP
   Kim H, 2015, OPHTHALMOLOGICA, V233, P146, DOI 10.1159/000380830
   Kim Hyun Woong, 2011, Korean J Ophthalmol, V25, P231, DOI 10.3341/kjo.2011.25.4.231
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kubisz P, 2010, ACTA DIABETOL, V47, P119, DOI 10.1007/s00592-009-0127-2
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Kuroda Y, 2014, INVEST OPHTH VIS SCI, V55, P6046, DOI 10.1167/iovs.14-14723
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee FL, 2012, ACTA OPHTHALMOL, V90, pe406, DOI 10.1111/j.1755-3768.2011.02262.x
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Lee JH, 2014, AM J OPHTHALMOL, V157, P710, DOI 10.1016/j.ajo.2013.12.011
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim F.P., 2015, BR J OPHTHALMOL
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lim L.S., 2013, ASIA PAC J OPHTHALMO, V2
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Luk FOJ, 2015, EYE, V29, P454, DOI 10.1038/eye.2015.31
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Mahdy RA, 2010, EYE, V24, P1576, DOI 10.1038/eye.2010.86
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Meng QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143924
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Ohno-Matsui K., 2016, PROG RETIN EYE RES
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2015, CLIN EXP OPTOM, V98, P478, DOI 10.1111/cxo.12265
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, OSLI RETINA, V45, P585, DOI 10.3928/23258160-20141008-04
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Pawlak K, 2008, CYTOKINE, V43, P98, DOI 10.1016/j.cyto.2008.03.011
   Pawlak K, 2007, CLIN BIOCHEM, V40, P81, DOI 10.1016/j.clinbiochem.2006.09.001
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rock KL, 2011, IMMUNOL REV, V243, P191, DOI 10.1111/j.1600-065X.2011.01040.x
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sadiq MA, 2016, DEV OPHTHALMOL, V55, P310, DOI 10.1159/000438953
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sawa M, 2012, JPN J OPHTHALMOL, V56, P470, DOI 10.1007/s10384-012-0154-3
   Say EAT, 2013, OPHTHAL SURG LAS IM, V44, P409, DOI 10.3928/23258160-20130715-12
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Semoun O., 2015, BR J OPHTHALMOL
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   Sun HP, 2014, INT J OPHTHALMOL-CHI, V7, P872, DOI 10.3980/j.issn.2222-3959.2014.05.25
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Suzuki M, 2014, RETINA-J RET VIT DIS, V34, P1216, DOI 10.1097/IAE.0000000000000045
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tano Y, 2008, JPN J OPHTHALMOL, V52, P99, DOI 10.1007/s10384-008-0512-3
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tateno Y., 2015, OPHTHALMIC GENET, P1
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchihashi T, 2014, CLIN OPHTHALMOL, V8, P2471, DOI 10.2147/OPTH.S71305
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Zeeburg EJT, 2013, GRAEF ARCH CLIN EXP, V251, P733, DOI 10.1007/s00417-012-2116-3
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wilgus TA, 2008, LAB INVEST, V88, P579, DOI 10.1038/labinvest.2008.36
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong T.Y., 2015, OPTHALMOLOG IN PRESS
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yoneyama S., 2016, RETINA
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Yoshikawa T, 2011, JPN J OPHTHALMOL, V55, P235, DOI 10.1007/s10384-011-0010-x
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zeng RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075711
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 324
TC 213
Z9 227
U1 3
U2 50
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2016
VL 53
BP 107
EP 139
DI 10.1016/j.preteyeres.2016.04.002
PG 33
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DQ3JS
UT WOS:000379099200005
PM 27094371
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Qualls, LG
   Hammill, BG
   Wang, F
   Lad, EM
   Schulman, KA
   Cousins, SW
   Curtis, LH
AF Qualls, Laura G.
   Hammill, Bradley G.
   Wang, Fang
   Lad, Eleonora M.
   Schulman, Kevin A.
   Cousins, Scott W.
   Curtis, Lesley H.
TI COSTS OF NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
   AMONG MEDICARE BENEFICIARIES, 2004-2008
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aged; aged 80 and over; angiogenesis inhibitors; factual databases;
   health care costs; health insurance reimbursement; macular degeneration;
   Medicare; photochemotherapy; retrospective studies; United States
ID VITREORETINAL INTERVENTIONS; UNITED-STATES; ICD-9-CM; BURDEN
AB Purpose: To examine associations between newly diagnosed neovascular age-related macular degeneration and direct medical costs.
   Methods: This retrospective observational study matched 23,133 Medicare beneficiaries diagnosed with neovascular age-related macular degeneration between 2004 and 2008 with a control group of 92,532 beneficiaries on the basis of age, sex, and race. The index date for each case-control set corresponded to the first diagnosis for the case. Main outcome measures were total costs per patient and age-related macular degeneration-related costs per case 1 year before and after the index date.
   Results: Mean cost per case in the year after diagnosis was $12,422, $4,884 higher than the year before diagnosis. Postindex costs were 41% higher for cases than controls after adjustment for preindex costs and comorbid conditions. Age-related macular degeneration-related costs represented 27% of total costs among cases in the postindex period and were 50% higher for patients diagnosed in 2008 than in 2004. This increase was attributable primarily to the introduction of intravitreous injections of vascular endothelial growth factor antagonists. Intravitreous injections averaged $203 for patients diagnosed in 2004 and $2,749 for patients diagnosed in 2008.
   Conclusion: Newly diagnosed neovascular age-related macular degeneration was associated with a substantial increase in total medical costs. Costs increased over time, reflecting growing use of anti-vascular endothelial growth factor therapies. RETINA 33:854-861, 2013
C1 [Qualls, Laura G.; Hammill, Bradley G.; Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
   [Wang, Fang] GlaxoSmithKline Inc, Global Hlth Outcomes, Philadelphia, PA USA.
   [Lad, Eleonora M.; Cousins, Scott W.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA.
   [Schulman, Kevin A.; Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
C3 Duke University; GlaxoSmithKline; Duke University; Duke University
RP Curtis, LH (通讯作者)，Duke Clin Res Inst, Durham, NC 27715 USA.
EM lesley.curtis@duke.edu
FU GlaxoSmithKline; Duke University; Alnylam Pharmaceuticals; Amylin
   Pharmaceuticals; Arthritis Foundation; Inspire Pharmaceuticals;
   Medtronic; Merck Co; NovaCardia; Novartis; Scios; Allergan; Johnson
   Johnson; OSI Eyetech
FX Supported by a research agreement between GlaxoSmithKline and Duke
   University. The sponsor had no role in the design or conduct of the
   study.; Dr. F. Wang is an employee of GlaxoSmithKline. Dr. K. A.
   Schulman reported receiving research support from Alnylam
   Pharmaceuticals, Amylin Pharmaceuticals, Arthritis Foundation, Inspire
   Pharmaceuticals, Medtronic, Merck & Co, NovaCardia, Novartis, and Scios;
   receiving personal income for consulting (<$10,000 per year) from Blue
   Cross and Blue Shield of North Carolina, The Commonwealth Fund, Forest
   Laboratories, Merck, and Orexigen Therapeutics; having equity in Alnylam
   Pharmaceuticals, General Electric, The Manufacturers Life Insurance
   Company, PepsiCo, and Procter & Gamble; having equity in and serving on
   the board of directors of Cancer Consultants, Inc; having equity in and
   serving on the executive board of Faculty Connection, LLC; having equity
   in and serving as a managing member of the Physician Education
   Leadership Institute; and having equity in and serving as a managing
   member of Tellus, LLC. Dr. L. H. Curtis reported receiving research
   support from Allergan, GlaxoSmithKline, Johnson & Johnson, Merck & Co,
   and OSI Eyetech. Drs. L. H. Curtis and K. A. Schulman have made
   available online detailed listings of financial disclosures
   (http://www.dcri.duke.edu/about-us/conflict-of-interest/).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown MM, 2008, CURR OPIN OPHTHALMOL, V19, P202, DOI 10.1097/ICU.0b013e3282fc9c35
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Foster WJ, 2010, BRIT J OPHTHALMOL, V94, P1118, DOI 10.1136/bjo.2009.170282
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Ke KM, 2006, DRUG AGING, V23, P217, DOI 10.2165/00002512-200623030-00004
   Kymes SN, 2009, MINERVA MED, V100, P69
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Shea AM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1748, DOI 10.1001/archopht.126.12.1748
   Smiddy WE, 2008, CURR OPIN OPHTHALMOL, V19, P195, DOI 10.1097/ICU.0b013e3282fc239f
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 27
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 854
EP 861
DI 10.1097/IAE.0b013e31826f065e
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900025
PM 23296047
DA 2022-11-30
ER

PT J
AU Hamada, S
   Jain, S
   Sivagnanavel, V
   Patel, N
   Chong, NV
AF Hamada, S
   Jain, S
   Sivagnanavel, V
   Patel, N
   Chong, NV
TI Drusen classification in bilateral drusen and fellow eye of exudative
   age-related macular degeneration
SO EYE
LA English
DT Article
ID BEAVER DAM EYE; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE; NATURAL COURSE;
   FOLLOW-UP; 2ND EYE; MACULOPATHY; PREVALENCE; ROTTERDAM; RISK
AB Aim To assess the value of the modified international classification system in screening high-risk patients with bilateral age-related maculopathy (ARM) from those with lower risk characteristics.
   Methods In total, 164 digital images of 106 patients with either bilateral ARM (group A) or the fellow eyes of unilateral exudative age-related macular degeneration (AMD) (Group B) were included. Patients with no signs of ARM in both eyes or those with bilateral late AMD were excluded. The images were randomised and then graded by two masked ophthalmologists based on the modified International Classification of ARM.
   Results The interobserver consistency between the two graders was high with a Kappa value of 0.82 (SE 0.34, P < 0.0001). There were no significant differences in the distribution of the stages of ARM between the two subgroups. Stage 3 was the most common stage in each group for both graders followed by stage 2a in the bilateral drusen group. Stages 1a, 2a and 2b were equally the next common stage in the fellow eye of chordial neovascularisation group.
   Conclusion A screening system based on clinical characteristics would be of value in risk prediction in a clinical setting. Type of Drusen alone, as identified by the modified International grading system, may not be reliably predictive in screening for patients who are at high risk of developing choroidal neovascularisation.
C1 Kings Coll Hosp London, Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Chong, NV (通讯作者)，Kings Coll Hosp London, Retinal Res Unit, Normandy Bldg,Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Chong, Ngaihang V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; 
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 21
TC 4
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2006
VL 20
IS 2
BP 199
EP 202
DI 10.1038/sj.eye.6701852
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 009SO
UT WOS:000235133200011
PM 15746948
OA Bronze
DA 2022-11-30
ER

PT J
AU Hwang, JC
   Del Priore, LV
   Freund, KB
   Chang, S
   Iranmanesh, R
AF Hwang, John C.
   Del Priore, Lucian V.
   Freund, K. Bailey
   Chang, Stanley
   Iranmanesh, Reza
TI Development of Subretinal Fibrosis After Anti-VEGF Treatment in
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID TISSUE GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION
AB BACKGROUND AND OBJECTIVE: To describe the development or progression of subfoveal fibrosis after anti-vascular endothelial growth factor (VEGF) therapy in the absence of significant subfoveal hemorrhage in neovascular age-related macular degeneration.
   PATIENTS AND METHODS: Retrospective case series.
   RESULTS: Seven eyes of seven patients with neovascular age-related macular degeneration developed subfoveal fibrosis after anti-VEGF therapy in the absence of significant subfoveal hemorrhage. Five of seven patients experienced vision loss of 0.3 logarithm of the minimum angle of resolution units or greater.
   CONCLUSION: Subfoveal fibrosis may develop or progress in neovascular age-related macular degeneration despite the absence of significant subfoveal hemorrhage and treatment with anti-VEGF. Development of anti-fibrotic therapeutics may be beneficial in reducing the incidence of subretinal fibrosis.
C1 [Hwang, John C.; Del Priore, Lucian V.; Chang, Stanley; Iranmanesh, Reza] Columbia Univ, Med Ctr, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Del Priore, Lucian V.; Freund, K. Bailey] Retina Macula Consultants New York, New York, NY USA.
C3 Columbia University
RP Iranmanesh, R (通讯作者)，Columbia Univ, Med Ctr, Edward S Harkness Eye Inst, 635 W 165th St, New York, NY 10032 USA.
EM ri2117@columbia.edu
RI Chang, Stanley/AAL-2741-2021; Freund, K. Bailey/V-7488-2018
OI HWANG, JOHN/0000-0001-7384-1968; Freund, K. Bailey/0000-0002-7888-9773
FU Research to Prevent Blindness, Inc., New York, New York
FX Supported by unrestricted funds from Research to Prevent Blindness,
   Inc., New York, New York.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
NR 9
TC 52
Z9 56
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2011
VL 42
IS 1
DI 10.3928/15428877-20100924-01
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 959PQ
UT WOS:000305325700001
PM 20954648
DA 2022-11-30
ER

PT J
AU Zeng, RP
   Wen, F
   Zhang, XZ
   Su, Y
AF Zeng, Renpan
   Wen, Feng
   Zhang, Xiongze
   Su, Yu
TI Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase
   9 elevated in polypoidal choroidal vasculopathy but not in age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; MORPHOMETRIC-ANALYSIS;
   TISSUE INHIBITOR; EXPRESSION; ASSOCIATION; FEATURES; DISEASE; VARIANT;
   LESIONS
AB Purpose: Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are the leading causes of vision loss in the elderly Asian population. Previous studies have confirmed that abnormal extracellular matrix (ECM) metabolism plays an important role in the pathogenesis of AMD and PCV. However, the dynamic metabolism of the ECM is closely regulated by matrix metalloproteinases (MMPs) and tissue metalloproteinase inhibitors (TIMPs). Whether MMPs and TIMPs participate in the pathogenesis of AMD and PCV remains unclear. The aim of this study was to investigate the correlation between circulating MMP and TIMP levels and AMD and PCV.
   Methods: The serum levels of MMPs (MMP1, MMP2, MMP3, and MMP9) and TIMPs (TIMP1 and TIMP3) were quantified using enzyme-linked immunosorbent assays in four groups of subjects (n=342): early AMD (group 1, n=75), neovascular AMD (group 2, n=89), PCV (group 3, n=98), and age-and gender-matched controls (group 4, n=80).
   Results: The mean concentrations of the two gelatinases, MMP2 and MMP9, in the PCV group were significantly higher than that of the control (p=0.001, p<0.001, respectively), early AMD (both p<0.001), and neovascular AMD (p=0.005, p=0.001, respectively) groups. Moreover, the serum MMP2 concentration was positively correlated with the serum MMP9 concentration in the PCV group (r=0.822, p<0.001). However, the mean concentrations of MMP2 and MMP9 in the early AMD and neovascular AMD groups were not significantly different from that of the control group (p>0.05). The mean serum levels of MMP1, MMP3, TIMP1, and TIMP3 were not significantly different among the four groups.
   Conclusions: This pilot study first reveals a link between increased levels of circulating gelatinases (MMP2 and MMP9) and PCV but not AMD, which may provide a biologically relevant marker of ECM metabolism in patients with PCV. This finding suggests that the two disorders may have different molecular mechanisms.
C1 [Zeng, Renpan; Wen, Feng; Zhang, Xiongze; Su, Yu] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
FU National Natural Science Foundation of China [81,271,011]; Fundamental
   Research Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81,271,011) and the Fundamental Research Funds of
   State Key Laboratory of Ophthalmology. The authors have no financial or
   conflicting interests to disclose.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen HY, 2012, MOL VIS, V18, P816
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Chew DKW, 2004, J VASC SURG, V40, P1001, DOI 10.1016/j.jvs.2004.08.035
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Ebrahem Q, 2011, INVEST OPHTH VIS SCI, V52, P6117, DOI 10.1167/iovs.10-5899
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Hadler-Olsen E, 2011, FEBS J, V278, P28, DOI 10.1111/j.1742-4658.2010.07920.x
   Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72
   Hobeika MJ, 2007, J VASC SURG, V45, P849, DOI 10.1016/j.jvs.2006.09.066
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li M, 2010, MOL VIS, V16, P231
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Lim CS, 2010, CURR VASC PHARMACOL, V8, P75, DOI 10.2174/157016110790226697
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   Zitka O, 2010, CURR MED CHEM, V17, P3751, DOI 10.2174/092986710793213724
   Zuo CG, 2012, MOL VIS, V18, P1787
NR 44
TC 35
Z9 40
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 21
PY 2013
VL 19
BP 729
EP 736
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 110BQ
UT WOS:000316417500010
PM 23559867
DA 2022-11-30
ER

PT J
AU You, QS
   Gaber, R
   Meshi, A
   Ramkumar, HL
   Alam, M
   Muftuoglu, IK
   Freeman, WR
AF You, Qi Sheng
   Gaber, Raouf
   Meshi, Amit
   Ramkumar, Hema L.
   Alam, Mostafa
   Muftuoglu, Ilkay Kilic
   Freeman, William R.
TI HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor;
   pro re nata; optical coherence tomography; aflibercept
ID ANTI-VEGF THERAPY; GROWTH-FACTOR THERAPY; TREATMENTS TRIALS;
   RANIBIZUMAB; BEVACIZUMAB; RECURRENT; OUTCOMES; VISION; RISK; TEAR
AB Purpose: To determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration).
   Methods: This was a retrospective interventional case series in which patients with wet age-related macular degeneration were treated with stepwise dose escalation. Non-vitrectomized patients resistant to monthly (Q4W) ranibizumab/bevacizumab were switched to 2 mg aflibercept every 8 weeks. With resistance, they were escalated to Q4W 2 mg aflibercept, then Q4W 4 mg (high dose high frequency, 4Q4W) aflibercept. Resistance was defined as >= 2 recurrences after being dry following >= 3 injections or persistent exudation on treatment of >= 5 injections.
   Results: Thirty-three eyes of 28 patients were treated with 4Q4W aflibercept and followed for a mean of 16 months. A dry retina (no intraretinal or subretinal fluid) was achieved after initiating 4Q4W aflibercept treatment at a mean of 3.8 months. Central foveal thickness, maximum foveal thickness, intraretinal fluid, subretinal fluid, and retinal pigment detachment height decreased significantly at 1 month after initiating the 4Q4W aflibercept, and the morphologic therapeutic effect was sustained until the last visit. Forty-five percent of eyes had one or more lines of vision improvement. New geographic atrophy developed in 9% of eyes during follow-up. No ocular or systemic adverse events occurred after initiating 4Q4W aflibercept.
   Conclusion: Intravitreal high-dose high-frequency aflibercept is an effective treatment for patients with refractory wet age-related macular degeneration.
C1 [You, Qi Sheng; Gaber, Raouf; Meshi, Amit; Ramkumar, Hema L.; Alam, Mostafa; Muftuoglu, Ilkay Kilic; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
   [You, Qi Sheng] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Alam, Mostafa] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
C3 University of California System; University of California San Diego;
   Capital Medical University; Egyptian Knowledge Bank (EKB); Tanta
   University
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM wrfreeman@ucsd.edu
RI You, Qisheng/AAG-7153-2020; Gaber, Raouf/GSN-8206-2022
OI You, Qisheng/0000-0003-0743-7320; 
FU UCSD Vision Research Center [P30EY022589]; Research to Prevent
   Blindness, NY; ICO-Retina Research Foundation Helmerich Fellowship;
   Beijing Talents Fund [2015000021223ZK22]; National Natural Science
   Foundation of China [81400422]; NATIONAL EYE INSTITUTE [P30EY022589]
   Funding Source: NIH RePORTER
FX Supported in part by UCSD Vision Research Center Core Grant P30EY022589,
   an unrestricted grant from Research to Prevent Blindness, NY (W.R.F.),
   ICO-Retina Research Foundation Helmerich Fellowship, Beijing Talents
   Fund (2015000021223ZK22), and National Natural Science Foundation of
   China (No. 81400422) (Q.S.Y.).
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 23
TC 13
Z9 14
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2018
VL 38
IS 6
BP 1156
EP 1165
DI 10.1097/IAE.0000000000001726
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CC
UT WOS:000440627100014
PM 28604541
OA Green Submitted, hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Tezel, TH
   Bora, NS
   Kaplan, HJ
AF Tezel, TH
   Bora, NS
   Kaplan, HJ
TI Pathogenesis of age-related macular degeneration
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; OXIDIZED LDL; EXPRESSION; ATHEROSCLEROSIS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in the developed world. The inability to prevent the development of AMD and its complications stems from our lack of knowledge of the underlying pathological mechanisms. A recent report described a rodent with chemokine deficiencies that developed retinal changes similar to those frequently observed in AMD and suggested an important role for macrophages and complement in the pathogenesis of this disease. Such novel insights into the possible causes of AMD might give rise to preventative and/or reconstructive treatments in the future.
C1 Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA.
C3 University of Louisville
RP Kaplan, HJ (通讯作者)，Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA.
EM hank.kaplan@louisville.edu
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   Hawkins BS, 1999, MOL VIS, V5
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaplan M, 2001, ARTERIOSCL THROM VAS, V21, P386, DOI 10.1161/01.ATV.21.3.386
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lloyd C, 1998, CURR OPIN NEPHROL HY, V7, P281, DOI 10.1097/00041552-199805000-00008
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nicolai U, 1993, Ger J Ophthalmol, V2, P195
   Okada H, 2000, KIDNEY INT, V57, P927, DOI 10.1046/j.1523-1755.2000.00909.x
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593
   Salomonsson L, 2002, EUR J CLIN INVEST, V32, P767, DOI 10.1046/j.1365-2362.2002.01072.x
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
NR 32
TC 46
Z9 58
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD SEP
PY 2004
VL 10
IS 9
BP 417
EP 420
DI 10.1016/j.molmed.2004.07.004
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 859AV
UT WOS:000224235200001
PM 15350892
DA 2022-11-30
ER

PT J
AU Orban, T
   Johnson, WM
   Dong, ZQ
   Maeda, T
   Maeda, A
   Sakai, T
   Tsuneoka, H
   Mieyal, JJ
   Palczewski, K
AF Orban, Tivadar
   Johnson, William M.
   Dong, Zhiqian
   Maeda, Tadao
   Maeda, Akiko
   Sakai, Tsutomu
   Tsuneoka, Hiroshi
   Mieyal, John J.
   Palczewski, Krzysztof
TI Serum levels of lipid metabolites in age-related macular degeneration
SO FASEB JOURNAL
LA English
DT Article
DE docosahexaenoic acid; arachidonic acid; risk evaluation; serum; mouse
   model
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; ANIMAL-MODELS;
   DARK-ADAPTATION; MOUSE RETINA; AGING BRAIN; BIOMARKERS; MUTATION; CELLS;
   IDENTIFICATION
AB Age-related macular degeneration (AMD) is a neurodegenerative disease that causes adult-onset blindness. There are 2 forms of this progressive disease: wet and dry. Currently there is no cure for AMD, but several treatment options have started to emergemaking early detection critical for therapeutic success. Analysis of the eyes of Abca4(-/-) Rdh8(-/-) mice that display light-induced retinal degeneration indicates that 11-cis-retinal and docosahexaenoic acid (DHA) levels were significantly decreased as compared with the eyes of control dark-adapted C57BL/6J mice. In addition, exposure to intense light correlated with higher levels of prostaglandin G2 in the eyes of Abca4(-/-) Rdh8(-/-) mice. Intense light exposure also loweredDHA levels in the eyes of wild-type C57BL/6J mice without discernible retinal degeneration. Analysis of human serumfrom patients with AMD recapitulated these dysregulated DHA levels and revealed dysregulation of arachidonic acid (AA) levels as well (similar to 32% increase in patients with AMDcomparedwith average levels in healthy individuals). From these observations, we then built a statistical model that included levels of DHA and AA from human serum. This model had a 74% probability of correctly identifying patients with AMD from controls. Addition of a genetic analysis for one of the most prevalent amino acid substitutions in the age-related maculopathy susceptibility 2 gene linked to AMD, Ala(69) -> Ser, did not improve the statisticalmodel. Thus, we have characterized a reliablemethod with the potential to detect AMDwithout a genetic component, paving the way for a larger-scale clinical evaluation. Our studies on mouse models along with the analysis of human serum suggest that our small molecule-based model may serve as an effective tool to estimate the risk of developing AMD.
C1 [Orban, Tivadar; Johnson, William M.; Maeda, Akiko; Mieyal, John J.; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Maeda, Tadao; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Sch Med, Cleveland, OH 44106 USA.
   [Dong, Zhiqian] Polgenix Inc, Cleveland, OH USA.
   [Sakai, Tsutomu; Tsuneoka, Hiroshi] Jikei Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Mieyal, John J.] Louis Stokes Vet Affairs Med Res Ctr, Cleveland, OH USA.
C3 Case Western Reserve University; Case Western Reserve University; Jikei
   University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Case Western Reserve University; Louis Stokes
   Cleveland Veterans Affairs Medical Center
RP Palczewski, K (通讯作者)，Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM kxp65@case.edu
OI DONG, ZHIQIAN/0000-0002-8748-4532
FU U.S. National Institutes of Health, National Eye Institute [EY009339,
   EY021126]; Foundation Fighting Blindness; Arnold and Mabel Beckman
   Foundation; NATIONAL EYE INSTITUTE [R01EY009339, R24EY021126] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [T32GM008803] Funding Source: NIH RePORTER
FX The authors thank Drs. Leslie T. Webster, Jr., Daniel Figeys, and
   members of the K.P. laboratory for helpful comments on this manuscript;
   and Drs. Philip D. Kiser, Marcin Golczak, and Yaroslav Tsybovsky (all
   from Case Western Reserve University) for support and advice during this
   study. This work was supported by funding from the U.S. National
   Institutes of Health, National Eye Institute Grants EY009339 and
   EY021126 (to K.P.), the Foundation Fighting Blindness, and the Arnold
   and Mabel Beckman Foundation. K.P. is a John H. Hord Professor of
   Pharmacology. The authors declare no conflicts of interest.
CR Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983
   Carroll J, 2013, CURR EYE RES, V38, P709, DOI 10.3109/02713683.2013.784792
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076
   Costa RA, 2006, PROG RETIN EYE RES, V25, P325, DOI 10.1016/j.preteyeres.2006.03.001
   de Ruijter W., 2009, BMJ-BRIT MED J, V338, P1
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gabriele ML, 2010, PROG RETIN EYE RES, V29, P556, DOI 10.1016/j.preteyeres.2010.05.005
   Gaffney AJ, 2013, DOC OPHTHALMOL, V127, P191, DOI 10.1007/s10633-013-9400-3
   GELFANT S, 1972, SCIENCE, V178, P357, DOI 10.1126/science.178.4059.357
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Grund B, 2010, CURR OPIN HIV AIDS, V5, P473, DOI 10.1097/COH.0b013e32833ed742
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guarente L, 1997, SCIENCE, V275, P943, DOI 10.1126/science.275.5302.943
   Gutchess A, 2014, SCIENCE, V346, P579, DOI 10.1126/science.1254604
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Heimann H, 2013, EYE, V27, P208, DOI 10.1038/eye.2012.251
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hunter JJ, 2011, BIOMED OPT EXPRESS, V2, P139, DOI 10.1364/BOE.2.000139
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lasko TA, 2005, J BIOMED INFORM, V38, P404, DOI 10.1016/j.jbi.2005.02.008
   Lindenberger U, 2014, SCIENCE, V346, P572, DOI 10.1126/science.1254403
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104
   Maeda Akiko, 2013, Drug Discov Today Dis Models, V10, pe163
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McMahon A, 2007, FEBS LETT, V581, P5459, DOI 10.1016/j.febslet.2007.10.050
   McMahon A, 2007, MOL VIS, V13, P258
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Morgan J, 2005, EXP EYE RES, V80, P297, DOI 10.1016/j.exer.2004.12.010
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Palczewska G, 2014, P NATL ACAD SCI USA, V111, pE5445, DOI 10.1073/pnas.1410162111
   Palczewska G, 2014, INVEST OPHTH VIS SCI, V55, P4438, DOI 10.1167/iovs.14-14395
   Palczewska G, 2014, NAT MED, V20, P785, DOI 10.1038/nm.3590
   Patti GJ, 2013, ANAL CHEM, V85, P798, DOI 10.1021/ac3029745
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shafto MA, 2014, SCIENCE, V346, P583, DOI 10.1126/science.1254404
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xia JG, 2013, METABOLOMICS, V9, P280, DOI 10.1007/s11306-012-0482-9
   Yoshida T, 2007, MOL VIS, V13, P545
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 71
TC 12
Z9 12
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2015
VL 29
IS 11
BP 4579
EP 4588
DI 10.1096/fj.15-275289
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CV8EZ
UT WOS:000364514700017
PM 26187344
OA Green Published
DA 2022-11-30
ER

PT J
AU Choudhury, F
   Varma, R
   McKean-Cowdin, R
   Klein, R
   Azen, SP
AF Choudhury, Farzana
   Varma, Rohit
   McKean-Cowdin, Roberta
   Klein, Ronald
   Azen, Stanley P.
CA Los Angeles Latino Eye Study Grp
TI Risk Factors for Four-Year Incidence and Progression of Age-Related
   Macular Degeneration: The Los Angeles Latino Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; BLUE-MOUNTAINS-EYE; OPEN-ANGLE GLAUCOMA;
   CARDIOVASCULAR-DISEASE; PULSE PRESSURE; 5-YEAR INCIDENCE; POOLED
   FINDINGS; TERM INCIDENCE; 3 CONTINENTS; MACULOPATHY
AB PURPOSE: To identify risk factors for 4-year incidence and progression of age-related macular degeneration (AMD) in adult Latinos.
   DESIGN: Population-based prospective cohort study.
   METHODS: Participants, aged 40 or older, from The Los Angeles Latino Eye Study (LALES) underwent standardized comprehensive ophthalmologic examinations at baseline and at 4 years of follow-up. Age-related macular degeneration was detected by grading 30-degree stereoscopic fundus photographs using the modified Wisconsin Age-Related Maculopathy Grading System. Multivariate stepwise logistic regression was used to examine the independent association of incidence and progression of AMD and baseline sociodemographic, behavioral, clinical, and ocular characteristics.
   RESULTS: Multivariate analyses revealed that older age (OR per decade of age: 1.52; 95% CI: 1.29, 1.85) and higher pulse pressure (OR per 10 mm Hg: 2.54; 95% CI: 1.36, 4.76) were independently associated with the incidence of any AMD. The same factors were associated with early AMD, soft indistinct drusen, and retinal pigmentary abnormalities. Additionally, presence of clinically diagnosed diabetes mellitus was independently associated with increased retinal pigment (OR: 1.66; 95% CI: 1.01, 2.85), and male gender was associated with retinal pigment epithelial depigmentation (OR 2.50; 95% CI: 1.48, 4.23). Older age (OR per decade of age: 2.20; 95% CI: 1.82, 2.67) and current smoking (OR: 2.85; 95% CI: 1.66, 4.90) were independently associated with progression of AMD.
   CONCLUSIONS: Several modifiable risk factors were associated with 4-year incidence and progression of AMD in Latinos. The results suggest that interventions aimed at reducing pulse pressure and promoting smoking cessation may reduce incidence and progression of AMD, respectively. (Am J Ophthalmol 2011;152:385-395. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Varma, Rohit; Azen, Stanley P.] Univ So Calif, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Varma, Rohit; Azen, Stanley P.] Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Choudhury, Farzana; Varma, Rohit; McKean-Cowdin, Roberta; Azen, Stanley P.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Wisconsin System; University of Wisconsin Madison
RP Varma, R (通讯作者)，Univ So Calif, Doheny Eye Inst, Keck Sch Med, 1450 San Pablo St DEI4900, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND [NEI U10-EY-11753,
   EY-03040]; Research to Prevent Blindness, New York; Pfizer Inc, New
   York; National Institute of Health & National Eye Institute (NIH-NEI);
   Alcon; Allergan; Aquesys; Genetech; Pfizer; Merck Co; Bausch Lomb
   Surgical; Replenish; NIH; Centers for Disease Control and Prevention
   (CDC, Atlanta, Georgia), Atlanta, Georgia; NATIONAL EYE INSTITUTE
   [U10EY011753, P30EY003040] Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY NATIONAL INSTITUTES OF
   HEALTH, BETHESDA, MARYLAND (Grants NEI U10-EY-11753 and EY-03040) and an
   unrestricted grant from Research to Prevent Blindness, New York, New
   York, and Pfizer Inc, New York, New York. Rohit Varma is a Research to
   Prevent Blindness Sybil B. Harrington Scholar. The authors have no
   proprietary or commercial interest in any materials discussed in the
   manuscript. Rohit Varma receives research support from National
   Institute of Health & National Eye Institute (NIH-NEI), Alcon, Allergan,
   Aquesys, Genetech, Pfizer, Merck & Co, Bausch & Lomb Surgical, and
   Replenish; Ronald Klein receives funding from NIH and Centers for
   Disease Control and Prevention (CDC, Atlanta, Georgia), Atlanta,
   Georgia; Stanley Azen, Roberta McKean-Cowdin, and Farzana Choudhury have
   funding from NIH-NEI. Involved in design and conduct of the study (R.V.,
   S.P.A.); collection, management, analysis, and interpretation of the
   data (F.C., R.M.C., R.K., S.P.A., RN.); and preparation, review, or
   approval of the manuscript (F.C., R.M.C., R.K., S.P.A., R.V.). The study
   protocol was approved by the Institutional Review Board (IRB)/Ethics
   Committee at the University of Southern California and all study
   procedures adhered to the recommendations of the Declaration of
   Helsinki. Written consent was obtained from all participants.
CR Chae CU, 1999, JAMA-J AM MED ASSOC, V281, P634, DOI 10.1001/jama.281.7.634
   Chopra V, 2008, OPHTHALMOLOGY, V115, P227, DOI 10.1016/j.ophtha.2007.04.049
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   COOPER RL, 1990, AUST NZ J OPHTHALMOL, V18, P421, DOI 10.1111/j.1442-9071.1990.tb01828.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Domanski M, 2002, JAMA-J AM MED ASSOC, V287, P2677, DOI 10.1001/jama.287.20.2677
   Domanski M, 2001, HYPERTENSION, V38, P793, DOI 10.1161/hy1001.092966
   EONG KA, 2008, INFORM HEALTHCARE, P47
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Mitchell GF, 2007, JAMA-J AM MED ASSOC, V297, P709, DOI 10.1001/jama.297.7.709
   Mitchell GF, 1999, CURR OPIN NEPHROL HY, V8, P335, DOI 10.1097/00041552-199905000-00010
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   National Center for Health Statistics, 2009, NATL HLTH NUTR EXAMI
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varma R, 2004, OPHTHALMOLOGY, V111, P1298, DOI 10.1016/j.ophtha.2004.03.002
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Varma R, 2010, AM J OPHTHALMOL, V149, P752, DOI 10.1016/j.ajo.2009.11.014
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
NR 49
TC 41
Z9 43
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2011
VL 152
IS 3
BP 385
EP 395
DI 10.1016/j.ajo.2011.02.025
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815IS
UT WOS:000294519900008
PM 21679916
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, W
   Dean, DC
   Kaplan, HJ
AF Wang, Wei
   Dean, Douglas C.
   Kaplan, Henry J.
TI Age-related Macular Degeneration
SO DISCOVERY MEDICINE
LA English
DT Article
AB Age-related Macular Degeneration (AMD) is the major cause of vision loss after age 50 in the United States. Although an important association of the complement cascade with AMD has recently been made, we still do not understand the pathogenesis of the disease. AMD is characterized by loss of the retinal pigment epithelium (RPE) within the macula (i.e., the center of the retina), and in turn, loss of the overlying foveal photoreceptors. Since RPE and photoreceptors can both be generated from stem cells using cell culture, there is hope for future cell replacement therapy. But, aging changes in Bruch's membrane, the scaffold on which the RPE are anchored, may complicate such therapy, and require surgical repair of Bruch's membrane to provide a suitable environment for cell survival and function. We have referred to such a multipronged approach of surgical reconstruction of the macular architecture in conjunction with cell transplantation as Maculoplasty. [Discovery Medicine 9(44):13-15, January 2010]
C1 [Wang, Wei; Dean, Douglas C.; Kaplan, Henry J.] Univ Louisville, Dept Ophthalmol, Louisville, KY 40202 USA.
C3 University of Louisville
RP Wang, W (通讯作者)，Univ Louisville, Dept Ophthalmol, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
NR 15
TC 11
Z9 12
U1 0
U2 1
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD JAN
PY 2010
VL 9
IS 44
BP 13
EP 15
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V27SR
UT WOS:000208633400002
PM 20102679
DA 2022-11-30
ER

PT J
AU Serra, R
   Coscas, F
   Pinna, A
   Cabral, D
   Coscas, G
   Souied, EH
AF Serra, Rita
   Coscas, Florence
   Pinna, Antonio
   Cabral, Diogo
   Coscas, Gabriel
   Souied, Eric H.
TI QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF
   INACTIVE MACULAR NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fractal dimension; lacunarity;
   quantitative optical coherence tomography angiography parameters;
   treatment-naive quiescent neovascularization; Type 1 choroidal
   neovascularization; perfusion density
AB Purpose: To compare quantitative optical coherence tomography angiography parameters between treatment-naive quiescent macular neovascularizations (MNVs) and previously treated nonexudative Type 1 MNVs, in patients with age-related macular degeneration. Methods: The eyes included in the study were analyzed by fluorescein angiography, indocyanine green angiography, spectral-domain optical coherence tomography, and optical coherence tomography angiography. According to their medical history and multimodal imaging evaluation, Type 1 MNVs were divided into 2 groups: 1) treatment-naive quiescent MNVs; 2) previously treated nonexudative Type 1 MNVs. Quantitative optical coherence tomography angiography parameters, including perfusion density (PD), fractal dimension (FD), and lacunarity (LAC) were calculated. Receiver operating characteristic curves, showing the ability of PD, FD, and LAC to discriminate between the two MNV groups, were built. Results: Twenty-two eyes with treatment-naive quiescent MNVs and 20 eyes with MNVs previously treated nonexudative Type 1 MNVs were analyzed. Mean FD and LAC were statistically different between the two study groups (P < 0.05). Lacunarity showed the best discrimination ability, followed by FD and PD (area under curve = 0.83, 0.78, 0.62, respectively). Conclusion: Results suggest that FD and LAC may be useful optical coherence tomography angiography biomarkers to objectively discriminate inactive MNVs with different prognosis, such as treatment-naive quiescent MNVs and previously treated nonexudative Type 1 MNVs, in age-related macular degeneration patients.
C1 [Serra, Rita] Univ Sassari, Dept Biomed & Surg Sci, Sassari, Italy.
   [Serra, Rita] Cittadella Univ Cagliari, Ist Ric Genet & Biomed IRGB, CNR, Monserrato, CA, Italy.
   [Serra, Rita; Coscas, Florence; Coscas, Gabriel] Ctr Ophtalmol Odeon, Paris, France.
   [Coscas, Florence; Coscas, Gabriel; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Pinna, Antonio] Univ Sassari, Dept Med Surg & Expt Sci, Ophthalmol Unit, Sassari, Italy.
   [Cabral, Diogo] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; University of
   Sassari
RP Coscas, F (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94010 Creteil, France.
EM coscas.f@gmail.com
RI Pinna, Antonio/H-5067-2018
OI Pinna, Antonio/0000-0003-3052-2662; SERRA, RITA/0000-0002-6341-1435
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Serra R., 2019, RETINA-J RET VIT DIS
   Serra R, 2018, EUR J OPHTHALMOL, V28, P234, DOI 10.5301/ejo.5001068
   Serra R, 2017, AM J OPHTHALMOL, V176, P108, DOI 10.1016/j.ajo.2016.12.027
   Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tolle CR, 2008, PHYSICA D, V237, P306, DOI 10.1016/j.physd.2007.09.017
NR 39
TC 4
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 93
EP 102
DI 10.1097/IAE.0000000000002807
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100014
PM 32281767
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Nangia, V
   Kulkarni, M
   Gupta, R
   Khare, A
AF Jonas, Jost B.
   Nangia, Vinay
   Kulkarni, Maithili
   Gupta, Rajesh
   Khare, Anshu
TI Associations of early age-related macular degeneration with ocular and
   general parameters. The central India eyes and medical study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; central India eye and medical study;
   hyperopia; low vision; refractive error; smoking; visual impairment
ID RISK-FACTORS; REFRACTIVE ERROR; MACULOPATHY; SMOKING; POPULATION;
   PREVALENCE; DISEASE
AB . Purpose: To assess associations between age-related macular degeneration (AMD) and ocular and general parameters. Methods: The Central India Eye and Medical Study, a population-based study performed in rural Central India, included 4711 subjects (aged 30+ years) out of 5885 eligible subjects (response rate: 80.1%). Fundus photographs were assessed using the Wisconsin Age-Related Maculopathy Grading system. Results: Fundus photographs were available for 4542 (96.4%) subjects. Early AMD was present in 215/4542 subjects (4.7 +/- 0.3%), and late AMD was detected in 8/4542 (0.2 +/- 0.03%) subjects. After adjustment for age, prevalence of AMD was significantly associated with hyperopic refractive error (p = 0.001), shorter axial length (p = 0.01), and higher corneal refractive power (p = 0.02). Each dioptre increase in hyperopic refraction or each millimetre decrease in axial length was associated with a 15% [odds ratio (OR):1.15; 95% confidence interval (CI): 1.06, 1.24] and 19% (OR: 0.81; 95%CI: 0.69, 0.95) increased probability of early AMD, respectively. AMD was not significantly associated with blood pressure, serum concentration of cholesterol, glycosylated haemoglobin Hb1Ac, high-density lipoproteins and postprandial glucose, gender, level of education, any parameter of smoking, alcohol consumption, psychiatric depression or of daily activities, anterior chamber depth, lens thickness, intraocular pressure, size of the optic disc, neuroretinal rim and parapapillary atrophy, nor amount of nuclear cataract and status after cataract surgery. If the statistical analysis was adjusted for age and refractive error, age-related macular degeneration was marginally significantly associated with a low intake of fruits (p = 0.06). Conclusions: Hyperopia (and short axial length) besides age was the single most important associated factor for AMD in adult Indians.
C1 [Jonas, Jost B.; Nangia, Vinay; Kulkarni, Maithili; Gupta, Rajesh; Khare, Anshu] Suraj Eye Inst, Nagpur 440004, Maharashtra, India.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Suraj Eye Institute; Ruprecht Karls University Heidelberg
RP Nangia, V (通讯作者)，Suraj Eye Inst, Plot 559, Nagpur 440004, Maharashtra, India.
EM nagpursuraj@gmail.com
FU Om Drishti Trust, Nagpur; Heidelberg Engineering Co. Heidelberg,
   Germany; Rotary Sight Saver Netherlands; Orbis India; Carl Zeiss Meditec
   Co., Jena, Germany
FX Supported by an unrestricted grant from Om Drishti Trust, Nagpur;
   Heidelberg Engineering Co. Heidelberg, Germany; Rotary Sight Saver
   Netherlands; Orbis India; and Carl Zeiss Meditec Co., Jena, Germany.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Nangia V, 2011, ACTA OPHTHALMOL
   Nangia V, 2008, ACTA OPHTHALMOL, V86, P103, DOI 10.1111/j.1600-0420.2007.00964.x
   Nangia V, 2010, OPHTHALMOLOGY, V117, P693, DOI 10.1016/j.ophtha.2009.09.037
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang S, 2009, OPHTHALMOLOGY, V116, P2373, DOI 10.1016/j.ophtha.2009.05.041
   Wang YX, 2011, ACTA OPHTHALMOL, V89, pE210, DOI 10.1111/j.1755-3768.2009.01787.x
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2010, GRAEF ARCH CLIN EXP, V248, P49, DOI 10.1007/s00417-009-1204-5
NR 27
TC 23
Z9 23
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2012
VL 90
IS 3
BP e185
EP e191
DI 10.1111/j.1755-3768.2011.02316.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932SS
UT WOS:000303311400004
PM 22269029
DA 2022-11-30
ER

PT J
AU Willeford, KT
   Rapp, J
AF Willeford, Kevin T.
   Rapp, Jerry
TI Smoking and Age-Related Macular Degeneration: Biochemical Mechanisms and
   Patient Support
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE cigarette smoke; age-related macular degeneration (AMD); reactive oxygen
   species (ROS); antioxidant defense mechanisms; public health awareness
ID CIGARETTE-SMOKING; EPITHELIAL-CELLS; VITAMIN-E; TOBACCO; HEALTH;
   CESSATION; BLINDNESS; SMOKERS; COMMUNICATION; MOTIVATION
AB A small percentage of the population associates smoking with ocular disease. Most optometrists do not stress the importance of smoking cessation to their patients, and the centrality of smoking regarding the risk for ocular disease is not emphasized in optometric education. Age-related macular degeneration has strong epidemiological associations with smoking, and so serves as an appropriate model for the adverse effects of cigarette smoke on the eye. This article aims to provide basic scientific information to optometrists and optometry students so that they can better understand the pathogenesis of age-related macular degeneration and provide education and support to their patients wishing to stop smoking. (Optom Vis Sci 2012;89:1662-1666)
C1 [Willeford, Kevin T.; Rapp, Jerry] SUNY Coll Optometry, Dept Biol Sci, New York, NY 10036 USA.
C3 State University of New York (SUNY) System; SUNY Optometry
RP Willeford, KT (通讯作者)，SUNY Coll Optometry, Dept Biol Sci, 33 W 42nd St, New York, NY 10036 USA.
EM kwilleford@sunyopt.edu
CR BROICH JR, 1980, INVEST OPHTH VIS SCI, V19, P1328
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Centers for Disease Control and Prevention, 2006, PRACT GUID WORK HLTH
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   CHIBA M, 1992, B WORLD HEALTH ORGAN, V70, P269
   CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784
   Davis SJ, 2012, RETINA-J RET VIT DIS, V32, P1171, DOI 10.1097/IAE.0b013e31823496b8
   DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hall S, 2004, HEALTH PSYCHOL, V23, P419, DOI 10.1037/0278-6133.23.4.419
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Handa S, 2011, EYE, V25, P1170, DOI 10.1038/eye.2011.143
   Hays JT, 2009, MAYO CLIN PROC, V84, P730, DOI 10.1016/S0025-6196(11)60523-5
   Hays JT, 2009, MAYO CLIN P, V84, P5
   Hughes JR, 2010, AM J PREV MED, V39, P285, DOI 10.1016/j.amepre.2010.05.002
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kennedy RD, 2011, OPTOMETRY VISION SCI, V88, P766, DOI 10.1097/OPX.0b013e318216b203
   Kennedy RD, 2011, OPTOMETRY, V82, P310, DOI 10.1016/j.optm.2010.10.014
   KONDO T, 1994, AM J RESP CRIT CARE, V149, P178, DOI 10.1164/ajrccm.149.1.8111579
   Loo DLS, 2009, CLIN EXP OPTOM, V92, P42, DOI 10.1111/j.1444-0938.2008.00283.x
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Matsumoto Y, 2008, EYE, V22, P961, DOI 10.1038/eye.2008.78
   MEZZETTI A, 1995, ATHEROSCLEROSIS, V112, P91, DOI 10.1016/0021-9150(94)05403-6
   PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Sheck LHN, 2009, CLIN EXP OPTOM, V92, P75, DOI 10.1111/j.1444-0938.2009.00348.x
   Shelley D, 2011, J DENT EDUC, V75, P527
   STEWART MA, 1995, CAN MED ASSOC J, V152, P1423
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P73
   Thompson C, 2007, OPHTHAL PHYSL OPT, V27, P389, DOI 10.1111/j.1475-1313.2007.00483.x
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   U.S. Department of Health and Human Services/Public Health Service, TREAT TOB US DEP
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc
NR 43
TC 3
Z9 4
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD NOV
PY 2012
VL 89
IS 11
BP 1662
EP 1666
DI 10.1097/OPX.0b013e31826c5df2
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 031HJ
UT WOS:000310629700014
PM 23034338
DA 2022-11-30
ER

PT J
AU Iaculli, C
   Barone, A
   Scudieri, M
   Palumbo, MG
   Delle Noci, N
AF Iaculli, Cristiana
   Barone, Antonio
   Scudieri, Marilisa
   Palumbo, Maria Giovanna
   Delle Noci, Nicola
TI OUTER RETINAL TUBULATION Characteristics in Patients With Neovascular
   Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE outer retinal tubulation; neovascular AMD; retinal sensitivity; spectral
   domain optical; coherence tomography
ID OPTICAL-COHERENCE-TOMOGRAPHY
AB Purpose:To assess the incidence, characteristics, best-corrected visual acuity (BCVA), central macular thickness (CMT), and retinal sensitivity correlations in patients with and without outer retinal tubulation (ORT) affected by subfoveal choroidal neovascularization due to neovascular age-related macular degeneration.Methods:Prospective case series including 78 eyes of 78 consecutive patients with subfoveal choroidal neovascularization due to neovascular age-related macular degeneration. Baseline and follow-up visits included BCVA, intraocular pressure, ophthalmoscopic examination, CMT as measured by spectral domain optical coherence tomography, and retinal sensitivity tested with fundus-related perimetry (MP-1). Fluorescent angiography was performed at baseline.Results:At the end of the follow-up period, the mean BCVA and CMT of patients with ORT were statistically different from those without ORT (BCVA: 0.61 0.13 vs. 0.37 +/- 1.59, P < 0.0001; CMT: 290 +/- 26.7 vs. 215.2 +/- 33.5 m; P < 0.0001). Patients with ORT showed a decreased mean retinal sensitivity compared with patients without ORT (6.31 +/- 2.5 dB vs. 9.89 +/- 5.43 dB; P < 0.0001).Conclusion:The results of this study investigating the BCVA, CMT, and retinal sensitivity detected by MP-1 between patients with and without ORT in neovascular age-related macular degeneration suggest that these parameters are statistically different in patients with ORT; this may be due to the pathogenesis of ORT formation, secondary to retinal pigment epithelial tears or photoreceptor damage. MP-1 microperimeter is a noninvasive instrument that provides useful information to better characterize the functional aspect of ORT in patients with age-related macular degeneration.
C1 [Iaculli, Cristiana; Barone, Antonio; Scudieri, Marilisa; Palumbo, Maria Giovanna; Delle Noci, Nicola] Univ Foggia, Policlin Foggia, Dept Ophthalmol, Foggia, Italy.
C3 University of Foggia
RP Barone, A (通讯作者)，Osped Riuniti Foggia, Viale Pinto 1, I-71100 Foggia, Italy.
EM antoniobarone79@yahoo.it
FU Novartis, Italy
FX The authors would like to thank Sheridan Henness, PhD, of Springer
   Healthcare Communications, who provided medical writing assistance with
   post-submission amendments. This assistance was funded by Novartis,
   Italy.
CR Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   PITTLER SJ, 1995, J CELL BIOL, V130, P431, DOI 10.1083/jcb.130.2.431
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Yannuzi LA., 2010, THE RETINAL ATLAS, P158
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 12
TC 6
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1979
EP 1984
DI 10.1097/IAE.0000000000000609
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000008
PM 26079476
DA 2022-11-30
ER

PT J
AU Huang, L
   Meng, Q
   Zhang, C
   Sun, Y
   Bai, Y
   Li, S
   Deng, X
   Wang, B
   Yu, W
   Zhao, M
   Li, X
AF Huang, L.
   Meng, Q.
   Zhang, C.
   Sun, Y.
   Bai, Y.
   Li, S.
   Deng, X.
   Wang, B.
   Yu, W.
   Zhao, M.
   Li, X.
TI Gene-gene interaction of CFH, ARMS2, and ARMS2/HTRA1 on the risk of
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy in Chinese population
SO EYE
LA English
DT Article
ID MULTIFACTOR-DIMENSIONALITY REDUCTION; COMPLEMENT-FACTOR-H; JAPANESE
   POPULATION; ASSOCIATION; VARIANTS; HTRA1; POLYMORPHISMS; HAPLOTYPE;
   REGION; SUSCEPTIBILITY
AB Purpose To evaluate the association and interaction of five single-nucleotide polymorphisms (SNPs) in three genes (CFH, ARMS2, and ARMS2/HTRA1) with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in Chinese population.
   Methods A total of 300 nAMD and 300 PCV patients and 301 normal subjects participated in the present study. The allelic variants of rs800292, rs2274700, rs3750847, rs3793917, and rs1065489 were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Gene-gene interactions were evaluated by the data mining approach multifactor-dimensionality reduction (MDR) method.
   Results The risk alleles of CFH rs800292, rs2274700, ARMS2 rs3057847, and ARMS2/HTRA1 rs3793917 showed significant difference between nAMD or PCV patients and controls (all P<0.01). The homozygosity of risk alleles for rs800292, rs2274700, rs3750847, and rs3793917 were significantly different between nAMD patients and controls (all P<0.01), and predisposed to PCV patients (all P<0.01). After cross-validation consistency (CVC) and permutation tests, the two-locus model rs2274700_rs3750847 has a balanced accuracy of 64.37% in predicting nAMD disease risk. The one-marker model, rs3750847, and two-locus model rs2274700_rs3750847 has a balanced accuracy of 66.07% and 65.89% in predicting PCV disease risk, respectively. Furthermore, CFH rs1065489 did not show significant association with nAMD (P>0.01), but was strongly associated with PCV in Chinese patients (P<0.001).
   Conclusions In this study, we found that the interaction of ARMS2 and ARMS2/HTRA1 is significantly associated with nAMD, and the interaction of CFH and ARMS2 is pronounced in PCV development in Chinese population.
C1 [Huang, L.; Meng, Q.; Sun, Y.; Bai, Y.; Li, S.; Deng, X.; Wang, B.; Yu, W.; Zhao, M.; Li, X.] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Huang, L.; Meng, Q.; Sun, Y.; Bai, Y.; Li, S.; Deng, X.; Wang, B.; Yu, W.; Zhao, M.; Li, X.] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Huang, L.; Meng, Q.; Sun, Y.; Bai, Y.; Li, S.; Deng, X.; Wang, B.; Yu, W.; Zhao, M.; Li, X.] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Abdominal Surg Oncol, Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Zhang, C.] Peking Univ, Peoples Hosp, Dept Clin Epidemiol, Beijing 100044, Peoples R China.
C3 Peking University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute & Hospital - CAMS; Peking Union
   Medical College; Peking University
RP Li, X (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM drlixiaoxin@163.com
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China (NSFC) [81100666,
   81170854]; Research Fund for Science and Technology Program of Beijing
   [Z121100005312006]
FX The first three authors contributed equally to this article and are
   cofirst authors. Dr Mingwei Zhao (zhaomingwei@medmail.com.cn) and Dr
   Xiaoxin Li contributed equally to the conduct of this research and are
   considered to be cocorresponding authors. This work was supported by the
   National Basic Research Program of China (973 Program, No.
   2011CB510200). the National Natural Science Foundation of China (NSFC,
   No. 81100666; 81170854), the Research Fund for Science and Technology
   Program of Beijing (No. Z121100005312006).
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bessho H, 2009, MOL VIS, V15, P1107
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boiko E V, 2013, Vestn Oftalmol, V129, P86
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 41
TC 9
Z9 10
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2015
VL 29
IS 5
BP 691
EP 698
DI 10.1038/eye.2015.32
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5JC
UT WOS:000354070900015
PM 25771815
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ruamviboonsuk, P
   Tadarati, M
   Singhanetr, P
   Wattanapokayakit, S
   Kunhapan, P
   Wanitchanon, T
   Wichukchinda, N
   Mushiroda, T
   Akiyama, M
   Momozawa, Y
   Kubo, M
   Mahasirimongkol, S
AF Ruamviboonsuk, Paisan
   Tadarati, Mongkol
   Singhanetr, Panisa
   Wattanapokayakit, Sukanya
   Kunhapan, Punna
   Wanitchanon, Thanyapat
   Wichukchinda, Nuanjun
   Mushiroda, Taisei
   Akiyama, Masato
   Momozawa, Yukihide
   Kubo, Michiaki
   Mahasirimongkol, Surakameth
TI Genome-wide association study of neovascular age-related macular
   degeneration in the Thai population
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VARIANTS; LOCI; POLYMORPHISM;
   GENETICS; THERAPY; BIOLOGY
AB We performed a genome-wide association study on 377 cases of neovascular age-related macular degeneration (AMD) and 1074 controls to determine the association of previously reported genetic variants associated with neovascular AMD in the Thai population. All patients were of Thai ancestry. We confirmed the association of age-related maculopathy susceptibility 2 (ARMS2) rs10490924 (P= 7.38 x 10-17), HTRA1 rs11200638 (P= 5.47 x 10-17) and complement factor H gene (CFH) rs800292 (P= 2.53 x 10-8) with neovascular AMD, all loci passing the genome-wide significance level (Po5.22 x 10-8). We also found association of the previously reported CFH rs10737680 (P= 1.76 x 10-6) locus in the discovery sample. Two loci not previously reported to be associated with neovascular AMD were selected for replication in 222 cases and 623 controls. The loci included LINCO1317 rs6733379 and rs2384550 on chromosome 12. LINCO1317 rs6733379 (P= 3.85 x 10-2) remained significantly associated with neovascular AMD after replication. In conclusion, we confirm that ARMS2, HTRA1 and CFH variants are associated with neovascular AMD in the Thai population. Findings from this study also suggest that variants contributing to the susceptibility of neovascular AMD in the Thai population are mostly similar to other Asians with additional local genetic risks that may specifically be identified in Thai population.
C1 [Ruamviboonsuk, Paisan; Tadarati, Mongkol; Singhanetr, Panisa] Rangsit Univ, Rajavithi Hosp, Dept Ophthalmol, Coll Med, 2 Phayathai Rd, Bangkok 10400, Thailand.
   [Wattanapokayakit, Sukanya; Kunhapan, Punna; Wanitchanon, Thanyapat; Wichukchinda, Nuanjun; Mahasirimongkol, Surakameth] Minist Publ Hlth, Med Life Sci Inst, Dept Med Sci, Med Genet Ctr, Nonthaburi, Thailand.
   [Mushiroda, Taisei] Ctr Integrat Med Sci, Lab Pharmacogen, Yokohama, Kanagawa, Japan.
   [Akiyama, Masato] RIKEN, Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan.
   [Momozawa, Yukihide; Kubo, Michiaki] Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan.
C3 Rajavithi Hospital; Rangsit University; Ministry of Public Health -
   Thailand; RIKEN
RP Ruamviboonsuk, P (通讯作者)，Rangsit Univ, Rajavithi Hosp, Dept Ophthalmol, Coll Med, 2 Phayathai Rd, Bangkok 10400, Thailand.
EM paisan.trs@gmail.com
RI Akiyama, Masato/AHC-2589-2022
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Chantaren P, 2012, CLIN OPHTHALMOL, V6, P465, DOI 10.2147/OPTH.S30529
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Constable IJ, 2016, ASIA-PAC J OPHTHALMO, V5, P300, DOI 10.1097/APO.0000000000000222
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumaramanickavel G, 2016, ASIA-PAC J OPHTHALMO, V5, P229, DOI 10.1097/APO.0000000000000223
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047
   Pearson TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
NR 21
TC 6
Z9 6
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD NOV
PY 2017
VL 62
IS 11
BP 957
EP 962
DI 10.1038/jhg.2017.72
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FK7GG
UT WOS:000413672700004
PM 28703135
DA 2022-11-30
ER

PT J
AU Smailhodzic, D
   van Asten, F
   Blom, AM
   Mohlin, FC
   den Hollander, AI
   van de Ven, JPH
   van Huet, RAC
   Groenewoud, JMM
   Tian, Y
   Berendschot, TTJM
   Lechanteur, YTE
   Fauser, S
   de Bruijn, C
   Daha, MR
   van der Wilt, GJ
   Hoyng, CB
   Klevering, BJ
AF Smailhodzic, Dzenita
   van Asten, Freekje
   Blom, Anna M.
   Mohlin, Frida C.
   den Hollander, Anneke I.
   van de Ven, Johannes P. H.
   van Huet, Ramon A. C.
   Groenewoud, Joannes M. M.
   Tian, Yuan
   Berendschot, Tos T. J. M.
   Lechanteur, Yara T. E.
   Fauser, Sascha
   de Bruijn, Chris
   Daha, Mohamed R.
   van der Wilt, Gert Jan
   Hoyng, Carel B.
   Klevering, B. Jeroen
TI Zinc Supplementation Inhibits Complement Activation in Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; BLUE MOUNTAINS EYE; DIETARY ANTIOXIDANTS;
   CLINICAL-TRIAL; RISK ALLELES; SYSTEM; PREVALENCE; CFH; RANIBIZUMAB;
   MACULOPATHY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. AMD is a multifactorial disorder but complement-mediated inflammation at the level of the retina plays a pivotal role. Oral zinc supplementation can reduce the progression of AMD but the precise mechanism of this protective effect is as yet unclear. We investigated whether zinc supplementation directly affects the degree of complement activation in AMD and whether there is a relation between serum complement catabolism during zinc administration and the complement factor H (CFH) gene or the Age-Related Maculopathy susceptibility 2 (ARMS2) genotype. In this open-label clinical study, 72 randomly selected AMD patients in various stages of AMD received a daily supplement of 50 mg zinc sulphate and 1 mg cupric sulphate for three months. Serum complement catabolism-defined as the C3d/C3 ratio-was measured at baseline, throughout the three months of supplementation and after discontinuation of zinc administration. Additionally, downstream inhibition of complement catabolism was evaluated by measurement of anaphylatoxin C5a. Furthermore, we investigated the effect of zinc on complement activation in vitro. AMD patients with high levels of complement catabolism at baseline exhibited a steeper decline in serum complement activation (p<0.001) during the three month zinc supplementation period compared to patients with low complement levels. There was no significant association of change in complement catabolism and CFH and ARMS2 genotype. In vitro zinc sulphate directly inhibits complement catabolism in hemolytic assays and membrane attack complex (MAC) deposition on RPE cells. This study provides evidence that daily administration of 50 mg zinc sulphate can inhibit complement catabolism in AMD patients with increased complement activation. This could explain part of the mechanism by which zinc slows AMD progression.
C1 [Smailhodzic, Dzenita; van Asten, Freekje; den Hollander, Anneke I.; van de Ven, Johannes P. H.; van Huet, Ramon A. C.; Lechanteur, Yara T. E.; Hoyng, Carel B.; Klevering, B. Jeroen] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Blom, Anna M.; Mohlin, Frida C.] Lund Univ, Sect Med Prot Chem, Dept Lab Med Malmo, Malmo, Sweden.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.; van der Wilt, Gert Jan] Radboud Univ Nijmegen Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands.
   [Tian, Yuan; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, Maastricht, Netherlands.
   [Fauser, Sascha] Univ Cologne, Dept Ophthalmol, D-50931 Cologne, Germany.
   [de Bruijn, Chris] Innomedics, Dusseldorf, Germany.
   [Daha, Mohamed R.] Leiden Univ Med Ctr, Dept Nephrol, Leiden, Netherlands.
C3 Radboud University Nijmegen; Lund University; Radboud University
   Nijmegen; Radboud University Nijmegen; Maastricht University; Maastricht
   University Medical Centre (MUMC); University of Cologne; Leiden
   University; Leiden University Medical Center (LUMC)
RP Klevering, BJ (通讯作者)，Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
EM Jeroen.Klevering@radboudumc.nl
RI Berendschot, Tos TJM/M-8509-2016; Groenewoud, Hans JMM/R-3588-2017; van
   der Wilt, G.J./H-8120-2014; Klevering, B.J./L-4434-2015; van Huet, Ramon
   AC/A-4652-2016; Lehtimäki, Terho/AAD-1094-2022; Blom,
   Anna/AFS-7369-2022; van Asten, Freekje/P-6028-2015; Hoyng,
   C.B./H-8050-2014; Blom, Anna/B-9607-2009; Lechanteur,
   Yara/ABB-6875-2020; Hollander, Anneke den/N-4911-2014
OI Berendschot, Tos TJM/0000-0002-8101-939X; Groenewoud, Hans
   JMM/0000-0002-4974-150X; van der Wilt, G.J./0000-0002-5856-762X; van
   Huet, Ramon AC/0000-0003-2786-3511; Lehtimäki,
   Terho/0000-0002-2555-4427; van Asten, Freekje/0000-0002-8141-4234; Blom,
   Anna/0000-0002-1348-1734; Lechanteur, Yara/0000-0003-0951-4625; Tian,
   Yuan/0000-0002-9551-9061
FU Netherlands Organisation for Scientific Research [016.096.309]; MD
   Fonds; Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting
   Researchfonds Oogheelkunde; Stichting Nederlands Oogheelkundig
   Onderzoek; Stichting Blindenhulp; Gelderse Blindenstichting; Swedish
   Research Council [K2012-66X-14928-09-5]; grant for clinical research
   (ALF)
FX This work was supported by the Netherlands Organisation for Scientific
   Research (grant 016.096.309), the MD Fonds, the Oogfonds, the Landelijke
   Stichting voor Blinden en Slechtzienden, the Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid, the Stichting Researchfonds
   Oogheelkunde, the Stichting Nederlands Oogheelkundig Onderzoek, the
   Stichting Blindenhulp, the Gelderse Blindenstichting, the Swedish
   Research Council (K2012-66X-14928-09-5) and the grant for clinical
   research (ALF). Zinc sulphate and cupric sulphate capsules were a
   generous gift from Sanmed, Almere, the Netherlands. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Chew E.Y., 2014, OPHTHALMOLOGY
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lowe NM, 2012, BRIT J NUTR, V108, P1962, DOI 10.1017/S0007114512004382
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   REDDINGIUS RE, 1993, PERITON DIALYSIS INT, V13, P214
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schell TC, 1996, J ANIM SCI, V74, P1584
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Siezenga MA, 2009, CLIN EXP IMMUNOL, V157, P98, DOI 10.1111/j.1365-2249.2009.03959.x
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WEDEKIND KJ, 1990, J ANIM SCI, V68, P684
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 54
TC 32
Z9 32
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 13
PY 2014
VL 9
IS 11
AR e112682
DI 10.1371/journal.pone.0112682
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AY6YT
UT WOS:000347709300085
PM 25393287
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zerbib, J
   Richard, F
   Puche, N
   Leveziel, N
   Cohen, SY
   Korobelnik, JF
   Sahel, J
   Munnich, A
   Kaplan, J
   Rozet, JM
   Souied, EH
AF Zerbib, Jennyfer
   Richard, Florence
   Puche, Nathalie
   Leveziel, Nicolas
   Cohen, Salomon Y.
   Korobelnik, Jean-Francois
   Sahel, Jose
   Munnich, Arnold
   Kaplan, Josseline
   Rozet, Jean-Michel
   Souied, Eric H.
TI R102G polymorphism of the C3 gene associated with exudative age-related
   macular degeneration in a French population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; GEOGRAPHIC ATROPHY; MOLECULAR
   ANALYSIS; CIGARETTE-SMOKING; POOLED FINDINGS; 3 CONTINENTS; FACTOR-B;
   SUSCEPTIBILITY; VARIANT
AB Purpose: Major genetic factors for age-related macular degeneration (AMD) have recently been identified as susceptibility risk factors, underlying the role of the complement pathway in AMD. Our purpose was to analyze the role of the R102G polymorphism of the complement component (C3) gene in a French population, in a case-control study.
   Methods: A total of 1,080 patients with exudative AMD and 406 controls were recruited and genotyped for Y402H of complement factor H (CFH), rs10490924 of age-related maculopathy susceptibility 2 (ARMS2), and R102G of the C3 gene.
   Results: The distribution of the R102G genotypes was significantly different in the AMD patients compared to controls (p = 0.02). The Odds Ratio compared to C/C individuals was 1.4 (95% CI 1.1-1.8) for C/G individuals and 1.4 (95% CI 0.8-2.4) for G/G individuals. In a dominant model, the adjusted Odds Ratio for carriers of the G allele is 1.4 (95% CI 1.01.9; p = 0.03).
   Conclusions: Our study shows C3 to be a moderate susceptibility gene for exudative AMD in the French population.
C1 [Zerbib, Jennyfer; Puche, Nathalie; Leveziel, Nicolas; Souied, Eric H.] Univ Paris 12, Hop Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Zerbib, Jennyfer; Munnich, Arnold; Kaplan, Josseline; Rozet, Jean-Michel] Hop Necker Enfants Malad, INSERM, Dept Genet, U781, Paris, France.
   [Richard, Florence] Univ Lille Nord France, INSERM, UMR744, Inst Pasteur, Lille, France.
   [Cohen, Salomon Y.] Ophthalmol Ctr Imaging & Laser, Paris, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, INSERM, U897, CHU Bordeaux, F-33076 Bordeaux, France.
   [Sahel, Jose] Univ Paris 06, INSERM, Inst Vis, Paris, France.
   [Souied, Eric H.] Unite Fonct Rech Clin, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Necker-Enfants Malades - APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; Universite de
   Lille; CHU Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite de
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP
RP Souied, EH (通讯作者)，Univ Paris 12, Hop Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Sahel, Jose-Alain/F-3172-2017; KOROBELNIK, Jean-Francois/A-5448-2016;
   ROZET, Jean-Michel/E-5737-2016; KAPLAN, Josseline/I-2622-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; ROZET,
   Jean-Michel/0000-0001-7951-7886; KAPLAN, Josseline/0000-0002-1849-8658;
   Nicolas, Leveziel/0000-0001-8533-9457
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 36
TC 21
Z9 21
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 15
PY 2010
VL 16
IS 145-50
BP 1324
EP 1330
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 643GN
UT WOS:000281283700002
PM 20664795
DA 2022-11-30
ER

PT J
AU Tian, J
   Yu, WZ
   Qin, XY
   Fang, K
   Chen, Q
   Hou, J
   Li, J
   Chen, DF
   Hu, YH
   Li, XX
AF Tian, Jun
   Yu, Wenzhen
   Qin, Xueying
   Fang, Kai
   Chen, Qing
   Hou, Jing
   Li, Juan
   Chen, Dafang
   Hu, Yonghua
   Li, Xiaoxin
TI Association of Genetic Polymorphisms and Age-Related Macular
   Degeneration in Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT-FACTOR-H; HTRA1 PROMOTER
   POLYMORPHISM; NONCODING VARIANT; INCREASES RISK; SERPING1 GENE; CFH; C3;
   HAPLOTYPE; SMOKING
AB PURPOSE. We explored associations between age-related macular degeneration (AMD) and genetic variants of 10 genes in a nationwide Chinese population.
   METHODS. In this multicenter case-control study, 535 AMD patients and 469 controls were recruited from 16 centers that spread from the north to the south of China. All participants underwent comprehensive eye examinations, and 40 single nucleotide polymorphisms (SNPs) of 10 genes were selected. DNA samples were genotyped with the MassArray system. The effect of the genotypes and haplotypes on AMD was assessed with logistic regression analysis, adjusted for age, sex, long-term residence, and family origin.
   RESULTS. In our study, 11 SNPs in complement H (CFH), 2 in age-related maculopathy susceptibility 2 (ARMS2), and 2 in high-temperature requirement factor A1 (HTRA1) were associated significantly with AMD. They were rs551397, rs800292, rs1329424, rs1061170, rs10801555, rs12124794, rs10733086, rs10737680, rs2274700, rs1410996, and rs380390 in CFH; rs10490924 and rs2736912 in ARMS2; and rs11200638 and rs3793917 in HTRA1. Three haplotypes in CFH, predisposed the patients significantly to AMD (P < 0.001, P = 0.001, and P < 0.001, respectively). With the sample size of our study, no relationship was found for AMD and the SNPs tested in complement 3 (C3); serpin peptidase inhibitor, clade G, member 1 (SERPING1); vascular endothelial growth factor (VEGF); cholesterol ester transfer protein (CETP); lipoprotein lipase (LPL); hepatic lipase (LIPC); and metallopeptidase inhibitor 3 (TIMP3) genes.
   CONCLUSIONS. Gene variants in CFH, ARMS2, and HTRA1 contribute to AMD in the Chinese population. (Invest Ophthalmol Vis Sci. 2012;53:4262-4269) DOI:10.1167/iovs.11-8542
C1 [Tian, Jun; Qin, Xueying; Fang, Kai; Chen, Dafang; Hu, Yonghua] Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100191, Peoples R China.
   [Yu, Wenzhen; Hou, Jing; Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Yu, Wenzhen; Hou, Jing; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Chen, Qing] Third Mil Med Univ, Prevent Med Coll, Dept Hyg Toxicol, Chongqing, Peoples R China.
   [Li, Juan] Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China.
C3 Peking University; Peking University; Army Medical University
RP Hu, YH (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM yhhu@bjmu.edu.cn; dr_lixiaoxin@163.com
RI 陈, 卿/Q-5601-2019
OI 陈, 卿/0000-0003-4108-7977
FU Ministry of Science and Technology of the People's Republic of China
   [2006BAI02B05]; National Basic Research Program of China (973 Program)
   [2011CB510200]
FX Supported by the Mega-projects of Science Research for the 11th
   Five-Year Plan from The Ministry of Science and Technology of the
   People's Republic of China (2006BAI02B05), and the National Basic
   Research Program of China (973 Program, 2011CB510200). The funding
   organization had no role in the design or conduct of this research.
CR Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Lu F, 2010, MOL VIS, V16, P1
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 40
TC 54
Z9 59
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2012
VL 53
IS 7
BP 4262
EP 4269
DI 10.1167/iovs.11-8542
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 971CM
UT WOS:000306181200117
PM 22618592
DA 2022-11-30
ER

PT J
AU Choi, KE
   Kim, SW
   Yun, C
   Oh, J
AF Choi, Kwang-Eon
   Kim, Seong-Woo
   Yun, Cheolmin
   Oh, Jaeryung
TI MORPHOLOGIC AND ANATOMICAL FEATURES OF TYPE 1 MACULAR NEOVASCULARIZATION
   TRUNKS IN AGE-RELATED MACULAR DEGENERATION USING OPTICAL COHERENCE
   TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; Bruch membrane; macular
   neovascularization; optical coherence tomography; optical coherence
   tomography angiography; trunk
ID SUBMACULAR SURGERY TRIALS; CHOROIDAL NEOVASCULARIZATION;
   CLINICOPATHOLOGICAL CORRELATION; POSTMORTEM EYES; LESIONS
AB Purpose: To evaluate the morphologic features of macular neovascularization (MNV) trunks at different layers using optical coherence tomography angiography. Methods: Type 1 MNV trunks in age-related macular degeneration were retrospectively evaluated at the subretinal pigment epithelium and sub-Bruch membrane (subBM) layers. The detectability and location of the trunks were compared. MNV trunks at the subBM layer on optical coherence tomography angiography B-scans were evaluated using a flow overlay. The correlations of the MNV trunk with optical coherence tomography angiography and optical coherence tomography parameters were evaluated. Results: Among the 63 included eyes, 27 showed core vessels at the subretinal pigment epithelium layer and 52 showed MNV trunks at the subBM layer, which were connected with the MNV at the subretinal pigment epithelium layer. The locations of the MNV trunks in each layer were different. MNV trunk types at the subBM layer were related to disease duration, distance from the large choroidal vessels, and MNV vessel density. The large choroidal vessel diameter was correlated with the MNV trunk diameter at the subBM layer. Conclusion: Macular neovascularization trunks at the subBM layer were detected more frequently than distal MNV trunks at the subretinal pigment epithelium layer. Macular neovascularization trunk features at the subBM layer may be related to disease duration and a large choroidal vessel.
C1 [Choi, Kwang-Eon; Kim, Seong-Woo; Yun, Cheolmin; Oh, Jaeryung] Korea Univ, Dept Ophthalmol, Coll Med, 148 Gurodong Ro, Seoul 08308, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Kim, SW (通讯作者)，Korea Univ, Dept Ophthalmol, Coll Med, 148 Gurodong Ro, Seoul 08308, South Korea.
EM ksw64723@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Bio & Medical Technology Development Program of the NRF; Korean
   government; Ministry of Science, ICT and Future Planning (MSIP)
   [NRF-2017M3A9E2056458, 2020R1A2C1005729]; Korea University Guro Hospital
   [O2001171]
FX Supported in part by the Bio & Medical Technology Development Program of
   the NRF, which is funded in part by the Korean government and the
   Ministry of Science, ICT and Future Planning (MSIP)
   (NRF-2017M3A9E2056458 and 2020R1A2C1005729) and by the Korea University
   Guro Hospital (O2001171).
CR Ahn J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-55606-9
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Carpenter CL, 2018, ADV EXP MED BIOL, V1074, P157, DOI 10.1007/978-3-319-75402-4_20
   Choi KE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70784-7
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kang SJ, 2007, BRIT J OPHTHALMOL, V91, P1602, DOI 10.1136/bjo.2007.121830
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Muir ER, 2011, NMR BIOMED, V24, P216, DOI 10.1002/nbm.1576
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Park SY, 2020, J KOR OPHTHALMOL SOC, V61, P482, DOI 10.3341/jkos.2020.61.5.482
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Skalet AH, 2017, RETINA-J RET VIT DIS, V37, P1620, DOI 10.1097/IAE.0000000000001672
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
NR 24
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2022
VL 42
IS 3
BP 494
EP 502
DI 10.1097/IAE.0000000000003331
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZD6KA
UT WOS:000758305500017
PM 34723899
DA 2022-11-30
ER

PT J
AU Yamauchi, Y
   Kemma, H
   Goto, H
   Nakamura, A
   Nagaoka, T
   Sota, T
AF Yamauchi, Yasuyuki
   Kemma, Hiroyuki
   Goto, Hiroshi
   Nakamura, Atsushi
   Nagaoka, Takashi
   Sota, Takayuki
TI Novel automated screening of age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Near-infrared hyperspectral imaging;
   Automated method for screening
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; SPECTRAL
   REFLECTANCE; 10-YEAR INCIDENCE; RANIBIZUMAB; VERTEPORFIN; PROGRESSION;
   MACULOPATHY
AB To determine the objective and quantitative hyperspectral parameters for distinguishing between age-related macular degeneration (AMD) and a normal macula.
   Near-infrared hyperspectral images were taken of 71 eyes of 62 AMD patients with exudative AMD and 21 eyes of 12 control subjects without AMD. The spatial information included a 480 x 321-pixel image in a 50A degrees field located at the ocular fundus and a 720-950-nm-per-pixel reflectance spectrum. Macular vectors were determined as the average spectrum for each macula, and reference vectors were used as average macular vectors for healthy volunteers. Variations in vector length and angle were calculated based on comparison with the reference vector. The AMD differentiation index was a parameter that minimized the plot overlap between AMD patients and controls.
   Statistically significant differences between the AMD patients and controls were noted. Receiver-operating characteristic curve analysis revealed an area under the curve of 0.888. The appropriate threshold values were attained for the proposed discrimination index, including 68 % sensitivity, 95 % specificity and 74 % accuracy.
   This study presents a simplified diagnostic index for the determination of age-related macular degeneration based on near-infrared spectra.
C1 [Yamauchi, Yasuyuki; Goto, Hiroshi] Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, Tokyo 1600023, Japan.
   [Yamauchi, Yasuyuki] Toda Chuo Gen Hosp, Dept Ophthalmol, Saitama, Japan.
   [Kemma, Hiroyuki; Nakamura, Atsushi; Sota, Takayuki] Waseda Univ, Dept Elect Engn & Biosci, Tokyo, Japan.
   [Nagaoka, Takashi] Waseda Univ, Inst Sci & Engn, Tokyo, Japan.
C3 Tokyo Medical University; Waseda University; Waseda University
RP Yamauchi, Y (通讯作者)，Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.
EM phthisis@nifty.com
OI Nagaoka, Takashi/0000-0002-7460-5008
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   BERNERT G, 1995, WIEN KLIN WOCHENSCHR, V107, P569
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Khoobehi B, 2004, INVEST OPHTH VIS SCI, V45, P1464, DOI 10.1167/iovs.03-1069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Nagaoka T, 2012, SKIN RES TECHNOL, V18, P301, DOI 10.1111/j.1600-0846.2011.00571.x
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schweitzer D, 1996, OPHTHALMIC RES, V28, P37, DOI 10.1159/000267955
   SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   Vo-Dinh T, 2004, IEEE ENG MED BIOL, V23, P40
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 28
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2012
VL 56
IS 6
BP 577
EP 583
DI 10.1007/s10384-012-0184-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 036AC
UT WOS:000310996200008
PM 22968294
DA 2022-11-30
ER

PT J
AU Shah, SP
   Hubschman, JP
   Gonzales, CR
   Schwartz, SD
AF Shah, Sumit P.
   Hubschman, Jean Pierre
   Gonzales, Christine R.
   Schwartz, Steven D.
TI Submacular Combination Treatment for Management of Acute, Massive
   Submacular Hemorrhage in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID TISSUE-PLASMINOGEN-ACTIVATOR; SUBRETINAL HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; INTRAVITREAL INJECTION; NATURAL-HISTORY; GAS; REMOVAL
AB A Surgical technique is described combining submacular anti-vascular endothelial growth factor (anti-VEGF) and recombinant tissue plasminogen activator (r-TPA) with pneumatic displacement of massive submacular hemorrhage in age-related macular degeneration. An 84-year-old man with a large, acute submacular hemorrhage secondary to age-related macular degeneration underwent combination vitrectomy, submacular anti-VEGF and r-TPA injection with Pneumatic displacement of the hemorrhage. At the last follow-up visit, 7 months after surgery, visual acuity was 20/80 with a small fibrovascular pigment epithelial detachment and atrophic retinal pigment epithelial changes. A 77-year-old woman with known age-related macular degeneration underwent a similar Surgical procedure for a similar acute, large submacular hemorrhage related to age-related macular degeneration. Nine months after surgery, the visual acuity was 20/70(-1). Combination submacular anti-VEGF therapy delivered at the time of pars plana vitrectomy and submacular tissue plasminogen activator assisted hemorrhage displacement may be a viable treatment strategy for the management massive submacular hemorrhage. [Ophthalmic Surg Lasers Imaging 2009;40:308-315.]
C1 [Schwartz, Steven D.] Univ Calif Los Angeles, Retina Div, Jules Stein Eye Inst, David Geffen Sch Med,Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Schwartz, SD (通讯作者)，Univ Calif Los Angeles, Retina Div, Jules Stein Eye Inst, David Geffen Sch Med,Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
OI Hubschman, Jean-Pierre/0000-0002-8631-3467
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P920
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Saika S, 1998, GRAEF ARCH CLIN EXP, V236, P196, DOI 10.1007/s004170050064
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
NR 29
TC 10
Z9 10
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2009
VL 40
IS 3
BP 308
EP 315
DI 10.3928/15428877-20090430-16
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 446RY
UT WOS:000266140000016
PM 19485299
DA 2022-11-30
ER

PT J
AU Astroz, P
   Miere, A
   Amoroso, F
   Semoun, O
   Khorrami, A
   Srour, M
   Querques, G
   Souied, EH
AF Astroz, Polina
   Miere, Alexandra
   Amoroso, Francesca
   Semoun, Oudy
   Khorrami, Alexis
   Srour, Mayer
   Querques, Giuseppe
   Souied, Eric H.
TI SUBRETINAL TRANSIENT HYPOREFLECTIVITY IN AGE-RELATED MACULAR
   DEGENERATION A Spectral Domain Optical Coherence Tomography Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral domain optical coherence tomography; age-related macular
   degeneration; subretinal transient hyporeflectivity
ID OUTER RETINAL TUBULATION; GEOGRAPHIC ATROPHY; EVOLUTION
AB Purpose: To describe and assess the prognostic significance of subretinal transient hyporeflectivity (STHR) on a novel spectral domain optical coherence tomography (SD-OCT) in age-related macular degeneration. Methods: Consecutive patients with age-related macular degeneration (AMD) presenting STHR, defined as a small, well-defined, round subretinal, hyporeflective lesion, on SD-OCT and without exudative signs were included. Clinical examination and SD-OCT (SPECTRALIS, Heidelberg Engineering, Heidelberg, Germany) were analyzed at inclusion, 1 month before inclusion, and until the onset of exudative signs during the 12-month follow-up. Results: Thirty-five STHR in 21 eyes of 20 patients were included. Among the 21 eyes, 2 eyes had early AMD, 1 eye had nonexudative asymptomatic macular neovascularization, and 18 eyes presented late AMD: 17 eyes neovascular AMD and 1 eye geographic atrophy. During the 2-month follow-up, 97.1% (34/35) of STHR disappeared. During the 12-month follow-up, 57.1% of eyes (12/21) developed exudative signs on 1 eye with early AMD and 11 eyes with neovascular AMD. Conclusion: Subretinal transient hyporeflectivity is a novel SD-OCT sign in patients with AMD. The eyes with isolated STHR should be closely monitored on a monthly basis to detect further exudation.
C1 [Astroz, Polina; Miere, Alexandra; Amoroso, Francesca; Semoun, Oudy; Khorrami, Alexis; Srour, Mayer; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est, Intercity Hosp, Dept Ophthalmol, Creteil, France.
   [Querques, Giuseppe] Univ Vita Salute, IRCCS Osped San Raffaete, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
EM esouied@hotmail.com
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210
CR Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fernandez-Avellaneda P, 2021, AM J OPHTHALMOL, V222, P112, DOI 10.1016/j.ajo.2020.09.003
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Sacconi R, 2020, EUR J OPHTHALMOL, V30, pNP24, DOI 10.1177/1120672119846437
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 16
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 653
EP 660
DI 10.1097/IAE.0000000000003377
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200009
PM 34907127
DA 2022-11-30
ER

PT J
AU Papadopoulos, Z
AF Papadopoulos, Zois
TI Aflibercept: A review of its effect on the treatment of exudative
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Aflibercept; ziv-aflibercept; anti-vascular endothelial growth factor;
   age-related macular degeneration; exudative age-related macular
   degeneration; urokinase-type plasminogen activator receptor; UPARANT
ID THROMBOEMBOLIC ADVERSE EVENTS; ANTI-VEGF DRUGS; INTRAVITREAL
   AFLIBERCEPT; PEPTIDE UPARANT; TRAP-EYE; RANIBIZUMAB; INJECTION;
   OUTCOMES; ANGIOGENESIS; BEVACIZUMAB
AB Considerable improvement has been achieved in the way in which exudative age-related macular degeneration is conventionally treated and in the associated visual outcomes and prognosis, thanks to the agents with effects against vascular endothelial growth factor (anti-VEGF). By comparison to earlier treatment approaches that involved the use of lasers, the anti-VEGF agents have made it possible to accomplish more positive visual and anatomical outcomes in cases of exudative age-related macular degeneration. Indeed, owing to their positive effects, anti-VEGF agents have quickly come to be considered the gold standard for the treatment of wet age-related macular degeneration. Aflibercept, the most recently approved intravitreally administered anti-VEGF, seems to mark another milestone in the treatment of wet age-related macular degeneration. This anti-VEGF agent presents a series of singular pharmacodynamic and pharmacokinetic attributes that provide it a number of biological benefits in relation to the treatment of choroidal neovascularization compared to other agents. These attributes include high level of affinity for the VEGF-A factor, an intravitreal half-life of great length, as well as the ability to serve as an antagonist for other growth factors besides VEGF. The impact of Aflibercept on the manner in which exudative age-related macular degeneration is managed was demonstrated by thoroughly reviewing the related literature. The present review article highlights the pharmacology, pharmacokinetics, safety and effectiveness of this anti-VEGF agent as well as the landmark clinical studies that have been carried out to establish this drug as a gold standard in the therapy of neovascular age-related macular degeneration. In addition, studies regarding the outcomes and effectiveness of the various dosage regimens, either as monotherapy or in combination with other agents, are also reviewed.
C1 [Papadopoulos, Zois] Massachusetts Eye & Ear Infirm, Harvard Med Sch, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Papadopoulos, Z (通讯作者)，Massachusetts Eye & Ear Infirm, Harvard Med Sch, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM zoispapadopoulos@gmail.com
CR Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Breuss JM, 2012, CELL ADHES MIGR, V6, P535, DOI 10.4161/cam.22243
   Cammalleri M, 2016, INVEST OPHTH VIS SCI, V57, P2600, DOI 10.1167/iovs.15-18758
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Dal Monte M, 2015, INVEST OPHTH VIS SCI, V56, P2392, DOI 10.1167/iovs.14-16323
   Dias JRD, 2019, RETINA-J RET VIT DIS, V39, P648, DOI 10.1097/IAE.0000000000002001
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Frampton JE, 2012, DRUG AGING, V29, P839, DOI 10.1007/s40266-012-0015-2
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hassan M, 2016, EXPERT OPIN BIOL TH, V16, P699, DOI 10.1517/14712598.2016.1167182
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Herkenne S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2403
   Horton S, 2017, PRESCRIBER, V28, P37
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Khanani AM, 2016, J OCUL PHARMACOL TH, V32, P216, DOI 10.1089/jop.2015.0152
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Kim Ju Young, 2015, Korean J Ophthalmol, V29, P325, DOI 10.3341/kjo.2015.29.5.325
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   RUSCIANO D, 2016, INVEST OPHTH VIS SCI, V57
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Uhrin P, 2013, CELL ADHES MIGR, V7, P23, DOI 10.4161/cam.22124
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 43
TC 13
Z9 13
U1 2
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2019
VL 29
IS 4
BP 368
EP 378
DI 10.1177/1120672119832432
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA II6ZB
UT WOS:000475341000007
PM 30813810
DA 2022-11-30
ER

PT J
AU Klein, R
   Cruickshanks, KJ
   Nash, SD
   Krantz, EM
   Nieto, FJ
   Huang, GH
   Pankow, JS
   Klein, BEK
AF Klein, Ronald
   Cruickshanks, Karen J.
   Nash, Scott D.
   Krantz, Elizabeth M.
   Javier Nieto, F.
   Huang, Guan H.
   Pankow, James S.
   Klein, Barbara E. K.
TI The Prevalence of Age-Related Macular Degeneration and Associated Risk
   Factors
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 15-YEAR CUMULATIVE INCIDENCE; BEAVER DAM; CARDIOVASCULAR-DISEASE;
   CIGARETTE-SMOKING; ALCOHOL-CONSUMPTION; 5-YEAR INCIDENCE; HEARING-LOSS;
   MACULOPATHY; WISCONSIN; EPIDEMIOLOGY
AB Objectives: To determine the prevalence of age-related macular degeneration (AMD) and to examine how retinal drusen, retinal pigmentary abnormalities, and early AMD are related to age, sex, and other risk factors.
   Participants: A total of 2810 people aged 21 to 84 years participating in the Beaver Dam Offspring Study.
   Methods: The presence and severity of various characteristics of drusen and other lesions typical of AMD were determined by grading digital color fundus images using the Wisconsin Age-Related Maculopathy Grading System.
   Results: Early AMD was present in 3.4% of the cohort and varied from 2.4% in those aged 21 to 34 years to 9.8% in those aged 65 years or older. In a multivariable model (expressed as odds ratio; 95% confidence interval), age (per 5 years of age, 1.22; 1.09-1.36), being male (1.65; 1.01-2.69), more pack-years of cigarettes smoked (1-10 vs 0, 1.31; 0.75-2.29; >= 11 vs 0, 1.67; 1.03-2.73), higher serum high-density lipoprotein cholesterol level (per 5 mg/dL, 0.91; 0.83-0.998), and hearing impairment (2.28; 1.41-3.71) were associated with early AMD. There were no associations of blood pressure level, body mass index, physical activity level, history of heavy drinking, white blood cell count, hematocrit level, platelet count, serum total cholesterol level, or carotid intimal-medial thickness with early AMD.
   Conclusions: These data indicate that early AMD is infrequent before age 55 years but increases with age thereafter. Early AMD is related to modifiable risk factors, eg, smoking and serum high-density lipoprotein cholesterol level.
C1 [Klein, Ronald; Cruickshanks, Karen J.; Krantz, Elizabeth M.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Cruickshanks, Karen J.; Nash, Scott D.; Javier Nieto, F.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Huang, Guan H.] Natl Chiao Tung Univ, Inst Stat, Hsinchu, Taiwan.
   [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   National Yang Ming Chiao Tung University; University of Minnesota
   System; University of Minnesota Twin Cities
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,Room 417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Datta, Sayantan/D-1369-2010
OI Pankow, James/0000-0001-7076-483X; Klein, Ronald/0000-0002-4428-6237
FU National Institutes of Health; Research to Prevent Blindness; National
   Institute on Aging, National Eye Institute, National Institute on
   Deafness and Other Communication Disorders [AG021917, R01AG021917];
   NATIONAL INSTITUTE ON AGING [R01AG021917] Funding Source: NIH RePORTER
FX This research was supported by grants AG021917 and R01AG021917 from the
   National Institute on Aging, National Eye Institute, National Institute
   on Deafness and Other Communication Disorders, and National Institutes
   of Health (Dr Cruickshanks), and, in part, by Senior Scientific
   Investigator Awards from Research to Prevent Blindness (Drs R. Klein and
   B.E.K. Klein).
CR *ARIC STUD GROUP, 1991, J NEUROIMAGING, V1, P68
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Carlsson CM, 2009, ALZ DIS ASSOC DIS, V23, P11, DOI 10.1097/WAD.0b013e3181850188
   Cruickshanks KJ, 2009, ANN NY ACAD SCI, V1170, P543, DOI 10.1111/j.1749-6632.2009.04103.x
   Cruickshanks Karen J, 2009, WMJ, V108, P271
   Cruickshanks KJ, 2003, ARCH OTOLARYNGOL, V129, P1041, DOI 10.1001/archotol.129.10.1041
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Gao FY, 2001, J AM STAT ASSOC, V96, P127, DOI 10.1198/016214501750332749
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, MACULAR DEGENERATION, P79
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   Riley WA, 1991, J NEUROIMAGING, V1, P168, DOI DOI 10.1111/JON199114168
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 42
TC 204
Z9 210
U1 0
U2 29
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2010
VL 128
IS 6
BP 750
EP 758
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 610QA
UT WOS:000278747900014
PM 20547953
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Lee, H
   Ji, B
   Chung, H
   Kim, HC
AF Lee, Hyungwoo
   Ji, Bokjun
   Chung, Hyewon
   Kim, Hyung Chan
TI CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI
   AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; hyperreflective foci; spectral domain optical coherence
   tomography; anti-VEGF; photoreceptor
ID RETINAL VEIN OCCLUSION; EDEMA; THERAPY; ACUITY
AB Purpose:To investigate the correlation between hyperreflective foci (HF) on spectral domain optical coherence tomography at baseline and visual outcomes after intravitreal anti-vascular endothelial growth factor injection in neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).Methods:The authors retrospectively reviewed the medical records of 44 patients with nAMD and 44 patients with PCV. The number of HF was counted according to the location of HF on spectral domain optical coherence tomography: neurosensory retinal layer, outer retinal layer, and subretinal layer. Statistical correlation between final visual acuity and pretreatment and posttreatment optical coherence tomographic parameters including the number of HF, the status of external limiting membrane and inner segment ellipsoid zone was evaluated.Results:The number of HF in all retinal layers was reduced in nAMD and PCV after treatment. In multivariate regression analysis, final visual acuity was associated with baseline visual acuity (P = 0.028), number of subretinal HF (P = 0.046), and ellipsoid zone disruption length (P = 0.009) in nAMD. In PCV, final visual acuity was associated with baseline visual acuity (P = 0.001), number of subretinal HF (P = 0.001), and pigment epithelial detachment thickness (P = 0.034). The baseline number of subretinal HF was correlated with final foveal thickness and thickness of subretinal fluid and choroidal neovascularization in nAMD (P = 0.002, P < 0.001, P = 0.009, respectively). In PCV, the baseline number of subretinal HF was correlated with final foveal thickness and ellipsoid zone and external limiting membrane disruption lengths (P = 0.027, P = 0.010, P = 0.020, respectively).Conclusion:The number of HF at subretinal layer on spectral domain optical coherence tomography at baseline might predict the final visual acuity after treatment in nAMD and PCV.
C1 [Lee, Hyungwoo; Ji, Bokjun; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 143729, South Korea.
EM eyekim@kuh.ac.kr
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology [NRF-2012M3A9B2028333]
FX This work was supported by the National Research Foundation of Korea
   (NRF) funded by the Ministry of Education, Science and Technology
   (NRF-2012M3A9B2028333).
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Choi BCK, 1998, AM J EPIDEMIOL, V148, P1127
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
NR 25
TC 21
Z9 23
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP 465
EP 475
DI 10.1097/IAE.0000000000000645
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG1MW
UT WOS:000371833200005
PM 26076214
DA 2022-11-30
ER

PT J
AU Lally, DR
   Gerstenblith, AT
   Regillo, CD
AF Lally, David R.
   Gerstenblith, Adam T.
   Regillo, Carl D.
TI Preferred therapies for neovascular age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE bevacizumab; macular degeneration; neovascularization; ranibizumab;
   vascular endothelial growth factor; VEGF trap-eye
ID INTRAVITREAL BEVACIZUMAB AVASTIN; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL; ANTI-VEGF AGENTS;
   PHOTODYNAMIC THERAPY; COMBINATION THERAPY; VERTEPORFIN THERAPY; 12-MONTH
   SAFETY; SHORT-TERM; RANIBIZUMAB
AB Purpose of review
   This report reviews the current treatment strategies and the most recent clinical trials in the treatment of neovascular age-related macular degeneration.
   Recent findings
   The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Additionally, level I evidence now exists for the noninferiority of bevacizumab, as compared to ranibizumab, in the treatment of neovascular age-related macular degeneration (AMD) through 1 year of follow-up. Aflibercept has emerged as a new anti-vascular endothelial growth factor (VEGF) therapy showing encouraging treatment results at 1 year. Novel treatments combined with anti-VEGF agents such as localized radiation are currently being investigated.
   Summary
   Anti-VEGF monotherapy remains the preferred therapy for the management of neovascular AMD at the present time. Aflibercept is a new, FDA-approved, effective, anti-VEGF agent available for clinical use. Ongoing clinical trials will help determine the optimal dosing regimens for all of these agents, as well as the long-term efficacy and safety of combination therapy modalities.
C1 [Lally, David R.; Gerstenblith, Adam T.; Regillo, Carl D.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
   [Regillo, Carl D.] Mid Atlantic Retina, Wyndmoor, PA USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
FU Genentech; Regeneron; Allergan; QLT; Neovista; GSK
FX C.D.R., MD, receives research grant support from Genentech, Regeneron,
   Allergan, QLT, Neovista, and GSK and is a consultant for Genentech,
   Regeneron, GSK, and QLT.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   [Anonymous], 2011 AM AC OPHTH M O
   [Anonymous], 2010, BAYER REGENERON REPO
   [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1232
   Arias Elizabeth, 2010, Natl Vital Stat Rep, V58, P1
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bolz M, 2008, 8 EURETINA C MAY 200
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Kent D, 2003, MOL VIS, V9, P747
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wan MJ, 2010, CAN J OPHTHALMOL, V45, P375, DOI 10.3129/i10-011
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 69
TC 41
Z9 43
U1 0
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2012
VL 23
IS 3
BP 182
EP 188
DI 10.1097/ICU.0b013e328352411c
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933TQ
UT WOS:000303386000004
PM 22450218
DA 2022-11-30
ER

PT J
AU MacDonald, IM
AF MacDonald, IM
TI Genetic aspects of age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; Best vitelliform macular dystrophy; macular degeneration;
   molecular genetic analysis; Sorsby's pseudo inflammatory fundus
   dystrophy; Stargardt disease
ID SUSCEPTIBILITY LOCI; TISSUE INHIBITOR; APOLIPOPROTEIN-E; EFEMP1
   MUTATION; DYSTROPHY; DISEASE; ABCR; ASSOCIATION; MACULOPATHY; FAMILY
AB Age-related macular degeneration (AMD) is a complex phenotype that has multiple causes, including genetic. This paper reviews pertinent single-gene disorders, polymorphisms in the human genome that modify disease severity, and maculopathies that provide insight into the pathogenesis of AMD and the function of the normal macula. The availability of DNA-based analysis for certain genes will likely increase the demand for genetic counselling of patients and families with AMD. Better knowledge of risks should help prevent blindness in these families.
C1 Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada.
C3 University of Alberta
RP MacDonald, IM (通讯作者)，Univ Alberta, Royal Alexandra Hosp, Dept Ophthalmol, Rm 2319,10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada.
EM macdonal@ualberta.ca
OI MacDonald, Ian/0000-0001-7472-8385
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   *CAN NAT I, 2003, CAN NAT I BLIND CLIE
   FISH G, 1988, BR J OPHTHALMOL, V106, P651
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   John R, 2004, JAIDS-J ACQ IMM DEF, V35, P1, DOI 10.1097/00126334-200401010-00001
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Matsumoto M, 2001, AM J OPHTHALMOL, V131, P810, DOI 10.1016/S0002-9394(00)00926-0
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Souied E, 2001, J FR OPHTALMOL, V24, P875
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 32
TC 4
Z9 6
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 288
EP 292
DI 10.1016/S0008-4182(05)80071-7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400004
PM 15947798
DA 2022-11-30
ER

PT J
AU Lin, JM
   Wan, L
   Tsai, YY
   Lin, HJ
   Tsai, Y
   Lee, CC
   Tsai, CH
   Tseng, SH
   Tsai, FJ
AF Lin, Jane-Ming
   Wan, Lei
   Tsai, Yi-Yu
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tseng, Sung-Huei
   Tsai, Fuu-Jen
TI Vascular endothelial growth factor gene polymorphisms in age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; FACTOR-H POLYMORPHISM; VEGF GENE;
   OCULAR NEOVASCULARIZATION; VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE;
   EXPRESSION; PEGAPTANIB; Y402H
AB PURPOSE: To investigate vascular endothelial growth factor (VEGF) gene polymorphisms in unrelated Taiwan Chinese patients with late age,related macular degeneration (AMD) and controls.
   DESIGN: Retrospective case-control study.
   METHODS: We enrolled 190 late AMD patients and 180 age-matched and gender-matched controls. Late AMD was classified as either dry (atrophic; grade 4) or wet (neovascular; grade 5) according to the International Age-Related Maculopathy Epidemiologic Study. Genomic deoxyribonucleic acid was prepared from peripheral blood obtained from all subjects. Polymerase chain reactions were used to analyze five candidate single-nucleotide polymorphisms (SNPs) in VEGF gene: +405C/G (rs2010963), -460 T/C (rs833061), +674 C/T (rs1413711), +936C/T (rs3025039), and -2578C/A (rs699947).
   RESULTS: Of the 190 late AMD patients, dry AMD was diagnosed in 104 and wet AMD in 86. Among the five candidate SNPs studied, only the +936 C/T was significantly associated with wet AMD (T allele: 30% in wet AMD vs 14% in controls; P = 1.45 x 10(-5); odds ratio, 2.61; 95% confidence interval, 1.68 to 4.07). No single haplotype was significantly associated with either late AMD or controls. Based on genotypes at both VEGF +936 C/T and the complement factor H (CFH) Y402H (rs1061170), the association of VEGF +936 C/T to AMD was significant when analyzed conditional on the presence of the CFH C risk allele and vice versa (P < .0001). The VEGF +936 C/T was in strong linkage disequilibrium with CFH Y402H (D' = 0.99).
   CONCLUSIONS: Both VEGF +936 C/T and CFH Y402H polymorphisms are dependently associated with wet AMD in the Taiwan Chinese population.
C1 [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan.
   [Lin, Jane-Ming; Tsai, Yi-Yu; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan.
   [Wan, Lei; Lee, Cheng-Chun; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.
   [Tsai, Yushin; Tsai, Fuu-Jen] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
   [Tseng, Sung-Huei] Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 70428, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; Asia
   University Taiwan; National Cheng Kung University; National Cheng Kung
   University Hospital
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Rd, Taichung 404, Taiwan.
EM d0704@mail.cmuh.org.tw
RI Wan, Lei/F-4719-2010; Tsai, Fuu-Jen/J-4140-2015
OI Wan, Lei/0000-0002-9525-3232
CR Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koukourakis MI, 2004, LUNG CANCER, V46, P293, DOI 10.1016/j.lungcan.2004.04.037
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260
   Stevens A, 2003, CANCER RES, V63, P812
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 39
TC 68
Z9 74
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2008
VL 145
IS 6
BP 1045
EP 1051
DI 10.1016/j.ajo.2008.01.027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307PS
UT WOS:000256331400017
PM 18378209
DA 2022-11-30
ER

PT J
AU Kawasaki, R
   Wang, JJ
   Amirul, FMA
   Rochtchina, E
   Aung, T
   Saw, SM
   Mitchell, P
   Wong, TY
AF Kawasaki, Ryo
   Wang, Jie Jin
   Amirul, F. M. Amirul
   Rochtchina, Elena
   Aung, Tin
   Saw, Seang Mei
   Mitchell, Paul
   Wong, Tien Yin
TI Is Bilateral Age-related Macular Degeneration Less Common in Asians than
   Caucasians?
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Epidemiology; Risk factors; Ethnicity;
   Singapore Malay Eye Study; Blue Mountains Eye Study
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; SINGAPORE MALAY
   EYE; BLUE-MOUNTAINS-EYE; CLINICAL CHARACTERISTICS; JAPANESE POPULATION;
   MACULOPATHY LESIONS; GENE POLYMORPHISMS; CHINESE PATIENTS; ASSOCIATION
AB Purpose: To compare the frequency and pattern of bilateral involvement of early and late age-related macular degeneration (AMD) between Asian Malays and Caucasians.
   Methods: We used cross-sectional data from the baseline examination for subjects aged 50-79 years in the Singapore Malay Eye Study (SiMES) (N = 2,453) and the Blue Mountains Eye Study (BMES) (N = 3,265). We assessed AMD signs using a common protocol modified from the Wisconsin Age-related Maculopathy Grading System at the University of Sydney. We compared frequencies or proportions of AMD cases with bilateral involvement between the two populations.
   Results: There were 173 cases and 169 cases with any AMD (either early or late AMD in at least one eye), and 78 cases (45.1%) and 52 cases (30.8%) with bilateral AMD in the BMES and the SiMES, respectively. Age-standardized frequency of bilateral involvement was comparable between the BMES (29.5%, 95% confidence interval(CI) 18.5-40.5%) and the SiMES (25.6%, 95% CI 17.0-34.0%). Older age was associated with higher risk of bilateral AMD (gender-adjusted odds ratio per 1 year for the BMES and the SiMES: 1.08 [95% CI 1.05-1.11] and 1.06 [95% CI 1.02-1.10], respectively).
   Conclusions: The frequency of bilateral AMD was comparable between Asian Malays in the SiMES and the Caucasian population of the BMES. Other than older age, we did not find any characteristics associated with the bilateral involvement of AMD.
C1 [Wong, Tien Yin] Natl Univ Singapore, FRANZCO, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 117548, Singapore.
   [Kawasaki, Ryo; Wang, Jie Jin; Amirul, F. M. Amirul; Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Kawasaki, Ryo] Yamagata Univ, Fac Med, Dept Ophthalmol & Visual Sci, Yamagata 990, Japan.
   [Wang, Jie Jin; Rochtchina, Elena; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Saw, Seang Mei] Natl Univ Singapore, Dept Epidemiol & Publ Hlth, Singapore 117548, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Yamagata University; University of Sydney;
   Westmead Institute for Medical Research; National University of
   Singapore
RP Wong, TY (通讯作者)，Natl Univ Singapore, FRANZCO, Singapore Eye Res Inst, Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 117548, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020; Kawasaki, Ryo/H-9716-2019; Wang, Jie
   Jin/P-1499-2014; wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014;
   Kawasaki, Ryo/B-7266-2009
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898;
   Kawasaki, Ryo/0000-0002-7492-6303
FU National Medical Research Council [0796/2003, STaR/0003/2008,
   IRG07nov013]; Biomedical Research Council [501/1/25-5]; Singapore and
   the Australian National Health & Medical Research Council [ID 974159,
   211069, 457349]; Centre for Clinical Research Excellence, Translational
   Clinical Research in Major Eye Diseases, Australia [529923]
FX This study was supported by the National Medical Research Council Grants
   No 0796/2003, STaR/0003/2008, IRG07nov013 and Biomedical Research
   Council Grant No 501/1/25-5, Singapore and the Australian National
   Health & Medical Research Council, Project grants ID 974159, 211069,
   457349, and Centre for Clinical Research Excellence
   #529923-Translational Clinical Research in Major Eye Diseases,
   Australia. The Centre for Eye Research Australia (CERA) receives
   Operation Infrastructure Support from the Victorian Government.
CR Ahmad OB, 2000, GPE DISCUSS PAP SER
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 29
TC 3
Z9 3
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2011
VL 18
IS 6
BP 253
EP 258
DI 10.3109/09286586.2011.602505
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 843DW
UT WOS:000296653500001
PM 22053833
DA 2022-11-30
ER

PT J
AU Robman, L
   McNeil, J
   Dimitrov, P
   Dowrick, A
   Tikellis, G
   Nicolas, C
   Cameron, J
   Guymer, R
   McGrath, B
   McCarty, C
AF Robman, L
   McNeil, J
   Dimitrov, P
   Dowrick, A
   Tikellis, G
   Nicolas, C
   Cameron, J
   Guymer, R
   McGrath, B
   McCarty, C
TI Methodology of the cardiovascular health and age-related maculopathy
   (CHARM) study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; methodology;
   progression; risk factors; cardiovascular disease; CHARM study
ID RISK-FACTORS; MACULAR DEGENERATION; VISUAL-ACUITY; ATHEROSCLEROSIS;
   IMPAIRMENT; SMOKING; DISEASE
AB Age-related macular degeneration (AMD) is responsible for the majority of visual impairment in the Western world. Epidemiological studies examining risk factors for AMD are needed to develop strategies for the prevention of blindness from this condition. A number of potentially modifiable risk factors for AMD have been identified; however, only smoking has been a consistent risk factor across the numerous studies. A growing body of evidence suggests that AMD and cardiovascular disease may have common risk factors. The Cardiovascular Health and Age Related Maculopathy (CHARM) Study was established to examine the risk factors for AMD and its progression, in particular risk factors associated with cardiovascular disease.
   Examining risk factors for prevalent AMD, cases with AMD were compared with age and gender matched controls with no AMD features. For the assessment of AMD progression, the study examined in 2001 and 2002 those participants with early AMD, or age-related maculopathy (ARM), who had undergone baseline examination between 1992 and 1995 and compared the characteristics of those who had progression of AMD with those who did not. The CHARM study involved both ophthalmic and cardiovascular examinations. Standardised clinical eye examination and grading of the macular stereo photographs were used to determine the AMD status and progression. To examine cardiovascular status, carotid artery ultrasound imaging, analysis of systemic arterial compliance, augmentation index and pulse wave velocity were performed. The traditional and novel risk factors for CVD such as levels of glucose, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fibrinogen, C-reactive protein, immunoglobulins A and M, homocysteine, oxidized LDL and the exposure to the Chlamydia Pneumonia infection were determined. DNA was collected for apolipoprotein E genotyping.
   The present paper outlines the primary aims of the CHARM study, the methodology involved and the recruitment results.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
   Monash Univ, Dept Vasc Sci, Melbourne, Vic 3004, Australia.
   Marshfield Med Res Fdn, Marshfield, WI 54449 USA.
C3 Centre for Eye Research Australia; University of Melbourne; Monash
   University; Monash University
RP Robman, L (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM liubov@unimelb.edu.au
RI McNeil, John/L-6440-2019; Cameron, james/GQP-4595-2022
OI McNeil, John/0000-0002-1049-5129; Cameron, james/0000-0003-0589-0367;
   Guymer, Robyn/0000-0002-9441-4356; McCarty,
   Catherine/0000-0003-1089-0142
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lehmann ED, 1996, LANCET, V348, P744, DOI 10.1016/S0140-6736(05)65619-X
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399
   Raven J. C., 1986, MANUAL RAVENS PROGR
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Taylor H, 1988, LENS RES, V5, P175
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Ware JE, 1998, SF 12 SCORE SF 12 PH
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 41
TC 20
Z9 20
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JUL
PY 2004
VL 11
IS 3
BP 161
EP 179
DI 10.1080/09286580490514469
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863AA
UT WOS:000224531400002
PM 15370549
DA 2022-11-30
ER

PT J
AU Gemenetzi, M
   Lotery, AJ
AF Gemenetzi, M.
   Lotery, A. J.
TI Complement pathway biomarkers and age-related macular degeneration
SO EYE
LA English
DT Review
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; FACTOR HY402H POLYMORPHISM;
   GENE POLYMORPHISM; BRUCHS MEMBRANE; SERPING1 GENE; INTRAVITREAL
   RANIBIZUMAB; GEOGRAPHIC ATROPHY; STRONG ASSOCIATION; COMMON VARIATION
AB In the age-related macular degeneration (AMD) 'inflammation model', local inflammation plus complement activation contributes to the pathogenesis and progression of the disease. Multiple genetic associations have now been established correlating the risk of development or progression of AMD. Stratifying patients by their AMD genetic profile may facilitate future AMD therapeutic trials resulting in meaningful clinical trial end points with smaller sample sizes and study duration.
C1 [Gemenetzi, M.] Kingston Hosp NHS Fdn Trust, Royal Eye Unit, Kingston Upon Thames, Surrey, England.
   [Lotery, A. J.] Southampton Univ Hosp, Southampton Eye Unit, Southampton, Hants, England.
   [Lotery, A. J.] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Clin & Expt Sci, Fac Med, Southampton Univ Hosp, South Lab & Path Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2013, NAT GENET, V45, p[433, 439e1]
   [Anonymous], 2007, HIGHL PRESCR INF MAC, P3
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Birch DG, 2002, AM J OPHTHALMOL, V133, P665, DOI 10.1016/S0002-9394(02)01338-7
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bomback AS, 2012, CLIN J AM SOC NEPHRO, V7, P748, DOI 10.2215/CJN.12901211
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borrelli E, 2012, INT J OPHTHALMOL-CHI, V5, P708, DOI 10.3980/j.issn.2222-3959.2012.06.11
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GASQUE P, 1995, J IMMUNOL, V154, P4726
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janeway CA, 2005, IMMUNOBIOLOGY
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P1239, DOI 10.2217/pgs.13.100
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu KP, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/510618
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maitournam A, 2005, STAT MED, V24, P329, DOI 10.1002/sim.1975
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Regillo CD, 2013, 2013 ANN M AM AC OPH
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schnatbaum K, 2006, BIOORG MED CHEM LETT, V16, P5088, DOI 10.1016/j.bmcl.2006.07.036
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schork NJ, 2010, J BIOPHARM STAT, V20, P315, DOI 10.1080/10543400903572779
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Stieger K, 2007, GENE THER, V14, P1668, DOI 10.1038/sj.gt.3303034
   Suzuki M, 2007, MOL VIS, V13, P772
   Tang S, 1999, J IMMUNOL, V162, P4336
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Volanakis J. E., 1998, HUMAN COMPLEMENT SYS
   WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Woldemussie E, 2007, VISUAL NEUROSCI, V24, P745, DOI 10.1017/S0952523807070605
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 131
TC 25
Z9 26
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2016
VL 30
IS 1
BP 1
EP 14
DI 10.1038/eye.2015.203
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA5PW
UT WOS:000367856000001
PM 26493033
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wong, EYH
   Guymer, RH
   Hassell, JB
   Keeffe, JE
AF Wong, EYH
   Guymer, RH
   Hassell, JB
   Keeffe, JE
TI The experience of age-related macular degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID VISION IMPAIRMENT; VISUAL IMPAIRMENT; PREVALENCE; MACULOPATHY; EYE;
   DISABILITY; AUSTRALIA; IMPACT
AB This qualitative article describes the impact of age-related macular degeneration (ARMD) among 15 participants: how a person makes sense of ARMD, the effect of ARMD on the person's quality of life, the psychological disturbances associated with the limitations of ARMD, and the influence of ARMD on social interactions. Such in-depth appreciation of the impact of ARMD will assist in the design of specific and appropriate rehabilitation programs to minimize limitations and enhance participation in people with ARMD.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 8002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
EM e.wong@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   FLICK U, 1998, INTRO QUALITATIVE RE, P62
   FLICK U, 1998, INTRO QUALITATIVE RE, P17
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Keeffe JE, 1999, AUST NZ J OPHTHALMOL, V27, P184, DOI 10.1046/j.1440-1606.1999.00179.x
   Keeffe JE, 1998, AUST NZ J OPHTHALMOL, V26, pS16, DOI 10.1111/j.1442-9071.1998.tb01360.x
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kleinschmidt JJ, 1999, J VISUAL IMPAIR BLIN, V93, P69, DOI 10.1177/0145482X9909300202
   Lincoln YS., 1998, STRATEGIES QUALITATI, P158
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MORSE JM, 1994, CRITICAL ISSUES IN QUALITATIVE RESEARCH METHODS, P23
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih L, 2000, CLIN EXP OPHTHALMOL, V28, P153, DOI 10.1046/j.1442-9071.2000.00303.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   World Health Organization, 2004, INT STAT CLASS DIS H
NR 23
TC 28
Z9 28
U1 1
U2 8
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2004
VL 98
IS 10
BP 629
EP 640
DI 10.1177/0145482X0409801007
PG 12
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 922IH
UT WOS:000228830100007
DA 2022-11-30
ER

PT J
AU Cekic, S
   Risimic, D
   Jovanovic, I
   Jocic, JD
AF Cekic, Sonja
   Risimic, Dijana
   Jovanovic, Ivan
   Jocic, Jasmina Djordjevic
TI Idiopathic polypoidal choroidal vasculopathy
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE choroid diseases; macular degeneration; tomography, optical coherence;
   fluorescein angiography; diagnosis; diagnosis, differential; choroid
   hemorrhage; prognosis
ID PIGMENT EPITHELIAL DETACHMENTS; PHOTODYNAMIC THERAPY; BLACK-WOMEN;
   FEATURES
AB Background. Idiopathic polypoidal choroidal vasculopathy (IPCV) is uncommon condition. It is considered to be a variant of neovascular age-related macular degeneration, but it can be also found in younger patients. Case report. We presented a case of otherwise healthy, 36-year-old women, with sudden unilateral visual impairment in the left eye and metamorphosia. Slit lamp biomicroscopy examination of the eye anterior segment was normal. Intraocular pressure determined by aplanation tonometry was 16 mmHg in both eyes. indirect slit lamp biomicroscopy examination showed signs of serosanquinous detachments of the retinal pigment epithelium. Fluorescein angiography showed a subretinal vessel network through the pigment epithelial atrophy with hyperfluorescence in superior part of serohemorrhagic pigment epithelial detachment and the inferior hypofluorescence, caused by hemorrhage. Optical coherence tomography proved detachment of the retinal pigment epithelium. Conclusion. In patients with IPCV a mild, natural course with spontaneous resorption of exudations and hemorrhage and improvement in visual acuity can be observed. There is no approved treatment at present.
C1 [Cekic, Sonja; Jocic, Jasmina Djordjevic] Clin Ctr Nis, Eye Clin, Nish 18000, Serbia.
   [Risimic, Dijana] Clin Ctr Serbia, Clin Eye Dis, Belgrade, Serbia.
   [Jovanovic, Ivan] Univ Nis, Fac Med, Dept Anat, Nish, Serbia.
C3 Clinical Centre of Serbia; University of Nis
RP Cekic, S (通讯作者)，Clin Ctr Nis, Eye Clin, Bulevar Dr Zorana Dindica 48, Nish 18000, Serbia.
EM sonjaziv@yahoo.com
OI Risimic, Dijana/0000-0001-9918-4302; Cekic, Sonja/0000-0002-7149-9043;
   Jovanovic, Ivan/0000-0002-3493-5344; Jovanovic, Ivan/0000-0002-5817-5124
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tsjuikawa A, 2007, RETINAL PIGMENT EPIT, V27, P832
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 18
TC 1
Z9 1
U1 0
U2 3
PU MILITARY MEDICAL ACAD-INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA
SN 0042-8450
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PD JAN
PY 2012
VL 69
IS 1
BP 85
EP 89
DI 10.2298/VSP1201085C
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 900CX
UT WOS:000300865300014
PM 22397302
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Querques, G
   Coscas, F
   Forte, R
   Massamba, N
   Sterkers, M
   Souied, EH
AF Querques, Giuseppe
   Coscas, Florence
   Forte, Raimondo
   Massamba, Nathalie
   Sterkers, Margaret
   Souied, Eric H.
TI Cystoid Macular Degeneration in Exudative Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; RETINAL TELANGIECTASIS; RANIBIZUMAB
AB PURPOSE: To investigate the prevalence and clinical significance of cystoid macular degeneration in eyes that underwent intravitreal ranibizumab injections for exudative age-related macular degeneration.
   DESIGN: Retrospective, interventional case series.
   METHODS: We reviewed the charts of 56 consecutive patients (19 male, 37 female; mean age +/- standard deviation, 80.81 +/- 4.8 years) with exudative age-related macular degeneration who received the last intravitreal ranibizumab injection at least 6 months before and were judged to have a fibroatrophic scar without signs of progression by fluorescein angiography or spectral-domain optical coherence tomography. Main outcome measures were the estimated prevalence and clinical significance of cystoid macular degeneration.
   RESULTS: Twenty-two eyes showed various combinations of degenerative pseudocysts, whereas 34 eyes did not show any pseudocysts. The 95% confidence interval for the prevalence estimate was 36.98% to 41.02%. Degenerative pseudocysts appeared square-shaped, did not change their overall appearance over time, and were located just below the internal limiting membrane in 11 eyes (50%), in the inner nuclear layer in 16 eyes (72.7%), in the outer nuclear layer in 8 eyes (36.3%), and in all the retinal layers in 6 eyes (27.2%). Best-corrected visual acuity improved in eyes with and without degenerative pseudocysts and decreased significantly in eyes with degenerative pseudocysts (P = .03). Mean central macular thickness decreased significantly (P < .001) to 324.1 mu m and to 328.2 mu m in eyes and without degenerative pseudocysts, respectively.
   CONCLUSIONS: Cystoid macular degeneration represents a well-distinguished clinical entity that may be detected in exudative age-related macular degeneration eyes showing a posttreatment fibroatrophic scar and should not be considered as a manifestation of choroidal neovascularization activity. (Am J Ophthalmol 2011; 152:100-107. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Querques, Giuseppe; Coscas, Florence; Forte, Raimondo; Massamba, Nathalie; Sterkers, Margaret; Souied, Eric H.] Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cohen SM, 2007, RETINA-J RET VIT DIS, V27, P59, DOI 10.1097/01.iae.0000256663.94734.e1
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudric A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1410, DOI 10.1001/archopht.124.10.1410
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Gualino V, 2005, AM J OPHTHALMOL, V140, P757, DOI 10.1016/j.ajo.2005.04.042
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LIDA T, 2003, RETINA, V23, P1
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spencer, 1996, OPHTHALMIC PATHOLOGY, P960
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   YANNUZZI LA, 1984, SURV OPHTHALMOL, V28, P540, DOI 10.1016/0039-6257(84)90238-8
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 18
TC 21
Z9 24
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2011
VL 152
IS 1
BP 100
EP 107
DI 10.1016/j.ajo.2011.01.027
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 789CI
UT WOS:000292490500017
PM 21570056
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Sharma, S
   Adelman, RA
AF Seddon, JM
   Sharma, S
   Adelman, RA
TI Evaluation of the clinical age-related maculopathy staging system
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; PROGRESSION; AGREEMENT; CLASSIFICATION;
   INTEROBSERVER; RELIABILITY; ASSOCIATION; GENE; ABCR
AB Objective: To evaluate a clinical classification system, the Clinical Age-Related Maculopathy Staging (CARMS) system, for age-related maculopathy (ARM) using a simple grading scale designed for clinical practice and clinical research protocols.
   Participants: Two hundred forty-six male and female participants with various stages of ARM who were enrolled during the first 4 years of a longitudinal study were selected for the evaluation of the CARMS system.
   Design: Cross-sectional comparison study.
   Methods: The CARMS system divides patients into 5 mutually exclusive categories based on slit-lamp assessment of drusen, retinal pigment epithelial irregularities, geographic atrophy, retinal pigment epithelial detachment, and choroidal neovascularization. Fundus photographs and clinical data of the subjects were used to evaluate this scale. Clinical grades assigned for 492 eyes of 246 patients with varying stages of ARM were compared with grades obtained from photographs evaluated by a reading center. To compare grades obtained from an inexperienced grader with those of an experienced grader, observations based on photographs from 50 randomly selected patients were reviewed. To quantify intraobserver agreement for photographic grades, observations from one observer were compared with those made at a later date by the same observer.
   Main Outcome Measures: Reliability and validity of the CARMS system in grading various stages of ARM based on clinical examination and photography.
   Results: The degree of overall agreement between the clinically assigned grade and photographic assessment for 492 eyes was substantial (exact overall agreement, 75%; unweighted kappa, 0.63; weighted kappa, 0.78). For advanced age-related macular degeneration, the sensitivity was 0.83, and specificity was 0.97. When assessing photographic grades, the degree of agreement between an inexperienced and an experienced grader was very high (unweighted kappa, 0.79; weighted kappa, 0.86), and the degree of intraobserver agreement was excellent (unweighted kappa, 0.92; weighted kappa, 0.97).
   Conclusions: The CARMS system, a 5-level clinical scale, is a valid and reliable staging system that can be used in both clinical practice and in clinical research protocols involving patients with all stages of ARM.
C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02114 USA.
   Queens Univ, Dept Ophthalmol, Kingston, ON K7L 3N6, Canada.
   Queens Univ, Dept Epidemiol, Kingston, ON K7L 3N6, Canada.
   Yale Univ, Med Ctr, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard T.H. Chan School of Public
   Health; Queens University - Canada; Queens University - Canada; Yale
   University
RP Seddon, JM (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1988, RETINA-J RET VIT DIS, V8, P102, DOI 10.1097/00006982-198808020-00004
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HALL JN, 1974, BRIT J PSYCHIAT, V125, P248, DOI 10.1192/bjp.125.3.248
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Landis JR., 1975, STAT NEERL, V29, P101, DOI [10.1111/j.1467-9574.1975.tb00254.x, DOI 10.1111/J.1467-9574.1975.TB00254.X]
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   SEDDON JM, 2005, RETINA MED RETINA, V2, P1017
   Sharma S, 1997, CAN J OPHTHALMOL, V32, P441
   Sparrow J M, 1997, Ophthalmic Epidemiol, V4, P49
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
NR 26
TC 204
Z9 213
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2006
VL 113
IS 2
BP 260
EP 266
DI 10.1016/j.ophtha.2005.11.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 011HL
UT WOS:000235258800013
PM 16458093
DA 2022-11-30
ER

PT J
AU Silva, RA
   Moshfeghi, AA
   Kaiser, PK
   Singh, RP
   Moshfeghi, DM
AF Silva, Ruwan A.
   Moshfeghi, Andrew A.
   Kaiser, Peter K.
   Singh, Rishi P.
   Moshfeghi, Darius M.
TI Radiation Treatment for Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Radiation; Age-Related Macular Degeneration; Retina; Choroidal
   Neovascular Membrane; Brachytherapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTERNAL-BEAM IRRADIATION;
   GROWTH-FACTOR VEGF; PHOTODYNAMIC THERAPY; HISTOLOGICAL-FINDINGS;
   CONTROLLED TRIAL; RADIOTHERAPY; MEMBRANES; MACULOPATHY; BRACHYTHERAPY
AB Age-related macular degeneration (AMD) remains a devastating cause of visual loss among elderly individuals. While considerable progress has been made towards combating the disease, most recently with intravitreal anti-VEGF agents, visual outcomes are still limited by continued retinal pigment epithelium (RPE) degeneration and subsequent neurosensory retinal atrophy. Among the promising new treatment options being explored, radiotherapy appears apt to address the multifactorial etiology of AMD. Current investigative studies underway will hopefully yield clinical efficacy to complement this theoretical suitability for arresting visual loss.
C1 [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Eye Inst Stanford, Dept Ophthalmol,Vitreoretinal Ctr, Palo Alto, CA 94303 USA.
   [Silva, Ruwan A.; Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Kaiser, Peter K.; Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Stanford University; Bascom Palmer Eye Institute; University of Miami;
   Cleveland Clinic Foundation
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Eye Inst Stanford, Dept Ophthalmol,Vitreoretinal Ctr, 2452 Watson Ct,Rm 2277, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X; Kaiser,
   Peter/0000-0001-5126-045X
CR Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Augustin AJ, 2002, KLIN MONATSBL AUGENH, V219, P631, DOI 10.1055/s-2002-35164
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUCHI ER, 1994, RETINA-J RET VIT DIS, V14, P370
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eter N, 2001, GRAEF ARCH CLIN EXP, V239, P923, DOI 10.1007/s00417-001-0391-5
   Eter Nicole, 2001, International Ophthalmology, V24, P13, DOI 10.1023/A:1014445524293
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   FOWLER J, 1993, INT J RADIAT BIOL, V63, P271, DOI 10.1080/09553009314550351
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   de Almeida LNF, 2009, ARQ BRAS OFTALMOL, V72, P567, DOI 10.1590/S0004-27492009000400027
   Furdova A, 2000, Bratisl Lek Listy, V101, P234
   Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Gragoudas ES, 1999, OPHTHALMOLOGY, V106, P1571, DOI 10.1016/S0161-6420(99)90455-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gremigni E, 2004, EUR J OPHTHALMOL, V14, P555, DOI 10.1177/112067210401400617
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Harino Seiyo, 1997, Nippon Ganka Gakkai Zasshi, V101, P341
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Howell RM, 2010, PHYS MED BIOL, V55, P7009, DOI 10.1088/0031-9155/55/23/S04
   Imaizumi N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011084
   Ivanov VN, 2010, CELL SIGNAL, V22, P1076, DOI 10.1016/j.cellsig.2010.02.010
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Kacperek A, 2001, PHYS MEDICA, V17, P7
   Kakolyris S, 2000, BRIT J CANCER, V82, P844, DOI 10.1054/bjoc.1999.1010
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   LIUTKEVICIENE R, MED KAUNAS LITHUANIA, V46, P89
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nieder C, 2006, CANCER TREAT REV, V32, P348, DOI 10.1016/j.ctrv.2006.03.006
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   Parsons J T, 1996, Oncology (Williston Park), V10, P837
   PARSONS JT, 1983, INT J RADIAT ONCOL, V9, P609, DOI 10.1016/0360-3016(83)90225-0
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Parsons JT, 1996, ONCOLOGY WILLISTON P, V10, P847
   Parsons JT, 1996, ONCOLOGY WILLISTON P, V10, P851
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scupola A, 2004, GRAEF ARCH CLIN EXP, V242, P605, DOI 10.1007/s00417-004-0870-6
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SILBERMAN AW, 1982, SURG GYNECOL OBSTET, V155, P577
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Timke C, 2008, CLIN CANCER RES, V14, P2210, DOI 10.1158/1078-0432.CCR-07-1893
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   VINORES SA, 2005, J CELL PHYSL, P749
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou J, 2008, J NEUROCHEM, V106, P2080, DOI 10.1111/j.1471-4159.2008.05558.x
NR 94
TC 13
Z9 13
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 121
EP 130
DI 10.3109/08820538.2011.554486
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200007
PM 21609224
DA 2022-11-30
ER

PT J
AU Conti, SM
   Kertes, PJ
AF Conti, SM
   Kertes, PJ
TI Surgical management of age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; choroidal neovascularization; hemorrhage; macular
   degeneration; subretinal neovascularization; surgery; tissue plasminogen
   activator
ID TISSUE-PLASMINOGEN-ACTIVATOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   360-DEGREES PERIPHERAL RETINECTOMY; RETINAL ANGIOMATOUS PROLIFERATION;
   THICK SUBMACULAR HEMORRHAGE; PARS-PLANA VITRECTOMY; PNEUMATIC
   DISPLACEMENT; SUBRETINAL HEMORRHAGE; LASER PHOTOCOAGULATION; FOVEAL
   TRANSLOCATION
AB The development of increasingly refined vitreoretinal surgical techniques has resulted in a variety of surgical procedures for age-related macular degeneration (AMD). These have included submacular surgery with removal of choroidal neovascular membranes and subretinal blood, intraoperative lysis of feeder vessels, pneumatic displacement of subretinal blood and macular translocation surgery. The goals of these procedures have been to improve upon the poor natural history of exudative AMD and restore useful central vision. This article reviews the varied approaches, results and complications of the surgical management of AMD.
C1 Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center
RP Kertes, PJ (通讯作者)，Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Rm M1 202A,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sw.ca
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Deramo VA, 2001, RETINA-J RET VIT DIS, V21, P304, DOI 10.1097/00006982-200108000-00002
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HERRIOT WJ, 1997, P 1997 UPD MAC SURG, P82
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 2004, AM J OPHTHALMOL, V138, P574, DOI 10.1016/j.ajo.2004.05.029
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Karlsson E, 1999, ACTA OPHTHALMOL SCAN, V77, P119
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ng EWM, 2004, OPHTHALMOLOGY, V111, P1889, DOI 10.1016/j.ophtha.2004.03.037
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   TOTH CA, 2003, P AAO RET DEB 2003 N, P201
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YEPREMYAN M, 2004, P AM SOC RET SPEC 22, P109
NR 65
TC 4
Z9 4
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 341
EP 351
DI 10.1016/S0008-4182(05)80077-8
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400010
PM 15947804
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Yanagi, Y
   Koizumi, H
   Matsumoto, H
   Cheung, CMG
   Gomi, F
   Iida, T
   Tsujikawa, A
AF Yamashiro, Kenji
   Yanagi, Yasuo
   Koizumi, Hideki
   Matsumoto, Hidetaka
   Cheung, Chui Ming Gemmy
   Gomi, Fumi
   Iida, Tomohiro
   Tsujikawa, Akitaka
TI Relationship between Pachychoroid and Polypoidal Choroidal Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; drusen-driven disease;
   pachychoroid-driven disease; pachychoroid neovasculopathy; polypoidal
   choroidal vasculopathy
ID 2 ANGIOGRAPHIC SUBTYPES; GROWTH-FACTOR THERAPY; FACTOR-H CFH;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB;
   CLINICAL CHARACTERISTICS; NEOVASCULOPATHY; AFLIBERCEPT; THICKNESS
AB Previous clinical studies have suggested that pachychoroid can induce macular neovascularization (MNV) to develop pachychoroid neovasculopathy (PNV) and that PNV can progress to polypoidal choroidal vasculopathy (PCV). Recent studies based on the pachychoroid concept are now gradually revealing the true nature of, at least some part of, PCV. However, previous studies on PNV and/or PCV have used different frameworks for the classification of PNV, PCV, and neovascular age-related macular degeneration (nAMD). These have hampered the rapid overhaul of the understanding of PCV. Some investigators have assumed that all PCV is pachychoroid-driven whereas other investigators have classified PCV into "pachychoroid PCV" and "non-pachychoroid PCV". Furthermore, since there is no consensus as to whether PNV includes PCV, some studies have included PCV with PNV, while other studies have excluded PCV from PNV. To address these gaps, we summarize previous studies on PCV and pachychoroid. Even before the proposal of the pachychoroid concept, previous studies had suggested that PCV could be divided into two subtypes, of which one was characterized by pachychoroid features. Previous studies had also provided keys to understand relationship between PCV and PNV. We here recommend a refined conceptual framework for future studies on PNV, PCV, and nAMD. Considering the current inconsistent understanding of PCV, we should be cautious about using the term PCV until we understand the true nature of PCV.
C1 [Yamashiro, Kenji] Kochi Univ, Kochi Med Sch, Dept Ophthalmol & Visual Sci, Nankoku, Kochi 7838505, Japan.
   [Yamashiro, Kenji; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
   [Yanagi, Yasuo] Yokohama City Univ, Dept Ophthalmol & Micro Technol, Yokohama, Kanagawa 2320024, Japan.
   [Yanagi, Yasuo; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Yanagi, Yasuo; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Ophthalmol Visual Sci Acad Clin Program, Duke NUS Med Sch, Singapore 169857, Singapore.
   [Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, Nishihara, Okinawa 9030215, Japan.
   [Matsumoto, Hidetaka] Gunma Univ, Dept Ophthalmol, Grad Sch Med, Maebashi, Gumma 3718511, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo 6638501, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo 1628666, Japan.
C3 Kochi University; Kyoto University; Yokohama City University; National
   University of Singapore; Singapore National Eye Center; National
   University of Singapore; University of Ryukyus; Gunma University; Hyogo
   College of Medicine; Tokyo Women's Medical University
RP Yamashiro, K (通讯作者)，Kochi Univ, Kochi Med Sch, Dept Ophthalmol & Visual Sci, Nankoku, Kochi 7838505, Japan.; Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
EM yamashk@kochi-u.ac.jp
OI Yanagi, Yasuo/0000-0002-0362-7285; Gomi, Fumi/0000-0003-0807-8817;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558; Cheung, Chui Ming Gemmy/0000-0003-3358-3516;
   Matsumoto, Hidetaka/0000-0003-2311-0280
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77566-1
   Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Demirel S, 2021, JPN J OPHTHALMOL, V65, P482, DOI 10.1007/s10384-021-00829-5
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Elfandi S, 2021, CLIN OPHTHALMOL, V15, P1539, DOI 10.2147/OPTH.S285257
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hikichi T, 2021, EYE, V35, P3367, DOI 10.1038/s41433-021-01418-z
   Hikichi T, 2009, RETINA-J RET VIT DIS, V29, P395, DOI 10.1097/IAE.0b013e318192f53a
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kang HG, 2021, GRAEF ARCH CLIN EXP, V259, P2391, DOI 10.1007/s00417-021-05180-6
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2168, DOI 10.1097/IAE.0000000000001845
   Kim YH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84650-7
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Koh A.H.C., 1999, INVESTIG OPHTHALMOL, V40, P5958
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee A, 2020, GRAEF ARCH CLIN EXP, V258, P1921, DOI 10.1007/s00417-020-04772-y
   Lee GW, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83650-x
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95904-9
   Matsumoto H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75789-w
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miki A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248760
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Naysan Jonathan, 2015, Int J Retina Vitreous, V1, P8
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Ooto S, 2010, GRAEF ARCH CLIN EXP, V248, P1077, DOI 10.1007/s00417-010-1338-5
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Sakamoto S, 2018, CLIN OPHTHALMOL, V12, P1137, DOI 10.2147/OPTH.S160961
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schworm B, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02022-1
   Schworm B, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65370-w
   Schworm B, 2020, GRAEF ARCH CLIN EXP, V258, P1013, DOI 10.1007/s00417-020-04623-w
   Shimizu Y, 2022, ACTA OPHTHALMOL, V100, pE943, DOI 10.1111/aos.15015
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tagawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73303-w
   Tamakoshi A., 1992, CASE CONTROL STUDY S, P134
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
   Tanaka K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87340-6
   Tanaka K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102168
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Yoon J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91589-2
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 97
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2022
VL 11
IS 15
AR 4614
DI 10.3390/jcm11154614
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 3R6GW
UT WOS:000839009700001
PM 35956229
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lanzetta, P
AF Lanzetta, Paolo
TI Advances in the treatment of neovascular age-related macular
   degeneration
SO EJHP PRACTICE
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; LASER
   PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB; VERTEPORFIN;
   LESIONS
AB The management of age-related macular degeneration has rapidly progressed following the development of the anti-vascular endothelial growth factor (VEGF) ranibizumab. Ongoing trials are helping to define appropriate treatment schedules to optimise the use of ranibizumab in clinical practice.
C1 Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazzale S Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
FU Novartis International AG, Basel, Switzerland
FX Medical writing assistance was provided by David Collison, PhD
   (Chameleon Communications International, London, UK), with funding from
   Novartis International AG, Basel, Switzerland.
CR Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Meyer CHEN, 2008, INVEST OPHTH VIS SCI, V49, P273
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 0
Z9 0
U1 0
U2 0
PU PHARMA PUBLISHING & MEDIA EUROPE-PPM EUROPE
PI MOL
PA POSTBUS 10001, MOL, B-2400, BELGIUM
SN 1781-9989
J9 EJHP PRACT
JI EJHP Pract.
PY 2008
VL 14
IS 6
BP 17
EP 20
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 394CU
UT WOS:000262424000015
DA 2022-11-30
ER

PT J
AU Jabbehdari, S
   Handa, JT
AF Jabbehdari, Sayena
   Handa, James T.
TI Oxidative stress as a therapeutic target for the prevention and
   treatment of early age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE aging; age-related macular degeneration; antioxidant therapy; oxidative
   stress
ID RETINAL-PIGMENT EPITHELIUM; REACTIVE OXYGEN; DIETARY-FAT;
   CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; GENE-EXPRESSION; BETA-CAROTENE;
   RPE CELLS; ASSOCIATION; PROGRESSION
AB Age-related macular degeneration, the leading cause of irreversible visual loss among older adults in developed countries, is a chronic, multifactorial, and progressive disease with the development of painless, central vision loss. Retinal pigment epithelial cell dysfunction is a core change in age-related macular degeneration that results from aging and the accu-mulated effects of genetic and environmental factors that, in part, is both caused by and leads to oxidative stress. In this review, we describe the role of oxidative stress, the cytoprotective oxidative stress pathways, and the impact of oxidative stress on critical cellular processes involved in age-related macular degeneration pathobiology. We also offer targeted therapy that may define how antioxidant therapy can either prevent or improve specific stages of age-related macular degeneration.
   (c) 2020 Elsevier Inc. All rights reserved.
C1 [Jabbehdari, Sayena] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Johns Hopkins University; Johns
   Hopkins Medicine
RP Handa, JT (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
FU Research to Prevent Blindness
FX This work was supported by an unrestricted grant to Wilmer Eye Institute
   by the Research to Prevent Blindness. J. T. H. is the Robert Bond Welch
   Professor.
CR Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Al-Dosari DI, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101161
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2017, CTR DIS CONTROL PREV, P20
   Areias FM, 2001, BIOCHEM PHARMACOL, V62, P111, DOI 10.1016/S0006-2952(01)00621-9
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Azuma K, 2012, MAR DRUGS, V10, P2337, DOI 10.3390/md10102337
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Bensellam M, 2015, DIABETOLOGIA, V58, P758, DOI 10.1007/s00125-015-3503-1
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Biswas SK, 2009, MOL ASPECTS MED, V30, P60, DOI 10.1016/j.mam.2008.07.001
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   Braakhuis Andrea, 2017, Diseases, V5, DOI 10.3390/diseases5010003
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Bryan JM, 2018, HUM MOL GENET, V27, P3325, DOI 10.1093/hmg/ddy239
   Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569
   Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Camelo S, 2016, OPHTHALMOLOGICA, V236, P53, DOI 10.1159/000446587
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chae SY, 2018, MOL MED REP, V18, P5182, DOI 10.3892/mmr.2018.9538
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen MC, 2015, MAR DRUGS, V13, P4436, DOI 10.3390/md13074436
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho KS, 2012, INVEST OPHTH VIS SCI, V53, P5344, DOI 10.1167/iovs.12-9827
   Chong YS, 2018, CUTAN OCUL TOXICOL, V37, P52, DOI 10.1080/15569527.2017.1335748
   Costantini E, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6039171
   Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063
   CROSS CE, 1993, ANN NY ACAD SCI, V686, P72, DOI 10.1111/j.1749-6632.1993.tb39157.x
   Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657
   Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Friedman D., 2008, VISION PROBLEMS US P
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Golbidi S, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0951-7
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2015, MOL CELL BIOL, V35, P1952, DOI 10.1128/MCB.00178-15
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerrison JB, 2014, AGE RELATED MACULAR
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim EK, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0301-2
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klettner A, 2016, MAR DRUGS, V14, DOI 10.3390/md14020031
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Korsvik C, 2007, CHEM COMMUN, P1056, DOI 10.1039/b615134e
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lee M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112497
   Lin W, 2008, J NEUROCHEM, V106, P464, DOI 10.1111/j.1471-4159.2008.05398.x
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marudhupandi T, 2014, Pak J Biol Sci, V17, P402, DOI 10.3923/pjbs.2014.402.407
   Meissner C, 2011, J NEUROCHEM, V117, P856, DOI 10.1111/j.1471-4159.2011.07253.x
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Orth DH, 1977, T SECT OPHTHALMOL AM, V83
   Parihar MS, 2013, CELL MOL BIOL, V59
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844
   Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Raman R, 2017, ASIA PAC J CLIN NUTR, V26, P572, DOI 10.6133/apjcn.082016.01
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rissiek B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00204
   Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9
   de Souza MCR, 2007, J APPL PHYCOL, V19, P153, DOI 10.1007/s10811-006-9121-z
   Roger Veronique L, 2011, Circulation, V123, pe18, DOI 10.1161/CIR.0b013e3182009701
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarks SH, BRIT J OPHTHALMOL
   Saxena N, 2015, INDIAN J OPHTHALMOL, V63, P516, DOI 10.4103/0301-4738.158533
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seeland S, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.123
   Serafini M, 2010, P NUTR SOC, V69, P273, DOI 10.1017/S002966511000162X
   Shao Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1479571
   Shin BY, 2012, FREE RADICAL BIO MED, V53, P834, DOI 10.1016/j.freeradbiomed.2012.06.026
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sorescu GP, 2004, CIRC RES, V95, P773, DOI 10.1161/01.RES.0000145728.22878.45
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tisi A, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107797
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Zanzottera EC, INVEST OPHTHALMOL VI, P3269
   Zhang ZH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.14
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
   Zorov DB, 2005, BIOCHEMISTRY-MOSCOW+, V70, P215, DOI 10.1007/s10541-005-0103-6
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 184
TC 16
Z9 17
U1 6
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2021
VL 66
IS 3
BP 423
EP 440
DI 10.1016/j.survophthal.2020.09.002
EA MAR 2021
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RI2EM
UT WOS:000636722800003
PM 32961209
DA 2022-11-30
ER

PT J
AU Okuma, H
   Mimura, T
   Goto, M
   Kamei, Y
   Yoshida, M
   Kondo, A
   Matsubara, M
AF Okuma, Hiroko
   Mimura, Tatsuya
   Goto, Mari
   Kamei, Yuko
   Yoshida, Maiko
   Kondo, Aki
   Matsubara, Masao
TI Effect of aflibercept in patients with age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Aflibercept; Typical AMD;
   Polypoidal choroidal vasculopathy; Posterior vitreous detachment
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; DIABETIC-RETINOPATHY;
   VITREOUS DETACHMENT; INJECTION; EDEMA; EYE
AB The purpose of this study was to evaluate the efficacy of standard induction therapy with intravitreal aflibercept (IVA) in patients with exudative age-related macular degeneration (AMD) at 6 months after completion of induction therapy. Eleven eyes with typical AMD (tAMD) and 13 eyes with polypoidal choroidal vasculopathy (PCV) received three monthly doses of IVA (2 mg/0.05 ml in weeks 0, 4, and 8) for treatment of exudative AMD. Best-corrected visual acuity (BCVA) was measured, and optical coherence tomography was performed at baseline and at each monthly visit until 6 months after IVA. Treatment failure was defined as persistent or recurrent AMD that presented with cystoid macular edema, serous retinal detachment, and pigment epithelium detachment. Mean logMAR BCVA was improved from 0.62 +/- A 0.46 at baseline to 0.54 +/- A 0.43 at 6 months after IVA (p < 0.05). The success rate was 95.8 % at 3 months and 75.0 % at 6 months after IVA. Failure of IVA was positively associated with the absence of PVD before treatment (r = 0.35) and with the AMD type (tAMD, r = 0.43) by univariate analysis. Cox proportional hazards analysis demonstrated that the absence of PVD before treatment was associated with an increased risk of failure of IVA (OR = 33.17, p = 0.0219). Three months of induction IVA achieved a high success rate in patients with AMD monitored for up to 6 months. Factors associated with failure of IVA were the absence of PVD and the presence of tAMD. Accordingly, continuation of IVA following induction therapy may be beneficial to manage AMD in patients with tAMD or those without PVD.
C1 [Okuma, Hiroko; Mimura, Tatsuya; Goto, Mari; Kamei, Yuko; Yoshida, Maiko; Kondo, Aki; Matsubara, Masao] Tokyo Womens Med Univ, Med Ctr East, Dept Ophthalmol, Arakawa Ku, 2-1-10 Nishiogu, Tokyo 1168567, Japan.
C3 Tokyo Women's Medical University
RP Mimura, T (通讯作者)，Tokyo Womens Med Univ, Med Ctr East, Dept Ophthalmol, Arakawa Ku, 2-1-10 Nishiogu, Tokyo 1168567, Japan.
EM mimurat-tky@umin.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Health Labour Sciences Research Grant from the Ministry of Health Labour
   and Welfare of Japan
FX This work was partly supported by a Grant-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan and by a Health Labour Sciences Research Grant from the
   Ministry of Health Labour and Welfare of Japan.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2008, DRUGS R&D, V9, P261
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Goldenberg DT, 2019, DEV OPHTHALMOL, V44, P31
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Itakura H, 2004, OPHTHALMOLOGY, V111, P1880, DOI 10.1016/j.ophtha.2004.03.035
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Noma H, 2008, EUR J OPHTHALMOL, V18, P1017, DOI 10.1177/112067210801800628
   Noma H, 2013, INT OPHTHALMOL, V33, P227, DOI 10.1007/s10792-012-9676-4
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PRAGER TC, 1982, ARCH OPHTHALMOL-CHIC, V100, P594
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Silva PS, 2009, OCUL IMMUNOL INFLAMM, V17, P216, DOI 10.1080/09273940802687838
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YOSHIDA A, 1984, ARCH OPHTHALMOL-CHIC, V102, P857
NR 28
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2016
VL 36
IS 2
BP 159
EP 169
DI 10.1007/s10792-015-0089-z
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI0JD
UT WOS:000373181000002
PM 26043678
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Jaffe, GJ
   Sarraf, D
   Freund, KB
   Sadda, SR
   Staurenghi, G
   Waheed, NK
   Chakravarthy, U
   Rosenfeld, PJ
   Holz, FG
   Souied, EH
   Cohen, SY
   Querques, G
   Ohno-Matsui, K
   Boyer, D
   Gaudric, A
   Blodi, B
   Baumal, CR
   Li, XX
   Coscas, GJ
   Brucker, A
   Singerman, L
   Luthert, P
   Schmitz-Valckenberg, S
   Schmidt-Erfurth, U
   Grossniklaus, HE
   Wilson, DJ
   Guymer, R
   Yannuzzi, LA
   Chew, EY
   Csaky, K
   Mones, JM
   Pauleikhoff, D
   Tadayoni, RR
   Fujimoto, J
AF Spaide, Richard F.
   Jaffe, Glenn J.
   Sarraf, David
   Freund, K. Bailey
   Sadda, Srinivas R.
   Staurenghi, Giovanni
   Waheed, Nadia K.
   Chakravarthy, Usha
   Rosenfeld, Philip J.
   Holz, Frank G.
   Souied, Eric H.
   Cohen, Salomon Y.
   Querques, Giuseppe
   Ohno-Matsui, Kyoko
   Boyer, David
   Gaudric, Alain
   Blodi, Barbara
   Baumal, Caroline R.
   Li, Xiaoxin
   Coscas, Gabriel J.
   Brucker, Alexander
   Singerman, Lawrence
   Luthert, Phil
   Schmitz-Valckenberg, Steffen
   Schmidt-Erfurth, Ursula
   Grossniklaus, Hans E.
   Wilson, David J.
   Guymer, Robyn
   Yannuzzi, Lawrence A.
   Chew, Emily Y.
   Csaky, Karl
   Mones, Jordi M.
   Pauleikhoff, Daniel
   Tadayoni, Ramin Ramin
   Fujimoto, James
TI Consensus Nomenclature for Reporting Neovascular Age-Related Macular
   Degeneration Data Consensus on Neovascular Age-Related Macular
   Degeneration Nomenclature Study Group
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE-GREEN VIDEOANGIOGRAPHY;
   RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL AFLIBERCEPT; GEOGRAPHIC
   ATROPHY; RANIBIZUMAB; STANDARDIZATION; CLASSIFICATION; PATHOGENESIS;
   DEFINITION
AB Purpose: To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.
   Design: Consensus meeting.
   Participants: An international panel of retina specialists, imaging and image reading center experts, and ocular pathologists.
   Methods: During several meetings organized under the auspices of the Macula Society, an international study group discussed and codified a set nomenclature framework for classifying the subtypes of neovascular AMD and associated lesion components.
   Main Outcome Measures: A consensus classification of neovascular AMD.
   Results: The study group created a standardized working definition of AMD. The components of neovascular AMD were defined and subclassified. Disease consequences of macular neovascularization were delineated.
   Conclusions: The framework of a consensus nomenclature system, a definition of AMD, and a delineation of the subtypes of neovascular AMD were developed. Establishing a uniform set of definitions will facilitate comparison of diverse patient groups and different studies. The framework presented is modified and updated readily, processes that are anticipated to occur on a periodic basis. The study group suggests that the consensus standards outlined in this article be used in future reported studies of neovascular AMD and clinical practice. (C) 2019 by the American Academy of Ophthalmology.
C1 [Spaide, Richard F.; Freund, K. Bailey; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Sarraf, David; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Staurenghi, Giovanni] Ist Sci San Raffaele, Milan, Italy.
   [Waheed, Nadia K.; Baumal, Caroline R.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Paris, France.
   [Cohen, Salomon Y.] Ophthalm Ctr Imaging & Laser, Paris, France.
   [Querques, Giuseppe] Univ Vita Salute San Raffele, IRCCS San Raffaele Hosp, Milan, Italy.
   [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol, Tokyo, Japan.
   [Boyer, David] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Gaudric, Alain; Tadayoni, Ramin Ramin] Univ Paris, Hop Lariboisiere, AP HP, Dept Ophthalmol, Paris, France.
   [Blodi, Barbara] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Li, Xiaoxin] Beijing Univ, Peoples Hosp, Peoples Eye Ctr, Dept Ophthalmol, Beijing, Peoples R China.
   [Coscas, Gabriel J.] Univ Paris 12, Dept Ophthalmol, Paris, France.
   [Brucker, Alexander] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Singerman, Lawrence] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH USA.
   [Luthert, Phil] UCL, Inst Ophthalmol, London, England.
   [Schmidt-Erfurth, Ursula] Univ Eye Hosp, Dept Ophthalmol, Vienna, Austria.
   [Grossniklaus, Hans E.] Emory Eye Ctr, Atlanta, GA USA.
   [Wilson, David J.] Oregon Hlth & Sci Univ, Portland, OR USA.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Csaky, Karl] Texas Retina Associates, Dallas, TX USA.
   [Mones, Jordi M.] Inst Macula, Barcelona, Spain.
   [Mones, Jordi M.] Barcelona Macula Fdn, Barcelona, Spain.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Fujimoto, James] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
C3 Vitreous Retina Macula Consultants of New York; Duke University; Doheny
   Eye Institute; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; Tufts University; Queens University
   Belfast; Bascom Palmer Eye Institute; University of Miami; University of
   Bonn; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Tokyo Medical & Dental
   University (TMDU); Retina Vitreous Associates Medical Group; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; University of Wisconsin System; University of
   Wisconsin Madison; Peking University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); University of Pennsylvania; Case
   Western Reserve University; University of London; University College
   London; Oregon Health & Science University; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); St. Franziskus-Hospital; Massachusetts Institute of Technology
   (MIT)
RP Spaide, RF (通讯作者)，Macula Consultants New York, Retina, Vitreous, 950 Third Ave,Third Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI mones, jordi/CAJ-2963-2022; Spaide, Richard/ABD-7368-2020; Freund, K.
   Bailey/V-7488-2018
OI mones, jordi/0000-0003-3685-2160; Chakravarthy,
   Usha/0000-0002-2606-3734; Freund, K. Bailey/0000-0002-7888-9773
FU Macula Society, Cleveland, OH; Heidelberg Engineering, Inc; Optovue Inc;
   Topcon Medical Systems, Inc; ZeissMeditec, Inc.
FX Supported in part by the Macula Society, Cleveland, OH; Heidelberg
   Engineering, Inc; Optovue Inc, Topcon Medical Systems, Inc, and
   ZeissMeditec, Inc. The sponsors had no role in the design or conduct of
   this research and no input in writing the article.
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   [Anonymous], 1987, STEREOSCOPIC ATLAS M
   Bagley DM, 2006, REGUL TOXICOL PHARM, V45, P206, DOI 10.1016/j.yrtph.2006.04.005
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cornet R, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-S1-S2
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Estrada NA, 2012, INT J NURS KNOWL, V23, P86, DOI 10.1111/j.2047-3095.2011.01201.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Klehr Joan, 2009, Int J Nurs Terminol Classif, V20, P169, DOI 10.1111/j.1744-618X.2009.01132.x
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Mayo C, 2015, INT J RADIAT ONCOL, V93, pE383, DOI 10.1016/j.ijrobp.2015.07.1525
   Novais EA, 2016, OSLI RETINA, V47, P201, DOI 10.3928/23258160-20160229-01
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sikorav A, 2017, BRIT J OPHTHALMOL, V101, P438, DOI 10.1136/bjophthalmol-2015-308065
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2010, ESSENT OPHTHALMOL, P169, DOI 10.1007/978-3-540-85540-8_15
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Srivastava SK, 2003, RETINA-J RET VIT DIS, V23, P712, DOI 10.1097/00006982-200310000-00019
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tohen M, 2009, BIPOLAR DISORD, V11, P453, DOI 10.1111/j.1399-5618.2009.00726.x
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 67
TC 194
Z9 203
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2020
VL 127
IS 5
BP 616
EP 636
DI 10.1016/j.ophtha.2019.11.004
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE7XR
UT WOS:000526937900020
PM 31864668
OA Green Published, hybrid, Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Iwase, T
   Baba, T
   Saito, Y
   Nizawa, T
   Yokouchi, H
   Kubota-Taniai, M
   Kitahashi, M
   Yamamoto, S
AF Iwase, Takehito
   Baba, Takayuki
   Saito, Yuya
   Nizawa, Tomohiro
   Yokouchi, Hirotaka
   Kubota-Taniai, Mariko
   Kitahashi, Masayasu
   Yamamoto, Shuichi
TI Surgical outcomes of vitrectomy for breakthrough vitreous hemorrhage in
   eyes with exudative age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Vitreous hemorrhage;
   Vitrectomy; Visual acuity; Ultrasonography
AB Purpose To report the outcomes of pars plana vitrectomy in cases with breakthrough vitreous hemorrhage (VH) secondary to exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy. We also investigated the relationship between the preoperative b-mode ultrasonographic findings and the postoperative visual acuity to determine if the ultrasonographic findings can predict the surgical outcome after pars plana vitrectomy. Methods This was a retrospective, interventional, case series. Twenty eyes of 20 patients were studied. The associations between the pre- and intraoperative factors and the final best-corrected visual acuity (BCVA) were determined. Recombinant tissue-plasminogen activator (tPA) was used in cases with massive hemorrhagic retinal detachment. Results Ten eyes with polypoidal choroidal vasculopathy (PCV), two eyes with choroidal neovascularization (CNV), and eight eyes with an unknown type of AMD were studied. The mean BCVA was 0.73 +/- 0.57 logarithm of the minimum angle of resolution (logMAR) units before developing the VH, 2.25 +/- 0.45 logMAR units before the surgery, and 1.52 +/- 0.87 logMAR units after the surgery. The BCVA improved significantly after the surgery (P = 0.004) but was significantly worse than that before developing the VH (P = 0.012). The cases of PCV had better final BCVA than cases of CNV (P = 0.043, Mann-Whitney test). The preoperative presence of a subretinal elevation at the macula detected by ultrasonography was significantly associated with a poorer final BCVA (P = 0.031). Conclusions Vitrectomy significantly improved visual function in the eyes with VH associated with exudative AMD. The eyes with PCV and no macular subretinal elevation on ultrasonography had a better visual prognosis.
C1 [Iwase, Takehito; Baba, Takayuki; Saito, Yuya; Nizawa, Tomohiro; Yokouchi, Hirotaka; Kubota-Taniai, Mariko; Kitahashi, Masayasu; Yamamoto, Shuichi] Chiba Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.
C3 Chiba University
RP Baba, T (通讯作者)，Chiba Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.
EM babatakayuki@nifty.com
CR Baek J, 2018, RETINA-J RET VIT DIS, V38, P1993, DOI 10.1097/IAE.0000000000001817
   Chaudhry NA, 2002, OPHTHALMIC SURG LAS, V33, P16
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57297-8
   KREIGER AE, 1983, RETINA-J RET VIT DIS, V3, P318, DOI 10.1097/00006982-198300340-00017
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moon SW, 2013, J OCUL PHARMACOL TH, V29, P556, DOI 10.1089/jop.2012.0148
   Narayanan Raja, 2015, Int J Retina Vitreous, V1, P25, DOI 10.1186/s40942-015-0025-4
   Roufail E, 2008, CLIN EXP OPHTHALMOL, V36, P36, DOI 10.1111/j.1442-9071.2007.01651.x
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 22
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAY
PY 2021
VL 41
IS 5
BP 1835
EP 1844
DI 10.1007/s10792-021-01744-x
EA FEB 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RV6IQ
UT WOS:000619914000001
PM 33611763
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Hosoda, Y
   Miyake, M
   Ooto, S
   Tsujikawa, A
AF Yamashiro, Kenji
   Hosoda, Yoshikatsu
   Miyake, Masahiro
   Ooto, Sotaro
   Tsujikawa, Akitaka
TI Characteristics of Pachychoroid Diseases and Age-Related Macular
   Degeneration: Multimodal Imaging and Genetic Backgrounds
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; genetic association; indocyanine green
   angiography; optical coherence tomography; pachychoroid disease
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; ENDOTHELIAL
   GROWTH-FACTOR; INDOCYANINE GREEN ANGIOGRAPHY; GENOME-WIDE ASSOCIATION;
   PIGMENT EPITHELIAL DETACHMENTS; HUMOR CYTOKINE LEVELS; AQUEOUS-HUMOR
AB The emergence of pachychoroid disease is changing the concept of age-related macular degeneration (AMD). The concept of pachychoroid diseases was developed through clinical observation of multimodal images of eyes with AMD and central serous chorioretinopathy; however, recent genetic studies have provided a proof of concept for pachychoroid spectrum disease, which should be differentiated from drusen-driven AMD. The genetic confirmation of pachychoroid concept further provides novel viewpoints to decode previously reported findings, which facilitates an understanding of the true nature of pachychoroid diseases and AMD. The purpose of this review was to elucidate the relationship between pachychoroid diseases and AMD by interpreting previous findings on pachychoroid diseases and AMD from the novel viewpoints of genetic associations. We confirmed that previous genetic studies supported the concept of pachychoroid diseases. From a genetic viewpoint, the presence of thick choroid and the presence of choroidal vascular hyperpermeability were important characteristics of pachychoroid spectrum diseases. Previous studies have also suggested the classification of polypoidal choroidal vasculopathy (PCV) into two subtypes, pachychoroid neovasculopathy and drusen-driven PCV. Genetic viewpoints will be beneficial to rearrange subtypes of drusen-driven AMD and pachychoroid spectrum diseases. Further genetic studies are needed to investigate pachyvessels, pachydrusen and the significance of polypoidal lesions in pachychoroid neovasculopathy and drusen-driven AMD/PCV.
C1 [Yamashiro, Kenji; Hosoda, Yoshikatsu; Miyake, Masahiro; Ooto, Sotaro; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
   [Yamashiro, Kenji] Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
C3 Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.; Yamashiro, K (通讯作者)，Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp; kubrick@kuhp.kyoto-u.ac.jp;
   miyakem@kuhp.kyoto-u.ac.jp; ohoto@kuhp.kyoto-u.ac.jp;
   tujikawa@kuhp.kyoto-u.ac.jp
OI Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Fernandez-Robredo P, 2008, OPHTHALMOLOGY, V115, P1632, DOI 10.1016/j.ophtha.2008.03.004
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Goktas A, 2014, EYE, V28, P1431, DOI 10.1038/eye.2014.219
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2009, RETINA-J RET VIT DIS, V29, P395, DOI 10.1097/IAE.0b013e318192f53a
   Hiroe T, 2018, OPHTHALMOL RETINA, V2, P152, DOI 10.1016/j.oret.2017.05.013
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2019, OPHTHALMOL RETINA, V3, P985, DOI 10.1016/j.oret.2019.05.025
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kang NH, 2013, EYE, V27, P387, DOI 10.1038/eye.2012.273
   Kawashima-Kumagai K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07526-9
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim FPM, 2016, BRIT J OPHTHALMOL, V100, P918, DOI 10.1136/bjophthalmol-2015-307055
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Manabe S, 2015, AM J OPHTHALMOL, V159, P644, DOI 10.1016/j.ajo.2015.01.006
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   MIYAKE M, 2019, INVEST OPHTH VIS SCI, V60
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Mohabati D, 2019, RETINA-J RET VIT DIS, V39, P2303, DOI 10.1097/IAE.0000000000002333
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Moschos MM, 2016, RETINA-J RET VIT DIS, V36, P402, DOI 10.1097/IAE.0000000000000693
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nomura Y, 2016, GRAEF ARCH CLIN EXP, V254, P53, DOI 10.1007/s00417-015-3006-2
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Oh JH, 2014, INVEST OPHTH VIS SCI, V55, P1502, DOI 10.1167/iovs.13-13183
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Pryds A, 2012, ACTA OPHTHALMOL, V90, P738, DOI 10.1111/j.1755-3768.2011.02157.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schellevis RL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43152-3
   Schellevis RL, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.576
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Shiihara H, 2019, GRAEF ARCH CLIN EXP, V257, P1879, DOI 10.1007/s00417-019-04399-8
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Sugano Y, 2013, JPN J OPHTHALMOL, V57, P294, DOI 10.1007/s10384-013-0230-3
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Tamakoshi A., 1992, CASE CONTROL STUDY S, P134
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang XY, 2014, GRAEF ARCH CLIN EXP, V252, P1033, DOI 10.1007/s00417-013-2505-2
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Weng SS, 2016, OPHTHALMOLOGICA, V236, P114, DOI 10.1159/000448630
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yamashiro K., 2019, J JPN OPHTHALMOL SOC, V123, P407
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yang LH, 2013, ACTA OPHTHALMOL, V91, pE358, DOI 10.1111/aos.12059
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 203
TC 22
Z9 23
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2020
VL 9
IS 7
AR 2034
DI 10.3390/jcm9072034
PG 37
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA MS3AF
UT WOS:000554152800001
PM 32610483
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ueda-Arakawa, N
   Tsujikawa, A
   Yamashiro, K
   Ooto, S
   Tamura, H
   Yoshimura, N
AF Ueda-Arakawa, Naoko
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Ooto, Sotaro
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI Visual prognosis of eyes with submacular hemorrhage associated with
   exudative age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography;
   Polypoidal choroidal vasculopathy; Submacular hemorrhage
ID OPTICAL COHERENCE TOMOGRAPHY; TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL
   HEMORRHAGE; CLINICOPATHOLOGICAL CORRELATION; PHOTODYNAMIC THERAPY;
   ULTRAHIGH-RESOLUTION; RETINAL THICKNESS; NATURAL-HISTORY; BEVACIZUMAB;
   MANAGEMENT
AB To study the retinal structural changes associated with submacular hemorrhage due to exudative age-related macular degeneration (AMD) and their relationships with visual prognosis.
   We retrospectively reviewed the medical records of 31 consecutive patients (31 eyes) with visual impairment due to an acute submacular hemorrhage associated with typical AMD (10 eyes) or polypoidal choroidal vasculopathy (21 eyes).
   Optical coherence tomography (OCT) revealed that submacular hemorrhage exhibited intense hyperreflectivity beneath the neurosensory retina and often seemed to infiltrate it. In the OCT sections, mild to moderate amorphous hyperreflectivity and/or hyperreflective dots were observed within the neurosensory retina, resulting in the loss of the junctions between the inner (IS) and outer (OS) segments of the photoreceptors. Of the 31 eyes, the foveal IS/OS line could be seen incompletely in 12 eyes and was totally absent in 16 eyes. The initial integrity of the foveal photoreceptor layer was correlated with the final visual acuity; the initial detection of the IS/OS just beneath the fovea was correlated with good final visual acuity (r = 0.375, p = 0.038).
   As a hallmark of integrity of the foveal photoreceptor layer, the initial detection of the IS/OS just beneath the fovea may predict good visual outcomes.
C1 [Ueda-Arakawa, Naoko; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P171
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P97
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Koshibu A, 1979, Nippon Ganka Gakkai Zasshi, V83, P386
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Mavrofrides EC, 2004, OPTICAL COHERENCE TO, P243
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ooto S, 2011, RETINA-J RET VIT DIS, V31, P527, DOI 10.1097/IAE.0b013e3181eef2db
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 2004, MED RETINA, P77
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsujikawa A, 2009, RETINA-J RET VIT DIS, V29, P782, DOI 10.1097/IAE.0b013e3181a2f26a
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
NR 43
TC 11
Z9 11
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2012
VL 56
IS 6
BP 589
EP 598
DI 10.1007/s10384-012-0191-y
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 036AC
UT WOS:000310996200010
PM 23053632
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Singh, A
   Falk, MK
   Subhi, Y
   Sorensen, TL
AF Singh, Amardeep
   Falk, Mads Kruger
   Subhi, Yousif
   Sorensen, Torben Lykke
TI The Association between Plasma 25-Hydroxyvitamin D and Subgroups in
   Age-Related Macular Degeneration: A Cross-Sectional Study
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D LEVELS; GROWTH-FACTOR-BETA; OXIDATIVE STRESS; INFLAMMATION;
   FIBROSIS; ANGIOGENESIS; INHIBITION; EXPRESSION; DISEASE; CANCER
AB Objectives: To evaluate potential differences in plasma 25-hydroxyvitamin in subtypes of age-related macular degeneration (AMD), and in patients in Clinical Age-Related Maculopathy Staging (CARMS) group 5 with or without subretinal fibrosis.
   Methods: This single-center cross-sectional study included 178 participants during a period of 20 months. Ninety-five patients belonged to CARMS 5; twelve belonged to CARMS 4; twenty-two belonged to CARMS 2 or 3; and 49 individuals did not have AMD (CARMS 1). Following a structured interview, a detailed bilateral retinal examination was performed and participants were allocated to their respective subgroups in accordance with the Clinical Age-Related Maculopathy Staging system. Plasma 25-hydroxyvitamin D2 and D3 were analyzed using liquid chromatography-tandem mass spectrometry. Genomic DNA was extracted from leukocytes and genotyped for single nucleotide polymorphisms (SNPs) in the vitamin D metabolism. Differences in plasma 25-hydroxyvitamin D were determined in the subgroups as well as between patients in CARMS 5 with or without subretinal fibrosis.
   Results: Plasma 25-hydroxyvitamin D was comparable in patients across CARMS groups 1 to 5 (p = 0.83). In CARMS 5, the presence of subretinal fibrosis was associated with significantly lower concentrations of 25-hydroxyvitamin D as compared to the absence of subretinal fibrosis (47.2 versus 75.6 nmol/L, p<0.001). Patients in CARMS 5 with subretinal fibrosis were more likely to have insufficient levels of 25-hydroxyvitamin D compared to patients without subretinal fibrosis (p = 0.006). No association was found between the SNPs rs10877012, rs2228570, rs4588, or rs7041 and AMD subgroups or plasma 25-hydroxyvitamin levels.
   Conclusions: This study suggests that the presence of subretinal fibrosis in patients belonging to CARMS 5 may be associated with a poor vitamin D status. Our observations warrant further investigation into the role of vitamin D in the development of subretinal fibrosis.
C1 [Singh, Amardeep] Copenhagen Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Roskilde, Denmark.
   Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Singh, A (通讯作者)，Copenhagen Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Roskilde, Denmark.
EM asingh@dadlnet.dk
RI Subhi, Yousif/ABG-6330-2020; Sørensen, Torben Lykke L/N-1417-2014;
   Singh, Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Sørensen, Torben Lykke
   L/0000-0002-6790-0199; 
FU Region Zealand's Research Fund; Velux Foundation; Danish Research Eye
   Foundation; Danish Eye Health Society (Vaern om Synet); Beckett
   Foundation; Synoptik Foundation
FX This study was funded by Region Zealand's Research Fund, the Velux
   Foundation, the Danish Research Eye Foundation, the Danish Eye Health
   Society (Vaern om Synet), the Beckett Foundation, and the Synoptik
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agborsangaya C, 2010, NUTR CANCER, V62, P51, DOI 10.1080/01635580903191460
   Akin F, 2012, J INVEST MED, V60, P869, DOI 10.2310/JIM.0b013e31825457cb
   Amtul Z, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.014
   Annweiler C, 2013, J ALZHEIMERS DIS, V33, P659, DOI 10.3233/JAD-2012-121432
   Annweiler C, 2012, COGN BEHAV NEUROL, V25, P121, DOI 10.1097/WNN.0b013e31826df647
   Annweiler C, 2012, OPHTHALMOLOGY, V119, P1090, DOI 10.1016/j.ophtha.2012.02.005
   Arnson Y, 2011, AUTOIMMUN REV, V10, P490, DOI 10.1016/j.autrev.2011.02.002
   Artaza JN, 2009, J ENDOCRINOL, V200, P207, DOI 10.1677/JOE-08-0241
   Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chen YZ, 2011, ARCH BIOCHEM BIOPHYS, V507, P241, DOI 10.1016/j.abb.2010.12.020
   Cheung FSG, 2012, EXPERT REV ANTICANC, V12, P811, DOI [10.1586/era.12.53, 10.1586/ERA.12.53]
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Guillot X, 2010, JOINT BONE SPINE, V77, P552, DOI 10.1016/j.jbspin.2010.09.018
   Halder SK, 2011, J CLIN ENDOCR METAB, V96, pE754, DOI 10.1210/jc.2010-2131
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q
   Isik S, 2012, EUR J INTERN MED, V23, P93, DOI 10.1016/j.ejim.2011.09.017
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koleganova N, 2009, NEPHROL DIAL TRANSPL, V24, P778, DOI 10.1093/ndt/gfn549
   Krishnan AV, 2011, ANNU REV PHARMACOL, V51, P311, DOI 10.1146/annurev-pharmtox-010510-100611
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028
   McGrath JJ, 2010, J STEROID BIOCHEM, V121, P471, DOI 10.1016/j.jsbmb.2010.03.073
   Meng JE, 2012, CANCER EPIDEM BIOMAR, V21, P916, DOI 10.1158/1055-9965.EPI-12-0026
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Petta S, 2010, HEPATOLOGY, V51, P1158, DOI 10.1002/hep.23489
   Ramirez AM, 2010, J STEROID BIOCHEM, V118, P142, DOI 10.1016/j.jsbmb.2009.11.004
   SCHECHTMAN KB, 1991, AM J PUBLIC HEALTH, V81, P771, DOI 10.2105/AJPH.81.6.771
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shanker J, 2011, CORONARY ARTERY DIS, V22, P324, DOI 10.1097/MCA.0b013e3283472a57
   Shen CL, 2012, J MED FOOD, V15, P269, DOI 10.1089/jmf.2011.0163
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354
NR 52
TC 28
Z9 28
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2013
VL 8
IS 7
AR e70948
DI 10.1371/journal.pone.0070948
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204MP
UT WOS:000323369700215
PM 23923033
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jahanfar, F
   Hamishehkar, H
AF Jahanfar, Farhad
   Hamishehkar, Hamed
TI Exploring the association of rs10490924 polymorphism with age-related
   macular degeneration: An in silico approach
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE ARMS2; Age-related macular degeneration; Rs10490924; In silico;
   Molecular dynamics; Ab initio
ID MOLECULAR-DYNAMICS; SUSCEPTIBILITY GENES; PHOSPHORYLATION; PREDICTION;
   ARMS2; PREVALENCE; SIMULATION; MUTATIONS; STABILITY; ACCURACY
AB The polymorphism rs10490924 (A69S) in the age-related maculopathy susceptibility 2 (ARMS2) gene is highly associated with age-related macular degeneration, which is the leading cause of blindness among the elderly population. ARMS2 gene encodes a putative small (11 kDa) protein, which the function and localization of the ARMS2 protein remain under debate. For a better understanding of functional impacts of A69S mutation, we performed a detailed analysis of an ARMS2 sequence with a broad set of bioinformatics tools. In silico analysis was followed to predict the tertiary structure, putative binding site regions, and binding site residues. Also, the effects of this mutation on protein stability, aggregation propensity, and homodimerization were analyzed. Next, a molecular dynamic simulation was carried out to understand the dynamic behavior of wild-type, A69S, and phosphorylated A69S structures. The results showed alterations in the putative post-translational modification sites on the ARMS2 protein, due to the mutation. Furthermore, the stability of protein and putative homodimer conformations were affected by the mutation. Molecular dynamic simulation results revealed that A69S mutation enhances the rigidity of the ARMS2 structure and residue serine at position 69 is buried and may not be phosphorylated; however, phosphorylated serine enhances the flexibility of the ARMS2 structure. In conclusion, our study provides new insights into the deleterious effects of A69S mutation on the ARMS2 structure. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Jahanfar, Farhad] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran.
   [Jahanfar, Farhad] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Hamishehkar, Hamed] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science
RP Hamishehkar, H (通讯作者)，Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
EM hamishehkarh@tbzmed.ac.ir
OI JAHANFAR, FARHAD/0000-0001-9079-8973
CR Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Capriotti E, 2005, NUCLEIC ACIDS RES, V33, pW306, DOI 10.1093/nar/gki375
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chauhan JS, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0067008, 10.1371/journal.pone.0080000]
   Conchillo-Sole O, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-65
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dinkel H, 2015, NUCLEIC ACIDS RES
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johansen MB, 2006, GLYCOBIOLOGY, V16, P844, DOI 10.1093/glycob/cwl009
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Karshikoff A, 2015, FEBS J, V282, P3899, DOI 10.1111/febs.13343
   Karve T. M., 2011, J AMINO ACIDS, V2011
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Metcalfe EE, 2005, BIOCHEMISTRY-US, V44, P4386, DOI 10.1021/bi047571e
   Ngan CH, 2012, BIOINFORMATICS, V28, P286, DOI 10.1093/bioinformatics/btr651
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Paterlini MG, 2005, BIOPHYS J, V88, P3243, DOI 10.1529/biophysj.104.054460
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pierce B, 2005, BIOINFORMATICS, V21, P1472, DOI 10.1093/bioinformatics/bti229
   Pires D. E., 2014, NUCLEIC ACIDS RES
   Pires DEV, 2014, BIOINFORMATICS, V30, P335, DOI 10.1093/bioinformatics/btt691
   Radivojac P, 2010, PROTEINS, V78, P365, DOI 10.1002/prot.22555
   Rousseau F, 2006, CURR OPIN STRUC BIOL, V16, P118, DOI 10.1016/j.sbi.2006.01.011
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Vlassara H, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-013-0453-1
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worth CL, 2011, NUCLEIC ACIDS RES, V39, pW215, DOI 10.1093/nar/gkr363
   Xu D, 2012, PROTEINS, V80, P1715, DOI 10.1002/prot.24065
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Yoshida T, 2007, MOL VIS, V13, P545
   Zambrano R., 2015, NUCLEIC ACIDS RES
NR 49
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD MAR
PY 2018
VL 80
BP 52
EP 58
DI 10.1016/j.jmgm.2017.12.023
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA GA1SW
UT WOS:000428098700008
PM 29316486
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Gobel, AP
   Thiele, S
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Goebel, Arno P.
   Thiele, Sarah
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI DEVELOPMENT OF INTRARETINAL CYSTOID LESIONS IN EYES WITH INTERMEDIATE
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; intraretinal cystoid lesions; optical
   coherence tomography; choroidal neovascularization
ID OPTICAL-COHERENCE-TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; NEOVASCULAR
   MACULOPATHY; PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; RANIBIZUMAB;
   PHOTOCOAGULATION; OVERESTIMATION; VERTEPORFIN; PROGRESSION
AB Purpose: To evaluate the development of intraretinal cystoid lesions (ICLs) in eyes with intermediate age-related macular degeneration.
   Methods: Serial multimodal retinal imaging data of 105 eyes from 87 age-related macular degeneration subjects (median age of 75.0 years) with no late age-related macular degeneration at baseline from the prospective longitudinal natural history "molecular diagnostic of age-related macular degeneration-study" were included. The presence of ICLs-defined as lacunar hyporeflective areas within the neurosensory retina-was determined by spectral-domain optical coherence tomography at Month 24. Both baseline and further follow-up data were additionally evaluated.
   Results: At Month 24, ICLs were identified in 12 of 105 (11.7%) eyes of which 4 had developed signs of choroidal neovascularization since baseline. Intraretinal cystoid lesions in these four eyes with choroidal neovascularization were mostly found at the level of the outer nuclear layer. Intraretinal cystoid lesions in the remaining 8 eyes occurred mainly at the level of the inner nuclear layer, showed smaller horizontal and vertical dimensions, and were not spatially confined to an increase in retinal thickness.
   Conclusion: The results indicate that ICLs may develop also in the absence of active neovascularization. Distinctive morphologic features and localization of ICLs may be indicative of different underlying pathogenetic mechanisms. If no manifest choroidal neovascularization can be established in the presence of ICLs, close monitoring as well as awareness and self-monitoring seem to be advisable.
C1 [Steinberg, Julia S.; Goebel, Arno P.; Thiele, Sarah; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brinkmann CK, 2010, OPHTHALMOLOGE, V107, P999, DOI 10.1007/s00347-010-2158-z
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim JH, 2013, GRAEF ARCH CLIN EXP, V251, P1091, DOI 10.1007/s00417-012-2147-9
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tan CSH, 2013, GRAEF ARCH CLIN EXP, V251, P2835, DOI 10.1007/s00417-013-2454-9
   Ziemssen F, 2015, OPHTHALMOLOGE
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 24
TC 12
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1548
EP 1556
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200034
PM 26716957
DA 2022-11-30
ER

PT J
AU Friedman, DS
   O'Colmain, B
   Tomany, SC
   McCarty, C
   de Jong, PTVM
   Nemesure, B
   Mitchell, P
   Kempen, J
   Congdon, N
AF Friedman, DS
   O'Colmain, B
   Tomany, SC
   McCarty, C
   de Jong, PTVM
   Nemesure, B
   Mitchell, P
   Kempen, J
   Congdon, N
CA Eye Dis Prevalence Res Grp
TI Prevalence of age-related macular degeneration in the United States
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL NEOVASCULAR LESIONS; BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT;
   LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; RACIAL-DIFFERENCES;
   CLINICAL-TRIALS; MACULOPATHY; POPULATION; BLINDNESS
AB Objective: To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender.
   Methods: Summary prevalence estimates of drusen 125 pin or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD.
   Results: The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy. More than 7 million individuals had drusen measuring 125 pin or larger and were, therefore, at substantial risk of developing AMD. Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020. Age-related macular degeneration was far more prevalent among white than among black persons.
   Conclusion: Age-related macular degeneration affects more than 1.75 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to almost 3 million by 2020.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   George Washington Univ, Med Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth & Hlth Serv, Washington, DC 20037 USA.
   Macro Int Inc, Calverton, MD USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA.
   Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   Westmead Hosp, Ctr Vis Res, Westmead, NSW 2145, Australia.
C3 Johns Hopkins University; Johns Hopkins Medicine; George Washington
   University; University of Wisconsin System; University of Wisconsin
   Madison; Centre for Eye Research Australia; University of Melbourne;
   Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   University of Amsterdam; Academic Medical Center Amsterdam; State
   University of New York (SUNY) System; SUNY Community College; State
   University of New York (SUNY) Stony Brook; University of Sydney;
   University of Sydney
RP Friedman, DS (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Wilmer 120,600 N Wolfe St, Baltimore, MD 21287 USA.
EM david.friedman@jhu.edu
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; Panchapakesan,
   Jai/E-4860-2016
OI Wang, Jie Jin/0000-0001-9491-4898; McCarty,
   Catherine/0000-0003-1089-0142; Friedman, David/0000-0002-2055-5797
FU NEI NIH HHS [R01 EY013460-03, R01 EY013460-02, R01 EY013460-01, R01
   EY013460] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013460]
   Funding Source: NIH RePORTER
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
NR 25
TC 1816
Z9 1893
U1 1
U2 137
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2004
VL 122
IS 4
BP 564
EP 572
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812GT
UT WOS:000220828700016
PM 15078675
DA 2022-11-30
ER

PT J
AU Kellner, U
   Kellner, S
   Weinitz, S
AF Kellner, Ulrich
   Kellner, Simone
   Weinitz, Silke
TI FUNDUS AUTOFLUORESCENCE (488 NM) AND NEAR-INFRARED AUTOFLUORESCENCE (787
   NM) VISUALIZE DIFFERENT RETINAL PIGMENT EPITHELIUM ALTERATIONS IN
   PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; geographic
   atrophy; near-infrared autofluorescence
ID GEOGRAPHIC ATROPHY; LIPOFUSCIN FLUOROPHORE; IN-VIVO; MELANIN; A2E;
   CLASSIFICATION; FLUORESCENCE; PATTERNS; CELLS; RPE
AB Purpose: The purpose of this study was to compare near-infrared fundus autofluorescence (NIA, excitation 787 nm, emission >800 nm) with fundus autofluorescence (FAF, excitation 488 nm, emission >500 nm) in patients with age-related macular degeneration (AMD).
   Methods: Fundus autofluorescence and NIA were obtained using a confocal scanning-laser ophthalmoscope (HRA2) in 308 eyes (172 patients) with AMD [age-related maculopathy (n = 116), geographic atrophy (n = 77), and neovascular AMD (n = 115)].
   Results: Retinal pigment epithelial alterations were detected with FAF and NIA in all eyes and showed a similar lesion size in 81.8%. In age-related maculopathy, spots of increased FAF (87.9%) were more frequent than spots of reduced FAF (26.7%). Spots of increased and reduced NIA were of similar frequency (66.4%). A higher relative intensity of FAF was more frequent (72.4%) than higher relative NIA intensity (16.4%), suggesting that loss of NIA usually precedes loss of FAF. The junctional zone of geographic atrophy presented with increased NIA (19.5%), increased FAF (10.4%), or an increase of both (22.1%). In neovascular AMD, exudative changes were better visualized with FAF (56.5%) compared with NIA (33.9%).
   Conclusion: Patterns of FAF and NIA indicate different involvement of lipofuscin and melanin in the pathophysiological process and provide further insight into the development of AMD and noninvasive monitoring of future therapeutic interventions. RETINA 30:6-15,2010
C1 [Kellner, Ulrich] AugenZentrum Siegburg, RetinaSci, D-53721 Siegburg, Germany.
   [Kellner, Ulrich; Kellner, Simone] RetinaScience, Bonn, Germany.
RP Kellner, U (通讯作者)，AugenZentrum Siegburg, RetinaSci, Europapl 3, D-53721 Siegburg, Germany.
EM kellneru@mac.com
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BUCHANAN TAS, 1984, AM J OPHTHALMOL, V97, P277, DOI 10.1016/0002-9394(84)90623-8
   Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fishkin N, 2003, ORG BIOMOL CHEM, V1, P1101, DOI 10.1039/b212213h
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner S, 2009, AM J OPHTHALMOL, V147, P895, DOI 10.1016/j.ajo.2008.12.023
   Kellner U, 2009, EYE, V23, P1349, DOI 10.1038/eye.2008.280
   Kellner U, 2008, DOC OPHTHALMOL, V116, P119, DOI 10.1007/s10633-007-9105-6
   Kellner U, 2006, INVEST OPHTH VIS SCI, V47, P3531, DOI 10.1167/iovs.05-1290
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kokkinou D, 2005, GRAEF ARCH CLIN EXP, V243, P1050, DOI 10.1007/s00417-005-1197-7
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Peters S, 2000, OPHTHALMIC RES, V32, P52, DOI 10.1159/000055589
   Peters S, 2006, Z NATURFORSCH C, V61, P427
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   RAKOCZY P, 1992, BIOL CELL, V76, P49, DOI 10.1016/0248-4900(92)90194-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SmithThomas L, 1996, CURR EYE RES, V15, P1079, DOI 10.3109/02713689608995139
   SPAIDE RF, 2007, ATLAS FUNDUS AUTOFLU
   Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 53
TC 90
Z9 96
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2010
VL 30
IS 1
BP 6
EP 15
DI 10.1097/IAE.0b013e3181b8348b
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZX
UT WOS:000278547300002
PM 20066766
DA 2022-11-30
ER

PT J
AU Shijo, T
   Sakurada, Y
   Yoneyama, S
   Sugiyama, A
   Kikushima, W
   Tanabe, N
   Iijima, H
AF Shijo, Taiyo
   Sakurada, Yoichi
   Yoneyama, Seigo
   Sugiyama, Atsushi
   Kikushima, Wataru
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI Prevalence and characteristics of pseudodrusen subtypes in advanced
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Pseudodrusen; Dot pseudodrusen; Ribbon pseudodrusen; Retinal angiomatous
   proliferation; Geographic atrophy
ID RETICULAR PSEUDODRUSEN; DRUSEN
AB The purpose of our study was to investigate the clinical and genetic characteristics of pseudodrusen subtypes and their incidence in advanced age-related macular degeneration (AMD).
   We studied 84 eyes from 84 patients with pseudodrusen associated with advanced AMD, including typical AMD, polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and geographic atrophy (GA). Multiple imaging modalities, including color fundus photography, spectral-domain optical coherence tomography (SD-OCT), near-infrared reflectance, and fundus autofluorescence, were employed to diagnose pseudodrusen and its subtypes. Subfoveal choroidal thickness was measured using SD-OCT. Subject eyes were classified into two subtypes, dot-dominant or ribbon-dominant, according to the maximum length of ribbon pseudodrusen. Genotyping was performed for ARMS2 A69S (rs10490924) and CFH I62V (rs800292) variants.
   The percentage of ribbon-dominant type pseudodrusen was significantly higher in eyes with RAP (69.6%) and GA (78.6%) compared with those with typical AMD (31.1%) (p = .0025 and .0017, respectively). Multivariate logistic regression analysis disclosed that incidence of female patients and coexisting large soft drusen was significantly higher in ribbon- than dot-dominant types (P = 0.014 and P = 0.008, respectively), while age, subfoveal choroidal thickness, and risk allele frequency for both ARMS2 A69S (rs10490924) and CFH I62V (rs800292) were not different between the two pseudodrusen subtypes.
   Among eyes with advanced AMD associated with pseudodrusen, ribbon-dominant type pseudodrusen were more prevalent in eyes with GA or RAP and were associated with large soft drusen and female patients.
C1 [Shijo, Taiyo; Sakurada, Yoichi; Yoneyama, Seigo; Sugiyama, Atsushi; Kikushima, Wataru; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU JSPS (Japan Society for the promotion of Science) KAKENHI [26861441]
FX This study was supported in part by JSPS (Japan Society for the
   promotion of Science) KAKENHI Grant Number 26861441.
CR Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 14
TC 8
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2017
VL 255
IS 6
BP 1125
EP 1131
DI 10.1007/s00417-017-3622-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV0NL
UT WOS:000401437600010
PM 28251353
DA 2022-11-30
ER

PT J
AU Auer-Grumbach, M
   Weger, M
   Fink-Puches, R
   Papic, L
   Frohlich, E
   Auer-Grumbach, P
   El Shabrawi-Caelen, L
   Ttl, MS
   Windpassinger, C
   Senderek, J
   Budka, H
   Trajanoski, S
   Janecke, AR
   Haas, A
   Metze, D
   Pieber, TR
   Guelly, C
AF Auer-Grumbach, Michaela
   Weger, Martin
   Fink-Puches, Regina
   Papic, Lea
   Froehlich, Eleonore
   Auer-Grumbach, Piet
   El Shabrawi-Caelen, Laila
   Ttl, Maria Schabhu
   Windpassinger, Christian
   Senderek, Jan
   Budka, Herbert
   Trajanoski, Slave
   Janecke, Andreas R.
   Haas, Anton
   Metze, Dieter
   Pieber, Thomas R.
   Guelly, Christian
TI Fibulin-5 mutations link inherited neuropathies, age-related macular
   degeneration and hyperelastic skin
SO BRAIN
LA English
DT Article
DE age-related macular degeneration; CMT; cutis laxa; fibulin-5; neuropathy
ID ELASTIC FIBER FORMATION; RECESSIVE CUTIS LAXA; MARIE-TOOTH-DISEASE;
   MISSENSE MUTATION; MOTOR NEUROPATHY; MPZ GENE; DOMINANT; INTEGRINS;
   TARGET; DOMAIN
AB To identify the disease-causing gene responsible for an autosomal dominantly inherited Charcot-Marie-Tooth neuropathy subtype in a family excluded for mutations in the common Charcot-Marie-Tooth genes, we used array-based sequence capture to simultaneously analyse the disease-linked protein coding exome at chromosome 14q32. A missense mutation in fibulin-5, encoding a widely expressed constituent of the extracellular matrix that has an essential role in elastic fibre assembly and has been shown to cause cutis laxa, was detected as the only novel non-synonymous sequence variant within the disease interval. Screening of 112 index probands with unclassified Charcot-Marie-Tooth neuropathies detected two further fibulin-5 missense mutations in two families with Charcot-Marie-Tooth disease and hyperextensible skin. Since fibulin-5 mutations have been described in patients with age-related macular degeneration, an additional 300 probands with exudative age-related macular degeneration were included in this study. Two further fibulin-5 missense mutations were identified in six patients. A mild to severe peripheral neuropathy was detected in the majority of patients with age-related macular degeneration carrying mutations in fibulin-5. This study identifies fibulin-5 as a gene involved in Charcot-Marie-Tooth neuropathies and reveals heterozygous fibulin-5 mutations in 2% of our patients with age-related macular degeneration. Furthermore, it adumbrates a new syndrome by linking concurrent pathologic alterations affecting peripheral nerves, eyes and skin to mutations in the fibulin-5 gene.
C1 [Auer-Grumbach, Michaela; Papic, Lea; Ttl, Maria Schabhu; Pieber, Thomas R.] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria.
   [Weger, Martin; Haas, Anton] Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   [Fink-Puches, Regina] Med Univ Graz, Dept Dermatol, A-8036 Graz, Austria.
   [Froehlich, Eleonore] Med Univ Graz, Med Res Ctr, A-8010 Graz, Austria.
   [Auer-Grumbach, Piet] Dermatol Off, A-8200 Gleisdorf, Austria.
   [Windpassinger, Christian] Med Univ Graz, Inst Human Genet, A-8010 Graz, Austria.
   [Senderek, Jan] ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland.
   [Budka, Herbert] Med Univ Vienna, Inst Neurol, A-1090 Vienna, Austria.
   [Janecke, Andreas R.] Innsbruck Med Univ, Dept Paediat 2, A-6020 Innsbruck, Austria.
   [Metze, Dieter] Med Univ Munster, Dept Dermatol, D-48149 Munster, Germany.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz; Medical University of Graz; Medical University of
   Graz; Swiss Federal Institutes of Technology Domain; ETH Zurich; Medical
   University of Vienna; Medical University of Innsbruck; University of
   Munster
RP Auer-Grumbach, M (通讯作者)，Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, Stiftingtalstr 24, A-8010 Graz, Austria.
EM michaela.auergrumbach@medunigraz.at
RI Senderek, Jan/F-8405-2015; Janecke, Andreas/AAA-5227-2019; Fröhlich,
   Eleonore/M-8943-2014; Budka, Herbert/I-3486-2019
OI Senderek, Jan/0000-0002-8263-1783; Fröhlich,
   Eleonore/0000-0002-6056-6829; Budka, Herbert/0000-0002-1933-1577;
   Pieber, Thomas/0000-0003-3554-0405; Janecke, Andreas/0000-0001-7155-0315
FU Austrian Science Fund (FWF) [P19455-B05]; Land Steiermark
   [A3-16.Z-24/2009-1, 2010-2]; Oesterreichische Nationalbank (ONB) [13010]
FX This work was supported by the Austrian Science Fund (FWF, P19455-B05),
   the Land Steiermark (A3-16.Z-24/2009-1, 2010-2) and the Oesterreichische
   Nationalbank (ONB, project 13010).
CR Auer-Grumbach M, 2005, ANN NEUROL, V57, P415, DOI 10.1002/ana.20410
   Auer-Grumbach M, 2010, NAT GENET, V42, P160, DOI 10.1038/ng.508
   Berti C, 2006, NEUROMOL MED, V8, P191, DOI 10.1385/NMM:8:1:191
   Choudhury R, 2009, J BIOL CHEM, V284, P24553, DOI 10.1074/jbc.M109.019364
   Claus S, 2008, J INVEST DERMATOL, V128, P1442, DOI 10.1038/sj.jid.5701211
   Crimella C, 2010, J MED GENET, V47, P712, DOI 10.1136/jmg.2010.077909
   De Jonghe P, 1999, BRAIN, V122, P281, DOI 10.1093/brain/122.2.281
   do Nascimento GM, 2010, AN BRAS DERMATOL, V85, P684, DOI 10.1590/S0365-05962010000500013
   Durieux AC, 2010, J MOL MED, V88, P339, DOI 10.1007/s00109-009-0587-4
   Elahi E, 2006, J INVEST DERMATOL, V126, P1506, DOI 10.1038/sj.jid.5700247
   Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354
   Gudbjartsson DF, 2005, NAT GENET, V37, P1015, DOI 10.1038/ng1005-1015
   Guelly C, 2011, AM J HUM GENET, V88, P99, DOI 10.1016/j.ajhg.2010.12.003
   Hodges E, 2007, NAT GENET, V39, P1522, DOI 10.1038/ng.2007.42
   Houlden H, 2008, NEUROLOGY, V71, P1660, DOI 10.1212/01.wnl.0000319696.14225.67
   Hu QR, 2006, HUM MOL GENET, V15, P3379, DOI 10.1093/hmg/ddl414
   Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Jones RPO, 2009, J BIOL CHEM, V284, P25938, DOI 10.1074/jbc.M109.011627
   Kabzinska D, 2007, AM J MED GENET A, V143A, P2196, DOI 10.1002/ajmg.a.31908
   Kadoya K, 2005, BRIT J DERMATOL, V153, P607, DOI 10.1111/j.1365-2133.2005.06716.x
   Kennerson ML, 2010, AM J HUM GENET, V86, P343, DOI 10.1016/j.ajhg.2010.01.027
   Lawson VH, 2005, NEUROLOGY, V65, P197, DOI 10.1212/01.wnl.0000168898.76071.70
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Lomas AC, 2007, BIOCHEM J, V405, P417, DOI 10.1042/BJ20070400
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Lupski JR, 2010, NEW ENGL J MED, V362, P1181, DOI 10.1056/NEJMoa0908094
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499
   Nicholson GA, 2008, NEUROLOGY, V70, P1678, DOI 10.1212/01.wnl.0000311275.89032.22
   Nikopoulos K, 2010, AM J HUM GENET, V86, P240, DOI 10.1016/j.ajhg.2009.12.016
   Rankin J, 2006, CLIN GENET, V70, P261, DOI 10.1111/j.1399-0004.2006.00677.x
   Reilly MM, 2009, J NEUROL NEUROSUR PS, V80, P1304, DOI 10.1136/jnnp.2008.158295
   Rodriguez C, 2008, DRUG NEWS PERSPECT, V21, P218, DOI 10.1358/dnp.2008.21.4.1213351
   Savasta S, 2011, CHILD NERV SYST, V27, P365, DOI 10.1007/s00381-010-1256-1
   Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039
   Shy ME, 2004, BRAIN, V127, P371, DOI 10.1093/brain/awh048
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sullivan KM, 2007, LAB INVEST, V87, P818, DOI 10.1038/labinvest.3700594
   Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3
   Tumer Z, 2010, EUR J HUM GENET, V18, P511, DOI 10.1038/ejhg.2009.187
   Van Maldergem L, 2003, GENEREVIEWS
   Voermans NC, 2009, ANN NEUROL, V65, P687, DOI 10.1002/ana.21643
   Yanagisawa H, 2009, J CELL COMMUN SIGNAL, V3, P337, DOI 10.1007/s12079-009-0065-3
   Zheng Q, 2007, MOL CELL BIOL, V27, P1083, DOI 10.1128/MCB.01330-06
NR 46
TC 52
Z9 55
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JUN
PY 2011
VL 134
BP 1839
EP 1852
DI 10.1093/brain/awr076
PN 6
PG 14
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 770CF
UT WOS:000291063900022
PM 21576112
OA Green Accepted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Warrian, KJ
   Lorenzana, LL
   Lankaranian, D
   Dugar, J
   Wizov, SS
   Spaeth, GL
AF Warrian, Kevin J.
   Lorenzana, Luciano L.
   Lankaranian, Dara
   Dugar, Jyoti
   Wizov, Sheryl S.
   Spaeth, George L.
TI ASSESSING AGE-RELATED MACULAR DEGENERATION WITH THE ADREV
   PERFORMANCE-BASED MEASURE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE macular degeneration; performance-based measure; visual function; visual
   assessment; disability
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; CONTRAST SENSITIVITY;
   SIGNIFICANCE TESTS; VISION; PERSONALITY; RESPONSIVENESS; BOOTSTRAP;
   AREDS
AB Purpose: To validate a new third-generation performance-based measure titled the "assessment of disability related to vision" (ADREV) in a study population of individuals with age-related macular degeneration.
   Methods: Patients with either exudative or nonexudative age-related macular degeneration, but without ocular comorbidity, completed the ADREV, the 25-item National Eye Institute's visual functioning questionnaire, and a range of clinical assessments. Correlations were calculated between the data provided by the ADREV, visual functioning questionnaire, and clinical ophthalmic measures. Regression and bootstrap analysis were preformed to determine the relative relationship between specific clinical measures and ADREV performance, while controlling for a range of potentially confounding factors.
   Results: One hundred twelve patients completed the study and correlative analysis showed that ADREV total and subscale scores were more related to nearly all measures of clinical ophthalmic status in comparison with the data provided by the visual functioning questionnaire. Significant correlative relationships between ADREV and visual functioning questionnaire scores showed moderate to high correlation. Central visual acuity and contrast sensitivity shared the strongest association with performance of activities.
   Conclusions: The ADREV is a valid instrument for the assessment of visual disability in patients with age-related macular degeneration. Furthermore, the data provided by this performance measure had stronger relationships with clinical indicators of visual impairment in comparison with self-report.
C1 [Spaeth, George L.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Warrian, KJ (通讯作者)，Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM kevinjwarrian@gmail.com
FU Pfizer; The Perelman Fund through the Wills Eye Institute of Jefferson
   Medical College; The Pearle Vision Foundation; The Glaucoma Service
   Foundation to Prevent Blindness
FX Supported by Pfizer, The Perelman Fund through the Wills Eye Institute
   of Jefferson Medical College, The Pearle Vision Foundation, and The
   Glaucoma Service Foundation to Prevent Blindness.
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Altangerel U, 2006, OPHTHAL EPIDEMIOL, V13, P67, DOI 10.1080/09286580500428500
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Davidson AC., 1997, BOOTSTRAP METHODS TH, V1st
   EBERT EM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1009
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Feldman PJ, 1999, J PERS SOC PSYCHOL, V77, P370, DOI 10.1037/0022-3514.77.2.370
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   Glantz S.A., 2002, PRIMER BIOSTATISTICS
   Harlow LL., 2005, ESSENCE MULTIVARIATE
   Haymes SA, 2001, OPTOMETRY VISION SCI, V78, P373, DOI 10.1097/00006324-200106000-00008
   Huber P.J., 2004, ROBUST STAT
   Hubert M, 1997, J STAT PLAN INFER, V57, P153, DOI 10.1016/S0378-3758(96)00041-9
   Kempen GIJM, 1997, HEALTH PSYCHOL, V16, P539, DOI 10.1037/0278-6133.16.6.539
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MARASCUILO LA, 1983, MULTIVARIATE STAT SO
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   McKnight C, 2003, J MED ETHICS, V29, P261, DOI 10.1136/jme.29.4.261
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   Rousseeuw P. J., 1987, WILEY SERIES PROBABI
   SHORACK GR, 1982, COMMUN STAT A-THEOR, V11, P961, DOI 10.1080/03610928208828286
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   THOMPSON B, 1993, J EXP EDUC, V61, P361, DOI 10.1080/00220973.1993.10806596
   Yamaoka K, 1998, QUAL LIFE RES, V7, P535, DOI 10.1023/A:1008830509237
NR 36
TC 12
Z9 12
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2009
VL 29
IS 1
BP 80
EP 90
DI 10.1097/IAE.0b013e318187f160
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 393YV
UT WOS:000262413300014
PM 18854790
DA 2022-11-30
ER

PT J
AU Nunes, RP
   Nobrega, MJ
   De Novelli, FJ
   Coral, SA
   Berti, TB
   Missen, MMD
   Correa, MC
AF Nunes, Renata Portella
   Nobrega, Mario Junqueira
   De Novelli, Fernando Jose
   Coral, Samuel Angelo
   Berti, Thais Bacha
   Drumm Missen, Marina Maria
   Correa, Marina Canuto
TI Causes of interruption of bevacizumab therapy in age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Choroidal neovascularization; Vascular endothelial
   growth factor A; Angiogenesis inhibitors/therapeutic use;
   Bevacizumab/therapeutic use
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; INTRAVITREAL BEVACIZUMAB;
   RANIBIZUMAB; AVASTIN
AB Purpose: To evaluate the rate and the causes of interruption of bevacizumab intravitreal therapy in patients with exudative age-related macular degeneration (AMD) in a referential eye-care center in Joinville, southern Brazil. Methods: Retrospective, non-comparative, consecutive case series. Cases included all patients with exudative age-related macular degeneration who were treated with one or more bevacizumab intravitreal injections at Sadalla Amin Ghanem Eye Hospital between January, 2006 and January, 2008. Data were obtained from patients' medical records and telephone interviews. Discontinuity criterion was the absence of patient follow-up after a minimum of 3 months from the last ophthalmic examination. Results: Eighty-two patients were treated. Among them, 24 (29.3%) interrupted follow-up inadvertently. The mean age was 75.2 years old (range 65-89 yo). Mean number of bevacizumab intravitreal injections was 2.0 (range 1-6). Nineteen patients answered to telephone questionnaires. The main alleged causes of discontinuity of therapy were unexpected poor visual results (8 cases, 42.1%), lack of information about follow-up visits (5 cases, 26.3%) and comorbidities (3 cases, 15.8%). Conclusions: A high number of patients interrupted follow-up after beginning bevacizumab therapy. Many of them related avoidable causes for discontinuity of treatment. Efforts must be done to improve education of age-related macular degeneration patients, especially in relation to functional outcomes and prolonged follow-up care.
C1 [Nunes, Renata Portella; Nobrega, Mario Junqueira; De Novelli, Fernando Jose; Coral, Samuel Angelo; Berti, Thais Bacha; Drumm Missen, Marina Maria; Correa, Marina Canuto] Hosp Olhos Sadalla Amin Ghanem, Retina & Vitreous Dept, Joinville, SC, Brazil.
RP Nunes, RP (通讯作者)，Av Ipe Amarelo 37, BR-88062298 Florianopolis, SC, Brazil.
EM reportella@hotmail.com
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2007, OPHTHALMOLOGY, V114, P400, DOI 10.1016/j.ophtha.2006.10.001
   Bonner P, 2009, ACTA OPHTHALMOL 0626, P1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2005, NEW ENGL J MED, V352, P1721
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAGOUDAS ES, 2005, ACP J CLUB, V143, P18
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   Wu L, 2009, JPN J OPHTHALMOL, V53, P125, DOI 10.1007/s10384-008-0622-y
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   1990, ARCH OPHTHALMOL, V108, P825
NR 20
TC 4
Z9 4
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2010
VL 73
IS 2
BP 146
EP 149
DI 10.1590/S0004-27492010000200009
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 612BQ
UT WOS:000278872200009
PM 20549043
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Zur, D
   Ben Simon, GJ
   Loewenstein, A
   Alster, Y
   Moisseiev, J
   Ullman, S
AF Zur, D
   Ben Simon, GJ
   Loewenstein, A
   Alster, Y
   Moisseiev, J
   Ullman, S
TI A novel high-resolution kinetic method for visual field mapping of
   scotoma in age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; FUNDUS PERIMETRY; MICROPERIMETRY;
   STABILITY; FIXATION; SURGERY; VISION; SITA
AB BACKGROUND AND OBJECTIVE: To examine a new high-resolution kinetic mapping method for scotoma in age-related macular degeneration.
   PATIENTS AND METHODS: A computer-based program for kinetic visual field mapping was tested in 10 healthy subjects and 14 patients with age-related macular degeneration and fixed preferred retinal locus. The stimulus was presented using a back projector on a screen located 40 cm from the subject. The findings were then compared with static results.
   RESULTS: Control group mapping revealed good congruency with the anatomic blind spot. Mapping of the 14 patients with age-related macular degeneration was rapid and revealed good accuracy. The average deviation of the mapping border from the anatomic scotoma border was no more than 3.1% of the scotoma radius. Static mapping of 7 of the patients with age-related macular degeneration was longer and revealed lower accuracy.
   CONCLUSIONS: The proposed method is more rapid, accurate, and consistent than static mapping. It allows accurate mapping of central scotoma with suprathreshold stimulus, and may be used in the future for detecting the early stages of age-related macular degeneration using subthreshold stimulus.
C1 Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.
   Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Goldschlerer Eye Inst, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-52621 Tel Hashomer, Israel.
C3 Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv
   University; Sackler Faculty of Medicine; Tel Aviv University; Sackler
   Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Ben Simon, GJ (通讯作者)，Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
CR Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   AVILA MP, 1985, ANN OPHTHALMOL, V17, P13
   BEBIE H, 1976, ACTA OPHTHALMOL, V54, P325
   Bengtsson B, 1998, ACTA OPHTHALMOL SCAN, V76, P431, DOI 10.1034/j.1600-0420.1998.760408.x
   Bengtsson B, 1998, ACTA OPHTHALMOL SCAN, V76, P165, DOI 10.1034/j.1600-0420.1998.760208.x
   CAMARDA RM, 1984, ITAL J NEUROL SCI, V5, P359, DOI 10.1007/BF02042617
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   DAGNELIE G, 1992, OPTOMETRY VISION S S, V69, P29
   DRUM B, 1987, APPL OPTICS, V26, P1415, DOI 10.1364/AO.26.001415
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   GELLERT W, 1977, VNR CONCISE ENCY MAT, P473
   JOHNSON CA, 1987, ARCH OPHTHALMOL-CHIC, V105, P73
   Kabanarou SA, 2002, INVEST OPHTH VIS SCI, V43, pU1048
   LIEBERMAN MF, 1992, COMPUTERIZED PERIMET, P1
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   MAINSTER MA, 1982, OPHTHALMOLOGY, V89, P852, DOI 10.1016/s0161-6420(82)34714-4
   Meyer JH, 1997, BRIT J OPHTHALMOL, V81, P355, DOI 10.1136/bjo.81.5.355
   NEWELL WF, 1982, OPHTHALMOLOGY PRINCI, P92
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Parks Stuart, 1996, Documenta Ophthalmologica, V92, P281, DOI 10.1007/BF02584082
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   Roux FE, 2001, J NEUROL NEUROSUR PS, V71, P505, DOI 10.1136/jnnp.71.4.505
   SABETES NR, 1996, RETINA, V16, P296
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SHIELDS MB, 1997, TXB GLAUCOMA, P107
   SJAARDA RN, 1993, OPHTHALMOLOGY, V100, P1513
   STEIN HA, 1988, OPHTHALMIC ASSISTANT, P411
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Toonen F, 1995, Ger J Ophthalmol, V4, P311
   Tornow RP, 1999, VISION RES, V39, P3630, DOI 10.1016/S0042-6989(99)00090-5
   Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009
   Van de Velde F J, 1990, Ophtalmologie, V4, P291
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 39
TC 0
Z9 1
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2004
VL 35
IS 5
BP 395
EP 405
DI 10.3928/1542-8877-20040901-08
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 853YN
UT WOS:000223867000006
PM 15497550
DA 2022-11-30
ER

PT J
AU Oz, O
   Ates, NA
   Tamer, L
   Yildirim, O
   Adiguzel, U
AF Oz, O
   Ates, NA
   Tamer, L
   Yildirim, O
   Adiguzel, U
TI Glutathione S-transferase M1, T1, and P1 gene polymorphism in exudative
   age-related macular degeneration: A preliminary report
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; oxidative stress; glutathione
   S-transferase; gene polymorphism
ID CIGARETTE-SMOKING; SUPERGENE FAMILY; RISK FACTOR; MACULOPATHY;
   ASSOCIATION
AB PURPOSE. To elucidate whether the gene polymorphisms of glutathione S-transferase (GST) 14 M1, T1, and P1 are associated with the development of exudative age-related macular degeneration.
   METHODS. The authors genotyped 35 white patients with exudative age-related macular degeneration and 159 healthy controls. Genomic DNA from peripheral blood was examined using polymerase chain reaction and defined for the genetic polymorphisms of GST.
   RESULTS. No association was observed between GSTM1, GSTT1, and GSTP1 polymorphisms and age-related macular degeneration risk (p > 0.05). The frequencies of the combination of the GSTM1 (null) and GSTP1 (mutant), GSTM1 (null), and GSTT1 (null) genotype polymorphisms in patients with exudative age-related macular degeneration differed greatly from those of the control group (p=0.001 OR [95% Cl]: 7.70 [2.28-25.98] and p=0.007 OR [95% Cl]: 3.88 [1.51-10.02], respectively).
   CONCLUSIONS. The present study suggests that the GSTM1 (null) and GSTT1 (null), GSTM1 (null), and GSTP1 (mutant) combinations may be a genetic risk factor for the development of exudative age-related macular degeneration. However, the potential role of GST polymorphisms as a marker of susceptibility to age-related macular degeneration needs further studies in a larger number of patients.
C1 Mersin Univ, Tip Fsak Hastanesi, Dept Biochem, TR-33079 Mersin, Turkey.
   Mersin Univ, Tip Fsak Hastanesi, Dept Ophthalmol, TR-33079 Mersin, Turkey.
   Mersin Univ, Tip Fsak Hastanesi, Dept Med Biol & Genet, TR-33079 Mersin, Turkey.
C3 Mersin University; Mersin University; Mersin University
RP Adiguzel, U (通讯作者)，Mersin Univ, Tip Fsak Hastanesi, Dept Biochem, TR-33079 Mersin, Turkey.
EM adiguzelu@mersin.edu.tr
RI ARAS, Nurcan/Q-2039-2015; Tamer, Lulufer/AAG-5796-2021
OI ARAS, Nurcan/0000-0002-3227-1150; 
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Board PG, 1997, BIOCHEM J, V328, P929
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Diclemans I, 1995, OPHTHALMOLOGY, V102, P205
   Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539
   Hong YJ, 2000, CLIN CHEM LAB MED, V38, P917, DOI 10.1515/CCLM.2000.134
   Juronen E, 2000, EXP EYE RES, V71, P447, DOI 10.1006/exer.2000.0899
   Kelders WPA, 2002, LARYNGOSCOPE, V112, P462, DOI 10.1097/00005537-200203000-00011
   KETTERER B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P97
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1999, AGE RELATED MACULAR, P69
   Ko Y, 2000, PHARMACOGENETICS, V10, P271, DOI 10.1097/00008571-200004000-00009
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   STRANGE RC, 1984, ANN HUM GENET, V48, P11, DOI 10.1111/j.1469-1809.1984.tb00829.x
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 31
TC 31
Z9 36
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2006
VL 16
IS 1
BP 105
EP 110
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017YG
UT WOS:000235728600017
PM 16496253
DA 2022-11-30
ER

PT J
AU Bozkurt, MK
   Ozturk, BT
   Kerimoglu, H
   Ersan, I
   Arbag, H
   Bozkurt, B
AF Bozkurt, M. K.
   Ozturk, B. T.
   Kerimoglu, H.
   Ersan, I.
   Arbag, H.
   Bozkurt, B.
TI Association of age-related macular degeneration with age-related hearing
   loss
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE Age-related Macular Degeneration; Presbycusis; Vision Loss
ID QUALITY-OF-LIFE; BEAVER DAM; IMPAIRMENT; VISION; MACULOPATHY
AB Objective: To assess the association between age-related macular degeneration and age-related hearing loss in Turkish subjects aged 50 years or older.
   Study design and setting: Prospective, case-control study within a tertiary university hospital.
   Subjects and methods: Fifty subjects with age-related macular degeneration and 43 healthy subjects underwent ophthalmological and otolaryngological examination. Statistical analyses were conducted for the poorer eye and ear, comparing age-related hearing loss and pure tone average in the macular degeneration group versus controls.
   Results: Median pure tone average was significantly poorer in the macular degeneration group (35 dBHL) compared with controls (23 dBHL). In the macular degeneration group, hearing loss was significantly greater in dry type (43 dBHL) than wet type (32 dBHL) cases. There was a significant difference between the prevalence of varying degrees of hearing loss in the macular degeneration versus control groups, being respectively: mild, 50 and 35 per cent; moderate, 20 and 5 per cent; and severe, 6 and 0 per cent. There was a weak, but significant correlation between each patient's visual acuity and pure tone average results (r(s) = -0.37, p < 0.001).
   Conclusion: Age-related hearing loss is more common in patients with age-related macular degeneration. Such patients should be questioned regarding hearing difficulty, and referred to an otolaryngologist if appropriate.
C1 [Bozkurt, M. K.; Arbag, H.] Selcuk Univ, Meram Med Fac, Dept Otolaryngol, Konya, Turkey.
   [Ozturk, B. T.; Kerimoglu, H.; Ersan, I.; Bozkurt, B.] Selcuk Univ, Meram Med Fac, Dept Ophthalmol, Konya, Turkey.
C3 Selcuk University; Selcuk University
RP Bozkurt, MK (通讯作者)，Selcuk Univ, Meram Med Fac, Dept Otolaryngol, TR-42080 Meram, Akyokus, Turkey.
EM bozkurtmetekaan@hotmail.com
RI bozkurt, mete/N-6168-2016; Arbag, Hamdi/AAF-9188-2020; bozkurt,
   banu/ACI-1564-2022; bozkurt, mete/AAB-6600-2020
OI bozkurt, mete/0000-0002-5022-6927; bozkurt, banu/0000-0002-9847-3521;
   bozkurt, mete/0000-0002-3153-3294
CR BESS FH, 1989, J AM GERIATR SOC, V37, P123, DOI 10.1111/j.1532-5415.1989.tb05870.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Campbell V A, 1999, MMWR CDC Surveill Summ, V48, P131
   Chia EM, 2007, EAR HEARING, V28, P187, DOI 10.1097/AUD.0b013e31803126b6
   Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465
   Cruickshanks KJ, 1998, AM J EPIDEMIOL, V148, P879
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Jee J, 2005, OPHTHAL EPIDEMIOL, V12, P199, DOI 10.1080/09286580590969707
   Klein BEK, 2001, AM J OPHTHALMOL, V132, P537, DOI 10.1016/S0002-9394(01)01126-6
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   PAUL J, 2002, OPHTHALMOLOGY, V109, P720
   RADEBEUL MR, 2009, MED MONATSSCHR PHARM, V32, P221
   SCHUKNECHT HF, 1964, ARCHIV OTOLARYNGOL, V80, P369
   Singh R, 1991, Indian J Ophthalmol, V39, P127
   WRIGHT A, 1987, ACTA OTO-LARYNGOL, P1
NR 18
TC 7
Z9 7
U1 1
U2 15
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD MAR
PY 2011
VL 125
IS 3
BP 231
EP 235
DI 10.1017/S0022215110002604
PG 5
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Otorhinolaryngology
GA 729GZ
UT WOS:000287938000003
PM 21205373
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Yoon, W
   Yoon, J
   Na, SK
   Lee, J
   Kim, J
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Yoon, Wontae
   Yoon, Jihyun
   Na, Seung Kwan
   Lee, Jihyun
   Kim, Jaemin
   Kim, Chul Gu
   Kim, Jong Woo
TI Development of Intraretinal Fluid in Neovascular Age-Related Macular
   Degeneration During Anti-Vascular Endothelial Growth Factor Treatment
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; MORPHOLOGY; RANIBIZUMAB;
   FEATURES; OUTCOMES; THERAPY
AB PURPOSE: To identify the risk factors of intraretinal fluid (IRF) development during anti-vascular endothelial growth factor (VEGF) treatment for neovascular age related macular degeneration (AMD).
   DESIGN: Retrospective cohort study.
   METHODS: A total of 425 treatment-naive patients with neovascular AMD who completed 24 months of follow-up were enrolled. All patients were treated with an initial series of 3 monthly loading doses of anti-VEGF injections, followed by further injections as required. Baseline characteristics were evaluated using multivariate modeling to determine the potential risk factors for IRF development.
   RESULTS: IRF occurred in 40.2% (171/425 eyes) of all participants during the maintenance phase after the loading injections. The development of IRF during followup negatively affected visual outcomes regardless of the presence of IRF at baseline. Multivariate analysis showed that larger areas of choroidal neovascularization (odds ratio [OR] 1.360; P < .001), the presence of IRF at baseline (OR 5.469; P < .001), and the presence of fibrovascular pigment epithelial detachment (OR 2.043; P = .022) were associated with an increased risk of IRF during follow-up. Type 1 (OR 2.005; P = .037) and type 2 macular neovascularization (MNV) (OR 2.643; P = .009) were also associated with a higher risk of IRF than aneurysmal type 1 MNV/polypoidal choroidal vasculopathy.
   CONCLUSIONS: The development of IRF during antiVEGF treatment for neovascular AMD has additional negative effects on visual outcomes regardless of the presence of IRF at baseline. Baseline risk factors, including choroidal neovascularization size, presence of IRF at baseline, presence of fibrovascular pigment epithelial detachment, and MNV subtype may influence the development of IRF during anti-VEGF treatment. (Am J Oph-thalmol 2021;234: 6-14.(C) 2021 Elsevier Inc. All rights reserved.)
C1 [Cho, Han Joo; Yoon, Wontae; Yoon, Jihyun; Na, Seung Kwan; Lee, Jihyun; Kim, Jaemin; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156 4ga Yeongdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Steinle NC, 2021, OPHTHALMOL RETINA, V5, P141, DOI 10.1016/j.oret.2020.07.003
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 28
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2022
VL 234
BP 6
EP 14
DI 10.1016/j.ajo.2021.07.026
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WZ2LN
UT WOS:000719803500002
PM 34339661
DA 2022-11-30
ER

PT J
AU Findlay, Q
   Jobling, AI
   Vessey, KA
   Greferath, U
   Phipps, JA
   Guymer, RH
   Fletcher, EL
AF Findlay, Quan
   Jobling, Andrew I.
   Vessey, Kirstan A.
   Greferath, Ursula
   Phipps, Joanna A.
   Guymer, Robyn H.
   Fletcher, Erica L.
TI Prophylactic laser in age-related macular degeneration: the past, the
   present and the future
SO EYE
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; RANDOMIZED CLINICAL-TRIAL; 3-NANOSECOND
   PULSE LASER; CONVENTIONAL PHOTOCOAGULATOR; CHOROIDAL NEOVASCULARIZATION;
   810-NANOMETER LASER; ELIGIBLE PATIENTS; BRUCHS MEMBRANE; LARGE DRUSEN;
   SOFT DRUSEN
AB The presence of drusen in the posterior eye is a hallmark feature of the early stages of age-related macular degeneration and their size is an indicator of risk of progression to vision-threatening forms of the disease. Since the initial observations that laser treatment can resolve drusen, there has been great interest in whether laser treatment can be used to reduce the progression of age-related macular degeneration. In this article, we review the development of lasers for the treatment of those with age-related macular degeneration. We provide an overview of the clinical trial results that demonstrated drusen resolution but that had mixed effects on progression of disease. In addition, we provide a summary of the recent developments in pulsed lasers that are designed to reduce the energy applied to the posterior eye to provide the therapeutic effects of conventional continuous wave lasers while reducing the secondary tissue effects.
C1 [Findlay, Quan; Jobling, Andrew I.; Vessey, Kirstan A.; Greferath, Ursula; Phipps, Joanna A.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Parkville, Vic, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Parkville, Vic, Australia.
EM rh.guymer@unimelb.edu.au
RI ; Jobling, Andrew/C-8221-2015; Fletcher, Erica/E-6364-2012
OI Greferath, Ursula/0000-0003-1028-648X; Jobling,
   Andrew/0000-0002-7827-3135; Fletcher, Erica/0000-0001-9412-9523; Guymer,
   Robyn/0000-0002-9441-4356; Vessey, Kirstan/0000-0003-1031-1964
FU National Health and Medical Research Council (Australia); Australian
   Research Council
FX We would like to thank Lidia Trogrlic for assistance in preparing Fig.
   1. The work described in this review was supported by grants from the
   National Health and Medical Research Council (Australia) and the
   Australian Research Council.
CR [Anonymous], 1998, Ophthalmology, V105, P11
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Johnson TM, 2005, GRAEF ARCH CLIN EXP, V243, P570, DOI 10.1007/s00417-004-1082-9
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim HD, 2016, INVEST OPHTH VIS SCI, V57, P3486, DOI 10.1167/iovs.16-19508
   Kim HD, 2015, INVEST OPHTH VIS SCI, V56, P122, DOI 10.1167/iovs.14-15132
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Luttrull JK, 2015, RETINA-J RET VIT DIS, V35, P1184, DOI 10.1097/IAE.0000000000000458
   Luttrull JK, 2012, RETINA-J RET VIT DIS, V32, P375, DOI 10.1097/IAE.0b013e3182206f6c
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mojana F, 2011, RETINA-J RET VIT DIS, V31, P235, DOI 10.1097/IAE.0b013e3181ec80ad
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Park YG, 2016, GRAEF ARCH CLIN EXP, V254, P1703, DOI 10.1007/s00417-015-3262-1
   Parodi MB, 2009, COCHRANE DB SYST REV, V3
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 54
TC 4
Z9 4
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2018
VL 32
IS 5
BP 972
EP 980
DI 10.1038/s41433-018-0035-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF3FR
UT WOS:000431831500014
PM 29520049
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Beaumont, PE
   Kang, HK
AF Beaumont, Paul E.
   Kang, H. Kwon
TI Lesion morphology in age-related macular degeneration and its
   therapeutic significance
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL; LASER
   PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY;
   NATURAL-HISTORY; VISUAL-ACUITY; TAP; OCCULT; MACULOPATHY
AB Objectives: To quantify and categorize the lesions of neovascular age-related macular degeneration on the basis of fluorescein angiographic morphology.
   Methods: We retrospectively reviewed 3580 consecutive cases of neovascular age-related macular degeneration. The lesions were graded in terms of the location, size, and composition and categorized according to the lesion components.
   Results: A comprehensive schema for lesion description and categorization is presented. There were 2642 subfoveal (73.8%), 658 juxtafoveal (18.4%), and 276 extrafoveal (7.7%) lesions. After disciform lesions were excluded, 1337 subfoveal (72.3%), 580 juxtafoveal (88.1%), and 242 extrafoveal lesions (87.7%) consisted of at least 50% choroidal neovascularization, most of which included a classic or an occult component but not both. Subfoveal lesions (mean size, 2.82 Macular Photocoagulation Study disc areas) were significantly larger than juxtafoveal (mean size, 0.89 Macular Photocoagulation Study disc areas) or extrafoveal lesions (mean size, 1.04 Macular Photocoagulation Study disc areas) (Kruskal Wallis, P < .001), but overall the lesions were substantially smaller than those found in the major trials. It is estimated that photodynamic therapy or photocoagulation may be offered to one half to two thirds of all patients with nondisciform neovascular age-related macular degeneration.
   Conclusion: The smaller lesion size and low proportion of mixed choroidal neovascularization lesions suggest that treatment benefit and eligibility may be greater in the clinical setting than previously thought.
C1 FRANZCO, Eye & Vis Res Inst, Sydney, NSW 2000, Australia.
   Prince Wales Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
RP Kang, HK (通讯作者)，FRANZCO, Eye & Vis Res Inst, 187 Macquarie St, Sydney, NSW 2000, Australia.
EM kwonkang@ozemail.com.au
CR Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 21
TC 7
Z9 7
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2006
VL 124
IS 6
BP 807
EP 812
DI 10.1001/archopht.124.6.807
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 051ZD
UT WOS:000238199300007
PM 16769834
OA Bronze
DA 2022-11-30
ER

PT J
AU Muste, JC
   Kalur, A
   Iyer, A
   Valentim, CCS
   Singh, RP
AF Muste, Justin C.
   Kalur, Aneesha
   Iyer, Amogh
   Valentim, Carolina C. S.
   Singh, Rishi P.
TI Photobiomodulation therapy in age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE exudative age-related macular degeneration; nonexudative age-related
   macular degeneration; photobiomodulation; photobiomodulation therapy
ID FACTOR-H POLYMORPHISM; 670 NM LIGHT; INFLAMMATION; MODEL; EYE
AB Purpose of review To review the available data supporting the use of photobiomodulation therapy (PBT) in the treatment of age-related macular degeneration (AMD). Recent findings PBT might be used in treating nonexudative AMD. Limited evidence suggests that exudative AMD may also benefit from PBT. The optimal device would deliver doses of 60 J/cm(2) or more with a multiwavelength composition through the pupil over short treatment intervals. Safe upper limits have not been established. More studies are needed to evaluate the efficacy of PBT in treating exudative and nonexudative AMD.
C1 [Muste, Justin C.; Kalur, Aneesha; Iyer, Amogh; Valentim, Carolina C. S.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, 9500 Euclid Ave,I-32, Cleveland, OH 44195 USA.
   [Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, Retina Serv, 9500 Euclid Ave, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, 9500 Euclid Ave,I-32, Cleveland, OH 44195 USA.
EM singhr@ccf.org
OI Carvalho Soares Valentim, Carolina/0000-0003-4203-6856; Muste,
   Justin/0000-0001-8478-038X
CR Albarracin R, 2012, PHOTOCHEM PHOTOBIOL, V88, P1418, DOI 10.1111/j.1751-1097.2012.01130.x
   [Anonymous], 2020, OTH STUD ID NUMB DIA
   [Anonymous], 2020, STUD PHOT TREAT NON
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Chen Y, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.035642
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Eells JT, 2016, ADV EXP MED BIOL, V854, P437, DOI 10.1007/978-3-319-17121-0_58
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fuma S, 2015, MOL VIS, V21, P883
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Grewal MK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041001
   Heinig N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072370
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokkinopoulos I, 2013, J PHOTOCH PHOTOBIO B, V122, P24, DOI 10.1016/j.jphotobiol.2013.03.003
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Re RN, 2016, OCHSNER J, V16, P502
   Richert E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23163
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Shinhmar H, 2020, J GERONTOL A-BIOL, V75, pE49, DOI 10.1093/gerona/glaa155
   Sivapathasuntharam C, 2017, NEUROBIOL AGING, V52, P66, DOI 10.1016/j.neurobiolaging.2017.01.001
   Tode J, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.11
   Veritti D, 2020, EXPERT OPIN PHARMACO, V21, P773, DOI 10.1080/14656566.2020.1736557
   Wang YP, 2019, INT J OPHTHALMOL-CHI, V12, P936, DOI 10.18240/ijo.2019.06.09
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 39
TC 1
Z9 1
U1 7
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2021
VL 32
IS 3
BP 225
EP 232
DI 10.1097/ICU.0000000000000742
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS7CW
UT WOS:000661913000008
PM 33606405
DA 2022-11-30
ER

PT J
AU Sahin, M
   Yuksel, H
   Sahin, A
   Cingu, AK
   Turkcu, FM
   Ozkurt, ZG
   Caca, I
AF Sahin, Muhammed
   Yuksel, Harun
   Sahin, Alparslan
   Cingu, Abdullah Kursat
   Turkcu, Fatih Mehmet
   Ozkurt, Zeynep Gursel
   Caca, Ihsan
TI Approach of Turkish ophthalmologists to micronutrition in age-related
   macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/prevention & control; Dietary supplements;
   Vi-tamins/administration & dosage; Lutein/administration & dosage;
   Guideline as topic/standards; Turkey
ID RANIBIZUMAB; RISK; ANTIOXIDANTS; PREVALENCE; ADHERENCE; SMOKING; DIET
AB Purpose: To evaluate the knowledge and behaviors of ophthalmologists in Turkey concerning micronutrition support in patients with age related macular degeneration (ARMD).
   Methods: This study involved 1,845 ophthalmologists. A scientific poll was sent to all participants by email. The survey covered the following: demographic features, subspecialty knowledge about micronutrition preference for prescribing micronutrition to age related macular degeneration patients, and the reason for this preference. If a participant indicated that he or she prescribed micronutrition, the participant was also asked to indicate the source of the treatment and supplemental treatments.
   Results: Of 1,845 ophthalmologists, 249 responded to the survey. Of the respondents, 9% (22) never, 43% (107) sometimes, 37% (92) frequently, and 11% (27) always used micronutrition. The most frequent prescribing subgroup was general ophthalmology (22%), followed by the retina-uvea subspecialty (13.9%). The micronutrition prescribing ratio was 54.8% in retina-uvea specialists when the "frequent" and "always" responses were combined. There was no statistically significant difference between subgroups with respect to prescribing micronutrition. Among the ophthalmologists prescribing micronutrition, 57.1% of them did not use the Age-Related Eye Disease Study-1 (AREDS) criteria, and only 31.3% prescribe micronutrition according to AREDS criteria. The results for the general ophthalmologist and retina-uvea specialist subgroups were similar, 56.3% vs 20.2%, and 54.1% vs 36.1%, respectively. Micronutrition was not recommended for the following reasons: expensive (55.4%), low patient expectancy (40%), no effect (30%), and low patient drug compliance (25.4%). Moreover, 55.2% of the clinicians recommended physical activities, dietary changes, and smoking cessation; 7.3% did not recommend these behavioral changes.
   Conclusion: This survey demonstrated that micronutrition preference in age related macular degeneration was low in ophthalmologists in Turkey. Additionally, retina specialists have a lower rate of prescribing micronutrition. Micronutrition support and behavior such as smoking cessation, dietary changes, etc. should be recommended more often to patients with age related macular degeneration.
C1 [Sahin, Muhammed; Yuksel, Harun; Sahin, Alparslan; Cingu, Abdullah Kursat; Turkcu, Fatih Mehmet; Ozkurt, Zeynep Gursel; Caca, Ihsan] Dicle Univ, Sch Med, Dept Ophthalmol, Diyarbakir, Turkey.
C3 Dicle University
RP Sahin, M (通讯作者)，Dicle Univ, Sch Med, Dept Ophthalmol, Diyarbakir, Turkey.
EM drmuhammedsahin@gmail.com
RI şahin, alparslan/K-6074-2012; Cingü, Abdullah/J-9423-2019
OI şahin, alparslan/0000-0003-2901-9699; sahin,
   muhammed/0000-0002-5229-7630
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Foster RA, 1997, MED J AUSTRALIA, V166, P331, DOI 10.5694/j.1326-5377.1997.tb122328.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gahche Jamie, 2011, NCHS Data Brief, P1
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Hopley C, 2003, CLIN EXP OPHTHALMOL, V31, P522, DOI 10.1046/j.1442-9071.2003.00715.x
   Jones AA, 2007, AUST FAM PHYSICIAN, V36, P1026
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RUFFOLO JJ, 1984, INVEST OPHTH VIS SCI, V25, P893
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 34
TC 3
Z9 3
U1 0
U2 6
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2015
VL 78
IS 1
BP 10
EP 14
DI 10.5935/0004-2749.20150004
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4OO
UT WOS:000350332900004
PM 25714530
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Brown, MM
   Brown, GC
   Lieske, HB
   Tran, I
   Turpcu, A
   Colman, S
AF Brown, Melissa M.
   Brown, Gary C.
   Lieske, Heidi B.
   Tran, Irwin
   Turpcu, Adam
   Colman, Shoshana
TI SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION IN THE UNITED STATES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular AMD costs; incremental societal; cross-sectional;
   prevalence-based; health care economic survey
ID QUALITY-OF-LIFE; PHOTODYNAMIC THERAPY; UTILITY VALUES; VISUAL
   IMPAIRMENT; EYES
AB Purpose:The purpose of this study was to use a cross-sectional prevalence-based health care economic survey to ascertain the annual, incremental, societal ophthalmic costs associated with neovascular age-related macular degeneration.Methods:Consecutive patients (n = 200) with neovascular age-related macular degeneration were studied. A Control Cohort included patients with good (20/20-20/25) vision, while Study Cohort vision levels included Subcohort 1: 20/30 to 20/50, Subcohort 2: 20/60 to 20/100, Subcohort 3: 20/200 to 20/400, and Subcohort 4: 20/800 to no light perception. An interviewer-administered, standardized, written survey assessed 1) direct ophthalmic medical, 2) direct nonophthalmic medical, 3) direct nonmedical, and 4) indirect medical costs accrued due solely to neovascular age-related macular degeneration.Results:The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984. Direct ophthalmic medical costs comprised 17.9% of Study Cohort societal ophthalmic costs, versus 74.1% of Control Cohort societal ophthalmic costs (P < 0.001) and 10.4% of 20/800 to no light perception subcohort costs. Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs.Conclusion:Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.
C1 [Brown, Melissa M.; Brown, Gary C.; Lieske, Heidi B.] Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
   [Brown, Melissa M.; Brown, Gary C.] Eye Res Inst, Philadelphia, PA USA.
   [Brown, Melissa M.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Res Dept, Philadelphia, PA 19107 USA.
   [Brown, Gary C.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   [Tran, Irwin] Genentech Roche, Healthcare Econ Unit, San Francisco, CA USA.
   [Turpcu, Adam; Colman, Shoshana] Genentech Inc, Healthcare Econ Unit, San Francisco, CA 94080 USA.
C3 Jefferson University; Jefferson University; Roche Holding; Genentech;
   Roche Holding; Genentech
RP Brown, GC (通讯作者)，Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
EM gbrown@valuebasedmedicine.com
FU Genentech, Inc, South San Francisco, CA; Center for Value-Based
   Medicine, Flourtown, PA; Genentech; Center for Value-Based Medicine
FX Supported in part by a grant from Genentech, Inc, South San Francisco,
   CA, and the Center for Value-Based Medicine, Flourtown, PA. The sponsors
   played no part in performance of the study, writing of the manuscript,
   or requiring direction of the study. The funding sponsors, Genentech,
   and the Center for Value-Based Medicine had the opportunity to review
   the article but did not have authority to change any aspect of the
   article.
CR Arias E, 2007, NATL VITAL STAT REPO, V59, P8
   Beauchamp G R, 1999, Trans Am Ophthalmol Soc, V97, P349
   Beauchamp GR, 1999, T AM OPHTHAL SOC, V97, P367
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2013, OPHTHALMOLOGY, V120, P2367, DOI 10.1016/j.ophtha.2013.04.030
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2010, EVID BASED OPHTHALMO, V11, P121
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Brown MM, 2009, EVIDENCE BASED OPHTH, V10, P107
   Brown MM, 2005, EVIDENCE BASED VALUE, P1
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Center for Medicare & Medicaid Services, PHYS FEE SCHED SEARC
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   Hirsch JD, 2007, SURV OPHTHALMOL, V52, P618, DOI 10.1016/j.survophthal.2007.08.017
   Internal Revenue Service, 2008, IRS ANN 2009 STAND M
   Jacobs JJ, 2006, BURDEN MUSCULOSKELET, P1
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Kymes SN, 2009, MINERVA MED, V100, P69
   MindTools.net, CALC GDP EXP APPR
   Nordhaus WD, 2002, 8818 NBER
   Office of the Actuary Centers for Medicare and Medicaid Services, NAT HLTH EXP PROJ
   Olsen TW, 2007, AM J OPHTHALMOL, V144, P281, DOI 10.1016/j.ajo.2007.05.005
   PreventBlindness.org, STAT VIS SCREEN STAN
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2002, EVID BASED OPHTHALMO, V3, P105
   Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
   Siskol AM, 2013, HLTH AFF MILLWOOD, V33, P1841
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Smith AF, 2000, BRIT J OPHTHALMOL, V84, P794, DOI 10.1136/bjo.84.7.794
   Social Security Administration, UND SUPL SEC INC SSI
   Stroupe KT, 2008, OPHTHAL EPIDEMIOL, V15, P84, DOI 10.1080/09286580802027836
   The World Health Organization, WORLD HLTH REP 2002, P47
   U. S. Department of Commerce Economics and Statistics Administration U. S. Census Bureau., 2001, AM DIS HOUS EC STUD, P15
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
NR 49
TC 35
Z9 36
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 285
EP 298
DI 10.1097/IAE.0000000000000717
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500008
PM 26428606
DA 2022-11-30
ER

PT J
AU Hautamaki, A
   Luoma, A
   Immonen, I
AF Hautamaki, Asta
   Luoma, Arto
   Immonen, Ilkka
TI ANTERIOR CHAMBER FLARE DURING BEVACIZUMAB TREATMENT IN EYES WITH
   EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; anterior chamber flare;
   bevacizumab; fluorescein angiography; optical coherence tomography
ID BLOOD-AQUEOUS BARRIER; RETINAL VEIN OCCLUSION; INTRAVITREAL INJECTION;
   INTRAOCULAR INFLAMMATION; CELL PHOTOMETRY; EDEMA
AB Purpose: To study the anterior chamber flare during bevacizumab treatment of exudative age-related macular degeneration.
   Methods: During a 2-year prospective follow-up, 50 patients recently diagnosed with exudative age-related macular degeneration were treated at once-a-month visits if subretinal or intraretinal fluid or a new hemorrhage was present in the lesion area. Flare was measured weekly during the first month and then monthly in both eyes.
   Results: Higher flare was associated with older age (P = 0.007, Linear Mixed Model), higher number of smoking pack-years (P = 0.019), macular cysts (P = 0.041), and pseudophakia (P = 0.003). The levels gradually increased during the follow-up (P, 0.0001) but less in the eyes with classic CNV (P = 0.011). Flare decreased during treatment-free periods lasting for at least two consecutive visits (P = 0.005). A peak in flare was observed 1 week after the first injection (P = 0.034, Wilcoxon signed rank test). In the fellow eyes, higher flare values in the beginning of the follow-up were associated with later conversion into exudative age-related macular degeneration (P = 0.015, Mann-Whitney U test).
   Conclusion: Anterior chamber flare correlated poorly with the CNV activity. Higher levels may, however, precede or exist early in the process that leads to the development of exudative age-related macular degeneration.
C1 [Hautamaki, Asta; Immonen, Ilkka] Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
   [Hautamaki, Asta; Immonen, Ilkka] Helsinki Univ Hosp, Helsinki, Finland.
   [Luoma, Arto] Univ Tampere, Sch Management, Tampere, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Tampere University
RP Hautamaki, A (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, POB 220, Helsinki 00029, Finland.
EM asta.hautamaki@hus.fi
RI Hautamaki, Asta/G-3098-2014
OI Hautamaki, Asta/0000-0002-9454-8434
FU Eye Foundation, Helsinki, Finland; Eye and Tissue Bank Foundation,
   Helsinki, Finland; Evald and Hilda Nissi Foundation, Helsinki, Finland;
   Mary and Georg C. Ehrnrooth Foundation, Helsinki, Finland
FX Supported by grants from The Eye Foundation, Helsinki, Finland; The Eye
   and Tissue Bank Foundation, Helsinki, Finland; The Evald and Hilda Nissi
   Foundation, Helsinki, Finland; and Mary and Georg C. Ehrnrooth
   Foundation, Helsinki, Finland. The funding organizations had no role in
   the design or conduct of this research.
CR Asano S, 2007, J OCUL PHARMACOL TH, V23, P577, DOI 10.1089/jop.2007.0057
   Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9
   Blaha GR, 2015, RETINA-J RET VIT DIS, V35, P577, DOI 10.1097/IAE.0000000000000334
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   CUZZANI OE, 1994, CAN J OPHTHALMOL, V29, P172
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ersoy L, 2013, BRIT J OPHTHALMOL, V97, P862, DOI 10.1136/bjophthalmol-2012-302995
   Eter N, 2004, GRAEF ARCH CLIN EXP, V242, P120, DOI 10.1007/s00417-003-0806-6
   Freddo TF, 2013, PROG RETIN EYE RES, V32, P181, DOI 10.1016/j.preteyeres.2012.10.004
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   GuillenMonterrubio OM, 1997, ACTA OPHTHALMOL SCAN, V75, P58
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kubota T, 1996, GRAEF ARCH CLIN EXP, V234, P285, DOI 10.1007/BF00220701
   Ladas JG, 2005, SURV OPHTHALMOL, V50, P27, DOI 10.1016/j.survophthal.2004.10.004
   MIYAKE K, 1992, OPHTHALMOLOGY, V99, P906
   Naik P, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-51
   NGUYEN NX, 1993, BRIT J OPHTHALMOL, V77, P280, DOI 10.1136/bjo.77.5.280
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SHAH SM, 1991, BRIT J OPHTHALMOL, V75, P348, DOI 10.1136/bjo.75.6.348
   SHAH SM, 1992, INVEST OPHTH VIS SCI, V33, P2878
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang LL, 2010, TOXICOL PATHOL, V38, P560, DOI 10.1177/0192623310368983
   Yeniad B, 2011, EUR J OPHTHALMOL, V21, P156, DOI 10.5301/EJO.2010.5239
   Zaczek A, 1999, EUR J OPHTHALMOL, V9, P158, DOI 10.1177/112067219900900303
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 34
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2183
EP 2190
DI 10.1097/IAE.0000000000001061
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800026
PM 27135211
DA 2022-11-30
ER

PT J
AU Dirani, A
   Gianniou, C
   Marchionno, L
   Decugis, D
   Mantel, I
AF Dirani, Ali
   Gianniou, Christina
   Marchionno, Laetitia
   Decugis, Doris
   Mantel, Irmela
TI INCIDENCE OF OUTER RETINAL TUBULATION IN RANIBIZUMAB-TREATED AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; FEATURES; ATROPHY
AB Purpose:
   To investigate the incidence of outer retinal tubulation (ORT) in ranibizumab-treated neovascular age-related macular degeneration patients.
   Methods:
   We included 480 consecutive patients (546 eyes) with neovascular age-related macular degeneration, who were treated with variable-dosing intravitreal ranibizumab, evaluated with spectral domain optical coherence tomography, and followed-up for a minimum period of 6 months. Optical coherence tomographies were evaluated for the first appearance of ORT, precursor signs, and type of underlying lesion. Visual acuity was also recorded.
   Results:
   Outer retinal tubulation was observed in 30% of eyes during a mean follow-up period of 26.7 months (SD, 13.5). Kaplan-Meier survival analysis revealed that the ORT incidence (2.5, 17.5, 28.4, and 41.6% at baseline, after 1, 2, and 4 years, respectively) continuously increased, despite visually effective anti-vascular endothelial growth factor treatment. Outer retinal tubulation was associated with a poorer functional benefit. Lower baseline visual acuity was associated with a higher risk of developing ORT.
   Conclusion:
   Incidence of ORT continuously increases despite visually optimal anti-vascular endothelial growth factor treatment of age-related macular degeneration. Outer retinal tubulation might be considered a prognostic factor for functional outcome and is relevant to avoid overtreatment.
C1 Univ Lausanne, Dept Ophthalmol, CH-1000 Lausanne 7, Switzerland.
   Fdn Asylum Blind, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, 15 Ave France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ellabban AA, 2012, EYE, V26, P1086, DOI 10.1038/eye.2012.101
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Kojima H, 2012, BRIT J OPHTHALMOL, V96, P390, DOI 10.1136/bjo.2010.199356
   Lee JY, 2014, OPHTHALMOLOGY
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Papastefanou VP, 2013, BRIT J OPHTHALMOL, V97, P1014, DOI 10.1136/bjophthalmol-2013-303234
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sergouniotis PI, 2012, OPHTHALMOLOGY, V119, P596, DOI 10.1016/j.ophtha.2011.09.017
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 19
TC 11
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2015
VL 35
IS 6
BP 1166
EP 1172
DI 10.1097/IAE.0000000000000439
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ7KJ
UT WOS:000355673600016
PM 25574786
DA 2022-11-30
ER

PT J
AU Reddy, U
   Kryzstolik, M
AF Reddy, U
   Kryzstolik, M
TI Antiangiogenic therapy with interferon alfa for neovascular age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL; MACULOPATHY; PREVALENCE
AB Background Antiangiogenic therapy is a new approach to the treatment of neovascular age-related macular degeneration. Interferon alfa is one antiangiogenic agent thought to function by inhibiting the migration and proliferation of vascular endothelial cells. It has been used in the treatment of hepatitis, solid tumors and hematologic malignancies.
   Objectives The aim of this review was to investigate interferon alfa as a treatment modality for neovascular age-related macular degeneration.
   Search strategy We searched and identified trials from the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Group Trials Register, in The Cochrane Library (Issue 2, 2005), MEDLINE (1966 to 2005/06 week 1), EMBASE (1980 to 2005/week 23), LILACS (Latin American and Caribbean Health Science Literature Database) (June 2005) and the reference lists of included studies.
   Selection criteria This review included randomized controlled trials evaluating interferon alfa therapy in people with neovascular age-related macular degeneration who were followed for at least one year.
   Data collection and analysis Both review authors independently extracted data and assessed trial quality. No data synthesis was conducted as only one trial met the inclusion criteria.
   Main results The one included trial enrolled and randomized 481 participants from 45 centers worldwide into four groups. The study allowed for analysis of the number of participants who had lost three or more lines of vision at 52 weeks in three interferon alfa-2a groups versus placebo. The results show an odds ratio of 1.60 (95% Confidence Interval 1.01 to 2.53) indicating that interferon is associated with a 60% increased odds of losing three or more lines at 52 weeks. This finding is marginally statistical with a P value of 0.04 and indicates that the treatment has the potential for harm rather than benefit.
   Authors' conclusions At present there is not enough evidence to recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration.
C1 Brown Univ, Sch Med, Providence, RI 02903 USA.
C3 Brown University
RP Reddy, U (通讯作者)，Brown Univ, Sch Med, Box G-8064,593 Eddy St, Providence, RI 02903 USA.
EM Usha_Reddy@brown.edu
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   EVANS J, 1995, STUDIES MED POPULATI
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Higgins JPT, 2005, COCHRANE LIB
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Krzystolik MG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MILLER WR, 2000, CLIN BREAST CANC S1, V1, P9
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   POLINER LS, 1993, OPHTHALMOLOGY, V100, P1417
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
NR 27
TC 9
Z9 9
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2006
IS 1
AR CD005138
DI 10.1002/14651858.CD005138.pub2
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 007OE
UT WOS:000234978200073
DA 2022-11-30
ER

PT J
AU Bourla, DH
   Young, TA
AF Bourla, Dan H.
   Young, Tara A.
TI Age-related macular degeneration: A practical approach to a challenging
   disease
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; risk
   factors; stages; treatment
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; EYE DISEASE; INTRAVITREAL TRIAMCINOLONE; VISUAL
   IMPAIRMENT; NATURAL-HISTORY; SEVERITY SCALE; MACULOPATHY; MODEL
AB Age-related macular degeneration (AMD) is the leading cause of blindness in older North Americans. The clinical spectrum, risk factors, pathophysiology, and potential therapeutic options for AMD warrant a careful review. Despite the growth in treatment options for this disease, there is no current curative therapy. Of critical importance is attention to modifiable risk factors-improvements in cardiovascular status, including smoking cessation, and routine ophthalmic monitoring for opportunities to provide early intervention. In addition, a low-vision assessment to investigate the potential use of visual assistive devices may be beneficial to any patient who has experienced a decrease in vision. Finally, education regarding the clinical course of age-related macular degeneration and accurate information with respect to the known benefits of available treatments will impart a better understanding of this disease to patients.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Young, TA (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, 100 Stein Plaza,DS 3-519, Los Angeles, CA 90095 USA.
EM young@jsei.ucla.edu
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Edwards R, 2005, ADV BOT RES, V42, P1, DOI 10.1016/S0065-2296(05)42001-7
   FERRIS FL, 2005, 18 AREDS, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIER J, 2003, INVEST OPHTH VIS SCI, P44
   Husain D., 1997, Investigative Ophthalmology and Visual Science, V38, pS501
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   PECKLIN L, 2001, OPHTHALMOLOGY, V108, P705
   Presta LG, 1997, CANCER RES, V57, P4593
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Tokuda K, 2004, ACTA OPHTHALMOL SCAN, V82, P189, DOI 10.1111/j.1600-0420.2004.00224.x
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
   Yeung CK, 2004, JPN J OPHTHALMOL, V48, P236, DOI 10.1007/s10384-003-0053-8
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 59
TC 27
Z9 34
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2006
VL 54
IS 7
BP 1130
EP 1135
DI 10.1111/j.1532-5415.2006.00771.x
PG 6
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 062XB
UT WOS:000238978900016
PM 16866687
DA 2022-11-30
ER

PT J
AU Nath, R
   Saxena, S
   Tewari, D
   Srivastava, P
   Ghatak, A
   Pandey, VC
AF Nath, R
   Saxena, S
   Tewari, D
   Srivastava, P
   Ghatak, A
   Pandey, VC
TI Elevated superoxide anion levels in age-related macular degeneration
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
ID ANTIOXIDANT ENZYMES; LIPID-PEROXIDATION; FREE-RADICALS; RISK-FACTORS;
   MEMBRANES; DISMUTASE; MECHANISM; ZINC
AB A study was undertaken to detect erythrocyte superoxide anion, superoxide dismutase enzyme activity and malonaldialdehyde levels in 20 cases of age-related macular degeneration (AMD) and matched controls. Superoxide anion activity and malonaldialdehyde levels in cases were significantly higher and superoxide dismutase levels were lower as compared to controls. Decreased visual acuity in AMD may result from oxidative stress-induced retinal damage.
C1 King Georges Med Coll, Dept Ophthalmol, Lucknow, Uttar Pradesh, India.
   Cent Drug Res Inst, Div Biochem, Lucknow 226001, Uttar Pradesh, India.
   Cent Drug Res Inst, Div Clin & Expt Med, Lucknow 226001, Uttar Pradesh, India.
C3 King George's Medical University; Council of Scientific & Industrial
   Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI);
   Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Drug Research Institute (CDRI)
RP Saxena, S (通讯作者)，G-19 River Bank Colony, Lucknow 226018, Uttar Pradesh, India.
CR ALDER VA, 1983, INVEST OPHTH VIS SCI, V24, P30
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   BALIN AK, 1986, DERMATOL CLIN, V4, P347, DOI 10.1016/S0733-8635(18)30798-8
   BONNESTAOUREL D, 1993, J LIPID MEDIATOR, V8, P111
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   GREEN S, 1956, J BIOL CHEM, V220, P237
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   JEFFCOAT R, 1984, FATTY ACID METABOLIS, P85
   KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130
   LEIBOVITZ BE, 1980, J GERONTOL, V35, P45, DOI 10.1093/geronj/35.1.45
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mason RP, 1997, FREE RADICAL BIO MED, V23, P419, DOI 10.1016/S0891-5849(97)00101-9
   MCCORD JM, 1985, NEW ENGL J MED, V312, P159
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Rao N A, 1990, Trans Am Ophthalmol Soc, V88, P797
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SILVERSTONE BZ, 1985, ANN OPHTHALMOL, V17, P419
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Taylor H R, 1989, Trans Am Ophthalmol Soc, V87, P802
   UTLEY HG, 1967, ARCH BIOCHEM BIOPHYS, V118, P29, DOI 10.1016/0003-9861(67)90273-1
   VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 34
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CONTEMPORARY OPHTHALMOLOGY
PI CHICAGO
PA 820 N ORLEANS, STE 208, CHICAGO, IL 60610 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD SUM-WIN
PY 2004
VL 36
IS 2
BP 111
EP 114
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884SR
UT WOS:000226107000008
DA 2022-11-30
ER

PT J
AU Jackson, GR
   Felix, T
   Owsley, C
AF Jackson, Gregory R.
   Felix, Tiffany
   Owsley, Cynthia
TI The Scotopic Sensitivity Tester-1 and the detection of early age-related
   macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; aging; dark adaptation; retina;
   scotopic vision
ID SORSBYS-FUNDUS-DYSTROPHY; DARK-ADAPTATION; CONTRAST SENSITIVITY;
   CLINICAL RESEARCH; GOOD ACUITY; OLDER EYES; VITAMIN-A; MACULOPATHY;
   ABNORMALITIES; ACTIVATION
AB Purpose: Previous research shows that dark adaptation is a marker of early age-related macular degeneration (ARMD), even when visual acuity remains good. This study evaluates whether a commercially available, off-the-shelf device for measuring dark adaptation, the Scotopic Sensitivity Tester-1 (SST-1), which uses a full-field stimulus, detects early ARMD as defined by fundus appearance. Funclus appearance is the gold standard method for defining the presence of ARMD.
   Methods: Dark adaptation was measured using the SST-1 in 12 young adults (mean age 23 years), 17 old adults with normal retinal health (mean age 69) and 19 old adults with early ARMD (mean age 74). Normal retinal health and presence of early ARMD were defined by masked grading of dilated fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Results: Older adults in normal retinal health exhibited slower dark adaptation as compared with young adults. No difference in the rate of dark adaptation was found between early ARMD patients and older adults in normal retinal health.
   Conclusions: Although the SST-1 differentiated between young and older adults, it failed to detect dark adaptation abnormalities in early ARMD when referenced against older adults in normal retinal health. This may be attributable to the full-field stimulation used by the SST-1, which may be better suited for characterizing retinal degenerations affecting large retinal areas than for focal macular diseases like ARMD.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
RI Owsley, Cynthia/B-7986-2014
FU NEI NIH HHS [R21 EY14071] Funding Source: Medline; NIA NIH HHS [R01
   AG04212] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY014071]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212]
   Funding Source: NIH RePORTER
CR Barlow H. B., 1972, HDB SENSORY PHYSL, P1
   BIRCH DG, 1995, INVEST OPHTH VIS SCI, V36, P1603
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Cideciyan AV, 1997, INVEST OPHTH VIS SCI, V38, P1786
   COILE DC, 1992, VISUAL NEUROSCI, V8, P27, DOI 10.1017/S0952523800006465
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1824
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   JACKSON GR, 2004, MACULAR DEGENERATION
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Peters A. Y., 2000, Documenta Ophthalmologica, V101, P1, DOI 10.1023/A:1002765024774
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sturr JF, 1997, VISION RES, V37, P475, DOI 10.1016/S0042-6989(96)00196-4
   Vingrys Algis J, 2004, Clin Exp Optom, V87, P63
NR 29
TC 12
Z9 15
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2006
VL 26
IS 4
BP 431
EP 437
DI 10.1111/j.1475-1313.2006.00390.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 066CU
UT WOS:000239208100011
PM 16792744
DA 2022-11-30
ER

PT J
AU Saprunova, VB
   Pilipenko, DI
   Alexeevsky, AV
   Fursova, AZ
   Kolosova, NG
   Bakeeva, LE
AF Saprunova, V. B.
   Pilipenko, D. I.
   Alexeevsky, A. V.
   Fursova, A. Zh.
   Kolosova, N. G.
   Bakeeva, L. E.
TI Lipofuscin granule dynamics during development of age-related macular
   degeneration
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE electron microscopy; age dependent macular degeneration; pigment
   epithelium; mitochondria; lipofuscin granules; oxidative stress; SkQ1
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; TRANSPORTER; EXPRESSION;
   DAMAGE; ABCR
AB The pigment epithelium cell structure and therapeutic effect of antioxidant SkQ1, selectively penetrating into mitochondria from eye drops, were studied upon development in OXYS rats of age-related retinopathy as a model of macular degeneration. The characteristic dynamics and ultrastructural peculiarities of the layer of electron-dense cytoplasmic structures of the pigment epithelium apex part and incorporated lipofuscin granules were revealed. The therapy of OXYS animals for 68 days using 250 nM SkQ1 drops decreased the extent of development of age-related macular degeneration. Electron-microscopic investigation showed that SkQ1 prevented development of ultrastructural changes in the pigment epithelium characteristic of macular degeneration, the condition of which after therapy with SkQ1 drops corresponded to ultrastructure of pigment epithelium in Wistar rats of the same age having no symptoms of retinal damage. It is supposed that ultrastructural changes in the electron-dense layer upon development of age-related macular degeneration are indicative of disturbances in the optical cycle functioning, especially of disturbances in functioning of photoreceptor membranes.
C1 [Saprunova, V. B.; Pilipenko, D. I.; Alexeevsky, A. V.; Bakeeva, L. E.] Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119991, Russia.
   [Saprunova, V. B.; Pilipenko, D. I.; Bakeeva, L. E.] Moscow MV Lomonosov State Univ, Mitoengn Ctr, Moscow 119991, Russia.
   [Fursova, A. Zh.; Kolosova, N. G.] Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
C3 Lomonosov Moscow State University; Lomonosov Moscow State University;
   Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS
RP Bakeeva, LE (通讯作者)，Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119991, Russia.
EM fxb@belozersky.msu.ru
RI Kolosova, Nataliya G/AAR-7409-2020; Kolosova, Nataliya G/P-3178-2015;
   Alexeevski, Andrei V/A-7935-2012; fursova, anzhella/AAE-1495-2022
OI Kolosova, Nataliya G/0000-0003-2398-8544; Kolosova, Nataliya
   G/0000-0003-2398-8544; Alexeevski, Andrei V/0000-0001-7939-9939;
   fursova, anzhella/0000-0001-6311-5452
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3
   Kolosova NG, 2006, NEUROBIOL AGING, V27, P1289, DOI 10.1016/j.neurobiolaging.2005.07.022
   Kolosova N. G., 2003, USPEKHI GERONTOL, V12, P143
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Menshikova E. B., 2002, B EKSP BIOL MED, V133, P207
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   OSTROVSKY MA, 2005, USP BIOL KHIM, V45, P173
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208
   Rumyantseva Y, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1176, DOI 10.1134/S0006297908110023
   Skulachev VP, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1385, DOI 10.1134/S0006297907120139
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   SOLOVEVA NA, 1975, GENETIKA+, V11, P63
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Suzuki M, 2007, MOL VIS, V13, P772
   Winkler BS, 1999, MOL VIS, V5
NR 21
TC 19
Z9 25
U1 0
U2 3
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD FEB
PY 2010
VL 75
IS 2
BP 130
EP 138
DI 10.1134/S0006297910020021
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 567PS
UT WOS:000275459700002
PM 20367599
DA 2022-11-30
ER

PT J
AU Cunningham, J
AF Cunningham, Jill
TI Recognizing age-related macular degeneration in primary care
SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
LA English
DT Article
DE age-related macular degeneration; AMD; blind-ness; primary care; eye
   condition; retinal disease
ID PATHOGENESIS; PROMISES; DISEASE
AB Age-related macular degeneration (AMD) is a disabling condition that results in central vision loss and significantly affects the quality of life for the growing population of older adults. Primary care providers play a vital role in early recognition of disease. This article reviews the risk factors, symptoms, physical examination findings, and management of AMD. Although there is no cure at this time, early referral and treatment may prevent some patients from progressing to complete vision loss.
C1 [Cunningham, Jill] Coll Osteopath Med, PA Program, Philadelphia, PA 19131 USA.
RP Cunningham, J (通讯作者)，Coll Osteopath Med, PA Program, Philadelphia, PA 19131 USA.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   American Academy of Ophthalmology, AG REL MAC DEG PPP U
   American Academy of Ophthalmology, COMPR AD MED EY EV
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Holz F.G., 2013, AGE RELATED MACULAR
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Marra KV, 2016, J AM GERIATR SOC, V64, P369, DOI 10.1111/jgs.13927
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
NR 17
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1547-1896
EI 0893-7400
J9 JAAPA-J AM ACAD PHYS
JI JAAPA-J. Am. Acad. Physician Assist.
PD MAR
PY 2017
VL 30
IS 3
BP 18
EP 22
DI 10.1097/01.JAA.0000512227.85313.05
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP3LA
UT WOS:000397282600007
PM 28151737
DA 2022-11-30
ER

PT J
AU Scharf, J
   Corradetti, G
   Corvi, F
   Sadda, S
   Sarraf, D
AF Scharf, Jackson
   Corradetti, Giulia
   Corvi, Federico
   Sadda, SriniVas
   Sarraf, David
TI Optical Coherence Tomography Angiography of the Choriocapillaris in
   Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; optical coherence tomography
   angiography; choriocapillaris; OCT-A; retinal imaging; macular
   neovascularization; choriocapillaris quantification; flow deficit
ID NEOVASCULARIZATION EARLY RESPONSE; CHOROIDAL NEOVASCULARIZATION;
   GEOGRAPHIC ATROPHY; TYPE-3 NEOVASCULARIZATION; QUANTITATIVE ASSESSMENT;
   OCT ANGIOGRAPHY; FLOW DEFICITS; MORPHOMETRIC-ANALYSIS; ULTRAHIGH-SPEED;
   BRUCHS MEMBRANE
AB The advent of optical coherence tomography angiography (OCTA) has allowed for remarkable advancements in our understanding of the role of the choriocapillaris in age-related macular degeneration (AMD). As a relatively new imaging modality, techniques to analyze and quantify choriocapillaris images are still evolving. Quantification of the choriocapillaris requires careful consideration of many factors, including the type of OCTA device, segmentation of the choriocapillaris slab, image processing techniques, and thresholding method. OCTA imaging shows that the choriocapillaris is impaired in intermediate non-neovascular AMD, and the severity of impairment may predict the advancement of disease. In advanced atrophic AMD, the choriocapillaris is severely impaired underneath the area of geographic atrophy, and the level of impairment surrounding the lesion predicts the rate of atrophy enlargement. Macular neovascularization can be readily identified and classified using OCTA, but it is still unclear if neovascularization features with OCTA can predict the lesion's level of activity. The choriocapillaris surrounding macular neovascularization is impaired while the more peripheral choriocapillaris is spared, implying that choriocapillaris disruption may drive neovascularization growth. With continued innovation in OCTA image acquisition and analysis methods, advancement in clinical applications and pathophysiologic discoveries in AMD are set to follow.
C1 [Scharf, Jackson] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10032 USA.
   [Corradetti, Giulia; Sadda, SriniVas; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Corradetti, Giulia; Corvi, Federico; Sadda, SriniVas] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Corvi, Federico] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, I-20157 Milan, Italy.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA 90073 USA.
C3 Columbia University; University of California System; University of
   California Los Angeles; Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of Milan; Luigi
   Sacco Hospital; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.; Sarraf, D (通讯作者)，Greater Los Angeles VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA 90073 USA.
EM jms2455@cumc.columbia.edu; gcorradetti@mednet.ucla.edu;
   federico.corvi@yahoo.it; ssadda@doheny.org; dsarraf@ucla.edu
RI Corradetti, Giulia/Q-5400-2019
OI Corradetti, Giulia/0000-0001-9213-5575; Corvi,
   Federico/0000-0002-2661-5500
FU Research To Prevent Blindness Inc., New York, NY, USA; Macula Foundation
   Inc., New York, NY, USA
FX This research received was funded by Research To Prevent Blindness Inc.
   (DS), New York, NY, USA and the Macula Foundation Inc. (DS), New York,
   NY, USA.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Alagorie AR, 2020, RETINA-J RET VIT DIS, V40, P2106, DOI 10.1097/IAE.0000000000002878
   Alagorie AR, 2020, GRAEF ARCH CLIN EXP, V258, P995, DOI 10.1007/s00417-020-04615-w
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Byon I, 2020, AM J OPHTHALMOL, V219, P21, DOI 10.1016/j.ajo.2020.05.027
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Chu ZD, 2021, AM J OPHTHALMOL, V222, P92, DOI 10.1016/j.ajo.2020.08.045
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34826-5
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Corradetti G, 2021, BRIT J OPHTHALMOL, V105, P1584, DOI 10.1136/bjophthalmol-2020-316893
   Corvi F, 2021, CURR EYE RES, V46, P871, DOI 10.1080/02713683.2020.1846756
   Corvi F, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.29
   Corvi F, 2021, EYE, V35, P110, DOI 10.1038/s41433-020-01217-y
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Corvi F, 2020, CAN J OPHTHALMOL, V55, P317, DOI 10.1016/j.jcjo.2020.03.011
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P291, DOI 10.1007/s00417-020-04821-6
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Falavarjani KG, 2017, J CURR OPHTHALMOL, V29, P1, DOI 10.1016/j.joco.2017.02.005
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Forster JC, 2017, HYPOXIA, V5, P21, DOI 10.2147/HP.S133231
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Hou KK, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.50
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   KREBS W, 1988, ARCH OPHTHALMOL-CHIC, V106, P1615, DOI 10.1001/archopht.1988.01060140783055
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Ledesma-Gil G, 2020, RETINA-J RET VIT DIS, V40, P1865, DOI 10.1097/IAE.0000000000002866
   Liu KK, 2020, GRAEF ARCH CLIN EXP, V258, P979, DOI 10.1007/s00417-020-04610-1
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Marques JP, 2016, OPHTHALMIC RES, V55, P145, DOI 10.1159/000442671
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mehta N, 2019, AM J OPHTHALMOL, V205, P54, DOI 10.1016/j.ajo.2019.03.008
   Mendonca LSM, 2021, OPHTHALMOLOGY, V128, P1109, DOI 10.1016/j.ophtha.2020.12.022
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Nassisi M, 2021, AM J OPHTHALMOL, V222, P302, DOI 10.1016/j.ajo.2020.04.018
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rebhun CB, 2018, OPHTHALMOL RETINA, V2, P306, DOI 10.1016/j.oret.2017.08.013
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Scharf JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.11
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Su L, 2020, GRAEF ARCH CLIN EXP, V258, P1173, DOI 10.1007/s00417-020-04639-2
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Uji A, 2018, ACTA OPHTHALMOL, V96, pE820, DOI 10.1111/aos.13740
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   YONEYA S, 1983, INT OPHTHALMOL, V6, P95, DOI 10.1007/BF00127637
   Zhang M, 2016, INVEST OPHTH VIS SCI, V57, P5101, DOI 10.1167/iovs.16-19776
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 115
TC 14
Z9 14
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2021
VL 10
IS 4
AR 751
DI 10.3390/jcm10040751
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QP7IK
UT WOS:000624006300001
PM 33668537
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nakai, S
   Honda, S
   Matsumiya, W
   Miki, A
   Nakamura, M
AF Nakai, Shunichiro
   Honda, Shigeru
   Matsumiya, Wataru
   Miki, Akiko
   Nakamura, Makoto
TI ARMS2 variants may predict the 3-year outcome of photodynamic therapy
   for wet age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ASSOCIATION; PROGRESSION
AB Purpose: To determine the association of age-related maculopathy susceptibility 2 (ARMS2) gene polymorphisms with the 3-year outcomes of photodynamic therapy (PDT) in wet age-related macular degeneration (wet AMD).
   Methods: The single nucleotide polymorphism (SNP) at rs10490924 in the ARMS2 gene of 65 patients with wet AMD who underwent PDT was genotyped using the TaqMan assay. The clinical characteristics and the outcomes of PDT were compared among the three genotypes at rs10490924. A multivariate regression analysis was performed to evaluate the influence of the clinical cofactors on the association of rs10490924 with the visual outcome at 36 months after the first PDT.
   Results: A significant difference was found among the genotypes in the age and the baseline lesion size. The patients with the GG genotype showed a significant improvement in vision, and the patients with the TT genotype showed a significant worsening of vision at all time points measured after the initial PDT. In the multivariate regression analysis, the number of the G allele at rs10490924 was associated with a significantly greater improvement in the baseline bestcorrected visual acuity (BCVA) at 36 months after the first PDT.
   Conclusions: ARMS2 variants are likely associated with the 3-year outcomes of PDT in patients with wet AMD.
C1 [Nakai, Shunichiro; Honda, Shigeru; Matsumiya, Wataru; Miki, Akiko; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Nakamura, Makoto/0000-0002-6464-4302
FU Japan Society for the Promotion of Science, Tokyo, Japan [16K11286]
FX This study was supported by a Grant-in Aid (C) 16K11286 (SH) from Japan
   Society for the Promotion of Science, Tokyo, Japan. The funding
   organization had no role in the design or conduct of this research. No
   author has commercial interests to be disclosed in the subject of the
   manuscript.
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brunicardi FC, 2011, WORLD J SURG, V35, P1693, DOI 10.1007/s00268-011-1056-0
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
NR 25
TC 4
Z9 4
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 26
PY 2017
VL 23
BP 514
EP 519
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA FB9XH
UT WOS:000406492200001
PM 28761324
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Chin, AWI
   Lim, L
   Baird, PN
AF Guymer, RH
   Chin, AWI
   Lim, L
   Baird, PN
TI HMG CoA reductase inhibitors (Statins): Do they have a role in
   age-related macular degeneration?
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; HMG CoA; prophylactic treatment;
   statins
ID C-REACTIVE PROTEIN; LOW-DENSITY-LIPOPROTEIN; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; PARAOXONASE GENE POLYMORPHISMS; APOLIPOPROTEIN-E
   POLYMORPHISM; ENDOTHELIAL GROWTH-FACTOR; RISK-FACTORS; BRUCHS MEMBRANE;
   CARDIOVASCULAR-DISEASE; DIETARY-FAT
AB Age-related macular degeneration is a progressive late onset disease affecting central vision. It is the leading cause of irreversible blindness in developed countries, and with the aging population the problem is increasing. Current treatment options are limited to the late stage of the disease when central vision is already under great threat, and even new treatments make little impact on the rate of blindness. Intervention earlier in the disease may prove more rewarding, but to date little progress has been made with this approach. Epidemiologic, genetic, and pathological evidence continues to accumulate, suggesting a possible link between risk factors for cardiovascular diseases and age-related macular degeneration. This article reviews the evidence and discusses the rationale behind the recent suggestions that cholesterol-lowering agents may be useful in the treatment of early age-related macular degeneration. The cholesterol-lowering family of drugs called statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) inhibitors with pleiotropic actions. Their therapeutic effects in cardiovascular disease and dyslipidaemia have been well proven. In this review we will outline the known actions of statins and discuss possible ways that they may impact on age-related macular degeneration. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, 32 Gisborne St, Melbourne, Vic 3002, Australia.
OI Lim, Lyndell/0000-0003-2491-685X; Baird, Paul/0000-0002-1305-3502;
   Guymer, Robyn/0000-0002-9441-4356
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BAIRD PN, 2002, CLIN EXP OPHTHALMO S, V30, P275
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blackman BT, 2002, NEW ENGL J MED, V346, P1914
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHU FC, 1979, ARCH OPHTHALMOL-CHIC, V97, P1926
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Davies MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/eurheartj/16.suppl_L.3
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   de Sotomayor MA, 2001, BIOCHEM BIOPH RES CO, V280, P486
   DEKNIJFF P, 1990, ATHEROSCLEROSIS, V83, P89
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P89
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R
   Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Franceschini G, 2001, AM J CARDIOL, V88, p9N
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gould AL, 1998, CIRCULATION, V97, P946
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Harper CR, 2001, ARCH INTERN MED, V161, P2185, DOI 10.1001/archinte.161.18.2185
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hess D C, 2001, Expert Opin Pharmacother, V2, P153, DOI 10.1517/14656566.2.1.153
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Horejsi B, 2000, PHYSIOL RES, V49, pS63
   Huang XD, 2000, J NUTR, V130, p1488S, DOI 10.1093/jn/130.5.1488S
   HUNNINGHAKE DB, 1990, ATHEROSCLEROSIS, V85, P81, DOI 10.1016/0021-9150(90)90185-L
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092
   Jialal I, 2001, CIRCULATION, V103, P1933
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Kuvin JT, 2003, CURR OPIN CARDIOL, V18, P295, DOI 10.1097/00001573-200307000-00009
   Kwak B, 2001, SWISS MED WKLY, V131, P41
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Li JJ, 2003, CORONARY ARTERY DIS, V14, P329, DOI 10.1097/01.mca.0000078062.22445.60
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mahley RW, 1999, J LIPID RES, V40, P1933
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mertens A, 2001, FASEB J, V15, P2073, DOI 10.1096/fj.01-0273rev
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990
   NOTKOLA IL, 1988, NEUROEPIEDMIOLOGY, V17, P14
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   OOSTERHUIS JA, 1978, EXCERPTA MED, V23, P242
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31
   Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253
   POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P
   PREUFER D, 1999, THROMB VASC BIOL, V19, P2894
   Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RICHARDSON PD, 1989, LANCET, V2, P941
   Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Rulon LL, 2000, BIOL TRACE ELEM RES, V75, P79, DOI 10.1385/BTER:75:1-3:79
   SANCHIS JIB, 2000, ANN MED, V32, P164
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P98, DOI 10.1136/bjo.57.2.98
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Scuteri A, 2001, AM J MED, V110, P28, DOI 10.1016/S0002-9343(00)00639-2
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Segal-Isaacson C J, 1999, Heart Dis, V1, P149
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   STEINMETZ RL, 1992, INVEST OPHTH VIS SCI, V33, P1633
   STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   Tonkin A, 1998, NEW ENGL J MED, V339, P1349
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wassmann S, 2003, CIRC RES, V93, pE98, DOI 10.1161/01.RES.0000099503.13312.7B
   WATTS R, 2001, TRIALS CARDIOVASC ME, V2, P118
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wolf G, 2002, NUTR REV, V60, P88, DOI 10.1301/00296640260042757
   Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
NR 189
TC 44
Z9 47
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2005
VL 50
IS 2
BP 194
EP 206
DI 10.1016/j.survophthal.2004.12.002
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 909TE
UT WOS:000227882800005
PM 15749309
DA 2022-11-30
ER

PT J
AU Lupidi, M
   Cerquaglia, A
   Chhablani, J
   Fiore, T
   Singh, SR
   Piccolino, FC
   Corbucci, R
   Coscas, F
   Coscas, G
   Cagini, C
AF Lupidi, Marco
   Cerquaglia, Alessio
   Chhablani, Jay
   Fiore, Tito
   Singh, Sumit Randhir
   Piccolino, Felice Cardillo
   Corbucci, Roberta
   Coscas, Florence
   Coscas, Gabriel
   Cagini, Carlo
TI Optical coherence tomography angiography in age-related macular
   degeneration: The game changer
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Optical coherence tomography angiography; age-related macular
   degeneration; choroidal neovascularization; exudative age-related
   macular degeneration
ID AMPLITUDE-DECORRELATION ANGIOGRAPHY; ONSET CHOROIDAL NEOVASCULARIZATION;
   RETINAL ANGIOMATOUS PROLIFERATION; PIGMENT EPITHELIAL DETACHMENT;
   INDOCYANINE GREEN ANGIOGRAPHY; GEOGRAPHIC ATROPHY; OCT ANGIOGRAPHY;
   FLUORESCEIN ANGIOGRAPHY; ULTRAHIGH-SPEED; SWEPT-SOURCE
AB Optical coherence tomography angiography is one of the biggest advances in ophthalmic imaging. It enables a depth-resolved assessment of the retinal and choroidal blood flow, far exceeding the levels of detail commonly obtained with dye angiographies. One of the first applications of optical coherence tomography angiography was in detecting the presence of choroidal neovascularization in age-related macular degeneration and establishing its position in relation to the retinal pigmented epithelium and Bruch's membrane, and thereby classifying the CNV as type 1, type 2, type 3, or mixed lesions. Optical coherence tomography angiograms, due to the longer wavelength used by optical coherence tomography, showed a more distinct choroidal neovascularization vascular pattern than fluorescein angiography, since there is less suffering from light scattering or is less obscured by overlying subretinal hemorrhages or exudation. Qualitative and quantitative assessments of optical coherence tomography angiography findings in exudative and nonexudative age-related macular degeneration have been largely investigated within the past 3 years both in clinical and experimental settings. This review constitutes an up-to-date of all the potential applications of optical coherence tomography angiography in age-related macular degeneration in order to better understand how to translate its theoretical usefulness into the current clinical practice.
C1 [Lupidi, Marco; Cerquaglia, Alessio; Fiore, Tito; Corbucci, Roberta; Cagini, Carlo] Univ Perugia, S Maria della Misericordia Hosp, Sect Ophthalmol, Dept Biomed & Surg Sci, Perugia, Italy.
   [Lupidi, Marco; Coscas, Florence; Coscas, Gabriel] Ctr Odeon, Paris, France.
   [Lupidi, Marco; Piccolino, Felice Cardillo] Macula Onlus Fdn, Genoa, Italy.
   [Chhablani, Jay; Singh, Sumit Randhir] LV Prasad Eye Inst, Dept Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Hyderabad, India.
   [Coscas, Florence; Coscas, Gabriel] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
C3 Hospital Santa Maria della Misericordia; University of Perugia; L. V.
   Prasad Eye Institute; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil
RP Coscas, G (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM gabriel.coscas@gmail.com
RI Cagini, Carlo/H-3431-2019; Cagini, Carlo/L-2914-2016
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219;
   Chhablani, Jay/0000-0003-1772-3558; Lupidi, Marco/0000-0002-6817-2488
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   McClintic SM, 2015, CLIN OPHTHALMOL, V9, P1299, DOI 10.2147/OPTH.S83701
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Naysan Jonathan, 2015, Int J Retina Vitreous, V1, P8
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Veronese C, 2016, RETINA-J RET VIT DIS, V36, P645, DOI 10.1097/IAE.0000000000000914
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 68
TC 19
Z9 20
U1 1
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2018
VL 28
IS 4
BP 349
EP 357
DI 10.1177/1120672118766807
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM9LJ
UT WOS:000438569400004
PM 29623720
OA hybrid
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Wykoff, CC
   Singh, RP
   Khanani, AM
   Do, DV
   Patel, H
   Patel, N
AF Kaiser, Peter K.
   Wykoff, Charles C.
   Singh, Rishi P.
   Khanani, Arshad M.
   Do, Diana V.
   Patel, Hersh
   Patel, Nikhil
TI RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE disease activity; dosing; intraretinal fluid; neovascular age-related
   macular degeneration; retinal thickness; subretinal fluid; subretinal
   pigment epithelium fluid; visual acuity
ID TREAT-AND-EXTEND; VISUAL-ACUITY; CONTROLLED-TRIAL; DOSING REGIMEN;
   RANIBIZUMAB; AFLIBERCEPT; BEVACIZUMAB; MORPHOLOGY; OUTCOMES; THERAPY
AB Purpose: Retinal fluid and thickness are important anatomical features of disease activity in neovascular age-related macular degeneration, as evidenced by clinical trials that have used these features for inclusion criteria, retreatment criteria, and outcome measures of the efficacy of intravitreal injections of anti-vascular endothelial growth factor agents. Methods: A literature review of anatomical measures of disease activity was conducted. Results: Treatment goals for neovascular age-related macular degeneration include improving/maintaining vision by drying the retina, and several analyses have evaluated the relationship between visual function and anatomy. The change in retinal thickness has been found to correlate with the change in the visual acuity, and variation in retinal thickness may predict visual acuity outcomes. In addition, specific fluid compartments may have different prognostic values. For example, the presence of intraretinal fluid has been associated with poorer visual acuity, whereas the presence of subretinal fluid has been associated with better visual acuity. Retinal fluid and thickness are important for selecting dosing interval durations in clinical trials and clinical practice. Conclusion: Retinal thickness and retinal fluid are common anatomical measures of disease activity in neovascular age-related macular degeneration. Further research is required to fully elucidate the relationship between anatomical features and visual outcomes in neovascular age-related macular degeneration.
C1 [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Amer, Retina Consultants Texas, Houston, TX USA.
   [Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, Ctr Ophthalm Bioinformat, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Khanani, Arshad M.] Sierra Eye Assoc, Reno, NV USA.
   [Khanani, Arshad M.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Do, Diana V.] Stanford Univ, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Patel, Hersh; Patel, Nikhil] Novartis Pharmaceut, E Hanover, NJ USA.
C3 Cleveland Clinic Foundation; The Methodist Hospital System; The
   Methodist Hospital - Houston; Cleveland Clinic Foundation; Nevada System
   of Higher Education (NSHE); University of Nevada Reno; Stanford
   University; Novartis
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM kaiserp@ccf.org; ccwmd@houstonretina.com; SINGHR@ccf.org;
   arshad.khanani@gmail.com; dianado@stanford.edu;
   hersh.patel.ophthalmics@gmail.com; snik36@gmail.com
FU NEI NIH HHS [P30 EY026877] Funding Source: Medline
CR Awh CC., 2020, RET SOC 2020 VR SEPT
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Freund KB., 2020, RETI SOC 2020 VR SEP
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM., 2019, AM SOC RET SPEC JUL
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jhaveri CD., 2019, AM SOC RET SPEC JUL
   Kaiser PK., 2020, RET SOC SEPT 2020
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Schmidt-Erfurth U, 2020, INVEST OPHTH VIS SCI, V61
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 44
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2021
VL 41
IS 8
BP 1579
EP 1586
DI 10.1097/IAE.0000000000003194
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5JN
UT WOS:000711803800001
PM 33949342
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wahl, HW
   Kammerer, A
   Holz, F
   Miller, D
   Becker, S
   Kaspar, R
   Himmelsbach, I
AF Wahl, Hans-Werner
   Kaemmerer, Annette
   Holz, Frank
   Miller, Daniel
   Becker, Stefanie
   Kaspar, Roman
   Himmelsbach, Ines
TI Psychosocial intervention for age-related macular degeneration: A pilot
   project
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID SELF-MANAGEMENT; OLDER-ADULTS; VISION LOSS; VISUAL IMPAIRMENT;
   ADAPTATION; DEPRESSION; PROGRAM
AB This study evaluated an emotion-focused and a problem-focused intervention designed for patients with age-related macular degeneration. It found a limited decrease in depression in the emotion-focused group and an increase in active problem orientation and in adaptation to vision loss in the problem-focused group.
C1 Heidelberg Univ, Dept Psychol Aging Res, Inst Psychol, D-69115 Heidelberg, Germany.
   Heidelberg Univ, Dept Clin Psychol, Inst Psychol, D-69117 Heidelberg, Germany.
   Univ Bonn, Dept Ophthalmol, Ophthalm Clin, D-53127 Bonn, Germany.
   Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
   Heidelberg Univ, Inst Gerontol, D-69120 Heidelberg, Germany.
   Goethe Univ Frankfurt, D-60054 Frankfurt, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; University of Bonn; Ruprecht Karls University Heidelberg;
   Ruprecht Karls University Heidelberg; Goethe University Frankfurt
RP Wahl, HW (通讯作者)，Heidelberg Univ, Dept Psychol Aging Res, Inst Psychol, Bergheimer Str 20, D-69115 Heidelberg, Germany.
EM wahl@dzfa.uni-heidelberg.de;
   annette.kaemmerer@psychologie.uni-heidelberg.de;
   frank.holz@ukb.uni-bonn.de; daniel_miller@med.uni-heidelberg.de;
   stefanie.becker@urz.uni-heidelberg.de; kaspar@dzfa.uni-heidelberg.de;
   himmelsbach@em.uni-frankfurt.de
RI Kaspar, Roman/AAD-5588-2022
OI Kaspar, Roman/0000-0002-5829-2363
CR Baltes P. B., 1982, AGING COGNITIVE PROC, P353, DOI DOI 10.1007/978-1-4684-4178-9_19
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Bortz J, 1995, FORSCHUNGSMETHODEN E
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   CREWS JE, 2000, LIGHTHOUSE HDB VISIO, V2, P1287
   DAHLINIVANOFF S, 2000, DEV EVALUATION HLTH
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   FILIPP SH, 1999, POSTTRAUMATIC STRESS, P43
   Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456
   HARSHBARGER C, 1980, J VISUAL IMPAIR BLIN, V74, P221
   Heyl V, 2001, J VISUAL IMPAIR BLIN, V95, P739, DOI 10.1177/0145482X0109501204
   Horowitz A, 1998, J VISUAL IMPAIR BLIN, V92, P30, DOI 10.1177/0145482X9809200106
   Horowitz A, 2000, LIGHTHOUSE HDB VISIO, V2, P1089
   Ivanoff SD, 2002, AM J OCCUP THER, V56, P322, DOI 10.5014/ajot.56.3.322
   Lazarus R.S., 1991, EMOTION ADAPTATION
   Muthny FA, 1989, FREIBURGER FRAGEBOGE
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rybarczyk B, 2001, BEHAV MED, V27, P15, DOI 10.1080/08964280109595768
   SCHULZ R, 1998, ANN REV GERONTOLOGY, V18
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   WAHL HW, 1997, ALTERE MENSCHEN SEHB
NR 28
TC 15
Z9 16
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD SEP
PY 2006
VL 100
IS 9
BP 533
EP 544
PG 12
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 092KC
UT WOS:000241094400004
DA 2022-11-30
ER

PT J
AU Shah, GK
   Sang, DN
   Hughes, MS
AF Shah, Gaurav K.
   Sang, Delia N.
   Hughes, Mark S.
TI VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE Avastin; bevacizumab; choroid; Lucentis; Macugen; neovascularization;
   pegaptanib; ranibizumab; verteporfin; Visudyne
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; RANDOMIZED
   CLINICAL-TRIALS; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL
   COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; TRIAMCINOLONE ACETONIDE;
   SURVIVAL FACTOR; RANIBIZUMAB; SAFETY
AB Background: Neovascular age-related macular degeneration is characterized by choroidal neovascularization that has a complex pathogenesis. Combining agents that have different mechanisms of action (i.e., verteporfin photodynamic therapy, antivascular endothelial growth factor, and/or anti-inflammatory therapies) could maximize clinical benefits through potential complementary effects. This review discusses findings from studies investigating this hypothesis.
   Methods: Articles were retrieved from PubMed using relevant search terms. Abstracts from recent scientific meetings and details of ongoing trials from clinicaltrials. gov were also included.
   Results: Following its approval, verteporfin was important in the management of choroidal neovascularization due to age-related macular degeneration for several years. Improved visual outcomes have now been reported with antiangiogenic agents (e.g., intravitreal ranibizumab), especially when frequently administered. Results from investigator-sponsored trials, retrospective case studies and Registries, which have provided insights into the latest findings from clinical practice in the "real-world" setting, as well as randomized controlled trials, suggest that a combination approach is generally well tolerated and may maintain improvements in visual and anatomic outcomes with fewer retreatments.
   Conclusion: A rationale exists for investigating combination approaches to target different processes in choroidal neovascularization pathogenesis, which may optimize treatment benefits in neovascular age-related macular degeneration. Encouraging data suggest that combination strategies are not associated with major adverse events.
C1 [Sang, Delia N.; Hughes, Mark S.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Ophthalm Consultants Boston,Dept Ophthalmol, Boston, MA 02114 USA.
   [Shah, Gaurav K.] Washington Univ, Sch Med, Barnes Retina Inst, St Louis, MO USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute; Ophthalmic Consultants of Boston; Washington University
   (WUSTL)
RP Hughes, MS (通讯作者)，Harvard Univ, Sch Med, Schepens Eye Res Inst, Ophthalm Consultants Boston,Dept Ophthalmol, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM Mark_Hughes@hms.harvard.edu
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2006, EUR J OPHTHALMOL, V16, P824, DOI 10.1177/112067210601600607
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   BANKER AS, 2008, IND OPHTH C, P221
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOYER DS, 2008, ANG M RITZ CARLT KEY
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN DM, 2006, RET PHYS 2006 S ATL
   Caprioni Francesco, 2007, Future Oncol, V3, P141, DOI 10.2217/14796694.3.2.141
   CONNOLLY BP, 2007, INVEST OPHTH VIS SCI, V48, P4555
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Elliott WJ, 2008, J CLIN HYPERTENS, V10, P20, DOI 10.1111/j.1524-6175.2007.08028.x
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Giaccone G, 2007, CLIN CANCER RES, V13, P1961, DOI 10.1158/1078-0432.CCR-06-2186
   Gille J, 2006, EXP DERMATOL, V15, P175, DOI 10.1111/j.1600-0625.2006.00400.x
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Han ES, 2007, EXPERT REV ANTICANC, V7, P1339, DOI 10.1586/14737140.7.10.1339
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   HOLZ FG, 2007, INVEST OPHTHALMOL VI, V48
   HOOPER PL, 2007, INVEST OPHTH VIS SCI, V48, P4537
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   HUGHES MS, 2007, AM SOC RET SPEC
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   JARZABEK J, 2007, INVEST OPHTH VIS SCI, V48, P1446
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Kaiser PK, 2005, AM J OPHTHALMOL, V139, P533, DOI 10.1016/j.ajo.2004.12.027
   Kent D, 2003, MOL VIS, V9, P747
   KISS CG, 2007, INVEST OPHTHALMOL VI, V48
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   LANZETTA P, 2007, INVEST OPHTHALMOL VI, V48
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Mancuso A, 2006, CRIT REV ONCOL HEMAT, V58, P231, DOI 10.1016/j.critrevonc.2006.02.004
   MERRILL PT, 2007, COMBINATION LUCENTIS
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   PEER J, 1995, LAB INVEST, V72, P638
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   *QLT INC, 2007, RED FLUENC VIS ANTIV
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   ROMERO RM, 2007, INVEST OPHTHALMOL VI, V48
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   SACU S, 2007, INVEST OPHTH VIS SCI, V48, P1831
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   SLAKTER JS, 2007, INVEST OPHTHALMOL VI, V48
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sturmer M, 2007, ANTIVIR THER, V12, P695
   TAIWO BO, 2006, AFR J MED MED SCI, V35, pS1
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P193, DOI 10.1001/archophthalmol.2007.40
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   TOLENTINO MJ, 2007, AM AC OPHTH AAO ANN
   TSUCHIYA D, 2007, INVEST OPHTH VIS SCI, V48, P4547
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   VIP Report No 5 Writing Comm, 2004, OPHTHALMOLOGY, V111, P2144
   Volcker M, 2006, OPHTHALMOLOGE, V103, P476, DOI 10.1007/s00347-006-1356-1
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Weir MR, 2008, J CLIN HYPERTENS, V10, P4, DOI 10.1111/j.1524-6175.2007.08134.x
   WOLF S, 2007, INVEST OPHTHALMOL VI, V48
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 113
TC 21
Z9 21
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 133
EP 148
DI 10.1097/IAE.0b013e3181960a28
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407BR
UT WOS:000263339100002
PM 19202423
DA 2022-11-30
ER

PT J
AU Pead, E
   Megaw, R
   Cameron, J
   Fleming, A
   Dhillon, B
   Trucco, E
   MacGilliuray, T
AF Pead, Emma
   Megaw, Roly
   Cameron, James
   Fleming, Alan
   Dhillon, Baljean
   Trucco, Emanuele
   MacGilliuray, Thomas
TI Automated detection of age-related macular degeneration in color fundus
   photography: a systematic review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; age-related disorders; artificial
   intelligence; machine learning; deep learning
ID DRUSEN DETECTION; BETA; DISEASE; CLASSIFICATION; PERFORMANCE; FEATURES
AB The rising prevalence of age-related eye diseases, particularly age-related macular degeneration, places an ever-increasing burden on health care providers. As new treatments emerge, it is necessary to develop methods for reliably assessing patients' disease status and stratifying risk of progression. The presence of drusen in the retina represents a key early feature in which size, number, and morphology are thought to correlate significantly with the risk of progression to sight-threatening age-related macular degeneration. Manual labeling of drusen on color fundus photographs by a human is labor intensive and is where automatic computerized detection would appreciably aid patient care. We review and evaluate current artificial intelligence methods and developments for the automated detection of drusen in the context of age-related macular degeneration. (C) 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Pead, Emma; MacGilliuray, Thomas] Univ Edinburgh, Ctr Clin Brain Sci, VAMPIRE Project, Edinburgh, Midlothian, Scotland.
   [Cameron, James] Univ Edinburgh, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Megaw, Roly; Dhillon, Baljean] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Fleming, Alan] Optos Plc, Queensferry House,Carnegie Campus, Dunfermline, Fife, Scotland.
   [Trucco, Emanuele] Univ Dundee, Comp Sch Sci & Engn, VAMPIRE Project, Dundee, Scotland.
C3 University of Edinburgh; University of Edinburgh; University of Dundee
RP Pead, E (通讯作者)，Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.
EM s1114329@sms.ed.ac.uk
OI Megaw, Roly/0000-0001-5605-4540; Fleming, Alan/0000-0003-0642-7331;
   Trucco, Emanuele/0000-0002-5055-0794; MacGillivray,
   Tom/0000-0001-5120-0086
FU Scottish Imaging Network; Platform for Scientific Excellence (SINAPSE)
   Collaboration; Optos plc.; Welcome Trust; Academy of Medical Sciences;
   Fight for Sight
FX The PhD studentship of E.P. is jointly funded by the Scottish Imaging
   Network, a Platform for Scientific Excellence (SINAPSE) Collaboration,
   and Optos plc. A.F. is employed by Optos plc. R.M. is funded by the
   Welcome Trust, the Academy of Medical Sciences and Fight for Sight.
CR Acharya UR, 2017, J COMPUT SCI-NETH, V20, P41, DOI 10.1016/j.jocs.2017.03.005
   AREDS, 2006, ARCH OPTHALMOLOGY, V123, P1484
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2011, 33 ANN INT C IEEEMBS, P3692
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chen T, ARXIV1512
   Cohen S, RETINA GALLERY FULL
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Duanggate C, 2008, 3 INT S BIOM ENG, P222
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Floriano Garcia A, 2011, THESIS
   Garcia-Floriano A, 2019, COMPUT ELECTR ENG, V75, P218, DOI 10.1016/j.compeleceng.2017.11.008
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Hall M., 2009, SIGKDD EXPLORATIONS, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Hall M. A., 1999, Proceedings of the Twelfth International Florida AI Research Society Conference, P235
   He K, 2016, ABS16030 CORR
   Heneghan C, 2002, MED IMAGE ANAL, V6, P407, DOI 10.1016/S1361-8415(02)00058-0
   Hijazi M, 2010, P INT JOINT C NEUR N, P1
   Hoover A., STRUCTURED ANAL RETI
   Iwama D, 2012, INVEST OPHTH VIS SCI, V53, P1576, DOI 10.1167/iovs.11-8103
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CC, 1999, ROTTERDAM STUDY, V120, P963
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Macgillivray TJ, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130832
   McGrory Sarah, 2017, Alzheimers Dement (Amst), V6, P91, DOI 10.1016/j.dadm.2016.11.001
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Niemeijer M, 2006, MED IMAGE ANAL, V10, P888, DOI 10.1016/j.media.2006.09.006
   Pellegrini Enrico, 2018, Alzheimers Dement (Amst), V10, P519, DOI 10.1016/j.dadm.2018.07.004
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   RNIB, KEY INF STAT
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Sermanet P., 2014, P ICLR
   STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   Thomson Kelsey L, 2015, Alzheimers Dement (Amst), V1, P136, DOI 10.1016/j.dadm.2015.03.001
   Trucco E, 2013, INVEST OPHTH VIS SCI, V54, P3546, DOI 10.1167/iovs.12-10347
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
   Zheng Y., FDN PREVENTION BLIND
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 62
TC 24
Z9 27
U1 5
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2019
VL 64
IS 4
BP 498
EP 511
DI 10.1016/j.survophthal.2019.02.003
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IG1NC
UT WOS:000473557300006
PM 30772363
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Manresa, N
   Mulero, J
   Losada, M
   Zafrilla, P
AF Manresa, N.
   Mulero, J.
   Losada, M.
   Zafrilla, P.
TI Influence of anti-VEGF about cardiovascular biomarkers in age related
   macular degeneration
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Anti-VEGF; exudative age related macular degeneration; homocysteine;
   lipids; C-Reactive protein
ID MYOCARDIAL-INFARCTION; HOMOCYSTEINE LEVELS; NITRIC-OXIDE; RANIBIZUMAB;
   RISK; DISCOVERY
AB Systemic VEGF inhibition disrupts endothelial homeostasis and accelerates the atherogenesis, suggesting that these events contribute to the clinical cardiovascular adverse events of VEGF-inhibiting therapies. The objective of the current study was to analyze the effect of anti-VEGF therapy on cardiovascular risk factors in patients with exudative age related macular degeneration. A total of 73 patients with exudative age related macular degeneration (without previous anti-VEGF therapy) were treated with two anti-VEGF: Ranibizumab and Pegaptanib sodium. The follow up was 6 months. The following parameters were determined before and after treatment: homocysteine, lipids (total cholesterol, triglycerides, HDL-c, LDL-c), C-Reactive Protein and fibrinogen. There were not statistically significant differences in parameters studied before and after treatment with both Pegaptanib sodium and Ranibizumab, except C-Reactive Protein. Of all patients analyzed, only 3 of them have initially C-Reactive Protein levels above normal levels and after antiangiogenic therapy, there was a significant increase in C-Reactive Protein. We have not found results in our study who to suspect that treatment with anti-VEGF in the patients with exudative age related macular degeneration increases cardiovascular risk predictors. However, after therapy was increased the CRP and fibrinogen may mean that anti-VEGF contribute an alteration of endothelial homeostasis in exudative AMD.
C1 [Manresa, N.; Mulero, J.; Zafrilla, P.] Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
   [Losada, M.] Univ Hosp Jose Ma Morales Meseguer, Murcia, Spain.
C3 Universidad Catolica de Murcia
RP Manresa, N (通讯作者)，Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
EM noemi-mr@hotmail.com
RI Zafrilla, Pilar/H-8132-2012
CR Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Gentile R, 2006, ANN INTERN MED, V145, p[98, 551]
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kong HY, 2013, J NUTR HEALTH AGING, V17, P527, DOI 10.1007/s12603-013-0026-7
   Liew Gerald, 2012, NEW ENGL J MED, P356
   Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSSI E, 1988, THROMB RES, V52, P453, DOI 10.1016/0049-3848(88)90029-1
   Ruiz Moreno JM, 2004, ANTIINFLAMATORIOS AN, P93
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Swart KMA, 2013, J NUTR HEALTH AGING, V17, P578, DOI 10.1007/s12603-013-0047-2
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
NR 35
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
EI 1760-4788
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD FEB
PY 2015
VL 19
IS 2
BP 228
EP 231
DI 10.1007/s12603-014-0531-3
PG 4
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA CC4DH
UT WOS:000350300500015
PM 25651450
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Yoneyama, S
   Sugiyama, A
   Tanabe, N
   Kikushima, W
   Mabuchi, F
   Kume, A
   Kubota, T
   Iijima, H
AF Sakurada, Yoichi
   Yoneyama, Seigo
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kikushima, Wataru
   Mabuchi, Fumihiko
   Kume, Atsuki
   Kubota, Takeo
   Iijima, Hiroyuki
TI Prevalence and Genetic Characteristics of Geographic Atrophy among
   Elderly Japanese with Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION; RETICULAR
   PSEUDODRUSEN; POPULATION; MACULOPATHY; SUBTYPES; EYES
AB Objective
   To investigate the prevalence and genetic characteristics of geographic atrophy (GA) among elderly Japanese with advanced age-related macular degeneration (AMD) in a clinic-based study.
   Methods
   Two-hundred and ninety consecutive patients with advanced AMD were classified into typical neovascular AMD, polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP) or geographic atrophy (GA). Genetic variants of ARMS2 A69S (rs10490924) and CFH I62V (rs800292) were genotyped using TaqMan Genotyping Assays. The clinical and genetic characteristics were compared between patients with and without GA.
   Results
   The number of patients diagnosed as having typical neovascular AMD, PCV, RAP and GA were 98 (33.8%), 151 (52.1%), 22 (7.5%) and 19 (6.6%), respectively. Of 19 patients with GA, 13 patients (68.4%) had unilateral GA with exudative AMD in the contralateral eye. Patients with GA were significantly older, with a higher prevalence of reticular pseudodrusen, bilateral involvement of advanced AMD and T-allele frequency of ARMS2 A69S compared with those with typical AMD and PCV; although there were no differences in the genetic and clinical characteristics among patients with GA and RAP.
   Conclusions
   The prevalence of GA was 6.6% among elderly Japanese with AMD. Patients with GA and RAP exhibited genetic and clinical similarities.
C1 [Sakurada, Yoichi; Yoneyama, Seigo; Sugiyama, Atsushi; Tanabe, Naohiko; Kikushima, Wataru; Mabuchi, Fumihiko; Kume, Atsuki; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Tokyo, Yamanashi, Japan.
   [Kubota, Takeo] Univ Yamanashi, Dept Epigenet, Fac Med, Chuo Ku, Tokyo, Yamanashi, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Tokyo, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
FU Japan Society for the Promotion of Science KAKENHI [23791972]
FX This work was supported by Japan Society for the Promotion of Science
   KAKENHI Grant Number 23791972 (YS).
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scholl HPN, 2007, MOL VIS, V13, P196
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tanaka K, 2011, MOL VIS, V17, P2751
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 27
Z9 27
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 26
PY 2016
VL 11
IS 2
AR e0149978
DI 10.1371/journal.pone.0149978
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF3UU
UT WOS:000371274400065
PM 26918864
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Querques, G
   Rosenfeld, PJ
   Cavallero, E
   Borrelli, E
   Corvi, F
   Querques, L
   Bandello, FM
   Zarbin, MA
AF Querques, Giuseppe
   Rosenfeld, Philip J.
   Cavallero, Edoardo
   Borrelli, Enrico
   Corvi, Federico
   Querques, Lea
   Bandello, Francesco M.
   Zarbin, Marco A.
TI Treatment of Dry Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Drusen; Geographic atrophy; Age-related macular degeneration; Treatment;
   Pathway; Drugs; Stem cells; Neurotrophic factors; Visual cycle;
   Oxidative damage
ID RETINAL-PIGMENT EPITHELIUM; CILIARY NEUROTROPHIC FACTOR; FACTOR-H
   POLYMORPHISM; CHOROIDAL BLOOD-FLOW; COMPLEMENT FACTOR-B; GEOGRAPHIC
   ATROPHY; DEHYDROGENASE-ACTIVITY; POTENTIAL THERAPY; BRUCHS MEMBRANE;
   OUTER SEGMENTS
AB A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. beta-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment. (C) 2014 S. Karger AG, Basel
C1 [Querques, Giuseppe] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Querques, Giuseppe; Cavallero, Edoardo; Borrelli, Enrico; Corvi, Federico; Querques, Lea; Bandello, Francesco M.] Univ Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Zarbin, Marco A.] Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Bascom
   Palmer Eye Institute; University of Miami; Rutgers State University New
   Brunswick; Rutgers State University Medical Center
RP Zarbin, MA (通讯作者)，Rutgers State Univ, Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Doctors Off Ctr, Room 6186,90 Bergen St, Newark, NJ 07103 USA.
EM zarbin@rutgers.edu
RI bandello, francesco/AAH-2405-2019; Corvi, Federico/AAD-7691-2021;
   Borrelli, Enrico/AAR-3693-2020
OI bandello, francesco/0000-0003-3238-9682; Corvi,
   Federico/0000-0002-2661-5500; Borrelli, Enrico/0000-0003-2815-5031;
   Querques, Giuseppe/0000-0002-3292-9581; Zarbin,
   Marco/0000-0002-7811-7132
CR AIZUSS DH, 1985, INVEST OPHTH VIS SCI, V26, P1262
   Akula JD, 2010, EXP EYE RES, V91, P153, DOI 10.1016/j.exer.2010.04.008
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P1104, DOI 10.1016/j.ajo.2011.12.010
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Casaroli-Marano R.P., 2014, CELL BASED THERAPY R
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Engelbert M, 2005, INVEST OPHTH VIS SCI, V46, P2479, DOI 10.1167/iovs.04-1139
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fairchild PJ, 2010, NAT REV IMMUNOL, V10, P868, DOI 10.1038/nri2878
   Farjo KM, 2009, INVEST OPHTH VIS SCI, V50, P5089, DOI 10.1167/iovs.09-3797
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   GIESE MJ, 1994, INVEST OPHTH VIS SCI, V35, P1026
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6
   Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2006, J BIOL CHEM, V281, P37697, DOI 10.1074/jbc.M608375200
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Melville H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-53
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x
   Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Ralston PG, 2010, INVEST OPHTH VIS SCI, V51
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Regillo CD, 2013, 2013 ANN M AM AC OPH
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tatton W, 2003, SURV OPHTHALMOL, V48, pS25, DOI 10.1016/S0039-6257(03)00005-5
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TINKLER JH, 1995, NAT MED, V1, P98
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zarbin M, 2012, DRUG DISCOV TODAY TH
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zeiss CJ, 2006, EXP EYE RES, V82, P395, DOI 10.1016/j.exer.2005.07.014
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 105
TC 31
Z9 34
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 52
IS 3
BP 107
EP 115
DI 10.1159/000363187
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS7QA
UT WOS:000344448900001
PM 25228171
OA Bronze
DA 2022-11-30
ER

PT J
AU Gohel, PS
   Mandava, N
   Olson, JL
   Durairaj, VD
AF Gohel, Parin S.
   Mandava, Naresh
   Olson, Jeffrey L.
   Durairaj, Vikram D.
TI Age-related macular degeneration: An update on treatment
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE age-related macular degeneration; antiangiogenic therapy; anti-VEGF;
   choroidal neovascularization; retina; vision loss
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ARGON-LASER PHOTOCOAGULATION;
   RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC THERAPY; VERTEPORFIN;
   MACULOPATHY; RANIBIZUMAB
AB Age-related macular degeneration is a chronic disease leading to progressive central vision loss. It is the leading cause of irreversible blindness in the United States, most commonly affecting white Caucasians aged more than 55 years. Typical symptoms include decreased central vision, central scotoma, and metamorphopsia. Patients with acute loss of vision should be promptly referred to an ophthalmologist. New antiangiogenic therapies have significantly improved visual prognosis in these patients. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Gohel, Parin S.; Mandava, Naresh; Olson, Jeffrey L.; Durairaj, Vikram D.] Univ Colorado, Sch Med, Dept Ophthalmol, Denver, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver
RP Durairaj, VD (通讯作者)，1675 N Ursula St,POB 6510,Mail Stop F731, Aurora, CO 80045 USA.
EM vikram.durairaj@uchsc.edu
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 11
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD APR
PY 2008
VL 121
IS 4
BP 279
EP 281
DI 10.1016/j.amjmed.2007.10.020
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 280JV
UT WOS:000254423700006
PM 18374683
DA 2022-11-30
ER

PT J
AU Larsen, PP
   Oishi, A
   Bedar, MS
   Heymer, PKR
   Clemens, CR
   Konig, S
   Gutfleisch, M
   Pauleikhoff, D
   Eter, N
   Wolf, A
   Holz, FG
   Krohne, TU
AF Larsen, Petra P.
   Oishi, Akio
   Bedar, Mohammad Seleman
   Heymer, Philipp K. R.
   Clemens, Christoph R.
   Koenig, Susanna
   Gutfleisch, Matthias
   Pauleikhoff, Daniel
   Eter, Nicole
   Wolf, Armin
   Holz, Frank G.
   Krohne, Tim U.
TI RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR
   DEGENERATION A Prospective Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE RPE rip; neovascular AMD; IIT; anti-VEGF therapy
ID GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; RISK-FACTORS; DETACHMENT;
   BEVACIZUMAB; INJECTION; MECHANISM; EYE; VISION
AB Purpose: To assess efficacy of intravitreal ranibizumab in retinal pigment epithelium tears secondary to neovascular age-related macular degeneration.
   Methods: The Ranibizumab In Pigment epithelial tears secondary to age-related macular degeneration (RIP) study is a prospective, single-arm, multicenter, investigator-initiated trial. Twenty four eyes of 24 patients with a retinal pigment epithelium tear secondary to age-related macular degeneration received monthly intravitreal injection of 0.5mg ranibizumab for 12 months, together with monthly assessments of morphologic and functional efficacy parameters. Primary outcome measure was mean best-corrected visual acuity at final visit compared with baseline.
   Results: Mean best-corrected visual acuity remained stable over the 12-month study period with 50.3 Early Treatment of Diabetic Retinopathy Study letters (+/- 18.7; Snellen equivalent 20/100) at baseline and 52.9 letters (+/- 19.7; Snellen equivalent 20/100) at final visit (P = 0.39). One eye (4%) experienced a vision loss of >= 15 letters, and 2 eyes (8%) gained >= 15 letters. Mean central retinal thickness decreased from 571 mu m (+/- 185 mu m) to 436 mu m (+/- 171 mu m; P = 0.0001). Vision-related quality of life was stable with a mean VFQ-25 score of 79.0 (+/- 10.8) at baseline and 74.3 (+/- 13.9) at final visit (P = 0.12).
   Conclusion: In retinal pigment epithelium tears secondary to age-related macular degeneration, monthly intravitreal ranibizumab therapy results in stabilization of visual acuity over 12 months.
C1 [Larsen, Petra P.; Oishi, Akio; Bedar, Mohammad Seleman; Heymer, Philipp K. R.; Holz, Frank G.; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Clemens, Christoph R.; Eter, Nicole] Univ Munster, Dept Ophthalmol, Munster, Germany.
   [Koenig, Susanna; Wolf, Armin] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
   [Gutfleisch, Matthias; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Bonn; University of Munster; University of Munich; St.
   Franziskus-Hospital
RP Krohne, TU (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM krohne@uni-bonn.de
RI Larsen, Petra/AAV-3114-2020; Krohne, Tim/AAG-4412-2020; Oishi,
   Akio/AAE-9996-2020; Krohne, Tim/D-1497-2013
OI Larsen, Petra/0000-0003-2486-632X; Oishi, Akio/0000-0002-0977-9458;
   Krohne, Tim/0000-0003-2280-925X
FU Novartis Pharma GmbH, Germany; Study Center Bonn (SZB), University
   Hospital Bonn; Institute of Medical Biometry, Informatics, and
   Epidemiology (IMBIE), University Hospital Bonn
FX Funding for this investigator-initiated trial was provided by Novartis
   Pharma GmbH, Germany. The authors acknowledge the support by the Study
   Center Bonn (SZB; Christoph Coch, MD), University Hospital Bonn, and the
   Institute of Medical Biometry, Informatics, and Epidemiology (IMBIE;
   Rolf Fimmers, PhD), University Hospital Bonn.
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kroyer K, 2008, ACTA OPHTHALMOL, V86, P338, DOI 10.1111/j.1600-0420.2007.00993.x
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Oishi A, 2018, RETINA-J RET VIT DIS, V38, P1331, DOI 10.1097/IAE.0000000000001688
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P1083, DOI 10.1097/IAE.0b013e318207d1a3
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   Yoshitani S, 2003, OPHTHALMIC SUR LA IM, V34, P217, DOI 10.3928/1542-8877-20030501-12
NR 41
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2019
VL 39
IS 12
BP 2369
EP 2377
DI 10.1097/IAE.0000000000002311
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9GG
UT WOS:000507478900027
PM 30198967
DA 2022-11-30
ER

PT J
AU Mata, NL
   Vogel, R
AF Mata, Nathan L.
   Vogel, Roger
TI Pharmacologic treatment of atrophic age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; drusen; dry AMD; geographic atrophy;
   lipofuscin; retina; retinal pigment epithelium; RPE
ID CILIARY NEUROTROPHIC FACTOR; COMPLEMENT FACTOR-H; CHOROIDAL BLOOD-FLOW;
   GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; OXIDATIVE STRESS;
   PHOTORECEPTOR DEGENERATION; DISEASE PROGRESSION; RETINAL STRUCTURE;
   FACTOR-RECEPTOR
AB Purpose of review
   To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration.
   Recent findings
   Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts.
   Summary
   As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.
C1 [Mata, Nathan L.; Vogel, Roger] Sirion Therapeut Inc, Tampa, FL 33619 USA.
RP Vogel, R (通讯作者)，Sirion Therapeut Inc, 9314 E Broadway Ave, Tampa, FL 33619 USA.
EM rogervogel@aol.com
CR AEBISCHER P, 1995, EUR NEUROL, V35, P65, DOI 10.1159/000117095
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beltran WA, 2003, INVEST OPHTH VIS SCI, V44, P3642, DOI 10.1167/iovs.02-0763
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   BUI TV, 2007, 3244 ARVO
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DUGEL P, 2009, RETINA TODAY, P2
   Dutcher JP, 2004, CLIN CANCER RES, V10, p6382S, DOI 10.1158/1078-0432.CCR-050008
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   FLECKENSTEIN M, 2010, INVEST OPHTH VIS SCI, V50, P3915
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fuhrmann S, 1998, J COMP NEUROL, V400, P244
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HELFAND SL, 1976, DEV BIOL, V50, P541, DOI 10.1016/0012-1606(76)90174-3
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   KATZ RS, 2009, 4918 ARVO
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUBOTA R, 2009, 5009 ARVO
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   LOCKE K, 2009, 967 ARVO
   MacDonald IM, 2007, CAN J OPHTHALMOL, V42, P399, DOI 10.3129/i07-039
   MARTIDIS A, 2004, AGE RELATED MACULAR, P925
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Napoli KL, 2001, THER DRUG MONIT, V23, P559, DOI 10.1097/00007691-200110000-00012
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Peterson WM, 2000, J NEUROSCI, V20, P4081
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Radu Roxana A, 2004, Novartis Found Symp, V255, P51
   RENGANATHAN K, 2009, 681 ARVO
   Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Seydewitz V, 2004, INVEST OPHTH VIS SCI, V45, P655, DOI 10.1167/iovs.03-0182
   Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Valter K, 2003, BRAIN RES, V985, P169, DOI 10.1016/S0006-8993(03)03130-5
   VARON S, 1979, BRAIN RES, V173, P29, DOI 10.1016/0006-8993(79)91093-X
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VOGEL R, 2009, 4919 ARVO
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WILLIAMS GA, 2009, 5003 ARVO
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zigler JS, 2003, FREE RADICAL BIO MED, V35, P1194, DOI 10.1016/S0891-5849(03)00505-7
NR 84
TC 15
Z9 17
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2010
VL 21
IS 3
BP 190
EP 196
DI 10.1097/ICU.0b013e32833866c8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 591NR
UT WOS:000277308300005
PM 20216419
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Sagong, M
   Lai, TYY
   Tan, GSW
   Ngah, NF
   Ohji, M
   Mitchell, P
   Yang, CH
   Ruamviboonsuk, P
   Wong, I
   Sakamoto, T
   Rajendran, A
   Chen, YX
   Lam, DSC
   Lai, CC
   Wong, TY
   Cheung, CMG
   Chang, A
   Koh, A
AF Chaikitmongkol, Voraporn
   Sagong, Min
   Lai, Timothy Y. Y.
   Tan, Gavin S. W.
   Ngah, Nor Fariza
   Ohji, Masahito
   Mitchell, Paul
   Yang, Chang-Hao
   Ruamviboonsuk, Paisan
   Wong, Ian
   Sakamoto, Taiji
   Rajendran, Anand
   Chen, Youxin
   Lam, Dennis S. C.
   Lai, Chi-Chun
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
   Chang, Andrew
   Koh, Adrian
TI Treat-and-Extend Regimens for the Management of Neovascular Age-related
   Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus
   and Recommendations From the Asia-Pacific Vitreo-retina Society
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE aflibercept; Asia-Pacific; bevacizumab; consensus; neovascular
   age-related macular degeneration; polypoidal choroidal vasculopathy;
   ranibizumab; treat-and-extend
ID PRO-RE-NATA; INTRAVITREAL AFLIBERCEPT INJECTION; INTRAOCULAR
   PHARMACOKINETICS; WORLD OUTCOMES; VEGF TRAP; RANIBIZUMAB; EFFICACY;
   THERAPY; SAFETY; BEVACIZUMAB
AB Purpose: Review and provide consensus recommendations on use of treat-and-extend (T&E) regimens for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) management with relevance for clinicians in the Asia-Pacific region.
   Methods: A systematic search of MEDLINE, EMBASE, and Cochrane databases, and abstract databases of the Asia-Pacific Vitreo-retina Society, European Society of Retina Specialists, American Academy of Ophthalmology, and Controversies in Ophthalmology: Asia-Australia congresses, was conducted to assess evidence for T&E regimens in nAMD. Only studies with >= 100 study eyes were included. An expert panel reviewed the results and key factors potentially influencing the use of T&E regimens in nAMD and PCV, and subsequently formed consensus recommendations for their application in the Asia-Pacific region.
   Results: Twenty-seven studies were included. Studies demonstrated that T&E regimens with aflibercept, ranibizumab, or bevacizumab in nAMD, and with aflibercept in PCV, were efficacious and safe. The recommendation for T&E is, after >= 3 consecutive monthly loading doses, treatment intervals can be extended by 2 to 4 weeks up to 12 to 16 weeks. When disease activity recurs, the recommendation is to reinject and shorten intervals by 2 to 4 weeks until fluid resolution, after which treatment intervals can again be extended. Intraretinal fluid should be treated until resolved; however, persistent minimal subretinal fluid after consecutive treatments may be tolerated with treatment intervals maintained or extended if the clinical condition is stable.
   Conclusions: T&E regimens are efficacious and safe for nAMD and PCV, can reduce the number of visits, and minimize the overall burden for clinicians and patients.
C1 [Chaikitmongkol, Voraporn] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Sagong, Min] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu, South Korea.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
   [Tan, Gavin S. W.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, NUS Med Sch, Singapore, Singapore.
   [Ngah, Nor Fariza] Hosp Shah Alam, Minist Hlth, Bangi, Selangor, Malaysia.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Shiga, Japan.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Yang, Chang-Hao] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
   [Ruamviboonsuk, Paisan] Rangsit Univ, Rajavithi Hosp, Coll Med, Dept Ophthalmol, Bangkok, Thailand.
   [Wong, Ian] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Peoples R China.
   [Sakamoto, Taiji] Kagoshima Univ, Dept Ophthalmol, Kagoshima, Japan.
   [Rajendran, Anand] Aravind Eye Care Syst, Retina Vitreous Serv, Chennai, India.
   [Chen, Youxin] Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Lam, Dennis S. C.] MER Dennis Lam & Partners Eye Ctr, MER Int Eye Care Grp, Hong Kong, Peoples R China.
   [Lai, Chi-Chun] Chinese Univ Hong Kong, MER Int Eye Res Ctr, Shenzhen, Peoples R China.
   [Wong, Tien Yin] Chang Gung Univ, Chang Gung Mem Hosp, Dept Ophthalmol, Coll Med,Linkou Med Ctr, Taoyuan, Taiwan.
   [Cheung, Chui Ming Gemmy] Univ Sydney, Sydney Eye Hosp, Sydney Retina Clin, Sydney, NSW, Australia.
   [Chang, Andrew] Camden Med Ctr, Eye & Retina Surg, Singapore, Singapore.
C3 Chiang Mai University; Yeungnam University; Chinese University of Hong
   Kong; National University of Singapore; Singapore National Eye Center;
   Kementerian Kesihatan Malaysia; Shiga University of Medical Science;
   University of Sydney; Westmead Institute for Medical Research; National
   Taiwan University; National Taiwan University Hospital; Rajavithi
   Hospital; Rangsit University; University of Hong Kong; Kagoshima
   University; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Peking Union Medical College Hospital; Chinese University of
   Hong Kong, Shenzhen; Chang Gung Memorial Hospital; Chang Gung
   University; University of Sydney
RP Chaikitmongkol, V (通讯作者)，Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.; Chaikitmongkol, V (通讯作者)，Chiang Mai Univ, Fac Med, Dept Ophthalmol, 110 Inthawaroros Rd,110 Inthawaroros Rd,Tambon Sr, Chiang Mai 50200, Thailand.
EM vchaikitmongkol@gmail.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU Bayer (South East Asia) Pte Ltd.
FX Bayer (South East Asia) Pte Ltd coordinated the collaboration and funded
   the systematic review. Medical writing support was provided by Jamie
   Harrison of Porterhouse Medical Ltd and was funded by Bayer (South East
   Asia) Pte Ltd.
CR Abdin AD, 2019, GRAEF ARCH CLIN EXP, V257, P1671, DOI 10.1007/s00417-019-04360-9
   Almuhtaseb H, 2018, EYE, V32, P8
   Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Aurell S, 2019, ACTA OPHTHALMOL, V97, P519, DOI 10.1111/aos.13989
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhende M, 2018, INDIAN J OPHTHALMOL, V66, P20, DOI 10.4103/ijo.IJO_902_17
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chaikitmongkol V, 2022, OPHTHALMOL RETINA, V6, P21, DOI 10.1016/j.oret.2021.03.012
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chen LJ, 2020, ASIA-PAC J OPHTHALMO, V9, P104, DOI 10.1097/01.APO.0000656976.47696.7d
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Chou YB, 2019, J CHIN MED ASSOC, V82, P659, DOI 10.1097/JCMA.0000000000000138
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Delaunay S, 2019, INVEST OPHTH VIS SCI, V60
   Do DV, 2020, RETINA-J RET VIT DIS, V40, P643, DOI 10.1097/IAE.0000000000002566
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Food and Drug Administration (FDA), 2019, FDA DRUG APPR PACK B
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P773, DOI 10.1089/jop.2017.0006
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Ito A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235213
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Korobelnik JF, 2021, GRAEF ARCH CLIN EXP, V259, P567, DOI 10.1007/s00417-021-05097-0
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumluang S, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1086-1
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lukic M, 2021, EUR J OPHTHALMOL, V31, P1940, DOI 10.1177/1120672120938565
   Mahmood S, 2018, INVEST OPHTH VIS SCI, V59
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Mitchell P, 2019, INVEST OPHTH VIS SCI, V60
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell P, 2017, INVEST OPHTH VIS SCI, V58
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Morizane-Hosokawa M, 2018, ACTA MED OKAYAMA, V72, P379, DOI 10.18926/AMO/56175
   Novartis, BEOV BROL GLOB US SA
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Ohji M, 2018, 12 C AS PAC VITR SOC
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Sagong M, 2021, CLIN OPHTHALMOL, V15, P1995, DOI 10.2147/OPTH.S303884
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Slakter JS., 2010, RETIN PHYS, V7, P35
   Spooner K, 2019, CLIN EXP OPHTHALMOL, V47, P63
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   Stone TW, 2019, PREFERENCES TRENDS M
   Tamachi T, 2020, OPHTHALMOL THER, V9, P1069, DOI 10.1007/s40123-020-00312-3
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   The Royal Australian and New Zealand College of Ophthalmologists (RANZCO), RANZCO TRIAG GUID FE
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POP AG 2019 HI
   Wan KH, 2020, ASIA-PAC J OPHTHALMO, V9, P279, DOI 10.1097/APO.0000000000000305
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Wong DT, 2020, RETINA-J RET VIT DIS, V40, P1010, DOI 10.1097/IAE.0000000000002713
   Wong RLM, 2020, ASIA-PAC J OPHTHALMO, V9, P281, DOI [10.1097/APO.0000000000000.308, 10.1097/APO.0000000000000308]
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Lu Y, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320953349
   Zacharaki F., 2020, 20 EUR SOC RET SPEC
NR 97
TC 0
Z9 0
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD NOV-DEC
PY 2021
VL 10
IS 6
BP 507
EP 518
DI 10.1097/APO.0000000000000445
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XS9YR
UT WOS:000733255600002
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shijo, T
   Sakurada, Y
   Fukuda, Y
   Yoneyama, S
   Sugiyama, A
   Matsubara, M
   Kikushima, W
   Tanabe, N
   Parikh, R
   Kashiwagi, K
AF Shijo, Taiyo
   Sakurada, Yoichi
   Fukuda, Yoshiko
   Yoneyama, Seigo
   Sugiyama, Atsushi
   Matsubara, Mio
   Kikushima, Wataru
   Tanabe, Naohiko
   Parikh, Ravi
   Kashiwagi, Kenji
TI Association of CRP levels with ARMS2 and CFH variants in age-related
   macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE C-reactive protein; Exudative age-related macular degeneration; ARMS2
   A69S; CFH I62V
ID C-REACTIVE PROTEIN; POLYPOIDAL CHOROIDAL VASCULOPATHY; POLYMORPHISM;
   A69S
AB Purpose To investigate whether plasma high sensitivity C-reactive protein (hs-CRP) level is associated with exudative age-related macular degeneration (AMD) as well as variants of ARMS2 A69S and CFH I62V in patients with exudative AMD. Methods A case-control study was done comparing CRP among patients with exudative AMD including those with polypoidal choroidal vasculopathy, typical AMD and retinal angiomatous proliferation, and CRP were also compared between cases and controls. Plasma CRP was measured from peripheral blood using latex nepherometry for all participants. Genotyping of ARMS2 A69S and CFH I62V was performed for all patients with exudative AMD using TaqMan technology. Results Among 125 patients with exudative AMD, including 31 with typical neovascular AMD, 73 with PCV and 21 with RAP lesions and 150 controls, CRP levels were higher in exudative AMD than in controls. (P = 2.7 x 10(-5)) There was not a significant difference in hs-CRP levels among AMD subtypes. Neither variants of ARMS2 nor CFH was associated with hs-CRP level in patients with exudative AMD. A multiple regression analysis revealed that gender male, presence of exudative AMD and presence of cardiovascular diseases were associated with increased plasma hs-CRP. Conclusions Plasma hs-CRP was elevated independent of variants of ARMS2 A69S and CFH I62V in patients with exudative AMD.
C1 [Shijo, Taiyo; Sakurada, Yoichi; Fukuda, Yoshiko; Yoneyama, Seigo; Sugiyama, Atsushi; Matsubara, Mio; Kikushima, Wataru; Tanabe, Naohiko; Kashiwagi, Kenji] Univ Yamanashi, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
   [Parikh, Ravi] NYU, Sch Med, New York, NY USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
C3 University of Yamanashi; New York University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
OI Sakurada, Yoichi/0000-0002-2894-0454; Parikh, Ravi/0000-0003-3369-4224
CR Ambreen F, 2015, MOL VIS, V21, P985
   Barrea L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102278
   Chen JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02226-x
   Fernandez-Robredo P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01862
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Pepys MB, 2003, J CLIN INVEST, V112, P299, DOI 10.1172/JCI200318921C
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Tutuncu Y, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5827041
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 20
TC 8
Z9 9
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2020
VL 40
IS 10
BP 2735
EP 2742
DI 10.1007/s10792-020-01460-y
EA JUN 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NS0QD
UT WOS:000538706600003
PM 32507953
DA 2022-11-30
ER

PT J
AU Gemenetzi, M
   Lotery, AJ
AF Gemenetzi, M.
   Lotery, A. J.
TI The role of epigenetics in age-related macular degeneration
SO EYE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; DNA METHYLATION; GENE-EXPRESSION; NADPH
   OXIDASE; UP-REGULATION; CHROMATIN-STRUCTURE; ALZHEIMERS-DISEASE; BRUCHS
   MEMBRANE; RISK-FACTORS; HYPOXIA
AB It is becoming increasingly evident that epigenetic mechanisms influence gene expression and can explain how interactions between genetics and the environment result in particular phenotypes during development. The extent to which this epigenetic effect contributes to phenotype heritability in age-related macular degeneration (AMD) is currently ill defined. However, emerging evidence suggests that epigenetic changes are relevant to AMD and as such provide an exciting new avenue of research for AMD. This review addresses information on the impact of posttranslational modification of the genome on the pathogenesis of AMD, such as DNA methylation changes affecting antioxidant gene expression, hypoxia-regulated alterations in chromatin structure, and histone acetylation status in relation to angiogenesis and inflammation. It also contains information on the role of non-coding RNA-mediated gene regulation in AMD at a posttranscriptional (before translation) level. Our aim was to review the epigenetic mechanisms that cause heritable changes in gene activity without changing the DNA sequence. We also describe some long-term alterations in the transcriptional potential of a cell, which are not necessarily heritable but remains to be defined in the future. Increasing understanding of the significance of common and rare genetic variants and their relationship to epigenetics and environmental influences may help in establishing methods to assess the risk of AMD. This in turn may allow new therapeutic interventions for the leading cause of central vision impairment in patients over the age of 50 years in developed countries. Search strategy
   We searched the MEDLINE/PubMed database following MeSH suggestions for articles including the terms: 'ocular epigenetic mechanisms', 'human disease epigenetics', and 'age-related macular degeneration genetics'. The headline used to locate related articles in PubMed was 'epigenetics in ocular disease', and to restrict search, we used the headlines 'DNA methylation in age related macular degeneration', 'altered gene expression in AMD pathogenesis'. A manual search was also based on references from these articles as well as review articles.
C1 [Gemenetzi, M.; Lotery, A. J.] Univ Southampton, Southampton Eye Unit, Southampton, Hants, England.
   [Lotery, A. J.] Univ Southampton, Southampton Univ Hosp, Fac Med, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Univ Hosp, Fac Med, South Lab & Path Block,Mailpoint 806, Southampton, Hants, England.
EM a.j.lotery@soton.ac.uk
CR Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001
   ADAMS J, 2008, NAT ED, V1, P129
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Barile GR, 2007, CURR MOL MED, V7, P758, DOI 10.2174/156652407783220778
   Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008
   Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Cui JG, 2004, NEUROCHEM RES, V29, P1731, DOI 10.1023/B:NERE.0000035809.70905.8a
   Cui JG, 2007, NEUROREPORT, V18, P115, DOI 10.1097/WNR.0b013e32801198bc
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0
   FREDERICK JM, 1982, J COMP NEUROL, V210, P65, DOI 10.1002/cne.902100108
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He SK, 2013, MOL VIS, V19, P665
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416
   JENNE DE, 1991, J BIOL CHEM, V266, P11030
   Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001
   Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Li MF, 2010, AAPS J, V12, P309, DOI 10.1208/s12248-010-9194-0
   Li YY, 2012, NEUROREPORT, V23, P168, DOI 10.1097/WNR.0b013e32834f4eb4
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Lukiw WJ, 2011, J TOXICOL ENV HEAL A, V74, P1460, DOI 10.1080/15287394.2011.618973
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1
   Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Payne Andrew J, 2013, Mo Med, V110, P429
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Pocrnich CE, 2009, CAN J OPHTHALMOL, V44, P431, DOI 10.3129/i09-109
   Pogue AI, 2011, J INORG BIOCHEM, V105, P1434, DOI 10.1016/j.jinorgbio.2011.05.012
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Scholl HP, 2007, MOL VIS, V13, P196
   Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Skalsky RL, 2007, J VIROL, V81, P12836, DOI 10.1128/JVI.01804-07
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Takata K, 2012, J PHARMACOL SCI, V118, P331, DOI 10.1254/jphs.11R10FM
   Tang YH, 2009, INT HEART J, V50, P377, DOI 10.1536/ihj.50.377
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Ule J, 2013, BIOCHEM SOC T, V41, P1532, DOI 10.1042/BST20130157
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Valinluck V, 2004, NUCLEIC ACIDS RES, V32, P4100, DOI 10.1093/nar/gkh739
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Winkler B S, 1999, Mol Vis, V5, P32
   Xu SB, 2009, PROG RETIN EYE RES, V28, P87, DOI 10.1016/j.preteyeres.2008.11.003
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang CX, 2010, J CARDIOVASC TRANSL, V3, P235, DOI 10.1007/s12265-010-9164-z
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 125
TC 44
Z9 47
U1 0
U2 28
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2014
VL 28
IS 12
BP 1407
EP 1417
DI 10.1038/eye.2014.225
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6FQ
UT WOS:000346365600002
PM 25233816
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Baer, K
   Noh, SR
   Kang, SW
   Kim, ES
   Yu, SY
AF Baer, Kunho
   Noh, Sung Rae
   Kang, Se Woong
   Kim, Eung Suk
   Yu, Seung-Young
TI Angiographic Subtypes of Neovascular Age-related Macular Degeneration in
   Korean: A New Diagnostic Challenge
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   RETINAL ANGIOMATOUS PROLIFERATION; RANIBIZUMAB; THERAPY; ASSOCIATION
AB Neovascular age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly population. Several classifications schemes have been developed to provide subtypes of neovascular AMD, which are known to be associated with visual prognosis. However, there is still a large proportion of patient with ambiguous findings according to current classification criteria. In this study, we classified treatment-naive neovascular AMD patients using novel angiographic classification system and investigated the incidence and clinical characteristics of AMD subtypes. Among 339 eyes, five AMD subtypes were identified: 41 (12.1%) with classic choroidal neovascularization (CNV), 30 (8.8%) with occult CNV, 91(26.8%) with microaneurysmal choroidal vasculopathy (MCV), 123 (36.3%) with polypoidal choroidal vasculopathy (PCV), and 54 (15.9%) with retinal angiomatous proliferation (RAP). MCV was younger than RAP (P < 0.001). Classic CNV presented with worse visual acuity compared with MCV at baseline (P < 0.001). Central macular subfield thickness was highest in RAP, and lowest in MCV (P = 0.036). Subfoveal choroidal thickness was highest in MCV, and lowest in RAP (P < 0.001). There was a significant difference in visual acuity at 12 months among five subtypes (P = 0.046). Our results highlight the importance of angiography for identifying AMD subtypes, particularly the novel MCV group being distinct from other subtypes.
C1 [Baer, Kunho] Dongguk Univ, Ilsan Hosp, Dept Ophthalmol, Goyang, South Korea.
   [Noh, Sung Rae; Kim, Eung Suk; Yu, Seung-Young] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Kang, Se Woong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Dongguk University; NHIS Ilsan Hospital; Kyung Hee University; Kyung Hee
   University Hospital; Sungkyunkwan University (SKKU); Samsung Medical
   Center
RP Yu, SY (通讯作者)，Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
EM syyu@khu.ac.kr
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2007, JPN J OPHTHALMOL, V51, P216, DOI 10.1007/s10384-006-0430-1
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peiretti E, 2015, RETINA-J RET VIT DIS, V35, P1360, DOI 10.1097/IAE.0000000000000529
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yuzawa M, 2015, INVEST OPHTH VIS SCI, V56, P3998, DOI 10.1167/iovs.15-17207
NR 29
TC 5
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 4
PY 2019
VL 9
AR 9701
DI 10.1038/s41598-019-46235-3
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IH1AL
UT WOS:000474223600047
PM 31273295
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fukuda, Y
   Sakurada, Y
   Yoneyama, S
   Kikushima, W
   Sugiyama, A
   Matsubara, M
   Tanabe, N
   Iijima, H
AF Fukuda, Yoshiko
   Sakurada, Yoichi
   Yoneyama, Seigo
   Kikushima, Wataru
   Sugiyama, Atsushi
   Matsubara, Mio
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI Clinical and genetic characteristics of pachydrusen in patients with
   exudative age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; SEVERITY SCALE; EYE DISEASE; DRUSEN; RISK; SPOTS
AB We investigated the clinical and genetic characteristics of patients with unilateral exudative age-related macular degeneration (AMD), including typical AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation, in whom pachydrusen was seen. Patients with unilateral exudative AMD with at least a 12-month follow-up period were included. According to the fellow eye condition, 327 consecutive patients were classified into 4 groups: Group 0: no drusen (42.8%), Group 1: pachydrusen (12.2%), Group 2: soft drusen (30.3%), Group 3: pseudodrusen with or without soft drusen (14.7%). Development of exudative AMD in the fellow eye was retrospectively studied for a 60-month period and this inter-group comparisons were performed. Genotyping was performed for ARMS2 A69S and CFH I62V. The thickness of the choroid in the fellow eyes increased significantly in Group 1 than in other groups (all P < 1.0 x 10(-7)). The development of exudative AMD in the fellow eye was significantly less frequent in Group 1 than in Groups 2 or 3 (P = 0.022 and 0.0015, respectively). Risk allele frequency of ARMS2 A69S was significantly lower in Group 1 than in Group 2 and 3 (all P < 1.0 x 10(-4)). Patients with pachydrusen have genetic and clinical characteristics distinct from those of soft drusen and pseudodrusen.
C1 [Fukuda, Yoshiko; Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Sugiyama, Atsushi; Matsubara, Mio; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
CR Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kawashima-Kumagai K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07526-9
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2018, GRAEF ARCH CLIN EXP, V256, P99, DOI 10.1007/s00417-017-3847-y
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 26
Z9 26
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 15
PY 2019
VL 9
AR 11906
DI 10.1038/s41598-019-48494-6
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IQ3VX
UT WOS:000480680800020
PM 31417165
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ogino, T
   Takeda, M
   Imaizumi, H
   Okushiba, U
AF Ogino, Tetsuo
   Takeda, Muneyasu
   Imaizumi, Hiroko
   Okushiba, Utako
TI Photodynamic therapy for age-related macular degeneration in Japanese
   patients: Results after one year
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; JAT study; photodynamic therapy;
   polypoidal choroidal vasculopathy; TAP study
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RANDOMIZED CLINICAL-TRIALS; BEAVER
   DAM EYE; REPORT NO. 1; VISUAL-ACUITY; NEOVASCULARIZATION SECONDARY;
   VERTEPORFIN; MACULOPATHY; TAP; PREVALENCE
AB Purpose: To evaluate the effects of photodynamic therapy (PDT) with verteporfin 1 year after treatment in Japanese patients with age-related macular degeneration (AMD) and subfoveal choroidal neovascularization.
   Methods: Between May 2004 and March 2005, PDT was performed on 102 eyes of 98 patients (60 men and 38 women) with AMD and subfoveal choroidal neovascularization. Patients were followed for at least 1.2 months after PDT.
   Results: The mean visual acuities in logarithm of the minimum angle of resolution (logMAR) units were 0.978 at baseline, 0.919 at 3 months, 0.895 at 6 months, 0.892 at 9 months, and 0.874 at 12 months. After PDT, the logMAR visual acuity improved by > 03 logMAR units or more in 28 eyes (27%) and deteriorated by > 0.3 logMAR units or more in 13 eyes (13%). Stable or improved vision was achieved in 93% of patients with polypoidal choroidal vasculopathy (PCV).
   Conclusions: The visual outcome in our patients was similar to that of an earlier major Japanese study, and similar to or better than outcomes in Western studies. Differences between Caucasians and Japanese might influence the characteristics of PCV. It is possible that PDT is more effective for AMD patients with PCV than for other AMD patients. Further observations and longer follow-up are necessary.
C1 Sapporo City Gen Hosp, Dept Ophthalmol, Chuo Ku, Sapporo, Hokkaido 0608604, Japan.
C3 Sapporo City General Hospital
RP Ogino, T (通讯作者)，Sapporo City Gen Hosp, Dept Ophthalmol, Chuo Ku, W 13,N 11, Sapporo, Hokkaido 0608604, Japan.
EM oginot@sapmed.ac.jp
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 21
Z9 30
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY-JUN
PY 2007
VL 51
IS 3
BP 210
EP 215
DI 10.1007/s10384-007-0436-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177UX
UT WOS:000247179100008
PM 17554484
DA 2022-11-30
ER

PT J
AU Jiang, W
   Chiou, GCY
AF Jiang, Wei
   Chiou, George C. Y.
TI Development of age-related macular degeneration experimental models
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; model
ID ENDOTHELIAL GROWTH-FACTOR; SUB-RPE DEPOSITS; PIGMENT EPITHELIAL-CELLS;
   CHOROIDAL NEOVASCULARIZATION; TRANSGENIC MICE; ANIMAL-MODEL; MOUSE
   MODEL; RETINAL DEGENERATION; BRUCHS MEMBRANE; DIETARY-FAT
AB We reviews different experimental models of age-related macular degeneration (AMD) used in recent studies. The most widely used one is Laser-induced choroidal neovascularization (CNV), which represents the late severe stage in the exudative form of AMD. Other models are based on several different pathogenesis, like geographic atrophy, drusen formation or multifactorial effects, like age, light, high fat, etc It is hoped that this article could become a good reference for researchers who need to choose suitable models for AMD study.
C1 [Chiou, George C. Y.] Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
   Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center
RP Chiou, GCY (通讯作者)，Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
EM chiou@medicine.tamhsc.edu
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferrington DA, 2006, EXP EYE RES, V83, P638, DOI 10.1016/j.exer.2006.03.003
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hoffmann S, 2006, GRAEF ARCH CLIN EXP, V244, P376, DOI 10.1007/s00417-004-1104-7
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ionita M A, 2002, Oftalmologia, V54, P82
   Ionita M A, 2003, Oftalmologia, V58, P29
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kinose F, 2005, MOL VIS, V11, P366
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Raz-Prag D, 2006, INVEST OPHTH VIS SCI, V47, P3603, DOI 10.1167/iovs.05-1527
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Samkoe KS, 2003, J BIOMED OPT, V8, P410, DOI 10.1117/1.1577117
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tanaka N, 2006, MOL THER, V13, P609, DOI 10.1016/j.ymthe.2005.08.024
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
NR 52
TC 0
Z9 0
U1 1
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2009
VL 2
IS 3
BP 189
EP 194
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BM
UT WOS:000282933900001
DA 2022-11-30
ER

PT J
AU Ehlers, JP
   Maldonado, R
   Sarin, N
   Toth, CA
AF Ehlers, Justis P.
   Maldonado, Ramiro
   Sarin, Neeru
   Toth, Cynthia A.
TI TREATMENT OF NON-AGE-RELATED MACULAR DEGENERATION SUBMACULAR DISEASES
   WITH MACULAR TRANSLOCATION SURGERY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adult vitelliform; Best disease; macular degeneration; macular
   translocation surgery; translocation surgery; MTS; myopic
   degenerationvv; submacular disease; POHS; ocular histoplasmosis
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; 360-DEGREES PERIPHERAL
   RETINECTOMY; VISUAL FUNCTION; MYOPIA; RANIBIZUMAB; RETINOTOMY;
   MANAGEMENT; DYSTROPHY
AB Purpose: To evaluate the use of macular translocation surgery 360 in blinding submacular diseases other than age-related macular degeneration.
   Methods: A retrospective, consecutive case review was performed of subjects treated with macular translocation surgery 360 for a submacular disease other than age-related macular degeneration. Primary outcome was change in visual acuity. Clinical data were collected and analyzed, including demographics, visual acuity, imaging features, surgery details, and complications.
   Results: The review identified 16 subjects who had undergone macular translocation surgery 360 from 1996 to 2009 for submacular diseases other than age-related macular degeneration. These diseases included Best disease (n = 2), angioid streaks (n = 1), pathologic myopia (n = 3), punctate inner choroidopathy (n = 2), presumed ocular histoplasmosis syndrome (n = 3), central serous chorioretinopathy (n = 1), adult-onset vitelliform macular dystrophy (n = 3), and North Carolina macular dystrophy (n = 1). Mean preop visual acuity was 20/135 (range, 20/50-20/500). A <= 3-line acuity loss was seen in 13 of 16 (81%) subjects. Mean postop visual acuity was 20/110 (range, 20/40-20/1,000). The most common postop complications included epiretinal membrane (50%), cystoid macular edema (31%), residual diplopia (25%), retinal detachment (13%), and recurrent choroidal neovascularization (13%). Mean follow-up was 28 months (range, 4-61 months).
   Conclusion: Macular translocation surgery 360 may be considered in subjects with progressive bilateral vision loss from various conditions other than age-related macular degeneration. Although a significant number of complications occurred, a large percentage of subjects gained >3 lines of visual acuity (38%) and achieved a final visual acuity of >= 20/50 (31%). RETINA 31: 1337-1346, 2011
C1 [Ehlers, Justis P.; Maldonado, Ramiro; Sarin, Neeru; Toth, Cynthia A.] Duke Eye Ctr, Retina Serv, Durham, NC USA.
C3 Duke University
RP Toth, CA (通讯作者)，Duke Univ, Med Ctr, Box 3802, Durham, NC 27710 USA.
EM Cynthia.toth@duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Maldonado, Ramiro/0000-0002-8440-2095
CR Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Eckardt C, 2004, GRAEF ARCH CLIN EXP, V242, P456, DOI 10.1007/s00417-004-0922-y
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hamelin N, 2002, AM J OPHTHALMOL, V133, P530, DOI 10.1016/S0002-9394(02)01335-1
   Klevering BJ, 2004, OPHTHALMOLOGY, V111, P546, DOI 10.1016/j.ophtha.2003.06.010
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Mateo Carlos, 2004, Semin Ophthalmol, V19, P29, DOI 10.1080/08820530490520013
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ng EWM, 2004, OPHTHALMOLOGY, V111, P1889, DOI 10.1016/j.ophtha.2004.03.037
   Querques G, 2009, CLIN OPHTHALMOL, V3, P693
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2001, AM J OPHTHALMOL, V131, P390, DOI 10.1016/S0002-9394(00)00809-6
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
NR 18
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2011
VL 31
IS 7
BP 1337
EP 1346
DI 10.1097/IAE.0b013e31820668cf
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 794CA
UT WOS:000292871700014
PM 21487342
DA 2022-11-30
ER

PT J
AU Matsumiya, W
   Honda, S
   Kusuhara, S
   Tsukahara, Y
   Negi, A
AF Matsumiya, Wataru
   Honda, Shigeru
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Negi, Akira
TI Effectiveness of intravitreal ranibizumab in exudative age-related
   macular degeneration (AMD): comparison between typical neovascular AMD
   and polypoidal choroidal vasculopathy over a 1 year follow-up
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal ranibizumab; Polypoidal choroidal vasculopathy; Typical
   neovascular age-related macular degeneration; One-year outcome
ID PHOTODYNAMIC THERAPY; DOSING REGIMEN; BEVACIZUMAB; EFFICACY; SAFETY;
   VERTEPORFIN
AB Background: The effects of intravitreal ranibizumab (IVR) against exudative age-related macular degeneration (AMD) may be different associated with the lesion phenotype. This study was conducted to compare the outcomes of IVR between two different phenotypes of exudative AMD: typical neovascular AMD (tAMD) and polypoidal choroidal vasculopathy (PCV).
   Methods: This is a retrospective cohort study of 54 eyes from 54 subfoveal exudative AMD patients (tAMD 24, PCV 30 eyes). Three consecutive IVR treatments (0.5 mg) were performed every month, followed by re-injections as needed. Change in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were then compared between the tAMD and PCV groups over 12 months of follow-up.
   Results: The mean BCVA was significantly improved (-0.11 logMAR units) at month 3 after the initial IVR (p < 0.001, Wilcoxon signed-rank test), and was sustained up to 12 months in all AMD patients (p = 0.02). In the subgroup analysis, the tAMD group showed a significant improvement in their mean BCVA (-0.06, -0.17, -0.15 and -0.16 logMAR units at 1, 3, 6 and 12 months, respectively), but there was only a slight but non-significant improvement in the PCV group. The improvement in the BCVA was significantly greater in the tAMD group than in the PCV group (p = 0.043, repeated measures ANOVA) over 12 months. Both phenotypes showed significant improvements in the CRT during 12 months after the initial IVR.
   Conclusions: IVR is an effective therapy for tAMD and PCV in the BCVA improvement in Japanese patients over 12 months of follow-up. The phenotype of tAMD showed a significantly better outcome with IVR than PCV in terms of BCVA improvement.
C1 [Matsumiya, Wataru; Honda, Shigeru; Kusuhara, Sentaro; Tsukahara, Yasutomo; Negi, Akira] Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kusuhara, Sentaro/0000-0002-6458-539X
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S. H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S. H.). The
   funding organization had no role in the design or conduct of this
   research.
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wada H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029351
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 40
TC 26
Z9 28
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 4
PY 2013
VL 13
AR 10
DI 10.1186/1471-2415-13-10
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 129PA
UT WOS:000317852500001
PM 23557322
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Feng, C
   Nielsen, MK
   Sorensen, TL
   Subhi, Y
AF Feng, Chen
   Nielsen, Marie Krogh
   Sorensen, Torben Lykke
   Subhi, Yousif
TI Systemic levels of C-reactive protein in patients with age-related
   macular degeneration: A systematic review with meta-analyses
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Review
DE Retinal ageing; Age-related macular degeneration; C-reactive protein;
   Inflammation
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; RISK-FACTORS;
   POLYMORPHISM INTERACTION; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS;
   ENDOTHELIAL DYSFUNCTION; CIRCULATING MONOCYTES; OXIDATIVE STRESS;
   PLASMA-LEVELS
AB Ageing of the retina is associated with the gradual accumulation of basal deposits and the formation of drusen. However, in some individuals this process is exacerbated and causes development of age-related macular degeneration. Late features of age-related macular degeneration include geographic atrophy of the neuroretina or choroidal neovascularization. Such changes lead to blurred vision, metamorphopsia, and scotoma, and is the leading cause of vision loss in developed countries. Chronic low-grade inflammation has been investigated because of its relationship to ageing and its role in the gap between chronological and biological ageing. Here, we systematically reviewed studies investigating systemic C-reactive protein in patients with age-related macular degeneration. We identified 53 studies with 60,598 participants (10,392 patients and 38,901 controls). Our meta-analyses revealed that early age-related macular degeneration was not associated to systemic C-reactive protein (Cohen's d = 0.03 [-0.04 to 0.10]; OR =1.06 [0.93-1.20]; P = 0.39) whereas late age-related macular degeneration (Cohen's d = 0.38 [0.24 to 0.51]; OR =1.99 [1.55-2.52]; P < 0.0001), and neovascular age-related macular degeneration (Cohen's d = 0.40 [0.24 to 0.56]; OR = 2.07 [1.55-2.76]; P < 0.0001) was associated with a small-to-moderate increase in systemic C-reactive protein. Our review provides an overview of this extensively studied field, provide summary estimates that provide insight into when and to what extent systemic C-reactive protein is associated with age-related macular degeneration, and help in distinguishing the potentially reversible disease processes from that of irreversible retinal ageing.
C1 [Feng, Chen; Sorensen, Torben Lykke] Wenzhou Med Univ, Eye Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Nielsen, Marie Krogh; Sorensen, Torben Lykke; Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif] Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
C3 Wenzhou Medical University; University of Copenhagen; Rigshospitalet;
   University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
CR Alic L, 2020, P NATL ACAD SCI USA, V117, P9942, DOI 10.1073/pnas.1913970117
   Ambreen F, 2015, MOL VIS, V21, P985
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arifoglu HB, 2016, AGING CLIN EXP RES, V28, P853, DOI 10.1007/s40520-015-0377-5
   Barbosa D, 2013, INVEST OPHTH VIS SCI, V54
   Black RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166468
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bonyadi MHJ, 2016, OPHTHALMIC GENET, V37, P465, DOI 10.3109/13816810.2015.1120317
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P422, DOI 10.1080/13816810.2016.1251947
   Bruunsgaard H, 2006, DAN MED BULL, V53, P285
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Cohn AC, 2013, AM J EPIDEMIOL, V177, P933, DOI 10.1093/aje/kws332
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Custodero C, 2018, AGEING RES REV, V46, P42, DOI 10.1016/j.arr.2018.05.004
   Danulescu R, 2013, MED-SURG J, V117, P328
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fernandez-Robredo P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01862
   Fischer WH, 1999, J IMMUNOL, V162, P453
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Furuya-Kanamori L, 2018, INT J EVID-BASED HEA, V16, P195, DOI 10.1097/XEB.0000000000000141
   Ghorbanihaghjo A, 2010, J MENS HEALTH, V7, P85, DOI 10.1016/j.jomh.2009.10.003
   Goverdhan S.V., 2005, INVEST OPHTHALMOL VI, V46, P1147
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Han XK, 2020, EUR J EPIDEMIOL, V35, P139, DOI 10.1007/s10654-019-00598-z
   Hashemi R, 2018, INTERV MED APPL SCI, V10, P127, DOI 10.1556/1646.10.2018.22
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Higgins J., 2019, COCHRANE HDB SYSTEMA, Vsecond, DOI DOI 10.1002/9781119536604
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jabs DA, 2019, AM J OPHTHALMOL, V199, P230, DOI 10.1016/j.ajo.2018.12.002
   Javadzadeh A, 2015, INT J OPHTHALMOL-CHI, V8, P556, DOI 10.3980/j.issn.2222-3959.2015.03.21
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonas JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204263
   KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Lange CAK, 2012, OPHTHALMOLOGICA, V227, P115, DOI 10.1159/000331418
   Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Manyal R., 2017, IND J CLIN BIOCH, V32, pS1
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Min JK, 2015, OCUL IMMUNOL INFLAMM, V23, P205, DOI 10.3109/09273948.2014.891755
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Pansarasa O, 2019, AGEING RES REV, V54, DOI 10.1016/j.arr.2019.100935
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodrigo F, 2018, INDIAN J OPHTHALMOL, V66, P89, DOI 10.4103/ijo.IJO_488_17
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Silva AS, 2012, MOL VIS, V18, P2288
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Soheilian R, 2017, INT OPHTHALMOL, V37, P1161, DOI 10.1007/s10792-016-0373-6
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subramani S, 2010, Med J Malaysia, V65, P36
   Taniguchi H, 2013, J ATHEROSCLER THROMB, V20, P903, DOI 10.5551/jat.18796
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Ye J, 2012, INVEST OPHTH VIS SCI, V53, P3885, DOI 10.1167/iovs.12-9820
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Zaliuniene D, 2008, EUR J OPHTHALMOL, V18, P384, DOI 10.1177/112067210801800312
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
NR 105
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD OCT
PY 2020
VL 191
AR 111353
DI 10.1016/j.mad.2020.111353
PG 16
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA OC9WT
UT WOS:000579507600022
PM 32937187
DA 2022-11-30
ER

PT J
AU Lu, XM
   Sun, XD
AF Lu, Xinmin
   Sun, Xiaodong
TI Profile of conbercept in the treatment of neovascular age-related
   macular degeneration
SO Drug Design Development and Therapy
LA English
DT Review
DE conbercept; KH902; age-related macular degeneration; vascular
   endothelial growth factor; neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; TISSUE
   XENOGRAFT MODEL; INTRAVITREAL RANIBIZUMAB; FUSION PROTEIN; VEGF-TRAP;
   BEVACIZUMAB; FP3; PHARMACOKINETICS; AFLIBERCEPT
AB In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD. VEGF regulates angiogenesis, enhances vascular permeability, and drives the formation of choroidal neovascularization. As a result of the introduction of anti-VEGF drugs, the incidence of blindness from neovascular AMD has greatly reduced. Anti-VEGF drugs are used as a first-line treatment for neovascular AMD. The most recent anti-VEGF drug is conbercept, also named KH902, which was approved for the treatment of neovascular AMD by the China Food and Drug Administration in December 2013. In this review, recent clinical information regarding the use of conbercept to treat neovascular AMD is summarized. Conbercept is a soluble receptor decoy that blocks all isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF, which has a high binding affinity to VEGF and a long half-life in vitreous. Preclinical studies have demonstrated its anti-angiogenesis activity in both ocular neovascular disease models and tumor models. Clinical trials of conbercept have shown its superior efficacy and safety. Patients respond well even with 3-month treatment intervals following loading doses once a month for 3 months. The potential therapeutic effect of conbercept on the treatment of polypoidal choroidal vasculopathy, a special type of neovascular AMD, is also promising. In summary, conbercept is a new treatment option for ophthalmologists and their patients and may help address the limitations of current anti-VEGF drugs.
C1 [Lu, Xinmin; Sun, Xiaodong] Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Sch Med, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
FU National Science Foundation for Distinguished Young Scholars [81425006];
   National Basic Research Program of China 973 Program [2011CB707506];
   National Natural Science Foundation of China [81271030]; Shanghai
   Creative Key Medical Research [1341195400]
FX This study is supported by grants from the National Science Foundation
   for Distinguished Young Scholars (81425006), National Basic Research
   Program of China 973 Program (2011CB707506), the National Natural
   Science Foundation of China (81271030), and Shanghai Creative Key
   Medical Research (1341195400).
CR Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bi TA, 2013, HEPATO-GASTROENTEROL, V60, P1950, DOI 10.5754/hge.13157
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Danis P, 2014, ANG EX DEG FEBR 8
   Dong XF, 2012, INT J MOL MED, V30, P126, DOI 10.3892/ijmm.2012.968
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Gao WL, 2012, HEPATO-GASTROENTEROL, V59, P2543, DOI 10.5754/hge12159
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang J, 2012, DIABETES OBES METAB, V14, P644, DOI 10.1111/j.1463-1326.2012.01584.x
   Ijiri S, GRAEFES ARCH CLIN EX
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Jin KT, 2012, ONCOL LETT, V3, P1052, DOI 10.3892/ol.2012.603
   Jin KT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028384
   Kaiser P, 2014, ANG EX DEG FEBR 8
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Khetan V, 2004, SURV OPHTHALMOL, V49, P620, DOI 10.1016/j.survophthal.2004.08.015
   Kisko K, 2011, FASEB J, V25, P2980, DOI 10.1096/fj.11-185397
   Lan HR, 2013, EXP THER MED, V5, P85, DOI 10.3892/etm.2012.773
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Wang F, 2013, GRAEF ARCH CLIN EXP, V251, P2131, DOI 10.1007/s00417-013-2392-6
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu DC, 2012, MOL THER, V20, P938, DOI 10.1038/mt.2011.285
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhou AY, 2013, OPHTHALMIC RES, V50, P180, DOI 10.1159/000353437
NR 63
TC 80
Z9 96
U1 4
U2 20
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2015
VL 9
DI 10.2147/DDDT.S67536
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CG4TL
UT WOS:000353279600001
PM 25960634
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Saade, C
   Ganti, B
   Marmor, M
   Freund, KB
   Smith, RT
AF Saade, Celine
   Ganti, Bhaskar
   Marmor, Michael
   Freund, K. Bailey
   Smith, R. Theodore
TI Risk characteristics of the combined geographic atrophy and choroidal
   neovascularisation phenotype in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POOLED FINDINGS; VARIANT; GENE
AB Aim To investigate the risk characteristics of the combined geographic atrophy (GA) and choroidal neovascularisation (CNV) phenotype of age-related macular degeneration (AMD) compared to GA or CNV.
   Methods Patients with advanced AMD were identified and divided into three groups using multimodal imaging: patients with GA in at least one eye, patients with CNV in at least one eye, and patients with simultaneous GA and CNV in at least one eye. Epidemiologic and clinical factors were gathered from patient questionnaires. Genotypes for age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) were determined.
   Results 42 patients with GA or CNV, and 16 patients with combined GA/CNV were identified. Patients with the combined phenotype were older (86.4 vs 81.8 years, p=0.049), and had a higher prevalence of advanced AMD in the fellow eye (81.3% vs 31.0%, p<0.001). CFH and ARMS2 risk alleles were not associated with the combined phenotype.
   Conclusions The combined GA/CNV phenotype has similar epidemiologic, clinical, and genetic features as GA and CNV, but occurs at an older age and is more associated with advanced AMD in the fellow eye, suggesting that all these phenotypes are part of the same spectrum of disease and that the combined phenotype represents an even more advanced form of AMD than either GA or CNV.
C1 [Saade, Celine; Ganti, Bhaskar; Freund, K. Bailey; Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
   [Marmor, Michael] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
   [Marmor, Michael] NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA.
   [Marmor, Michael] NYU, Sch Med, Dept Med, New York, NY 10016 USA.
   [Freund, K. Bailey] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 New York University; New York University; New York University; New York
   University; Columbia University; Vitreous Retina Macula Consultants of
   New York; Manhattan Eye Ear & Throat Hospital
RP Smith, RT (通讯作者)，NYU, Langone Med Ctr, Dept Ophthalmol, 462 First Ave,NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; smith,
   theodore/0000-0002-1693-943X; Marmor, Michael/0000-0001-6605-2661
FU National Institutes of Health/National Eye Institute [R01 EY015520];
   Research to Prevent Blindness; Foundation Fighting Blindness; Macula
   Foundation, Inc.; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source:
   NIH RePORTER
FX Research was supported by National Institutes of Health/National Eye
   Institute grant R01 EY015520 (RTS), unrestricted funds from Research to
   Prevent Blindness (RTS), an individual investigator research award from
   the Foundation Fighting Blindness (RTS), and The Macula Foundation, Inc.
   (KBF). The funding organisations had no role in the study design; in the
   collection, analysis, and interpretation of the data; in the writing of
   the report; or in the decision to submit for publication.
CR [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   [Anonymous], 1993, Arch Ophthalmol, V111, P1189
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kansagara D, 2012, NUTR SUPPLEMENTS AGE
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 25
TC 13
Z9 14
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1729
EP 1732
DI 10.1136/bjophthalmol-2014-305005
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0AB
UT WOS:000345284300024
PM 25091949
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hogg, RE
   Woodside, JV
   McGrath, A
   Young, IS
   Vioque, JL
   Chakravarthy, U
   de Jong, PT
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Fletcher, AE
AF Hogg, Ruth E.
   Woodside, Jayne V.
   McGrath, Alanna
   Young, Ian S.
   Vioque, Jesus L.
   Chakravarthy, Usha
   de Jong, Paulus T.
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Fletcher, Astrid E.
TI Mediterranean Diet Score and Its Association with Age-Related Macular
   Degeneration The European Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; VITAMIN-C;
   MACULOPATHY; PREVALENCE; CONSUMPTION; PROGRESSION; ADHERENCE; OLDER
AB Purpose: To examine associations between adherence to a Mediterranean diet and prevalence of age-related macular degeneration (AMD) in countries ranging from Southern to Northern Europe.
   Design: Cross-sectional, population-based epidemiologic study.
   Participants: Of 5060 randomly sampled people aged 65 years or older from 7 study centers across Europe (Norway, Estonia, United Kingdom, France, Italy, Greece, and Spain), full dietary data were available in 4753. The mean age of participants was 73.2 years (standard deviation, 5.6), and 55% were women.
   Methods: Participants underwent an eye examination and digital retinal color photography. The images were graded at a single center. Dietary intake during the previous 12 months was assessed by using a semiquantitative food-frequency questionnaire (FFQ). A previously published Mediterranean Diet Score (MDS) was used to classify participants according to their responses on the FFQ. Multivariable logistic regression was used to investigate the association of the MDS score and AMD, taking account of potential confounders and the multicenter study design.
   Main Outcome Measures: Images were graded according to the International Classification System for age-related maculopathy and stratified using the Rotterdam staging system into 5 exclusive stages (AMD 0-4) and a separate category of large drusen (>= 125 mu m). Age-related macular degeneration 4 included neovascular AMD (nvAMD) and geographic atrophy (GA).
   Results: Increasing MDS was associated with reduced odds of nvAMD in unadjusted and confounder-adjusted analysis. Compared with the lowest MDS adherence (<= 4 score), those in the highest category MDS adherence (>6 score) showed lower odds of nvAMD (odds ratio, 0.53; 0.27-1.04; P trend = 0.01). The association with MDS did not differ by Y204H risk allele (P = 0.89). For all early AMD (grade 1-3), there was no relationship with MDS (P trend = 0.9). There was a weak trend (P = 0.1) between MDS and large drusen; those in the highest category of MDS had 20% reduced odds compared with those in the lowest (P = 0.05).
   Conclusions: This study adds to the limited evidence of the protective effect of adherence to a Mediterranean dietary pattern in those with late AMD, although it does not support previous reports of a relationship with genetic susceptibility. Interventions to encourage the adoption of the Mediterranean diet should be developed, and methods by which such behavior change can be achieved and maintained investigated. (C) 2016 by the American Academy of Ophthalmology
C1 [Hogg, Ruth E.; Woodside, Jayne V.; McGrath, Alanna; Young, Ian S.; Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
   [Vioque, Jesus L.] Univ Miguel Hernandez, CIBER Epidemiol & Salud Publ, Alicante, Spain.
   [de Jong, Paulus T.] Acad Med Ctr, Dept Ophthalmol, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Univ Bergen, Stavanger Univ Hosp, Eye Dept, Bergen, Norway.
   [Soubrane, Gisele] Univ Paris 12, Clin Ophthalmol, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, Osped Civile Maggiore, Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, Thessaloniki, Greece.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
C3 Queens University Belfast; CIBER - Centro de Investigacion Biomedica en
   Red; CIBERESP; Universidad Miguel Hernandez de Elche; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; National Institute for Health Development -
   Estonia; Stavanger University Hospital; University of Bergen; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); University of Verona; Aristotle
   University of Thessaloniki; University of London; London School of
   Hygiene & Tropical Medicine
RP Woodside, JV (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM j.woodside@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Vioque, Jesus/0000-0002-2284-148X;
   Topouzis, Fotis/0000-0002-8966-537X; Rahu, Mati/0000-0001-7172-8048;
   Woodside, Jayne/0000-0002-5691-4659; Chakravarthy,
   Usha/0000-0002-2606-3734; Young, Ian/0000-0003-3890-3152
FU European Union; European Commission; Ministry of Education and Science,
   Tallinn, Estonia [01921112s02]; Fondo de Investigacion Sanitaria
   (Madrid, Spain) [FIS 01/1692E, RCESP C 03/09]; Oficina de Ciencia y
   Tecnologia Generalitat Valenciana (Valencia, Spain) [CTGCA/2002/06];
   Thomas Pocklington Trust; MRC [G0901530, MR/J000388/1] Funding Source:
   UKRI; Medical Research Council [MC_CF023241, G0901530, MR/J000388/1]
   Funding Source: researchfish
FX I.S.Y.: Grant - European Union.; A.E.F.: Grant and travel support -
   European Commission.; M.R.: Financed by the Ministry of Education and
   Science, Tallinn, Estonia (Target funding no. 01921112s02). Additional
   funding in Alicante was received from the Fondo de Investigacion
   Sanitaria (Madrid, Spain) (grant nos. FIS 01/1692E, RCESP C 03/09) and
   Oficina de Ciencia y Tecnologia Generalitat Valenciana (Valencia, Spain)
   (grant no. CTGCA/2002/06). The Thomas Pocklington Trust funded
   conversion of dietary data to nutrients.
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   CRAFT NE, 1992, J CHROMATOGR, V589, P171, DOI 10.1016/0021-9673(92)80019-Q
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holland B, 1991, MCCANCE WIDD COMP FO
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lasheras C, 2000, AM J CLIN NUTR, V71, P987
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Martinez-Gonzalez MA, 2004, EUR J CLIN NUTR, V58, P1550, DOI 10.1038/sj.ejcn.1602004
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Schwingshackl L, 2014, INT J CANCER, V135, P1884, DOI 10.1002/ijc.28824
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   US Department of Agriculture ARS, 2005, USDA NAT NUTR DAT ST
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vioque J, 2007, BRIT J NUTR, V97, P977, DOI 10.1017/S0007114507659017
   VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25
   Willett W., 1990, NUTR EPIDEMIOLOGY
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 42
TC 41
Z9 41
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2017
VL 124
IS 1
BP 82
EP 89
DI 10.1016/j.ophtha.2016.09.019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK4KZ
UT WOS:000393896900026
PM 27825655
OA Green Accepted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Veritti, D
   Sarao, V
   Lanzetta, P
AF Veritti, Daniele
   Sarao, Valentina
   Lanzetta, Paolo
TI Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Bevacizumab Choroidal
   neovascularization; Pegaptanib; Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   THERAPY; SAFETY; PHARMACOKINETICS; INJECTION; TRIAL
AB Purpose: Neovascular age-related macular degeneration (AMD) is a leading cause of blindness, with an increasing incidence as the elderly population expands. Large, multi-center, randomized, clinical trials have been conducted exploring the safety and efficacy of anti-VEGF treatments. This paper aims to discuss the safety and efficacy of pegaptanib, ranibizumab, aflibercept and bevacizumab. New therapeutic agents and treatment strategies are also discussed. Procedures: Evidence available from prospective, multicenter, clinical studies and from a selective literature search is utilized to present the results of VEGF inhibition in neovascular AMD and to generate evidence-based recommendations. Results: Anti-VEGF treatment is indicated in choroidal neovascularization with active disease and produces a significant benefit in visual acuity. Conclusions:With the advent of anti-VEGF therapy, the prognosis of choroidal neovascularization has changed dramatically. Data from well-conducted clinical trials suggest that approved anti-VEGF drugs are effective and well tolerated. Copyright (C) 2012 S. Karger AG, Basel
C1 [Veritti, Daniele; Sarao, Valentina; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, IT-33100 Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria della Misericordia, IT-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348
CR [Anonymous], QLT ANN 12 MONTH RES
   [Anonymous], 12 MONTH RES DENA LI
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gower EW, 2011, FORT LAUD ARVO M
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2011, ORL AM AC OPHTH ANN
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lai TY, 2010, FORT LAUD ARVO M
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Moshfeghi AA, 2005, OPHTHALMOLOGY, V112, P1035
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 48
Z9 48
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 227
SU 1
BP 11
EP 20
DI 10.1159/000337154
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 935VG
UT WOS:000303549700003
PM 22517121
DA 2022-11-30
ER

PT J
AU Thi, HCT
   Rambaud, C
   Despretz, P
   Boucart, M
AF Thi Ha Chau Tran
   Rambaud, Camille
   Despretz, Pascal
   Boucart, Muriel
TI Scene Perception in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; NATURAL SCENES; LOW-VISION;
   RECOGNITION; PSYCHOPHYSICS; CATEGORIZATION; DISABILITY; PERIMETRY;
   CONTRAST
AB PURPOSE. To assess the scene gist recognition in eyes with age-related macular degeneration (AMD) and to study the relationship between scene recognition and macular function.
   METHODS. Twenty-seven patients with age-related macular degeneration with a visual acuity lower than 20/50 and 17 age-matched controls were included. All patients underwent a visual field test, fundus autofluorescence, and fluorescein angiography to assess the visual field defect and the lesion size. The stimuli were colored photographs of natural scenes displayed on a 30-inch screen. Two scene categorization tasks were performed: natural versus urban and indoor versus outdoor scenes. Participants were given a target (e.g., indoor scenes) and asked to press a key when they saw a picture corresponding to that target. Accuracy and response times were recorded.
   RESULTS. Patients with AMD were able to accomplish both categorization tasks with a high correct detection rate (above 75% correct), though performance was lower than in controls for both natural/urban scenes and indoor/outdoor scenes. Patients with AMD were more accurate and faster for natural/urban scenes than for indoor/outdoor scenes, but performance did not differ between the two categories in controls. No significant correlation was found between performance for scene categorization and clinical variables such as visual acuity, type of AMD, size of the scotoma, and size of the lesion.
   CONCLUSIONS. Scene gist recognition can be accomplished with the low spatial resolution of peripheral vision. These results support the "scene-centered approach" that initial scene recognition is based on the global scene properties and not on the objects it contains. (Invest Ophthalmol Vis Sci. 2010;51:6868-6874) DOI:10.1167/iovs.10-5517
C1 [Thi Ha Chau Tran; Despretz, Pascal; Boucart, Muriel] Univ Lille Nord France, CNRS, Lab Neurosci & Pathol Fonctionnell, Lille, France.
   [Thi Ha Chau Tran; Rambaud, Camille] Hop St Vincent De Paul, Serv Ophtalmol, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille
RP Boucart, M (通讯作者)，Hop Roger Salengro, CHRU Lille, Lab Neurosci & Pathol Fonctionnelles, F-59037 Lille, France.
EM m-boucart@chru-lille.fr
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU Centre National de la Recherche Scientifique
FX Supported by a grant from the Programme Interdisciplinaire
   "longevite-vieillissement" by the Centre National de la Recherche
   Scientifique (MB).
CR Balas B, 2009, J VISION, V9, DOI [10.1167/9.2.16, 10.1167/9.12.13]
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Boucart M, 2010, VIS COGN, V18, P839, DOI 10.1080/13506280903287845
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Greene MR, 2009, PSYCHOL SCI, V20, P464, DOI 10.1111/j.1467-9280.2009.02316.x
   Greene MR, 2009, COGNITIVE PSYCHOL, V58, P137, DOI 10.1016/j.cogpsych.2008.06.001
   Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220
   Henderson JM, 1999, ANNU REV PSYCHOL, V50, P243, DOI 10.1146/annurev.psych.50.1.243
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Joubert OR, 2007, VISION RES, V47, P3286, DOI 10.1016/j.visres.2007.09.013
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Larson AM, 2009, J VISION, V9, DOI 10.1167/9.10.6
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Levy I, 2001, NAT NEUROSCI, V4, P533, DOI 10.1038/87490
   Mace MJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005927
   Mace MJM, 2005, EUR J NEUROSCI, V21, P2007, DOI 10.1111/j.1460-9568.2005.04029.x
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   Oliva A, 2001, INT J COMPUT VISION, V42, P145, DOI 10.1023/A:1011139631724
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   Oliva Aude, 2005, P251, DOI 10.1016/B978-012375731-9/50045-8
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Rousselet GA, 2005, VIS COGN, V12, P852, DOI 10.1080/13506280444000553
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   TANNER WP, 1954, PSYCHOL REV, V61, P401, DOI 10.1037/h0058700
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Torralba A, 2003, NETWORK-COMP NEURAL, V14, P391, DOI 10.1088/0954-898X/14/3/302
NR 34
TC 24
Z9 24
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6868
EP 6874
DI 10.1167/iovs.10-5517
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500100
PM 21123770
DA 2022-11-30
ER

PT J
AU Zou, YH
   Chiou, GCY
AF Zou, Yan-Hong
   Chiou, George C. Y.
TI Pharmacological therapy in age -related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; pharmacological therapy; photodynamic
   therapy; vascular endothelial growth factor; anecortave acetate;
   choroidal blood flow
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   PHOTODYNAMIC THERAPY; RAT MODEL; FACTOR VEGF; INHIBITION; LUTEIN;
   MACULOPATHY
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in individuals aged over 65 in the United States and other industrialized nations. Till now, we have limited choices of treatment for this kind of disease. Treatment available can be grouped into two major categories: physical and pharmacological therapies. The former received extensive attention with little success whereas the latter attracted new attention with great hope of success. The pharmacological therapies include photodynamic therapy (PDT), steroids, vascular endothelial growth factor (VEGF) inhibitors, extracellular matrix(ECM) modifiers, gene therapy, nutrition supplements, choroidal blood flow facilitators and the like. PDT treatment is the only available effective treatment for certain forms of neovascular AMD. Anecortave acetate, as a synthetic derivative of cortisol, might stabilize vision in patients with predominantly classic subfoveal choroidal neovascularization (CNV) for up to 6 months through subtenon juxtascleral depot application. Intravitreous injection of VEGF aptamer stabilized or improved vision in 87.5% of patients with subfoveal CNV 3 months after treatment. Malfunction of choroidal blood flow is found in early stage of AMD. Elevation of intravascular pressure is the crucial hemodynamic factor in age-related macular degeneration, resulting in a decrease of the blood flow of choriocapillaries. Chain reactions are triggered which lead to retinal pigment epithelium(RPE) degeneration, Bruch's membrane breakdown,CNV formation,AMD and blindness in the end. Therefore, specific drugs that can increase the choroidal blood flow could be very useful to prevent AMD from developing and worsening.Although most of them are still in the experimental stage,it is hopeful to find a way to treat AMD at the early stage and to prevent the disease to be triggered and developed.
C1 [Chiou, George C. Y.] Texas A&M Univ, Syst Hlth Sci Ctr, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
   Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Pharmacol & Toxicol, Coll Med, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center
RP Chiou, GCY (通讯作者)，Texas A&M Univ, Syst Hlth Sci Ctr, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
EM chiou@medicine.tamhsc.edu
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   AUEONG KG, 2002, AGE RELATED MACULAR, P289
   AUGUSTIN AJ, 2004, GRAEFES ARCH CLIN EX, V28
   Baffi J, 2001, INVEST OPHTH VIS SCI, V42, pS227
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Blumenkranz MS, 2002, AGE-RELATED MACULAR DEGENERATION, P203
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro PA, 2002, AGE-RELATED MACULAR DEGENERATION, P267
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Csaky K, 2003, OPHTHALMOLOGY, V110, P879
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxel CJ, 2002, AGE-RELATED MACULAR DEGENERATION, P225
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friberg TR, 2002, AGE-RELATED MACULAR DEGENERATION, P343
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GILLIES M, 2002, CLIN EXPT OPHTHALM S, V30, pA64
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   IP M, 2000, OPHTHAL SURG LAS IM, V31, P359
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaven C, 2001, OPHTHALMOLOGICA, V215, P284, DOI 10.1159/000050875
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koh HJ, 2004, INVEST OPHTH VIS SCI, V45, P635, DOI 10.1167/iovs.03-0735
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   McCabe FJ, 2002, AGE-RELATED MACULAR DEGENERATION, P325
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Peterson K, 1996, SCIENCE, V271, P441
   PRZYDRYGA J, 2002, CLIN EXPT OPHTHALM S, V30, pA66
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rao PK, 2002, AGE-RELATED MACULAR DEGENERATION, P277
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Renno RZ, 2004, ARCH OPHTHALMOL-CHIC, V122, P1002, DOI 10.1001/archopht.122.7.1002
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rogers AH, 2002, AGE-RELATED MACULAR DEGENERATION, P259
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sippy BD, 2002, AGE-RELATED MACULAR DEGENERATION, P1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yoken J, 2002, AGE-RELATED MACULAR DEGENERATION, P181
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 73
TC 0
Z9 0
U1 1
U2 6
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2008
VL 1
IS 3
BP 264
EP 272
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13QY
UT WOS:000207682500016
DA 2022-11-30
ER

PT J
AU Velez-Montoya, R
   Oliver, SCN
   Olson, JL
   Fine, SL
   Quiroz-Mercado, H
   Mandava, N
AF Velez-Montoya, Raul
   Oliver, Scott C. N.
   Olson, Jeffrey L.
   Fine, Stuart L.
   Quiroz-Mercado, Hugo
   Mandava, Naresh
TI CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION
   Genetics, Epidemiology, and Prevention
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE genetic; epidemiology; risk factors; age-related macular degeneration;
   pharmacoeconomics; VEGF; prevention
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION;
   CHLAMYDIA-PNEUMONIAE INFECTION; APOLIPOPROTEIN-E POLYMORPHISMS; FACTOR
   HY402H POLYMORPHISM; TOLL-LIKE RECEPTOR-3; EYE DISEASE; GEOGRAPHIC
   ATROPHY; VISUAL IMPAIRMENT
AB Purpose: To address the most dynamic and current issues concerning human genetics, risk factors, pharmacoeconomics, and prevention regarding age-related macular degeneration.
   Methods: An online review of the database Pubmed and Ovid was performed, searching for the key words: age-related macular degeneration, AMD, pharmacoeconomics, risk factors, VEGF, prevention, genetics and their compound phrases. The search was limited to articles published since 1985 to date. All returned articles were carefully screened and their references were manually reviewed for additional relevant data. The webpage www.clinicaltrials.gov was also accessed in search of relevant research trials.
   Results: A total of 366 articles were reviewed, including 64 additional articles extracted from the references and 25 webpages and online databases from different institutions. At the end, only 244 references were included in this review.
   Conclusion: Age-related macular degeneration is a complex multifactorial disease that has an uneven manifestation around the world but with one common denominator, it is increasing and spreading. The economic burden that this disease poses in developed nations will increase in the coming years. Effective preventive therapies need to be developed in the near future.
C1 [Velez-Montoya, Raul; Oliver, Scott C. N.; Olson, Jeffrey L.; Fine, Stuart L.; Mandava, Naresh] Univ Colorado, Sch Med, Rocky Mt Lions Eye Inst, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Quiroz-Mercado, Hugo] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Ophthalmol, Denver, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Denver Health Medical Center; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   Denver
RP Velez-Montoya, R (通讯作者)，Univ Colorado, Sch Med, Rocky Mt Lions Eye Inst, Dept Ophthalmol, Anschutz Med Campus,1675 Aurora Court, Aurora, CO 80045 USA.
EM raul.velez-montoya@ucdenver.edu
OI Oliver, Scott/0000-0002-3654-6502
FU Genetech; Ophthotech; Thrombogenics; National Eye Institute, NIH
FX Supported by Genetech, Ophthotech, and Thrombogenics (S.C.N.O., J.L.O.,
   and N.M.) and the National Eye Institute, NIH (S.L.F.).
CR Access Economics Pty Limited for the Centre for Eye Research Australia, 2006, IMP AG REL MAC DEG D
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2012, AM J MED GENET A, V158A, pix
   Apte RS, 2001, OPHTHALMOLOGY, V108, P693, DOI 10.1016/S0161-6420(00)00653-9
   Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Bender NK, 1998, J THROMB THROMBOLYS, V5, P257, DOI 10.1023/A:1008852127668
   Bernanke David H., 2002, Anatomical Record, V269, P198, DOI 10.1002/ar.10139
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brierley KL, 2012, CANCER J, V18, P303, DOI 10.1097/PPO.0b013e3182609490
   BROWN LF, 1997, EXS, V79, P233
   Buhrmann RHW, 2006, FORECASTING VISION L
   Bureau USC. United States Census Bureau, 2009, US POP PROJ
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Carroll DN, 2002, ANN PHARMACOTHER, V36, P1950, DOI 10.1345/aph.1A314
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   CROSS CE, 1993, ANN NY ACAD SCI, V686, P72, DOI 10.1111/j.1749-6632.1993.tb39157.x
   Cross CE, 1993, ANN NY ACAD SCI, V686, P89
   CTEU Bristol, 2009, RAND CONTR TRIAL ALT
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
   ECB, 2006, MONTHLY B DEC
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eritsland J, 1996, AM J CARDIOL, V77, P31, DOI 10.1016/S0002-9149(97)89130-8
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Foran SE, 2003, ARCH PATHOL LAB MED, V127, P1603
   Foster WJ, 2010, BRIT J OPHTHALMOL, V94, P1118, DOI 10.1136/bjo.2009.170282
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602, DOI 10.1016/s0161-6420(91)32252-8
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Holloway T B, 1928, Trans Am Ophthalmol Soc, V26, P206
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarvik GP, 1997, ANN EPIDEMIOL, V7, P357, DOI 10.1016/S1047-2797(97)00028-8
   Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kimoto K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/852183
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2010, CURR OPIN OPHTHALMOL, V21, P190, DOI 10.1097/ICU.0b013e32833866c8
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Narendran N, 2005, EYE, V19, P11, DOI 10.1038/sj.eye.6701435
   Neroev V V, 2007, Vestn Oftalmol, V123, P23
   Nicolucci A, 2010, DIABETIC MED, V27, P1041, DOI 10.1111/j.1464-5491.2010.03055.x
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Relf M, 1997, CANCER RES, V57, P963
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Roy S, 2002, FREE RADICAL RES, V36, P1023, DOI 10.1080/1071576021000006662
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seng KC, 2008, EUR J HUM GENET, V16, P554, DOI 10.1038/ejhg.2008.12
   Serhan CN, 2005, PHARMACOL THERAPEUT, V105, P7, DOI 10.1016/j.pharmthera.2004.09.002
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Taylor EN, 2009, J AM SOC NEPHROL, V20, P2253, DOI 10.1681/ASN.2009030276
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   United Nations, 2009, WORLD POP AG 2009
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Velez-Montoya R, 2010, CLIN OPHTHALMOL, V4, P947, DOI 10.2147/OPTH.S11650
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weger M, 2007, MOL VIS, V13, P1274
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yoshida T, 2007, MOL VIS, V13, P545
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 243
TC 87
Z9 90
U1 0
U2 37
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2014
VL 34
IS 3
BP 423
EP 441
DI 10.1097/IAE.0000000000000036
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DL
UT WOS:000336960100005
PM 24285245
DA 2022-11-30
ER

PT J
AU Horie-Inoue, K
   Inoue, S
AF Horie-Inoue, Kuniko
   Inoue, Satoshi
TI Genomic aspects of age-related macular degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Review
DE Age-related macular degeneration (AMD); Complement factor H (CFH);
   Age-related maculopathy susceptibility; protein 2 (ARMS2); HTRA1;
   Genome-wide association study (GWAS); Single nucleotide polymorphism
   (SNP)
ID COMPLEMENT-FACTOR-H; RETINAL-PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; HTRA1 PROMOTER POLYMORPHISM; CHROMOSOME 10Q26 LOCUS;
   CIGARETTE-SMOKING; WIDE ASSOCIATION; JAPANESE POPULATION; GENE
   POLYMORPHISM; RISK-FACTORS
AB Age-related macular degeneration (AMD) is a major late-onset posterior eye disease that causes central vision to deteriorate among elderly populations. The predominant lesion of AMD is the macula, at the interface between the outer retina and the inner choroid. Recent advances in genetics have revealed that inflammatory and angiogenic pathways play critical roles in the pathophysiology of AMD. Genome-wide association studies have identified ARMS2/HTRA1 and CFH as major AMD susceptibility genes. Genetic studies for AMD will contribute to the prevention of central vision loss, the development of new treatment, and the maintenance of quality of vision for productive aging. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Hidaka City, Saitama 3501231, Japan.
   [Inoue, Satoshi] Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Tokyo, Japan.
C3 Saitama Medical University; University of Tokyo
RP Horie-Inoue, K (通讯作者)，Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, 1371-1 Yamane, Hidaka City, Saitama 3501231, Japan.
EM khorie07@saitama-med.ac.jp
FU Mitsui Sumitomo Insurance Welfare Foundation; Saitama Medical
   University; Ministry of Education, Culture, Sports, Science, and
   Technology (MEXT)
FX This work was supported by Research Grant (K.H.-I.) from Mitsui Sumitomo
   Insurance Welfare Foundation, Institutional Grant (K.H.-I.) from Saitama
   Medical University, Grants-in-Aid, and Support Project of Strategic
   Research Center in Private Univer-sities (S.I.) from the Ministry of
   Education, Culture, Sports, Science, and Technology (MEXT). The authors
   gratefully acknowledge Drs. Takashi Tsuchihashi, Keisuke Mori, and Shin
   Yoneya for their clinical data and suggestions.
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Coscas G., 2014, AM J OPHTHALMOL
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche L.G., 2014, ANN REV GENOMICS HUM
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hirt-Minkowski P, 2010, NEPHRON CLIN PRACT, V114, pC219, DOI 10.1159/000276545
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hueck W, 1912, BEITR PATHOL ANAT AL, V54, P68
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R., 2014, AM J OPHTHALMOL
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kunchithapautham K., 2014, J BIOL CHEM, P7
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lopes J, 2013, AM J PATHOL, V182, P2241, DOI 10.1016/j.ajpath.2013.02.011
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mckay GJ, 2010, MOL VIS, V16, P194
   Messias-Reason IJ, 2003, TISSUE ANTIGENS, V62, P308, DOI 10.1034/j.1399-0039.2003.00101.x
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Minor EA, 2013, INVEST OPHTH VIS SCI, V54, P5913, DOI 10.1167/iovs.13-12273
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Oishi M, 2013, INVEST OPHTH VIS SCI, V54, P7492, DOI 10.1167/iovs.13-12825
   Okamoto H, 2006, MOL VIS, V12, P156
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P2976, DOI 10.1167/iovs.10-6232
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weger M, 2007, MOL VIS, V13, P1274
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 MIA
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yoshida T, 2007, MOL VIS, V13, P545
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zettler PJ, 2014, JAMA INTERN MED, V174, P493, DOI 10.1001/jamainternmed.2013.14706
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 204
TC 41
Z9 42
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 19
PY 2014
VL 452
IS 2
SI SI
BP 263
EP 275
DI 10.1016/j.bbrc.2014.08.013
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AQ5PJ
UT WOS:000342860800008
PM 25111812
DA 2022-11-30
ER

PT J
AU Bakthavatsalam, M
   Ng, DSC
   Lai, FHP
   Tang, FY
   Brelen, ME
   Tsang, CW
   Lai, TYY
   Cheung, CYL
AF Bakthavatsalam, Malini
   Ng, Danny Siu-Chun
   Lai, Frank Hiu-Ping
   Tang, Fang Yao
   Brelen, Marten Erik
   Tsang, Chi Wai
   Lai, Timothy Yuk-Yau
   Cheung, Carol Yim-Lui
TI Choroidal structures in polypoidal choroidal vasculopathy, neovascular
   age-related maculopathy, and healthy eyes determined by binarization of
   swept source optical coherence tomographic images
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Optical coherence tomography; Choroidal imaging
ID MACULAR DEGENERATION; THICKNESS; VASCULATURE; CHORIOCAPILLARIS; FEATURES
AB Purpose To evaluate quantitatively the choroidal vascularity in polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (AMD) patients compared to healthy controls.
   Methods All eyes underwent swept source optical coherence tomography (OCT), and choroidal images were binarized into blood vessels lumen and stroma. The choroidal vascular index (CVI) was defined as the ratio of luminal area (LA) over total choroidal area of the subfoveal region with a width of 1500 mu m.
   Results The study included 73 patients with neovascular AMD or PCV with mean +/- standard deviation (SD) age of 71.8 +/- 9.3 years, which was older than the mean age of 65.1 +/- 10.8 years of 72 healthy eyes from control group (p < 0.01). The 44 PCV eyes had significantly higher mean SFCT of 214.23 +/- 95.21 mu m than neovascular AMD eyes (172.74 +/- 96.48 mu m, p = 0.03) and greater luminal area (0.23 +/- 0.09 mm(2) vs. 0.19 +/- 0.08 mm(2), p = 0.05). After adjusting for age, axial length, and gender in multivariate regression analysis, the SFCT of PCV and neovascular AMD eyes were not significantly different from healthy eyes (195.55 +/- 93.11 mu m), but the CVI of both PCV (64.94 +/- 5.43%, p = 0.01) and neovascular AMD (62.54 +/- 5.57%, p = < 0.01) were significantly lower than control (68.53 +/- 5.91%).
   Conclusion Despite physiological changes of choroidal vasculature due to aging, the choroidal morphology is different in PCV, neovascular AMD and healthy eyes, which has implication on disease pathogenesis.
C1 [Bakthavatsalam, Malini; Ng, Danny Siu-Chun; Tang, Fang Yao; Brelen, Marten Erik; Tsang, Chi Wai; Lai, Timothy Yuk-Yau; Cheung, Carol Yim-Lui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, 4-F Hong Kong Eye Hosp,147K Argyle St, Mongkok, Hong Kong, Peoples R China.
   [Lai, Frank Hiu-Ping] Caritas Med Ctr, Dept Ophthalmol, New Kowloon, Hong Kong, Peoples R China.
   [Brelen, Marten Erik] Prince Wales Hosp, Dept Ophthalmol, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Ng, DSC (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, 4-F Hong Kong Eye Hosp,147K Argyle St, Mongkok, Hong Kong, Peoples R China.
EM dannyng@cuhk.edu.hk
RI Brelen, Marten E./D-1133-2016; Ng, Danny Siu Chun/AAG-3081-2020; Cheung,
   Carol Y./G-7895-2016; Lai, Timothy Y Y/AAC-2120-2020; Cheung,
   Carol/AAF-1101-2020; TANG, Fangyao/AAF-2824-2020
OI Ng, Danny Siu Chun/0000-0001-6566-1019; Lai, Timothy Y
   Y/0000-0002-7832-6428; Cheung, Carol/0000-0002-9672-1819; Cheung,
   Carol/0000-0003-0869-859X; Lai, Hiu Ping/0000-0002-4446-3790
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Duan L, 2013, OPT EXPRESS, V21, P15787, DOI 10.1364/OE.21.015787
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Niblack W, 1986, ADV COMPUTER GRAPHIC
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Seidel G, 2015, AM J OPHTHALMOL, V159, P365, DOI 10.1016/j.ajo.2014.11.002
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
NR 50
TC 29
Z9 31
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2017
VL 255
IS 5
BP 935
EP 943
DI 10.1007/s00417-017-3591-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV0ND
UT WOS:000401436500009
PM 28150038
DA 2022-11-30
ER

PT J
AU Amato, A
   Arrigo, A
   Borghesan, F
   Aragona, E
   Vigano, C
   Saladino, A
   Bandello, F
   Parodi, MB
AF Amato, Alessia
   Arrigo, Alessandro
   Borghesan, Federico
   Aragona, Emanuela
   Vigano, Chiara
   Saladino, Andrea
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI BASELINE SATTLER LAYER-CHORIOCAPILLARIS COMPLEX THICKNESS CUTOFFS
   ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION PROGRESSION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age related macular degeneration; OCT; choroidal thickness; Sattler
   layer; Haller layer
ID CHOROIDAL THICKNESS; GEOGRAPHIC ATROPHY; MORPHOMETRIC-ANALYSIS; VISUAL
   IMPAIRMENT; BRUCHS MEMBRANE; RISK-FACTORS; PREVALENCE; HALLERS; EYES
AB Purpose: To assess the relationship between choroidal overall and sublayer thickness and age-related macular degeneration (AMD) stage progression. Methods: A prospective, observational case series was performed. Two hundred and sixty-two eyes of 262 patients with different stages of AMD were imaged by optical coherence tomography. Age-related macular degeneration stage, choroidal thickness, Sattler layer-choriocapillaris complex thickness (SLCCT), and Haller layer thickness were determined at the baseline visit, at a 1-year follow-up visit, at a 2-year follow up visit, and at a final visit (performed after a mean of 5 +/- 1 year from the baseline visit). Results: Baseline AMD stages were distributed as follows: early AMD (30 eyes; 12%), intermediate AMD (97 eyes; 39%), and late AMD (126 eyes; 49%). At the final follow-up, AMD stages were so distributed: early AMD (14 eyes; 6%), intermediate AMD (83 eyes; 33%), and late AMD (156 eyes; 61%). Each group showed a statistically significant decrease in choroidal thickness values over the entire follow-up (P < 0.001), and SLCCT reduction was associated with AMD progression (P < 0.001). Moreover, SLCCT quantitative cutoffs of mu m and mu m were associated with a moderate and high probability of AMD progression, respectively, and SLCCT quantitative cutoffs of mu m and mu m implied a moderate and high probability of macular neovascularization onset, respectively. Conclusion: Progressive choroidal impairment contributes to AMD progression. Among choroidal layers, a reduced SLCCT is a promising biomarker of disease worsening, and its quantitative evaluation could help to identify patients at higher risk of stage advancement.
C1 [Amato, Alessia; Arrigo, Alessandro; Borghesan, Federico; Aragona, Emanuela; Vigano, Chiara; Saladino, Andrea; Bandello, Francesco; Parodi, Maurizio Battaglia] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Amato, A (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM amato.alessia@hsr.it
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bouteleux V, 2019, GRAEF ARCH CLIN EXP, V257, P699, DOI 10.1007/s00417-018-04216-8
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Broadhead GK, 2017, OPHTHALMIC RES, V58, P27, DOI 10.1159/000464447
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Kumar JB, 2019, BRIT J OPHTHALMOL, V103, P918, DOI 10.1136/bjophthalmol-2018-312625
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2022
VL 42
IS 9
BP 1683
EP 1692
DI 10.1097/IAE.0000000000003530
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W9IM
UT WOS:000842662100009
PM 35594570
DA 2022-11-30
ER

PT J
AU Naysan, J
   Jung, JJ
   Dansingani, KK
   Balaratnasingam, C
   Freund, KB
AF Naysan, Jonathan
   Jung, Jesse J.
   Dansingani, Kunal K.
   Balaratnasingam, Chandrakumar
   Freund, K. Bailey
TI TYPE 2 (SUBRETINAL) NEOVASCULARIZATION IN AGE-RELATED MACULAR
   DEGENERATION ASSOCIATED WITH PURE RETICULAR PSEUDODRUSEN PHENOTYPE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anatomical classification; choroidal
   neovascularization; drusen; neovascularization; reticular pseudodrusen;
   subretinal drusenoid deposits
ID CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; DRUSENOID DEPOSITS;
   INTRAVITREAL BEVACIZUMAB; CLINICAL CHARACTERISTICS; LESION TYPE; 2ND
   EYES; RANIBIZUMAB; SYMMETRY; PREVALENCE
AB Purpose:To report the association of pure type 2 neovascularization (NV) in age-related macular degeneration occurring almost exclusively in patients with reticular pseudodrusen.Methods:An observational retrospective cohort study of all eyes receiving antivascular endothelial growth factor therapy for newly diagnosed neovascular age-related macular degeneration by a single practitioner over a 6-year period. Only patients with treatment-naive, pure type 2 NV who also had either pre-neovascular imaging of the study eye or imaging of a nonneovascular fellow eye available to determine baseline characteristics including drusen type and choroidal thickness were incuded.Results:Of 694 patients treated for neovascular age-related macular degeneration, only 8 met the inclusion criteria with pure type 2 NV. Of these, 7 (88%) had exclusively reticular pseudodrusen (5 in the nonneovascular fellow eye, 2 in the study eye before developing NV). Six (75%) patients in the affected neovascular eye and 6 (75%) in the fellow nonneovascular eye had choroidal thickness <120 m. Mean follow-up was 46 months (range, 3.0-63.3). Best-corrected vision improved from 20/89 (range, 20/30-20/796) at baseline to 20/60 (range, 20/20-20/399) at last follow-up.Conclusion:Pure type 2 NV is rare in age-related macular degeneration, occurring almost exclusively in patients with reticular pseudodrusen and thin choroids.
C1 [Naysan, Jonathan; Jung, Jesse J.; Dansingani, Kunal K.; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
   [Naysan, Jonathan; Jung, Jesse J.; Dansingani, Kunal K.; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Naysan, Jonathan; Jung, Jesse J.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Naysan, Jonathan; Freund, K. Bailey] North Shore Long Isl Jewish Hlth Syst, Dept Ophthalmol, Manhasset, NY USA.
   [Jung, Jesse J.; Freund, K. Bailey] Columbia Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; Northwell Health; Columbia
   University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018; Dansingani, Kunal/D-1025-2015
OI Freund, K. Bailey/0000-0002-7888-9773; Dansingani,
   Kunal/0000-0002-7430-8601
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat
   Hospital, New York; Macula Foundation, Inc, New York, NY
FX Supported by LuEsther T. Mertz Retinal Research Center, Manhattan Eye,
   Ear and Throat Hospital, New York and The Macula Foundation, Inc, New
   York, NY.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baxter SL, 2013, AM J OPHTHALMOL, V156, P468, DOI 10.1016/j.ajo.2013.04.040
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   D'Ambrosio E, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/450428
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Erol MK, 2014, SEMIN OPHTHALMOL, V29, P108, DOI 10.3109/08820538.2013.839716
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Furuta M, 2013, RETINA-J RET VIT DIS, V33, P71, DOI 10.1097/IAE.0b013e318263ceb4
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gliem M, 2013, RETINA-J RET VIT DIS, V33, P1300, DOI 10.1097/IAE.0b013e3182914d2b
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Liang F, 2009, GRAEF ARCH CLIN EXP, V247, P1285, DOI 10.1007/s00417-009-1098-2
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Milani P, 2012, CLIN OPHTHALMOL, V6, P1885, DOI 10.2147/OPTH.S34649
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Parodi MB, 2014, BRIT J OPHTHALMOL, V98, P519, DOI 10.1136/bjophthalmol-2013-304237
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Pauleikhoff D, 1990, Fortschr Ophthalmol, V87, P429
   Prasad Arun, 2009, Retin Cases Brief Rep, V3, P125, DOI 10.1097/ICB.0b013e31815e9903
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sainz Gomez C, 2002, Arch Soc Esp Oftalmol, V77, P123
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P67, DOI 10.1111/j.1442-9071.2011.02719.x
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 56
TC 19
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP 449
EP 457
DI 10.1097/IAE.0000000000000758
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG1MW
UT WOS:000371833200003
PM 26383711
DA 2022-11-30
ER

PT J
AU Kang, JH
   Wu, J
   Cho, EY
   Ogata, S
   Jacques, P
   Taylor, A
   Chiu, CJ
   Wiggs, JL
   Seddon, JM
   Hankinson, SE
   Schaumberg, DA
   Pasquale, LR
AF Kang, Jae H.
   Wu, Juan
   Cho, Eunyoung
   Ogata, Soshiro
   Jacques, Paul
   Taylor, Allen
   Chiu, Chung-Jung
   Wiggs, Janey L.
   Seddon, Johanna M.
   Hankinson, Susan E.
   Schaumberg, Debra A.
   Pasquale, Louis R.
TI Contribution of the Nurses' Health Study to the Epidemiology of
   Cataract, Age-Related Macular Degeneration, and Glaucoma
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; VISUAL IMPAIRMENT;
   PREVALENCE; RISK; PSEUDOEXFOLIATION; SUSCEPTIBILITY; DISEASE; LOCI
AB Objectives. To review the contribution of the Nurses' Health Study (NHS) to understanding the genetic and lifestyle factors that influence the risk of cataract, age-related macular degeneration, and glaucoma.
   Methods. We performed a narrative review of the publications of the NHS between 1976 and 2016.
   Results. The NHS has helped to elucidate the roles of genetics, lifestyle factors (e.g., cigarette smoking associated with cataract extraction and age-related macular degeneration), medical conditions (e.g., diabetes associated with cataract extraction and glaucoma), and dietary factors (e.g., greater carotenoid intake and lower glycemic diet associated with lower risk of age-related macular degeneration) in the etiology of degree and progression of lens opacities, cataract extraction, age-related macular degeneration, primary open-angle glaucoma, and exfoliation glaucoma.
   Conclusions. The findings from the NHS, combined with those of other studies, have provided compelling evidence to support public health recommendations for helping to prevent age-related eye diseases: abstinence from cigarette smoking, maintenance of healthy weight and diabetes prevention, and a healthy diet rich in fruits and vegetables.
C1 [Kang, Jae H.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Kang, Jae H.; Wiggs, Janey L.; Pasquale, Louis R.] Harvard Med Sch, Boston, MA USA.
   [Wu, Juan] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Ogata, Soshiro] Osaka Univ, Grad Sch Med, Dept Hlth Promot Sci, Suita, Osaka, Japan.
   [Jacques, Paul; Taylor, Allen; Chiu, Chung-Jung] Tufts Univ, Lab Nutr & Vis Res, Jean Mayer USDA Human Nutr Ctr Aging, Boston, MA 02111 USA.
   [Wiggs, Janey L.; Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Seddon, Johanna M.] Tufts Univ, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Tufts Med Ctr,Sch Med, Boston, MA 02111 USA.
   [Hankinson, Susan E.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA 01003 USA.
   [Schaumberg, Debra A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard T.H. Chan School of
   Public Health; Brown University; Osaka University; Tufts University;
   United States Department of Agriculture (USDA); Harvard University;
   Massachusetts Eye & Ear Infirmary; Tufts Medical Center; Tufts
   University; University of Massachusetts System; University of
   Massachusetts Amherst; Harvard University; Harvard T.H. Chan School of
   Public Health
RP Kang, JH (通讯作者)，Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM nhjhk@channing.harvard.edu
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU National Institutes of Health; Arthur Ashley Foundation [UM1 CA186107,
   UM1 CA167552, EY09611, EY015473, R21 EY022766, R01 EY020928, R01
   EY022305]; Harvard Medical Distinguished Ophthalmology Scholar award;
   JSPS KAKENHI [15J03698]; Harvard Glaucoma Center of Excellence; NATIONAL
   CANCER INSTITUTE [UM1CA167552, UM1CA186107] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY020928, R01EY026979, R01EY015473,
   R21EY022766, R01EY009611, R01EY022305] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health and the
   Arthur Ashley Foundation (grants UM1 CA186107; UM1 CA167552; EY09611;
   EY015473 to L. R. P.; and R21 EY022766, R01 EY020928, and R01 EY022305
   to J. L. W); a Harvard Medical Distinguished Ophthalmology Scholar award
   (to L. R. P.); and JSPS KAKENHI (grant 15J03698 to S. O.). L. R. P. and
   J. L. W. were also supported by the Harvard Glaucoma Center of
   Excellence.
CR Altinas O, 2004, OPHTHALMOLOGICA, V218, P120, DOI 10.1159/000076148
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], POPULATION ESTIMATES
   [Anonymous], 2014, LETS MAK NEXT GEN TO
   Astrom S, 2007, ACTA OPHTHALMOL SCAN, V85, P828, DOI 10.1111/j.1600-0420.2007.00992.x
   Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482
   Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013
   Biswas S, 2004, MOL CELL BIOCHEM, V261, P151, DOI 10.1023/B:MCBI.0000028750.78760.6f
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Coleman AL, 2008, AM J OPHTHALMOL, V145, P1081, DOI 10.1016/j.ajo.2008.01.022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kumar DM, 2007, J GLAUCOMA, V16, P334
   Levi J., 2012, F FAT OBESITY THREAT
   Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, P156, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]
   Mathew MC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004567.pub2
   Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084
   National Eye Institute, 2015, FACTS CAT
   Naumann GOH, 1998, OPHTHALMOLOGY, V105, P951, DOI 10.1016/S0161-6420(98)96020-1
   Park LK, 2012, P NUTR SOC, V71, P75, DOI 10.1017/S0029665111003302
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ramdas WD, 2011, ARCH OPHTHALMOL-CHIC, V129, P767, DOI 10.1001/archophthalmol.2010.373
   Rein DB, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12818
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Saaddine JB, 2003, OPHTHALMOLOGY, V110, P253, DOI 10.1016/S0161-6420(02)01839-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shen L, 2016, AM J EPIDEMIOL, V183, P147, DOI 10.1093/aje/kwv204
   TAYLOR HR, 1980, AUST J OPHTHALMOL, V8, P289, DOI 10.1111/j.1442-9071.1980.tb00285.x
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   *US DEP HHS, 2004, 2004 SURG GEN REP HL
   Weikel KA, 2014, NUTR REV, V72, P30, DOI 10.1111/nure.12077
   West S, 2007, OPHTHAL EPIDEMIOL, V14, P173, DOI 10.1080/09286580701423151
   World Health Organization (WHO), 2013, UN EYE HLTH GLOB ACT
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
   Xu F, 2012, GRAEF ARCH CLIN EXP, V250, P1067, DOI 10.1007/s00417-011-1877-4
   Ye J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089923
   Zhou MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102972
NR 44
TC 15
Z9 17
U1 0
U2 18
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2016
VL 106
IS 9
BP 1684
EP 1689
DI 10.2105/AJPH.2016.303317
PG 6
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA EC4CB
UT WOS:000388072300036
PM 27459452
OA Green Published
DA 2022-11-30
ER

PT J
AU Ennis, S
   Jomary, C
   Mullins, R
   Cree, A
   Chen, XL
   MacLeod, A
   Jones, S
   Collins, A
   Stone, E
   Lotery, A
AF Ennis, Sarah
   Jomary, Catherine
   Mullins, Robert
   Cree, Angela
   Chen, Xaoli
   MacLeod, Alex
   Jones, Stephen
   Collins, Andrew
   Stone, Edwin
   Lotery, Andrew
TI Association between the SERPING1 gene and age-related macular
   degeneration: a two-stage case-control study
SO LANCET
LA English
DT Article
ID COMPLEMENT FACTOR-H; RANIBIZUMAB; RISK; POLYMORPHISM; METAANALYSIS;
   BEVACIZUMAB; MECHANISMS; INHIBITOR; COMPONENT; DISEASE
AB Background Age-related macular degeneration is the most prevalent form of visual impairment and blindness in developed countries. Genetic studies have made advancements in establishing the molecular cause of this disease, identifying mutations in the complement factor H (CFH) gene and a locus on chromosome 10 encompassing the HTRA1/LOC387715/ARMS2 genes. Variants in complement 3 (C3) and an HLA locus containing both factor B and C2 genes have also been implicated. We aimed to identify further genetic risk factors for this disease.
   Methods We used a case-control study design in a UK sample of patients with age-related macular degeneration (n=479) and controls (n=479) and undertook a low-density screen of 32 genes using 93 single nucleotide polymorphisms (SNPs). Genes were selected as candidates on the basis of potential functional relevance to age-related macular degeneration. Significant initial findings were confirmed by replication in an independent US cohort of 248 unrelated patients with disease and 252 controls, and by high-density genotyping around association signals.
   Findings The SNP variant rs2511989, located within intron six of the SERPING1 gene, showed highly significant genotypic association with age-related macular degeneration (uncorrected p=4.0x10(-5), corrected p=0.00372). We detected no evidence for association between disease and the other 31 candidate genes. The odds ratio for age-related macular degeneration in rs251.1989 G/A heterozygotes compared with wild type G/G homozygotes was 0 . 63 (95% CI 0 . 47-0 . 84). A similar comparison of the A/A homozygotes with the wild type yielded an odds ratio of 0 . 44 (0.31-0 . 64). We replicated the observed genotypic association in a US cohort (p=0.008). Furthermore, a secondary high-density genotyping study across the SERPING1 gene region identified five additional S N P variants similarly associated with age-related macular degeneration (rs2244169, rs2511990, rs2509897, rs1005510, and rs2511988).
   Interpretation Genetic variation in SERPING1 significantly alters susceptibility to age-related macular degeneration. SERPING1 encodes the C1 inhibitor, which has a crucial role in inhibition of complement component 1 (C1) and might implicate the classic pathway of complement activation in this disease.
   Funding Macula Vision Research Foundation, the Macular Disease Society, the Wellcome Trust, Brian Mercer Trust, the American Health Assistance Foundation, National institutes of Health, the Howard Hughes Medical Institute.
C1 [Jomary, Catherine; Cree, Angela; Chen, Xaoli; Lotery, Andrew] Southampton Gen Hosp, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
   [MacLeod, Alex; Lotery, Andrew] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   [Ennis, Sarah; Collins, Andrew] Southampton Gen Hosp, Div Human Genet, Genet Epidemiol & Bioinformat Grp, Southampton SO16 6YD, Hants, England.
   [Mullins, Robert; Stone, Edwin] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Jones, Stephen] Kings Coll London, Rayne Inst, St Thomas Hosp, London WC2R 2LS, England.
   [Stone, Edwin] Howard Hughes Med Inst, Chevy Chase, MD USA.
C3 University of Southampton; University of Southampton; University of
   Southampton; University of Iowa; Guy's & St Thomas' NHS Foundation
   Trust; University of London; King's College London; Howard Hughes
   Medical Institute
RP Lotery, A (通讯作者)，Southampton Gen Hosp, Clin Neurosci Div, Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@southampton.ac.uk
RI Collins, Andrew/A-6595-2010; Mullins, Robert F/I-6717-2013; Jomary,
   Catherine/A-2854-2011; Collins, Andrew/S-2196-2019
OI Collins, Andrew/0000-0001-7108-0771; Collins,
   Andrew/0000-0001-7108-0771; Stone, Edwin M./0000-0003-3343-4414; Lotery,
   Andrew/0000-0001-5541-4305; Cree, Angela/0000-0002-1987-8900; Mullins,
   Robert/0000-0002-5006-0891
FU Macula Vision Research Foundation (MVRF); Macular Disease Society;
   Wellcome Trust; Brian Mercer Trust; American Health Assistance
   Foundation; N I H [EY-017451, EY-016822]; Howard Hughes Medical
   Institute; NATIONAL EYE INSTITUTE [R01EY016822, R01EY017451] Funding
   Source: NIH RePORTER
FX For the UK studies. this research was supported by the Macula Vision
   Research Foundation (MVRF), the Macular Disease Society, the Wellcome
   Trust, Brian Mercer Trust, and the American Health Assistance
   Foundation. Aspects of the US-based study were Funded by the MVRF (RM),
   N I H grants EY-017451 (RM) and EY-016822 (B). and the Howard Hughes
   Medical Institute (ES). We thank Helen Griffiths, Elizabeth Faidley.
   Benjamin Roos, and Jessica Skeie for providing laboratory assistance;
   The Southampton WTCRF muses for help with sample collection; Lee Murphy
   and Angie Fawkes at the Edinburgh WTCRF: Jane Collier at KBioscience:
   and all study participants for agreeing to contribute to this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUFFONE GJ, 1985, CLIN CHEM, V31, P164
   Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510
   DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354
   DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mullins RF, 2006, MOL VIS, V12, P224
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Raftery JP, 2007, BRIT MED J, V334, P381, DOI 10.1136/bmj.39128.708565.3A
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Steemers FJ, 2005, PHARMACOGENOMICS, V6, P777, DOI 10.2217/14622416.6.7.777
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
NR 30
TC 129
Z9 132
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 22
PY 2008
VL 372
IS 9652
BP 1828
EP 1834
DI 10.1016/S0140-6736(08)61348-3
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 375KG
UT WOS:000261112000025
PM 18842294
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Aslam, T
   Delcourt, C
   Silva, R
   Holz, FG
   Leys, A
   Layana, AG
   Souied, E
AF Aslam, Tariq
   Delcourt, Cecile
   Silva, Rufino
   Holz, Frank G.
   Leys, Anita
   Garcia Layana, Alfredo
   Souied, Eric
TI Micronutrients in Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Macular degeneration; Nutrition; Micronutrients; Vitamin C;
   beta-Carotene; Vitamin E; Zinc; Lutein; Zeaxanthin; Omega-3
ID FATTY-ACID INTAKE; VITAMIN-E; ANTIOXIDANT STATUS; FISH CONSUMPTION;
   5-YEAR INCIDENCE; DIETARY-FAT; MACULOPATHY; RISK; LUTEIN; ASSOCIATIONS
AB Several lines of evidence from in vitro and in vivo studies suggest that specific micronutrients may have beneficial effects in age-related macular degeneration (AMD). Such effects appear to be complex and may include filtering short wavelength light and attenuating oxidative and inflammatory damage as well as other structural and physiological factors. There is clinical evidence for potential benefits from vitamin C, beta-carotene, vitamin E and zinc, as well as emerging epidemiological and clinical data for the carotenoids lutein and zeaxanthin and for omega-3 fatty acids. A survey of the literature suggests that some specific micronutrients may be of value in treating or preventing AMD, but further prospective studies are needed to further identify and characterize their effects and place in therapy. copyright (C) 2012 S. Karger AG, Basel
C1 [Aslam, Tariq] Univ Manchester, Manchester Royal Eye Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Aslam, Tariq] Univ Manchester, Inst Human Dev, Manchester, Lancs, England.
   [Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
   [Delcourt, Cecile] ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
   [Silva, Rufino] Univ Coimbra, Univ Hosp Coimbra, Coimbra, Portugal.
   [Silva, Rufino] AIBILI, Coimbra, Portugal.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Leys, Anita] Katholieke Univ Leuven Hosp, Louvain, Belgium.
   [Garcia Layana, Alfredo] Univ Navarra Clin, Pamplona, Spain.
   [Souied, Eric] Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; UDICE-French Research Universities; Universite de Bordeaux;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; University of Bonn; Flanders Institute
   for Biotechnology (VIB); KU Leuven; University Hospital Leuven;
   University of Navarra; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil
RP Aslam, T (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM tariq.aslam@manchester.ac.uk
RI Silva, Rufino M/J-2817-2012; Delcourt, Cecile/I-2627-2013; Aslam,
   Tariq/A-8532-2016
OI Silva, Rufino M/0000-0001-8676-0833; Delcourt,
   Cecile/0000-0002-2099-0481; Aslam, Tariq/0000-0002-9739-7280
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Carriere I, 2007, INT J VITAM NUTR RES, V77, P57, DOI 10.1024/0300-9831.77.1.57
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   1993, ARCH OPHTHALMOL, V111, P104
NR 30
TC 9
Z9 9
U1 0
U2 17
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 2
BP 75
EP 79
DI 10.1159/000343708
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085NO
UT WOS:000314621700002
PM 23171595
OA Bronze
DA 2022-11-30
ER

PT J
AU Alten, F
   Clemens, CR
   Milojcic, C
   Eter, N
AF Alten, Florian
   Clemens, Christoph R.
   Milojcic, Carolin
   Eter, Nicole
TI SUBRETINAL DRUSENOID DEPOSITS ASSOCIATED WITH PIGMENT EPITHELIUM
   DETACHMENT IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; reticular drusen; reticular
   pseudodrusen; subretinal drusenoid deposits; pigment epithelium
   detachment; scanning laser ophthalmoscopy; near-infrared reflectance;
   spectral-domain optical coherence tomography
ID FACTOR-H POLYMORPHISM; RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY;
   MACULOPATHY; RISK; PREVALENCE; PROGRESSION; ARMS2
AB Purpose: To characterize retrospectively subretinal drusenoid deposits (SDD) in patients with pigment epithelium detachment (PED) secondary to age-related macular degeneration.
   Methods: Confocal scanning laser ophthalmoscopy near-infrared reflectance images (820 nm) were recorded in 208 eyes of 104 patients with serous, drusenoid, or vascularized PED because of age-related macular degeneration in at least 1 eye. The digital images were evaluated by two independent readers with subsequent senior reader arbitration for prevalence of SDD.
   Results: Serous PED was present in only two patients and was therefore not included in the statistical analysis. Subretinal drusenoid deposits were detected in 55 of 102 (53.9%) patients in at least 1 eye. Forty-six of those 55 patients showed SDD bilaterally (83.6%). Subretinal drusenoid deposits were present in 51 (50%) right eyes and 50 (49.0%) left eyes. One hundred and forty-six of 204 eyes showed a PED secondary to age-related macular degeneration of which 111 (76%) were vascularized and 35 (24%) drusenoid. Prevalence of SDD was correlated with age (P < 0.0001) and female gender (P = 0.014), but not with the type of PED (P = 0.174). Cohen kappa statistics showed good interobserver agreement for infrared imaging (0.78 for right eyes, 0.74 for left eyes).
   Conclusion: Subretinal drusenoid deposits represent a common phenotypic characteristic in eyes with PED because of age-related macular degeneration. As described in previous studies, SDD are readily identified using confocal scanning laser ophthalmoscopy imaging technology. Future studies should pursue the pathophysiologic role and the predictive value of the presence of SDD in the development of PED and a subsequent rip of the retinal pigment epithelium. RETINA 32:1727-1732, 2012
C1 [Alten, Florian; Clemens, Christoph R.; Eter, Nicole] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
   [Milojcic, Carolin] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Munster; University of Bonn
RP Alten, F (通讯作者)，Univ Munster, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM florian.alten@ukmuenster.de
FU Novartis; Pfizer; Heidelberg Engineering; Bayer
FX Heidelberg Engineering provided the Department of Ophthalmology,
   University of Muenster, with a further Spectralis HRA+OCT for research
   purposes. FA and CRC received lecture fees (Novartis), NE received
   lecture and travel fees (Novartis, Pfizer, Heidelberg Engineering,
   Bayer). The sponsors or funding organizations had no role in the design
   or conduct of this research.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 20
Z9 20
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1727
EP 1732
DI 10.1097/IAE.0b013e3182475b03
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800004
PM 22466490
DA 2022-11-30
ER

PT J
AU Li, XX
   Hu, YH
   Sun, XD
   Zhang, JJ
   Zhang, MN
AF Li, Xiaoxin
   Hu, Yonghua
   Sun, Xiaodong
   Zhang, Junjun
   Zhang, Maonian
CA Neovasc Age-Related Macular Degene
TI Bevacizumab for Neovascular Age-related Macular Degeneration in China
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; AVASTIN THERAPY; RANIBIZUMAB; PHARMACOKINETICS;
   SAFETY
AB Objective: To evaluate 2 different dosing regimens of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) patients in China.
   Design: Multicenter, randomized, prospective, open-label clinical trial.
   Participants: One hundred eighty-five patients with active neovascular AMD, exclusion of a macular scar, choroidal neovascularization not resulting from AMD, and polypoidal choroidal vasculopathy.
   Intervention: Patients were assigned randomly to receive intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91) or every 12 weeks (regimen B, n = 94).
   Main Outcome Measures: The primary outcome measure was a comparison of the mean change in visual acuity from baseline. The secondary outcome measure was a comparison of the proportion of patients with a change in visual acuity of 15 letters or more. Adverse events were monitored.
   Results: One-hundred eighty five patients were enrolled. At 48 weeks, the increase in the mean visual acuity measurements from baseline were 12.58 letters in regimen A and 10.06 letters in regimen B (P = 0.288). At 48 weeks, the percentage of eyes losing fewer than 15 letters was 96.2% in regimen A and 93.9% in regimen B (P = 0.720). At 48 weeks, the median decrease in central retinal thickness measurements from baseline was 119 mu m in regimen A and 60 mu m in regimen B (P = 0.221). Adverse events during the 48 weeks included anterior chamber inflammation in 17 patients (18.7%) from regimen A and 9 patients (9.6%) from regimen B (P = 0.075). There were no other notable ocular adverse events in either group.
   Conclusions: Intravitreal bevacizumab improved visual acuity and decreased macular thickness in patients with neovascular AMD when dosed either every 6 weeks or every 12 weeks after 3 doses given at 6-week intervals. Although there were no statistically significant differences between the 2 regimens, the results tended to favor the group dosed every 6 weeks (regimen A).
C1 [Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
   [Hu, Yonghua] Peking Univ, Sch Publ Hlth, Beijing 100044, Peoples R China.
   [Zhang, Junjun] Sichuan Univ, Dept Ophthalmol, W China Hosp, Chengdu 610064, Peoples R China.
   [Zhang, Maonian] PLA, Dept Ophthalmol, Gen Hosp, Beijing, Peoples R China.
C3 Peking University; Shanghai Jiao Tong University; Peking University;
   Sichuan University
RP Li, XX (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, 11 Xizhimen S St, Beijing 100044, Peoples R China.
EM dr_lixiaoxin@163.com
FU National Key Technology Research and Development Program in the 11th
   Five-Year Plan of China [2006BAI02B05]
FX Supported by the National Key Technology Research and Development
   Program in the 11th Five-Year Plan of China (no. 2006BAI02B05). This
   trial is listed on ClinicalTrials. gov, number NCT01306591.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Guan GH, 1989, ZHONGHUA YAN DI BING, V5, P208
   He MG, 1994, ZHONGHUA YAN DI BING, V10, P115
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tufail A, 2010, BMJ-BRIT MED J, V340, P2459
   Wu Z Q, 1992, Zhonghua Yan Ke Za Zhi, V28, P246
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
   Zou HD, 2009, ZHONGHUA YAN KE ZA Z, V45, P786
NR 20
TC 17
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2087
EP 2093
DI 10.1016/j.ophtha.2012.05.016
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030PF
UT WOS:000310581900023
PM 22818896
DA 2022-11-30
ER

PT J
AU Liu, W
AF Liu, Wu
TI Current management of submacular hemorrhage in age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE submacular; hemorrhage; macular degeneration; surgery
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; SUBRETINAL
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; INTRAVITREAL INJECTION; SURGICAL
   REMOVAL; NATURAL-HISTORY; GAS INJECTION; DRAINAGE; SURGERY
AB Submacular Hemorrhage (SMH) in age-related macular degeneration (AMD) represents a challenging disorder for vision protection. Varied surgical interventions have been suggested in its management. The author herein reviewed some aspects related to SMH in AMD such as its risk factors, secondary damages, natural course and surgical management including different techniques, outcomes and complications.
C1 Capital Med Univ, Beijing Tongren Hosp, Ctr Eye, Beijing 100730, Peoples R China.
C3 Capital Medical University
RP Liu, W (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Ctr Eye, Beijing 100730, Peoples R China.
EM wuli-ubj@yahoo.com
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chaudhry NA, 1999, OPHTHALMIC SURG LAS, V30, P176
   Chaudhry NA, 2007, OPHTHAL SURG LAS IM, V38, P64, DOI 10.3928/15428877-20070101-11
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Cheng Xiang-rong, 2007, ACTA BOTANICA BOREALI-OCCIDENTALIA SINICA, V27, P321
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Iguchi Y, 2006, BRIT J OPHTHALMOL, V90, P1256, DOI 10.1136/bjo.2006.099259
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   KIMURA AE, 1994, RETINA-J RET VIT DIS, V14, P83, DOI 10.1097/00006982-199401000-00018
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   LU L, 2000, CHIN J OCUL FUNDUS D, V16, P217
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ratanasukon M, 2005, EYE, V19, P1328, DOI 10.1038/sj.eye.6701769
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   TANG Y, 2006, INT J OPHTHALMOL, V6, P1393
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P808, DOI 10.1097/00006982-200410000-00024
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
   Zhang Cheng-fen, 2003, Zhonghua Yan Ke Za Zhi, V39, P415
   Zhang X, 2007, INT J OPHTHALMOL, V7, P1674
NR 45
TC 0
Z9 0
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2009
VL 2
IS 1
BP 77
EP 81
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BK
UT WOS:000282933700019
DA 2022-11-30
ER

PT J
AU Wong, DT
   Lambrou, GN
   Loewenstein, A
   Pearce, I
   Okada, AA
AF Wong, David T.
   Lambrou, George N.
   Loewenstein, Anat
   Pearce, Ian
   Okada, Annabelle A.
CA Vision Acad Steering Comm
TI SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN
   CASES OF FUTILITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE AMD; anti-VEGF; neovascular age-related macular degeneration; treatment
   futility; Vision Academy
ID PIGMENT EPITHELIAL TEARS; GROWTH-FACTOR THERAPY; ANTI-VEGF AGENTS;
   INTRAVITREAL BEVACIZUMAB; INTRAOCULAR-PRESSURE; SUBMACULAR HEMORRHAGE;
   PHOTODYNAMIC THERAPY; MEDICAL FUTILITY; RANIBIZUMAB; INJECTION
AB Purpose: To provide guidance on the management of patients with neovascular age-related macular degeneration and its subtypes who respond poorly to anti-vascular endothelial growth factor (anti-VEGF) therapy, and to identify cases where suspending anti-VEGF treatment may be warranted. Methods: Through a literature review and the combined knowledge and clinical experience of retinal experts, the Steering Committee of the Bayer-sponsored Vision Academy developed an algorithm for determining when to suspend anti-VEGF treatment of neovascular age-related macular degeneration in cases of futility. Results: Consideration of factors that may cause suboptimal response to anti-VEGF therapy, such as undertreatment or misdiagnosis of the underlying condition, and factors that may preclude continued treatment, such as injection- or drug-induced complications, is necessary for adjusting treatment protocols in patients who respond poorly to anti-VEGF. If poor response to treatment persists after switching to an alternative anti-VEGF agent and no change in response is observed after withholding treatment for a predetermined period of time ("treatment pause"), anti-VEGF treatment may be considered futile and should be suspended. Conclusion: This publication introduces an algorithm to guide the management of neovascular age-related macular degeneration in patients showing poor response to anti-VEGF treatment and provides expert guidance for suspending anti-VEGF treatment in cases of futility.
C1 [Wong, David T.] Univ Toronto, Toronto, ON, Canada.
   [Wong, David T.] St Michaels Hosp, Toronto, ON, Canada.
   [Lambrou, George N.] Global Med Affairs Ophthalmol, Bayer, Switzerland.
   [Loewenstein, Anat] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Pearce, Ian] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Okada, Annabelle A.] Kyorin Univ, Sch Med, Tokyo, Japan.
C3 University of Toronto; University of Toronto; University Toronto
   Affiliates; Saint Michaels Hospital Toronto; Bayer AG; Tel Aviv
   University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical
   Center; Royal Liverpool & Broadgreen University Hospitals NHS Trust;
   Royal Liverpool University Hospital; University of Liverpool; Kyorin
   University
RP Wong, DT (通讯作者)，Univ Toronto, Dept Ophthal Mol & Vis Sci, St Michaels Hosp, 801-61 Queen St East, Toronto, ON M5C 2T2, Canada.
EM David.wong@unityhealth.to
FU Bayer
FX Medical writing assistance was provided by Jamie Harrison of Porterhouse
   Medical Ltd, and editorial assistance was provided by Complete
   HealthVizion, Ltd; funded by Bayer.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chong V, 2016, EYE, V30, P1526, DOI 10.1038/eye.2016.202
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Empeslidis T, 2014, OPEN OPHTHALMOL J, V8, P101, DOI 10.2174/1874364101408010101
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Feltgen N, 2014, DTSCH ARZTEBL INT, V111, P12, DOI 10.3238/arztebl.2014.0012
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Liu EM, 2017, J VITREORETIN DIS, V1, P34
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schneiderman LJ, 2011, J BIOETHIC INQ, V8, P123, DOI 10.1007/s11673-011-9293-3
   SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949
   Scott IU, 2009, OPHTHALMOLOGY, V116, P504, DOI 10.1016/j.ophtha.2008.10.017
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vision Academy Steering Committee, VIS AC VIEWP MAN SUB
   Waizel M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0471-x
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 57
TC 5
Z9 6
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2020
VL 40
IS 6
BP 1010
EP 1020
DI 10.1097/IAE.0000000000002713
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LW6LN
UT WOS:000539255800006
PM 31876889
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jhingan, M
   Cavichini, M
   Amador, M
   Dans, K
   Bartsch, DU
   Cheng, LY
   Chhablani, J
   Freeman, WR
AF Jhingan, Mahima
   Cavichini, Melina
   Amador, Manuel
   Dans, Kunny
   Bartsch, Dirk-Uwe
   Cheng, Lingyun
   Chhablani, Jay
   Freeman, William R.
TI CHOROIDAL IMAGING BIOMARKERS TO PREDICT HIGHLY RESPONSIVE AND RESISTANT
   CASES TREATED WITH STANDARDIZED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   REGIMEN IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroid; choroidal thickness; choroidal vascularity index; predictor of
   response; neovascular AMD; wet AMD
ID OPTICAL COHERENCE TOMOGRAPHY; THICKNESS
AB Purpose: To determine structural predictors of treatment response in neovascular age-related macular degeneration analyzing optical coherence tomography (OCT)-related biomarkers. Methods: A retrospective review of patients undergoing treatment for neovascular age-related macular degeneration at a tertiary institute was performed at presentation. High-intensity regimen included eyes on long-term anti-vascular endothelial growth factor treatment with the inability to extend beyond a month without a relapse and needed double the dose of medication (n = 25). Low-intensity regimen had eyes that went into long-term remission after at least three injections and remained dry for more than a year until the last visit (n = 20). Multimodal imaging including fluorescein angiogram, OCT, and comprehensive ocular evaluation were done. Choroidal vascularity index, total choroidal area, luminal area, subfoveal choroidal thickness, choriocapillaris thickness and Haller and Sattler layer thickness were analyzed for statistical significance. Results: The groups had no significant difference at baseline in age, gender, incidence of reticular pseudodrusen, polypoidal choroidal vasculopathy feature on OCT, type of choroidal neovascular membrane, and geographic atrophy. Multinomial logistic regression revealed that thicker subfoveal choroidal thickness and larger total choroidal area were the significant predictors of poor response to anti-vascular endothelial growth factor treatment (E = 0.02; P = 0.02; E = 1.82; P = 0.0075). Conclusion: Thicker subfoveal choroidal thickness and higher total choroidal area are useful variables to predict a poor treatment response.
C1 [Jhingan, Mahima; Cavichini, Melina; Amador, Manuel; Dans, Kunny; Bartsch, Dirk-Uwe; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, Louisiana Jolla, CA USA.
   [Jhingan, Mahima] Aravind Eye Hosp, Vitreoretinal Serv, Madurai, Tamil Nadu, India.
   [Cavichini, Melina] Fac Med ABC, Dept Oftalmol, Santo Andre, SP, Brazil.
   [Amador, Manuel] Inst Barraquer Amer, Escuela Super Oftalmol, Bogota, Colombia.
   Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA USA.
C3 University of California System; University of California San Diego;
   Faculdade de Medicina do ABC; University of California System;
   University of California San Diego; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM wrfreeman@ucsd.edu
FU UCSD Vision Research Center Core Grant [P30EY022589]; Research to
   Prevent Blindness, NY
FX Supported in part by UCSD Vision Research Center Core Grant P30EY022589,
   an unrestricted grant from Research to Prevent Blindness, NY (W.R.F.).
CR Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Almeida DRP, 2015, JAMA OPHTHALMOL, V133, P297, DOI 10.1001/jamaophthalmol.2014.5168
   Barteselli G, 2016, RETINA-J RET VIT DIS, V36, P1153, DOI 10.1097/IAE.0000000000000842
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Egawa M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0127-7
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Singh SR, 2019, SURV OPHTHALMOL, V64, P312, DOI 10.1016/j.survophthal.2018.11.002
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
NR 20
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2115
EP 2121
DI 10.1097/IAE.0000000000003156
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500015
PM 34543243
DA 2022-11-30
ER

PT J
AU Hartmann, KI
   Bartsch, DUG
   Cheng, LY
   Kim, JS
   Gomez, ML
   Klein, H
   Freeman, WR
AF Hartmann, Kathrin I.
   Bartsch, Dirk-Uwe G.
   Cheng, Lingyun
   Kim, Jae S.
   Gomez, Maria L.
   Klein, Helaina
   Freeman, William R.
TI SCANNING LASER OPHTHALMOSCOPE IMAGING STABILIZED MICROPERIMETRY IN DRY
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE SLO microperimetry; spectral-domain OCT; dry AMD; structure-function
   correlation; drusen; geographic atrophy; inner segment-outer segment
   junction
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC
   ATROPHY; DRUSEN; MACULOPATHY; PERIMETRY; SENSITIVITY
AB Purpose: To determine the effect of drusen and geographic atrophy (GA) in dry age-related macular degeneration on retinal sensitivity using an eye tracking scanning laser ophthalmoscope microperimetry.
   Methods: A total of 44 eyes from 22 patients with dry age-related macular degeneration and drusen and 11 patients with GA were imaged with scanning laser ophthalmoscope microperimetry (OPKO Health, Miami, FL). A custom microperimetry pattern was used to evaluate retinal sensitivity to a Goldmann III size target (108 mu m on the retina). The perimetry used a 4-2 stepladder algorithm to determine maximal sensitivity. Microperimetry and optical coherence tomography were performed using a standardized protocol. Twenty-eight eyes with drusen and 16 eyes with GA were analyzed.
   Results: Retinal sensitivity overlying drusen was significantly reduced compared with the adjacent uninvolved retina. There was a significant correlation between retinal sensitivity and drusen volume, as well as the grading of the photoreceptor inner segment/outer segment junction score. In patients with GA, an absolute scotoma was confirmed. Retinal sensitivity at the margin of GA was significantly decreased compared with the adjacent uninvolved retina.
   Conclusion: Scanning laser ophthalmoscope microperimetry is able to detect changes in retinal sensitivity in AMD patients overlying drusen and at the margin of GA. It is a useful device to grade focal retinal sensitivity in patients with dry age-related macular degeneration. RETINA 31: 1323-1331, 2011
C1 [Hartmann, Kathrin I.; Bartsch, Dirk-Uwe G.; Cheng, Lingyun; Kim, Jae S.; Gomez, Maria L.; Klein, Helaina; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, La Jolla, CA 92037 USA.
   [Hartmann, Kathrin I.] Univ Munich, Dept Ophthalmol, Munich, Germany.
C3 University of California System; University of California San Diego;
   University of Munich
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
FU National Institutes of Health [NEI EY 07366, EY 016323]; RPB, Inc;
   Jacobs Retina Center; NATIONAL EYE INSTITUTE [R01EY007366, R01EY016323]
   Funding Source: NIH RePORTER
FX Supported in part by the National Institutes of Health Grants NEI EY
   07366 (to W.R.F.) and EY 016323 (to D.-U.G.B.), RPB, Inc, and an
   unrestricted grant from the Jacobs Retina Center. Dr. Freeman has been a
   consultant to OPKO Inc.
CR Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Cacho I, 2010, OPTOMETRY VISION SCI, V87, P344, DOI 10.1097/OPX.0b013e3181d9515c
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kozak I, 2009, RETINA, V30, P431
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Lima VC, 2010, BRIT J OPHTHALMOL, V94, P64, DOI 10.1136/bjo.2009.159772
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Midena E, 2007, EUR J OPHTHALMOL, V17, P63, DOI 10.1177/112067210701700109
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varano M, 2010, RETINA-J RET VIT DIS, V30, P413, DOI 10.1097/IAE.0b013e3181bd2d23
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 59
Z9 60
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2011
VL 31
IS 7
BP 1323
EP 1331
DI 10.1097/IAE.0b013e31820a6850
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 794CA
UT WOS:000292871700012
PM 21540764
DA 2022-11-30
ER

PT J
AU Chong, EW
   Guymer, RH
   Klein, R
   Klein, BE
   Cotch, MF
   Wang, JJ
   Shlipak, MG
   Wong, TY
AF Chong, Elaine W.
   Guymer, Robyn H.
   Klein, Ronald
   Klein, Barbara E.
   Cotch, Mary Frances
   Wang, Jie Jin
   Shlipak, Michael G.
   Wong, Tien Y.
TI Is Renal Function Associated with Early Age-Related Macular
   Degeneration?
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; kidney; renal function
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; COMPLEMENT-FACTOR-H;
   BLUE-MOUNTAINS-EYE; GLOMERULONEPHRITIS TYPE-II; SERUM CYSTATIN-C; BEAVER
   DAM EYE; FUNDUS CHANGES; RISK; PREVALENCE
AB Purpose. Age-related macular degeneration (AMD) and chronic kidney disease both involve immune dysregulation and may share underlying pathophysiologic changes to systemic homeostasis. Hence, we aim to evaluate associations between impaired kidney function and early AMD, in a search for urinary biomarkers for AMD.
   Methods. A population-based, cross-sectional analysis of persons aged 45 to 84 years was conducted with renal function measured using serum creatinine and cystatin C levels and the estimated glomerular filtration rate (eGFR) calculated. Age-related macular degeneration status was ascertained from retinal photographs.
   Results. Of 5874 participants, 221 had early AMD. High serum cystatin C and low eGFR (<= 60 ml/min/1.73 m(2)) were not associated with early AMD in our multivariate analyses. Among normotensive persons, however, highest versus other deciles of cystatin C were associated with an increased prevalence of early AMD (odds ratio, 1.80; 95% confidence interval, 1.00 to 3.23).
   Conclusions. Results could not confirm an association between kidney function and early AMD. The borderline association between cystatin C and early AMD in normotensive persons require further verification.
C1 [Chong, Elaine W.; Guymer, Robyn H.; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Klein, Ronald; Klein, Barbara E.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA.
   [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Wisconsin System; University of Wisconsin Madison; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Sydney; University of California System; University of
   California San Francisco; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); San Francisco VA Medical Center; University
   of California System; University of California San Francisco; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   San Francisco VA Medical Center; National University of Singapore;
   Singapore National Eye Center
RP Chong, EW (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM elainechongwt@alumni.unimelb.edu.au
RI wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Wong, Tien
   Yin/AAC-9724-2020
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Guymer, Robyn/0000-0002-9441-4356; Cotch, Mary
   Frances/0000-0002-2046-4350
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165,
   N01-HC-95169]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS
   [N01HC095169, N01HC095165, N01HC095159] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [ZIAEY000403] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL095169, R44HL095169,
   R21HL095165] Funding Source: NIH RePORTER
FX This study was supported by contracts N01-HC-95159 through N01-HC-95165
   and N01-HC-95169 from the National Heart, Lung, and Blood Institute.
CR Anavekar N, 2005, MED J AUSTRALIA, V183, P138, DOI 10.5694/j.1326-5377.2005.tb06958.x
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Dharnidharka VR, 2002, AM J KIDNEY DIS, V40, P221, DOI 10.1053/ajkd.2002.34487
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Filler G, 2005, CLIN BIOCHEM, V38, P1, DOI 10.1016/j.clinbiochem.2004.09.025
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Grubb A, 2005, CLIN CHEM, V51, P1420, DOI 10.1373/clinchem.2005.051557
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Im E, 2007, EXP EYE RES, V84, P383, DOI 10.1016/j.exer.2006.05.017
   Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Multi-Ethnic Study of Atherosclerosis (MESA), MULT ETHN STUD ATH M
   National Kidney Foundation, CHRON KIDN DIS CKD W
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Poggio ED, 2005, J AM SOC NEPHROL, V16, P459, DOI 10.1681/ASN.2004060447
   Sarnak MJ, 2005, ANN INTERN MED, V142, P497, DOI 10.7326/0003-4819-142-7-200504050-00008
   Shlipak MG, 2007, NAT CLIN PRACT NEPHR, V3, P188, DOI 10.1038/ncpneph0404
   Shlipak MG, 2006, ANN INTERN MED, V145, P237, DOI 10.7326/0003-4819-145-4-200608150-00003
   Shlipak MG, 2013, NEW ENGL J MED, V369, P932, DOI 10.1056/NEJMoa1214234
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   World Health Organisation (WHO), GLOB DAT BOD MASS IN
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
NR 40
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 860
EP 864
DI 10.1097/OPX.0000000000000288
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500008
PM 24879085
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Patel, M
   Chan, CC
AF Patel, Mrinali
   Chan, Chi-Chao
TI Immunopathological aspects of age-related macular degeneration
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE age-relatedmacular degeneration (AMD); inflammation; complement;
   macrophage; microglia
ID COMPLEMENT FACTOR-H; CHLAMYDIA-PNEUMONIAE INFECTION; INDUCED CHOROIDAL
   NEOVASCULARIZATION; C-REACTIVE PROTEIN; RETINAL-PIGMENT EPITHELIUM;
   BEAVER DAM EYE; ALTERNATIVE PATHWAY; ENDOTHELIAL-CELLS; DRUSEN
   FORMATION; MURINE MODEL
AB Age-related macular degeneration (AMD) represents a leading cause of blindness worldwide. While the clinical and histopathological aspects of AMD are well characterized, its etiology and pathogenesis remain unclear. Recent findings suggest a role for immunologic processes in AMD pathogenesis, including the age-related generation of extracellular deposits inside the Brusch membrane and beneath the retinal pigment epithelium, recruitment of macrophages for clearance of these deposits, complement activation, recruitment of tissue-destructive macrophages, microglial activation and accumulation, and proinflammatory effects of chronic inflammation by Chlamydia pneumoniae. This review discusses the evidence for the role of inflammation in human AMD and in animal models of AMD.
C1 [Patel, Mrinali; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Patel, Mrinali] Howard Hughes Med Inst, Chevy Chase, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Howard Hughes Medical Institute
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103,NIH NEI, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
FU NATIONAL EYE INSTITUTE [ZIAEY000418, Z01EY000222] Funding Source: NIH
   RePORTER; Howard Hughes Medical Institute Funding Source: Medline;
   Intramural NIH HHS [Z01 EY000418-04] Funding Source: Medline
CR AbdelRahman YM, 2005, FEMS MICROBIOL REV, V29, P949, DOI 10.1016/j.femsre.2005.03.002
   Adamus Grazyna, 2002, Int Rev Immunol, V21, P209, DOI 10.1080/08830180212068
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brito BE, 1999, INVEST OPHTH VIS SCI, V40, P2583
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 1998, BRIT J OPHTHALMOL, V82, P91, DOI 10.1136/bjo.82.1.91
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky K, 2004, ARCH OPHTHALMOL-CHIC, V122, P650, DOI 10.1001/archopht.122.4.650
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DERODRIGUEZ CS, 2004, MOL IMMUNOL, V41, P355
   DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   MacIntyre A, 2003, J NEUROSCI RES, V71, P740, DOI 10.1002/jnr.10519
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ooi KGJ, 2006, CLIN MED RES, V4, P294, DOI 10.3121/cmr.4.4.294
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rao NA, 2003, INVEST OPHTH VIS SCI, V44, P22, DOI 10.1167/iovs.02-0199
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith JR, 1998, IMMUNOL CELL BIOL, V76, P497, DOI 10.1046/j.1440-1711.1998.00783.x
   Suzuki M, 2007, MOL VIS, V13, P772
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yamaguchi H, 2002, INFECT IMMUN, V70, P2392, DOI 10.1128/IAI.70.5.2392-2398.2002
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2006, FEMS MICROBIOL LETT, V260, P17, DOI 10.1111/j.1574-6968.2006.00286.x
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 94
TC 123
Z9 162
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2297
EI 1863-2300
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD APR
PY 2008
VL 30
IS 2
BP 97
EP 110
DI 10.1007/s00281-008-0112-9
PG 14
WC Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology
GA 296CA
UT WOS:000255519900004
PM 18299834
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Erbezci, M
   Ozturk, T
AF Erbezci, Murat
   Ozturk, Taylan
TI PREFERRED RETINAL LOCUS LOCATIONS IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macula degeneration; central scotoma; low vision; preferred
   retinal locus; scanning laser ophthalmoscope
ID ECCENTRIC FIXATION; SCOTOMAS; DISEASE; EYES
AB Purpose: An evaluation of the preferred retinal locus (PRL) in patients with age-related macular degeneration and a central scotoma is becoming a standard of care in the practice of low-vision rehabilitation. This is a retrospective study of PRL specifications and whether they have a correlation with the best-corrected visual acuities of patients with age-related macular degeneration.
   Methods: Seventy-two patients with macular degeneration (144 eyes) were included in the study. The PRLs were evaluated monocularly with a scanning laser ophthalmoscope. Each PRL's location, the fovea-PRL distance, the PRL edge of the lesion distance, and PRL stability were measured with the built-in caliper of the ophthalmoscope.
   Results: The most frequent location of a PRL was nasal (29.2%). The PRL was located in the left visual field of 34.0% of the patients. The best-corrected visual acuity values were positively correlated with the lesion's vertical and horizontal dimensions, as well as its surface area, the PRL-fovea distance, the PRL border of the lesion distance, and PRL stability.
   Conclusion: The clinical PRL evaluation methodology that we describe can be used to facilitate making decisions on how to provide best visual rehabilitation to patients with a central scotoma.
C1 [Erbezci, Murat] Erbezci Eye Clin, Plevne Bulvari 20-2, TR-35220 Izmir, Turkey.
   [Ozturk, Taylan] Dokuz Eylul Univ, Dept Ophthalmol, Sch Med, Izmir, Turkey.
C3 Dokuz Eylul University
RP Erbezci, M (通讯作者)，Erbezci Eye Clin, Plevne Bulvari 20-2, TR-35220 Izmir, Turkey.
EM murat@muraterbezci.com
RI Ozturk, Taylan/AAC-6680-2019; Erbezci, Murat/R-3435-2019
OI Ozturk, Taylan/0000-0001-6633-0553; Erbezci, Murat/0000-0003-2163-2157
CR Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Deruaz A, 2004, BRIT J OPHTHALMOL, V88, P461, DOI 10.1136/bjo.2003.025601
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   DRASDO N, 1974, BRIT J OPHTHALMOL, V58, P709, DOI 10.1136/bjo.58.8.709
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Fuchs W., 1938, SOURCE BOOK GESTALT, P357
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   Kisilevsky E, 2016, CAN J OPHTHALMOL, V51, P362, DOI 10.1016/j.jcjo.2016.01.007
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Liu HT, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.3
   Liu R, 2016, J VISION, V16, DOI 10.1167/16.6.10
   Riss-Jayle M, 2008, J FR OPHTALMOL, V31, P379, DOI 10.1016/S0181-5512(08)71432-3
   SANSBURY RV, 1973, J OPT SOC AM, V63, P612, DOI 10.1364/JOSA.63.000612
   Schonbach EM, 2017, OPHTHALMOL RETINA, V1, P68, DOI 10.1016/j.oret.2016.08.009
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2015, OPTOMETRY VISION SCI, V92, P863, DOI 10.1097/OPX.0000000000000641
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 30
TC 11
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2018
VL 38
IS 12
BP 2372
EP 2378
DI 10.1097/IAE.0000000000001897
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1WG
UT WOS:000454008700018
PM 29065012
DA 2022-11-30
ER

PT J
AU Patel, S
AF Patel, Samir
TI COMBINATION THERAPY FOR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeration and anti-PDGF (E10030); integrin a5b1
   (Volociximab); anticomplement; combination therapy and AMD
ID RANIBIZUMAB; DRUSEN; ANGIOGENESIS; BIOMARKERS; INTEGRINS; GROWTH
AB Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis in age-related macular degeneration (AMD) and is a validated therapeutic target. However, combination of anti-VEGF agents with complementary inhibition of other mediators of angiogenesis, such as platelet-derived growth factor and integrin alpha 5 beta 1, may result in enhanced visual acuity. Other concomitant treatments, such as inhibitors of inflammation, may generate an even stronger barrier to the progression of AMD than that now observed in individuals receiving anti-VEGF therapies alone. Experimental studies are providing support for the general principles of combination treatment in AMD. RETINA 29:S45-S48, 2009
C1 Ophthotech Corp, Princeton, NJ 08540 USA.
RP Patel, S (通讯作者)，Ophthotech Corp, Princeton, NJ 08540 USA.
EM samir.patel@ophthotech.com
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bhaskar V, 2008, INVEST NEW DRUG, V26, P7, DOI 10.1007/s10637-007-9078-z
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   GIESE MJ, 1994, INVEST OPHTH VIS SCI, V35, P1026
   Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
NR 18
TC 13
Z9 23
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S45
EP S48
DI 10.1097/IAE.0b013e3181ad22d5
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700017
PM 19553801
DA 2022-11-30
ER

PT J
AU Chin, YC
   Wong, TY
   Cheung, CMG
   Cheung, CYL
   Zheng, YF
   Mitchell, P
   Huang, HQ
   Wang, JJ
   Ikram, MK
AF Chin, You Chuen
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
   Cheung, Carol Yim-Lui
   Zheng, Yingfeng
   Mitchell, Paul
   Huang, HuiQi
   Wang, Jie Jin
   Ikram, Mohammad Kamran
TI Retinal Vascular Caliber and Age-related Macular Degeneration in an
   Indian Population from Singapore
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; microvasculature; retinal vascular
   imaging
ID BLUE-MOUNTAINS-EYE; BEAVER DAM EYE; VESSEL DIAMETERS; MALAY EYE;
   RISK-FACTORS; MACULOPATHY; PREVALENCE; ASSOCIATION; METHODOLOGY; DISEASE
AB Purpose: To examine the association between retinal vascular caliber and early age-related macular degeneration (AMD) in an Indian population.
   Methods: A total of 3112 Indian participants aged >= 40 years from the population-based Singapore Indian Eye Study who had data available on retinal vascular caliber measurements and AMD status were included. Retinal arteriolar and venular calibers were measured from digital photographs using computer-assisted software according to a standardized protocol. Images of the macular region were graded according to the modified Wisconsin age-related maculopathy grading system. Right eyes were selected for analyses. Binary logistic regression models were used to assess the association, adjusting for age, sex, systolic blood pressure, total cholesterol, random blood glucose, body mass index, and the companion retinal vascular caliber.
   Results: A total of 107 participants (3.4%) were diagnosed with early AMD. Neither arteriolar nor venular caliber was related to AMD. For early AMD, the age-, sex-, and companion retinal vascular caliber-adjusted odds ratio (OR) per standard deviation (SD) decrease in arteriolar caliber was 0.95 (95% CI 0.84-1.31; p = 0.671), and per SD increase in venular caliber was OR: 0.96 (95% CI: 0.77-1.20); p = 0.714. No trend was found after categorizing retinal vascular calibers into quartiles. Multivariate adjustment and stratified analyses did not alter these results.
   Conclusion: Retinal vascular calibers were not related to early AMD among Indian participants. These findings differ from those of several previous studies performed in Caucasian and Asian populations.
C1 [Chin, You Chuen; Wong, Tien Yin; Cheung, Chui Ming Gemmy; Cheung, Carol Yim-Lui; Zheng, Yingfeng; Huang, HuiQi; Ikram, Mohammad Kamran] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Chin, You Chuen; Wong, Tien Yin; Ikram, Mohammad Kamran] Natl Univ Hlth Syst, Dept Ophthalmol, Singapore, Singapore.
   [Wong, Tien Yin; Wang, Jie Jin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Ikram, Mohammad Kamran] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Ikram, Mohammad Kamran] Natl Univ Hlth Syst, Memory Aging & Cognit Ctr, Singapore, Singapore.
   [Ikram, Mohammad Kamran] Natl Univ Singapore, Duke NUS Grad Med Sch, Off Clin Sci, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; University
   of Sydney; Westmead Institute for Medical Research; Erasmus University
   Rotterdam; Erasmus MC; National University of Singapore; National
   University of Singapore
RP Ikram, MK (通讯作者)，The Academia, 20 Coll Rd,Discovery Tower Level 6,Room 119, Singapore 169856, Singapore.
EM kamran_ikram@nuhs.edu.sg
RI Cheung, Carol Y./G-7895-2016; Cheung, Carol/AAF-1101-2020; Zheng,
   Yingfeng/AAE-2983-2022; Wong, Tien Yin/AAC-9724-2020; Zheng,
   Yingfeng/CAE-9225-2022; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014; wang, jie/GRS-0942-2022
OI Cheung, Carol/0000-0002-9672-1819; Wong, Tien Yin/0000-0002-8448-1264;
   Zheng, Yingfeng/0000-0002-0914-7864; Wang, Jie Jin/0000-0001-9491-4898;
   Ikram, Mohammad Kamran/0000-0003-0173-9571; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Cheung, Carol/0000-0003-0869-859X
FU Biomedical Research Council (BMRC), Singapore [08/1/35/19/550]
FX This work was supported by a grant from the Biomedical Research Council
   (BMRC), 08/1/35/19/550, Singapore.
CR [Anonymous], 2009, ACT PLAN PREV AV BLI
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Ghosh Arnab, 2010, J Cardiovasc Dis Res, V1, P81, DOI 10.4103/0975-3583.64441
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Nguyen TT, 2006, TRENDS ENDOCRIN MET, V17, P262, DOI 10.1016/j.tem.2006.07.006
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tsai ASH, 2011, DIABETES RES CLIN PR, V94, P291, DOI 10.1016/j.diabres.2011.07.032
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
NR 27
TC 5
Z9 5
U1 0
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2014
VL 21
IS 4
BP 224
EP 229
DI 10.3109/09286586.2014.926941
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM4EV
UT WOS:000339806800004
PM 24945891
DA 2022-11-30
ER

PT J
AU Miki, A
   Honda, S
   Kondo, N
   Negi, A
AF Miki, Akiko
   Honda, Shigeru
   Kondo, Naoshi
   Negi, Akira
TI The Association of Age-related Maculopathy Susceptibility 2 (ARMS2) and
   Complement Factor H (CFH) Variants with Two Angiographic Subtypes of
   Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related maculopathy susceptibility 2 (ARMS2); complement factor H
   (CFH); indocyanine green angiography; polypoidal choroidal vasculopathy;
   polymorphism
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; VISUAL PROGNOSIS; LESION
   SIZE; GENOTYPE; MULTICENTER; PHENOTYPE; FEATURES; HYOGO
AB Purpose: To compare the association of age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) variants between two different angiographic phenotypes of polypoidal choroidal vasculopathy (PCV).
   Methods: We included 175 Japanese patients with PCV and 150 age- and sex-matched controls. PCV was classified into two phenotypes (Type 1 and Type 2) according to the presence or absence of the feeding vessels found in indocyanine-green angiography. The single nucleotide polymorphism (SNP) at rs10490924 (A69S) in ARMS2 and rs800292 (I62V), rs1061170 (Y402H) in the CFH region were genotyped using the TaqMan assay.
   Results: The minor allele frequency (MAF) of rs10490924 was significantly different between Type 1 PCV (n = 81) and control (p < 0.0001), while no difference was found between Type 2 PCV (n = 94) and control (p = 0.20). The MAF of rs800292 was significantly different between each type of PCV and control (p < 0.0001 and 0.0001 for Type 1 versus control and Type 2 versus control, respectively). The MAF of rs1061170 was not significantly different between either type of PCV and control (p = 0.084 and 0.15, respectively).
   Conclusions: There may be significantly different associations in the genetic variants of ARMS2 between two angiographic phenotypes of PCV.
C1 [Miki, Akiko; Honda, Shigeru; Kondo, Naoshi; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organization had no role in the design or conduct of this
   research.
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bessho H, 2011, MOL VIS, V17, P977
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 19
Z9 21
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2013
VL 34
IS 3
BP 146
EP 150
DI 10.3109/13816810.2012.749288
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 180IC
UT WOS:000321586400004
PM 23289808
DA 2022-11-30
ER

PT J
AU Jeganathan, VSE
   Kawasaki, R
   Wang, JJ
   Aung, T
   Mitchell, P
   Saw, SM
   Wong, TY
AF Jeganathan, V. Swetha E.
   Kawasaki, Ryo
   Wang, Jie Jin
   Aung, Tin
   Mitchell, Paul
   Saw, Seang-Mei
   Wong, Tien Y.
TI Retinal Vascular Caliber and Age-related Macular Degeneration: The
   Singapore Malay Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; JAPANESE POPULATION; VESSEL DIAMETERS; GRADING
   SYSTEM; NITRIC-OXIDE; MACULOPATHY; PREVALENCE
AB PURPOSE: To investigate the relationship between retinal vascular caliber and age-related macular degeneration (AMD).
   DESIGN: Population-based cross-sectional study.
   METHODS: Three thousand two hundred and eighty (78.7% response rate) Malay Singaporeans aged 40 to 80 years residing in 15 districts of Singapore underwent retinal photography. Retinal vessel caliber was measured from retinal photographs using a validated computer-based technique. AMD was assessed following a modified Wisconsin Age-Related Maculopathy Grading System.
   RESULTS: Retinal data were available from 3,265 subjects (99.5% of 3,280) for this study. Early and late AMD prevalence were 4.9% (n = 160) and 0.7% (n = 23) of the population, respectively, or in 205 (3.1%) and 30 (0.5%) eyes examined, respectively. After controlling for age and arteriolar caliber, wider venular caliber was associated with higher prevalence of early AMD (odds ratio [OR] per one standard deviation [SDI increment in venular caliber, 1.53; 95% confidence interval [CI], 1.13 to 2.09). This association remained significant after further adjustment for gender, smoking, hypertension, diabetes, and body mass index (OR per one SD, 1.52; 95% CI, 1.11 to 2.09). There was no significant association between retinal arteriolar caliber and early AMD, or between arteriolar or venular caliber and late AMD.
   CONCLUSIONS: Wider venular caliber was associated independently with early AMD. This finding may suggest that pathogenic processes linking to wider venular caliber be shared by early AMD and common cardiovascular risk factors such as inflammation, dyslipidemia, and endothelial dysfunction. (Am J Ophthalmol 2008; 146:954-959. (C) 2008 by Elsevier Inc. All rights reserved.)
C1 [Jeganathan, V. Swetha E.; Kawasaki, Ryo; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, CERA, Melbourne, Vic 8002, Australia.
   [Jeganathan, V. Swetha E.; Aung, Tin; Saw, Seang-Mei; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Aung, Tin; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
C3 University of Melbourne; National University of Singapore; Singapore
   National Eye Center; University of Sydney; National University of
   Singapore; National University of Singapore
RP Wang, JJ (通讯作者)，Univ Melbourne, CERA, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM jiejw@unimelb.edu.au
RI Kawasaki, Ryo/B-7266-2009; wang, jie/GRS-0942-2022; Wong, Tien
   Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014; Kawasaki,
   Ryo/H-9716-2019; Wang, Jie Jin/P-1499-2014
OI Kawasaki, Ryo/0000-0002-7492-6303; Wong, Tien Yin/0000-0002-8448-1264;
   Wang, Jie Jin/0000-0001-9491-4898
FU NATIONAL MEDICAL RESEARCH COUNCIL [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/l/25-5]; Singapore Tissue Network;
   Ministry of Health, Singapore
FX THIS STUDY WAS SUPPORTED BY THE NATIONAL MEDICAL RESEARCH COUNCIL GRANT
   NOS. 0796/2003, 0863/2004, AND CSI/0002/2005 and Biomedical Research
   Council Grant No. 501/l/25-5. Additional support was provided by the
   Singapore Tissue Network and the Ministry of Health, Singapore. The
   authors indicate no financial conflict of interest. Involved in design
   of study (T.A., P.M., S.S.-M., T.Y.W., P.M.); conduct Of Study (T.A.,
   S.S.-M., T.Y.W.); Collection of data (T.Y.W.); management (T.Y.W.),
   analysis (V.S.E.J., R.K.), and interpretation (V.S.E.J., R.K., J.J.W.)
   of data; preparation of manuscript (V.S.E.J., R.K., J.J.W., T.Y.W.); and
   review and approval of manuscript (V.S.E.J., R.K., J.JW., S.S.M.,
   T.Y.W.). The study followed the principles of the Declaration of
   Helsinki, with ethics approval obtained from the Singapore Eye Research
   Institute
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cohen J, 1998, PROG CLIN BIOL RES, V397, P169
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feke GT, 2007, AM J OPHTHALMOL, V144, P482, DOI 10.1016/j.ajo.2007.05.033
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   KAWASAKI R, OPHTHALMOLO IN PRESS
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Liew G, 2007, INVEST OPHTH VIS SCI, V48, P52, DOI 10.1167/iovs.06-0672
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nguyen TT, 2006, TRENDS ENDOCRIN MET, V17, P262, DOI 10.1016/j.tem.2006.07.006
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   SUN C, SURV OPHTHA IN PRESS
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2005, AM J HYPERTENS, V18, P297, DOI 10.1016/j.amjhyper.2004.11.023
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
NR 33
TC 43
Z9 45
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2008
VL 146
IS 6
BP 954
EP 959
DI 10.1016/j.ajo.2008.07.006
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 378UH
UT WOS:000261349200024
PM 18760764
DA 2022-11-30
ER

PT J
AU Kan, MY
   Liu, FT
   Weng, XL
   Ye, JY
   Wang, T
   Xu, MQ
   He, L
   Liu, Y
AF Kan, Mengyuan
   Liu, Fatao
   Weng, Xiaoling
   Ye, Junyi
   Wang, Ting
   Xu, Mingqing
   He, Lin
   Liu, Yun
TI Association study of newly identified age-related macular degeneration
   susceptible loci SOD2, MBP, and C8orf42 in Han Chinese population
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration; Han Chinese population; Association
   study
ID MANGANESE SUPEROXIDE-DISMUTASE; RISK; GENES; MACULOPATHY; PREVALENCE
AB A recent genome-wide association study has reported three newly identified susceptible loci (rs2842992 near the gene SOD2, rs1789110 near the gene MBP and rs722782 near the gene C8orf42) to be associated with the geographic atrophy subtype of age-related macular degeneration in European-descent population. We investigated the correlation between these variants and advanced age-related macular degeneration for the first time in a Han Chinese cohort; however, no evidence supports these previously identified loci contribute to advanced age-related macular degeneration susceptibility in Chinese population.
C1 [Kan, Mengyuan; Liu, Fatao; Wang, Ting; He, Lin] Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
   [Weng, Xiaoling; Ye, Junyi; He, Lin; Liu, Yun] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Xu, Mingqing; He, Lin] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200030, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institutes for Biological
   Sciences, CAS; Fudan University; Shanghai Jiao Tong University
RP He, L (通讯作者)，Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
EM helin@bio-x.cn; superliuyun@gmail.com
FU 973 Program [2010CB529600, 2011CB504000]; National Key Technology RD
   Program [2012BAI01B09]; National Natural Science Foundation of China
   [31200954, 81121001, 81361120389]
FX This work was supported by the 973 Program (2010CB529600, 2011CB504000),
   the National Key Technology R&D Program (2012BAI01B09), and the National
   Natural Science Foundation of China (31200954, 81121001, 81361120389).
   We specially thank Dr. Dingguo Qian from Department of Ophthalmology,
   Putuo Peoples' Hospital, Zhoushan, China, who helped to collect the
   study subjects and provide clinical diagnosis for AMD.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kondo N, 2009, MOL VIS, V15, P1819
   Ma XY, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-20
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
NR 21
TC 7
Z9 7
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD MAR 25
PY 2014
VL 9
AR 73
DI 10.1186/1746-1596-9-73
PG 4
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AF3MN
UT WOS:000334616500003
PM 24667176
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Balaskas, K
   Nourrit, V
   Dinsdale, M
   Henson, DB
   Aslam, T
AF Balaskas, Konstantinos
   Nourrit, Vincent
   Dinsdale, Michelle
   Henson, David B.
   Aslam, Tariq
TI Differences in spectral absorption properties between active neovascular
   macular degeneration and mild age related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB This study examines the differences in spectral absorption properties between the maculae of patients with active neovascular macular degeneration and those with early age related maculopathy (ARM). Patients attending for management of neovascular age related macular degeneration (AMD) underwent multispectral imaging with a system comprising of a modified digital fundus camera coupled with a 250-W tungsten-halogen lamp and a liquid crystal fast-tuneable filter. Images were obtained at 8 wavelengths between 496 and 700 nm. Aligned images were used to generate a DLA (differential light absorption, a measure of spectral absorption properties) map of the macular area. DLA maps were generated for both eyes of 10 sequential patients attending for anti-vascular endothelial growth factor injections. Each of these patients had active leaking neovascular AMD in one eye and early ARM or milder disease in the fellow eye. Eyes with neovascular AMD demonstrated lower average levels of DLA compared with their fellow eyes with early ARM (p=0.037, t test). The significant difference in DLA demonstrates the potential of multispectral imaging for differentiating the two pathologies non-invasively.
C1 [Balaskas, Konstantinos; Henson, David B.; Aslam, Tariq] Cent Manchester Healthcare Fdn Trust, Manchester Royal Eye Hosp, Dept Med Retina, Manchester, Lancs, England.
   [Nourrit, Vincent; Dinsdale, Michelle; Henson, David B.; Aslam, Tariq] Univ Manchester, Manchester, Lancs, England.
   [Nourrit, Vincent; Dinsdale, Michelle; Henson, David B.; Aslam, Tariq] Manchester Biomed Res Ctr, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester
RP Balaskas, K (通讯作者)，Cent Manchester Healthcare Fdn Trust, Manchester Royal Eye Hosp, Dept Med Retina, Manchester, Lancs, England.
EM Konstantinos.balaskas@gmail.com
RI Nourrit, Vincent/B-3236-2008; Balaskas, Konstantinos/ABD-5979-2020;
   Aslam, Tariq/A-8532-2016
OI Nourrit, Vincent/0000-0002-1949-2207; Balaskas,
   Konstantinos/0000-0002-7690-6277; Henson, David/0000-0002-9272-7295;
   Aslam, Tariq/0000-0002-9739-7280
FU Central Manchester Foundation Trust research and innovation division/
   biomedical research centre; Welcome Trust
FX This work was supported by a grant from the Central Manchester
   Foundation Trust research and innovation division/ biomedical research
   centre and Welcome Trust clinical research facility.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Denniss J, 2011, INVEST OPHTH VIS SCI, V52, P8732, DOI 10.1167/iovs.11-8302
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mordant DJ, 2011, INVEST OPHTH VIS SCI, V52, P2851, DOI 10.1167/iovs.10-6217
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Yoneya S, 2002, OPHTHALMOLOGY, V109, P1521, DOI 10.1016/S0161-6420(02)01109-0
NR 9
TC 4
Z9 4
U1 1
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2013
VL 97
IS 5
BP 558
EP 560
DI 10.1136/bjophthalmol-2012-302305
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126AG
UT WOS:000317582900005
PM 23137662
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Segato, T
   Scopa, P
   Masetto, M
   Ceca, S
   Cavarzeran, F
   Peto, T
AF Piermarocchi, Stefano
   Segato, Tatiana
   Scopa, Pasquale
   Masetto, Morena
   Ceca, Stela
   Cavarzeran, Fabiano
   Peto, Tunde
CA PAMDI Study Grp
TI The Prevalence of Age-Related Macular Degeneration in Italy (PAMDI)
   Study: Report 1
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Prevalence of age-related macular
   degeneration; Risk factors of age-related macular degeneration; Fundus
   photography; Visual function questionnaire; Food frequency questionnaire
ID VISUAL IMPAIRMENT; MACULOPATHY; PROGRESSION; ADULTS
AB Purpose: The present study aimed to estimate prevalence and risk factors associated with age-related macular degeneration (ARMD) in an Italian population and to analyze differences between urban and rural communities.
   Methods: We conducted a population-based cross-sectional study among elderly residents in Northeast Italy. Participants were divided into urban and rural groups based on whether they lived in the city of Padova or the villages of Teolo and Torreglia, respectively. Fundus photographs were graded according to the International Classification for Age-related Maculopathy.
   Results: A total of 1162 randomly selected subjects aged 61 years or more were invited to participate in the study. We examined 885 subjects, and 845 were eligible for fundus photograph grading. ARMD was estimated to affect 62.7% of the whole population (drusen 63-124 mu m = 48.3%; drusen >= 125 mu m = 10.4%; advanced ARMD = 4.1%). Age was confirmed as a risk factor for drusen >= 125 mu m and advanced ARMD (Odds Ratio [OR] = 1.47, 95% Confidence Interval [CI] 1.28-1.69 and OR = 1.62, 95% CI 1.28-2.05, respectively, for a 5-year increase in age). The rural group appeared to be at a higher risk of developing large drusen compared to the urban sample (OR = 1.61, 95% CI 1.01-2.63) when adjusting for age and gender.
   Conclusions: The results confirmed that ARMD affects a high percentage of the elderly population in Italy. This study does not support the hypothesis that living in a rural environment or belonging to a population of the Mediterranean basin may be protective against the intermediate stages of the disease.
C1 [Piermarocchi, Stefano] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Masetto, Morena] Abano Terme Hosp, Abano Terme, Italy.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of Padua; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM stefano.piermarocchi@unipd.it
RI Turrini, Aida/K-5353-2016; TURRINI, AIDA/P-2413-2019; Peto,
   Tunde/G-8812-2018; Angi, Martina/C-9462-2017
OI Turrini, Aida/0000-0002-2188-9406; TURRINI, AIDA/0000-0002-2188-9406;
   Peto, Tunde/0000-0001-6265-0381; Angi, Martina/0000-0003-2703-2056
FU University of Padova, Italy; United Kingdom NIHR
FX Stefano Piermarocchi had full access to all data in the study and takes
   responsibility for the integrity of the data and the accuracy of the
   data analysis. The PAMDI Study Group would like to thank the University
   of Padova, Italy for funding. Tunde Peto would like to thank the United
   Kingdom NIHR for their support that enabled participation in this study.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   August CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Cochran WG., 2007, SAMPLING TECHNIQUES
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   HSIEH FY, 1989, STAT MED, V8, P795, DOI 10.1002/sim.4780080704
   *ISTAT, 2005, AN POP RES
   *ISTAT, 2005, ANN STAT DEM
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kurinij N, 1988, INT C DIET ASS METH
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   *SAS I INC, 2004, SAS STAT 9 1 3 US GU
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 20
Z9 21
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JUN
PY 2011
VL 18
IS 3
BP 129
EP 136
DI 10.3109/09286586.2011.574334
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 768RL
UT WOS:000290954700005
PM 21609241
DA 2022-11-30
ER

PT J
AU Peretiahina, D
   Shakun, K
   Ulianov, V
   Ulianova, N
AF Peretiahina, Daria
   Shakun, Konstantin
   Ulianov, Vadym
   Ulianova, Nadiia
TI The Role of Retinal Plasticity in the Formation of Irreversible Retinal
   Deformations in Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; retinal plasticity; retinal pigment
   epithelium detachment; drusen mechanical stress
AB Purpose To construct a realistic physical model of viscoelastic retinal stretching and, on its basis, derive a universal quantitative criterion of irreversible retinal deformations during age-related macular degeneration. Methods In this work, standard methods of nonlinear fracture mechanics of ductile and viscoelastic materials were applied to study the evolution of retinal deformation progress in patients with neovascular age-related macular degeneration in the area of large druses or subretinal or sub-retinal pigment epithelium fluid accumulation. A two-dimensional rhombic model of viscoelastic Kelvin-Feucht primitives was used to reconstruct the parameters included in the approximation of the creep strain growth rate. A clinical case of a patient with age-related macular degeneration and retinal pigment epithelium detachment in the macula was taken as a basis for theoretical research. The patient underwent retinal optical coherent tomography on DRI Swept-Source OCT. Results A closed realistic theoretical model of retinal stretching in the projection of retinal pigment epithelium elevation due to its detachment or drusen based on a two-dimensional rhombic Kelvin-Feucht primitives model was constructed. The calculation of stress in the retinal tissue with consistent consideration of creep effects was performed. Conclusions The time of critical retinal loading - a new quantitative criterion for the irreversibility of retinal stretching in age-related macular degeneration is proposed. This criterion allows the prediction of the functional outcome of antiangiogenic therapy in patients with age-related macular degeneration with identical initial retinal morphometric parameters.
C1 [Peretiahina, Daria] Odessa Natl Med Univ, Ophthalmol Dept, Odessa, Ukraine.
   [Shakun, Konstantin] Natl Univ, Dept Phys & Chem, Odessa Maritime Acad, Odessa, Ukraine.
   [Ulianov, Vadym] Lesya Ukrainka Volyn Natl Univ, Dept Histol & Med Biol, Lutsk, Ukraine.
   [Ulianova, Nadiia] Volyn Reg Clin Hosp, Reg Ophthalmol Ctr, Lutsk, Ukraine.
   [Ulianova, Nadiia] Lesya Ukrainka Volyn Natl Univ, Dept Clin Med, Lutsk, Ukraine.
C3 Odessa National Medical University; Ministry of Education & Science of
   Ukraine; National University Odessa Maritime Academy; Ministry of
   Education & Science of Ukraine; Lesya Ukrainka Volyn National
   University; Ministry of Education & Science of Ukraine; Lesya Ukrainka
   Volyn National University
RP Peretiahina, D (通讯作者)，Odessa Natl Med Univ, Ophthalmol Dept, Odessa, Ukraine.
EM d.peretyagina@gmail.com
RI Ulianova, Nadiia A./AAC-9652-2019
OI Ulianova, Nadiia A./0000-0003-0802-240X; Ulianov,
   Vadym/0000-0002-8793-5137; Shakun, Konstantin/0000-0001-5269-4399
CR Astafyev VI., 2001, NELINEJNAYA MEKHANIK
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Campbell IC, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026286
   Family F, 2010, PHYSCS PROC, V4, P21, DOI 10.1016/j.phpro.2010.08.006
   Fang MY, 2021, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319602
   Farahmand B., 1997, FATIGUE FRACTURE MEC
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Jones BW., 1995, WEBVISION ORG RETINA, P15211560
   JONES IL, 1992, EYE, V6, P556, DOI 10.1038/eye.1992.121
   Kachanov L.M., 1960, TEORIYA POLZUCHESTI
   Kobelev A. V., 2005, Acta of Bioengineering and Biomechanics, V7, P23
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Metrangolo C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/9994098
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Morgan JE, 2004, EYE, V18, P1089, DOI 10.1038/sj.eye.6701574
   Qian XQ, 2015, BIO-MED MATER ENG, V26, pS287, DOI 10.3233/BME-151316
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Rickett T, 2011, J MED SYST, V35, P787, DOI 10.1007/s10916-010-9468-1
   Robotnov YN., 1977, ELEMENTY NASLEDSTVEN
   Robotnov YN., 1987, VVEDENIE MEKHANIKU R
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Safadi MM, 2014, INT J SOLIDS STRUCT, V51, P3265, DOI 10.1016/j.ijsolstr.2014.05.025
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   SKRZYPEK JJ, 1993, PLASTICITY CREEP
   Sopakayang R, 2011, MED ENG PHYS, V33, P1056, DOI 10.1016/j.medengphy.2011.04.012
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yakymenko I., 2019, OFTALMOLOGIJA VOSTOC, V9, P31
   Yakymenko I., 2018, VOSTOCHNAJA EVROPA, V8, P475
   Yakymenko IV., 2019, OFTALMOL ZH, V82, P3, DOI [10.31288/oftalmolzh2019538, DOI 10.31288/OFTALMOLZH2019538]
   Zehnder AT, 2012, LECT NOTES APPL COMP, V62, P1, DOI 10.1007/978-94-007-2595-9
NR 32
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL 3
PY 2022
VL 47
IS 7
BP 1043
EP 1049
DI 10.1080/02713683.2022.2059810
EA MAY 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2T6WG
UT WOS:000799418300001
PM 35577414
DA 2022-11-30
ER

PT J
AU Stewart, MW
   Garg, S
   Newman, EM
   Jeffords, E
   Konopinska, J
   Jackson, S
   Sikorski, BL
   Rawner, ES
AF Stewart, Michael W.
   Garg, Seema
   Newman, Erin M.
   Jeffords, Elizabeth
   Konopinska, Joanna
   Jackson, Sam
   Sikorski, Bartosz L.
   Rawner, Esther S.
TI SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY
   DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE CCR3; neovascular age-related macular degeneration; oral treatment;
   SD-OCT morphology; treatment-naive; visual acuity improvement; receptor
   antagonist
ID BEVACIZUMAB AVASTIN THERAPY; CHOROIDAL NEOVASCULARIZATION; CCR3;
   RANIBIZUMAB; GROWTH
AB Purpose: To evaluate the safety and therapeutic effects of orally administered AKST4290 (formerly BI 144807 and ALK4290) in treatment-naive patients with neovascular age-related macular degeneration. Methods: In this prospective, multicenter, open-label Phase 2a pilot clinical study, 30 patients with newly diagnosed neovascular age-related macular degeneration self-administered AKST4290 (400 mg) orally twice daily for 6 weeks. Patients were examined weekly for safety, to measure best-corrected visual acuity (BCVA), and to perform exploratory morphologic assessments. The primary endpoint was the mean change in BCVA from baseline to end of treatment, and the secondary endpoint was safety. Exploratory endpoints investigated potential changes in macular morphology. Results: Mean BCVA improved by +7.0 letters (95% CI, 2.2-11.7); 24 patients (82.8%) had stable or improved BCVA, with 6 (20.7%) gaining >= 15 letters. No patients experienced severe or serious adverse events. Conclusion: In this 6-week study, AKST4290 treatment was associated with improved BCVA scores in patients with treatment-naive neovascular age-related macular degeneration. All adverse events were mild or moderate in severity and no safety issues were identified. Treatment of neovascular age-related macular degeneration with AKST4290 warrants further investigation in randomized, placebo-controlled trials.
C1 [Stewart, Michael W.] Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
   [Garg, Seema; Newman, Erin M.; Jeffords, Elizabeth; Jackson, Sam; Rawner, Esther S.] Alkahest Inc, San Carlos, CA USA.
   [Konopinska, Joanna] Med Univ Bialystok, Bialystok, Poland.
   [Sikorski, Bartosz L.] Nicolaus Copernicus Univ, Dept Ophthalmol, Bydgoszcz, Poland.
C3 Mayo Clinic; Medical University of Bialystok; Nicolaus Copernicus
   University
RP Stewart, MW (通讯作者)，Mayo Clin, Ophthalmol, 4500 San Pablo Rd 5, Jacksonville, FL 32224 USA.
EM Stewart.Michael@mayo.edu
RI Sikorski, Bartosz L/AHD-2057-2022
OI Sikorski, Bartosz L/0000-0001-5357-9560
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Deng Y, 2014, AM ASS PHARM SCIENTI
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Iwase T, 2013, INVEST OPHTH VIS SCI, V54, P503, DOI 10.1167/iovs.12-10473
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kuse Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00207
   MacCumber M, 2019, AM ACAD OPHTHALMOLOG
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Riaz M, 2017, NEURAL REGEN RES, V12, P584, DOI 10.4103/1673-5374.205094
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
NR 27
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2022
VL 42
IS 6
BP 1038
EP 1046
DI 10.1097/IAE.0000000000003446
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1K9HA
UT WOS:000798904200008
PM 35537111
DA 2022-11-30
ER

PT J
AU Fernandes, AR
   Zielinska, A
   Sanchez-Lopez, E
   dos Santos, T
   Garcia, ML
   Silva, AM
   Karczewski, J
   Souto, EB
AF Rita Fernandes, Ana
   Zielinska, Aleksandra
   Sanchez-Lopez, Elena
   dos Santos, Tiago
   Luisa Garcia, Maria
   Silva, Amelia M.
   Karczewski, Jacek
   Souto, Eliana B.
TI Exudative versus Nonexudative Age-Related Macular Degeneration:
   Physiopathology and Treatment Options
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; inflammatory cascade; antiangiogenic
   agents; choroidal neovascularization; geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL-COHERENCE-TOMOGRAPHY; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR VEGF; GEOGRAPHIC ATROPHY;
   PHOTODYNAMIC THERAPY; EYE DISEASE; FOLLOW-UP; INTRAVITREAL BEVACIZUMAB;
   FUNDUS AUTOFLUORESCENCE
AB Age-related macular degeneration (AMD) is an eye disease typically associated with the aging and can be classified into two types-namely, the exudative and the nonexudative AMD. Currently available treatments for exudative AMD use intravitreal injections, which are associated with high risk of infection that can lead to endophthalmitis, while no successful treatments yet exist for the nonexudative form of AMD. In addition to the pharmacologic therapies administered by intravitreal injection already approved by the Food and Drug Administration (FDA) in exudative AMD, there are some laser treatments approved that can be used in combination with the pharmacological therapies. In this review, we discuss the latest developments of treatment options for AMD. Relevant literature available from 1993 was used, which included original articles and reviews available in PubMed database and also information collected from Clinical Trials Gov website using "age-related macular degeneration" and "antiangiogenic therapies" as keywords. The clinical trials search was limited to ongoing trials from 2015 to date.
C1 [Rita Fernandes, Ana; dos Santos, Tiago] Univ Porto, i3s Inst Res & Innovat Hlth, R Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Rita Fernandes, Ana; dos Santos, Tiago] Univ Porto, INEB Biomed Engn Inst, Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Rita Fernandes, Ana] Univ Porto, FEUP Fac Engn, R Dr Roberto Frias, P-4200465 Porto, Portugal.
   [Rita Fernandes, Ana; Sanchez-Lopez, Elena; Luisa Garcia, Maria] Univ Barcelona, Fac Pharm, Dept Pharm Pharmaceut Technol & Phys Chem, Barcelona 08001, Spain.
   [Rita Fernandes, Ana; Silva, Amelia M.] UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.
   [Zielinska, Aleksandra] Polish Acad Sci, Inst Human Genet, Strzeszynska 32, PL-60479 Poznan, Poland.
   [Sanchez-Lopez, Elena; Luisa Garcia, Maria] Univ Barcelona, Inst Nanosci & Nanotechnol IN2UB, Barcelona 08001, Spain.
   [Silva, Amelia M.] Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, UTAD, P-5001801 Vila Real, Portugal.
   [Karczewski, Jacek] Poznan Univ Med Sci, Dept Environm Med, PL-60479 Poznan, Poland.
   [Karczewski, Jacek] Poznan Univ Med Sci, H Swiecicki Univ Hosp, Dept Gastroenterol Dietet & Internal Dis, PL-60355 Poznan, Poland.
   [Souto, Eliana B.] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua de Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Souto, Eliana B.] Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.
   [Souto, Eliana B.] LABBELS Associate Lab, P-4800122 Braga, Portugal.
C3 Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; University of Barcelona; University of Tras-os-Montes & Alto
   Douro; Polish Academy of Sciences; Institute of Human Genetics of the
   Polish Academy of Sciences; University of Barcelona; University of
   Tras-os-Montes & Alto Douro; Poznan University of Medical Sciences;
   Poznan University of Medical Sciences; Universidade do Porto;
   Universidade do Minho
RP Karczewski, J (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60479 Poznan, Poland.; Karczewski, J (通讯作者)，Poznan Univ Med Sci, H Swiecicki Univ Hosp, Dept Gastroenterol Dietet & Internal Dis, PL-60355 Poznan, Poland.; Souto, EB (通讯作者)，Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua de Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.; Souto, EB (通讯作者)，Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.; Souto, EB (通讯作者)，LABBELS Associate Lab, P-4800122 Braga, Portugal.
EM anaritavfernandes@gmail.com; aleksandra.zielinska@igcz.poznan.pl;
   esanchezlopez@ub.edu; tiago.f.santos@ineb.up.pt; marisagarcia@ub.edu;
   amsilva@utad.pt; jkarczewski@ump.edu.pl; ebsouto@ff.up.pt
RI Souto, Eliana/GQZ-3071-2022; Souto, Eliana/T-1645-2019; Silva, Amélia
   M/J-7128-2013; Sanchez Lopez, Elena/O-7645-2018
OI Souto, Eliana/0000-0002-9737-6017; Silva, Amélia M/0000-0002-7524-9914;
   Sanchez Lopez, Elena/0000-0003-2571-108X; Fernandes,
   Ana/0000-0002-8787-7854; Zielinska, Aleksandra/0000-0003-2603-1377
FU Portuguese Science and Technology Foundation (FCT) from the Ministry of
   Science and Technology (MCTES), European Social Fund (FSE) of EU
   [SFRH/BD/130555/2017, UIDB/04033/2020]; European Funds (PRODER/COMPETE);
   FEDER under the Partnership Agreement PT2020; National Science Centre
   within the MINIATURA 4 [2020/04/X/ST5/00789]; START 2021 Program of the
   Foundation for Polish Science (FNP)
FX This work was funded by the Portuguese Science and Technology Foundation
   (FCT) from the Ministry of Science and Technology (MCTES), European
   Social Fund (FSE) of EU, for the scholarship SFRH/BD/130555/2017 granted
   to A. R. Fernandes, and for the projects (CEB strategic fund) and
   UIDB/04033/2020 (CITAB), co-funded by European Funds (PRODER/COMPETE)
   and FEDER, under the Partnership Agreement PT2020. The work was also
   supported by the National Science Centre within the MINIATURA 4 for
   single research activity (grant no: 2020/04/X/ST5/00789) and by the
   START 2021 Program of the Foundation for Polish Science (FNP) granted to
   A. Zieli ' nska.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anand-Apte B., 2010, ENCY EYE
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Arepalli S, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00325-5
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blodi Barbara A, 2004, Insight, V29, P15
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Breukink MB, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0939-z
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P6, DOI 10.1186/s40942-017-0066-y
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chabbar I., 2020, SAUDI J MED PHARM SC, V6, P466, DOI [10.36348/sjmps.2020.v06i06.010, DOI 10.36348/SJMPS.2020.V06I06.010]
   Chen L, 2020, EXP THER MED, V19, P3691, DOI 10.3892/etm.2020.8641
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Cohen MN, 2021, BRIT J OPHTHALMOL, V105, P716, DOI 10.1136/bjophthalmol-2020-316511
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Di Carlo E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153297
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Ghasemi M, 2018, ARTIF CELL NANOMED B, V46, P1694, DOI 10.1080/21691401.2017.1391820
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gujral GS, 2019, J CURR OPHTHALMOL, V31, P411, DOI 10.1016/j.joco.2019.09.001
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2012, RETINA-J RET VIT DIS, V32, P2150, DOI 10.1097/IAE.0b013e3182576d07
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jones M, 2020, OPHTHAL EPIDEMIOL, V27, P399, DOI 10.1080/09286586.2020.1762229
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane P.A., 2013, CURR OPHTHALMOL REP, V1, P1, DOI [10.1007/s40135-012-0005-x, DOI 10.1007/S40135-012-0005-X]
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Kinnunen K, 2012, ANN MED, V44, P1, DOI 10.3109/07853890.2010.532150
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kolar P., 2013, AGE RELATED MACULAR, P105
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   Lai Timothy Y Y, 2015, Trans Am Ophthalmol Soc, V113, pT8
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mallias I., 2017, OPHTHALMOL J, V2, P69, DOI [10.5603/OJ.2017.0016, DOI 10.5603/OJ.2017.0016]
   Marmor MF, 2000, SURV OPHTHALMOL, V44, P343, DOI 10.1016/S0039-6257(99)00113-7
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Papadopoulos Z, 2020, CURR MED SCI, V40, P851, DOI 10.1007/s11596-020-2253-6
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Ratnayake K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28254-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahay P., 2018, RETIN MED SURG MANAG, P168
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Savastano MC, 2021, EUR J OPHTHALMOL, V31, P514, DOI 10.1177/1120672120909769
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma A, 2020, EYE, V34, P1006, DOI 10.1038/s41433-019-0722-6
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P2, DOI 10.1136/bjophthalmol-2019-314443
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Talks SJ, 2017, ASIA-PAC J OPHTHALMO, V6, P498, DOI 10.22608/APO.2017305
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Victor A.A., 2019, VISUAL IMPAIRMENT BL
   Wirfs M.J., 2021, APRN PAS COMPLETE GU
   Wolf A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910362
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu KY, 2018, CAN J OPHTHALMOL, V53, P168, DOI 10.1016/j.jcjo.2017.08.006
   Xu XY, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8445-y
   Yamashiro K, 2021, JPN J OPHTHALMOL, V65, P741, DOI 10.1007/s10384-021-00869-x
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Lu Y, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320953349
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 178
TC 6
Z9 6
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 5
AR 2592
DI 10.3390/ijms23052592
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0C3GI
UT WOS:000775205400001
PM 35269743
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bellezza, I
AF Bellezza, Ilaria
TI Oxidative Stress in Age-Related Macular Degeneration: Nrf2 as
   Therapeutic Target
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE oxidative stress; light-induced photooxidative damage; cigarette smoke;
   aging; Nrf2 activators
ID PIGMENT EPITHELIAL-CELLS; TRANSCRIPTION FACTOR NRF2; RETINAL LIGHT
   DAMAGE; PROTECTS RPE CELLS; MEDITERRANEAN DIET; CIGARETTE-SMOKING;
   SULFORAPHANE; ACTIVATION; PERMEABILITY; INFLAMMATION
AB Age-related macular degeneration is one of the leading causes of vision loss in the elderly. Genetics, environmental insults, and age-related issues are risk factors for the development of the disease. All these risk factors are linked to the induction of oxidative stress. In young subjects retinal pigment epithelial cells mitigate reactive oxygen generation by the elimination of dysfunctional mitochondria, via mitophagy, and by increasing antioxidant defenses via Nrf2 activation. The high amount of UV light absorbed by the retina, together with cigarette smoking, cooperate with the aging process to increase the amount of reactive oxygen species generated by retinal pigment epithelium where oxidative stress arises. Moreover, in the elderly both the mitophagic process and Nrf2 activation are impaired thus causing retinal cell death. This review will focus on the impact of oxidative stress on the pathogenesis of age-related macular degeneration and analyze the natural and synthetic Nrf2-activating compounds that have been tested as potential therapeutic agents for the disease.
C1 [Bellezza, Ilaria] Univ Perugia, Dept Expt Med, Perugia, Italy.
C3 University of Perugia
RP Bellezza, I (通讯作者)，Univ Perugia, Dept Expt Med, Perugia, Italy.
EM ilaria.bellezza@unipg.it
RI BELLEZZA, ILARIA/AAA-8099-2022
OI BELLEZZA, ILARIA/0000-0002-8106-1600
CR Baba K, 2018, J BIOL RHYTHM, V33, P441, DOI 10.1177/0748730418783648
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Bellezza I, 2014, INT J BIOCHEM CELL B, V51, P159, DOI 10.1016/j.biocel.2014.03.023
   Bellezza Ilaria, 2010, Cancers (Basel), V2, P483, DOI 10.3390/cancers2020483
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Dinkova-Kostova AT, 2015, FREE RADIC BIOL ME B, V88, P179, DOI DOI 10.1016/J.FREERADBI0MED.2015.04.036
   Dulull NK, 2018, CURR MOL PHARMACOL, V11, P237, DOI 10.2174/1874467211666180125163009
   Early JO, 2018, P NATL ACAD SCI USA, V115, pE8460, DOI 10.1073/pnas.1800431115
   Ewald CY, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7100130
   Farboud B, 1999, MOL VIS, V5, pU1
   Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Govindaraju VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182420
   Grottelli S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081332
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Inoue Y, 2017, J NEUROCHEM, V141, P750, DOI 10.1111/jnc.14029
   Ivanov IV, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700377
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Jacob KD, 2013, MECH AGEING DEV, V134, P139, DOI 10.1016/j.mad.2013.02.008
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Laurent V, 2017, EXP EYE RES, V165, P90, DOI 10.1016/j.exer.2017.09.007
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   Li Y, 2013, TOXICOL APPL PHARM, V272, P726, DOI 10.1016/j.taap.2013.07.029
   Lin L, 2006, CELL MOL IMMUNOL, V3, P351
   Liu XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111835
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mansoor S, 2014, INDIAN J OPHTHALMOL, V62, P16, DOI 10.4103/0301-4738.126168
   Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017
   Martucci M, 2017, NUTR REV, V75, P442, DOI 10.1093/nutrit/nux013
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakagami Y, 2015, BRIT J PHARMACOL, V172, P1237, DOI 10.1111/bph.12999
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   O'Mealey GB, 2017, REDOX BIOL, V11, P103, DOI 10.1016/j.redox.2016.11.007
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Orhan C, 2016, J OCUL PHARMACOL TH, V32, P631, DOI 10.1089/jop.2015.0154
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rom O, 2013, RESP PHYSIOL NEUROBI, V187, P5, DOI 10.1016/j.resp.2013.01.013
   Ruben MD, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat8806
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   SIES H, 1985, PHILOS T ROY SOC B, V311, P617, DOI 10.1098/rstb.1985.0168
   Sohal RS, 2012, FREE RADICAL BIO MED, V52, P539, DOI 10.1016/j.freeradbiomed.2011.10.445
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Xie XB, 2017, MOL VIS, V23, P520
   Yu MZ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070842
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhuang Yong, 2014, Inflammation & Allergy Drug Targets, V13, P153
NR 78
TC 79
Z9 82
U1 4
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 5
PY 2018
VL 9
AR 1280
DI 10.3389/fphar.2018.01280
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GZ3KC
UT WOS:000449284500001
PM 30455645
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kuroda, Y
   Yamashiro, K
   Ooto, S
   Tamura, H
   Oishi, A
   Nakanishi, H
   Miyata, M
   Hata, M
   Takahashi, A
   Wakazono, T
   Yoshimura, N
   Tsujikawa, A
AF Kuroda, Yoshimasa
   Yamashiro, Kenji
   Ooto, Sotaro
   Tamura, Hiroshi
   Oishi, Akio
   Nakanishi, Hideo
   Miyata, Manabu
   Hata, Masayuki
   Takahashi, Ayako
   Wakazono, Tomotaka
   Yoshimura, Nagahisa
   Tsujikawa, Akitaka
TI MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor therapy; macular atrophy; optical coherence tomography; macular
   morphology; aflibercept
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL THICKNESS; PIGMENT
   EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; RANIBIZUMAB; VEGF; PROGRESSION;
   INJECTION; THERAPY; RISK
AB Purpose: To investigate the incidence and predictors of macular atrophy during treatment with aflibercept for neovascular age-related macular degeneration in Japanese patients.
   Methods: This study included patients with treatment-naive subfoveal neovascular age-related macular degeneration treated from December 2012 through January 2015. Patients were treated with bi-monthly aflibercept injections after 3 monthly loading injections for the first year. Diagnosis of retinal pigment epithelial atrophy was made based on color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence. Baseline characteristics and morphological features were analyzed for their association with the development of macular atrophy.
   Results: This study included 123 eyes that had no baseline macular atrophy and treated with aflibercept injections for 12 months. Thirteen eyes (10.6%) developed new macular atrophy at 12 months. Logistic regression analysis showed that the presence of intraretinal fluid and thinner subfoveal choroidal thickness at baseline were associated with the development of macular atrophy after aflibercept treatment.
   Conclusion: Macular atrophy developed in about 10% of eyes with neovascular age-related macular degeneration during 12 months of treatment with a fixed regimen of aflibercept. Intraretinal fluid and subfoveal choroidal thickness seem to be predictors for development of macular atrophy after anti-vascular endothelial growth factor (VEGF) therapy.
C1 [Kuroda, Yoshimasa; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Oishi, Akio; Nakanishi, Hideo; Miyata, Manabu; Hata, Masayuki; Takahashi, Ayako; Wakazono, Tomotaka; Yoshimura, Nagahisa; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yamashiro, Kenji] Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018; TAMURA, Hiroshi/H-1855-2011; Oishi,
   Akio/AAE-9996-2020
OI TAMURA, Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Miyata,
   Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan; Innovative Techno-Hub for Integrated Medical Bio-imaging
   of the Project for Developing Innovation Systems; Ministry of Education,
   Culture, Sports, Science and Technology (MEXT) in Japan; Alcon, Tokyo,
   Japan; Canon, Tokyo, Japan; Santen, Osaka, Japan; Novartis, Tokyo,
   Japan; Bayer, Tokyo, Japan; Pfizer, Tokyo, Japan; Senju, Osaka, Japan;
   Nidek, Gamagori, Japan; Kowa, Nagoya, Japan; AMO Japan, Tokyo, Japan;
   Grants-in-Aid for Scientific Research [26861451] Funding Source: KAKEN
FX Supported in part by the Japan Society for the Promotion of Science
   (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research, no.
   21592256), the Japan National Society for the Prevention of Blindness,
   Tokyo, Japan and the Innovative Techno-Hub for Integrated Medical
   Bio-imaging of the Project for Developing Innovation Systems, from the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT) in
   Japan.; S. Ooto: Alcon, Tokyo, Japan (financial support). A. Oishi:
   Alcon, Tokyo, Japan (financial support). N. Yoshimura: Canon, Tokyo,
   Japan (financial support); Santen, Osaka, Japan (financial support);
   Novartis, Tokyo, Japan (financial support); Bayer, Tokyo, Japan
   (financial support). A. Tsujikawa: Pfizer, Tokyo, Japan (financial
   support); Bayer, Tokyo, Japan (financial support); Novartis, Tokyo,
   Japan (financial support); Santen, Osaka, Japan (financial support);
   Senju, Osaka, Japan (financial support); Alcon, Tokyo, Japan (financial
   support); Nidek, Gamagori, Japan (financial support); Kowa, Nagoya,
   Japan (financial support); AMO Japan, Tokyo, Japan (financial support).
   The remaining authors have no conflicting interests to disclose.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 29
TC 18
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2018
VL 38
IS 9
BP 1743
EP 1750
DI 10.1097/IAE.0000000000001765
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VL
UT WOS:000454003500013
PM 28691937
DA 2022-11-30
ER

PT J
AU Samelska, K
   Kupis, M
   Izdebska, J
   Kaminska, A
   Skopinski, P
AF Samelska, Katarzyna
   Kupis, Magdalena
   Izdebska, Justyna
   Kaminska, Anna
   Skopinski, Piotr
TI Novel approach to antiangiogenic factors in age-related macular
   degeneration therapy
SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
DE age-related macular degeneration; axitinib; AMD; eculizumab; gene
   therapy; brolu-cizumab; abicipar pegol; faricimab; lampalizumab;
   pegcetacoplan
ID MEMBRANE ATTACK COMPLEX; GEOGRAPHIC ATROPHY SECONDARY; ENDOTHELIAL
   GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; GENE-THERAPY; PHOTODYNAMIC
   THERAPY; CLINICAL-TRIALS; VEGF; EXPRESSION; EPITHELIUM
AB Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among the population above 85 worldwide. There are two main types of AMD: neovascular and dry AMD. Neovascular AMD leads to macular changes resulting from abnormal choroidal neovascularization. Untreated neovascular AMD leads to scar formation and irreversible sight deterioration. Dry AMD in consequence leads to atrophic changes of the macula. The last decades brought a breakthrough in the therapy of neovascular age-related macular degeneration by introduction of, firstly, photodynamic therapy and, later, anti-VEGF agents administered intravitreally in order to stop neoangiogenesis. However, the treatment of dry AMD is still challenging. Among the directions in dry AMD treatment, the most promising are complement cascade inhibitors and complement cascade targeted gene therapy. In the article we outline the main directions in up-to-date experimental and practical approaches to wet and dry AMD therapy with the emphasis on antiangiogenic factors and gene therapy focused on the inhibition of pathological angiogenesis.
C1 [Samelska, Katarzyna; Kupis, Magdalena; Izdebska, Justyna; Kaminska, Anna] Med Univ Warsaw, Dept Ophthalmol, Warsaw, Poland.
   [Samelska, Katarzyna; Kupis, Magdalena; Izdebska, Justyna; Kaminska, Anna; Skopinski, Piotr] SPKSO Ophthalm Univ Hosp, Warsaw, Poland.
   [Skopinski, Piotr] Med Univ Warsaw, Dept Histol & Embryol, Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw
RP Samelska, K (通讯作者)，SPKSO Ophthalm Univ Hosp, Dept Ophthalmol, Warsaw, Poland.
EM samelskakatarzyna@gmail.com
OI Samelska, Katarzyna/0000-0003-0366-1448
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Birke MT, 2014, GENE THER, V21, P507, DOI 10.1038/gt.2014.24
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Boyer DS, 2009, INVEST OPHTH VIS SCI, V50, P1260
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chalam KV, 2014, JAMA OPHTHALMOL, V132, P1350, DOI 10.1001/jamaophthalmol.2014.2356
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   Ciulla TA, 2007, INVESTIGATIVE OPHTHA, V48
   clinicaltrials.gov/, ADVM 022 INTR GEN TH
   clinicaltrials.gov, RGX 314 GEN THER ADM
   DAmico DJ, 2004, INVEST OPHTHALMOL VI, V45
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Ghodasra DH, 2016, AM J OPHTHALMOL, V161, P104, DOI 10.1016/j.ajo.2015.09.033
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Guha TK, 2017, COMPUT STRUCT BIOTEC, V15, P146, DOI 10.1016/j.csbj.2016.12.006
   Gunaydin G, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.691697
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P1006, DOI 10.1001/jamaophthalmol.2020.3537
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Kim BJ, 2020, OPHTHALMOL RETINA, V4, P889, DOI 10.1016/j.oret.2020.03.019
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Koponen S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020219
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Leaderer D, 2015, J GENE MED, V17, P101, DOI 10.1002/jgm.2829
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lin FL, 2020, MOL THER, V28, P2120, DOI 10.1016/j.ymthe.2020.06.029
   Lin JB, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132890
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   molecularpartners, ALLERGAN MOL PARTNER
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Patel PJ, 2007, INVEST OPHTHALMOL VI, V48
   Radomska-Lesniewska DM, 2017, CENT EUR J IMMUNOL, V42, P370, DOI 10.5114/ceji.2017.72804
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Samelska K, 2021, CENT EUR J IMMUNOL, V46, P111, DOI 10.5114/ceji.2021.104328
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Skopinski P, 2021, CENT EUR J IMMUNOL, V46, P105, DOI 10.5114/ceji.2021.104329
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Weleber RG, 2016, OPHTHALMOLOGY, V123, P1606, DOI 10.1016/j.ophtha.2016.03.003
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
NR 81
TC 0
Z9 0
U1 1
U2 1
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1426-3912
EI 1644-4124
J9 CENT EUR J IMMUNOL
JI Central Eur. J. Immunol.
PY 2022
VL 47
IS 1
BP 117
EP 123
DI 10.5114/ceji.2022.113103
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 1K8OQ
UT WOS:000798855600014
PM 35600160
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gonalves, FTI
   Cezario, SM
   Calastri, MCJ
   Oliveira, CIF
   Souza, DRS
   Pinhel, MAD
   Cotrim, CC
   Jorge, R
   Siqueira, RC
AF Iasbeck Gonalves, Fernanda Tanaka
   Cezario, Sabrina Mayara
   Jessica Calastri, Maria Clara
   Ferreira Oliveira, Camila Ive
   Silva Souza, Doroteia Rossi
   de Souza Pinhel, Marcela Augusta
   Cotrim, Carina Costa
   Jorge, Rodrigo
   Siqueira, Rubens Camargo
TI Influence of VEGF-C936T genetic variant on age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Vascular endothelial growth factor A; Enzyme-linked immunosorbent assay;
   Polymerase chain reaction; Genetic polymorphism; Macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PLASMA-LEVELS; VEGF GENE; RISK-FACTORS;
   POLYMORPHISMS
AB Purpose: To evaluate the association between the VEGF-C936T polymorphism and serum vascular endothelial growth factor (VEGF) levels, lifestyle, and demographic parameters in patients with age-related macular degeneration (AMD).
   Methods: A total of 183 individuals were enrolled in the present study, including 88 patients with AMD receiving clinical and pharmacological treatment (study group, SG) and 95 individuals without AMD as controls (control group, CG). The presence of the VEGF-C936T polymorphism and serum VEGF levels were determined using polymerase chain reaction/restriction fragment length polymorphism and enzyme-linked immunosorbent assay, respectively. Significance was set at P < 0.05 for all statistical analyses.
   Results: The homozygous wild-type genotype (CC) and the C allele were predominant in both groups (P = 0.934 and P = 0.938, respectively). Serum VEGF levels (assessed in 57% and 31% of patients in the SG and CG, respectively) were comparable between groups (SG, 307.9 +/- 223.6 pg/mL; CG, 305.1 +/- 212.3 pg/mL; P = 0.955). A significantly higher prevalence of smoking (44% vs 25%; P = 0.01) and hypertension (66% vs 48%; P = 0.025) was observed in the SG than in the CG. The distribution of alcohol consumption and dyslipidemia was similar between groups (P > 0.05).
   Conclusions: In the present study group of Brazilian patients, the VEGF-C936T polymorphism was not found to be associated with age-related macular degeneration. However, smoking and systemic arterial hypertension (SAH) were found to be potential independent risk factors for the development of age-related macular degeneration. Comparable serum VEGF levels in both study groups may reflect the efficacy of pharmacological treatment of AMD.
C1 [Iasbeck Gonalves, Fernanda Tanaka; Cezario, Sabrina Mayara; Jessica Calastri, Maria Clara; Ferreira Oliveira, Camila Ive; Silva Souza, Doroteia Rossi] Fac Med Sao Jose do Rio Preto FAMERP, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   [de Souza Pinhel, Marcela Augusta] Fac Med Sao Jose do Rio Preto FAMERP, Ribeirao Preto, SP, Brazil.
   [Cotrim, Carina Costa; Jorge, Rodrigo; Siqueira, Rubens Camargo] Fac Med Sao Jose do Rio Preto FAMERP, Dept Ophthalmol, Ribeirao Preto, SP, Brazil.
RP Gonalves, FTI (通讯作者)，Fac Med Sao Jose do Rio Preto FAMERP, Posgrad Ciencias Saude, Ave Brigadeiro Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM fernandatig@gmail.com
RI Calastri, Maria Clara J/K-5529-2015; Souza, Dorotéia/AAR-7748-2021
OI Calastri, Maria Clara J/0000-0003-4413-8207; Siqueira,
   Rubens/0000-0003-4563-1570
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo" (FAPESP); Medical
   School of Sao Jose do Rio Preto (FAMERP)
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo" (FAPESP) and the Medical School of Sao Jose do Rio Preto
   (FAMERP).
CR Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Huang C, 2013, MOL VIS, V19, P1211
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kataoka N, 2006, CANCER EPIDEM BIOMAR, V15, P1148, DOI 10.1158/1055-9965.EPI-05-0871
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu Yuqing, 2014, Genet Test Mol Biomarkers, V18, P245, DOI 10.1089/gtmb.2013.0368
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Salazar LA, 1998, CLIN CHEM, V44, P1748
   Santos RV, 2009, CURR ANTHROPOL, V50, P787, DOI 10.1086/644532
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Wolf G, 2004, BREAST CANCER RES TR, V88, P205, DOI 10.1007/s10549-004-0724-2
NR 25
TC 5
Z9 7
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD SEP-OCT
PY 2015
VL 78
IS 5
BP 290
EP 294
DI 10.5935/0004-2749.20150077
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT8SO
UT WOS:000363087000006
PM 26466227
OA gold
DA 2022-11-30
ER

PT J
AU Stewart, MW
AF Stewart, Michael W.
TI Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related
   macular degeneration
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; anti-VEGF drugs;
   bevacizumab; intravitreal injections; ranibizumab; VEGF; VEGF Trap
ID COHERENCE TOMOGRAPHY FINDINGS; VASCULAR-PERMEABILITY FACTOR;
   GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION;
   BEVACIZUMAB AVASTIN(R); VISUAL IMPAIRMENT; LEGAL BLINDNESS; CELLS
   SECRETE; IN-VITRO
AB Aflibercept, a soluble receptor molecule that binds VEGF, has been recently approved for the treatment of exudative age-related macular degeneration. This fusion protein with binding sequences from VEGF receptors 1 and 2 possesses high binding affinity for isomers of VEGF-A, VEGF-B and PlGF, and prevents VEGF from initiating proliferation and migration of vascular endothelial cells. Phase III trials showed that intravitreal aflibercept given monthly or every 2 months produces visual improvement and decrease in macular thickness comparable with monthly ranibizumab. The second year of the trials demonstrated that as-needed aflibercept maintained vision with few required injections. Aflibercept promises to decrease the treatment burden faced by patients with exudative age-related macular degeneration.
EM stewart.michael@mayo.edu
FU Regeneron; Bayer
FX The author's employer has received research support from Regeneron and
   Bayer. The author has served on advisory boards for Regeneron and
   Allergan. The author has no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Busbee BG, 2011, AM AC OPHTH ANN M OR
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CHAN CK, 1994, OPHTHALMOLOGY, V101, P289
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Christoforidis JB, 2011, INVEST OPHTH VIS SCI, V52, P5899, DOI 10.1167/iovs.10-6862
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Furfine E, INVEST OPHTHALMOL VI, V47, P1430
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Oliveira HB, 2010, EUR J OPHTHALMOL, V20, P48, DOI 10.1177/112067211002000106
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   STEWART MA, 2011, EYE REPORTS, V45, P1
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   US Census Bureau Population Division, 2000, NAT POP PROJ SUMM TA
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zhong XF, 2011, MOL VIS, V17, P492
NR 62
TC 20
Z9 20
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD MAR
PY 2013
VL 6
IS 2
BP 103
EP 113
DI 10.1586/ECP.12.81
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V37SI
UT WOS:000209295100007
PM 23473589
DA 2022-11-30
ER

PT J
AU Ozcaliskan, S
   Balci, S
   Yenerel, NM
AF Ozcaliskan, Sehnaz
   Balci, Sevcan
   Yenerel, Nursal Melda
TI Choroidal vascularity index determined by binarization of enhanced depth
   imaging optical coherence tomography images in eyes with intermediate
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; choroidal thickness; choroidal
   vascularity index; optical coherence tomography
ID RETINAL-PIGMENT EPITHELIUM; MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE;
   AXIAL LENGTH; THICKNESS; PROGRESSION; MACULOPATHY; PREVALENCE; AMD
AB Purpose
   To evaluate choroidal structural changes in patients with intermediate age-related macular degeneration using choroidal vascularity index.
   Methods
   The eyes of patients with intermediate age-related macular degeneration and controls were evaluated with enhanced depth imaging optical coherence tomography images. Subfoveal choroidal area was segmented into luminal area and stromal area by the binarization technique on enhanced depth imaging optical coherence tomography images using ImageJ software. Choroidal vascularity index was defined as the ratio of luminal area to total circumscribed subfoveal choroidal area.
   Results
   Fifty-seven eyes with intermediate age-related macular degeneration and 60 healthy control eyes were included in the study. The choroidal vascularity index was computed as 59.53% +/- 4.9% in the intermediate age-related macular degeneration group and as 62.7% +/- 4.3% in the control group (p = 0.002). Patients with age-related macular degeneration showed significantly lower values of stromal area and higher values of luminal area compared to control subjects (0.51 +/- 0.22 vs 0.87 +/- 0.21, p < 0.001 and 0.74 +/- 0.22 vs 0.52 +/- 0.18, p < 0.001, respectively).
   Conclusion
   Eyes with intermediate age-related macular degeneration demonstrated reduced choroidal vascularity index compared to healthy eyes. Choroidal vascularity index seems to be a potential non-invasive quantitative method for studying structural changes of the choroid in patients with intermediate age-related macular degeneration.
C1 [Ozcaliskan, Sehnaz] Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
   [Balci, Sevcan; Yenerel, Nursal Melda] Univ Hlth Sci, Haydarpa Numune Training & Res Hosp, Tibbiye Cd 23, TR-34668 Istanbul, Turkey.
C3 University of Health Sciences Turkey
RP Balci, S (通讯作者)，Univ Hlth Sci, Haydarpa Numune Training & Res Hosp, Tibbiye Cd 23, TR-34668 Istanbul, Turkey.
EM svcnyldz@hotmail.com
RI Balci, Sevcan Yildiz/AAW-9338-2020; Balci, Sevcan/CAF-6805-2022;
   Ozcaliskan, Sehnaz/AAA-1305-2021; Ozcaliskan, Sehnaz/ABC-9911-2020
OI Balci, Sevcan Yildiz/0000-0002-1695-0583; Balci,
   Sevcan/0000-0002-1695-0583; Ozcaliskan, Sehnaz/0000-0002-3783-3570; 
CR Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   He XG, 2019, INT J OPHTHALMOL-CHI, V12, P1465, DOI 10.18240/ijo.2019.09.15
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Lee Geun Young, 2017, Korean J Ophthalmol, V31, P151, DOI 10.3341/kjo.2017.31.2.151
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 30
TC 8
Z9 9
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1512
EP 1518
AR 1120672120919341
DI 10.1177/1120672120919341
EA APR 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000533933400001
PM 32329371
DA 2022-11-30
ER

PT J
AU Tasman, W
   Rovner, B
AF Tasman, W
   Rovner, B
TI Age-related macular degeneration: treating the whole patient
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; depression; dietary supplementation; macular degeneration;
   nutrition; support groups
ID DEPRESSION; MACULOPATHY
AB Ophthalmologists can help to improve the quality of life for patients with age-related macular degeneration (AMD) by treating the whole patient. Patients should be encouraged to seek psychiatric care for depression, especially if symptoms are persistent. They may also cope better with their vision loss by participating in AMD support groups. For earlier diagnosis of AMD, patients at high risk should be screened; if large drusen are present, nutritional suggestions can be made. Until treatments to prevent vision loss or to restore vision are available, these approaches provide optimal care.
C1 Wills Eye Hosp & Res Inst, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University
RP Tasman, W (通讯作者)，Wills Eye Hosp & Res Inst, 840 Walnut St,Ste 1510, Philadelphia, PA 19107 USA.
EM wst1@ureach.com
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
   TIELSCH JM, 1994, VISION PROBLEMS US R, P24
NR 18
TC 10
Z9 10
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 389
EP 391
DI 10.1016/S0008-4182(05)80082-1
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400015
PM 15947809
DA 2022-11-30
ER

PT J
AU Mello, E
   Falsini, B
   Zuppi, C
   Giardina, B
   Concolino, P
   Capoluongo, E
AF Mello, Enrica
   Falsini, Benedetto
   Zuppi, Cecilia
   Giardina, Bruno
   Concolino, Paola
   Capoluongo, Ettore
TI Rapid detection of CFH (p.Y402H) and ARMS2 (p.A69S) polymorphisms in
   age-related macular degeneration using high-resolution melting analysis
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE age-related macular degeneration (AMD); age-related maculopathy
   susceptibility 2 (ARMS2); complement factor H (CFH); high resolution
   melting (HRM); polymorphism
ID COMPLEMENT FACTOR-H; ASSOCIATION; LOC387715; GENOTYPES; DISEASE; Y402H;
   RISK; GENE
AB Background: Age-related macular degeneration (AMD) is a complex disorder causing irreversible central vision loss. Complement Factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) are now widely accepted as important AMD susceptibility genes. In particular, two specific variants, CFH p.Y402H and ARMS2 p.A69S, have been reported as strongly AMD associated. In order to perform the genetic screening of these single nucleotide polymorphisms (SNPs), we describe a high resolution melting analysis (HRM) as a rapid closed tube mutation scanning assay.
   Methods: To validate HRM genotyping, 94 DNA samples from AMD patients (previously genotyped by sequence analysis) were analyzed. PCR amplification and melting curve analysis were performed in the LightCycler 480 Real-Time PCR System. In order to evaluate the accuracy of the HRM assay, we performed a blinded study of 20 unknown independent samples.
   Results: We correctly genotyped all samples. In fact, all samples corresponded to the previous genotype assignments.
   Conclusions: Early identification of individuals with genetic risk variants CFH p.Y402H and ARMS2 p.A69S is clinically important for the definition of AMD status. High-resolution DNA melting is homogenous, accurate and rapid method for CFH and ARMS2 genotyping.
C1 [Mello, Enrica; Zuppi, Cecilia; Giardina, Bruno; Concolino, Paola; Capoluongo, Ettore] Catholic Univ, Mol Biol Lab, Inst Biochem & Clin Biochem, Rome, Italy.
   [Falsini, Benedetto] Catholic Univ, Dept Ophthalmol & Otolaryngol, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Concolino, P (通讯作者)，Univ Cattolica Sacro Cuore, Lab Clin Mol Diagnost, Largo A Gemelli 8, I-00168 Rome, Italy.
EM paolaconcolino78@libero.it
RI Falsini, Benedetto/AAC-5907-2022; concolino, paola/AAB-7427-2022;
   Falsini, Benedetto/V-1070-2019
OI Falsini, Benedetto/0000-0002-1694-1062; CAPOLUONGO, Ettore
   Domenico/0000-0003-4402-8403; Concolino, Paola/0000-0002-3472-8898;
   Falsini, Benedetto/0000-0002-3569-4968
FU Institute of Biochemistry and Clinical Biochemistry, Catholic University
   of Rome
FX The study was carried out by means of funding of Institute of
   Biochemistry and Clinical Biochemistry, Catholic University of Rome.
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Reed GH, 2007, PHARMACOGENOMICS, V8, P597, DOI 10.2217/14622416.8.6.597
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
NR 12
TC 6
Z9 6
U1 0
U2 1
PU WALTER DE GRUYTER & CO
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD JUN
PY 2012
VL 50
IS 6
BP 1031
EP 1034
DI 10.1515/cclm-2011-0859
PG 4
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 963OO
UT WOS:000305631600010
PM 22706242
DA 2022-11-30
ER

PT J
AU Ersoy, L
   Schick, T
   de Graft, D
   Felsch, M
   Hoyng, CB
   den Hollander, AI
   Kirchhof, B
   Fauser, S
   Liakopoulos, S
AF Ersoy, L.
   Schick, T.
   de Graft, D.
   Felsch, M.
   Hoyng, C. B.
   den Hollander, A. I.
   Kirchhof, B.
   Fauser, S.
   Liakopoulos, S.
TI Extramacular drusen are highly associated with age-related macular
   degeneration, but not with CFH and ARMS2 genotypes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; GRADING SYSTEM; MACULOPATHY; GENE; EYE;
   POLYMORPHISM; RISK; CLASSIFICATION; PROGRESSION; DISEASE
AB Background To evaluate the association of extramacular drusen (EMD) with age-related macular degeneration (AMD) and with complement factor H (CFH rs1061170) and age-related maculopathy susceptibility 2 (ARMS2 rs10490924) polymorphisms in individuals with and without AMD.
   Methods In this case-control study, AMD staging was performed in 622 individuals. EMD were defined as >= 10 drusen (including >= 1 intermediate drusen) outside the Early Treatment of Diabetic Retinopathy Study Grid within field 2. Genotype associations for CFH and ARMS2 variants were assessed using logistic regression analysis.
   Results EMD (n=213) showed a strong association with AMD (OR=3.85; p=1.66x10(-13)). AMD (n=316) was strongly associated with CFH (p=1.78x10(-7)) and ARMS2 genotypes (p=1.67x10(-8)). After adjustment for AMD, age and gender, EMD were neither associated with CFH (p=0.11) nor with ARMS2 (p=0.45) genotypes. In individuals without AMD, the groups with and without EMD showed no differences regarding both genetic variants.
   Conclusions The strong association between drusen within and outside of the macula suggests a common pathogenesis. However, EMD were not AMD-independently associated with CFH or ARMS2 genotypes. Our results indicate that patients without AMD but with EMD can serve as controls in studies evaluating AMD risk factors. Further studies are required to elucidate the aetiology and clinical relevance of EMD.
C1 [Ersoy, L.; Schick, T.; Kirchhof, B.; Fauser, S.; Liakopoulos, S.] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
   [Ersoy, L.; Schick, T.; de Graft, D.; Liakopoulos, S.] Univ Hosp Cologne, Dept Ophthalmol, Cologne Image Reading Ctr, Cologne, Germany.
   [Felsch, M.] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany.
   [Hoyng, C. B.; den Hollander, A. I.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [den Hollander, A. I.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; University of Cologne;
   Radboud University Nijmegen; Radboud University Nijmegen
RP Liakopoulos, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM liakopoulos@uk-koeln.de
RI Hollander, Anneke den/N-4911-2014
FU Ilse Palm Foundation, Germany; Retinovit Foundation, Germany
FX Supported in part by Ilse Palm Foundation, Germany, and the Retinovit
   Foundation, Germany.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Weger M, 2007, MOL VIS, V13, P1274
   1981, INVEST OPHTHALMOL 2, V21, P1
NR 22
TC 4
Z9 4
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2016
VL 100
IS 8
BP 1047
EP 1051
DI 10.1136/bjophthalmol-2015-306806
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4JR
UT WOS:000380747900006
PM 26614632
DA 2022-11-30
ER

PT J
AU Liu, Y
   Wen, F
   Huang, SH
   Luo, GW
   Yan, H
   Sun, ZH
   Wu, DH
AF Liu, Yan
   Wen, Feng
   Huang, Shizhou
   Luo, Guangwei
   Yan, Hong
   Sun, Zuhua
   Wu, Dezheng
TI Subtype lesions of neovascular age-related macular degeneration in
   Chinese patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE neovascular age-related macular degeneration; choroidal
   neovascularization; polypoidal choroidal vasculopathy; retinal
   angiomatous proliferation
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ANASTOMOSES; DETACHMENTS; ANGIOGRAPHY; FEATURES
AB Purpose To identify the subtype frequency and clinical features of neovascular age-related macular degeneration (AMD) in Chinese patients.
   Methods From January 2003 to August 2006, we investigated prospectively 155 newly diagnosed patients with presumed neovascular AMD. Fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were performed in both eyes of all patients. Subtype frequency and clinical features were recorded according to their angiograms.
   Results Three subtypes of lesion were noted, which were polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP) and mixed lesions. Of the 155 patients, 105 (67.7%) had choroidal neovascularization (CNV) of the typical type seen in AMD, 38 (24.5%) had PCV and seven (4.5%) had RAP. In five (3.2%) additional cases, mixed lesions were noted. In 38 cases (47 eyes) with PCV, the rates of subfoveal, juxtafoveal and extrafoveal lesion were respectively 29.8% (14 eyes), 8.5% (four eyes), and 61.7% (29 eyes), compared with 75.6%, 14.6% and 9.8% for CNV lesion (P < 0.01). The percentage of subfoveal lesion in PCV group was significantly lower than that in the CNV group (P < 0.01). The location of the RAP lesion was subfoveal in two (28.6%) eyes, juxtafoveal in three (42.9%) eyes and extrafoveal in two (28.6%) eyes. The five eyes with mixed lesions were all PCV coexisting with CNV at the same eye, and in all of the five cases, CNV was subfoveal while PCV was extrafoveal.
   Conclusions In this hospital-based study, PCV accounts for 24.5% of neovascular AMD and is the most common subtype, RAP is less frequent (4.5%), and mixed lesions are much less common in Chinese patients. PCV is least likely to involve the fovea in neovascular AMD.
C1 Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Peoples R China.
EM wenfeng208@yahoo.com.cn
CR Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Kuerzinger GRK, 2006, KLIN MONATSBL AUGENH, V223, P691, DOI 10.1055/s-2006-926977
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 13
TC 148
Z9 181
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2007
VL 245
IS 10
BP 1441
EP 1445
DI 10.1007/s00417-007-0575-8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209RJ
UT WOS:000249405400005
PM 17406882
DA 2022-11-30
ER

PT J
AU Layana, AG
   Minnella, AM
   Garhofer, G
   Aslam, T
   Holz, FG
   Leys, A
   Silva, R
   Delcourt, C
   Souied, E
   Seddon, JM
AF Garcia Layana, Alfredo
   Minnella, Angelo Maria
   Garhoefer, Gerhard
   Aslam, Tariq
   Holz, Frank G.
   Leys, Anita
   Silva, Rufino
   Delcourt, Cecile
   Souied, Eric
   Seddon, Johanna M.
TI Vitamin D and Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Review
DE vitamin D; age-related macular degeneration; inflammation; angiogenesis
ID RETINAL-PIGMENT EPITHELIUM; AMYLOID-BETA; D DEFICIENCY;
   25-HYDROXYVITAMIN D; D METABOLISM; VISION LOSS; ASSOCIATION; D-3;
   PATHOGENESIS; CALCITRIOL
AB In recent years, the relationship between vitamin D and health has received growing attention from the scientific and medical communities. Vitamin D deficiencies have been repeatedly associated with various acute and chronic diseases, including age-related macular degeneration (AMD). Its active metabolite, 1 alpha,25-dihydoxy vitamin D, acts as a modulator of cell proliferation, differentiation and apoptosis, and cumulative data from experimental and observational studies suggest that relatively a lower vitamin D status could be a potential risk factor for the development of early and/or late AMD. Herein, we made a narrative review of the mechanisms linking a potential role of vitamin D with the current concepts of AMD pathophysiology.
C1 [Garcia Layana, Alfredo] Univ Navarra, Clin Univ Navarra, Pamplona 31009, Spain.
   [Minnella, Angelo Maria] Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, Lgo F Vito 1, I-00168 Rome, Italy.
   [Garhoefer, Gerhard] Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Aslam, Tariq] Univ Manchester, Sch Pharm & Optometry, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England.
   [Aslam, Tariq] Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester M13 9WL, Lancs, England.
   [Aslam, Tariq] Heriot Watt Univ, Edinburgh EH14 4AS, Midlothian, Scotland.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53107 Bonn, Germany.
   [Leys, Anita] Univ Hosp Leuven, Dept Ophthalmol, B-3000 Leuven, Belgium.
   [Silva, Rufino] Univ Coimbra, Inst Biomed Imaging & Life Sci IBILI, Fac Med, P-3000548 Coimbra, Portugal.
   [Silva, Rufino] CHUC, Dept Ophthalmol, P-3000548 Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, CHUC, Inst Biomed Imaging & Life Sci IBILI FMUC, Fac Med, P-3000548 Coimbra, Portugal.
   [Silva, Rufino] CHUC, Assoc Innovat & Biomed Res Light & Image AIBILI, P-3000548 Coimbra, Portugal.
   [Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team LEHA,UMR 1219, F-33000 Bordeaux, France.
   [Souied, Eric] Univ Paris Est, Hop Intercommunal Creteil, F-94010 Creteil, France.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
C3 University of Navarra; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli; University of Vienna; University of Manchester;
   University of Manchester; Heriot Watt University; University of Bonn; KU
   Leuven; University Hospital Leuven; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Tufts
   University; Tufts Medical Center
RP Layana, AG (通讯作者)，Univ Navarra, Clin Univ Navarra, Pamplona 31009, Spain.
EM aglayana@unav.es; aminnella59@gmail.com;
   gerhard.garhoefer@meduniwien.ac.at; tariq.aslam@manchester.ac.uk;
   Frank.Holz@ukb.uni-bonn.de; anita.leys@uzleuven.be;
   rufino.silva@oftalmologia.co.pt; Cecile.Delcourt@isped.u-bordeaux2.fr;
   eric.souied@chicreteil.fr; jseddon@tuftsmedicalcenter.org
RI Aslam, Tariq/A-8532-2016
OI Aslam, Tariq/0000-0002-9739-7280; Silva, Rufino/0000-0001-8676-0833
FU Laboratoires Thea, France
FX The authors thank Thierry Radeau, for medical writing assistance in the
   preparation of this manuscript. Laboratoires Thea, France funded the
   medical writing assistance and covered the publication costs, but had no
   role in the design of the study, in the collection, analysis, or
   interpretation of data.
CR Adams JS, 2012, ARCH BIOCHEM BIOPHYS, V523, P95, DOI 10.1016/j.abb.2012.02.016
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bahar-Shany K, 2010, J CELL PHYSIOL, V222, P729, DOI 10.1002/jcp.22004
   Ben-Shoshan M, 2007, MOL CANCER THER, V6, P1433, DOI 10.1158/1535-7163.MCT-06-0677
   Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008-1454
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Body JJ, 2012, OSTEOPOROSIS INT, V23, pS1, DOI 10.1007/s00198-011-1891-8
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campbell FC, 2010, BIOCHEM PHARMACOL, V79, P1, DOI 10.1016/j.bcp.2009.09.005
   Cashman KD, 2016, AM J CLIN NUTR, V103, P1033, DOI 10.3945/ajcn.115.120873
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi Dongseok, 2008, J Ocul Biol Dis Infor, V1, P37, DOI 10.1007/s12177-008-9007-1
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Diker-Cohen T, 2006, APOPTOSIS, V11, P519, DOI 10.1007/s10495-006-5115-1
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleet JC, 2004, J NUTR, V134, P3215, DOI 10.1093/jn/134.12.3215
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Goltzman D, 2015, BBA-GENE REGUL MECH, V1849, P171, DOI 10.1016/j.bbagrm.2014.05.026
   Haussler MR, 2011, BEST PRACT RES CL EN, V25, P543, DOI 10.1016/j.beem.2011.05.010
   Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029
   Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick Michael F, 2014, Adv Exp Med Biol, V810, P1
   Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011
   Hossein-nezhad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058725
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921
   Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11
   Kassi E, 2013, CIRCULATION, V128, P2517, DOI 10.1161/CIRCULATIONAHA.113.002654
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Majewski S, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P97
   Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Pahl L, 2013, EXP EYE RES, V116, P234, DOI 10.1016/j.exer.2013.09.012
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Penn J, 2015, DIS MODEL MECH, V8, P131, DOI 10.1242/dmm.017194
   Pramyothin P, 2011, OBESITY, V19, P2228, DOI 10.1038/oby.2011.170
   Prietl B, 2013, NUTRIENTS, V5, P2502, DOI 10.3390/nu5072502
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Wang HB, 2016, MOL VIS, V22, P189
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wu W, 2016, INVEST OPHTH VIS SCI, V57, P2168, DOI 10.1167/iovs.15-18218
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zerwekh JE, 2008, AM J CLIN NUTR, V87, p1087S, DOI 10.1093/ajcn/87.4.1087S
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 87
TC 25
Z9 25
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2017
VL 9
IS 10
AR 1120
DI 10.3390/nu9101120
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA FM0DM
UT WOS:000414629900076
PM 29027953
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Augustin, A
AF Augustin, Albert
TI TRIPLE THERAPY FOR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; vascular
   endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; TRIAMCINOLONE
AB Choroidal neovascularization is a hallmark sign of wet age-related macular degeneration (AMD) but it is not an isolated feature. Several processes are likely to contribute to the fibrotic scarring and vision loss that accompanies progressive disease. In a pilot study, a triple therapy approach to wet AMD was based on the goals of halting choroidal neovascularization, controlling the inflammatory response, and modifying proliferative factors. To address each of these goals, respectively, patients received photodynamic therapy, bevacizumab, and the steroid dexamethasone. The encouraging rate of response, including significant improvements in visual acuity, is consistent with the combined activities of these agents and provides the basis for more definitive studies. RETINA 29:S5-S8, 2009
C1 Klinikum Karlsruhe, Augenklin, D-76133 Karlsruhe, Germany.
C3 Municipal Hospital Karlsruhe; University of Hamburg; University Medical
   Center Hamburg-Eppendorf
RP Augustin, A (通讯作者)，Klinikum Karlsruhe, Augenklin, D-76133 Karlsruhe, Germany.
EM albertaugustin@compuserve.com
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P193, DOI 10.1001/archophthalmol.2007.40
NR 4
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S5
EP S8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700003
DA 2022-11-30
ER

PT J
AU Amaro, MH
   Holler, AB
AF Amaro, Miguel Hage
   Holler, Aaron Brock
TI Predominantly hemorrhagic choroidal neovascular lesion from exsudative
   age-related macular degeneration treated with intravitreal ranibizumab
   therapy
SO REVISTA BRASILEIRA DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/drug therapy; Choroidal neovascularization/drug
   therapy; Angiogenesis inhibitors/therapeutic use; Antibodies monoclonal;
   Case reports
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBMACULAR HEMORRHAGE; SUBRETINAL
   HEMORRHAGE; INJECTION; MANAGEMENT; GAS; VERTEPORFIN; BEVACIZUMAB;
   SECONDARY
AB The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy. Monthly ranibizumab (six intravitreal injections) displayed a promising response but this limited report is insufficient to guarantee the indication for all predominantly hemorrhagic choroidal neovascular lesion from neovascular age-related macular degeneration. Further studies will be necessary for complete validation of our results for all predominantly hemorrhagic choroidal neovascular lesions from CNV due to AMD.
C1 [Amaro, Miguel Hage; Holler, Aaron Brock] Univ Iowa, Retina Serv, Iowa City, IA 52242 USA.
C3 University of Iowa
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2006, NEW ENGL J MED, V355, P1493
   Brown DM, 2006, NEW ENGL J MED, V355, P1409
   Chang MA, 2011, COMMENT RETINA, V31, P1749
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Gass J. D. M., 1997, STEREOSCOPIC ATLAS M, P49
   Gass JD, 1973, T AM ACAD OPHTHALMOL, V77, pOP310
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gragoudas ES, 2005, NEW ENGL J MED, V352, P1720
   GRAGOUDAS ES, 2005, ACP J CLUB, V143, P18
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Handwerger BA, 2002, COMMENT ARCH OPHTHAL, V120, P203
   Handwerger BA, 2002, COMMENT ARCH OPHTHAL, V120, P102
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hassan AS, 2000, OPHTHALMOLOGY, V107, P2119
   Hassan AS, 2000, COMMENT OPHTHALMOLOG, V107, P2118
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hattenbach LO, 2002, OPHTHALMOLOGY, V109, P825, DOI 10.1016/S0161-6420(02)01036-9
   Hattenbach LO, 2002, KLIN MONATSBL AUGENH, V219, P512, DOI 10.1055/s-2002-33584
   Hattenbach LO, 2002, COMMENT OPHTHALMOLOG, V109, P824
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
NR 34
TC 0
Z9 0
U1 1
U2 1
PU SOC BRASILEIRA OFTALMOLOGIA
PI RIO DE JANEIRO
PA RUA SAO SALVADOR 107, RIO DE JANEIRO, 22231-170, BRAZIL
SN 0034-7280
J9 REV BRAS OFTALMOL
JI Rev. Bras. Oftalmol.
PD MAY-JUN
PY 2013
VL 72
IS 3
BP 185
EP 187
DI 10.1590/S0034-72802013000300009
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 247XR
UT WOS:000326657900009
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Velilla, S
   Garcia-Medina, JJ
   Garcia-Layana, A
   Dolz-Marco, R
   Pons-Vazquez, S
   Pinazo-Duran, MD
   Gomez-Ulla, F
   Arevalo, JF
   Diaz-Llopis, M
   Gallego-Pinazo, R
AF Velilla, Sara
   Javier Garcia-Medina, Jose
   Garcia-Layana, Alfredo
   Dolz-Marco, Rosa
   Pons-Vazquez, Sheila
   Dolores Pinazo-Duran, M.
   Gomez-Ulla, Francisco
   Arevalo, J. Fernando
   Diaz-Llopis, Manuel
   Gallego-Pinazo, Roberto
TI Smoking and Age-Related Macular Degeneration: Review and Update
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; INTRAVITREAL RANIBIZUMAB THERAPY; ENDOTHELIAL
   PROGENITOR CELLS; INDUCED-OXIDATIVE STRESS; HUMAN LUNG FIBROBLASTS;
   C-REACTIVE PROTEIN; GROWTH-FACTOR VEGF; CIGARETTE-SMOKE; RISK-FACTORS;
   VISUAL IMPAIRMENT
AB Age-related macular degeneration (AMD) is one of the main socioeconomical health issues worldwide. AMD has a multifactorial etiology with a variety of risk factors. Smoking is the most important modifiable risk factor for AMD development and progression. The present review summarizes the epidemiological studies evaluating the association between smoking and AMD, the mechanisms through which smoking induces damage to the chorioretinal tissues, and the relevance of advising patients to quit smoking for their visual health.
C1 [Velilla, Sara] San Pedro Hosp, Dept Ophthalmol, Logrono 26006, Spain.
   [Velilla, Sara; Garcia-Layana, Alfredo; Dolores Pinazo-Duran, M.; Gomez-Ulla, Francisco; Diaz-Llopis, Manuel; Gallego-Pinazo, Roberto] Inst Salud Carlos III, RETICS Oftared, Madrid 28029, Spain.
   [Javier Garcia-Medina, Jose] Reina Sofia Gen Univ Hosp, Dept Ophthalmol, Murcia 30003, Spain.
   [Javier Garcia-Medina, Jose] Univ Murcia, Fac Med, Dept Ophthalmol & Optometry, Murcia 301000, Spain.
   [Javier Garcia-Medina, Jose; Dolz-Marco, Rosa; Pons-Vazquez, Sheila; Dolores Pinazo-Duran, M.; Gallego-Pinazo, Roberto] Univ Valencia, Fac Med & Odontol, Dept Surg Ophthalmol, Ophthalm Res Unit Santiago Grisolia, Valencia 46010, Spain.
   [Garcia-Layana, Alfredo] Univ Navarra Clin, Dept Ophthalmol, Pamplona 31008, Spain.
   [Dolz-Marco, Rosa; Diaz-Llopis, Manuel; Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia 46026, Spain.
   [Dolores Pinazo-Duran, M.; Diaz-Llopis, Manuel] Univ Valencia, Fac Med & Odontol, Valencia 46010, Spain.
   [Gomez-Ulla, Francisco] Gomez Ulla Inst Ophthalmol, Santiago De Compostela 15706, Spain.
   [Gomez-Ulla, Francisco] Univ Santiago de Compostela, Santiago De Compostela 15705, Spain.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Vitreoretinal Div, Riyhad 12329, Saudi Arabia.
C3 Instituto de Salud Carlos III; University of Murcia; University of
   Valencia; University of Navarra; University of Valencia; Universidade de
   Santiago de Compostela; Johns Hopkins University; Johns Hopkins
   Medicine; King Khaled Eye Specialist Hospital
RP Gallego-Pinazo, R (通讯作者)，Inst Salud Carlos III, RETICS Oftared, Madrid 28029, Spain.
EM robertogallego@comv.es
RI Datta, Sayantan/D-1369-2010
OI Garcia-Medina, Jose Javier/0000-0002-6245-7271; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949; Dolz-Marco, Rosa/0000-0002-2963-2541;
   Pinazo-Duran, Maria Dolores/0000-0002-0118-7837
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Baglole CJ, 2008, AM J PHYSIOL-LUNG C, V295, pL624, DOI 10.1152/ajplung.90215.2008
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benowitz NL, 2003, PROG CARDIOVASC DIS, V46, P91, DOI 10.1016/S0033-0620(03)00087-2
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Brogan AP, 2005, P NATL ACAD SCI USA, V102, P10433, DOI 10.1073/pnas.0504721102
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   CONNEY AH, 1982, CANCER RES, V42, P4875
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gallego-Pinazo R., 2012, Arch Soc Esp Oftalmol, V87, P247, DOI 10.1016/j.oftal.2011.09.018
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Heeschen C, 2006, J AM COLL CARDIOL, V48, P2553, DOI 10.1016/j.jacc.2006.07.066
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076
   Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jager R. D., 2006, NEW ENGL J MED, V358, P2606
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lee J, 2012, LIFE SCI, V91, P1058, DOI 10.1016/j.lfs.2012.06.032
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martey CA, 2004, AM J PHYSIOL-LUNG C, V287, pL981, DOI 10.1152/ajplung.00239.2003
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ozguner F, 2005, TOXICOL IND HEALTH, V21, P21, DOI 10.1191/0748233705th211oa
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2008, ALBERT JAKOBIECS PRI, V1, P413
   Shapiro SD, 2004, AM J RESP CELL MOL, V31, P481, DOI 10.1165/rcmb.F285
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Sharma A, 2012, INDIAN J OPHTHALMOL, V60, P189, DOI 10.4103/0301-4738.95869
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Takeuchi A, 2009, INVEST OPHTH VIS SCI, V50, P3410, DOI 10.1167/iovs.08-2299
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179
   Yao J., 2013, PROTEOMICS
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Yu M, 2011, BIOCHEM CELL BIOL, V89, P405, DOI 10.1139/O11-032
   ZHU BQ, 1995, AM HEART J, V130, P1270, DOI 10.1016/0002-8703(95)90154-X
NR 108
TC 85
Z9 90
U1 1
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 895147
DI 10.1155/2013/895147
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271KI
UT WOS:000328390200001
PM 24368940
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Isizaki, E
   Morishita, S
   Sato, T
   Fukumoto, M
   Suzuki, H
   Kida, T
   Ueki, M
   Ikeda, T
AF Isizaki, Eisuke
   Morishita, Seita
   Sato, Takaki
   Fukumoto, Masanori
   Suzuki, Hiroyuki
   Kida, Teruyo
   Ueki, Mari
   Ikeda, Tsunehiko
TI Treatment of massive subretinal hematoma associated with age-related
   macular degeneration using vitrectomy with intentional giant tear
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (ARMD); Polypoidal choroidal
   vasculopathy (PCV); Intentional giant retinal tear; Subretinal
   hemorrhage; Silicone oil; Vitrectomy
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; THICK SUBMACULAR
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; VITREOMACULAR TRACTION; INJECTION;
   MANAGEMENT; GAS
AB The purpose of this study was to report the surgical outcomes after creating a 120A degrees intentional giant retinal tear for use in removing hemorrhage and subretinal proliferative tissue in patients with polypoidal choroidal vasculopathy (PCV) or age-related macular degeneration (ARMD). This study involved 12 eyes of 12 patients (10 eyes: PCV, 2 eyes: ARMD). After removal of the lens in phakic eyes, we performed a vitrectomy with artificial posterior vitreous detachment. Subsequently, a 120A degrees intentional giant retinal tear was created in the temporal periphery, the retina was then turned, and the subretinal hemorrhage and proliferative tissue were removed. In order to preserve as much of the retinal pigment epithelium (RPE) as possible, we used a bimanual technique under direct visualization. After stretching the retina by use of perfluorocarbon liquid (PFCL), we performed endophotocoagulation around the tear followed by PFCL/silicone oil exchange. Except for 1 eye in which extensive loss of the RPE occurred, the fundus findings and the visual acuity (VA) improved in all patients. In addition, postoperative VA improved to a parts per thousand yen20/50 in 3 eyes in which the macular RPE was preserved. This surgical procedure is an effective treatment for PCV or ARMD patients with extensive subretinal hemorrhage and proliferative tissue.
C1 [Isizaki, Eisuke; Morishita, Seita; Sato, Takaki; Fukumoto, Masanori; Suzuki, Hiroyuki; Kida, Teruyo; Ueki, Mari; Ikeda, Tsunehiko] Osaka Med Coll, Dept Ophthalmol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
C3 Osaka Medical College
RP Ikeda, T (通讯作者)，Osaka Med Coll, Dept Ophthalmol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
EM tikeda@poh.osaka-med.ac.jp
OI Ishizaki, Eisuke/0000-0003-0393-3327
CR Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
NR 21
TC 5
Z9 6
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2016
VL 36
IS 2
BP 199
EP 206
DI 10.1007/s10792-015-0102-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI0JD
UT WOS:000373181000007
PM 26216161
DA 2022-11-30
ER

PT J
AU Lee, H
   Lee, M
   Kim, MA
   Chung, H
   Kim, HC
AF Lee, Hyungwoo
   Lee, Minsub
   Kim, Myung Ae
   Chung, Hyewon
   Kim, Hyung Chan
TI ASSOCIATION OF TREATMENT RESPONSE WITH QUANTITATIVE CHANGES IN CHOROIDAL
   NEOVASCULARIZATION AND CHOROIDAL VESSEL IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; en face optical coherence tomography;
   fractal dimension; Haller's layer; lacunarity; optical coherence
   tomography angiography; neovascular age-related macular degeneration;
   outer choroidal vessel; polypoidal choroidal vasculopathy; vessel
   diameter
ID OPTICAL COHERENCE TOMOGRAPHY; TYPE-1 NEOVASCULARIZATION; ANGIOGRAPHY;
   PATHOGENESIS; DIAGNOSIS
AB Purpose: To evaluate the association between treatment response and quantitative morphological changes in choroidal neovascularization and outer choroidal vessels using optical coherence tomography angiography (OCTA) and en face OCT in neovascular age-related macular degeneration (nAMD). Methods: We retrospectively analyzed 75 eyes of typical nAMD patients and 53 polypoidal choroidal vasculopathy eyes of 124 patients with OCTA performed at least 6 months after initial antivascular endothelial growth factor treatment. Quantitative parameters, including vessel area, vessel diameter, branch vessel length, fractal dimension, and lacunarity were analyzed based on en face images of the choroidal neovascularization and choroidal vessel in Haller's layer. Parameters associated with loss of logarithm of the minimum angle of resolution visual acuity with the basis of 0.3 and the treatment interval (good vs. poor responder based on 12 weeks) were analyzed. Analyses were conducted for "before OCTA" (initial visit to OCTA) and "after OCTA" (OCTA to 6 months post-OCTA). Results: In typical nAMD, visual acuity loss before OCTA was associated with a higher SD of choroidal neovascularization diameter and lower choroidal fractal dimension. Visual acuity loss after OCTA in typical nAMD was associated with higher lacunarity of the choroid. Poor responders before OCTA were not associated with any factor. Poor responders after OCTA were associated with a lower SD of outer choroidal vessel diameter in typical nAMD. In polypoidal choroidal vasculopathy, no factor was associated with clinical outcomes in either period. Conclusion: Quantitative analyses of choroidal neovascularization on OCTA and choroidal vessels on en face OCT provide information about treatment response, including changes in visual acuity and treatment interval, in nAMD.
C1 [Lee, Hyungwoo; Lee, Minsub; Kim, Myung Ae; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Dept Ophthalmol, Med Ctr, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM eyekim@kuh.ac.kr
FU Konkuk University Medical Center Research Grant 2018
FX Supported by Konkuk University Medical Center Research Grant 2018. The
   sponsor or funding organization had no role in the design or conduct of
   this research.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   [Anonymous], 2013, FRACLAC IMAGEJ
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Gewaily DY, 2014, AM J OPHTHALMOL, V158, P525, DOI 10.1016/j.ajo.2014.06.004
   Hotaling NA, 2015, BIOMATERIALS, V61, P327, DOI 10.1016/j.biomaterials.2015.05.015
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003
   Kedzia Alicja, 2002, Med Sci Monit, V8, pMT46
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   SMITH TG, 1989, J NEUROSCI METH, V27, P173, DOI 10.1016/0165-0270(89)90100-3
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   SUTERA SP, 1993, ANNU REV FLUID MECH, V25, P1, DOI 10.1146/annurev.fl.25.010193.000245
   Talu S, 2013, CURR EYE RES, V38, P781, DOI 10.3109/02713683.2013.779722
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 31
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1704
EP 1718
DI 10.1097/IAE.0000000000002678
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800009
PM 31725526
DA 2022-11-30
ER

PT J
AU Frei, A
   Woitzek, K
   Wang, M
   Held, U
   Rosemann, T
AF Frei, Anja
   Woitzek, Katja
   Wang, Mathyas
   Held, Ulrike
   Rosemann, Thomas
TI The chronic care for age-related macular degeneration study (CHARMED):
   Study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
ID CHRONIC ILLNESS CARE; QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE;
   PATIENT ASSESSMENT; CLINICAL-RESEARCH; CASE-MANAGEMENT; CHOROIDAL
   NEOVASCULARIZATION; SUBMACULAR SURGERY; HEALTH-CARE; EYE
AB Background: Neovascular age-related macular degeneration is the leading cause of irreversible blindness in people 50 years of age or older in the developed world. As in other chronic diseases, several effective treatments are available, but in clinical daily practice there is an evidence performance gap. The Chronic Care Model represents an evidence-based framework for the care of chronically ill patients and aims at closing that gap. However, no data are available regarding patients with neovascular age-related macular degeneration.
   Methods/Design: CHARMED is a multicenter randomized controlled trial. The study challenges the hypothesis that the implementation of core elements of the Chronic Care Model (patient empowerment, delivering evidence based information, clinical information system, reminder system with structured follow up and frequent monitoring) via a specially trained Chronic Care Coach in Swiss centres for neovascular age-related macular degeneration results in better visual acuity (primary outcome) and an increased disease specific quality of life (secondary outcome) in patients with neovascular age-related macular degeneration. According to the power calculation, a total sample size of 352 patients is needed (drop out rate of 25%). 14 specialised medical doctors from leading ophtalmologic centres in Switzerland will include 25 patients. In each centre, a Chronic Care Coach will provide disease specific care according to the Chronic Care Model for intervention group. Patients from the control group will be treated as usual. Baseline measurements will be taken in month III - XII, starting in March 2011. Follow-up data will be collected after 6 months and 1 year.
   Discussion: Multiple studies have shown that implementing Chronic Care Model elements improve clinical outcomes as well as process parameters in different chronic diseases as osteoarthritis, depression or e. g. the cardiovascular risk profile of diabetes patients. This study will be the first to assess this approach in neovascular age-related macular degeneration. If our hypothesis will be confirmed, the implementation of this approach in routine care for patients with with neovascular age-related macular degeneration should be considered.
C1 [Frei, Anja; Woitzek, Katja; Wang, Mathyas; Rosemann, Thomas] Univ Zurich, Inst Gen Practice & Hlth Serv Res, CH-8091 Zurich, Switzerland.
   [Frei, Anja; Held, Ulrike] Univ Zurich, Horten Ctr Patient Oriented Res, CH-8091 Zurich, Switzerland.
C3 University of Zurich; University of Zurich
RP Woitzek, K (通讯作者)，Univ Zurich, Inst Gen Practice & Hlth Serv Res, Pestalozzistr 24, CH-8091 Zurich, Switzerland.
EM katja.woitzek@usz.ch
RI Held, Ulrike/O-8328-2019; Held, Ulrike/D-3666-2013
OI Frei, Anja/0000-0002-7134-1000; Held, Ulrike/0000-0003-3105-5840
FU Institute of General Practice and Health Services Research, University
   of Zurich; Zukunft Hausarzt, Zurcher Stiftung zur Forderung der
   Hausarztmedizin
FX This trial is funded by the Institute of General Practice and Health
   Services Research, University of Zurich and by the "Zukunft Hausarzt,
   Zurcher Stiftung zur Forderung der Hausarztmedizin".
CR Bonomi AE, 2002, HEALTH SERV RES, V37, P791, DOI 10.1111/1475-6773.00049
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Epping-Jordan JE, 2004, QUAL SAF HEALTH CARE, V13, P299, DOI 10.1136/qshc.2004.010744
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gensichen J, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-101
   GENSICHEN J, 2010, COMMUNITY MENTAL HLT, P1
   Gensichen J, 2009, ANN INTERN MED, V151, P369, DOI 10.7326/0003-4819-151-6-200909150-00001
   Glasgow RE, 2005, DIABETES CARE, V28, P2655, DOI 10.2337/diacare.28.11.2655
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   GUPTA B, 2010, BR J OPHTHALMOL
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Hirneiss C, 2007, BRIT J OPHTHALMOL, V91, P481, DOI 10.1136/bjo.2006.102376
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507
   Lowe B, 2004, J AFFECT DISORDERS, V81, P61, DOI 10.1016/S0165-0327(03)00198-8
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MANGIONE CM, 2000, VFQ 25 MANUAL VERSIO
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosemann T, 2007, ARTHRIT RHEUM-ARTHR, V57, P1390, DOI 10.1002/art.23080
   Rosemann T, 2007, J EVAL CLIN PRACT, V13, P806, DOI 10.1111/j.1365-2753.2007.00786.x
   Sassa Y, 2010, CLIN OPHTHALMOL, V4, P275
   STEURERSTEY C, 2010, J EVAL CLIN PRACT
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Szecsenyi J, 2008, DIABETES CARE, V31, P1150, DOI 10.2337/dc07-2104
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Tsai AC, 2005, AM J MANAG CARE, V11, P478
   Wagner E H, 1998, Eff Clin Pract, V1, P2
   Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64
   World Health Organization, 2003, INTRO DRUG UTILIZATI
NR 36
TC 3
Z9 3
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD OCT 11
PY 2011
VL 12
AR 221
DI 10.1186/1745-6215-12-221
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 846SG
UT WOS:000296922900001
PM 21985296
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Goold, LA
   Edussuriya, K
   Sennanayake, S
   Senaratne, T
   Selva, D
   Sullivan, TR
   Casson, RJ
AF Goold, L. A.
   Edussuriya, K.
   Sennanayake, S.
   Senaratne, T.
   Selva, D.
   Sullivan, T. R.
   Casson, R. J.
TI Prevalence and determinants of age-related macular degeneration in
   central Sri Lanka: the Kandy Eye Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; VISUAL IMPAIRMENT; CATARACT-SURGERY; RISK-FACTORS;
   JAPANESE POPULATION; LOW-VISION; RURAL-POPULATION; 5-YEAR INCIDENCE;
   OLDER ADULTS; SOUTH-INDIA
AB Aims To determine the prevalence, associations and risk factors for age-related macular degeneration (ARMD) in central Sri Lanka.
   Methods The study was a population-based, cross-sectional survey of residents aged >= 40 years in rural Sri Lanka. ARMD was assessed on dilated fundoscopy using the International Age-Related Maculopathy Epidemiology Study Group classification system.
   Results Of the 1721 subjects identified, 1375 participated (79.9%). Of the participants, 1013 were aged >= 50 years (73.6%). The prevalence of any ARMD (adjusted for study design) was 4.72 (95% CI 2.22 to 7.20)% with 3.82 (95% CI 1.60 to 6.04)% early ARMD and 1.70 (95% CI 0.14 to 3.27)% late ARMD. Age (p<0.001) and Sinhalese ethnicity (p = 0.016) were significantly associated with ARMD. Men had a tendency toward a higher prevalence of ARMD than women, although this was not statistically significant (p = 0.081). Ocular risk factors such as cortical cataract (p = 0.024) and pseudophakia (p - 0.003) were associated with ARMD on the univariate but not multivariate analyses. Illiteracy and the identification of social supports were significantly associated with ARMD on univariate analyses. However, only social support was statistically significant after multivariate analysis (p = 0.024).
   Conclusions Although the prevalence of ARMD is slightly lower in Sri Lanka than surrounding regions, it contributes to a higher proportion of visual impairment, including blindness. Risk factors include age and Sinhalese ethnicity.
C1 [Goold, L. A.; Selva, D.; Casson, R. J.] S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia.
   [Edussuriya, K.; Sennanayake, S.; Senaratne, T.] Kandy Ctr Save Sight, Kandy, Sri Lanka.
   [Sullivan, T. R.] Univ Adelaide, Discipline Publ Hlth, Adelaide, SA, Australia.
C3 University of Adelaide
RP Goold, LA (通讯作者)，S Australian Inst Ophthalmol, North Terrace, Adelaide, SA 5000, Australia.
EM lgoold@med.usyd.edu.au
RI Casson, Robert/D-1561-2013
OI Sullivan, Thomas/0000-0002-6930-5406
FU Pfizer
FX The Kandy Eye Study was supported financially from an unrestricted grant
   from Pfizer.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Edussuriya K, 2009, OPHTHALMOLOGY, V116, P52, DOI 10.1016/j.ophtha.2008.08.034
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P1075, DOI 10.1136/bjo.87.9.1075
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
NR 25
TC 3
Z9 3
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2010
VL 94
IS 2
BP 150
EP 153
DI 10.1136/bjo.2009.163808
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552WR
UT WOS:000274325500003
PM 19713196
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Vaziri, K
   Moshfeghi, DM
   Moshfeghi, AA
AF Vaziri, Kamyar
   Moshfeghi, Darius M.
   Moshfeghi, Andrew A.
TI Feasibility of Telemedicine in Detecting Diabetic Retinopathy and
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Diabetic retinopathy; macular degeneration; telemedicine; teleretina;
   teleophthalmology
ID INTRAVITREAL BEVACIZUMAB AVASTIN; COLOR FUNDUS PHOTOGRAPHY; VISUAL
   IMPAIRMENT; PREVALENCE; CARE; EYE; TELEOPHTHALMOLOGY; OPHTHALMOSCOPY;
   MACULOPATHY; POPULATION
AB Age-related macular degeneration and diabetic retinopathy are important causes of visual impairment and blindness in the world. Because of recent advances and newly available treatment modalities along with the devastating consequences associated with late stages of these diseases, much attention has been paid to the importance of early detection and improving patient access to specialist care. Telemedicine or, more specifically, digital retinal imaging utilizing telemedical technology has been proposed as an important alternative screening and management strategy to help meet this demand. In this paper, we perform a literature review and analysis that evaluates the validity and feasibility of telemedicine in detecting diabetic retinopathy and age-related macular degeneration. Understanding both the progress and barriers to progress that have been demonstrated in these two areas is important for future telemedicine research projects and innovations in telemedicine technology.
C1 [Vaziri, Kamyar; Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Palm Beach Gardens, FL 33418 USA.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Horngren Vitreoretinal Ctr, Byers Eye Inst Stanford, Palo Alto, CA 94305 USA.
C3 Bascom Palmer Eye Institute; Stanford University
RP Moshfeghi, AA (通讯作者)，Bascom Palmer Eye Inst, 7101 Fairway Dr, Palm Beach Gardens, FL 33418 USA.
EM amoshfeghi@gmail.com
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
FU NIH Center [P30EY014801]; Research to Prevent Blindness; Departmentof
   Defense (DOD) [W81XWH-09-1-0675]; NATIONAL EYE INSTITUTE [P30EY014801]
   Funding Source: NIH RePORTER
FX Supported by NIH Center Core Grant P30EY014801, Research to Prevent
   Blindness Unrestricted Grant, Departmentof Defense (DOD-Grant#
   W81XWH-09-1-0675).
CR Abramoff MD, 2005, TELEMED J E-HEALTH, V11, P668, DOI 10.1089/tmj.2005.11.668
   American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   [Anonymous], 2010, PREF PRACT PATT GUID
   Aoki N, 2004, DIABETES CARE, V27, P1095, DOI 10.2337/diacare.27.5.1095
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Boucher MC, 2005, CAN J OPHTHALMOL, V40, P734, DOI 10.1016/S0008-4182(05)80091-2
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conlin PR, 2006, J REHABIL RES DEV, V43, P741, DOI 10.1682/JRRD.2005.08.0146
   Fransen SR, 2002, OPHTHALMOLOGY, V109, P595, DOI 10.1016/S0161-6420(01)00990-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Gomez-Ulla F, 2008, TELEMED J E-HEALTH, V14, P912, DOI 10.1089/tmj.2008.0013
   Hartnett ME, 2005, ARCH OPHTHALMOL-CHIC, V123, P387, DOI 10.1001/archopht.123.3.387
   HO T, 1992, SURV OPHTHALMOL, V37, P190, DOI 10.1016/0039-6257(92)90137-I
   Hubbard LD, 2011, ARCH OPHTHALMOL-CHIC, V129, P718, DOI 10.1001/archophthalmol.2011.136
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki S, 2003, TELEMED J E-HEALTH, V9, P235, DOI 10.1089/153056203322502614
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kernt M, 2012, DIABETES CARE, V35, P2459, DOI 10.2337/dc12-0346
   KIRKPATRICK JNP, 1995, BRIT J OPHTHALMOL, V79, P892, DOI 10.1136/bjo.79.10.892
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Klein R, 2002, AM J OPHTHALMOL, V134, P261, DOI 10.1016/S0002-9394(02)01593-3
   Klein R, 2008, PREVALENCE AGE RELAT
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Lee MS, 2000, RETINA-J RET VIT DIS, V20, P275, DOI 10.1097/00006982-200005000-00008
   Li HK, 2011, TELEMED E-HEALTH, V17, P814, DOI 10.1089/tmj.2011.0075
   Li HK, 2011, RETINA-J RET VIT DIS, V31, P1553, DOI 10.1097/IAE.0b013e3182084273
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Linkous JD, 2004, TELEMED J E-HEALTH, V10, P469, DOI 10.1089/tmj.2004.10.469
   Maberley D, 2003, CAN MED ASSOC J, V168, P160
   Maberley DAL, 2002, CAN J PUBLIC HEALTH, V93, P229, DOI 10.1007/BF03405006
   Massin P, 2005, DIABETES METAB, V31, P153, DOI 10.1016/S1262-3636(07)70181-7
   Mukamel D B, 1999, Ophthalmic Epidemiol, V6, P61
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Paul PG, 2006, TELEMED J E-HEALTH, V12, P571, DOI 10.1089/tmj.2006.12.571
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Rein DB, 2011, HEALTH SERV RES, V46, P1534, DOI 10.1111/j.1475-6773.2011.01263.x
   Richter GM, 2009, SURV OPHTHALMOL, V54, P671, DOI 10.1016/j.survophthal.2009.02.020
   Romero-Aroca P, 2010, CLIN OPHTHALMOL, V4, P1481, DOI 10.2147/OPTH.S14521
   Rudnisky CJ, 2007, OPHTHALMOLOGY, V114, P1748, DOI 10.1016/j.ophtha.2006.12.010
   Schiffman RM, 2005, OPHTHAL SURG LAS IM, V36, P46
   Schoenfeld ER, 2001, OPHTHALMOLOGY, V108, P563, DOI 10.1016/S0161-6420(00)00600-X
   Silva PS, 2012, AM J OPHTHALMOL, V154, P549, DOI 10.1016/j.ajo.2012.03.019
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Taylor CR, 2007, DIABETES CARE, V30, P574, DOI 10.2337/dc06-1509
   The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Vingerling JR, 1992, OPHTHALMOLOGY, V99, P933
   Vujosevic S, 2009, AM J OPHTHALMOL, V148, P111, DOI 10.1016/j.ajo.2009.02.031
   Whited JD, 2005, TELEMED J E-HEALTH, V11, P641, DOI 10.1089/tmj.2005.11.641
   Williams GA, 2004, OPHTHALMOLOGY, V111, P1055, DOI 10.1016/j.ophtha.2004.02.004
   Zeimer R, 2002, INVEST OPHTH VIS SCI, V43, P1581
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 68
TC 17
Z9 18
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAR
PY 2015
VL 30
IS 2
BP 81
EP 95
DI 10.3109/08820538.2013.825727
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC6CF
UT WOS:000350451500001
PM 24171781
DA 2022-11-30
ER

PT J
AU Kim, KL
   Joo, K
   Park, SJ
   Park, KH
   Woo, SJ
AF Kim, Kyoung Lae
   Joo, Kwangsic
   Park, Sang Jun
   Park, Kyu Hyung
   Woo, Se Joon
TI Progression from intermediate to neovascular age-related macular
   degeneration according to drusen subtypes: Bundang AMD cohort study
   report 3
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; neovascular change; pachydrusen; soft
   drusen
ID RETICULAR PSEUDODRUSEN; RISK-FACTORS; PREVALENCE; ASSOCIATION; EYE
AB Purpose To investigate the ophthalmic risk factors related to neovascular change and the subtype-wise incidence of progression from intermediate to neovascular age-related macular degeneration (AMD). Methods In this retrospective cohort study, 632 eyes with intermediate AMD from 418 patients (older than 50 years) were enrolled. The systemic factors and ophthalmic factors were statistically analysed with respect to neovascular change. Results The 5-year cumulative incidence of progression to neovascular AMD (nAMD) from intermediate AMD was 17.8% and 17.0% in eyes with soft drusen and pachydrusen (p = 0.316). Older age (p = 0.025), preexisting nAMD in the fellow eye (p < 0.001), and reticular pseudodrusen (RPD; p = 0.007) were associated with the risk of progression to nAMD. In reference to soft drusen, pachydrusen was associated with progression to polypoidal choroidal vasculopathy (PCV; p < 0.001) and not to typical nAMD (p = 0.064). Conclusions The ophthalmic risk factors related to the progression of nAMD from intermediate AMD were found to be preexisting nAMD in the fellow eye and RPD. Pachydrusen showed a similar incidence of neovascular change with soft drusen, and was associated with the progression to PCV but not to typical nAMD.
C1 [Kim, Kyoung Lae; Joo, Kwangsic; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnam, South Korea.
   [Kim, Kyoung Lae] Gangwon Natl Univ, Dept Ophthalmol, Gangwon Natl Univ Hosp, Coll Med, Chunchon, South Korea.
C3 Seoul National University (SNU); Kangwon National University
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI ; Woo, Se Joon/I-7357-2013; Park, Sang Jun/C-3234-2015
OI Park, Kyu Hyung/0000-0002-5516-8121; Woo, Se Joon/0000-0003-3692-7169;
   Park, Sang Jun/0000-0003-0542-2758
FU National Research Foundation ofKorea(NRF)grant fundedbytheKorea
   government (MSIT) [2020R1F1A1072795]
FX This work was supported by the National Research Foundation
   ofKorea(NRF)grant fundedbytheKorea government (MSIT) (No.
   2020R1F1A1072795). The fundingorganizationhadnoroleinthedesignorconduct
   of this study.
CR Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Roh M, 2018, OPHTHALMOL RETINA, V2, P475, DOI 10.1016/j.oret.2017.08.021
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P371, DOI 10.4103/ijo.IJO_1173_18
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang HB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52163-z
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 25
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2022
VL 100
IS 3
BP E710
EP E718
DI 10.1111/aos.14960
EA AUG 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0L1ID
UT WOS:000684431200001
PM 34390191
DA 2022-11-30
ER

EF